{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.document_loaders import PyPDFLoader\n",
    "from langchain.vectorstores import Chroma\n",
    "from langchain.embeddings.openai import OpenAIEmbeddings\n",
    "from langchain.document_loaders import UnstructuredPDFLoader\n",
    "# from langchain.llms import OpenAI\n",
    "from langchain.chat_models import ChatOpenAI\n",
    "from langchain.chains.question_answering import load_qa_chain\n",
    "\n",
    "from langchain.document_loaders import PyPDFDirectoryLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "\n",
    "from coexpert.params import OPENAI_API_KEY\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Document(page_content='REFERENCE GUIDE\\nRESONATE™HFICD,\\nRESONATE™ELICD,\\nPERCIVA™HFICD,\\nPERCIVA™ICD,\\nVIGILANT™ELICD,\\nMOMENTUM™ELICD\\nIMPLANTABLE CARDIO VERTER DEFIBRILLATOR\\nRREEFFD520,D521,D532,D533,D420,D421,D432,D433,D500,D501,D512,D513,\\nD400,D401,D412,D413,D220,D221,D232,D233,D120,D121\\nCAUTION: Federallaw(USA)\\nrestricts thisdevicetosalebyoron\\ntheorderofaphysician trainedor\\nexperience dindeviceimplant and\\nfollow-up procedures.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 0}), Document(page_content='', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 1}), Document(page_content='ABOUTTHISMANUAL\\nThisliteratureisintended forusebyprofessionals trainedorexperienc edindeviceimplant and/orfollow-up\\nprocedures.\\nThesefamilies ofimplantable cardioverter defibrillators (ICDs)containbothsingle-anddual-chamber pulse\\ngeneratorsthatprovideventricular tachyarrhythmia therapy,bradycardia pacing,andavarietyofdiagnostic tools.\\nThePhysician Technical Manual, usedinconjunction withtheZOOMVIEW software,isintended toprovideinformation\\nmostrelevantforimplanting thepulsegenerator.ThePhysician Technical Manualalsocontainsinformation suchas\\nwarnings/cautions, potential adverse events,mechanical specifications, longevity ,hyperbaric therapy,and\\nprogramming considerations. ThisReferenc eGuideprovidesfurtherdescriptions ofprogrammable features and\\ndiagnostics.\\nSummaries oftherelevantclinicalstudiessupporting theseproducts areavailable asseparatedocuments. The\\nfollowing clinicalsummaries areapprovedasapplicable tosomeorallofthedevicesdescribed inthismanual:\\n•MADITII\\n•GDT1000 Sensing AcuteStudy\\n•VENTAK AVII\\n•VITALITY\\n•VITALITY DS\\n•COGENT-4 FieldFollowing Study\\n•IVORY\\n•CAPTIVATE\\n•MADIT-RIT\\nForinformation aboutMRIscanning, refertotheImageReady MRConditional Defibrillation SystemMRITechnical\\nGuide.\\nToviewanddownload anyofthesedocuments, gotowww.bostonscientific -elabeling.c om.\\nRefertotheHeartLogic Technical Guideforinformation abouttheHeartLogic HeartFailureDiagnostic Service.\\nThisproduct familyincludes single-anddual-chamber models, withfeaturevariations. Thismanualdescribes thefull-\\nfeaturedmodel(e.g.,adual-chamber modelwithZIPtelemetry).\\nThisguidemaycontainreferenceinformation formodelnumbers thatarenotcurrentlyapproved forsaleinall\\ngeographies.Foracompletelistofmodelnumbers approved inyourgeography,consultwithyourlocalsales\\nrepresentative.Somemodelnumbers maycontainfewerfeatures; forthosedevices,disregarddescriptions ofthe\\nunavailable features.Descriptions foundwithinthismanualapplytoalldevicetiersunlessotherwisenoted.\\nThescreenillustrationsusedinthismanualareintended tofamiliarize youwiththegeneralscreenlayout.Theactual\\nscreensyouseewheninterrogatingorprogramming thepulsegenerator willvarybasedonthemodeland\\nprogrammed paramet ers.\\nLATITUDE NXTisaremotemonitoring systemthatprovides pulsegeneratordataforclinicians. Allpulsegenerators\\ndescribed inthismanualaredesigned tobeLATITUDE NXTenabled; availability variesbyregion.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 2}), Document(page_content='Acomplete listofprogrammable options isprovidedintheappendix (\"Programmable Options\" onpageA-1).The\\nactualvaluesyouseewheninterrogatingorprogramming thepulsegeneratorwillvarybasedonthemodeland\\nprogrammed parameters.\\nThetextconventions discussed belowareusedthroughout thismanual.\\nPRMKEYS ThenamesofProgrammer/Rec order/Monitor (PRM)\\nkeysappearincapitalletters(e.g.,PROGRAM,\\nINTERROGATE).\\n1.,2.,3. Numberedlistsareusedforinstructions thatshouldbe\\nfollowed intheordergiven.\\n• Bulleted listsareusedwhentheinformation isnot\\nsequential.\\nThefollowing acronyms maybeusedinthismanual:\\nA Atrial\\nAF AtrialFibrillation\\nAFib AtrialFibrillation\\nAFR AtrialFlutterResponse\\nAGC Automatic GainControl\\nAIVR AcceleratedIdioventricular Rhythm\\nAT AtrialTachycar dia\\nATP Antitachycardia Pacing\\nATR AtrialTachyResponse\\nAV Atrioventricular\\nBCL BurstCycleLength\\nBPEG BritishPacingandElectrophysiology Group\\nBTR BradyTachyResponse\\nCPR Cardiopulmon aryResuscitation\\nDFT Defibrillation Threshold\\nEAS ElectronicArticleSurveillance\\nECG Electrocardiogram\\nEF Ejection Fraction\\nEGM Electrogram\\nEL Extended Longevity\\nEMI Electromagnetic Interfere nce\\nEP Electrophysiology; Electrophysiologic\\nFCC FederalCommunications Commission\\nHE HighEnergy\\nHRV HeartRateVariability\\nIBP Indications-Based Programming\\nICD Implantable Cardioverter Defibrillator\\nLRL LowerRateLimit\\nMI Myocard ialInfarction\\nMICS Medical Implant Communication Service\\nMPR Maximum PacingRate\\nMRI Magnetic Resonanc eImaging\\nMSR Maximum SensorRate\\nMTR Maximum TrackingRate\\nMV MinuteVentilation\\nNASPE NorthAmerican SocietyofPacingandElectrophysiology\\nNSR NormalSinusRhythm\\nPAC Prematu reAtrialContraction\\nPAT Paroxysmal AtrialTachycar dia', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 3}), Document(page_content='PES Programmed Electrical Stimulation\\nPMT Pacemaker-Mediated Tachycar dia\\nPRM Programmer/Rec order/Monitor\\nPSA PacingSystemAnalyzer\\nPTM PatientTriggere dMonitor\\nPOST Post-OperativeSystemTest\\nPVARP Post-Ventricular AtrialRefractoryPeriod\\nPVC PrematureVentricular Contract ion\\nRAAT RightAtrialAutomatic Threshold\\nRADAR RadioDetection andRanging\\nRF RadioFrequency\\nRV RightVentricular\\nRVAT RightVentricular Automatic Threshold\\nRVRP RightVentricular Refractory Period\\nSAM SignalArtifactMonitor\\nSCD Sudden CardiacDeath\\nSDANN StandardDeviation ofAveraged Normal-to-Normal R-Rintervals\\nSRD Sustained RateDuration\\nSVT Supraventricular Tachycar dia\\nTARP TotalAtrialRefractoryPeriod\\nTENS Transcutaneous Electrical NerveStimulation\\nV Ventricular\\nVF Ventricular Fibrillation\\nVFib Ventricular Fibrillation\\nVRP Ventricular RefractoryPeriod\\nVRR Ventricular RateRegulation\\nVT Ventricular Tachycardia\\nVTR Ventricular Tachycardia Response\\nThefollowing aretrademarks ofBostonScientific Corporat ionoritsaffiliates:\\nAcuShock, EASYVIEW,ENDURALIFE, HeartLogic, IMAGEREADY, LATITUDE, MOMENTUM, Onset/Stability ,PaceSafe,\\nPERCIVA, QuickConvert, QUICKNOTES,RESONATE, RHYTHM ID,RHYTHMMATCH, RightRate, RYTHMIQ ,SafetyCore,\\nSmartBlanking, VENTAK, VIGILANT, VITALITY, ZIP,ZOOM,ZOOMVIEW.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 4}), Document(page_content='', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 5}), Document(page_content='TABLEOFCONTENTS\\nUSINGTHEPROGRAMMER .....................................................................................................1-1\\nCHAPTER 1\\nLATITUDE Programming System...............................................................................................1-2\\nSoftwareTerminology andNavigation .......................................................................................1-2\\nMainScreen..................................................................................................................1-2\\nPRMModeIndicator ........................................................................................................1-3\\nECG/EGM Display...........................................................................................................1-3\\nToolbar........................................................................................................................1-5\\nTabs............................................................................................................................1-5\\nButtons........................................................................................................................1-5\\nIcons...........................................................................................................................1-5\\nCommon Objects............................................................................................................1-7\\nUseofColor..................................................................................................................1-7\\nDemonstra tionMode.............................................................................................................1-8\\nCommunicating withthePulseGenerator ...................................................................................1-8\\nZIPTelemetr y................................................................................................................1-8\\nStarting aWanded Telemetr ySession..................................................................................1-9\\nStarting aZIPTelemetr ySession ........................................................................................1-9\\nEndingaTelemetr ySession ..............................................................................................1-9\\nZIPTelemetr ySecurity .....................................................................................................1-9\\nIndications-Based Programming (IBP).......................................................................................1-11\\nManualProgramming ...........................................................................................................1-13\\nDIVERTTHERAPY .................................................................................................................1-14\\nSTATSHOCK.......................................................................................................................1-14\\nSTATPACE.........................................................................................................................1-15\\nDataManagement ...............................................................................................................1-15\\nPatientInformation ........................................................................................................1-15\\nDataStorage................................................................................................................1-16\\nDeviceMemory.............................................................................................................1-17\\nPrint..........................................................................................................................1-17\\nSafetyMode.......................................................................................................................1-17\\nBackupPacemak er.........................................................................................................1-18\\nBackupDefibrillator ........................................................................................................1-18\\nTACHYARRHYTHMIA DETECTION .............................................................................................2-1\\nCHAPTER 2\\nDeviceMode......................................................................................................................2-2\\nVentricular TachyMode...................................................................................................2-2\\nElectrocautery ProtectionMode.........................................................................................2-2\\nMRIProtectionMode......................................................................................................2-3\\nRateSensing ......................................................................................................................2-4', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 6}), Document(page_content='Calculating RatesandRefractoryPeriods.............................................................................2-4\\nVentricular RateThresholds andZones...............................................................................2-5\\nUseofAtrialInformation .................................................................................................2-5\\nVentricular Detection ............................................................................................................2-6\\nVentricular Detection Enhancemen tSuites............................................................................2-7\\nVentricular Redetection ..................................................................................................2-10\\nVentricular Post-shockDetection Enhance ments....................................................................2-11\\nVentricular Detection Details............................................................................................2-11\\nTACHYARRHYTHMIA THERAPY ...............................................................................................3-1\\nCHAPTER 3\\nVentricular Therapy..............................................................................................................3-2\\nVentricular TherapyPrescription........................................................................................3-2\\nVentricular TherapySelection ...........................................................................................3-2\\nVentricular Redetection afterVentricular TherapyDelivery........................................................3-6\\nVentricular Redetection afterVentricular ATPTherapy.............................................................3-6\\nVentricular Redetection afterVentricular ShockTherapy...........................................................3-7\\nAntitachycar diaPacingTherapiesandParamet ers.........................................................................3-7\\nBurstParamet ers...........................................................................................................3-8\\nCoupling IntervalandCoupling IntervalDecremen t................................................................3-9\\nBurstCycleLength(BCL).................................................................................................3-10\\nMinimum Interval..........................................................................................................3-11\\nBurstScheme ...............................................................................................................3-11\\nRampScheme ..............................................................................................................3-11\\nScanScheme...............................................................................................................3-12\\nRamp/Scan Scheme ......................................................................................................3-12\\nATPPulseWidthandATPAmplitude .................................................................................3-13\\nVentricular ATPTime-out ................................................................................................3-13\\nQUICKCONVERT ATP.....................................................................................................3-14\\nVentricular ShockTherapyandParameters ................................................................................3-15\\nVentricular ShockVector.................................................................................................3-15\\nVentricular ShockEnergy................................................................................................3-15\\nChargeTime................................................................................................................3-15\\nWaveform Polarity........................................................................................................3-17\\nCommitted Shock/Reco nfirmation oftheVentricular Arrhythmia ...............................................3-17\\nPACINGTHERAPIES ..............................................................................................................4-1\\nCHAPTER 4\\nPacingTherapies.................................................................................................................4-2\\nBasicParamete rs.................................................................................................................4-2\\nBradyMode.................................................................................................................4-3\\nLowerRateLimit(LRL)....................................................................................................4-4\\nMaximum TrackingRate(MTR)..........................................................................................4-5\\nMaximum SensorRate(MSR)............................................................................................4-6\\nRunaway Protection .......................................................................................................4-7\\nPulseWidth.................................................................................................................4-7\\nAmplitude ...................................................................................................................4-8\\nPaceSafe .....................................................................................................................4-8\\nSensitivity ...................................................................................................................4-16\\nPost-TherapyPacing...........................................................................................................4-18', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 7}), Document(page_content='Post-ShockPacingDelay................................................................................................4-19\\nPost-Therapy Period......................................................................................................4-19\\nTempora ryBradyPacing......................................................................................................4-19\\nMinuteVentilation /Respiratory SensorandSignalArtifactMonitor ................................................4-20\\nMinuteVentilation/Respirat orySensor(MV/Respiratory Sensor)...............................................4-20\\nSignalArtifactMonitor DeviceDiagnostic ............................................................................4-23\\nRateAdaptive PacingandSensorTrending...............................................................................4-27\\nRateAdaptive Pacing....................................................................................................4-27\\nAccelerometer .............................................................................................................4-27\\nMinuteVentilation (MV).................................................................................................4-32\\nSensorTrending...........................................................................................................4-42\\nAtrialTachyResponse. .........................................................................................................4-44\\nATRModeSwitch.........................................................................................................4-44\\nVentricular RateRegulation (VRR).....................................................................................4-47\\nAtrialFlutterResponse (AFR)...........................................................................................4-47\\nPMTTermination ..........................................................................................................4-48\\nRateEnhance ments............................................................................................................4-49\\nRateHysteresis............................................................................................................4-49\\nRateSmoothing ...........................................................................................................4-50\\nRateSmoothing Example BasedonaDual-Chamber TrackingMode..........................................4-52\\nLeadConfiguration .............................................................................................................4-52\\nAVDelay..........................................................................................................................4-53\\nPacedAVDelay............................................................................................................4-53\\nSensedAVDelay..........................................................................................................4-54\\nAVSearch+................................................................................................................4-55\\nRYTHMIQ....................................................................................................................4-56\\nRefractory.........................................................................................................................4-57\\nA-Refractory-PVARP....................................................................................................4-57\\nARefractory-samechamber ...........................................................................................4-59\\nRV-Refractory (RVRP).....................................................................................................4-59\\nCross-Chamber Blanking .................................................................................................4-60\\nNoiseResponse .................................................................................................................4-63\\nVentricular TachySensing Interactions.....................................................................................4-65\\nSYSTEMDIAGNOSTICS ..........................................................................................................5-1\\nCHAPTER 5\\nSummary Dialog.................................................................................................................5-2\\nBatteryStatus.....................................................................................................................5-2\\nCapacitor Re-formation ...................................................................................................5-6\\nChargeTimeMeasurement..............................................................................................5-6\\nLastDelivered Ventricular Shock........................................................................................5-6\\nLeadsStatus.......................................................................................................................5-7\\nPost-OperativeSystemTest(POST)..........................................................................................5-11', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 8}), Document(page_content='LeadTests........................................................................................................................5-12\\nIntrinsic Amplitude Test.................................................................................................5-13\\nLeadImpedanc eTest....................................................................................................5-13\\nPaceThresholdTest......................................................................................................5-14\\nPATIENTDIAGNOSTICS ANDFOLLOWUP..................................................................................6-1\\nCHAPTER 6\\nTherapyHistory..................................................................................................................6-2\\nArrhythmia Logbook ............................................................................................................6-2\\nSnapshot ...........................................................................................................................6-8\\nHistograms ........................................................................................................................6-9\\nCounters ...........................................................................................................................6-9\\nVentricular TachyCounters ...............................................................................................6-9\\nBradyCounters ............................................................................................................6-10\\nHeartRateVariability (HRV)...................................................................................................6-10\\nTrends.............................................................................................................................6-13\\nPostImplant features ..........................................................................................................6-17\\nPatientTriggeredMonitor (PTM).......................................................................................6-17\\nBeeperFeature............................................................................................................6-18\\nMagnet Feature ...........................................................................................................6-23\\nELECTROPHYSIOLOGIC TESTING...............................................................................................7-1\\nCHAPTER 7\\nEPTestFeatures...................................................................................................................7-2\\nTemporary EPMode........................................................................................................7-2\\nEPTestScreen...............................................................................................................7-2\\nInduction Methods ...............................................................................................................7-4\\nVFibInduction ..............................................................................................................7-4\\nShockonTInduction .......................................................................................................7-5\\nBackupVentricular PacingDuringAtrialEPTesting..................................................................7-5\\nProgrammed Electrical Stimulation (PES).............................................................................7-6\\n50Hz/Manual BurstPacing...............................................................................................7-7\\nCommanded TherapyMethods ...............................................................................................7-8\\nCommanded Shock........................................................................................................7-8\\nCommanded ATP..........................................................................................................7-9\\nPROGRAMMABLE OPTIONS...................................................................................................A-1\\nAPPENDIX A\\nPACEMAKER INTERACTION ....................................................................................................B-1\\nAPPENDIX B\\nSYMBOLSONPACKAGING .....................................................................................................C-1\\nAPPENDIX C\\nSymbolsonPackaging ...........................................................................................................C-1', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 9}), Document(page_content='1-1\\nUSINGTHEPROGRAMMER\\nCHAPTER 1\\nThischaptercontainsthefollowing topics:\\n•“LATITUDE Programming System”onpage1-2\\n•“Softwar eTerminology andNavigation” onpage1-2\\n•“Demonstr ationMode”onpage1-8\\n•“Communicating withthePulseGenerator” onpage1-8\\n•“Indications-Based Programming (IBP)”onpage1-11\\n•“Manual Programming” onpage1-13\\n•“DIVERT THERAPY” onpage1-14\\n•“STATSHOCK” onpage1-14\\n•“STATPACE”onpage1-15\\n•“DataManagement” onpage1-15\\n•“SafetyMode”onpage1-17', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 10}), Document(page_content='1-2UsingtheProgrammer\\nLATITUDE Programming System\\nLATITUDE PROGRAMMING SYSTEM\\nThesepulsegeneratorscanbeusedonlywiththeModel3300LATITUDE Programming System.TheLATITUDE\\nProgramming Systemistheexternalportionofthepulsegeneratorsystem.\\nNOTE:The2868software application onthemodel3120LATITUDE Programming Systemisoutdated andshould\\nnotbeusedwiththepulsegenerators.Forassistanc e,call+1.651.582.4000 (worldwide) orcontactyourlocalBoston\\nScientific representative.\\nThe3300LATITUDE Programming Systemincludes:\\n•Model3300Programmer\\n•Model3868SoftwareApplication\\n•Model6395AccessoryTelemetr yWand\\nThesoftwareprovidesadvance ddeviceprogramming andpatientmonitoring technology .Itwasdesigned withthe\\nintentto:\\n•Enhance deviceprogramming capability\\n•Improvepatientanddevicemonitoring performanc e\\n•Simplify andexpedite programming andmonitoring tasks\\nYoucanusetheLATITUDE Programming Systemtodothefollowing:\\n•Interrogatethepulsegenerator\\n•Programthepulsegeneratortoprovide avarietyoftherapyoptions\\n•Accessthepulsegenerator’sdiagnostic features\\n•Perform noninvasive diagnostic testing\\n•Accesstherapyhistorydata\\n•Storea12secondtraceoftheECG/EGM displayfromanyscreen\\n•AccessaninteractiveDemonstr ationModeorPatientDataModewithout thepresenceofapulsegenerator\\n•Printpatientdataincluding pulsegeneratortherapy options andtherapyhistorydata\\n•Savepatientdata\\nYoucanprogramthepulsegeneratorusingtwomethods: automatically usingIBPormanually .\\nFormoredetailed information aboutusingthePRMorZOOMWirelessTransmitter ,refertothePRMOperator’s\\nManualorZOOMWirelessTransmitt erReferenceGuide.\\nRefertothe3300Programming System’s familyofoperator’smanuals forspecificinformation aboutthe3300\\nProgrammer,itsPSA,patientdatamanagement, andnetworking andconnectivity .\\nSOFTWARE TERMINOLOGY ANDNAVIGATION\\nThissectionprovidesanoverview ofthePRMsystem.\\nMainScreen\\nThemainPRMscreenisshownbelow,followed byadescription ofthecomponents (Figure1–1MainScreenonpage\\n1-3).', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 11}), Document(page_content='UsingtheProgrammer\\nPRMModeIndicator1-3\\n1\\n2\\n3\\n4\\n5\\n6\\n7\\n8\\nxxxxxxxxx xxxxxxxxx\\nxxxxxx xxx\\nxxxxxxxxxxxxx\\nxxxx\\n[1]Patientname,[2]PRMModeIndicator ,[3]devicename,[4]Detailsbutton,[5]tabs,[6]toolbar,[7]devicemodel,[8]ECG/EGM display\\nFigure1–1.MainScreen\\nPRMModeIndicator\\nThePRMModeIndicator displays atthetopofthescreentoidentify thecurrentPRMoperationalmode.\\nPatient—indicates thatthePRMisdisplaying data\\nobtained bycommunicating withadevice.\\nPatientData—indicates thatthePRMisdisplaying\\nstoredpatientdata.\\nDemoMode—indicates thatthePRMisdisplaying\\nsampledataandoperatingindemonstratio nmode.\\nECG/EGM Display\\nTheWirelessECGfeatureisavailable inRESONATE HF,RESONATE, PERCIVA HF,PERCIVA, andMOMENTUM devices.\\nTheECGareaofthescreenshowsreal-time statusinformation aboutthepatientandthepulsegeneratorthatcanbe\\nusefulinevaluating systemperformanc e.Thefollowing typesoftracescanbeselected:\\n•SurfaceECGsaretransmittedfrombodysurfaceleadelectrodesthatareconnected tothePRM,andcanbe\\ndisplayed without interrogating thepulsegenerator.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 12}), Document(page_content='1-4 UsingtheProgrammer\\nECG/EGM Display\\n•Real-time EGMsaretransmitted fromthepace/sense orshocking electrodes, andareoftenusedtoevaluate lead\\nsystemintegrity andhelpidentify faultssuchasleadfractures, insulation breaks,ordislodgments.\\nReal-time EGMscanonlybedisplayed uponinterrogationofthepulsegenerator.Because theyrelyonZIPor\\nwanded telemetry ,theyaresusceptibletoradiofrequency interference.Significant interferencemaycausea\\nbreakordrop-outofreal-time EGMs(\"ZIPTelemetry Security\" onpage1-9).\\n•Atanytime,a12secondtraceoftheECG/EGM displaycanbestoredbypressingtheSnapshot buttonfromany\\nscreen.\\nNOTE:IfthePRMisleftidlefor15minutes (or28minutes ifthepulsegeneratorwasinStorageModeat\\ninterrogation) real-time EGMsareshutoff.ThePRMprovidesadialogboxallowing real-timeEGMstobe\\nrestored.\\nNOTE:Inthepresenceoftelemetr yinterference,thereal-time intracardiacEGMtracesandmarkers may\\nbecomemisaligned fromthereal-timesurfaceECGtraces.Whenthetelemetry linkhasimproved,re-selectanyof\\ntheintracardiac EGMtracestocausere-initialization.\\n•WirelessECGisaformofreal-timeEGMthatmimicsasurfaceECGbyusingashocking leadproximal coiltocan\\nvectorformeasuring heartactivity.UnlessthedeviceisstillinStorage mode,thefirst(top)traceonthedisplay\\nwilldefaulttoWireless ECG.\\nCAUTION: WirelessECGissusceptible toRFinterferenc e,andmayhaveanintermittent orlostsignal.If\\ninterfere nceispresent,especially duringdiagnostic testing, consider usingasurfaceECGinstead.\\nNOTE:WirelessECGsareonlyavailable withdual-coil shockleads.\\nYoucanselecttheDetailsbuttontoenlargetheECG/EGM screen.Thefollowing options areavailable:\\n•ShowDeviceMarkers—displays annotated eventmarkers,whichidentify certainintrinsic cardiacanddevice-\\nrelatedevents,andprovideinformation suchassensed/pac edevents,decision ofdetection criteria,andtherapy\\ndelivery\\n•EnableSurfaceFilter—minimizes noiseonthesurfaceECG\\n•DisplayPacingSpikes—sho wsdetected pacingspikes,annotated byamarkeronthesurfaceECGwaveform\\n•TraceSpeed—adjusts thespeedofthetrace(0,25,or50mm/s).Asthespeedisincreased,thetime/horizontal\\nscaleisexpanded\\n•Gain—adjusts theamplitude/vertical scale(AUTO,1,2,5,10,or20mm/mV) foreachchannel. Asthegainis\\nincreased,theamplitude ofthesignalisenlarged\\nYoucanprintreal-timeEGMs,whichincludeannotated eventmarkers, byperforming thefollowing steps:\\n1.PressoneoftheprintspeedkeysonthePRM(e.g.,speedkey25)tobeginprinting.\\n2.Pressthe0(zero)speedkeytostopprinting.\\n3.Pressthepaper-feedkeytofullyejectthelastprintedsheet.\\nYoucanprintdefinitions oftheannotated markersbypressing thecalibrationkeywhiletheEGMisprinting.\\nAlternatively youcanprintafullreportcontaining thedefinitions ofalloftheannotated markers byperforming the\\nfollowing steps:\\n1.Fromthetoolbar,clicktheReports button.TheReports window displays.\\n2.SelecttheMarkerLegendcheckbox.\\n3.ClickthePrintbutton.TheMarkerLegendReportissenttotheprinter.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 13}), Document(page_content='UsingtheProgrammer\\nToolbar1-5\\nToolbar\\nThetoolbarallowsyoutoperform thefollowing tasks:\\n•Selectsystemutilities\\n•Generatereports\\n•Interrogateandprogramthepulsegenerator\\n•Viewpending orprogrammed changes\\n•Viewattentions andwarnings\\n•EndyourPRMsession\\nTabs\\nTabsallowyoutoselectPRMtasks,suchasviewing summary dataorprogramming devicesettings. Selecting atab\\ndisplays theassociated screen.Manyscreenscontainadditional tabs,whichallowyoutoaccessmoredetailed\\nsettings andinformation.\\nButtons\\nButtons arelocatedonscreensanddialogsthroughout theapplication. Buttons allowyoutoperform varioustasks,\\nincluding:\\n•Obtaindetailed information\\n•Viewsettingdetails\\n•Setprogrammable values\\n•Loadinitialvalues\\nWhenabuttonselection opensawindow infrontoftheMainScreen,aClosebuttondisplays intheupper-right\\ncornerofthewindow toallowyoutoclosethewindow andreturntotheMainScreen.\\nIcons\\nIconsaregraphicelements that,whenselected, mayinitiateanactivity,displaylistsoroptions, orchangethe\\ninformation displayed.\\nDetails—opens awindow containing detailed\\ninformation.\\nPatient—opens awindow withpatientinformation\\ndetails.\\nLeads—opens awindow withdetailsonleads.\\nBattery—opens awindow withdetailsonthepulse\\ngeneratorbattery.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 14}), Document(page_content='1-6UsingtheProgrammer\\nIcons\\nCheck—indicates thatanoptionisselected.\\nEvent—indicates thataneventhasoccurred.Whenyou\\nviewtheTrendstimeline ontheEventstab,eventicons\\ndisplaywherevereventshaveoccurred.Selecting an\\neventsicondisplays detailsabouttheevent.\\nInformation—indicates information thatisprovidedfor\\nreference.\\nActionIcons\\nRun—causes theprogrammertoperform anaction.\\nHold—causes theprogrammertopauseanaction.\\nContinue—causes theprogrammertocontinue an\\naction.\\nSnapshot —causes theprogrammer tostorea12second\\ntraceoftheECG/EGM displayfromanyscreen.\\nSliderIcons\\nHorizontalSlider—indicates thatasliderobjectcanbe\\nclickedanddragged leftorright.\\nVerticalSlider—indicates thatasliderobjectcanbe\\nclickedanddragged upordown.\\nSortIcons\\nSortAscending—indicates thatAscendingsortis\\ncurrentlyselected onatablecolumnsortbutton.(e.g.,1,\\n2,3,4,5)\\nSortDescending—indicates thatDescendingsortis\\ncurrentlyselected onatablecolumnsortbutton.(e.g.,\\n5,4,3,2,1)\\nIncrement andDecrement Icons\\nIncrement—indicates thatanassociated valuecanbe\\nincremented.\\nDecrement—indicates thatanassociated valuecanbe\\ndecremented.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 15}), Document(page_content='UsingtheProgrammer\\nCommon Objects1-7\\nScrollIcons\\nScrollLeft—indicates thatanassociated itemcanbe\\nscrolledleft.\\nScrollRight—indicates thatanassociated itemcanbe\\nscrolledright.\\nScrollUp—indicates thatanassociated itemcanbe\\nscrolledup.\\nScrollDown—indicates thatanassociated itemcanbe\\nscrolleddown.\\nCommon Objects\\nCommon objectssuchasstatusbars,scrollbars,menus,anddialogsareusedthroughout theapplication. These\\noperatesimilarly totheobjectsfoundinwebbrowsersandothercomputer applications.\\nUseofColor\\nColorsandsymbols areusedtohighlight buttons, icons,andotherobjects, aswellascertaintypesofinformation.\\nTheuseofspecificcolorconventions andsymbols isintended toprovide amoreconsistent userexperience and\\nsimplify programming. Refertothetablebelowtounderstand howcolorsandsymbols areusedonthePRMscreens\\n(Table1–1PRMcolorconventions onpage1-7).\\nTable1–1.PRMcolorconventions\\nColor Meaning Examples Symbol\\nRed Indicates warning conditions Theselected parameter valueisnot\\nallowed; clicktheredwarning button\\ntoopentheParameter Interactions\\nscreen,whichprovides information\\naboutcorrectiveaction.\\nDeviceandpatientdiagnostic\\ninformation thatrequiresserious\\nconsideration.\\nYellow Indicates conditionsrequiring your\\nattentionTheselected parameter valueis\\nallowed, butnotrecommended; click\\ntheyellowattention buttontoopen\\ntheParameterInteractionsscreen,\\nwhichprovides information about\\ncorrectiveaction.\\nDeviceandpatientdiagnostic\\ninformation thatshouldbeaddressed.\\nGreen Indicates acceptable changes or\\nconditionsTheselected parameter valueis\\nallowed, butisstillpending.\\nThereisnodeviceorpatient\\ndiagnostic information requiring your\\nspecificattention.\\nWhite Indicates thevaluethatiscurrently\\nprogrammed', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 16}), Document(page_content='1-8UsingtheProgrammer\\nDemonstration Mode\\nDEMONSTRATION MODE\\nThePRMincludes aDemonstr ationModefeature,whichenables thePRMtobeusedasaself-teaching tool.When\\nselected, thismodeallowsyoutopracticePRMscreennavigation without interrogat ingapulsegenerator.Youcan\\nuseDemonstr ationModetofamiliarize yourself withmanyofthespecificscreensequenc esthatwilldisplaywhen\\ninterrogatingorprogramming aspecificpulsegenerator.YoucanalsouseDemonstration Modetoexamineavailable\\nfeatures, parameters, andinformation.\\nToaccessDemonstra tionMode,selecttheappropriat ePGfromtheSelectPGscreen,andthenselectDemofromthe\\nSelectPGModedialog.WhenthePRMisoperatinginDemonstr ationMode,thePRMModeIndicator displays the\\nDemoModeicon.Thepulsegeneratorcannotbeprogrammed whenthePRMisoperatinginDemonstr ationMode.\\nExittheDemonstration Modebeforeattempting tointerrogate orprogramthepulsegenerator.\\nCOMMUNICATING WITHTHEPULSEGENERATOR\\nThePRMcommunicates withthepulsegeneratorusingatelemetr ywand.\\nAfterinitiating communication withthewand,thePRMcanusewandless ZIPtelemetr y(two-way RFcommunication)\\ntointerface withRFcapable pulsegenerator models.\\nTelemetr yisrequired to:\\n•Directcommands fromthePRMsystem, suchas:\\n–INTERROGATE\\n–PROGRAM\\n–STATSHOCK\\n–STATPACE\\n–DIVERTTHERAPY\\n•Modifydeviceparametersettings\\n•Conduct EPtesting\\n•Conduct diagnostic testsincluding thefollowing:\\n–Pacingimpedance tests\\n–Pacingthreshold tests\\n–Intrinsic amplitude tests\\n•Perform manualcapacitor re-form\\nZIPTelemetry\\nZIPtelemetry operatesintheMICS(Medical Implant Communication Service) telemetry bandwithatransmit\\nfrequencyof402to405MHz(FCCID:ESCCRMG17912).\\nZIPtelemetry isawandless, two-way RFcommun icationoptionthatallowsthePRMsystemtocommun icatewith\\ntheseRFcapable pulsegenerators.\\n•RFcommunication isenabled bytheZOOMWireless Transmitt erunitconnecte dtothePRM.Wheninitiating\\ncommunication, wanded telemetry isneeded. WhenZIPtelemetry isreadyforuse,amessage willdisplayonthe', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 17}), Document(page_content='UsingtheProgrammer\\nStartingaWandedTelemetry Session1-9\\nPRMscreenindicating thatthewandcanberemoved.Otherwise,thesessionwillcontinuewithwanded\\ntelemetry .\\nZIPtelemetr yoffersthefollowing advantages overtradition alwanded telemetry:\\n•Thefasterdatatransmission speedmeanslesstimeisrequired fordeviceinterrogation\\n•Datatransmission overalongerdistance(within3m[10ft])minimizes theneedtokeepthewandinthesterile\\nfieldduringimplant, whichmayreducetheriskofinfection\\n•Continuous telemetr yispossible duringtheentireimplant procedure,allowing monitoring ofpulsegenerator\\nperformanc eandleadintegrity duringimplant\\n•Allowsthephysician tocontinue withtheoperatingprocedurewhilethedeviceisbeingprogrammed forthe\\npatient\\nRegardlessofwhether ZIPtelemetr yisbeingused,wanded communication isstillavailable.\\nStartingaWandedTelemetry Session\\nFollowthisproceduretobeginawanded telemetr ycommunication session:\\n1.Makesurethetelemetry wandisconnected tothePRMsystemandisavailable throughout thesession.\\n2.Position thewandoverthepulsegeneratoratadistancenotgreaterthan6cm(2.4inches).\\n3.UsethePRMtoInterrogatethepulsegenerator.\\n4.Retainthewandposition whenever communication isrequired.\\nStartingaZIPTelemetrySession\\nFollowthisproceduretobeginaZIPtelemetry communication session:\\n1.VerifythattheZOOMWirelessTransmitter isconnecte dtothePRMviatheUSBcableandthatthegreenlighton\\ntopofthetransmitter isilluminated (indicating thetransmitter isreadyforuse).\\n2.Startawanded telemetry session. Verifythatthewandcordiswithinreachofthepulsegeneratortoenablethe\\nuseofwanded telemetr yshoulditbecomenecessary.\\n3.Keepthetelemetr ywandinposition untileitheramessage appears, indicating thatthetelemetry wandmaybe\\nremoved fromproximityofthepulsegenerator,ortheZIPtelemetry lightilluminates onthePRMsystem.\\nEndingaTelemetry Session\\nSelecttheEndSession buttontoquitatelemetr ysessionandreturntothestartupscreen.Youcanchoosetoendthe\\nsessionorreturntothecurrentsession. Uponendingasession, thePRMsystemterminates allcommunication with\\nthepulsegenerator.\\nZIPTelemetry Security\\nThepulsegeneratorcontainsacompliant low-power transceiver.Thepulsegeneratorcanonlybeinterrogatedor\\nprogrammed byRFsignalsthatemploytheproprietary ZIPtelemetr yprotocol.Thepulsegenerator verifiesthatitis\\ncommunicating withaZOOMVIEW systembeforerespondingtoanyRFsignals. Thepulsegeneratorstores,transmits,\\nandreceivesindividually identifiable healthinformation inanencrypted format.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 18}), Document(page_content='1-10UsingtheProgrammer\\nZIPTelemetry Security\\nZIPtelemetry ispossible whenallofthefollowing condition saremet:\\n•ZIPtelemetry forthePRMisenabled\\n•TheZOOMWireless Transmitt erisconnected tothePRMviatheUSBcable\\n•Theindicator lightontopoftheZOOMWirelessTransmitterisgreen;indicating thetransmitter isreadyforuse\\n•ThepulsegeneratoriswithinrangeofthePRMsystem\\n•ThepulsegeneratorhasnotreachedExplant; notethatatotalof1.5hoursofZIPtelemetr ywillbeavailable after\\nthepulsegeneratorreaches Explant\\n•Thepulsegeneratorbatterycapacity isnotdepleted\\n•PulsegeneratorisnotinMRIProtectionMode\\nInordertomeetlocalcommunications rulesandregulations, ZIPtelemetry shouldnotbeusedwhenthepulse\\ngeneratorisoutsideitsnormaloperating temperatureof20°C–45°C (68°F–113°F).\\nCommunication canbesupported between multiple PRMsandpulsegeneratorsatatime,asindependent sessions.\\nSignalsfromothersessions usingRFcommunication orinterferencefromotherRFsourcesmayinterferewithor\\npreventZIPtelemetry communication.\\nCAUTION: RFsignalsfromdevicesthatoperateatfrequencies nearthatofthepulsegenerator mayinterrupt ZIP\\ntelemetry whileinterrogating orprogramming thepulsegenerator.ThisRFinterferencecanbereducedbyincreasing\\nthedistance between theinterfering deviceandthePRMandpulsegenerator .\\nRadiofrequencyinterferencemaytemporarilydisruptZIPtelemetry communication. ThePRMwillnormally\\nreestablish ZIPcommunication whentheRFinterferenc eendsorsubsides. Because continued RFinterferencemay\\npreventZIPtelemetry communication, thesystemisdesigned tousewanded telemetr ywhenZIPtelemetr yisnot\\navailable.\\nIfZIPtelemetr yisnotavailable duetointerferenc eoriftheZOOMWirelessTransmitterisunplugged ornot\\nfunctioning properly,wanded telemetry communication withthePRMcanbeestablished. Thesystemprovides the\\nfollowing feedback toindicate thatZIPtelemetr yisnotavailable:\\n•TheZIPtelemetry indicator lightonthePRMturnsoff\\n•Thegreenindicator lightontheZOOMWirelessTransmitterisoff\\n•Ifeventmarkersand/orEGMsareactivated, transmission oftheeventmarkersand/orEGMswillbeinterrupted\\n•Ifacommand orotheractionhasbeenrequested, thePRMdisplays anotification indicating thewandshouldbe\\nplacedinrangeofthepulsegenerator\\nZIPtelemetry operatesconsistently withwanded telemetry—no programming stepcanbecompleted unlesstheentire\\nprogramming command hasbeenreceivedandconfirmed bythepulsegenerator .\\nThepulsegenerator cannotbemisprogr ammed asaresultofinterrupted ZIPtelemetr y.Interruptions ofZIPtelemetry\\nmaybecausedbyRFsignalsthatoperate atfrequencies nearthatofthepulsegeneratorandarestrongenough to\\ncompetewiththeZIPtelemetr ylinkbetween thepulsegeneratorandthePRM.Significant interferencemayresultin\\nabreakordrop-outs ofreal-timeEGMs.Ifcommands areinterrupted, thePRMdisplays amessage toplacethewand\\nonthepulsegenerator.Repeated displays ofthismessage mayindicate thepresenceofintermittent interfere nce.\\nThesesituations canberesolved byrepositioning theZOOMWireless Transmitter attached tothePRMorbyusing\\nstandardwanded telemetry .Therewillbenointerruption ofdevicefunctionality ortherapyduringthisperiod.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 19}), Document(page_content=\"UsingtheProgrammer\\nZIPTelemetry Security1-11\\nNOTE:WhenbothZIPandwanded telemetr yarebeingused(forexample,switching fromZIPtowanded because\\nofthepresenceofinterference),thepulsegenerator willcommunicate withtheprogrammer byZIPtelemetr ywhen\\npossible. Ifwanded telemetr yonlyisdesired,settheCommunication Mode(accessedviatheUtilitiesbutton)touse\\nthewandforalltelemetr y.\\nNOTE:Toconservebatterylongevity ,aZIPtelemetr ysessionwillbeterminated ifthepulsegenerator completely\\nlosescommunication withthePRMforacontinuous periodofonehour(or73minutes ifthedevicewasinStorage\\nModeatinterrogatio n).Wanded telemetry mustbeusedtore-establish communication withthepulsegeneratorafter\\nthisperiodhaselapsed.\\nConsiderations forReducing Interference\\nIncreasingthedistance fromthesourceofinterfering signalsmayenabletheuseoftheZIPtelemetry channel.\\nRepositioning theZOOMWirelessTransmittermayimprove ZIPtelemetr yperformanc e.IfZIPtelemetry performanc e\\nisnotsatisfactory ,theoptionofusingwanded telemetry isavailable.\\nDepending ontheenvironment andPRMorientation relativetothepulsegenerator ,thesystemiscapable of\\nmaintaining ZIPtelemetry commun icationatdistances upto3m(10ft).Foroptimum ZIPtelemetr ycommunication,\\nposition theZOOMWirelessTransmitter within3m(10ft)ofthepulsegeneratorandremoveanyobstruction\\nbetween theZOOMWirelessTransmitterandthepulsegenerator .\\nPositioning theZOOMWirelessTransmitteratleast1m(3ft)awayfromwallsormetalobjectsandensuring thepulse\\ngenerator(priortoimplant) isnotindirectcontactwithanymetalobjectsmayreducesignalreflection and/orsignal\\nblocking.\\nAvoidplacingtheZOOMWireless Transmitter incloseproximitytomonitors, high-frequency electrosur gical\\nequipment, orstrongmagnetic fieldssincethetelemetr ylinkmaybeimpaired .\\nEnsuring therearenoobstructions (e.g.,equipment, metalfurniture,people, orwalls)between theZOOMWireless\\nTransmitter andpulsegeneratormayimprovesignalquality.Personnel orobjectsthatmomentarily movebetween\\ntheZOOMWireless Transmitt erandpulsegenerator duringZIPtelemetr ymaytemporarilyinterrupt commun ication,\\nbutwillnotaffectdevicefunctionality ortherapy.\\nChecking thetimerequired tocomplete aninterrogatio nafterZIPtelemetry isestablished canprovideanindication\\nofwhether interferenceispresent.Ifaninterrogation usingZIPtelemetr ytakeslessthan20seconds,thecurrent\\nenvironment islikelyfreeofinterference.Interroga tiontimeslongerthan20seconds(orshortintervalsofEGMdrop-\\nouts)indicate thatinterfere ncemaybepresent.\\nINDICATIONS-BASED PROGRAMMING (IBP)\\nIBPisatoolthatprovides specificprogramming recommendations basedonthepatient’s clinicalneedsandprimary\\nindications.\\nIBPisaclinicalapproachtoprogramming thatwasdeveloped basedonphysician consultation andcasestudies. The\\nintentofIBPistoenhance patientoutcomes andsavetimebyprovidingbaseprogramming recommendations that\\nyoucancustomize asneeded. IBPsystematically presentsthespecificfeaturesintended forusewiththeclinical\\nconditions youidentify intheIBPuserinterface, andallowsyoutotakemaximum advantage ofthepulsegenerator's\\ncapabilities.\\nIBPcanbeaccessedfromtheSettings tabonthemainapplication screen(Figure1–2Indications-based Programming\\nscreenonpage1-12).\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 20}), Document(page_content='1-12UsingtheProgrammer\\nZIPTelemetry Security\\nFigure1–2.Indications-based Programming screen\\nIndications areclustered ingeneralcategories asillustratedabove.Theintentforeachcategoryofindications is\\ndescribed below:\\n•SinusNode\\n–IfNormalisselected, theintentistoallowintrinsic atrialeventsandprovideRVpacingwhennecessary.\\n–IfChronotropically Incompetent isselected, theintentistoproviderate-adaptive pacing.\\n–IfSickSinusSyndromeisselected, theintentistoprovide atrialpacingsupport.\\n•AVNode\\n–IfNormalor1stDegreeBlockisselected, theintentistoallowintrinsic AVconduction andprovideRVpacing\\nwhennecessary .\\n–If2ndDegreeBlockisselected, theintentistoallowintrinsic AVconduction andprovideAVsequential\\npacingwhenconduction isnotpresent.\\n–IfComplete HeartBlockisselected, theintentistoprovideAVsequential pacing.\\nNOTE:Theselected settings forAFandSinusNodemayaffectthesuggested valuefortheNormal/1st Degree\\nBlocksettingofAVNode.\\n•AtrialArrhythmias\\n–IfParoxysmal/P ersistent isselected, theintentistoavoidtracking atrialarrhythmias byusingATRMode\\nSwitchwhenadual-chamber pacingmodeissuggested.\\n–IfPermanent/Chr onicAFisselected, theintentistoproviderate-adaptive RVpacing.\\n•Ventricular Arrhythmias\\n–WhenHistoryofVF/SCDisselected, a2-zoneconfiguration withthefollowing ratethresholds andtherapies\\nisprovided:\\n–180bpmfortheVFzonewithQUICKCONVERT ATPandallshocksenabled andsettoMaximum Energy\\n–160bpmfortheVTzonewiththerapy disabled (Monitor Only)\\n–WhenProphylaxis forVT/VFisselected, a2-zoneconfiguration withthefollowing ratethresholds and\\ntherapies isprovided:', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 21}), Document(page_content='UsingtheProgrammer\\nManualProgramming1-13\\n–200bpmfortheVFzonewithQUICKCONVERT ATPandallshocksenabled andsettoMaximum Energy\\n–170bpmfortheVTzonewiththerapydisabled (Monitor Only)\\n–WhenHistoryofVT/VFisselected, a2-zoneconfiguration withthefollowing ratethresholds andtherapiesis\\nprovided:\\n–200bpmfortheVFzonewithQUICKCONVERT ATPandallshocksenabled andsettoMaximum Energy\\n–160bpmfortheVTzonewithATPandallshocksenabled andsettoMaximum Energy\\n–Rhythm IDenabled\\n–WhenVFOnlyisselected, theintentistoprovideasingleVFzoneof220bpmwithonlyshocksenabled and\\nsettomaximum energy.\\nAfterchoosing appropriat epatientindications, selecttheViewRecommended Settings buttontoviewasummary of\\ntheprogramming recommen dations(Figure1–3ProposedSettings Summary screenonpage1-13).\\nNOTE:Youmustviewtherecommended settings beforeyoucanprogramthem.Selecting theViewRecommen ded\\nSettings buttonallowsyoutoviewthesettings thatarerecommended basedontheindications thatyouselected.\\nViewing therecommended settings doesnotoverwrite anypending (i.e.,notyetprogrammed) parameter changes.\\nYoumustchoosetoprogramorrejecttherecommended settings afterviewing them.Ifyouchoosetorejectthe\\nrecommen dedsettings, allofyourpending settings willberestored.Ifyouchoosetoprogramtherecommended\\nsettings, anypending parameterchanges willbeoverwritten.\\nFigure1–3.ProposedSettingsSummary screen\\nTheProposed Settings Summar yscreendisplays theprimary programming recommendations. Additional details\\naboutallchanged paramet ersareavailable byselecting theViewChanges buttonfromthetoolbar.Youhavethe\\noptiontoprogramtheproposed settings orrejectthem,aslongastelemetry isstillengaged:\\n•Program—select theProgramthisProfilebuttontoaccepttheproposedsettings.\\n•Reject—select theRejectthisProfilebuttontorejecttheproposedsettings; thisactionwillreturnyoutothemain\\nIBPscreenwithnochanges made.\\nMANUAL PROGRAMMING\\nManualprogramming controlssuchasslidersandmenusareavailable toallowyoutoindividually adjustpulse\\ngeneratorprogramsettings.\\nManualprogramming controlsarelocatedontheSettings Summary tab,whichcanbeaccessedfromtheSettings tab\\norbyselecting theSettings Summary buttonontheSummary tab.Refertootherfeaturedescriptions inthismanual', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 22}), Document(page_content='1-14 UsingtheProgrammer\\nDIVERTTHERAPY\\nforspecificmanualprogramming information andinstructions. Referto\"Programmable Options\" onpageA-1for\\ndetailed listingsofavailable settings.\\nDIVERTTHERAPY\\nWhenthepulsegeneratorischarging todeliverashock,theshockdelivery maybediverted fromthepatient. If\\ndiverted, theshockdoesnotcountasoneofthetotalnumber ofshocksthatmaybedeliveredduringanepisode. If\\nredetection occursandmoreshocktherapyisrequired,andifmoreshocksareavailable inthetherapyprescription,\\nthepulsegeneratorwillchargeagaintodeliversubsequent shocks.\\nAlso,theDIVERTTHERAPY keycanbepressedtodivertATPtherapyinmidburst. Ifredetection occurs,theATP\\nscheme willnotbeusedagainandthenextprogrammed therapyinthesequence willbeinitiated.\\n1.Ifyouarenotalreadyinasession, position thetelemetry wandwithinrangeofthepulsegenerator andstarta\\ncommunication session.\\n2.PresstheDIVERTTHERAPY key.Amessage window willappearindicating thatadivertattempt isbeingmade.\\n3.Ifusingwanded telemetry ,maintain thewandposition untilthemessage window disappears, indicating the\\nshockhasbeendiverted. Prematur elyremoving thewand(breakingthetelemetr ylink)mayallowthepulse\\ngenerator tocontinuechargingandtodelivertheshock.\\nNOTE:Thereisa500msdelaybetween theendofchargingandshockdelivery designed toprovide aminimum\\nperiodfortheDIVERTTHERAPY command. Afterthistime,pressingDIVERTTHERAPY maynotdiverttheshock.\\nTheDIVERTTHERAPY keycanbeusedtoterminate anydiagnostic testinprogress,aswellasElectrocautery\\nProtectionMode(ifusingwanded telemetr y,maintain thetelemetr ywandposition untilthedivertfunction is\\ncompletetoavoidinterruption tothedivertcommand).\\nTheDIVERTTHERAPY keycanalsobeusedtoterminate MRIProtection Mode.\\nSTATSHOCK\\nAnonprogrammable, maximum-output STATSHOCKcanbedelivered tothepatientatanytimeduringa\\ncommun icationsession. TheSTATSHOCKcanbedeliveredwhenthepulsegenerator’sTachyModeisprogrammed to\\nanymode.Thisfunction doesnotaffecttheprogrammed shocksequenc es(lower-energyshockscanbedelivered\\nfollowing aSTATSHOCK)anddoesnotcountasoneofthetotalnumber ofshocksinatherapysequenc eforagiven\\nepisode. TheoutputoftheSTATSHOCKisatthemaximum-output energyandattheprogrammed polarity and\\nwaveform; STATSHOCKisalwayscommitte dregardless ofprogrammed paramet ers.\\n1.Ifyouarenotalreadyinasession, position thetelemetry wandwithinrangeofthepulsegenerator .\\n2.PresstheSTATSHOCKkey.Amessage window appears withinformation abouttheshockandinstructions to\\ninitiatetheshock.\\n3.Toinitiatetheshock,presstheSTATSHOCKkeyagain.Adifferentmessage window appears indicating thatSTAT\\nSHOCKisinprocess.Whentheshockhasbeendelivered,themessage window disappears.\\n4.Subsequent high-energ ySTATSHOCKS maybedeliveredbyrepeatingtheprevioussteps.\\nNOTE:TheSTATSHOCKmaybediverted usingtheDIVERTTHERAPY key.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 23}), Document(page_content='UsingtheProgrammer\\nSTATPACE1-15\\nNOTE:Following STATSHOCKdelivery,iftheTachyModeisprogrammed toMonitor OnlyorMonitor +Therapy,\\npost-shockredetectionisinitiated (initialdetection criteriaandenhancements arenotused).IftheTachyModeis\\nprogrammed toMonitor +Therapyandredetection determines thatfurthertherapyisrequired, theprogrammed\\nsequenc eoftherapywillberesumed orinitiated, including ATPand/orlow-energy shocks.\\nNOTE:STATSHOCKwillterminate ElectrocauteryProtection ModeandMRIProtectionMode.\\nSTATPACE\\nEmergencybradycardiapacingusingtheSTATPACEcommand setsthebradycar diaoperationtoparametersintended\\ntoensurecapture.\\n1.Ifyouarenotalreadyinasession, position thetelemetr ywandwithinrangeofthepulsegenerator.\\n2.PresstheSTATPACEkey.Amessage window displays theSTATPACEvalues.\\n3.PresstheSTATPACEkeyasecondtime.Amessage indicates thatSTATPACEisbeingperformed, followed by\\ntheSTATPACEvalues.\\n4.SelecttheClosebuttononthemessage window.\\n5.TostopSTATPACE,reprogramthepulsegenerator.\\nNOTE:STATPACEwillterminate Electrocautery ProtectionModeandMRIProtectionMode.\\nCAUTION: Whenapulsegeneratorisprogrammed toSTATPACEsettings, itwillcontinuetopaceatthehigh-\\nenergySTATPACEvaluesifitisnotreprogrammed. TheuseofSTATPACEparameterswilllikelydecreasedevice\\nlongevity .\\nTheSTATPACEparametervaluesarelistedbelow(Table1–2STATPACEParameter Valuesonpage1-15).\\nTable1–2.STATPACEParameter Values\\nParameter Values\\nMode VVI\\nLowerRateLimit 60ppm\\nInterval 1000ms\\nAmplitude 7.5V\\nPulseWidth 1.0ms\\nPacedRefractory 250ms\\nPost-shockPacing VVI\\nDATAMANAGEMENT\\nThePRMsystemallowsyoutoview,print,store,orretrievepatientandpulsegenerator data.Thissectiondescribes\\nthePRMdatamanagement capabilities.\\nPatientInformation\\nInformation aboutthepatientcanbestoredinpulsegeneratormemory .Theinformation isaccessible fromthe\\nSummary screenbyselecting thePatienticon.Thisinformation includes, butisnotlimitedto,thefollowing:', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 24}), Document(page_content=\"1-16UsingtheProgrammer\\nDataStorage\\n•Patientandphysician data\\n•Pulsegeneratorserialnumber\\n•Implant date\\n•Leadconfigurations\\n•Implant testmeasurements\\nTheinformation canberetrieved atanytimebyinterrogating thepulsegenerator andviewing itonthePRMscreen\\norprinting itasareport.\\nNOTE:Ifthedataforpatientdateofbirth,gender,orfitnesslevelarechanged withinPatientInformation, the\\ncorresponding valueinMinuteVentilation willautomatically change. Likewise,ifthedataforfitnesslevelischanged\\nwithinMinuteVentilation, thecorresponding valueinPatientInformation willautomatically change.\\nNOTE:Thedataentered forpatientSleepSchedule isusedfortheSleepInclinetrend.\\nDataStorage\\nThePRMsystemallowsyoutosavepulsegeneratordatatothePRMharddriveoraremovable floppydatadisk.Data\\nsavedtothePRMcanalsobetransferred toaremovabl eUSBpendrive.\\nSavedpulsegenerator dataincludes, butisnotlimitedto,thefollowing:\\n•Therapyhistory\\n•Programmed parametervalues\\n•Trending values\\n•HRV\\n•Histogram paced/sen sedcounters\\nSelecttheUtilitiesbutton,andthenselecttheDataStorage tabtoaccessthefollowing options:\\n•ReadDisk—allows youtoretrievesavedpulsegeneratordatafromafloppydisk.\\n•SaveAll—allows youtosavepulsegenerator datatoeitherafloppydisk(diskmustbeinserted) orthePRMhard\\ndrive(ifnofloppydiskisdetected). DatasavedtoafloppydiskcanberetrievedusingtheReadDiskoption\\ndescribed above.DatasavedtothePRMcanberead,deleted, orexported toaUSBpendrivefromthePRM\\nstartupscreen.Reports areavailable inPDFformat.RefertothePRMOperator's Manualformoreinformation.\\nNOTE:Whilethedataisbeingsaved,amessage ontheright-handsideoftheSystemStatusscreenindicates\\nwherethedataisbeingsaved.\\nConsider thefollowing whenstoringandretrieving pulsegeneratordata:\\n•Nomorethan400uniquepatientrecordsmaybesavedtothePRM.Whenapulsegenerator isinterrogated, the\\nPRMevaluates ifthereisalreadyarecordonfileforthispulsegenerator,orifanewrecordwillneedtobe\\ncreated.Ifanewrecordisneeded, andthePRMisatthe400recordcapacity,theoldestrecordonfilewillbe\\ndeleted tocreatespaceforthenewpatientrecord.\\n•Whenperforming multiple patientcheckups, besuretostartanewsessionforeachpatient.\\n•BesuretosaveallpulsegeneratordatatoeitherafloppydiskorUSBpendrivebeforereturningaPRMtoBoston\\nScientific, asallpatientandpulsegeneratordatawillbeerasedfromthePRMwhenitisreturned.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 25}), Document(page_content='UsingtheProgrammer\\nDeviceMemory1-17\\n•Toprotectpatientprivacy,pulsegeneratordatacanbeencryptedbeforeitistransferr edtoaUSBpendrive.\\nDeviceMemory\\nTheDeviceMemory utilityallowsyoutoretrieve, save,andprintpulsegeneratormemory data,whichisintended for\\nusebyaBostonScientific representative forclinicalandtroubleshooting purposes. Thisutilityshouldonlybeused\\nwhendirected byaBostonScientific representative. Digitalmediawithdevicememory datacontainsprotectedhealth\\ninformation andthereforeshouldbehandled inaccordancewithapplicable privacyandsecurity policiesand\\nregulations.\\nNOTE:UsetheDataStoragetabtoaccesspulsegenerator dataforclinician use(\"DataStorage\"onpage1-16).\\nPrint\\nYoucanprintPRMreportsbyusingtheinternal printer,orbyconnectingtoanexternalprinter.Toprintareport,\\nselecttheReports button.Thenselectthereportyouwishtoprintfromthefollowing categories:\\n•Follow-up reports\\n•Episode reports\\n•Otherreports(includes devicesettings, patientdata,andotherinformation)\\nSAFETYMODE\\nThepulsegeneratorisequipped withdedicated SafetyCorehardwarethatisintended toprovidelife-sustaining\\ntherapyifcertainnonrecoverable orrepeatfaultcondition soccurandcauseasystemreset.Thesetypesoffaults\\nindicate alossofcomponent integrity inthepulsegenerator\\'s centralprocessingunit(CPU),including the\\nmicroprocessor,programcode,andsystemmemory .Usingminimal hardware(i.e.,unipolar leadconfiguration), Safety\\nCoreoperatesindependently andactsasabackuptothesecomponents.\\nSafetyCorealsomonitors thedeviceduringnormalpacing;ifnormalpacingdoesnotoccur,SafetyCoredelivers an\\nescapepace,andasystemresetisinitiated.\\nIfthepulsegeneratorexperienc esthreeresetswithinapproximately 48hours,thedevicerevertstoSafetyModeand\\ndevicereplacement shouldbeconsidered. Thefollowing willalsooccur:\\n•Thepulsegeneratorwillbeep16timesevery6hours.Thisbeeping isdisabled oncethedevicehasbeen\\ninterrogatedwithaPRM.\\nWARNING: Determine thebeepertypebeforeanMRIscan.TheArmature Beepermaynolongerbeusable\\nfollowing anMRIscan.Coming incontactwiththestrongmagnetic fieldofanMRIscanner maycauseapermanent\\nlossoftheArmatureBeepervolume. Thiscannotberecovered,evenafterleavingtheMRIscanenvironment and\\nexitingMRIProtection Mode.FortheArmatureBeeper,beforeanMRIscanisperformed, aphysician andpatient\\nshouldweighthebenefitoftheMRIscanagainsttheriskoflosingtheBeeper; aftertheMRIscan,perform Beeper\\nevaluation testtodetermine iftheBeeperisusable.IftheBeeperisnotusable,itisstronglyrecommended that\\npatients arefollowed onLATITUDE NXTafteranMRIscaniftheyarenotalready.Otherwise, anin-clinic follow-up\\nschedule ofeverythreemonths isstronglyrecommended tomonitor deviceperformance.\\nNOTE:Forinstructions onhowtodetermine thebeepertype,referencethe“Determine BeeperType”subsection of\\n\"Beeper Feature\" onpage6-18.Forinstructions onperforming theBeeperevaluation test,see\"Beeper Feature\" on\\npage6-18.\\n•ZIPtelemetr yisunavailable forcommunicating withthePRMwhenSafetyModeisactive;wanded telemetry\\nmustbeusedinstead.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 26}), Document(page_content='1-18UsingtheProgrammer\\nBackupPacemaker\\n•LATITUDE NXTwillalertthatSafetyModehasbeenactivated.\\n•Uponinterrogation, awarning screenisdisplayed indicating thatthepulsegeneratorisinSafetyMode,and\\ndirectingyoutocontactBostonScientific.\\nBackupPacemaker\\nSafetyModeprovides ventricular pacing,withthefollowing fixedparameters:\\n•BradyMode—VVI\\n•LRL—72.5 ppm\\n•PulseAmplitude—5.0 V\\n•PulseWidth—1.0 ms\\n•RVRefractoryPeriod(RVRP)—250 ms\\n•RVSensitivity—AGC 0.25mV\\n•RVleadconfiguration—Unipolar\\n•NoiseResponse—VOO\\n•Post-ShockPacingDelay—3 sec\\nWARNING: Intherareeventthatnon-recoverable orrepeatfaultconditions occurwhilethedeviceisprogrammed\\ninMRIProtection Mode,thesubsequent devicebehavior willbedetermined bytheMRIProtection BradyMode\\nsetting.\\n•IfMRIBradyModeissettoOff,thedevicewillenterSafetyMode(permanent VVIunipolar pacingandtachycard ia\\ntherapyenabled).\\n•IfMRIBradyModeissettoasynchron ouspacing(AOO,VOO,DOO),bothbradycardiatherapyandtachycard ia\\ntherapywillbepermanently disabled.\\nBackupDefibrillator\\nWhenSafetyModeisactivated, TachyModeisautomatically programmed toMonitor +Therapy toprovide single-\\nzonetachyarrhythmia detection andtherapy.TachyModemaystillbeprogrammed toOffwhileinSafetyMode.\\nNOTE:Ifadditional faultsaredetected whileinSafetyMode,tachyarrhythmia therapywillbedisabled.\\nWhileinSafetyMode,thetachyarrhythmia therapyislimitedto5maximum-energy committe dshocksperepisode.\\nTachyarrhythmia detection andtherapyparamet ersarefixedasfollows:\\n•VFRateThreshold—165 ppm\\n•Duration—1 sec\\n•Shockpolarity—initial\\n•Shockwaveform—biphasic\\n•ShockVector—V-TRIAD\\nMagnet application willimmediately inhibittherapy,although chargingmaycontinue.Afterthemagnet hasbeen\\nappliedfor1second,therapy isdiverted anddetection isinhibited. Themagnet mustthenberemovedfor2seconds', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 27}), Document(page_content='UsingtheProgrammer\\nBackupDefibrillator1-19\\ninordertoallowdetection tocontinue.Also,SafetyModedisables normalbeeping behavior following magnet\\napplication.\\nWARNING: Intherareeventthatnon-recoverable orrepeatfaultconditions occurwhilethedeviceisprogrammed\\ninMRIProtectionMode,thesubsequent devicebehavior willbedetermined bytheMRIProtectionBradyMode\\nsetting.\\n•IfMRIBradyModeissettoOff,thedevicewillenterSafetyMode(permanent VVIunipolar pacingandtachycardia\\ntherapyenabled).\\n•IfMRIBradyModeissettoasynchronouspacing(AOO,VOO,DOO),bothbradycar diatherapyandtachycard ia\\ntherapywillbepermanently disabled.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 28}), Document(page_content='1-20UsingtheProgrammer\\nBackupDefibrillator', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 29}), Document(page_content='2-1\\nTACHYARRHYTHMIA DETECTION\\nCHAPTER 2\\nThischaptercontainsthefollowing topics:\\n•“DeviceMode”onpage2-2\\n•“RateSensing” onpage2-4\\n•“Ventricular Detection” onpage2-6', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 30}), Document(page_content='2-2Tachyarrhythmia Detection\\nDeviceMode\\nDEVICEMODE\\nTheDeviceModeallowsyoutoprogramthedevicetoprovide thetypeoftherapyanddetection desired.\\nVentricular TachyMode\\nTheVentricular TachyModecontrolstheavailability ofthedetection andtherapy functions intheventricle (Table2–1\\nDevicefeatureavailability intheVentricular TachyModesettings onpage2-2).\\nYoucanprogramtheVentricular TachyModetothefollowing modes:\\n•Off––disables ventricular tachyarrhythmia detection andautomatic ventricular therapy delivery.Thismodeis\\nusefulduringimplant orexplant,whenconnectingtheleadstoordisconnecting themfromthepulsegenerator.\\n•Monitor Only––enables ventricular tachyarrhythmia detection andepisode storage,butdoesnotautomatically\\ndelivertherapy tothepatient. Thismodeisusefulincontrolledenvironments, suchasduringEPtesting, exercise\\ntesting, andimmediately postoper ative,wherealternate therapy (e.g.,externaldefibrillation) isavailable.\\n•Monitor +Therapy––enables thefullrangeofventricular detection andventricular therapyoptions.\\nTable2–1.Devicefeatureavailability intheVentricular TachyModesettings\\nDevicefeatures Ventricular TachyMode\\nOff MonitorOnly Monitor+Therapy\\nRatesensing XaX X\\nBradycardia pacing X X X\\nVentricular Detection/Therapy History XbX X\\nSTATSHOCK X X X\\nSTATPACE X X X\\nReal-time annotated EGMs X X X\\nVentricular tachyarrhythmia detection X X\\nCommanded Ventricular ATP X Xc\\nCommanded Ventricular Shock X X\\nVentricular EPTest XdXd\\nAutomatic ventricular tachyarrhythmia therapy X\\na.Inordertoenableventricular sensing whentheVentricular TachyModeisprogrammed toOff,youmustprogramtheBradyModetoamodewithventricular sensing.\\nb.Whileprogrammed toOffMode,thepulsegenerator willstoreonlySTATSHOCKinhistory.\\nc.WhentheVentricular TachyModeisMonitor +Therapy,theEPTempVModemustbeprogramm edtoMonitor OnlyinordertousetheCommanded Ventricular ATP.\\nd.NotallformsofEPTestsareavailable inthismode.\\nElectrocauteryProtectionMode\\nElectrocauteryProtection Modeprovidesasynchron ouspacingattheprogrammed outputs andLRL.Tachyarrhythmia\\ndetection andtherapyfeaturesaredeactivated.\\nWhenElectrocauteryProtectionisenabled, theBradyModeswitches toanXOOmode(whereXisdetermined bythe\\nprogrammed BradyMode).Otherpacingparamet ersremainattheprogrammed settings (including pacingoutput). If\\nBradyModeisOffpriortoenabling ElectrocauteryProtection, itwillremainOffduringElectrocautery Protection.Once\\nenabled, Electrocautery Protectiondoesnotrequireconstant telemetry toremainactive.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 31}), Document(page_content='Tachyarrhythmia Detection\\nDeviceMode2-3\\nAftercancelling Electrocaute ryProtection,thefollowing modeswillreverttothepreviously programmed settings:\\n•Ventricular TachyMode\\n•BradyMode\\nAfterattempting toenableElectrocautery ProtectionMode,refertothemessage onthePRMscreenconfirmingthat\\nElectrocautery Protectionisactive.\\nExceptforSTATSHOCKandSTATPACE,nocommanded therapies,inductions, diagnostic tests,orprinting ofreports\\nwillbeallowed whileElectrocauteryProtection isenabled.\\nApplication ofamagnet whilethedeviceisinElectrocautery ProtectionhasnoeffectonTachyMode.\\nToenableanddisableElectrocautery Protection Mode,perform thefollowing steps:\\n1.SelecttheTachyModebuttonfromthetopofthePRMscreen.\\n2.SelectthecheckboxtoEnableElectrocautery Protection.\\n3.SelecttheApplyChanges buttontoenableElectrocautery ProtectionMode.Adialogwindow willappear,\\nindicating thatElectrocautery Protectionisactive.\\n4.SelecttheCancelElectrocautery Protectionbuttononthedialogwindow toreturnthedevicetothepreviously\\nprogrammed mode.Electrocaute ryProtectioncanalsobecancelledbyselecting STATSHOCK,STATPACE,or\\nDIVERTTHERAPY onthePRM.\\nMRIProtectionMode\\nThisfeatureisavailable inRESONATE HF,RESONATE, PERCIVA HF,PERCIVA, VIGILANT, andMOMENTUM devices.\\nForacomplete description ofMRIProtection Mode,alistofMRConditional devices,andadditional information about\\ntheImageReady MRConditional Defibrillation System,refertotheImageReady MRConditional Defibrillation System\\nMRITechnical Guide.\\nWARNING: RESONATE HF,RESONATE, PERCIVA HF,PERCIVA, VIGILANT andMOMENTUM devicesareconsidered MR\\nConditional. Forthesedevices, unlessalloftheMRIConditions ofUsearemet,MRIscanning ofthepatientdoesnot\\nmeetMRConditional requirements fortheimplanted system. Significant harmtoordeathofthepatientand/or\\ndamage totheimplanted systemmayresult.Donotexposepatients withnon-MR Conditional devicestoMRI\\nscanning. Strongmagnetic fieldsmaydamage thepulsegeneratorand/orleadsystem, possibly resulting ininjuryto\\nordeathofthepatient.\\nForadditional warnings, precautions,Conditions ofUse,andpotential adverse eventsapplicable whentheConditions\\nofUsearemetornotmet,refertotheImageReady MRConditional Defibrillation SystemMRITechnical Guide.\\nMRIProtectionModemodifies certainpulsegenerator functions inordertomitigate risksassociated withexposing\\nthedefibrillation systemtotheMRIenvironment.\\nMRIProtectionModeisaccessedviatheTachyModebutton.Choosing MRIProtectionModewillinitiateasequenc eof\\ndialogboxestoassesstheeligibility andreadiness ofthepatientandthepatient’s pacingsystemtoundergoanMR\\nConditional MRIscan.Detailed programming instructions, theConditions forUse,andacomprehensive listofMRI-\\nrelatedwarnings andprecautionsareprovidedintheImageReady MRConditional Defibrillation SystemMRITechnical\\nGuide.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 32}), Document(page_content='2-4Tachyarrhythmia Detection\\nRateSensing\\nInMRIProtectionMode:\\n•Pacingmodeoptions includeasynchronouspacing(DOO,AOO,VOO)ornopacing(Off).Asynchronouspacing\\nshouldonlybeusedifthepatientispacing-dependent. IfMRIProtection BradyModeisprogrammed toOff,the\\npatientwillnotreceivetherapyuntilMRIProtectionModeisexited.Offshouldonlybeusedifthepatientis\\njudgedtobeclinically capable ofreceivingnopacingduringthetimethepulsegeneratorisinMRIProtection\\nMode,including duringthescan.\\n•Tachycardia therapyissuspended.\\n•BeeperisturnedOff.\\n•ZIPTelemetr yissuspended.\\nMRIProtection Modeisterminated bymanualexitorbysettingtheuser-programmed automatic MRIProtection\\nTime-out period(refertotheImageReady MRConditional Defibrillation SystemMRITechnical GuideforMRI\\nProtectionModeprogramming instructions). STATPACE,STATSHOCKandDIVERTTHERAPY willalsoterminate MRI\\nProtectionMode.WhenMRIProtectionModeisexited,allparameters (exceptfortheArmature Beeper) returntothe\\npreviouslyprogrammed settings (see\"Beeper Feature\" onpage6-18toreferencethe“Determine BeeperType”\\nsubsection).\\nNOTE:Itisrecommended toperform Beeperevaluation testaftereachMRIscan(\"Beeper Feature\" onpage6-18).\\nInsituations wheretheMRIscandidnotoccur,theArmatureBeepercanbeturnedbackonafterexitingMRI\\nProtectionMode.\\nRATESENSING\\nRatesensing iscriticaltoalldetection decisions. Thepulsegeneratorreliesonthefollowing todetermine cardiac\\ncyclelength:\\n•Bipolarelectrodes intheatriumandrightventricle.\\n•Automatic gain-controlled sensing circuitforratesensing. Thiscircuitensures properratesensing by\\ncompensati ngforchanging ordiminished signalamplitudes.\\nCalculating RatesandRefractory Periods\\nThepulsegenerator evaluates rateonaninterval-by-inter valbasis.Following asenseddepolarization, acyclelength\\nismeasuredandcomparedtotheprogrammed detection parameters.\\nThepulsegenerator usesrefractoryperiodsfollowing pacedandsensedintrinsic events;intrinsic eventsthatfall\\nwithintheseperiodsareignoredfordetection purposes. Therefractoryperiods, together withnoisewindows, may\\npreventthesensing ofnonphysiologic signalsandthepotential delivery ofunwanted therapy.Thenonprogr ammable\\nrefractory periodsareasfollows:\\n•85msatrialrefractory following anatrialsensedevent\\n•150msatrialrefractory following anatrialpaceinDDD(R)andDDI(R)modes\\n•135msRVrefractoryfollowing anRVsensedevent\\n•135msrefractoryfollowing acapacitor charge(sensing isignored inallchambers)\\n•500msrefractory following shockdelivery (sensing isignoredinallchambers)', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 33}), Document(page_content='Tachyarrhythmia Detection\\nUseofAtrialInformation2-5\\nVentricular RateThresholds andZones\\nThepulsegeneratorcompareseachsensedRVcardiaccycleintervalagainsttheprogrammed Ventricular\\nTachyarrhythmia RateThreshold.\\nAVentricular Tachyarrhythmia Zoneisarangeofheartratesdefined byatleastoneprogrammed Ventricular\\nTachyarrhythmia RateThreshold.Youcanprogramfrom1to3Ventricular Tachyarrhythmia Zones,eachofwhichcan\\nbetreatedbyaseparate therapy prescription (Table2–2Nominal valuesforVentricular RateThresholdconfigurations\\nonpage2-5,Figure2–1Ventricular TachyDetection settings onpage2-5).\\nTable2–2.NominalvaluesforVentricular RateThreshold configurations\\nVentricular ZoneConfiguration VT-1Zone VTZone VFZone\\n1Zone –– –– 200bpm\\n2Zones –– 170bpm 200bpm\\n3Zones 140bpm 170bpm 200bpm\\nFigure2–1.Ventricular TachyDetection settings\\n•Ratethresholds inadjacent zonesmustdifferbyatleast20bpm\\n•ThelowestVentricular Tachyarrhythmia RateThresholdmustbeatleast5bpmhigherthantheMTR,MSR,and\\ntheMPR\\n•ThelowestVentricular Tachyarrhythmia RateThresholdmustbeatleast15bpmhigherthantheLRL\\nUseofAtrialInformation\\nTheatrialratemaybeusedto:\\n•Inhibitventricular therapyinthepresenceofatrialfibrillation oratrialflutter\\n•Bypassventricular therapyinhibitors iftheventricular rateisfasterthantheatrialrate\\nAtrialsensing canbeprogrammed toOnorOffinanydualorsinglechamber BradyMode.Thepulsegeneratorwill\\nrespondtoatrialsensing regardlessofwhether anatrialleadisimplanted.\\nTheremaybeclinicalsituations inwhichatrialleadinformation isnotuseful(e.g.,chronicatrialfibrillation, faultyor\\ndislodged atriallead,plugged atrialport).\\nCAUTION: Ifanatrialleadisnotimplanted (portisplugged instead), oranatrialleadisabandoned butremains\\nconnected totheheader,deviceprogramming shouldbeconsistent withthenumber andtypeofleadsactually in\\nuse.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 34}), Document(page_content=\"2-6Tachyarrhythmia Detection\\nVentricular Detection\\nIfanatrialleadwillnotbeused,usethefollowing programming recommendations toensureappropriatedevice\\nbehavior:\\n•ProgramtheatrialleadtoOff,toprevent atrialsensing andminimizeaccrualofatrialcounters .\\nNOTE:AnatrialEPtestshouldnotbeperformed iftheatrialleadisprogrammed toOff.\\nCAUTION: Whenatrialsensing isprogrammed toOffinaDDI(R)orDDD(R)mode,anyatrialpacingthatoccurswill\\nbeasynchro nous.Additionally ,features thatrequireatrialsensing maynotfunction asexpected.\\n•ProgramtheBradyModetoVVIorVVI(R),topreventatrialpacingandensurethatatrialinformation isnotused\\ntodrivebradypacing.\\n•Programthefollowing ventricular detection enhancements toOff,toensuretherapydecisions arenotbasedon\\natrialmeasurem ents:\\n–InitialandPost-ShockVRate>ARate(forOnset/Stability)\\n–InitialandPost-ShockAFibRateThreshold (forOnset/Stability)\\n–AtrialTachyarrhythmia Discrimination (forRhythm ID)\\nNOTE:Youshouldalsoreviewand,ifnecessary,adjustStability settings.\\n•ProgramtheAtrialIntrinsic Amplitude andAtrialImpedanc edailyleadmeasurementstoOfftodisableatrial\\ndiagnostics (e.g.,atrialAmplitude andImpedanc e).\\n•Duringfollow-up visits,considerdeselecting theatrialreal-timeEGM.\\nIfanatrialleadisusedinthefuture,theseprogramming adjustments shouldbereevaluate d,andthepulsegenerator\\nshouldbeprogrammed appropriatelyforusewithanatriallead.\\nVENTRICULAR DETECTION\\nVentricular detection consists ofthefollowing components:\\n•Initialventricular detection\\n•Reconfirmation/c ommitted shock\\n•Redetection andpost-shockdetection\\nInitialventricular detection criteriaconsistoftheprogrammable parameters RateandDuration .Thedetection criteria\\nmayalsoincludeoneofthefollowing detection enhancement suites,whichmaybeusedduringinitialandpost-shock\\nventricular detection toaddspecificity beyond RateandDuration:\\n•Onset/Stability\\n•Rhythm ID\\nThepulsegenerator initiates ventricular therapywhenitdetermines thatdetection ismet.Ventricular detection ismet\\nwhenallofthefollowing occur:\\n•Aventricular zone’sdetection window becomes andremainssatisfied throughout Duration\\n•Theventricular zone’sDuration expires\\n•Ahigherventricular zone'sdetection window isnotsatisfied\\n•Detection enhancements (ifprogrammed toOn)indicate therapy\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 35}), Document(page_content=\"Tachyarrhythmia Detection\\nVentricular Detection Enhancement Suites2-7\\n•Thelastdetected intervalisintheventricular zone\\nIftheabovecriteriaarenotmet,therapyisnotinitiated andthepulsegeneratorcontinues toevaluate intervals.\\nWARNING: DuringMRIProtection Mode,Tachycar diatherapyissuspended. Thesystemwillnotdetectventricular\\narrhythmias andthepatientwillnotreceiveATPorshockdefibrillation therapyuntilthepulsegenerator is\\nprogrammed backtonormaloperation.Onlyscanthepatientifjudgedtobeclinically capable oftolerating no\\nTachycar diaprotectionfortheentiredurationinwhichthepulsegenerator isinMRIProtectionMode.\\nVentricular Detection Enhancemen tSuites\\nOneofthefollowing ventricular detection enhancemen tsuitesmaybeprogrammed toprovide specificity beyond\\nRateandDuration (Table2–3Detection enhanceme ntsuitesavailable perzoneonpage2-7):\\n•Rhythm ID\\n•Onset/Stability\\nDetection enhance mentsuitesarenotavailable intheVFzone.\\nTable2–3.Detection enhancement suitesavailable perzone\\nVT-1Zone VTZone VFZone\\n3-zoneconfigur ationaRhythm ID\\nOnset/StabilityRhythm ID\\nOnset/StabilitydNone\\n3-zoneconfigur ation(withMonitor Onlyzone)bc None Rhythm ID\\nOnset/StabilityNone\\n2-zoneconfigur ation Rhythm ID\\nOnset/StabilityNone\\n2-zoneconfigur ation(withMonitor Onlyzone)b None None\\n1-zoneconfigur ation None\\na.Ifthedetection enhancement suiteisenabled ina3-zoneconfiguration, itappliestoboththeVT-1andVTzones.\\nb.Detection enhancement suitesarenotavailable inthelowestzoneofamulti-zoneconfigur ationwhenthezoneisusedasaMonitor Onlyzone(notherapy programmed forthatzone).\\nc.Fordevicesprogrammed toa3zoneconfigur ationwithVT-1programmed toMonitor Onlyanddetection enhancements OnintheVTzone,rhythmdiscrimination willbeapplied whena\\ntachycardia meetsInitialDetection intheMonitor Onlyzoneandtheratesubsequently accelerates totheVTzone.Inthiscase,InitialDetection isrestarted anddetection enhancements are\\navailable intheVTzone.\\nd.ShockifUnstable istheonlyOnset/Stability detection enhance mentavailable intheVTzoneofa3-zoneconfigur ation(applies onlyto3-zoneconfigur ationwithout aMonitor Onlyzone).\\nNOTE:Thereisnoclinicaldatatosuggest thatonedetection enhancemen tsuiteissuperior totheotherforany\\ngivenpatientindication. Therefore,individual programming andevaluation ofdetection enhancement specificity is\\nrecommen ded.\\nRhythmID\\nRhythm IDusesVectorTimingandCorrelation analysis inaddition toatrialandventricular intervalanalysis to\\ndetermine ifapatient's rhythmshouldbetreated(VT)oriftherapyshouldbeinhibited (SVT).\\nWithRhythm ID,thepulsegeneratorperforms avectortimingandcorrelation analysis usingtheshockEGMandrate\\nEGM.Basedonthisdata,itsavesareferencetemplate ofthepatient's normalsinusrhythm.\\nDuringRhythm IDanalysis, thepulsegeneratorfirstdetermines iftheventricular rateisgreaterthantheatrialrate.If\\nso,therapywillbeinitiated. Iftheventricular rateisnotgreaterthantheatrialrate,Rhythm IDevaluates the\\nfollowing criteriatodetermine iftherapyshouldbeinhibited orinitiated:\\n•VectorTimingandCorrelation analysis duringInitialDetection determines iftherhythmisSVTbycomparing itto\\nthepreviouslystoredreferencetemplate. IftherhythmisdeclaredSVT,therapyisinhibited. Fordeviceswith\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 36}), Document(page_content='2-8Tachyarrhythmia Detection\\nVentricular Detection Enhancement Suites\\nRhythmMatch Threshold, thecorrelation between thepatient\\'s rhythmandthereferencetemplate mustbeequal\\ntoorgreaterthantheprogrammed RhythmMatch Thresholdfortherhythmtobedeclared SVTandtherapy\\ninhibited (\"Vector TimingandCorrelation\"onpage2-21).\\n•IfVectorTimingandCorrelation doesnotdeclaretherhythmSVT,Stability andAFibRateThresholddetermine if\\ntheventricular rhythmisunstable andtheatrialrateisfast.Iftheventricular rhythmisunstable andtheatrial\\nrateisfast,therhythmisdeclaredSVTandtherapyisinhibited.\\nRhythm IDdoesnotconsideratrialdetection criteria(VRate>ARateorAgreaterthanAFibRateThreshold)forthe\\nfollowing configurations:\\n•Single-chamber devices\\n•Dual-chamber devicesifAtrialTachyarrhythmia Discrimination isprogrammed toOff\\nWhenconfiguredthisway,Stability isnotevaluated forInitialDetection. Thismaybeusefulininstanceswhereatrial\\nleadproblemshaveoccurred.Fortheseconfigurations, therapyisinhibited atInitialDetection iftherhythmis\\ndeclaredSVT(basedonVectorTimingandCorrelatio n).Otherwise, therapyisinitiated.\\nTwomethods areavailable forthedevicetoautomatically acquireaRhythm IDreferencetemplate: passiveand\\nactive.Theactivemethod maybeusefulforpatients whoarefrequently ventricular paced.\\nIfthepassivemethod isenabled, thepulsegeneratorwillattempt tocollecttheRhythm IDreferencetemplate every\\ntwohoursusingtheprogrammed bradysettings. Updates startbetween 2and4hoursafterthedevicehasbeen\\nremovedfromStorage mode.\\nIftheactivemethod isenabled andsevendayshavepassedsincethelastsuccessfulcollectionofareference\\ntemplate, thenevery28hoursthedeviceautomatically analyzes thepatient\\'s intrinsic rhythmbyadjusting thebrady\\nparamet ers.DuringaRhythm IDactivereferencetemplate update, thefollowing willoccur:\\n1.Thedeviceverifiesthatthepatientisatrest(asmeasuredbytheaccelerometerinput).\\n2.Thedeviceenables acontrolled pacingratedecreasetotheprogrammed Rhythm IDFallback LRL.Duringthis\\nfallback period,thefollowing occurs:\\n•Thedevicetemporarilyswitches thepacingmodetoDDI,VDI,VVI,AAI,orOff(accordingtotheprogrammed\\nbradymode)andextendstheAVDelayupto400ms.\\n•RateSmoothing, ATR,RateHysteresis, RateSearchHysteresis,AVSearch+,anddynamic programming\\n(excluding dynamic VRP)aresuspended.\\n3.AftertheFallback period,pacingparameters arerestoredtonormalprogrammed paramet ers.Fallback periods\\noccurnomorethanonceperdayandwilltypically lastlessthanoneminute.\\nAmethod formanually commanding thedevicetoacquireaRhythm IDreferencetemplate isalsoavailable.\\nNOTE:IfRhythm IDisnotenabled, amanualreferencetemplate updatecanstillbeperformed. Shouldan\\narrhythmia occur,thisallowsthedevicetoperform VectorTimingandCorrelation analysis and,fordeviceswith\\nRhythmMatch Threshold,recordthemeasuredRhythmMatch valueofthearrhythmia intheepisode data.However ,\\ntheVectorTimingandCorrelationanalysis resultwillnotbeusedtodetermine ifthepatient\\'s rhythmisVTorSVT.\\nDuringamanualRhythm IDreferencetemplate update, thepulsegenerator willperform thefollowing tasks:\\n1.Enableacontrolled ratedecreasetotheprogrammed Rhythm IDFallback LRL.Duringthefallback period,the\\nfollowing occurs:', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 37}), Document(page_content=\"Tachyarrhythmia Detection\\nOnset/Stability2-9\\n•Thedevicetemporarilyswitches totheprogrammed ManualRhythm IDBradyModeandextends theAV\\nDelayupto400ms.\\n•RateSmoothing, ATR,RateHysteresis,RateSearchHysteresis,AVSearch+,anddynamic programming\\n(excludingdynamic VRP)aresuspended.\\n2.AftertheFallback interval, pacingparametersarerestored tonormalprogrammed parameters. Thisprocesswill\\ntypically lastlessthanoneminute.\\nNOTE:Rhythm IDFallback LRLsettings shouldbeselected suchthatnormalsinusrhythms arepromoted(e.g.,\\nnormalAVnodeconduction). Caremustbeusedwhenselecting LRLlessthan50ppm(ratesthatapproachthe\\npatient’s ventricular escaperates).Ventricular escaperhythms duringRhythm IDupdates mayresultininappropriate\\ntherapydecisions.\\nNOTE:AnacquiredRhythm IDreferencetemplate willbeusedtoperform VectorTimingandCorrelationanalysis\\nuntilanewerreferencetemplate isacquired.\\nNOTE:AmanualRhythm IDreferencetemplate updateshouldnotbecommanded immediately aftershock\\ntherapy.Itmaytakeseveralminutes forirregularities inEGMmorphology causedbytheshocktosubside.\\nConsider thefollowing whenusingRhythm ID:\\n•Rhythm IDdetermines whether therapy willbeinhibited ornotattheendofDuration.Ifthedecision istoinhibit\\ntherapy,thenRhythm ID(including VectorTimingandCorrelation, VRate>ARate,AFibRateThreshold,and\\nStability) continues tobereevaluated beat-by-beat. UseoftheSustained RateDuration (SRD)featurewilllimit\\ninhibition oftherapybyRhythm IDtothelengthoftheprogrammed SRD.\\n•Rhythm IDwillnotinhibittherapyintheVFzone.Programming theVFratethresholdlowerthantherateoffast\\nrhythms willpreventRhythm IDfrominhibiting therapyforthoserhythms.\\n•Programming AtrialTachyarrhythmia Discrimination toOnpreventsRhythm IDfrominhibiting therapyifthe\\nventricular rateisfasterthantheatrialrate.\\n•IfnoRhythm IDreferencetemplate haseverbeenacquired,Rhythm IDusesonlyStability andAFibRate\\nThresholdtodiscriminate between VTandSVT,because VectorTimingandCorrelation analysis cannotbe\\nperformed. Furthermore, ifRhythm IDdoesnotconsideratrialdetection criteria,andnoreferencetemplate has\\nbeenacquired,nodetection enhancemen tswillbeevaluated duringInitialDetection.\\nOnset/Stability\\nTheOnset/Stability detection enhanceme ntsuiteanalyzes thecardiaccycleintervalstodetermine ifapatient's\\nrhythmshouldbetreated(VT)oriftherapy shouldbeinhibited (SVT).\\nOnset/Stability allowsyoutoprogramdetection enhancements byidentifying thedesiredtypeofrhythm\\ndiscrimination: atrialtachyarrhythmia, sinustachycardia, orpolymorphic VT(Table2–4Onset/Stability rhythm\\ndiscrimination available perzoneonpage2-9).\\nTable2–4.Onset/Stability rhythmdiscrimination available perzone\\nVT-1Zone VTZone VFZone\\n3-zoneConfiguration AtrialTachyarrhythmia Polymorphic VTa None\\nSinusTachycardia\\n3-zoneConfiguration\\n(withMonitor Onlyzone)bcNone AtrialTachyarrhythmia None\\nSinusTachycardia\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 38}), Document(page_content=\"2-10Tachyarrhythmia Detection\\nReconfirmation/Committed Shock\\nTable2–4.Onset/Stability rhythmdiscrimination available perzone(continued)\\nVT-1Zone VTZone VFZone\\nPolymorphic VTa\\n2-zoneConfigura tion AtrialTachyarrhythmia None\\nSinusTachycardia\\nPolymorphic VTa\\n2-zoneConfigura tion(withMonitor Onlyzone)b None None\\n1-zoneConfigura tion None\\na.Polymorphic VTDiscrimination isonlyavailable intheVTzone.\\nb.Rhythm discrimination isnotavailable inthelowestzoneofamulti-zone configur ationifthezoneisusedasaMonitor Onlyzone(notherapy programmed forthatzone).\\nc.Fordevicesprogrammed toa3zoneconfigura tionwithVT-1programmed toMonitor Onlyanddetection enhancements OnintheVTzone,rhythmdiscrimination willbeappliedwhena\\ntachycardia meetsInitialDetection intheMonitor Onlyzoneandtheratesubsequently acceleratestotheVTzone.Inthiscase,InitialDetection isrestarted anddetection enhancements are\\navailable intheVTzone.\\nReconfirmation/Committed Shock\\nReconfirmation referstothemonitoring performed bythedeviceduringandimmediately following capacitor\\nchargingforashock.WhentheCommitted Shockparameterisprogrammed toOff,thedeviceisallowed toreconfirm\\nthatashockshouldbedelivered.\\nVentricular Redetection\\nVentricular Redetection occursfollowing any:\\n•Ventricular therapydelivery\\n•Diverted therapyduetoreconfirmation analysis (diverted-rec onfirm)\\n•Manually diverted therapy\\n•Therapynotavailable atDetection Met(exceptwhentheVT-1zoneisprogrammed toMonitor Only,inwhichcase\\nInitialDetection isrestarted)\\nRedetection usesthesameventricular detection window processandprogrammed tachycard iaRatethresholds as\\nInitialDetection toidentify atachyarrhythmia.\\nTheprimary differencesbetween InitialDetection andRedetection aretheDuration parameters usedandthe\\ndetection enhance mentsthatareavailable:\\n•Ifventricular shocktherapyisdelivered,thefollowing willoccur:\\n–Theredetectionduration timeisdetermined bythevalueofthePost-shockDuration paramet er\\n–Detection enhance ments(exceptforOnset,ShockifUnstable, andVectorTimingandCorrelation)are\\navailable duringredetection\\n•Ifventricular ATPisdeliveredoriftherapyisdiverted orunavailable, thefollowing willoccur:\\n–Theredetectionduration timeisdetermined bytheRedetection Durationparamet er\\n–Detection enhance ments(exceptforShockifUnstable) arenotavailable duringredetection\\nWhichever durationisdetermined tobeappropriate,thattypeofduration(Redetection orPost-Shock)willbeineffect\\ninallzonesateachzone'sprogrammed durationvalue.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 39}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Post-shockDetection Enhancemen ts2-11\\nVentricular Post-shockDetection Enhancemen ts\\nWhenprogrammed toOn,thefollowing ventricular post-shockdetection enhancements willbeineffectfollowing the\\nPost-shockDuration:\\n•Post-shockVRate>ARate\\n•Post-ShockAFibRateThreshold\\n•Post-shockStability\\n•Post-shockSRD\\n•Post-shockRhythm ID(usesAFibRateThreshold, Stability, VRate>ARate,andSRD)\\nWiththeexceptionofRhythm ID,allpost-shockdetection enhance mentsperform thesameasthecorresponding\\nInitialDetection enhancement s(withRhythm ID,VectorTimingandCorrelationisnotavailable post-shock).\\nPost-shockStability maybeusedtopreventshock-inducedAFfromcausing thepulsegeneratortodeliverundesired\\nadditional shocks(Figure2–2Post-shockDuration andPost-shockStability analysis onpage2-11.)\\nTheAFibRateThresholdcanbeprogrammed inconjunction withPost-shockStability tofurtherdiscriminate AFand\\npreventthepulsegenerator fromdelivering undesire dventricular shocktherapy.\\n0 s 5 s\\n20 s\\n0 s\\n15 s\\nLowest zone \\ndetection window \\nsatisfied.\\nPost-shock Duration = 5 s\\nPost-shock SRD = 15 sPost-shock \\nDuration starts in \\nlowest zone.\\nPost-shock Duration \\nexpires.\\nEvaluate Stability . If \\nstable, charge and \\nshock. If unstable, inhibit \\ntherapy . Post-shock \\nSRD timer starts.\\nContinue Pos t-shock Stabi\\nlity \\nanalysis thro ughout S\\nRD time \\nas long as th e detect\\nion \\nwindow rema ins satis\\nfied.\\nIf Stability indicates \\ntherapy , charge and \\nshock.\\nPost-shock SRD times out. \\nCharge and deliver shock if \\ntherapy had been inhibited \\nduring SRD.\\nShock\\nFigure2–2.Post-shockDuration andPost-shockStabilityanalysis\\nVentricular Detection Details\\nThepulsegeneratorusesthefollowing information todetermine appropriatetherapydelivery:\\n•Ventricular detection windows\\n•Durationparamete r\\n•Redetection durationandpost-shockduration\\n•Ventricular episodes\\n•Ventricular detection enhancement s\\nVentricular Detection Windows\\nAppropriatetherapy delivery isdependent uponaccuratelyclassifying apatient’s rhythm. Toensurethatappropriat e\\ntherapyisdelivered,thepulsegeneratoremploys detection windows todifferentiatetachycardias.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 40}), Document(page_content='2-12Tachyarrhythmia Detection\\nVentricular Detection Windows\\nEachventricular zonehasadetection window thatconsistsofthe10mostrecentRVR–Rintervals measuredbythe\\npulsegenerator.Aseachnewintervalismeasured, itiscompared toeachzone’sprogrammed ratethresholdand\\nclassified aseitherfastorslow(i.e.,aboveorbelowtheratethreshold)ineachdetection window.\\nThepulsegenerator preparesforapotential episode whenitcounts3consecutive fastintervals.Thedetection\\nwindow issatisfied andanepisode isdeclaredwhen8outof10fastintervalsarecounted.Thedetection window will\\nremainsatisfied aslongas6of10intervalsremainclassified asfast.Ifthenumber offastintervals fallsbelow6,the\\nzone’sdetection window isnolongersatisfied. Thezone’sdetection window willonlybecomeresatisfiedwhen8of\\n10intervals areagainclassified asfast(Figure2–3Ventricular detection window satisfied onpage2-12).\\n630 600 6\\n00 380 37\\n0 390 380\\n 370 600 \\n370 350 3\\n70 490 50\\n0 500 500\\n 500 370 \\nS \\nS S S F F\\n F F F F \\nF F S S S\\n S S F \\nF \\n6 of 10 i\\nntervals \\nare fast,\\n VF windo\\nw not sat\\nisfied. \\n8 of 10 i\\nntervals \\nare fast,\\n VF windo\\nw is sati\\nsfied. \\n7 of 10 i\\nntervals \\nare fast,\\n VF windo\\nw remains\\n satisfie\\nd. \\n7 of 10 i\\nntervals \\nare fast,\\n VF windo\\nw not sat\\nisfied. \\n6 of 10 i\\nntervals \\nare fast,\\n VF windo\\nw remains\\n satisfie\\nd. \\n5 of 10 i\\nntervals \\nare fast,\\n VF windo\\nw is no l\\nonger sat\\nisfied. \\n6 of 10 i\\nntervals \\nare fast,\\n VF \\nwindow is\\n not yet \\nresatisfi\\ned \\n7 of 10 i\\nntervals \\nare fast,\\n VF \\nwindow is\\n not yet \\nresatisfi\\ned \\n8 of 10 i\\nntervals \\nare fast,\\n VF \\nwindow is\\n resatisf\\nied \\nVF \\nwindow \\nIntervals\\n \\nin ms \\nVF Zone R\\nate = 150\\n min\\n-1 \\n(bpm) = 4\\n00 ms \\nS = Slow \\nF = Fast \\nOne-zone \\nconfigura\\ntion \\nRight \\nVentricle\\n \\nFigure2–3.Ventricular detection windowsatisfied\\nBecause RateThreshold inthehigherzonesmustbeprogrammed atavaluegreaterthanRateThresholdinlower\\nzones,anintervalclassified asfastinahigherwindow wouldalsobeclassified asfastinanylowerwindows (Figure\\n2–4Interactionofventricular detection windows, 2-zoneconfiguration onpage2-12).\\n630 600 600 370 390 380 275 275 600 \\n275 250 250 \\nS S S S F F F F F \\nF F F \\n240 240 \\nF F \\nS S S S S S S F F \\nF F F F F \\n240 \\nF \\nF \\nVF Zone Rate = 200 min\\n-1 \\n(bpm) = 300 ms \\nVT Zone Rate = 150 min\\n-1 \\n(bpm) = 400 ms \\nS = Slow F = Fast \\nIntervals in ms \\n8 of 10 intervals are fast, VF window is satisfied. \\n7 of 10 intervals are fast, VF window not satisfied. \\n6 of 10 intervals are fast, VF window not satisfied. \\n8 of 10 intervals are fast, VT  window is satisfied. 7 of 10 intervals are fast, VT  window not satisfied. \\n6 of 10 intervals are fast, VT  window not satisfied. \\nVF window \\nVT window \\nFigure2–4.Interaction ofventricular detection windows, 2-zoneconfiguration', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 41}), Document(page_content=\"Tachyarrhythmia Detection\\nVentricular Detection Windows2-13\\nDuration Parameter\\nTheDuration parameterisatimerthatmeasuresthelengthoftimeineachzonethatarhythmmustbesustained\\nbeforetherapyisdelivered.\\nADuration timerbeginswhenitsrespective zone’sdetection window issatisfied. Theprogrammed Duration timeis\\ncheckedfollowing everycardiaccycletodetermine ifithasexpired.\\nNOTE:SincetheDuration timerisexamined synchronouslywithacardiaccycle,theprogrammed Duration maybe\\nexceededbyuptoonefullcardiaccycle.\\n•Aslongasthezone’sdetection window remains satisfied, theDurationtimercontinues toelapse.Ifthelast\\ndetected intervalisinthezonewhenitsDuration timeexpires,detection isconsidered metandtherapyis\\ninitiated (assuming noprogrammed detection enhancemen tsinhibittherapydelivery) (Figure2–5Ventricular\\nDurationtimeronpage2-13).\\n•Ifthelastdetected intervalisnotinthezone,therapyisnotinitiated. Eachsubsequent intervalwillbechecked\\nuntilanintervalisintheoriginal zone,orthewindow isnolongersatisfied (Figure2–6Lastdetected intervalon\\npage2-13).\\n•IfatanypointduringDurationazone’sdetection window detectsfewerthan6of10fastintervals,thatzone's\\nDurationisresetto0(Figure2–7Ventricular Duration resetonpage2-14).Duration willstartagainonlyifthe\\ndetection window becomes resatisfied.\\nVT detection window remains satisfied during \\nVT Duration. \\nVT Duration expires and the \\nnext detected interval is in the \\nVT zone, detection is met. \\n ATP therapy is initiated. VT window satisfied. \\nVT Duration starts. \\nVT Duration 1-30 s \\nVT detected \\nRight V entricle \\nDurationstartswhenawindow becomes satisfied andcontinues toelapseaslongastheventricular detection window remains satisfied. Detection ismetwhenDuration expiresandthenext\\ndetected intervalisinthesameventricular zone.\\nFigure2–5.Ventricular Duration timer\\nVT detection window remains satisfied during \\nVT Duration.\\nVT Duration expires and the last \\ndetected interval is not in the \\nsame zone, detection in that \\nzone is not met. Therapy in that \\nzone is not initiated.VT window satisfied. \\nVT Duration starts.\\nVT detected VT Duration 1-30 s\\nRight ventricle\\nFigure2–6.Lastdetected interval\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 42}), Document(page_content='2-14Tachyarrhythmia Detection\\nVentricular Detection Windows\\nVT detection window is no longer satisfied; fewer \\nthan 6 of 10 intervals are classified as fast. \\nVT window satisfied. \\nVT Duration starts. VT Duration resets  to zero. VT  Duration will start \\nagain when the win dow becomes resatisfied. Need 8 of 10 intervals classified as fast to restart VT  Duration. VT Duration 1-30 seconds VT detected \\nRight ventricle \\nDuration resetswhenduringtheDuration periodthewindow isnolongersatisfied.\\nFigure2–7.Ventricular Duration reset\\nADurationisprogrammed foreachventricular zone.Different valuesareavailable depending ontheconfigur ation\\nprogrammed (Table2–5Durationprogrammable rangesbyventricular zoneandconfiguration onpage2-14).The\\nDuration programmed inlowerventricular ratezonesmustbegreaterthanorequaltohigherventricular zones.\\nLongerDurationsmaybeusedtopreventthedevicefrominitiating treatment ofnon-sustained arrhythmias.\\nTable2–5.Duration programmable rangesbyventricular zoneandconfiguration\\nConfiguration VT-1ZoneaVTZoneaVFZoneb\\n1Zone –– –– 1–15seconds\\n2Zones –– 1–30seconds 1–15seconds\\n3Zones 1–60seconds 1–30seconds 1–15seconds\\na.Themaximum redetectduration fortheVT-1andVTzonesis15seconds.\\nb.IntheVFzone,theredetect andpost-shockduration isfixedat1second.\\nDuration inaMulti-zoneConfiguration\\nDuration timersrunindependently ofeachotherwithintheirrespective ventricular zones.\\n•Ifthearrhythmia isdetected inthehighestzone,thatzone’sDuration timertakesprecedenceoverthelower\\nzones’timers;thelowerzones’Duration timerscontinuetoelapsebutareignoredwhilethehigherzone’s\\nDuration timerruns.\\n•Ifthehigherzone’sDuration expiresanddetection ismet,therapyforthatzonewillbeinitiated regardless of\\nwhether thelowerzones’Duration timershaveexpired.\\n•Ifthehigherzone’sdetection window doesnotremainsatisfied, thentheDurationtimersforthelower\\nventricular zonesarenolongerignored.\\nProgrammed therapyforlowerventricular zoneswillbeinitiated whenalowerventricular zone’sdurationismetand\\nnohigherventricular zone’swindow issatisfied (Figure2–8Interaction ofventricular Duration, 2-zoneconfiguration,\\nchargingonpage2-15,Figure2–9Interaction ofventricular Duration, 2-zoneconfiguration, chargingdelayed onpage\\n2-15).', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 43}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Detection Windows2-15\\nVF window satisfied. \\nVF Duration starts. \\nVF Duration 1 s \\nVF window remains satisfied. VF Duration expires \\nand detection is met. Charging begins. VT  Duration \\nexpires during charging, but is ignored. \\nCharging \\nVT window satisfied. \\nVT Duration starts. VT detected VT Duration 5 s \\nVF detected \\nFigure2–8.Interaction ofventricular Duration, 2-zoneconfiguration,charging\\nVF window satisfied. \\nVF Duration starts. \\nVF window does not remain satisfied. \\nVF Duration is not satisfied. \\nVT Detection is met. \\nVT window satisfied. \\n VT Duration starts. VT Duration expires. Detection is not met \\n because VF window is satisfied. VT detected \\nVF detected \\nVF Duration 1 s \\nVT Duration 5 s \\nCharging \\nFigure2–9.Interaction ofventricular Duration, 2-zoneconfiguration, chargingdelayed\\nVentricular Redetection Duration andPost-shockDuration\\nDurationparamet ersareusedtoidentify tachyarrhythmias duringtheventricular redetection process.\\n•Redetection Durationisappliedfollowing delivery ofATPtherapy(exceptQUICKCONVERT ATP),adiverted-\\nreconfirm, manually diverted therapy,oriftherapyisunavailable atDetection Met(Figure2–10Redetection\\nfollowing ventricular ATPdelivery onpage2-16).\\n•Post-shockDuration isappliedfollowing shocktherapydelivery (Figure2–11Redetection following ventricular\\nshockdelivery onpage2-16).\\nRedetection Duration isprogrammable inthelowerventricular zonesofamulti-zone configuration. Itis\\nnonprogrammable intheVFZone.Post-shockDuration canbeprogrammed inthesamemanner; thevalues\\nprogrammed inthelowerventricular ratezonesmustbegreaterthanorequaltothevaluesprogrammed inthe\\nhigherzones.\\nTohelpminimize timetopotential therapy,itisrecommended thatRedetection Duration intheVT-1andVTzonesof\\nmulti-zo neconfigurations beprogrammed atlessthanorequalto5seconds.\\nItisrecommended thatPost-shockDuration intheVT-1andVTzonesofmulti-zone configur ationsalsobe\\nprogrammed atlessthanorequalto5seconds.However ,youmayprogramforlongerdurationsifshock-induced,\\nnon-sustained, high-raterhythms, suchasacceleratedidioventricular rhythm(AIVR)orAFareevident. Thelonger\\ndurationsmayallowtherhythmtoreturntoalowerratebeforeredetectionismet.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 44}), Document(page_content='2-16Tachyarrhythmia Detection\\nVentricular Episodes\\n3 s\\n8 of 10 intervals are \\nfast, window satisfied\\nStart \\nRedetection \\nDuration\\nStart \\nRedetection\\nATP therapy programmed. \\nRedetection Duration programmed at 3 s.Initial Detection met\\nATP therapy ATP therapy\\nRedetection \\nDuration expires. \\nDetection met.\\nStart Redetection\\nLook for 8 of 10 fast intervals\\nIgnored Ignored\\nFigure2–10.Redetection following ventricular ATPdelivery\\n3 s\\nShock therapy programmed. Post-shock \\nDuration programmed at 3 s.Initial Detection met Start Redetection Start Post-shock \\nDuration\\nPost-shock \\nDuration expires. \\nDetection met.\\nStart Redetection\\nCharging\\n8 intervals are fast\\nCharging\\nLook for 8 of 10 fast intervals\\nShock Shock\\nIgnored Ignored\\nFigure2–11.Redetection following ventricular shockdelivery\\nVentricular Episodes\\nIfthreeconsecutive fastventricular beatsaredetected, thenthepulsegenerator startsmonitoring foradetection\\nwindow tobesatisfied. Whenanyzone’sdetection window becomes satisfied, thepulsegeneratorperforms the\\nfollowing:\\n•Declares thestartofaventricular episode\\n•Increments theepisode number\\n•Allocates memory forhistorydataandelectrogramstorage\\n•Beginsdurationtimersinzoneswheredetection windows aresatisfied\\nTheventricular episode isdeclaredcomplete whenalldetection windows arenolongersatisfied andremain\\nunsatisfied foraspecified time.\\nEachventricular tachyepisode isclassified asTreatedorNon-Treated(Figure2–12Treatedepisode, ventricular mode\\nisMonitor +TherapyandATPisdeliveredonpage2-17throughFigure2–16Treated episode, ventricular modeis\\nMonitor +TherapyandEnd-of-Episode timerisresetto0onpage2-18).\\n•ATreatedepisode isoneinwhichtherapyisdelivered\\n•ANon-Treatedepisode isoneinwhichnotherapyisdelivered\\nForaTreatedepisode, anEnd-of-Episode timerstartsaftertherapyisdelivered.ForaNon-Treated episode, anEnd-\\nof-Episode timerstartsatthepointthatthepulsegenerator recognizesthatalldetection windows arenolonger\\nsatisfied. TheEnd-of-Episode timeintervalisintended toallowthepatienttostabilizebeforeInitialDetection and\\ninitialtherapyareusedagain.Theepisode isdeclaredcomplete ifnodetection window becomessatisfied fora\\nspecified timefollowing thelasttherapyattempt (Table2–6End-of-Episode Timeronpage2-17).Ifanywindow\\nbecomes satisfied whiletheEnd-of-Episode timeriselapsing, theEnd-of-Episode timerisresettozero.Itwillstart', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 45}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Episodes2-17\\nagainwheneithertherapyisattempted orallwindows arenotsatisfied (Figure2–16Treatedepisode, ventricular\\nmodeisMonitor +TherapyandEnd-of-Episode timerisresetto0onpage2-18).\\nOnceanepisode hasbeendeclared complete, thepulsegeneratorwillapplyInitialDetection andtherapyto\\nsubsequent tachyarrhythmias.\\nTable2–6.End-of-Episode Timer\\nEpisodeClassification Ventricular End-of-Episode Timer\\n(elapsedtimerequired todeclareepisodeover)\\nNon-Treated (notherapy delivered) 10seconds\\nTreated (onlyATPtherapy delivered) 10seconds\\nTreated (anyshocktherapydelivered) 30seconds\\nNOTE:Theepisode isterminated immediately iftheTachyModeisreprogrammed, aninduction method orlead\\ntestisattempted beforetheEnd-of-Episode timeout,oranyventricular detection orventricular therapyparameters\\narereprogrammed.\\nCoupling \\nInterval \\nDetection window does \\nnot become satisfied. \\nEnd-of-Episode times out. \\nEpisode is over . Detection met. \\nDeliver ATP. Start Duration. \\nStart episode. Start End-of -\\nEpisode timer .Detection window remains satisfied. \\nATP Burst \\n10 s \\nDetection window satisfied. \\nFigure2–12.Treatedepisode,ventricular modeisMonitor+TherapyandATPisdelivered\\nDetection window remains satisfied. \\nDetection met. \\nStart Charging. Start Duration. \\nStart episode. Detection window satisfied. \\nCharging \\nShoc k \\nEnd-of-Episode times out. \\nEpisode is over . Start End-of-Episode timer . \\n30 s \\nDetection window does not become satisfied. \\nFigure2–13.Treatedepisode,ventricular modeisMonitor+Therapyandshockisdelivered\\nStart Duration. \\nStart episode.\\nDuration did not expire. \\nDuration resets to zero. \\nStart End-of-Episode timer .End-of-Episode times out. \\nEpisode is over .\\nDetection window is no longer satisfied; fewer than 6 \\nof 10 intervals are classified as fast.\\nDetection window satisfied.\\n10 s\\nDetection window does not become satisfied.\\nFigure2–14.Non-Treated episode, ventricular modeisMonitor+TherapyorMonitorOnly,durationisnotexpired', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 46}), Document(page_content='2-18Tachyarrhythmia Detection\\nVentricular Detection Enhancements\\n10 s\\nTachyarrh\\nythmia sp\\nontaneous\\nly conver\\nts.\\nReconfirmation monitors rhythm for five of ten \\nslow intervals during charging.\\nEnd-of-Episode \\ntimes out. \\nEpisode is over .\\nReconfirmation indicates \\ntachyarrhythmia not present; \\nshock not delivered. Start \\nEnd-of-Episode timer .Start Duration. \\nStart episode.\\nDetection met. \\nStart Charging.\\nDetection window \\nsatisfied.\\nF = Fast\\nS = Slow\\nDetection window remains satisfied.\\nF\\nS SSS\\nS\\nCharging\\nRight V entricle\\nThisexample assumes Committed Shockisprogrammed toOff.\\nFigure2–15.Non-Treated episode, ventricular modeisMonitor+Therapyandchargingisstoppedpriortoshockdelivery\\nDetection window \\nsatisfied. \\nStart End-of -\\nEpisode timer .\\nStart Post-shock \\nDuration \\nEnd-of-Episode \\ntimer resets to zero. Detection met. \\nStart Charging. \\nRestart End-of-Episode timer . End-of-Episode times \\nout. Episode is over . \\nCharging \\n30 s \\nShock Shock \\nVentricular rate \\nremains fast. \\nDetection window does not become satisfied. \\nRight V entricle \\nThisexample illustrates aTreatedEpisode whenVentricular ModeisMonitor +Therapy.TheEnd-of-Episode timerisresetto0whenaventricular detection window becomes satisfied after\\nventricular therapy delivery,butpriortotheepisode time-out beingreached. Inthisexample,2shocksweredelivered intheepisode.\\nFigure2–16.Treatedepisode,ventricular modeisMonitor+TherapyandEnd-of-Episode timerisresetto0\\nVentricular Detection Enhancements\\nVentricular detection enhancements addspecificity totheRateandDuration detection criteria.Youmayprogram\\nventricular detection enhancements toperform thefollowing:\\n•Delayorinhibittherapy delivery\\n•Override therapyinhibition\\n•Bypassasequence ofATPtherapyinfavorofshocktherapy\\nVentricular detection enhancements maybeprogrammed tooneofthefollowing:\\n•Rhythm ID\\n•Onset/Stability\\n•Off(i.e.,RateOnly)\\nIfOffisselected, onlytheventricular rateanddurationareusedfortherapydecisions.\\nIfeitherRhythm IDorOnset/Stability isselected, enhancement parameters areusedinaddition toventricular Rate\\nandDuration fortherapy decisions (Table2–7Enhancement parameters available withdetection enhancements on\\npage2-19)asfollows:', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 47}), Document(page_content=\"Tachyarrhythmia Detection\\nVentricular Detection Enhancemen ts2-19\\n•VectorTimingandCorrelation inhibitstherapywhentheconduction vector(EGMmorphology andtiming)during\\ntachyarrhythmia matches areferenceconduction vectorofthepatient's normalsinusrhythm.\\n•VRate>ARatecanbeusedtooverride theinhibitdecision ofOnset,Stability, VectorTimingandCorrelation,\\nand/orAFibRateThreshold. VRate>ARatecanbeusedtodeliverventricular therapyanytime theventricular\\nrateisgreaterthantheatrialrate.\\n•AFibRateThreshold canbeprogrammed (together withstability) toinhibitventricular therapyiftheatrialrhythm\\nisfast.\\n•Stability canbeprogrammed toinhibitventricular therapydelivery iftheventricular rhythmisunstable.\\n•ShockifUnstable canbeprogrammed tobypasstheventricular ATPtherapyanddelivershocktherapyifthe\\nventricular rhythmisdeclaredUnstable.\\n•Onsetcanbeprogrammed toinhibitventricular therapy ifthepatient's heartrateincreasesgradually.\\n•SRDenables thepulsegeneratortooverride theStability, Onset,VectorTimingandCorrelation,and/orAFibRate\\nThresholdparameters' decision toinhibitventricular therapyifthehighratecontinuesthroughout the\\nprogrammed timeperiod.\\nTable2–7.Enhancementparameters available withdetection enhancements\\nEnhancement Parameter RhythmID Onset/Stability\\nInitial Post-Shock Initial Post-Shock\\nVectorTimingandCorrelationa X –– –– ––\\nVRate>ARate(dual-chamber devicesonly) XbcXbcX X\\nAFibRateThreshold (dual-chamber devicesonly) XbdXbdXeXe\\nStability (toinhibit) XfXfX X\\nShockifUnstable –– –– X ––\\nOnset –– –– X ––\\nSRDgX X X X\\na.Thisenhancement isnotindividually programmable.\\nb.WhenRhythm IDisselected, thisenhancement isautomatically enabled whenAtrialTachyarrhythmia Discrimination isprogrammed toOn.However ,itisnotavailable insinglechamber\\ndevicesorwhentheAtrialTachyarrhythmia Discrimination isprogrammed toOffindualchamber devices.\\nc.Thisenhancement isnotindividually programm ablewhenRhythm IDisenabled.\\nd.WhenRhythm IDisselected, thisparameter usesthesamevalueforbothInitialandPost-ShockDetection. Itcannotbeindependently enabled ordisabled forPost-ShockDetection.\\ne.WhenOnset/Stability isselected, thisparameter canbeenabled anddisabled independently forPost-ShockDetection. Ifenabled, itusesthesamevalueastheInitialDetection.\\nf.WhenRhythm IDisenabled andAtrialTachyarrhythmia Discrimination isprogramm edtoOnindualchamber devices, thisenhancement usesthesamevalueforbothInitialandPost-Shock\\nDetection. Insinglechamber devices,orwhenAtrialTachyarrhythmia Discrimination isprogrammed toOff,thisenhancement isautomatically disabled forInitialDetection, butisstill\\nenabled forPost-ShockDetection.\\ng.SRDisavailable whendetection enhancements, whichinhibittherapy,areprogrammed.\\nSomeofthesedetection enhance mentparametersarealsoindependently programmable asPost-Shockparameters\\n(Table2–7Enhancement parameters available withdetection enhancements onpage2-19).\\nTheindividual detection enhancemen tparamete rsthatareavailable depend onthenumber oftachyzonesthatare\\nprogrammed: 3,2,or1(Table2–8Individual Ventricular Detection Enhancemen tsavailable inmultizone\\nconfigurations onpage2-20).\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 48}), Document(page_content='2-20Tachyarrhythmia Detection\\nVentricular Detection Enhancements\\nTable2–8.Individual Ventricular Detection Enhancements available inmultizone configurations\\nVT-1Zone VTZone VFZone\\n3-zoneconfiguration VectorTimingandCorrelation\\nVRate>ARate\\nAFibRateThreshold\\nStability (toInhibit)\\nOnset\\nSRDVectorTimingandCorrelationa\\nVRate>ARatea\\nAFibRateThresholda\\nStability (toInhibit)a\\nShockifUnstable\\nSRDa––\\n3-zoneconfiguration\\n(withMonitor Onlyzone)bc–– VectorTimingandCorrelation\\nVRate>ARate\\nAFibRateThreshold\\nStability (toInhibit)\\nShockifUnstabled\\nOnset\\nSRD––\\n2-zoneconfiguration VectorTimingandCorrelation\\nVRate>ARate\\nAFibRateThreshold\\nStability (toInhibit)\\nShockifUnstabled\\nOnset\\nSRD––\\n2-zoneconfiguration (withMonitor Onlyzone)b –– ––\\n1-zoneconfiguration ––\\na.Enhancement isavailable inthemiddlezoneofa3-zoneconfigur ationonlywhenRhythm IDisenabled.\\nb.Detection enhancements arenotavailable inthelowestzoneofamulti-zone configur ationwhenitisusedasaMonitor Onlyzone(notherapy programm edforthatzone).\\nc.Fordevicesprogrammed toa3zoneconfigura tionwithVT-1programmed toMonitor Onlyanddetection enhancements OnintheVTzone,rhythmdiscrimination willbeappliedwhena\\ntachycardia meetsInitialDetection intheMonitor Onlyzoneandtheratesubsequently acceleratestotheVTzone.Inthiscase,InitialDetection isrestarted anddetection enhancements are\\navailable intheVTzone.\\nd.ShockifUnstable cannotbeprogrammed oninthesamezoneasotherdetection enhancements thatareprogrammed toinhibittherapy(Onset,Stability,andAFibRateThreshold).\\nWhenaspecificrhythmdiscrimination isselected, youcanmodifythevaluesforthedetection enhancemen tsthatare\\nsuitable fordiscriminating thatrhythm. Nominal valuesareshowninthefollowing table;however ,youcanusethose\\nvaluesatyourdiscretion.\\nTable2–9.Nominalvaluesforinitialdetection andredetection enhancements\\nOnset/Stability RhythmID\\nParameter Atrial\\nTachyarrhythmia\\nDiscriminationSinusTachycardia\\nDiscriminationPolymorphic VT\\nDiscriminationAtrial\\nTachyarrhythmia\\nDiscrimination OnAtrial\\nTachyarrhythmia\\nDiscrimination Off\\nVectorTimingandCorrelation –– –– –– OnaOna\\nVRate>ARate(dual-chamber modelsonly) On On –– Onb ––\\nAFibRateThreshold(dual-chamber models\\nonly)170bpm –– –– 170bpm ––\\nStability (Inhibit) 20ms\\n(DRdevices)\\n30ms\\n(VRdevices)–– –– 20ms\\n(DRdevices)\\n30ms\\n(VRdevices)30ms\\nOnset(InitialDetection only) –– 9% –– –– ––\\nSRDInitial 3:00minutes:\\nseconds3:00minutes:\\nseconds–– 3:00minutes:\\nseconds3:00minutes:\\nseconds', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 49}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Detection Enhancemen ts2-21\\nTable2–9.Nominalvaluesforinitialdetection andredetection enhancements (continued)\\nOnset/Stability RhythmID\\nParameter Atrial\\nTachyarrhythmia\\nDiscriminationSinusTachycardia\\nDiscriminationPolymorphic VT\\nDiscriminationAtrial\\nTachyarrhythmia\\nDiscrimination OnAtrial\\nTachyarrhythmia\\nDiscrimination Off\\nSRDRedetection 0:15minutes:\\nseconds–– –– 0:15minutes:\\nseconds0:15minutes:\\nseconds\\nShockifUnstable –– –– 30ms –– ––\\na.Parameter isnotindividually programmable.\\nb.Parameter isnotindividually programmable whenRhythm IDisenabled.\\nVectorTimingandCorrelation\\nVectorTimingandCorrelatio ncomparesEGMsignalsforanunknown rhythmwithastoredreferencetemplate ofthe\\nEGMsignalsofanormalsinusrhythm(NSR).Rhythms thatarenotsimilar(i.e.notcorrelated) tothestoredreference\\ntemplate areclassified asVT.Rhythms thatarecorrelatedwiththestoredreferencetemplate areclassified asSVT.\\nRhythm IDusesthisclassification duringInitialDetection tomakeadecision totreatortoinhibittherapy.\\nWhenafastrhythmissensed, eachbeatoftherhythmiscompared tothestoredreferencetemplate. Thepulse\\ngeneratormeasuresthecorrelationofthedetected waveform tothestoredreferencetemplate, andclassifies each\\nbeatascorrelatedoruncorrelated.AbeatintheVFzoneisalwayscountedasuncorrelated,evenifithasahigh\\nmeasuredcorrelation value.\\nThepulsegeneratorthenclassifies thedetected rhythmasSVTorVTbasedonthecalculations:\\n•Ifatleast3outof10beatsarecorrelated,therhythmisclassified asSVT,shownasRID+intheannotated\\nelectrograms\\n•Iffewerthan3outof10beatsarecorrelated, therhythmisclassified asVT,shownasRID-intheannotated\\nelectrograms\\nRhythmMatch Threshold\\nThisfeatureisavailable inRESONATE HF,RESONATE, PERCIVA HF,PERCIVA, andMOMENTUM devices.\\nProgramming theRhythmMatch ThresholdparameterwilladjustthethresholdusedbyVectorTimingandCorrelation\\ntodetermine whether apatient\\'s rhythmcorrelatestotheirnormalsinusrhythmtemplate. Byadjusting the\\nRhythmMatch Threshold,youcanadjusthowthepulsegeneratordiscriminates between VTandSVT.\\nTheRhythmMatch Threshold isprogrammable between 70%and96%,withanominal valueof94%.DuringVector\\nTimingandCorrelationanalysis, thepulsegenerator usestheprogrammed RhythmMatch Thresholdasthecriteriafor\\nclassifying thepatient\\'s rhythmaseitherVTorSVT(\"Vector TimingandCorrelation\"onpage2-21).\\nThepulsegeneratorrecordsaRhythmMatch scoreforthedetected rhythmbasedonthecalculated correlationvalues\\nusedtoclassifytherhythmasVTorSVT.UptotwomeasuredRhythmMatch valuesmayberecorded:oneifand\\nwhentherapy isfirstinhibited (byRhythm ID),andoneifandwhentherapyisattempted. Themeasured\\nRhythmMatch valuesarerecordedevenifRhythm IDisnotenabled, aslongasareferencetemplate hasbeen\\nacquired.\\nIfRhythm IDisenabled, eachbeat\\'smeasured correlation value,aswellasanindication ofwhether thebeatwas\\nclassified ascorrelated oruncorrelated,isrecordedinthestoredelectrogr amsduringInitialDetection. These\\nmeasuredcorrelation valuesmaybehelpfulindetermining thebestRhythmMatch Thresholdvaluetoprogramforthe\\npatient. Inaddition, measuredcorrelationvaluesforVFbeatsmaybehelpfulinprogramming theVFzonerate\\nthreshold.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 50}), Document(page_content=\"2-22Tachyarrhythmia Detection\\nVentricular Detection Enhancements\\nNOTE:Undercertaincircumstanc es,therecordedcorrelationdataforsomeindividual beatsmaynotbedisplayed\\nontheprogrammer screen.\\nNOTE:Whenthememory allocated toEGMstorageisfull,thedeviceoverwritesolderEGMdatasegments inorder\\ntostorenewEGMdata.Eventsmustbesavedinordertopreservethecalculated RhythmMatch valuesandthe\\nmeasuredbeat-to-beat correlation valuesforfuturereference.\\nWhenreprogramming theRhythmMatch Thresholdvalue,considerthefollowing:\\n•ResultsfromtheUSVITALITY clinicalstudyprovideevidenceofthesafetyandeffectiveness oftheVITALITY with\\nRhythm ID.IntheUSVITALITY study,theRhythmMatch Thresholdwas94%1\\n•ReviewthemeasuredRhythmMatch valuesforprevious episodes ofVTandSVT(induced orspontaneous)\\n•Toincreasethelikelihoodofappropriatetreatment ofVT,theRhythmMatch Thresholdshouldbeprogrammed\\nabovethemeasuredRhythmMatch valuesofanyVTs\\n•Toincreasethelikelihoodofappropriateinhibition oftherapyforSVT,theRhythmMatch Threshold shouldbe\\nprogrammed belowthemeasured RhythmMatch valuesofanySVTs\\n•Ingeneral,thesensitivity ofVTdetection declines withlowerprogrammed RhythmMatch Thresholdvalues,\\nthereforeformaximum sensitivity toVT,thehighestappropriateRhythmMatch Thresholdvalueshouldbe\\nprogrammed.\\n•Measure dRhythmMatch valuesmayalsobeusefulforprogramming otherRhythm IDparameters including Atrial\\nTachyarrhythmia Discrimination, AFibRateThreshold,andStability\\n•BydecreasingtheRhythmMatch Threshold,thefollowing willoccur(Figure2–17Programming theRhythmMatch\\nthresholdonpage2-23):\\n–Thepatient's rhythmismorelikelytocorrelatetothestoredreferencetemplate\\n–Thepulsegeneratorwillbelesssensitive toVT\\n–ThepulsegeneratorwillbemorelikelytoclassifytherhythmasSVTandinhibittherapy\\n–IftheRhythmMatch Threshold isprogrammed toolow,VTcouldgountreate d\\n•ByincreasingtheRhythmMatch Threshold,thefollowing willoccur(Figure2–17Programming theRhythmMatch\\nthresholdonpage2-23):\\n–Thepatient's rhythmislesslikelytocorrelatetothestoredreferencetemplate\\n–Thepulsegeneratorwillbemoresensitive toVT\\n–ThepulsegeneratorwillbelesslikelytoclassifytherhythmasSVTandinhibittherapy\\n–IftheRhythmMatch Threshold isprogrammed toohigh,therapymaynotbeinhibited forSVTepisodes\\nTherefore,itisimportant toreviewpastepisodes ofVTandSVTanddetermine whatRhythmMatch Thresholdis\\nsufficiently abovethepatient's correlation valuesforVT,butstillbelowthecorrelation valuesforSVT.Thismayallow\\nthepulsegeneratortomoreaccuratelydistinguish between VTandSVT,andpotentially reducedelivery of\\ninappropr iatetherapy.\\n1.TheUSVITALITY ClinicalSummary canbefoundatwww.bostonscientific -elabeling.com.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 51}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Detection Enhancemen ts2-23\\n94%\\n 96% 80% 90% 70%\\n[1]Nominal RhythmMatch Threshold value[2]Lesssensitive toVT,morespecificforSVT[3]Moresensitive toVT,lessspecificforSVT\\nFigure2–17.Programming theRhythmMatch threshold\\nSeeFigure2–18Relationship between sensitivity andspecificity usingRhythmMatch Thresholdonpage2-23foran\\nillustrationoftherelationship between sensitivity andspecificity toVTatthepopulation levelastheRhythmMatch\\nThresholdvalueisincreasedordecreased(RhythmMatch Thresholdisprogrammable between 70%and96%,witha\\nnominal valueof94%).Ingeneral,astheRhythmMatch Threshold isincreased,sensitivity toVTincreases,and\\nspecificity forSVTdecreases.AstheRhythmMatch Thresholdisdecreased, sensitivity toVTdecreases,andspecificity\\nforSVTincreases. Thisrelationship canalsobestatedasfollows: athigherprogrammed RhythmMatch Threshold\\nvalues,anarrhythmia ismorelikelytobeclassified asVTandlesslikelytobeclassified asSVT,whileatlower\\nprogrammed RhythmMatch Thresholdvalues,anarrhythmia ismorelikelytobeclassified asSVTandlesslikelytobe\\nclassified asVT.\\nNotethattheUSVITALITY clinicalstudydemonstrated thatwiththeRhythmMatch Thresholdvaluepermanently\\nprogrammed to94%,observed sensitivity toVTwas100%andobservedspecificity toSVTwas94%forspontaneous\\nepisodes.\\n100%\\n65%\\n70 96\\n[1]Programmed RhythmMatch Threshold (%)[2]Sensitivity orspecificity percentage[3]Sensitivity toVT[4]Specificity forSVT\\nFigure2–18.Relationship between sensitivity andspecificity usingRhythmMatch Threshold\\nVRate>ARate\\nTheVRate>ARate(ventricular rategreaterthanatrialrate)enhancement comparestheatrialandventricular ratesto\\nclassifythetypeoffastventricular rhythm. Whentheventricular rateisgreaterthantheatrialrate,therapy willbe\\ninitiated regardlessoftheanalysis oftheotherprogrammed detection enhancements.\\nAnalysis ismadebycomparing theaverage rateofthelast10ventricular intervalspriortotheendofDurationtothe\\naveragerateofthelast10atrialintervals priortotheendofDuration (Figure2–19VRate>ARateanalysis onpage2-\\n24).Iffewerthan10atrialintervalsareavailable, thoseintervals willbeusedtocalculate theaverageatrialrate.This\\nanalysis isperformed usingthefollowing criteria:', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 52}), Document(page_content='2-24Tachyarrhythmia Detection\\nVentricular Detection Enhancements\\n•Iftheaverageventricular rateisgreaterthantheaverageatrialratebyatleast10bpm,theventricular rateis\\ndeclaredtobefasterthantheatrialrate(indicated asTrueontheEpisode DetailReport), andtherapywillbe\\ninitiated.\\n•Iftheaverageventricular rateisnotgreaterthantheaverage atrialratebyatleast10bpm(indicated asFalseon\\ntheEpisode DetailReport), therapymaycontinue tobeinhibited. TheEpisode DetailReportwillindicate the\\nmeasuredvalueeventhoughtheparamete rmaybeprogrammed toOff.\\nIftherapyisinhibited, theVRate>ARateanalysis continuesuntileithertheventricular rateisgreaterthantheatrial\\nrateorotherenhancements indicate therapytreatment, atwhichtimetherapy willbeinitiated.\\nNOTE:VRate>ARateisnotevaluated duringredetection following ATPtherapy.\\n400 380 420 390 410 400 360 440 410 \\n390 \\n580 620 600 640 560 600 580 600 \\n620 \\n1 2 3 4 5 6 7 8 9 \\n1 2 3 4 5 6 7 8 \\nNumber of \\nIntervals \\nIntervals \\nin ms \\nThird fast interval (of the 8 out \\nof 10 that satisfy the detection \\nwindow) \\nStart Duration. \\nEvaluate Onset. \\nCompute the sum of 10 most recent ventricular \\nintervals. Average = 400 ms = 150 min\\n-1\\n (bpm).\\nDuration expired. \\nOnset is gradual. \\nAnalyze V Rate > A Rate. \\nDeliver therapy because V > A. Average ventricular rate (150 min\\n-1\\n \\n[bpm]) is greater than average \\natrial rate (100 min\\n-1\\n [bpm]) by at \\nleast 10 bpm, so delivery therapy .\\nCompu te the su m of the atrial intervals. \\nAverage = 600 ms = 100 min\\n-1\\n (bpm).\\nNumber of Intervals \\nIntervals in \\nms \\nAtrium \\nVentricle \\nVT detected \\nATP therapy \\nFigure2–19.VRate>ARateanalysis\\nVRate>ARatecanbeprogrammed tobypassinhibitors (VectorTimingandCorrelation, AFibRateThreshold,\\nStability, and/orOnset)andinitiatetherapyintheeventthattheventricular rateisfasterthantheatrialrate.\\nNOTE:Referto\"UseofAtrialInformation\" onpage2-5foradditional information aboutdeviceperformanc ewhen\\ntheatrialleadisprogrammed toOff.\\nNOTE:InaRhythm IDconfiguration, theevaluation ofVRate>ARateislinkedtotheAFibRateThreshold.IfAtrial\\nTachyarrhythmia Discrimination isprogrammed toOff,theAFibRateThresholdandVRate>ARatedetection\\nenhancement sarenotevaluated.\\nAFibRateThreshold\\nAFibRateThresholdanalysis identifies AFbycomparingtheatrialratetotheprogrammed AFibRateThreshold.\\nAFibRateThresholdcannotbeenabled without alsoenabling theStability detection enhance ment.Thedevice\\nanalyzes bothparamet erstodetermine whether towithhold ordelivertherapy.\\nIftheintrinsic atrialrateisgreaterthantheAFibRateThresholdandtheventricular rhythmisclassified asUnstable,\\ntheventricular rhythmisdeclaredtobeduetoAF.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 53}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Detection Enhancemen ts2-25\\nTheintrinsic atrialrateisdeclaredtobeabovetheAFibRateThreshold inthefollowing manner (Figure2–20\\nInteractionofAFibRateThreshold andStability onpage2-25):\\n•Atrialanalysis beginsatinitiation ofventricular tachyarrhythmia detection. Eachatrialintervalisclassified as\\nfasterorslowerthantheAFibRateThreshold Interval.\\n•When6ofthelast10intervalsareclassified asfasterthantheAFibRateThreshold, thedevicedeclaresAFtobe\\npresent.\\n•Ventricular stability isthenchecked.Ifunstable, therapyisinhibited.\\nIntheeventthatventricular therapyisnotdelivered, theatrialratecontinuestobeexamine d.Aslongas4of10\\nintervals remainclassified asfast,AFisconsider edpresent.Therapyisinhibited byAFibRateThreshold/Stability until\\nanyofthefollowing occur:\\n•TheatrialratedropsbelowtheAFibRateThreshold\\n•Theventricular rhythmbecomesstable\\n•Ifprogrammed toOn,VRate>ARateistrue\\n•SRDtimesout\\n1 2 3 4 5\\n 6 7 8 \\nOnly 3 of 10 intervals are \\nabove the AFib Rate Threshold \\n4 of 10 > AFib Rate Threshold \\n4 of 10 intervals must remain \\n> AFib Ra\\nte Thresh\\nold \\n6 of 10 atrial intervals are greater \\nthan AFib Rate Threshold \\nThird fast interval (of the 8 \\nout of 10 that satisfy the \\ndetection window) \\nDetection satisfied. \\nStart duration. \\nStart episode. \\nStart Stability analysis. Atrial rate > \\nAFib Rate \\nThreshold. \\nDuration expires. \\nAtrial rate > AFib Rate Threshold. \\nRhythm declared unstable. \\nTherapy is inhibited. Rhythm remains unstable. \\nAtrial rate is less than \\nAFib Rate Threshold. \\nInitiate therapy . ATP thera\\npy \\nVT detect\\ned \\nVentricle\\nAtrium \\nFigure2–20.Interaction ofAFibRateThreshold andStability\\nWhenAFibRateThreshold andStability areusedalone,ventricular therapyisinitiated whenastablerhythmis\\ndeclared.Ventricular therapyisinitiated foranunstable rhythmwhenitisdetermined thattheatrialrateislessthan\\ntheAFibRateThreshold(Table2–10AFibRateThresholdandStability combinations andresulting therapyonpage2-\\n26).WhenAFibRateThresholdandStability areusedwithotherinhibitor enhancemen ts,ventricular therapyisnot\\nalwaysinitiated whennolongerinhibited byAFibRateThreshold/Stability. Therapymaycontinuetobeinhibited by\\notherprogrammed detection enhancements, suchasOnset(whentheOnset/Stability detection enhancement suiteis\\nenabled) orVectorTimingandCorrelation(whentheRhythm IDdetection enhance mentsuiteisenabled).\\nConsider thefollowing information duringtheseinteractions:\\n•TheAFibRateThresholdandVRate>ARatedetection enhancement sarenotevaluated ifAtrialTachyarrhythmia\\nDiscrimination isprogrammed toOffinaRhythm IDconfiguration.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 54}), Document(page_content='2-26Tachyarrhythmia Detection\\nVentricular Detection Enhancements\\n•Because theAFibRateThresholdisnotevaluated duringredetection (following ventricular ATPtherapydelivery,\\nanyaborted ventricular therapy,ortherapynotavailable), theEpisode DetailReportwillnotdisplaydataforthe\\nenhancement duringredetection,eventhoughtheparameterisprogrammed On.\\n•TheAFibRateThreshold enhancement isnotevaluated forarrhythmia detection inthefollowing cases;however ,\\ntheEpisode DetailReportwillstilldisplaythedatafortheAFibRateThreshold enhancement basedona\\nthresholdof170bpm:\\n–TheAFibRateThresholdisprogrammed toOff\\n–Ventricular Zonesisprogrammed to1\\n–Nodetection enhancement suiteisenabled\\n•Anatrialsenseeventwillonlybeclassified asAFwhiletheAFibRateThresholdisbeingevaluated forarrhythmia\\ndetection.\\nTable2–10.AFibRateThreshold andStabilitycombinationsandresulting therapy\\nDetected Ventricular RhythmaTherapyDecisionb\\nUnstable, A>AFibRateThreshold Inhibit\\nStable,A>AFibRateThreshold Treat\\nUnstable, A<AFibRateThreshold Treat\\nStable,A<AFibRateThreshold Treat\\na.Ifthedetected ventricular rhythmchanges, thentheappropriate, corresponding rowinthetableisevaluated.\\nb.Decisions toinhibitcanbeoverridden byV>Aorexpiration ofSRD.\\nNOTE:Referto\"UseofAtrialInformation\" onpage2-5foradditional information aboutdeviceperformanc ewhen\\ntheatrialleadisprogrammed toOff.\\nStabilityAnalysis\\nStability analysis distinguishes Unstable (irregular)ventricular rhythms fromStable(regular) ventricular rhythms. This\\nisaccomplished bymeasuring thedegreeofvariability ofthetachycard iaR–Rintervals.\\nThisdegreeofvariability ,whenusedalone,mayallowthedevicetodistinguish conducted AF(whichmayproduce\\ngreaterR–Rvariability) frommonomorphic VT(whichistypically stable).ItalsomaybeusedtodifferentiateMVTs\\n(whicharepaceterminable) frompolymorphic VTsandVF(whicharetypically notpaceterminable).\\nBasedonthepatient\\'s needs,youmaychoosetoprogramStability asaninhibitor topreventtherapyforAF,oruse\\nstability analysis todirectthetypeoftherapytobedelivered(ShockifUnstable).\\nThestability algorithm calculates RVR–Rintervaldifferences.Thesedifferencesarecalculated throughout Duration;\\nanaveragedifferenceisalsocalculated. WhenDurationexpires,rhythmstability isevaluated bycomparing the\\ncurrentaveragedifferencetotheprogrammed Stability thresholdand/orShockifUnstable thresholds. Iftheaverage\\ndifferenceisgreaterthantheprogrammed thresholds, therhythmisdeclared Unstable. Independent thresholds are\\navailable fortheStability (toinhibit)orShockifUnstable functions; youcannotprogrambothinthesameventricular\\nzone.\\nThepulsegenerator performs stability calculations forallepisodes (evenwhenStability isprogrammed toOff)and\\nstorestheresultsinTherapyHistory.Thisstoreddatamaybeusedtoselectanappropriate stability threshold.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 55}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Detection Enhancemen ts2-27\\nStabilitytoInhibit\\nTheStability paramet ermayhelpyouidentify rapidrhythms originating intheatrium,suchasAF.Theserhythms may\\nresultinunstable ventricular rhythms whoserateexceedsthelowestratethresholdandshouldnotbetreated.Ifa\\nrhythmisdeclaredstablewhenDuration expires,programmed therapywillbedelivered.Iftherhythmisdeclared\\nUnstable, ventricular therapywillbeinhibited.\\nAttheendofinitialDuration, ifatachycard iaisdeclaredUnstable andventricular therapyisinhibited, thepulse\\ngeneratorcontinuestoevaluate forstability oneachnewdetected interval(Figure2–21Stability evaluation when\\nDurationexpiresonpage2-27).Therapywillnotbeinhibited byStability if:\\n•VRate>ARatedeclarestheventricular rategreaterthantheatrialrate\\n•TheSRDhasexpired(ifprogrammed toOn)\\nVentricular therapyisnotalwaysinitiated whennolongerinhibited byStability. Therapymaycontinuetobeinhibited\\nbyotherprogrammed detection enhancements, suchasOnset(whentheOnset/Stability detection enhancement\\nsuiteisenabled) orVectorTimingandCorrelation (whentheRhythm IDdetection enhancement suiteisenabled).\\nNOTE:Ventricular Therapycanalsobeinhibited throughanalysis oftheStability algorithm asitisusedwiththe\\nAFibRateThresholdenhancement .\\nUnstable  intervals \\nDetection window satisfied. \\nStart Duration. \\nStability analysis begins. \\nDuration expires. \\nRhythm declared unstable. \\nStart SRD. \\nTherapy inhibited until rhythm stabilizes, V is greater \\nthan A, or SRD times out. Stability analysis continues \\nFigure2–21.Stabilityevaluation whenDuration expires\\nShockifUnstable\\nWhenprogrammed toShockifUnstable, thestability analysis helpsdetermine ifventricular ATPtherapyshouldbe\\nbypassed inpreferenceforthefirstprogrammed ventricular shocktherapy(whichmaybelow-orhigh-energ y)forthe\\nventricular zone(Figure2–22ShockifUnstable onpage2-28).\\nDynamic ventricular arrhythmias suchaspolymorphic VTorVFmaybesensedataratelowerthanthehighest\\nventricular ratethresholdandcanbeclassified asUnstable. Sincethesensedrhythmmaybedetected inalower\\nventricular zoneinwhichATPmaybeprogrammed, thestability analysis maybeusedtoskipovertheprogrammed\\nventricular ATPtherapiesandinsteadprovideshockstothepatient. Stability isevaluated oneachdetection/\\nredetection cycle,including evaluation between burstsofanATPscheme. Onceaventricular shockhasbeendelivered\\ninanepisode, theShockifUnstable function nolongeraffectstherapyselection.\\nShockifUnstable maybeusedonlyintheVTzoneofa2-or3-zoneconfiguration. Youcannotprogramitina2-zone\\nconfiguration ifStability orOnsetisalreadyprogrammed toOn,orifPostVShockStability orAFibRateThreshold is\\nprogrammed toOn.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 56}), Document(page_content='2-28Tachyarrhythmia Detection\\nVentricular Detection Enhancements\\nDetection window satisfied. \\nStart Duration. \\nStability analysis begins. \\nDuration expires. \\nRhythm declared stable. \\nDeliver programmed ATP \\ntherapy . \\nStart \\nRedetection. \\nDetection window \\nsatisfied. \\nStart Redetection \\nDuration. \\nReanalyze Stability . Redetection Duration expires. \\nRhythm declared unstable. \\nSkip remaining ATP and \\nproceed to the first \\nprogrammed shock therapy . Charging \\nShock \\nATP Burst \\nFigure2–22.ShockifUnstable\\nOnset\\nOnsetdifferentiatesphysiologic sinustachycard ias,whichtypically beginslowly,frompathologic tachycard ias,which\\ntypically beginabruptly .Itmeasurestherateoftransition intheventricular rhythmfromslowratestotachycard ia.If\\ntherateincrease isgradual, itenables thedevicetoinhibitventricular therapyinthelowesttachycard iaratezone.\\nWhenadetection window becomes satisfied, thepulsegeneratorbeginscalculating forsuddenOnsetinatwo-stage\\nsequenc e.\\n•Stage1measurestheventricular intervalspriortothestartoftheepisode andlocatesthepairofadjacent\\nintervals(pivotpoint)wherethecyclelengthdecreasedthemost.Ifthedecrease incyclelengthisequaltoor\\ngreaterthantheprogrammed Onsetvalue,stage1declares suddenOnset.\\n•Stage2thencompares additional intervals.Ifthedifferencebetween theaverage intervalbeforethepivotpoint\\nand3outofthefirst4intervals following thepivotpointisequaltoorgreaterthantheprogrammed Onset\\nThreshold, stage2declaressuddenOnset.\\nIfbothstagesdeclaretherhythmsudden, therapy willbeinitiated. Ifeitherstageindicates agradualonset,initial\\nventricular therapywillbeinhibited inthelowestzone.Therapy willnotbeinhibited byOnsetif:\\n•Therateaccelerates toahigherventricular zone\\n•Information fromtheatrialleaddetermines thattheRVrateisfasterthantheatrialrate(VRate>ARate\\nprogrammed toOn)\\n•TheSRDtimerexpires\\nOnsetismeasuredusingRVintervalsonly.Itcanbeprogrammed asapercentageofcyclelengthorasaninterval\\nlength(inms).Itislimitedtothelowesttherapyzoneofamulti-zone configur ation.Theselected Onsetvalue\\nrepresents theminimum differencethatmustexistbetween intervalsthatareaboveandbelowthelowest\\nprogrammed ratethreshold.Thepulsegeneratorperforms Onsetcalculations (evenwhenthefeatureisprogrammed\\ntoOff)forallepisodes exceptinduced orcommanded episodes. ThemeasuredOnsetresultsfromatwo-stage\\ncalculation arestoredinTherapyHistory.Thisstoreddatamaybeusedtoprogramanappropriate Onsetvalue.\\nSustained RateDuration (SRD)\\nSustained RateDuration allowsdelivery oftheprogrammed ventricular therapy whenatachycardia issustained fora\\nprogrammed periodbeyond Duration ,buttheprogrammed therapyinhibitors (VectorTimingandCorrelation, AFib\\nRateThreshold,Onset,and/orStability) indicate towithhold therapy(Figure2–23Combination ofOnsetORStability,\\nSRDprogrammed ononpage2-29).', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 57}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Detection Enhancemen ts2-29\\n0 s 5 s 35 s\\n0 s\\n30 s\\nDuration = 5 seconds\\nSRD = 30 seconds\\nEvaluate programmed detection \\nenhancements. If enhancements \\nindicate to inhibit therapy , start \\nSRD timer; otherwise, deliver \\ntherapy .\\nContinue detection \\nenhancement \\nanalysis throughout \\nSRD time.\\nIf detection \\nenhancements \\nindicate therapy , \\ndeliver therapy .\\nSRD times out. \\nDeliver therapy .\\nDetection window \\nsatisfied\\nDuration starts. Start \\ndetection enhancement \\nanalysis.Duration expires.\\nFigure2–23.Combination ofOnsetORStability,SRDprogrammed on\\nSRDisavailable inazoneonlywhenaninhibitor enhance mentisprogrammed oninthatzone.WhentheRhythm ID\\ndetection enhancement suiteisenabled, SRDmaybeprogrammed separatelyfortheVTandVT-1zones.\\n•Aprogrammed SRDtimerbeginsifventricular therapyiswithheld whentheDuration expiresinazonewhere\\ndetection enhancements areprogrammed On.\\n•Ifthedetection window inthelowestzoneismaintained fortheprogrammed SRDperiod,theprogrammed\\nventricular therapywillbedeliveredattheendoftheVT-1SRDperiodifVT-1SRDisprogrammed andtherhythm\\nisintheVT-1zone.TherapywillbedeliveredattheendoftheVTSRDperiodifVTSRDisprogrammed andthe\\nrhythmisintheVTzone.\\n•Iftherateacceleratestoahigherventricular zone,detection enhancemen tsarenotprogrammed toOninthe\\nhigherzone,andtheDurationforthehigherzoneexpires,therapyisinitiated inthatzonewithout waitingfor\\nSRDtime-out inalowerventricular zone.IfSRDisprogrammed toOff,anSRDtimerwillnotstartwhenDuration\\nexpires,thusallowing detection enhancemen tstopotentially inhibittherapy indefinitely .\\nAnindependent Post-shockSRDvaluemaybeprogrammed.\\nCombinations ofAFibRateThreshold, Stability,andVectorTimingandCorrelation\\nThecombination ofAFibRateThreshold, Stability, andVectorTimingandCorrelationaddspecificity toventricular\\ndetection beyond rateandduration.Inaddition tousingAFibRateThresholdandStability toidentify AF,this\\ncombination ofenhancement susesVectorTimingandCorrelation analysis todifferentiate SVTrhythms fromVT\\nrhythms basedonconduction patterns withintheheart.\\nTheAFibRateThreshold,Stability, andVectorTimingandCorrelationdetection enhanceme ntcombinat ionalso\\nincludes VRate>ARate;bothAFibRateThreshold andVRate>ARateareenabled whenAtrialTachyarrhythmia\\nDiscrimination isprogrammed toOn.Thiscombination isonlyavailable whentheRhythm IDdetection enhancement\\nsuiteisenabled, andonlyforInitialDetection (Table2–11AFibRateThreshold,Stability,andVectorTimingand\\nCorrelationcombinations andresulting therapydecision ifAtrialTachyarrhythmia Discrimination isprogrammed toOn\\nonpage2-29).\\nIfVRate>ARateisprogrammed toOn(byprogramming AtrialTachyarrhythmia Discrimination toOn)andisTrue,it\\nwilltakeprecedenceoverallinhibitor enhancemen ts.\\nTable2–11.AFibRateThreshold, Stability,andVectorTimingandCorrelation combinations andresulting therapydecisionifAtrialTachyarrhythmia\\nDiscrimination isprogrammed toOn\\nDetected Ventricular RhythmabcTherapyDecisiond\\nCorrelated, Unstable, A>AFibRateThreshold Inhibit\\nCorrelated, Unstable, A<AFibRateThreshold Inhibit\\nUncorrelated,Unstable, A>AFibRateThreshold Inhibit', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 58}), Document(page_content='2-30Tachyarrhythmia Detection\\nVentricular Detection Enhancements\\nTable2–11.AFibRateThreshold, Stability,andVectorTimingandCorrelation combinations andresulting therapydecisionifAtrialTachyarrhythmia\\nDiscrimination isprogrammed toOn(continued)\\nDetected Ventricular RhythmabcTherapyDecisiond\\nUncorrelated,Unstable, A<AFibRateThreshold Treat\\nCorrelated,Stable,A>AFibRateThreshold Inhibit\\nCorrelated,Stable,A<AFibRateThreshold Inhibit\\nUncorrelated,Stable,A>AFibRateThreshold Treat\\nUncorrelated,Stable,A<AFibRateThreshold Treat\\na.Ifthedetected ventricular rhythmchanges, thentheappropriate, corresponding rowinthetableisevaluated.\\nb.IfaRhythm IDreferencetemplate isnotavailable, thedetected ventricular rhythmisconsider edtobeUncorrelated.\\nc.ForPost-ShockDetection (ifenabled), VectorTimingandCorrelation isconsider edtobeUncorrelated.\\nd.Decisions toinhibitcanbeoverridden byV>Aorexpiration ofSRD.\\nWhenAtrialTachyarrhythmia Discrimination isprogrammed toOff,thenVectorTimingandCorrelationisusedfor\\nInitialDetection andStability isusedforPost-ShockDetection. VRate>ARateandAFibRateThresholdarenolonger\\nused(Table2–12VectorTimingandCorrelationandStability combinations withresulting therapydecision ifAtrial\\nTachyarrhythmia Discrimination isprogrammed toOffonpage2-30).\\nTable2–12.VectorTimingandCorrelation andStabilitycombinations withresulting therapydecisionifAtrialTachyarrhythmia Discrimination is\\nprogrammed toOff\\nDetectionabDetected Ventricular RhythmacTherapyDecision\\nInitial Correlated Inhibitd\\nInitial Uncorrelated Treat\\nPost-Shock Unstable Inhibitd\\nPost-Shock Stable Treat\\na.Ifthedetected ventricular rhythmchanges, thentheappropriate, corresponding rowinthetableisevaluated.\\nb.IfAtrialTachyarrhythmia Discrimination isprogrammed toOff,thenVectorTimingandCorrelation isusedforInitialDetection, andStability isusedforPost-ShockDetection.\\nc.IfaRhythm IDreferencetemplate isnotavailable, thedetected ventricular rhythmisconsider edtobeUncorrelated.\\nd.Decision toinhibitcanbeoverridden byexpirationofSRD.\\nCombinations ofAFibRateThreshold, Stability,andOnset\\nThecombination ofAFibRateThreshold,Stability, andOnsetaddspecificity toventricular detection beyond rateand\\nduration.Thiscombination ofdetection enhancements isavailable onlywhentheOnset/Stability detection\\nenhancement suiteisenabled andisavailable onlyforInitialDetection. Whendetection enhancements areenabled,\\ntheywillacttorecommend orinhibittherapyforaspecificzone.\\nIfAFibRateThreshold,Stability, andOnsetparametersareallprogrammed toOn,ventricular therapy willbeinitiated\\niftherhythmhasasuddenonsetprovided thateithertheventricular rateisstableortheatrialrateislessthanthe\\nAFibRateThreshold(Table2–13AFibRateThreshold,Stability,andOnsetcombination sandresultingventricular\\ntherapyonpage2-30).\\nTable2–13.AFibRateThreshold, Stability,andOnsetcombinatio nsandresulting ventricular therapy\\nDetected Ventricular RhythmaTherapyDecisionb\\nGradual, Unstable, A>AFibRateThreshold Inhibit\\nGradual, Unstable, A<AFibRateThreshold Inhibit\\nSudden, Unstable, A>AFibRateThreshold Inhibit\\nSudden, Unstable, A<AFibRateThreshold Treatc', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 59}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Detection Enhancemen ts2-31\\nTable2–13.AFibRateThreshold, Stability,andOnsetcombinations andresulting ventricular therapy (continued)\\nDetected Ventricular RhythmaTherapyDecisionb\\nGradual, Stable,A>AFibRateThreshold Treat\\nGradual, Stable,A<AFibRateThreshold Inhibit\\nSudden, Stable,A>AFibRateThreshold Treat\\nSudden, Stable,A<AFibRateThreshold Treat\\na.Ifthedetected ventricular rhythmchanges, thentheappropriate, corresponding rowinthetableisevaluated.\\nb.Decisions toinhibitcanbeoverridden byV>AorexpirationofSRD.\\nc.IfVRate>ARateisprogrammed toOnandisFalse,ventricular therapy willbeinhibited because therhythmisunstable.\\nIfVRate>ARateisprogrammed toOnandisTrue,itwilltakeprecedenceoverallinhibitor enhancement s.\\nCombinations ofOnsetandStability\\nWhenStability isprogrammed toinhibit,itmaybecombined withOnsettoprovide evengreaterspecificity in\\nclassifying arrhythmias.\\nThiscombination ofdetection enhanceme ntsisavailable onlywhentheOnset/Stability detection enhance mentsuite\\nisenabled andisavailable onlyforInitialDetection. Theenhancement scanbeprogrammed toinitiateventricular\\ntherapyifthefollowing options areselected (Table2–14Combinations ofOnsetAndStability andresultingtherapy on\\npage2-31):\\n•BothOnsetAndStability indicate totreat\\n•EitherOnsetOrStability indicates totreat\\nBasedontheseprogramming decisions, ventricular therapyisinhibited whenanyofthefollowing criteriaismet:\\n•Ifthecombination programmed isOnsetAndStability, ventricular therapyisinhibited ifeitherparamet er\\nindicates thattherapyshouldbewithheld; thatis,therhythmisgradual Orunstable (theAndcondition totreatis\\nnotsatisfied).\\n•Ifthecombination programmed isOnsetOrStability, ventricular therapyisinhibited immediately attheendof\\nDurationonlyifbothparamet ersindicate thattherapyshouldbewithheld; thatis,therhythmisgradual and\\nunstable (theOrcondition totreatisnotsatisfied).\\nIneithercase,ventricular therapywillbeinitiated onlyiftheAnd/Orcondition stotreataresatisfied. Whenthesetwo\\ncombinations (And/Or) areusedinconjunction withSRD,andtheAnd/Orconditions arenotsatisfied, ventricular\\ntherapywillbeinhibited untilVRate>ARateisTrueorSRDtimesout(Table2–14Combinations ofOnsetAnd\\nStability andresultingtherapyonpage2-31).\\nTable2–14.Combinations ofOnsetAndStabilityandresulting therapy\\nDetection Rhythm OnsetAndStabilityCombinationabcOnsetOrStabilityCombinationc\\nGradual, Unstable Inhibit Inhibit\\nGradual, Stable Inhibit Treat\\nSudden, Unstable Inhibit Treat\\nSudden, Stable Treat Treat\\na.Ifthedetected ventricular rhythmchanges, thentheappropriate, corresponding rowinthetableisevaluated.\\nb.TheAndcombination isthenominal settingwhenbothareenabled.\\nc.Decisions toinhibitcanbeoverridden byV>AorexpirationofSRD.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 60}), Document(page_content='2-32Tachyarrhythmia Detection\\nVentricular Detection Enhancements', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 61}), Document(page_content='3-1\\nTACHYARRHYTHMIA THERAPY\\nCHAPTER 3\\nThischaptercontainsthefollowing topics:\\n•“Ventricular Therapy” onpage3-2\\n•“Antitachycar diaPacingTherapies andParameters” onpage3-7\\n•“Ventricular ShockTherapyandParamete rs”onpage3-15', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 62}), Document(page_content='3-2Tachyarrhythmia Therapy\\nVentricular Therapy\\nVENTRICULAR THERAPY\\nThepulsegenerator candeliverthefollowing typesoftherapy toterminate VTorVF:\\n•Antitachycardia pacing(ATP)\\n•Cardioversion/defibr illationshocks\\nATPpacingschemes areburstsofpacingpulsesdelivered between theventricular pace/sense electrodes. Shocksare\\nhigh-voltage biphasic pulsesdeliveredthroughtheshocking electrodessynchronously withdetected heartactivity.\\nWARNING: DuringMRIProtectionMode,Tachycardia therapyissuspended. Thesystemwillnotdetectventricular\\narrhythmias andthepatientwillnotreceiveATPorshockdefibrillation therapyuntilthepulsegeneratoris\\nprogrammed backtonormaloperation.Onlyscanthepatientifjudgedtobeclinically capable oftoleratin gno\\nTachycar diaprotectionfortheentireduration inwhichthepulsegeneratorisinMRIProtection Mode.\\nVentricular TherapyPrescription\\nAventricular therapyprescriptiondetermines thetypeoftherapytobedeliveredinaparticular ventricular ratezone.\\nItconsists ofventricular ATPand/orshocks.Eachventricular zonemaybeprogrammed withindependent ventricular\\ntherapyprescriptions (Figure3–1Ventricular therapyprescription,3-zoneconfiguration onpage3-2).\\nLowest strength Highest strength\\nWithin each zone, therapy strength must be  in ascending order .\\nZone\\nATP1\\n2\\nATP2\\n2\\nQUICK \\nCONVERT ATP\\nShock 1\\n1\\nShock 2\\n1\\nRemaining (Maximum) \\nShocks\\n1\\nVF\\nVT\\nVT-1\\nNot available\\nAll ATP type\\ns \\navailable\\nOn/Of f\\nN/A\\nN/A\\n0.1-max J\\n0.1-max J\\n0.1-max J\\n0.1-max J\\n0.1-max J\\n0.1-max J\\nmax J\\nmax J\\nmax J\\nAll ATP type\\ns \\navailable\\nAll ATP type\\ns \\navailable\\nAll ATP type\\ns \\navailable\\nBetween \\nzones, \\ntherapy \\nstrengths \\nare not \\nrestricted.\\n1 \\nIn the lowest zone of a multi-zone config uration, some or all of the shocks may be programmed to Of f, starting with the maximum shocks \\nfirst. If the maximum shocks are program med to Of f, then Shock 2 can be programmed to Of f. If Shock 2 is programmed to Of f, then \\nShock 1 can be programmed to Of f. If th e arrhythmia persists in the lowest zone when some or all of the shocks are programmed to Of f, \\nno further therapy will be delivered unle ss the arrhythmia accelerates to a higher zone. A Disab\\nle Therap\\ny button \\nis availa\\nble in th\\ne VT or \\nVT-1 zone\\ns’ therap\\ny window \\nto quickl\\ny disable\\n all ATP \\nand Shock\\n therapy \\nin that z\\none.\\n2\\n Ventricular ATP therapy can be programmed as Off, Burst, Ramp, Scan, or Ramp/Scan in VT-1 and VT zones.\\nFigure3–1.Ventricular therapyprescription, 3-zoneconfiguration\\nThetherapieswithinaventricular zonemustbeorderedinascending therapystrengths. Allventricular ATPtherapies\\nareconsider edtobeofequalstrength,butareoflowerstrengththananyshocktherapy.Thestrengthoftheshock\\ntherapiesisdetermined bytheprogrammed energy.Inamulti-zone configuration, therapiesinahigherventricular\\nzonemaybeoflesser,greater,orequalstrength tothoseinalowerventricular zone;however ,withineachzonethe\\ntherapiesmustbeprogrammed inequalorincreasingenergyoutput.\\nVentricular TherapySelection\\nThepulsegenerator determines whichventricular therapytodeliverbasedonthefollowing rules:\\n•Eachsuccessivetherapydelivery mustbegreaterthanorequaltothestrengthoftheprevioustherapyina\\nventricular episode. Whenever aventricular shocktherapyhasbeendelivered,nofurtherventricular ATPtherapy\\nisallowed inthatepisode sinceATPtherapyisoflowerstrengththanshocktherapy.Eachsubsequent ventricular\\nshockdelivery mustbeofequalorgreaterstrength regardlessofventricular zonechanges duringaventricular\\nepisode.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 63}), Document(page_content='Tachyarrhythmia Therapy\\nVentricular TherapySelection3-3\\n•Eachventricular ATPscheme (whichmayconsistofmultiple bursts)canonlybedeliveredonceduringa\\nventricular episode.\\n•Upto8shocksmaybedeliveredinaventricular episode. Thefirst2shocksareprogrammable. Thefollowing\\nmaximum-ener gy,non-programmable shocksareavailable ineachzone:\\n–VT-1zone:3maximum-energy shocks\\n–VTzone:4maximum-energy shocks\\n–VFzone:6maximum-energy shocks\\nNOTE:Intheeventashockisdiverted withtheDIVERTTHERAPY programmercommand, bymagnet application or\\nduetoaDiverted-Rec onfirm,thediverted shockisnotcountedasoneoftheavailable shocksforthat\\ntachyarrhythmia episode. Also,commanded therapies andSTATSHOCKarenotcountedasoneoftheavailable\\nshocksforanepisode anddonotaffectsubsequent therapyselection.\\nBasedoninitialventricular detection criteria,thepulsegeneratorselectsthefirstprescribed therapyintheventricular\\nzoneinwhichthetachyarrhythmia isdetected (i.e.,detection ismet;referto\"Ventricular Detection\" onpage2-6).\\nAfterdelivering theselected therapy,thepulsegeneratorbeginsredetection todetermine whether thearrhythmia\\nhasbeenconverted.\\n•Ifthearrhythmia isconverted toaratebelowthelowestprogrammed threshold,thepulsegeneratorcontinues\\nmonitoring untiltheendoftheepisode isdeclared.Whentheepisode ends,thepulsegeneratorwillagainuse\\ninitialventricular detection criteriaforanewepisode. Whenanewepisode isdeclared,thefirstprescribed\\ntherapywillbedeliveredagain.\\n•Ifthearrhythmia isnotconvertedandanarrhythmia isredetected inthesameventricular zone,thenext\\nprogrammed therapyinthatzoneisselected anddelivered(Figure3–2Therapydelivery progression, arrhythmia\\nremainsinsamezoneasinitiallydetected onpage3-4),followed againbyredetection.Ifthearrhythmia persists\\ninthesamezone,thetherapywillprogressinthatzone.\\n•Ifanarrhythmia crossesventricular zones(acceleratesordecelerates)following therapy delivery andisredetected\\ninahigherorlowerventricular zone,atherapyofequalorgreaterstrength thanthepreviouslydeliveredtherapy\\nisselected fromthedetected zoneanddelivered.Forshocktherapy,thepulsegenerator determines whichshock\\ntodeliverpriortocapacitor charging basedonthedetected ratethreshold.Ifduringcapacitor charging,the\\ntachyarrhythmia accelerates ordeceleratesfromtheinitialdetected rate,thepredetermined energywillstillbe\\ndelivered.\\nRefertoFigure3–3Therapy delivery progression,ATP1intheVTzoneandshock2intheVFzoneonpage3-4\\nthroughFigure3–10Therapy delivery progression,ATP1inVTzoneacceleratestherhythm, QUICKCONVERT ATP\\nisskipped inVFzoneonpage3-6.\\nRedetection isperformed aftereachtherapydelivertodetermine iffurthertherapyisrequired. Usethefollowing\\ninformation wheninterpret ingthetherapyprogression figures:\\n•Aftereachredetection cycle,therapy delivery progressesinthedirection indicated bythecirclednumbers.\\n•Upward slopinglinesindicate accelerationofthearrhythmia toahigherventricular zone.\\n•Downwar dslopinglinesindicate deceleration intoalowerventricular zone.\\n•TheloweststrengththerapyisintheATPcolumns;thetherapystrengthsincreaseasyoumovetotherightinthe\\ntable.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 64}), Document(page_content='3-4Tachyarrhythmia Therapy\\nVentricular TherapySelection\\nNOTE:IntheVT-1zoneofa3-zoneconfiguration ortheVTzoneofa2-zoneconfiguration, oneortwoATP\\nschemes maybeprogrammed astheonlytherapy,withallshocksinthelowestzoneprogrammed toOff.Ifthose\\npacingschemes donotterminate anarrhythmia detected inthelowestzone,nofurthertherapywillbedeliveredin\\ntheepisode unlesstherateisredetected inahigherzone.\\n1 \\n3 \\n2 \\n4 \\n5 \\n6 \\n7 \\nZone ATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 \\nRemaining Shocks \\nVF \\nVT \\nVT-1 \\nOn/Of f \\nN/A \\nN/A \\n5 J \\n3 J \\n0.1 J \\n11 J \\n9 J \\n2 J \\nBurst Scan \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nFigure3–2.Therapydeliveryprogression, arrhythmia remainsinsamezoneasinitiallydetected\\n1 \\n3 \\n6 \\n7 \\n8 \\n9 \\n4 \\n5 \\n2 \\nZone \\nATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 \\nRemaining Shocks \\nVF \\nVT \\nVT-1 \\nOn/Of f \\nN/A \\nN/A \\n2 J \\n3 J \\n0.1 J \\n11 J \\n9 J \\n2 J \\nBurst Off \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nWhen the rhythm accelerates to the VF zone, Shock \\n2 in the VF zone is delivered since Shock 1 is a lower \\nenergy level than Shock 1 in the VT  zone. \\nATP1 in the VT  zone is delivered \\nbecause it is considered of equal \\nstrength to VT -1 ATP2 therapy . \\nFigure3–3.Therapydeliveryprogression, ATP1intheVTzoneandshock2intheVFzone\\n3 \\n1 \\n8 \\n9 \\n5 \\n4 \\n2 \\n6 \\n7 \\nZone \\nATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 \\nRemaining Shocks \\nVF \\nVT \\nVT-1 \\nOn/Of f \\nN/A \\nN/A \\n11 J \\n5 J \\n3 J \\n17 J \\n9 J \\n5 J \\nBurst Scan \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nWhen the rhythm accelerates back to the VT  \\nzone, ATP2 therapy is delivered because ATP1 \\nhas already been used during the episode. \\nFigure3–4.Therapydeliveryprogression, ATP2therapy', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 65}), Document(page_content='Tachyarrhythmia Therapy\\nVentricular TherapySelection3-5\\n3 \\n5 \\n2 \\n1 \\n4 \\n6 \\n8 \\n9 \\n7 \\nZone ATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 Remaining Shocks \\nVF \\nVT \\nVT-1 \\nOn/Of f \\nN/A \\nN/A \\n5 J \\n1.1 J \\n3 J \\n11 J \\n9 J \\n5 J \\nBurst Scan \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nThis is the thi rd shock, since \\ntwo programm able shocks \\nhave been de livered. \\nWhen the rhy thm decelerates to the VT -1 zone, ATP2 of the VT -1 zone is \\nnot delivered since a shock had already been delivered in the VT  zone. So \\nthe next highe r strength therapy (Shock 1 of the VT -1 zone) is delivered. \\nFigure3–5.Therapydeliveryprogression, shock1intheVT-1zone\\n3 \\n2 \\n1 \\n4 \\nZone \\nATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 \\nRemaining Shocks \\nVF \\nVT \\nVT-1 \\nOn/Of f \\nN/A \\nN/A \\n2 J \\n3 J \\n0.1 J \\n11 J \\n9 J \\n2 J \\nBurst Scan \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nOff Off Off \\nIf the arrhythm ia persists in the VT -1 zone after the second shock delivery , \\nno further shoc k therapy will be delivered unless the arrhythmia ac celerates \\nto a higher zon e sin ce Shocks 3-5 are programmed Of f in the VT -1 zone. \\nFigure3–6.Therapydeliveryprogression, shocks3to5programmed toOffintheVT-1zone\\n5 \\n6 \\n7 \\n3 \\n2 \\n1 \\n4 \\n10 \\n8 \\n9 \\nThe arrhythm ia accelerated back to the VF zone, the \\nseventh shoc k is delivered. The arrhythmia persists in \\nthe VF zone s o the eighth (and final) s hock is delivered. \\nA sixth shock  is delivered \\nsince the arrh ythmia is in \\nthe VF zone. \\nThe arrhythmia decelerated to a low er zone, an \\nadditional shock would not be delive red until the \\narrhythmia accelerated back to the V F zone. Zone ATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 Remaining Shocks \\nVF \\nVT \\nVT-1 \\nOn/Of f \\nN/A \\nN/A \\n2 J \\n3 J \\n0.1 J \\n11 J \\n9 J \\n2 J \\nBurst Off \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nFigure3–7.Therapydeliveryprogression, sixthshockdelivered', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 66}), Document(page_content='3-6Tachyarrhythmia Therapy\\nVentricular Redetection afterVentricular TherapyDelivery\\n1 \\n3 \\n2 \\nZone \\nATP1 ATP2 \\nIf reconfirmation indicates the arrhythmia persists \\nafter delivery of QUICK CONVER T ATP, the device \\nimmediately begins charging for Shock 1. \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 \\nRemaining Shocks \\nVF \\nVT \\nVT-1 \\nOn \\nN/A \\nN/A \\n11 J \\n3 J \\n0.1 J \\n21 J \\n9 J \\n2 J \\nBurst Scan \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nFigure3–8.Therapydeliveryprogression, QUICKCONVERT ATPandshockintheVFzone\\n2 \\n1 \\n4 \\n5 \\n3 \\nZone \\nATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 \\nRemaining Shocks \\nVF \\nVT \\nVT-1 \\nOn \\nN/A \\nN/A \\n2 J \\n3 J \\n0.1 J \\n11 J \\n9 J \\n2 J \\nBurst Scan \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nATP1 in the VT  zone is delivered because \\nit is considered of equal strength to QUICK \\nCONVER T ATP therapy. \\nFigure3–9.Therapydeliveryprogression, QUICKCONVERT ATPdeceleratestherhythm,ATP1andshockdelivered intheVTzone\\n1 \\n2 \\n3 \\nZone \\nATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 \\nRemaining Shocks \\nVF \\nVT \\nVT-1 \\nOn \\nN/A \\nN/A \\n11 J \\n3 J \\n0.1 J \\n21 J \\n9 J \\n2 J \\nBurst Scan \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nWhen the rhythm accelerates to the VF zone, Shock \\n1 is delivered because QUICK CONVER T ATP is \\nonly available as the first therapy in an episode. \\nFigure3–10.Therapydeliveryprogression, ATP1inVTzoneaccelerates therhythm,QUICKCONVERT ATPisskippedinVFzone\\nVentricular Redetection afterVentricular TherapyDelivery\\nAfterventricular therapydelivery,thepulsegenerator usesredetectioncriteriatoevaluate therhythmanddetermine\\nwhether moretherapyisappropriate. Whenredetection criteriaaresatisfied, therulesfortherapyselection then\\ndetermine thetypeoftherapy todeliver.\\nVentricular Redetection afterVentricular ATPTherapy\\nVentricular Redetection afterventricular ATPtherapydetermines ifanarrhythmia hasbeenterminated.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 67}), Document(page_content='Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters3-7\\nAsaventricular ATPscheme isdelivered, thepulsegeneratormonitors thecardiacrateaftereachburstanduses\\nventricular detection windows (looking for8of10fastintervals) andtheVentricular Redetection Durationto\\ndetermine ifthearrhythmia hasterminated.\\nTheATPscheme willcontinue withthenextburstsinthesequenc euntilanyoneofthefollowing condition sis\\nsatisfied:\\n•Redetection declaresthatthetherapyhasbeensuccessful(end-of-episode)\\n•Thespecified number ofATPburstsinthescheme hasbeendelivered\\n•TheATPTime-out fortheventricular zonehasexpired\\n•Thedetected ventricular arrhythmia ratechanges toadifferentventricular ratezone,whereby adifferent therapy\\nisselected\\n•ShockIfUnstable forcesthedevicetoskiptheremainingATPtherapyandinitiateshocktherapy\\n•ADIVERTTHERAPY command isreceivedfromthePRMduringdelivery ofaburstofascheme\\n•Amagnet abortoccursduringdelivery ofascheme\\n•Thetemporary TachyModehaschanged\\n•Acommanded therapyisrequested\\n•Theepisode endsduetoreprogrammed TachyMode,reprogrammed ventricular tachyparamet ers,orattempted\\ninduction method orleadtest\\nNOTE:Aborting anATPburstterminates theaffected ATPscheme. Iffurthertherapyisrequired,thenext\\nprogrammed therapy(eitherATPorshocks)intheprescription isinitiated.\\nVentricular Redetection afterVentricular ShockTherapy\\nVentricular Redetection afterventricular shocktherapydetermines ifanarrhythmia hasbeenterminated.\\nAsshocktherapyisdelivered,thepulsegeneratormonitors thecardiacrateaftereachshockandusesventricular\\ndetection windows (looking for8of10fastintervals)andpost-shockdetection enhance ments,ifapplicable, to\\ndetermine ifthearrhythmia hasbeenterminated. Shocktherapywillcontinueuntiloneofthefollowing condition sis\\nsatisfied:\\n•Redetection declaresthetherapyhasbeensuccessful(end-of-episode)\\n•Allavailable ventricular shockshavebeendeliveredforanepisode\\n•TherhythmisredetectedineithertheVTorVT-1zone,theavailable number ofprogrammed shock(s) inthose\\nzoneshasbeendelivered andthearrhythmia staysinoneoftheselowerzones\\nIfallavailable shockshavebeendeliveredforanepisode, nofurthertherapyisavailable untilthepulsegenerator\\nmonitors aratebelowthelowestratethreshold for30secondsandend-of-episode isdeclared.\\nANTITACHYCARDIA PACINGTHERAPIES ANDPARAMETERS\\nAntitachycar diaPacing(ATP)therapyandparametersenablethepulsegeneratortointerrupt thefollowing fast\\nrhythms bydelivering aseriesofcritically timedpacingpulses:', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 68}), Document(page_content='3-8Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters\\n•Monomorphic ventricular tachycardia\\n•Supraventricular tachycardias\\nATPTherapyisdelivered whenthelastsensedeventfulfillstheprogrammed detection criteria(Figure3–11ATP\\ntherapybasicparametersareCoupling Interval, BurstCycleLength, Number ofBursts,andNumber ofPulseswithin\\neachburst.onpage3-8).\\nAnATPscheme maybecustomized withthefollowing paramet ers:\\n•Number ofBurstsdelivered\\n•Number ofpulseswithineachburst\\n•Coupling Interval\\n•BurstCycleLength\\n•Minimum pacinginterval\\nTheseparameters canbeprogrammed toproducethefollowing ATPtherapyschemes:\\n•Burst\\n•Ramp\\n•Scan\\n•Ramp/Scan\\nTheATPAmplitude andPulseWidtharecommontoallschemes. Theyareindependently programmable fromthe\\nnormalpacingsettings. TheATPAmplitude andPulseWidthsharethesameprogrammable valueasthepost-therapy\\npacingsettings.\\nCoupling \\nInterval\\nCoupling \\nInterval\\nBurst Cycle Length\\nBurst 1\\nBurst 2\\nATP SchemeRedet ection\\nATP Pace Pulse\\nBurst Cycle Length\\nFigure3–11.ATPtherapybasicparameters areCoupling Interval,BurstCycleLength,NumberofBursts,andNumberofPulseswithineachburst.\\nBurstParameters\\nAburstisaseriesofcritically timedpacingpulsesdeliveredbythepulsegeneratorduringATPtherapy.By\\nprogramming Burstparameters, youcanoptimize ATPtherapyforthepatient.\\nAllATPschemes haveseveralparameters incommon .Inaddition toprogramming thetypeofscheme (Off,Burst,\\nRamp,Scan,Ramp/Scan), thefollowing Burstparamete rsareprogrammable (Figure3–12InteractionofMaximum\\nNumber ofPulsesandNumber ofBurstsonpage3-9):', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 69}), Document(page_content=\"Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters3-9\\n•TheNumber ofBurstsparamete rdetermines thenumber ofburstsusedinanATPscheme andmaybe\\nprogrammed independently foreachATPscheme. Programming theparamet ertoOffwilldeactivate theATP\\nscheme.\\n•TheInitialPulseCountparameterdetermines thenumber ofpulsesdelivered inthefirstburstofascheme.\\n•ThePulseIncrement paramete rdetermines thenumber ofpulsesperbursttobeincreasedforeachsuccessive\\nburstinthescheme.\\n•TheMaximum Number ofPulsesparamete rdetermines thegreatestnumber ofpulsesusedinanATPburstand\\nmaybeprogrammed independently foreachATPscheme. Afterthemaximum number ofpulsesisreachedina\\nburst,eachadditional burstremaining inthescheme containstheprogrammed Maximum Number ofPulses.The\\nparameterisavailable onlyifthePulseIncrement isgreaterthanzero.\\nCoupling \\nInterval\\nRedetect\\nRedetect Redetect\\nDetection \\nSatisfied\\nBurst 1; Initial \\npulse count at 3\\nBurst 2; Pulse count \\nincremented by 1\\nBurst 3; Pulse count \\nincremented by 1; \\nMaximum Number of \\nPulses reached\\nBurst 4; (programmed \\nnumber); Pulse count \\nremaining at Maximum \\nNumber of Pulses (5)\\nNumber of Bursts = 4\\nInitial Pulse Count = 3\\nPulse Increment = 1\\nMaximum Number of Pulses = 5\\nFigure3–12.Interaction ofMaximum NumberofPulsesandNumberofBursts\\nCoupling IntervalandCoupling IntervalDecrement\\nTheCoupling Intervalcontrolsthetimingofthefirstpulseinaburst.Itdefinesthetimebetween thelastsensed\\neventthatfulfillsthedetection criteriaanddelivery ofthefirstpulseinaburst.\\nTheCoupling Intervalisprogrammed independent fromtheBurstCycleLength. Thisallowsaggressiverampsand\\nscanstobeusedwithout compromising captureofthefirstpacingpulseinaburst.TheCoupling Intervalcanbe\\nprogrammed asanyofthefollowing:\\n•Adaptive, withtimingspecified aspercentages ofthecomputed averageheartrate\\n•Afixedinterval, withtimingspecified inabsolute time(ms)independent ofthemeasuredaveragerate\\nWhenprogrammed asadaptive, theCoupling Intervaladjuststothepatient's rhythmbasedonafour-cycleaverage\\n(Figure3–13Adaptive Coupling Interval,Coupling IntervalDecrement andScanDecrementprogrammed to0onpage\\n3-10).TheCoupling IntervalDecrement maybeprogrammed suchthattheCoupling Intervaldecreases fromoneburst\\ntothenextwithinamultiple-burst scheme (Figure3–14Coupling IntervalDecrementonpage3-10).\\nNOTE:YoucannotprogramanATPburstthatlastslongerthan15seconds. Thelengthofanadaptive burstis\\ncalculated basedontheintervaloftheventricular zoneinwhichtheATPisprogrammed, whichmeansitisbasedon\\nworst-casetiming.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 70}), Document(page_content='3-10Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters\\nCoupling Interval = 382 ms\\n4-Cycle A verage = 420 ms\\n400 \\nms\\n410 \\nms\\n420 \\nms\\n450 \\nms\\nCoupling Interval (C.I.) = 91%\\nFirst C.I. is 420 x 91% = 382 ms\\nSecond C.I. is 400 x 91% = 364 ms\\nThe 4-cycle average is calculated on the four cycles prior to each tachycardia therapy delivery \\nonly when no Decrement (Coupling Interval or Scan) is programmed.\\nCoupling Interval = 364 ms\\n4-Cycle A verage = 400 ms\\nFigure3–13.Adaptive Coupling Interval,Coupling IntervalDecrement andScanDecrement programmed to0\\nCoupling Interval = 91%\\nC.I. Decrement = 10 ms\\n4-Cycle A verage = 420 ms\\nCoupling \\nInterval = \\n382 ms\\nCoupling Interval Decrement\\n(4-cycle average is not recalculated)\\nCoupling \\nInterval = \\n372 ms\\nPaced PulsesLast sensed \\nR-wave that fulfills \\nredetection\\nRedetection \\nsatisfied\\nPaced PulsesLast sensed \\nR-wave that fulfills \\ndetection\\nDetection satisfied\\n400 \\nms\\n410 \\nms\\n420 \\nms\\n450 \\nms\\nFigure3–14.Coupling IntervalDecrement\\nThefollowing information shouldbetakenintoconsideration whenprogramming theCoupling IntervalandCoupling\\nIntervalDecremen t:\\n•WhentheCoupling IntervalDecrementisprogrammed toOn,theprogrammed ATPscheme iscalledaScan\\n•WhentheCoupling Intervalisprogrammed asadaptive, theCoupling Intervalwillnotre-adapt following\\nredetection whenthefollowing areprogrammed toOn(greater thanzero):\\n–Coupling IntervalDecrement––the decrementvaluedetermines thetimingofthefirstpulseinsubsequent\\nbursts\\n–ScanDecrement––the decrement valuedetermines thetimingofthesecondpulseinsubsequent bursts\\nBurstCycleLength(BCL)\\nTheBurstCycleLengthcontrolstheintervalbetween pacingpulsesaftertheCoupling Interval.\\nThistimingiscontrolledinthesamefashionastheCoupling Interval: rateadaptive tothesensedtachycard iaorfixed\\ntimespecified inms.\\nNOTE:Anadaptive BCLisaffected inthesamemanner asanadaptive Coupling Interval; theaveragecyclelengthis\\nnotcontinually recalculated forsubsequent burstsiftheScanDecrementorCoupling IntervalDecremen tare\\nprogrammed toOn.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 71}), Document(page_content=\"Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters3-11\\nThefollowing paramet ersmaybeprogrammed todecrement theburstcyclelengthduringanATPscheme:\\n•RampDecrement controlsthepulsetimingwithinagivenburst\\n•ScanDecremen tcontrolsthepulsetimingbetween bursts\\nMinimum Interval\\nTheMinimum IntervallimitstheCoupling IntervalandtheBCLinBurst,Ramp,andScan.\\nIftheCoupling Intervalreaches thelimit,subsequent Coupling Intervalswillremainattheminimum value.Likewise, if\\ntheBCLreaches thelimit,subsequent BCLswillremainattheminimum value.TheCoupling IntervalandBCLmay\\nreachthelimitindependently .\\nBurstScheme\\nABurstscheme isasequenc eofcritically timedpacingpulsesintended tointerrupt areentrantloop,usuallydelivered\\nataratefasterthanthepatient's tachycard ia.\\nAnATPscheme isdefined asaBurst(asindicated onthePRMscreen)whenthetimingofallpacingintervalswithina\\nburstisthesame.ThefirstBCLofeachBurstisdetermined bytheprogrammed BCL.Whenthenumber ofpulses\\nprogrammed inaBurstisgreaterthanone,youcanusetheBCLtocontrolthetimingbetween thesepacedpulses\\n(Figure3–15Adaptive-rate Burstscheme onpage3-11).\\nCoupling \\nInterval\\n400 \\nms\\n410 \\nms\\n420 \\nms\\n450 \\nms\\n315\\nms \\nBCL\\n315\\nms \\nBCL\\n315\\nms \\nBCL\\n315\\nms \\nBCL\\nCoupling \\nInterval\\n300\\nms \\nBCL\\n300\\nms \\nBCL\\n300\\nms \\nBCL\\n300\\nms \\nBCL\\nBurst\\n4-Cycle A verage = 400 ms\\nBurst\\n4-Cycle A verage = 420 ms\\nBCL = 75%\\n420 ms x .75 = 315 ms\\n400 ms x .75 = 300 ms\\nThe first BCL  of each burst is calculated by multiplying the 4-cycle average prior  to \\ndelivery of the first pacing pulse of the burst by the BCL  percentage.\\nFigure3–15.Adaptive-rate Burstscheme\\nRampScheme\\nARampscheme isaburstinwhicheachpaced-to-pac edintervalwithintheburstisshortened (decremented).\\nToprogramaRampscheme, program(inms)theRampDecreme nttospecifyhowmuchthepaced-to-pac edinterval\\nshouldbeshortened, andtheScanDecrementandCoupling IntervalDecrementeachto0ms.Aseachadditional\\npacedpulseinaburstisdelivered,itsintervalisshortened bytheprogrammed RampDecrement untileitherofthe\\nfollowing occur:\\n•Thelastpacedpulseoftheburstisdelivered\\n•TheMinimum Intervalisreached\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 72}), Document(page_content='3-12Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters\\nIfsubsequent burstsarerequired,theprogrammed RampDecrementwillbeappliedbasedonthecalculated BCLof\\nthatsubsequent burst(Figure3–16Adaptive RampScheme, Coupling IntervalDecreme ntandScanDecrement\\nprogrammed to0onpage3-12).\\nBurst Cycle Length = 75%\\nRamp Decrement (R-R Within Burst) = 10 ms\\nScan Decrement (R-R Between Bursts) = 0 ms\\nC.I. Decrement = 0 ms\\nMinimum Interval = 265 ms\\n300 \\nms\\n290 \\nms\\n280 \\nms\\n270 \\nms\\n4-Cycle A verage \\n= 400 ms\\nRamp Ramp4-Cycle A verage \\n= 380 ms\\nReadapt 75%\\n285 \\nms\\n275 \\nms\\n265 \\nms\\n265\\nms\\nMinimum interval reached; \\nsubsequent interval is not \\ndecremented.\\nRedetect\\nFigure3–16.Adaptive RampScheme,Coupling IntervalDecrement andScanDecrement programmed to0\\nScanScheme\\nAScanscheme isaburstinwhichtheBCLofeachburstinascheme issystematically shortened (decremented)\\nbetween successivebursts.\\nYoucanprogramaScanscheme byprogramming theScanDecrementtospecifytheBCLdecrementtoavalue\\ngreaterthan0ms,whiletheRampDecrementisprogrammed to0ms.TheBCLofsubsequent burstsisdetermined\\nbysubtractingtheScanDecrementfromtheBCLoftheprevious burst(Figure3–17Scanscheme, nonadaptive BCLand\\nScanDecrement programmed ononpage3-12).\\nInitial BCL  is determined and then Scan \\nDecrement is applied on the next burst \\nBCL of previous Burst is determined and then Scan \\nDecrement is applied again on the next burst \\n300 \\nms \\n300 \\nms \\n300 \\nms \\n300 \\nms \\n290 \\nms \\n290 \\nms \\n290 \\nms \\n290 \\nms \\n280 \\nms \\n280 \\nms \\n280 \\nms \\n280 \\nms \\nBurst Cycle Length = 300 ms \\nScan Decrement = 10 ms \\nRamp Decrement = 0 ms \\nCoupling Interval Decrement = 0 ms Scan Scan \\nRedetect Redetect \\nScan \\nFigure3–17.Scanscheme,nonadaptive BCLandScanDecrement programmed on\\nRamp/Scan Scheme\\nARamp/Scan scheme isasequence ofbursts.Eachscheme containsaRampDecrement andaScanDecrement\\n(Figure3–18Ramp/Scan scheme, interaction ofATPparamet ersonpage3-13).', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 73}), Document(page_content='Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters3-13\\n290 \\nms\\n270 \\nms\\n280 \\nms\\n270 \\nms*\\n240 \\nms\\n250 \\nms\\n260 \\nms\\n240 \\nms\\n250 \\nms\\n220 \\nms\\n220 \\nms\\n230 \\nms\\nMinimum \\ninterval \\nreached\\n4-Cycle \\nAverage \\n= 370 ms\\nPARAMETER\\nNumber of Bursts\\nPulses per Burst:\\n    Initial\\n    Increment\\n    Maximum\\nCoupling Interval\\n    Decrement\\nBurst Cycle Length\\n    Ramp Decrement\\n    Scan Decrement\\nMinimum IntervalVALUE\\n3\\n4\\n1\\n6\\n81%\\n0 ms\\n78%\\n10 ms\\n20 ms\\n220 ms* When a Scan Decrement is programmed to On, the Coupling Interval and \\nBCL, if programmed as a percentage, will not re-adapt following redetection.\\nMaximum Number of Pulses \\nreached (6) and Maximum \\nNumber of Bursts reached (3)\\nNumber o f Pulses \\nincremen ted by 1\\nRamp Burst Ramp/Scan Burst Ramp/Scan Burst\\nRedetect\\nRedetect\\nC.I. 300 ms\\nScan Scan\\nC.I. 300 ms* C.I. 300 ms*\\nFigure3–18.Ramp/Scan scheme,interaction ofATPparameters\\nToprogramaRamp/Scan scheme, boththeScanDecrementandRampDecremen tareprogrammed tovaluesgreater\\nthan0ms.\\nATPPulseWidthandATPAmplitude\\nTheATPPulseWidthisthedurationofapacingpulse.TheATPAmplitude istheleadingedgevoltageofapacing\\npulse.\\nTheATPPulseWidthandATPAmplitude paramet erssharethesamevalueastheposttherapypacingPulseWidth\\nandAmplitude. Iftheprogrammable valueischanged foroneparameter ,thatvaluewillbereflected intheother\\nparameters.\\nTheprogrammed ATPPulseWidthandATPAmplitude aresharedforallATPschemes regardlessofzoneandposition\\ninaprescription.TheATPAmplitude andPulseWidthsharethesameprogrammable valueasthepost-therapy\\npacingsettings.\\nVentricular ATPTime-out\\nTheVentricular ATPTime-out forcesthepulsegeneratortoskipoveranyremaining ATPtherapy inaventricular zone\\ntobegindelivering ventricular shocktherapy programmed inthesamezone.Thisparameteriseffective onlyfor\\nventricular therapydelivery.\\nTheATPTime-out maybeusedintheVTorVT-1zoneaslongasATPtherapyisprogrammed toOn.Timervaluesare\\nindependent, although VT-1ATPTime-out mustbeequaltoorgreaterthantheVTATPTime-out.\\nThetimerstartswhenthefirstburstisdeliveredandcontinuesuntilanyofthefollowing occur:\\n•Thetimerexpires(Figure3–19ATPTime-out expiration onpage3-14)\\n•Aventricular shockisdelivered\\n•Theventricular episode ends', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 74}), Document(page_content='3-14Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters\\nThetime-out isexamined aftereachredetection sequence todetermine iffurtherATPburstscanbedelivered.Ifthe\\ntime-out hasbeenreached orexceeded,furtherATPtherapywillnotbeinitiated duringthatventricular episode. The\\ntime-out willnotterminate aburstinprocess.\\nDetection window met.\\nStart episode.\\nStart Duration.\\nStart stability analysis.\\nDuration expires.\\nInitiate A TP therapy .\\nStart A TP Time-out.\\nRedetection Duration expires.\\nInitiate shock therapy .\\nCharge\\nRedetect Red\\netect\\nATP Time-out expires\\n30 s\\nFigure3–19.ATPTime-out expiration\\nNOTE:Onceaventricular shockhasbeendeliveredduringaventricular episode, ATPwillnolongerbeinvoked,\\nirrespective ofthetimeremaining ontheATPTime-out timer.\\nThetimeralonedoesnotinvoketherapy;therateandduration criteriaanddetection enhancements muststillbe\\nsatisfied inorderforashocktherapytobedelivered.\\nIfthreezonesareprogrammed, youmayprogramATPTime-out settings ineachofthelowertwoventricular zones\\n(Figure3–20ATPTime-outs, 3-zoneconfiguration onpage3-14).\\n0 s 10 s \\n20 s 30 s\\n 40 s \\nVF Zone \\nVT Zone \\nVT-1 Zone\\n \\nVT Detect\\nion \\nwindow sa\\ntisfied. \\nDuration \\nstarts. \\nStart epi\\nsode. \\nVT Detect\\nion met. \\nTherapy i\\nntitiated\\n. \\nStart ATP\\n Time-out\\n. \\nATP Time-\\nout \\nexpires i\\nn VT zone\\n.\\nVT-1 \\nTime-out \\nexpires. \\nVT\\n-1 Detect\\nion met. \\nInitiate \\nshock the\\nrapy. \\nProgramme\\nd therapy\\n for lowe\\nr zones: \\nVT-1 ATP \\nTime-out \\n= 40 s \\nVT ATP Ti\\nme-out = \\n30 s \\nATP is pr\\nogrammed \\nin VT-1 a\\nnd VT zon\\nes. \\nR\\nedetectio\\nn and \\nATP burst\\ns \\nATP Time-\\nout \\nATP 1 ATP\\n 1 \\nBurst 1 B\\nurst 5 \\nRedetect \\nCharging \\nRhythm changes to VT-1 zone \\nFigure3–20.ATPTime-outs, 3-zoneconfiguration\\nQUICKCONVERT ATP\\nQUICKCONVERT ATPprovidesanadditional optiontotreatafast,monomorphic VTthatisdetected intheVFzone,\\nbeforeadvancing toshocktherapy.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 75}), Document(page_content=\"Tachyarrhythmia Therapy\\nVentricular ShockTherapyandParameters3-15\\nWhenQUICKCONVERT ATPisprogrammed toOn,thepulsegeneratordelivers oneburstofATPconsisting of8\\npacingpulseswithan88%Coupling Intervaland88%BCL.\\nQUICKCONVERT ATPisusedonlyasthefirsttherapyattempted inanepisode. IntheeventthatQUICKCONVERT ATP\\nisunsuccessfulinconverting therhythmandshocktherapy isrequired,thefeature's algorithm minimize sthedelayto\\nbeginchargingbyusingreconfirmation toevaluate whether ATPtherapysuccessfullytreatedthearrhythmia:\\n•If2outof3intervalsfollowing delivery ofQUICKCONVERT ATParefasterthanthelowestratethreshold,the\\nattempt isconsideredunsuccessfulandchargingbeginsforanon-commi ttedshock.\\n•If2outof3intervalsareslow,shocktherapyisdiverted andthepulsegeneratorentersredetection. Ifredetection\\nissatisfied following adiverted shock,thenextshockwillbecommitt ed.\\nNOTE:QUICKCONVERT ATPisnotappliedtoanyrhythmaboveamaximum rateof250bpm.\\nVENTRICULAR SHOCKTHERAPY ANDPARAMETERS\\nThepulsegeneratordelivers shockssynchronoustoasensedevent.Theshockvector,energylevel,andpolarity of\\ntheshocksareprogrammable.\\nVentricular ShockVector\\nTheprogrammed Ventricular ShockVectorindicates thevectorofenergydelivery forventricular shocktherapy.\\nThefollowing programmable configur ationsareavailable:\\n•RVCoiltoRACoilandCan––this vectorisalsoknownastheV-TRIAD vector.Itusesthemetallic housing ofthe\\npulsegenerator asanactiveelectrode (“hotcan”)combined withatwo-electrode defibrillation lead.Energyis\\nsentviaadual-curr entpathway fromthedistalshocking electrode totheproximalelectrodeandtothepulse\\ngeneratorcase.\\n•RVCoiltoCan––this vectorusesthemetallic housing ofthepulsegeneratorasanactiveelectrode(“hotcan”).\\nEnergyissentfromthedistalshocking electrode tothepulsegeneratorcase.Thisconfiguration shouldbe\\nselected whenusingasingle-coil lead.\\n•RVCoiltoRACoil––this vectorremovesthepulsegeneratorcaseasanactiveelectrodeandisalsoknownasa\\n“coldcan”vector.Energyissentfromthedistalshocking electrode totheproximalelectrode.Thisvectorshould\\nneverbeusedwithasingle-co illead,asashockwillnotbedelivered.\\nVentricular ShockEnergy\\nVentricular shockenergydetermines thestrengthofshocktherapydeliveredbythepulsegenerator.\\nShockoutputremains constantoverthelifetime ofthepulsegenerator,regardlessofchanges inleadimpedance or\\nbatteryvoltage. Theconstantoutputisaccomplished byvaryingpulsewidthtoadjusttochanges inleadimpedance.\\nThefirsttwoshocksineachventricular zonecanbeprogrammed tooptimize chargetime,longevity ,andsafety\\nmargins.Theremaining shockenergiesineachzonearenonprogrammable atthemaximum-energy value.\\nChargeTime\\nChargeTimeisthetimethepulsegenerator requirestochargefordelivery oftheprogrammed shockenergy.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 76}), Document(page_content='3-16Tachyarrhythmia Therapy\\nVentricular ShockTherapyandParameters\\nChargeTimeisdependent onthefollowing:\\n•Programmed outputenergylevel\\n•Batterycondition\\n•Condition oftheenergystoragecapacitors\\nChargetimesincreaseasthepulsegeneratorisprogrammed tohigherenergyoutputlevelsandasthebattery\\ndepletes (Table3–1Typicalchargetimerequiredat37degrees Catthebeginning oflifeonpage3-16).Ifacharge\\ntimeisgreaterthan15seconds,thepulsegenerator schedules anautomatic capacitor re-formation foronehourlater.\\nIfthechargetimeduringre-formatio nalsoexceeds15seconds, batterystatusischanged toExplant.\\nCapacitor deformation canoccurduringinactive periodsandmayresultinaslightlylongerchargetime.Toreducethe\\nimpactofcapacitor deformation onchargetime,thecapacitors areautomatically reformed.\\nTable3–1.Typicalchargetimerequired at37degreesCatthebeginning oflife\\nEnergyStored(J)aEnergyDelivered (J)bChargeTime(seconds)c\\n11.0 10.0 2.0(RESONATE HF,RESONATE, VIGILANT, MOMENTUM)\\n2.1(PERCIVA HFandPERCIVA)\\n17.0 15.0 3.2(RESONATE HF,RESONATE, VIGILANT, MOMENTUM)\\n3.4(PERCIVA HFandPERCIVA)\\n26.0 22.0 5.1(RESONATE HF,RESONATE, VIGILANT, MOMENTUM)\\n5.4(PERCIVA HFandPERCIVA)\\n41.0 35.0 8.4(RESONATE HF,RESONATE, VIGILANT, MOMENTUM)\\n9.2(PERCIVA HFandPERCIVA)\\na.Valuesindicate theenergylevelstoredonthecapacitors andcorrespondtothevalueprogrammed forshockenergyparameters.\\nb.Theenergydelivered indicates theshockenergyleveldelivered through theshocking electrodes.\\nc.Chargetimesshownareatbeginning oflifeaftercapacitor re-formation.\\nTable3–2.Typicalmaximum-ener gychargetimeoverthelifeofRESONATE HF,RESONATE, VIGILANT, andMOMENTUM pulsegenerators\\nChargeRemaining (Ah)aMaximum-ener gyChargeTimeRange(seconds)\\n2.0to0.7 8to11\\n0.7to0.15 9to14\\na.Fordualchamber devices,ChargeRemaining atexplantistypically 0.15Ah,andresidual capacity is0.12Ah.Forsinglechamber devices,ChargeRemaining atexplantistypically 0.14Ah,\\nandresidual capacity is0.12Ah.Thesemayvarydepending ontheamount oftherapy delivered overthelifeofthepulsegenerator .Residual capacity isusedtosupport devicefunction\\nbetween ExplantandBatteryCapacity Depleted indicators.\\nTable3–3.Typicalmaximum-ener gychargetimeoverthelifeofPERCIVAHFandPERCIVApulsegenerators\\nChargeRemaining (Ah)aMaximum-ener gyChargeTimeRange(seconds)\\n1.2to0.4 8to12\\n0.4to0.15 10to14\\na.Fordualchamber devices,ChargeRemaining atexplantistypically 0.15Ah,andresidual capacity is0.13Ah.Forsinglechamber devices, ChargeRemaining atexplantistypically 0.14Ah,\\nandresidual capacity is0.12Ah.Thesemayvarydepending ontheamount oftherapy delivered overthelifeofthepulsegenerator .Residual capacity isusedtosupport devicefunction\\nbetween ExplantandBatteryCapacity Depleted indicators.\\nNOTE:Themaximum-energy chargetimerangesabovearebasedupontheoretic alelectrical principles andverified\\nbenchtestingonly.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 77}), Document(page_content='Tachyarrhythmia Therapy\\nVentricular ShockTherapyandParameters3-17\\nWaveformPolarity\\nWaveform polarity reflectstherelationship between theleadingedgevoltages onthedefibrillating outputelectrodes.\\nAllshockswillbedeliveredusingabiphasic waveform (Figure3–21Biphasic waveform onpage3-17).\\n•Thepeakshockvoltage(V1)is728Vat41J,531Vat21J,and51Vat0.1J.\\nTheselection oftheshockpolarity appliestoallshocksdeliveredbythedevice.Iftheprecedingshocksinazoneare\\nunsuccessful,thelastshockofthatzonewillbeautomatically delivered ataninverted polarity tothepreviousshock\\n(initialorreversed) (Figure3–22Polarity ofshockdelivery onpage3-17).\\nCAUTION: ForIS-1/DF-1 leads,neverchangetheshockwaveform polarity byphysically switching theleadanodes\\nandcathodes inthepulsegeneratorheader—use theprogrammable Polarity feature. Devicedamage or\\nnonconversion ofthearrhythmia post-operativelymayresultifthepolarity isswitched physically .\\nBiphasic\\nV1\\nV2\\nPW1\\nPW2\\nV3\\nV4\\nPW = Pulse Widt\\nh\\nPW2 =  PW1 x 0.\\n66\\nV2 = V 3\\nFigure3–21.Biphasicwaveform\\n+\\n–\\n+\\n–\\n+\\n–\\nInitial polarity Reverse polarity\\nFigure3–22.Polarityofshockdelivery\\nCommitted Shock/Reconf irmationoftheVentricular Arrhythmia\\nCommitted Shock/Recon firmation referstothemonitoring performed bythepulsegenerator beforedelivery ofa\\nventricular shock.\\nIfthepatientissubjecttonon-sustained arrhythmias, reconfirmation maybedesirable inordertopreventdelivery of\\nunnecessaryshockstothepatient.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 78}), Document(page_content='3-18Tachyarrhythmia Therapy\\nVentricular ShockTherapyandParameters\\nThedevicemonitors tachyarrhythmias duringandimmediately following capacitor charging.Duringthistime,it\\nchecksforthespontaneous conversionofthetachyarrhythmia anddetermines whether ventricular shocktherapy\\nshouldbedelivered; itdoesnotaffecttherapy selection.\\nVentricular shocktherapycanbeprogrammed ascommitted ornon-committed. IftheCommitted Shockfeatureis\\nprogrammed toOn,theshockisdelivered synchronously withthefirstsensedR-wavefollowing a500-ms delayafter\\nthecapacitors arecharged,whether thearrhythmia issustained ornot(Figure3–23Committed Shockisprogrammed\\ntoOn,Reconfirmation isOffonpage3-18).The500-ms delayallowsaminimum timeforadivertcommand tobe\\nissuedfromthePRM,ifdesired. IfthereisnosensedR-wavedetected within2secondsfollowing theendof\\ncharging,theventricular shockisdeliveredasynchro nouslyattheendofthe2-second interval.\\nShock\\n2 3 4 5 6 7 8 9 10\\n1112 1\\nF F F F F F F F F\\nF\\nShock is committed.\\nSynchronize with R-wave and deliver shock.\\nDuration complete. \\nStart charging.\\nRefractory \\nperiod\\nDivert window\\nCharging\\n500 ms\\n135 ms\\nRedetect ion starts.\\nDetection  window \\nsatisfied\\n.\\nPost-Sho ck Duratio\\nn starts.\\nNumber of intervals\\n(F = Fast)\\nFigure3–23.Committed Shockisprogrammed toOn,Reconfirmation isOff\\nNOTE:Thereisaforced135-msrefractory periodfollowing theendofcharging;eventsthatoccurduringthefirst\\n135msofthe500-ms delayareignored.\\nIftheCommitted Shockfeatureisprogrammed toOff,Reconfirmation consistsofthefollowing steps:\\n1.Duringcapacitor charging,thepulsegeneratorcontinues tosensethearrhythmia. Sensedandpacedbeatsare\\nevaluated. If5slowbeats(sensed orpaced)arecountedina10-beat detection window (or4consecutive slow\\nbeatsafteranunsuccessfulQUICKCONVERT ATPattempt), thepulsegeneratorstopschargingandconsidersthis\\naDiverted-Recon firm.\\n2.If5of10beatsarenotdetected asslow(orlessthan4consecutive slowbeatsafteranunsuccessfulQUICK\\nCONVERT ATPattempt) andcharging completes, post-chargereconfirmation isperformed afterchargingends.\\nAfterthepost-chargerefractoryandthefirstsensedevent,thepulsegenerator measures upto3intervals\\nfollowing chargingandcomparesthemtothelowestratethreshold.\\n•If2ofthe3intervalsfollowing chargingarefasterthanthelowestratethreshold,theshockwillbedelivered\\nsynchronously withthesecondfastevent.\\n•If2ofthe3intervalsfollowing chargingareslowerthanthelowestratethreshold,theshockwillnotbe\\ndelivered. Ifnobeatsaresensed, pacingwillbeginattheprogrammed LRLfollowing the2-second no-sense\\nperiod.Ifashockisnotdelivered,orifpacingpulsesaredelivered, thisisalsoconsidered aDiverted-\\nReconfirm.\\nIfashockisrequiredafterredetection, thechargetimefortheshockmaybeshort.\\nThereconfirmation algorithm willnotallowtwoconsecutive Diverted-Recon firmcycles.Ifthearrhythmia isdetected\\nafteraDiverted-Rec onfirm,thenextshockintheepisode isdelivered asifCommitted Shockwereprogrammed toOn.\\nOnceashockhasbeendelivered,thereconfirmation algorithm canbeappliedagain(Figure3–24Committed Shockis\\nprogrammed toOff,reconfirmation isOnonpage3-19).', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 79}), Document(page_content='Tachyarrhythmia Therapy\\nVentricular ShockTherapyandParameters3-19\\n2 3 4 5 6 7 8 1\\n2 3 4 5\\n1\\n2 3 1\\nIntervals are measured and compared to the lowest Rate threshold. If 2 of 3 are slow , \\nthe shock will not be delivered. If 2 of 3 are fast, the shock will be delivered.\\nReconfirmation  determi\\nnes arrhyth\\nmia \\nis no longer pre sent. Sho\\nck is not \\ndelivered. If no  beats are\\n sensed, \\npacing will star t.\\nDuration complete. \\nStart charging.Refractory \\nperiodDivert \\nwindowIntervals are measured \\nduring charging.\\nCharging\\n500 ms\\n135 ms\\nFigure3–24.Committed Shockisprogrammed toOff,reconfirmation isOn', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 80}), Document(page_content='3-20Tachyarrhythmia Therapy\\nVentricular ShockTherapyandParameters', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 81}), Document(page_content='4-1\\nPACINGTHERAPIES\\nCHAPTER 4\\nThischaptercontainsthefollowing topics:\\n•“Pacing Therapies”onpage4-2\\n•“BasicParamet ers”onpage4-2\\n•“Post-TherapyPacing” onpage4-18\\n•“Tempor aryBradyPacing” onpage4-19\\n•“Minute Ventilation /Respiratory SensorandSignalArtifactMonitor” onpage4-20\\n•“RateAdaptive PacingandSensorTrending” onpage4-27\\n•“AtrialTachyResponse” onpage4-44\\n•“RateEnhancements” onpage4-49\\n•“LeadConfigurati on”onpage4-52\\n•“AVDelay”onpage4-53\\n•“Refractory”onpage4-57\\n•“NoiseResponse” onpage4-63\\n•“Ventricular TachySensing Interactions” onpage4-65', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 82}), Document(page_content='4-2PacingTherapies\\nPacingTherapies\\nPACINGTHERAPIES\\nSingle-chamber ICDsprovide ventricular bipolar(pace/se nse)normalandpost-therapybradycardia pacing,including\\nadaptive-r atemodes.Dual-chamber ICDsprovide bothatrialandventricular bipolar(pace/sense) normalandpost-\\ntherapybradycardiapacing,including adaptive-r atemodes.\\nWARNING: DuringMRIProtectionMode,ifBradyModeisprogrammed toOff,Bradycardia therapyissuspended.\\nThepatientwillnotreceivepacinguntilthepulsegeneratorisprogrammed backtonormaloperation. Onlyprogram\\nBradyModetoOffduringMRIProtectionModeandscanthepatientifjudgedtobeclinically capable oftolerating no\\nBradycardia therapy(including pacing-dependence orneedforoverdrive pacing)fortheentiredurationinwhichthe\\npulsegeneratorisinMRIProtectionMode.\\nThebradycardia pacingfunction isindependent ofthetachycard iadetection andtherapy functions ofthedevice,with\\ntheexceptionofinterval-to-inter valsensing.\\nThepulsegenerator providesthefollowing typesoftherapies:\\nNormalBradycardia Pacing\\n•Iftheintrinsic heartratefallsbelowtheprogrammed pacingrate(i.e.,LRL),thedevicedelivers pacingpulsesat\\ntheprogrammed settings.\\n•Adaptive-rate pacingallowsthepulsegeneratortoadaptthepacingratetothepatient\\'s changing activitylevels\\nand/orphysiologic needs.\\nPost-Therapy Pacing—alternative bradycardia pacingtherapymaybedeliveredforaprogrammed periodtoensure\\ncaptureafterdelivery ofashock.\\nAdditional Options\\n•Temporary BradycardiaPacing—allows theclinician toexamine alternate therapieswhilemaintaining the\\npreviously programmed normalpacingsettings inthepulsegeneratormemory (\"Tempor aryBradyPacing\"on\\npage4-19).\\n•STATPACE—initiates emergency ventricular pacingathighoutputsettings whencommanded viatheProgrammer\\nusingtelemetry communication (\"STATPACE\"onpage1-15).\\nBASICPARAMETERS\\nNormalSettings includethefollowing:\\n•Pacingparamete rs,whichareindependently programmable frompost-therapyandtemporarypacingparameters\\n•PacingandSensing\\n•Leads\\n•Sensors andTrending\\nPost-TherapySettings includethefollowing:\\n•Pacingparamete rs,whichareindependently programmable fromnormalandtemporarypacingparameters\\n•Post-ventricular shock', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 83}), Document(page_content='PacingTherapies\\nBasicParameters4-3\\nInteractive Limits\\nBecause manyfeatureswithprogrammable parametersinteract, programmed valuesmustbecompatible acrosssuch\\nfeatures.Whenvaluesrequested bytheuserareincompatible withexistingparameters, theProgrammerscreen\\ndisplays analertdescribing theincompatibility andeitherprohibits theselection orinstructs theusertoproceedwith\\ncaution(\"UseofColor\"onpage1-7).\\nBradyMode\\nBradymodesprovide programmable options tohelpindividualiz epatienttherapy.\\nThispulsegeneratorincludes thepacingmodesidentified intheProgrammable Options appendix.\\nDDDandDDDR\\nIntheabsence ofsensedP-andR-waves, pacingpulseswillbedeliveredtotheatriumandtheventricle attheLRL\\n(DDD)orthesensor-indicated rate(DDDR), separatedbytheAVDelay.AsensedP-wavewillinhibitanatrialpaceand\\nstarttheAVDelay.AttheendoftheAVDelay,aventricular pacewillbedeliveredunlessinhibited byasensedR-\\nwave.\\nDDIandDDIR\\nIntheabsence ofsensedP-andR-waves, pacingpulseswillbedeliveredtotheatriumandtheventricle attheLRL\\n(DDI)orthesensor-indicated rate(DDIR),separatedbytheAVDelay.AsensedP-wavewillinhibitanatrialpacebut\\nwillnotstarttheAVDelay.\\nVDDandVDDR\\nIntheabsence ofsensedP-andR-waves, pacingpulseswillbedeliveredtotheventricle attheLRL(VDD)orthe\\nsensor-indicated rate(VDDR). AsensedP-wavewillstarttheAVDelay.AttheendoftheAVDelay,aventricular pace\\nwillbedeliveredunlessinhibited byasensedR-wave. AsensedR-waveorapacedventricular eventwilldetermine\\nthetimingofthenextventricular pace.\\nVVIandVVIR\\nInVVI(R)mode,sensing andpacingoccuronlyintheventricle. Intheabsence ofsensedevents,pacingpulseswillbe\\ndeliveredtotheventricle attheLRL(VVI)orthesensor-indicated rate(VVIR).AsensedR-waveorapacedventricular\\neventwilldetermine thetimingofthenextventricular pace.\\nAAIandAAIR\\nInAAI(R)mode,sensing andpacingoccuronlyintheatrium.Intheabsence ofsensedevents,pacingpulseswillbe\\ndeliveredtotheatriumattheLRL(AAI)orthesensor-indicated rate(AAIR).AsensedP-waveorapacedatrialevent\\nwilldetermine thetimingofthenextatrialpace.\\nDual-Chamber Modes\\nDonotuseDDD(R)andVDD(R)modesinthefollowing situations:\\n•Inpatients withchronicrefractory atrialtachyarrhythmias (atrialfibrillation orflutter),whichmaytrigger\\nventricular pacing\\n•Inthepresenceofslowretrogradeconduction thatinduces PMT,whichcannotbecontrolledbyreprogramming\\nselective parameter values', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 84}), Document(page_content='4-4 PacingTherapies\\nBasicParameters\\nAtrialPacingModes\\nInDDD(R), DDI(R),andAAI(R)modes,atrialpacingmaybeineffective inthepresenceofchronicatrialfibrillation or\\nflutterorinanatriumthatdoesnotrespondtoelectrical stimulation. Inaddition, thepresenceofclinically significant\\nconductiondisturbances maycontraindicate theuseofatrialpacing.\\nWARNING: Donotuseatrialtrackingmodesinpatients withchronicrefractory atrialtachyarrhythmias. Trackingof\\natrialarrhythmias couldresultinventricular tachyarrhythmias.\\nNOTE:Ifaseparatepacemak erisdesired, adedicated bipolarpacemak erisrecommended (\"Pacemak erInteraction\"\\nonpageB-1).\\nNOTE:Referto\"UseofAtrialInformation\" onpage2-5foradditional information aboutdeviceperformanc ewhen\\ntheatrialleadisprogrammed toOff.\\nIfyouhaveanyquestions regarding theindividualization ofpatienttherapy,contactBostonScientific usingthe\\ninformation onthebackcover.\\nLowerRateLimit(LRL)\\nLRListhenumber ofpulsesperminuteatwhichthepulsegeneratorpacesintheabsenceofsensedintrinsic activity.\\nAslongastheventricle isbeingpaced(orifaPVCoccurs),theintervalistimedfromoneventricular eventtothenext.\\nWhenever aneventissensedintheventricle (e.g.,intrinsic AVconduction occursbeforetheAVDelayelapses), the\\ntimingbaseswitches fromventricular -basedtimingtomodified atrial-based timing(Figure4–1LRLtimingtransitions\\nonpage4-4).Thisswitching oftimingbaseensures accuratepacingratessincethedifferencebetween theintrinsic\\nAVconduction andprogrammed AVDelayisappliedtothenextV–Ainterval.\\nAV\\nAV\\nAV\\nAV AV\\nVA\\nVA\\nVA VA\\nVA\\nAA\\nAA\\nAA\\nAA\\nVA + d\\nd\\nTransitio\\nn from V-\\nV timing \\nto A-A ti\\nming\\nTransition from A-A timing to V-V timing\\nIllustration oftimingtransitions (d=thedifferenc ebetween AVDelayandtheAVintervalinthefirstcycleduringwhichintrinsic conduction occurs.Thevalueofdis\\nappliedtothenextV–Aintervaltoprovide asmooth transition without affecting A–Aintervals).\\nFigure4–1.LRLtimingtransitions', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 85}), Document(page_content='PacingTherapies\\nBasicParameters4-5\\nMaximum TrackingRate(MTR)\\nTheMTRisthemaximum rateatwhichthepacedventricular ratetracks1:1withnonrefractorysensedatrialeventsin\\ntheabsenceofasensedventricular eventwithintheprogrammed AVDelay.MTRappliestoatrialsynchronouspacing\\nmodes,namelyDDD(R)andVDD(R).\\nConsider thefollowing whenprogramming MTR:\\n•Thepatient\\'s condition, age,andgeneralhealth\\n•Thepatient\\'s sinusnodefunction\\n•AhighMTRmaybeinappropriateforpatients whoexperience anginaorothersymptoms ofmyocardi alischemia\\nathigherrates\\nNOTE:Ifthepulsegenerator isoperatinginDDDRorVDDRmode,theMSRandMTRmaybeprogrammed\\nindependently todifferentvalues.\\nUpperRateBehavior\\nWhenthesensedatrialrateisbetween theprogrammed LRLandMTR,1:1ventricular pacingwilloccurintheabsence\\nofasensedventricular eventwithintheprogrammed AVDelay.IfthesensedatrialrateexceedstheMTR,thepulse\\ngeneratorbeginsaWenckebach-like behavior toprevent thepacedventricular ratefromexceedingtheMTR.This\\nWenckebach-like behavior ischaracterizedbyaprogressive lengthening oftheAVDelayuntilanoccasional P-waveis\\nnottrackedbecause itfallsintothePVARP.Thisresultsinanoccasional lossof1:1tracking asthepulsegenerator\\nsynchronizesitspacedventricular ratetothenextsensedP-wave. Shouldthesensedatrialratecontinue toincrease\\nfurtherabovetheMTR,theratioofsensedatrialeventstosequentially pacedventricular eventsbecomesloweruntil,\\neventually ,2:1blockresults(e.g.,5:4,4:3,3:2,andfinally2:1).\\nThesensing window shouldbemaximized byprogramming theappropriat eAVDelayandPVARP.Atratescloseto\\ntheMTR,thesensing window canbemaximized byprogramming Dynamic AVDelayandDynamic PVARP,and\\nWenckebachbehavior willbeminimized.\\nHighrateatrialtracking islimitedbytheprogrammed MTRandthetotalatrialrefractory period(TARP)(AVDelay+\\nPVARP=TARP).Inordertoavoidcomplete closureofthesensing window atMTR,thePRMwillnotallowaTARP\\nintervalthatislonger(lowerpacingrate)thantheprogrammed MTRinterval.\\nIftheTARPintervalisshorter(higherpacingrate)thantheintervaloftheprogrammed MTR,thenthepulse\\ngenerator\\'sWenckebach-like behavior limitstheventricular pacingratetotheMTR.IftheTARPintervalisequaltothe\\nintervaloftheprogrammed MTR,2:1blockmayoccurwithatrialratesabovetheMTR.\\nThePRMdoesnotconsidertheAVDelayassociated withAVSearch+whencalculating theTARPinterval(\"AVSearch\\n+\"onpage4-55).\\nRapidchanges inthepacedventricular rate(e.g.,Wenckebach-like, 2:1block)causedbysensedatrialratesabovethe\\nMTRmaybedampened oreliminated bytheimplementation ofanyofthefollowing:\\n•AFR\\n•ATR\\n•RateSmoothing parametersandsensorinput\\nNOTE:Forthepurpose ofatrialtachycardia detection andhistogramupdates, atrialeventsaredetected throughout\\nthecardiaccycle(exceptduringatrialblanking), including AVDelayandPVARP.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 86}), Document(page_content=\"4-6PacingTherapies\\nBasicParameters\\nExamples\\nIftheatrialrateexceedstheMTR,theAVDelaywillbeprogressively lengthened (AV')untilanoccasional P-waveis\\nnottrackedbecause itfallsintotheatrialrefractoryperiod(Figure4–2Wenckebachbehavior atMTRonpage4-6).\\nThisresultsinoccasional lossof1:1trackingasthepulsegeneratorsynchroniz esitspacedventricular ratetothenext\\ntrackedP-wave(pacemakerWenckebac h).\\nAVPVARPAV PVARPAV’P VARP AVPVA RPAV’PVAR P MTR MTR MTR\\nMTR MTR\\nFigure4–2.Wenckebach behavior atMTR\\nAnother typeofpulsegeneratorupperratebehavior (2:1block)canoccurwhentrackinghighatrialrates.Inthistype\\nofbehavior ,everyotherintrinsic atrialeventoccursduringPVARPand,thus,isnottracked(Figure4–3Pacemak er2:1\\nblockonpage4-6).Thisresultsina2:1ratioofatrial-to-ventricular eventsorasuddendropintheventricular paced\\nratetohalfoftheatrialrate.Atfasteratrialrates,severalatrialeventscanfallintheTARPperiod,resulting inthe\\npulsegeneratortrackingonlyeverythirdorfourthP-wave. Theblockthenoccursatratessuchas3:1or4:1.\\nAVPVA RP AVPVA RP AVPVA RP AVPVA RP\\nIllustration ofpacemak er2:1block,inwhicheveryotherP-wavefallsinsidethePVARPinterval.\\nFigure4–3.Pacemaker2:1block\\nMaximum SensorRate(MSR)\\nMSRisthemaximum pacingrateallowed asaresultofrate-adaptive sensorcontrol.\\nConsider thefollowing whenprogramming MSR:\\n•Patient's condition, age,andgeneralhealth:\\n–Adaptive-rate pacingathigherratesmaybeinappropriateforpatients whoexperience anginaorother\\nsymptoms ofmyocardi alischemia atthesehigherrates\\n–AnappropriateMSRshouldbeselected basedonanassessment ofthehighestpacingratethatthepatient\\ncantoleratewell\\nNOTE:IfthepulsegeneratorisoperatinginDDDRorVDDRmode,theMSRandMTRmaybeprogrammed\\nindependently todifferent values.\\nMSRisindependently programmable at,above,orbelowtheMTR.IftheMSRsettingishigherthantheMTR,pacing\\nabovetheMTRmayoccurifthesensorrateexceedstheMTR.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 87}), Document(page_content=\"PacingTherapies\\nBasicParameters4-7\\nPacingabovetheMSR(whenprogrammed lowerthantheMTR)canonlyoccurinresponse tosensedintrinsic atrial\\nactivity.\\nCAUTION: Adaptive-rate pacingisnotlimitedbyrefractory periods. Alongrefractory periodprogrammed in\\ncombination withahighMSRcanresultinasynchron ouspacingduringrefractoryperiodssincethecombination can\\ncauseaverysmallsensing window ornoneatall.UseDynamic AVDelayorDynamic PVARPtooptimize sensing\\nwindows. Ifyouareprogramming afixedAVDelay,considerthesensing outcomes.\\nWithintrinsic conduction, thepulsegenerator maintains theA–Apacingratebyextending theV–Ainterval.This\\nextensionisdetermined bythedegreeofdifferencebetween theAVDelayandtheintrinsic ventricular conduction—\\noftenreferredtoasmodified atrial-based timing(Figure4–4VAintervalextensionandMSRonpage4-7).\\nPacing wi\\nthout mod\\nified \\natrial-ba\\nsed timin\\ng\\nPacing wi\\nth modifi\\ned \\natrial-ba\\nsed timin\\ng\\n1\\n50 ms 200 \\nms\\nA\\nV\\nVA\\nAV + VA\\nForced VA\\n extensio\\nn\\n150 ms 250\\n ms\\nAV\\nVA\\nAV + VA +\\n extensio\\nn\\nMSR 400 m\\ns (150 mi\\nn\\n-1\\n [ppm])\\nAV 150 ms\\n (conduct\\ned event)\\nVA 200 ms\\nPacing in\\nterval = \\nAV + VA =\\n 350 ms\\nMSR 400 m\\ns (150 mi\\nn\\n-1\\n [ppm])\\nAV 150 ms\\n (conduct\\ned event)\\nVA 200 ms\\nVA Ext. 5\\n0 ms\\n Pacing in terval = AV + VA +  VA exten sion = 40 0 ms\\nThepulsegenerator's timingalgorithm provides effective pacingattheMSRwithintrinsic ventricular conduction. Extending theVAintervalprevents theApacefromexceeding theMSRathigh\\nrates.\\nFigure4–4.VAintervalextension andMSR\\nRunaway Protection\\nRunaway protection isdesigned toprevent pacingrateaccelerationsabovetheMTR/MSR formostsingle-co mponent\\nfailures.Thisfeatureisnotprogrammable andoperatesindependently fromthepulsegenerator'smainpacing\\ncircuitry.\\nRunaway protection preventsthepacingratefromincreasingabove205ppm.\\nNOTE:Magnet application doesnotaffectthepacingrate(pulseinterval).\\nNOTE:Runaway Protectionisnotanabsolute assuranc ethatrunaways willnotoccur.\\nDuringPES,ManualBurstPacing,andATP,runaway protectionistemporarilysuspended toallowforhigh-rate\\npacing.\\nPulseWidth\\nPulseWidth,alsoreferredtoaspulseduration,determines howlongtheoutputpulsewillbeappliedbetween the\\npacingelectrodes.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 88}), Document(page_content=\"4-8PacingTherapies\\nPaceSafe\\nConsider thefollowing whenprogramming PulseWidth:\\n•PulseWidthsareindependently programmable foreachchamber .\\n•IfaPulseWidthThresholdTestisperformed, aminimum 3Xpulsewidthsafetymarginisrecommended.\\n•Theenergydeliveredtotheheartisdirectlyproportiona ltothePulseWidth;doubling thePulseWidthdoubles\\ntheenergydelivered.Therefore,programming ashorterPulseWidthwhilemaintaining anadequate safety\\nmarginmayincreasebatterylongevity .Toprevent lossofcapture, exercisecautionwhenprogramming\\npermanent PulseWidthvaluesoflessthan0.3ms(Figure4–5Pulsewaveform onpage4-8).\\nPulse Width (ms)\\nAmplitude (V)\\nFigure4–5.Pulsewaveform\\nAmplitude\\nThepulseAmplitude, orvoltageoftheoutputpulse,ismeasuredattheleadingedgeoftheoutputpulse(Figure4–5\\nPulsewaveform onpage4-8).\\nConsider thefollowing whenprogramming Amplitude:\\n•Amplitudes areindependently programmable foreachchamber .\\n•BradyModemaybeprogrammed toOffviapermanent ortempora ryprogramming. Ineffect,thisturns\\nAmplitude Offtomonitor thepatient's underlying rhythm.\\n•Theprogrammed Amplitude isrecommended tobeaminimum of2Xthecapturethresholdtoprovideadequate\\nsafetymargin. Lowerpaceamplitudes willpreserve/e xtendlongevity .Theprogrammed Amplitude shouldbea\\nbalance ofadequate safetymarginandeffectuponbatterylongevity .IfPaceSafe isprogrammed On,itwill\\nautomatically provideanadequate safetymarginandmayhelpextendbatterylongevity .\\n•Theenergydeliveredtotheheartisdirectlyproportiona ltothesquareoftheAmplitude; doubling theAmplitude\\nquadruples theenergydelivered.Therefor e,programming toalowerAmplitude whilemaintaining anadequate\\nsafetymarginmayincreasebatterylongevity .\\nPaceSafe\\nPaceSafeRightAtrialAutomatic Threshold (RAAT)\\nPaceSafe RAATisdesigned todynamically adjusttheatrialpacingoutputtoensurecaptureoftheatriumby\\noptimizing theoutputvoltageto2Xthecapturethresholdtoprovide adequate safetymargin(forthresholds lessthan\\norequalto2.5V).RAATwillmeasure pacingthresholds between 0.2Vand4.0Vat0.4msandtheoutputwillbea\\nminimum of2.0Vandamaximum of5.0Vwithafixedpulsewidthof0.4ms.\\nNOTE:Tofunction properly,RAATrequiresafunctional RVleadandabipolaratriallead.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 89}), Document(page_content='PacingTherapies\\nPaceSafe4-9\\nNOTE:RAATisonlyavailable inpulsegeneratorsprogrammed toDDD(R)andDDI(R)modesaswellasDDI(R)\\nFallback Mode.\\nRAATcanbeprogrammed onbyselecting AutofromtheAtrialAmplitude parameteroptions. Programming theatrial\\noutputtoAutowillautomatically adjustthePulseWidthto0.4msandsettheatrialvoltageoutputtoaninitialvalue\\nof5.0Vunlessthereisasuccessfultestresultwithinthelast24hours.\\nNOTE:Priortoprogramming RAATon,consider performing aCommanded AtrialAutomatic Threshold\\nMeasurementtoverifythatthefeaturefunctions asexpected.RAATtestingisperformed inaunipolar configuration\\nandtheremaybeadiscrepancybetween unipolar andbipolarthresholds. Ifthebipolarthresholdisgreaterthanthe\\nunipolar thresholdbymorethan0.5V,considerprogramming afixedAtrialAmplitude.\\nRAATisdesigned toworkwithtypicalleadimplant criteriaandanatrialthresholdbetween 0.2Vand4.0Vat0.4ms.\\nTheRAATalgorithm thenmeasurestheatrialpacingthreshold eachdayandadjuststhevoltageoutput.During\\ntesting, RAATmeasuresanevokedresponsesignaltoconfirm thateachatrialpacingoutputcapturestheatrium.If\\nthedeviceisunabletorepeatedly measure anevokedresponsesignalofsufficient amplitude, a“LowER”or“Noise”\\nmessage maybedisplayed andthealgorithm willdefaultto5.0Vpacingamplitude. Consider programming afixed\\natrialpacingamplitude inthesesituations andre-check withaCommanded RAATtestatalaterfollow-up; maturation\\nofthelead-tissue interfacemayimprovetheperformanc eofRAAT.\\nIftestingissuccessful,theAtrialAmplitude isadjusted to2Xthehighestmeasuredthresholdofthelast7successful\\nambulatory tests(outputAmplitude between 2.0Vand5.0V).Seventestsareusedtoaccountforcircadian cycle\\neffectsonthresholdandensureanadequate safetymargin. Thisalsoallowsforarapidincrease inoutputduetoa\\nsuddenriseinthreshold whilerequiring consistently lowerthreshold measurementstodecreaseoutput(i.e.,onelow\\nthresholdmeasurementwillnotcauseadecrease inoutput)(Figure4–6EffectofthresholdchangeonRAATpacing\\noutputonpage4-9).\\nNOTE:Sinceoutputissetto2Xthecapturethreshold toprovideadequate safetymarginandRVpacingoccurs\\nshortlyafteratrialpacing,thereisnobeat-to-beat captureverification orbackupatrialpacingatanytime.\\nWhenDailyTrendisselected alongwithafixedAmplitude, automatic atrialthresholdmeasurementswilloccurevery\\n21hourswithnochangetoprogrammed output.\\nTheRAATfeatureisdesigned tooperatewithalargerangeofpacingleads(e.g.,highimpedance ,lowimpedance,\\ntinedfixation, orpositive fixation).\\n6.0\\n5.0\\n4.0\\n3.0\\n2.0\\n1.0\\n0.\\n0\\nV\\na\\nl\\nu\\ne\\n \\n(\\nV\\n)\\nDay\\n5 10 15 20 25\\n70 30 35 40 4\\n5 50 55 60 65\\nThreshold\\nPace Outp\\nut\\nOne high \\nthreshold\\n causes a\\nn \\nimmediate\\n rise in \\npacing ou\\ntput\\nOne low t\\nhreshold \\ndoes not \\n change th e pacing output Lead aler\\nt trigger\\ned on \\n 4th day o f failed testing\\nFigure4–6.Effectofthreshold changeonRAATpacingoutput', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 90}), Document(page_content='4-10PacingTherapies\\nPaceSafe\\nAmbulator yAtrialAutomatic Threshold Measurement\\nTestingusesanRAtip>>can(unipolar) pacingvectorandanRAring>>can(unipolar) sensing vectoreventhough\\ntheatrialleadisprogrammed toanormalbradyBipolarPace/Sense configuration.\\nWhenRAATissettoAutoorDailyTrend,ambulator yatrialautomatic thresholdmeasurementsareconducted every\\n21hoursandthefollowing paramet ersareadjusted toensureavalidmeasurementisobtained:\\n•Moderemains unchanged fromcurrentmodeunlessRYTHMIQ isonandinAAI(R)mode;inthatcasethemode\\nwillswitchtoDDD(R)fortesting.\\n•Starting atrialpacingamplitude istheoutputthatRAATiscurrently using.IfthatAmplitude valuefailsorifno\\nprevious resultsareavailable, thestarting Amplitude is4.0V.\\n•Thepacingamplitude willdecrementin0.5Vstepsabove3.5Vandin0.1Vstepsatorbelow3.5V.\\n•PacedAVDelayisfixedat85ms.\\n•SensedAVDelayisfixedat55ms.\\n•Initialpacingrateissettotheaverageatrialrate,theLRLorsensor-indicated rate,whichever isfaster.\\n•Ifthereareaninsufficient number ofatrialpacesoriffusionoccurs,theatrialpacingratewillbeincreasedby\\n10ppm(itmaybeincreasedasecondtime),butwillnotexceedthelowestoftheMTR,MSR,MPR,110bpm,or\\n5bpmbelowthelowestVTDetection Rate.\\nFollowing initialization paces,thepulsegeneratorwilldecrement theatrialoutputevery3pacesuntilathresholdis\\ndetermined. Iflossofcaptureoccurstwiceataparticular outputlevel,thresholdisdeclaredasthepreviousoutput\\nlevelthatdemonstrated consistentcapture. If3capturedbeatsoccuratanyparticular outputlevel,outputdecrements\\ntothenextlevel.\\nNOTE:ToensurethatlossofcaptureduringRAATdoesnotencouragePMT(andalsoendthetestprematu relydue\\ntotoomanyatrialsenses), thepulsegeneratorusesaPMTalgorithm. Following thelossofcaptureofanyatrialbeat,\\nthePVARPfollowing thatventricular eventisextended to500mstopreventtrackingofasubsequent P-wave.\\nIfdailytestingisunsuccessful,RAATwillreturntothepreviously determined outputandthepulsegenerator will\\nperform upto3re-attempts athourlyintervals. Ifasuccessfultestdoesnotoccurfor4days,aLeadAlertwillbe\\ntriggeredandRAATwillenterSuspension.\\nRightAtrialAutomatic Threshold Suspension\\nIfambulatory testingfailsinAutomodefor4consecutive days,RAATwillgointoaSuspension modeandthepacing\\noutputwilloperateat5.0Vand0.4ms.Testingwillcontinueeachdaywithupto3re-attempts toevaluate\\nthresholds andthepulsegeneratorwilladjusttoaloweroutputsettingwhenindicated byasuccessfultest.\\nAlthough RAATisdesigned toworkwithawiderangeofleads,insomepatients theleadsignalsmayhinder\\nsuccessfuldetermination oftheatrialthreshold.Intheseinstances, RAATwillcontinually operateintheSuspension\\nmodeat5.0V.Insituations whereSuspension modepersists foranextendedperiodoftime,itisrecommended to\\nturnRAAToffbyprogramming afixedatrialoutput.\\nCommanded AtrialAutomatic Threshold Measurement\\nAnautomatic thresholdmeasurementcanbecommanded viatheThreshold Testsscreenbyselecting AutoAmplitude\\nastheTestType.Iftestingcompletes successfullyandRAATisprogrammed on,theoutputwillautomatically beset\\nto2Xthattest’smeasuredthreshold(between 2.0Vand5.0V).Thelast7successfuldailymeasurem entsarecleared', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 91}), Document(page_content='PacingTherapies\\nPaceSafe4-11\\nandthecurrentcommanded testresultisusedasthefirstsuccessfultestofanew7testcycle.Thisistoensurethat\\ntherewillbeanimmediate outputadjustment basedonthecurrentcommanded testresultratherthanonolder\\nambulatory testdata.Thiscanbeconfirmedbyobservin gtheoutputvoltageontheBradySettings screen,whichwill\\nshowtheactualoperatingvoltageoftheRAATalgorithm.\\nIftestingisunsuccessful,theThresholdTestsscreenwilldisplayafailurecodeindicating thereasonthetestwasnot\\nsuccessful,andtheoutputwillreturntothepreviouslysetlevel(Table4–1ThresholdTestCodesonpage4-11).\\nNOTE:FortheinitialAtrialThresholdtestafterthepulsegeneratorisimplanted, theTestTypefieldisseededto\\nAuto.ChoosethedesiredtesttypefromtheTestTypefieldoptions, andadjustanyotherprogrammable valuesas\\nappropriate.\\nNOTE:Commanded testingrequiresafunctional bipolaratrialleadandmaybeperformed inAAImode.\\nTestResultsandLeadAlerts\\nAstoredEGMforthemostrecentsuccessfulambulator ytestwillbestoredintheArrhythmia Logbook (\"Arrhythmia\\nLogbook\" onpage6-2).RefertotheDailyMeasure mentsscreenfortheresultingthresholdvalue.Ifdesired, the\\nstoredEGMcanbereviewed todetermine wherelossofcaptureoccurred.\\nUpto12months ofAmbulatory ThresholdTestresults,aswellastestfailurecodesandleadalerts,canbefound\\nwithintheDailyMeasurement andTrendsscreens.Toprovidefurtherinformation onthereasonfortestfailure,a\\nfailurecodeisprovided foreachdayinwhichtestingfails.Additionally ,failurecodesareprovidedontheThreshold\\nTestscreenifacommanded automatic thresholdtestdoesnotcompletesuccessfully.ThresholdTestFailureCodesare\\nlistedbelow(Table4–1ThresholdTestCodesonpage4-11).\\nThefollowing scenarioswilltriggertheCheckAtrialLeadalert:\\n•Threshold>Programmed Amplitude willbedisplayed ifRAATisinDailyTrendmodeandtheambulatory test\\nresultsofthelast4consecutive daysexceedthemanually programmed fixedoutput.\\n•Automatic ThresholdSuspension willbedisplayed ifnosuccessfultestsareperformed for4consecutive daysin\\nAutoorDailyTrendmode.\\nTable4–1.Threshold TestCodes\\nCode Reason\\nN/R:devicetelem. Telemetry startedduringanambulatory test\\nN/R:comm.lost Telemetry waslostduringacommanded test\\nN/R:nocapture Capturewasnotobtained atthestarting amplitude foracommandedtestor\\ncaptureis>4.0Vforanambulator ytest\\nN/R:modeswitch ATRmodeswitcheitherstartedorstopped\\nN/R:fusionevents Toomanyconsecutiveortoomanytotalfusioneventsoccurred\\nNodatacollected Minimum pacingamplitude wasreached without losingcaptureforan\\nambulatory test,orneitherAutonorDailyTrendisturnedontoobtainan\\nambulatory result\\nN/R:batterylow Testwasskipped duetoBatteryCapacity Depleted\\nN/R:noise Toomanyconsecutivesensechannel noiseorEvokedResponse noisecycles\\noccurred\\nN/R:incompa t.mode Incompatible Bradymodewaspresent(e.g.VDIFallback Mode)\\nN/R:ratetoohigh Ratewastoohighatthestartofthetest,arateincreasewouldraisetheratetoo\\nhighormorethan2rateincreases wererequired', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 92}), Document(page_content='4-12PacingTherapies\\nPaceSafe\\nTable4–1.Threshold TestCodes(continued)\\nCode Reason\\nN/R:usercancelled Commanded testwasstopped bytheuser\\nN/R:intrinsic beats Toomanycardiaccyclesoccurredduringthetest\\nN/R:testdelayed Testwasdelayed duetotelemetry beingactive,VTepisode alreadyinprogress,\\nElectrocautery mode,MRIProtection Mode,orRAATwasturnedonwhilethe\\ndeviceremained inStorage mode.Codedisplayed regardless ofwhether Autoor\\nDailyTrendisturnedonoroff.\\nN/R:vent.episode AVentricular Episode startedduringtesting\\nN/R:respiration Respiratory artifactwastoohigh\\nN/R:lowER TheEvokedResponse signalcouldnotbeassessed adequately\\nAutoN/R Minimum pacingamplitude wasreachedwithout losingcapturefora\\ncommanded test,ortelemetry ismanually cancelled duringacommande dtest\\nN/R:recentshock Ventricular shocktherapywasdelivered lessthan60minutes priortothe\\nscheduled startofanambulator ytest\\nPaceSafeRightVentricular Automatic Threshold (RVAT)\\nPaceSafe RVATisdesigned todynamically adjusttherightventricular pacingoutputtoensurecaptureoftheventricle\\nbyoptimizing theoutputvoltageto2Xthecapturethresholdtoprovide adequate safetymargin(forthresholds less\\nthanorequalto2.5V).RVATwillmeasurepacingthresholds between 0.2Vand5.0Vat0.4ms,andtheoutputwill\\nbeaminimum of2.0Vandamaximum of5.0VwithafixedPulseWidthof0.4ms.\\nNOTE:RVATisavailable inDDD(R), DDI(R),VDD(R), andVVI(R)modes,aswellasduringVDI(R)andDDI(R)Fallback\\nModes.\\nRVATcanbeprogrammed onbyselecting AutofromtheVentricular Amplitude paramet eroptions. Ifstarting froma\\nfixedamplitude greaterthan5.0V,programafixedamplitude of5.0Vpriortoselecting Auto.Programming the\\nventricular outputtoAutowillautomatically adjustthePulseWidthto0.4msandsettheventricular voltageoutput\\ntoaninitialvalueof5.0Vunlessthereisasuccessfultestresultwithinthelast24hours.\\nNOTE:Priortoprogramming RVATon,considerperforming aCommanded Ventricular Automatic Threshold\\nMeasurementtoverifythatthefeaturefunctions asexpected.\\nRVATisdesigned toworkwithtypicalleadimplant criteriaandmeasureaventricular threshold between 0.2Vand\\n5.0Vat0.4ms.\\nTheRVATalgorithm thenmeasurestheventricular pacingthreshold eachdayandadjuststhevoltageoutput.During\\ntesting, RVATusesanevokedresponsesignaltoconfirmthateachventricular pacingoutputcaptures theventricle.\\nTheevokedresponse issensedbetween theRVcoilandcan.Thisconfiguration provides ahighelectrode surfacearea\\nwhichresultsinasmallafterpotential, smallerpacingartifact, andimproves sensing oftheevokedresponse.\\nIftestingissuccessful,theVentricular Amplitude isadjusted to2Xthehighestmeasuredthresholdofthelast7\\nsuccessfulambulatory testsbetween 2.0Vand5.0V.Seventestsareusedtoaccountforcircadiancycleeffectson\\nthresholdandensureanadequate safetymargin.Thisalsoallowsforarapidincreaseinoutputduetoasuddenrise\\ninthresholdwhilerequiring consistently lowerthresholdmeasurements todecrease output(i.e.onelowthreshold\\nmeasurementwillnotcauseadecreaseinoutput)(Figure4–7Effectofthreshold changes onRVATpacingoutputon\\npage4-13).\\nNOTE:Sinceoutputissetto2Xthecapturethresholdtoprovideadequate safetymargin, thereisnobeat-to-beat\\ncaptureverification.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 93}), Document(page_content='PacingTherapies\\nPaceSafe4-13\\nWhenDailyTrendisselected alongwithafixedAmplitude, automatic ventricular threshold measurementswilloccur\\nevery21hourswithnochangetoprogrammed output.\\nTheRVATfeatureisdesigned tooperate withalargerangeofpacingleads(e.g.,highimpedance, lowimpedance ,\\nintegratedbipolar,dedicated bipolar).\\n6.0\\n5.0\\n4.0\\n3.0\\n2.0\\n1.0\\n0.\\n0\\nV\\na\\nl\\nu\\ne\\n \\n(\\nV\\n)\\nDay\\n5 10 15 20 25\\n70 30 35 40 4\\n5 50 55 60 65\\nThreshold\\nPace Outp\\nut\\nOne high \\nthreshold\\n causes a\\nn \\nimmediate\\n rise in \\npacing ou\\ntput\\nOne low t\\nhreshold \\ndoes not \\n change th e pacing output Lead aler\\nt trigger\\ned on \\n 4th day o f failed testing\\nFigure4–7.Effectofthreshold changesonRVATpacingoutput\\nAmbulatory RightVentricular Automatic Threshold Measurement\\nWhenRVATissettoAutoorDailyTrend,ambulatory ventricular automatic threshold measurementsareconducted\\nevery21hours.\\nInatrialtrackingmodes,theautomatic threshold measurementadjuststhefollowing parameters tohelpensurea\\nvalidmeasurement isobtained:\\n•PacedAVDelayisfixedat60ms.\\n•SensedAVDelayisfixedat30ms.\\n•V-Blank AfterA-Paceisfixedat85ms.\\n•Starting ventricular pacingoutputamplitude istheoutputwhichRVATiscurrentlyusing(orwouldbeusingwhen\\nRVATissettoDailyTrendonly).Ifthatamplitude failsorifnopreviousresultsareavailable, thestarting\\namplitude is5.0V.\\n•Thepacingamplitude willdecrement in0.5Vstepsabove3.5Vandin0.1Vstepsatorbelow3.5V.\\n•Abackuppulseisdelivered approximately 90msaftertheprimary pacingpulsewhenlossofcaptureisdetected.\\nInnontrackingmodes,theautomatic thresholdmeasurement adjuststhefollowing parameterstohelpensureavalid\\nmeasurementisobtained:\\n•PacedAVDelayisfixedat60ms.\\n•V-Blank AfterA-Paceisfixedat85ms.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 94}), Document(page_content='4-14 PacingTherapies\\nPaceSafe\\n•Starting ventricular pacingoutputamplitude istheoutputwhichRVATiscurrentlyusing(orwouldbeusingwhen\\nRVATissettoDailyTrendonly).Ifthatamplitude failsorifnopreviousresultsareavailable, thestarting\\namplitude is5.0V.\\n•Thepacingamplitude willdecrementin0.5Vstepsabove3.5Vandin0.1Vstepsatorbelow3.5V.\\n•Abackuppulseisdeliveredapproximately90msaftertheprimarypacingpulsewhenlossofcaptureisdetected.\\n•Theventricular pacingratewillbeincreasedby10ppmabovethecurrentrate(pacedorintrinsic) andiscapped\\natthelowestoftheMPR,MSR,110bpm,or5bpmbelowthelowestVTDetection Rate.\\nNOTE:Iffusion(whichcouldpotentially beanoisebeat)isdetected, theamplitude ofthenextpacewillbeat5.0V\\nifthetestingvoltageisabove1.0V;otherwise, theamplitude ofthenextpacewillbeat2.5V.\\nFollowing initialization paces,thepulsegeneratorwilldecrement theventricular outputevery3pacesuntila\\nthresholdisdetermined. Additional pacingpulseswillbeissuedifthereisfusionorintermittent lossofcapture.\\nThresholdisdeclaredastheprevious outputlevelthatdemonstrated consistent capture.\\nIfdailytestingisunsuccessful,RVATwillreturntothepreviously determined outputandthedevicewillperform upto\\n3re-attempts athourlyintervals. Ifasuccessfultestdoesnotoccurfor4days,aLeadAlertwillbetriggered andRVAT\\nwillenterSuspension.\\nRightVentricular Automatic Threshold Suspension\\nIfambulatory testingfailsinAutomodefor4consecutive days,RVATwillgointoaSuspension modeandthepacing\\noutputwilloperateat5.0Vand0.4ms.Testingwillcontinueeachdaywithupto3re-attempts toevaluate\\nthresholds andthepulsegeneratorwilladjusttoaloweroutputsettingwhenindicated byasuccessfultest.\\nAlthough RVATisdesigned toworkwithawiderangeofleads,insomepatients theleadsignalsmayhinder\\nsuccessfuldetermination oftheventricular threshold.Intheseinstances,RVATwillcontinuallyoperate inthe\\nSuspension modeat5.0V.Insituations whereSuspension modepersists foranextendedperiodoftime,itis\\nrecommended toturnRVAToffbyprogramming afixedventricular output.\\nCommanded RightVentricular Automatic Threshold Measurement\\nAnautomatic thresholdmeasurementcanbecommanded viatheThreshold Testsscreenbyselecting AutoAmplitude\\nastheTestType.Iftestingcompletes successfullyandRVATisprogrammed on,theoutputwillautomatically beset\\nto2Xthattest’smeasuredthreshold(between 2.0Vand5.0V).Thelast7successfuldailymeasurem entsarecleared\\nandthecurrentcommanded testresultisusedasthefirstsuccessfultestofanew7testcycle.Thisistoensurethat\\ntherewillbeanimmediate outputadjustment basedonthecurrentcommanded testresultratherthanonolder\\nambulator ytestdata.Thiscanbeconfirmed byobserving theoutputvoltageontheBradySettings screen,whichwill\\nshowtheactualoperatingvoltageoftheRVATalgorithm.\\nBackuppacingisdeliveredapproximately90msaftertheprimary paceforeverylossofcapturebeatduring\\ncomman dedtesting.\\nIftestingisunsuccessful,theThresholdTestsscreenwilldisplaythereasonthetestwasnotsuccessful,andthe\\noutputwillreturntothepreviouslysetlevel(Table4–2Threshold TestFailureCodesonpage4-15).\\nNOTE:FortheinitialVentricular Threshold Testafterthepulsegeneratorisimplanted, theTestTypefieldisseeded\\ntoAuto.ChoosethedesiredtesttypefromtheTestTypefieldoptions, andadjustanyotherprogrammable valuesas\\nappropriate.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 95}), Document(page_content='PacingTherapies\\nPaceSafe4-15\\nTestResultsandLeadAlerts\\nAstoredEGMforthemostrecentsuccessfulambulator ytestwillbestoredintheArrhythmia Logbook (\"Arrhythmia\\nLogbook\" onpage6-2).RefertotheDailyMeasure mentsscreenfortheresultingthresholdvalue.Ifdesired, the\\nstoredEGMcanbereviewed todetermine wherelossofcaptureoccurred.\\nUpto12months ofAmbulatory ThresholdTestresults,aswellastestfailurecodesandleadalerts,canbefound\\nwithintheDailyMeasurement andTrendsscreens.Toprovidefurtherinformation onthereasonfortestfailure,a\\nfailurecodeisprovided foreachdayinwhichtestingfails.Additionally ,failurecodesareprovidedontheThreshold\\nTestscreenifacommanded automatic thresholdtestdoesnotcompletesuccessfully.ThresholdTestFailureCodesare\\nlistedbelow(Table4–2Threshold TestFailureCodesonpage4-15).\\nThefollowing scenarioswilltriggertheCheckRVLeadalert:\\n•Threshold>Programmed Amplitude willbedisplayed ifRVATisinDailyTrendmodeandtheambulator ytest\\nresultsofthelast4consecutive daysexceedthemanually programmed fixedoutput.\\n•Automatic ThresholdSuspension willbedisplayed ifnosuccessfultestsareperformed for4consecutive daysin\\nAutoorDailyTrendmode.\\nTable4–2.Threshold TestFailureCodes\\nCode Reason\\nN/R:devicetelem. Telemetry startedduringanambulatory test\\nN/R:comm.lost Telemetry waslostduringacommanded test\\nN/R:nocapture Capturewasnotobtained atthestarting amplitude foracommandedtest\\nN/R:modeswitch ATReitherstartedorstopped (testing willnotfailifATRisalreadyactiveand\\nstaysactiveduringtesting)\\nNodatacollected Minimum pacingamplitude wasreached without losingcapture, neitherAuto\\nnorDailyTrendwasturnedontoobtainanambulatory testresult,lossof\\ncaptureoccurredat5.0V,oraninadequate number ofinitialization paces\\noccurred\\nN/R:batterylow Testwasskipped duetoBatteryCapacity Depleted\\nN/R:noise Toomanyconsecutivesensechannel noisecyclesoccurred\\nN/R:ratetoohigh Ratewastoohighatthestartofthetest,orduringtesting\\nN/R:usercancelled Commanded testwasstopped bytheuser\\nN/R:intrinsic beats Toomanycardiaccyclesoccurredduringthetestorinitialization restartedtoo\\nmanytimes\\nN/R:testdelayed Testwasdelayed duetotelemetry beingactive,VTepisode alreadyinprogress,\\nElectrocauterymode,MRIProtection Mode,orRVATwasturnedonwhilethe\\ndeviceremained inStorage mode.Codedisplayed regardlessofwhether Autoor\\nDailyTrendisturnedonoroff.\\nN/R:vent.episode AVentricular Episode startedduringtesting\\nAutoN/R Minimum pacingamplitude wasreached without losingcapturefora\\ncommandedtestortelemetry ismanually cancelledduringacommanded test\\nN/R:fusionevents Testfailedduetotoomanyconsecutive fusionbeats\\nN/R:recentshock Ventricular shocktherapy wasdeliveredlessthan60minutes priortothe\\nscheduled startofanambulatory test', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 96}), Document(page_content='4-16PacingTherapies\\nPaceSafe\\nSensitivity\\nTheSensitivity featureallowsthepulsegenerator todetectintrinsic cardiacsignalsthatexceedtheprogrammed\\nsensitivity value.Adjusting theSensitivity valueallowsyoutoshifttheatrialand/orventricular sensing rangeto\\nhigherorlowersensitivity .Alldetection andtimingdecisions arebasedonthesensedcardiacsignals. Atrialand\\nventricular Sensitivity valuesareindependently programmable.\\n•HighSensitivity (lowprogrammed value)—when Sensitivity isprogrammed toaverysensitive setting, thepulse\\ngeneratormaydetectsignalsunrelatedtocardiacdepolarization (oversensing, suchassensing ofmyopotentials)\\n•LowSensitivity (highprogrammed value)—when Sensitivity isprogrammed toalesssensitive setting, thepulse\\ngeneratormaynotdetectthecardiacdepolarization signal(undersensing)\\nItisrecommended thattheSensitivity parameter settings beleftatthenominal valuesunlesstroubleshooting\\ndetermines thatanother valuemaybemoreappropriate.Whilethenominal valueisprimarily indicated forbothatrial\\nandventricular sensing, anadjustment canbemadeif,inararesituation, atrialorventricular oversensing/\\nundersensing hasbeenobserved(e.g.,inhibition ofbradycardia pacingorinappropr iatetherapy)\\nShoulditbecome necessarytoadjusttheSensitivity parameterinachamber ,alwayschoosethesettingthatprovides\\nappropriatesensing ofintrinsic activityandbestresolvesoversensing/undersensing.\\nIfpropersensing cannotberestored withanadjustment orifanyundersensing oroversensing isobserved after\\nmakingachange, consider anyofthefollowing (takingintoaccountindividual patientcharacteristic s):\\n•ReprogramtheAGCsensitivity value\\n•ReprogramtheRefractoryorcross-chamber blanking periodappropriat elytoaddress theobserved undersensing\\noroversensing\\n•Reposition thelead\\n•Implant anewsensing lead\\nAfteranychangetoSensitivity, evaluate thepulsegeneratorforappropriat esensing andpacing.\\nCAUTION: Following anysensing rangeadjustment oranymodification ofthesensing lead,alwaysverify\\nappropriatesensing. Programming Sensitivity tothehighestvalue(lowestsensitivity) mayresultindelayed detection\\norundersensing ofcardiacactivity.Likewise,programming tothelowestvalue(highest sensitivity) mayresultin\\noversensing ofnon-cardiac signals.\\nAutomatic GainControl\\nThepulsegenerator usesdigitalAutomatic GainControl(AGC)todynamically adjustthesensitivity inboththeatrium\\nandtheventricle. Thepulsegeneratorhasindependent AGCcircuitsforeachchamber .\\nCardiacsignalscanvarywidelyinsizeandrate;thereforethepulsegeneratorneedstheabilityto:\\n•Senseanintrinsic beat,regardless ofrateorsize\\n•Adjusttosensevaryingamplitude signals, butnotoverreacttoaberrant beats\\n•Senseanyintrinsic activityafterapacedbeat\\n•IgnoreT-waves\\n•Ignorenoise\\nTheprogrammable AGCvalueistheminimum sensitivity value(floor)thatcouldbereachedbetween onebeatand\\nthenextbeat.Thisprogrammable valueisnotafixedvaluepresent throughout thecardiaccycle;rather,the', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 97}), Document(page_content='PacingTherapies\\nPaceSafe4-17\\nsensitivity levelbeginsatahighervalue(basedonthepeakofasensedeventorafixedvalueforapacedevent)and\\ndecrementstowards theprogrammed floor(Figure4–8AGCsensing onpage4-18).\\nAGCwilltypically reachtheprogrammable floorduringpacing(orwithlowamplitude signals). Butwhenmoderat eor\\nhighamplitude signalsaresensed, AGCwilltypically belesssensitive andnotreachtheprogrammable floor.\\nTheAGCcircuitineachrespective chamber processesanelectrogr amsignalviaatwostepprocesstooptimize\\nsensing ofpotentially rapidlychanging cardiacsignals. Theprocessisillustratedinthefigurebelow(Figure4–8AGC\\nsensing onpage4-18):\\n•Firststep\\n1.AGCusesarollingaverageofprevioussignalpeakstocalculate asearchareawherethenextpeakwill\\nlikelyoccur.\\n–Ifthepreviousbeatissensed, itisincorporated intotherollingpeakaverage.\\n–Ifthepreviousbeatispaced,thepeakaverageiscalculated usingtherollingaverage andapaced\\npeakvalue.Thepacedpeakvaluedepends onthesettings:\\n–Fornominal ormoresensitive settings, itisafixedvalue(initialvalue4.8mVintheRV;initial\\nvalue2.4mVintheRA).\\n–Forlesssensitive settings, itisahighervaluecalculated usingtheprogrammed AGCfloor\\nvalue(forexample,ifRVsensitivity isprogrammed totheleastsensitive settingorthehighest\\nvalueof1.5mV,thepacedpeakvalue=12mV).\\nThepeakaverageisthenusedtoboundanareawithMAX(maximum) andMIN(minimum) limits.\\n•Secondstep\\n2.AGCsensesthepeakoftheintrinsic beat(orusesthecalculated peakforapacedbeatasdescribed above)\\n3.Itholdsthesensitivity levelatthepeak(orMAX)throughtheabsolute refractoryperiod+15ms.\\n4.Itdropsto75%ofthesensedpeakorcalculated peakaverageforpacedevents(ventricular pacedevents\\nonly).\\n5.AGCbecomes moresensitive by7/8ofthepreviousstep.\\n6.Sensedbeatstepsare35msfortheRVand25msfortheatrium.Pacedbeatstepsareadjusted basedon\\nthepacingintervaltoensureanapproximately 50mssensing window attheMINlevel.\\n7.ItreachestheMIN(orprogrammed AGCFloor).\\n–Theprogrammed AGCFloorwillnotbereachediftheMINvalueishigher.\\n8.TheAGCremainsattheMIN(orprogrammed AGCfloor)untilanewbeatissensed, orthepacinginterval\\ntimesoutandapaceisdelivered.\\nNOTE:Ifanewbeatissensedasthesensitivity levelstepsdown,AGCstartsoveratStep1.\\nNOTE:Iftheamplitude ofasignalisbelowthesensitivity thresholdineffectatthetimethesignaloccurs,\\nitwillnotbesensed.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 98}), Document(page_content='4-18PacingTherapies\\nPost-Therapy Pacing\\nSensed Ev ent Programme\\nd AGC \\nfloor val\\nue\\nMIN\\nMAX\\nPeak\\nAbsolute \\nsensing \\nlimit (32\\n mV)\\nFigure4–8.AGCsensing\\nAnonprogrammable Dynamic NoiseAlgorithm isactiveinratechannels whereAGCsensing isused.TheDynamic\\nNoiseAlgorithm isintended tohelpfilteroutpersistent noise.TheDynamic NoiseAlgorithm isaseparatenoise\\nchannel foreachchamber thatcontinuously measures thebaseline signalthatispresent andisdesigned toadjust\\nthesensitivity floortominimizetheeffectsofnoise.\\nThealgorithm usesthecharacteristics ofasignal(frequency andenergy)toclassifyitasnoise.Whenpersistent noise\\nispresent,thealgorithm isdesigned tominimize itsimpact,whichmayhelptopreventoversensing myopotentials\\nandtheassociated inhibition ofpacing.Noisethataffectsthesensing floormaybevisibleontheintracardiacEGMs,\\nbutwouldnotbemarked assensedbeats.However ,ifthenoiseissignificant, thefloormayrisetoalevelabovethe\\nintrinsic electrogramandtheprogrammed NoiseResponse behavior (asynchronous pacingorInhibitPacing)willoccur\\n(\"NoiseResponse\" onpage4-63).\\nNOTE:TheDynamic NoiseAlgorithm doesnotensurethatAGCwillalwaysaccurately distinguish intrinsic activity\\nfromnoise.\\nPOST-THERAPY PACING\\nPost-therapypacingprovidesalternate pacingtherapyfollowing thedelivery ofanyshock.\\nThepacingmodeandpacingtherapiesusedfollowing ashockarethesameastheprogrammed Normalpacing\\nsettings.\\nThefollowing pacingparameters canbeprogrammed independently fromtheNormalpacingsettings:\\n•PacingParamete rs—LRL, Amplitude, andPulseWidth\\n•PostTherapyPeriod', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 99}), Document(page_content='PacingTherapies\\nPost-Therapy Pacing4-19\\nPost-ShockPacingDelay\\nThePost-ShockPacingDelaydetermines theearliestpossible startofpost-shockpacingfollowing thedelivery ofa\\nventricular shockandisfixedat2.25seconds.\\nThetimingoftheinitialpacingpulseinthePostTherapy Perioddepends onthecardiacactivityduringthePost-\\nShockPacingDelay.\\n•IfR-waves (and/or P-waves fordual-chamber pacingmodes)aresensedduringthePost-ShockPacingDelay,the\\ndevicepacesonlywhenthesensedrateisslowerthanthepost-therapyLRL.\\n•IfnoR-waves (and/or P-waves fordual-chamber pacingmodes)aresensedduringthePost-ShockPacingDelay\\noriftheintervalsincetheprecedingP-orR-wavewasgreaterthantheescapeinterval,apacingpulseis\\ndeliveredattheendofthePost-ShockPacingDelay.\\nSubsequent pacingpulsesaredeliveredasrequired, depending onthepacingprescription.\\nPost-Therapy Period\\nThePostTherapyPerioddetermines howlongthepulsegeneratoroperatesusingthepost-therapyparamet ervalues.\\nThePostTherapyPeriodfunctions asfollows:\\n•TheperiodstartswhenthePost-ShockPacingDelayexpires\\n•Oncompletio nofthispacingperiod,thepulsegeneratorrevertstotheprogrammed Normalpacingvalues\\n•Whileinprocess,thepacingperiodisnotaffected bytheendofthecurrentepisode\\nTEMPORAR YBRADYPACING\\nThepulsegeneratorcanbeprogrammed withtempora rypacingparameter valuesthatdifferfromtheprogrammed\\nNormalSettings. Thisallowsyoutoexaminealternate pacingtherapieswhilemaintaining thepreviously programmed\\nNormalSettings inthepulsegenerator memory .DuringtheTemporaryfunction, allotherbradycardiafeatures not\\nlistedonthescreenaredisabled.\\nNOTE:Post-therapyvaluesarenotaffected.\\nTousethisfunction, followthesesteps:\\n1.FromtheTeststab,selecttheTempBradytabtodisplaythetemporary parameters.\\nNOTE:Post-therapyvaluesarenotshownevenifpost-therapyispresentlyineffect.\\n2.Selectthedesiredvalues;thesevaluesareindependent fromotherpacingfunctions.\\nNOTE:Temporary BradyinteractivelimitsmustbecorrectedbeforeTemporarypacingcanoccur.\\nNOTE:IfOffisselected astheTemporary BradyMode,thepulsegeneratorwillnotsenseorpacewhile\\nTemporarypacingmodeisineffect.\\n3.Establish telemetr ycommunication, thenselecttheStartbutton.Pacingbeginsatthetemporary values.Adialog\\nboxindicates thattemporaryparamet ersarebeingused,andaStopbuttonisprovided.\\nNOTE:Tempora rypacingcannotbestartedwhileatachyarrhythmia episode isinprogress.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 100}), Document(page_content='4-20PacingTherapies\\nMinuteVentilation /Respiratory SensorandSignalArtifactMonitor\\nNOTE:Emergency therapyistheonlyfunction thatcanbeinitiated untiltheTemporary function isstopped.\\n4.TostoptheTemporary pacingmode,selecttheStopbutton.TheTemporary pacingmodealsostopswhenyou\\ncommand emergencytherapyfromthePRM,whenyouselectDIVERTTHERAPY, oriftelemetry islost.\\nOnceTemporary pacingmodeisstopped, pacingrevertstothepreviously programmed Normal/Post -Therapy\\nsettings.\\nMINUTEVENTILATION /RESPIRATOR YSENSORANDSIGNALARTIFACT MONITOR\\nMinuteVentilation/Respirator ySensor(MV/Respiratory Sensor)\\nThePGusestheMinuteVentilation (MV)/Respirato rySensortomeasuretransthorac icimpedance. Theresulting\\ntransthoracic impedance measurementsareusedfortwopurposes:\\n•Tocollectrespiration -related dataforuseingeneratingtrends,suchastheRespiratory Ratetrend.\\n•Tomeasureminuteventilation (MV),theproductofrespiration rateandtidalvolume. MVcanbeusedtoincrease\\nthepacingratetomeetthepatient’s corresponding physiologic need.RefertoMinuteVentilation (\"Minute\\nVentilation \"onpage4-32)formoreinformation.\\nWhentheMV/Respiratory Sensorisprogrammed toOnorPassive(MV),approximately every50ms(20Hz),the\\ndevicewilldeliverasubthresholdexcitationcurrentwaveform between theRARingelectrode orRVCoilandCan(the\\nMV/Respir atorySensorsignal).Theapplication ofcurrentbetween theRARingelectrode orRVCoilandtheCanwill\\ncreateanelectrical fieldacrossthethorax,modulated byrespiration.Duringinspiratio nthetransthor acicimpedance is\\nhigh,andduringexpirationitislow.Thedevicemeasurestheresultingvoltagemodulations between theleadtip\\nelectrodeandtheCan.\\nNOTE:IfanRAleadisnotused,onlytheRVvectorisavailable.\\nNOTE:Leadsmaybeprogrammed toUnipolar orBipolar,butafunctioning bipolarleadmustbepresent.\\nirepresentsexcitation output(current), Vrepresentsmeasurement ofresulting voltage(volts)\\nFigure4–9.Measurement oftransthoracic impedance usingtheRVlead\\nWhentheRA/RVleadsandleadterminal connections areoperating asintended, theMV/Respir atorySensorsignalis\\nappropriatelyfilteredandthereforeisnotdetected bythedeviceordisplayed onelectrogr ams(EGMs). However ,\\nintermittency relatedtointegrity oftheleadordevice-leadconnectionhasthepotential tocreateatransienthigh\\nimpedance condition. Ahighimpedance conditionmayresultintheMV/Respir atorySensorsignalbecomingvisible\\nonEGMsandpotentially subjecttooversensing ontheRAand/orRVchannels.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 101}), Document(page_content='PacingTherapies\\nMinuteVentilation /Respiratory SensorandSignalArtifactMonitor4-21\\nTheMV/Respir atorySensorprovidestwomechanisms formeasuring theintegrity ofthesensorvectors:\\n•WhentheSignalArtifactMonitor (SAM)devicediagnostic isprogrammed toOn,theSAMcontinually monitors the\\nEGMforsensorartifacts. Fordetails,see\"DeviceBehavior whenSAMisOn\"onpage4-23.\\n•WhentheSAMisprogrammed toOff,thedeviceperforms MV/Respir atorySensorvectorimpedance\\nmeasurementsapproximatelyeveryhourtoassessleadandleadconnection integrity .Fordetails,see\"Device\\nBehavior whenSAMisOff\"onpage4-24.\\nCAUTION: Formaximum sensitivity indetecting andpreventing potential signalartifact-generated oversensing, itis\\nrecommen dedthattheSignalArtifactMonitor (SAM)isprogrammed OnanytimetheMV/Respir atorySensoris\\nprogrammed toOnorPassive. Turning theSignalArtifactMonitor Offmayputthepatientatincreasedriskof\\noversensing, unlesstheMV/Respir atorySensorisalsoprogrammed Off.\\nMV/Respiratory SensorProgrammable Parameters\\nThefollowing paramet ersfortheMV/Respir atorySensorareprogrammable.\\nFordeviceswhereMVrateresponsive pacingisavailable, theMVSensorcanbeprogrammed toOn,Passive, Off,or\\nATROnly:\\n•On:enables RightRate pacingandrespiration-relat edtrending. Ifthedeviceisprogrammed toanon-rate\\nadaptive mode,theOnsettingisnotavailable.\\n•Passive: enables respiration-r elatedtrendingonly.\\n•ATROnly:enables rateresponsive pacingonlyduringATRFallback. Ifthepulsegenerator ispermanently\\nprogrammed toanon-rateadaptive mode,butarateadaptive ATRFallback modeisselected, theMVfieldwill\\ndisplayATROnly.\\n•Off:norate-responsive pacingorrespiration -related trendingisavailable.\\nExcitation Currentcontrolstheamplitude oftheMV/Respir atorySensorsignalandcanbesetto80uAor320uA.\\nVectorSelection controlshowtheactiveMV/Respir atorySensorvectorisdetermined bythedevice,andcanbesetto:\\n•AOnly:theMV/Respir atorySensorisrestricted toRAvectors.\\n•RVOnly:theMV/Respiratory SensorisrestrictedtoRVvectors.\\n•AutoSelect:eitherAorRVwillbeautomatically determined bythedevice.Thevectorselection behavior when\\nsettoAutoSelectdepends onwhether theSignalArtifactMonitor isOnorOff.RefertoSAMDeviceDiagnostic\\n(\"Signal ArtifactMonitor DeviceDiagnostic\" onpage4-23)formoredetails.\\nNOTE:WhentheSAMisON,itmonitors boththeRAandtheRVEGMforsignalartifacts, regardless ofhowVector\\nSelection isprogrammed. VectorSelection onlydetermines whichvectorisusedtomeasuretheMV/Respir atory\\nSensorsignal.\\nCAUTION: ProgramtheMV/Respir atorySensortoOffduringmechanical ventilation. Otherwise,thefollowing may\\noccur:\\n•InappropriateMVSensor-drivenrate\\n•Misleading respiration-based trending', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 102}), Document(page_content='4-22PacingTherapies\\nMinuteVentilation /Respiratory SensorandSignalArtifactMonitor\\nCAUTION: Anymedical equipment, treatment, therapy,ordiagnostic testthatintroduc eselectrical currentintothe\\npatienthasthepotential tointerferewithpulsegeneratorfunction.\\n•External patientmonitors (e.g.,respiratory monitors, surfaceECGmonitors, hemodynamic monitors) maycause:\\n–Inappropriate MVSensor-driven rate(uptomaximum sensor-drivenrate)\\n–Misleading respiration-based trending\\nToresolvesuspected interactionswithRespirato rySensor-baseddiagnostics, deactivate thepulsegenerator\\'s\\nRespiratory Sensorbyprogramming ittoOff.\\nMV/Respiratory SensorStatus\\nTheMV/Respir atorySensorinitiates calibrationwheninitiallyactivated afterdeviceimplant andaftersensor\\nsuspension duetonoiseorotherconditions.Refertoadditional information aboutcalibration in\"Minute Ventilation \"\\nonpage4-32.Thestatusofthesensorisindicated bytheappropriateMV/Respir atorySensorstatusmessage, as\\nsummarized inMV/Respir atorySensorStatusMessages (Table4–3MV/Respir atorySensorStatusMessages onpage\\n4-22).Sensorstatusisreported ontheMinuteVentilation SensorDetailsscreen(deviceswithMVrateresponsive\\npacing(Figure4–10MinuteVentilation SensorDetailsonpage4-23))orRespiratory SensorDetailsscreen(devices\\nwithout MVrateresponsive pacing).\\nIfaVentricular Tachyepisode isdeclared(8outof10fastbeats),thesensorwillbesuspended forthedurationofthe\\nepisode. Oncetheepisode hasended,MVdrivenpacingwillresumeunlessanautomatic 6-hourcalibrationoccurs\\nduetoalongepisode oroutofrangeleadimpedances (testperformed atendofepisode).\\nTable4–3.MV/Respirator ySensorStatusMessages\\nSensorStatus MVSensorDrivenPacing MV/Respiratory SensorDataCollection for\\nTrendinga\\nOff No No\\nInitializing No No\\nAutoCalibration inProgress No Yes\\nCalibrated YesbYes\\nSuspended No No\\nSuspended: NoValidLead No No\\nSuspended: NoiseDetected No Yes\\nSuspended: Telemetry NocYes\\nSuspended: TachyEpisode No No\\nDisabled bydevicediagnostic No No\\nRateHold:Telemetry NocdeYes\\nManualCalibrationinProgress NoeYes\\na.Individual Trendsdetermine ifdatacollectedduringSuspension isvalidandincorpora tedintoTrendresults.\\nb.IftheMV/Respiratory Sensorisprogrammed toPassive, MV/Respir atorySensor-drivenpacingwillnotoccur.\\nc.Inductive (wanded) telemetry mayinterfere withthedevice\\'s MV/Respiratory sensorfunction. MVdrivenpacingratesmayholdatthecurrentrateandRespiratory\\nRateTrenddatacollection issuspended forapproximately oneminuteimmediately following anyinterrogation orprogramming command (RateHold).Longer\\ndelays(uptoseveralminutes) willbeindicated byastatusofSuspended: Telemetry .IfMVdrivenratechanges aredesiredpriortotherateholdorsuspension\\nperiods, allowtheMVdrivenratetoreachthedesiredratepriortousinginductive telemetry ,oruseRFtelemetry tocommunicate withthedevice.\\nd.RatewillholdatthecurrentMVindicated valueforuptooneminute; furtherMVbasedratechanges willnotoccurwiththissensorstatus.\\ne.StatusappliestoMVrateresponsive pacingdevicesonly.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 103}), Document(page_content='PacingTherapies\\nMinuteVentilation /Respiratory SensorandSignalArtifactMonitor4-23\\nSignalArtifactMonitorDeviceDiagnostic\\nTheSignalArtifactMonitor (SAM)isadevicediagnostic thatmonitors theEGMforMV/Respir atorySensorsignal\\nartifacts andmeasuresMV/Respir atorySensorvectorleadimpedance values.Ifartifacts aredetected oraMV/\\nRespiratorySensorvectorleadimpedance valueisoutofrange,SAMeitherswitches theMV/Respir atorySensor\\nvector,ordisables thesensor(Figure4–10MinuteVentilation SensorDetailsonpage4-23).Inaddition, anepisode is\\ncreatedthatincludes EGMsanddiagnostic leadimpedance data.\\nTheSAMisnominally OnwhenMV/Respir atorySensorisprogrammed toOnorPassive(MV).Signalartifacts canbe\\ngeneratedwhentheMV/Respir atorySensorissettoanyvalueexceptOff.Therefor e,itisrecommended tokeepSAM\\nOnunlesstheMV/Respir atorySensorisprogrammed toOff.Recommended SAMSettings arelistedbelow(Table4–4\\nRecommended SignalArtifactMonitor (SAM)Settings onpage4-23).\\nCAUTION: Turning theSignalArtifactMonitor Offmayputthepatientatincreasedriskofoversensing, unlessthe\\nMV/Respir atorySensorisalsoprogrammed toOff.\\nTable4–4.Recommended SignalArtifactMonitor(SAM)Settings\\nMVSensorSetting Possibletogenerate SignalArtifact Recommend edSAMSetting\\nOn Yes On\\nPassive Yes On\\nATROnly Yes On\\nOff No N/A\\nRespiratory SensorSetting Possibletogenerate SignalArtifact Recommend edSAMSetting\\nOn Yes On\\nOff No N/A\\nFigure4–10.MinuteVentilation SensorDetails\\nDeviceBehavior whenSAMisOn\\nTheSAMcontinuously monitors theEGMforMV/Respir atorySensorsignalartifacts thatmayresultinoversensing. At\\nthetimeofartifactdetection, impedance valuesfortheMV/Respir atorySensorvectorsaremeasured,andpacedlead\\nimpedanc esarealsomeasured.ASAMepisode iscreatedthatrecordstheEGMwithartifactandallassociated vector\\nandleadimpedance values.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 104}), Document(page_content='4-24PacingTherapies\\nMinuteVentilation /Respiratory SensorandSignalArtifactMonitor\\nDepending onthesettingoftheMV/Respir atorySensorVectorSelection parameter,twooutcome sarepossible (as\\ndescribed inTable4–5ResultofEGMartifactdetection bySAMonpage4-24):\\n•TheactivesensorvectorsswitchfromAtoV,or\\n•Thesensorisdisabled bySAM.\\nNOTE:TheSAMisanintervalbasedalgorithm, therefore,thealgorithm mayidentify othersignals(including atrial\\narrhythmias) asMV/Respir atorySensorsignalartifacts, iftheymeetthealgorithm’s criteria.\\nNOTE:Impedance measurementsrecordedbySAMareindependent ofdailyleadimpedance measurements. They\\ndonotappearonthedailyleadimpedance trendgraphsandwillnottriggerLeadSafetySwitch.\\nTable4–5.ResultofEGMartifactdetection bySAM\\nIfMV/Respiratory SensorVectorSelection\\nissettoAndtheactivevector\\nwasDeviceresponse toEGMartifactbeingdetected\\nAutoSelect ASAMepisode created\\nMeasure MV/Respiratory SensorRVvector’s impedance values:\\n•Ifinrange:SwitchtheactivesensorvectortoRVab\\n•Ifoutofrange:secondSAMepisode createdandMV/\\nRespirato rySensorisDisabled\\nAutoSelect RV\\nSAMepisodecreatedandMV/Respiratory SensorDisabled AOnly A\\nRVOnly RV\\na.IfaMV/Respiratory Sensorvectorswitchoccurs,anautomatic 6-hourcalibration willoccur(noMVrateresponsive pacingoccursduringthe6-hourcalibration\\nperiod).\\nb.AcceptableMV/Respiratory Sensorvectorimpedanc evaluesare100-1500 ΩfortheringtoCanvector,200-2000 ΩforthetiptoCanvector,and20–200Ωforthe\\ncoiltocanvector.Thesevaluesarenotaffected byimpedance alertlimitsprogrammed forDailyleadimpedanc emeasurements.\\nDuringaprogrammersession, activemonitoring forartifacts isnotperformed. However ,programming theMV/\\nRespiratory Sensorsettings maytriggerasensorvectorimpedance measurement. Iftheresulting MV/Respir atory\\nSensorvectorimpedance isoutofrange,aSAMepisode iscreated,andthesensorvectormaybeswitched orthe\\nsensormaybedisabled depending onvectorselection settings.\\nAdisabled MV/Respir atorySensorwillremaininthatstateuntilmanually reprogrammed fromtheMVSensorDetails\\nscreen(Figure4–10MinuteVentilation SensorDetailsonpage4-23).NoMVrate-responsive pacingandno\\nrespiratory-related trendingwilloccurwhilethesensorisdisabled.\\nDeviceBehavior whenSAMisOff\\nIfSAMisprogrammed toOff,MV/Respir atorySensorvectorimpedance measurements areperformed hourly(Table\\n4–6Deviceresponsetoout-of-rang eimpedance valuefoundduringhourlyleadcheckonpage4-25).Whenthe\\nVectorSelection paramet erissettoAutoSelect,ifthemeasuredimpedance forthecurrentlyutilizedvector(for\\nexample,RA)isoutofrange,theimpedance forthealternate vector(forexample, RV)isevaluated todetermine if\\nthatvectorcanbeutilized. Ifthemeasuredimpedance forthealternate vectorisinrange,thenthealternate vector\\nbecomes theactivevector.Ifbothvectorsareoutofrange,thesensorissuspended foronehour.Leadintegrity will\\ncontinuetobetestedeveryhourtoevaluate iftheMV/Respiratory Sensorcanresumeusingoneofthevectorsor\\nremainsuspended. IfaMV/Respiratory Sensorvectorswitchoccurs,anautomatic 6-hourcalibrationwilloccur(noMV\\nrateresponsivepacingoccursduringthe6-hourcalibrationperiod).', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 105}), Document(page_content='PacingTherapies\\nMinuteVentilation /Respiratory SensorandSignalArtifactMonitor4-25\\nTable4–6.Deviceresponse toout-of-range impedance valuefoundduringhourlyleadcheck\\nIfMV/Respiratory SensorVectorSelection\\nissettoAndtheactivevector\\nisThenthedeviceresponse toanout-of-range impedance is\\nAutoSelect AorRV Switchtothealternate vectorifalternate vectorimpedance isin\\nrangea\\nIfthealternate vectorimpedance isoutofrange,theMV/\\nRespiratory Sensorissuspended, re-testafteronehour\\nAOnly A\\nMV/Respiratory Sensorsuspended, re-testafteronehour\\nRVOnly RV\\na.IfaMV/Respiratory Sensorvectorswitchoccurs,anautomatic 6-hourcalibration willoccur(noMVrateresponsive pacingoccursduringthe6-hourcalibration\\nperiod).\\nUnlikewhenSAMisprogrammed toOn,nomonitoring forEGMartifacts occursandnoSAMepisodes arecreated.\\nSignalArtifactMonitorEpisodes\\nSAMepisode detailsarerecordedintheArrhythmia Logbook (\"Arrhythmia Logbook\" onpage6-2).ToviewSAM\\nepisode details,selectthedesiredepisode ontheArrhythmia Logbook screen.TheEventSummary screendisplays\\ndetailsabouttheSAMepisode (Figure4–11SignalArtifactMonitor Episode Summar yonpage4-25).\\nTheSummary tabprovidesalinktothescreenwheresensordetailsarefound(thebuttonwillbelabeled‘MVSensor\\nDetails’or‘Respirato rySensorDetails’, depending onthedevicemodelandavailability ofMVrateresponsive pacing).\\nThescreendisplays programming options fortheMV/Respiratory SensorandSAM(Figure4–10MinuteVentilation\\nSensorDetailsonpage4-23).RefertoMV/Respiratory SensorProgrammable Parameters(\"MV/Respiratory Sensor\\nProgrammable Paramete rs\"onpage4-21)formoreinformation onprogramming options.\\nFigure4–11.SignalArtifactMonitorEpisodeSummary', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 106}), Document(page_content='4-26PacingTherapies\\nMinuteVentilation /Respiratory SensorandSignalArtifactMonitor\\nTwotypesofSAMepisodes canbegenerated; MV/Respiratory SensorDisabled, orMV/Respir atorySensorVector\\nSwitched. BothtypesincludeanEGM,aswellasimpedance valuesrecordedatthetimeofepisode creationfor:\\n•Available MV/Respiratory Sensorvectors\\n•PacingLeads\\nTheEGMtabdisplays theEGMrecordedatthetimeofSAMepisode creation. Whendeviceconditions resultinthe\\nsensorexcitationsignalbeingdetected onthesensechannel, thesignalartifactisvisibleonthecorresponding trace\\nasaregular,rapidlyrepeating (20Hz)patternofpeaksthatmayresemblenon-physiologic noise(Figure4–12Signal\\nArtifactMonitor Episode EGMonpage4-26).Theamplitude anddurationofthesensorsignalartifactontheEGMcan\\nbevariable, andmaybemodulated bypostural,respiratory,orcardiacmotion.\\nSomeSAMepisodes maygenerate EGMswithnovisiblesignalartifact. Thisistheexpectedbehavior whenthesensor\\nvectorimpedance measurementwastriggeredbysomething otherthanadetected signalartifact. Forexample,when\\nSAMisOnandtheMV/Respir atorySensorsettingischanged fromOfforDisabled toOnorPassive, asensorvector\\nimpedance measurementistriggered. Ifout-of-rangeimpedance( s)aredetected, aSAMepisode willbecreated.\\nFigure4–12.SignalArtifactMonitorEpisodeEGM\\nSignalArtifactMonitorEpisodeDataandProgramming Considerations\\nSAMepisode data(impedanc evaluesfortheindividual sensorvectors) mayhelpindetermining thesourceof\\ntransienthighimpedance condition s.Ingeneral,transienthighimpedance conditionsmaybecausedbyalead\\nconductorfracture,under-insertion oftheleadterminal, oraxial/radial motionoftheleadterminal’s ringelectrode\\nwithinthedeviceheader.\\nWhentheMV/Respiratory Sensorisdisabled bytheSAM:\\n•FromtheLeadsStatusSummary screen(\"LeadsStatus\"onpage5-7),checkfortransienthighimpedance\\ncondition sorsignificant changes overtimeinthedailyleadimpedance measurements.\\n•Perform leadtestingfromtheLeadTestsscreen(\"LeadTests\"onpage5-12).', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 107}), Document(page_content=\"PacingTherapies\\nRateAdaptive PacingandSensorTrending4-27\\nIfaproblemwiththeleadissuspected, toreducethepotential forMV/Respir atorySensorsignalartifact-generated\\noversensing, considerprogramming totheopposite VectorSelection paramet er,orprogramming theMV/Respiratory\\nSensortoOff.\\nIfdailyleadimpedance measurementsandleadimpedance trendslooknormal, considerthepatient’s needforMV/\\nRespiratorySensor-associated trendsand/orMVrateresponsive pacing.Ifnotneeded, turntheMV/Respir atory\\nSensorOffandcontinue tomonitor thelead.\\nIfrespiration-r elatedtrenddataand/orMVrateresponsivepacingisdesired, keeptheSAMprogrammed toOn.The\\nMinuteVentilation SensorDetailsscreenmaybeusedtoadjusttheMV/Respir atorySensorVectorSelection\\nparametertousetheopposite lead(Figure4–10MinuteVentilation SensorDetailsonpage4-23).TheExcitation\\nCurrentcontrolstheamplitude oftheMV/Respiratory Sensorsignalandcanalsobeadjusted. Programming the\\nExcitation Currentto80uAmayreducetheamplitude ofexcitationpulsesiftheyappearontheEGM,thereby\\ndecreasingthelikelihoodofartifacts beingoversensed. However ,alowerexcitationpulseamplitude hasthepotential\\ntoresultinmorefrequentsuspension oftheMV/Respir atorySensorduetoexternalnoiseinterfering withthe\\nsensor’s function.\\nForamoredetailed discussion ofVectorSelection andExcitation Currentprogramming, pleasecontactBoston\\nScientific usingtheinformation onthebackcover.\\nAllprogramming decisions shouldbebasedontheindividual patient’s condition, indications andtherapyneeds.\\nRATEADAPTIVE PACINGANDSENSORTRENDING\\nRateAdaptive Pacing\\nInrateadaptive pacingmodes(i.e.,anymodeendingwithR),sensors areusedtodetectchanges inthepatient's\\nactivityleveland/orphysiologic demand andincreasethepacingrateaccordingly.Rateadaptive pacingisintended\\nforpatients whoexhibitchronotropicincompetence andwhowouldbenefitfromincreasedpacingratesthatare\\nconcurrent withincreasedactivityleveland/orphysiologic need.\\nThedevicecanbeprogrammed tousetheAccelerometer, MinuteVentilation, orablendofboth.Theclinicalbenefit\\nofrateadaptive pacingusingeitherofthesesensors hasbeenshowninpreviousclinicalstudies.\\nCAUTION: Rateadaptive pacingshouldbeusedwithcareinpatients whoareunabletotolerate increased pacing\\nrates.\\nWhenrateadaptive parameters areprogrammed, thepacingrateincreasesinresponse toincreasedactivitylevel\\nand/orphysiologic need,thendecreasesasappropriat e.\\nNOTE:Activityinvolving minimal upperbodymotion, suchasbicycling, mayresultinonlyamoderatepacing\\nresponse fromtheaccelerometer.\\nNOTE:RateAdaptive Pacinghasbeenshowntobepotentially proarrhythmic. Usecautionwhenprogramming\\nadaptive-r atefeatures.\\nAccelerometer\\nTheaccelerometerdetectsmotionthatisassociated withapatient's physical activityandgeneratesanelectronic\\nsignalthatisproportional totheamount ofbodymotion. Basedonaccelerometerinput,thepulsegenerator\\nestimates thepatient's energyexpenditure asaresultofexercise,thentranslates itintoarateincrease.\\nThepulsegeneratorsensesbodymotionbymeansofanintegrated circuitaccelerometer.Theaccelerometersensor\\nresponds toactivityinthefrequency rangeoftypicalphysiologic activity(1–10Hz).Theaccelerometerevaluates both\\nthefrequency andtheamplitude ofthesensorsignal.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 108}), Document(page_content=\"4-28PacingTherapies\\nRateAdaptive PacingandSensorTrending\\n•Frequencyreflectshowoftenanactivityoccurs(e.g.,thenumber ofstepstakenperminuteduringabriskwalk)\\n•Amplitude reflectstheforceofmotion(e.g.,themoredeliberatestepstakenwhilewalking)\\nOncedetected, analgorithm translates themeasuredacceleration intoarateincrease abovetheLRL.\\nBecause theaccelerometer isnotincontactwiththepulsegeneratorcase,itdoesnotrespond tosimplestatic\\npressureonthedevicecase.\\nTherearethreeAccelerometersettings: Off,On,andATROnly.Whenyouprogramtherespective rate-responsive\\nmodesforNormalSettings andATRFallback, thatactionautomatically updates theAccelerometersetting. Ifthepulse\\ngeneratorispermanently programmed toanon–rateadaptive mode,itispossible toprogramtheATRFallback mode\\ntoanadaptive-ra temodeusingtheaccelerometer sensor.Inthiscase,theAccelerometerfieldwilldisplayATROnly.\\nThefollowing programmable paramet erscontrolthepulsegenerator'sresponse tothesensorvaluesgeneratedby\\ntheAccelerometer:\\n•Response Factor\\n•ActivityThreshold\\n•Reaction Time\\n•RecoveryTime\\nResponse Factor(Accelerometer)\\nResponse Factor(accelerometer) determines thepacingrateincrease thatwilloccurabovetheLRLatvariouslevelsof\\npatientactivity(Figure4–13Response Factorandpacedrateonpage4-28).\\n•HighResponse Factor––r esultsinlessactivityrequiredforthepacingratetoreachtheMSR\\n•LowResponse Factor––r esultsinmoreactivityrequiredforthepacingratetoreachtheMSR\\nNOTE:Programming Response FactorforNormalSettings alsochanges thecorresponding selection forPost-\\nTherapySettings.\\nRate Res pons e Slopes \\n16 14 12 10 8 6 4 2 1 \\nMSR \\nLRL \\nLow High \\nActivity \\nPaced rate \\nN\\no\\nm\\ni\\nn\\na\\nl\\n \\nFigure4–13.Response Factorandpacedrate\\nThepacingrateachieved canbelimitedeitherbythedetected activitylevelortheprogrammed MSR.Ifthedetected\\nactivitylevelresultsinasteady-state ratebelowtheMSR,thepacingratecanstillincreasewhenthedetected activity\\nlevelsincrease(Figure4–14Response Factorinexercisetestonpage4-29).Thesteady-state response isindependent\\noftheprogrammed reaction andrecovery times.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 109}), Document(page_content=\"PacingTherapies\\nRateAdaptive PacingandSensorTrending4-29\\nResponse Factor \\nMSR \\nPaced rate \\nLRL \\nRest Stage 1 Rest Stage 2 \\nTime Higher Response \\nSetting \\nLower Response \\nsetting \\nNominal \\nResponse Setting \\nLower \\nHigher \\nThisfigureshowstheeffectofhigherandlowersettings duringatheoretical two-stage exercisetest.\\nFigure4–14.Response Factorinexercisetest\\nProgramming theLRLupordownmovestheentireresponse upordownwithout changing itsshape.\\nActivityThreshold\\nActivityThresholdpreventsrateincreasesduetolow-intensity ,extraneous motion(e.g.,motioncausedbyrespiration,\\nheartbeat,orinsomecasestremorassociated withParkinson's disease).\\nActivityThresholdrepresentstheactivitylevelthatmustbeexceededbeforethesensor-drivenpacingratewill\\nincrease.Thepulsegenerator willnotincreasethepacedrateabovetheLRLuntiltheactivitysignalincreasesabove\\ntheActivityThreshold.AnActivityThreshold settingshouldallowarateincrease withminoractivity,suchaswalking,\\nbutbehighenough sothepacingratewillnotincreaseinappropriatelywhenthepatientisinactive (Figure4–15\\nActivityThresholdandrateresponseonpage4-29andFigure4–16ActivityThreshold inexercisetestonpage4-30).\\n•Lowersetting––less motionisrequiredtoincreasethepacingrate\\n•Highersetting––more motionisrequired toincrease thepacingrate\\nNOTE:Programming theActivityThresholdforNormalSettings alsochanges thecorresponding selection forPost-\\nTherapySettings.\\nActivity Threshold\\nMSR\\nLRL\\nLow High\\nActivityLow\\nM\\ned\\ni\\num\\nM\\ned-\\nLo\\nM\\ned-\\nHi\\nHigh\\nV\\n-\\nHigh\\nV\\n-\\nLow\\nPa\\nced r\\na\\nte\\nFigure4–15.ActivityThreshold andrateresponse\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 110}), Document(page_content='4-30PacingTherapies\\nRateAdaptive PacingandSensorTrending\\nActivity Threshold\\nMSR\\nPa\\nced r\\na\\nte\\nLRL\\nRest Stage 1 Rest Stage 2\\nTimeLower threshold \\nsetting\\nHigher threshold\\n \\nsetting\\nNomin al threshold \\nsetting\\nThisfiguredemonstrates theeffectofincreased ordecreased ActivityThreshold settings inresponse toatheoretical two-stage exercisetest.\\nFigure4–16.ActivityThreshold inexercisetest\\nReactionTime\\nReaction Timedetermines howquicklythepacingratewillrisetoanewlevelonceanincrease inactivitylevelis\\ndetected.\\nReaction Timeaffectsonlythetimerequiredforarateincreasetooccur.Thevalueselected determines thetime\\nrequiredforthepacedratetomovefromtheLRLtotheMSRforamaximum levelofactivity(Figure4–17Reaction\\nTimeandpacedrateonpage4-30andFigure4–18Reaction Timeinexercisetestonpage4-31).\\n•ShortReaction Time:resultsinarapidincreaseinthepacingrate\\n•LongReaction Time:resultsinaslowerincreaseinthepacingrate\\nNOTE:Programming Reaction TimeforNormalSettings alsochanges thecorresponding selection forPost-Therapy\\nSettings.\\nReaction Slopes\\nMSR\\nLRL\\n0 10 20 30 40 50\\nSeconds\\nP\\nace\\nd\\n \\nr\\nate\\nS\\nh\\no\\nr\\nt\\nN\\no\\nm\\ni\\nn\\na\\nl\\nL\\no\\nn\\ng\\nFigure4–17.ReactionTimeandpacedrate', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 111}), Document(page_content='PacingTherapies\\nRateAdaptive PacingandSensorTrending4-31\\nReaction T ime\\nMSR\\nLRL\\nRest Stage 1 Rest Stage 2\\nTimeShorter\\nLonger\\nP\\nace\\nd\\n \\nr\\nate\\nShorter \\nReaction Tim\\ne\\nLonger \\nReaction Tim\\ne\\nNominal \\nReaction Tim\\ne\\nFigure4–18.ReactionTimeinexercisetest\\nRecoveryTime\\nRecoveryTimedetermines thetimerequiredforthepacedratetodecrease fromtheMSRtotheLRLintheabsenceof\\nactivity.Whenpatientactivityconcludes, RecoveryTimeisusedtopreventanabruptdecreaseinpacingrate(Figure\\n4–19Recovery Timeandpacedrateonpage4-31andFigure4–20RecoveryTimeinexercisetestonpage4-32).\\n•ShortRecoveryTime––resu ltsinafasterdecreaseinpacingrateafterpatientactivitylowersorstops\\n•LongRecoveryTime––results inaslowerdecreaseinpacingrateafterpatientactivitylowersorstops\\nNOTE:Programming Recovery TimeforNormalSettings alsochanges thecorresponding selection forPost-\\nTherapy Settings.\\nRecovery Curves\\nMSR\\nPa\\nce\\nd\\n r\\nat\\ne\\nLRL\\n0246 161412108\\nMinutes\\nThereare15settings available; onlytheeven-numbered settings areshown.\\nFigure4–19.RecoveryTimeandpacedrate', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 112}), Document(page_content='4-32PacingTherapies\\nRateAdaptive PacingandSensorTrending\\nRecovery T ime\\nMSR\\nPa\\nce\\nd\\n r\\nat\\ne\\nLRL\\nRest Stage 1 Rest Stage 2\\nTimeLonger \\nRecovery Tim\\ne\\nNomin al \\nRecovery Tim\\ne\\nThefigureshowstheeffectoflongerandshortersettings duringatheoretical two-stage exercisetest.\\nFigure4–20.Recovery Timeinexercisetest\\nMinuteVentilation (MV)\\nThisfeatureisavailable inRESONATE HF,PERCIVA HF,andMOMENTUM devices.\\nThepulsegenerator’s MinuteVentilation/Respirato rySensorusestransthoracic impedance toevaluate andmeasure\\nminuteventilation (MV),whichistheproductofrespirationrateandtidalvolume. BasedontheMVmeasurement,the\\npulsegeneratorcalculates thesensor-indicated pacingrate.\\nForadetailed description ofMinuteVentilation/Respirato rySensorfunction, refertoMinuteVentilation/Respiratory\\nSensor(\"Minute Ventilation/Respiratory Sensor\" onpage4-20).ToenableMV-driven pacing,thepacingmodemust\\nbesettoarate-adaptive mode(anymodeendinginR),andtheMinuteVentilation/Respiratory Sensormustbe\\nprogrammed toOn.\\nCAUTION: DonotprogramtheMVSensortoOnuntilafterthepulsegeneratorhasbeenimplanted andsystem\\nintegrity hasbeentestedandverified.\\nCAUTION: Forpatients withrespiratorydisorder sorabnormal breathingpatterns, thephysician shouldusemedical\\njudgment whenprogramming theMVSensortoOn.Tomitigate inappropriat esensor-drivenrates,thephysician may\\nevaluate therateresponseandconsideralowerResponse Factor.\\nCAUTION: ProgramtheMV/Respiratory SensortoOffduringmechanical ventilation. Otherwise, thefollowing may\\noccur:\\n•InappropriateMVSensor-drivenrate\\n•Misleading respiration -basedtrending\\nCAUTION: Anymedical equipment, treatment, therapy,ordiagnostic testthatintroduc eselectrical currentintothe\\npatienthasthepotential tointerferewithpulsegeneratorfunction.\\n•External patientmonitors (e.g.,respiratory monitors, surfaceECGmonitors, hemodynamic monitors) maycause:\\n–Inappropriate MVSensor-driven rate(uptomaximum sensor-drivenrate)\\n–Misleading respiration-based trending\\nToresolvesuspected interactionswithRespirato rySensor-baseddiagnostics, deactivate thepulsegenerator\\'s\\nRespiratory Sensorbyprogramming ittoOff.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 113}), Document(page_content='PacingTherapies\\nRateAdaptive PacingandSensorTrending4-33\\nMVRateResponse Algorithm\\nThepulsegeneratorkeepsalong-term moving average(baseline) oftheseMVmeasurements(updated every4\\nminutes) aswellasashort-term(approximately 30-second) moving average,whichisupdated every7.5seconds.The\\ndifferencebetween theshort-termaverageandlong-term baseline isusedtodetermine themagnitude oftherate\\nincreaseovertheLRL,ordecreasedowntotheLRL.Following aperiodofexertionandhighMVratedrive,the\\npatient’s short-termaveragewilldecreaseandeventually dropbelowthebaseline. Asitdecreases,theMVSensor-\\nindicated ratedecreases downtotheLRL.Theincreaseordecreaseinthesensor-indicated rateoccursatamaximum\\nof2ppmpercycle(Figure4–21Differencebetween MVshort-termaverageandMVbaseline onpage4-33).The\\nalgorithm supports breathingratesupto72bpm.\\nM\\nV\\n∆\\n \\nM\\nV\\nTime (app\\nroximatel\\ny 24 hour\\ns)\\n Time (app roximatel y 24 hour s) Short-ter\\nm average\\nBaseline\\nTop:Thebaseline (long-term average) followsthedriftoftheshort-termaverage. Bottom: Thedifferenc ebetween theshort-andlong-term average isusedfor\\nincreasingthesensor-drivenrateuponexertion.\\nFigure4–21.Differencebetween MVshort-term averageandMVbaseline\\nNOTE:Whenever amagnet isappliedandtheMagnet Response hasbeenprogrammed toPaceAsync,thedevice\\nwillpaceasynchronously atthemagnet rateandwillnotrespond toMVdata.\\nToactivate theMVSensor,thesystemneedsameasureofthebaseline orrestingMV(Sensorcalibration).Methods\\nforcalibrationinclude:\\n•Automatic Calibration. Anautomatic, 6-hourcalibrationwilloccurwhenever MVisprogrammed toOnor\\nPassive. NoMV-driven rateresponse orhourlyleadintegrity checkswilloccurduringthe6-hourcalibrationtime.\\nIfMVisprogrammed toOnatimplant, thefirsthourlyleadcheckwithacceptable leadimpedance valueswill\\nbegina2-hourwaitperiodfollowed bythe6-hourcalibration.This2-hourperiodwillbeindicated byasensor\\nstatusofInitializing andisintended toallowtheimplantation proceduretobecompleted.\\nNOTE:IfMVisprogrammed toOnorPassiveatthetimeofentryintoMRIProtection Mode,uponexitfrom\\nMRIProtectionMode,anautomatic 6–hourcalibrationwillbegin.IfMV-driven rateresponseisdesiredsooner,a\\nmanualcalibrationcanbeperformed.\\n•ManualCalibration. Whenever MVisprogrammed On,(including duringthe2-hourperiodfollowing lead\\nattachment) thesensorcanbecalibratedmanually .Ifthecalibrationissuccessful,MV-driven rateresponsetakes\\neffectwithinoneminute. FromtheRightRate PacingDetailsscreen,selecttheStartSensorCalibrationbuttonto\\ninitiatethemanualcalibrationprocess.Manualcalibration maytakeaslittleas2minutes orasmuchas5minutes\\ntocomplete ,depending onwhether noiseisencounter edduringdatacollection. Thepatientshouldberesting\\nquietlyandbreathingnormally forafewminutes priortoandduringthemanualcalibration.WhenManual', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 114}), Document(page_content='4-34PacingTherapies\\nRateAdaptive PacingandSensorTrending\\ncalibrationisinitiated, asensorleadintegrity checkisperformed. IfanMVvectorwithin-range impedance s\\ncannotbefound,ManualcalibrationfailsduetonovalidMVleadvector.Ifthemanualcalibrationfailsdueto\\nnoise,itwillbeindicated byaSuspended: NoiseDetected sensorstatusandthe6-hourautomatic calibrationwill\\nautomatically begin.\\nIfasensorleadintegrity checkisperformed, Manualcalibration startsonthefirstMVvectorwithin-range\\nimpedances. IfanMVvectorwithin-rangeimpedances cannotbefound,ManualcalibrationfailsduetonovalidMV\\nleadvector.\\nThepossible resultsoftheManualcalibrationandthecorresponding MVbehavior aredescribed inTable4–7Manual\\nCalibration Resultsonpage4-34asfollows:\\nTable4–7.ManualCalibration Results\\nManualCalibration Result MVBehavior\\nSuccessfulcalibrationMV-driven rateresponse takeseffectwithinoneminute.\\nCalibration failsduetonovalidMVleadvectorIfSAMisOn:\\n•SAMepisode(s) arecreated.\\n•TheMVSensorisdisabled.\\n•ThesensorstatusisDisabled bydevicediagnostic.\\nIfSAMisOff:\\n•Thepulsegeneratorcheckshourlyforavalidvectorandstartsthe6-hour\\ncalibration ifavalidvectorisdetected.\\nCalibration failsduetonoiseThesensorstatusisSuspended: NoiseDetected.\\nThe6-hourcalibration automatically beginswhennoiseisnolongerdetected.\\nNOTE:TheManualCalibrationmethod willnotbeavailable uponinitialinterrogationwhileinformation suchas\\nArrhythmia Logbook episodes areretrievedfromthedevice.Thiswillbeindicated byadimmed StartSensor\\nCalibration iconandmayoccurforsecondstominutes depending ontheamount ofdatabeingretrieved.\\nThereisnoclinicaldifferencebetween theAutomatic andtheManualcalibrationmethods. AsuccessfulManual\\ncalibrationsimplyallowsabaseline tobeobtained andMV-driven rateresponse tobeginuponcompletion of\\ncalibration.Neithercalibrationmethod requiresthattelemetr ycommunication bemaintained forthedurationofthe\\ncalibration.\\nCAUTION: ToobtainanaccurateMVbaseline following anysurgicalprocedureinvolving thepulsegeneratoror\\nleads,anew,manualcalibration shouldbeperformed. Leadmaturation,airentrapmentinthepocket,pulse\\ngeneratormotionduetoinadequate suturing, externaldefibrillation orcardioversion, orotherpatientcomplications\\n(e.g.,pneumothor ax)requireanewMVbaseline forappropriat eMVbehavior .\\nForoptimal rateresponse,avarietyofMinuteVentilation parameters canbeprogrammed viatheRightRate Pacing\\nareaontheRightRate PacingSettings screen.Theseinclude:\\n•Response Factor\\n•Ventilatory Threshold\\n•Ventilatory ThresholdResponse\\n•FitnessLevel', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 115}), Document(page_content=\"PacingTherapies\\nRateAdaptive PacingandSensorTrending4-35\\nResponse Factor(MinuteVentilation)\\nAnincreaseinMVoverbaseline duetoanincreaseinmetabolic demand willbedetected bythepulsegenerator and\\nconverted byitsalgorithm intoanincreasedpacingrate.Therelationship between thedetected increaseinMVand\\ntheresultingincreaseinthesensor-indicated rateisestablished bytheMVResponse Factor.\\nTheResponse Factorparamete rdetermines thepacingratethatwilloccurabovetheLRLatvariouselevated levelsof\\nMV.LargerresponsefactorvalueswillresultinhighersensorratesforagivenMVlevel(Figure4–22Relationship\\nbetween theprogrammed Response Factorsettingandrateresponse onpage4-35).Theeffectsofhigherandlower\\nResponse Factorsettings onsensor-drivenpacingrateduringatheoretic altwo-stage exercisetestareillustrated\\nbelow(Figure4–23EffectsofResponse Factorsettings inatwo-stage exercisetestonpage4-35).\\nResponse \\nFactor\\n161412108\\n6421\\nMSR\\nLRL\\nLow High\\n ∆ MV\\nP\\na\\nc\\ne\\nd\\n \\nr\\na\\nt\\ne\\n5\\nFigure4–22.Relationship between theprogrammed Response Factorsettingandrateresponse\\nResponse Factor \\nMSR \\nPaced rate \\nLRL \\nRest Stage 1 Rest Stage 2 \\nTime Higher Response \\nSetting \\nLower Response \\nsetting \\nNominal \\nResponse Setting \\nLower \\nHigher \\nFigure4–23.EffectsofResponse Factorsettingsinatwo-stage exercisetest\\nVentilatory Threshold andVentilator yThreshold Response\\nVentilatory Threshold isaphysiologic termdescribing thepointduringexercisewhenthebreathing rateincreases\\nfasterthantheheartrate(sometimes referredtoasAnaerobicorLactateThreshold).\\nTheResponse FactorcontrolstheMVrateresponseforsensorratesbetween theLRLandtheVentilatory Threshold.\\nTheVentilatory ThresholdResponse controlstheMVrateresponse whenthesensorrateisabovetheVentilator y\\nThreshold.\\nTheVentilatory ThresholdandVentilatory ThresholdResponse canbeeithermanually programmed orautomatically\\nderivedfrompatientinformation. Theclinician canselectDerivefromPatientAttributes fromtheRightRate Pacing\\nDetailsscreentoobtainsettings basedonthepatient's ageandgender(andFitnessLevel,seebelow).Asparamete rs\\narechanged, thegraphwilllikewiseadjusttodemonstrate theeffectofthenewprogramming onoverallrate\\nresponse (Figure4–24Ventilatory ThresholdandVentilatory Threshold Response onpage4-36).IftheDateofBirthor\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 116}), Document(page_content='4-36PacingTherapies\\nRateAdaptive PacingandSensorTrending\\nGenderisadjusted onthePatientInformation screen,thenewvalueswillalsobereflectedontheRightRate Pacing\\nDetailsscreen.\\nFigure4–24.Ventilatory Threshold andVentilator yThreshold Response\\nThephysiologic relationship between MVandrateisapproximately bilinearasshown(Figure4–25Typicalphysiologic\\nrelationship between MVandheartrateonpage4-36).DuringexerciselevelsuptotheVentilatory Threshold,this\\nrelationship canbeapproximatedbyalinearrelationship.Atexertion levelsabovetheVentilatory Threshold, the\\nrelationship isstillapproximately linear,butatareducedslope.Therelationship between thetwoslopesvariesfrom\\npersontopersonanddepends onseveralfactorssuchasgender,age,andexercisefrequency andintensity .Thepulse\\ngeneratorsallowprogramming ofaslopeabovetheVentilatory Thresholdthatislesssteepandthusdesigned to\\nmimicthephysiologic relationship between respirationrateandheartrate.TheVentilatory Threshold Response is\\nprogrammed asapercentageoftheResponse Factor.Ventilatory ThresholdResponse isineffectatratesabovethe\\nVentilatory ThresholdandwillresultinalessaggressiveresponsetoMVathigherrates(Figure4–26Ventilator y\\nThresholdResponse onpage4-37).\\nMinute VentilationVentilato\\nry \\nThreshold\\nR\\ne\\ns\\np\\no\\nn\\ns\\ne\\n \\nF\\na\\nc\\nt\\no\\nr\\nResting \\nheart rat\\ne\\nMV\\n0\\nMV\\nT\\nH\\ne\\na\\nr\\nt\\n \\nR\\na\\nt\\ne\\nMV0=restingMV;MVT=MVattheVentilatory Threshold\\nFigure4–25.Typicalphysiologic relationship between MVandheartrate', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 117}), Document(page_content='PacingTherapies\\nRateAdaptive PacingandSensorTrending4-37\\nOff\\n85%\\n70%\\n55%\\nH\\ne\\na\\nr\\nt\\n \\nR\\na\\nt\\ne\\n Relative MV MV\\n0\\nMV\\nT\\nLRL\\nVentilato\\nry Thresh\\nold\\nV\\nentilator\\ny Thresho\\nld Respon\\nse\\nTheResponse FactorislinearfromtherestingstateuptotheVentilatory Threshold (MV0=restingMV;MVT=MVattheVentilatory Threshold).\\nFigure4–26.Ventilator yThreshold Response\\nFitnessLevel\\nTheselected FitnessLevelwillautomatically determine anappropriateVentilatory ThresholdResponse factorandrate\\natwhichtheMVbaseline willbefixed.\\nTable4–8.RecommendedFitnessLevelsettings\\nRecommended FitnessLevelsetting Patientactivitylevel\\nSedentary Littletonophysical activity\\nActive Regular walking andlowimpactactivities\\nAthletic Moderateintensity ,non-competitive jogging/biking\\nEnduranc eSports Strenuous, competitive activities suchasmarathons\\nThebaseline (long-term average) isfixedforupto4.5hours.Thisallowsactivepatients whoexerciseforalong\\nduration(e.g.,long-distance runners) tomaintain anadequate sensor-drivenratethroughout theexerciseperiod.The\\nbaseline willbefixedwhenthesensorindicated rateisabove110ppmfortheFitnessLevelsettingofEnduranc e\\nSportsor90ppmfortheotherthreeFitnessLevelsettings (Table4–8Recommended FitnessLevelsettings onpage\\n4-37).After4.5hours,orwhenthesensorratefallsbelow90ppmor110ppmasdefined above,baseline adaptation\\nwillbere-enabled.\\nPhysicalActivityEvaluation\\nFollowing medical judgment, healthcareprofessionals mayaskpatients toengage inlighttomoderate physical\\nactivity,suchasahallwalkorwalking upanddownsteps,toassessthepulsegenerator’srateresponse. This\\nevaluation isusedtoinformtheprogramming ofrateadaptive pacingforthepatient\\'s detected activitylevel.For\\npatients whoengage inenduranc esports,strenuousphysical activitymayresultinamoreaccurateassessment of\\nrateresponse.\\nPriortostarting thephysical activityevaluation:\\n•Ensurethatpatients arehealthyenough toparticipate.\\n•Reviewandconsiderprinting thepatient’s previous25-hour SensorTrendingdata.Formoreinformation, referto\\nSensorTrending(\"Sensor Trending\"onpage4-42).', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 118}), Document(page_content='4-38PacingTherapies\\nRateAdaptive PacingandSensorTrending\\n•TheBeattoBeatRecordingMethod (asdescribed in\"Sensor Trending\" onpage4-42)isrecommended during\\nphysical activityevaluations tomanually optimizesensorrates.\\nNOTE:SensorTrending resultsmaybeprintedviatheReports tab.\\nAfterthephysical activityevaluation, interrogatethepatient’s deviceasdescribed in“Working withTrendingData”\\nandreviewtherateresponsedata.Thisrateresponse datacanbecompared totheprevious25-hour dataprinted\\npriortothetest.Itisrecommen dedtoresettheRecordingMethod tothemodeusedpriortothephysical activity\\nevaluation (e.g.,30-Second Average).\\nOptimizing RateResponse forPhysicalActivity\\nSensorTrendingprovidesagraphicaldisplayofthepulsegenerator\\'srateresponse tothepatient\\'s detected activity\\nlevelduringexercise(\"Sensor Trending\"onpage4-42).TheSensorTrendinggraphasshown(Figure4–27Rate\\nResponse beforeMVSensorprogrammed toOnonpage4-38)displays rateresponsedataforapatientbefore\\nprogramming theMVSensortoOn.TheActualRate(blackline)representsthepatient’s heartratedatainDDDmode\\nwhenMVSensorisprogrammed toPassive; thepatient’s heartratewasapproximately 85bpmafterengaging in\\nphysical activity.\\nFigure4–27.RateResponse beforeMVSensorprogrammed toOn\\nThesecondSensorTrendinggraph(Figure4–28RateResponse afterMVSensorprogrammed toOnonpage4-39)\\ndisplays theheartrateresponse forthesamepatientaftertheMVSensorwasprogrammed toOn.TheSensorreplay\\n(orangeline)depictsthesensor-drivenheartrateresponsethatwasapproximately 105bpmafterthepatient\\nengaged inphysical activity.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 119}), Document(page_content='PacingTherapies\\nRateAdaptive PacingandSensorTrending4-39\\nFigure4–28.RateResponse afterMVSensorprogrammed toOn\\nForpatients whoarechronotropically incompetent, considerprogramming thedevicetorateresponsivemode(e.g.,\\nDDDR)withtheMVSensortoOn.Forexample, chronotropically incompetent patients, suchasthosewhoseheartrate\\nis<100bpmduringphysical activityandtheprevious 24-hours, maybenefitfromdeviceoptimization forrate\\nadaptive pacing.\\nAftersettingtheMVSensortoOn,therateresponsecanbeoptimized toachieve anappropriateheartrateduring\\nfutureexercise.Consider programming therateresponsefactortotargetamaximum SensorReplayrateas\\nappropriatebasedonthepatient’s clinicalcondition(e.g.,70%to80%ofthepatient’s agepredictedmaximal heart\\nrate(APMHR)). Thisprogramming canbedoneincrementally accordingtothepatient’s clinicalconditionduring\\nclinicalfollow-up. NotethatthesensorrateislimitedbyMSRandLRL.Therefore,whenreprogramming thedevice,\\nconsiderre-optimizing usingthesefeatures.\\nDual-Sensor Blending\\nWhenever boththeAccelerometerandtheMVsensorareprogrammed Onforrateadaptive pacing,thetwosensor-\\nindicated ratesareblended toproducearate-dependent, weighted averageresponse. Asaresult,theblended\\nresponse willalwaysbeequaltooneoftheratesorbetween thetworates.Whenever theAccelerometerresponseis\\nlessthantheMVresponse, thesensorblending willbe100%MV-based. IftheAccelerometerresponseisgreaterthan\\ntheMVresponse, theblending willrangefromapproximately 80%Accelerometer and20%MVwhenthe\\nAccelerometer rateisatLRL,toapproximately 40%Accelerometer and60%MVwhentheAccelerometerrateisat\\nMSR.\\nThefollowing examplesillustrate theblending algorithm operation.\\nExample1\\nTheAccelerometer detectsmotionwithasimultaneous MVincrease(Figure4–29Blended response withan\\nAccelerometer Reaction Timeof30secondsonpage4-40).Uponexercise,theblended responsewillpromptly (within\\n4seconds)increasetheratebasedontheAccelerometerresponse. Astheratecontinues toincrease,theblended\\nresponse willbemoving towardtheMVresponse, butwillalwaysremainbetween theAccelerometer andMV\\nresponses. Athigherrates,thechanges inAccelerometer inputwillhavealessereffectontheblended response (only\\n40%atMSR),whereas changes inMVwillhaveamoresignificant effect.Atcessation ofexercise,theAccelerometer\\nratewilldecreaseasprescribedbytheRecoveryTimeparameterand,inthisexample,willdropbelowtheMV\\nresponse. Asaresult,thealgorithm willswitchovertoa100%MVblendduringtherecovery phaseforaslongasthe\\nAccelerometer response remainsbelowtheMVresponse. Whenusingdual-sensor blending, retainthenominal\\nAccelerometer valueof2minutes. Thisallowsthephysiologic MVsignaltocontrolrateadaptive pacingintheexercise\\nrecovery phase.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 120}), Document(page_content='4-40PacingTherapies\\nRateAdaptive PacingandSensorTrending\\nAccelerom\\neter\\nB\\nlend\\nMinute Ve\\nntilation\\n100\\n50\\n0\\n Time (sec onds)\\nS\\ne\\nn\\ns\\no\\nr\\n \\nr\\na\\nt\\ne\\n \\ni\\nn\\nc\\nr\\ne\\na\\ns\\ne\\n \\n(\\nm\\ni\\nn\\n-\\n1\\n \\n(\\np\\np\\nm\\n)\\n)\\n0 250 200 15\\n0 100 50\\nFigure4–29.Blendedresponse withanAccelerometerReactionTimeof30seconds\\nTheaggressiveness ofresponseattheonsetofexercisecanbecontrolledbyprogramming ashorterAccelerometer\\nReaction Time(Figure4–30Blended responsewithanAccelerometerReaction Timeof20seconds onpage4-40).\\nAccelerom\\neter\\nB\\nlend\\nMinute Ve\\nntilation\\n100\\n50\\n0\\n Time (sec onds)\\nS\\ne\\nn\\ns\\no\\nr\\n \\nr\\na\\nt\\ne\\n \\ni\\nn\\nc\\nr\\ne\\na\\ns\\ne\\n \\n(\\nm\\ni\\nn\\n-\\n1\\n \\n(\\np\\np\\nm\\n)\\n)\\n0 250 200 15\\n0 100 50\\nFigure4–30.Blendedresponse withanAccelerometerReactionTimeof20seconds\\nExample2\\nTheAccelerometerdetectsmotionwithlittleMVincrease(Figure4–31Blended response: Accelerometerdetects\\nmotionwithlittleornoincrease inMVonpage4-40).Theresponse oftheblended sensorwillbelimitedto\\napproximately60%oftheAccelerometerresponse.OncetheAccelerometerresponse dropsbelowtheMVresponse\\nduringrecovery,theblended response willbe100%MV-driven.\\nAccelerom\\neter\\nB\\nlend\\nMinute Ve\\nntilation\\n100\\n50\\n0\\n Time (sec onds)\\nS\\ne\\nn\\ns\\no\\nr\\n \\nr\\na\\nt\\ne\\n \\ni\\nn\\nc\\nr\\ne\\na\\ns\\ne\\n \\n(\\nm\\ni\\nn\\n-\\n1\\n \\n(\\np\\np\\nm\\n)\\n)\\n0 250 200 15\\n0 100 50\\nFigure4–31.Blendedresponse: AccelerometerdetectsmotionwithlittleornoincreaseinMV\\nExample3\\nMVincreaseswithlittleAccelerometer rateincrease(Figure4–32Blended response: MVincreasewithlittleorno\\nmotiondetected bytheAccelerometeronpage4-41).Theblended responsewillinitiallyincreasewiththe\\nAccelerometerresponse,butastheMVresponseincreasesovertheAccelerometerresponse,theblended response\\nwillbe100%MV-driven. Thisprovidesadequate responseduringincreases inmetabolic demand underconditions of\\nlittleornoupperbodymovement.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 121}), Document(page_content='PacingTherapies\\nRateAdaptive PacingandSensorTrending4-41\\nAccelerom\\neter\\nBlend\\nMinute Ve\\nntilation\\n100\\n50\\n0\\n Ti me (secon ds)\\nS\\ne\\nn\\ns\\no\\nr\\n \\nr\\na\\nt\\ne\\n \\ni\\nn\\nc\\nr\\ne\\na\\ns\\ne\\n \\n(\\nm\\ni\\nn\\n-\\n1\\n \\n(\\np\\np\\nm\\n)\\n)\\n0 250 200 15\\n0 100 50\\nFigure4–32.Blendedresponse: MVincreasewithlittleornomotiondetected bytheAccelerometer\\nFollow-up DeviceAssessments\\nAfterprogramming theMVSensororAccelerometer, parameters associated withrateresponsecanbeadjusted at\\nsubsequent devicechecks.Consider checking histogramsandadjusting paramete rsifpatients complain ofshortness\\nofbreathortiredness whileexercising,orreportahighheartrateforprolongedperiodsoftime.Also,consider\\nresetting theHistograms whenever parameters associated withrate-response areadjusted (referto\"Histograms\" on\\npage6-9).\\nLowandHighResponse Factor\\nHistogramsmayprovideanindication thatparameters associated withrateresponse (e.g.Response Factor,MSR,etc.)\\ncanbeadjusted toachieve thedesiredheartrate.Anincreasedamount ofpacingatMSRmayindicate thatthe\\nResponse Factorissettoohigh(Figure4–33HighResponse Factoronpage4-41)ortheMSRissettoolowasshown\\n(Figure4–34LowResponse Factoronpage4-42).InthehistogramasshowninFigure4–33HighResponse Factoron\\npage4-41,considerwhether itisappropriat etolowertheResponse FactororraisetheMSR.\\nFigure4–33.HighResponse Factor\\nInthehistograms asshowninFigure4–34LowResponse Factoronpage4-42,theResponse Factormaybetoolow\\nasindicated byalargepercentageofbeatsinasinglebin,e.g.,>70%.Inthiscase,considerprogressively increasing\\ntheprogrammed Response Factor.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 122}), Document(page_content=\"4-42PacingTherapies\\nRateAdaptive PacingandSensorTrending\\nFigure4–34.LowResponse Factor\\nSensorTrending\\nSensorTrendingprovidesagraphicaldisplayofthepulsegenerator'srateresponse tothepatient's detected activity\\nleveland/orphysiologic needandprovides usefulinformation duringexercisetesting. Thisdataallowstheclinician to\\nadaptthesensor-drivenpacingratetocorrespondtothepatient's actualneed.\\nTheSensorTrendinggraphandSensorTrendingSetupparamet ersareviewable viatheRateAdaptive Pacingscreen\\n(Figure4–35SensorTrending graphonpage4-42).\\nFigure4–35.SensorTrending graph\\nSetupofSensorTrendingincludes thefollowing options:\\n•RecordingMethod—pro grammable:\\n–30-Second Average—r ecordsandplotstheaveragerateevery30seconds.\\n–BeattoBeat—rec ordsandplotstherateofeverybeat.\\nNOTE:BeattoBeatisrecommen dedwhenusinghallwalksorshorterperiodsofactivitytomanually\\noptimize sensorrates.\\n–Off—notrendingdataisgathered.\\n•Duration––no n-programmable andbasedontheselected RecordingMethod:\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 123}), Document(page_content=\"PacingTherapies\\nRateAdaptive PacingandSensorTrending4-43\\n–WhenRecordingMethod issettoOffor30-SecondAverage––Du rationisapproximately 25hours.\\n–WhenRecordingMethod issettoBeattoBeat––Dur ationisapproximately 40minutes at75bpm.\\n•DataStorage—progr ammable:\\n–Continuous—con tainsthemostrecentdataavailable. Storagestartswhensetupisconfirmed and\\ncontinuously recordsthelatestinformation, overwritingtheoldestdatauntiltheinformation isretrieved.\\nThisoptionallowsyoutoviewdatafortherecordingduration immediately priortodataretrieval.\\n–Fixed—storage startswhensetupisconfirmedandcontinuesuntildevicememory storageisfull.Thisallows\\nyoutoviewdatafrominitialsetupforafixedamount oftime.\\nThepulsegeneratorcollectsandstoresrateandsensordatawhichisthendisplayed onthePRMinagraphicalformat\\nasthepatient's ActualRateandSensorReplayduringtherecordingtime.\\nTheActualRate(blackline)indicates thepatient's heartrateduringactivity(whether pacedorsensed). TheSensor\\nReplay(orangeline)depictsthesensor-drivenheartrateresponse withthecurrentsensorparametersettings.\\nAstheslideralongthehorizontalaxisofthegraphismoved,actualandsensor-indicated heartratesaredisplayed for\\nparticular datapoints.Additionally ,theatrialeventsrepresented byaparticular datapoint(singlebeator30-second\\naverage)areclassified anddisplayed nexttotheActualRate.Eventsareclassified anddisplayed asoneormoreof\\nthefollowing: Paced,Sensed, SensedinATR,VT.Thiseventtypewillreflectventricular eventsinVVI(R)modes.\\nCurrentsensorparameters canbeadjusted toviewtheresultingchangetosensorratebehavior without havingto\\nrepeatanexercisetest.\\nThepulsegeneratorcancollectandstoredatainrateadaptive andnon-rate adaptive modes:\\n•Innon-rate adaptive modes,thetrending iscollectedviathePassivesensorsetting. Passiveallowsforsensor\\ndatacollection thatcanbeusedtooptimize thesensors intheabsenceofthesensor-drivenrateresponse.\\nHowever ,whenthesensorsettingisPassive, SensorReplaydatawillnotbedisplayed onthegraphuntilarate\\nresponsive modeisselected.\\nThepulsegeneratorwillrecordSensorTrendingdatawhilewanded orRFtelemetr yisactive.\\nWhentheheartrateiscompletely sensor-driven, smalldifferencesbetween theActualRateandSensorReplaymay\\nstillbeobservedbecause theyarecalculated independently byslightlydifferentmethods.\\nWorkingwithSensorTrending Data\\nTousetheSensorTrendingfunction, followthesesteps:\\n1.Following anexercisesession, navigate totheSensorTrendinggraphandpressInterrogatetoupdatetrending\\ninformation. Trending dataisretrieved oninitialinterrogation. Ifasessionremainsactivewhilethepatient\\nengages inlighttomoderatephysical activity,pressInterrogateagaintoupdatethetrending information.\\n2.SelecttheViewbuttontoexpandorcompresstheamount ofdataviewedatonetime.Thestartandenddates\\nandtimesatthebottomofthegraphwillchangetoreflectthetimeperiodrepresented onthegraph.The30\\nSecondAverage RecordingMethod hasoptions for1to25hours,andtheBeattoBeatRecordingMethod has\\noptions for5to40minutes.\\n3.Toadjustwhichdataisdisplayed onthegraphortoviewparticular datapoints,movetheslider(s) alongthe\\nhorizontalaxesatthebottomofthedisplaywindows.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 124}), Document(page_content=\"4-44 PacingTherapies\\nAtrialTachyResponse\\n4.Adjustthesensorparamet erstotherightofthegraphtoseehowadjustments intherateadaptive pacing\\nparameters willaffectthesensorresponse(orangeline).Astheseparameters and/ortheMSRandLRLare\\nchanged onthescreen,theapplication willmodifythegraphtoillustratetheresulting effects.Ifthepatient's\\nheartrateisappropriat efortheactivityperformed, nosensoroptimization isnecessary.\\n5.Whenapatient's heartrateiswithinthedesiredrangefortheactivityperformed, selectProgram.\\nNOTE:SensorTrending resultsmaybeprintedviatheReports tab.BoththePresent (currentlyprogrammed) and\\nReplay(clinician adjusted) parameters areprovidedinaddition tothecurrentgraphasrepresented onthe\\nprogrammerscreen.\\nNOTE:Sensoradjustments shouldnotbebasedondatawhichiscollected duringtheMVcalibrationtimeperiod.\\nATRIALTACHYRESPONSE\\nATRModeSwitch\\nATRisdesigned tolimittheamount oftimethattheventricular pacedrateisattheMTRorexhibits upper-rate\\nbehavior (2:1blockorWenckebac h)inresponse toapathological atrialarrhythmia.\\nInthepresenceofdetected atrialactivitythatexceedstheATRTriggerRate,thepulsegeneratorswitches thepacing\\nmodefromatrackingmodetoanontrackingmodeasfollows:\\n•FromDDD(R)toDDI(R)orVDI(R)\\n•FromVDD(R)toVDI(R)\\nAnexample ofATRbehavior isshown(Figure4–36ATRbehavior onpage4-44).\\nATR Count\\ner\\nDurati\\non Counte\\nr\\n0 8\\nDetect Dur\\nation Fall\\nback Reset\\n0 8\\nExit Coun\\nt = 8\\n8 atr\\nial cycle\\ns < \\nATR\\n Trigger \\nRate\\nN\\nE\\nntry Coun\\nt = 8\\n8 atrial \\ncycles > \\nATR Trig\\nger Rate\\nRate\\nAtrial \\ntachycard\\nia \\nstarts\\nRate Smoo\\nthing \\n applied h ere Atrial \\ntachycard\\nia \\nconfirmed\\nATR Durat\\nion \\nfulfilled\\nAtrial \\ntachycard\\nia \\nterminate\\ns\\nMODE SWIT\\nCHING\\nDDDR VDIR\\nDDDR\\nAtrial \\ntachycard\\nia \\nterminati\\non \\nconfirmed\\nRate \\nSmoothing\\n \\napplied \\nhereATR Trigg\\ner Rate =\\n \\n170 min\\n-1\\n (ppm)\\nMTR = \\n120 \\nmin\\n-1\\n (pp\\nm)\\nAtrial Ra\\nte\\nRight Ven\\ntricular \\nRate\\nSensor Ra\\nte\\nATR/VTR F\\nallback \\nLRL = 70 \\nmin\\n-1 \\n (ppm)\\nLRL\\n = 60 min\\n-1\\n (p\\npm)\\nFigure4–36.ATRbehavior\\nNOTE:Parameter settings thatreducetheatrialsensing window mayinhibitATRtherapy.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 125}), Document(page_content='PacingTherapies\\nAtrialTachyResponse4-45\\nATRTriggerRate\\nTheATRTriggerRatedetermines therateatwhichthepulsegeneratorbeginstodetectatrialtachycard ias.\\nThepulsegeneratormonitors atrialeventsthroughout thepacingcycle,exceptduringtheatrialblanking periodand\\nthenoiserejection intervals. AtrialeventsfasterthantheTriggerRateincrease theATRdetection counter;atrial\\neventsslowerthantheTriggerRatedecreasethecounter.\\nWhentheATRdetection counterreachestheprogrammed entrycount,theATRDuration begins.WhentheATR\\ndetection counter countsdownfromtheprogrammed ExitCountvaluetozeroatanypointintime,ATRDuration\\nand/orfallback areterminated, andtheATRalgorithm isreset.Aneventmarkerisgenerated whenever theATR\\ndetection counter isincremented ordecremented.\\nNOTE:Duringpost-therapypacing,ATRfunctions thesameasinnormalpacing.\\nATRDuration\\nATRDuration isaprogrammable valuethatdetermines thenumber ofventricular cyclesduringwhichtheatrialevents\\ncontinue tobeevaluated afterinitialdetection (entrycount)ismet.Thisfeatureisintended toavoidmodeswitching\\nduetoshort,nonsustained episodes ofatrialtachycard ia.IftheATRcounterreacheszeroduringATRDuration,the\\nATRalgorithm willbereset,andnomodeswitchwilloccur.\\nIftheatrialtachycardia persists fortheprogrammed ATRDuration, thenmodeswitching occursandtheFallback\\nModeandFallback Timebegin.\\nEntryCount\\nTheEntryCountdetermines howquicklyanatrialarrhythmia isinitiallydetected.\\nThelowertheprogrammable value,thefewerthefastatrialeventsrequiredtofulfillinitialdetection. Oncethe\\nnumber offastatrialeventsdetected equalstheprogrammable EntryCount,ATRDuration begins,andtheExitCount\\nisenabled.\\nCAUTION: Exercisecarewhenprogramming theEntryCounttolowvaluesinconjunction withashortATRDuration.\\nThiscombination allowsmodeswitching withveryfewfastatrialbeats.Forexample, iftheEntryCountwas\\nprogrammed to2andtheATRDuration to0,ATRmodeswitching couldoccuron2fastatrialintervals.Inthese\\ninstances,ashortseriesofpremature atrialeventscouldcausethedevicetomodeswitch.\\nExitCount\\nTheExitCountdetermines howquicklytheATRalgorithm isterminated oncetheatrialarrhythmia isnolonger\\ndetected.\\nThelowertheprogrammed value,themorequicklythepulsegenerator willreturntoanatrialtracking modeoncean\\natrialarrhythmia terminates. Oncethenumber ofslowatrialeventsdetected equalstheprogrammable ExitCount,\\nATRDuration and/orFallback willbeterminated, andtheATRalgorithm willbereset.TheATRExitCountis\\ndecremented byatrialeventsslowerthantheATRTriggerRateorbyanyventricular eventthatoccursmorethantwo\\nsecondsafterthelastatrialevent.\\nCAUTION: Exercisecarewhenprogramming theExitCounttolowvalues.Forexample, iftheExitCountwas\\nprogrammed to2,afewcyclesofatrialundersensing couldcausetermination ofmodeswitching.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 126}), Document(page_content='4-46PacingTherapies\\nAtrialTachyResponse\\nFallbackMode\\nFallback Modeisthenontracking pacingmodethatthepulsegeneratorautomatically switches towhenATRDuration\\nisfulfilled.\\nAfterswitching modes,thepulsegeneratorgraduallydecreasestheventricular pacedrate.Thisdecrease iscontrolled\\nbytheFallback Timeparameter .\\nNOTE:Dual-chamber pacingfallback modevaluesareonlyavailable whentheNormalpacingmodeisalsosetto\\ndual-chamber .\\nNOTE:ATRFallback modemaybeprogrammed rateresponsive evenifthepermanent bradymodeisnon-rate\\nresponsive. Inthisscenario,thesensorparameters willindicate “ATROnly”.\\nFallbackTime\\nFallback TimecontrolshowquicklythepacedratewilldecreasefromtheMTRtotheATR/VTR Fallback LRLduring\\nfallback. Thepacedratewilldecreasetothehighestofthesensor-indicated rate,VRRrate,ortheATR/VTR Fallback\\nLRL.\\nDuringfallback, thefollowing features aredisabled:\\n•RateSmoothing—disabled untilfallback reaches theATR/VTR Fallback LRLorthesensor-indicated rate.IfVRRis\\nenabled, thenRateSmoothing isdisabled throughout themodeswitch\\n•RateHysteresis\\n•AVSearch+\\n•PVARPExtension\\nFallbackLRL\\nTheATR/VTR Fallback LRListheprogrammed lowerratetowhichtheratedecreases duringmodeswitching. The\\nATR/VTR Fallback LRLmaybeprogrammed higherorlowerthanthepermanent bradyLRL.\\nTheratewilldecrease tothehighestamongthesensor-indicated rate(whenapplicable), theVRRrate(ifenabled),\\nandtheATR/VTR Fallback LRL.\\nTheATR/VTR Fallback LRLisalsotheBackupVVIpacingrateduringbackuppacinginthepresenceofdetected\\nventricular arrhythmias.\\nEndofATREpisode\\nTheEndofATREpisode identifies thepointwhenthepulsegeneratorrevertstoAV-synchr onousoperation because\\ntheatrialarrhythmia isnolongerdetected.\\nWiththetermination ofthearrhythmia, theATRExitCountdecrementsfromitsprogrammed valueuntilitreaches0.\\nWhentheATRExitCountreaches0,thepacingmodeautomatically switches totheprogrammed tracking mode,and\\nAV-synchr onousoperation isrestored.\\nVentricular TachyResponse (VTR)\\nVTRservesasanautomatic modeswitchforbackupVVIpacinginthepresenceofdetected ventricular\\ntachyarrhythmias.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 127}), Document(page_content='PacingTherapies\\nAtrialTachyResponse4-47\\nWhendetection issatisfied inaventricular tachycardia zone,thepacingmodeswitches toVVI(RV)ortoOffifthe\\ncurrentmodeisAAI(R)orOff.\\nWhenthemodeswitches, backuppacingoccursattheprogrammed ATR/VTR Fallback LRLandusestheprogrammed\\nATPventricular PulseWidthandAmplitude values.\\nVentricular RateRegulation (VRR)\\nVRRisdesigned toreducetheV–Vcyclelengthvariability duringpartially conducted atrialarrhythmias bymodestly\\nincreasingtheventricular pacingrate.\\nTheVRRalgorithm calculates aVRR-indicated pacingintervalbasedonaweighted sumofthecurrentV–Vcycle\\nlengthandthepreviousVRR-indicated pacingintervals.\\n•Pacedintervals havemoreinfluence thansensedintervalssuchthatpacedeventscauseadecreaseintheVRR-\\nindicated rate.\\n•Forsensedintervals,theVRR-indicated ratemaybeincreased;however ,theinfluence istempered bythe\\nprevioushistory.\\n•TheVRR-indicated rateisfurtherboundbytheLRLandtheVRRMPR.\\nWhenVRRisprogrammed onintrackingmodes,itisonlyactivewhenanATRmodeswitchhasoccurred.Oncethe\\ntrackingmodeoperationresumes atthetermination oftheatrialarrhythmia, VRRbecomesinactive. Intracking\\nmodeswherebothRateSmoothing andVRRareprogrammed on,RateSmoothing isdisabled whenVRRisactive\\nduringATRandre-enabled oncetheATRterminates.\\nWhenprogrammed oninnontrackingmodes,VRRiscontinually activeandupdates theVRR-indicated pacingrate\\nandthesmoothed averageoneachcardiaccycle.\\nVentricular RateRegulation Maximum PacingRate(VRRMPR)\\nTheVRRMPRlimitsthemaximum pacingrateforVRR.\\nVRRoperatesbetween theLRLandtheMPR.\\nAtrialFlutterResponse (AFR)\\nAtrialFlutterResponse isdesigned to:\\n•Preventpacingintothevulnerable periodfollowing anatrialsense.Pacingintothevulnerable periodcouldoccur\\nifanatrialpaceisscheduled soonafterarefractoryatrialsense.\\n•Provideimmediate nontracking ofatrialrateshigherthantheAFRTriggerRate.\\nThenontrackingbehavior ismaintained foraslongasatrialeventscontinually exceedtheAFRTriggerRate.\\nExample: WhenAFRisprogrammed to170ppm,adetected atrialeventinsidethePVARPorapreviouslytriggered\\nAFRintervalstartsanAFRwindow of353ms(170ppm).Atrialdetection insidetheAFRisclassified asasensewithin\\ntherefractory periodandisnottracked.AtrialtrackingmayonlyoccurafterbothPVARPandtheAFRwindow expire.\\nPacedatrialeventsscheduled insideanAFRwindow aredelayed untiltheAFRwindow expires.Iftherearefewerthan\\n50msremainin gbeforethesubsequent ventricular pace,theatrialpaceisinhibited forthecycle.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 128}), Document(page_content=\"4-48PacingTherapies\\nAtrialTachyResponse\\nVentricular pacingisnotaffected byAFRandwilltakeplaceasscheduled. Thewideprogrammable rangeforAFR\\nTriggerratesallowsforappropriatesensing ofslowatrialflutters. High-rate atrialsensing maycontinuously retrigger\\ntheAFRwindow,effectively resulting inbehavior similartotheVDI(R)fallback mode.\\nNOTE:Foratrialarrhythmias thatmeettheprogrammed AFRratecriteria,usingtheAFRfeaturewillresultinslower\\nventricular pacingrates.\\nNOTE:WhenbothAFRandATRareactiveinthepresenceofatrialarrhythmias, nontrackingventricular paced\\nbehavior mayoccursooner,buttheATRModeSwitchmaytakelonger.Thisisbecause theATRDurationfeature\\ncountsventricular cyclesformeeting durationandtheAFRfeatureslowstheventricular pacedresponse tofastatrial\\narrhythmias.\\nPMTTermination\\nPMTTermination detectsandattempts tointerrupt pacemak er-mediated tachycardia (PMT)conditions.\\nAVsynchrony maybelostformanyreasons, including atrialfibrillation, PVCs,PACs,atrialoversensing, orlossofatrial\\ncapture. Ifthepatienthasanintactretrogradeconduction pathway whenAVsynchron yislost,theunsynchr onized\\nbeatmayconduct retrogradetotheatrium,resulting inpremature atrialdepolarization. InDDD(R)andVDD(R)pacing\\nmodes,thedevicemaydetectandtrackretrogradeconductedP-waves thatfalloutsideofPVARP.Therepeated cycle\\nofsensing andtrackingretrogradeconductionisknownasPMT,whichcanresultintriggeredventricular pacingrates\\nashighastheMTR.Programming certainrefractory periods(e.g.,PVARPafterPVC)canreducethelikelihood of\\ntrackingretrogradeevents.RateSmoothing canalsobeusefulincontrolling thepulsegenerator's response to\\nretrogradeconduction.\\nWhenthepulsegenerator'sresponse toretrogradeconduction hasnotbeencontrolledbydeviceprogramming, PMT\\nTermination (whenprogrammed toOn)isusedtodetectandterminate PMTwithin16cyclesofonsetwhenthe\\nfollowing conditions havebeenmet:\\n•16successiveventricular pacesarecountedattheMTRfollowing atrialsensedevents\\n•All16V–Aintervalsarewithin32ms(preceding orfollowing) ofthesecondV–AintervalmeasuredatMTRduring\\nthe16ventricular pacedevents(todistinguish Wenckebac hbehavior fromPMT)\\nWhenbothconditions aremet,thepulsegeneratorsetsthePVARPtoafixedsettingof500msforonecardiaccycle\\ninanattempt tobreakthePMT.Ifbothcondition sarenotmet,thepulsegeneratorcontinuestomonitor successive\\nventricular pacesforthepresenceofaPMT.\\nWhenPMTTermination isprogrammed toOn,thepulsegeneratorstoresPMTepisodes intheArrhythmia Logbook.\\nNOTE:Although theV–Aintervalevaluation helpsdiscriminate truePMT(stableV–Aintervals) fromupperrate\\nbehavior duetosinustachycard iaornormalexerciseresponse (typically unstable V–Aintervals),itispossible thata\\npatient’s intrinsic atrialratecanmeetPMTdetection criteria.Insuchcases,ifPMTTermination isprogrammed On,the\\nalgorithm willdeclaretherhythmaPMTandextendPVARPonthe16thcycle.\\nNOTE:Because retrogradeconduction timesmayvaryoverapatient's lifetime duetotheirchanging medical\\ncondition,occasional programming changes maybenecessary.\\nIfretrogradeconduction isevidentinastoredEGM,youcanevaluate theelectrogramand/orperform athresholdtest\\ntoconfirm appropriate atrialpacingandsensing. IfstoredEGMsarenotavailable forreview,followthesestepstouse\\nthePRMtoassistinV–Aintervalevaluation:\\n1.FromtheTestsscreen,selecttheTempBradytab.\\n2.Programanappropriateatrialsensing modethatprovides atrialmarkers(VDD,DDD,orDDI).\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 129}), Document(page_content='PacingTherapies\\nRateEnhancemen ts4-49\\n3.Programthemaximum PVARPtoavalueshorterthantheaverageretrogradeconduction time.\\nNOTE:Scientific literaturesuggests thattheaverageretrogradeconduction timeis235±50ms(witharange\\nof110–450 ms).1\\n4.ProgramtheLRLtoensurepacingabovetheintrinsic atrialrate(e.g.,90,100,110…).\\n5.Beginprinting thereal-time ECG.\\n6.SelecttheStartbuttontoactivate thetemporaryparamete rs.\\n7.Whentestingiscomplete forthespecified LRLvalue,selecttheStopbutton.\\n8.Stopprinting thereal-time ECG.\\n9.Evaluate theECGstripforV–Aconduction (VPfollowed byanAS).Lookforstableandconsistentintervals\\nsuggestive ofretrogradeconduction.\\n•Ifretrogradeconduction wasidentified, comparetheretrogradeV–Aintervaltimetotheprogrammed\\nrefractory period.Consider programming PVARPtotheappropriatevaluesothattheretrogradeeventisnot\\ntracked.\\n•Ifretrogradeconduction wasnotidentified, thePMTepisode maybearesultofnormalupperratebehavior .\\nReviewHistograms toseehowoftentherateisattheMTR,andconsiderraisingtheMTR(ifclinically\\nappropriate).\\n10.Ifnecessary,repeatthisprocedurewithdifferentLRLvalues,asretrogradeconduction mayoccuratdifferent\\nrates.\\nRATEENHANCEMENTS\\nRateHysteresis\\nRateHysteresis canimprovedevicelongevity byreducing thenumber ofpacingstimuli.Indual-chamber models, this\\nfeatureisavailable inDDD,DDI,VVI,andAAImodes.Insingle-chamber models, thisfeatureisavailable inVVImode.\\nInDDD,DDI,andAAImodes,RateHysteresisisactivated byasinglenonrefractoryatrialsensedevent.\\nNOTE:RateHysteresisisactivated anddeactivated byventricular eventsinVVImode(e.g.,intrinsic activity,paced\\nactivity).\\nInDDD,DDI,andAAImodes,Hysteresis isdeactivated byasingleatrialpaceattheHysteresisRate.InDDDmode,\\nHysteresisisdeactivated byanatrialrateabovetheMTR.\\nWhenRateSmoothing Downisenabled, RateHysteresisremains ineffectuntilpacingoccursattheHysteresisRate.\\nThisallowsRateSmoothing tocontrolthetransition totheHysteres isRate.\\nHysteresis Offset\\nHysteresisOffsetisusedtolowertheescaperatebelowtheLRLwhenthepulsegeneratorsensesintrinsic atrial\\nactivity.\\nIfintrinsic activitybelowtheLRLoccurs,thenHysteresisOffsetallowsinhibition ofpacinguntiltheLRLminus\\nHysteresisOffsetisreached. Asaresult,thepatientmightbenefitfromlongerperiodsofsinusrhythm.\\n1.Furman S,HayesD.L.,Holmes D.R.,APracticeofCardiacPacing.3rded.MountKisco,NewYork:FuturaPublishing Co.;1993:74-75.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 130}), Document(page_content=\"4-50PacingTherapies\\nRateHysteresis\\nSearchHysteresis\\nWhenSearchHysteresisisenabled, thepulsegeneratorperiodically lowerstheescaperatebytheprogrammed\\nHysteresisOffsetinordertorevealpotential intrinsic atrialactivitybelowtheLRL.Theprogrammed number ofsearch\\ncyclesmustbeconsecutively atrialpacedforasearchtooccur.\\nExample: Atarateof70ppmandasearchintervalof256cycles,asearchforintrinsic atrialactivitywouldoccur\\napproximatelyevery3.7minutes (256÷70=3.7).\\nDuringSearchHysteresis,thepacingrateislowered bytheHysteresis Offsetforupto8cardiaccycles.Ifintrinsic\\nactivityissensedduringthesearchperiod,Hysteresiswillremainactiveuntilanatrialpaceoccursatthehysteresis\\noffsetrate.\\nRateSmoothing isdisabled duringthesearchcycles.Ifnointrinsic atrialactivityisdetected duringthe8-cyclesearch,\\nthepacingrateisbrought uptotheLRL.RateSmoothing Up,ifenabled, controlsthepacingrateincrease.\\nRateSmoothing\\nRateSmoothing controlsthepulsegenerator'sresponsetoatrialand/orventricular ratefluctuations thatcause\\nsuddenchanges inpacingintervals. RateSmoothing isanimportant enhance menttoATRbecause itcansignificantly\\nreducetheratefluctuations associated withtheonsetandcessationofatrialarrhythmias.\\nWithout RateSmoothing, asudden, largeatrialrateincreasewillcauseasimultaneous suddenincreaseinthepaced\\nventricular rateashighastheprogrammed MTR.Patients whoexperienc elargevariations intheirventricular paced\\nratecanfeelsymptomatic duringtheseepisodes. RateSmoothing canpreventthesesuddenratechanges andthe\\naccompanying symptoms (suchaspalpitations, dyspnea, anddizziness).\\nInanormalconduction system, limitedcycle-to-cycle ratevariations occur.However ,thepacedratecanchange\\ndramatic allyfromonebeattothenextinthepresenceofanyofthefollowing:\\n•Sinoatrial diseasesuchassinuspauseorarrest,sinoatrial block,andbrady-tachy syndrome\\n•PACsand/orPVCs\\n•Pacemak erWenckebach\\n•Intermittent, brief,self-terminating SVTs,andatrialflutter/fibrillation\\n•RetrogradeP-waves\\n•Pulsegeneratorsensing ofmyopotential signals, EMI,crosstalk, etc.\\nInsingle-chamber modes,RateSmoothing operates between:\\n•TheLRLandtheMPRwhenprogrammed VVIorAAI\\n•TheLRLandtheMSRwhenprogrammed VVIRorAAIR\\nIndual-chamber modes,RateSmoothing operatesbetween:\\n•TheLRLandthegreateroftheMSRorMTRwhenprogrammed DDD(R)orVDD(R)\\n•TheLRLandMPRwhenprogrammed toDDI\\n•TheLRLandMSRwhenprogrammed toDDIR\\nRateSmoothing isalsoapplicable between theHysteresisRateandLRLwhenHysteresisisactive,exceptduring\\nSearchHysteresis.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 131}), Document(page_content=\"PacingTherapies\\nRateHysteresis4-51\\nWhenRateSmoothing isprogrammed toOn,itisfunctional except:\\n•Duringthe8cyclesofrateSearchHysteresis\\n•DuringATRFallback untilfallback reachestheATRLRL,thesensor-indicated rate,ortheVRRinterval\\n•DuringVRRwhenactive\\n•Upontriggering PMTTermination\\n•Immediately following programmed LRLincreases\\n•Whentheintrinsic rateisabovetheMTR\\nProgrammable Values\\nRateSmoothing valuesareapercentageoftheRVR–Rinterval(3%to25%in3%increments) andcanbe\\nindependently programmed for:\\n•Increase—Rate Smoothing Up\\n•Decrease—Rate Smoothing Down\\n•Off\\nThepulsegeneratorstoresthemostrecentR–Rintervalinmemory.R-waves maybeeitherintrinsic orpaced.Based\\nonthisR–Rintervalandtheprogrammed RateSmoothing value,thedevicelimitsthevariation inpacedrateona\\nbeattobeatbasis.\\nItisimportant toascertain thepatient's physiologic cycle-to-cycle variation andprogramtheRateSmoothing\\nparametertoavaluethatprotectsagainstpathologic intervalchanges, yetallowsphysiologic intervalchanges in\\nresponse toincreasesinactivityorexercise.\\nRateSmoothing Up\\nRateSmoothing Upcontrolsthelargestpacingrateincrease allowed whentheintrinsic orsensorrateisincreasing.\\nRateSmoothing Down\\nRateSmoothing Downcontrolsthelargestpacingratedecrease allowed whentheintrinsic orsensorrateis\\ndecreasing.\\nNOTE:WhenRateSmoothing Downisprogrammed OnandRateSmoothing Upisprogrammed Off,thepulse\\ngeneratorwillautomatically prevent fastintrinsic beats(e.g.,PVCs)fromresettingtheRateSmoothing Downescape\\nrateanyfasterthan12%percycle.\\nRateSmoothing Maximum PacingRate(MPR)\\nTheRateSmoothing Maximum PacingRateplacesalimitonthemaximum pacingratethatRateSmoothing can\\nreach.\\nTheRateSmoothing Downparamet errequiresaprogrammed MPRwheninAAI,VVI,orDDI.RateSmoothing will\\nthenbeusedonlybetween theMPRandtheLRLortheHysteresisRate(ifapplicable).\\nWhenbothVRRandRateSmoothing areprogrammed onintheVVI(R)orDDI(R)mode,VRRwillhavepriority.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 132}), Document(page_content='4-52PacingTherapies\\nRateSmoothing ExampleBasedonaDual-Chamber TrackingMode\\nRateSmoothing ExampleBasedonaDual-Chamber TrackingMode\\nBasedonthemostrecentR–Rintervalstoredinmemory andtheprogrammed RateSmoothing value,thepulse\\ngeneratorsetsupthetwosynchronization windows forthenextcycle:onefortheatriumandonefortheventricle.\\nThesynchronization windows aredefined below:\\nVentricular synchron izationwindow: previousR–Rinterval±RateSmoothing value\\nAtrialsynchronization window: (previousR–Rinterval±RateSmoothing value)-AVDelay\\nThefollowing example explainshowthesewindows arecalculated (Figure4–37Ratesmoothing synchron ization\\nwindow onpage4-52):\\n•PreviousR–Rinterval=800ms\\n•AVDelay=150ms\\n•RateSmoothing Up=9%\\n•RateSmoothing Down=6%\\nThewindows wouldbecalculated asfollows:\\nVentricular Synchronization Window =800-9%to800+6%=800ms-72msto800ms+48ms=728msto\\n848ms\\nAtrialSynchronization Window =Ventricular Synchronization Window -AVDelay=728ms-150msto848ms-\\n150ms=578msto698ms\\nThetimingforbothwindows isinitiated attheendofeveryventricular event(R–Rinterval).\\nIfpacedactivityistooccur,itmustoccurwithintheappropriatesynchronization window.\\nPaced A V Delay (150 ms)\\nAtrial \\nEvent\\nAtrial \\nEvent\\nR-R Interval (800 ms)\\nRV Event\\nAtrial Smoothing Window\\n578 ms 650 ms 698 ms\\nRV Smoothing Window728 ms 800 ms 848 ms RV Event\\nFigure4–37.Ratesmoothing synchronization window\\nLEADCONFIGURATION\\nThepulsegenerator hasindependently programmable leadconfigurationsforthefollowing:\\n•Atrium(indual-chamber models)\\n•RightVentricle\\nTheatrialandRVleadsaresettoBipolarpacingandsensing. Theatrialleadhastheoptionofbeingprogrammed\\nOff.\\nTheinputimpedance is>100KΩforeachsense/pac eelectrodepair.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 133}), Document(page_content=\"PacingTherapies\\nAVDelay4-53\\nAVDELAY\\nAVDelayistheprogrammable timeperiodfromtheoccurrenceofeitherapacedorsensedrightatrialeventtoa\\npacedRVevent.\\nAVDelayisdesigned tohelppreservetheheart'sAVsynchrony .Ifasensedrightventricular eventdoesnotoccur\\nduringtheAVDelayfollowing anatrialevent,thepulsegeneratordelivers aventricular pacingpulsewhentheAV\\nDelayexpires.\\nAVDelaycanbeprogrammed tooneorbothofthefollowing operations:\\n•PacedAVDelay\\n•SensedAVDelay\\nAVDelayisapplicable inDDD(R), DDI(R),DOOorVDD(R)modes.\\nNOTE:LongfixedAVintervalsmaybeselected toavoidunnecessary RVpacing.However ,programming longfixed\\nAVintervals,insomecases,maybeassociated withPMT,diastolic mitralinsufficiency ,orpacemak ersyndrome.Asan\\nalternative toprogramming longfixedAVintervals,considerAVSearch+toavoidunnecessaryRVpacing.\\nPacedAVDelay\\nPacedAVDelaycorresponds totheAVDelayfollowing anatrialpace.\\nWhentheminimum AVDelayvalueislessthanthemaximum AVDelayvalue,thenthePacedAVDelayisscaled\\ndynamically accordingtothecurrentpacingrate.Dynamic AVDelayprovides amorephysiologic responsetorate\\nchanges byautomatically shortening thePacedAVDelayorSensedAVDelaywitheachintervalduringanincreasein\\natrialrate.Thishelpsminimize theoccurrenceoflargeratechanges attheupperratelimitandallowsone-to-one\\ntrackingathigherrates.\\nThepulsegeneratorautomatically calculates alinearrelationship basedontheintervallengthoftheprevious A–Aor\\nV–Vcycle(depending ontheprevious eventtype)andtheprogrammed valuesforthefollowing:\\n•Minimum AVDelay\\n•Maximum AVDelay\\n•LRL\\n•MTR\\n•MSR\\n•MPR\\nTheDynamic AVDelayisnotadjusted following aPVCorwhenthepreviouscardiaccyclewaslimitedbytheMTR.\\nIftheatrialrateisatorbelowtheLRL(e.g.,hysteresis), themaximum AVDelayisused.Iftheatrialrateisatorabove\\nthehigheroftheMTR,MSR,orMPR,theprogrammed minimum AVDelayisused.\\nWhentheatrialrateisbetween theLRLandthehigheroftheMTR,MSR,andMPR,thepulsegeneratorcalculates the\\nlinearrelationship todetermine theDynamic AVDelay.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 134}), Document(page_content='4-54 PacingTherapies\\nAVDelay\\nMaximum \\nAV Delay\\nMinimum \\nAV Delay\\nShorter o\\nf MTR int\\nerval \\nor\\n MSR inte\\nrval\\nLRL Inter\\nval\\nDynamic A\\nV Delay\\nHysteresi\\ns \\n rate inte rval\\nFigure4–38.DynamicAVDelay\\nTheAVDelaymaybeprogrammed toeitherafixedordynamic valueasfollows:\\n•FixedAVDelay—occurs whenPacedAVDelayminimum andmaximum valuesareequal\\n•Dynamic AVDelay—occ urswhenPacedAVDelayminimum andmaximum valuesarenotequal\\nSensedAVDelay\\nSensedAVDelaycorresponds totheAVDelayafterasensedatrialevent.\\nSensedAVDelaymaybeprogrammed toavalueshorterthanorequaltothePacedAVDelay.Ashortervalueis\\nintended tocompens ateforthedifferenc eintimingbetween pacedatrialeventsandsensedatrialevents(Figure4–\\n39SensedAVDelayonpage4-54).\\nSAV \\nPAV \\nAp As Vp Ap = Paced atrial event \\nAs = Sensed atrial event \\nVp = Paced ventricular event \\n \\nSAV = Sensed AV Delay (As-Vp interval) \\nPAV = Paced AV Delay (Ap-Vp interval) \\nFigure4–39.SensedAVDelay\\nThehemodynamic impactoftheSensedAVDelaydepends ontheappropriateness ofthetimingbetween theatrial\\nandventricular contractions. Atrialpacinginitiates atrialelectrical excitation, whereasatrialsensing canonlyoccur\\naftertheonsetofspontaneous atrialexcitation. Thedelaybetween initiation andsensing depends onthelead\\nlocation andconduction. Asaresult,whenSensedAVDelayisprogrammed tothesamevalueasPacedAVDelay,the\\nhemodynamic AVintervalwilldifferbetween pacedandsensedatrialevents.\\nWhenthedeviceisprogrammed toDDD(R), itisrecommended thatthepatientbetestedtodetermine theoptimal\\nAVDelayduringatrialsensing andatrialpacing.Iftheoptimal AVDelaysaredifferent,thiscanbereflectedby\\nprogramming differentPacedAVDelayandSensedAVDelayparameter settings.\\nUsingSensedAVDelaywithPacedAVDelay—Fixed', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 135}), Document(page_content='PacingTherapies\\nAVDelay4-55\\nWhenPacedAVDelayisprogrammed toafixedvalue,thentheSensedAVDelaywillbefixedattheprogrammed\\nSensedAVDelayvalue.\\nUsingSensedAVDelaywithPacedAVDelay—Dynamic\\nWhenPacedAVDelayisprogrammed asdynamic, thentheSensedAVDelaywillalsobedynamic.\\nDynamic SensedAVDelayandPacedAVDelayarebasedontheatrialrate.Toreflecttheshortening ofthePR\\nintervalduringperiodsofincreasedmetabolic demand, theAVDelayshortens linearlyfromtheprogrammed\\n(maximum) valueattheLRL(orhysteresis rate)toavaluedetermined bytheratioofminimum andmaximum AV\\nDelayatthehigheroftheMTR,MSR,orMPR(Figure4–40Dynamic andSensedAVDelayfunction onpage4-55).\\nWhenDynamic AVDelayisused,ifthemaximum SensedAVDelayvalueisprogrammed asshorterthanthe\\nmaximum PacedAVDelayvalue,thentheminimum SensedAVDelayvaluewillalsobeshorterthantheminimum\\nPacedAVDelayvalue.\\nNOTE:Theminimum SensedAVDelayvalueisprogrammable onlyinVDD(R)mode.\\nMaximum \\nPaced A V \\nDelay\\nMinimum \\nPaced A V \\nDelay\\nShorter of MTR \\nor MSR Interval\\nLRL Interval Hysteresis Rate \\nInterval\\nPaced A V Delay\\nSensed A V Delay\\nFigure4–40.DynamicandSensedAVDelayfunction\\nAVSearch+\\nAVSearch+isdesigned topromoteintrinsic A–Vconduction ifpresentbyallowing AVconduction tooccurbeyond\\ntheprogrammed AVDelay.Inpatients withexercise-dependent, firstdegreeorseconddegreeAVnodalblock,this\\nintrinsic AVconduction canimprove hemodynamic performanc eandincreasedevicelongevity byreducingthe\\namount ofventricular pacingpulses.\\nWhenAVSearch+isenabled, theAVDelayislengthened periodically (SearchInterval) forupto8consecutive paced\\norsensedcardiaccycles.TheAVSearch+AVDelayremains activeaslongastheintrinsic PRintervalsareshorterthan\\ntheprogrammed SearchAVDelayvalue.\\nThepulsegeneratorrevertstotheprogrammed AVDelayatthefollowing points:\\n•Whenthe8-cyclesearchexpireswithout sensing intrinsic ventricular activity\\n•Whentwoventricular pacedeventsoccurwithina10-cycle moving window', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 136}), Document(page_content='4-56PacingTherapies\\nAVDelay\\nSearchAVDelay\\nTheSearchAVDelayparamete rdetermines thelengthofthesensedandpacedAVdelaysduringthesearchcycles\\nandduringtheAVhysteresis period.\\nNOTE:TheSearchAVDelayvaluemustbeprogrammed tolongerthanthemaximum PacedAVDelay.Dynamic AV\\nDelayandSensedAVDelayarenotappliedduringAVSearch+.\\nThePRMdoesnotconsidertheAVDelayassociated withAVSearch+whencalculating theTARPinterval.Thisisso\\nthatlongerAVDelays,without interactions, canbeprogrammed forpatients withintactAVconduction. Notethatif\\nAVSearch+isutilizedinthismanner,Wenckebach-like behavior mayoccuratrateslowerthantheMTRifconduction\\nislost.\\nNOTE:LongfixedAVintervals maybeselected toavoidunnecessary RVpacing.However ,programming longfixed\\nAVintervals,insomecases,maybeassociated withPMT,diastolic mitralinsufficiency orpacemak ersyndrome.Asan\\nalternative toprogramming longfixedAVintervals, considerAVSearch+toavoidunnecessary RVpacing.\\nSearchInterval\\nTheSearchIntervalcontrolsthefrequencyatwhichAVSearch+willattempt asearch.\\nSearch be\\ngins \\nContinued\\n operatio\\nn at\\ne\\nxtended A\\nV Delay a\\nnd \\ninhibited\\n VP\\nVP to avo\\nid \\ndropped b\\neat\\nReturn to\\n programm\\ned \\nAV Delay \\nand new S\\nearch \\nInterval \\ncount beg\\nins\\n3\\n2nd cycle\\n1 2 3 1\\n7\\n1\\n8\\n1\\n9\\nAV Delay\\n200 ms\\nAV Delay\\n400 ms\\nPR Interv\\nal\\n350 ms\\nAV Delay\\n400 ms\\nAV Delay\\n200 ms\\n VS VP VP VP V P VS VS 1\\nAV Delay\\n400 ms\\n VP\\nFigure4–41.AVSearch+\\nRYTHMIQ\\nRYTHMIQ isdesigned toeliminate unnecessary ventricular pacingforpatients whoappeartohavenormalAV\\nconduction, andtopreventclinically significant pausesasdefined bythe2008ACC/AHA/HRS guidelines2.RYTHMIQ\\noperatesinanAAI(R)pacingmodewithVVIbackupduringtimesofnormalconduction. IflossofAVsynchronyis\\ndetected, thenthemodeautomatically switches toDDD(R)torestoreAVsynchron y.Ifnormalconduction returns,then\\nthemodeautomatically switches backtoAAI(R)withVVIbackup.RYTHMIQ doesnotrequiredropped ventricular\\nbeatstoswitchtoDDD(R)pacing.\\nRYTHMIQ isavailable onlywhentheNormalBradyModeisprogrammed toDDD(R). IftheNormalBradyModeisDDD,\\nthenRYTHMIQcanbesettoeitherAAIWithVVIBackuporOff.IftheNormalBradyModeisDDDR,thenRYTHMIQ can\\nbesettoeitherAAIRWithVVIBackuporOff.\\nThefollowing occursduringtheRYTHMIQ stageofAAI(R)withVVIbackup:\\n•Thedeviceprovides AAI(R)pacingattheLRLand/orsensorindicated rate.\\n2.ACC/AHA/HRS 2008Guidelines forDevice-Based Therapy ofCardiacRhythm Abnormalities. JournaloftheAmerican CollegeofCardiology,\\nVol.51(21),May27,2008.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 137}), Document(page_content='PacingTherapies\\nRefractory4-57\\n•ThedeviceprovidesbackupVVIpacingatarateof15ppmslowerthantheLRL.ThebackupVVIpacingrateis\\nlimitedtonoslowerthan30ppmandnofasterthan60ppm.Whenthereisconsistent conduction, ventricular\\npacingdoesnotoccurastheVVIbackupmoderunsinthebackgroun datareducedLRL.\\n•Thedevicemonitors forlossofAVsynchron y.If3slowventricular beatsaredetected inawindow of11beats,\\nthenthedeviceautomatically switches toDDD(R)mode.AslowbeatforRYTHMIQisdefined asaventricular pace\\norventricular sensedeventthatisatleast150msslowerthantheAAI(R)pacinginterval.\\nThefollowing occursduringtheRYTHMIQ stageofDDD(R):\\n•ThedeviceprovidesDDD(R)pacingaccordingtothenormalprogrammed parameters.\\n•ThedeviceusesAVSearch+toperiodically checkforareturnofintrinsic conduction. IfAVSearch+remains inAV\\nhysteresisforatleast25cardiaccycles,andlessthan2ofthelast10cyclesareventricular paced,thenthedevice\\nautomatically switches thepacingmodebacktoAAI(R)withVVIbackup.\\nWhenRYTHMIQ detectslossofAVsynchron y,thedevicerecordsaRYTHMIQepisode alongwith20secondsof\\nelectrogramdata(10secondsbeforethemodeswitch,10secondsafterthemodeswitch). TheRYTHMIQepisode will\\nbenotedbythePRMandcanbeinspected indetailbyselecting theappropriateepisode fromtheArrhythmia\\nLogbook screen.WhentheDDD(R)stageofRYTHMIQ isactive,theRYTHMIQ episode isidentified as“InProgress”.\\nFeaturesavailable duringtheDDD(R)stageofRYTHMIQ maynotbeavailable duringtheAAI(R)stageofRYTHMIQ.\\nTheexceptionsareATR,RateAdaptive Pacing,andRateSmoothing. IfATRisprogrammed onforDDD(R), itwillalso\\nbeactiveduringAAI(R),andmayperform anATRModeSwitchfromeitherRYTHMIQ stage.Whentheatrial\\narrhythmia ends,thepacingmodewillresumetheRYTHMIQ stagethatwasactivebeforetheATRModeSwitch.If\\nRateSmoothing isprogrammed OnforDDD(R), thenRateSmoothing willbeactiveduringAAI(R);RateSmoothing\\nwillnotaltertheVVIbackup-pacing rate.\\nIfyouwanttheswitchfromAAI(R)withVVIBackuptoDDD(R)toonlyoccuronce,thenprogramAVSearch+toOff.In\\nthiscase,thepulsegenerator remainsinDDD(R)modeuntilreprogramming occurs.\\nREFRACTOR Y\\nRefractoryperiodsaretheintervals following pacedorsensedeventsduringwhichthepulsegeneratorisnot\\ninhibited ortriggeredbydetected electrical activity.Theysuppress (orprevent)oversensing ofpulsegenerator\\nartifacts andevokedresponses following apacingpulse.Theyalsopromoteappropriatesensing ofasingle,wide,\\nintrinsic complexandpreventthesensing ofotherintrinsic signalartifacts (e.g.,aT-waveorfar-fieldR-wave).\\nRefertomoreinformation aboutrefractoryperiods(\"Calculating RatesandRefractoryPeriods\" onpage2-4).\\nNOTE:RateAdaptive Pacingisnotinhibited duringrefractory periods.\\nA-Refractory -PVARP\\nPVARPisdefined accordingtothepacingmode:\\n•Single-chamber atrialmodes: AAI(R)—the timeperiodafterasensedorpacedatrialeventwhenanatrialsense\\neventdoesnotinhibitanatrialpace.\\n•Dual-chamber modes: DDD(R), DDI(R),VDD(R)—the timeperiodafterasensedorpacedRVeventwhenanatrial\\neventdoesnotinhibitanatrialpaceortriggeraventricular pace.TheAtrialRefractoryperiodprevents the\\ntrackingofretrogradeatrialactivityinitiated intheventricle.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 138}), Document(page_content=\"4-58PacingTherapies\\nRefractory\\nPVARPcanbeprogrammed toafixedvalueortoadynamic valuecalculated basedonthepreviouscardiaccycles.To\\nprogramafixedPVARP,settheminimum andmaximum tothesamevalue.PVARPwillautomatically bedynamic if\\ntheminimum valueislessthanthemaximum value.\\nAlongAtrialRefractoryperiodshortens thebradyatrialsensing window.Programming longAtrialRefractoryperiods\\nincombination withcertainAVDelayperiodscancause2:1blocktooccurabruptly attheprogrammed MTR.\\nInDDD(R)andVDD(R)pacingmodes,thepulsegeneratormaydetectretrogradeconduction intheatrium,causing\\ntriggeredventricular pacingratesashighastheMTR(i.e.,PMT).Retrogradeconduction timesmayvaryovera\\npatient's lifetime asafunction ofchanging autonomic tone.Iftestingdoesnotrevealretrogradeconductionat\\nimplantation, itmaystilloccuratalatertime.Thisproblem canusuallybeavoided byincreasingtheatrialrefractory\\nperiodtoavaluethatexceedstheretrogradeconductiontime.\\nIncontrollingthepulsegenerator'sresponse toretrogradeconduction, itmayalsobeusefultoprogramthe\\nfollowing:\\n•PVARPafterPVC\\n•PMTTermination\\n•RateSmoothing\\nDynamicPVARP\\nProgramming ofDynamic PVARPandDynamic AVDelayoptimizes thesensing window athigherrates,allowing\\nupperratebehavior (e.g.,2:1blockandpacemak erWenckebach)inDDD(R)andVDD(R)modestobesignificantly\\nreduced,evenathigherMTRsettings. Atthesametime,Dynamic PVARPreducesthelikelihoodofPMTsatlower\\nrates.Dynamic PVARPalsoreducesthelikelihood ofcompetit iveatrialpacing.\\nThepulsegenerator automatically calculates theDynamic PVARPusingaweighted averageofthepreviouscardiac\\ncycles.Thisresultsinashortening ofthePVARPinalinearfashionastherateincreases. Whentheaverage rateis\\nbetween theLRLandtheMTRorapplicable upperratelimit,thepulsegenerator calculates theDynamic PVARP\\naccordingtothelinearrelationship shown(Figure4–42Dynamic PVARPonpage4-58).Thisrelationship is\\ndetermined bytheprogrammed valuesforMinimum PVARP,Maximum PVARP,theLRL,andtheMTRorapplicable\\nupperratelimit.\\nCAUTION: Programming minimum PVARPlessthanretrogradeV–Aconduction mayincrease thelikelihood ofa\\nPMT.\\nMaximum \\nPVARP\\nMinimum \\nPVARP\\nMTR Inter\\nval\\nLRL Inter\\nval\\nDynamic P\\nVARP\\nHysteresi\\ns \\n rate inte rval\\nFigure4–42.DynamicPVARP\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 139}), Document(page_content='PacingTherapies\\nRefractory4-59\\nMaximum PVARP\\nIftheaverage rateisequaltoorlowerthantheLRL(e.g.,hysteresis), theMaximum PVARPisused.\\nMinimum PVARP\\nIftheaverage rateisequaltoorhigherthantheMTRinterval,theprogrammed Minimum PVARPisused.\\nPVARPafterPVC\\nPVARPafterPVCisdesigned tohelpprevent PMTduetoretrogradeconduction, whichcanoccurduetoaPVC.\\nWhenthepulsegeneratordetectsasensedRVeventwithout detecting aprecedingatrialsensedevent(refractory or\\nnon-refractory) ordelivering anatrialpace,theAtrialRefractoryperiodautomatically extendstotheprogrammed\\nPVARPafterPVCvalueforonecardiaccycle.AfteraPVCisdetected, thetimingcyclesresetautomatically .PVARP\\nextendsnomorefrequentlythaneveryothercardiaccycle.\\nThepulsegeneratorautomatically extendsthePVARPtothePVARPafterPVCvalueforonecardiaccycleinthese\\nadditional situations:\\n•Ifanatrialpaceisinhibited duetoAtrialFlutterResponse\\n•Afteraventricular escapepacethatisnotprecededbyanatrialsenseinVDD(R)mode\\n•Whenthedevicetransitions fromanon-atrial trackingmodetoanatrialtracking mode(e.g.,exitsATRFallback,\\ntransitions fromtemporarynon-atrial tracking modetopermanent atrialtrackingmode)\\n•WhenthedevicereturnsfromElectrocaute ryProtectionModeorMRIProtection Modetoanatrialtrackingmode\\nARefractory -samechamber\\nDual-chamber Modes\\nAtrialRefractory provides anintervalfollowing anatrialpacedorsensedeventwhenadditional atrialsensedevents\\ndonotimpactthetimingofpacingdelivery.\\nThefollowing arenonprogr ammable intervalsfordual-chamber modes:\\n•85msAtrialRefractoryfollowing anatrialsensedevent\\n•150msAtrialRefractoryfollowing anatrialpaceinDDD(R)andDDI(R)modes\\nRV-Refractory (RVRP)\\nTheprogrammable RVRPprovides anintervalfollowing anRVpaceeventduringwhichRVsensedeventsdonot\\nimpactthetimingofpacingdelivery.\\nAdditionally ,a135msnonprogr ammable refractoryperiodprovidesanintervalfollowing anRVsensedeventduring\\nwhichfurtherRVsensedeventsdonotimpactthetimingofpacingdelivery.\\nTheprogramming andfunction oftheVentricular RefractoryPeriodinVVI(R)modeisthesameindual-andsingle-\\nchamber devices.AnyeventwhichfallsintoVRPisnotdetected ormarked (unlessitoccurswithinthenoisewindow),\\nanddoesnotimpacttimingcycles.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 140}), Document(page_content='4-60PacingTherapies\\nRefractory\\nRVRPisavailable inanymodewhereventricular sensing isenabled, andRVRPcanbeprogrammed toafixedor\\ndynamic interval(Figure4–43Relationship between ventricular rateandrefractoryintervalonpage4-60):\\n•Fixed—RVRP remainsattheprogrammed, fixedRVRPvaluebetween theLRLandtheapplicable upperratelimit\\n(MPR,MTRorMSR).\\n•Dynamic—RVRP shortens asventricular pacingincreasesfromtheLRLtotheapplicable upperratelimit,allowing\\nadequate timeforRVsensing.\\n–Maximum—if thepacingrateislessthanorequaltotheLRL(i.e.,hysteresis),theprogrammed Maximum\\nVRPisusedastheRVRP.\\n–Minimum—if thepacingrateisequaltotheapplicable upperratelimit,theprogrammed Minimum VRPis\\nusedastheRVRP.\\nDy\\nnami\\nc VRP \\ns\\nhort\\nens\\nSensing w\\nindow \\nis optimi zed\\nFigure4–43.Relationship between ventricular rateandrefractory interval\\nToprovideanadequate sensing window,thefollowing Refractory value(fixedordynamic) programming is\\nrecommended:\\n•Single-chamber modes—less thanorequaltoone-half theLRLinms\\n•Dual-chamber modes—less thanorequaltoone-half theapplicable upperratelimitinms\\nTheuseofalongRVRPshortens theventricular sensing window.\\nProgramming theVentricular RefractoryPeriodtoavaluegreaterthanPVARPcanleadtocompetitive pacing.For\\nexample,iftheVentricular RefractoryislongerthanPVARP,anatrialeventcanbeappropriately sensedfollowing\\nPVARPandintrinsic conduction totheventricle fallsintotheVentricular RefractoryPeriod.Inthiscase,thedevicewill\\nnotsensetheventricular depolarization andwillpaceattheendoftheAVDelay,resulting incompetitive pacing.\\nCross-Chamber Blanking\\nCross-chamber blanking periodsaredesigned topromote appropriate sensing ofin-chamber eventsandprevent\\noversensing ofactivityinanother chamber (e.g.,cross-talk, far-fieldsensing).\\nCross-chamber blanking periodsareinitiated bypacedand/orsensedeventsinanadjacent chamber .Forexample, a\\nblanking periodisinitiated intherightventricle eachtimeapacingpulseisdeliveredtotherightatrium;this\\npreventsthedevicefromdetecting theatrialpacedeventintherightventricle.\\nCross-chamber Blanking canbeprogrammed toSmartorafixedvalue.SmartBlanking isdesigned topromote\\nappropriatesensing ofin-chamber eventsbyshortening thecross-chamber blanking period(37.5msfollowing paced\\neventsand15msfollowing sensedevents)andpreventoversensing ofcross-chamber eventsbyautomatically raising\\ntheAGCthresholdforsensing attheexpirationoftheSmartBlanking period.\\nSmartBlanking doesnotchangetheprogrammed AGCSensitivity settings.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 141}), Document(page_content='PacingTherapies\\nRefractory4-61\\nNOTE:SmartBlanking periodswillbelengthened to85msifasame-chamber blanking periodoraretriggerable\\nnoisewindow isactivewhentheSmartBlanking periodbegins.Forexample,ifanRVsenseoccurswithintheatrial\\nrefractoryperiod,theA-Blank afterRV-Sense crosschamber blankwillbe85ms.\\nCAUTION: Sensitivity adjustments associated withSmartBlanking maynotbesufficient toinhibitdetection ofcross-\\nchamber artifacts ifthecross-chamber artifacts aretoolarge.Consider otherfactorsthatimpactthesize/amplitude of\\ncross-chamber artifacts including lead-placement, pacingoutput,programmed Sensitivity settings, shockoutput,and\\ntimesincelastdeliveredshock.\\nRV-Blank afterA-Pace\\nRV-Blank afterA-Paceisacross-chamber blanking perioddesigned topromotetheappropriate sensing ofRVevents\\nandprevent oversensing ofcross-chamber eventsfollowing anatrialpace.\\nIfRV-Blank afterA-Paceisprogrammed toafixedperiod,thepulsegeneratorwilldisregardRVeventsforthe\\ndurationselected following anatrialpace.Ifafixedperiodischosen, thenthereistheincreasedpotential for\\nundersensing ofR-waves (e.g.,PVCs)inthecross-chamber blanking periodafteratrialpacing.\\nIfthevalueisprogrammed toSmart,thepulsegeneratorautomatically raisestheAGCthresholdforsensing atthe\\nexpiration oftheSmartBlanking periodinordertoaidrejection ofcross-chamber atrialevents.Thispromotessensing\\nofR-waves thatmayhaveotherwisefallenintothecross-chamber Blanking period.SmartBlanking doesnotchange\\ntheprogrammed Sensitivity settings.\\nSmartBlanking isdesigned topromote sensing ofR-waves, andshouldonlybeconsideredwhenPVCsoccurduring\\nthecross-chamber blanking periodfollowing anatrialpaceandarenotproperly sensed.\\nWhenSmartBlanking isused,itispossible thatpolarization artifacts following atrialpacingmaybedetected asR-\\nwaves.Theseartifacts arelikelyaresultofvoltagebuild-up ontheventricular sensing leadfollowing tachytherapyor\\nhigh-output ventricular pacing,andmayinhibitventricular pacing.\\nWhenadjusting Blanking, consider thefollowing:\\n•Ifthepatientispacemak er-dependent, testforpropersensing aftershocktherapy.Ifoversensing isoccurring\\npost-shock,bepreparedtousetheSTATPACEcommand.\\n•Topromote continuous pacingforpacemaker-dependent patients, itmaybepreferabletolessenthepotential for\\nventricular oversensing ofatrialpacedartifacts byprogramming alongerblanking period.However ,programming\\nalongerblanking periodmayincrease thelikelihood ofundersensing R-waves (e.g.,PVCs,shouldtheyoccur\\nwithintheRV-Blank afterA-Pacecross-chamber blanking period).\\n•Forpatients withahighpercentageofatrialpacingandfrequentPVCswhoarenotpacemaker-dependent, itmay\\nbepreferabletoshorten theblanking periodtolessenthepotential forundersensing aPVC(shoulditoccurinthe\\ncross-chamber blanking periodfollowing anatrialpacedevent).However ,ashorterblanking periodmayincrease\\nthelikelihoodforventricular oversensing ofanatrialpacedevent.\\nA-BlankafterV-Pace\\nA-Blank afterV-Paceisacross-chamber blanking perioddesigned topromotetheappropriatesensing ofP-waves\\nandprevent oversensing ofcross-chamber eventsfollowing aventricular pace.\\nIfthevalueisprogrammed toSmart,thepulsegeneratorautomatically raisestheAGCthresholdforsensing atthe\\nexpiration oftheSmartBlanking periodinordertoaidrejection ofcross-chamber ventricular events.Thispromotes\\nsensing ofP-waves thatmayhaveotherwisefalleninthecross-chamber blanking period.SmartBlanking doesnot\\nchangetheprogrammed Sensitivity settings.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 142}), Document(page_content='4-62PacingTherapies\\nRefractory\\nA-BlankafterRV-Sense\\nA-Blank afterRV-Sense isacross-chamber blanking perioddesigned topromoteappropriat esensing ofP-waves and\\npreventoversensing ofcross-chamber eventsfollowing anRV-sensed event.\\nIfthevalueisprogrammed toSmart,thepulsegenerator automatically raisestheAGCthreshold forsensing atthe\\nexpiration oftheSmartBlanking periodinordertoaidrejection ofcross-chamber RVevents.Thispromotes sensing\\nofP-waves thatmayhaveotherwise falleninthecross-chamber blanking period.SmartBlanking doesnotchangethe\\nprogrammed Sensitivity settings.\\nRefertothefollowing illustrations:\\nAV Delay \\nafter pac\\ned atrial\\n event (p\\nrogrammab\\nle; \\nincludes \\n150 ms ab\\nsolute re\\nfractory)\\nAV Delay \\nafter sen\\nsed atria\\nl event (\\nprogramma\\nble, \\ninc\\nludes 85 \\nms absolu\\nte refrac\\ntory)\\nAtrial Re\\nfractory-\\nPVARP (pr\\nogrammabl\\ne; includ\\nes \\nprogramma\\nble atria\\nl cross c\\nhamber bl\\nank)\\nV-A inter\\nval (may \\nbe length\\nened by \\nmodified \\natrial ti\\nming)\\nV Sensed \\nRefractor\\ny (135 ms\\n)\\nVentricular Refractory (programmable)Ventricul\\nar Cross \\nChamber B\\nlank (pro\\ngrammable\\n)\\nA sensed\\nV sensed\\nA sensed\\nV paced\\nA paced\\nV sensed\\nA paced\\nV paced\\nECG\\nAtrial Ch\\nannel\\nVentricul\\nar Channe\\nl\\nFigure4–44.Refractory periods,dual-chamber pacingmodes\\nA sensed*\\nV paced\\nA sensed*\\nV sensed\\nA sensed*\\nV paced\\nECG\\nAtrial Ch\\nannel\\nVentricul\\nar Channe\\nl\\nAtrial Se\\nnsed Refr\\nactory (8\\n5 ms)\\nV Sensed \\nRefractor\\ny (135 ms\\n)\\nVentricul\\nar Refrac\\ntory (pro\\ngrammable\\n)\\nAtrial Cross Chamber Blank (programmable)* An RA s\\nense occu\\nrs during\\n VVI \\npa\\ncing due \\nto the ta\\nchycardia\\n \\nfu\\nnction of\\n the puls\\ne generat\\nor.\\nFigure4–45.Refractory periods,VVIpacingmode', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 143}), Document(page_content='PacingTherapies\\nRefractory4-63\\nSensed Atrial Refractory-PV ARP (programmable; \\nincludes 85 ms absolute refractory) \\nRV Sensed Refractory (135 ms) \\nCross Chamber Blank (programmable \\natrial and R V) \\nPaced Atrial Refractory-PV ARP (programmable; \\nincludes 150 ms absolute refractory) ECG \\nAtrial Sensing \\nVentricular Sensing \\nA sensed \\nRV sensed* \\nA paced \\nRV sensed* \\n* An RV sense occurs during AAI \\npacing due to the tachycardia \\nfunction of the pulse generator . \\nFigure4–46.Refractory periods,AAIpacingmode;DR\\nNOISERESPONSE\\nNoisewindows andblanking periodsaredesigned topreventinappropriatetherapyorpacinginhibition duetocross-\\nchamber oversensing.\\nNoiseResponse allowstheclinician tochoosewhether topaceorinhibitpacinginthepresenceofnoise.\\nAretriggerable, 40-msnoisewindow existswithineachrefractory andfixed(non-smart) cross-chamber blanking\\nperiod.Thewindow isinitiated byeitherasensedorpacedevent.Boththenoisewindow andtherefractoryperiod\\nmustbecompletedforeachcardiaccycleinonechamber beforethenexteventrestartsthetiminginthesame\\nchamber .Recurrentnoiseactivitymaycausethenoisewindow torestart,extending thenoisewindow andpossibly\\ntheeffective refractoryperiodorblanking period.\\nTheNoiseResponse parametercanbeprogrammed toInhibitPacingoranasynchron ousmode.Theavailable\\nasynchronousmodewillautomatically correspond tothepermanent BradyMode(i.e.,VVIpermanent modewillhave\\nVOOnoiseresponse).IfNoiseResponse isprogrammed toanasynchronousmodeandthenoisepersists sothatthe\\nnoisewindow isextendedlongerthantheprogrammed pacinginterval, thepulsegeneratorpacesasynchro nouslyat\\ntheprogrammed pacingrateuntilthenoiseceases.IfNoiseResponse isprogrammed toInhibitPacingandpersistent\\nnoiseoccurs,thepulsegenerator willnotpaceinthenoisychamber untilafterthenoiseceases.TheInhibitPacing\\nmodeisintended forpatients whosearrhythmias maybetriggeredbyasynchron ouspacing.\\nRefertothefollowing illustrations.\\nECG \\nRV Sensing \\nRV Paced \\nevent \\nRV Sensed \\nevent \\nNoise window (40 ms) \\nRV Refractory: \\nsensed = nonprogrammable \\npaced = programmable \\nFigure4–47.Refractory periodsandnoisewindows, RV', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 144}), Document(page_content='4-64PacingTherapies\\nRefractory\\nECG\\nA Sensing\\nA Paced \\nevent\\nA Sensed \\nevent\\nNoise win\\ndow (40 m\\ns)\\nA Refract\\nory:\\nsensed\\npaced\\nFigure4–48.Refractory periodsandnoisewindows, RA\\nInaddition, anonprogrammable Dynamic NoiseAlgorithm isactiveinallratechannels.\\nTheDynamic NoiseAlgorithm usesaseparatenoisechannel tocontinuously measure thebaseline signalandadjust\\nthesensing floortoavoidnoisedetection. Thisalgorithm isintended tohelppreventoversensing ofmyopotential\\nsignalsandtheproblems associated withoversensing.\\nThefollowing noiseeventmarkersaregenerated:\\nSingle-Chamber\\n•Themarker[VS]occurswhenthenoisewindow isinitiallytriggeredfollowing aVpace\\n•Ifretriggered for340ms,themarkerVNoccurs\\n•Withcontinuous retriggers, themarkerVNoccursfrequently\\nDual-Chamber\\n•Depending onthechamber wherenoiseisoccurring, themarker[AS]or[VS]occurswhenthenoisewindow is\\ninitiallytriggeredfollowing apace\\n•Ifretriggered for340ms,themarkerANorVNoccurs\\n•Withcontinuous retriggers, themarkerANorVNoccursfrequently\\n•Ifasynchronouspacingoccursduetocontinuous noise,themarkersAP-Ns,VP-Nswilloccur\\nNOTE:Inpacer-dependent patients, usecarewhenconsidering settingNoiseResponse toInhibitPacingaspacing\\nwillnotoccurinthepresenceofnoise.\\nNoiseResponse example\\nCross-chamber sensing thatoccursearlyintheAVDelaymaybedetected bytheRVsenseamplifiers duringthefixed\\nblanking period,butisnotresponded toexcepttoextendthenoiserejection interval. The40msnoiserejection\\nintervalcontinues toretrigger untilthenoiseisnolongerdetected, uptothelengthoftheAVDelay.Ifnoise\\ncontinuesthroughout thedurationoftheAVDelay,thedevicewilldeliverapacingpulsewhentheAVDelaytimer\\nexpires,preventingventricular inhibition duetonoise.Ifaventricular pacingspikeisdelivered underconditions of\\ncontinuous noise,aVP-Nsmarkernotation appears ontheintracardiacelectrogram(Figure4–49NoiseResponse\\n(fixedblanking) onpage4-65).\\nIfnoiseceasespriortotheexpiration oftheAVDelay,thedevicecandetectanintrinsic beatthatoccursatanytime\\nbeyond the40msretriggerablenoiseintervalandinitiateanewcardiaccycle.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 145}), Document(page_content='PacingTherapies\\nVentricular TachySensingInteractions4-65\\n65 ms\\n40 ms\\n40 ms\\n40 ms\\n40 ms\\n40 ms\\n40 ms\\n120 ms\\nS\\nurface el\\nectrogram\\nProgramma\\nble AV De\\nlay\\nProgramma\\nble V-Bla\\nnk after \\nA-Pace\\n40 ms ret\\nriggerabl\\ne noise w\\nindow\\nAP\\nVP-Ns ann\\notation a\\nt end \\nof the AV DelayNoise sti\\nll presen\\nt even \\nafter AV \\nDelay exp\\nires\\nVentricul\\nar pace \\ndelivered\\n in the \\npresence \\nof noise\\nNoise int\\nerval ext\\nended \\nfor durat\\nion of AV\\n Delay\\nFigure4–49.NoiseResponse (fixedblanking)\\nVENTRICULAR TACHYSENSINGINTERACTIONS\\nRefractoryperiodsandblanking intervalsareanintegralpartofthepulsegeneratorsensing system. Theyareusedto\\nefficiently suppress detection ofpulsegeneratorartifacts (e.g.,apaceorshock)andcertainintrinsic signalartifacts (e.\\ng.,aT-waveorfar-fieldR-wave). Thepulsegeneratordoesnotdiscriminate between eventsthatoccurduring\\nRefractoryperiodsandblanking intervals.Asaresult,allevents(pulsegeneratorartifacts, intrinsic artifacts, and\\nintrinsic events)thatoccurduringarefractoryperiodorblanking intervalareignoredforpurposes ofpacingtiming\\ncyclesandVentricular TachyDetection.\\nCertainprogrammed combinatio nsofpacingparameters areknowntointerfere withventricular tachydetection.\\nWhenanintrinsic beatfromaVToccursduringapulsegeneratorrefractoryperiod,theVTbeatwillnotbedetected.\\nAsaresult,detection andtherapy ofthearrhythmia maybedelayed untilenough VTbeatsaredetected tosatisfythe\\ntachydetection criteria(\"Ventricular Detection Windows\" onpage2-11).\\nPacingParameter Combination Examples\\nThefollowing examplesillustrate theeffectsofcertainpacingparamete rcombinations onventricular sensing. When\\nprogramming pulsegeneratorpacingandtachydetection parameters, considerthepossible interactionsofthese\\nfeaturesinlightoftheexpectedarrhythmias. Ingeneral,thePRMscreendisplays Parameter InteractionAttentions\\nandadvisory messages toinformyouaboutprogramming combinations thatcouldinteracttocausethesescenarios;\\ntheinteractionscanberesolvedbyreprogramming thepacingRate,AVDelayand/orrefractory/blanking periods.\\nExample1:Ventricular Undersensing DuetoVentricular Refractory Period\\nIfthepulsegeneratorisprogrammed asfollows, aVTthatoccurssynchronous withthepacingwillnotbedetected:\\n•BradyMode=VVI\\n•LRL=75ppm(800ms)\\n•VRP=500ms\\n•VTZone=150bpm(400ms)\\nInthisscenario,thepulsegeneratorisVVIpacingatLRL(800ms).A500msVRPfollowseachventricular pace.VT\\nbeatsthatoccurduringVRPareignored forpurposes ofpacemakertimingandVentricular TachyDetection/Thera py.\\nIfastableVTof400msstartssimultaneously withaventricular pace,theVTwillnotbedetected because everybeat\\nwilloccurduringthe500msVRP,eitherconcurrentwithaventricular paceor400msafterapace(Figure4–50\\nVentricular undersensing duetoVRPonpage4-66).\\nNOTE:Itisnotrequired fortheVTtostartconcurrently withapaceforundersensing tooccur.Inthisexample, all\\npacingwillbeinhibited andtachydetection willsubsequently occur,assoonasasingleVTbeatisdetected.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 146}), Document(page_content='4-66PacingTherapies\\nVentricular TachySensingInteractions\\nVP VP VP VP\\n(VT) (VT) (VT) (VT) (VT) (VT) (VT)\\nVRP = 500 ms\\n400 ms\\n LRL = 800 ms\\nFigure4–50.Ventricular undersensing duetoVRP\\nWhentheprogramming interactiondescribed inthisscenario ispresent,amessage willdescribe theinteraction of\\nVRPwithLRL.Inrate-responsive ortrackingmodes(e.g.,DDDR),similarmessages maydescribe theinteraction of\\nVRPwithMTR,MSR,orMPR.Alongwitheachmessage, thepertinent programmable parameters aredisplayed to\\nassistyouinresolvingtheinteraction.Programming Dynamic VRPcanbeusefulinresolvingthesetypesof\\ninteractions.\\nExample2:Ventricular Undersensing DueToV-BlankAfterA-Pace\\nCertainprogrammed combinations ofdual-chamber pacingparametersmayalsointerferewithVentricular Tachy\\nDetection. Whendual-chamber pacingoccurs,pulsegeneratorrefractoryperiodsareinitiated bybothatrialand\\nventricular paces.Theventricular refractoryperiodfollowing aventricular paceiscontrolled bytheVRPparamete r;the\\nventricular refractoryperiodfollowing anatrialpaceiscontrolled bytheV-Blank AfterA-Paceparameter.\\nUndersensing ofaVTduetothepulsegenerator refractoryperiodsmayoccurwhenthepulsegeneratorispacingat\\noraboveLRL.Forexample, ifthepulsegeneratorisrate-adaptive pacingat100ppm(600ms)andisprogrammed as\\nfollows, thenaVTthatoccurssynchronouswiththepacingmaynotbedetected:\\n•LRL=90ppm(667ms),MTR/MSR =130ppm(460ms)\\n•BradyMode=DDDR,FixedAVdelay=300ms\\n•VRP=230ms\\n•V-Blank AfterA-Pace=65ms\\n•VTZone=150bpm(400ms)\\nInthisscenario,thepulsegeneratorisDDDRpacingat600ms.AVRPof230msfollowseachventricular pace;a\\nVentricular RefractoryPeriodof65ms(V-Blank afterA-Pace) followseachatrialpace;anatrialpaceoccurs300ms\\naftereachventricular pace.VTbeatsthatoccurduringeitherrefractory periodareignoredforpurposes ofpacemak er\\ntimingandVentricular TachyDetection/Ther apy.IfastableVTof350msstarts,thentheVTwillnotbedetected\\nbecause mostbeatswilloccurduringaventricular refractoryperiod,eitherV-Blank afterA-PaceorVRP.SomeVT\\nbeatswillbedetected, butnotenough tosatisfythe8of10tachydetection criteria(\"Ventricular Detection Windows\"\\nonpage2-11).\\nNOTE:ItisnotrequiredfortheVTtostartconcurrently witharefractoryperiodorblanking intervalfor\\nundersensing tooccur.Inthisexample, itislikelythattheVTwillnotbedetected untileithertheVTacceleratesto\\nfasterthan350msorthesensor-drivenpacingratechanges from600ms.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 147}), Document(page_content='PacingTherapies\\nVentricular TachySensingInteractions4-67\\nVT (VT) (VT) VT VS*\\nAP AP\\nAV = 300 ms\\nVRP\\n230 ms\\nVP\\n600 ms\\n350 ms\\n 350 ms 700 ms 600 ms 450 ms\\nRepeat pattern\\nAP, VP, AP, VS, VT\\nFigure4–51.Ventricular undersensing duetoV-BlankafterA-Pace\\nWhentheprogramming interactiondescribed inthisscenarioispresent, amessage willdescribe theinteractionof\\nTachyRateThreshold withLRLandAVDelay.Similarmessages maydescribe theinteraction ofV-Blank afterA-Pace\\nwithMTR,MPR,orLRL.Alongwitheachmessage, thepertinent programmable parameters aredisplayed toassist\\nyouinresolving theinteraction.Programming Dynamic VRPcanbeusefulinresolving thesetypesofinteractions.\\nProgramming Considerations\\nCertainprogrammed combinatio nsofpacingparameters areknowntointerfere withVentricular TachyDetection. The\\nriskofventricular tachyundersensing duetodevicerefractoryperiodsisindicated bytheinteractivewarnings onthe\\nparameterscreen.\\nAswithalldeviceprogramming, youshouldevaluate thebenefits andtherisksoftheprogrammed features foreach\\npatient(forexample,thebenefitofRateSmoothing withalongAVDelayversustheriskofventricular tachy\\nundersensing).\\nThefollowing programming recommendations areprovided toreducetheriskofventricular undersensing duetothe\\nrefractoryperiodcausedbyanatrialpace(V-Blank afterA-Pace):\\n•Ifadual-chamber pacingmodewithRateSmoothing orRateAdaptive Pacingisnecessary:\\n–ReducetheLRL\\n–Shorten theAVDelayoruseDynamic AVDelayandreducetheminimum Dynamic AVDelaysetting\\n–ReducetheSearchAVDelayforAVSearch+\\n–IncreasetheDownRateSmoothing percentagetothelargestpossible value\\n–DecreasetheRecoveryTimeforRateAdaptive Pacingmodes\\n–ReducetheMTRorMPRifDownRateSmoothing ison\\n–ReducetheMSRifthepacingmodeisrateadaptive\\n•IfRateSmoothing orRateAdaptive Pacingarenotrequiredforthepatient, consider programming thesefeatures\\nOff.Programming thesefeatures Offcanreducethelikelihood ofatrialpacingatelevated rates.\\n•Ifatrialpacingisnotrequiredforthepatient, consider usingVDDratherthanDDDpacingmode.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 148}), Document(page_content='4-68PacingTherapies\\nVentricular TachySensingInteractions\\n•Incertainusagescenarios,youmayelecttoprogramlongAVDelaystoreduceventricular pacingforpatients with\\nlongPRintervals,whileprovidingsensorpacingorRateSmoothing toaddress otherpatientneeds.\\n•Incertainusagescenarios,ifapatternofatrialpacingandVTbeatsisdetected, theBradyTachyResponse (BTR)\\nfeaturewillautomatically adjusttheAVDelaytofacilitate confirmation ofasuspected VT.IfnoVTispresent,the\\nAVDelayisreturned totheprogrammed value.Forprogramming scenarioswheretheautomatic AVDelay\\nadjustment mayoccur,aspecificParameter InteractionAttention willnotbedisplayed.\\nFordiscussion ofdetailsandadditional information regarding theseorotherprogrammed settings, pleasecontact\\nBostonScientific usingtheinformation onthebackcover.\\nInsummar y,whenprogramming thepulsegeneratorpacingandtachydetection paramete rs,itisusefultoconsider\\nthepossible interactions ofthesefeatures inlightoftheexpected arrhythmias ofaparticular patient. Ingeneral,the\\ninteractionswillbebroughttoyourattention throughParameterInteraction Attention messages onthePRMscreen\\nandcanberesolvedbyreprogramming thepacingRate,AVDelay,and/orrefractory/blanking periods.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 149}), Document(page_content='5-1\\nSYSTEMDIAGNOSTICS\\nCHAPTER 5\\nThischaptercontainsthefollowing topics:\\n•“Summary Dialog”onpage5-2\\n•“Battery Status”onpage5-2\\n•“LeadsStatus”onpage5-7\\n•“Post-OperativeSystemTest(POST)” onpage5-11\\n•“LeadTests”onpage5-12', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 150}), Document(page_content='5-2SystemDiagnostics\\nSummary Dialog\\nSUMMARY DIALOG\\nUponinterrogation, aSummar ydialogisdisplayed. Itincludes LeadsandPOSTinformation, Batterystatus\\nindications, approximatetimetoexplant, andanEventsnotification foranyepisodes sincethelastreset.Inaddition,\\namagnet notification willappearifthepulsegeneratordetectsthepresenceofamagnet.\\nFigure5–1.Summary dialog\\nPotential statussymbols includeOK,Attention, orWarning (\"UseofColor\"onpage1-7).Potential messages are\\ndescribed inthefollowing sections:\\n•Leads—\"Leads Status\"onpage5-7\\n•Battery— \"Battery Status\"onpage5-2\\n•Events—\"Therapy History\" onpage6-2\\nOncetheClosebuttonisselected, theWarning orAttention symbols forLeadsandBatterywillnotappearon\\nsubsequent interrogatio nsuntiladditional eventstriggering analertconditionoccur.Eventswillcontinuetoappear\\nuntilanyhistorycounter Resetbuttonisselected.\\nBATTERYSTATUS\\nThepulsegenerator automatically monitors batterycapacity andperformance. Batterystatusinformation isprovided\\nviaseveralscreens:\\n•Summary dialog—displays abasicstatusmessage aboutremaining batterycapacity (\"Summary Dialog\"onpage\\n5-2).\\n•Summary tab(ontheMainScreen)—displays thesamebasicstatusmessage astheSummary dialog,alongwith\\nthebatterystatusgauge(\"MainScreen\"onpage1-2).\\n•BatteryStatusSummar yscreen(accessedfromtheSummary tab)—displays additional batterystatusinformation\\naboutremaining batterycapacity andChargeTime(\"Battery StatusSummar yScreen\"onpage5-3).', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 151}), Document(page_content='SystemDiagnostics\\nBatteryStatusSummary Screen5-3\\n•BatteryDetailscreen(accessedfromtheBatteryStatusSummary screen)—pr ovidesdetailed information about\\nbatteryuse,capacity,andperformanc e(\"Battery DetailSummar yScreen\"onpage5-5).\\nBatteryStatusSummaryScreen\\nTheBatteryStatusSummar yscreenprovides thefollowing keyinformation aboutbatterycapacity andperformance.\\nTimeRemaining\\nThissectionofthescreendisplays thefollowing items:\\n•Batterystatusgauge—displays avisualindication ofthetimeremaining toexplant.\\n•Approximate timetoexplant––displays theestimate ofcalendar timeremaining untilthepulsegeneratorreaches\\ntheExplantstatus.\\nThisestimate iscalculated usingbatterycapacity consumed, chargeremaining, andpowerconsumption at\\ncurrentprogrammed settings.\\nWheninsufficient usagehistoryisavailable, Approxim atetimetoexplantmaychangebetween interrogation\\nsessions. Thisfluctuation isnormal, andoccursasthepulsegeneratorcollectsnewdataandcancalculate amore\\nstableprediction. Approxim atetimetoexplantwillbemorestableafterseveralweeksofusage.Causesof\\nfluctuation mayincludethefollowing:\\n–Ifcertainbradyfeatures thataffectpacingoutputarereprogrammed, theApproxim atetimetoexplantwill\\nbeforecasted basedontheexpected changes inpowerconsumption fromthereprogrammed features. The\\nnexttimethepulsegeneratorisinterrogat ed,thePRMwillresumedisplaying Approximate timetoexplant\\nbasedonrecentusagehistory.Asnewdataiscollected, Approximatetimetoexplantwilllikelystabilizenear\\ntheinitialforecast.\\n–Forseveraldayspost-implant, thePRMwilldisplayastaticApproximate timetoexplantbasedonmodel-\\ndependent data.Onceenough usagedatahasbeencollected,device-specific predictions willbecalculated\\nanddisplayed.\\nChargeTime\\nThissectionofthescreendisplays theamount oftimeittookthepulsegenerator tochargeforthemostrecent\\nmaximum-ener gyshockorcapacitor re-formation.\\nBatteryDetailicon\\nWhenselected, thisicondisplays theBatteryDetailSummar yscreen(\"Battery DetailSummar yScreen\"onpage5-5).\\nBatteryStatusIndicators\\nThefollowing batterystatusindicators appearinthebatterystatusgauge.Theindicated Approxim atetimetoexplant\\niscalculated basedonthepulsegenerator\\'scurrentprogrammed parameters.\\nOneYearRemaining—appr oximately oneyearoffullpulsegeneratorfunction remains(Approximate timetoexplant\\nisoneyear).\\nExplant—the batteryisnearing depletion, andpulsegeneratorreplacement mustbescheduled. OnceExplantstatusis\\nreachedthereissufficient batterycapacity tomonitor andpace100%underexistingconditions forthreemonths and\\ntodeliverthreemaximum-energy shocks,ortodeliversixmaximum energyshockswithnopacing.WhenExplant\\nstatusisreached, 1.5hoursofZIPtelemetry remain.Consider usingwanded telemetry .', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 152}), Document(page_content='5-4 SystemDiagnostics\\nBatteryStatusIndicators\\nNOTE:Whenthe1.5hoursoftelemetry areexhausted,aLATITUDE alertisgenerated.\\nBatteryCapacity Depleted—pulse generatorfunctionality islimited, andtherapiescannolongerbeguaranteed.This\\nstatusisreached threemonths afterExplantstatusisreached. Thepatientshouldbescheduled forimmediate device\\nreplacement. Uponinterrogation,theLimitedDeviceFunctionality screenisdisplayed (allotherscreensaredisabled).\\nThisscreenprovidesbatterystatusinformation andaccesstoremaining devicefunctionality .ZIPtelemetr yisno\\nlongeravailable.\\nNOTE:ALATITUDE alertisgenerated,afterwhichLATITUDE NXTceasesinterrogations ofthedevice.\\nWhenthedevicereachesBatteryCapacity Depleted status,functionality islimitedtothefollowing:\\n•BradyModewillbechanged asdescribed below:\\nBradyModepriortoBatteryCapacity Depleted Indicator BradyModeafterBatteryCapacity Depleted Indicator\\nDDD(R), DDI(R),VDD(R), VVI(R) VVI\\nAAI(R) AAI\\nOff Off\\n•BradyModeandVentricular TachyModecanbeprogrammed toOff;nootherparametersareprogrammable\\n•Oneventricular zone(VF)witharatethresholdof165bpm\\n•Wanded telemetry only(RFtelemetr yisdisabled)\\n•Maximum-energy shocksandmanualcapacitor reformatio nsonly(ATPtherapy andlow-energy shocksare\\ndisabled)\\n•AnLRLof50ppm\\nAtBatteryCapacity Depleted status,thefollowing features aredisabled:\\n•DailyMeasurementtrends\\n•Bradyenhancements (e.g.,rateresponse, RateSmoothing)\\n•PaceSafe RVAutomatic Threshold (theoutputisfixedatthecurrentoutputvalue)\\n•PaceSafe RAAutomatic Threshold(theoutputisfixedatthecurrentoutputvalue)\\n•Episode storage\\n•Diagnostic andEPTests\\n•Real-time EGMs\\n•MVsensor\\n•Accelerometer\\nIfthedevicereaches apointwhereinsufficient batterycapacity isavailable forcontinued operation,thedevicewill\\nreverttoStorageMode.InStorage Mode,nofunctionality isavailable.\\nWARNING: MRIscanning afterExplantstatushasbeenreachedmayleadtoprematurebatterydepletion, a\\nshortened devicereplacement window,orsuddenlossoftherapy.Afterperforming anMRIscanonadevicethathas\\nreachedExplantstatus,verifypulsegeneratorfunction andschedule devicereplacement.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 153}), Document(page_content=\"SystemDiagnostics\\nBatteryDetailSummary Screen5-5\\nNOTE:Thedeviceusestheprogrammed parameters andrecentusagehistorytopredictApproximate timeto\\nexplant.Greaterthannormalbatteryusagemayresultinthesubsequent day'sApproxim atetimetoexplantto\\nappearlessthanexpected.\\nNOTE:Asabackupmethod, Explantisdeclaredwhentwoconsecutive chargetimesexceed15secondseach.Ifa\\nChargeTimeisgreaterthan15seconds, thepulsegeneratorschedules anautomatic capacitor re-formation forone\\nhourlater.IftheChargeTimeduringre-formation alsoexceeds15seconds,thebatterystatusischanged toExplant.\\nBatteryDetailSummaryScreen\\nTheBatteryDetailsummar yscreenprovidesthefollowing information aboutpulsegenerator batterystatus(Figure5–\\n2BatteryDetailsummary screenonpage5-6):\\n•LastDelivered Shock––date, Energy,ChargeTime,andShockImpedance data.\\n•BeepwhenExplantIsIndicated––if thisfeatureisprogrammed toOn,thepulsegenerator emits16beeping tones\\neverysixhoursafteritreachestheExplantindicator .Thetonecanthenbeprogrammed toOff.Evenwhenthis\\nfeatureisprogrammed toOff,itisautomatically reactivated whentheBatteryCapacity Depleted indicator is\\nreached.\\nCAUTION: Patients shouldbeadvised tocontacttheirphysician immediately iftheyheartonescomingfrom\\ntheirdevice.\\n•LastCapacitor Re-form—date andChargeTime.\\n•ManualRe-form Capacitor—this featureisusedtocommand acapacitor re-formation whenneeded.\\n•ChargeRemaining (measured inampere-hours)—the amount ofchargeremaining basedonthepulsegenerator's\\nprogrammed paramete rsuntilthebatteryisdepleted.\\n•PowerConsumption (measured inmicrowatts)—the average dailypowerbeingusedbythepulsegenerator,\\nbasedoncurrentlyprogrammed parameters. Powerconsumption isincluded inthecalculations thatdetermine\\nApproximate timetoexplantandtheneedleposition onthebatterystatusgauge.\\n•PowerConsumption Percentage—compar esthepowerconsumptionatthepulsegenerator'scurrently\\nprogrammed paramete rswiththepowerconsumption ofthestandardparameters usedtoquotedevice\\nlongevity .\\nIfanyofthefollowing paramete rs(whichaffectpacingoutput)arereprogrammed, thePowerConsumption and\\nPowerConsumption Percentagevaluesareadjusted accordingly:\\n•Amplitude\\n•PulseWidth\\n•BradyMode\\n•LRL\\n•MSR\\n•PaceSafe\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 154}), Document(page_content=\"5-6SystemDiagnostics\\nCapacitor Re-formation\\nFigure5–2.BatteryDetailsummary screen\\nCapacitor Re-formation\\nAutomatic Capacitor Re-form.Capacitor deformation mayoccurduringperiodswhennoshocksaredelivered,\\nresultinginlongerchargetimes.Toreducetheeffectofcapacitor deformation onChargeTime,thecapacitors are\\nautomatically re-formed. Toneswillnotbeemitted fromthepulsegeneratorduringautomatic capacitor re-formations\\n(eveniftheBeepDuringCapacitor Chargefeatureisprogrammed toOn).Duringacapacitor re-formation, theCharge\\nTimeismeasuredandstoredforlaterretrieval.\\nManualCapacitor Re-form. Manualcapacitor re-formsarenotnecessary,butmaybecommanded viathePRMas\\nfollows:\\n1.SelecttheManualRe-form Capacitor buttonontheBatteryDetailscreenandensurethattelemetr y\\ncommunication isestablished. Amessage willappearindicating thatthecapacitors arecharging. Warbling tones\\nfromthepulsegenerator(iftheBeepDuringCapacitor Chargefeatureisprogrammed toOn)willsoundwhilethe\\ncapacitors arecharging.\\n2.Theentirere-formcycletypically takeslessthan15seconds.Aftercompletion ofthecycle,thecapacitor energyis\\ndelivered tothepulsegenerator'sinternal testload.TheinitialChargeTimeisdisplayed ontheBatteryDetail\\nscreen.\\nChargeTimeMeasurement\\nThepulsegenerator measurestheChargeTimewhenever itscapacitors charge.Thelastmeasured valueisstoredin\\npulsegeneratormemory anddisplayed bythePRMsystemontheBatteryDetailscreen.\\nLastDelivered Ventricular Shock\\nWhenashockhasbeendeliveredtothepatient, thefollowing information fromthelastshockdeliveredisstoredin\\nthepulsegenerator'smemory anddisplayed ontheBatteryDetailscreen:\\n•Date\\n•Energylevel\\n•ChargeTime\\n•Shocking leadImpedanc e\\nThisdoesnotincludeautocapacitor re-forms orshocksthatmayhavebeendiverted. Ifafaultcondition is\\nencountered (i.e.,HighorLowImpedance ),thefaultwillbeindicated sothatcorrective actionmaybetaken.\\nNOTE:Forshocksof1.0Jorless,theaccuracyoftheimpedance measurem entdecreases.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 155}), Document(page_content='SystemDiagnostics\\nLeadsStatus5-7\\nLEADSSTATUS\\nDailyMeasurements\\nThedeviceperforms thefollowing measurements every21hoursandreportsthemdaily:\\n•DailyIntrinsic Amplitude measurement:thedevicewillautomatically attempt tomeasure theintrinsic P-andR-\\nwaveamplitudes foreachcardiacchamber inwhichtheDailyIntrinsic Amplitude measurementisenabled\\nregardless ofthepacingmode.Thismeasurementwillnotaffectnormalpacing.Thedevicewillmonitor upto\\n255cardiaccyclestofindasensedsignaltoobtainasuccessfulmeasurement.\\n•Dailylead(PaceImpedanc e)measurement:\\n–Pacelead(s)—the devicewillautomatically attempt tomeasurethepaceleadimpedance foreachchamber in\\nwhichtheDailyPaceImpedance testisenabled, regardless ofthepacingmode.ToconducttheLead\\nImpedance Testthedeviceutilizesasub-pacing thresholdsignalthatwillnotinterferewithnormalpacingor\\nsensing.\\n–TheHighImpedance Limitisnominally setto2000Ω,andisprogrammable in250Ωincrementsbetween\\n2000Ωand3000Ω.TheLowImpedanc eLimitisnominally setto200Ω,andisprogrammable between 200\\nand500Ωin50Ωincrements.\\nConsider thefollowing factorswhenchoosing avaluefortheImpedance Limits:\\n–Forchronicleads,historical impedance measurementsforthelead,aswellasotherelectrical\\nperformance indicators suchasstability overtime\\n–Fornewlyimplanted leads,thestarting measured impedance value\\nNOTE:Depending onleadmaturation effects,duringfollow-up testingthephysician maychooseto\\nreprogramtheImpedance Limits.\\n–Pacingdependence ofthepatient\\n–Recommended impedance rangeforthelead(s)beingused,ifavailable\\n•Dailylead(ShockImpedanc e)measurement:\\n–Shocklead—the devicewillautomatically attempt tomeasure theshockleadimpedance. Duringashock\\nLeadImpedanc eTest,thepulsegenerator delivers asubthresholdenergypulsethrough theshocking\\nelectrodes.Theseimpedance measurementsmayshowsomevariation overtime,sincetheyaretakenevery\\n21hoursand,thus,atdifferenttimesoftheday.\\n–TheShockLowImpedance Limitisfixedat20Ω.TheShockHighImpedance Limitisnominally setto125Ω,\\nandisprogrammable between 125and200Ωin25Ωincrements. Consider thefollowing factorswhen\\nchoosing avaluefortheHighImpedanc eLimit:\\n–Forchronicleads,historical impedance measurementsforthelead,aswellasotherelectrical\\nperformance indicators suchasstability overtime\\n–Fornewlyimplanted leads,thestarting measured impedance value\\nNOTE:Depending onleadmaturation effects,duringfollow-up testingthephysician maychooseto\\nreprogramtheHighImpedanc eLimit.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 156}), Document(page_content='5-8SystemDiagnostics\\nLeadsStatus\\n–Recommen dedimpedance rangeforthelead(s)beingused,ifavailable\\n–Theimpedance valueofahighormaximum energyShockImpedance test\\nNOTE:Whenacommanded ordailyshockLeadImpedanc eTestresultisabove125Ωandthe\\nprogrammed ShockHighImpedance Limitisgreaterthan125Ω,confirmpropersystemoperation by\\ndelivering ahigh-energ yshock.\\n–Thepulsegeneratorcontainsabeeperthatemitsaudibletonestocommun icatestatusinformation. The\\nbeeperincludes aprogrammable featurethat,whenprogrammed On,willcausethepulsegeneratorto\\nemittoneswhenDailyImpedance valuesareoutofrange.TheBeepWhenOut-of-Range indicator\\nconsistsof16tonesrepeated everysixhours.Whenthisfeatureisprogrammed Off,thereisnoaudible\\nindication ofoutofrangeDailyImpedance values.Referto\"Beeper Feature\" onpage6-18.\\n•PaceSafe dailythresholdmeasurements—when PaceSafe isprogrammed toAutoorDailyTrend,thedevicewill\\nautomatically attempt tomeasure thepacingthresholdinthechamber forwhichPaceSafe isprogrammed. To\\nconduct thetest,thedeviceadjuststhenecessary parameters tofacilitate thetest.\\nBasicleadstatusinformation isdisplayed ontheSummary screen.Detailed dataaredisplayed inagraphicalformat\\nontheLeadsStatussummary screen,whichcanbeaccessedbyselecting theleadsiconontheSummary screen\\n(Figure5–3LeadsStatussummary screenonpage5-9).\\nPossible leadsstatusmessages areasfollows(Table5–1Leadmeasurem entreporting onpage5-8):\\n•Leadmeasurementsarewithinrange.\\n•CheckLead(message willspecifywhichlead)—indicates dailyleadmeasurement(s) areoutofrange.To\\ndetermine whichmeasurementisoutofrange,evaluate thecorresponding lead\\'sdailymeasurementresults.\\nNOTE:Adetailed description ofPaceSafe–spec ificmessages including notification ofleadtestfailuresandlead\\nalertsisavailable (\"PaceSafe\" onpage4-8).\\nTable5–1.Leadmeasurement reporting\\nLeadMeasurement Reported Values Out-of-Range Limits\\nAPaceImpedance (Ω) 200to3000 Low:≤programmed AtrialLowImpedance Limit\\nHigh:≥programmed AtrialHighImpedance Limit\\nRVPaceImpedance (Ω) 200to3000 Low:≤programmed RightVentricular Low\\nImpedance Limit\\nHigh:≥programmed RightVentricular High\\nImpedance Limit\\nShockImpedance (Ω) 0to200 Low:≤20\\nHigh:≥programmed ShockHighImpedance Limit\\nP-Wave Amplitude (mV) 0.1to25.0 Low:≤0.5\\nHigh:none\\nR-Wave (RV)Amplitude (mV) 0.1to25.0 Low:≤3.0\\nHigh:none\\nTheLeadsStatussummar yscreenprovidesdailymeasurement detailsforapplicable leads(Figure5–3LeadsStatus\\nsummary screenonpage5-9):\\n•Thegraphshowsdailymeasurements fromthepast52weeks.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 157}), Document(page_content=\"SystemDiagnostics\\nLeadsStatus5-9\\n•Usethetabsacrossthetopofthescreentoviewdataforeachlead.SelecttheSetuptabtoenableordisable\\nspecificdailyleadmeasurementsortosettheImpedance Limitvalues.\\n•EachdatapointrepresentsthedailymeasurementorPOSTresultsforagivenday.Toviewspecificresultsfora\\nday,movethehorizontalslideroverthecorresponding datapointorgap.\\n•Anout-of-rangemeasurementwillplotapointatthecorresponding maximum orminimum value.\\n•Agapwillbegeneratedifthedeviceisunabletoobtainavalidmeasurementforthatday.\\n•Themostrecentdailymeasurements orPOSTresultsaredisplayed atthebottomofthescreen.\\n[1]Usetabstoselecttheappropriate lead[2]Resultsfortheselected day[3]Resultsformostrecentday[4]Y-axisadjustsbasedonmeasured results[5]Usehorizontal slidertoviewdatafora\\nspecificday\\nFigure5–3.LeadsStatussummaryscreen\\nIfthedeviceisunabletoobtainoneormoredailymeasurementsatthescheduled time,uptothreere-attempts will\\nbeperformed atone-hour intervals.Re-attempts donotchangethetimingofdailymeasurements. Thenextday's\\nmeasurementwillbescheduled 21hoursfromtheinitialattempt.\\nIfavalidmeasureisnotrecordedaftertheinitialattempt plusthreere-attempts, orisnotrecordedattheendofa\\n24-hour timeblock,themeasurement willbereported asInvalidDataorNodatacollected (N/R).\\nBecause eightmeasurementsarerecordedinsevendays,onedaywillcontaintwomeasurements:\\n•Ifoneofthemeasurements isvalidandoneinvalidforAmplitude andImpedance, theinvalidmeasurementwill\\nbereported. Ifbothmeasurements arevalid,themostrecentvaluewillbereported. ForThreshold,ifone\\nmeasurementisvalidandoneinvalid,thevalidmeasurement willbereported. Ifbothmeasurementsarevalid,\\nthehighestvaluewillbereported.\\nIftheSummar yscreenindicates thataleadshouldbecheckedandtheIntrinsic Amplitude andImpedance graphsdo\\nnotshowanyout-of-rangevaluesorgaps,thetestthatresulted intheout-of-rang evaluemeetsoneofthefollowing\\nconditions:\\n•Testoccurredwithinthecurrent24hoursandhasnotyetbeensavedwiththedailymeasurements\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 158}), Document(page_content='5-10SystemDiagnostics\\nLeadsStatus\\nTable5–2.IntrinsicAmplitude: DailyMeasurement Conditions, Programmer Display,andGraphical Representation\\nCondition Programmer Display Graphical Representation\\nIn-range amplitude measurement Measurementvalue Plottedpoint\\nElectrode configur ationisprogrammed toOff/None Nodatacollected Gap\\nAlleventsduringthetestperiodarepaced Paced Gap\\nNoisedetected duringthetestperiod Noise Gap\\nSensedeventsdefined asaPVC PVC Gap\\nSensedeventsdefined asaPAC PAC Gap\\nOut-of-range amplitude measurements (mV) 0.1,0.2,...,0.5(RAlead)withattention icon\\n0.1,0.2,...,3.0(ventricular lead)withattention iconPlottedpoint\\n<0.1withattention icon Plottedpointatcorresponding minimum\\n>25withattention icon Plottedpointatcorresponding maximuma\\na.Whenthevaluemeasured is>25mV,anattention symbolisdisplayed onthegrapheventhoughnoalertisgenerated onthesummary screens.\\nTable5–3.LeadImpedance: DailyMeasurement Conditions, Programmer Display,andGraphical Representation\\nCondition Programmer Display Graphical Representation\\nIn-range impedance measurement Measurementvalue Plottedpoint\\nElectrode Configuration isprogrammed Off/None InvalidData Gap\\nNoisedetected duringthetestperiod Noise Gap\\nOut-of-range impedance measurements (paceleads)\\n(Ω)MeasuredvaluegreaterthanorequaltothePace\\nHighImpedance Limitwithattention icon\\nMeasuredvaluelessthanorequaltothePaceLow\\nImpedance Limitwithattention iconPlottedpoint\\n>Maximum PaceHighImpedance Limitwith\\nattention icon\\n<Minimum PaceLowImpedance Limitwith\\nattention iconPlottedpointatcorresponding minimum or\\nmaximuma\\nOut-of-range impedance measurements (shocklead)\\n(Ω)Measuredvaluegreaterthanorequaltothe\\nprogrammed ShockHighImpedance Limit(125–200)\\nwithattention icon\\n0;attention icongenerated at≤20Plottedpoint\\n>200;attention icongenerated Plottedpointatcorresponding maximumb\\na.Selecting thesepointswillnotdisplaythenumerical value,butwillindicate thatthevalueisabovetheupperrangelimitorbelowthelowerrangelimit,asappropriate.\\nb.Selecting thesepointswillnotdisplaythenumerical value,butwillindicate thatthevalueisabovetheupperrangelimit.\\nTable5–4.PaceSafeAutomatic Threshold: DailyMeasurement Conditions, Programmer Display,andGraphical Representation\\nCondition Programmer Display Graphical Representation\\nIn-range threshold measurement Measurementvalue Plottedpoint\\nFeatureisnotenabled Nodatacollected Gap\\nTestfailuresoroutofrangemeasureme nts Various Gap\\nNOTE:Seeadetailed listoffailurecodesforPaceSafeThresholdtests(\"PaceSafe\" onpage4-8).', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 159}), Document(page_content='SystemDiagnostics\\nLeadsStatus5-11\\nUnderthefollowing conditions, Intrinsic Amplitude andLeadImpedance measurements willnotbeattempted. The\\nprogrammer displaywillindicate NodatacollectedorInvalidData,andtherewillbeagapinthegraphical\\nrepresentation:\\n•Tachyepisode isinprogress\\n•Tachytherapyisactive\\n•Telemetry isactive\\n•Post-Therapyparamete rsareineffect\\n•Devicebatterycapacity isdepleted\\n•LATITUDE interrogationisinprogress\\n•PulsegeneratorisinElectrocautery ProtectionMode\\n•PulsegeneratorisinMRIProtectionMode\\nSeeadetailed description ofcondition sunderwhichPaceSafe measurements willnotbeattempted (\"PaceSafe\" on\\npage4-8).\\nPOST-OPERATIVE SYSTEMTEST(POST)\\nThePOSTfeatureprovidesanautomatic device/leadcheckatapre-dete rminedtimeafterPOSTisinitiated. Thishelps\\ndocument propersystemfunctionality without requiring manualsystemtesting, whichhelpsfacilitate same-day\\ndischarge.Theusercanselecttheamount oftimeafterPOSTisinitiated whenautomatic leadtestresultsaredesired.\\nAnyadjustments tothenominal testresultstimemustbeprogrammed priortoinitiating POST.\\nPOSTisinitiated automatically uponexitingMRIProtectionModewithafixeddesiredresultstimeofonehour.\\nIfenabled, automatic Intrinsic Amplitude, Impedance, andPaceThreshold testingwillbeattempted onehourpriorto\\nthedesiredtestresultstime.Uponinterrogation,statusofthetesting(scheduled torun,in-progress,complete) will\\nbeprovided ontheSummary dialog,Summar yscreen,andPOSTscreenforthefirst48hoursafterPOSTwas\\ninitiated. Testresultsareavailable onthePOSTscreenandcanbeprintedonQuickNotesandFollow-Up Reports.\\nNOTE:Pacingparametersmaybetempora rilyadjusted tohelpensureavalidmeasurement isobtained.\\nIfthedeviceisunabletoobtainoneormorevalidmeasurementsontheinitialattempt, re-attempts willbe\\nperformed tohelpfacilitate ameasurement.Testingmaycomplete uptoonehourafterthetestresultstimeifre-\\nattempts arerequired.Ifavalidmeasurementisnotobtained, and/orifautomatic dailymeasurementsoccurpriorto\\nprinting thereport,thedailymeasurement resultmayberecorded(\"LeadsStatus\"onpage5-7).\\nOncetestingiscomplete,resultswillbedisplayed onthePOSTscreenforthefirst48hoursafterPOSTwasinitiated\\n(Figure5–4POSTScreenonpage5-12).Resultsaredisplayed similarly todailymeasurementsontheLeadsStatus\\nscreen(\"LeadsStatus\"onpage5-7).', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 160}), Document(page_content='5-12SystemDiagnostics\\nLeadTests\\nFigure5–4.POSTScreen\\nLEADTESTS\\nThefollowing leadtestsareavailable (Figure5–5LeadTestsscreenonpage5-12):\\n•PaceImpedance\\n•ShockImpedanc e\\n•Intrinsic Amplitude\\n•PaceThreshold\\nFigure5–5.LeadTestsscreen\\nLeadTestscanbeaccessedbyusingthefollowing steps:\\n1.Fromthemainscreen,selecttheTeststab.\\n2.FromtheTestsscreen,selecttheLeadTeststab.\\nAllleadtestsmaybeperformed following threedifferentprocesses:\\n•ViatheLeadTestsscreen––allows youtoperform thesameleadtestsacrossallchambers\\n•Byselecting thedesiredchamber button––allows youtoperform alltestsonthesamelead', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 161}), Document(page_content=\"SystemDiagnostics\\nLeadTests5-13\\n•Byselecting theRunAllTestsbutton––automatically performs Intrinsic Amplitude andLeadImpedance testsand\\nallowsyoutoperform PaceThresholdtests\\nIntrinsicAmplitude Test\\nTheIntrinsic Amplitude Testmeasurestheintrinsic P-andR-waveamplitudes fortherespective chambers.\\nAnIntrinsic Amplitude Testcanbeperformed fromtheLeadTestsscreenbycompleting thefollowing steps:\\n1.Youmaychangethefollowing preselectedvaluesasnecessarytoelicitintrinsic activityinthechamber(s) being\\ntested:\\n•Programmed NormalBradyMode\\n•LRLat30ppm\\n•AVDelayat300ms\\n2.SelecttheIntrinsic Amplitude button.Duringthetest,awindow willdisplaythetest'sprogress.Selecting and\\nholding theIntrinsic Amplitude Buttonwillcausemeasurementstoberepeatedforupto10seconds oruntilthe\\nbuttonisreleased.Whenthewindow closes,thesametestcanbeperformed againbyselecting theIntrinsic\\nAmplitude button.Tocancelthetest,selecttheCancelbuttonorpresstheDIVERTTHERAPY keyonthePRM.\\n3.Whenthetestiscomplete, theIntrinsic Amplitude measurementwillbedisplayed astheCurrentmeasurement\\n(notinparentheses). Ifthetestisrepeated duringthesamesession, theCurrentmeasurement willbeupdated\\nwiththenewresult.NotethatthePrevious Session measurement(displayed inparentheses) isfromthemost\\nrecentpastsessionduringwhichthistestwasperformed.\\nNOTE:Thetestresultsfromthelastmeasurementarestoredinpulsegeneratormemory ,retrieved duringthe\\ninitialinterrogation, anddisplayed ontheLeadTestsscreen.Themeasurements arealsoprovidedontheQuickNotes\\nreport.\\nLeadImpedanc eTest\\nALeadImpedanc eTestcanbeperformed andusedasarelativemeasureofleadintegrity overtime.\\nIftheleadintegrity isinquestion, standardleadtroubleshooting testsshouldbeusedtoassesstheleadsystem\\nintegrity .\\nTroubleshooting testsinclude, butarenotlimitedto,thefollowing:\\n•Electrogramanalysis withpocketmanipulation and/orisometrics\\n•X-rayorfluoroscopicimagereview\\n•Additional maximum-energy shocks\\n•Programming theShockLeadVector\\n•WirelessECG\\n•Invasive visualinspection\\nAShockImpedanc etestisausefultoolindetecting shocking leadintegrity changes overtime.Evaluating this\\ninformation together withtheLastDelivered ShockImpedance (displayed ontheBatteryDetailscreen)ora\\nsubsequent high-energ yShockImpedance andothernon-invasive diagnostic techniques mayhelptroubleshoot\\npotential leadsystemconditions.\\nAtestresultofNOISEisreported ifavalidmeasurementcouldnotbeobtained (likelyduetoEMI).\\nShorted andopenshockleadfailureswillbereported as0Ωand>200Ω,respectively .\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 162}), Document(page_content='5-14 SystemDiagnostics\\nLeadTests\\nNOTE:TheShockImpedanc etestmayresultinslightlyhighervaluesthandeliveredShockImpedance\\nmeasurements.\\nBothlow-ener gyandhigh-energ yimpedance testshavethefollowing clinicallimitations:\\n•Ahigh-ormaximum-energy shocktestdoesnotexposeallformsofopenleadcondition s.Shockleadimpedance\\nmeasuredduringacommanded maximum-energy shockmayappearnormalwhencertaintypesofopenlead\\ncondition sexist(e.g.,leadconductorfractureoraloosesetscrew), astheenergydeliveredcouldjumporarc\\nacrosssmallgaps.Acommanded low-ener gyimpedance testisamorerobusttoolforidentifying andverifying a\\npotential openshocking leadcondition.\\n•Alow-ener gyLeadImpedanc eTestdoesnotexposeallformsofshorted leadconditions. Alow-energy\\nimpedance testmayappearnormalwhencertaintypesofshorted leadconditions exist(e.g.,abradedleadbody\\ninsulation orleadcrushed between clavicleandfirstrib),astestenergyisinsufficient tojumporarcacrosssmall\\ngapsbetween exposedconductors. Amaximum-energy shockisamorerobusttoolforidentifying andverifying a\\npotential shorted shocking leadcondition.\\nPaceandShockleadimpedance testscanbeperformed fromtheLeadTestsscreenbycompleting thefollowing\\nsteps:\\n1.Selectthedesiredleadimpedance testbutton.Selecting andholding abuttonwillcausemeasurementstobe\\nrepeated forupto10secondsoruntilthebuttonisreleased.\\n2.Duringthetest,awindow willdisplaythetestprogress.Whenthewindow closes,thesametestcanbe\\nperformed byonceagainselecting thedesiredleadimpedance testbutton.Tocancelthetest,selecttheCancel\\nbuttonorpresstheDIVERTTHERAPY keyonthePRM.\\n3.Whenthetestiscomplete ,theimpedance measurement willbedisplayed astheCurrentmeasurement(notin\\nparentheses). Ifthetestisrepeated duringthesamesession, theCurrentmeasurementwillbeupdated withthe\\nnewresult.NotethatthePrevious Session measurement(displayed inparentheses) isfromthemostrecentpast\\nsessionduringwhichthistestwasperformed.\\n4.SelecttheIndividual VectorBreakdownbuttontoviewadditional outofrangeShockImpedanc etestinformation.\\nThePreviousandCurrentSession resultsforindividual shockvectorswillbeprovided.\\n5.IfthetestresultsinNOISE,considerthefollowing mitigation options:\\n•Repeatthetest\\n•Switchtelemetr ymodes\\n•Remove othersourcesofelectromagnetic interference\\nNOTE:Thetestresultsfromthelastmeasurement arestoredinpulsegeneratormemory ,retrieved duringthe\\ninitialinterrogation,anddisplayed ontheLeadTestsscreen.Themeasurementsarealsoprovided ontheQuickNotes\\nreport.\\nPaceThreshold Test\\nThePaceThreshold Testdetermines theminimum outputneeded forcaptureinaspecificchamber .\\nTheventricular andatrialpaceamplitude thresholdtestscanbeperformed manually orautomatically .WhenPaceSafe\\nisprogrammed toAuto,theresultsofthecommanded automatic amplitude testsmaybeusedtoadjustthePaceSafe\\noutputlevels.\\nVentricular andatrialpulsewidththresholdtestsareperformed manually byselecting thePulseWidthoptiononthe\\nPaceThresholddetailsscreen.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 163}), Document(page_content='SystemDiagnostics\\nLeadTests5-15\\nManualPaceThreshold Test\\nAminimum 2Xvoltagecapturethresholdor3Xpulsewidthcapturethresholdforeachchamber isrecommended to\\nprovideanadequate safetymarginandhelppreservebatterylongevity .Thestarting parametervaluesare\\nautomatically calculated priortotesting. Thetestbeginsataspecified starting valueandstepsthatvaluedown\\n(Amplitude orPulseWidth)asthetestprogresses.ThePRMbeepswitheachdecrement.Thevaluesusedduringthe\\nthresholdtestareprogrammable. Theparametersareonlyineffectduringthetest.\\nNOTE:IfDDDmodeischosen, selecting eithertheatrialorventricular testwillcausethepacingoutputtodecrease\\nonlyinthechamber selected.\\nOncethetestisstarted, thedeviceoperateswiththespecified bradyparameters. Usingtheprogrammed number of\\ncyclesperstep,thedevicethendecrements (stepsdown)theselected testtypeparameter(Amplitude orPulseWidth)\\nuntilthetestiscomplete. Real-time electrogramsandannotated eventmarkers, whichincludethevaluesbeing\\ntested,continuetobeavailable duringthresholdtesting. Thedisplaywillautomatically adjusttoreflectthechamber\\nbeingtested.\\nDuringthethresholdtest,theprogrammerdisplays thetestparamet ersinawindow whilethetestisinprogress.To\\npausethetestorperform amanualadjustment, selecttheHoldbuttononthewindow.Selectthe+or−buttonto\\nmanually increaseordecreasethevaluebeingtested.Tocontinue thetest,selecttheContinue button.\\nThethresholdtestiscomplete andallparamet ersarereturnedtothenormalprogrammed valueswhenanyofthe\\nfollowing occur:\\n•Thetestisterminated viaacomman dfromthePRM(e.g.,pressingtheEndTestbuttonorDIVERTTHERAPY key).\\n•Thelowestavailable settingforAmplitude orPulseWidthisreached andtheprogrammed number ofcycleshas\\ncompleted.\\n•Telemetry communication isinterrupted.\\nApacethresholdtestcanbeperformed fromtheLeadTestsscreenusingthefollowing steps:\\n1.Selectthedesiredchamber tobetested.\\n2.SelectthePaceThresholddetailsbutton.\\n3.Selectthetesttype.\\n4.Changethefollowing parametervaluesasdesiredtoelicitpacinginthechamber(s) beingtested:\\n•Mode\\n•LRL\\n•PacedAVDelay\\n•Amplitude\\n•PulseWidth\\n•CyclesperStep\\nForDDDmode,theNormalBradyMTRisused.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 164}), Document(page_content='5-16SystemDiagnostics\\nLeadTests\\n5.WatchtheECGdisplayandstopthetestbyselecting theEndTestbuttonorpressing theDIVERTTHERAPY key\\nwhenlossofcaptureisobserved.Ifthetestcontinuesuntiltheprogrammed number ofcyclesatthelowest\\nsettinghaveoccurred,thetestisautomatically terminated. Thefinalthresholdtestvaluewillbedisplayed (the\\nvalueisonestepabovethevaluewhenthetestwasterminated). A10secondtrace(priortolossofcapture) is\\nautomatically storedandcanbedisplayed andanalyzed byselecting theSnapshot tab(\"Snapshot\" onpage6-8).\\nNOTE:Thethresholdtestresultcanbeeditedbyselecting theEditToday\\'s TestbuttonontheThresholdTest\\nscreen.\\n6.Whenthetestiscomplete ,thethresholdmeasurement willbedisplayed astheCurrentmeasurement(notin\\nparentheses). Ifthetestisrepeated duringthesamesession, theCurrentmeasurementwillbeupdated withthe\\nnewresult.NotethatthePrevious Session measurement(displayed inparentheses) isfromthemostrecentpast\\nsessionduringwhichthistestwasperformed.\\n7.Toperform another test,makechanges tothetestparamet ervaluesifdesired, thenbeginagain.Resultsofthe\\nnewtestwillbedisplayed.\\nNOTE:Thetestresultsfromthemostrecentmeasurementarestoredinpulsegeneratormemory ,retrieved during\\ninitialinterrogation,anddisplayed ontheLeadTestsscreenandontheLeadsStatusscreen.Themeasurementsare\\nalsoprovidedontheQuickNotesreport.\\nCommanded Automatic PaceThreshold Test\\nCommanded automatic thresholdtestsdifferfromthemanualtestsinthefollowing ways:\\n•Commanded automatic thresholdtestsareavailable forAmplitude, butnotPulseWidth.\\n•Thefollowing parameters arefixed(vs.programmable inmanualtests):\\n–PacedAVDelay\\n–PulseWidth\\n–Cyclesperstep\\nNOTE:Changetheprogrammable paramet ersasdesiredtoelicitpacinginthechamber beingtested.\\n•Additional eventmarkersareavailable including lossofcapture, fusion,andbackuppacing(wherebackuppacing\\nisavailable).\\n•Oncestarted, acommanded automatic threshold testcannotbepaused, onlycancelled.\\n•PaceSafe automatically determines whenthetestiscompleted andautomatically stopsthetest.\\n•Whencomplete, thetestautomatically stopsanddisplays thethreshold, whichisthelastoutputlevelthat\\ndemonstrated consistent capture. A10secondtrace(priortolossofcapture) isautomatically storedandcanbe\\ndisplayed andanalyzed byselecting theSnapshot tab(\"Snapshot\" onpage6-8).\\n•Testresultscannotbeedited.\\nNOTE:Nobackupatrialpacingisprovidedduringacommanded automatic rightatrialthresholdtest.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 165}), Document(page_content='6-1\\nPATIENTDIAGNOSTICS ANDFOLLOWUP\\nCHAPTER 6\\nThischaptercontainsthefollowing topics:\\n•“TherapyHistory” onpage6-2\\n•“Arrhythmia Logbook” onpage6-2\\n•“Snapshot” onpage6-8\\n•“Histogra ms”onpage6-9\\n•“Counters” onpage6-9\\n•“HeartRateVariability (HRV)”onpage6-10\\n•“Trends”onpage6-13\\n•“PostImplant features” onpage6-17', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 166}), Document(page_content='6-2PatientDiagnostics andFollowUp\\nTherapyHistory\\nTHERAPY HISTORY\\nThepulsegenerator automatically recordsdatathatcanbehelpfulwhenevaluating thepatient\\'s condition andthe\\neffectiveness ofpulsegeneratorprogramming.\\nTherapyhistorydatacanbereviewed atvariouslevelsofdetailusingthePRM:\\n•Arrhythmia Logbook—provides detailed information foreachdetected episode (\"Arrhythmia Logbook\" onpage6-\\n2)\\n•Histograms andCounters—displays thetotalnumber andpercentageofpacedandsensedeventsduringa\\nparticular recordingperiod(\"Histograms\" onpage6-9and\"Counters\" onpage6-9)\\n•HeartRateVariability (HRV)—measur eschanges inthepatient\\'s intrinsic heartratewithina24-hour collection\\nperiod(\"HeartRateVariability\" onpage6-10)\\n•Trends—pr ovidesagraphical viewofspecificpatient, pulsegenerator,andleaddata(\"Trends\"onpage6-13)\\nNOTE:TheSummary dialogandSummary tabdisplayaprioritize dlistofeventsthathaveoccurredsincethelast\\nreset.ThislistwillonlyincludeVF,andVT/VT-1 andATR(ifitlastedmorethan48hours)episodes, andMRI\\nProtectionModeevents.\\nARRHYTHMIA LOGBOOK\\nTheArrhythmia Logbook provides accesstothefollowing detailed information aboutepisodes ofalltypes(Figure6–1\\nArrhythmia Logbook screenonpage6-3):\\n•Thenumber,date,andtimeoftheevent\\n•Thetypeofeventwithtachyarrhythmia zone\\n•Asummary oftherapydeliveredorattempted (ifapplicable)\\n•Duration oftheevent(whenapplicable)\\n•Electrogr amswithannotated markers\\n•Intervals\\nNOTE:Thedataincludeinformation fromallactiveelectrodes.Thedevicecompressesthehistorydatatostorea\\nmaximum of17minutes ofelectrogramdata(13minutes withPatientTriggered Monitor enabled). However ,the\\namount oftimeactually storedmayvarybasedonthedatabeingcompressed (e.g.,noiseontheEGMoranepisode\\nofVF).', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 167}), Document(page_content='PatientDiagnostics andFollowUp\\nArrhythmia Logbook6-3\\nFigure6–1.Arrhythmia Logbook screen\\nThepriority,maximum number,andminimum number ofepisodes thatthepulsegeneratorstoresundernormal\\nconditions variesbyepisode type(Table6–1Episode Priorityonpage6-4).Aslongasdevicememory allocated for\\nepisode dataisnotfull,thepulsegeneratorstoresuptothemaximum number ofepisodes allowed foreachepisode\\ntype.Theminimum number ofepisodes foreachepisode typeensures thatallepisode typesarerepresented by\\nprotecting afewlowpriorityepisodes frombeingoverwrittenbyhighpriorityepisodes whendevicememory isfull.\\nOncedevicememory isfull,thepulsegeneratorattempts toprioritizeandoverwrite storedepisodes accordingtothe\\nfollowing rules:\\n1.Ifdevicememory isfull,andthereareepisodes olderthan18months, thentheoldestofthelowestpriority\\nepisodes fromtheseepisode typeswillbedeleted (regardless iftheminimum number ofepisodes arestored).\\n2.Ifdevicememory isfull,andthereareepisode typesthathavemorethantheminimum number ofepisodes\\nstored,thentheoldestofthelowestpriorityepisodes fromtheseepisode typeswillbedeleted. Inthiscase,the\\nlowpriorityepisodes arenotdeleted iftheirnumber ofstoredepisodes islessthantheminimum number.\\n3.Ifdevicememory isfull,andtherearenoepisode typesthathavemorethantheminimum number ofepisodes\\nstored,thentheoldestofthelowestpriorityepisodes ofallepisode typeswillbedeleted.\\n4.Ifthemaximum number ofepisodes hasbeenreached withinanepisode type,theoldestepisode ofthattype\\nwillbedeleted.\\n•Fornon-commanded episodes, theepisode typeforVT-1,VT,andVFepisodes isdetermined accordingtothe\\nzoneDuration thatexpiresfirst.IfnozoneDuration expiresduringanepisode, theepisode typeisNonsustained.\\n•Anepisode inprogresshasthehighestpriorityuntilitstypecanbedetermined.\\nNOTE:Oncehistorydataissaved,itcanbeaccessedatanytimewithout deviceinterrogation.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 168}), Document(page_content='6-4PatientDiagnostics andFollowUp\\nArrhythmia Logbook\\nTable6–1.EpisodePriority\\nEpisodeType Priority Maximum numberof\\nstoredepisodesMinimum numberof\\nstoredepisodes with\\ndetailedreportsMaximum numberof\\nstoredepisodes with\\ndetailedreports\\nVF/VT/VT-1 withshocka 1 50 5 30\\nPTM(Patient Triggered\\nMonitor)1 5 1 1\\nVF/VT/VT-1 withATPb2 30 2 15\\nVF/VT/VT-1 withno\\ntherapy(Duration Met)c3 20 1 10\\nCmdV 4 2 0 2\\nNonSustV (Durationnot\\nmet)4 10 0 2\\nRAAutod4 1 1 1\\nRVAuto 4 1 1 1\\nATRd4 10 1 3\\nPMTd4 5 1 3\\nAPMRTe4 1 1 1\\nRYTHMIQd4 10 1 3\\na.MayalsoincludeATPtherapy.\\nb.ATPwithout shocktherapy\\nc.Notherapy defined asDurationMetwith:anInhibitdecision, detection intheMonitor Onlyzone,thelastsensedintervalnotinthezone,oraDivert-Reconfirm.\\nd.Notavailable inVRmodels.\\ne.Advanced PatientManagement realtime(APMRT)eventsarepresenting EGMs,captured andstoredonthepulsegenerator duringLATITUDE Communicator follow-\\nups.\\nTodisplayArrhythmia Logbook data,usethefollowing steps:\\n1.FromtheEventstab,selectArrhythmia Logbook. Ifnecessary,thepulsegeneratorwillbeautomatically\\ninterrogated andcurrentdatawillbedisplayed. Savedpatientdataalsocanbedisplayed (\"DataStorage\"on\\npage1-16).\\n2.Whileretrieving thedata,theprogrammer willdisplayawindow indicating theprogressoftheinterrogation. No\\ninformation willbedisplayed ifyouselecttheCancelbuttonbeforeallofthestoreddataareretrieved.\\n3.UsethesliderandViewbuttontocontroltherangeofdatesfortheeventsyouwanttodisplayinthetable.\\n4.SelecttheDetailsbuttonofaneventinthetabletodisplaytheeventdetails.Eventdetails,available ifthe\\ndetailsbuttonispresent,areusefulinevaluating eachepisode. TheStoredEventscreenwillappear,andyoucan\\nbrowsebetween thefollowing tabsformoreinformation abouttheevent:\\n•EventsSummar y\\n•EGM\\n•Intervals\\n5.Selectacolumnheaderbuttontosorttheeventsbythatcolumn. Toreversetheorder,selectthecolumnheader\\nagain.\\n6.Tosavespecificevents,selecttheeventandchoosetheSavebutton.Toprintspecificevents,selecttheevent\\nandchooseReports fromthetoolbar.ChoosetheSelected Episodes reportandselectthePrintbutton.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 169}), Document(page_content='PatientDiagnostics andFollowUp\\nArrhythmia Logbook6-5\\nNOTE:An“in-progress”episode willnotbesaved;anepisode mustbecomplete beforeitwillbesavedbythe\\napplication.\\nToviewepisode details,selecttheDetailsbuttonnexttothedesiredepisode ontheArrhythmia Logbook screen.The\\nStoredEventscreenwillappear,andyoucanbrowsebetween theSummary, EGM,andIntervals tabs.\\nEventsSummary\\nTheEventsSummary screendisplays additional detailsabouttheselected episode corresponding totheArrhythmia\\nLogbook.\\nThesummary datamayincludethefollowing:\\n•Episode number,date,time,type(e.g.,VF,VT,VT-1,spontaneous/Induce d,orPTM)\\n•Averageatrialandventricular rates\\n•Typeoftherapydelivered\\n•ForATPtherapy,thetimeoftherapydelivery andthenumber ofbursts\\n•Forshocktherapy,thestarttimeofcharging, chargetime,impedance, andenergylevel\\n•Duration\\n•AtrialrateatPMTstart(PMTeventsonly)\\nStoredElectrogramswithAnnotated Markers\\nThepulsegeneratorcanstoreannotated electrogr amssensedfromthefollowing leadspriortotheonsetofan\\nepisode, aroundduration met,andaroundtherapystartandend:\\n•Shocklead\\n•RVpace/senselead\\n•Atrialpace/sense lead\\n•PaceSafeEvokedResponse (ER)(PaceSafe episodes only)\\nTheparticular annotated electrogr amsstoreddepend upontheepisode type.Inthissection, EGMreferstoboth\\nelectrogramsandtheassociated annotated markers.TheEGMstoragecapacity variesdepending onEGMsignal\\ncondition andheartrate.Thetotalamount ofstoredEGMdataassociated withanepisode maybelimited; EGMsfrom\\nthemiddleoftheepisode mayberemoved forepisodes greaterthan4minutes induration.\\nWhenthememory allocated toEGMstorageisfull,thedeviceoverwritesolderEGMdatasegments inordertostore\\nthenewEGMdata.TheEGMisrecordedinsegments consisting ofepisode Onset,Attempt, andEndEGMStorage.\\nEachsegment ofdataisvisiblewhentheleftcaliperisinthespecificsection.\\nThefollowing information isretained:\\n•Onsetretainsupto25seconds ofdatapriortoDuration expiring\\n•Reconfirmation retainsupto20secondsofdatapriortotherapydelivery\\n•Therapydataisdisplayed. InthecaseofATPtherapy,upto20secondsofatleastthefirstandlastburstforeach\\nscheme willberetained', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 170}), Document(page_content='6-6PatientDiagnostics andFollowUp\\nArrhythmia Logbook\\n•Post-therapy ordiverted therapyretainsupto10secondsofdata\\nEpisode Onsetreferstotheperiodoftime(measured inseconds)ofEGMpriortothefirstattempt.\\nOnsetincludes thefollowing information:\\n•Typeofevent\\n•Average RARateatthestartofEvent\\n•Average RVRateatthestartofEvent\\n•Programming ofDetection Enhance ments(RateOnly,Rhythm ID,orOnset/Stability)\\n•Acquisition timestamp ofRhythm IDreferencetemplate\\n•RhythmMatch Threshold (asprogrammed) (RESONATE HF,RESONATE, PERCIVA HF,PERCIVA, andMOMENTUM\\ndevices)\\n•Measure dRhythmMatch value(ifareferencetemplate hasbeenacquired,theeventhasnoattempts, andthe\\npulsegeneratorinhibited therapy)(RESONATE HF,RESONATE, PERCIVA HF,PERCIVA, andMOMENTUM devices)\\nAttempt information maybedisplayed asAttempt orInProgress,ifanattempt isinprogress.Attempt includes the\\nfollowing information:\\n•Detection information:\\n–Average RARateatstartofAttempt\\n–Average RVRateatstartofAttempt\\n–RateZone\\n•Measure dValuesofDetection Enhancements\\n•TherapyAttempt Information:\\n–Attempt Number\\n–Type(aborted, commanded, orinhibited)\\n–Number ofbursts(ATPattempt)\\n–ChargeTime(shockattempt)\\n–Leadimpedance (shockattempt)\\n–LeadPolarity (shockattempt)\\n–Shockfaults(shockattempt)\\n–ReasonforNoTherapy\\nTheEndEGMStoragestartsfollowing therapydelivery andstoresupto10seconds ofEGM.Thefollowing figure\\nshowstherelationship between theventricular tachyepisode EGMstorageandsurfaceECGstripchartrecording\\n(Figure6–2Relationship between ventricular tachyepisode EGMstorageandsurfaceECGstripchartrecordingon\\npage6-7).', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 171}), Document(page_content='PatientDiagnostics andFollowUp\\nArrhythmia Logbook6-7\\nDuration expires Charging begins Start End-of -\\nEpisode timer\\nEnd-of-Episode \\ntimes out. \\nEpisode is over . \\n5 s 10 s 10 s\\n10 s \\n10 s 10 s 10 s 10 s \\nNote: Charging may begin \\nwhen duration expires. Shock \\n10 s\\n5 s\\nDetection window\\nsatisfied 8 of 10\\nfast beats\\nFigure6–2.Relationship between ventricular tachyepisodeEGMstorageandsurfaceECGstripchartrecording\\nNOTE:Referto\"UseofAtrialInformation\" onpage2-5foradditional information aboutdeviceperformanc ewhen\\ntheatrialleadisprogrammed toOff.\\nToviewtheEGMdata,selecttheDetailsbuttonofthedesiredepisode ontheArrhythmia Logbook screen.\\nUsethefollowing stepstoviewspecificdetailsabouteachepisode:\\n1.SelecttheEGMtab.\\n•EGMstripsfortheappropriatesourcesaredisplayed. Eachstripincludes theEGMssensedduringthe\\nepisode withthecorresponding annotated markers.Blueverticalbarsindicate thesegment (Onset,Attempt,\\nEnd)boundaries.\\nNOTE:Formarkerdefinitions, selecttheReports buttononthePRMandviewtheMarkerLegendReport.\\n•Usethesliderundertheupperdisplaywindow toviewdifferentsections ofthestoredEGM.\\n•AdjustthetraceSpeedasneeded (10,25,50,100mm/s).AstheSpeedisincreased,thetime/horiz ontal\\nscaleisexpanded.\\nNOTE:Adjusting thetraceSpeedisforon-screen viewing only;theprintspeedofastoredEGMissetto25\\nmm/s.\\n•Usetheelectroniccaliper(sliderbar)tomeasurethedistance/timebetween signalsaswellasmeasurethe\\namplitude ofsignals.\\n–Thedistance between signalscanbemeasuredbymoving eachcalipertothedesiredpointsonthe\\nEGM.Thetime(inmilliseconds orseconds)between thetwocalipers willbedisplayed.\\n–Theamplitude ofthesignalcanbemeasuredbymoving theleft-handcaliperoverthepeakofthe\\ndesiredsignal.Thevalue(inmillivolts) ofthesignalwillbedisplayed ontheleftsideoftheEGM.The\\nsignalismeasuredfrombaseline topeak,eitherpositive ornegative. AdjustthetraceSpeedand/or\\namplitude scaleasneeded tohelpfacilitate anamplitude measurement.\\n•Adjusttheamplitude/vertical scaleasneeded (0.2,0.5,1,2,5,10,20mm/mV) foreachchannel usingthe\\nup/down arrowbuttons locatedontherightsideofthetracedisplay.Asthegainisincreased,theamplitude\\nofthesignalisenlarged.\\n2.SelectthePrevious EventorNextEventbuttontodisplayadifferenteventstrip.\\n3.Toprinttheentireepisode report,selectthePrintEventbutton.Tosavetheentireepisode report,selectthe\\nSavebutton.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 172}), Document(page_content='6-8PatientDiagnostics andFollowUp\\nArrhythmia Logbook\\nIntervals\\nThepulsegenerator storeseventmarkers andassociated timestamps. ThePRMderiveseventintervals fromthe\\neventmarkersandtimestamps.\\nToviewtheepisode intervals,usethefollowing steps:\\n1.FromtheStoredEventscreen,selecttheIntervals tab.Ifalloftheepisode dataisnotvisibleinthewindow,use\\nthescrollbartoviewmoredata.\\n2.SelectthePreviousEventortheNextEventbuttontodisplayapreviousormorecurrentepisode, oneepisode at\\natime.\\n3.SelectthePrintEventbuttontoprinttheentireepisode report.\\n4.SelecttheSavebuttontosavetheentireepisode report.\\nSNAPSHO T\\nA12-secondtraceoftheECG/EGM displaycanbestoredatanytimebypressingtheSnapshot buttonfromany\\nscreen.Atraceisalsoautomatically storedfollowing aPaceThresholdTest.Afteratracehasbeenstored,itcanbe\\ndisplayed andanalyzed byselecting theSnapshot tab.\\nThetraceswhicharecurrentlyselected ontheECG/EGM displayaswellasannotated markers willbecaptured forup\\nto10secondsbeforeandupto2secondsaftertheSnapshot buttonwasselected. IfaSnapshot wasautomatically\\nstoredduringaPaceThreshold Test,itwillbe10secondslong,endingwiththetermination ofthetest.\\nNOTE:TheSnapshot lengthwillbereducedifthetracesontheECG/EGM displayarechanged orthesession\\nstartedwithin10secondsofpressing theSnapshot button.\\nUpto6time-stamped Snapshots willbestoredintheProgrammer memory forthecurrentsessiononly.Oncethe\\nsessionhasbeenterminated byexitingtheapplication softwareorbyinterrogatinganewpatient, thedatawillbe\\nlost.Ifmorethan6Snapshots arestoredinoneProgrammer session, theoldestwillbeoverwritten.\\nUsethefollowing stepstoviewastoredSnapshot:\\n1.FromtheEventstab,selecttheSnapshot tab.\\n2.SelectthePreviousSnapshot orNextSnapshot buttontodisplayadifferenttrace.\\n3.Usethesliderundertheupperdisplaywindow toviewdifferentsections ofthestoredSnapshot.\\n4.AdjusttheSpeedasneeded (10,25,50,100mm/s).AstheSpeedisincreased, thetime/horizontal scaleis\\nexpanded.\\n5.Usetheelectroniccaliper(sliderbar)tomeasurethedistance /timebetween, signalsaswellasmeasure the\\namplitude ofsignals.\\n•Thedistance between signalscanbemeasured bymoving eachcalipertothedesiredpointsonthe\\nSnapshot. Thetime(inmilliseco ndsorseconds)between thetwocalipers willbedisplayed.\\n•Theamplitude ofthesignalcanbemeasuredbymoving theleft-handcaliperoverthepeakofthedesired\\nsignal.Thevalue(inmillivolts) ofthesignalwillbedisplayed ontheleftsideoftheSnapshot. Thesignalis\\nmeasured frombaseline topeak,eitherpositive ornegative. AdjusttheSpeedand/oramplitude scaleas\\nneeded tohelpfacilitate anamplitude measurement.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 173}), Document(page_content=\"PatientDiagnostics andFollowUp\\nCounters6-9\\n6.Adjusttheamplitude/vertical scaleasneeded (0.2,0.5,1,2,5,10,20mm/mV) foreachchannel usingtheup/\\ndownarrowbuttons locatedontherightsideofthetracedisplay.Asthegainisincreased,theamplitude ofthe\\nsignalisenlarged.\\n7.ToprinttheSnapshot thatiscurrentlybeingviewed, selectthePrintbutton.TosavetheSnapshot thatis\\ncurrentlybeingviewed, selecttheSavebutton.SelectSaveAllSnapshots tosaveallstoredSnapshot traces.\\nHISTOGRAMS\\nTheHistograms featureretrieves information fromthepulsegeneratoranddisplays thetotalnumber andpercentage\\nofpacedandsensedeventsforthechamber .\\nHistogramsdatacanprovide thefollowing clinicalinformation:\\n•Thedistribution ofthepatient's heartrates\\n•Howtheratioofpacedtosensedbeatsvariesbyrate\\n•Howtheventricle responds topacedandsensedatrialbeatsacrossrates\\nUsethefollowing stepstoaccesstheHistograms screen:\\n1.FromtheEventsscreen,selectthePatientDiagnostics tab.\\n2.Theinitialdisplayshowsthepacedandsenseddatasincethelasttimethecounterswerereset.\\n3.SelecttheDetailsbuttontodisplaythedatatypeandtimeperiod.\\n4.SelecttheRateCountsbuttonontheDetailsscreentoviewratecountsbychamber .ForRESONATE HF,\\nRESONATE, PERCIVA HF,PERCIVA, andMOMENTUM devices,thiscanbeusedtoviewRVratecountsduringAT/\\nAFevents.\\nAllHistograms canberesetbyselecting theResetbuttonfromanyPatientDiagnostics Detailsscreen.Histogram data\\ncanbesavedtothePRMandprintedviatheReports tab.\\nCOUNTERS\\nThefollowing countersarerecordedbythepulsegenerator anddisplayed onthePatientDiagnostics screen:\\n•Ventricular Tachy\\n•Brady\\nVentricular TachyCounters\\nInformation aboutVentricular TachyCounters isavailable byselecting theVentricular TachyCounters Detailsbutton.\\nThisscreendisplays Ventricular Episode, Ventricular Therapy,andClinicalcounters. Foreachcounter,thenumber of\\neventssincelastresetanddevicetotalsaredisplayed. Ventricular TachyEpisode counterscontainsthefollowing data:\\n•TotalEpisodes\\n•Treated––VF, VT,VT-1,andCommanded\\n•Non-Treated––No TherapyProgrammed, Nonsustained, andOtherUntreated Episodes\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 174}), Document(page_content=\"6-10PatientDiagnostics andFollowUp\\nCounters\\nVentricular TachyTherapycountersconsistofventricular shockandATPtherapyattempts. Theycanprovideuseful\\ndataabouttheeffectiveness ofapatient's therapy prescription. Thesecounters includethefollowing information:\\n•ATPDelivered\\n•ATP%Successful––the percentoftimethatthearrhythmia isconverted andtheepisode endswithout delivery of\\naprogrammed shock\\n•ShocksDelivered\\n•FirstShock%Successful––the percentoftimethatthearrhythmia isconvertedandtheepisode endswithout\\nrequiringasecondprogrammed shock\\n•ShocksDiverted\\nTheventricular ATPcounter isincremented atthestartofthedelivery ofthefirstburstofanATPscheme. Subsequent\\nATPburstsinthesamescheme arenotcountedindividually duringthesameepisode. AnATPscheme iscountedas\\ndiverted onlyifitisdiverted priortodelivery ofthefirstburst.\\nTheMRICounters withintheClinicalCounters sectiondisplays thenumber oftimesthedevicewasprogrammed into\\nMRIProtection Mode,regardless ifanMRIscanwasperformed (available onlyinMRConditional devices).\\nBradyCounters\\nInformation aboutBradyCounters isdisplayed byselecting theBradyCounters Detailsbutton.Thisscreendisplays\\ntheBradyepisode counters. Foreachcounter,thenumber ofeventssincelastresetandresetbeforelastare\\ndisplayed. BradyCounters containsthefollowing details:\\n•Percentofatrialpaced\\n•PercentofRVpaced\\n•Intrinsic Promotion––includes RateHysteresis%SuccessfulandAVSearch+%Successful\\n•AtrialArrhythmia––includes percentageoftimeinAT/AF,TotalTimeinAT/AF(min,hr,ordays),Episodes by\\nDuration andTotalPACs.Inaddition, forRESONATE HF,RESONATE, PERCIVA HF,PERCIVA, andMOMENTUM\\ndevices, whenatleastoneATReventhasbeenstoredsincethelastreset,datafortheLongest AT/AFandFastest\\nVSRateinAT/AFispresentedontheSummary screenandonprintedreports.\\nNOTE:AT/AF%andTotalTimeinAT/AFrecordsanddisplays dataforamaximum ofoneyear.\\n•Ventricular Counters––includes TotalPVCsandThreeorMorePVCs\\nAllCounters canberesetbyselecting theResetbuttonfromanyPatientDiagnostics Detailsscreen.Counter datacan\\nbesavedtothePRMandprintedviatheReports tab.\\nHEARTRATEVARIABILITY (HRV)\\nHeartRateVariability (HRV)isameasure ofthechanges inapatient’s intrinsic heartratewithina24-hour collection\\nperiod.\\nHRVdataarecollected onlyindualchamber devices.\\nThisfeaturecanassistinevaluating theclinicalstatusofheartfailurepatients.\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 175}), Document(page_content='PatientDiagnostics andFollowUp\\nCounters6-11\\nHRV,asmeasuredbySDANNandHRVFootprint, isanobjective, physiological measure thatcanidentify heartfailure\\npatients athigherriskofmortality .Specifically ,depressed HRVcanbeusedasapredictorofriskofmortality afteran\\nacutemyocardial infarction.1AnormalSDANNvalueis127plusorminus35ms.1HigherSDANNvalues(indicating\\ngreatervariability ofheartrate)havebeenassociated withlowerriskofmortality .234Similarly ,alargerHRVFootprint\\nalsoindicates greaterheartratevariability andhasbeenassociated withlowermortality risk.234\\nTheHRVmonitor featureprovidesthefollowing information usingtheintrinsic intervaldatafromthe24-hour\\ncollection periodthatmeetstheHRVcollectioncriteria(Figure6–3HeartRateVariability displayonpage6-11):\\n•Dateandtimethe24-hour collectionperiodwascomplete d.\\n•%ofTimeUsed—displays thepercentageoftimeduringthe24-hour collectionperiodinwhichtherearevalid\\nintrinsic beats.Ifthe%ofTimeUsedfallsbelow67%,datawillnotbedisplayed forthatcollection period.\\n•HRVFootprint plot—shows thepercentageofthegraphareausedbytheHRVplot.Thegraphareaportrays an\\n“at-a-glanc esnapshot” ofthedistribution ofvariability versusheartrateovera24-hour period.Thetrended\\npercentage isanormalized scorebasedonthefootprint inthegraph.\\n•StandardDeviation ofAveraged NormalRtoRintervals (SDANN)—the HRVcollectionperiodcomprises 2885-\\nminutesegments (24-hours) ofintrinsic intervals.TheSDANNisthestandarddeviation oftheaveragesofintrinsic\\nintervals inthe2885-minute segments. Thismeasurementisalsoavailable intheTrends.\\n•CurrentNormalBradyparameters––Mode, LRL,MTR,andSensedAVDelay.\\n•AnHRVplotforcurrentandpreviouscollectionperiodsincluding alinethatshowsthemeanheartrate.TheHRV\\nplotsummarizes thecardiacvariation onacycle-to-cycle basis.Thex-axisshowstheheartraterange;they-axis\\nshowsthebeat-to-beat variability displayed inmilliseconds. Thecolorindicates thefrequency ofbeatsatany\\nparticular heartrateandheartratevariability combination.\\nFigure6–3.HeartRateVariability display\\nConsider thefollowing information whenusingHRV:\\n•Thecardiaccycle(R–Rinterval) inHRVisdetermined byRVsensedandpacedevents.\\n1.Electrophysiology TaskForceoftheEuropean SocietyofCardiologyandtheNorthAmerican SocietyofPacingandElectrophysiology .\\nCirculation,93:1043-1065, 1996.\\n2.F.R.Gilliametal.,JournalofElectrocar diology,40:336-342, 2007.\\n3.F.R.Gilliametal.,PACE,30:56-64, 2007.\\n4.J.P.Singhetal.,Europace,12:7–8,2010.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 176}), Document(page_content='6-12PatientDiagnostics andFollowUp\\nCounters\\n•Programming thepacingparamete rscausesthedataacquiredforthecurrent24-hour collectionperiodtobe\\ninvalid.\\n•Thedevicesavesonlyonesetofvaluesandcorresponding HRVplotfortheReferenc eportionofthescreen.Once\\nthevaluesarecopiedfromLastMeasured toReferenc e,olderdatacannotberetrieved.\\n•ThefirsttimetheHRVfeatureisused,theReferenc escreenwillshowthedatafromthefirstvalid24-hour\\ncollectionperiod.\\nFollowthestepsbelowtoviewHRV:\\n1.ToaccesstheHRVmonitor screen,selecttheEventstab.\\n2.FromtheEventsscreen,selectthePatientDiagnostics tab.\\n3.SelecttheHeartFailureManagement Detailsbutton.\\n4.SelecttheHRVtabtoviewtheLastMeasure dandReferenc edata.\\n5.TocopytheLastMeasure dHRVmeasurementsintotheReferenc esection, selecttheCopyFromLastto\\nReferenc ebutton.\\nTheHRVmonitor screendisplays asetofmeasurementsandaHRVplotbasedonthemostrecent24-hour collection\\nperiodintheLastMeasuredportionofthescreen;measurementsfromapreviously savedcollectionperiodare\\ndisplayed intheReferenc eportionofthescreen.Bothcollection periodscanbeviewedsimultaneously tocompare\\ndatathatcouldshowtrendsinthepatient’s HRVchanges overaperiodoftime.BysavingtheLastMeasuredvalues\\ntotheReferenceportionofthescreen,youcanviewthelastmeasureddataduringalatersession.\\nHRVCollection Criteria\\nOnlyvalidsinusrhythmintervals areusedintheHRVdatacalculations. ForHRV,validintervalsarethosewhich\\nincludeonlyvalidHRVevents.\\nValidHRVeventsarelistedbelow:\\n•ASwithanintervalnotfasterthanMTR,followed byaVS\\n•ASfollowed byVPattheprogrammed AVDelay\\nInvalidHRVeventsareasfollows:\\n•AP/VSorAP/VP\\n•ASwithanintervalfasterthanMTR\\n•Non-trackedVPevents\\n•Consecutive ASevents(nointerveningVevent)\\n•VP-Ns\\n•RateSmoothing events(e.g.,RVP↑)\\n•PVC', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 177}), Document(page_content='PatientDiagnostics andFollowUp\\nTrends6-13\\nHRVdatamaynotbereported foravarietyofreasons; themostcommon areasfollows:\\n•Lessthan67%ofthe24-hour collectionperiod(approxi mately16hours)contains validHRVevents\\n•BradyParamet erswereprogrammed withinthelast24hours\\nAnexampleofhowHRVdataisrecordedisshown(Figure6–4Example ofHRVdatacollectiononpage6-13).Inthis\\nexample,theHRVdatainthefirstcollectionperiodisinvalidbecause theBradyParameters wereprogrammed after\\nthedevicewastakenoutofStorage.HRVdataissuccessfullycalculated andreported attheendofthesecond24-\\nhourcollection period.Subsequent HRVdataisnotreported untiltheendofCollection Period5.\\nInvalid\\nValid\\nValid Invalid\\nInvalid\\n24-hour \\nCollection \\nPeriod 1\\nCollection Period 1:\\nInvalid HR V due to Brady \\nparameters modification \\n(programming)Collection Period 2:\\nValid HR V; greater than 67% \\nof collection criteria met; HR V \\nfootprint created\\nCollection Period 3:\\nInvalid HR V due to Brady \\nparameter modifications \\n(programming)Collection Period 4:\\nInvalid HR V; less than 67% \\nof daily intervals were valid\\nCollection Period 5:\\nValid HR V; greater than 67% \\nof collection criteria met\\n24-hour \\nCollection \\nPeriod 2\\n24-hour \\nCollection \\nPeriod 3\\n24-hour \\nCollection \\nPeriod 4\\n24-hour \\nCollection \\nPeriod 5\\n24 hour \\ncollection \\nperiod begins\\nFigure6–4.ExampleofHRVdatacollection\\nTRENDS\\nTrendsprovideagraphical viewofspecificpatient, device,andleaddata.Thisdatacanbeusefulwhenevaluating\\nyourpatient\\'s conditionandtheeffectiveness ofprogrammed parameters. Unlessotherwise notedbelow,dataforall\\ntrendsisreported every24hoursandisavailable forupto1year.Formanytrends,avalueof“N/R”isreportedif\\nthereisinsufficient orinvaliddataforthecollectionperiod.\\nThefollowing trendsareavailable:\\n•Events––displays bothatrialandventricular eventsstoredintheArrhythmia Logbook, organizedbydateandtype\\n(\"Arrhythmia Logbook\" onpage6-2).Thistrendisupdated whenever anepisode iscomplete d,andmaycontain\\ndatathatisolderthan1year.\\n•ActivityLevel––displays ameasure ofthepatient\\'s dailyactivityrepresented bythe“PercentofDayActive”.\\n•AT/AFBurden––displays atrendofthetotalnumber ofATRModeSwitcheventsandthetotalamount oftime\\nspentinanATRModeSwitchperday.\\n•RVRateduringAT/AF(RESONATE HF,RESONATE, PERCIVA HF,PERCIVA, andMOMENTUM devices)—displays a\\ntrendofthepatient’s MeanandMaximum RVrateduringATRevents.TheMeanrateiscalculated usingboth\\npacedandsensedbeatswhiletheMaximum rateisarollingaverageofsensedbeats.Insomecases,theMean\\nratemaybehigherthantheMaximum rate.\\n•PacingPercent(RESONATE HF,RESONATE, PERCIVA HF,PERCIVA, andMOMENTUM devices)—displays the\\npercentage ofpacedeventsforeachchamber .', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 178}), Document(page_content='6-14PatientDiagnostics andFollowUp\\nTrends\\n•Respiratory Rate––displays atrendofthepatient\\'s dailyminimum, maximum, andmedian respiratory ratevalues\\n(\"Respiratory RateTrend\"onpage6-15).\\n•HeartRate––displays atrendofthepatient\\'s dailymaximum, mean,andminimum heartrate.\\n•SDANN(Standar dDeviation ofAveragedNormal-to-Normal R-Rintervals)—displays atrendofthestandard\\ndeviation oftheaverages ofintrinsic intervals overthe24-hour collection period(whichiscomprised of2885-\\nminutesegments). OnlyintervalsthatmeettheHRVcollectioncriteriaareconsidered valid.\\nAnormalSDANNvalueis127plusorminus35ms.5\\n•HRVFootprint––displays thepercentageofthegraphareausedbytheHRVFootprint plot,illustrating the\\ndistribution ofvariability versusheartrateovera24-hour period.Thetrendedpercentageisanormaliz edscore\\nbasedonthefootprint inthegraph.Refertoadditional information aboutHRV(\"HeartRateVariability\" onpage\\n6-10).\\n•Leadimpedance andamplitude—displays trendsofthedailyintrinsic amplitude andleadimpedance\\nmeasurements(\"LeadsStatus\"onpage5-7).\\n•APaceThreshold—displays atrendofthedailyrightatrialpacingthresholds.\\n•RVPaceThreshold—displays atrendofthedailyrightventricular pacingthresholds.\\n•S1heartsound—displays atrendofthepatient’s device-measured S1heartsound.S1heartsoundisviewable only\\nontheHeartFailureManagement screen.Refertoadditional information aboutS1andS3HeartSounds(\"S1and\\nS3HeartSounds\" onpage6-15).\\n•S3heartsound—displays atrendofthepatient’s device-measured S3heartsound.S3heartsoundisviewable\\nonlyontheHeartFailureManagement screen.Refertoadditional information aboutS1andS3HeartSounds(\"S1\\nandS3HeartSounds\" onpage6-15).\\n•HeartLogic Index—displays atrendofthepatient’s HeartLogic Index.HeartLogic Indexisviewable onlyonthe\\nHeartFailureManagement. Refertoadditional information aboutHeartLogic Index(\"HeartLogic Index\"onpage6-\\n15).\\n•ThoracicImpedanc e—displays atrendofthepatient’s dailyaveragethoracicimpedance. Viewable onlyonthe\\nHeartFailureManagement screen.See\"Thoracic Impedanc e\"onpage6-16fordetails.\\n•NightHeartRate—displays atrendofthepatient’s averageheartratebetween midnight and6am.Viewable\\nonlyontheHeartFailureManagement screen.See\"NightHeartRate\"onpage6-16fordetails.\\n•SleepIncline—displays atrendofthepatient’s averageinclineduringsleeptime.Viewable onlyontheHeart\\nFailureManagement screen.See\"SleepIncline\"onpage6-16fordetails.\\nFollowthestepsbelowtoaccessTrends:\\n1.FromtheEventsscreen,selecttheTrendsTab.\\n2.ChoosetheSelectTrendsbuttontospecifythetrendsyouwanttoview.Youcanchoosefromthefollowing\\ncategories:\\n•HeartFailure––includes HeartRate,SDANN, andHRVFootprint trends.\\n5.Electrophysiology TaskForceoftheEuropean SocietyofCardiology andtheNorthAmerican SocietyofPacingandElectrophysiology .\\nCirculation, 93:1043-1065, 1996.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 179}), Document(page_content='PatientDiagnostics andFollowUp\\nTrends6-15\\n•AtrialArrhythmia––includes AT/AFBurden, RVRateduringAT/AF,andRespirato ryRate(RESONATE HF,\\nRESONATE, PERCIVA HF,PERCIVA, andMOMENTUM devices).Forothermodels, theAtrialArrhythmia\\ncategory includes Events,HeartRate,andAT/AFBurdentrends.\\n•Activity––includes HeartRate,ActivityLevel,andRespiratory Ratetrends.\\n•Custom––allows youtoselectvarioustrendstocustomiz etheinformation displayed ontheTrendsscreen.\\nThedisplayonthescreencanbeviewedinthefollowing manner:\\n•SelectthedesiredtimeontheViewbuttontochoosethelengthofvisibletrenddata.\\n•Adjustthestartandenddatesbymoving thehorizontalslideratthetopofthewindow.Youcanalsoadjust\\nthesedatesusingthescrollleftandscrollrighticons.\\n•Movetheverticalaxisacrossthegraphbymoving thehorizontal slideratthebottomofthedisplaywindow.\\nInaddition, thefollowing trendisavailable onLATITUDE NXT:\\n•VTherapy––displays anindication ofshockorATPtherapy foreachday.IfbothshockandATPtherapyare\\ndeliveredforagivenday,ashockwillbeindicated forthatday.\\nRespiratory RateTrend\\nTheRespiratory Ratetrenddisplays agraphofthepatient\\'s dailyminimum, maximum, andmedian respiratoryrate\\nvalues.Thesedailyvaluesarestoredforuptooneyeartocreatealongitudinal displayofphysiological data.\\nNOTE:TheAmerican CollegeofCardiology (ACC)/American HeartAssociation (AHA)guidelines recommend the\\nmeasurementanddocumentation ofphysiological vitalsignsincluding respiratory rateforcardiacpatients.6\\nEnsuretheMV/Respir atorySensorisprogrammed toOn(orPassivefortheMVSensor)forRespirato ryRatetrend\\ndatatobecollected anddisplayed (\"Minute Ventilation/Respirato rySensor\" onpage4-20).\\nMovethehorizontal slideroveradatapointtoviewthevaluesforagivendate.Atleast16hoursofdatamustbe\\ncollected forvaluestobecalculated andplottedtotheRespiratory Ratetrend.Ifinsufficient datawascollected,no\\ndatapointwillbeplottedandtherewillbeagapinthetrendline.ThisgapwillbelabeledasN/Rtoindicate that\\ninsufficient ornodatawascollected.\\nS1andS3HeartSounds\\nTheS1andS3HeartSoundssensorusesthepulsegenerator’saccelerometertodetectcardiacvibrations,whichare\\nusedtodetermine thedevice-mea suredintensities ofS1andS3.Thedailyvalueofeachtrendisaggregated from\\nmultiple samples eachday.Aheartsoundsamplecannotbetakenifthepatient’s heartrateistoohighortoo\\nvariable. Ifaminimum number ofvalidsamples arenotcollected, thenadailyvaluewillnotbeavailable forthatday.\\nHeartLogic Index\\nTheHeartLogic Indexaggregate smeasurements frommultiple device-basedsensors (HeartSounds, Thoracic\\nImpedanc e,Respiratio n,andNightHeartRate)andreflectschanges overtimeinthepatient’s sensortrenddatafrom\\ntheirrespective baseline values.HeartLogic provides additive information forclinicians touseincontextwith\\nstandard-of-care patienttreatment andshouldnotreplacestandard-of-care treatment.\\n6.ACC/AHA HeartFailureClinicalDataStandards.Circulation,Vol.112(12),September 20,2005.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 180}), Document(page_content=\"6-16PatientDiagnostics andFollowUp\\nTrends\\nNOTE:Thenominal HeartLogic Thresholdis16.Aspecificpatient’s HeartLogic Thresholdcanbeconfirmed in\\nLATITUDE NXT.\\nThoracicImpedance\\nTheThoracicImpedance sensormeasuresimpedance between electrodesontheRVleadandthepulsegenerator\\n(PG)can.ThoracicImpedance maybeassociated withthefluidlevelinthepatient’s chestandmaytrackfluidlevel\\nchanges. Whenapatient’s fluidlevelincreases, thoracic impedance decreases.\\nNightHeartRate\\nTheNightHeartRatesensormeasuresapatient’s heartratebetween thehoursofmidnight and6am.Thisperiodis\\nnon-programmable. Thedatafromthistrendcanbeaffected ifapatienttravelstoanother timezoneorifthepulse\\ngenerator(PG)clockisincorrect.ThePGclockcanbeprogrammed bysynchron izingittotheprogrammerclockatthe\\ntimeofdeviceinterrogation.ForaccuratePGclockprogramming, itisimportant toensurethattheprogrammerclock\\niscorrect.\\nSleepIncline\\nTheSleepInclinesensormeasuresthepatient's averagenighttime elevation angles(sleepincline).\\nInitialization andcalibrationmustbecompleted beforeSleepInclinetrending occurs.Initialization isautomatic;\\ncalibrationrequiresclinician andpatientaction.\\n•Initialization\\nTheinitialization oftheSleepInclinesensoroccursautomatically afterimplant andtypically takes5-7days.\\nInitialization maytakelongerifapatientlacksdiversity intheirbodyorientations duringthisperiod.\\nOncetheinitialization iscomplete,calibrationcantakeplace.\\n•Calibration\\nCalibration isperformed viatheprogrammerduringapatientfollow-up visit,afterimplant andinitialization are\\ncomplete .Calibration determines PGorientation withinthepatient’s body.Toperform calibration, thepatient\\nmustadoptanuprightposture,eithersittingorstanding, beforethephysician pressestheCalibrate buttonon\\ntheprogrammer .TheCalibrate buttonisshowninFigure6–5HeartFailureManagement Setupscreenonpage6-\\n16.\\nFigure6–5.HeartFailureManagement Setupscreen\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 181}), Document(page_content='PatientDiagnostics andFollowUp\\nPostImplantfeatures6-17\\nTheprogrammernotifiestheclinician ofthecompletion ofcalibrationfortheparticular posture.Ifnotenough\\nstabledatawascollected, theprogrammerwillindicate thisandaskfortheposturetoberepeated.\\nWhileanuprightpostureistheonlyrequired postureforcalibratingtheSleepInclinesensor,accuracyisincreased\\nbyperforming asecondcalibrationusingasupineposture.Repeattheaboveprocesstocollectreadings forthe\\nsecondposture.\\nTheaccuracyofthesleepinclinetrenddepends onaproperbodycalibration.Ifthepatientisnotfullyverticalor\\nhorizontalwhentheprogrammercapturestheuprightandsupineposturesrespectively ,thenthetrendvalueswill\\nbedistorted.\\nCalibrationcanberepeatedasoftenastheclinician desires.\\n•Trending\\nTheSleepInclineTrendaggregatesperiodic measurem entsoverthepatient’s sleepschedule. Toprogramthe\\npatient’s sleepschedule, accesstheGeneral tabofthePatientInformation screen.\\nThefirstsampleistaken1houraftertheprogrammed SleepStartandthelastsampleistaken1hourpriortothe\\nendoftheprogrammed SleepDuration .Forameasurement tobesuccessful,thepatientmustbeatlowactivity.\\nPOSTIMPLANT FEATURES\\nPatientTriggered Monitor(PTM)\\nPatientTriggere dMonitor allowsthepatienttotriggerthestorageofEGMs,intervals,andannotated markerdata\\nduringasymptomatic episode byplacingamagnet overthedevice.Instructthepatienttoplacethemagnet onthe\\ndevicebrieflyandonetimeonly.\\nPatientTriggere dMonitor isenabled byselecting StoreEGMasthedesiredMagnet Response. Thiscanbefoundin\\ntheMagnet andBeepersectionontheV-Tachy TherapySetupscreen.\\nWhenPTMisenabled, thepatientcantriggerdatastoragebyholding amagnet overthedeviceforatleast2\\nseconds.Thedevicewillstoredataforupto2minutes priortoandupto1minuteaftermagnet application. The\\nstoreddataincludetheepisode number,ratesatmagnet application, andstarttimeanddateofmagnet application.\\nAfteroneEGMisgenerated andstored,PTMisdisabled. Tostoreanother EGM,thePTMfeaturemustbere-enabled\\nusingtheprogrammer .If60dayselapseandthepatientdidnottriggerdatastorage,PTMisautomatically disabled.\\nWhendataarestored,thecorresponding episode typeisrecordedasPTMintheArrhythmia Logbook.\\nCAUTION: UsecarewhenusingPatientTriggeredMonitor, because thefollowing conditions willexistwhileitis\\nenabled:\\n•Allothermagnet features, including inhibiting therapy,aredisabled. TheMagnet/Beeper featurewillnotindicate\\nmagnet position.\\n•Devicelongevity isimpacted. Tohelpreducethelongevity impact,PTMonlyallowsstorageofoneepisode, and\\nPTMisautomatically disabled after60daysifdatastoragewasnevertriggered.\\n•OncetheEGMisstored(or60dayselapses), PTMisdisabled andthedeviceMagnet Response automatically will\\nbesettoInhibitTherapy.However ,thepulsegenerator willnotinhibittherapyuntilthemagnet isremoved for3\\nsecondsandplacedonthedeviceagain.\\nToprogramthePatientTriggeredMonitor feature, followthesesteps:', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 182}), Document(page_content='6-18PatientDiagnostics andFollowUp\\nPostImplantfeatures\\n1.FromtheSettings tabonthemainscreen,selectSettings Summary.\\n2.FromtheSettings Summary tab,selectVentricular TachyTherapy.\\n3.FromVentricular TachyTherapy,selecttheV-Tachy TherapySetupdetailsbutton.\\n4.ProgramtheMagnet Response toStoreEGM.\\n5.Determine ifthepatientiscapable ofactivating thisfeaturepriortobeinggiventhemagnet andpriorto\\nenabling PatientTriggeredMonitor. Remind thepatienttoavoidstrongmagnetic fieldssothefeatureisnot\\ninadvertently triggered.\\n6.Consider havingthepatientinitiateastoredEGMatthetimePatientTriggered Monitor isenabled toassistwith\\npatienteducation andfeaturevalidation. Verifytheactivation ofthefeatureontheArrhythmia Logbook screen.\\nWARNING: Ifdesired, ensurethatPatientTriggeredMonitor isenabled priortosending thepatienthomeby\\nconfirming theMagnet Response isprogrammed toStoreEGM.Ifthefeatureisinadvertently leftintheInhibit\\nTherapy setting, thepatientcouldpotentially disabletachyarrhythmia detection andtherapy.\\nWARNING: OncethePatientTriggeredMonitor featurehasbeentriggeredbythemagnet andanEGMhas\\nbeenstored,orafter60dayshaveelapsed fromthedaythatStoreEGMwasenabled, theMagnet Response\\nprogramming automatically willbesettoInhibitTherapy. Whenthishappens, thepatientshouldnotapplythe\\nmagnet because tachyarrhythmia therapycouldbeinhibited.\\nNOTE:WhentheMagnet Response programming hasautomatically beensettoInhibitTherapy,magnet\\napplication willcausethedevicetoemitbeeping tones.Informthepatientthatiftheyheartonescomingfrom\\ntheirdeviceafterapplying themagnet, theyshouldremovethemagnet.\\n7.PatientTriggeredMonitor canonlybeenabled fora60-dayperiodoftime.Todisablethefeaturewithinthe60-\\ndaytimeperiod,reprogramtheMagnet Response toasettingotherthanStoreEGM.When60dayshavepassed\\nsinceenabling PatientTriggered Monitor, thefeaturewillautomatically disableitselfandtheMagnet Response\\nwillreverttoInhibitTherapy.Tore-enablethefeature, repeatthesesteps.\\nForadditional information, contactBostonScientific usingtheinformation onthebackcover.\\nBeeperFeature\\nTheBeeperincludes bothprogrammable andnonprogr ammable features (referto“Programmable Features”\\nsubsection of\"Beeper Feature\" onpage6-18).\\nProgrammable Features\\nThefollowing Beeperfeatures areprogrammable:\\n•BeepDuringCapacitor Charge—When programmed toOn,regardless oftheTachyMode,awarbling tonewill\\nsoundcontinuously whilethepulsegeneratorischarging(exceptwhenchargingduringanautocapacitor re-\\nform).Thetonewillcontinue untilcharging iscomplete. Whenthisfeatureisprogrammed toOff,thereisno\\naudibleindication thatthepulsegeneratorischarging.ThisfeatureisusefulduringEPtesting.\\n•BeepwhenExplantisIndicated—When thisfeatureisprogrammed toOn,thepulsegeneratoremitstonesupon\\nreaching Explant. TheExplantindicator consistsof16tonesrepeatedeverysixhoursafterthepulsegenerator\\nreaches Explantuntilthefeatureisturnedoffviatheprogrammer.Whenthisfeatureisprogrammed toOff,there\\nisnoaudibleindication ofExplant.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 183}), Document(page_content='PatientDiagnostics andFollowUp\\nPostImplantfeatures6-19\\n•BeepWhenOut-of-Range—When thisfeatureisprogrammed toOn,thepulsegeneratoremitstoneswhenDaily\\nImpedanc evaluesareoutofrange.Itisseparatelyprogrammable foreachpacingleadimpedance aswellas\\nshockimpedance. TheOut-of-Range indicator consistsof16tonesrepeated everysixhours.Whenthisfeatureis\\nprogrammed toOff,thereisnoaudibleindication ofDailyImpedanc evalues.\\nPerform thefollowing stepstoprogramtheMagnet andBeeperfeatures:\\nMagnetandBeeperResponse\\n1.SelecttheSettings tab.\\n2.FromVentricular Tachy,selecttheTherapy button.\\n3.SelecttheV-Tachy Therapy Setupbutton.\\n4.Enterthedesiredvalues.\\nBeepwhenExplantisIndicated\\n1.SelecttheSummar ytab.\\n2.SelecttheBatterybutton.\\n3.FromtheBatteryStatussummary screen,selecttheBatteryDetailbutton.\\n4.FromtheBatteryDetailsummary screen,selectthedesiredvalueforBeepwhenExplantisIndicated.\\nBeepWhenOut-of-Range\\n1.SelecttheSummar ytab.\\n2.SelecttheLeadsbutton.\\n3.FromtheLeadsStatussummary screen,selecttheSetuptab.\\n4.SelectthedesiredvaluesforBeepWhenOut-of-Range.\\nNOTE:WhentheMagnet Response isprogrammed toInhibitTherapy,magnet application willcauseothertypesof\\nbeeping tonestobeemitted, depending onthedevicemode.Referto\"Magnet Feature\"onpage6-23formore\\ninformation.\\nNonprogrammable Features\\nThefollowing Beeperfeaturesarenonprogrammable:\\n•Batterycapacity depleted—Regard lessofwhether BeepwhenExplantIsIndicated isprogrammed toOnorOff,\\noncethebatterycapacity isdepleted, thepulsegeneratorwillemittheexplantindicator tones\\n•Faultcodetones—For certainfaultcodesorwhenSafetyModeisentered,thepulsegeneratorwillbeep16times\\nevery6hours.\\nNOTE:Beeping tonesmayemitundernonprogrammable scenariosinresponse todeviceself-diagnostic testing.\\nAdvisepatients tohavetheirpulsegeneratorcheckedwhenever theyheartonescomingfromthedevice.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 184}), Document(page_content='6-20PatientDiagnostics andFollowUp\\nPostImplantfeatures\\nConfigure BeeperSettings\\nPerform thefollowing stepstoprogramtheConfigur eBeeperSettings:\\n1.SelecttheSettings tab.\\n2.SelecttheBeepertab.\\n3.SelectthedesiredvalueforBeeper.\\n4.Beeperevaluation test:AfterturningontheBeeper, ensureitisaudiblebyplacingamagnet overthedeviceand\\nlistening forbeeps.IftheBeeperisaudible, leavetheBeeperOn.IftheBeeperisnotaudible, consider\\nprogramingtheBeepertoOff.\\nHearing capability ofthepatientandthecaregiver(s)mayvary.Itisrecommended toperform Beeperevaluation test\\nduringeachfollowup.\\nWARNING: IftheBeeperisinaudible orprogrammed Off,itisstronglyrecommended thatthepatientisfollowed\\nonLATITUDE NXT,and/ormaintains anin-clinic follow-up schedule ofevery3months.\\nThefollowing aresituations thatwillnolongertriggertheBeepertoemitaudibletonesoncetheBeeperisturned\\nOff.\\nTable6–2.Situations thatwillnolongertriggeraudibleBeepertonesoncetheBeeperisturnedOff\\nProgrammable Beeperoptions•BeepDuringCapacitor Charge\\n•BeepWhenOut-of-Range\\n•BeepwhenExplantisIndicated\\nNon-Pro grammable Beeperoptions•Application ofthepatientmagnet overthepulsegenerator in\\ncertainsituations (e.g.confirmingTachycard iaMode)\\n•Batterycapacity depleted (EndofLife(EOL))\\n•Batteryfaultalert\\n•Highvoltagefaultalert\\nTheBeeperwillemittonesfollowing reversion ofthepulsegeneratortoSafetyModeOperationordevicereseteven\\naftertheBeeperisturnedOff.\\nOnceturnedOff,anotification thattheBeeperisturnedOffappears ontheSummary dialog(Figure6–6BeeperOff\\nSummary dialogonpage6-21).', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 185}), Document(page_content='PatientDiagnostics andFollowUp\\nPostImplantfeatures6-21\\nFigure6–6.BeeperOffSummary dialog\\nWhentheBeeperisprogrammed fromOfftoOn,allprogrammable andnon-programmable Beeperfeatures willbe\\nreverted totheirnominal values(\"Magnet andBeeperFunctions PgmOp\" onpageA-10).\\nDetermine BeeperType\\nThepulsegeneratorcontainseitheranArmatureorPiezobeeper.\\n•TheArmature Beepercontains amagnetic component andmaybedamaged bythestrongmagnetic fields\\nassociated withMRIscanners. BeforeundergoinganMRIscan,thepatientandphysician shouldweighthe\\nbenefitoftheMRIscanagainsttheriskoflosingbeeperfunction. TheBeepermaybeinaudible duetoMRIscan,\\nandshouldbetestedpostMRIscan.\\n•ThePiezoBeeperdoesnotcontainanymagnetic components, andisdesigned towithstand thestrongmagnetic\\nfieldsassociated withMRIscanners without beingdamaged.\\nTodetermine theBeepertype,ensuretheModel3868Programmer SoftwareApplication isversion1.08oraboveand\\ninterrogatethedeviceusingtheModel3300Programmer.TheBeepertypeisdisplayed ontheBeepertab(Figure6–7\\nBeeperTabonpage6-22).', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 186}), Document(page_content='6-22PatientDiagnostics andFollowUp\\nPostImplantfeatures\\nFigure6–7.BeeperTab\\nNOTE:Screens willdifferdepending onbeepertypeandMRIProtectionModeavailability .\\nImpactofMRIScanonArmature Beeper\\nTheArmatureBeepermaynolongerbeusablefollowing anMRIscan.Coming incontactwiththestrongmagnetic\\nfieldofanMRIscanner maycauseapermanent lossoftheArmatureBeepervolume. Thiscannotberecovered,even\\nafterleavingtheMRscanenvironment andexitingMRIProtection Mode.Thesystemproactivelyturnsoffthe\\nprogrammable andnon-progr ammable Beeperfeatures whenMRIProtectionModeisprogrammed. TheArmature\\nBeeperwillremainOffuponexitingMRIProtection Mode.Uponinterrogation,anotification willbeprovidedonthe\\nSummary dialogthattheBeeperisoff.AfterexitingfromMRIProtectionMode,theBeepercanbeturnedbackon\\nusingtheConfigure BeeperSettings optionontheBeepertabifdesired. AfterturningtheBeeperbackon,ensureitis\\nstillaudiblebychecking theaudibletonesusingthemagnet. IftheBeeperisinaudible, considerreprogramingthe\\nBeepertoOff.\\nWARNING: Determine thebeepertypebeforeanMRIscan.TheArmatureBeepermaynolongerbeusable\\nfollowing anMRIscan.Coming incontactwiththestrongmagnetic fieldofanMRIscanner maycauseapermanent\\nlossoftheArmature Beepervolume. Thiscannotberecovered,evenafterleavingtheMRIscanenvironment and\\nexitingMRIProtectionMode.FortheArmatureBeeper,beforeanMRIscanisperformed, aphysician andpatient\\nshouldweighthebenefitoftheMRIscanagainsttheriskoflosingtheBeeper; aftertheMRIscan,perform Beeper\\nevaluation testtodetermine iftheBeeperisusable.IftheBeeperisnotusable,itisstronglyrecommended that\\npatients arefollowed onLATITUDE NXTafteranMRIscaniftheyarenotalready.Otherwise,anin-clinic follow-up\\nschedule ofeverythreemonths isstronglyrecommended tomonitor deviceperformanc e.\\nNOTE:Forinstructions onhowtodetermine thebeepertype,referencethe“Determine BeeperType”subsection of\\n\"Beeper Feature\" onpage6-18.Forinstructions onperforming theBeeperevaluation test,see\"Beeper Feature\" on\\npage6-18.\\nNOTE:Itisrecommended toperform Beeperevaluation testaftereachMRIscan.Insituations wheretheMRIscan\\ndidnotoccur,theArmatureBeepercanbeprogrammed OnafterexitingMRIProtectionMode.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 187}), Document(page_content='PatientDiagnostics andFollowUp\\nPostImplantfeatures6-23\\nMagnetFeature\\nThemagnet featureallowscertaindevicefunctions tobetriggered whenamagnet greaterthan60gaussisplacedin\\ncloseproximitytothepulsegenerator(Figure6–8Properposition ofmagnet toactivate thepulsegeneratormagnet\\nfeatureonpage6-23).\\nPosition the magnet over the \\npulse generator as shown.\\nMagnet\\n3.0 cm\\nPulse generator\\nTop View\\nFigure6–8.Properpositionofmagnettoactivatethepulsegenerator magnetfeature\\nThepulsegeneratorMagnet Response settings canbeprogrammed tocontrolthebehavior ofthepulsegenerator\\nwhenamagnet isdetected. TheMagnet Response settings arelocatedintheMagnet andBeepersectionoftheV-\\nTachyTherapySetupscreen.\\nThefollowing Magnet Response settings areavailable:\\n•Off—noresponse\\n•StoreEGM—patient monitoring datawillbestored\\n•InhibitTherapy—therapy willbestopped\\nOff\\nWhentheMagnet Response isprogrammed toOff,application ofthemagnet willhavenoeffectonthepulse\\ngenerator.\\nStoreEGM\\nWhentheMagnet Response isprogrammed toStoreEGM,application ofthemagnet willactivate thePatient\\nTriggeredMonitor functionality (\"Patient TriggeredMonitor\" onpage6-17).\\nInhibitTherapy\\nWhentheMagnet Response isprogrammed toInhibitTherapy,application ofthemagnet willinhibitand/ordivert\\nchargingforashock,divertashockthatisabouttobedelivered,orinhibitand/ordivertfurtherATPtherapy.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 188}), Document(page_content='6-24PatientDiagnostics andFollowUp\\nPostImplantfeatures\\nWhenMagnet Response isprogrammed toInhibitTherapy,initiation oftachyarrhythmia therapy andarrhythmia\\ninduction isinhibited anytimethemagnet isproperlypositioned overthepulsegenerator.Thetachyarrhythmia\\ndetection processcontinues, buttherapyorinduction cannotbetriggered.Whenamagnet isplacedoverthepulse\\ngenerator,thefollowing willoccur:\\n•IftheTachyModeisMonitor +Therapywhenthemagnet isapplied, theTachyModechanges temporarilyto\\nMonitor OnlymodeandwillremaininMonitor Onlymodeaslongasthemagnet isapplied. Threesecondsafter\\nthemagnet isremoved,themodewillreturntothepreviouslyprogrammed mode.\\n•Ifthepulsegeneratorischargingtodelivershocktherapy whenthemagnet isapplied, thechargingcontinues\\nbutisthenterminated withinonetotwosecondsofmagnet application, andthechargeisdiverted. (Thisdelay\\noccursincasethemagnet isinadvertently passedoverthedevicewhentherapyinhibition isnotdesired.) The\\npulsegeneratorremains intemporary Monitor Onlymodewhilethemagnet isapplied. Nofurthertherapyis\\ninitiated untilthemagnet isremoved; however ,detection willcontinue.\\n•Ifchargingiscompleteorcompletes withinthe1–2seconddelayperiod,holding themagnet overthepulse\\ngeneratorformorethantwosecondswilldiverttheshock.(Ifthemagnet isremoved duringthedelayperiod,the\\nshockcouldstillbedelivered.)Shockswillnotbedeliveredwiththemagnet inplace.\\n•Ifthepulsegeneratorisinitiating fibrillation induction orATPpulses,itterminates thedelivery afteronetotwo\\nseconds ofmagnet application. Nofurtherinduction orATPpulsesequenc esareinitiated untilthemagnet is\\nremoved.\\n•IftheTachyModeisMonitor OnlyorOff,magnet application willproduceaconstant tonetoindicate thatthe\\ndeviceisinanon-therapy mode.\\n•IftheTachyModeisMonitor +Therapy,magnet application willcausethepulsegeneratortobeeponceper\\nsecondtoindicate thatthedeviceisinatherapymode.\\n•IfthepulsegeneratorisinElectrocautery Protection Mode,magnet application willproducebeeping consistent\\nwithwhichever TachyModewasactivewhenthepulsegenerator wasplacedintoElectrocautery Protection Mode.\\nForexample, ifElectrocautery ProtectionModewasenabled whentheTachyModewassettoMonitor +Therapy,\\nmagnet application willcausethepulsegeneratortobeeponcepersecond.\\nNOTE:Iftachydetection occurswhilethemagnet isinplace,detailed therapyhistorywillindicate thattherapywas\\nnotdelivered because thedevicewasinMonitor Onlymode.\\nNOTE:Themagnet featureissuspended whenthepulsegeneratorisinMRIProtection Mode.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 189}), Document(page_content='7-1\\nELECTROPHYSIOLOGIC TESTING\\nCHAPTER 7\\nThischaptercontainsthefollowing topics:\\n•“EPTestFeatures” onpage7-2\\n•“Induction Methods” onpage7-4\\n•“Commanded TherapyMethods” onpage7-8', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 190}), Document(page_content=\"7-2Electrophysiologic Testing\\nEPTestFeatures\\nEPTESTFEATURES\\nElectrophysiologic (EP)Testingfeatures enableyoutoinduceandterminate arrhythmias noninvasively inorderto\\nmonitor andtesttheeffectiveness ofselected detection criteriaandtherapies.TheEPTestfeatures canbeusedin\\nconjunction withtheECGdisplaysothatreal-timetracesmaybeviewed. Thestatusofthepulsegenerator/patient\\ninteractionisalsodisplayed.\\nWARNING: Alwayshaveexternal defibrillation equipment available duringimplant andelectrophy siologic testing. If\\nnotterminated inatimelyfashion, aninduced ventricular tachyarrhythmia canresultinthepatient's death.\\nThefeaturesallowing noninvasive EPtestingofarrhythmias includethefollowing:\\n•VFibinduction\\n•ShockonTinduction\\n•Programmed electrical stimulation (PES)induction/termination\\n•50Hz/Manual Burstpacinginduction/termination\\n•Commanded Shocktherapy\\n•Commanded ATPtherapy\\nTemporary EPMode\\nTemporary EPModeallowsyoutoprogramthedevicemodetoatemporaryvalueforEPtestdelivery,andensures\\nthatthenormaldevicemoderemainsunchanged.\\nEPTestScreen\\nTheEPTestscreendisplays thereal-time statusofthedetection andtherapyprocessofthepulsegeneratorwhen\\ntelemetry communication isoccurring. Viewing thisdisplayallowsyoutoinduceandtesteitheraprogrammed\\ndetection/therapy prescription oroptional therapieswhilemonitoring thepulsegenerator'sprogress.\\nRefertotheEPTestscreen(Figure7–1EPTestScreenonpage7-2):\\nFigure7–1.EPTestScreen\\nThescreenprovides thefollowing information:\\n•Statusmessages indicate detection andtherapystatusandaredescribed below:\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 191}), Document(page_content='Electrophysiologic Testing\\nEPTestFeatures7-3\\n–Ventricular episode status—if anepisode isoccurring, thedurationoftheepisode isdisplayed. (Ifitisgreater\\nthan10minutes, thenitisdisplayed as>10:00m:s).\\n–Ventricular detection status—if anepisode isoccurring, itindicates whether ventricular detection isinInitial\\nDetection, Redetection, orthezoneinwhichthatdetection ismet.Ifnoepisode isoccurring, the\\nprogrammerwillalsodisplaythetime(inminutes) sincethelastventricular therapy(upto10minutes).\\n–BradypacingandSRDstatus.\\n–Thetypeoftherapyinitiated andthezone.\\n–ThestatusofthetherapysuchasInProgress,Diverted, orDelivered.\\n•Durationtimer—Pro gression ofthedurationtimerisgraphicallydisplayed usingascale.Thebarinthescale\\nmovesfromlefttorighttoshowthepercentcomplete ofprogrammed duration. Whenduration isexpiredand\\ntherapydelivery begins,thebarisremoved.\\n•Detection status—The statusforeachprogrammed detection enhance mentisdisplayed. Whenenhancement\\ncriteriaaremet,amarkappears intheadjacent box.\\n•Therapyprescriptions—Only thosetherapyprescriptions thatareprogrammed aredisplayed. Aseachtherapyis\\ndelivered,acheckmarkornumber willappearintheboxadjacenttotherespective therapy.ATPtherapies\\nindicate thescheme typeaswellastheprogrammed number ofburstsinthescheme. Anumber willappearand\\nincrement(1,2,etc.)intheATPtherapyboxeachtimeanATPburstisdelivered. Shocktherapie sindicate the\\nprogrammed energylevelfortheprogrammable shocks.Anumber willappearandincrement (1,2,etc.)inthe\\nMaxboxeachtimeamaximum-energy shockisdelivered.\\nFollowthestepsbelowtoperform EPTestfunctions:\\n1.SelecttheTeststab,thenselecttheEPTeststab.\\n2.Establish telemetr ycommunication. Telemetr ycommunication between theprogrammer andthepulsegenerator\\nshouldbemaintained throughout allEPtestprocedures.\\n3.SetBackupPacingandEPTestPacingOutputs asdesired.\\nNOTE:BackupPacingduringEPtestingisnotavailable insingle-chamber devices.\\n4.ProgramtheEPTempVModeappropriatetotheEPTestmethod (Table7–1EPTempVModeforEPTest\\nFunctions onpage7-3).\\nTable7–1.EPTempVModeforEPTestFunctions\\nEPTempVMode\\nEPTestMethodaMonitor+TherapydMonitorOnlyeOff\\n50Hz/Manual Burstb X\\nPESbX\\nVFibc X\\nShockonTc X', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 192}), Document(page_content='7-4 Electrophysiologic Testing\\nInduction Methods\\nTable7–1.EPTempVModeforEPTestFunctions (continued)\\nEPTempVMode\\nEPTestMethodaMonitor+TherapydMonitorOnlyeOff\\nCommanded ATPc X\\nCommanded ShockcX X\\na.EPfunctions cannotbeperformed ifthepulsegenerator isinStorage Mode.\\nb.Available method forbothatrialandventricular induction.\\nc.Available method onlyforventricular induction.\\nd.TheVentricular TachyModemustbeprogrammed toMonitor +Therapy.\\ne.TheVentricular TachyModemustbeprogramm edtoMonitor OnlyorMonitor +Therapy.\\nINDUCTION METHODS\\nEachEPTestmethod available fromtheEPTestscreenisdescribed belowwithinstructions. Duringanytypeof\\ninduction/termination, thepulsegeneratorperforms nootheractivityuntilthetesthasceased,atwhichtimethe\\nprogrammed modewilltakeeffectandthepulsegeneratorwillrespondaccordingly.\\nConsider thefollowing information whenusingthesemethods:\\n•Allinductions andtachycardia therapydelivery areinhibited whenamagnet ispositioned overthepulse\\ngenerator(ifmagnet response issettoInhibitTherapy)\\n•Pacingpulsesduringinduction aredeliveredattheprogrammed EPTestpacingparamet ers\\nVFibInduction\\nVFibinduction usestheshocking electrodestostimulate therightventricle atveryfastrates.\\nThefollowing settings areavailable toallowuseoftheminimum energynecessaryforinduction:\\n•VFibLowdelivers astimulation waveform of9volts\\n•VFibHighdelivers astimulation waveform of15volts\\nPerforming VFibInduction\\nNOTE:Thepatientshouldbesedated priortodelivery offibrillation induction pulses.Thelargesurfaceareaofthe\\nshocking electrodestendstostimulate thesurroundingmuscleandcanbeuncomfortable.\\n1.SelecttheVFiboption.Buttons foreachtestandanEnablecheckbox aredisplayed.\\n2.SelecttheEnablecheckbox.\\n3.SelectthedesiredHoldforFibbuttontoinitiatedelivery ofthefibrillation induction train.Theinduction trainis\\ndelivered upto15secondsaslongasthebuttonisheldandthetelemetry linkismaintained.\\nDuringinduction thepulsegenerator isautomatically disabled fromdetecting, andautomatically re-enabled\\nfollowing induction delivery.IfVFibinduction isinitiated duringanepisode, theend-of-episode isdeclared\\nbeforetheVFibinduction pulsesarestarted. Anewepisode (withinitialdetection andtherapy) canbedeclared\\naftertheVFibinduction iscompleted. EventmarkersandEGMsareinterrupted duringVFibinduction andwill\\nautomatically restartfollowing induction.\\n4.Tostoptheinduction train,releasethebutton(thebuttonwillbecome dimmed again).Following theinduction,\\nthepulsegenerator automatically restartsdetection andPost-shockPacingisactivated.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 193}), Document(page_content='Electrophysiologic Testing\\nInduction Methods7-5\\n5.Todeliveranother fibrillation induction, repeatthesesteps.\\nShockonTInduction\\nAShockonTwaveinduction method allowsthedevicetodeliveradrivetrain(upto30equallytimedpacingpulses,\\norS1pulses)throughtheventricular pace/senseelectrodesfollowed byshockdeliverythrough theshocking\\nelectrodes(Figure7–2ShockonTinduction drivetrainonpage7-5).\\n400 400 400 400 400 400 \\nS1 S1 S1 S1 S1 S1 \\nLast sensed or \\npaced beat \\nCoupling \\nInterval \\nDrive Pulses Shock \\nS1 Interval \\nFigure7–2.ShockonTinduction drivetrain\\nTheinitialS1pulsefollowsthelastsensedorpacedeventattheS1Interval.Theshockiscoupled tothelastS1pulse\\nofthedrivetrain.\\nPerforming ShockonTInduction\\n1.SelecttheShockonToption.Theprogrammable induction paramet erswillbedisplayed.\\n2.Selectthedesiredvalueforeachparameter .\\n3.SelecttheEnablecheckbox. TheInducebuttonwillnolongerbedimmed.\\n4.SelecttheInducebuttontobegindelivery ofthedrivetrain.Thepulsesaredeliveredinsequenc euntilthe\\nprogrammed number ofpulsesisreached.Onceinduction isinitiated, thedrivetraindelivery willnotstopifyou\\ninterrupt telemetr ycommunication. Whiletelemetr yisactive,pressing theDIVERTTHERAPY keywillstop\\ninduction delivery.\\n5.ShockonTinduction iscomplete whenthedrivetrainandshockaredelivered,atwhichtimethepulsegenerator\\nautomatically restartsdetection andPost-shockPacingisthenactivated.\\nNOTE:Priortodrivetraindelivery,toneswillbeheardindicating capacitor charginginpreparationforshock\\ndelivery.\\nNOTE:TheshockdeliveredduringShockonTinduction doesnotincrementepisode ortherapycounters.\\nBackupVentricular PacingDuringAtrialEPTesting\\nBackupventricular pacingisavailable duringatrialEPtesting(PES,50Hz/Manual Burst)regardlessofthe\\nprogrammed NormalorPost-therapypacingmodes.\\nNOTE:BackupPacingisperformed inVOOmode.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 194}), Document(page_content='7-6Electrophysiologic Testing\\nInduction Methods\\nNOTE:BackupPacingduringEPtestingisnotavailable insingle-chamber devices.\\nIndual-chamber devices, programthebackuppacingparametersbyselecting theEPTestPacingbutton.Backup\\nPacingparamet ersareindependently programmable fromthepermanent pacingparameters. BackupPacingcanalso\\nbedisabled byprogramming theBackupPacingModetoOff.\\nProgrammed Electrical Stimulation (PES)\\nPESinduction allowsthepulsegeneratortodeliverupto30equallytimedpacingpulses(S1)followed byupto4\\nprematurestimuli(S2–S5)toinduceorterminate arrhythmias. Drivepulses,orS1pulses,areintended tocaptureand\\ndrivetheheartatarateslightlyfasterthantheintrinsic rate.Thisensures thatthetimingoftheprematu reextra\\nstimuliwillbeaccuratelycoupled withthecardiaccycle(Figure7–3PESinduction drivetrainonpage7-6).\\nTheinitialS1pulseiscoupledtothelastsensedorpacedbeatattheS1Interval. AllpulsesaredeliveredinXOO\\nmodes(whereXisthechamber) attheprogrammed EPTestpacingparameters.\\nForAtrialPES,backuppacingparamete rsareprovided.\\nNOTE:BackupPacingduringEPtestingisnotavailable insingle-chamber devices.\\nS1 S1 S1 S1 S1 S2 S3\\n600 400 600 600 600 600 450\\nCoupling \\nInterval\\nCoupling \\nIntervalExtra \\nStimuliDrive Pulses\\nFigure7–3.PESinduction drivetrain\\nPerforming PESInduction\\n1.Inadual-chamber device,choosetheAtriumorVentricle tab,depending onwhichchamber youwanttopace.\\n2.SelectthePESoption.Buttons fortheS1–S5pulsesandthecorresponding burstcyclelengthsaredisplayed.\\n3.SelectthedesiredvaluefortheS1–S5intervals (Figure7–4PESinduction options onpage7-6).Youcaneither\\nselectavalueboxforthedesiredSintervalandchooseavaluefromtheboxorusetheplusorminussymbols to\\nchangethevaluevisibleinthevaluebox.\\nFigure7–4.PESinduction options\\n4.SelecttheEnablecheckbox.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 195}), Document(page_content='Electrophysiologic Testing\\n50Hz/Manual BurstPacing7-7\\n5.Select(donothold)theInducebuttontobegindelivery ofthedrivetrain.Whentheprogrammed number ofS1\\npulsesisdelivered, thepulsegeneratorwillthendelivertheprogrammed S2–S5pulses.Thepulsesaredelivered\\ninsequenc euntilapulseisencountered thatissettoOff(e.g.,ifS1andS2aresetto600ms,andS3isOff,then\\nS3,S4,andS5willnotbedelivered). Onceinduction isinitiated, thePESdelivery willnotstopifyouinterrupt\\ntelemetry commun ication.(Whiletelemetry isactive,pressingtheDIVERTTHERAPY keywillstopinduction\\ndelivery.)\\n6.PESinduction iscompletewhenthedrivetrainandextrastimuliaredelivered,atwhichtimethepulsegenerator\\nautomatically restartsdetection.\\nNOTE:EnsurethePESinduction iscompletebeforebeginning another induction.\\nNOTE:WhenPESisusedtoterminate anarrhythmia thathasbeendetected (andanepisode declared),the\\nepisode isterminated whenthePESiscommanded regardless ofwhether itissuccessfulornot.Anewepisode\\ncanbedeclared afterthePESinduction iscompleted. ThePESitselfisnotrecordedintherapyhistory; thismay\\nresultinseveralepisodes beingcountedintherapyhistory.\\nNOTE:Real-time EGMsandannotated eventmarkerswillcontinue tobedisplayed duringtheentiretest\\nsequenc e.\\n50Hz/Manual BurstPacing\\n50HzpacingandManualBurstpacingarebothusedtoinduceorterminate arrhythmias whendeliveredtothe\\ndesiredchamber .Pacingparameters areprogrammable forManualBurstbutarefixedfor50Hzpacing.\\nManualBurstand50Hzpacingpulsesaredelivered inXOOmode(whereXisthechamber) attheprogrammed EP\\nTestpacingparamet ers.ForAtrialManualBurstand50Hz,backuppacingparameters areprovided.\\nNOTE:BackupPacingduringEPtestingisnotavailable insingle-chamber devices.\\nPerforming ManualBurstPacing\\n1.Inadual-chamber device,choosetheAtriumorVentricle tab,depending onwhichchamber youwanttopace.\\n2.Selectthe50Hz/Manual Burstoption.\\n3.SelectthedesiredvaluefortheBurstInterval,Minimum, andDecrement. Thisindicates thecyclelengthofthe\\nintervals inthedrivetrain.\\n4.SelecttheEnablecheckbox.\\n5.Todelivertheburst,selectandholdtheHoldforBurstbutton.\\nTheventricular ManualBurstwillbedeliveredupto30secondsaslongastheHoldforBurstbuttonisheldand\\nthetelemetr ylinkismaintained.\\nTheatrialManualBurstwillbedeliveredupto45seconds aslongastheHoldforBurstbuttonisheldandthe\\ntelemetry linkismaintained.\\nTheintervalswillcontinue tobedecremented untiltheMinimum intervalisreached, thenallfurtherpulseswill\\nbeattheMinimum interval.\\n6.Tostoptheburstdelivery,releasetheHoldforBurstbutton.TheHoldforBurstbuttonwillbecome dimmed\\nagain.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 196}), Document(page_content='7-8Electrophysiologic Testing\\nCommanded TherapyMethods\\n7.Todeliveradditional ManualBurstpacing,repeatthesesteps.\\nPerforming 50HzBurstPacing\\n1.Inadual-chamber device,choosetheAtriumorVentricle tab,depending onwhichchamber youwanttopace.\\n2.Selectthe50Hz/Manual Burstoption.\\n3.SelecttheEnablecheckbox.\\n4.Todelivertheburst,selectandholdtheHoldfor50HzBurstbutton.\\nTheventricular 50HzBurstwillbedeliveredupto30secondsaslongastheHoldforBurstbuttonisheldand\\nthetelemetry linkismaintained.\\nTheatrial50HzBurstwillbedeliveredupto45seconds aslongastheHoldforBurstbuttonisheldandthe\\ntelemetr ylinkismaintained.\\nNOTE:DuringHoldfor50HzBurstpacing,theS1Intervalisautomatically setto20msandtheDecreme ntto\\n0.Thesevalueswillnotbedisplayed onthescreen.\\n5.Tostoptheburstdelivery,releasetheHoldfor50HzBurstbutton.TheHoldfor50HzBurstbuttonwillbecome\\ndimmed again.\\n6.Todeliveradditional 50HzBurstpacing,repeatthesesteps.\\nNOTE:Real-time EGMsandannotated eventmarkers willcontinuetobedisplayed duringtheentiretestsequenc e.\\nCOMMANDED THERAPY METHODS\\nThecommanded EPtestmethods, Commanded ShockandCommanded ATP,maybedeliveredindependently ofthe\\nprogrammed detection andtherapyparamete rs.Ifthepulsegenerator isintheprocessofdelivering therapywhena\\ncomman dedmethod isinitiated, theEPTestfunction overrides andabortsthetherapyinprocess.Ifanepisode isnot\\ninprogress,thenaCommanded Ventricular Episode willberecordedintheArrhythmia Logbook. Commanded Shock\\nandCommanded ATPdelivery isinhibited whentheDIVERTTHERAPY keyispressedorwhenamagnet ispositioned\\noverthepulsegenerator,ifitisprogrammed toInhibitTherapy.\\nCommanded Shock\\nTheCommanded Shockfeatureallowsdelivery ofashockwithprogrammable EnergyandCoupling Interval.\\nAllCommanded ShocksareCommitted anddeliveredR-Wave synchronouslywhentheCoupling Intervalis\\nprogrammed toSync.ShockWaveform andPolarity areidentical todetection-initiated shocksbutaprogrammed\\nCoupling Intervalmaybespecified. TheCoupling Intervalisinitiated atthepointwheretheshockwouldhavebeen\\ndeliveredinSyncmode,butisinsteaddeliveredattheprogrammed Coupling Interval. Following anyCommanded\\nShockdelivery,Post-ShockRedetection isusedandPost-shockPacingisactivated.\\nPerforming Commanded ShockDelivery\\n1.SelecttheCommanded Shockoption.\\n2.SelectthedesiredvaluesfortheCoupling IntervalandShockEnergy.\\n3.SelecttheEnablecheckbox. TheDeliverShockbuttonwillbecome available.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 197}), Document(page_content='Electrophysiologic Testing\\nCommanded TherapyMethods7-9\\n4.SelecttheDeliverShockbuttontoinitiateshockdelivery.TheCommanded Shockisrecordedintherapyhistory.\\n5.Todeliversubsequent shocks,repeatthesesteps.\\nCommanded ATP\\nCommanded ATPallowsyoutomanually deliverATPschemes, independent oftheprogrammed detection and\\ntherapyparameters. Youcanconfigure theCommanded ATPbyeitherselecting thetypeofATPscheme orby\\nprogramming ATPparamete rsontheDetailsscreeninordertodeliverCommanded ATP.\\nTheEPTempVModemustbeprogrammed toMonitor OnlytoensuretheCommanded ATPdoesnotinterferewith\\ndetection-initiated ATP.\\nPerforming Commanded ATP\\n1.Ifthepulsegenerator Ventricular TachyModeisnotcurrentlyprogrammed toMonitor Only,selecttheMonitor\\nOnlyEPTempVModeoption.\\n2.SelectthetypeofATPscheme andselectthevalueforNumber ofBursts.\\n3.SelecttheStartVentricular ATPbuttontoinitiatethefirstburstintheselected ATPscheme. TheBursts\\nRemaining counterwilldecrement aseachburstiscomplete d.\\n4.SelecttheContinue buttonforeachadditional burstdelivery desired. Ifallburstsinascheme havebeen\\ndelivered,theBurstsRemaining counter willreturntotheinitialcount,andtheContinue buttonwillbedimmed.\\n5.OtherATPschemes maybeselected atanytime;selectthedesiredscheme andrepeattheabovesequenc e.The\\nCommanded ATPisrecordedasaphysician-commanded therapy counter anddisplayed onthecountersscreen.\\n6.AfterusingCommanded ATP,remember toprogramtheEPTempVModetoMonitor +Therapy orleavethe\\nscreensothattheEPTempVModeisendedandthepermanent TachyModeisresumed.\\nNOTE:IfanybuttonotherthantheContinue buttonisselected duringdelivery ofaCommanded ATPscheme, the\\nscheme willberesetandtheBurstsRemaining boxwillberestored toitsinitialvalue.TheStartVentricular ATP\\nbuttonmustbereselectedtoinitiatethescheme again.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 198}), Document(page_content='7-10Electrophysiologic Testing\\nCommanded TherapyMethods', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 199}), Document(page_content='A-1\\nPROGRAMMABLE OPTIONS\\nAPPENDIX A\\nTableA–1.ZIPTelemetry settings\\nParameter Programmable Values Nominala\\nCommunication Mode EnableuseofZIPtelemetry (Mayrequirelimiteduse\\nofwand);Usewandforalltelemetr yEnableuseofZIPtelemetry (Mayrequirelimiteduse\\nofwand)\\na.IftheCommunication Modeisselected viatheUtilitiesbuttononthePRMStartupscreen,theNominal settingwithintheZOOMVIEW Programmer software application willcorrespondto\\nthevaluechosenontheStartupscreen.\\nTableA–2.TachyModeparameter\\nParameter Programmable Values Nominal\\nTachyMode Off;Monitor Only;Monitor +Therapy; Enable\\nElectrocautery Protection; EnableMRIProtectionaStorage\\na.Available inmodelswiththeMRIProtection Modefeature.\\nTableA–3.Ventricular Zonesparameter\\nParameter Programmable Values Nominal\\nVentricular Zones 1;2;3 1\\nTableA–4.Detection parameters for1-zone,2-zone,and3-zoneconfigurations\\nParameter VT-1Zone VTZone VFZone Nominal\\nRatea(bpm)3zones\\n(interval sinms)90;95;...;200(667–300) 110;115;...;210(545–286);\\n220(273)130;135;...;210(462–286);\\n220;230;240;250(273–240)140(Toleranc e±5ms)forVT-\\n1Zone\\n170(Toleranc e±5ms)forVT\\nZone\\n200(Toleranc e±5ms)forVF\\nZone\\nRatea(bpm)2zones\\n(interval sinms)–– 90;95;...;210(667–286); 220\\n(273)110;115;...;210(545–286);\\n220;230;240;250(273–240)170(Toleranc e±5ms)forVT\\nZone\\n200(Toleranc e±5ms)forVF\\nZone\\nRatea(bpm)1zone(intervals\\ninms)–– –– 90;95;...;210(667–286);220\\n(273)200(Toleranc e±5ms)\\nInitialDurationb(sec)3zones 1.0;1.5;...;5.0;6.0;7.0;...;\\n15.0;20.0;25.0;...;60.01.0;1.5;...;5.0;6.0;7.0;...;\\n15.0;20.0;25.0;30.01.0;1.5;...;5.0;6.0;7.0;...;\\n15.02.5(Toleranc e±1cardiac\\ncycle)forVT-1Zone\\n2.5(Toleranc e±1cardiac\\ncycle)forVTZone\\n2.5(Toleranc e±1cardiac\\ncycle)forVFZone\\nInitialDurationb(sec)2zones –– 1.0;1.5;...;5.0;6.0;7.0;...;\\n15.0;20.0;25.0;30.01.0;1.5;...;5.0;6.0;7.0;...;\\n15.02.5(Toleranc e±1cardiac\\ncycle)forVTZone\\n2.5(Toleranc e±1cardiac\\ncycle)forVFZone\\nInitialDuration(sec)1zone –– –– 1.0;1.5;...;5.0;6.0;7.0;...;\\n15.02.5(Toleranc e±1cardiac\\ncycle)\\nRedetection Durationb(sec)3\\nzones1.0;1.5;...;5.0;6.0;7.0;...;\\n15.01.0;1.5;...;5.0;6.0;7.0;...;\\n15.01.0(nonprog rammable) 1.0(Toleranc e±1cardiac\\ncycle)forallzones\\nRedetection Duration (sec)2\\nzones–– 1.0;1.5;...;5.0;6.0;7.0;...;\\n15.01.0(nonprog rammable) 1.0(Toleranc e±1cardiac\\ncycle)forallzones', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 200}), Document(page_content='A-2Programmable Options\\nTableA–4.Detection parameters for1-zone,2-zone,and3-zoneconfigurations (continued)\\nParameter VT-1Zone VTZone VFZone Nominal\\nRedetection Duration(sec)1\\nzone–– –– 1.0(nonprogr ammable) 1.0(Toleranc e±1cardiac\\ncycle)\\nPost-shockDurationb(sec)3\\nzones1.0;1.5;...;5.0;6.0;7.0;...;\\n15.0;20.0;25.0;...;60.01.0;1.5;...;5.0;6.0;7.0;...;\\n15.0;20.0;25.0;30.01.0(nonprogr ammable) 1.0(Toleranc e±1cardiac\\ncycle)forallzones\\nPost-shockDuration (sec)2\\nzones–– 1.0;1.5;...;5.0;6.0;7.0;...;\\n15.0;20.0;25.0;30.01.0(nonprogr ammable) 1.0(Toleranc e±1cardiac\\ncycle)forallzones\\nPost-shockDuration (sec)1\\nzone–– –– 1.0(nonprogr ammable) 1.0(Toleranc e±1cardiac\\ncycle)\\na.TheRatedifferencebetween eachtachyzonemustbeatleast20bpm.ThelowestTachyRateThreshold mustbe≥5bpmhigherthantheMaximum Tracking Rate,Maximum SensorRate,\\nandtheMaximum PacingRate;andthelowestTachyRateThreshold mustbe≥15bpmhigherthantheLowerRateLimit.\\nb.TheDuration inazonemustbeequaltoorgreaterthantheDuration inthenexthighestzone.\\nTableA–5.Ventricular Detection EnhancementTypefor2-zoneand3-zoneconfigurations\\nParameter Programmable Values Nominal\\nDetection EnhancementType Off;Rhythm IDa;Onset/Stability Rhythm ID\\na.Available inmodelswiththeRhythm IDfeature.\\nTableA–6.Onset/Stability detection enhancement parameters for2-zoneand3-zoneconfigurations\\nParameter VT-1Zone VTZone VFZone Nominal\\nDetection Enhancement3\\nzonesOff;On Off;On –– On(VT-1);Off(VT)\\nDetection Enhancement2\\nzones–– Off;On –– On\\nVRate>ARate3zonesaOff;On –– –– On\\nVRate>ARate2zones –– Off;On –– On\\nAFibRateThreshold(bpm)3\\nzonesabOff;100;110;...;300 –– –– 170(Toleranc e±5ms)\\nAFibRateThreshold(bpm)2\\nzonesb–– Off;100;110;...;300 –– 170(Toleranc e±5ms)\\nStability (ms)3zonesa Off;6;8;...;32;35;40;...;\\n60;70;80;...;120–– –– 20(DR);30(VR)(Toleranc e±5\\nms)\\nStability (ms)2zones –– Off;6;8;...;32;35;40;...;\\n60;70;80;...;120–– 20(DR);30(VR)(Toleranc e±5\\nms)\\nShockIfUnstable (ms)3zones –– Off;6;8;...;32;35;40;...;\\n60;70;80;...;120–– 30(Toleranc e±5ms)\\nShockIfUnstable (ms)2zones –– Off;6;8;...;32;35;40;...;\\n60;70;80;...;120–– Off(Toleranc e±5ms)\\nOnset(%orms)3zonesa Off;9;12;16;19;...;3741;44;\\n47;50%or50;60;...;250ms–– –– 9%(Toleranc e±5ms)\\nOnset(%orms)2zones –– Off;9;12;16;19;...;37;41;\\n44;47;50%or50;60;...;250\\nms–– 9%(Toleranc e±5ms)\\nStability And/OrOnset3\\nzonesaAnd;Or –– –– And\\nStability And/OrOnset2\\nzones–– And;Or –– And', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 201}), Document(page_content='Programmable Options A-3\\nTableA–6.Onset/Stability detection enhancem entparameters for2-zoneand3-zoneconfigurations (continued)\\nParameter VT-1Zone VTZone VFZone Nominal\\nSustained RateDuration(min:\\nsec)3zonesaOff;00:10;00:15;...;00:55;\\n01:00;01:15;...;02:00;02:30;\\n03:00;...;10:00;15:00;\\n20:00;...;60:00–– –– 03:00(Toleranc e±1cardiac\\ncycle)\\nSustained RateDuration(min:\\nsec)2zones–– Off;00:10;00:15;...;00:55;\\n01:00;01:15;...;02:00;02:30;\\n03:00;...;10:00;15:00;\\n20:00;...;60:00–– 03:00(Toleranc e±1cardiac\\ncycle)\\nAtrialTachyarrhythmia\\nDiscrimination 3zonesaOff;On –– –– On\\nAtrialTachyarrhythmia\\nDiscrimination 2zones–– Off;On –– On\\nSinusTachycardia\\nDiscrimination 3zonesaOff;On –– –– On\\nSinusTachycardia\\nDiscrimination 2zones–– Off;On –– On\\nPolymorphic VTDiscrimination\\n3zones–– Off;On –– On\\nPolymorphic VTDiscrimination\\n2zones–– Off;On –– Off\\na.IfallVT-1therapy isprogramm edtoOff,detection enhancements willapplyintheVTzone,nottheVT-1zone.\\nb.AlloftheAFibRateThresholds arelinkedtotheATRTriggerRateandAtrialFlutterResponse Rate.Ifanyoneoftheseratesisreprogrammed, theotherswillautomatically changetothe\\nsamevalue.\\nTableA–7.RhythmIDdetection enhancement parameters for2-zoneand3-zoneconfigurations\\nParameter VT-1Zone VTZone VFZone Nominal\\nInitialDetection Enhancement\\n3zonesOff;On Off;On –– On(VT-1);Off(VT)\\nInitialDetection Enhancement\\n2zones–– Off;On –– On\\nSustained RateDuration(min:\\nsec)3zonesOff;00:10;00:15;...;01:00;\\n01:15;...;02:00;02:30;...;\\n10:00;15:00;...;60:00Off;00:10;00:15;...;01:00;\\n01:15;...;02:00;02:30;...;\\n10:00;15:00;...;60:00–– 03:00(VT-1andVT)\\n(Toleranc e±1cardiaccycle)\\nSustained RateDuration(min:\\nsec)2zones–– Off;00:10;00:15;...;01:00;\\n01:15;...;02:00;02:30;...;\\n10:00;15:00;...;60:00–– 03:00(Toleranc e±1cardiac\\ncycle)\\nPassiveMethod 3zones(one\\nvalueforallzones)Off;On Off;On –– On\\nPassiveMethod 2zones –– Off;On –– On\\nActiveMethod 3zones(one\\nvalueforallzones)Off;On Off;On –– On\\nActiveMethod 2zones –– Off;On –– On\\nRhythmMatch Threshold (%)3\\nzones(onevalueforallzones)70;71;...;96 70;71;...;96 –– 94\\nRhythmMatch Threshold (%)2\\nzones–– 70;71;...;96 –– 94\\nTemporary LRL(ppm)3zones\\n(onevalueforallzones)UseNormalBradyLRL;30;35;\\n...;105UseNormalBradyLRL;30;35;\\n...;105–– UseNormalBradyLRL\\n(Toleranc e±5ms)\\nTemporary LRL(ppm)2zones –– UseNormalBradyLRL;30;35;\\n...;105–– UseNormalBradyLRL\\n(Toleranc e±5ms)', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 202}), Document(page_content='A-4 Programmable Options\\nTableA–7.RhythmIDdetection enhancement parameters for2-zoneand3-zoneconfigurations (continued)\\nParameter VT-1Zone VTZone VFZone Nominal\\nAtrialTachyDiscrimination 3\\nzones(onevalueforallzones)Off;On Off;On –– On\\nAtrialTachyDiscrimination 2\\nzones–– Off;On –– On\\nAFibRateThreshold(bpm)3\\nzones(onevalueforallzones)\\nac100;110;...;300 100;110;...;300 –– 170(Toleranc e±5ms)\\nAFibRateThreshold(bpm)2\\nzonesac–– 100;110;...;300 –– 170(Toleranc e±5ms)\\nStability (ms)3zones(one\\nvalueforallzones)ab6;8;...;32;35;40;...;60;70;\\n...;1206;8;...;32;35;40;...;60;70;\\n...;120–– 20(DR);30(VR)(Toleranc e±5\\nms)\\nStability (ms)2zonesab –– 6;8;...;32;35;40;...;60;70;\\n...;120–– 20(DR);30(VR)(Toleranc e±5\\nms)\\na.Thisparameter isusedininitialdetection andPost-shockDetection. Changing thevalueforinitialdetection willchangethevalueforPost-Therapy Brady.\\nb.TheStability parameter onlyappliesinPost-shockforVRdevices.\\nc.AlloftheAFibRateThresholds arelinkedtotheATRTriggerRateandAtrialFlutterResponse Rate.Ifanyoneoftheseratesisreprogrammed, theotherswillautomatically changetothe\\nsamevalue.\\nTableA–8.Post-shockOnset/Stability detection enhancement parameters for2-zoneand3-zoneconfigurations\\nParameter VT-1Zone VTZone VFZone Nominal\\nPost-shockVRate>ARate3\\nzonesaOff;On –– –– On\\nPost-shockVRate>ARate2\\nzones–– Off;On –– On\\nPost-shockAFibRate\\nThreshold (bpm)3zonesabOff;100;110;...;300 –– –– 170(Toleranc e±5ms)\\nPost-shockAFibRate\\nThreshold (bpm)2zonesb–– Off;100;110;...;300 –– 170(Toleranc e±5ms)\\nPost-shockStability (ms)3\\nzonesaOff;6;8;...;32;35;40;...;\\n60;70;80;...;120–– –– 20(DR);30(VR)(Toleranc e±5\\nms)\\nPost-shockStability (ms)2\\nzones–– Off;6;8;...;32;35;40;...;\\n60;70;80;...;120–– 20(DR);30(VR)(Toleranc e±5\\nms)\\nPost-shockSustained Rate\\nDuration(min:sec) 3zonesaOff;00:10;00:15;...;00:55;\\n01:00;01:15;...;02:00;02:30;\\n03:00;...;10:00;15:00;\\n20:00;...;60:00–– –– 00:15(Tolerance±1cardiac\\ncycle)\\nPost-shockSustained Rate\\nDuration(min:sec) 2zones–– Off;00:10;00:15;...;00:55;\\n01:00;01:15;...;02:00;02:30;\\n03:00;...;10:00;15:00;\\n20:00;...;60:00–– 00:15(Tolerance±1cardiac\\ncycle)\\na.IfallVT-1therapy isprogrammed toOff,detection enhancements willapplyintheVTzone,nottheVT-1zone.\\nb.AlloftheAFibRateThresholds arelinkedtotheATRTriggerRateandAtrialFlutterResponse Rate.Ifanyoneoftheseratesisreprogrammed, theotherswillautomatically changetothe\\nsamevalue.\\nTableA–9.Post-shockRhythmIDdetection enhancement parameters for2-zoneand3-zoneconfigurations\\nParameter VT-1Zone VTZone VFZone Nominal\\nPostShockDetection\\nEnhance ment3zonesOff;On Off;On –– Off\\nPostShockDetection\\nEnhance ment2zones–– Off;On –– Off', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 203}), Document(page_content='Programmable Options A-5\\nTableA–9.Post-shockRhythmIDdetection enhancement parameters for2-zoneand3-zoneconfigurations (continued)\\nParameter VT-1Zone VTZone VFZone Nominal\\nPostShockSustained Rate\\nDuration (min:sec) 3zonesOff;00:10;00:15;...;00:55;\\n01:00;01:15;...;02:00;02:30;\\n...;10:00;15:00;...;60:00Off;00:10;00:15;...;00:55;\\n01:00;01:15;...;02:00;02:30;\\n...;10:00;15:00;...;60:00–– 0:15(Toleranc e±1cardiac\\ncycle)\\nPostShockSustained Rate\\nDuration (min:sec) 2zones–– Off;00:10;00:15;...;00:55;\\n01:00;01:15;...;02:00;02:30;\\n...;10:00;15:00;...;60:00–– 0:15(Toleranc e±1cardiac\\ncycle)\\nAFibRateThreshold (bpm)3\\nzones(onevalueforallzones)\\nac100;110;...;300 100;110;...;300 –– 170(Toleranc e±5ms)\\nAFibRateThreshold (bpm)2\\nzonesac–– 100;110;...;300 –– 170(Toleranc e±5ms)\\nStability (ms)3zones(one\\nvalueforallzones)ab6;8;...;32;35;40;...;60;70;\\n...;1206;8;...;32;35;40;...;60;70;\\n...;120–– 20(DR);30(VR)(Tolerance±5\\nms)\\nStability (ms)2zonesab –– 6;8;...;32;35;40;...;60;70;\\n...;120–– 20(DR);30(VR)(Tolerance±5\\nms)\\na.Thisparameter isusedininitialdetection andPost-shockDetection. Changing thevalueforinitialdetection willchangethevalueforPost-Therapy Brady.\\nb.TheStability parameter onlyappliesinPost-shockforVRdevices.\\nc.AlloftheAFibRateThresholds arelinkedtotheATRTriggerRateandAtrialFlutterResponse Rate.Ifanyoneoftheseratesisreprogrammed, theotherswillautomatically changetothe\\nsamevalue.\\nTableA–10.Ventricular ATPparameters (specified intoa750Ωload)\\nParameter VT-1Zone VTZone VFZone Nominal\\nATPType3zones Off;Burst;Ramp;Scan;\\nRamp/ScanOff;Burst;Ramp;Scan;\\nRamp/Scan–– Off(VT-1);Burst(VTATP1);\\nRamp(VTATP2)\\nATPType2zones –– Off;Burst;Ramp;Scan;\\nRamp/Scan–– Off(VTATP1andVTATP2)\\nNumber ofBursts(per\\nscheme) 3zonesOff;1;2;...;30 Off;1;2;...;30 –– Off(VT-1);2(VTATP1);1(VT\\nATP2)\\nNumber ofBursts(per\\nscheme) 2zones–– Off;1;2;...;30 –– Off(VTATP1andVTATP2)\\nInitialPulse(pulses) 3zones 1;2;...;30 1;2;...;30 –– 4(VT-1);10(VT)\\nInitialPulse(pulses) 2zones –– 1;2;...;30 –– 10\\nPulseIncrement (pulses) 3\\nzones0;1;...;5 0;1;...;5 –– 0\\nPulseIncrement (pulses) 2\\nzones–– 0;1;...;5 –– 0\\nMaximum Number ofPulses3\\nzones1;2;...;30 1;2;...;30 –– 4(VT-1);10(VT)\\nMaximum Number ofPulses2\\nzones–– 1;2;...;30 –– 10\\nCoupling Interval(%orms)3\\nzones50;53;56;59;63;66;...;84;\\n88;91;94;97%or120;130;\\n...;750ms50;53;56;59;63;66;...;84;\\n88;91;94;97%or120;130;\\n...;750ms–– 81%(Toleranc e±5ms)\\nCoupling Interval(%orms)2\\nzones–– 50;53;56;59;63;66;...;84;\\n88;91;94;97%or120;130;\\n...;750ms–– 81%(Toleranc e±5ms)\\nCoupling IntervalDecrement\\n(ms)3zonesd0;2;...;30 0;2;...;30 –– 10(Toleranc e+/-5ms)when\\nATPtypeisScanandRamp/\\nScan;otherwise 0(Toleranc e\\n+/-5ms)', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 204}), Document(page_content='A-6Programmable Options\\nTableA–10.Ventricular ATPparameters (specified intoa750Ωload)(continued)\\nParameter VT-1Zone VTZone VFZone Nominal\\nCoupling IntervalDecrement\\n(ms)2zonesd–– 0;2;...;30 –– 10(Toleranc e+/-5ms)when\\nATPtypeisScanandRamp/\\nScan;otherwise0(Toleranc e\\n+/-5ms)\\nBurstCycleLength(BCL)(%or\\nms)3zones50;53;56;59;63;66;...;84;\\n88;91;94;97%or120;130;\\n...;750ms50;53;56;59;63;66;...;84;\\n88;91;94;97%or120;130;\\n...;750ms–– 81%(Toleranc e±5ms)\\nBurstCycleLength(BCL)(%or\\nms)2zones–– 50;53;56;59;63;66;...;84;\\n88;91;94;97%or120;130;\\n...;750ms–– 81%(Toleranc e±5ms)\\nRampDecrement (ms)3\\nzonese0;2;...;30 0;2;...;30 –– 10(Toleranc e+/-5ms)when\\nATPtypeisRampandRamp/\\nScan;otherwise0(Toleranc e\\n+/-5ms)\\nRampDecrement (ms)2\\nzonese–– 0;2;...;30 –– 10(Toleranc e+/-5ms)when\\nATPtypeisRampandRamp/\\nScan;otherwise0(Toleranc e\\n+/-5ms)\\nScanDecrement (ms)3\\nzonesd0;2;...;30 0;2;...;30 –– 10(Toleranc e+/-5ms)when\\nATPtypeisScanandRamp/\\nScan;otherwise0(Toleranc e\\n+/-5ms)\\nScanDecrement (ms)2\\nzonesd–– 0;2;...;30 –– 10(Toleranc e+/-5ms)when\\nATPtypeisScanandRamp/\\nScan;otherwise0(Toleranc e\\n+/-5ms)\\nMinimum Interval(ms)3\\nzones120;130;...;400 120;130;...;400 –– 220(Tolerance±5ms)\\nMinimum Interval(ms)2\\nzones–– 120;130;...;400 –– 220(Tolerance±5ms)\\nRightVentricular ATPPulse\\nWidtha(ms)3zones(one\\nvalueforallzones)0.1;0.2;...;2.0 0.1;0.2;...;2.0 –– 1.0(Toleranc e±0.03msat<\\n1.8ms;±0.08msat≥1.8ms)\\nRightVentricular ATPPulse\\nWidtha(ms)2zones(one\\nvalueforallzones)–– 0.1;0.2;...;2.0 –– 1.0(Toleranc e±0.03msat<\\n1.8ms;±0.08msat≥1.8ms)\\nRightVentricular ATP\\nAmplitudea(V)3zones(one\\nvalueforallzones)0.1;0.2;...;3.5;4.0;...;7.5 0.1;0.2;...;3.5;4.0;...;7.5 –– 5.0(Toleranc e±15%or±100\\nmV,whichever isgreater)\\nRightVentricular ATP\\nAmplitudea(V)2zones(one\\nvalueforallzones)–– 0.1;0.2;...;3.5;4.0;...;7.5 –– 5.0(Toleranc e±15%or±100\\nmV,whichever isgreater)\\nATPTime-outb(min:sec) 3\\nzonesOff;00:10;00:15;…;01:00;\\n01:15;…;02:00; 02:30;\\n..;10:00; 15:00;..;60:00Off;00:10;00:15;…;01:00;\\n01:15;…;02:00; 02:30;\\n..;10:00; 15:00;..;60:00–– 01:00', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 205}), Document(page_content='Programmable Options A-7\\nTableA–10.Ventricular ATPparameters (specified intoa750Ωload)(continued)\\nParameter VT-1Zone VTZone VFZone Nominal\\nATPTime-out (min:sec) 2\\nzones–– Off;00:10;00:15;…;01:00;\\n01:15;…;02:00; 02:30;\\n..;10:00; 15:00;..;60:00–– 01:00\\nQUICKCONVERT ATP(VFOnly)\\n1,2,or3zones–– –– Off;On On\\na.Theprogrammed Amplitude andPulseWidthvaluesaffectPostTherapy BradyPacing,butareseparately programmable fromNormalBradyPacing,Temporary BradyPacing,andEPTest.\\nb.TheVT-1ATPTime-out mustbegreaterthanorequaltotheVTATPTime-out.\\nc.ValuesapplyifBurstisselected fortheVT-1ATPparameter.\\nd.ValuesapplyonlyifATPtypeisScanorRamp/Scan\\ne.ValuesapplyonlyifATPtypeisRamporRamp/Scan\\nTableA–11.Ventricular ShockParameters\\nParameter Programmable Values Nominal\\nShocks1and2energy,2zonesabcOff;0.1;0.3;0.6;0.9;1.1;1.7;2;3;5;6;7;9;11;14;\\n17;21;23;26;29;31;36;41Off(VT)\\n41J(VF)(Tolerance+150/-60% for0.1J;±60%for\\n0.3J;±40%for0.6–3J;±20%for5–36J;±10%for\\n41J)\\nShocks1and2energy,3zonesabcOff;0.1;0.3;0.6;0.9;1.1;1.7;2;3;5;6;7;9;11;14;\\n17;21;23;26;29;31;36;41Off(VT-1)\\n41J(VTandVF)(Toleranc e+150/-60% for0.1J;±\\n60%for0.3J;±40%for0.6–3J;±20%for5–36J;\\n±10%for41J)\\nEnergyofRemaining Shocks,2zonesacOff;41 Off(VT)\\n41J(VF)(Tolerance±10%for41J)\\nEnergyofRemaining Shocks,3zonesacOff;41 Off(VT-1)\\n41J(VTandVF)(Toleranc e±10%for41J)\\nLeadPolaritydInitial;Reversed Initial\\nCommitted Shock Off;On Off\\nShockLeadVector RVCoiltoRACoilandCan;RVCoiltoCan;RVCoilto\\nRACoilRVCoiltoRACoilandCan\\na.Biphasic energyisspecified.\\nb.TheShock2energylevelmustbegreaterthanorequaltotheShock1energylevel.\\nc.InaVT-1zoneofa3-zoneconfigur ationoraVTzoneofa2-zoneconfigur ation,allorsomeoftheshocksmaybeprogrammed toOffwhileothershocksinthatzoneareprogrammed in\\njoules.\\nd.Acommanded STATSHOCKisdelivered attheprogrammed Polarity.\\nTableA–12.Pacingtherapyparameters (Normal,Post-Therapy,andTemporar y)(specified intoa750Ωload)\\nParameter Programmable Values Nominal\\nModeaeiDDD(R); DDI(R);VDD(R); VVI(R);AAI(R);Off;\\nTemporary: DDD;DDI;DOO;VDD;VVI;VOO;AAI;\\nAOO;OffDDD(DR);VVI(VR)\\nRYTHMIQhOff;AAI(R)withVVIBackup Off\\nLowerRateLimit(LRL)abc(ppm) 30;35;...;185 60(Toleranc e±5ms)\\nMaximum Tracking Rate(MTR)e(ppm) 50;55;...;185 130(Toleranc e±5ms)\\nMaximum SensorRate(MSR)eh(ppm) 50;55;...;185 130(Toleranc e±5ms)', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 206}), Document(page_content=\"A-8Programmable Options\\nTableA–12.Pacingtherapyparameters (Normal, Post-Therapy,andTemporary) (specified intoa750Ωload)(continued)\\nParameter Programmable Values Nominal\\nPulseAmplitudeacd(atrium) (V) Auto;0.1;0.2;...3.5;4.0;...;5.0;\\nTemporary:0.1;0.2;...;3.5;4.0;...;5.03.5(5.0post-therapy) (Toleranc e±15%or±100mV,\\nwhichever isgreater)\\nPulseAmplitudeacd(rightventricle) (V) Auto;0.1;0.2;...;3.5;4.0;...;7.5;\\nTemporary:0.1;0.2;...;3.5;4.0;...;7.53.5(5.0post-therapy) (Toleranc e±15%or±100mV,\\nwhichever isgreater)\\nPulseAmplitude DailyTrendm(independently\\nprogrammable ineachchamber)Disabled; Enabled Enabled\\nPulseWidthacdk(atrium, rightventricle) (ms) 0.1;0.2,...,2.0 0.4(1.0post-therapy) (Tolerance±0.03msat<1.8\\nms;±0.08msat≥1.8ms)\\nAtrialPace/Sense Configura tionaeBipolar; Off Bipolar\\nAccelerometerehOn;Passive Passive\\nAccelerometer ActivityThresholdehVeryHigh;High;Medium High;Medium; Medium\\nLow;Low;VeryLowMedium\\nAccelerometer Reaction Timeeh(sec) 10;20;...;50 30\\nAccelerometer Response Factoreh1;2;...;16 8\\nAccelerometer Recovery Timeeh(min) 2;3;...;16 2\\nMinuteVentilationehOn;Passive; Off Passive\\nMinuteVentilation Response Factoreh1;2;...;16 8\\nMinuteVentilation FitnessLevel Sedentary; Active;Athletic; Enduranc eSports Active\\nPatient's Agel≤5;6–10;11–15;...;91–95;≥96 56–60\\nPatient's GenderlMale;Female Male\\nVentilatory Threshold (ppm) 30;35;...;185 120(Toleranc e±5ms)\\nVentilatory Threshold Response (%) Off;85;70;55 70\\nMaximum PVARPae(ms) 150;160;...;500 280(Tolerance±5ms)\\nMinimum PVARPae(ms) 150;160;...;500 240(Tolerance±5ms)\\nPVARPAfterPVCae(ms) Off;150;200;...;500 400(Toleranc e±5ms)\\nV-Blank AfterA-Paceaf(ms) 45;65;85;Smart 65(Toleranc e±5ms)\\nA-Blank AfterV-Paceaf(ms) 45;65;85;Smart Smart(Toleranc e±5ms)\\nA-Blank AfterV-Senseaf(ms) 45;65;85;Smart Smart(Toleranc e±5ms)\\nMaximum VRP(rightventricle)ae(ms) 150;160;...;500 250(Toleranc e±5ms)\\nMinimum VRP(rightventricle)ag(ms) 150;160;...;500 230(DR);250(VR)(Toleranc e±5ms)\\nMaximum PacedAVDelayae(ms) 30;40;...;400 180(Toleranc e±5ms)\\nMinimum PacedAVDelayae(ms) 30;40;...;400 80(Tolerance±5ms)\\nMaximum SensedAVDelayae(ms) 30;40;...;400 150(Toleranc e±5ms)\\nMinimum SensedAVDelayae(ms) 30;40;...;400 65(Toleranc e±5ms)\\nAVSearch+ehOff;On Off\\nAVSearch+SearchIntervaleh(cycles) 32;64;128;256;512;1024 32(Toleranc e±1cycle)\\nAVSearch+SearchAVDelayeh(ms) 30;40;...;400 300(Toleranc e±5ms)\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 207}), Document(page_content='Programmable Options A-9\\nTableA–12.Pacingtherapyparameters (Normal,Post-Therapy,andTemporar y)(specified intoa750Ωload)(continued)\\nParameter Programmable Values Nominal\\nRespiratory SensoraeOff;On Off\\nRespiration-r elatedTrendsnoOff;On On\\nRateHysteresis Hysteresis Offseteh(ppm) -80;-75;...;-5;Off Off(Tolerance±5ms)\\nRateHysteresis SearchHysteresiseh(cycles) Off;256;512;1024;2048;4096 Off(Tolerance±1cycle)\\nRateSmoothing (up,down)eh(%) Off;3;6;9;12;15;18;21;25 Off(Tolerance±1%)\\nRateSmoothing Maximum PacingRate(MPR)e(\\nppm)50;55;...;185 130(Toleranc e±5ms)\\nNoiseResponseaejAOO;VOO;DOO;InhibitPacing DOOforDDD(R)andDDI(R)modes;VOOforVDD(R)\\nandVVI(R)modes; AOOforAAI(R)mode\\nPostTherapy PacingPeriod(min:sec) (available post-\\nshockonly)00:15;00:30;00:45;01:00;01:30;02:00;03:00;\\n04:00;05:00;10:00;15:00;30:00;45:00;and\\n60:0000:30(Toleranc e±1cardiaccycle)\\na.Theprogrammed NormalBradyvalueswillbeusedasthenominal valuesforTemporary Bradypacing.\\nb.Thebasicpulseperiodisequaltothepacingrateandthepulseinterval(nohysteresis). Runaway protection circuitry inhibitsbradycar diapacingabove205ppm.Magnet application does\\nnotaffectpacingrate(testpulseinterval).\\nc.Separately programm ableforATP/Post -shock,Temporary Brady,andEPTest.\\nd.Valuesarenotaffected bytemperatur evariation withintherange20°–43°C.\\ne.Thisparameter isusedglobally inNormalBradypacingandPost-Therapy Bradypacing.Changing thevalueforNormalBradywillchangethevalueforPost-Therapy Brady.\\nf.Thisparameterisautomatically settoatleast85msforPost-Therapy Brady.\\ng.Thisparameter isautomatically adjusted inPost-Therapy Bradytoallowappropriate sensing.\\nh.Thisparameter isdisabled duringTemporary Brady.\\ni.Theprogrammable valuesforVRdevicesonlyincludeVVI(R),Off;Temporary: VVI,VOO,Off\\nj.Theprogrammable valuesforVRdevicesonlyincludes VOOandInhibitPacingandassuchthenominal isVOO.\\nk.WhenthePulseAmplitude issettoAutoorPulseAmplitude DailyTrendisenabled thePulseWidthisfixedat0.4ms.\\nl.Thisparameter isusedforcalculating Ventilatory Threshold Response.\\nm.Thisparameter isautomatically enabled ifAutoisselected forthePulseAmplitude.\\nn.ThisvalueislocatedontheLeadSetupscreen.\\no.ThisparameterisusedtocontroltheRespiratorySensor.\\nTableA–13.AtrialTachyParameters\\nParameter Programmable Values Nominal\\nATRModeSwitchabOff;On On\\nATRTriggerRateabd(bpm) 100;110;...;300 170(Toleranc e±5ms)\\nATRDurationab(cycles) 0;8;16;32;64;128;256;512;1024;2048 8(Toleranc e±1cardiaccycle)\\nATREntryCountab(cycles) 1;2;...;8 8\\nATRExitCountab(cycles) 1;2;...;8 8\\nATRFallback Modebe VDI;DDI;VDIR;DDIR DDI\\nATRFallback Timeab(min:sec) 00:00;00:15;00:30;00:45;01:00;01:15;01:30;\\n01:45;02:0000:30\\nATR/VTR Fallback LRLab(ppm) 30;35;...;185 70(Toleranc e±5ms)\\nATRVentricular RateRegulation (VRR)ab Off;On On\\nATRMaximum PacingRate(MPR)ab(ppm) 50;55;...;185 130(Toleranc e±5ms)\\nAtrialFlutterResponsebcOff;On Off\\nAtrialFlutterResponse TriggerRatebcd(bpm) 100;110;...;300 170(Toleranc e±5ms)\\nPMTTerminationbcOff;On On', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 208}), Document(page_content='A-10Programmable Options\\nTableA–13.AtrialTachyParameters (continued)\\nParameter Programmable Values Nominal\\nVentricular RateRegulation (VRR)bc Off;On Off\\nVRRMaximum PacingRate(MPR)bc(ppm) 50;55;...;185 130(Toleranc e±5ms)\\na.Theprogrammed NormalBradyvalueswillbeusedasthenominal valuesforTemporary Bradypacing.\\nb.Thisparameter isusedglobally inNormalBradypacingandPost-Therapy Bradypacing.Changing thevalueforNormalBradywillchangethevalueforPost-Therapy Brady.\\nc.Thisparametergetsdisabled duringTemporary Brady.\\nd.ATRTriggerRateandAtrialFlutterResponse RatearelinkedtoalltheAFibRateThresholds. Ifanyoneoftheseratesisreprogrammed, theotherswillautomatically changetothesame\\nvalue.\\ne.IfNormalBradyATRFallback ModeisDDIRorDDI,thenTemporary BradyATRFallback ModeisDDI.IfNormalBradyATRFallback ModeisVDIRorVDI,thenTemporary BradyATRFallback\\nModeisVDI.\\nTableA–14.MRIProtectionparameters\\nParameter Programmable Values Nominal\\nMRIBradyMode Off;VOO;AOO;DOO ––\\nMRILowerRateLimit(LRL)(ppm) 30;35;...;100 20ppmabovethenormalmodeLRL\\nMRIAtrialAmplitude (V) 2.0;2.1;…;3.5;4.0;…;5.0 5.0(Toleranc e±15%or±100mV,whichever is\\ngreater)a\\nMRIRightVentricular Amplitude (V) 2.0;2.1;…;3.5;4.0;…;5.0 5.0(Toleranc e±15%or±100mV,whichever is\\ngreater)a\\nMRIProtection Time-out (hours) Off;3;6;9;12 6\\na.Duringthetransition intotheMRIProtection Mode,itmaytakeupto6cardiacpacingcyclesforthepaceamplitude tomeetthespecified tolerancerange.\\nTableA–15.MagnetandBeeperfunctions\\nParameter Programmable Values Nominal\\nMagnet Response Off;StoreEGM;InhibitTherapy InhibitTherapy\\nBeepDuringCapacitor Charge Off;On Off\\nBeepWhenExplantisIndicated Off;On On\\nAtrialBeepWhenOut-of-Range Off;On Off\\nVentricular BeepWhenOut-of-Range Off;On Off\\nShockBeepWhenOut-of-Range Off;On Off\\nBeeper Off;On On\\nTableA–16.Sensitivity Adjustment\\nParameter Programmable Values Nominal\\nAtrialSensitivitya(mV) AGC0.15;AGC0.2;AGC0.25;AGC0.3;AGC0.4;…;\\nAGC1.0;AGC1.5AGC0.25\\nRightVentricular Sensitivitya(mV) AGC0.15;AGC0.2;AGC0.25;AGC0.3;AGC0.4;…;\\nAGC1.0;AGC1.5AGC0.6\\na.WithCENELEC waveform, perEN45502-2-2:2008.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 209}), Document(page_content='Programmable Options A-11\\nTableA–17.DailyLeadMeasurements\\nParameter Programmable Values Nominal\\nAtrialDailyIntrinsic Amplitude On;Off On\\nVentricular DailyIntrinsic Amplitude On;Off On\\nAtrialDailyImpedance On;Off On\\nVentricular DailyImpedance On;Off On\\nShockDailyImpedance On;Off On\\nAtrialLowImpedance Limit(Ω) 200;250;...;500 200\\nAtrialHighImpedance Limit(Ω) 2000;2250;...; 3000 2000\\nVentricular LowImpedance Limit(Ω) 200;250;...;500 200\\nVentricular HighImpedance Limit(Ω) 2000;2250;...; 3000 2000\\nShockHighImpedance Limit(Ω) 125;150;175;200 125\\nPost-Operative SystemTest(POST)(hours) 2;3;...;24 12\\nTableA–18.Ventricular Commanded ATP\\nParameteraProgrammable Values Nominal\\nCommanded Ventricular ATP(Type) Burst;Ramp;Scan;Ramp/Scan Burst\\nNumber OfBursts 1;2;...;30 30\\nInitialPulsesperBurst(pulses) 1;2;...;30 4\\nPulseIncrement (pulses) 0;1;..;5 0\\nMaximum Number ofPulses 1;2;...;30 4\\nCoupling Interval(%orms) 50;53;56;59;63;66;...;84;88;91;94;97%or120;\\n130;...;750ms81%(Toleranc e±5ms)\\nCoupling IntervalDecrement (ms) 0;2;...;30 0(Toleranc e±5ms)\\nBurstCycleLength(BCL)(%orms) 50;53;56;59;63;66;...;84;88;91;94;97%or120;\\n130;...;750ms81%(Toleranc e±5ms)\\nRampDecrement (ms) 0;2;...;30 0(Toleranc e±5ms)\\nScanDecrement (ms) 0;2;...;30 0(Toleranc e±5ms)\\nMinimum Interval(ms) 120;130;...;400 200(Toleranc e±5ms)\\na.Theventricular Commanded ATPPulseWidthandAmplitude valuesarethesameasprogrammed forventricular ATPtherapy.\\nTableA–19.50Hz/Manual BurstPacing\\nParameteraProgrammable Values Nominal\\nBurstInterval(ms) 20;30;...;750 600(Toleranc e±5ms)\\nMinimum Interval(ms) 20;30;...;750 200(Toleranc e±5ms)\\nDecrement (ms) 0;10;...;50 50(Toleranc e±5ms)\\na.Applied totheatriumorventricle depending onthechamber selected.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 210}), Document(page_content='A-12Programmable Options\\nTableA–20.Ventricular Commanded Shock\\nParameter Programmable Values Nominal\\nShock(J)(storedenergy) 0.1;0.3;0.6;0.9;1.1;1.7;2;3;5;6;7;9;11;14;17;\\n21;23;26;29;31;36;4141J(Tolerance+150/-60% for0.1J;±60%for0.3J;±\\n40%for0.6–3J;±20%for5–36J;±10%for41J)\\nCoupling Interval(ms) SYNC;50;60;...;500 SYNC\\nTableA–21.VFib(Ventricular Fibrillation) Induction\\nParameter Values\\nVFibHigh 15V(nonprog rammable) (Toleranc e±10V)\\nVFibLow 9V(nonprog rammable) (Toleranc e±7V)\\nTableA–22.ShockonTInduction\\nParameter Programmable Values Nominal\\nShock(J)(storedenergy) 0.1;0.3;0.6;0.9;1.1;1.7;2;3;5;6;7;9;11;14;17;\\n21;23;26;29;31;36;411.1J(Toleranc e+150/-60% for0.1J;±60%for0.3J;\\n±40%for0.6–3J;±20%for5–36J;±10%for41J)\\nNumber ofS1Pulses 1;2;...;30 8\\nS1Interval(ms) 120;130;...;750 400\\nCoupling Interval(ms) SYNC;10;20;...;500 310\\nTableA–23.SensorTrending\\nParameter Programmable Values Nominal\\nRecordingMethod BeatToBeat;Off;30SecondAverage 30SecondAverage\\nDataStorage Continuous; Fixed Continuous\\nTableA–24.BackupEPTest\\nParameter Programmable Values Nominal\\nBackupPacingModeacOff;On On\\nBackupPacingLowerRateLimitabc(ppm) 30;35;…;185 60(Toleranc e±5ms)\\nBackupPacingVRefractoryabc(ms) 150;160;…;500 250(Toleranc e±5ms)\\nEPTestPacingOutputs AtrialAmplitude (dual-\\nchamber modelswhentestisintheatrium)(V)Off;0.1;0.2;…;3.5;4.0;…;5.0 5.0(Toleranc e±15%or100mV,whichever is\\ngreater)\\nEPTestPacingOutputs Amplitude (single-chamber\\nmodels) (V)Off;0.1;0.2;…;3.5;4.0;…;7.5 7.5(Toleranc e+/-15%or100mV,whichever is\\ngreater)\\nEPTestPacingOutputs VAmplitude (dualchamber\\nmodels) (V)Off;0.1;0.2;…;3.5;4.0;…;7.5 7.5(Toleranc e±15%or100mV,whichever isgreater)\\nEPTestPacingOutputs AtrialPulseWidth(dual-\\nchamber modelswhentestisintheatrium)(ms)0.1;0.2;…;2.0 1.0(Toleranc e±0.03msat<1.8ms;±0.08msat≥\\n1.8ms)\\nEPTestPacingOutputs PulseWidth(single-chamber\\nmodels) (ms)0.1;0.2;…;2.0 1.0(Toleranc e±0.03msat<1.8ms;±0.08msat≥\\n1.8ms)\\nEPTestPacingOutputs VPulseWidth(dual-chamber\\nmodels) (ms)0.1;0.2;…;2.0 1.0(Toleranc e±0.03msat<1.8ms;±0.08msat≥\\n1.8ms)\\na.Thisparameter onlyapplieswhenthetestisintheatrium.\\nb.Theprogrammed NormalBradyvaluewillbeusedasthenominal value.\\nc.Notapplicable tosingle-chamber models.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 211}), Document(page_content='Programmable Options A-13\\nTableA–25.PES(Programmed Electrical Stimulation)\\nParameteraProgrammable Values Nominal\\nNumber ofS1Intervals (pulses) 1;2;...;30 8\\nS2Decrement (ms) 0;10;...;50 0\\nS1Interval(ms) 120;130;...;750 600(Toleranc e±5ms)\\nS2Interval(ms) Off;120;130;...;750 600(Toleranc e±5ms)\\nS3Interval(ms) Off;120;130;...;750 Off(Tolerance±5ms)\\nS4Interval(ms) Off;120;130;...;750 Off(Tolerance±5ms)\\nS5Interval(ms) Off;120;130;...;750 Off(Tolerance±5ms)\\na.Applied totheatriumorventricle ascommandedbytheprogrammer.\\nTableA–26.MVSensorSettings\\nParameter Programmable Values Nominal\\nSignalArtifactMonitor (SAM) On,Off On\\nExcitation Current 80uA,320uA 320uA\\nVectorSelection AutoSelect,RAOnly,RVOnly AutoSelect', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 212}), Document(page_content='A-14 Programmable Options', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 213}), Document(page_content=\"B-1\\nPACEMAKER INTERACTION\\nAPPENDIX B\\nTheremaybeinstances wherepatients mayhaveaseparatetemporaryorpermanent pacemak er.Temporary or\\npermanent pacemak erscaninteractwithanICDandcaninterferewiththeidentification oftachyarrhythmias inthe\\nfollowing ways:\\n•Duringatachyarrhythmia, ifthepacemak erdoesnotsensethearrhythmia andpaces,andthepacingpulse\\ndetected fromtheICDrate-sensing electrodeislargeenough, itcouldcausetheICDtointerpret thepacingasa\\nnormalrhythmattherateofthepacemak er.TheICDwouldneitherdetectthearrhythmia nordelivertherapy.\\n•Thepacemak ercouldpresentsignalstotheICDresulting fromthefollowing events:\\n–Inappropriatesensing\\n–Leaddislodgment\\n–Failuretocapture\\nThiscouldcausetheICD'sratemeasurementtobefasterthanthepatient's actualheartrate.Asaresult,theICD\\ncoulddeliverinappropriate therapy.\\n•Conduction delaycouldcausetheICDtocountbothpacemak erartifactandventricular depolarization. Thiscould\\nresultininappropriate ICDtherapy.\\nForthesereasons, theuseofapacemak erthatresultsinpacemak erandICDinteraction isnotrecommended.\\nUnipolar pacemak ersarecontraindicated forusewithanICD.\\nConsider thefollowing actionsifaseparatepacemakerisused:\\n•Alwaysdeactivate apatient’s ICDwhen:\\n–UsingtemporarybipolarortemporaryAVsequential pacing\\n–Reprogramming aseparateimplanted pacemaker\\nIfcardioversion ordefibrillation isneeded atsuchtimes,useanexternaldefibrillator .\\n•TheICDrate-sensing electrodesshouldbeasfarfromthepacingelectrodesaspossible.\\n•Afterimplanting thepacingleads,examine thesignalsfromtheICDrate-sensing electrodes toensurethat\\nminimal pacemakerartifacts arepresent.\\n•Sinceitisdifficulttopredicttherelativemagnitudes ofpacemakerartifacts andvarioustachyarrhythmia\\nelectrogramsthatmayoccurchronically orduringEPtesting, itisimportant toreduceartifacts toaminimum.\\n•Allofthepatient’s rhythms shouldbeinducedwhiletheICDisactivated andtheseparate pacemak eris\\nprogrammed toanasynchronous modeatmaximum output.Thisshouldprovide thegreatestopportunity for\\ninhibition ofarrhythmia detection duetopacemak erartifacts. Leadsmayhavetoberepositionedtoeliminate\\nartifacts.\\n•Toreducethepossibility ofpacemak erinteraction,considertestingtheseparatepacemak erbyprogramming itto\\nthefollowing settings:\\n–Thelowestamplitude allowable forsafecaptureinthechronicstate\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 214}), Document(page_content=\"B-2Pacemake rInteraction\\n–Themaximum sensitivity toensurethatpacingisinhibited duringVF\\n–Theminimum cardiacrateacceptable forthepatient\\nAlsoconsider usingrate-sensing andpacemak erleadswithcloseintraelectr odespacing (e.g.,11mm).\\n•Consider turningoffthebradycar diapacingfunction oftheICDorprogramming thatfunction toaratelessthan\\ntheseparatepacemakerrate.\\n•Forpacingcontrolfollowing anyshocktherapy,considerwhether tousetheICD'spost-therapybradycardia\\npacingfeatureathigherratesandoutputs ortheseparatepacemak er.\\nThefollowing testprocedureaidsindetermining thepotential forpacemak er/ICDinteraction (FigureB–1Test\\nprocedureforpacemaker-ICDinteraction onpageB-3).\", metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 215}), Document(page_content='Pacemak erInteraction B-3\\nTest for \\ninappropr\\niate tach\\ny therapy\\n \\ndue to multiple counting of pacing \\nartifacts/depolarization.\\nObserve the electrogram on the \\nrate-sensing electrodes by reviewing \\nthe rate-sensing recording on the \\nPRM programming system. Note the \\namplitude of the pacing artifact on the \\nICD pulse generator rate-sensing \\nelectrogram. If the amplitude of the \\npacing artifact is 1/3 or more of the \\nR-wave amplitude, reposition the \\nrate-sensing electrodes.\\nProgram pulse generator ventricular \\ntachy mode to Monitor Only . Enable \\nevent markers.\\nProgram PSA/pacemaker to either a \\nrate greater than the intrinsic rate or \\nan asynchronous mode (e.g., DOO, \\nAOO, VOO).\\nIf multiple counting is noted, reposition \\nthe pacing leads and/or rate-sensing \\nelectrode as appropriate.\\nIf it was necessary to decrease \\npacemaker output settings during \\ntesting, to eliminate multiple counting, \\nrecord maximum allowable settings \\nfor future reference should the need \\nfor reprogramming occur .\\nSTEP  ONE\\nSTEP  THREE\\nSTEP  T\\nWO\\nTest for \\ninappropr\\niate inhi\\nbition of\\n \\ntachy therap y due to detection of \\npacing artifa cts instead of the \\narrhythmia.\\nTest all \\ntachyarrh\\nythmias.\\nEnable pulse generator event \\nmarkers.\\nProgram PS A/pacemaker to an \\nasynchronou s mode (e.g., DOO, \\nAOO, VOO)  at maximum amplitude \\nand pulse w idth.\\nVeri\\nfy approp\\nriate non\\ndetection\\n of \\npacing artifact.\\nInduce tachyarrhythmia. Observe \\nevent markers and electrogram \\nfor pacing artifact.\\nBE PREP ARED TO \\nDELIVER A\\n STAT \\nICD SHOCK  IF THE ARRHYTHMIA  IS \\nNOT  SENSE D.\\nIf inappropriate therapy inhibition is \\nnoted, reduce pacemaker output \\nand/or reposition rate-sensing leads.\\nREPEA T ICD CO\\nNVERSION \\nMUST \\nTHEN BE PERFORMED.\\nIf it was necessary to decrease output \\nsettings during testing, to prevent \\noversensing of pacing artifact during \\nthe arrhythmia, record maximum \\nallowable settings for future reference \\nshould the need for reprogramming \\noccur .\\nNOTE:   The Ma\\ngnet also\\n can be u\\nsed to as\\nsess pace\\nmaker int\\neraction \\nif the ma\\ngnet func\\ntion is e\\nnabled. P\\nlacing th\\ne magnet \\nover a device in a ventricular Monitor + Therapy mode should produce tones.Final device programming.\\nFollowing conversion testing, \\nreinterrogate the pacemaker to ensure \\nthat the mode or other parameters \\nhave not been altered or that the ICD \\npulse generator shock did not damage \\nthe pacemaker .\\nProgram pacemaker to desired mode, \\nrate, amplitudes, and pulse widths.\\nRecord if the programmed pacing \\noutput is suf ficient to ensure capture \\npost-shock; if not, consider \\nprogramming the ICD pulse generator \\npost-shock pacing at high outputs and \\nat a rate greater than the pacemaker \\nrate.\\nProgram the  pulse generator \\nventricular ta chy mode to \\nMonitor + Therapy.\\nFigureB–1.Testprocedureforpacemaker-ICDinteraction', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 216}), Document(page_content='B-4 Pacemake rInteraction', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 217}), Document(page_content='C-1\\nSYMBOLSONPACKAGING\\nAPPENDIX C\\nSYMBOLSONPACKAGING\\nThefollowing symbols maybeusedonpackaging andlabeling:\\nTableC–1.Symbolsonpackaging\\nSymbol Description\\nReferenc eNumber\\nContents\\nPulsegenerator\\nTorquewrench\\nLiteratur eenclosed\\nSerialNumber\\nUseBy\\nLotNumber\\nDateofManufacture\\nNon-Ionizing Electromagne ticRadiation\\nSterilized usingethylene oxide.\\nDoNotResterilize\\nSingleuse.Donotre-use.\\nDonotuseifpackage isdamaged.\\nDangerous Voltage\\n.\\nb\\no\\ns\\nt\\no\\nn\\ns\\nc\\ni\\ne\\nn\\nt\\ni\\nf\\ni\\nc\\n-\\ne\\nl\\na\\nb\\ne\\nl\\ni\\nn\\ng\\n.\\nc\\no\\nm\\nw\\nw\\nw\\n \\nConsultinstructions foruseonthiswebsite: www.bostonscientific -elabeling.c om\\nTemperatur elimitation.', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 218}), Document(page_content='C-2Symbols onPackaging\\nTableC–1.Symbolsonpackaging (continued)\\nSymbol Description\\nPlacetelemetr ywandhere\\n,\\nOpenHere\\nManufacturer\\nMRConditional\\nCRT-DRA,RV,LV\\nICDRA,RV\\nICDRV\\nUncoateddevice\\nRFTelemetry\\nDoublesterilebarriersystem', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 219}), Document(page_content='INDEX\\nSymbols\\n50Hz/manual burstpacing7-7\\nA\\nA-blank\\nafterRV-sense 4-62\\nafterV-pace4-61\\nA-tachy response(ATR)\\nmodeswitch4-44\\nAccelerate,inzone3-2\\nAccelerometer 4-27\\nactivitythreshold4-29\\nreaction time4-30\\nrecoverytime4-31\\nresponsefactor4-28\\nActivitythreshold4-29\\nAdaptive-rat epacing4-27\\nAFibratethreshold 2-24,2-29–2-30\\nAGC(automatic gaincontrol)4-16\\nAmplitude 4-8\\nATP(antitachycardia pacing)3-13\\nintrinsic test5-13\\nApplication screen1-2\\nArrhythmia logbook 6-2\\nepisode detail6-5\\neventssummary 6-5\\ninterval6-8\\nstoredEGM6-5\\nATP(antitachycar diapacing)3-7\\namplitude 3-13\\nburstcyclelength(BCL)3-10\\nburstscheme 3-11\\ncommanded, EPtest7-9\\ncoupling interval3-9\\nminimum interval3-11\\nnumber ofbursts3-8\\npulsecount3-8\\npulsewidth3-13\\nrampscheme 3-11\\nramp/scan scheme 3-12\\nredetection afterATP2-15\\nscanscheme 3-12\\ntime-out 3-13\\nATR(atrialtachyresponse)\\natrialflutterresponse 4-47\\nduration4-45\\nendofATRepisode 4-46\\nentrycount4-45\\nexitcount4-45\\nLRL,fallback 4-46\\nmaximum pacingrate4-47\\nmodeswitch4-44\\nmode,fallback 4-46\\nPMTtermination 4-48ratethreshold4-45\\ntime,fallback 4-46\\nventricular rateregulation4-47\\nVTR(ventricular tachyresponse)4-46\\nATRTriggerRate4-45\\nAtrial\\nrefractoryperiod,postventricular atrial(PVARP) 4-57\\nrefractoryperiod,samechamber 4-59\\nuseofatrialinformation 2-5\\nAtrialflutterresponse4-47\\nAtrialtachy\\nATRmodeswitch4-44\\natrialflutterresponse4-47\\nPMTtermination 4-48\\nventricular rateregulation4-47\\nAttention conditions,yellow1-7\\nAutomatic Intrinsic Rhythm ID2-7\\nAutomatic threshold\\nRAAT4-8\\nRVAT4-12\\nAVdelay4-53\\npaced4-53\\nRYTHMIQ 4-56\\nsensed4-54\\nAVDelay\\nSearch4-56\\nAVSearch+4-55\\nSearchAVDelay4-56\\nSearchInterval4-56\\nB\\nBackupventricular pacingduringatrialstimulation, EPtest7-5\\nBattery\\nExplantstatus5-3\\nicon1-5\\nindicator 5-3\\nstatus5-2\\nBeep\\nduringcapacitor charge5-6\\nfeaturesetup6-18\\nBlanking 4-60\\nA-blank afterRV-sense 4-62\\nA-blank afterV-pace4-61\\nRV-blank afterA-pace4-61\\nBlended Sensors 4-39\\nBradyTachyResponse (BTR)4-68\\nBurst\\nATP(antitachycar diapacing)3-8\\ncyclelength(BCL)3-10\\nminimum interval3-11\\nnumber ofbursts3-8–3-9\\npacing,50Hz/manual burst7-7\\nparameter3-8\\npulsecount3-8', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 220}), Document(page_content='scheme 3-11\\nButtons, software1-5\\nC\\nCapacitor\\ndeformation 3-16,5-6\\nre-formatio n5-6\\nChargetime3-15\\nmeasurement5-6\\nCheck\\nicon1-6\\nCommanded\\nATP,EPtest7-9\\nshock,EPtest7-8\\ntherapy,EPtest7-8\\nCommitted shock2-10,3-17\\nCommunication, telemetr y\\nRadiofrequency (RF)1-8\\nContinue\\nicon1-6\\nCounter\\nbrady6-10\\ntherapyhistory6-9\\nventricular 6-9\\nCoupling interval3-9\\ndecrement3-9\\nD\\nDailymeasurements5-7\\nData\\ndisk1-16\\npatient1-15\\nstorage1-16\\nUSB1-16\\nDecelerate,inzone3-2\\nDecrement\\ncoupling interval3-9\\nrampscheme 3-11\\nscanscheme 3-12\\nDefibrillation\\nbackupdefibrillator ,safetymode1-18\\nDemonstr ation\\nProgrammer/rec order/monitor (PRM)mode1-3,1-8\\nDetailicon1-5\\nDetection\\nAFibratethreshold2-24\\nduration2-13\\nenhancement 2-7,2-18\\nepisode 2-16\\nonset2-28\\nratesensing 2-4\\nratethreshold 2-5\\nreconfirmation/c ommitted shock3-17redetection 2-10\\nRhythmMatch Threshold2-21\\nstability 2-26\\nsustained rateduration(SRD)2-28\\ntachyarrhythmia 2-2\\ntachyarrhythmia, safetymode1-18\\nVrate>Arate2-23\\nvectortimingandcorrelation 2-21\\nventricular ,initial2-6\\nwindow 2-11\\nDevice\\nmemory 1-17\\nmode2-2\\nDevicebehavior whenSAMisOff4-24\\nDevicebehavior whenSAMisOn4-23\\nDiagnostic\\nbatterystatus5-2\\nheartratevariability (HRV)6-10\\nhistogram6-9\\nleadtest5-12\\npatienttriggeredmonitor 6-17\\nDisk\\ndata1-16\\nread1-16\\nsave1-16\\nDIVERTTHERAPY 1-14\\nDual-Sensor Blending 4-39\\nDuration 2-13\\nATR(atrialtachyresponse) 4-45\\npost-shock2-15\\nredetection 2-15\\nDynamic NoiseAlgorithm 4-18,4-64\\nE\\nECG(electrocar diogram)\\ndisplay1-3\\nsurface1-3\\nwireless1-4\\nEGM(electrogram)\\ndisplay1-3\\nreal-time 1-3\\nElectrocautery\\nmode2-2\\nElectrode,leadconfiguration 4-52\\nEndofATRepisode 4-46\\nEnergy\\nshock3-15\\nEnhance ment\\ndetection 2-7,2-18\\nEntrycount4-45\\nEPtest(electrophysiologic test)7-2\\nATP,commanded 7-9\\nbackupventricular pacingduringatrialstimulation 7-5\\nburstpacing,50Hz/manual 7-7\\ncommanded therapy7-8\\nfibrillation 7-4\\ninduction 7-4', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 221}), Document(page_content='mode,temporary7-2\\nprogrammed electrical stimulation (PES)7-6\\nshockonT7-5\\nshock,commanded 7-8\\nVFib7-4\\nEpisode 2-16\\nendofATR4-46\\nNon-Trea ted2-16\\nnontreate d6-9\\ntreated6-9\\nTreated2-16\\nventricular 2-16\\nEvent\\ncounter 6-9\\nicon1-6\\nsummary 6-5\\ntherapyhistory6-2\\nExitcount4-45\\nF\\nFallback, atrialmodeswitch\\nLRL4-46\\nmode4-46\\ntime4-46\\nFibrillation\\nVFibinduction 7-4\\nFitnessLevel4-37\\nFollow-up\\nLeadstatus5-7\\nFollow-up DeviceAssessments 4-41\\nH\\nHeartratevariability (HRV)6-10\\nHeartLogic Index6-15\\nHistogram6-9\\nHold\\nicon1-6\\nHorizontalslider\\nicon1-6\\nHysteresis,rate4-49\\nI\\nIcon\\nbattery1-5\\ncheck1-6\\ncontinue 1-6\\ndetails1-5\\nevent1-6\\nhold1-6\\nhorizontalslider1-6incrementanddecrement1-6\\ninformation 1-6\\nlead1-5\\npatient1-5\\npatientinformation 1-15\\nProgrammer/r ecorder/monitor (PRM)modeindicator 1-3\\nrun1-6\\nscrolling1-7\\nsnapshot 1-6\\nsorting1-6\\nverticalslider1-6\\nImpedanc etest,lead5-13\\nImplant\\npost,information 6-17\\nIncrementanddecrement\\nicon1-6\\nIndications BasedProgramming (IBP)1-11\\nInduction, EPtest7-4\\nInformation\\nicon1-6\\nimplant 1-15\\nlead1-15\\npatient1-15\\nInterrogate1-9\\nInterval\\narrhythmia logbook 6-8\\ncoupling, ATP3-9\\nminimum, burstcyclelength3-11\\nIntrinsic amplitude test5-13\\nL\\nLastdeliveredshock5-6\\nLATITUDE Programming System\\ncomponents 1-2\\nLead\\nconfiguration 4-52\\nDailymeasurements5-7\\nicon1-5\\nimpedance 5-13\\nintrinsic amplitude 5-13\\nLeadstatus5-7\\npacethreshold5-14\\ntest5-12\\nLogbook 6-2\\nLowerratelimit(LRL)4-4\\nM\\nMagnet\\nfeaturesetup6-23\\ninhibittachytherapy 6-23\\nManualprogramming 1-13\\nManual/50 Hzburstpacing7-7\\nMaximum', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 222}), Document(page_content='pacingrate4-47\\nsensorrate(MSR)4-6\\ntracking rate(MTR)4-5\\nMaximum pacingrate\\nratesmoothing 4-51\\nMemory,device1-17\\nMinimum\\ninterval3-11\\nMinuteVentilation 4-32\\nfitnesslevel4-37\\nresponsefactor4-35\\nVentilatory Threshold 4-35\\nVentilatory Threshold Response 4-35\\nMode\\nDemonstration 1-8\\ndevice2-2\\nelectrocautery 2-2\\nfallback ATR(atrialtachyresponse) 4-46\\npacing4-3\\nProgrammer/rec order/monitor (PRM)1-3\\ntempora ry,EPtest7-2\\nventricular tachy2-2\\nMRIProtectionMode2-3\\nMV/Respir atorySensorProgrammable Parameters4-21\\nMV/Respir atorySensorStatus4-22\\nN\\nNightHeartRate6-16\\nNoise\\nblanking andnoiserejection4-60\\nDynamic NoiseAlgorithm 4-18,4-64\\nresponse4-63\\nNominal parameter settingA-1\\nNumber ofbursts3-8\\npulsecount3-9\\nO\\nOnset2-9,2-28,2-30–2-31\\nOptimizing rateresponseforphysical activity4-38\\nP\\nPace\\nSTATPACE1-15\\nPacethreshold test5-14\\nPaceSafe\\nRAAT4-8\\nRVAT4-12\\nPacing\\nadaptive-rate 4-27\\namplitude 4-8ATRmodeswitch4-44\\nAVdelay4-53\\nbackupduringatrialstimulation 7-5\\nbackuppacemak erinsafetymode1-18\\nburst,50Hz/manual 7-7\\nIndications BasedProgramming (IBP)1-11\\nlowerratelimit(LRL)4-4\\nmaximum sensorrate(MSR)4-6\\nmaximum trackingrate(MTR)4-5\\nmode4-3\\nnoiseresponse4-63\\nPaceSafeRAAT4-8\\nPaceSafeRVAT4-12\\nparameter,basic4-2\\nposttherapy4-19\\npost-therapy4-18\\npulsewidth4-7\\nrefractory4-57\\nrunaway protection4-7\\nsensitivity 4-16\\nsensor4-42\\ntemporary4-19\\ntherapy4-2\\nPackage\\nsymbolonC-1\\nPatient\\ninformation icon1-5\\nPatientInformation 1-15\\nPatienttriggered monitor 6-17\\nPES(programmed electrical stimulation) 7-6\\nPhysical activityevaluation 4-37\\nPMT(pacemak er-mediated tachycardia) termination 4-48\\nPolarity\\nshock3-17\\nPOST5-11\\nPostimplant information 6-17\\nbeeperfeature6-18\\nmagnet feature6-23\\nPost-Operative\\nSystemTest5-11\\nPost-shock\\ndetection paramete r2-11\\nduration2-15\\npacing4-19\\nPost-therapypacing4-18\\nPrematureventricular contraction(PVC)4-59\\nPrescription\\ntherapy3-2\\nPrint\\nreport1-17\\nPrinter\\nexternal1-17\\nProgram1-11\\nProgrammable option,parameterA-1\\nProgrammer/rec order/monito r(PRM)1-2\\ncontrols1-2,1-13\\nDemonstr ationmode1-8\\nmodes1-3\\nsoftwareterminology 1-2\\nuseofcolor1-7', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 223}), Document(page_content='Programming recommendation 1-11,1-13\\nProtection\\nrunaway 4-7\\nPulseamplitude 4-8\\nPulsecount3-8\\nPulsegenerator (PG)\\nmemory 1-17\\nreplacementindicators 5-3\\nPulsewidth4-7\\nATP(antitachycardia pacing)3-13\\nPVARP(postventricular atrialrefractoryperiod)4-57\\nafterPVC(prematu reventricular contraction) 4-59\\ndynamic PVARP4-58\\nPVC(premature ventricular contraction) 4-59\\nQ\\nQUICKCONVERT ATP3-14\\nQuit\\nendingatelemetry session1-9\\nR\\nRAAT(rightatrialautomatic threshold)4-8\\nRadiofrequency (RF)\\noperating temperatur e,telemetry 1-10\\nstarting telemetr y1-9\\ntelemetr y1-8\\nRampscheme 3-11\\nRamp/Scan scheme 3-12\\nRate\\nadaptive 4-27\\nAFibthreshold2-24\\ncalculation 2-4\\nlowerlimit(LRL)4-4\\nmaximum sensor4-6\\nmaximum tracking4-5\\nsensing 2-4\\nsustained rateduration(SRD)2-28\\nthreshold,ventricular 2-5\\nVrate>Arate2-23\\nventricular 2-5\\nzone2-5\\nRateadaptive pacing4-27\\nRateenhancement, pacing\\nratehysteresis 4-49\\nratesmoothing 4-50\\nRateHysteresis 4-49\\nhysteresis offset4-49\\nsearchhysteresis 4-50\\nRatesmoothing 4-50\\ndown4-51\\nMaximum pacingrate4-51\\nup4-51\\nRatethreshold, ATR4-45Reaction time4-30\\nReaddata1-16\\nReconfirmation 2-10,3-17\\nRecoverytime4-31\\nRedwarning conditions 1-7\\nRedetection 2-10\\nafterATPdelivery 2-15,3-6\\naftershockdelivery 2-15,3-7\\nduration2-15\\nventricular 3-6\\nReform, capacitor 5-6\\nRefractory\\natrial,postventricular (PVARP) 4-57\\natrial,samechamber 4-59\\nblanking andnoiserejection 4-60\\nPVARPafterPVC4-59\\nrightventricular (RVRP)4-59\\nRefractory;pacing\\nrefractory4-57\\nReplacemen tIndicators 5-3\\nReport,printed1-3,1-15\\nECG/EGM 1-3\\nRespirato rySensor4-20\\nResponse factor,accelerometer4-28\\nResponse Factor,MinuteVentilation 4-35\\nRhythm\\nID,automatic intrinsic 2-7\\nRhythmMatch Threshold2-21\\nRightventricular refractory(RVRP)4-59\\nRightRate Pacing4-32\\nRun\\nicon1-6\\nRunaway protection4-7\\nRV-blank afterA-pace4-61\\nRVAT(rightventricular automatic threshold) 4-12\\nRYTHMIQ 4-56\\nS\\nS1andS3HeartSounds6-15\\nSafetycore1-17\\nSafetymode1-17\\nSafetyTachyMode1-18\\nSavedata1-16\\nScanscheme 3-12\\nScreen,programmer application 1-2\\nScrolling\\nicon1-7\\nSearch+,AV4-55\\nSearchAVDelay4-56\\nSearchInterval4-56\\nSecurity\\nZIPtelemetr y1-9\\nSensing, rate2-4\\nSensitivity 4-16\\nAGC(automatic gaincontrol)4-16\\nSensorandtrending, pacing4-42\\naccelerometer4-27', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 224}), Document(page_content='adaptive-rate 4-27\\nmaximum sensorrate(MSR)4-6\\nminuteventilation 4-32\\nSetting\\nparamete rvalueA-1\\nzoneconfiguration 2-5\\nShock\\nchargetime,energy3-15,5-6\\ncommanded, EPtest7-8\\ncommitted 3-17\\ndiverting 1-14\\nenergy3-15\\nimpedance 5-13\\nlastdelivered5-6\\nonTinduction 7-5\\npolarity 3-17\\npost-shockpacing4-19\\nredetection 2-15\\nselection 3-2\\nsequenc e3-2\\nSTATSHOCK1-14\\ntherapy3-15\\nventricular therapy3-15\\nwaveform 3-17\\nShockifunstable 2-27\\nShockonTinduction 7-5\\nSignalArtifactMonitor DeviceDiagnostic 4-23\\nSignalArtifactMonitor episode dataandprogramming\\nconsider ations4-26\\nSignalArtifactMonitor Episodes 4-25\\nSleepIncline6-16\\nSnapshot 6-8\\nicon1-6\\nSoftwareApplication 1-2\\npurpose 1-2\\nSoftwareterminology 1-2\\nSorting\\nicon1-6\\nStability 2-9,2-26,2-29–2-31\\nSTATPACE1-15\\nSTATSHOCK1-14\\nStimulation, PESinduction 7-6\\nStoredEGM\\narrhythmia logbook 6-5\\nSustained rateduration(SRD)2-28\\nSymbol\\nonpackage C-1\\nSystemTest\\nPost-Operative 5-11\\nT\\nTabs,software1-5\\nTachymode2-2\\nSafetyMode1-18\\nTachyarrhythmia\\ndetection 2-2\\ndetection insafetymode1-18Indications BasedProgramming (IBP)1-12\\ntherapy3-2\\ntherapyinsafetymode1-18\\nzone2-5\\nTelemetr y\\nendingatelemetr ysession1-9\\noperatingtemperature,ZIP1-10\\nstarting ZIP1-9\\nwand1-8\\nwanded 1-9\\nZIP1-8\\nTemporary\\npacing4-19\\nTest\\nEP(electrophysiologic) 7-2\\nintrinsic amplitude 5-13\\nlead5-12\\nleadimpedance 5-13\\npacethreshold5-14\\nTherapy\\nATP(antitachycar diapacing)3-7\\npacing4-2\\npost-shockpacing4-19\\nprescription 3-2\\nselection 3-2\\nshock3-15\\ntachyarrhythmia 3-2\\ntachyarrhythmia, safetymode1-18\\nTherapyhistory6-2\\narrhythmia logbook 6-2\\ncounter6-9\\nheartratevariability (HRV)6-10\\nhistogram6-9\\npatienttriggeredmonitor 6-17\\nThoracicImpedance 6-16\\nThreshold\\nAFibrate2-24\\nrate2-5\\nThreshold,activity4-29\\nTime-out, ATP3-13\\nTiming\\nblanking 4-60\\nPVARPafterPVC4-59\\nTiming, pacing4-57\\nToolbar 1-5\\nTrending\\nsensor4-42\\nTrends6-13\\nHeartLogic Index6-15\\nNightHeartRate6-16\\nrespiratoryrate6-15\\nS1andS3HeartSounds6-15\\nSleepIncline6-16\\nThoracicImpedance 6-16\\nU\\nUpperRateBehavior 4-5', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 225}), Document(page_content='USB1-16\\nV\\nVrate>Arate2-23\\nVectortimingandcorrelation 2-21,2-29\\nRhythmMatch Threshold 2-21\\nVentilatory Threshold 4-35\\nVentilatory Threshold Response 4-35\\nVentricular\\nATP(antitachycardia pacing)3-7\\ndetection, tachyarrhythmia 2-6\\nredetection afterventricular ATPtherapy3-6\\nredetection afterventricular shocktherapy3-7\\nredetection afterventricular therapydelivery 3-6\\nshocktherapy3-15\\ntachymode2-2\\ntachyarrhythmia therapy 3-2\\nVentricular rateregulation 4-47\\nmaximum pacingrate4-47\\nVentricular shockvector3-15\\nVerticalslider\\nicon1-6\\nVFibinduction 7-4\\nVTR(ventricular tachyresponse) 4-46\\nW\\nWand,telemetry 1-2,1-8–1-9\\nWarning conditions, red1-7\\nWaveform, shock3-17\\nWenckebach4-50\\nWindow\\ndetection 2-11\\nY\\nYellowattention conditions 1-7\\nZ\\nZIPtelemetr y1-8\\nadvantages 1-9\\nindicator light1-9\\noperating temperatur e1-10\\nradiofrequency (RF)1-9\\nsecurity 1-9\\nsession1-9\\nZone\\nconfiguration 2-5\\nventricular 2-5ventricular tachyarrhythmia 2-5\\nZOOMVIEW Software Application\\nscreensandicons1-2\\nuseofcolor1-7', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 226}), Document(page_content='', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 227}), Document(page_content='', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 228}), Document(page_content='BostonScientific Corporation\\n4100Hamline Avenue North\\nSt.Paul,MN55112-5798 USA\\nwww.bostonscientific.com\\n1.800.CARDIAC (227.3422)\\n+1.651.582.4000\\n©2020BostonScientific Corporation oritsaffiliates.\\nAllrightsreserved.\\n51114088-001 ENUS2020-10\\n*51114088-001*', metadata={'source': 'raw_data/51114088-001A_NG4 Tachy MRI ICD_RG_en_S.pdf', 'page': 229}), Document(page_content='PROGRAMMER USER’S MANUAL\\nEMBLEM™ S‑ICD Programmer3200\\nCAUTION:  Federal law (USA) restricts this device to sale \\nby or on the order of a physician trained or experienced \\nin device implant and follow-up procedures.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 0}), Document(page_content='', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 1}), Document(page_content='LIST OF ACRONYMS\\nAC Alternating current LCD Liquid crystal display\\nAF Atrial Fibrillation MRI Magnetic resonance imaging\\nATP Anti-tachycardia pacing NSR Normal sinus rhythm\\nCRT Cardiac resynchronization therapy RF Radio Frequency\\nCPR Cardiopulmonary resuscitation RFI Radio Frequency Interference\\nECG Electrocardiogram RFID Radio Frequency Identification\\nEMI Electromagnetic interference S-ECG Subcutaneous electrocardiogram\\nEOL End of life S-ICDSubcutaneous implantable cardioverter \\ndefibrillator\\nERI Elective replacement indicator USB Universal serial bus\\nESD Electrostatic discharge VAC Voltage alternating current\\nFCC Federal Communications Commission VF Ventricular fibrillation\\nGUI Graphic User Interface VT Ventricular tachycardia\\nIC Industry Canada\\nThis literature is intended for use by professionals trained or experienced in device implant and/or follow-up procedures.\\nThe following are trademarks of Boston Scientific Corporation or its affiliates: EMBLEM, IMAGEREADY, AF Monitor.The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks is under license.microSD™ is a trademark or registered trademark of SD-3C, LLCThis product may be protected by one or more patents. Patent information can be obtained at http://www.bostonscientific.com/patents.© Copyright 2021 Boston Scientific Corporation or its affiliates. All rights reserved.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 2}), Document(page_content='', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 3}), Document(page_content='TABLE OF CONTENTS\\nGENERAL DESCRIPTION  ............................................................................................................................. 1\\nDescription  ............................................................................................................................................ 1\\nIntended Use of Programmer  ............................................................................................................... 1\\nIndications for Use  ................................................................................................................................ 1\\nContraindications  .................................................................................................................................. 1\\nRelated Information .............................................................................................................................. 2\\nProgrammer Warnings and Precautions  ............................................................................................... 2\\nProgrammer Warnings  ............................................................................................................................. 2\\nGeneral  ............................................................................................................................................. 2\\nConditions for Operation  .................................................................................................................. 3\\nProgrammer Precautions  ......................................................................................................................... 4\\nGeneral  ............................................................................................................................................. 4\\nConditions for Operation  .................................................................................................................. 4\\nImplantation  ............................................................................................................................... ...... 5\\nStorage and Handling  ...................................................................................................................... 5\\nPotential Adverse Events  ......................................................................................................................... 5\\nOPERATION  ............................................................................................................................................... 9\\nProgrammer Setup  ................................................................................................................................ 9\\nPackaging  ................................................................................................................................................. 9\\nProgrammer Controls and Connections  ................................................................................................... 9\\nCharging the Programmer  ....................................................................................................................... 10\\nUsing the Programmer .......................................................................................................................... 11\\nTurning the Programmer On  .................................................................................................................... 11\\nChanging the Programmer Volume Level  ................................................................................................ 11\\nPlacing the Programmer in Suspend Mode  ............................................................................................. 11\\nTurning the Programmer Off  ................................................................................................................... 11\\nUsing the Programmer Touch Screen  ....................................................................................................... 12', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 4}), Document(page_content='Using the Wand  ....................................................................................................................................... 12\\nNavigation................................................................................................................................................ 13\\nScreen Header  .......................................................................................................................................... 13\\nNavigation Bar  ......................................................................................................................................... 14\\nRestarting the Programmer  ..................................................................................................................... 15\\nConfiguring the Programmer  ................................................................................................................ 16\\nConfiguring Programmer Settings  ........................................................................................................... 16\\nDate and Time Format  ............................................................................................................................. 17\\nTime Zone  ................................................................................................................................................ 18\\nLanguage Preference  ............................................................................................................................... 19\\nPrinter Selection  ....................................................................................................................................... 19\\nProgrammer Software Version  ................................................................................................................. 20\\nBluetooth® Data Export  ........................................................................................................................... 21\\nProgrammer Modes of Operation  ......................................................................................................... 22\\nOnline Behavior  ....................................................................................................................................... 22\\nOffline Behavior  ....................................................................................................................................... 23\\nStored Patient Sessions  ............................................................................................................................ 23\\nTo view stored patient sessions:  .............................................................................................................. 23\\nTo purge stored patient sessions:  ............................................................................................................ 23\\nModes of Operation for the Pulse Generator  ....................................................................................... 23\\nShelf Mode  .............................................................................................................................................. 24\\nTherapy On Mode  .................................................................................................................................... 24\\nTherapy Off Mode  .................................................................................................................................... 24\\nMRI Protection Mode  ............................................................................................................................... 24\\nConnecting and Disconnecting from the S -ICD Pulse Generator  .......................................................... 25\\nScanning for Pulse Generators  ................................................................................................................. 25\\nConnecting to a Pulse Generator  ............................................................................................................. 26\\nConnecting to a Pulse Generator in Shelf Mode  ..................................................................................... 26', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 5}), Document(page_content='Connecting to an Implanted Pulse Generator  ......................................................................................... 27\\nEnding a Patient Session .......................................................................................................................... 27\\nProgramming the Pulse Generator at Implant  ..................................................................................... 29\\nEntering Electrode Information  ................................................................................................................ 30\\nCreating the Patient Chart  ........................................................................................................................ 31\\nAutomatic Setup  ...................................................................................................................................... 32\\nProgramming Therapy Parameters  .......................................................................................................... 34\\nDefibrillation Testing  ............................................................................................................................... 36\\nPerforming a Follow Up  ........................................................................................................................ 39\\nPrinting Reports from the Programmer  ................................................................................................ 40\\nPrinting Reports  ....................................................................................................................................... 40\\nSummary Report  ...................................................................................................................................... 41\\nCaptured S-ECG Report  ............................................................................................................................ 42\\nEpisode Reports  ....................................................................................................................................... 42\\nExport Patient Data  ............................................................................................................................... 43\\nExport using Bluetooth®  wireless technology  ......................................................................................... 43\\nExport using a microSD™ card  ................................................................................................................. 44\\nS-ECG Features ....................................................................................................................................... 45\\nS-ECG Rhythm Strip Markers  .................................................................................................................... 45\\nS-ECG Scale Settings  ................................................................................................................................ 46\\nCapturing and viewing S-ECG Strips  ........................................................................................................ 47\\nTo manually capture a new S-ECG rhythm strip:  ...................................................................................... 48\\nViewing previously captured S-ECGs  ....................................................................................................... 48\\nUtilities Screen  ...................................................................................................................................... 49\\nAcquire Reference S-ECG .......................................................................................................................... 49\\nCapture All Sense Vectors  ........................................................................................................................ 50\\nBeeper Control  ......................................................................................................................................... 50\\nReset Beeper  ............................................................................................................................... .....51', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 6}), Document(page_content='Disable Beeper (SQ-Rx devices)  ....................................................................................................... 51\\nEnable/Disable Beeper (EMBLEM S -ICD devices)  ............................................................................. 52\\nManual Setup  ........................................................................................................................................... 52\\nSMART Settings  ........................................................................................................................................ 54\\nSMART Charge  .................................................................................................................................. 54\\nDisabling SMART Pass  ...................................................................................................................... 55\\nAF Monitor  ............................................................................................................................................... 55\\nAdditional Programmer Functions  ....................................................................................................... 56\\nRescue Shock  ........................................................................................................................................... 56\\nManual Shock  ........................................................................................................................................... 58\\nS-ICD System Magnet Use  ........................................................................................................................ 58\\nMAINTENANCE  .......................................................................................................................................... 59\\nCharging the Programmer  ....................................................................................................................... 59\\nCleaning the Programmer and Wand  ...................................................................................................... 59\\nService  ...................................................................................................................................................... 60\\nMaintenance Check  .................................................................................................................................. 60\\nSafety Measurements  .............................................................................................................................. 60\\nDisposal of Programmer and Accessories  ................................................................................................ 61\\nTROUBLESHOOTING  ................................................................................................................................... 61\\nInability to Print  ....................................................................................................................................... 61\\nNo Printer Available  ................................................................................................................................. 61\\nTouch Screen Inactive while Connected to AC Power  ............................................................................... 62\\nLoss of Communication with Printer  ........................................................................................................ 62\\nInability to Communicate With the Pulse Generator  ................................................................................ 62\\nCOMPLIANCE STATEMENTS  ........................................................................................................................ 62\\nEMI/RFI  .................................................................................................................................................... 62\\nEssential Performance  ............................................................................................................................. 63\\nFederal Communications Commission (FCC) Compliance  ......................................................................... 63', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 7}), Document(page_content='Industry Canada (IC) Compliance ...................................................................................................... 64\\nDECLARATIONS TABLES  ............................................................................................................................. 64\\nSPECIFICATIONS  ......................................................................................................................................... 67\\nDEFINITION OF PACKAGING LABEL AND DEVICE SYMBOLS  ........................................................................ 69\\nWARRANTY  ............................................................................................................................................... 71\\nLimited Warranty  ..................................................................................................................................... 71\\nAPPENDIX A: INSERTION AND REMOVAL OF THE microSD™ CARD  ............................................................ 72', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 8}), Document(page_content='', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 9}), Document(page_content='1EMBLEM™ S‑ICD PROGRAMMER: GENERAL DESCRIPTION\\nGENERAL DESCRIPTION\\nDescription\\nThe EMBLEM    S - ICD Programmer (the “Programmer”) is a component of Boston Scientific’s subcutaneous \\nimplantable cardioverter defibrillator system (the S -ICD System) which is prescribed for patients when cardiac \\narrhythmia management is warranted. Implantable components of the S -ICD System include the EMBLEM \\nS-ICD pulse generator and the EMBLEM S -ICD subcutaneous electrode.\\nThe Programmer is a non–sterile, non–implantable, tablet computer controlled by a graphic user interface \\n(GUI) displayed on a touchscreen. The Programmer is powered by either AC line power or an internal lithium ion battery pack. The Programmer uses a connected RF telemetry wand to communicate wirelessly with the \\nS-ICD pulse generator in order to adjust programmable settings and to collect patient data. The EMBLEM \\nS-ICD Programmer is also compatible with the Cameron Health (Model 1010) SQ-Rx pulse generator. The \\nProgrammer features and functions described in this manual apply to the Boston Scientific S -ICD System as \\nwell as to the Cameron Health S -ICD System.\\nThe S -ICD System is designed for ease of use and simplicity of patient management. The S -ICD System has \\na number of automatic functions designed to reduce the amount of time required for implantation, initial programming and patient follow up.\\nGo to www.bostonscientific-elabeling.com for additional technical reference guides.\\nIntended Use of Programmer\\nThe Programmer is intended to communicate with the implanted pulse generator using wireless telemetry. \\nThe Programmer software controls all such telemetry functions.\\nIndications for Use\\nThe S -ICD System is intended to provide defibrillation therapy for the treatment of life-threatening ventricular \\ntachyarrhythmias in patients who do not have symptomatic bradycardia, incessant ventricular tachycardia, or spontaneous, frequently recurring ventricular tachycardia that is reliably terminated with anti-tachycardia pacing.\\nContraindications\\nUnipolar stimulation and impedance-based features are contraindicated for use with the S -ICD System.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 10}), Document(page_content='2EMBLEM™ S‑ICD PROGRAMMER: GENERAL DESCRIPTION\\nRelated Information\\nBefore using the S -ICD system, read and follow all instructions, warnings, and precautions provided in this \\nmanual and in the manuals for the other system components, including the applicable S -ICD pulse generator, \\nsubcutaneous electrode, and electrode implant tools user’s manuals.\\nThis guide may contain reference information for pulse generator model numbers that are not currently \\napproved for sale in all geographies. For a complete list of model numbers approved in your geography, consult with your local sales representative. Some model numbers may contain fewer features; for those devices, disregard descriptions of the unavailable features. Descriptions found within this manual apply to all device tiers unless otherwise noted.\\nRefer to the IMAGEREADY MR Conditional S -ICD System MRI Technical Guide (hereafter referred to as the MRI \\nTechnical Guide) for information about MRI scanning.\\nProgrammer Warnings and Precautions\\nThe following warnings and precautions apply specifically to the Model 3200 Programmer component of the \\nS-ICD System.\\nFor Warnings and Precautions that are specific to the S -ICD system and/or the process of implanting the \\nsystem, refer to the EMBLEM™ S -ICD User’s Manual, and/or the manual of the relevant system component.\\nProgrammer Warnings\\nGeneral\\n• Modifications. No modification of this equipment is allowed unless approved by Boston Scientific.\\n• Programmer is MR Unsafe. The Programmer is MR Unsafe and must remain outside the MRI site Zone III (and higher) as defined by the American College of Radiology Guidance Document on MR Safe Practices\\n1. Under no circumstances should the Programmer be brought into the MRI scanner \\nroom, the control room, or the MRI site Zone III or IV areas. \\n• High temperatures. Do not subject the Programmer to temperatures outside of the -10°\\xa0C to 55° C (14° F to 131° F) storage range. Exposure to high temperatures may cause the Programmer to overheat or ignite, and may possibly reduce its performance and service life.\\n• Extreme temperatures. Do not discard the Programmer in a fire, incinerate, or subject it to temperatures that exceed 100° C (212° F). This could cause the Programmer to explode.\\n1 K anal E, Barkovich AJ, Bell C, et al. ACR guidance document on MR safe practices: 2013. J. Magn. Reson. Imaging 2013;37:501-530.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 11}), Document(page_content='3EMBLEM™ S‑ICD PROGRAMMER: GENERAL DESCRIPTION\\n• Do not immerse. Do not immerse the Programmer in liquid of any kind. If the Programmer does get \\nwet, contact customer service for information about returning the Programmer to Boston Scientific. Do not attempt to dry the Programmer in an oven, microwave, or dryer because this poses a risk of overheating or explosion.\\nConditions for Operation\\n• Device Software Update. During a device software update, tachycardia therapy is suspended. Always monitor the patient and have external defibrillation equipment available during interrogation.\\n• Secure Programmer. Ensure this Programmer is used by professionals trained or experienced in device implant and/or follow-up procedures. Take appropriate measures to prevent unauthorized use or tampering of the Programmer.\\n• Use only the supplied external power supply. Use the Programmer only with the external power supply packaged with the Programmer. Using other power supplies may cause damage to the Programmer.\\n• Electric shock. To avoid risk of electric shock, the Programmer’s external power supply must only be connected to a grounded electrical outlet.\\n• Damaged Programmer or power supply. Never use a damaged external power supply or a damaged Programmer. Doing so could result in user injury, patient injury, or a lack of therapy delivery.\\n• Interference with nearby equipment. By design, the Programmer emits radio frequencies in the 402-405 MHz and 2.4 GHz bands. This may interfere with nearby medical or office equipment. When using the Programmer, closely monitor equipment in the vicinity to verify normal operation. It may be necessary to take mitigation measures, such as reorienting or relocating the Programmer or shielding the location.\\n• Interference with Programmer communication. The presence of other equipment operating in the same frequency bands used by the Programmer (402-405 MHz for the pulse generator and 2.4 GHz for the printer) may interfere with communication. Interference can occur even if the other equipment complies with the International Special Committee on Radio Interference (CISPR) emission requirements. This RF interference can be reduced by increasing the distance between the interfering device and the Programmer and pulse generator or printer. If communication problems persist, refer to the Troubleshooting section of this manual.\\n• Use of non-approved accessories. The use of any accessories with the Programmer other than those specified by Boston Scientific in this manual may result in increased emissions or decreased immunity of the Programmer and may cause decreased functionality or unintended operational behavior of the Programmer. Anyone connecting such accessories to the Programmer may be configuring a medical system and is responsible to ensure that the system complies with the requirements of IEC/EN 60601-1, Clause 16 for medical electrical systems.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 12}), Document(page_content='4EMBLEM™ S‑ICD PROGRAMMER: GENERAL DESCRIPTION\\n• Programmer location. Use of this equipment adjacent to or stacked with other equipment should be \\navoided because it could result in improper operation. If such use is necessary, this equipment and the other equipment should be observed to verify that they are operating normally.\\n• Radio frequency (RF) communications equipment. Keep all RF communications equipment (including peripherals such as antennas, wands, and cables) at least 30 cm (12 in) away from the Model 3200 Programmer, including cables specified by Boston Scientific, to avoid degradation of the performance of this equipment.\\nProgrammer Precautions\\nGeneral\\n• Wand use. Use only the Model 3203 telemetry wand with the Programmer.\\n• Do not disassemble. Do not disassemble or alter any parts of the Programmer.\\n• Changes or modifications. Changes or modifications not expressly approved by Boston Scientific could void the user’s authority to operate the equipment.\\n• Device communication. Use only the designated Boston Scientific S -ICD Programmer and \\nappropriate software application to communicate with and program the S -ICD pulse generator.\\n• Intended users. The Programmer is intended for use by or under the direction of healthcare professionals only.\\n• Sensitive Information. To prevent sensitive personal information from being transmitted to inappropriate devices or printers when using Bluetooth® wireless connections, make certain to only connect with known Bluetooth® devices.\\nConditions for Operation\\n• Beeper Disable. In the Programmer steps to program and test the Beeper, selecting “No, Disable Beeper” will disable beeping functionality for alert conditions, when a magnet is placed over the \\ndevice, and when the S -ICD application connects to the device.\\n• Disconnecting the Programmer. Mains isolation is achieved by disconnecting the external power supply power cord from the AC electrical outlet. Do not position the Programmer or the external power supply in a manner that would make it difficult to disconnect that cord.\\n• Programmer use. The Programmer is not waterproof or explosion-proof and cannot be sterilized. Do not use it in the presence of flammable gas mixtures containing anesthetics, oxygen, or nitrous oxide.\\n• Confirm communication. Confirm that the Programmer is in communication with the intended \\nimplanted S -ICD pulse generator.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 13}), Document(page_content='5EMBLEM™ S‑ICD PROGRAMMER: GENERAL DESCRIPTION\\n• Electrostatic discharge. The Programmer may be affected by ESD. If ESD occurs and the \\nProgrammer’s functionality is affected, attempt to reset the Programmer or contact Boston Scientific for instructions. Do not touch or connect the telemetry wand to the Programmer unless ESD precautionary procedures are used.\\nImplantation\\n• Telemetry wand. The wand is a non-sterile device. Do not sterilize the wand. The wand must be contained in a sterile barrier before use in the sterile field.\\n• Programmer must remain outside the sterile field. The Programmer is non-sterile and cannot be sterilized. It must remain outside the sterile field.\\nStorage and Handling\\n• Mishandling. Mishandling (such as dropping or crushing) could damage the Programmer. If you suspect damage to the Programmer, contact your Boston Scientific representative or the customer service department for instructions and return packaging.\\n• Broken or cracked screen. The display on the Programmer is made of glass or acrylic and could break if the Programmer is dropped or if it receives significant impact. Do not use if screen is broken or cracked as this could cause injury.\\n• Magnet handling. Do not place a magnet on the Programmer.\\n• Data Storage. The Programmer and digital data storage media, such as microSD™memory cards, used with the Programmer may contain sensitive personal information. These should be handled in accordance with applicable privacy and security policies and regulations. \\nPotential Adverse Events\\nPotential adverse events related to implantation of the S -ICD System may include, but are not limited to, the \\nfollowing:\\n• Acceleration/induction of atrial or ventricular arrhythmia\\n• Adverse reaction to induction testing\\n• Allergic/adverse reaction to system or medication\\n• Bleeding\\n• Conductor fracture\\n• Cyst formation\\n• Death', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 14}), Document(page_content='6EMBLEM™ S‑ICD PROGRAMMER: GENERAL DESCRIPTION\\n• Delayed therapy delivery\\n• Discomfort or prolonged healing of incision\\n• Electrode deformation and/or breakage\\n• Electrode insulation failure\\n• Erosion/extrusion\\n• Failure to deliver therapy\\n• Fever\\n• Hematoma/seroma\\n• Hemothorax\\n• Improper electrode connection to the device\\n• Inability to communicate with the device\\n• Inability to defibrillate or pace\\n• Inappropriate post-shock pacing\\n• Inappropriate shock delivery\\n• Infection\\n• Injury to or pain in upper extremity including clavicle, shoulder, and arm\\n• Keloid formation\\n• Migration or dislodgement\\n• Muscle/nerve stimulation\\n• Nerve damage\\n• Organ injury or perforation\\n• Pneumothorax\\n• Post-shock/post-pace discomfort\\n• Premature battery depletion\\n• Random component failures\\n• Stroke\\n• Subcutaneous emphysema', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 15}), Document(page_content='7EMBLEM™ S‑ICD PROGRAMMER: GENERAL DESCRIPTION\\n• Surgical revision or replacement of the system\\n• Syncope\\n• Tissue damage\\n• Tissue redness, irritation, numbness or necrosis\\n• Vessel injury or perforation\\nTransient procedural adverse events are expected in some patients. These include, but are not limited to, \\ndiscomfort, pain and other systemic symptoms that might be related to medications or other interventions performed during implant.\\nFor a list of potential adverse events associated with MRI scanning, refer to the MRI Technical Guide.\\nIf any adverse events occur, invasive corrective action and/or S -ICD System modification or removal may be \\nrequired.\\nPatients who receive an S -ICD System may also develop psychological disorders that include, but are not \\nlimited to, the following:\\n• Depression/anxiety\\n• Fear of device malfunction\\n• Fear of shocks\\n• Phantom shocks\\nAny serious incident that occurs in relation to this device should be reported to Boston Scientific and relevant \\nlocal regulatory authority.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 16}), Document(page_content='8EMBLEM™ S‑ICD PROGRAMMER:  ', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 17}), Document(page_content='9EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nOPERATION\\nProgrammer Setup\\nPackaging\\nProgrammer components include:\\n• Model 3200 Programmer with pre-loaded software\\n• Model 3203 Telemetry Wand\\n• Model 3204 External power supply and AC power cord\\nVisually inspect the packaging to ensure the contents are complete. Do not use if there is evidence of damage.\\nIn case of damage return the product to Boston Scientific. For return packaging and instructions, contact \\nBoston Scientific using the information on the back cover of this manual.\\nProgrammer Controls and Connections\\nFigure 1: microSD™ slotPower buttonVolume control\\nTelemetry wand connector port\\nExternal power supply port\\nControls and external connections', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 18}), Document(page_content='10EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nCharging the Programmer\\nThe Programmer is primarily intended to be operated while connected to the AC-powered external power \\nsupply, but may also be operated on battery power provided that the internal battery is adequately charged. The Programmer is recharged whenever it is connected to the AC-powered external power supply. When not in use, it is recommended that the Programmer remain connected to the external power supply in order to maintain an adequate battery charge.\\nNote:  Current session data may be lost if a 45 minute period of inactivity occurs during an active \\ntelemetry session and the Programmer is not connected to AC power.\\nTypical charge time for a fully discharged battery is 5 hours. However, more time may be required if the Programmer is in use while being recharged.\\nThe Battery Status indicator located on the upper right corner of the screen displays the status of the main \\nbattery power when the unit is in use:\\n• All four bars are illuminated (green) – The battery is 100% charged\\n• Three bars are illuminated (green) – The battery is 75% charged\\n• Two bars are illuminated (yellow) – The battery is 50% charged\\n• One bar is illuminated (red) – The battery is 25% charged\\nThe Programmer displays one of the following alert screens as battery power gets progressively lower.\\n• Programmer Battery Low\\n• Programmer Battery Critical\\n• Out Of Power\\nTo charge the Programmer:\\n1. Connect the external power supply cable to the Programmer (Figure 1 on page 9).\\n2. Plug the external power supply cord into an AC power outlet.\\nWARNING:  Use the Programmer only with the external power supply packaged with the Programmer. Using other power supplies may cause damage to the Programmer.\\nWARNING:  To avoid risk of electric shock, the Programmer’s external power supply must only be connected to a grounded electrical outlet.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 19}), Document(page_content='11EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nUsing the Programmer\\nWARNING:  During a device software update, tachycardia therapy is suspended. Always monitor the \\npatient and have external defibrillation equipment available during interrogation.\\nTurning the Programmer On\\nThe Programmer power button is located in the recess above and behind the left corner of the screen (Figure 1). Press and hold the button until the display screen is active.\\nNote:  If the Programmer cannot be turned on while it is connected to AC power via the external \\npower supply, first unplug the external power supply cord from the Programmer. Press \\nand hold the Programmer power button until the display screen is active. AC power via the \\nexternal power supply can then be reconnected.\\nChanging the Programmer Volume Level\\nThe volume level of Programmer-generated sounds may be temporarily adjusted using the volume control (Figure 1 on page 9). This level is automatically reset when the Programmer is restarted.\\nPlacing the Programmer in Suspend Mode\\nThe Programmer has a Suspend Mode which is activated automatically to conserve power. The display will be blank when this mode is in effect.\\nThe Programmer enters Suspend Mode whenever:\\n• The power button is momentarily pressed and released\\n• The Programmer is not connected to the external power supply, it is not in active communication with an \\nS-ICD pulse generator, and no user activity has occurred for 15 minutes\\nMomentarily pressing the power button will resume normal operation.\\nTurning the Programmer Off\\nThere are two ways to turn the Programmer off:\\n1. Press and hold the power button until the System shutdown menu appears. Select Power off from the \\npopup and confirm by pressing OK.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 20}), Document(page_content='12EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n2. From the Programmer start-up screen, press the Power Off button and select OK at the confirmation \\nprompt.\\nUsing the Programmer Touch Screen\\nThe Programmer is equipped with an LCD touch screen. The screen can be adjusted to the desired viewing \\nangle by using the kick-stand located on the back of the Programmer. All interaction with the Programmer is conducted using the fingers to touch the appropriate areas on the screen. Scroll on-screen lists by sliding a finger up and down the list. An on-screen keyboard is presented whenever text entry is required.\\nCaution:  The display on the Programmer is made of glass or acrylic and could break if the Programmer is dropped or if it receives significant impact. Do not use if screen is broken or cracked as this could cause injury.\\nUsing the Wand\\nThe Model 3203 wand (“the wand”) makes it possible for this Programmer to communicate with the pulse generator.\\nCaution:  Use only the Model 3203 telemetry wand with the Programmer.\\nCaution:  The wand is a non-sterile device. Do not sterilize the wand. The wand must be contained in a sterile barrier before use in the sterile field\\nCaution:  The Programmer is non-sterile and cannot be sterilized. It must remain outside the sterile field.\\nTo connect the wand to the Programmer, slide the wand cable connector over the communication connector port located on the rear edge of the Programmer (Figure 1 on page 9).\\nTo disconnect the wand, grasp the wand cable connector and gently pull it straight off the communication \\nconnector port.\\nNote:  Do not pull or yank on the cable to disconnect the wand from the Programmer. Such \\naction could cause hidden damage to the cable. A damaged cable might reduce wireless \\ncommunication capabilities and require a replacement wand.\\nOptimal telemetry depends on the wand being placed directly over the implanted pulse generator. Although it may appear that the Programmer is in communication with the pulse generator at greater distances, programming should always be performed with the wand placed directly over the implanted pulse generator.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 21}), Document(page_content='13EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nWARNING:  The presence of other equipment operating in the same frequency bands used by the \\nProgrammer (402-405 MHz for the pulse generator and 2.4 GHz for the printer) may interfere with communication. Interference can occur even if the other equipment complies with the International Special Committee on Radio Interference (CISPR) emission requirements. This RF interference can be reduced by increasing the distance between the interfering device and the Programmer and pulse generator or printer. If communication problems persist, refer to the Troubleshooting section of this manual.\\nWhen telemetry loss occurs, the display screen will turn yellow and a message will appear with the text “Communication Loss” to alert the user. Reposition the wand to establish communication. The Programmer will return to the screen that was active before telemetry loss if the pulse generator is found and programming can continue.\\nNote:  If communication cannot be reestablished, the session should be ended and restarted by \\nscanning for the pulse generator.\\nNavigation\\nThe Programmer’s graphic user interface (GUI) facilitates management and control of the S -ICD System. The \\nNavigation Bar and on-screen icons at the top of the screen allow the user to navigate programming software screens. In addition, a continuous subcutaneous electrocardiogram (S-ECG) is displayed along the bottom of the screen during Online (active) communication with the pulse generator.\\nScreen Header\\nWhen the Programmer is Offline (inactive communication), the screen header displays the Battery Status Indicator.\\nWhen viewing Offline Stored Sessions, the screen header displays:\\n• Patient name\\n• Therapy On/Off\\n• Battery status indicator\\nWhen the Programmer is Online (active communication), the screen header displays:\\n• Therapy On/Off\\n• Patient name\\n• Patient heart rate', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 22}), Document(page_content='14EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n• Programmer Battery and Telemetry status indicator\\n• Screen title\\n• Rescue shock icon\\nNavigation Bar\\nThe Navigation Bar is the primary method for navigating the Online Programmer screens. The bar is located \\nalong the top edge of the Programmer screen and chosen screens appear with their selection icon highlighted.\\nTable 1: Icon descriptions on page 14 provides a list of the Programmer icons and their corresponding \\ndescriptions.\\nTable 1: Icon descriptions\\nIcon Description User Application\\n Main Menu Icon Allows user to return to the main menu.\\n Automatic Setup Icon Allows user to access the Automatic Setup menu.\\n Device Settings Icon Allows user to access the S -ICD device settings screen.\\n Device Status Icon (open folder and closed folder)Allows user to access the S -ICD device status screen. User can \\nview number of shocks delivered since the last update as well as \\nthe S -ICD device battery life.\\n Patient View IconAllows user to access the patient chart screen. User can view \\ninformation on the S -ICD device battery life.\\n Captured and Stored Episodes S-ECG IconAllows user to access captured S-ECG and stored episode screens.\\n Induction Test Icon Allows user to access induction screen.\\n', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 23}), Document(page_content='15EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nTable 1: Icon descriptions\\nIcon Description User Application\\n Manual Shock Icon Allows user to access the manual shock screen.\\n Battery & Telemetry MeterLeft side of the meter allows user to view the Programmer’s \\nbattery status. The right side of the meter allows viewing of telemetry signal strength.\\n Capture S-ECG Allows user to capture a live S-ECG.\\n S-ECG Display SettingsAllows user to modify the zoom and sweep speed on the live S-ECG.\\n Heart Rate Icon Allows user to view current heart rate.\\n Rescue Shock Icon Allows user to administer a rescue shock\\nOption Selection Switch Allows user to select one of two options, e.g. A or B\\nRestarting the Programmer\\nThe Programmer’s operating system is self-monitoring and is generally able to sense many system error conditions and automatically initiate a restart sequence in response. Follow the on-screen instructions to complete the Programmer-initiated restart sequence.\\nThe Programmer may need to be manually restarted if:\\n• You cannot exit a screen\\n• The operating system stops responding\\nA manual restart is accomplished by pressing and holding the power button until the system shutdown menu \\nappears on the screen. Select Restart from the popup and confirm by pressing OK.\\n', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 24}), Document(page_content='16EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nIf the Programmer does not respond to a restart process, contact Boston Scientific using the information on \\nthe back cover of this manual.\\nConfiguring the Programmer\\nConfiguring Programmer Settings\\nThe Programmer should be configured before communication with a pulse generator is attempted. This includes setting the date and time format, time zone, language and printer. Once these settings are configured during the initial setup process they become the default parameters and will not normally need to be changed with each session.\\nTo configure the Programmer settings:\\n1. Select the Programmer Settings button on the Programmer start-up screen (Figure 2) to display the \\nProgrammer Settings screen (Figure 3 on page 17).\\nFigure 2: Programmer start-up screen\\n', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 25}), Document(page_content='17EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nFigure 3: \\n Programmer Settings screen\\n2. Select the corresponding line to access each setting. The settings that can be configured include:\\n• Date and time format\\n• Time zone\\n• Language\\n• Printer\\nDate and Time Format\\nTo set the date and time format:\\n1. Select Set Date and Time Format on the Programmer Settings screen (Figure 3). The Date and Time \\nSettings screen appears.\\n2. Select the desired date format.\\n3. Select the Save button to save the changes and return to the Programmer Settings screen, or select Cancel \\nto return to the Programmer Settings screen without saving the changes.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 26}), Document(page_content='18EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nTime Zone\\nThe time zone setting controls two S -ICD System parameters, one for the Programmer (the time shown on \\nscreens and printed reports), the other for pulse generators (the electronic filter that is intended to minimize \\nelectromagnetic interference {EMI}).\\nChoosing the correct time zone setting for the Programmer will result in the electronic filter of interrogated \\npulse generators being set to the appropriate regional electrical power line frequency.\\nSpecifically, the pulse generator line frequency filter is automatically programmed to either 50 Hz or 60 Hz, \\nbased on the time zone setting of the interrogating Programmer.\\nTo set the time zone\\n1. Select Set Time Zone on the Programmer Settings screen. The time zone selection screen appears (Figure \\n4 on page 19).\\n2. Select the time zone button for the zone in which the Programmer will be used. A check mark will appear \\nin the selected button.\\n3. Select the Save button to save the changes and return to the Programmer Settings screen, or select Cancel \\nto return to the Programmer Settings screen without saving the changes.\\nIn the rare cases where a single time zone setting includes regional power line frequency differences, two \\nline frequency options are available. Choose the option with the correct frequency for the region where the Programmer is located.\\nBecause a Programmer will set the time zone (and electronic frequency filter) of pulse generators it \\ninterrogates to match its own time zone setting, be aware that travelling patients whose devices are interrogated in time zones or countries other than the one in which they reside may need to have their pulse generator time zone reset upon returning home. ', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 27}), Document(page_content='19EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nFigure 4: \\n Set Time Zone screen (scrollable list)\\nLanguage Preference\\nTo set the language preference:\\n1. Select Set Language on the Programmer Settings screen. The Language Settings screen appears. Scroll the \\nlist and select a language.\\n2. Select the Save button to save the changes or select Cancel to return to the Programmer Settings screen \\nwithout saving the changes. If the language is changed the Programmer will automatically restart and \\nreturn to the Startup screen.\\nPrinter Selection\\nThe Programmer communicates with the printer via Bluetooth®  wireless technology. Only Boston Scientific-\\napproved printers should be paired and used with the Programmer. To select a printer to be paired and used with the Programmer:\\nNote:  Some printers require pairing confirmation on the Programmer and printer. In \\nsuch a case, refer to the printer manufacturer’s documentation for more detail.\\n1. Ensure the printer is on and, depending on your specific printer, that the wireless function is enabled or \\nthe wireless adapter is in the printer’s USB port.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 28}), Document(page_content='20EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n2. Select Printer Setup on the Programmer Settings screen. The Printer Setup screen (Figure 5) may appear \\nwith a previously configured printer displayed as the default printer. If a default printer has not already \\nbeen selected and configured, the screen will be empty and the Programmer will scan the area to locate wireless printers. A Scan Progress Bar will appear informing the user that the Programmer is currently scanning for printers. \\nFigure 5: \\nPrinter Setup screen\\n3. Select the printer of choice from among those found during the scan. If none were found, a window will \\nappear stating that there are no printers. Rescan or select the Cancel button to return to the Programmer Settings screen.\\n4. Optionally, select the desired printer from the list and rename it using the on-screen keyboard (up to 15 \\ncharacters). The printer serial number will appear with the printer selection.\\n5. Select the Save button to save the changes and return to the Programmer Settings screen, or select Cancel \\nto return to the Programmer Settings screen without saving the changes. A confirmation screen will appear when the printer setup is completed.\\nNote:  Refer to the Troubleshooting section for information about printer problems.\\nProgrammer Software Version\\nTo view the Programmer’s software version:', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 29}), Document(page_content='21EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n1. Select About Programmer on the Programmer Settings screen. The Programmer Software Version \\ninformation screen appears.\\n2. The Programmer Software Version information screen displays the current version of the Programmer \\nsoftware. Select the Continue button to return to the Programmer Settings screen.\\nNote:  The printed reports also contain the Programmer software versions.\\nBluetooth® Data Export\\nThe Programmer can be configured to wirelessly export patient data to desktop or notebook computers that \\nare equipped with Bluetooth® wireless technology. The Programmer and each computer must be individually \\npaired in order to use the wireless data export function. The procedure for pairing the Programmer with a computer is different from the procedure used to pair the Programmer with the printer.\\nNote:  Data transfer is supported for computers running Windows. The data transfer feature is not \\navailable for tablets or smartphones.\\n1. Ensure the computer to be paired has been made discoverable, since the Programmer searches for nearby \\ncomputers during the pairing process.\\nNote:  Detailed instructions for accomplishing this are found in the Microsoft Windows \\nhelp files under the general heading of “Why can’t I connect my Bluetooth® \\ndevice to my computer?” \\n2. Once the target computer has been made discoverable, select the Export Programmer Data button on the \\nProgrammer start-up screen. The Export Programmer Data Over Bluetooth®  screen will appear. Select the \\nSet Up Authorized Computers button to scan for nearby computers and begin the pairing process.\\n3. When the scan is complete the screen will list the discovered computers (the three computers having the \\nstrongest Bluetooth®  signals) under the heading Unauthorized Computers Nearby (Figure 6). Choose the \\ncomputer you wish to pair with and press the plus button next to it to complete the pairing process.\\n4. During the pairing process, both the Programmer and the computer will present identical numeric \\npasskeys and both machines will ask you to confirm that the two numbers are the same. The passkey is only presented while pairing and is used to verify that the correct machines are being paired.\\n5. Successful pairing is indicated when the listing for the subject computer appears in the Authorized \\nComputers column instead of the Unauthorized Computers Nearby column.\\n6. Authorized computers may be renamed if desired. Press and hold the listing for the computer until the \\nRename an Authorized Computer popup appears.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 30}), Document(page_content='22EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nFigure 6: \\n Choosing a computer to authorize for Bluetooth®  data transfer\\nProgrammer Modes of Operation\\nOnline Behavior\\nThe Programmer’s interface varies according to whether the Programmer is Online (actively communicating) or \\nOffline (not communicating) with a selected pulse generator.\\nAn Online session begins when the Programmer establishes a telemetry link with a specific pulse generator. \\nA yellow alert screen is displayed if the telemetry signal is lost between the Programmer and the pulse generator for more than five seconds during active communication. This may occur if the wand is moved out of the telemetry communications range or if noise or interfering objects inhibit communication. Programming commands, including Rescue Shocks, will not be available until telemetry is reestablished.\\nTelemetry reconnection may occur automatically if the reason for the telemetry loss has been remedied, e.g. \\nmoving the wand back into telemetry range of the pulse generator or removing the source of interference or noise. Restart the session if the telemetry link does not resume within one minute.\\nNote:  When in active communication with a pulse generator, the Programmer emits an audible \\nnotification to indicate that the pulse generator is preparing to deliver a shock, whether \\nthat shock is commanded or is in response to a detected arrhythmia. The notification \\ncontinues until the shock is either delivered or aborted.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 31}), Document(page_content='23EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nOffline Behavior\\nThe Programmer is Offline when it is not actively communicating with a pulse generator. Programmer settings \\ncan be accessed and stored patient sessions can be viewed and/or printed during Offline sessions.\\nStored Patient Sessions\\nDuring a patient follow-up visit, the Programmer will retrieve data from the pulse generator memory. The Programmer will store up to 50 patient sessions or 90 days of patient session data. When the 51st session occurs, the Programmer will automatically replace the oldest stored session with the new data. Additionally, when the 90th day passes after a patient session was stored, the Programmer will automatically delete that patient session when the Programmer is next powered up.\\nA stored session includes the following information:\\n• Captured S-ECG Reports (including Induction S-ECGs)\\n• Episode History (including any downloaded episodes)\\n• Patient Data\\n• Programmed Device Settings\\nTo view stored patient sessions:\\n1. From the Programmer start-up screen, select Stored Patient Sessions.\\n2. Select the desired patient session.\\nTo purge stored patient sessions:\\n1. From the Programmer start-up screen, select Stored Patient Sessions.\\n2. Select the Purge All Data button.\\n3. A confirmation dialog appears. Select OK to purge all the stored patient session data.\\nModes of Operation for the Pulse Generator\\nThe pulse generator has the following modes of operation:\\n• Shelf\\n• Therapy On\\n• Therapy Off', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 32}), Document(page_content='24EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n• MRI Protection Mode\\nShelf Mode \\nThe Shelf mode is a low power consumption state intended for storage only. When a pulse generator in Shelf \\nmode is interrogated by a Programmer, it exits Shelf mode and defaults to Therapy Off mode. A full-energy capacitor reformation is performed and the pulse generator is prepared for set-up. Once the pulse generator is taken out of Shelf mode, it cannot be reprogrammed back into Shelf mode.\\nTherapy On Mode\\nThe Therapy On mode is the primary operating mode of the pulse generator, allowing automatic detection of, and response to, ventricular tachyarrhythmias.\\nTherapy Off Mode\\nThe Therapy Off mode disables automatic therapy delivery while still allowing manual control of shock delivery. Programmable parameters may be viewed and adjusted via the Programmer. The subcutaneous electrogram (S-ECG) may be displayed or printed from this mode.\\nThe pulse generator defaults to Therapy Off mode when it is taken out of Shelf mode.\\nNote:  Manual and rescue shock therapy are available when the device is set to Therapy On or \\nTherapy Off mode and is actively communicating with a pulse generator, but only after the \\ninitial Setup process is complete. Refer to Automatic Setup on page 32.\\nMRI Protection Mode\\nMRI Protection Mode is available in EMBLEM S -ICD devices.\\nMRI Protection Mode modifies certain pulse generator functions in order to mitigate risks associated with \\nexposing the S -ICD system to the MRI environment. Choosing MRI Protection Mode will initiate a sequence of \\nscreens to assess the patient’s eligibility and readiness to undergo an MR Conditional MRI scan. Refer to the \\nSummary Report to find out whether the device has been in MRI Protection Mode. For a complete description of MRI Protection Mode, a list of MR Conditional devices, and additional information about the IMAGEREADY \\nS-ICD System, refer to the MRI Technical Guide.\\nPrior to the patient undergoing an MRI scan, an IMAGEREADY S -ICD System must be programmed to the MRI \\nProtection Mode using the Programmer. In MRI Protection Mode:', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 33}), Document(page_content='25EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n• Tachycardia therapy is suspended\\n• A Time-out feature is nominally set to 6 hours, with programmable values of 6, 9, 12, and 24 hours\\n• Beeper is disabled\\nMRI Protection Mode is terminated by manual exit or through the user-programmed automatic MRI Protection \\nTime-out period (refer to the MRI Technical Guide for MRI Protection Mode programming instructions.) Rescue Shock will also terminate MRI Protection Mode. When MRI Protection Mode is exited, all parameters (except for the beeper) return to the previously programmed settings.\\nWARNING:  The beeper may no longer be usable following an MRI scan. Coming in contact with the strong magnetic field of an MRI scanner may cause a permanent loss of the beeper volume. This cannot be recovered, even after leaving the MR scan environment and exiting MRI Protection Mode. Before an MRI procedure is performed, a physician and patient should weigh the benefit of the MR procedure against the risk of losing the beeper. It is strongly recommended that patients are followed on LATITUDE NXT after an MRI scan if they are not already. Otherwise, an in-clinic follow-up schedule of every three months is strongly recommended to monitor device performance.\\nNote:  The beeper can be re-enabled after exiting MRI Protection Mode. (See Enable/Disable \\nBeeper (EMBLEM S -ICD devices) on page 52 .) \\nConnecting and Disconnecting from the S -ICD Pulse Generator\\nThis section provides the information necessary for selecting, connecting to, and disconnecting from the pulse generator.\\nWARNING:  During a device software update, tachycardia therapy is suspended. Always monitor the patient and have external defibrillation equipment available during interrogation.\\nCaution:  Use only the designated Boston Scientific S -ICD Programmer and appropriate \\nsoftware application to communicate with and program the S -ICD pulse generator.\\nScanning for Pulse Generators\\n1. Select the Scan For Devices button on the Programmer start-up screen (Figure 2 on page 16). The Scan \\nProgress Bar is displayed during the scanning process, at the conclusion of which the Device List screen appears. Select the Cancel button at any time to end the scanning process.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 34}), Document(page_content='26EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n2. When the scanning process is complete, a list of all pulse generators detected (up to 16) will be displayed \\non the Device List screen (Figure 7 on page 26). The devices that are in Shelf mode will be displayed \\nas “Not Implanted.” Any devices that were previously taken out of Shelf mode are displayed either as “Implanted” or with the stored patient name.\\nFigure 7: \\nDevice List screen (scrollable list)\\n3. If the desired pulse generator is not listed, select the Scan Again button to re-initiate the scanning \\nprocess. Select the Cancel button to return to the Programmer start-up screen.\\nNote:  Refer to the Inability to Communicate With the Pulse Generator heading within \\nthe Troubleshooting section for further assistance.\\nConnecting to a Pulse Generator\\nSelect the desired pulse generator from the Device List screen (Figure 7) to initiate the communication session.\\nNote:  Regardless of how many pulse generators are located by a scan, the user must select a \\nspecific pulse generator from the list in order to begin active communication.\\nConnecting to a Pulse Generator in Shelf Mode \\n1. The Programmer connects to the selected pulse generator after the selection is made. A window will \\nappear indicating connection is in process.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 35}), Document(page_content='27EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n2. The Device Identification screen appears once communication is established with the pulse generator.\\nNote:  The Device Identification screen is visible only while connecting to a pulse \\ngenerator in Shelf mode.\\n3. The device model and serial numbers are automatically acquired and displayed during the initial scanning \\nprocess. Select Continue to remove the device from Shelf mode and prepare for implantation, or select \\nCancel to return to the Device List screen.\\nConnecting to an Implanted Pulse Generator \\nIf an implanted pulse generator is chosen from the Device List screen, the following connection sequence occurs:\\n1. The Programmer connects to the selected pulse generator after the selection is made. A window will \\nappear indicating connection is in process.\\nDuring the connection process informational messages and warning messages may display  e.g. Smart Pass has been disabled.\\n2. The Device Status screen appears once communication is established with the pulse generator.\\nWARNING:  During a device software update, tachycardia therapy is suspended. Always monitor the patient and have external defibrillation equipment available during interrogation.\\nEnding a Patient Session\\nTo end an Online patient session and return the Programmer to its Offline operation mode:\\n1. Select the Main Menu icon on the Navigation Bar. The Main Menu screen appears.\\n2. Select the End Session button (Figure 8 on page 28).', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 36}), Document(page_content='28EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nFigure 8: \\n Main Menu screen\\n3. Warning messages (Figure 9 on page 29) will be displayed to the user if any of the following conditions \\nexist:\\n• Therapy mode is programmed to Off\\n• Reference S-ECG has not been acquired\\n• Automatic or Manual Setup has not been completed\\n• Optimization has not been completed. This message is displayed if Setup Optimization was \\nnot performed during the Automatic Setup process\\n• SMART Pass is not enabled', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 37}), Document(page_content='29EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nFigure 9: \\n Session incomplete message\\n4. Select the Continue button to end the patient session and return to the Programmer start-up screen, or \\nselect Cancel to remain Online and return to the Main Menu screen.\\nNote:  Once the Continue button is selected, the session is stored and communication is \\nterminated.\\nNote:  A telemetry session must be terminated using the End Session process as \\ndescribed in steps 1 through 4 above in order for data obtained during that \\nsession to be saved. If the Programmer is powered off during a session, either \\nautomatically or manually, session data will not be saved.\\nNote:  In order to confirm that Therapy Mode is set to On upon disconnection, always use \\nthe End Session process and review all displayed warning messages.\\nProgramming the Pulse Generator at Implant\\nThis section provides the information necessary for programming the pulse generator during an implant.\\nWARNING:  During a device software update, tachycardia therapy is suspended. Always monitor the \\npatient and have external defibrillation equipment available during interrogation.\\nCaution:  Allow the pulse generator to reach an operating temperature range 25° C-45° C (77°\\xa0F-113°\\xa0F) before using telemetry communication ', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 38}), Document(page_content='30EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\ncapabilities, programming, or implanting the pulse generator because \\ntemperature extremes may affect initial device function.\\nCaution:  Use only the Model 3203 telemetry wand with the Programmer.\\nCaution:  The wand is a non-sterile device. Do not sterilize the wand. The wand must be contained in a sterile barrier before use in the sterile field.\\nCaution:  The Programmer is non-sterile and cannot be sterilized. It must remain outside the sterile field.\\nCaution:  Confirm that the Programmer is in communication with the \\nintended implanted S -ICD pulse generator.\\nEntering Electrode Information\\nThe Programmer maintains information on the implanted electrode. To record this information for a patient’s new or replacement electrode:\\n1. Select the Main Menu icon.\\n2. Select the Implant button.\\n3. Select the Automatic Setup icon in the Navigation Bar. The Automatic Setup screen appears (Figure 12 on \\npage 33).\\n4. Select Set Electrode ID button.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 39}), Document(page_content='31EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nFigure 10: \\n Select the Set Electrode ID button to enter electrode information\\nNote:  ECG and heart rate information is not present on the Automatic Setup and Electrode ID \\nsetup screens until the electrode has been connected to the pulse generator.\\n5. Enter the electrode model and serial number.\\n6. Select the Program button to save the information. A confirmation screen will appear during \\ncommunication with the device. Select Cancel to cancel information storage and return to the Automatic \\nSetup screen.\\nCreating the Patient Chart\\nThis chart contains reference information for the patient. To set up the patient chart:\\n1. Select the Main Menu icon on the Navigation Bar.\\n2. Select the Implant button.\\n3.  Select the Patient View icon to access the Patient View screen (Figure 11).\\n4. The pulse generator model and serial numbers appear on the first line of the chart. The electrode model \\nand serial numbers appear on the second line of the chart. The implant date appears on the third line of the chart. Using the on-screen keyboard, enter the following patient information:\\n• Patient Name:   up t o 25 characters\\n• Doctor Name:   up t o 25 characters', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 40}), Document(page_content='32EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n• Doctor Info:   up t o 25 characters\\n• Notes:   up t o 100 characters\\nFigure 11: \\n Patient View screen\\nNote:  The Notes field will automatically wrap the text with the presence of a space \\nbetween any characters within the first line.\\n5. Select the Save button to update the pulse generator with the patient information.\\nNote:  Failure to save the new patient information will result in loss of the entered data.\\nAutomatic Setup\\nBefore the S -ICD device can be activated, it must go through an initial Automatic Setup Process at the time of \\nthe implant.\\nThe Automatic Setup Process is initiated as follows:\\n1. Select the Main Menu icon.\\n2. Select the Implant button.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 41}), Document(page_content='33EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n3. Select the Automatic Setup icon on the navigation bar. The Automatic Setup screen appears. Select the \\nAutomatic Setup button on this screen to advance to the next screen.\\n4. Select Continue if the patient’s heart rate is less than 130 bpm (Figure 12). For rates greater than 130 bpm, \\nselect the Cancel button and refer to Manual Setup on page 52.\\nFigure 12: \\n Automatic Setup screen\\n5. Once started the Automatic Setup will:\\n• Perform the shock electrode integrity check to measure electrode impedance. Normal sub-\\nthreshold impedance range is < 400 Ohms.\\n• Select the best sensing configuration. SMART Pass will be automatically configured based on the amplitude of the ECG signals in the selected vector. The sense electrode configuration appears on the printed report and can be viewed via the Manual Setup process. The status of SMART Pass (On/Off) is displayed on the SMART Settings Programmer screen and Summary Report. (For more information on SMART Charge and SMART Pass, see SMART Settings on page 54.)\\n• Select the appropriate gain setting. The selected sense gain appears on the Printed Report and can be viewed via the Manual Setup process.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 42}), Document(page_content='34EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nFigure 13: \\n Measuring electrode impedance\\nThe overall progress of the Automatic Setup process is shown in the status bar (Figure 13). \\nWhen each function is complete, the arrow next to the function moves to a down position.\\n6. The Automatic Setup optimization process will be initiated. The Programmer will display a message \\nrequesting that the patient sit up. If Automatic Setup is being performed during implant, or if the patient is unable to sit up for some other reason, this step can be omitted by selecting the Skip button. If desired, Automatic Setup can be repeated during a follow-up session to include the optimization step.\\n7. Select the Continue button to finish the Automatic Setup process. A confirmation screen will appear when \\nAutomatic Setup is complete.\\n8. Following the optional optimization process, the Acquire Reference S-ECG screen is displayed. Select the \\nContinue button to acquire a reference S-ECG.\\n9. Once the Reference S-ECG acquisition process begins, a status screen appears. The process may take up to \\none minute, during which the patient should remain still. During this process, a template of the patient’s baseline QRS complex is stored in the pulse generator. Select Cancel at any time to end Reference S-ECG acquisition. When acquisition is complete, select the Continue button.\\nProgramming Therapy Parameters\\nOnce Automatic Setup has been completed, the pulse generator therapy parameters may be selected.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 43}), Document(page_content='35EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nTo set the therapy parameters:\\n1. Select the Main Menu icon on the Navigation Bar.\\n2. Select the Implant button.\\n3. Select the Device Settings icon on the Navigation Bar to display the Device Settings screen (Figure 14 on \\npage 35).\\nFigure 14: \\n  Device Settings screen\\n4. Select the desired therapy mode using the On/Off Therapy switch.\\n5. Select and drag the Conditional Shock Zone (yellow) and Shock Zone (red) slider bars to set the desired \\nzone configuration.\\nNote:  The S-ICD System Clinical Investigation demonstrated a significant reduction in \\ninappropriate therapy with the activation of the Conditional Shock Zone prior to hospital \\ndischarge (see the S-ICD pulse generator user’s manual for a summary of the Clinical \\nInvestigation).\\n• The Shock Zone is programmable between 170 and 250 bpm in steps of 10 bpm.\\n• The Conditional Shock Zone is programmable between 170 and 240 bpm in steps of 10 bpm. \\nEnhanced detection criteria are automatically enabled when the Conditional Shock Zone is programmed.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 44}), Document(page_content='36EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n• When programming both the Shock Zone and Conditional Shock Zone, maintain at least a \\n10 bpm difference between the two zones. If the Conditional Shock Zone slider (yellow) is dragged over the Shock Zone slider (red), the two sliders will merge to create a single Shock Zone.\\n6. If post-shock pacing is desired, set the Post Shock Pacing switch to the On position. (Post-shock \\nbradycardia pacing occurs at a non-programmable rate of 50 bpm for up to 30 seconds. Pacing is inhibited if the intrinsic rate is greater than 50 bpm.)\\n7. Select the Program button to apply the changes and program the pulse generator. A message confirming \\nthat the pulse generator settings were successfully programmed will appear. Select the Continue button to return to the Device Settings screen.\\n8. If the pulse generator does not accept the programming, a message with instructions will appear on the \\nDevice Settings screen. Press the Continue button after following the instructions.\\nWARNING:  The presence of other equipment operating in the same frequency bands used by the Programmer (402-405 MHz for the pulse generator and 2.4 GHz for the printer) may interfere with communication. Interference can occur even if the other equipment complies with the International Special Committee on Radio Interference (CISPR) emission requirements. This RF interference can be reduced by increasing the distance between the interfering device and the Programmer and pulse generator or printer. If communication problems persist, refer to the Troubleshooting section of this manual.\\n9. Once programming is confirmed, select the Continue button to proceed to the next operation.\\nNote:  The Pending Program Changes screen will appear if changes made to pulse \\ngenerator settings on the Device Settings screen were not successfully applied to \\nthe pulse generator. Select Cancel to return to the Device Settings screen and save \\nall settings changes, or Continue to abandon all pulse generator setting changes.\\nDefibrillation Testing\\nOnce the pulse generator is implanted and Therapy Mode is programmed On, defibrillation testing may be conducted. Prior to arrhythmia induction during implant procedure, the following recommendations for arm positioning are intended to reduce the potential for injury of the clavicle, arm and shoulder in the event of forceful muscle contraction:\\n• Avoid tight strapping of the arm to the arm board, and consider loosening arm restraints.\\n• Remove any wedge elevation below the torso, if used during the implant procedure, taking care to preserve the sterile field.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 45}), Document(page_content='37EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n• Create a smaller angle of arm abduction from the torso by adducting the arm as close to the torso as \\nfeasible, taking care to preserve the sterile field. Temporarily place the hand in a neutral position while the arm is in a more adducted position, reverting to a supinated position if the arm needs to be abducted again. \\nWARNING:  During arrhythmia induction, the induction current and subsequent shock may result in forceful contraction of the pectoralis major muscle which can exert significant acute forces on the glenohumeral joint as well as on the clavicle. This, in conjunction with a tightly restrained arm, may result in injury to the clavicle, shoulder, and arm, including dislocation and fracture.\\nWARNING:  Always have external defibrillation equipment and medical personnel skilled in CPR available during implant and follow-up testing. If not terminated in a timely fashion, an induced ventricular tachyarrhythmia can result in the patient’s death.\\nCaution:  Successful VF or VT conversion during arrhythmia conversion testing is no assurance that conversion will occur post-operatively. Be aware that changes in the patient’s condition, drug regimen, and other factors may change the DFT, which may result in nonconversion of the arrhythmia post-operatively. Verify with a conversion test that the patient’s tachyarrhythmias can be detected and terminated by the pulse generator system if the patient’s status has changed or parameters have been reprogrammed.\\nNote:  Defibrillation testing is recommended at implant, replacement, and concomitant device \\nimplants to confirm the ability of the S -ICD System to sense and convert VF.\\nNote:  When the Hold to Induce button is pressed during defibrillation testing, the Programmer \\nbegins capturing the episode data generated during the test. This data is available for \\nviewing and printing. (See Capturing and viewing S-ECG Strips on page 47 and Captured \\nS-ECG Report on page 42.)\\nTo induce VF and test the S -ICD System:\\n1. Select the Main Menu icon on the Navigation Bar to access the Main Menu.\\n2. Select the Shock Test button to setup the induction test (Figure 15).\\n3. Select either standard (STD) or reverse (REV) polarity.\\n4. Select and drag the red marker to set the desired shock energy for the first delivered shock. The shock \\nenergy may be programmed from 10 to 80 J. A 15 J safety margin is recommended for defibrillation testing.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 46}), Document(page_content='38EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nFigure 15: \\n Setting the desired first shock energy for defibrillation testing\\n5. Select the Continue button to display the next Induction Test screen or select the Cancel button to return \\nto the Main Menu screen.\\nNote:  Ensure that noise markers (“N”) are not present on the S-ECG prior to induction. \\nThe presence of noise markers may delay detection and therapy delivery.\\n6. On the Induction Test screen, select the check box to enable the Hold to Induce button.\\n7. Select and hold the Hold To Induce button for the desired duration.\\nThe following functions occur during the test:\\n• The S -ICD System induces ventricular fibrillation using 200 mA alternating current (AC) at 50 \\nHz. Induction continues until the Hold To Induce button is released (up to a maximum of 10 \\nseconds per attempt).\\nNote:  If necessary, the induction can be terminated by disconnecting the wand \\nfrom the Programmer.\\n• Arrhythmia detection and the Live S-ECG are suspended during induction. Once the Hold to Induce button is released, the Programmer displays the patient’s rhythm.\\n• Upon detection and confirmation of an induced arrhythmia, the S -ICD System automatically \\ndelivers a shock at the programmed energy output and polarity.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 47}), Document(page_content='39EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nNote:  When in active communication with a pulse generator, the Programmer \\nemits an audible notification to indicate that the pulse generator is \\npreparing to deliver a shock, whether that shock is commanded or is in \\nresponse to a detected arrhythmia. The notification continues until the \\nshock is either delivered or aborted.\\n• If the shock fails to convert the arrhythmia, re-detection occurs and subsequent shocks are \\ndelivered at the pulse generator’s maximum energy output (80 J).\\nNote:  Evaluate the sensing markers during the induced rhythm that follows the \\nrelease of the Hold To Induce button. The S -ICD System uses a lengthened \\nrhythm detection period. Consistent tachy “T” markers indicate that \\ntachyarrhythmia detection is occurring, and that capacitor charging is \\nimminent. If a high degree of amplitude variation is noted during the \\narrhythmia, a slight delay may be expected prior to capacitor charging or \\nshock delivery.\\nNote:  The pulse generator can deliver a maximum of five shocks per episode. An \\n80 J rescue shock can be delivered at any time prior to therapy delivery by \\npressing the Rescue Shock icon.\\n• The Programmer will start capturing S-ECG data when the Hold to Induce button is pressed. The Captured S-ECG will cover the time period six seconds before the button is pressed and up to 102 seconds afterwards, for a maximum total of 108 seconds. The Induction S-ECGs will be viewable and printable from the Captured S-ECG screen, labeled as “Induction S-ECG”. \\n8. At any time prior to therapy delivery, the programmed energy may be aborted by selecting the red Abort \\nbutton.\\n9. Select the Exit button to return to the Main Menu screen.\\nPerforming a Follow Up\\nFor a complete guide on clinical follow-up, see the section on post implant follow-up procedures in the \\nEMBLEM™ S -ICD User’s Manual.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 48}), Document(page_content='40EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nPrinting Reports from the Programmer\\nPrinting Reports\\nPatient reports can be printed before or after a patient session is ended. It is recommended that a final report \\nbe printed immediately following the implant procedure. There are three patient reports:\\n• Summary Report\\n• Captured S-ECG Report\\n• Episode Reports\\nTo print patient reports from either an Online or Offline session:\\n1. Select the Main Menu icon to display the Main Menu screen.\\n2. Select the Print Reports button to display the Print Reports screen (Figure 16 on page 40).\\nFigure 16: \\n Print Reports screen\\n3. Select the desired report type. A check mark will appear next to the selected report. Report types are \\ndescribed below.\\n4. Select the Print button to print the selected report.\\n5. Select the Cancel button to return to the previously accessed screen.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 49}), Document(page_content='41EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nSummary Report\\nTo print a summary report, select the Summary Report option on the Print Reports screen and press the Print \\nbutton. The report will print for either the current active session (if the Programmer is Online) or for the chosen stored session (if the Programmer is Offline.)\\nThe Summary Report includes the following information:\\n• Printed Report Date\\n• Programmer Software Version\\n• Pulse generator Software Version\\n• Patient Name\\n• Date of Last Follow-Up\\n• Date of Current Follow-Up\\n• Implant Date\\n• Pulse generator Model/Serial Number\\n• Electrode Model/Serial Number\\n• Therapy Parameters\\n• SMART Charge Delay\\n• SMART Pass status (On/Off)\\n• Programmed Gain Settings and Sensing Configuration\\n• Pulse generator Integrity Check, if applicable\\n• Initial Shock Polarity Configuration\\n• Days with measured AF\\n• Estimate of measured AF\\n• Beeper Status (if disabled)\\n• MRI Information\\n• Episode Summary: Since Last Follow-Up and Since Initial Implant\\n• Battery Status\\n• Electrode Impedance Measurement', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 50}), Document(page_content='42EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nCaptured S-ECG Report\\nTo print a Captured S-ECG report:\\n1. Select the Captured S-ECG Reports option from the Print Reports screen.\\n2. A scrollable list containing both Captured S-ECG and Induction S-ECG strips is displayed (Figure 19). Select \\nthe desired S-ECG(s) to be printed by placing a check mark next to the selection(s).\\nFigure 17: \\n Captured S-ECG list (scrollable)\\n3. Select Continue to return to the Print Reports screen.\\n4. Select the Print button to print the selected report and return to the previously accessed screen.\\n5. Select the Cancel button to return to the previously accessed screen without printing the report.\\nEpisode Reports\\nTo print an Episode Report:\\n1. Select the Episode Reports option on the Print Reports screen.\\n2. The Select Episode Reports screen appears showing a list of the stored episodes (Figure 20). Select the \\nepisode(s) to be printed. A check mark appears next to the selected episode(s).', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 51}), Document(page_content='43EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nNote:  In order to be available for printing, episodes must have been individually \\nselected and viewed from the Episodes Screen (Figure 18 on page 43).\\nFigure 18: \\n Select Episode Reports screen (scrollable)\\n3. Select Continue to return to the Print Reports screen. Either 12 seconds or 44 seconds of pre-episode \\nS-ECG data may be selected using the radio buttons below the Episode Reports row. The default value for \\nEpisode Report Onset is 12 seconds.\\n4. Select the Print button to print the selected report and return to the previously accessed screen.\\n5. Select the Cancel button to return to the previously accessed screen without printing the report.\\nExport Patient Data\\nPatient data saved on the Programmer may be exported to a desktop or notebook computer using either of two means: wirelessly, over a pre-configured \\nBluetooth®  pairing, or with a Model 3205 microSD™ log data \\ncard. (For information about Bluetooth®  pairing between the Programmer and a desktop or laptop computer, \\nsee Bluetooth ® Data Export on page 21.)\\nExport using Bluetooth® wireless technology\\nEnsure that the Programmer and the intended recipient computer are within 10 meters (33 feet) of each other before attempting a \\nBluetooth®  wireless data transfer.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 52}), Document(page_content='44EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n1. Select the Export Programmer Data button on the Programmer start-up screen. The Export Programmer \\nData Over Bluetooth®  screen will appear.\\n2. Select one of the three export options (Export Today’s Data, Export Last Seven Days, Export All). The \\n“Select a receiving computer” pop-up window will appear.\\nNote:  The Export Today’s Data and Export Last Seven Days options typically take less \\ntime to complete than the Export All option.\\n3. The pop-up contains a scrollable list of all of the computers the Programmer has been paired with. Select \\nthe intended receiving computer from the list to begin the transfer.\\nNote:  Although every paired computer is listed in the scrollable box, only those within \\n10 meters (33 feet) of the Programmer can participate in a file transfer. Once \\none of the three export options has been selected, the Programmer will prepare \\nthe file transfer package and attempt the wireless transfer. An error message \\nwill appear if the transfer cannot be completed. Should this occur, move the \\nProgrammer to within 10 meters of the intended receiving computer or choose \\nanother computer within that distance. Restart the export process by selecting \\none of the three export options on the Export Programmer Data Over Bluetooth® \\nscreen.\\nExport using a microSD™ card\\nData may also be exported using a microSD™ card. For security reasons, the Programmer will only export data \\nto Model 3205 microSD™ log data cards. Using any other microSD™ card will cause an error message (invalid card) to appear.\\n1. Navigate to the Programmer start-up screen.\\n2. Insert the card into the microSD™ slot according to the instructions presented in Appendix A: Insertion \\nand Removal of the microSD™ Card . The instructions are also provided with Model 3205 microSD™ \\nlog data card. A Copy Data screen will appear when the microSD™ card has been properly inserted and recognized.\\nNote:  An invalid card error message will appear if any card other than a Model 3205 \\nmicroSD™ log data card is inserted. The message may also appear if the \\nProgrammer does not recognize the Model 3205 card after insertion. Should this \\noccur, remove the card and select the OK button on the error screen. Wait for the \\nProgrammer start-up screen to reappear and then reinsert the card.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 53}), Document(page_content='45EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n3. Select the Copy Data button on this screen and the next screen.\\n4. A confirmation screen is presented when the copy process is complete. Selecting the OK button will return \\nthe Programmer to its start-up screen.\\n5. Remove the microSD™ card according to the instruction sheet (Appendix A).\\nNote:  Navigating away from and returning to the start-up screen with the microSD™ card still \\ninserted will cause the export process to begin again.\\nS-ECG Features\\nThe Programmer provides the capability to view, adjust and capture the streaming S-ECG from the pulse \\ngenerator.\\nS-ECG Rhythm Strip Markers\\nThe system provides annotations to identify specific events on the S-ECG. These markers are shown in Table 2: S-ECG Markers on Programmer Display Screens and Printed Reports on page 46 .', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 54}), Document(page_content='46EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nTable 2: S-ECG Markers on Programmer Display Screens and Printed Reports\\nDescription Marker\\nCharging aC\\nSensed Beat S\\nNoisy Beat N\\nPaced Beat P\\nTachy Detection T\\nDiscard Beat •\\nReturn to NSR a\\nShock\\nEpisode data compressed or not available\\na Marker present on printed report but not on Programmer display screen.\\nS-ECG Scale Settings\\nTo adjust the real-time S-ECG amplitude and display speed scale settings:\\n1. Select the S-ECG Display Settings icon located to the right of the Live S-ECG window. The S-ECG Settings \\nscreen is displayed.\\n2. Select and drag the Gain or Sweep Speed Scale bars as desired (Figure 21). The S-ECG scale will change \\naccording to the selected setting. The gain setting controls the visual gain. The Programmer defaults to \\nFull Range for pulse generators with a gain setting of 1x and to 1/2 Range for pulse generators with a gain setting of 2x. The Sweep Speed slider controls the display speed of the scrolling Live S-ECG. The nominal sweep speed setting is 25 mm/sec.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 55}), Document(page_content='47EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nNote:  Amplitude settings and display speed adjustments on scrolling real-time S-ECG \\nand Captured S-ECGs affect the display screen settings only and have no impact \\non the pulse generator settings for sensing.\\nFigure 19: \\n Adjusting Gain and Sweep Speed\\nCapturing and viewing S-ECG Strips\\nThe Programmer can display and store real-time S-ECG rhythm strips. The Programmer saves a maximum of \\n50 recordings generated by:\\n1. Manually-captured twelve-second S-ECGs using the Capture S-ECG button which include:\\n• 8.5 seconds before activation of the Capture S-ECG button\\n• 3.5 seconds after activation of the Capture S-ECG button\\n2. S-ECGs captured automatically during induction testing which include:\\n• 6 seconds before the induce button is pressed\\n• Up to 102 seconds after the induce button is pressed\\nNote:  The S -ICD suspends detection of sensed events for 1 .6 seconds after a shock has \\nbeen delivered. As a result, the S-ECG rhythm strip will not contain event markers \\nduring this 1. 6 second post-shock interval. ', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 56}), Document(page_content='48EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nIf an additional recording is required, then the oldest previous recording is replaced with the new recording.\\nTo manually capture a new S-ECG rhythm strip:\\n1. Select the Capture S-ECG button located to the left of the Live S-ECG window. The S-ECG will scroll across \\nthe display screen. Calipers appear below the Captured S-ECG rhythm strip. Each 12-second recording is \\ndate and time stamped according to the Programmer’s date and time setting.\\nNote:  Induction S-ECGs are automatically generated during induction testing without \\nadditional user input.\\n2. Select and move the calipers across the S-ECG strip to measure intervals as desired.\\n3. Select the Continue button to return to the previously accessed screen.\\nIt is also possible to capture S-ECGs corresponding to all three sense vectors (Primary, Secondary, and Alternate) by using the Capture All Sense Vectors button on the Utilities screen (Figure 20 on page 49).\\nViewing previously captured S-ECGs\\nWhen the Programmer is Online:\\n1. Select the Main Menu icon.\\n2. Select the Follow Up button.\\n3. Select the Captured and Stored Episode S-ECG icon. The Captured S-ECG screen appears.\\n4. Select one Captured S-ECG or Induction S-ECG from the list. The S-ECG details screen appears.\\n5. Select and drag the calipers to view details.\\n6. Select the Continue button to return to the Captured S-ECG list screen.\\nWhen the Programmer is Offline:\\n1. Select the Stored Patient Sessions button from either the Programmer start-up screen or the Main Menu.\\n2. Select the desired stored patient session.\\n3. Select one Captured S-ECG from the list. The Captured S-ECG Details screen appears.\\nNote:  Not all stored patient sessions contain captured S-ECGs. A message to that effect \\nis presented when such patient sessions are opened. In this event select the Main \\nMenu icon, then select the End Session button. This action returns you to the \\nProgrammer start-up screen.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 57}), Document(page_content='49EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n4. Select and drag the calipers to view details.\\n5. Select the Continue button to return to the Captured S-ECG list screen.\\nUtilities Screen\\nThe Programmer Utilities screen provides access to additional device features. These may include Acquire \\nReference S-ECG, Capture All Sense Vectors, Beeper Control, Manual Setup, SMART Settings, and AF Monitor.\\nTo access the Utilities screen during an Online session:\\n1. Select the Main Menu icon to display the Main Menu screen.\\n2. Select the Utilities button. The Utilities screen appears (Figure 20 on page 49).\\nFigure 20: \\n Utilities screen\\nAcquire Reference S-ECG\\nTo acquire a manual Reference S-ECG:\\n1. From the Utilities screen (accessible from the Main Menu screen), select the Acquire Reference S-ECG \\nbutton to access the Acquire Reference S-ECG screen.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 58}), Document(page_content='50EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n2. Select Continue to acquire a Reference S-ECG. The Programmer will begin acquiring the Reference S-ECG. \\nA message will appear requesting that the patient remain still. The reference S-ECG QRS template is \\nrecorded and stored in the pulse generator.\\n3. Select the Continue button to complete the process and return to the Utilities screen. The Cancel button \\ncan be used at any time to end S-ECG acquisition and return to the Utilities screen.\\nCapture All Sense Vectors\\nThe Capture All Sense Vectors button on the Utilities screen configures temporary Programmer settings that allow you to capture S-ECGs generated from each of the three sense vectors (Primary, Secondary, and Alternate). This process takes approximately one minute. The Programmer returns to its original settings configuration after all S-ECGs have been captured.\\nTo capture the three sense vectors:\\n1. From the Utilities screen (accessible from the Main Menu screen), select the Capture All Sense Vectors \\nbutton.\\n2. The Capturing 12 Second S-ECG screen will appear and display the status of the sense vector capture \\nprocess.\\nOnce captured, the three S-ECGs can be viewed by following the steps outlined in Viewing previously \\ncaptured S-ECGs  on page 48.\\nBeeper Control\\nThe pulse generator has an internal warning system (beeper) that may emit an audible tone to alert the patient to certain device conditions that require prompt consultation with the physician. These conditions may include:\\n• Electrode impedance out of range\\n• Prolonged charge times\\n• Failed Device Integrity Check\\n• Irregular battery depletion\\nThis internal warning system is automatically activated at time of implant. Once triggered, if the beeper is enabled, tones beep for 16 seconds every nine hours until the trigger condition has been resolved. If the triggering condition reoccurs, then the tones will once again alert the patient to consult the physician.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 59}), Document(page_content='51EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nCaution:  Patients should be advised to contact their physician immediately \\nif they hear tones coming from their device.\\nNote:  Access to the Reset Beeper display screen is enabled only when an alert condition occurs. If \\nan alert condition is activated, a notification screen will appear upon connection.\\nWARNING:  The beeper may no longer be usable following an MRI scan. Coming in contact with the strong magnetic field of an MRI scanner may cause a permanent loss of the beeper volume. This cannot be recovered, even after leaving the MR scan environment and exiting MRI Protection Mode. Before an MRI procedure is performed, a physician and patient should weigh the benefit of the MR procedure against the risk of losing the beeper. It is strongly recommended that patients are followed on LATITUDE NXT after an MRI scan if they are not already. Otherwise, an in-clinic follow-up schedule of every three months is strongly recommended to monitor device performance.\\nReset Beeper\\nTo reset the beeper, select the Beeper Control button from the Utilities screen (accessible from the Main Menu) to open the Set Beeper Function screen.\\nSelect the Reset Beeper button to suspend audible beeping tones triggered by an alert condition. If the alert \\ncondition is not corrected, the audible beeping tones will be reactivated during the next automatic S -ICD \\nSystem self-check.\\nDisable Beeper (SQ-Rx devices)\\nIn SQ-Rx devices, Beeper Control allows for the deactivation of beeping on alert conditions (Disable Beeper). \\nPerform the following steps to disable the beeper:\\nNote:  The Disable Beeper function is only available once device ERI or EOL is reached.\\n1. From the Utilities screen, select Beeper Control to open the Set Beeper Function screen.\\n2. Select Disable Beeper to disable the beeper for the device.\\nNote:  This will permanently disable all beeping on alert conditions for the SQ-Rx device. \\nHowever, this will not affect beeper functionality for when a magnet is placed on the device \\nor when a Programmer connects to the device.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 60}), Document(page_content='52EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nEnable/Disable Beeper (EMBLEM S -ICD devices)\\nIn EMBLEM S -ICD devices, the beeper must be tested before being enabled or disabled. Perform the following \\nsteps to test the beeper:\\nNote:  For EMBLEM S -ICD devices, the Test Beeper function is only available when beeping for an \\nalert condition is not active.\\n1. From the Utilities screen, select Beeper Control.\\n2. Select the Test Beeper button from the Set Beeper Function screen.\\n3. Evaluate if the beeper is audible using a stethoscope.\\n4. If the beeper is audible, select the Yes, Enable Beeper button. If the beeper is not audible or you wish to \\npermanently disable beeping functionality, select the No, Disable Beeper button.\\nCAUTION:  In the Programmer steps to program and test the Beeper, selecting “No, Disable Beeper” \\nwill disable beeping functionality for alert conditions, when a magnet is placed over the \\ndevice, and when the S -ICD application connects to the device.\\nIf the beeper is not audible to the patient, it is strongly recommended that the patient has a follow-up schedule of every three months either on LATITUDE NXT or in-clinic to monitor device performance.\\nFor additional information regarding the beeper, refer to the MRI Technical Guide or contact Boston Scientific \\nusing the information on the back cover.\\nManual Setup\\nManual Setup enables the user to perform the electrode integrity test and select the electrode sensing configuration and gain setting in the pulse generator. During Manual Setup, the system will also automatically enable SMART Pass if appropriate.\\n1. From the Utilities screen (accessible from the Main Menu screen), select the Manual Setup button. The \\nMeasure Impedance screen appears.\\n2. Select the Test button to perform the electrode integrity test.\\n3. Select the Continue button.\\n4. There are three available sensing vectors that can be manually selected from the Manual Setup screen \\n(Figure 21 on page 53):\\n• Primary: Sensing from the proximal electrode ring on the subcutaneous electrode to the surface of the active pulse generator', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 61}), Document(page_content='53EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n• Secondary: Sensing from the distal sensing electrode ring on the subcutaneous electrode to \\nthe surface of the active pulse generator\\n• Alternate: Sensing from the distal sensing electrode ring to the proximal sensing electrode ring on the subcutaneous electrode\\nThe gain setting adjusts the sensed S-ECG signal sensitivity. It may be manually selected with the Select Gain switch on the Manual Setup screen.\\nFigure 21: \\nManual Setup screen with sensing vector and gain options\\n• 1x Gain (± 4 mV):  1x Gain should be sele cted when the signal amplitude is large enough to \\ncause clipping when the 2x gain is selected.\\n• 2x Gain (± 2 mV):  2x Gain should be sele cted when the signal amplitude is small enough to \\nallow use of a more sensitive setting without causing clipping of the captured signal. The 2x gain selection amplifies the signal twice as much as the 1x gain selection.\\nNote:  The gain setting may affect certification phase performance. Specifically, using 2x gain may \\nimprove identification of noise.\\nTo program the manually selected sense configuration:\\n1. Select the Program button to save the sense vector and gain settings.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 62}), Document(page_content='54EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\n2. Select the Continue button. When the continue button is selected, the device will automatically evaluate if \\nSMART Pass should be enabled. Refer to the S -ICD User’s Manual for additional information about SMART \\nPass. For assistance, contact Boston Scientific using the information on the back cover.\\n3. The Acquire Reference S-ECG process is automatically enabled during the Manual Setup Process. Select \\nthe Continue button to acquire a reference S-ECG. A confirmation screen will appear when the captured \\nreference S-ECG is acquired.\\nSMART Settings\\nThe SMART Settings screen allows the user to access information and functions for the SMART Charge and SMART Pass features.\\nSMART Charge\\nThrough the SMART Charge feature, the pulse generator charge initiation sequence adapts to the occurrence of non-sustained ventricular arrhythmia episodes by delaying capacitor charging. This conserves battery life and may prevent unnecessary shocks for non-sustained arrhythmias. Refer to the pulse generator manual for further information about the SMART Charge feature.\\nSMART Charge is enabled automatically when an untreated ventricular arrhythmia episode is recorded. \\nResetting returns the SMART Charge value to zero. To reset the SMART Charge feature:\\n1. From the Utilities screen (accessible from the Main Menu screen), select the SMART Settings button. The \\nSMART Settings screen appears (Figure 22).', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 63}), Document(page_content='55EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nFigure 22: \\n SMART Settings screen\\n2. Select the Reset button to reset the SMART Charge to zero or press Cancel to return to the Utilities screen \\nwithout resetting the SMART Charge.\\n3. A confirmation window will appear with the message: “SMART Charge successfully reset.”\\n4. Press the Continue button to return to the Utilities screen.\\nDisabling SMART Pass\\nThe SMART Pass feature is designed to reduce oversensing while still maintaining an appropriate sensing \\nmargin. The device continuously monitors the ECG signal amplitude and automatically disables SMART Pass if under-sensing is suspected.\\nSMART Pass can be manually disabled if under-sensing is suspected by selecting the Disable button on the \\nSMART Settings screen. \\nNote:  If SMART Pass is disabled, another automatic or manual setup must be performed to  \\nre-enable the feature.\\nAF Monitor\\nThe AF Monitor feature is designed to assist in the diagnosis of atrial fibrillation.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 64}), Document(page_content='56EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nThe AF Monitor feature can be enabled/disabled using the On/Off switch accessed through the AF Monitor \\nbutton on the Utilities screen. \\nNote:  Print desired reports and/or save session data (via End Session) prior to programming AF \\nMonitor Off. When AF Monitor is programmed Off, currently stored AF Monitor statistics are \\ncleared and can no longer be printed or saved.\\nSelect the Program button to apply the changes and program the pulse generator. \\nThe following statistics are available on the Programmer screen by selecting the AF Monitor button:\\n• Days with measured AF: Provides the number of days within the last 90 where AF was detected\\n• Estimate of measured AF: Provides the total percent of detected AF within the last 90 days\\nRefer to the S -ICD User’s Manual for further information about AF Monitor.\\nAdditional Programmer Functions\\nRescue Shock\\nThe Rescue Shock icon is available in the navigation bar on the Programmer display when the Setup \\nProcess is complete and a pulse generator is actively communicating with the Programmer. During active communication, a maximum (80 J) rescue shock can be delivered upon Programmer command.\\nTo deliver a rescue shock:\\n1. Select the red Rescue Shock Icon at the top of the Programmer screen. The Rescue Shock screen appears \\n(Figure 23).', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 65}), Document(page_content='57EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nFigure 23: \\n  Rescue Shock screen\\n2. Select the Shock button to begin charging the pulse generator for a Rescue shock. A red background \\nscreen with the word “Charging” will appear. Selecting the Abort button will prevent delivery of a rescue \\nshock and will return to the Device Settings screen.\\n3. A confirmation screen will appear with notification that the shock was delivered successfully along with \\nthe corresponding shock impedance.\\nWARNING:  High shocking electrode impedance may reduce VT/VF conversion success.\\nCaution:  A reported shock impedance value of greater than 110 ohms from a delivered shock could indicate sub-optimal system placement. Care should be taken to place both the pulse generator and electrode directly on the fascia without underlying adipose tissue. Adipose tissue can add significant impedance to the high voltage shock current pathway.\\nCaution:  A reported shock impedance value of less than 25 ohms from a delivered shock could indicate a problem with the pulse generator. The delivered shock may have been compromised, and/or any future therapy from the pulse generator may be compromised. If a reported impedance value of less than 25 ohms is observed, correct functioning of the pulse generator should be verified.\\nIf for any reason the shock could not be delivered, a red background screen will appear with a message stating “The shock could not be delivered.”', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 66}), Document(page_content='58EMBLEM™ S‑ICD PROGRAMMER: OPERATION\\nNote:  In the event telemetry is lost, pulse generator commands— including Rescue Shocks— will \\nnot be available until telemetry is reestablished.\\nManual Shock\\nManual Shock allows the user to deliver a synchronized shock during a sinus rhythm, an atrial rhythm or a \\nventricular rhythm. The shock energy level is user-configured in the 10 to 80 joule range and the polarity is also user-configured (Figure 24 on page 58). Manual shock may also be utilized at a low energy to assess system impedance/integrity either at implant or as warranted by patient condition. A manual shock may be administered with the Therapy Mode set to On or Off.\\nTo access Manual Shock, select the Shock Test button on the main menu. The Induction Test screen will appear. \\nSelect the Manual Shock icon in the navigation bar at the top of the screen to view the Manual Shock Test screen. \\nFigure 24: \\nManual shock\\nS-ICD System Magnet Use\\nA Boston Scientific magnet or Cameron Health magnet greater than 60 gauss is a non-sterile accessory that may be used to temporarily inhibit the delivery of therapy from the pulse generator.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 67}), Document(page_content='59EMBLEM™ S‑ICD PROGRAMMER: MAINTENANCE\\nFor detailed information about using the magnet, refer to the appropriate S -ICD User’s Manual.\\nBehaviors of magnet application include:\\n• Suspend arrhythmia detection and inhibit shock therapy delivery\\n• Terminate post-shock pacing therapy\\n• Prohibit arrhythmia induction testing\\n• Activate the pulse generator’s beeper with each detected QRS complex for 60 seconds if beeper is turned \\non and is audible\\nWARNING:  Use caution when placing a magnet over the S -ICD pulse generator because it suspends \\narrhythmia detection and therapy response. Removing the magnet resumes arrhythmia detection and therapy response. \\nWARNING:  In patients with a deep implant placement (greater distance between the magnet and the pulse generator) magnet application may fail to elicit the magnet response. In this case the magnet cannot be used to inhibit therapy.\\nCaution:  Do not place a magnet on the Programmer.\\nNote:  A Programmer commanded Rescue Shock can override the use of the magnet as long \\nas the magnet was in place prior to the initiation of the programming command. If the \\nmagnet is applied after the initial command, the Rescue Shock will be terminated.\\nNote:  Magnet application does not affect wireless communication between the pulse generator \\nand the Programmer.\\nMAINTENANCE\\nCharging the Programmer\\nWhen not in use, it is recommended that the Programmer remain connected to the external power supply, which in turn is connected to the AC mains. This will ensure that the internal battery is adequately charged.\\nCleaning the Programmer and Wand\\nKeep the Programmer away from dust and dirt. Do not use harsh chemicals, cleaning solvents, or strong detergents to clean the Programmer and wand.\\nTo clean the Programmer and wand as needed:', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 68}), Document(page_content='60EMBLEM™ S‑ICD PROGRAMMER: MAINTENANCE\\n1. Turn the Programmer off.\\n2. Gently wipe the Programmer screen with a soft, clean, dry cloth.\\n3. Clean the Programmer plastic case and the wand by wiping them with an isopropyl alcohol-moistened \\ncloth.\\n4. Dry the Programmer immediately to remove residue.\\nService\\nThere are no user-accessible or user-serviceable parts or components in the Programmer. If any service, repair, \\nor replacement of internal components is needed, the Programmer must be returned to Boston Scientific. For instructions and return packaging, contact Boston Scientific using the information on the back cover of this manual.\\nWhen requesting service, please provide information concerning the nature of the failure and the manner in \\nwhich the equipment was used when the failure occurred. The model number and serial number should also be provided.\\nMaintenance Check\\nPrior to each use, you should perform a visual inspection and verify the following:\\n• Mechanical and functional integrity of the Programmer, cables, and accessories.\\n• Legibility and adherence of the Programmer labels.\\n• That the Programmer start-up screen appears a few seconds after you turn on the Programmer. (The normal power-up process verifies that the Programmer has passed its internal checks and is ready for use.)\\nSafety Measurements\\nNational regulations may require that the user, manufacturer, or manufacturer representative periodically perform and document safety tests of the Programmer. If such testing is required in your country, follow the testing interval and extent of testing as regulated in your country. If you do not know the national regulations in your country, please contact Boston Scientific using the information on the back cover of this manual. If IEC/EN 62353 is a required standard in your country, but no specific testing or interval is specified, it is recommended that you perform these safety tests using the direct method as specified in IEC/EN 62353 at an interval of every 24 months. Test values are shown in the Nominal Specifications table (Table 11).', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 69}), Document(page_content='61EMBLEM™ S‑ICD PROGRAMMER: TROUBLESHOOTING\\nDisposal of Programmer and Accessories\\nThe Programmer and accessories are designed to provide years of service under typical use. When no longer \\nneeded:\\n• Return or exchange a Programmer by contacting Boston Scientific using the information on the back cover of this manual. Do not dispose of the Programmer in the trash or at electronics recycling facilities as it may contain sensitive personal information.\\n• Dispose of accessories (wand and power cord) in a separate collection for electrical and electronic equipment. Do not place accessories in the trash.\\n• Dispose of digital data storage media, such as microSD™ memory cards, in accordance with applicable privacy and security policies and regulations.\\nTROUBLESHOOTING\\nThis section presents potential Programmer issues and the possible solutions. Of note, restarting the Programmer can often resolve many of the issues listed below. The Programmer can be restarted by pressing and holding the power button until the system shutdown menu appears and then choosing the “Restart” option.\\nContact Boston Scientific using the information on the back cover of this manual for additional assistance.\\nInability to Print\\nIf unable to print, follow the steps below:\\n1. Ensure that the printer is turned On and that it contains paper and a sufficient ink supply.\\n2. Check printer feed for paper jam.\\n3. Ensure, as applicable, that the wireless function is enabled on the printer or that the Bluetooth® wireless \\nadapter is fully inserted into the USB slot on the printer.\\nNo Printer Available\\nThe No Printer Available screen will appear if a printer was not set up. Select the Try Again button or refer to \\nthe Printer Selection section for instructions.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 70}), Document(page_content='62EMBLEM™ S‑ICD PROGRAMMER: COMPLIANCE STATEMENTS\\nTouch Screen Inactive while Connected to AC Power\\nIf the touch screen does not function while the Programmer is connected AC power via the external power \\nsupply, disconnect and reconnect the external power supply and restart the Programmer.\\nLoss of Communication with Printer\\nWhen communication between the Programmer and the printer fails, a Printing Error screen will appear with a message stating “Error while printing reports. Press ‘Continue’ to try printing any remaining reports, or ‘Cancel’ to cancel the current print job.”\\nIf this occurs:\\n1. Select the Try Again button to reconnect to the printer.\\n2. Ensure, as applicable, that the wireless function is enabled on the printer or that the Bluetooth®  wireless \\nadapter is fully inserted into the USB slot on the printer.\\n3. Move the Programmer closer to the printer.\\n4. Move any devices and the associated cables that may be interfering with the RF communication.\\nInability to Communicate With the Pulse Generator\\nIf the Programmer is unable to communicate with the pulse generator, follow the steps below:\\n1. Attempt to reposition the wand.\\n2. Select Scan For Devices from the Programmer start-up screen or select Scan Again from the Device List \\nscreen to locate the desired device.\\n3. Move any equipment and associated cables that may be interfering with RF communication.\\n4. If available, attempt to communicate using a different S -ICD System Programmer and/or wand.\\n5. Apply a pulse generator magnet to the pulse generator to elicit beeper tones. Remove the magnet and \\nre-attempt communication.\\nCOMPLIANCE STATEMENTS\\nEMI/RFI\\nThis equipment has been tested and found to comply with the applicable limits for medical devices, IEC 60601-\\n1-2:2014 or Active Implantable Medical Device Directive 90/385/EEC.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 71}), Document(page_content='63EMBLEM™ S‑ICD PROGRAMMER: COMPLIANCE STATEMENTS\\nAlthough this testing shows the device to provide reasonable protection against harmful interference in a \\ntypical medical installation, there is no guarantee that interference will not occur in a particular installation. If the device does cause harmful interference the user is encouraged to try and correct the interference by the following measures:\\n• Reorient or relocate the device\\n• Increase the separation between the devices\\n• Connect the equipment to an outlet on a different circuit\\n• Contact Boston Scientific using the information on the back cover of this manual.\\nEssential Performance\\nIn order for the Model 3200 Programmer to meet its intended use, it must interrogate and maintain a \\ncommunications link with an S -ICD pulse generator as well as being able to appropriately detect touch screen \\nbutton presses. Therefore those functions that pertain to communications with the implanted cardioverter defibrillator and detection of touch screen presses are considered essential performance.\\nFederal Communications Commission (FCC) Compliance\\nFCC ID: ESCCRM320014\\nContains: FCC ID ESCCRM70514This device complies with part 15 of the FCC Rules. Operation is subject to the following two conditions:\\n1. This device may not cause harmful interference, and\\n2. This device must accept any interference received, including interference that may cause undesired \\noperation\\nThis transmitter is authorized by rule under the Medical Device Radiocommunication Service (in part 95 of \\nthe FCC Rules) and must not cause harmful interference to stations operating in the 400.150–406.000 MHz band in the Meteorological Aids ( i.e. transmitters and receivers used to communicate weather data), the Meteorological Satellite, or the Earth Exploration Satellite Services and must accept interference that may be caused by such stations, including interference that may cause undesired operation. This transmitter shall be used only in accordance with the FCC Rules governing the Medical Device Radiocommunication Service. Analog and digital voice communications are prohibited. ', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 72}), Document(page_content='64EMBLEM™ S‑ICD PROGRAMMER: DECLARATIONS TABLES\\nAlthough this transmitter has been approved by the Federal Communications Commission, there is no \\nguarantee that it will not receive interference or that any particular transmission from this transmitter will be free from interference.\\nCaution:  Changes or modifications not expressly approved by Boston Scientific could void the user’s authority to operate the equipment.\\nIndustry Canada (IC) Compliance\\nIC 4794A-CRM32004 Contains: IC 4794A-CRM7054\\nThis device complies with Industry Canada license-exempt RSS standard(s). Operation is subject to the \\nfollowing two conditions:\\n1. This device may not cause harmful interference, and\\n2. This device must accept any interference received, including interference that may cause undesired \\noperation.\\nThis device may not interfere with stations operating in the 400.150-406.000\\xa0MHz band in the meteorological aids, meteorological-satellite, and earth exploration-satellite services, and must accept any interference received, including interference that may cause undesired operation.\\nThe electromagnetic emissions and immunity information is provided in Table 3: Guidance and Manufacturer’s \\nDeclaration—Electromagnetic Compatibility on page 65 .\\nDECLARATIONS TABLES\\nThe EMBLEM S -ICD Programmer, Model 3200, is suitable for use in professional health care facility \\nenvironments. The customer or the user of this system should assure that it is used in such an environment.\\nThe emissions characteristics of this equipment make it suitable for use in industrial areas and hospitals \\n(CISPR 11 class A). If it is used in a residential environment (for which CISPR 11 class B is normally required) this equipment might not offer adequate protection to radio-frequency communication services. The user might need to take mitigation measures, such as relocating or re-orienting the equipment.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 73}), Document(page_content='65EMBLEM™ S‑ICD PROGRAMMER: DECLARATIONS TABLES\\nTable 3: Guidance and Manufacturer’s Declaration—Electromagnetic Compatibility\\nTest Compliance Electromagnetic environment—guidance\\nProximity fields from RF wireless communications \\nequipmentCISPR 11Group 1Class A The EMBLEM S -ICD Programmer, Model 3200, \\nuses RF energy only for its intended uses in communication with the implanted device or connectivity functions. Its RF emissions are very low and are not likely to cause any interference in nearby electronic equipment.\\nProtection of the public mains network CISPR 11 Class A\\nIEC 61000-3-2\\nIEC 61000-3-3\\nThe EMBLEM S -ICD Programmer, Model 3200, is \\nsuitable for use in professional health care facility environments.\\nElectrostatic Discharge ± 8 kV contact\\n± 2 kV, ± 4 kV, ± 8 kV, and\\n± 15 kV air\\nRadiated RF EM field 3 V/m from 80 MHz to \\n2.7 GHz\\nProximity fields from RF wireless communications equipment380 - 390 MHz: 27 V/m430 - 470 MHz: 28 V/m704 - 787 MHz: 9 V/m800 - 960 MHz: 28 V/m1700 - 1900 MHz: 28 V/m2400 - 2570 MHz: 28 V/m5100 - 5800 MHz: 9 V/m\\nRated power frequency magnetic field 30 A/m\\nElectrical fast transients/ bursts ± 2 kV input AC power± 1 kV SIP/SOP\\nSurges line-to-line ± 0.5 kV, ± 1 kV input AC power\\nSurges line-to-ground ± 0.5 kV, ± 1 kV, ± 2 kV input AC power', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 74}), Document(page_content='66EMBLEM™ S‑ICD PROGRAMMER: DECLARATIONS TABLES\\nTable 3: Guidance and Manufacturer’s Declaration—Electromagnetic Compatibility\\nTest Compliance Electromagnetic environment—guidance\\nConducted disturbances induced by RF fields 3 V/m from 0.15 MHz to 80 \\nMHz 6 V/m in ISM bands from 0.15 MHz to 80 MHzThe ISM bands between 0.15 MHz and 80 MHz are 6.765 MHz to 6.795 MHz 13.553 MHz to 13.567 MHz 26.957 MHz to 27.283 MHz 40.66 MHz to 40.70 MHz.\\nThe amateur radio bands between 0.15 MHz and \\n80 MHz are:1.8 MHz to 2.0 MHz\\n3.5 MHz to 4.0 MHz\\n5.3 MHz to 5.4 MHz\\n7.0 MHz to 7.3 MHz\\n10.1 MHz to 10.15 MHz\\n14.0 MHz to 14.2 MHz18.07 MHz to 18.17 MHz\\n21.0 MHz to 21.4 MHz\\n24.89 MHz to 24.99 MHz\\n28.0 MHz to 29.7 MHz50.0 MHz to 54.0 MHz.\\nVoltage dips\\na0% UT for 0.5 cycle at 0°, \\n45°, 90°, 135°, 180°, 225°, 270°, and 315° 0% \\nUT for 1 \\ncycle and 70% UT for 25/30 \\ncycles at 0°\\nVoltage interruptionsa0% UT for 250/300 cycles\\na. Voltage dips and interruptions: UT is the AC mains voltage prior to application of the test level\\nTable 4: EMI/RFI Information: Programmer-to-Pulse Generator Communication\\nSpecification Medical Implant Communications Service (MICS)\\nFrequency band 402-405 MHz\\nModulation type FSK\\nRadiated Power <25 μW\\nBandwidth < 300 KHz', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 75}), Document(page_content='67EMBLEM™ S‑ICD PROGRAMMER: SPECIFICATIONS\\nTable 5: EMI/RFI Information: Bluetooth® Wireless Printing and Data Transfer\\nSpecification Bluetooth®  wireless technology\\nFrequency band 2.402-2 .480 GHz\\nModulation type GFSK, π/4-DQPSK, 8DPSK\\nRadiated power <10 mW\\nBandwidth < 1.5 MHz\\nTable 6: Product Guidelines\\nComponent Requirement\\nDC Power\\nBattery pack type 4000 mAh 3 .7 volt lithium-ion battery pack\\nCharge time Approximately 5 hours\\nPower Supply\\nInput 100 – 240 VAC, 50 – 60 Hz, 0 .5 A\\nOutput 5.5 VDC, 3 .64 A\\nPower: 20 W\\nManufacturer/Model Elpac Power Systems MWA020005A\\nEnvironment Operating Storage and Transport\\nTemperature 15° C to +38° C (+59° F to +100° F) -10° C to +55° C (+14° F to +131° F)\\nRelative humidity 5% to 93% maximum at 40° C, non-\\ncondensing5% to 93% maximum at 40° C, non-condensing\\nAtmospheric pressure 50 kPa to 106 kPa (7.252 psi to 15 .374 psi)50 kPa to 106 kPa (7.252 psi to 15 .374 psi)\\nSPECIFICATIONS\\nTable 7: Specifications\\nParameter Specification\\nSafety classification Class I\\nIngress protection rating IXP0', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 76}), Document(page_content='68EMBLEM™ S‑ICD PROGRAMMER: SPECIFICATIONS\\nTable 7: Specifications\\nParameter Specification\\nDimensions\\nWidth x Depth x Height24.0 cm x 12. 7 cm x 2. 6 cm\\n9.4 in x 5 .0 in x 1. 0 in\\nWeight 0.6 kg, 1.3 lbs\\nStandard Screen Display WVGA, 1024 x 600 pixels, 16M TFT\\nTable 8: Nominal Specifications (with device connected to external power supply)\\nCharacteristic Nominal\\nElectrical Safety Testing – IEC 60601-1:2012\\nEarth resistance Not accessible\\nEarth leakage current 5 mA Normal Condition (NC)\\n10 mA Single Fault Condition (SFC)\\nPatient leakage current 100 μA Normal Condition (NC)\\n500 μA Single Fault Condition (SFC) (mains on applied parts)\\nElectrical Safety Testing – IEC 62353:2008 allowed values\\nProtective Earth Resistance Not accessible\\nEquipment leakage — direct method 500 μA\\nPatient leakage current — direct method (Wand, BF) <= 5000 μA\\nInsulation resistance Not accessible\\nSafety Features\\nDefibrillator protection To 5000 V, 400 J', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 77}), Document(page_content='69EMBLEM™ S‑ICD PROGRAMMER: DEFINITION OF PACKAGING LABEL AND DEVICE SYMBOLS\\nDEFINITION OF PACKAGING LABEL AND DEVICE SYMBOLS\\nTable 9: Packaging and Device Symbols: Model 3200 Programmer\\nThe following symbols may be used on the Model 3200 Programmer, its accessories, and their packaging. \\nSymbol Specification Symbol Specification\\nFollow instructions for use on this website:\\nwww.bostonscientific-elabeling.comType BF applied part\\nElectrostatic sensitive device Non-ionizing electromagnetic radiation\\nTemperature limitation Humidity limitation\\nAtmospheric pressure limitation Manufacturer \\nSerial Number Date of manufacture\\nReference number Authorized representative in the \\nEuropean community\\nLot number Non-sterile\\nACMA compliance mark Australian sponsor address\\nPower plug storage Door, open\\nConsult instructions for use on this \\nwebsite:  www.bostonscientific-elabeling.com Wand', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 78}), Document(page_content='70EMBLEM™ S‑ICD PROGRAMMER: DEFINITION OF PACKAGING LABEL AND DEVICE SYMBOLS\\nTable 9: Packaging and Device Symbols: Model 3200 Programmer\\nThe following symbols may be used on the Model 3200 Programmer, its accessories, and their packaging. \\nSymbol Specification Symbol Specification\\nSeparate collection Proper insertion of microSD™\\nNew Zealand R-NZ RF compliance mark External power supply port\\nMedical device under EU legislation MR unsafe\\nPart Number Programmer\\nContents Power Cord\\nPower supply Literature enclosed\\nMark for nationally recognized testing for \\nsafety standards', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 79}), Document(page_content='71EMBLEM™ S‑ICD PROGRAMMER: WARRANTY\\nWARRANTY\\nLimited Warranty\\nA limited warranty may apply to this Programmer. For warranty eligibility and to obtain a copy of the limited \\nwarranty, contact Boston Scientific using the information on the back cover.', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 80}), Document(page_content='72EMBLEM™ S‑ICD PROGRAMMER: WARRANTY\\nLift the microSD™ slot cover and \\nswing it away. Conﬁ  rm that there \\nis no card in the slot.Place the microSD™ card into the empty slot with the lettering fac-ing the the same direction as the Programmer screen. Gently press the card into the slot until it latches into place. There \\nwill be increasing spring resis-tance followed by a softly audible click which indicates that the latch is activated.The properly mounted card will be ﬂ ush with the slot opening \\nsurface.Close the microSD™ slot cover.\\nLift the microSD™ slot cover and swing it away. Verify that a card is in the slot.Press the edge of the card with your ﬁ  ngernail until the latch \\nreleases and you hear a click. Let the card gradually come out until you hear a second click, then remove your ﬁ  nger. At this point it is safe to remove the card, although it may be dif-ﬁ cult to grasp the card with your \\nﬁ ngers. In this case the spring \\ntensioner inside the slot can be used to eject the card.Use a ﬁ  ngertip to slightly press \\nthe card back into the slot, then quickly slide your ﬁ  nger away \\nbefore the card latches back into place. Note  that the card may travel some distance when it is ejected.\\nRepeat this procedure as needed \\nuntil card is ejected. Close the microSD™ slot cover.Model 3200 S-ICD Programmer  \\nInsert microSD™ Remove microSD™APPENDIX A: INSERTION AND REMOVAL OF THE MICROSD™ CARD', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 81}), Document(page_content='', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 82}), Document(page_content='92346968-002  EN US  2021-11*92346968-002*Boston Scientific Corporation\\n4100 Hamline Avenue NorthSt. Paul, MN 55112-5798 USA\\n1.800.CARDIAC (227.3422)\\n+1.651.582.4000\\nwww.IFU-BSCI.com', metadata={'source': 'raw_data/92346968-002_EMBLEM_S-ICD_Programmer_PUM_en_S.pdf', 'page': 83}), Document(page_content='MRITECHNICAL GUIDE\\nIMAGEREADY™MR\\nConditional Defibrillation\\nSystem\\nRREEFFD000, D001, D002, D003, D010, D011, D012, D013, D020, D021, D022, D023,\\nD050, D051, D052, D053, D120, D121, D140, D141, D142, D143, D150, D151, D152, D153,\\nD160, D161, D162, D163, D220, D221, D232, D233, D400, D401, D412, D413, D420,\\nD421, D432, D433, D500, D501, D512, D513, D520, D521, D532, D533, G050, G051,\\nG056, G058, G124, G125, G128, G138, G140, G141, G146, G148, G150, G151, G156,\\nG158, G160, G161, G166, G168, G224, G225, G228, G237, G247, G248, G424, G425,\\nG428, G437, G447, G448, G524, G525, G528, G537, G547, G548, 0127, 0128, 0129,\\n0137, 0138, 0139, 0143, 0147, 0148, 0149, 0153, 0157, 0158, 0159, 0170, 0171, 0172,\\n0173, 0174, 0175, 0176, 0177, 0180, 0181, 0182, 0183, 0184, 0185, 0186, 0187, 0262,\\n0263, 0265, 0266, 0272, 0273, 0275, 0276, 0282, 0283, 0285, 0286, 0292, 0293,\\n0295, 0296, 0636, 0650, 0651, 0652, 0653, 0654, 0655, 0657, 0658, 0662, 0663,\\n0665, 0672, 0673, 0675, 0676, 0682, 0683, 0685, 0686, 0692, 0693, 0695, 0696,\\n4469, 4470, 4471, 4472, 4473, 4474, 4479, 4480, 4542, 4543, 4544, 4591, 4592, 4593,\\n4603, 4671, 4672, 4674, 4675, 4677, 4678, 6100, 6220, 6221, 6402, 6403, 6773, 6996,\\n7145, 7148, 7735, 7736, 7740, 7741, 7742, 7840, 7841, 7842\\nCAUTION: Federal law(USA)\\nrestricts thisdevice tosalebyoron\\ntheorder ofaphysician trained or\\nexperience dindevice implant and\\nfollow-up procedures.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 0}), Document(page_content='', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 1}), Document(page_content='ABOUTTHISMANUAL\\nThismanual isintended forusebyphysicians andother health careprofessionals (HCPs) involved inmanaging\\npatients withanImageReady MRConditional Defibrillation System, aswellasradiologists andother HCPs involved in\\nperforming magnetic resonance imaging (MRI) scans onsuch patients.\\nNOTE: Forthepurposes ofthisTechnical Guide, MRIisused asagener alterm andencompasses allMR-based\\nclinical imaging activities. Inaddition, information inthisguide applies onlytohydrogen proto nMRIscanners.\\nRead thismanual initsentirety befor escanning patients whoareimplanted withanImageReady MRConditional\\nDefibrillation System.\\nThismanual contains:\\n•Information about theImageReady MRConditional Defibrillation System (Boston Scientific transvenous ICDsand\\nCRT-Ds)\\n•Information about ImageReady MRConditional Defibrillation System patients whocanandcannot undergo an\\nMRIscanandtheConditions ofUsethatmust bemetinorderforanMRIscantobeperformed\\n•Instructions forcarryingoutanMRIscanonImageReady MRConditional Defibrillation System patients\\nHow tousethismanual:\\n1.Refer tothepatient’s recordstolocate model numbers forallcompone ntsofthepatient’s implanted system.\\n2.Refer to\"System Configuration for1.5Tesla (T)and3Tesla (T)\"onpage 1-2todetermine ifallcomponents ofthe\\npatient’s implanted system arefound within thetables. Ifanyofthecompon entscannot befound within the\\ntables, thesystem isnotanImageReady MRConditional Defibrillation System.\\nNOTE: Multiple Boston Scientific ImageReady MRITechnical Guides areavailable based ontherap ytype, for\\nexample, apacing system versus adefibrillation system. Ifaparticular pulse gener atormodel isnotrepresented\\ninthismanual, refertotheother Boston Scientific ImageReady MRITechnical Guides. Ifaparticular model isnot\\nrepresented inanyBoston Scientific ImageReady MRITechnical Guide, thepatient’s implanted system isnotan\\nImageReady MRConditional system.\\nRefer tothePhysician’s Technical Manual, Referenc eGuide, Leads Manual, Clinician Manual, orProgr ammer\\nOperator’s Manual fordetailed information about non-MRI aspects ofimplantation, feature s,progr amming, anduse\\nofthecomponents oftheDefibrillation System.\\nNOTE: These pulse gener ators canbeused onlywiththeModel 3300 LATITUDE Progr amming System. The\\nLATITUDE Programming System istheexternal portion ofthepulse generator system.\\nNOTE: The2868 softwar eapplication onthemodel 3120 LATITUDE progr amming system isoutdated andshould\\nnotbeused withthepulse gener ators. Forassistanc e,call+1.651.582.4000 (worldwide) orcontact yourlocal Boston\\nScientific representative.\\nThefollowing aretrademarks ofBoston Scientific Corporat ionoritsaffiliates:\\nACUITY, AUTOGEN, DYNAGEN, EASYTRAK, ENDO TAKRELIANCE, FINELINE, IMAGEREADY, INGEVITY, INOGEN, LATITUDE,\\nMOMENTUM, ORIGEN, PaceSafe, PERCIVA, RELIANCE 4-FRONT, RESONATE, VIGILANT.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 2}), Document(page_content='', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 3}), Document(page_content='TABLEOFCONTENTS\\nINTRODUCTION TOTHEMRCONDITIONAL DEFIBRILLATION SYSTEM...............................................1-1\\nCHAPTER 1\\nSystem Description ...............................................................................................................1-2\\nSystem Configur ation for1.5Tesla (T)and3Tesla (T)...............................................................1-2\\nMRIConditions ofUse...........................................................................................................1-4\\nCardiology ....................................................................................................................1-5\\nRadiology .....................................................................................................................1-5\\nMRIProtection Mode .............................................................................................................1-7\\nMRIBasic Concepts ...............................................................................................................1-7\\nMRConditional Defibrillation System Warnings andPrecautions .......................................................1-8\\nGeneral ........................................................................................................................1-8\\nProgr amming Considera tions.............................................................................................1-9\\nSafety Mode ..................................................................................................................1-9\\nMRISiteZone IIIExclusions .............................................................................................1-10\\nPrecautions .................................................................................................................1-10\\nPotential Adverse Events ......................................................................................................1-10\\nMRISCANPROCEDURE ..........................................................................................................2-1\\nCHAPTER 2\\nPatient Flow.......................................................................................................................2-2\\nMRIProtection Mode Genera lInformation .................................................................................2-3\\nPre-Sc anActivities ...............................................................................................................2-4\\nProgr amming thePulse Generator foraScan........................................................................2-4\\nConfirming MRIScanner Settings andConfigur ation ...............................................................2-11\\nPreparing thePatient fortheScan ....................................................................................2-12\\nAfter theScan....................................................................................................................2-12\\nCARDIOLOGY CHECKLIST FORTHEIMAGEREADY DEFIBRILLATION SYSTEM......................................A-1\\nAPPENDIX A\\nRADIOLOGY CHECKLIST FORTHEIMAGEREADY DEFIBRILLATION SYSTEM........................................B-1\\nAPPENDIX B\\nDETERMINE BEEPERTYPE......................................................................................................C-1\\nAPPENDIX C\\nIMAGEREADY DEFIBRILLATION SYSTEMCOMPONENTS FOR1.5TAND3T.......................................D-1\\nAPPENDIX D\\nMRCONDITIONAL DEFIBRILLATOR PROGRAMMER REPORTS .........................................................E-1\\nAPPENDIX E\\nSYMBOLSONPACKAGING .....................................................................................................F-1\\nAPPENDIX F', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 4}), Document(page_content='', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 5}), Document(page_content='1-1\\nINTRODUCTION TOTHEMRCONDITIONAL DEFIBRILLATION SYSTEM\\nCHAPTER 1\\nThischapter contains thefollowing topics:\\n•“Syste mDescription” onpage 1-2\\n•“MRI Conditions ofUse” onpage 1-4\\n•“MRI Prote ction Mode” onpage 1-7\\n•“MRI Basic Conce pts”onpage 1-7\\n•“MRConditional Defibrillation System Warnings andPrecautions” onpage 1-8\\n•“Potential Adverse Events” onpage 1-10', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 6}), Document(page_content='1-2Introduction totheMRConditional Defibrillation System\\nSystemDescription\\nSYSTEMDESCRIPTION\\nAnImageReady MRConditional Defibrillation System consists ofspecific Boston Scientific model components\\nincluding pulse generators, leads, accessories, theProgr ammer ,andtheProgr ammer Software Application. Anypart\\nofthebody maybeimaged. Boston Scientific MRConditional pulse gener ators andleads, when used together ,have\\nmitigated risksassociated withMRIscans ascompar edtoconvention alpulse gener ators andleads. Theimplanted\\nsystem, asopposed toitsconstituent parts, isdetermined tohave thestatus ofMRConditional asdescribed inASTM\\nF2503:2008. Prior tothepatient under going anMRIscan, theImageReady MRConditional Defibrillation System must\\nbeprogr ammed toMRIProtection Mode. MRIProtection Mode modifies thebehavior ofthepulse generator to\\naccommodate theMRIscanner electro magnetic environment (\"MRI Protection Mode General Information\" onpage 2-\\n3).ATime-out feature canbeprogr ammed toallow automatic exitfrom MRIProte ction Mode after asetnumber of\\nhours chosen bytheuser.These feature shave been evaluated toverify their effectiveness. Other MRI-relate drisksare\\nfurther reduc edbyadherenc etotheconditions forscanning specified inthisTechnical Guide.\\nOnly specific combinations ofpulse gener ators andleads constitute anImageReady Defibrillation System. Consult the\\nfollowing tables todistinguish between combinations thatarevalid forusewith1.5Tor3Tscanners. Forthemodel\\nnumbers ofMRConditional Defibrillation System components, see\"System Configur ation for1.5Tesla (T)and3Tesla\\n(T)\"onpage 1-2.\\nForadditional information, seetheBoston Scientific Website athttp://www .bostonscientific.com/imager eady orcall\\n1.844.4BSCMRI (1.844.427.2674).\\nForadditional technical reference guides, gotowww.bostonscientific -elabeling.com .\\nSystemConfiguration for1.5Tesla(T)and3Tesla(T)\\nGrayshading ofmodel rows indicates components compatible withboth 1.5Tand3Tscanners. An‘x’indicates MR\\nConditional status atthemagnet strength indicated.\\nTable1–1.CRT-DPulseGenerators —ImageReady MRConditional Defibrillation System\\nComponent ModelNumber(s) MRStatus 1.5T 3T\\nCRT-DPulseGenerators\\nAUTOGEN X4CRT-D G166, G168 MRConditional X\\nAUTOGEN CRT-D G160, G161 MRConditional X\\nDYNAGEN X4CRT-D G156, G158 MRConditional X\\nDYNAGEN CRT-D G150, G151 MRConditional X\\nINOGEN X4CRT-D G146, G148 MRConditional X\\nINOGEN CRT-D G140, G141 MRConditional X\\nMOMENTUM CRT-D X4 G128, G138 MRConditional X\\nMOMENTUM CRT-D G124, G125 MRConditional X\\nORIGEN X4CRT-D G056, G058 MRConditional X\\nORIGEN CRT-D G050, G051 MRConditional X\\nRESONATE HFCRT-DG524, G525, G528,\\nG548MRConditional X\\nG537, G547 MRConditional X X\\nRESONATE X4CRT-DG428, G448 MRConditional X\\nG437, G447 MRConditional X X\\nRESONATE CRT-D G424, G425 MRConditional X', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 7}), Document(page_content='Introduction totheMRConditional Defibrillation System\\nSystemConfiguration for1.5Tesla(T)and3Tesla(T)1-3\\nTable1–1.CRT-DPulseGenerators —ImageReady MRConditional Defibrillation System(continued)\\nComponent ModelNumber(s) MRStatus 1.5T 3T\\nVIGILANT X4CRT-DG228, G248 MRConditional X\\nG237, G247 MRConditional X X\\nVIGILANT CRT-D G224, G225 MRConditional X\\nTable1–2.ICDPulseGenerators —ImageReady MRConditional Defibrillation System\\nComponent ModelNumber(s) MRStatus 1.5T 3T\\nICDPulseGenerators\\nAUTOGEN ELICD D160, D161, D162, D163 MRConditional X\\nDYNAGEN ELICD D150, D151, D152, D153 MRConditional X\\nDYNAGEN MINI ICDD020, D021, D022,\\nD023MRConditional X\\nINOGEN ELICD D140, D141, D142, D143 MRConditional X\\nINOGEN MINI ICD D010, D011, D012, D013 MRConditional X\\nMOMENTUM ELICD D120, D121 MRConditional X\\nORIGEN ELICDD050, D051, D052,\\nD053MRConditional X\\nORIGEN MINI ICDD000, D001, D002,\\nD003MRConditional X\\nPERCIVA HFICDD500, D501 MRConditional X\\nD512, D513 MRConditional X X\\nPERCIVA ICDD400, D401 MRConditional X\\nD412, D413 MRConditional X X\\nRESONATE HFICDD520, D521 MRConditional X\\nD532, D533 MRConditional X X\\nRESONATE ELICDD420, D421 MRConditional X\\nD432, D433 MRConditional X X\\nVIGILANT ELICDD220, D221 MRConditional X\\nD232, D233 MRConditional X X\\nTable1–3.LeadsandAccessories—ImageReady MRConditional Defibrillation System\\nComponent ModelNumber(s) MRStatus 1.5T 3T\\nLeadsandAccessories\\nRightAtrialLeadsandAccessories\\nFINELINE IISterox Pacing Leads 4479, 4480 MRConditional X X\\nFINELINE IISterox EZPacing Leads 4469, 4470, 4471,\\n4472, 4473, 4474MRConditional X X\\nSuture Sleeves forFINELINE IILeads 6220, 6221 MRConditional X X\\nINGEVITY MRIPacing Leads (Tined Fixation) 7735, 7736 MRConditional X X\\nINGEVITY MRIPacing Leads (Extendable/\\nRetractable Fixation)7740, 7741, 7742 MRConditional X X', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 8}), Document(page_content='1-4 Introduction totheMRConditional Defibrillation System\\nMRIConditions ofUse\\nTable1–3.LeadsandAccessories—ImageReady MRConditional Defibrillation System (continued)\\nComponent ModelNumber(s) MRStatus 1.5T 3T\\nINGEVITY+ Pacing Leads (Extendable/Retr actable\\nFixation)7840, 7841, 7842 MRConditional X X\\nSuture Sleeve forINGEVITY MRI/INGEVITY+\\nLeads6402 MRConditional X X\\nIS-1Lead PortPlug 7145 MRConditional X X\\nRightVentricular LeadsandAccessories\\nENDO TAKRELIANCE (IS-1) Leads –Single Coil 0127, 0128, 0129, 0137,\\n0138, 0139, 0170, 0171,\\n0172, 0173, 0180, 0181,\\n0182, 0183MRConditional X\\nDF-1Lead PortPlugforENDO TAKRELIANCE (IS-1)\\nLeads –Single Coil6996 MRConditional X\\nENDO TAKRELIANCE (IS-1) Leads –Dual Coil 0143, 0147, 0148, 0149,\\n0153, 0157, 0158, 0159,\\n0174, 0175, 0176, 0177,\\n0184, 0185, 0186, 0187MRConditional X\\nENDO TAKRELIANCE (DF4) Defibrillation Leads 0262, 0263, 0265,\\n0266, 0272, 0273, 0275,\\n0276, 0282, 0283,\\n0285, 0286, 0292,\\n0293, 0295, 0296MRConditional X X\\nRELIANCE 4-FRONT (DF4) Defibrillation Leads 0636, 0650, 0651,\\n0652, 0653, 0654,\\n0655, 0657, 0658,\\n0662, 0663, 0665,\\n0672, 0673, 0675,\\n0676, 0682, 0683,\\n0685, 0686, 0692,\\n0693, 0695, 0696MRConditional X X\\nSuture Sleeve forRELIANCE 4-FRONT Leads 6403 MRConditional X X\\nLeftVentricular LeadsandAccessories\\nACUITY Spiral Leads 4591, 4592, 4593 MRConditional X\\nSuture Sleeve forACUITY Spiral Leads 6100 MRConditional X\\nACUITY X4(IS4)Pacing Leads 4671, 4672, 4674, 4675,\\n4677, 4678MRConditional X X\\nSuture Sleeve forACUITY X4Leads 4603 MRConditional X X\\nEASYTR AK2(IS-1) Leads 4542, 4543, 4544 MRConditional X\\nSuture Sleeve forEASYTRAK 2Leads 6773 MRConditional X\\nIS4/DF4 Lead PortPlug 7148 MRConditional X X\\nIS-1Lead PortPlug 7145 MRConditional X\\nMRICONDITIONS OFUSE\\nThefollowing Conditions ofUsemust bemetinorderforapatient withanImageReady Defibrillation System to\\nunder goanMRIscan. Adher ence totheConditions ofUsemust beverified prior toeach scantoensure thatthemost\\nup-to-date information hasbeen used toassess thepatient’s eligibility andreadiness foranMRConditional scan.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 9}), Document(page_content='Introduction totheMRConditional Defibrillation System\\nCardiology1-5\\nCardiology\\n1.Patient isimplanted withanImageReady MRConditional Defibrillation System (see\"System Description\" onpage\\n1-2).\\nOnly aBoston Scientific MRConditional pulse gener atorandlead(s), withallports occup iedbyaleadorport\\nplug, constitute anImageReady MRConditional Defibrillation System. Another manufacturer\\'s MR\\nConditional pulse generator combined withaBoston Scientific MRConditional lead(orviceversa) does not\\nconstitute anMRConditional System.\\n2.Noother active orabandoned implanted devices, components, oraccessories presen tsuch asleadadaptors,\\nextenders, leads, orpulse gener ators.\\nMitigation ofrisksassociated withMRIscans hasnotbeen demonstrate dwhen other cardiacimplants or\\naccessories such asleadadaptors, extenders, orabandoned leads orpulse generators areprese nt.\\n3.Pulse gener atorisinMRIProte ction Mode during scan.\\n4.Assoon asMRIProtection Mode isprogr ammed, thepatient must becontinuously monitored bypulse oximetry\\nandelectr ocardiogr aphy (ECG). Ensure backuptherap yisavailable (external rescue).\\n5.Patient isjudged tobeclinically capable oftolerating noTachycardia protection fortheentireduration inwhich\\nthepulse gener atorisinMRIProtection Mode.\\n6.Pulse gener atorimplant location restricted toleftorright pectoral region.\\n7.Atleast six(6)weeks have elapsed sinceimplantation and/or anyleadrevision orsurgica lmodification oftheMR\\nConditional Defibrillation System.\\nAsix-week period allows forhealing andscartissue formation, which reduce theimpact ofpotential risks\\nassociated withMRIscans such asheating ormovement.\\n8.Noevidenc eofafractur edleadorcompromised pulse gener ator-lead system integrity .\\nMitigation ofrisksassociated withMRIscans hasnotbeen demonstrate diftheleadand/or thepulse\\ngenerator -lead system integrity arecompromised.\\nRadiology\\nThismanual introduces useofanewparameter forlimiting RFexposur eduring certain 3Tscans.\\nB1+rmsisameasure ofRFexposu rethatisdiffere ntfromSAR. Itisused instead ofSARforlimiting 3Tscans witha\\npatient landmark (scan isocenter) inferior totheC7vertebr a.B1+rmsisnotdisplayed onall3Tscanners.\\nImportant: IfyouareunfamiliarwithB1+rms,orareunsureifitisavailable onyour3Tscanner,eitherlimit\\nscansto1.5TandNormalMode,orcontacttheMRIscannermanufacturerformoreinformation.\\n1.Horizontal, hydrogen proton, closed bore scanners only\\n2.MRImagnet strength of1.5T(64MHz) or3T(128MHz)\\n3.Spatial gradient nogreat erthan 20T/m(2,000 G/cm)\\n4.RFexposure limits:\\n1.5T\\n• Normal Operating Modeamust beobserved fortheentire active scansession (whole body averaged SAR, ≤2.0watts/kilogr am(W/\\nkg);Head SAR, ≤3.2W/kg)\\n3T(Patient landmark/scan isocenteratorsuperior totheC7vertebra)\\n• Normal Operating Mode orFirstLevel Controlled Operating Mode must beobserved fortheentire active scansession', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 10}), Document(page_content='1-6Introduction totheMRConditional Defibrillation System\\nRadiology\\n3T(Patient landmark/scan isocenter inferior totheC7vertebra)\\n• B1+rmsmust be≤2.8microtesla (µT)\\nWARNING: IftheB1+rmsparameter value isnotdisplayed onthe3TMRIscanner system, donotperform 3Tscans withapatient\\nlandmark (scan isocenter) inferior totheC7vertebr a.Such scans donotmeet theRadiology Conditions ofUse.\\n5.GradientField limits: Maximum specified gradient slew rate≤200T/m/s peraxis\\n6.There arenorestrictions forpositioning thedefibrillation system within theintegr atedbody coiloftheMRIscanner .Theuseofreceive-only\\ncoilsisnotrestricted. Local transmitcoilsmaybeused, butshould notbeplaced directly overthedefibrillation system.\\n7.Patient insupine orprone position only.\\n8.Patient must becontinuously monitored bypulse oximetry andelectrocar diograp hy(ECG) fortheentire duration inwhich thepulse generator\\nisinMRIProtection Mode. Ensure backup therapy isavailable (external rescue).\\na.Asdefined inIEC60601-2-33, 201.3.224, 3rdEdition.\\nThesystem respo nsetoconditions other than those listed above fortheradiolo gyconditions hasnotbeen evaluated.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 11}), Document(page_content='Introduction totheMRConditional Defibrillation System\\nMRIProtectionMode1-7\\nFor3Tscans, when thepatient landmark (scan isocenter) isatorsuperior totheC7vertebr a,thescanmust belimited\\ntoNormal Operating Mode orFirstLevel Controlled Operating Mode. When thepatient landmark (scan isocenter) is\\ninferior toC7,theB1+rmsparamete rmust belimited to≤2.8microtesla (µT). Ifusing ascanner thatdoes notdisplay\\nB1+rms,donotscanat3Twhen thepatient landmark (scan isocenter) isinferior toC7.\\nFigure1–1.LimitingParameters for3TMRIScanning\\nMRIPROTECTIONMODE\\nInprepar ation foranMRIscan, thepulse gener atormust beprogr ammed intoMRIProtection Mode using the\\nProgrammer .MRIProtection Mode modifies certain pulse gener atorfunctions inorder tomitigate risks\\nassociated withexposing theImageReady MRConditional System totheMRIenvironment. Foralistoffeatur esand\\nfunctions thataresuspended inMRIProtection Mode, see\"MRI Protection Mode General Information\" onpage 2-3.\\nMRIBASICCONCEPTS\\nMRIisadiagnostic toolthatuses threetypes ofmagnetic andelectromagne ticfields toimage softtissue inthebody:\\n•Astatic magnetic fieldgener atedbyasuperc onducting electro magnet coil,1.5Tor3Tinstrength.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 12}), Document(page_content='1-8Introduction totheMRConditional Defibrillation System\\nMRConditional Defibrillation SystemWarnings andPrecautions\\n•Gradient magnetic fields ofmuch lower intensity ,butwithhighratesofchange overtime. Three setsofgradient\\ncoilsareused tocreate thegradient fields.\\n•Apulsed radiofreque ncy(RF)fieldproduced bytransmission RFcoils(appr oximately 64MHzfor1.5Tand128\\nMHzfor3T).\\nThese fields maycreatephysical forcesorelectrical curren tsthatcanaffect thefunctioning ofactive implantable\\nmedical devices(AIMDs) such aspulse gener ators andleads. Therefor e,onlypatients implanted withanMR\\nConditional system areeligible tobescanned. Furthermor e,bycomplying withtheMRIConditions ofUse,outlined in\\nthisTechnical Guide (\"MRI Conditions ofUse\" onpage 1-4),ImageReady MRConditional System patients canundergo\\nMRIscans withrisksmitigated tothebestcurrentstandar dofcare.\\nMRCONDITIONAL DEFIBRILLATION SYSTEMWARNINGS ANDPRECAUTIONS\\nGeneral\\nWARNING: Unless alloftheMRIConditions ofUse(\"MRI Conditions ofUse\" onpage 1-4)aremet, MRIscanning of\\nthepatient does notmeet MRConditional requir ements fortheimplanted system, andsignificant harm toordeath of\\nthepatient and/or damage totheimplanted system mayresult.\\nForpotential adverse events applicable when theConditions ofUsearemetornotmet, see\"Potential Adverse\\nEvents\" onpage 1-10.\\nWARNING: MRIscanning after Explant status hasbeen reached mayleadtopremature battery depletion, a\\nshortened device replacement window ,orsudden lossoftherap y.After performing anMRIscanonadevice thathas\\nreached Explant status, verify pulse genera torfunction andschedule devicereplac ement.\\nWARNING: When theTime-out parameter isprogr ammed toavalue other than Off,thepatient must beoutofthe\\nscanner before thetime programmed elapses. Otherwise, thepatient willnolonger meet Conditions ofUse(\"MRI\\nConditions ofUse\" onpage 1-4).\\nWARNING: Determine thebeeper typebefor eanMRIscan. TheArmatur eBeeper maynolonger beusable\\nfollowing anMRIscan. Coming incontact withthestrongmagnetic fieldofanMRIscanner maycause apermanent\\nlossoftheArmature Beeper volume. Thiscannot berecover ed,even after leaving theMRIscanenvironment and\\nexiting MRIProtection Mode. FortheArmatur eBeeper ,befor eanMRIscanisperformed, aphysician andpatient\\nshould weigh thebenefit oftheMRIscanagainst theriskoflosing theBeeper; after theMRIscan, perform Beeper\\nevaluation testtodetermine iftheBeeper isusable. IftheBeeper isnotusable, itisstrong lyrecommended that\\npatients arefollowed onLATITUDE NXTafter anMRIscaniftheyarenotalready .Other wise, anin-clinic follow-up\\nschedule ofevery threemonths isstrongly recommended tomonitor device performanc e.\\nNOTE: Forinstructions onhowtodetermine thebeeper type, seethe“Determine Beeper Type” appendix ofthis\\nmanual. Forinstructions onperforming theBeeper evaluation test,seetheEvaluate Device stepin\"After theScan\" on\\npage 2-12.\\nWARNING: During MRIProtection Mode, thepatient willnotreceive Tachycardia therap y(including ATPand\\ndefibrillation), and,ifBradyMode isprogr ammed toOff,willnotreceiveBradycardia pacing (including backuppacing)\\nandCardiac Resynchronization Therapy .Therefor ethepatient must becontinuously monitored fortheentire duration\\ninwhich thesystem isinMRIProtection Mode, including during thescan.\\nWARNING: IftheB1+rmsparamete rvalue isnotdisplayed onthe3TMRIscanner system, donotperform 3T\\nscans withapatient landmark (scan isocenter) inferior totheC7vertebra. Such scans donotmeet theRadiology\\nConditions ofUse.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 13}), Document(page_content='Introduction totheMRConditional Defibrillation System\\nProgramming Considerations1-9\\nProgramming Considerations\\nWARNING: IftheMRIProte ction Time-out value isprogr ammed toOff,thepatient willnotreceiveTachycar dia\\nthera py,andthepacing options arelimited toOfforAsynchr onous until thepulse gener atorisprogr ammed outof\\nMRIProtection Mode andback tonormal operation.\\nWARNING: Usecaution when progr amming MRIProtection Mode inpacing-dependent patients whohave high\\nright atrial andright ventricular pacing thresholds onthepaced lead(s) (>2.0V).Themaximum pacing amplitude in\\nMRIProtection Mode is5.0V,which maylimittheavailable pacing amplitude safety marginforpatients withhigh\\npacing thresholds. Failur etomaintain sufficient pacing amplitude safety marginmayresultinlossofcapture.\\nWARNING: During MRIProtection Mode, Tachycar diatherap yissuspended. Thesystem willnotdetect ventricular\\narrhythmias andthepatient willnotreceiveATPorshock defibrillation therap yuntil thepulse generator is\\nprogrammed back tonormal operation. Only scanthepatient ifjudged tobeclinically capable oftolerating no\\nTachycar diaprote ction fortheentireduration inwhich thepulse generator isinMRIProtection Mode.\\nWARNING: During MRIProtection Mode, ifBradyMode isprogrammed toOff,Bradycar diatherap yandCardiac\\nResynchr onization Therapy(CRT) aresuspended. Thepatient willnotreceive pacing until thepulse gener atoris\\nprogrammed back tonormal operation. Only program BradyMode toOffduring MRIProte ction Mode andscanthe\\npatient ifjudged tobeclinically capable oftolerat ingnoBradycardia therap y(including pacing-dependenc eorneed\\nforoverd rivepacing) andnoCRTfortheentiredurat ioninwhich thepulse gener atorisinMRIProte ction Mode. Itis\\nrecommen dedtohave aprogr ammer powered OnneartheMRIroomincasethepatient develops theurgent need\\nforpacing. Patients withthefollowing conditions mayhave increased riskofdeveloping transient pacing-\\ndependenc e:\\n•Atriskforintermittent AVblock (forexample, those withprogr essive AVblock, orahistory ofunexplained\\nsyncope)\\n•Atriskfortrifascicular block (alternating bundle branchblock orPRinterval >200mswithLBBB orother\\nbifascicular block)\\nWARNING: Theriskofarrhythmia maybeincreased withasynchron ouspacing (AOO ,VOO,DOO). When\\nprogramming asynchron ouspacing during MRIProtection Mode, select apacing ratethatavoids competitive pacing\\nandminimize thetime inMRIProte ction Mode.\\nWARNING: IfBradycar dia,CRT,and/or Tachycardia therap yareprogr ammed Offprior toentering MRIProte ction\\nMode, thetherap ywillremain Offwhen theMRIProtection Time-out elapses after theprogr ammed time period.\\nSafetyMode\\nWARNING: Donotperform anMRIscanonapatient whose device hasentered Safety Mode. Safety Mode pacing is\\nVVIunipolar ,which, intheMRIenvironment, subjects thepatient toincreased riskofarrhythmia induction,\\ninappr opriate pacing, inhibition ofpacing, orirregular intermittent capture orpacing.\\nWARNING: Intherareevent thatnon-rec overable orrepeat fault conditions occur while thedeviceisprogr ammed\\ninMRIProtection Mode, thesubsequent devicebehavior willbedetermined bytheMRIProtection BradyMode\\nsetting.\\n•IfMRIBrady Mode issettoOff,thedevicewillenter Safety Mode (permanent VVIunipolar pacing andtachycardia\\ntherap yenabled).\\n•IfMRIBrady Mode issettoasynchr onous pacing (AOO ,VOO,DOO), both bradycar diatherap yandtachycard ia\\ntherap ywillbepermanently disabled.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 14}), Document(page_content='1-10Introduction totheMRConditional Defibrillation System\\nMRISiteZoneIIIExclusions\\nMRISiteZoneIIIExclusions\\nWARNING: TheProgr ammer isMRUnsafe andmust remain outside theMRIsiteZone III(and higher) asdefined by\\ntheAmerican College ofRadiology Guidanc eDocument onMRSafePractic es1.Under nocircumstanc esshould the\\nProgr ammer bebroughtintotheMRIscanner room, thecontrolroom, ortheMRIsiteZone IIIorIVareas.\\nWARNING: Implant ofthesystem cannot beperformed inanMRIsiteZone III(and higher) asdefined bythe\\nAmerican College ofRadiology Guidanc eDocument onMRSafePractices1.Some oftheaccessories packaged with\\npulse gener ators andleads, including thetorque wrench andstylet wires,arenotMRConditional andshould notbe\\nbroughtintotheMRIscanner room, thecontrolroom, ortheMRIsiteZone IIIorIVareas.\\nPrecautions\\nCAUTION: Thephysician choosing MRIProtection Mode paramete rvalues willneed toexerciseprofessional\\njudgment todetermine anindividual patient’s ability totolerat ethedevice settings requir edforMRConditional\\nscanning, inconjunction withthephysical conditions requir edduring ascan(forexample, prolonged time inasupine\\nposition).\\nCAUTION: Patients withelevated body tempera tureorcompromised thermoregulation atthetime ofthescanmay\\nbeatincreased riskofpocketdiscomfo rtassociated withdevice heating.\\nCAUTION: Thepresen ceoftheimplanted defibrillation system maycause MRIimage artifacts (see\"Preparing the\\nPatient fortheScan\" onpage 2-12).\\nNOTE: Allnormal risksassociated withanMRIprocedur eapply toMRIscans withtheMRConditional Defibrillation\\nSystem. Consult MRIscanner documentation foracomplete listofrisksassociated withMRIscanning.\\nNOTE: Other implanted device sorpatient conditions maycause apatient tobeineligible foranMRIscan,\\nindependent ofthestatus ofthepatient’s ImageReady MRConditional Defibrillation System.\\nPOTENTIALADVERSE EVENTS\\nPotential adverse events differ depending onwhether theMRIConditions ofUse(\"MRI Conditions ofUse\" onpage 1-\\n4)aremet. Foracomplete listofpotential adverse events, refertothePhysician\\'s Technical Manual forthepulse\\ngener ator.\\nMRIscanning ofpatients when theConditions ofUsearemetcouldresult inthefollowing potential adverse events:\\n•Arrhythmia induction\\n•Bradycardia\\n•Patient death\\n•Patient discomf ortduetoslight movement orheating ofthedevice\\n•Sideeffects ofpacing atafixed highratesuch ascompetitio nwithintrinsic rhythms andarrhythmias. Competitive\\npacing mayincrease therateofpacing induced arrhythmia until thedevice isreprogr ammed.\\n•Syncope\\n•Worsening heart failure\\n1. Kanal E,Barkovich AJ,BellC,etal.ACRguidance document onMRsafepractic es:2013. J.Magn. Reson. Imaging 2013;37:501-530.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 15}), Document(page_content='Introduction totheMRConditional Defibrillation System\\nPotential AdverseEvents1-11\\nMRIscanning ofpatients when theConditions ofUseareNOTmetcouldresult inthefollowing potential adverse\\nevents:\\n•Arrhythmia induction\\n•Bradycard ia\\n•Damage tothepulse gener atorand/or leads\\n•Erraticpulse gener atorbehavior\\n•Inappr opriate pacing, inhibition ofpacing, failuretopace\\n•Increased rateofleaddislodgement (within sixweeks ofimplant orrevision ofsystem)\\n•Irregular orintermittent capture orpacing\\n•Lossofdefibrillation therap y\\n•Pacing threshold changes\\n•Patient death\\n•Patient discomfort duetomovement orheating ofthedevice\\n•Physical movement ofpulse generator and/or leads\\n•Sensing changes\\n•Syncope\\n•Worsening heart failure', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 16}), Document(page_content='1-12Introduction totheMRConditional Defibrillation System\\nPotential AdverseEvents', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 17}), Document(page_content='2-1\\nMRISCANPROCEDURE\\nCHAPTER 2\\nThischapter contains thefollowing topics:\\n•“Patient Flow” onpage 2-2\\n•“MRI Prote ction Mode General Information” onpage 2-3\\n•“Pre-Sc anActivities” onpage 2-4\\n•“After theScan” onpage 2-12', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 18}), Document(page_content='2-2MRIScan Proce dure\\nPatientFlow\\nBefore proceeding withanMRIscan, verify thatthepatient andtheMRIscanner meet theMRIConditions ofUse\\n(\"MRI Conditions ofUse\" onpage 1-4).Thisverification must beperformed prior toeach scantoensure thatthemost\\nup-to-date information hasbeen used toassess thepatient’s eligibility andreadiness foranMRConditional scan.\\nWARNING: Unless alloftheMRIConditions ofUse(\"MRI Conditions ofUse\" onpage 1-4)aremet, MRIscanning of\\nthepatient does notmeet MRConditional requir ements fortheimplanted system, andsignificant harm toordeath of\\nthepatient and/or damage totheimplanted system mayresult.\\nForpotential adverse events applicable when theConditions ofUsearemetornotmet, see\"Potential Adverse\\nEvents\" onpage 1-10.\\nPATIENTFLOW\\nAsample patient flowsequenc eforanImageReady Defibrillation System patient whoneeds anMRIscanisdescribed\\nbelow .Foramoredetailed description oftheprogramming andscanning procedure,seethischapter .\\n1.MRIrecommen dedtopatient byspecialist (forexample, orthopedist oroncologist).\\n2.Patient orspecialist orradiologist contacts theelectr ophysiologist/cardiologist whomanages thepatient’s MR\\nConditional Defibrillation System.\\n3.Electrophys iologist/cardiologist determines patient eligibility forscanpertheinformation inthisTechnical Guide,\\nandensures commun ication ofpatient eligibility toHCPs involved inperforming theMRIscan. Usethe\\nprogr ammer todetermine thebeeper type(forinformation ondetermining thebeeper type, seethe“Determine\\nBeeper Type” appendix ofthismanual). FortheArmature Beeper ,befor eanMRIprocedur eisperformed, a\\nphysician andpatient should weigh thebenefit oftheMRprocedure against theriskoflosing theBeeper (Figure\\n2–9Beeper OffSummar ydialog onpage 2-11).\\n4.Ifthepatient iseligible, theProgr ammer isused toputthepulse gener atorintoMRIProte ction Mode asclose in\\ntime tothescanasreasonable. Ensure continuous monitoring ofthepatient while inMRIProtection Mode. The\\nMRIProtection Settings Report isprinted, placed inthepatient\\'s file,andprovided toradiology personnel. The\\nreport documents MRIProte ction Mode settings anddetails. IftheTime-out feature isused, thereport includes\\ntheexacttime anddatewhen MRIProtection Mode willexpire.\\n5.Theradiolo gistchecks thepatient fileandanycommunication fromtheelectr ophysiologist/cardiolo gist.Ifthe\\nTime-out feature isused, theradiologist verifies thatadequate time remains tocomplet ethescan. Ensure\\ncontinuous monitoring ofthepatient befor e,during, andafter theMRIscan.\\nNOTE: Thepatient must becontinuously monitored fortheentiredurationinwhich thesystem isinMRI\\nProtection Mode. Continuous monitoring includes maintaining normal voice andvisual contact, aswellas\\nmonitoring pulse oximetry andECGfortheentiredurationthatthepulse genera torisinMRIProtection Mode.\\nEnsure thatanexternal defibrillator andmedical personnel skilled incardiopulmonary resuscitation (CPR) are\\npresent when thepatient isputintoMRIProtection Mode.\\n6.Patient under goes scanaccording totheconditions ofusedescribed inthisTechnical Guide.\\n7.Thepulse gener atorisreturned topre-MRI operation, either automatically iftheTime-out parameter wasset,or\\nmanually using theProgr ammer .Perform follow-up testing oftheimplanted system. FortheArmatur eBeeper ,\\nperform theBeeper evaluation testtodetermine iftheBeeper isusable (seetheEvaluate Devic estepin\"After\\ntheScan\" onpage 2-12). IftheBeeper isnotusable, itisstrongly recommended thatpatients arefollowed on\\nLATITUDE NXTafter anMRIscaniftheyarenotalready.Otherwise, anin-clinic follow-up schedule ofeverythree\\nmonths isstrongly recommended tomonitor device performance.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 19}), Document(page_content='MRIScan Procedure\\nMRIProtectionModeGeneralInformation2-3\\nMRIPROTECTIONMODEGENERAL INFORMATION\\nPrior tothepatient under going anMRIscan, anImageReady MRConditional Defibrillation System must be\\nprogrammed totheMRIProtection Mode using theProgr ammer .See\"Progr amming thePulse Generato rforaScan\"\\nonpage 2-4fordetails about programming thepulse generator intoMRIProtection Mode.\\nTachycar diatherap yissuspended inMRIProte ction Mode.\\nPacing mode options include asynchro nous pacing (DOO ,AOO,VOO) ornopacing (Off). Asynchr onous pacing should\\nonlybeused ifthepatient ispacing-dependent. IfMRIProtection BradyMode isprogr ammed toOff,thepatient will\\nnotreceive therap yuntilMRIProtection Mode isexited.Offshould onlybeused ifthepatient isjudged tobe\\nclinically capable ofreceivin gnopacing during thetime thepulse gener atorisinMRIProte ction Mode, including\\nduring thescan.\\nConsider ations prior tochoosing asynchr onous pacing include:\\n•Determine whether thepatient ispacing-dependent.\\n•Determine which chamber(s) need tobepaced.\\n•Consider thepossibility ofarrhythmia induction withasynchron ouspacing.\\n•Patients withthefollowing conditions mayhave increased riskofdeveloping transient pacing-dependence:\\n1.Atriskforintermittent AVblock (forexample, those withprogressive AVblock, orahistor yofunexp lained\\nsyncope)\\n2.Atriskfortrifascicular block (alternating bundle branc hblock orPRinterv al>200mswithLBBB orother\\nbifascicular block)\\nTheBeeper isOffinMRIProtection Mode. TheArmature Beeper willstayOffafter exiting MRIProtection Mode\\n(Figur e2–9Beeper OffSummary dialog onpage 2-11). FortheArmatur eBeeper ,perform Beeper evaluation (seethe\\nEvaluate Devic estepin\"After theScan\" onpage 2-12) anddetermine iftheBeeper isusable following anMRIscan\\n(\"After theScan\" onpage 2-12). IftheBeeper isnotusable, itisstrong lyrecommended thatpatients arefollowed on\\nLATITUDE NXTafter anMRIscaniftheyarenotalready.Otherwise, anin-clinic follow-up schedule ofevery three\\nmonths isstrongly recommen dedtomonitor device performanc e.\\nThefollowing features andfunctions aresuspended inMRIProte ction Mode:\\n•Bradycard iasensing\\n•Tachycar diadetection andtherap y\\n•PaceSaf eautomatic threshold(s)\\n•Daily diagnostics (Lead Impedance ,Intrinsic Amplitude, Pace Threshold)\\n•Motion andrespiratory sensors\\n•Magnet detection\\n•RFtelemetry\\n•Battery voltage monitoring', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 20}), Document(page_content='2-4MRIScan Proce dure\\nPre-Scan Activities\\n•LeftVentricular MultiSite Pacing (CRT-D)\\nThefollowing device conditions willpreclude theuserfromhaving theoption toenter MRIProtection Mode (seethe\\nRefere nceGuide forthepulse generator foradditional information about these conditions):\\n•Battery capacity status isDepleted\\n•Pulse gener atorisinStorageMode\\n•Pulse gener atorisinElectro cauter yMode\\n•Pulse gener atorisinSafety Coreoperation (Safety Mode)\\n•Diagnostic testisinprogr ess\\n•EPtestisinprogr ess\\nNOTE: Sixhours inMRIProtection Mode reduc espulse gener atorlongevity byapproximately 3days (CRT-D) or4\\ndays (ICD).\\nWARNING: MRIscanning after Explant status hasbeen reached mayleadtopremature battery depletion, a\\nshortened device replacement window ,orsudden lossoftherap y.After performing anMRIscanonadevice thathas\\nreached Explant status, verify pulse genera torfunction andschedule devicereplac ement.\\nPRE-SCAN ACTIVITIES\\nThreeactivities arerequir edbefor etheMRIscantakesplace :\\n1.Prepar ethepulse gener atorforthescanbyprogramming intoMRIProte ction Mode (\"Progr amming thePulse\\nGenerator foraScan\" onpage 2-4)\\n2.Confirm theMRIscanner settings andconfigurat ions(\"Confirming MRIScanner Settings andConfiguration\" on\\npage 2-11)\\n3.Prepar ethepatient forthescan(\"Prepar ingthePatient fortheScan\" onpage 2-12)\\nProgramming thePulseGenerator foraScan\\nUsetheProgr ammer toprogr amthepulse gener atorintoMRIProtection Mode.\\nNOTE: See\"MRConditional Defibrillation System Warnings andPrecautions\" onpage 1-8foracomplete listof\\nWarnings andPrecautions.\\nNOTE: Maintain accesstotheprogrammer wand aswanded telemetry isrequir edtoenter MRIProtection\\nMode.\\nCAUTION: Thephysician choosing MRIProtection Mode parameter values willneed toexercise professional\\njudgment todetermine anindividual patient’s ability totolerate thedevice settings required forMRConditional\\nscanning, inconjunction withthephysical conditions required during ascan(forexample, prolo nged time ina\\nsupine position).\\nPrior tostarting programming, print theDevic eSettings Report asareference forchoosing Bradysettings inMRI\\nProte ction Mode.\\nFromtheMain screen,usetheTachy Mode button toenable MRIProtection Mode. TheChange Devic eMode screen is\\ndisplayed (Figure 2–1Change Device Mode dialog onpage 2-5).', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 21}), Document(page_content='MRIScan Procedure\\nProgramming thePulseGenerator foraScan2-5\\nNOTE: Screens maydiffer depending onbeeper typeanddevice type.\\nFigure2–1.ChangeDeviceModedialog\\nSelect theEnable MRIProtection button andthen choose Continue toproceedwithentry intoMRIProtection Mode.\\nTheMRIProtection Checklist screen isdisplayed (Figure 2–2MRIProtection Checklist onpage 2-5). TheChecklist\\nsummariz estheconditions thatmust bemetatthetime ofscanning inorder forapatient tobeeligible foranMR\\nConditional scan. Re-verification isrequir edbefor eevery scantoguardagainst thepossibility thatchanges inthe\\nsystem orpatient occurr edsubsequent totheoriginal pulse gener ator/system implant.\\nFigure2–2.MRIProtectionChecklist\\nIftheConditions ofUseasdescribed inthismanual aremet, select theContinue withMRIProtection button. Asa\\nresult, theProgram MRIProtection screenappears (Figure 2–3Program MRIProtection dialog onpage 2-6).\\nIftheConditions ofUsearenotmet, select theCancel button toreturntonormal system operation anddonot\\nproceed withtheMRIscan(thepatient shall notunder goanMRIscan).', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 22}), Document(page_content='2-6MRIScan Proce dure\\nProgramming thePulseGenerator foraScan\\nFigure2–3.ProgramMRIProtectiondialog\\nSelect aBradyMode (Figure 2–3Program MRIProtection dialog onpage 2-6). Pacing mode options include\\nasynchro nous pacing (DOO ,AOO,VOO) ornopacing (Off).Asynchronous pacing should onlybeused ifthepatient is\\npacing-dependent.\\nWARNING: During MRIProtection Mode, ifBradyMode isprogrammed toOff,Bradycar diatherap yandCardiac\\nResynchr onization Therapy(CRT) aresuspended. Thepatient willnotreceive pacing until thepulse gener atoris\\nprogrammed back tonormal operation. Only program BradyMode toOffduring MRIProte ction Mode andscan\\nthepatient ifjudged tobeclinically capable oftolerating noBradycardia therap y(including pacing-dependence\\norneed foroverd rivepacing) andnoCRTfortheentireduration inwhich thepulse generator isinMRIProtection\\nMode. Itisrecommended tohave aprogrammer powered OnneartheMRIroom incasethepatient develops\\ntheurgent need forpacing. Patients withthefollowing conditions mayhave increased riskofdeveloping\\ntransient pacing-dependence :\\n•Atriskforintermittent AVblock (forexample, those withprogr essive AVblock, orahistory ofunexplained\\nsyncope)\\n•Atriskfortrifascicular block (alternating bundle branchblock orPRinterval >200mswithLBBB orother\\nbifascicular block)\\nIfasynchr onous pacing isrequired, progr amthefollowing additional pacing parameters (Figure 2–4Program MRI\\nProte ction dialog withparameters onpage 2-7).\\n•Lower ratelimitdefaults to20ppm above normal mode LRL(programmable innormal increments toamaximum\\nvalue 100ppm)\\nNOTE: Because MRIProtection Mode pacing isasynchron ous,when setting thelower ratelimit, consider\\nthepatient’s intrinsic ratetoavoid competitive pacing.\\n•Atrial andright ventricular amplitude default to5.0V(programmable innormal increments from2.0Vto5.0V)\\nandpulse width fixed at1.0ms\\nNOTE: Progr amming pacing amplitude below 5.0Visprovided asanoption incaseofextracardiac\\nstimulation (forexample, diaphragmatic stimulation).\\nWARNING: Usecaution when progr amming MRIProte ction Mode inpacing-dependent patients whohave\\nhighright atrial andright ventricular pacing thresholds onthepaced lead(s) (>2.0V).Themaximum pacing\\namplitude inMRIProtection Mode is5.0V,which maylimittheavailable pacing amplitude safety marginfor\\npatients withhighpacing thresholds. Failure tomaintain sufficient pacing amplitude safety margin may\\nresult inlossofcapture .', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 23}), Document(page_content='MRIScan Procedure\\nProgramming thePulseGenerator foraScan2-7\\n•Leftventricular amplitude defaults tothenormal Bradyvalue when within therangeof2.0Vto5.0V(inclusive)\\n(programmable innormal increments from 2.0Vto5.0V)andpulse width defaults tothenormal Bradysetting\\n(programmable innormal increments from 0.1msto2.0ms)\\nNOTE: Ifthenormal Brady value isoutside ofthe2.0Vto5.0Vrange,theMRIamplitude value willbeset\\ntothenearestendofthevalue range. Forexample, ifthenormal Bradyvalue is1.0V,theMRIvalue willbe\\nsetto2.0V.\\nNOTE: InMRIProtection Mode, theminimum allowed pacing amplitude is2.0V.Patients whose devices\\narenominally programmed withLVpacing amplitude lessthan 2.0Vmayexperienc eextracardiac\\nstimulation orphrenic nervestimulation (PNS) inMRIProtection Mode astheresultoftheincreased LV\\npacing amplitude. Ifthepatient does notrequir eLVpacing, consider progr amming theMRIProtection\\nVentricular Pacing Chamber toRVOnly andminimize thetimeinMRIProtection Mode.\\nFigure2–4.ProgramMRIProtectiondialogwithparameters\\nSetMRIProtection Time-out (nominally setto6hours; programmable values ofOff,3,6,9,12hours). TheMRI\\nProtection Mode Time-out function allows theusertochoose thelength oftimethepulse generator remains inMRI\\nProtection Mode. Check thattheprogr ammer clock issettothecorrecttime anddatetoensure theaccuracy ofthe\\nprojected expiration time (displayed onthescreenandontheprinted MRIProte ction Settings Report). When the\\nprogrammed time haselapsed, thepulse generator automatically exitsMRIProtection Mode andallparameters\\n(except fortheArmatur eBeeper settings) returntotheprevio uslyprogr ammed settings.\\nWARNING: When theTime-out parameter isprogr ammed toavalue other than Off,thepatient must beoutof\\nthescanner befor ethetime progr ammed elapses. Other wise, thepatient willnolonger meet Conditions ofUse\\n(\"MRI Conditions ofUse\" onpage 1-4).\\nWARNING: IftheMRIProtection Time-out value isprogrammed toOff,thepatient willnotreceive Tachycardia\\ntherap y,andthepacing options arelimited toOfforAsynchronous untilthepulse generator isprogrammed out\\nofMRIProtection Mode andback tonormal operation.\\nSelect theProgr amMRIProtection button. TheMRIProte ction Progr ammed screenappears when thedevice has\\nsuccessfullybeen programmed intoMRIProtection Mode atthesettings indicated (Figure 2–5MRIProtection\\nProgrammed dialog onpage 2-8). Donotproceed withthescanuntil theMRIProtection Progr ammed screenisseen\\ntoconfirmthatthedevice isinMRIProte ction Mode.\\nNOTE: Useofthewand isnecessary tocomplete entryintoMRIProtection Mode. Keep thewand inplace until\\nreceiving confirmation thatMRIProtection Mode isprogr ammed.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 24}), Document(page_content=\"2-8MRIScan Proce dure\\nProgramming thePulseGenerator foraScan\\nFigure2–5.MRIProtectionProgrammed dialog\\nWARNING: During MRIProtection Mode, thepatient willnotreceiveTachycar diatherapy (including ATPand\\ndefibrillation), and,ifBradyMode isprogr ammed toOff,willnotreceive Bradycard iapacing (including backup\\npacing) andCardiac Resynchr onization Therapy.Therefor ethepatient must becontinuously monitored forthe\\nentireduration inwhich thesystem isinMRIProte ction Mode, including during thescan.\\nContinuously monitor thepatient fortheentire duration inwhich thesystem isinMRIProte ction Mode. Continuous\\nmonitoring includes maintaining normal voiceandvisual contact, aswellasmonitoring pulse oximetry andECGfor\\ntheentire duration thatthepulse gener atorisinMRIProte ction Mode. Ensure thatanexternal defibrillator and\\nmedical personnel skilled incardiopulmonary resuscitation (CPR) arepresent aslongasthepulse gener atorisinMRI\\nProte ction Mode, including during thescan, should thepatient requir eexternal rescue.\\nOnceMRIProtection Mode hassuccessfully been progr ammed, print acopy oftheMRIProtection Settings Report by\\nselecting thePrint Settings button ontheMRIProtection Mode Progr ammed screen.Thereport liststhesettings in\\noperation during MRIProtection Mode. IftheTime-out feature isused, thereportincludes thetime anddatewhen\\nMRIProtection Mode willexpire,returning thepulse gener atortothepre-MR IProtection Mode settings.\\nTheprinted report canbeplaced inthepatient's fileandused byradiology personnel, forexample, toconfirm that\\nsufficient time remains tocomplete theMRIscan. Sample MRIProtection Settings Report printouts areshown with\\ntheTime-out setto6hours (Figure E–1Sample MRIProte ction Settings Report printout withTime-out setto6hours\\nonpage E-1)andwiththeTime-out settoOff(Figure E–2Sample MRIProtection Settings Report printout withTime-\\noutsettoOff(Page 1)onpage E-2).\\nSelect theEndSession button toendthecurren tprogr ammer session withMRIProtection Mode active inthepulse\\ngener ator(Figure 2–6EndSession Confirmation dialog onpage 2-8).\\nFigure2–6.EndSessionConfirmation dialog\", metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 25}), Document(page_content='MRIScan Procedure\\nProgramming thePulseGenerator foraScan2-9\\nEnsur ethattheHCPs involved inperforming theMRIscanhave received themodel numbers ofthepulse generator\\nandlead(s) implanted inthepatient.\\nConditions Assessed DuringProgramming\\nCertain conditions willprevent entryintoMRIProtection Mode. These include:\\n•Aventricular episode asdetected andrecogniz edbythepulse gener atorisinprogress\\n•Magnet prese nceisdetected bymagnet sensor\\n•Pulse gener atorisinSTAT PACE orSTAT SHOCK mode\\nIfoneormore ofthese conditions arepresent, adialog boxwillappear describing thecondition, andMRI\\nProte ction Mode cannot beentered. Forexample, seeFigure 2–7Episode inprogr essattention message onpage\\n2-9.\\nFigure2–7.Episodeinprogressattention message\\nInaddition tothecondition slisted above thatprevententryintoMRIProtection Mode, threeother conditions are\\nassessed bytheProgr ammer during programming: leadimpedance, time sinceimplant, andpacing threshold.\\n1.LeadImpedanc e\\nAuserrequest toenter theMRIProtection Mode triggers aleadimpedance testinallchambers andashock\\nleadimpedance test.Iftheleadimpedance values obtained from thistesting areoutside theprogrammed\\nnormal range, theProgr ammer providesadialog boxrecommending areview oftheassociated risksifthe\\nuserchooses toproceed. Thedialog provides theoption ofcontinuing withMRIProtection Mode inthe\\npresenc eofthese conditions, orcancelling entryintoMRIProtection Mode. Thedialog boxthatappears in\\nthecaseofanout-of-range leadimpedance value isshown inFigure 2–8Lead impedance outofrange\\nattention message onpage 2-10.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 26}), Document(page_content='2-10MRIScan Proce dure\\nProgramming thePulseGenerator foraScan\\nFigure2–8.Leadimpedance outofrangeattention message\\n2.TimeSinceImplant\\nTheProgr ammer alsodetermines thetime since implant, based onthedateandtime when thepulse\\ngener atorwastakenoutofStorageMode.\\nNOTE: IftheProgrammer clock isnotsettothecorrect time anddate, thisdetermination maynotbe\\naccurate.\\nIfthecalculated time since exitfromStorageMode islessthan 6weeks, theProgr ammer provides adialog\\nboxrecommending areviewoftheassociated risksiftheuserchooses toproceed.Thedialog providesthe\\noption ofcontinuing withMRIProte ction Mode inthepresence ofthese conditions, orcancellin gentry into\\nMRIProte ction Mode.\\n3.PacingThreshold\\nIfthemost recently recordedRAandRVpacing threshold measur ements aregreaterthan 2.0V,the\\nProgr ammer provides adialog boxrecommen ding theuseofcaution forpacing-dependent patients. The\\ndialog providestheoption ofcontinuing withMRIProte ction Mode inthepresence ofthese condition s,or\\ncancelling entryintoMRIProte ction Mode.\\nWARNING: Usecaution when programming MRIProtection Mode inpacing-dependent patients who\\nhave highright atrial andright ventricular pacing thresholds onthepaced lead(s) (>2.0V).The\\nmaximum pacing amplitude inMRIProtection Mode is5.0V,which maylimittheavailable pacing\\namplitude safety margin forpatients withhighpacing thresholds. Failur etomaintain sufficient pacing\\namplitude safety margin mayresultinlossofcapture.\\nArmature Beeper\\nTheArmature Beeper maynolonger beusable following anMRIscan. Coming incontact withthestrong\\nmagnetic fieldofanMRIscanner maycause apermanent lossoftheArmature Beeper volume. Thiscannot be\\nrecover ed,even after leaving theMRscanenvironment andexiting MRIProtection Mode. Thesystem proactively\\nturns offtheprogr ammable andnon-progr ammable Armature Beeper options when MRIProtection Mode is\\nprogrammed. TheArmatur eBeeper willremain Offupon exiting MRIProte ction Mode.\\nUpon subsequent interrogat ions, anotification thattheBeeper isOffandthedateMRIProte ction Mode waslast\\nprogrammed willbeprovided ontheinitial Summary dialog (Figure 2–9Beeper OffSummary dialog onpage 2-\\n11).', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 27}), Document(page_content='MRIScan Procedure\\nConfirming MRIScannerSettingsandConfiguration2-11\\nFigure2–9.BeeperOffSummary dialog\\nThefollowing aresituations thatwillnolonger trigger theArmature Beeper toemit audible tones oncethe\\ndevice isprogrammed intoMRIProtection Mode.\\nTable2–1.Situations thatwillnolongertriggeraudibleBeepertonesoncethedeviceisprogrammed intoMRIProtectionMode\\nProgrammable Beeper options• Beep During Capacitor Charge\\n• Beep When Out-of-Range\\n• Beep when Explant isIndicated\\nNon-Pro grammable Beeper options• Application ofthepatient magnet overthepulse generator in\\ncertain situations (e.g.confirming Tachycardia Mode)\\n• Battery capacity depleted (EndofLife(EOL))\\n• Battery fault alert\\n• High voltage fault alert\\nTheBeeper willemit tones following reversion ofthepulse generator toSafety Mode Operation ordevice reset\\neven after thedevice isprogrammed intoMRIProte ction Mode. ButtheArmatur eBeeper volume inthedevice\\nmaybedecreased andmaybeinaudible.\\nNOTE: After anMRIscan, perform Beeper evaluation testtodetermine iftheArmatur eBeeper isusable\\n(seetheEvaluate Devic estepin\"After theScan\" onpage 2-12). IftheBeeper isnotusable, itisstrong ly\\nrecommen dedthatpatients arefollowed onLATITUDE NXTafter anMRIscaniftheyarenotalready.\\nOtherwise, anin-clinic follow-up schedule ofeverythreemonths isstrongly recommended tomonitor\\ndeviceperformanc e(\"After theScan\" onpage 2-12). Insituations wheretheMRIscandidnotoccur,the\\nArmatur eBeeper canbeprogrammed back Onafter exiting MRIProtection Mode.\\nConfirming MRIScannerSettingsandConfiguration\\nEnsur ethattheMRIscanner equipment meets the\"MRI Conditions ofUse\" onpage 1-4.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 28}), Document(page_content='2-12MRIScan Proce dure\\nPreparing thePatientfortheScan\\nPreparing thePatientfortheScan\\nIftheMRIProtection Mode Time-out feature isbeing used, besuretonote thetime atwhich thepulse gener atoris\\nscheduled toexitMRIProtection Mode. Refer toFigure 2–5MRIProtection Progr ammed dialog onpage 2-8.\\nNOTE: Ifthetime remain ingisnotsufficient forthepatient tounder gotheMRIscan, re-interrogate thedevice and\\nreprogr amtheTime-out value asdesired(see\"Progr amming thePulse Generato rforaScan\" onpage 2-4).\\nWARNING: When theTime-out parameter isprogr ammed toavalue other than Off,thepatient must beoutofthe\\nscanner before thetime programmed elapses. Otherwise, thepatient willnolonger meet Conditions ofUse(\"MRI\\nConditions ofUse\" onpage 1-4).\\nPatient position within thebore must beprone orsupine, andtheappro priate monitoring system must beputin\\nplace (pulse oximetr yandECG). See\"MRI Conditions ofUse\" onpage 1-4.\\nWARNING: During MRIProtection Mode, thepatient willnotreceive Tachycardia therap y(including ATPand\\ndefibrillation), and,ifBradyMode isprogr ammed toOff,willnotreceiveBradycardia pacing (including backuppacing)\\nandCardiac Resynchronization Therapy .Therefor ethepatient must becontinuously monitored fortheentire duration\\ninwhich thesystem isinMRIProtection Mode, including during thescan.\\nImage distortion andartifacts must beconsider edwhen planning anMRIscanandwhen interpret ingMRIimages in\\nproximitytothepulse gener atorand/or leads. Distortion andartifacts mayoccur beyond theboundaries ofthepulse\\ngener ator.Only minor artifacts arepresen taroundtheleads.\\nAFTERTHESCAN\\n1.ExitMRIProtection\\nMRIProtection Mode canbeexitedeither automatically ormanually .Exitoccurs automatically after the\\nprogr ammed number ofhours haselapsed iftheTime-out feature issettoanumerical value. IftheTimer is\\nprogr ammed toOff,exitisperformed manually using theProgr ammer (seeManual ExitfromMRIProtection\\nMode). After exitfromMRIProtection Mode, check system integrity byrunning leadimpedance ,pacing\\nthreshold, andintrinsic amplitude tests.\\nForRESONATE HF,RESONATE, PERCIVA HF,PERCIVA, VIGILANT, andMOMENTUM devices, onexitfromMRI\\nProtection Mode, asummary report oftheMRIisstored asanMRIepisode andcanbeprinted asanepisode\\nreport. Asample report printout isshown inFigure E–3Sample stored event detail printout onpage E-2.TheMRI\\nProtection episode canalsobeaccessed andviewed viatheArrhythmia Logbook. TheMRIepisode canalsobe\\nviewed ontheArrhythmia Logbook viaremote patient monitoring (ifavailable).\\nTime-out (automatic) ExitfromMRIProtectionMode\\nIftheMRIProtection Mode Time-out parameter wasprogr ammed toavalue other than Off,thepulse generator\\nwillexitMRIProtection Mode automatically after theselected number ofhours, andthesystem willreturnto\\npreviously progr ammed settings (exceptfortheArmature Beeper andMinute Ventilation asdescribed below).\\nManualExitfromMRIProtectionMode\\nAlternatively ,iftheTime-out feature wasprogr ammed Off,oranytime manual cancellation ofMRIProte ction\\nMode isdesired, theProgr ammer isused totakethepulse gener atoroutofMRIProtection Mode.\\nDonotleave thepulse generator inMRIProtection Mode anylonger than necessary following thescan. To\\nmanually exitMRIProtection Mode, perform thefollowing steps:\\na.Interr ogate thepulse generator using thewand (RFtelemetr yisdisabled inMRIProte ction Mode).', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 29}), Document(page_content='MRIScan Procedure\\nAftertheScan2-13\\nb.Select theExitMRIProtection Mode button from theMRIProtection Programmed screen (Figure 2–10MRI\\nProtection Programmed dialog onpage 2-13).\\nNOTE: Ifnecessary ,STAT PACE, STAT SHOCK, orDIVERT THERAPY canalsobeused toexitMRIProtection\\nMode. STAT PACE willinitiate STAT PACE pacing paramet ers(seethepulse gener ator’s Referenc eGuide for\\nmore information about STAT PACE).\\nFigure2–10.MRIProtectionProgrammed dialog\\n2.Evaluate Device\\nFollowing user-initiated cancellatio nofMRIProte ction Mode, theProgrammer willautomatically navigate tothe\\nLead Tests screenandprompt theusertoperform leadtests (Figur e2–11MRIProtection Exited dialog onpage 2-\\n13).\\nFigure2–11.MRIProtectionExiteddialog\\nPerform thefollowing leadmeasur ements andevaluate theresults:\\n•Intrinsic Amplitude\\n•Lead Impedanc e\\n•Pace Threshold', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 30}), Document(page_content='2-14MRIScan Proce dure\\nAftertheScan\\nPerform these tests subsequent toautomatic (Time-out) exitfrom MRIProtection Mode aswell. When testing is\\ncomplete, itisrecommended thattheProgr ammer beused tosave allpatient data.\\nForRESONATE HF,RESONATE, PERCIVA HF,PERCIVA, CHARISMA, VIGILANT, andMOMENTUM devices,thepulse\\ngenerator willautomatically initiate Post-Oper ative System Test(POST) upon exitfromMRIProtection mode.\\nAutomatic Intrinsic Amplitude, Lead Impedance, andPace Threshold testing (ifenabled) willbeattempted with\\nresults available inonehour.Foradditional information about POST, seetheRefere nceGuide forthepulse\\ngenerator .\\nUpon exitfromMRIProtection Mode, whether automatically ormanually ,allparameters areimmediately\\nrestor edtopre-MRI Protection Mode values withthefollowing exception(s):\\na.Restor ation offunction oftheMinute Ventilation sensor isdelayed upon exitfromMRIProtection Mode.\\nIfMVisprogr ammed toOnorPassive atthetime ofentryintoMRIProtection Mode, upon exitfrom the\\nmode, anautomatic six-hour calibr ation ofthesensor willbegin. MV-driven rateresponse isnotavailable\\nduring thiscalibr ation period. IfMV-driven raterespon seisdesired sooner ,amanual calibra tioncanbe\\nperformed. Manual calibr ation iscompleted infiveminutes orless.Foradditional information about MV\\ncalibr ation, seetheReferenc eGuide forthepulse gener ator.\\nb.TheArmature Beeper willremain Offupon exiting MRIProtection Mode. After exiting MRIProtection Mode,\\nperform theBeeper evaluation test(Figure 2–12Configur eBeeper Settings screenonpage 2-14).\\nFigure2–12.Configure BeeperSettingsscreen\\nPerform thefollowing steps toperform theBeeper evaluation test:\\ni.Select theSettings tab.\\nii.Select theBeeper tab.\\niii.Select thedesired value fortheBeeper.\\niv.After turning ontheBeeper ,ensure itisstillaudible byplacing amagnet overthedevice andlistening\\nforbeeps. IftheBeeper isaudible, leave theBeeper On.IftheBeeper isnotaudible, consider\\nprogr aming theBeeper toOff.IftheBeeper isnotaudible, itisstrongly recommended thatpatients are\\nfollowed onLATITUDE NXTafter anMRIscaniftheyarenotalready.Otherwise, anin-clinic follow-up\\nschedule ofeverythreemonths isstrongly recommended tomonitor device performanc e.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 31}), Document(page_content='MRIScan Procedure\\nAftertheScan2-15\\nWhen theBeeper isprogr ammed back On,allprogr ammable andnon-pr ogrammable Beeper features will\\nbereverted totheir nominal values.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 32}), Document(page_content='2-16MRIScan Proce dure\\nAftertheScan', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 33}), Document(page_content='A-1\\nCARDIOLOGY CHECKLIST FORTHEIMAGEREADY DEFIBRILLATION SYSTEM\\nAPPENDIX A\\nThisappendix isprovided forconvenience. Refer totheremainder ofthisTechnical Guide forthefulllistofWarnings\\nandPrecautions andcomplete instructions forusing theImageReady Defibrillation System.\\nConditions ofUse–Cardiology Scanning Procedure\\nThefollowing Conditions ofUsemust bemetinorder forapatient\\nwithanImageReady Defibrillation System toundergo anMRIscan.\\nPatient isimplanted withanImageReady MRConditional\\nDefibrillation System (\"ImageReady Defibrillation System Components\\nfor1.5Tand3T\"onpage D-1).\\nNoother active orabandoned implanted devices, compon entsor\\naccessories presen tsuch asleadadaptors, extenders, leads orpulse\\ngenerators.\\nPulse generat orinMRIProtection Mode during scan.\\nAssoon asMRIProtection Mode isprogr ammed, thepatient must\\nbecontinuously monitored bypulse oximetry andelectrocar diograp hy\\n(ECG). Ensure backup therapy isavailable (external rescue).\\nPatient isjudged tobeclinically capable oftolerating no\\nTachycardia protection fortheentire duration inwhich thepulse\\ngenerator isinMRIProtection Mode.\\nPulse generat orimplant location restricted toleftorright pectoral\\nregion.\\nAtleast six(6)weeks have elapsed since implantation and/or any\\nleadrevision orsurgical modification oftheMRConditional\\nDefibrillation System.\\nNoevidence ofafractured leadorcompr omised pulse generator -\\nleadsystem integrity .Pre-scan\\n1.Ensure patient meets allCardiology Conditions ofUseforMRI\\nscanning (seeleftcolumn).\\n2.Determine theBeeper Type. Exposure toMRIscanning maycause a\\npermanent lossoftheArmature Beeper volume. FortheArmature\\nBeeper, thephysician andpatient should weigh thebenefit oftheMR\\nprocedure against theriskoflosing theBeeper.\\n3.Ensure thattheHCPs involved inperforming theMRIscanhave\\nreceived themodel numbers ofthepulse generator andlead(s)\\nimplanted inthepatient.\\n4.Asclose tothestartofthescanaspossible, progr amthepulse\\ngenerator intoMRIProtection Mode andbegin continuous monitoring\\nofthepatient.\\n5.Print theMRIProtection Settings Report, place itinthepatient’s\\nfile,andprovide toradiology personnel.\\n• Thereportdocuments MRIProtection Mode settings anddetails.\\nIftheTime-out featur eisused, thereport includes theexact time\\nanddatewhen MRIProtection Mode willexpire.\\nDuringScan\\n6.Ensure thepatient iscontinuously monitored bypulse oximetry and\\nelectrocar diography (ECG), withbackup thera pyavailable (external\\nrescue), while thedevice isinMRIProtection Mode.\\nAfterscan\\n7.Ensure thepulse generat orisreturned topre-MRI operation, either\\nautomatically iftheTime-out parameter wasset,ormanually using\\ntheProgr ammer .Perform follow-up testing ofthedefibrillation\\nsystem after exitingMRIProtection Mode, andcontinue patient\\nmonitoring untilthepulse generator isreturned topre-M RIoperation.\\n8.TheArmature Beeper willremain OFFupon exitingMRIProtection\\nMode.\\n9.Perform theBeeper evaluation testafter exitingMRIProtection\\nMode.\\nWARNING: Unless alloftheMRIConditions ofUsearemet, MRIscanning ofthepatient does notmeet MR\\nConditional requirements fortheimplanted system, andsignificant harm toordeath ofthepatient and/or damage to\\ntheimplanted system mayresult.\\nWARNING: Usecaution when progr amming MRIProtection Mode inpacing-dependent patients whohave high\\nright atrial andright ventricular pacing thresholds onthepaced lead(s) (>2.0V).Themaximum pacing amplitude in\\nMRIProtection Mode is5.0V,which maylimittheavailable pacing amplitude safety marginforpatients withhigh\\npacing thresholds. Failur etomaintain sufficient pacing amplitude safety marginmayresultinlossofcapture.\\nWARNING: Theriskofarrhythmia maybeincreased withasynchron ouspacing (AOO ,VOO,DOO). When\\nprogramming asynchron ouspacing during MRIProtection Mode, select apacing ratethatavoids competitive pacing\\nandminimize thetime inMRIProte ction Mode.\\nWARNING: IftheMRIProte ction Time-out value isprogr ammed toOff,thepatient willnotreceiveTachycar dia\\nthera py,andthepacing options arelimited toOfforAsynchr onous until thepulse gener atorisprogr ammed outof\\nMRIProtection Mode andback tonormal operation.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 34}), Document(page_content='A-2CARDIOLOGY CHECKLIST FORTHEIMAGEREADY DEFIBRILLATION SYSTEM\\nWARNING: TheProgr ammer isMRUnsafe andmust remain outside theMRIsiteZone III(and higher) asdefined by\\ntheAmerican College ofRadiology Guidanc eDocument onMRSafePractic es1.Under nocircumstanc esshould the\\nProgr ammer bebroughtintotheMRIscanner room, thecontrolroom, ortheMRIsiteZone IIIorIVareas.\\nWARNING: Determine thebeeper typebefor eanMRIscan. TheArmatur eBeeper maynolonger beusable\\nfollowing anMRIscan. Coming incontact withthestrongmagnetic fieldofanMRIscanner maycause apermanent\\nlossoftheArmature Beeper volume. Thiscannot berecover ed,even after leaving theMRIscanenvironment and\\nexiting MRIProtection Mode. FortheArmatur eBeeper ,befor eanMRIscanisperformed, aphysician andpatient\\nshould weigh thebenefit oftheMRIscanagainst theriskoflosing theBeeper; after theMRIscan, perform Beeper\\nevaluation testtodetermine iftheBeeper isusable. IftheBeeper isnotusable, itisstrong lyrecommended that\\npatients arefollowed onLATITUDE NXTafter anMRIscaniftheyarenotalready .Other wise, anin-clinic follow-up\\nschedule ofevery threemonths isstrongly recommended tomonitor device performanc e.\\nNOTE: Forinstructions onhowtodetermine thebeeper type, seethe“Determine Beeper Type” appendix ofthis\\nmanual. Forinstructions onperforming theBeeper evaluation test,seetheEvaluate Device stepin\"After theScan\" on\\npage 2-12.\\n1. Kanal E,Barkovich AJ,BellC,etal.ACRguidance document onMRsafepractic es:2013. J.Magn. Reson. Imaging 2013;37:501-530.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 35}), Document(page_content='B-1\\nRADIOLOGY CHECKLIST FORTHEIMAGEREADY DEFIBRILLATION SYSTEM\\nAPPENDIX B\\nThisappendix isprovided forconvenience. Refer totheremainder ofthisTechnical Guide forthefulllistofWarnings\\nandPrecautions andcomplete instructions forusing theImageReady Defibrillation System.\\nThismanual introduces useofanewparameter forlimiting RFexposur eduring certain 3Tscans.\\nB1+rmsisameasure ofRFexposu rethatisdiffere ntfromSAR. Itisused instead ofSARforlimiting 3Tscans witha\\npatient landmark (scan isocenter) inferior totheC7vertebr a.B1+rmsisnotdisplayed onall3Tscanners.\\nImportant: IfyouareunfamiliarwithB1+rms,orareunsureifitisavailable onyour3Tscanner,eitherlimit\\nscansto1.5TandNormalMode,orcontacttheMRIscannermanufacturerformoreinformation.\\nConditions ofUse–Radiology Scanning Procedure\\nThefollowing Conditions ofUsemust bemetinorder forapatient\\nwithanImageReady Defibrillation System toundergo anMRIscan.\\nHorizontal, hydrogen proton ,closed bore scanners only.\\nMRImagnet strength of1.5T(64MHz) or3T(128MHz). See\\n\"ImageReady Defibrillation System Components for1.5Tand3T\"on\\npage D-1.\\nSpatial gradient nogreater than 20T/m(2,000 G/cm).\\nRFexposur elimits:\\n1.5T\\n• Normal Operating Modeamust beobserv edfortheentire active\\nscansession (whole body averaged SAR, ≤2.0watts/kilogram\\n(W/kg); Head SAR, ≤3.2W/kg)\\n3T(Patient landmark/scan isocenter atorsuperior totheC7vertebr a)\\n• Normal Operating Mode orFirstLevel Controlled Operating Mode\\nmust beobserved fortheentire active scansession\\n3T(Patient landmark/scan isocenter inferior totheC7vertebra)\\n• B1+rmsmust be≤2.8microtesla (µT)\\nWARNING: IftheB1+rmsparameter value isnotdisplayed onthe3T\\nMRIscanner system, donotperform 3Tscans withapatient landmark\\n(scan isocenter) inferior totheC7vertebr a.Such scans donotmeet the\\nRadiology Conditions ofUse.\\nMaximum specified gradien tslew rate≤200T/m/s peraxis.\\nThere arenorestrictions forpositioning thedefibrillation system\\nwithin theintegrated body coiloftheMRIscanner .Theuseofreceive-\\nonlycoilsisnotrestricted. Local transmit coilsmaybeused, but\\nshould notbeplaced directly overthedefibrillation system.\\nPatient insupine orprone position only.\\nPatient must becontinuously monitored bypulse oximetry and\\nelectrocar diograp hy(ECG) fortheentire duration inwhich thepulse\\ngenerator isinMRIProtection Mode. Ensure backupthera pyis\\navailable (external rescue) .Pre-scan\\n1.Ensure Cardio logyhascleared thepatient forscanning eligibility\\nbased ontheCardiolo gyMRIConditions ofUse(\"Cardiology Checklist\\nfortheImageReady Defibrillation System\" onpage A-1).\\n2.Asclose tothestartofthescanaspossible, thepatient’s pulse\\ngenerator isprogr ammed intoMRIProtection Mode andcontinuous\\nmonitoring ofthepatient begins.\\n3.Refer totheMRIProtection Settings Report toconfirm thatthe\\npatient’s device isinMRIProtection Mode. IftheTime-out feature is\\nused, thereport includes theexact time anddatewhen MRI\\nProtection Mode willexpire.Verifythatadequate timeremainsto\\ncomplete thescan.\\nDuringScan\\n4.Ensure thepatient iscontinuously monitored bypulse oximetry and\\nelectrocar diography (ECG), withbackup thera pyavailable (external\\nrescue), while thedevice isinMRIProtection Mode.\\nAfterscan\\n5.Ensure thepulse generator isreturned topre-MRI operation, either\\nautomatically iftheTime-out parameter wasset,ormanually using\\ntheProgr ammer .Perform follow-up testing ofthedefibrillation\\nsystem after exitingMRIProtection Mode, andcontinue patient\\nmonitoring untilthepulse generator isreturned topre-M RIoperation.\\na.Asdefined inIEC60601-2-33, 201.3.224, 3rdEdition.\\nWARNING: Unless alloftheMRIConditions ofUsearemet, MRIscanning ofthepatient does notmeet MR\\nConditional requirements fortheimplanted system, andsignificant harm toordeath ofthepatient and/or damage to\\ntheimplanted system mayresult.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 36}), Document(page_content='B-2RADIOLOGY CHECKLIST FORTHEIMAGEREADY DEFIBRILLATION SYSTEM\\nWARNING: TheProgr ammer isMRUnsafe andmust remain outside theMRIsiteZone III(and higher) asdefined by\\ntheAmerican College ofRadiology Guidanc eDocument onMRSafePractic es1.Under nocircumstanc esshould the\\nProgr ammer bebroughtintotheMRIscanner room, thecontrolroom, ortheMRIsiteZone IIIorIVareas.\\nCAUTION: Thepresen ceoftheimplanted defibrillation system maycause MRIimage artifacts.\\nFor3Tscans, when thepatient landmark (scan isocenter) isatorsuperior totheC7vertebra, thescanmust belimited\\ntoNormal Operating Mode orFirstLevel Controlled Operati ngMode. When thepatient landmark (scan isocen ter)is\\ninferior toC7,theB1+rmsparameter must belimited to≤2.8micro tesla (µT). Ifusing ascanner thatdoes notdisplay\\nB1+rms,donotscanat3Twhen thepatient landmark (scan isocen ter)isinferior toC7.\\nFigureB–1.LimitingParameters for3TMRIScanning\\n1. Kanal E,Barkovich AJ,BellC,etal.ACRguidance document onMRsafepractic es:2013. J.Magn. Reson. Imaging 2013;37:501-530.', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 37}), Document(page_content='C-1\\nDETERMINE BEEPERTYPE\\nAPPENDIX C\\nThepulse gener atorcontai nseither anArmatur eorPiezobeeper .\\n•TheArmature Beeper contains amagnetic component andmaybedamaged bythestrongmagnetic fields\\nassociated withMRIscanners. Before under going anMRIscan, thepatient andphysician should weigh the\\nbenefit oftheMRIscanagainst theriskoflosing beeper function. TheBeeper maybeinaudible duetoMRIscan,\\nandshould betested postMRIscan.\\n•ThePiezoBeeper does notcontain anymagnetic components, andisdesigned towithstand thestrongmagnetic\\nfields associated withMRIscanners without being damaged.\\nTodetermine theBeeper type, ensure theModel 3868 Programmer Softwar eApplication isversion 1.08orabove and\\ninterr ogate thedevice using theModel 3300 Progr ammer .\\nFigureC–1.BeeperTabArmature\\nNOTE: Screens willdiffer depending onbeeper typeandMRIProtection Mode availability .', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 38}), Document(page_content='C-2DETERMINE BEEPER TYPE', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 39}), Document(page_content='D-1\\nIMAGEREADY DEFIBRILLATION SYSTEMCOMPONENTS FOR1.5TAND3T\\nAPPENDIX D\\nOnly specific combination sofpulse gener ators andleads constitute anImageReady Defibrillation System thatisvalid\\nforusewith1.5Tor3Tscanners.\\nGrayshading ofmodel rowsindicates compon entscompatible withboth 1.5Tand3Tscanners. An‘x’indicates MR\\nConditional status atthemagnet strength indicated.\\nCRT-DPulseGenerators —ImageReady MRConditional Defibrillation SystemComponents\\nComponent ModelNumber(s) MRStatus 1.5T 3T\\nCRT-DPulseGenerators\\nAUTOGEN X4CRT-D G166, G168 MRConditional X\\nAUTOGEN CRT-D G160, G161 MRConditional X\\nDYNAGEN X4CRT-D G156, G158 MRConditional X\\nDYNAGEN CRT-D G150, G151 MRConditional X\\nINOGEN X4CRT-D G146, G148 MRConditional X\\nINOGEN CRT-D G140, G141 MRConditional X\\nMOMENTUM CRT-D X4 G128, G138 MRConditional X\\nMOMENTUM CRT-D G124, G125 MRConditional X\\nORIGEN X4CRT-D G056, G058 MRConditional X\\nORIGEN CRT-D G050, G051 MRConditional X\\nRESONATE HFCRT-DG524, G525, G528,\\nG548MRConditional X\\nG537, G547 MRConditional X X\\nRESONATE X4CRT-DG428, G448 MRConditional X\\nG437, G447 MRConditional X X\\nRESONATE CRT-D G424, G425 MRConditional X\\nVIGILANT X4CRT-DG228, G248 MRConditional X\\nG237, G247 MRConditional X X\\nVIGILANT CRT-D G224, G225 MRConditional X\\nICDPulseGenerators —ImageReady MRConditional Defibrillation SystemComponents\\nComponent ModelNumber(s) MRStatus 1.5T 3T\\nICDPulseGenerators\\nAUTOGEN ELICD D160, D161, D162, D163 MRConditional X\\nDYNAGEN ELICD D150, D151, D152, D153 MRConditional X\\nDYNAGEN MINI ICDD020, D021, D022,\\nD023MRConditional X\\nINOGEN ELICD D140, D141, D142, D143 MRConditional X\\nINOGEN MINI ICD D010, D011, D012, D013 MRConditional X', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 40}), Document(page_content='D-2IMAGEREADY DEFIBRILLATION SYSTEM COMPONENTS FOR1.5Tand3T\\nComponent ModelNumber(s) MRStatus 1.5T 3T\\nMOMENTUM ELICD D120, D121 MRConditional X\\nORIGEN ELICDD050, D051, D052,\\nD053MRConditional X\\nORIGEN MINI ICDD000, D001, D002,\\nD003MRConditional X\\nPERCIVA HFICDD500, D501 MRConditional X\\nD512, D513 MRConditional X X\\nPERCIVA ICDD400, D401 MRConditional X\\nD412, D413 MRConditional X X\\nRESONATE HFICDD520, D521 MRConditional X\\nD532, D533 MRConditional X X\\nRESONATE ELICDD420, D421 MRConditional X\\nD432, D433 MRConditional X X\\nVIGILANT ELICDD220, D221 MRConditional X\\nD232, D233 MRConditional X X\\nLeadsandAccessories—ImageReady MRConditional Defibrillation SystemComponents\\nComponent ModelNumber(s) MRStatus 1.5T 3T\\nLeadsandAccessories\\nRightAtrialLeadsandAccessories\\nFINELINE IISterox Pacing Leads 4479, 4480 MRConditional X X\\nFINELINE IISterox EZPacing Leads 4469, 4470, 4471,\\n4472, 4473, 4474MRConditional X X\\nSuture Sleeves forFINELINE IILeads 6220, 6221 MRConditional X X\\nINGEVITY MRIPacing Leads (Tined Fixation) 7735, 7736 MRConditional X X\\nINGEVITY MRIPacing Leads (Extendable/\\nRetractab leFixation)7740, 7741, 7742 MRConditional X X\\nINGEVITY+ Pacing Leads (Extendable/Retr actable\\nFixation)7840, 7841, 7842 MRConditional X X\\nSuture Sleeve forINGEVITY MRILeads 6402 MRConditional X X\\nIS-1Lead PortPlug 7145 MRConditional X X\\nRightVentricular LeadsandAccessories\\nENDO TAKRELIANCE (IS-1) Leads –Single Coil 0127, 0128, 0129, 0137,\\n0138, 0139, 0170, 0171,\\n0172, 0173, 0180, 0181,\\n0182, 0183MRConditional X\\nDF-1Lead PortPlugforENDO TAKRELIANCE (IS-1)\\nLeads –Single Coil6996 MRConditional X\\nENDO TAKRELIANCE (IS-1) Leads –Dual Coil 0143, 0147, 0148, 0149,\\n0153, 0157, 0158, 0159,\\n0174, 0175, 0176, 0177,\\n0184, 0185, 0186, 0187MRConditional X\\nENDO TAKRELIANCE (DF4) Defibrillation Leads 0262, 0263, 0265,\\n0266, 0272, 0273,MRConditional X X', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 41}), Document(page_content='IMAGEREADY DEFIBRILLATION SYSTEM COMPONENTS FOR1.5Tand3TD-3\\nComponent ModelNumber(s) MRStatus 1.5T 3T\\n0275, 0276, 0282,\\n0283, 0285, 0286,\\n0292, 0293, 0295,\\n0296\\nRELIANCE 4-FRONT (DF4) Defibrillation Leads 0636, 0650, 0651,\\n0652, 0653, 0654,\\n0655, 0657, 0658,\\n0662, 0663, 0665,\\n0672, 0673, 0675,\\n0676, 0682, 0683,\\n0685, 0686, 0692,\\n0693, 0695, 0696MRConditional X X\\nSuture Sleeve forRELIANCE 4-FRONT Leads 6403 MRConditional X X\\nLeftVentricular LeadsandAccessories\\nACUITY Spiral Leads 4591, 4592, 4593 MRConditional X\\nSuture Sleeve forACUITY Spiral Leads 6100 MRConditional X\\nACUITY X4(IS4)Pacing Leads 4671, 4672, 4674, 4675,\\n4677, 4678MRConditional X X\\nSuture Sleeve forACUITY X4Leads 4603 MRConditional X X\\nEASYTRAK 2(IS-1) Leads 4542, 4543, 4544 MRConditional X\\nSuture Sleeve forEASYTR AK2Leads 6773 MRConditional X\\nIS4/DF4 Lead PortPlug 7148 MRConditional X X\\nIS-1Lead PortPlug 7145 MRConditional X', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 42}), Document(page_content='D-4 IMAGEREADY DEFIBRILLATION SYSTEM COMPONENTS FOR1.5Tand3T', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 43}), Document(page_content='E-1\\nMRCONDITIONAL DEFIBRILLATOR PROGRAMMER REPORTS\\nAPPENDIX E\\n1\\n}\\n2\\n[1]Twenty-four hour time format isused. [2]Measurement Date column indicates thedatetheLeads Data were collected, which maybeprior tothedateoftheMRI\\nProtection Settings Report itself.\\nFigureE–1.SampleMRIProtectionSettingsReportprintoutwithTime-out setto6hours', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 44}), Document(page_content='E-2MRCONDITIONAL DEFIBRILLATOR PROGRAMMER REPORTS\\nFigureE–2.SampleMRIProtectionSettingsReportprintoutwithTime-out settoOff(Page1)\\nForRESONATE HF,RESONATE, PERCIVA HF,PERCIVA, VIGILANT, andMOMENTUM device s\\nFigureE–3.Samplestoredeventdetailprintout', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 45}), Document(page_content='F-1\\nSYMBOLSONPACKAGING\\nAPPENDIX F\\nThefollowing symbols maybeused onpackaging andlabeling.\\nTableF–1.SymbolsonPackaging\\nSymbol Description\\nMRConditional\\nReferenc eNumber', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 46}), Document(page_content='F-2Symbols onPackaging', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 47}), Document(page_content='INDEX\\nA\\nAbandoned leads orpulse gener ators 1-5\\nActive implantable medical devices(AIMDs) 1-7\\nACUITY Spiral 1-2\\nACUITY X41-2\\nArmatur eBeeper 2-10\\nArrhythmia Logbook 2-12\\nAUTOGEN 1-2\\nB\\nBattery capacity status 2-4\\nBeeper 2-14\\nC\\nCardiology Checklist A-1\\nClosed bore 1-5\\nCoils 1-7\\nreceive-only 1-5\\ntransm it1-5\\nConfigur eBeeper Settings 2-14\\nD\\nDIVERT THERAPY 2-13\\nDYNAGEN 1-2\\nE\\nEASYTRAK 21-2\\nElectr ocautery Mode 2-4\\nENDO TAKRELIANCE 1-2\\nF\\nFINELINE II1-2\\nFractured lead1-5\\nI\\nImage distortion 2-12ImageReady MRConditional Defibrillation System 1-2,1-5\\nINGEVITY MRI1-2\\nINGEVITY+ 1-2\\nINOGEN 1-2\\nIntrinsic amplitude 2-3,2-12–2-13\\nL\\nLead impedance 2-3,2-9,2-12–2-13\\nLeads\\nACUITY Spiral 1-2\\nACUITY X41-2\\nEASYTRAK 21-2\\nENDO TAKRELIANCE 1-2\\nFINELINE II1-2\\nINGEVITY MRI1-2\\nINGEVITY+ 1-2\\nRELIANCE 4–FRONT 1-2\\nM\\nMagnet sensor 2-9\\nMinute Ventilation 2-14\\nModels forusewith1.5T1-2\\nModels forusewith3T1-2\\nMOMENTUM 1-2\\nMonitoring patient 1-5,2-8\\nMRImagnet strength\\n1.5T1-2\\n1.5Tesla 1-2,1-5,1-7\\n3T1-2\\n3Tesla 1-2,1-5,1-7\\nMRIProte ction Checklist 2-5\\nMRIProte ction episode 2-12\\nMRIProte ction Mode 1-5,1-7,2-4\\nautomatic exit2-12\\nconditions preventing entry 2-4,2-9\\nentry into2-4\\nmanual exit2-7–2-8, 2-12\\nsuspended features andfunctions 2-3\\nTime-out feature 1-2,2-2–2-3, 2-7–2-8, 2-12–2-13\\nMRIProte ction Settings Report 2-2,2-8\\nN\\nNormal operati ngmode 1-5', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 48}), Document(page_content='O\\nOperating mode\\nnormal 1-5\\nORIGEN 1-2\\nP\\nPacing threshold 2-12–2-13\\nPacing threshold changes 1-11\\nPatient position 1-5,2-12\\nPERCIVA 1-2\\nPERCIVA HF1-2\\nProgrammer 1-2\\nProgrammer wand 2-4,2-7,2-12\\nPulse generators\\nAUTOGEN 1-2\\nDYNAGEN 1-2\\nINOGEN 1-2\\nMOMENTUM 1-2\\nORIGEN 1-2\\nPERCIVA 1-2\\nPERCIVA HF1-2\\nRESONATE 1-2\\nRESONATE HF1-2\\nVIGILANT 1-2\\nPulse oximetr y1-5,2-12\\nQ\\nQuick Refer ence Guide D-1\\nR\\nRadiology Checklist B-1\\nReceive-only coils1-5\\nRELIANCE 4–FRONT 1-2\\nReports E-1\\nRESONATE 1-2\\nRESONATE HF1-2\\nRFtelemetry 2-3–2-4, 2-12\\nS\\nSafety Coreopera tion2-4\\nSARlimits 1-5\\nSixweeks sinceimplant 1-5,1-11\\nSpecific Absorption Rate (SAR) limits 1-5\\nSTAT PACE 2-13\\nSTAT PACE mode 2-9\\nSTAT SHOCK 2-13STAT SHOCK mode 2-9\\nStorageMode 2-4,2-10\\nSystem integrity 2-12\\ncompromised 1-5\\nT\\nTachycar diaprotection 1-5\\nTesla\\n1.5T1-2,1-5,1-7\\n3T1-2,1-5,1-7\\nTime since implant 2-10\\nTransmit coils1-5\\nV\\nVentricular episode 2-9\\nVIGILANT 1-2', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 49}), Document(page_content='', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 50}), Document(page_content='Boston Scientific Corporation\\n4100 Hamline Avenue North\\nSt.Paul, MN55112–5798 USA\\nwww.bostonscientific.com\\n1.800.CARDIAC (227.3422)\\n+1.651.582.4000\\n©2020 Boston Scientific Corporation oritsaffiliates.\\nAllrights reserved.\\n51114094-001 ENUS2020-08\\n*51114094-001*', metadata={'source': 'raw_data/51114094-001A_IMAGEREADY_MRITG_en_S.pdf', 'page': 51}), Document(page_content='1ImageReadyTM MR Conditional Defibrillation System \\nPatient Guide for MRI Scans\\nOverview \\nMagnetic Resonance Imaging (MRI) is a diagnostic test that uses a powerful magnet and radio waves to produce \\nimages of the human body. Most defibrillation systems are not compatible with an MRI scan procedure or with being near MRI scanners. However, some defibrillator patients need to have MRI scans to diagnose their health conditions and determine proper treatment. Boston Scientific has a defibrillation system that can be scanned when certain conditions are met. This includes programming the defibrillator to special settings for MRI.\\nYou MAY be eligible to have an MRI scan if you are implanted with the Boston Scientific ImageReady MR Conditional \\nDefibrillation System which has been tested for use with MRI scans. Your heart doctor or healthcare provider will work with you to determine if you and your defibrillation system can undergo an MRI scan.\\nTalk to your heart doctor about the risks and benefits of having an MRI scan.\\nYour defibrillator system contains an Armature or Piezo Beeper. The Piezo Beeper is designed to withstand the \\nstrong magnetic fields associated with MRI scanners without being damaged. The Armature Beeper contains a magnetic component, therefore coming into contact with the strong magnetic field of an MRI scanner may cause a permanent loss of Armature Beeper volume on the defibrillator. Talk to your heart doctor to determine the beeper type in your defibrillator system. For Armature Beeper, talk to your heart doctor to weigh the benefit of the MRI procedure against the risk of losing the Beeper.\\nCommon Questions \\nTo be eligible for an MRI scan, you must have an ImageReady MR Conditional Defibrillation System implanted. The clinic performing the scan must use an MRI machine that meets the conditions of use of the ImageReady Defibrillation System. \\nCommon questions include:\\n1. Am I able to have an MRI scan? \\n• If a healthcare provider recommends an MRI scan, talk to your heart doctor before scheduling your MRI \\nscan.\\n• Coming into contact with the strong magnetic field of an MRI scanner may cause a permanent loss of the Armature Beeper volume on the defibrillator. Talk to your heart doctor to weigh the benefit of the MRI procedure against the risk of losing the Armature Beeper.\\n• Your heart doctor will check you and your ImageReady Defibrillation System to determine if you are eligible for an MRI scan.\\n• Even if your defibrillation system is eligible, you may have other implanted devices or metal in your body that may prevent you from having an MRI scan.\\nThe following is a trademark of Boston Scientific Corporation or its affiliates: IMAGEREADY.', metadata={'source': 'raw_data/51114097-001A_ImageReady_MRIPG_en_S.pdf', 'page': 0}), Document(page_content='2• You must be physically capable of having an MRI scan. This means that you can lay flat during the scan, and \\ntolerate how the defibrillator functions during the scan.\\n• Always check with your heart doctor or a healthcare provider if you have questions before or after the MRI \\nscan.  \\n2. What can I expect during an MRI scan? \\n• Your implanted defibrillation system is listed on your current medical device ID card. You should keep this \\ncard with you at all times, and take it with you to the MRI facility.\\n• Before the scan, your defibrillator will be programmed to the MRI settings. These settings are necessary for you to receive an MRI scan. While programmed to these settings, the device cannot deliver shocks and may not provide pacing therapy. Your heart rate may feel different from what you are accustomed to. Therefore, talk to your heart doctor to understand the monitoring you will receive for the entire time your defibrillation system is in the MRI settings.\\n• Your defibrillator may stay in the MRI settings for a limited time. If so, you or your caregiver may be notified of the duration of time your device will remain in the MRI settings. The MRI scan needs to be completed before that time expires.\\n• You may see signs at the MRI facility that warn you not to enter if you have a defibrillator. These signs apply to defibrillation systems that are not eligible, programmed, and cleared to have an MRI scan. Always check with a healthcare provider if you have questions.\\n• During the MRI scan, you may experience the following: \\n - Loud noises are part of a normal MRI scan; the noises are not coming from your defibrillator.\\n - Slight movement, vibration, or a warm sensation from the defibrillator.\\n3. What happens after the scan? \\n• After the scan, follow the directions provided by your heart doctor or healthcare provider.\\n• Your implanted ImageReady Defibrillation System may be checked after the MRI to ensure it is working normally. The defibrillation system may be manually programmed out of the MRI settings, or it may return to your normal settings automatically after a specific period of time set by your heart doctor.\\n• Due to the potential permanent loss of Armature Beeper volume on the defibrillator caused by an MRI scan, your heart doctor may recommend using a patient monitoring system or more frequent in-clinic follow-ups after an MRI scan.\\n• If you experience any new symptoms after the scan, contact your heart doctor or healthcare provider.\\n• If you need additional MRI scans, you and your ImageReady Defibrillation System must be checked for eligibility for a scan each time. If your implanted defibrillation system has changed, for example by implant of a new defibrillator or lead wires, or if aspects of your health have changed, it is possible that you are no longer eligible for an MRI scan.  ', metadata={'source': 'raw_data/51114097-001A_ImageReady_MRIPG_en_S.pdf', 'page': 1}), Document(page_content='3', metadata={'source': 'raw_data/51114097-001A_ImageReady_MRIPG_en_S.pdf', 'page': 2}), Document(page_content='4For additional reference information, go to \\nwww.bostonscientific.com/patientlabeling.\\n          Manufacturer\\nBoston Scientific Corporation \\n4100 Hamline Avenue North  St. Paul, MN 55112-5798 USA  Tel: 651.582.4000  Medical Professionals:  \\n1.800.CARDIAC (227.3422)  Patients and Families:  \\n1.866.484.3268  www.bostonscientific.com\\n© 2020 Boston Scientific Corporation or its affiliates. \\nAll rights reserved. \\n51114097-001  en USA  2020-10 \\n*51114097-001*', metadata={'source': 'raw_data/51114097-001A_ImageReady_MRIPG_en_S.pdf', 'page': 3}), Document(page_content='PHYSICIAN’S TECHNICAL MANUAL\\nRESONATE™HFICD,\\nRESONATE™ELICD,\\nPERCIVA™HFICD,\\nPERCIVA™ICD,\\nVIGILANT™ELICD,\\nMOMENTUM™ELICD\\nIMPLANTABLE CARDIOVERTER DEFIBRILLATOR\\nREFD520,D521,D532,D533,D420,D421,D432,D433,D500,D501,D512,D513,D400,D401,\\nD412,D413,D220,D221,D232,D233,D120,D121\\nCAUTION: Federallaw(USA)restricts\\nthisdevicetosalebyoronthe\\norderofaphysician trainedor\\nexperiencedindeviceimplantand\\nfollow-up procedures.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 0}), Document(page_content='', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 1}), Document(page_content='TableofContents\\nTrademarkStatement ..........................................................................................................................1\\nAdditional Information .........................................................................................................................1\\nDeviceDescription ...............................................................................................................................1\\nRelatedInformation .............................................................................................................................4\\nIndications andUsage..........................................................................................................................5\\nContraindications................................................................................................................................5\\nWarnings...........................................................................................................................................6\\nPrecautions........................................................................................................................................8\\nSupplemental Precautionary Information ...............................................................................................20\\nPost-TherapyPulseGeneratorFollowUp......................................................................................20\\nMagneticResonance Imaging(MRI)..............................................................................................21\\nTranscutaneous ElectricalNerveStimulation (TENS).........................................................................24\\nElectrocautery andRadioFrequency (RF)Ablation...........................................................................25\\nIonizingRadiation ....................................................................................................................26\\nElevatedPressures....................................................................................................................27\\nPotentialAdverseEvents....................................................................................................................29\\nMechanical Specifications. ....................................................................................................................31\\nItemsIncludedinPackage..................................................................................................................35\\nSymbolsonPackaging .......................................................................................................................36\\nCharacteristics asShipped...................................................................................................................40\\nX-RayIdentifier.................................................................................................................................42\\nFederalCommunications Commission (FCC)............................................................................................43\\nPulseGenerator Longevity ..................................................................................................................43\\nWarrantyInformation .........................................................................................................................49\\nProductReliability .............................................................................................................................50\\nPatientCounseling Information ............................................................................................................50', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 2}), Document(page_content='PatientHandbook ....................................................................................................................52\\nLeadConnections ..............................................................................................................................52\\nImplanting thePulseGenerator...........................................................................................................55\\nCheckEquipment .....................................................................................................................56\\nInterrogate andCheckthePulseGenerator....................................................................................56\\nImplanttheLeadSystem...........................................................................................................57\\nTakeBaselineMeasurements. .....................................................................................................59\\nFormtheImplantation Pocket......................................................................................................61\\nConnecttheLeadstothePulseGenerator .....................................................................................63\\nEvaluateLeadSignals...............................................................................................................66\\nProgramthePulseGenerator .....................................................................................................69\\nTestforAbilitytoConvertVentricular Fibrillation andInducible\\nArrhythmias ....................................................................................................................71\\nTachyarrhythmia ProgrammingConsiderations. ..............................................................................74\\nImplantthePulseGenerator. ......................................................................................................76\\nComplete andReturntheImplantation Form..................................................................................77\\nBidirectional TorqueWrench.................................................................................................................77\\nFollowUpTesting.............................................................................................................................79\\nExplantation andDisposal....................................................................................................................81', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 3}), Document(page_content='1TRADEMARK STATEMENT\\nThefollowing aretrademarks ofBostonScientificCorporation oritsaffiliates:\\nAcuShock, EASYVIEW ,ENDURALIFE,HeartLogic, IMAGEREADY ,LATITUDE, MOMENTUM, Onset/Stability ,\\nPaceSafe, PERCIVA,QuickConvert, QUICKNOTES, RESONA TE,RHYTHM ID,RHYTHMMA TCH,\\nRYTHMIQ, SafetyCore,SmartBlanking, VENTAK,VIGILANT ,ZIP,ZOOM,ZOOMVIEW.\\nADDITIONAL INFORMATION\\nForadditional referenceinformation, gotowww.bostonscientific -elabeling.com.\\nDEVICEDESCRIPTION\\nThismanualcontainsinformation abouttheRESONATE HF,RESONATE, PERCIVAHF,PERCIVA,VIGILANT, andMOMENTUM\\nfamiliesofimplantable cardioverterdefibrillators (ICDs),whichcontainthefollowing typesofpulsegenerators (specificmodels\\narelistedin\"Mechanical Specifications\" onpage31):\\n•VR—single-chamber ICDcombining ventricular tachyarrhythmia therapywithventricular pacingandsensing\\n•DR—dual-chamber ICDcombining ventricular tachyarrhythmia therapywithventricular andatrialpacingandsensing\\nNOTE:Thismanualmaycontaininformation formodelnumbersthatarenotcurrentlyapproved forsaleinallgeographies.\\nForacompletelistofmodelnumbersapproved inyourgeography ,consultwithyourlocalsalesrepresentative. Somemodel\\nnumbersmaycontainfewerfeatures;forthosedevices,disregardinformation aboutunavailable features.\\nNOTE:RESONATE HF,RESONATE, PERCIVAHF,PERCIVA,VIGILANT, andMOMENTUM devicesareconsideredMRConditional.\\nReferto\"Magnetic ResonanceImaging(MRI)\"onpage21andtheImageReady MRConditional Defibrillation SystemMRI\\nTechnicalGuideformoreinformation.\\nTherapies\\nThesepulsegenerators haveasmall,thin,physiologic shapethatminimizespocketsizeandmayminimizedevicemigration.\\nTheyprovideavarietyoftherapies, including:', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 4}), Document(page_content='2•Ventricular tachyarrhythmia therapy,whichisusedtotreatrhythmsassociated withsuddencardiacdeath(SCD)suchas\\nVTandVF\\n•Bradycardiapacing,includingadaptiveratepacing,todetectandtreatbradyarrhythmias andtoprovidecardiacrate\\nsupportafterdefibrillation therapy\\nCardioversion/defibrillation therapiesinclude:\\n•Arangeoflow-andhigh-energy shocksusingabiphasicwaveform\\n•Thechoiceofmultipleshockvectors:\\n–Distalshockelectrode toproximalshockelectrode andpulsegenerator case(TRIADelectrode system)\\n–Distalshockelectrode toproximalshockelectrode (RVCoiltoRACoil)\\n–Distalshockelectrode topulsegenerator case(RVCoiltoCan)\\nLeads\\nThepulsegenerator hasindependently programmable outputsandacceptsoneormoreofthefollowing leads,depending on\\nthemodel:\\n•OneIS-11atriallead\\n•OneDF-1/IS-12cardioversion/defibrillation lead\\n•OneDF4-LLHH orDF4-LLHO3multipolar connector cardioversion/defibrillation lead\\nLeadswitheitheraGDT-LLHH/LLHO orDF4-LLHH/LLHO labelareequivalent andarecompatiblewithadevicecontainingeither\\naGDT-LLHH orDF4-LLHH port.\\nThepulsegenerator andtheleadsconstitute theimplantable portionofthepulsegenerator system.\\n1.IS-1referstotheinternational standardISO5841-3:2013.\\n2.DF-1referstotheinternational standardISO11318:2002.\\n3.DF4referstotheinternational standardISO27186:2010.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 5}), Document(page_content=\"3NOTE:UseofBostonScientificMRConditional leadsisrequiredforanimplanted systemtobeconsideredMRConditional.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnicalGuideformodelnumbersofpulsegenerators,\\nleads,accessories,andothersystemcomponents neededtosatisfytheConditions ofUse.\\nProgramming System\\nThesepulsegenerators canonlybeusedwiththeModel3300LATITUDE ProgrammingSystem.TheLATITUDE Programming\\nSystemistheexternalportionofthepulsegenerator system.\\nNOTE:The2868softwareapplication onthemodel3120LATITUDE programmingsystemisoutdatedandshouldnotbeused\\nwiththepulsegenerators. Forassistance, call+1.651.582.4000 (worldwide) orcontactyourlocalBostonScientificrepresentative.\\nThe3300LATITUDE ProgrammingSystemincludes:\\n•Model3300Programmer\\n•Model3868SoftwareApplication\\n•Model6395AccessoryTelemetry Wand\\nYoucanusetheprogrammingsystemtodothefollowing:\\n•Interrogate thepulsegenerator\\n•Programthepulsegenerator toprovideavarietyoftherapyoptions\\n•Accessthepulsegenerator's diagnostic features\\n•Performnoninvasive diagnostic testing\\n•Accesstherapyhistorydata\\n•Storea12secondtraceoftheECG/EGM displayfromanyscreen\\n•Accessaninteractive Demonstration ModeorPatientDataModewithoutthepresenceofapulsegenerator\\n•Printpatientdataincludingpulsegenerator therapyoptionsandtherapyhistorydata\\n•Savepatientdata\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 6}), Document(page_content=\"4Youcanprogramthepulsegenerator usingtwomethods: automatically usingIndications-Based Programming(IBP)or\\nmanually.\\nRELATEDINFORMATION\\nRefertothelead'sinstruction manualforimplantinformation, generalwarningsandprecautions, indications, contraindications,\\nandtechnicalspecifications. Readthismaterialcarefullyforimplantprocedureinstructions specifictothechosenlead\\nconfigurations.\\nRefertothePRMsystemOperator's ManualorZOOMWirelessTransmitterReferenceGuideforspecificinformation aboutthe\\nPRMorZOOMWirelessTransmitter suchassetup,maintenance, andhandling.\\nRefertothesepulsegenerators’ ReferenceGuideforadditional referenceinformation suchasusingthePRMsoftware,\\ntachyarrhythmia detection andtherapy,pacingtherapy,sensing,anddiagnostics.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnicalGuideforinformation aboutMRIscanning.\\nRefertotheHeartLogic TechnicalGuideforinformation abouttheHeartLogic HeartFailureDiagnostic Service.\\nLATITUDE NXTisaremotemonitoring systemthatprovidespulsegenerator dataforclinicians. Allpulsegenerators described in\\nthismanualaredesignedtobeLATITUDE NXTenabled;availability variesbyregion.\\n•Physicians/Clinicians—LATITUDE NXTenablesyoutoperiodically monitorbothpatientanddevicestatusremotelyand\\nautomatically .TheLATITUDE NXTsystemprovidespatientdatathatcanbeusedaspartoftheclinicalevaluation ofthe\\npatient.\\n•Patients—A keycomponent ofthesystemistheLATITUDE Communicator ,aneasy-to-use, in-homemonitoring device.\\nTheCommunicator automatically readsimplanted devicedatafromacompatible BostonScientificpulsegenerator at\\ntimesscheduled bythephysician. TheCommunicator sendsthisdatatotheLATITUDE NXTsecureserver.TheLATITUDE\\nNXTserverdisplaysthepatientdataontheLATITUDE NXTWebsite,whichisreadilyaccessibleovertheInternetto\\nauthorized physicians andclinicians.\\nRefertotheLATITUDE NXTClinicianManualformoreinformation.\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 7}), Document(page_content='5INTENDED AUDIENCE\\nThisliteratureisintendedforusebyprofessionalstrainedorexperience dindeviceimplantand/orfollow-up procedures.\\nINDICATIONS ANDUSAGE\\nBostonScientificimplantable cardioverter defibrillators (ICDs)areintendedtoprovideventricular antitachycardia pacing(ATP)\\nandventricular defibrillation forautomated treatment oflife-threatenin gventricular arrhythmias.\\nCONTRAINDICATIONS\\nTheseBostonScientificpulsegenerators arecontraindicatedforthefollowing patients:\\n•Patientswhoseventricular tachyarrhythmias mayhavereversiblecause,suchas:\\n•Digitalisintoxication\\n•Electrolyte imbalance\\n•Hypoxia\\n•Sepsis\\n•Patientswhoseventricular tachyarrhythmias haveatransientcause,suchas:\\n•Acutemyocardial infarction (MI)\\n•Electrocution\\n•Drowning\\n•Patientswhohaveaunipolarpacemaker', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 8}), Document(page_content=\"6WARNINGS\\nGeneral\\n•Labelingknowledge. Readthismanualthoroughly beforeimplantation toavoiddamagetothepulsegenerator and/or\\nlead.Suchdamagecanresultinpatientinjuryordeath.\\n•Forsinglepatient/singleprocedureuseonly.Donotreuse,reprocess,orresterilize.Reuse,reprocessing,or\\nresterilization maycompromisethestructuralintegrityofthedeviceand/orleadtodevicefailurewhich,inturn,mayresult\\ninpatientinjury,illness,ordeath.Reuse,reprocessing,orresterilization mayalsocreateariskofcontamination ofthe\\ndeviceand/orcausepatientinfectionorcross-infection, including, butnotlimitedto,thetransmission ofinfectious\\ndisease(s) fromonepatienttoanother.Contamination ofthedevicemayleadtoinjury,illness,ordeathofthepatient.\\n•Backupdefibrillation protection. Alwayshaveexternaldefibrillation equipment availableduringimplantand\\nelectrophysiologic testing.Ifnotterminated inatimelyfashion,aninducedventricular tachyarrhythmia canresultinthe\\npatient'sdeath.\\n•Resuscitation availability .Ensurethatanexternaldefibrillator andmedicalpersonnel skilledinCPRarepresentduring\\npost-implantdevicetestingshouldthepatientrequireexternalrescue.\\n•Separatepulsegenerator. Donotusethispulsegenerator withanotherpulsegenerator.Thiscombination couldcause\\npulsegenerator interaction, resultinginpatientinjuryoralackoftherapydelivery.\\nHandling\\n•Avoidshockduringhandling. Programthepulsegenerator TachyMode(s)toOffduringimplant,explant,orpostmortem\\nprocedurestoavoidinadvertent highvoltageshocks.\\n•Donotkinkleads.Donotkink,twist,orbraidtheleadwithotherleadsasdoingsocouldcauseleadinsulation abrasion\\ndamageorconductordamage.\\n•HandlingtheleadwithoutConnector Tool.ForleadsthatrequiretheuseofaConnector Tool,usecautionhandlingthe\\nleadterminalwhentheConnector Toolisnotpresentonthelead.Donotdirectlycontacttheleadterminalwithany\\nsurgicalinstruments orelectricalconnections suchasPSA(alligator) clips,ECGconnections, forceps,hemostats, and\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 9}), Document(page_content='7clamps.Thiscoulddamagetheleadterminal,possiblycompromisingthesealingintegrityandresultinlossoftherapyor\\ninappropriatetherapy,suchasashortwithintheheader.\\n•Handlingtheterminalwhiletunneling. DonotcontactanyotherportionoftheDF4–LLHH orDF4–LLHO leadterminal,\\notherthantheterminalpin,evenwhentheleadcapisinplace.\\nProgramming andDeviceOperations\\n•Atrialtrackingmodes.Donotuseatrialtrackingmodesinpatientswithchronicrefractoryatrialtachyarrhythmias.\\nTrackingofatrialarrhythmias couldresultinventricular tachyarrhythmias.\\nPost-Implant\\n•Protectedenvironments. Advisepatientstoseekmedicalguidancebeforeenteringenvironments thatcouldadversely\\naffecttheoperation oftheactiveimplantable medicaldevice,includingareasprotected byawarningnoticethatprevents\\nentrybypatientswhohaveapulsegenerator.\\n•MagneticResonance Imaging(MRI)exposure. RESONATE HF,RESONATE, PERCIVAHF,PERCIVA,VIGILANT and\\nMOMENTUM devicesareconsideredMRConditional. Forthesedevices,unlessalloftheMRIConditions ofUsearemet,\\nMRIscanningofthepatientdoesnotmeetMRConditional requirements fortheimplanted system.Significant harmtoor\\ndeathofthepatientand/ordamagetotheimplanted systemmayresult.Donotexposepatientswithnon-MRConditional\\ndevicestoMRIscanning. Strongmagneticfieldsmaydamagethepulsegenerator and/orleadsystem,possiblyresulting\\nininjurytoordeathofthepatient.\\nForpotentialadverseeventsapplicable whentheConditions ofUsearemetornotmet,refertotheImageReady MR\\nConditional Defibrillation SystemMRITechnicalGuide.Foradditional warnings, precautions, andConditions ofUse,refer\\nto\"Magnetic ResonanceImaging(MRI)\"onpage21.\\n•Diathermy .Donotsubjectapatientwithanimplanted pulsegenerator and/orleadtodiathermy sincediathermy may\\ncausefibrillation, burningofthemyocardium, andirreversible damagetothepulsegenerator becauseofinduced\\ncurrents.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 10}), Document(page_content='8•EnsurePTMisenabled. Ifdesired,ensurethatPatientTriggered Monitorisenabledpriortosendingthepatienthomeby\\nconfirming theMagnetResponse isprogrammedtoStoreEGM.Ifthefeatureisinadvertently leftintheInhibitTherapy\\nsetting,thepatientcouldpotentially disabletachyarrhythmia detection andtherapy.\\n•MagnetResponse settoInhibitTherapy.OncethePatientTriggered Monitorfeaturehasbeentriggeredbythemagnet\\nandanEGMhasbeenstored,orafter60dayshaveelapsedfromthedaythatStoreEGMwasenabled,theMagnet\\nResponse programmingautomatically willbesettoInhibitTherapy.Whenthishappens,thepatientshouldnotapplythe\\nmagnetbecausetachyarrhythmia therapycouldbeinhibited.\\nPRECAUTIONS\\nClinicalConsiderations\\n•Pacemaker-mediated tachycardia (PMT).Programmingminimum PVARPlessthanretrogradeV–Aconduction may\\nincreasethelikelihood ofaPMT.\\n•MVSensormodes.ThesafetyandefficacyoftheMVSensormodeshavenotbeenclinicallyestablished inpatientswith\\nabdominal implantsites.\\n•MVSensormodeperformance. MVSensorperformance maybeadversely affectedundertransientconditions suchas\\npneumothorax, pericardial effusion,orpleuraleffusion.ConsiderprogrammingtheMVSensorOffuntiltheseconditions\\nareresolved.\\n•Adaptive-rate modes.Adaptive-rate modesbasedcompletelyorinpartonMVmightbeinappropriateforpatientswho\\ncanachieverespiratorycyclesshorterthanonesecond(greaterthan60breathsperminute).Higherrespiration rates\\nattenuate theimpedance signal,whichdiminishes theMVrateresponse(i.e.,thepacingratewilldroptowardthe\\nprogrammedLRL).\\nAdaptive-rate modesbasedcompletely orinpartonMVshouldnotbeusedforpatientswith:\\n•Aseparatepacemaker\\n•Aleadotherthanabipolartransvenous lead—MVmeasurement hasonlybeentestedwithabipolartransvenous\\nlead', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 11}), Document(page_content=\"9•Amechanical ventilator—use oftheventilator mightresultinaninappropriate MVSensor-drivenrate\\nSterilization andStorage\\n•Ifpackageisdamaged. Theblistertraysandcontentsaresterilizedwithethyleneoxidegasbeforefinalpackaging.\\nWhenthepulsegenerator and/orleadisreceived,itissterileprovidedthecontainer isintact.Ifthepackaging iswet,\\npunctured,opened,orotherwise damaged, returnthepulsegenerator and/orleadtoBostonScientific.\\n•Ifdeviceisdropped.Donotimplantadevicewhichhasbeendroppedwhileoutsideofitsintactshelfpackage.Donot\\nimplantadevicewhichhasbeendroppedfromaheightofmorethan24inches(61cm)whilewithinitsintactshelf\\npackage.Sterility,integrity,and/orfunctioncannotbeguaranteedundertheseconditions, andthedeviceshouldbe\\nreturnedtoBostonScientificforinspection.\\n•Storagetemperature andequilibration. Recommended storagetemperaturesare0°C–50°C (32°F–122°F). Allowthe\\ndevicetoreachapropertemperatur ebeforeusingtelemetry communication capabilities, programming,orimplanting the\\ndevicebecausetemperatur eextremesmayaffectinitialdevicefunction.\\n•Devicestorage.Storethepulsegenerator inacleanareaawayfrommagnets, kitscontaining magnets, andsourcesof\\nEMItoavoiddevicedamage.\\n•Usebydate.Implantthepulsegenerator and/orleadbeforeorontheUSEBYdateonthepackagelabelbecausethis\\ndatereflectsavalidatedshelflife.Forexample,ifthedateisJanuary1,donotimplantonorafterJanuary2.\\nImplantation\\n•Expectedbenefits. Determine whethertheexpecteddevicebenefitsprovidedbyprogrammable optionsoutweigh the\\npossibility ofmorerapidbatterydepletion.\\n•Evaluatepatientforsurgery.Theremaybeadditional factorsregardingthepatient'soverallhealthandmedical\\nconditionthat,whilenotrelatedtodevicefunctionorpurpose,couldrenderthepatientapoorcandidate forimplantation\\nofthissystem.Cardiachealthadvocacygroupsmayhavepublished guidelines thatmaybehelpfulinconductingthis\\nevaluation.\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 12}), Document(page_content='10•Leadcompatibility .Priortoimplantation, confirmthelead-to-pulse generator compatibility .Usingincompatible leads\\nandpulsegenerators candamagetheconnector and/orresultinpotentialadverseconsequenc es,suchasundersensing of\\ncardiacactivityorfailuretodelivernecessary therapy.\\n•Telemetry wand.Makesureasteriletelemetry wandisavailableshouldlossofZIPtelemetry occur.Verifythatthewand\\ncaneasilybeconnectedtotheprogrammerandiswithinreachofthepulsegenerator.\\n•Line-powered equipment. Exerciseextremecautioniftestingleadsusingline-powere dequipment becauseleakage\\ncurrentexceeding10µAcaninduceventricular fibrillation. Ensurethatanyline-powere dequipment iswithin\\nspecifications.\\n•Replacement device.Implanting areplacement deviceinasubcutaneous pocketthatpreviously housedalargerdevice\\nmayresultinpocketairentrapment, migration, erosion,orinsufficient grounding betweenthedeviceandtissue.Irrigating\\nthepocketwithsterilesalinesolutiondecreases thepossibility ofpocketairentrapment andinsufficient grounding.\\nSuturingthedeviceinplacereducesthepossibility ofmigrationanderosion.\\n•Donotbendtheleadnearthelead-header interface. Inserttheleadterminalstraightintotheleadport.Donotbend\\ntheleadnearthelead-header interface. Improperinsertioncancauseinsulation orconnectordamage.\\n•Absenceofalead.Theabsenceofaleadorpluginaleadportmayaffectdeviceperformance andpotentially leavethe\\npatientwithouteffectivetherapy.Ifaleadisnotused,verifythattheplugandlabeledheaderportmatch(i.e.,IS-1,DF-1,\\norDF4).Fullyinserttheplugintheunusedportandthentightenthesetscrewontotheplug.Verifyappropriat edevice\\nfunctionusingtheprogrammer.\\n•Afunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriate sensingandpacinginall\\nchambers, regardlessofprogrammedconfiguration.ThisincludesdualchamberdevicesprogrammedtoAAI(R).\\n•Lackofafunctional RVleadmayresultinundersensing, and/oroversensing andleavethepatientwithouteffective\\ntherapy.\\n•Electrodeconnections.Donotinsertaleadintothepulsegenerator connector withouttakingthefollowing precautions\\ntoensureproperleadinsertion:', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 13}), Document(page_content='11•Insertthetorquewrenchintothepreslitdepression ofthesealplugbeforeinsertingtheleadintotheport,to\\nreleaseanytrappedfluidorair.\\n•Visuallyverifythatthesetscrewissufficiently retractedtoallowinsertion. Usethetorquewrenchtoloosenthe\\nsetscrewifnecessary.\\n•Fullyinserteachleadintoitsleadportandthentightenthesetscrewontotheterminalpin.\\n•Defibrillation leadimpedance. Iftotalshockingleadimpedance duringimplantislessthan20Ω,verifytheproximalcoil\\nisnotincontactwiththepulsegenerator surface.Ameasurement oflessthan20Ωisanindication ofashortsomewhere\\ninthesystem.Ifrepeatedmeasurements showthetotalshockingleadimpedance islessthan20Ω,theleadand/orpulse\\ngenerator mayneedtobereplaced.\\n•Shuntingenergy.Donotallowanyobjectthatiselectrically conductive tocomeintocontactwiththeleadordevice\\nduringinduction becauseitmayshuntenergy,resultinginlessenergygettingtothepatient,andmaydamagethe\\nimplanted system.\\n•Donotsuturedirectlyoverlead.Donotsuturedirectlyovertheleadbody,asthismaycausestructural damage.Usethe\\nsuturesleevetosecuretheleadproximaltothevenousentrysitetopreventleadmovement.\\n•MVSensor.DonotprogramtheMVSensortoOnuntilafterthepulsegenerator hasbeenimplanted andsystemintegrity\\nhasbeentestedandverified.\\n•Programming MVSensorforrespiratory disorders orabnormal breathing. Forpatientswithrespiratorydisordersor\\nabnormal breathing patterns,thephysician shouldusemedicaljudgment whenprogrammingtheMVSensortoOn.To\\nmitigateinappropriate sensor-drivenrates,thephysician mayevaluatetherateresponseandconsideralowerResponse\\nFactor.\\nDeviceProgramming\\n•Devicecommunication. Useonlythedesignated programm erandsoftwareapplication tocommunicatewiththispulse\\ngenerator.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 14}), Document(page_content='12•STATPACEsettings. Whenapulsegenerator isprogrammedtoSTATPACEsettings,itwillcontinuetopaceatthehigh-\\nenergySTATPACEvaluesifitisnotreprogrammed.TheuseofSTATPACEparameters willlikelydecreasedevicelongevity.\\n•Pacingandsensingmargins.ConsiderleadmaturationinyourchoiceofPacingAmplitude, pacingPulseWidth,and\\nSensitivity settings.\\n•AnacutePacingThreshold greaterthan1.5VorachronicPacingThreshold greaterthan3Vcanresultinlossof\\ncapturebecausethresholds mayincreaseovertime.\\n•AnR-WaveAmplitude lessthan5mVoraP-WaveAmplitude lessthan2mVcanresultinundersensing because\\nthesensedamplitude maydecreaseafterimplantation.\\n•PacingLeadImpedance shouldbegreaterthantheprogrammedLowImpedance Limitandlessthanthe\\nprogrammedHighImpedanceLimit.\\n•Properprogramming oftheshockvector.IftheShockVectorisprogrammedtoRVcoil>>RAcoilandtheleaddoesnot\\nhaveanRAcoil,shockingwillnotoccur.\\n•Programming forsupraventricular tachyarrhythmias (SVTs).Determine ifthedeviceandprogrammable optionsare\\nappropriate forpatientswithSVTsbecauseSVTscaninitiateunwanted devicetherapy.\\n•Adaptive-rate pacing.Rateadaptivepacingshouldbeusedwithcareinpatientswhoareunabletotolerateincreased\\npacingrates.\\n•Ventricular refractory periods(VRPs)inadaptive-rate pacing.Adaptive-rate pacingisnotlimitedbyrefractoryperiods.\\nAlongrefractoryperiodprogrammedincombination withahighMSRcanresultinasynchronous pacingduringrefractory\\nperiodssincethecombination cancauseaverysmallsensingwindowornoneatall.UseDynamicAVDelayorDynamic\\nPVARPtooptimizesensingwindows. IfyouareprogrammingafixedAVDelay,considerthesensingoutcomes.\\n•Shockwaveform polarity.ForIS-1/DF-1leads,neverchangetheshockwaveform polaritybyphysically switching thelead\\nanodesandcathodesinthepulsegenerator header—usetheprogramm ablePolarityfeature.Devicedamageor\\nnonconversion ofthearrhythmia post-operatively mayresultifthepolarityisswitchedphysically.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 15}), Document(page_content=\"13•TachyModetoOff.Topreventinappropriate shocks,ensurethatthepulsegenerator's TachyModeisprogrammedtoOff\\nwhennotinuseandbeforehandlingthedevice.Fortachyarrhythmia detection andtherapy,verifythattheTachyModeis\\nprogrammedtoMonitor+Therapy.\\n•Atrialoversensing. Takecaretoensurethatartifactsfromtheventricles arenotpresentontheatrialchannel,oratrial\\noversensing mayresult.Ifventricular artifactsarepresentintheatrialchannel,theatrialleadmayneedtoberepositioned\\ntominimizeitsinteraction.\\n•ATRentrycount.ExercisecarewhenprogrammingtheEntryCounttolowvaluesinconjunction withashortATR\\nDuration.Thiscombinationallowsmodeswitching withveryfewfastatrialbeats.Forexample,iftheEntryCountwas\\nprogrammedto2andtheATRDurationto0,ATRmodeswitching couldoccuron2fastatrialintervals.Intheseinstances,\\nashortseriesofprematureatrialeventscouldcausethedevicetomodeswitch.\\n•ATRexitcount.ExercisecarewhenprogrammingtheExitCounttolowvalues.Forexample,iftheExitCountwas\\nprogrammedto2,afewcyclesofatrialundersensing couldcausetermination ofmodeswitching.\\n•Properprogramming withoutanatriallead.Ifanatrialleadisnotimplanted (portispluggedinstead),oranatriallead\\nisabandoned butremainsconnected totheheader,deviceprogrammingshouldbeconsistent withthenumberandtype\\nofleadsactuallyinuse.\\n•Atrialsensingprogrammed toOff.WhenatrialsensingisprogrammedtoOffinaDDI(R)orDDD(R)mode,anyatrial\\npacingthatoccurswillbeasynchronous .Additionally ,featuresthatrequireatrialsensingmaynotfunctionasexpected.\\n•Cross-chamber artifacts. Sensitivity adjustments associated withSmartBlankingmaynotbesufficienttoinhibitdetection\\nofcross-chamber artifactsifthecross-chamber artifactsaretoolarge.Considerotherfactorsthatimpactthesize/\\namplitude ofcross-chamber artifactsincludinglead-placement, pacingoutput,programmedSensitivity settings,shock\\noutput,andtimesincelastdeliveredshock.\\n•SignalArtifactMonitorProgramming Considerations. Formaximum sensitivity indetecting andpreventing potential\\nsignalartifact-generatedoversensing, itisrecommended thattheSignalArtifactMonitor(SAM)isprogrammedOnany\\ntimetheMV/Respir atorySensorisprogrammedtoOnorPassive.TurningtheSignalArtifactMonitorOffmayputthe\\npatientatincreased riskofoversensing, unlesstheMV/Respiratory SensorisalsoprogrammedOff.\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 16}), Document(page_content='14•TurningtheSignalArtifactMonitorOff.TurningtheSignalArtifactMonitorOffmayputthepatientatincreased riskof\\noversensing, unlesstheMV/Respiratory Sensorisalsoprogramm edtoOff.\\n•MVRecalibration. ToobtainanaccurateMVbaselinefollowing anysurgicalprocedureinvolvingthepulsegenerator or\\nleads,anew,manualcalibration shouldbeperformed. Leadmaturation, airentrapmen tinthepocket,pulsegenerator\\nmotionduetoinadequate suturing,externaldefibrillation orcardioversion, orotherpatientcomplications (e.g.,\\npneumothorax) requireanewMVbaselineforappropriate MVbehavior.\\n•Sensingadjustment. Following anysensingrangeadjustment oranymodification ofthesensinglead,alwaysverify\\nappropriate sensing.ProgrammingSensitivity tothehighestvalue(lowestsensitivity) mayresultindelayeddetection or\\nundersensing ofcardiacactivity.Likewise,programmingtothelowestvalue(highestsensitivity) mayresultinoversensing\\nofnon-cardiac signals.\\n•Patientsheartonescomingfromtheirdevice.Patientsshouldbeadvisedtocontacttheirphysician immediately ifthey\\nheartonescomingfromtheirdevice.\\n•UseofPatientTriggered Monitor.UsecarewhenusingPatientTriggered Monitor,becausethefollowing conditionswill\\nexistwhileitisenabled:\\n•Allothermagnetfeatures,includinginhibiting therapy,aredisabled.TheMagnet/Beeper featurewillnotindicate\\nmagnetposition.\\n•Devicelongevityisimpacted. Tohelpreducethelongevityimpact,PTMonlyallowsstorageofoneepisode,and\\nPTMisautomatically disabledafter60daysifdatastoragewasnevertriggered.\\n•OncetheEGMisstored(or60dayselapses),PTMisdisabledandthedeviceMagnetResponse automatically willbe\\nsettoInhibitTherapy.However,thepulsegenerator willnotinhibittherapyuntilthemagnetisremovedfor3\\nsecondsandplacedonthedeviceagain.\\nEnvironmental andMedicalTherapyHazards\\n•Avoidelectromagnetic interference (EMI).AdvisepatientstoavoidsourcesofEMIbecauseEMImaycausethepulse\\ngenerator todeliverinappropriate therapyorinhibitappropriate therapy.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 17}), Document(page_content='15MovingawayfromthesourceoftheEMIorturningoffthesourceusuallyallowsthepulsegenerator toreturntonormal\\noperation.\\nExamples ofpotentialEMIsourcesare:\\n•Electricalpowersources,arcweldingorresistanceweldingequipment, androboticjacks\\n•Highvoltagepowerdistribution lines\\n•Electricalsmeltingfurnaces\\n•LargeRFtransmitterssuchasradar\\n•Radiotransmitters,includingthoseusedtocontroltoys\\n•Electronic surveillance (antitheft) devices\\n•Analternator onacarthatisrunning\\n•Medicaltreatments anddiagnostic testsinwhichanelectricalcurrentispassedthroughthebody,suchasTENS,\\nelectrocautery ,electrolysis/thermolysis, electrodiagnostic testing,electromyogr aphy,ornerveconduction studies\\n•Anyexternally applieddevicethatusesanautomatic leaddetection alarmsystem(e.g.,anEKGmachine)\\n•WirelessECG.WirelessECGissusceptibletoRFinterferenc e,andmayhaveanintermittent orlostsignal.Ifinterferenc eis\\npresent,especially duringdiagnostic testing,considerusingasurfaceECGinstead.\\nHospitalandMedicalEnvironments\\n•Mechanical ventilators. ProgramtheMV/Respir atorySensortoOffduringmechanical ventilation. Otherwise, the\\nfollowing mayoccur:\\n•Inappropriate MVSensor-drivenrate\\n•Misleading respiration-based trending', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 18}), Document(page_content='16•Conducted electricalcurrent.Anymedicalequipment, treatment, therapy,ordiagnostic testthatintroduceselectrical\\ncurrentintothepatienthasthepotentialtointerferewithpulsegenerator function.\\n•Externalpatientmonitors(e.g.,respiratorymonitors, surfaceECGmonitors, hemodynamic monitors) maycause:\\n–Inappropriate MVSensor-driven rate(uptomaximum sensor-drivenrate)\\n–Misleading respiration-based trending\\n•Medicaltherapies, treatments, anddiagnostic teststhatuseconducted electricalcurrent(e.g.,TENS,electrocautery ,\\nelectrolysis/thermolysis, electrodiagn ostictesting,electromyogr aphy,ornerveconductionstudies)mayinterfere\\nwithordamagethepulsegenerator.ProgramthedevicetoElectrocautery Protection Modepriortothetreatment,\\nandmonitordeviceperformance duringthetreatment. Afterthetreatment, verifypulsegenerator function(\"Post-\\nTherapyPulseGeneratorFollowUp\"onpage20).\\nToresolvesuspected interactions withRespiratory Sensor-baseddiagnostics, deactivate thepulsegenerator\\' sRespiratory\\nSensorbyprogrammingittoOff.\\n•Internaldefibrillation. Donotuseinternaldefibrillation paddlesorcathetersunlessthepulsegenerator isdisconnect ed\\nfromtheleadsbecausetheleadsmayshuntenergy.Thiscouldresultininjurytothepatientanddamagetothe\\nimplanted system.\\n•Externaldefibrillation. Itcantakeupto15secondsforsensingtorecoverafteranexternalshockisdelivered. Innon-\\nemergency situations, forpacemakerdependent patients,considerprogrammingthepulsegenerator toanasynchronous\\npacingmodeandprogrammingtheMV/Respiratory SensortoOffpriortoperforming externalcardioversion or\\ndefibrillation.\\nAvoidplacingapad(orpaddle)directlyoveranysubcutaneous leads.\\nExternaldefibrillation orcardioversioncandamagethepulsegenerator.Tohelppreventdamagetothepulsegenerator,\\nconsiderthefollowing:\\n•Avoidplacingapad(orpaddle)directlyoverthepulsegenerator.Positionthepads(orpaddles)asfarfromthe\\npulsegenerator aspossible.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 19}), Document(page_content='17•Positionthepads(orpaddles)inaposterior-anteriororientation whenthedeviceisimplanted intherightpectoral\\nregionorananterior-apexorientation whenthedeviceisimplanted intheleftpectoralregion.\\n•Setenergyoutputofexternaldefibrillation equipment aslowasclinicallyacceptable.\\nFollowing externalcardioversion ordefibrillation, verifypulsegenerator function(\"Post-TherapyPulseGeneratorFollow\\nUp\"onpage20).\\n•Lithotripsy .Extracorporealshockwavelithotripsy (ESWL)maycauseelectromagnetic interferenc ewithordamagetothe\\npulsegenerator.IfESWLismedically necessary,considerthefollowing tominimizethepotentialforencountering\\ninteraction:\\n•FocustheESWLbeamatleast15cm(6in)awayfromthepulsegenerator.\\n•Depending onthepacingneedsofthepatient,programtheBradyModetoOfforanon-rate-r esponsive VVImode.\\n•ProgramtheTachyModetoOfftopreventinappropriate shocks.\\n•Ultrasound energy.Therapeutic ultrasound (e.g.,lithotripsy) energymaydamagethepulsegenerator.Iftherapeutic\\nultrasoundenergymustbeused,avoidfocusingnearthepulsegenerator site.Diagnostic ultrasound(e.g.,\\nechocardiography)isnotknowntobeharmfultothepulsegenerator.\\n•Electricalinterference. Electricalinterferenceor“noise”fromdevicessuchaselectrocautery andmonitoring equipment\\nmayinterferewithestablishing ormaintaining telemetry forinterrogating orprogrammingthedevice.Inthepresenceof\\nsuchinterferenc e,movetheprogrammerawayfromelectricaldevices,andensurethatthewandcordandcablesarenot\\ncrossingoneanother.Iftelemetry iscancelledasaresultofinterferenc e,thedeviceshouldbere-interrogatedpriorto\\nevaluating information frompulsegenerator memory.\\n•Radiofrequency (RF)interference. RFsignalsfromdevicesthatoperateatfrequencies nearthatofthepulsegenerator\\nmayinterruptZIPtelemetry whileinterrogating orprogrammingthepulsegenerator.ThisRFinterferenc ecanbereduced\\nbyincreasing thedistancebetweentheinterfering deviceandthePRMandpulsegenerator.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 20}), Document(page_content='18•Centrallineguidewire insertion. Usecautionwheninsertingguidewires forplacement ofothertypesofcentralvenous\\ncathetersystemssuchasPIClinesorHickmancathetersinlocationswherepulsegenerator leadsmaybeencounter ed.\\nInsertionofsuchguidewiresintoveinscontaining leadscouldresultintheleadsbeingdamaged ordislodged.\\nHomeandOccupationalEnvironments\\n•Homeappliances. Homeappliancesthatareingoodworkingorderandproperlygrounded donotusuallyproduce\\nenoughEMItointerferewithpulsegenerator operation. Therehavebeenreportsofpulsegenerator disturbances caused\\nbyelectrichandtoolsorelectricrazorsuseddirectlyoverthepulsegenerator implantsite.\\n•Magneticfields.Advisepatientsthatextendedexposuretostrong(greaterthan10gaussor1mTesla)magnetic fields\\nmaytriggerthemagnetfeature.Examples ofmagneticsourcesinclude:\\n•Industrial transformers andmotors\\n•MRIscanners\\nNOTE:ThemagnetfeatureisdisabledwhenthedeviceisinMRIProtection Mode.Referto\"Magnetic Resonance\\nImaging(MRI)\"onpage21andtheImageReady MRConditional Defibrillation SystemMRITechnicalGuideformore\\ninformation.\\n•Largestereospeakers\\n•Telephone receiversifheldwithin1.27cm(0.5inches)ofthepulsegenerator\\n•MagneticwandssuchasthoseusedforairportsecurityandintheBingogame\\n•ElectronicArticleSurveillance (EAS)andsecuritysystems. Advisepatientshowtoavoidimpacttocardiacdevice\\nfunctionduetoantitheftandsecuritygates,tagdeactivators, ortagreadersthatincluderadiofrequency identification\\n(RFID)equipment. Thesesystemsmaybefoundattheentrancesandexitsofstores,atcheckoutcounters,inpublic\\nlibraries,andinpoint-of-entryaccesscontrolsystems.Patientsshouldavoidlingeringnearorleaningagainstantitheft\\nandsecuritygatesandtagreaders.Inaddition,patientsshouldavoidleaningagainstcheckoutcounter-mounted and\\nhandheld tagdeactivation systems.Anti-theft gates,securitygates,andentrycontrolsystemsareunlikelytoaffectcardiac\\ndevicefunctionwhenpatientswalkthroughthematanormalpace.Ifthepatientisnearanelectronic antitheft,security,', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 21}), Document(page_content=\"19orentrycontrolsystemandexperience ssymptoms, theyshouldpromptlymoveawayfromnearbyequipment andinform\\ntheirdoctor.\\n•Cellularphones.Advisepatientstoholdcellularphonestotheearoppositethesideoftheimplanted device.Patients\\nshouldnotcarryacellularphonethatisturnedoninabreastpocketoronabeltwithin15cm(6inches)oftheimplanted\\ndevicesincesomecellularphonesmaycausethepulsegenerator todeliverinappropriate therapyorinhibitappropriate\\ntherapy.\\nFollow-up Testing\\n•Conversion testing.SuccessfulVForVTconversion duringarrhythmia conversion testingisnoassurancethatconversion\\nwilloccurpost-operatively .Beawarethatchangesinthepatient'scondition,drugregimen,andotherfactorsmaychange\\ntheDFT,whichmayresultinnonconversion ofthearrhythmia post-operatively .\\n•Pacingthreshold testing.Ifthepatient'scondition ordrugregimenhaschangedordeviceparametershavebeen\\nreprogrammed,considerperforming apacingthreshold testtoconfirmadequate marginsforpacecapture.\\n•Follow-up considerations forpatientsleavingthecountry.Pulsegenerator follow-up considerationsshouldbemade\\ninadvanceforpatientswhoplantotravelorrelocatepost-implanttoacountryotherthanthecountryinwhichtheir\\ndevicewasimplanted. Regulatory approvalstatusfordevicesandassociated programmersoftwareconfigurationsvaries\\nbycountry;certaincountriesmaynothaveapprovalorcapability tofollowspecificproducts.\\nContactBostonScientific, usingtheinformation onthebackcover,forhelpindetermining feasibility ofdevicefollow-up in\\nthepatient'sdestination country.\\nExplantandDisposal\\n•Incineration. Besurethatthepulsegenerator isremovedbeforecremation. Cremation andincineration temperatur es\\nmightcausethepulsegenerator toexplode.\\n•Devicehandling. Beforeexplanting, cleaning,orshippingthedevice,completethefollowing actionstoprevent\\nunwanted shocks,overwriting ofimportant therapyhistorydata,andaudibletones:\\n•Programthepulsegenerator TachyandBradyModestoOff.\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 22}), Document(page_content='20•ProgramtheMagnetResponse featuretoOff.\\n•ProgramtheBeepwhenExplantisIndicatedfeaturetoOff.\\n•ProgramtheBeepWhenOut-of-Range featuretoOff.\\n•Handlingattimeofdisposal. Cleananddisinfectthedeviceusingstandardbiohazard handlingtechniques sinceall\\nexplanted components areconsideredbiohazardous.\\nSUPPLEMENTAL PRECAUTIONARY INFORMATION\\nPost-TherapyPulseGenerator FollowUp\\nFollowing anysurgeryormedicalprocedurewiththepotentialtoaffectpulsegenerator function,youshouldperforma\\nthoroughfollow-up, whichmayincludethefollowing:\\n•Interrogating thepulsegenerator withaprogrammer\\n•Reviewing clinicaleventsandfaultcodes\\n•Reviewing theArrhythmia Logbook, includingstoredelectrograms(EGMs)\\n•Reviewing real-timeEGMs\\n•Testingtheleads(threshold,amplitude, andimpedance)\\n•Performing amanualcapacitorre-formation\\n•Reviewing MVSensor-baseddiagnostics, MVSensorperformance, andperforming amanualMVSensorcalibration if\\ndesired\\n•Reviewing RespiratorySensor-baseddiagnostics\\n•Verifyingbatterystatus\\n•Programminganypermanent bradyparametertoanewvalueandthenreprogrammingitbacktothedesiredvalue\\n•ProgrammingtheTachyModetoanewvalueandthenreprogramming itbacktothedesiredvalue', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 23}), Document(page_content='21•Savingallpatientdata\\n•Verifyingtheappropriate finalprogrammingpriortoallowingthepatienttoleavetheclinic\\nMagneticResonance Imaging(MRI)\\nMRIProtection ModeisavailableinRESONATE HF,RESONATE, PERCIVAHF,PERCIVA,VIGILANT, andMOMENTUM devices.\\nThefollowing Warnings andPrecautions, andConditions ofUseareapplicable toMRIscanningofpatientsimplanted withan\\nImageReady MRConditional Defibrillation System.RefertotheImageReady MRConditional Defibrillation SystemMRITechnical\\nGuideatwww.bostonscientific -elabeling.com foracomprehensivelistofWarnings andPrecautions, andConditions ofUsethat\\nareapplicable toMRIscanningofpatientsimplanted withanImageReady MRConditional Defibrillation System.\\nMRConditional Defibrillation SystemWarnings andPrecautions\\nWARNING: RESONATE HF,RESONATE, PERCIVAHF,PERCIVA,VIGILANT andMOMENTUM devicesareconsideredMR\\nConditional. Forthesedevices,unlessalloftheMRIConditions ofUsearemet,MRIscanningofthepatientdoesnotmeetMR\\nConditional requirementsfortheimplanted system.Significant harmtoordeathofthepatientand/ordamagetotheimplanted\\nsystemmayresult.Donotexposepatientswithnon-MRConditional devicestoMRIscanning. Strongmagneticfieldsmay\\ndamagethepulsegenerator and/orleadsystem,possiblyresultingininjurytoordeathofthepatient.\\nForpotentialadverseeventsapplicable whentheConditions ofUsearemetornotmet,refertotheImageReady MRConditional\\nDefibrillation SystemMRITechnicalGuide.Foradditional warnings, precautions, andConditions ofUse,referto\"Magnetic\\nResonance Imaging(MRI)\"onpage21.\\nWARNING: MRIscanningafterExplantstatushasbeenreachedmayleadtopremature batterydepletion, ashortened device\\nreplacementwindow,orsuddenlossoftherapy.Afterperforming anMRIscanonadevicethathasreachedExplantstatus,\\nverifypulsegenerator function(\"Post-TherapyPulseGenerator FollowUp\"onpage20)andscheduledevicereplacement.\\nWARNING: Determine thebeepertypebeforeanMRIscan.TheArmature Beepermaynolongerbeusablefollowing anMRI\\nscan.Comingincontactwiththestrongmagnetic fieldofanMRIscannermaycauseapermanent lossoftheArmature Beeper\\nvolume.Thiscannotberecovered,evenafterleavingtheMRIscanenvironment andexitingMRIProtection Mode.Forthe\\nArmature Beeper,beforeanMRIscanisperformed, aphysician andpatientshouldweighthebenefitoftheMRIscanagainst', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 24}), Document(page_content='22theriskoflosingtheBeeper;aftertheMRIscan,performBeeperevaluation testtodetermine iftheBeeperisusable.Ifthe\\nBeeperisnotusable,itisstronglyrecommended thatpatientsarefollowedonLATITUDE NXTafteranMRIscaniftheyarenot\\nalready.Otherwise, anin-clinicfollow-up scheduleofeverythreemonthsisstronglyrecommended tomonitordevice\\nperformance.\\nWARNING: DuringMRIProtection Mode,thepatientwillnotreceiveTachycardiatherapy(including ATPanddefibrillation),\\nand,ifBradyModeisprogrammedtoOff,willnotreceiveBradycardiapacing(including backuppacing)andCardiac\\nResynchronization Therapy.Thereforethepatientmustbecontinuously monitored fortheentiredurationinwhichthesystemis\\ninMRIProtection Mode,includingduringthescan.\\nWARNING: IftheMRIProtection Time-outvalueisprogrammedtoOff,thepatientwillnotreceiveTachycardia therapy,and\\nthepacingoptionsarelimitedtoOfforAsynchronous untilthepulsegenerator isprogrammedoutofMRIProtection Modeand\\nbacktonormaloperation.\\nWARNING: DuringMRIProtection Mode,Tachycardiatherapyissuspended. Thesystemwillnotdetectventricular\\narrhythmias andthepatientwillnotreceiveATPorshockdefibrillation therapyuntilthepulsegenerator isprogrammedbackto\\nnormaloperation. Onlyscanthepatientifjudgedtobeclinicallycapableoftolerating noTachycardiaprotection fortheentire\\ndurationinwhichthepulsegenerator isinMRIProtection Mode.\\nWARNING: Theriskofarrhythmia maybeincreased withasynchronous pacing(AOO,VOO,DOO).Whenprogramming\\nasynchronou spacingduringMRIProtection Mode,selectapacingratethatavoidscompetitive pacingandminimizethetimein\\nMRIProtection Mode.\\nWARNING: Intherareeventthatnon-recoverableorrepeatfaultconditions occurwhilethedeviceisprogramm edinMRI\\nProtectionMode,thesubsequent devicebehaviorwillbedetermined bytheMRIProtection BradyModesetting.\\n•IfMRIBradyModeissettoOff,thedevicewillenterSafetyMode(permanent VVIunipolarpacingandtachycardia\\ntherapyenabled).\\n•IfMRIBradyModeissettoasynchronous pacing(AOO,VOO,DOO),bothbradycardiatherapyandtachycardiatherapy\\nwillbepermanently disabled.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 25}), Document(page_content='23WARNING: TheProgrammerisMRUnsafeandmustremainoutsidetheMRIsiteZoneIII(andhigher)asdefinedbythe\\nAmerican CollegeofRadiology Guidance Document onMRSafePractices4.Undernocircumstanc esshouldtheProgrammerbe\\nbroughtintotheMRIscannerroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nWARNING: Implantofthesystemcannotbeperformed inanMRIsiteZoneIII(andhigher)asdefinedbytheAmerican\\nCollegeofRadiology Guidance Document onMRSafePractices4.Someoftheaccessoriespackaged withpulsegenerators and\\nleads,includingthetorquewrenchandstyletwires,arenotMRConditional andshouldnotbebroughtintotheMRIscanner\\nroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nCAUTION: Thephysician choosingMRIProtectionModeparameter valueswillneedtoexerciseprofessionaljudgment to\\ndetermine anindividual patient’sabilitytotoleratethedevicesettingsrequiredforMRConditional scanning, inconjunction with\\nthephysicalconditions requiredduringascan(forexample,prolonged timeinasupineposition).\\nCAUTION: Thepresenceoftheimplanted defibrillation systemmaycauseMRIimageartifacts.\\nNOTE:Otherimplanted devicesorpatientconditions maycauseapatienttobeineligibleforanMRIscan,independent ofthe\\nstatusofthepatient’sImageReady MRConditional Defibrillation System.\\nMRConditions ofUse\\nThefollowing subsetoftheMRIConditions ofUsepertainstoimplantation andmustbemetinorderforapatientwithan\\nImageReady Defibrillation SystemtoundergoanMRIscan.AdherencetotheConditions ofUsemustbeverifiedpriortoeach\\nscantoensurethatthemostuptodateinformation hasbeenusedtoassessthepatient’seligibilityandreadiness foranMR\\nConditional scan.RefertotheImageReady MRConditional Defibrillation SystemMRITechnicalGuideatwww.bostonscientific -\\nelabeling.com foracomprehensive listofWarnings andPrecautions, andConditions ofUsethatareapplicable toMRIscanning\\nofpatientsimplanted withanImageReady MRConditional Defibrillation System.\\nCardiology\\n1.Patientisimplanted withanImageReady MRConditional Defibrillation System\\n4.KanalE,Barkovich AJ,BellC,etal.ACRguidancedocument onMRsafepractices:2013.J.Magn.Reson.Imaging2013;37:501-530.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 26}), Document(page_content='242.Nootheractiveorabandoned implanted devices,components, oraccessoriespresentsuchasleadadaptors, extenders,\\nleads,orpulsegenerators\\n3.PatientisjudgedtobeclinicallycapableoftoleratingnoTachycardia protectionfortheentiredurationinwhichthepulse\\ngenerator isinMRIProtection Mode\\n4.Pulsegenerator implantlocationrestricted toleftorrightpectoralregion\\n5.Atleastsix(6)weekshaveelapsedsinceimplantation and/oranyleadrevisionorsurgicalmodification oftheMR\\nConditional Defibrillation System\\n6.Noevidenceofafracturedleadorcompromisedpulsegenerator-leadsystemintegrity\\nTranscutaneous ElectricalNerveStimulation (TENS)\\nCAUTION: TENSinvolvespassingelectricalcurrentthroughthebody,andmayinterferewithpulsegenerator function.IfTENS\\nismedically necessary,evaluatetheTENStherapysettingsforcompatibility withthepulsegenerator.Thefollowing guidelines\\nmayreducethelikelihood ofinteraction:\\n•PlacetheTENSelectrodes asclosetogetherandasfarawayfromthepulsegenerator andleadsaspossible.\\n•Usethelowestclinically-appropriate TENSenergyoutput.\\n•Considercardiacmonitoring duringTENSuse,especially forpacemaker-dependent patients.\\nAdditional stepscanbetakentohelpreduceinterferenc eduringin-clinicuseofTENS:\\n•Ifinterferenceissuspected duringin-clinicuse,turnofftheTENSunit.\\n•DonotchangeTENSsettingsuntilyouhaveverifiedthatthenewsettingsdonotinterferewithpulsegenerator function.\\nIfTENSismedically necessary outsidetheclinicalsetting(at-homeuse),providepatientswiththefollowing instructions:\\n•DonotchangetheTENSsettingsorelectrodepositionsunlessinstructed todoso.\\n•EndeachTENSsessionbyturningofftheunitbeforeremoving theelectrodes.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 27}), Document(page_content='25•IfthepatientreceivesashockduringTENSuse,oriftheyexperiencesymptoms oflightheadedness, dizziness, orlossof\\nconsciousness, theyshouldturnofftheTENSunitandcontacttheirphysician.\\nFollowthesestepstousethePRMtoevaluatepulsegenerator functionduringTENSuse:\\n1.Programthepulsegenerator TachyModetoMonitorOnly.\\n2.Observereal-timeEGMsatprescribed TENSoutputsettings,notingwhenappropriate sensingorinterferenc eoccurs.\\nNOTE:Patienttriggeredmonitoring maybeusedasanadditional methodtoconfirmdevicefunctionduringTENSuse.\\n3.Whenfinished,turnofftheTENSunitandreprogramtheTachyModetoMonitor+Therapy.\\nYoushouldalsoperformathorough follow-up evaluation ofthepulsegenerator following TENS,toensurethatdevicefunction\\nhasnotbeencompromised(\"Post-TherapyPulseGenerator FollowUp\"onpage20).\\nForadditional information, contactBostonScientificusingtheinformation onthebackcover.\\nElectrocauteryandRadioFrequency (RF)Ablation\\nCAUTION: Electrocautery andRFablationmayinduceventricular arrhythmias and/orfibrillation, andmaycauseasynchronous\\npacing,inhibition ofpacing,inappropriate shocks,and/orareduction inpulsegenerator pacingoutputpossiblyleadingtoloss\\nofcapture.RFablationmayalsocauseventricular pacinguptotheMTRand/orchangesinpacingthresholds.Additionally ,\\nexercisecautionwhenperforming anyothertypeofcardiacablationprocedureinpatientswithimplanted devices.\\nIfelectrocautery orRFablationismedically necessary,observethefollowing tominimizerisktothepatientanddevice:\\n•Depending onthepacingneedsofthepatient,programtheTachyModetoElectrocautery Protection ModeorOff.\\n•Havetemporary pacingandexternaldefibrillation equipment available.\\n•Avoiddirectcontactbetweentheelectrocautery equipment orablationcathetersandthepulsegenerator andleads.RF\\nablationclosetotheleadelectrode maydamagethelead-tissue interface.\\n•Keepthepathoftheelectricalcurrentasfarawayaspossiblefromthepulsegenerator andleads.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 28}), Document(page_content=\"26•IfRFablationand/orelectrocautery isperformed ontissuenearthedeviceorleads,monitorpre-andpost-\\nmeasurements forsensingandpacingthresholds andimpedances todetermine theintegrityandstabilityofthesystem.\\n•Forelectrocautery ,useabipolarelectrocautery systemwherepossibleanduseshort,intermittent, andirregularburstsat\\nthelowestfeasibleenergylevels.\\n•RFablationequipment maycausetelemetry interferenc ebetweenthepulsegenerator andPRM.Ifdeviceprogramming\\nchangesarenecessary duringanRFablationprocedure,turnofftheRFablationequipment beforeinterrogation.\\nWhentheprocedureisfinished,canceltheElectrocautery Protection ModeorprogramTachyModetoMonitor+Therapyin\\nordertoreactivate thepreviously programmedtherapymodes.\\nIonizingRadiation\\nCAUTION: Itisnotpossibletospecifyasaferadiationdosageorguaranteeproperpulsegenerator functionfollowing\\nexposuretoionizingradiation. Multiplefactorscollectivelydetermine theimpactofradiationtherapyonanimplanted pulse\\ngenerator,includingproximity ofthepulsegenerator totheradiationbeam,typeandenergyleveloftheradiationbeam,dose\\nrate,totaldosedeliveredoverthelifeofthepulsegenerator,andshieldingofthepulsegenerator.Theimpactofionizing\\nradiationwillalsovaryfromonepulsegenerator toanotherandmayrangefromnochangesinfunctiontoalossofpacingand\\ndefibrillation therapy.\\nSourcesofionizingradiationvarysignificantly intheirpotentialimpactonanimplanted pulsegenerator.Severaltherapeutic\\nradiationsourcesarecapableofinterfering withordamaging animplanted pulsegenerator,includingthoseusedforthe\\ntreatmentofcancer,suchasradioactive cobalt,linearaccelerators,radioactive seeds,andbetatrons.\\nPriortoacourseoftherapeutic radiationtreatment, thepatient'sradiationoncologist andcardiologist orelectrophysiologist\\nshouldconsiderallpatientmanagement options,includingincreased follow-up anddevicereplacement.Otherconsiderations\\ninclude:\\n•Maximizing shieldingofthepulsegenerator withinthetreatment field\\n•Determining theappropriate levelofpatientmonitoring duringtreatment\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 29}), Document(page_content='27Evaluatepulsegenerator operation duringandfollowing thecourseofradiationtreatment toexerciseasmuchdevice\\nfunctionality aspossible(\"Post-TherapyPulseGenerator FollowUp\"onpage20).Theextent,timing,andfrequency ofthis\\nevaluation relativetotheradiationtherapyregimenaredependent uponcurrentpatienthealth,andthereforeshouldbe\\ndetermined bytheattending cardiologist orelectrophysiologist.\\nManypulsegenerator diagnostics areperformed automatically onceperhour,sopulsegenerator evaluation shouldnotbe\\nconcluded untilpulsegenerator diagnostics havebeenupdatedandreviewed(atleastonehourafterradiationexposure).The\\neffectsofradiationexposureontheimplanted pulsegenerator mayremainundetected untilsometimefollowing exposure.For\\nthisreason,continuetomonitorpulsegenerator functioncloselyandusecautionwhenprogrammingafeatureintheweeksor\\nmonthsfollowing radiationtherapy.\\nElevatedPressures\\nTheInternational Standards Organization (ISO)hasnotapproved astandardize dpressuretestforimplantable pulsegenerators\\nthatexperiencehyperbaric oxygentherapy(HBOT)orSCUBAdiving.However,BostonScientificdeveloped atestprotocolto\\nevaluatedeviceperformance uponexposuretoelevatedatmospheric pressures.Thefollowing summary ofpressuretesting\\nshouldnotbeviewedasandisnotanendorsement ofHBOTorSCUBAdiving.\\nCAUTION: ElevatedpressuresduetoHBOTorSCUBAdivingmaydamagethepulsegenerator.Duringlaboratory testing,all\\npulsegenerators inthetestsamplefunctioned asdesigned whenexposedtomorethan1000cyclesatapressureupto5.0\\nATA.Laboratory testingdidnotcharacteriz etheimpactofelevatedpressureonpulsegenerator performance orphysiological\\nresponsewhileimplanted inahumanbody.\\nPressureforeachtestcyclebeganatambient/r oompressure,increased toahighpressurelevel,andthenreturnedtoambient\\npressure.Although dwelltime(theamountoftimeunderelevatedpressure)mayhaveanimpactonhumanphysiology ,testing\\nindicateditdidnotimpactpulsegenerator performance. Pressurevalueequivalencies areprovidedbelow(Table1Pressure\\nValueEquivalencies onpage28).', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 30}), Document(page_content='28Table1.PressureValueEquivalencies\\nPressurevalueequivalencies\\nAtmospheres Absolute 5.0ATA\\nSeawaterdeptha40m(130ft)\\nPressure,absolute 72.8psia\\nPressure,gaugeb58.1psig\\nBar 5.0\\nkPaAbsolute 500\\na.Allpressureswerederivedassuming seawaterdensityof1030kg/m3.\\nb.Pressureasreadonagaugeordial(psia=psig+14.7psi).\\nPriortoSCUBAdivingorstartinganHBOTprogram,thepatient\\'sattending cardiologist orelectrophysiologist shouldbe\\nconsultedtofullyunderstand thepotentialconsequenc esrelativetothepatient\\'sspecifichealthcondition. ADiveMedicine\\nSpecialist mayalsobeconsulted priortoSCUBAdiving.\\nMorefrequentdevicefollow-up maybewarranted inconjunctionwithHBOTorSCUBAdiving.Evaluatepulsegenerator\\noperationfollowing highpressureexposure(\"Post-TherapyPulseGeneratorFollowUp\"onpage20).Theextent,timing,and\\nfrequencyofthisevaluation relativetothehighpressureexposurearedependent uponcurrentpatienthealth,andshouldbe\\ndetermined bytheattending cardiologist orelectrophysiologist.\\nIfyouhaveadditional questions, orwouldlikemoredetailregardingthetestprotocolortestresultsspecifictoHBOTorSCUBA\\ndiving,contactBostonScientificusingtheinformation onthebackcover.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 31}), Document(page_content='29POTENTIALADVERSEEVENTS\\nBasedontheliteratureandonpulsegenerator and/orleadimplantexperience ,thefollowing alphabetical listincludesthe\\npossibleadverseeventsassociated withimplantation ofproductsdescribed inthisliterature:\\n•Airembolism\\n•Allergicreaction\\n•Bleeding\\n•Bradycardia\\n•Cardiactamponade\\n•Chronicnervedamage\\n•Component failure\\n•Conductor coilfracture\\n•Death\\n•Elevatedthresholds\\n•Erosion\\n•Excessive fibrotictissuegrowth\\n•Extracardiacstimulation (muscle/nerve stimulation)\\n•Failuretoconvertaninducedarrhythmia\\n•Fluidaccumulation\\n•Foreignbodyrejectionphenomena\\n•Formation ofhematomas orseromas\\n•Heartblock\\n•Heartfailurefollowing chronicRVapicalpacing\\n•Inabilitytodefibrillate orpace', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 32}), Document(page_content='30•Inappropriate therapy(e.g.,shocksandantitachycardia pacing[ATP]whereapplicable, pacing)\\n•Incisional pain\\n•Incomplete leadconnection withpulsegenerator\\n•Infectionincludingendocarditis\\n•Insulating myocardium duringdefibrillation withinternalorexternalpaddles\\n•Leaddislodgment\\n•Leadfracture\\n•Leadinsulation breakage orabrasion\\n•Leadperforation\\n•Leadtipdeformation and/orbreakage\\n•Localtissuereaction\\n•Lossofcapture\\n•Myocardial infarction (MI)\\n•Myocardial necrosis\\n•Myocardial trauma(e.g.,tissuedamage,valvedamage)\\n•Myopotential sensing\\n•Oversensing/undersensing\\n•Pacemaker-mediated tachycardia (PMT)(Appliestodual-chamber devicesonly.)\\n•Pericardial rub,effusion\\n•Pneumothorax\\n•Pulsegenerator migration\\n•Shuntingcurrentduringdefibrillation withinternalorexternalpaddles\\n•Syncope', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 33}), Document(page_content='31•Tachyarrhythmias, whichincludeaccelerationofarrhythmias andearly,recurrentatrialfibrillation\\n•Thrombosis/thr omboemboli\\n•Valvedamage\\n•Vasovagal response\\n•Venousocclusion\\n•Venoustrauma(e.g.,perforation, dissection, erosion)\\n•Worsening heartfailure\\nForalistofpotentialadverseeventsassociated withMRIscanning, refertotheImageReady MRConditional Defibrillation\\nSystemMRITechnicalGuide.\\nPatientsmaydeveloppsychological intolerancetoapulsegenerator systemandmayexperience thefollowing:\\n•Dependency\\n•Depression\\n•Fearofprematurebatterydepletion\\n•Fearofshockingwhileconscious\\n•Fearthatshockingcapability maybelost\\n•Imagined shocking\\n•Fearofdevicemalfunction\\nMECHANICAL SPECIFICATIONS\\nAllRESONATE HFICDandExtended Longevity (EL)ICDmodelshaveacaseelectrodesurfaceareaof6192mm².Usablebattery\\ncapacityis1.8AhandresidualusablebatterycapacityatExplantis0.12Ahforsinglechamberdevicesand0.12Ahfordual\\nchamberdevices.Mechanical specifications specifictoeachmodelarelistedbelow.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 34}), Document(page_content='32AllPERCIVAHFICDandPERCIVAICDmodelshaveacaseelectrode surfaceareaof5487mm².Usablebatterycapacityis1.1Ah\\nandresidualusablebatterycapacityatExplantis0.12Ahforsinglechamberdevicesand0.13Ahfordualchamberdevices.\\nMechanical specifications specifictoeachmodelarelistedbelow.\\nTable2.Mechanical Specifications -RESONATE HFICDs\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nD520(VR) 5.37x7.79x0.99 70.7 31.5 RV:IS-1/DF–1 Yes\\nD521(DR) 5.37x7.79x0.99 71.0 31.5 RA:IS-1;RV:IS-\\n1/DF–1Yes\\nD532(VR) 5.37x7.36x0.99 68.9 29.5 RV:DF4 Yes\\nD533(DR) 5.37x7.68x0.99 71.4 31.0 RA:IS-1;RV:DF4 Yes\\nTable3.Mechanical Specifications -RESONATE Extended Longevity (EL)ICDs\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nD420(VR) 5.37x7.79x0.99 70.7 31.5 RV:IS-1/DF–1 Yes\\nD421(DR) 5.37x7.79x0.99 71.0 31.5 RA:IS-1;RV:IS-\\n1/DF–1Yes', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 35}), Document(page_content='33Table3.Mechanical Specifications -RESONATE Extended Longevity (EL)ICDs(continued)\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nD432(VR) 5.37x7.36x0.99 68.9 29.5 RV:DF4 Yes\\nD433(DR) 5.37x7.68x0.99 71.4 31.0 RA:IS-1;RV:DF4 Yes\\nTable4.Mechanical Specifications -PERCIVAHFICDs\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nD500(VR) 5.23x7.14x0.99 61.9 28.5 RV:IS-1/DF–1 Yes\\nD501(DR) 5.23x7.14x0.99 62.3 28.5 RA:IS-1;RV:IS-\\n1/DF–1Yes\\nD512(VR) 5.23x6.71x0.99 60.0 26.5 RV:DF4 Yes\\nD513(DR) 5.23x7.03x0.99 62.5 28.0 RA:IS-1;RV:DF4 Yes', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 36}), Document(page_content='34Table5.Mechanical Specifications -PERCIVAICDs\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nD400(VR) 5.23x7.14x0.99 61.9 28.5 RV:IS-1/DF–1 Yes\\nD401(DR) 5.23x7.14x0.99 62.3 28.5 RA:IS-1;RV:IS-\\n1/DF–1Yes\\nD412(VR) 5.23x6.71x0.99 60.0 26.5 RV:DF4 Yes\\nD413(DR) 5.23x7.03x0.99 62.5 28.0 RA:IS-1;RV:DF4 Yes\\nTable6.Mechanical Specifications -VIGILANTExtended Longevity (EL)ICDs\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nD220(VR) 5.37x7.79x0.99 70.7 31.5 RV:IS-1/DF–1 Yes\\nD221(DR) 5.37x7.79x0.99 71.0 31.5 RA:IS-1;RV:IS-\\n1/DF–1Yes\\nD232(VR) 5.37x7.36x0.99 68.9 29.5 RV:DF4 Yes\\nD233(DR) 5.37x7.68x0.99 71.4 31.0 RA:IS-1;RV:DF4 Yes', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 37}), Document(page_content='35Table7.Mechanical Specifications -MOMENTUM Extended Longevity (EL)ICDs\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume(cm3)Connector TypeMRConditional\\nD120(VR) 5.37x7.79x0.99 70.7 31.5 RV:IS-1/DF–1 Yes\\nD121(DR) 5.37x7.79x0.99 71.0 31.5 RA:IS-1;RV:IS-\\n1/DF–1Yes\\nMaterialspecifications areshownbelow:\\n•Case:hermetically sealedtitanium\\n•Header:implantation-grade polymer\\n•PowerSupply(RESONATE HFandEL):lithium-manganese dioxidecell;BostonScientificENDURALIFE; 401988\\n•PowerSupply(PERCIVAHFandPERCIVA): lithium-manganese dioxidecell;BostonScientific; 400010\\nITEMSINCLUDED INPACKAGE\\nThefollowing itemsareincludedwiththepulsegenerator:\\n•Onetorquewrench\\n•Productliterature\\nNOTE:Accessories(e.g.,wrenches) areintendedforone-timeuseonly.Theyshouldnotberesterilizedorreused.\\nWARNING: Implantofthesystemcannotbeperformed inanMRIsiteZoneIII(andhigher)asdefinedbytheAmerican\\nCollegeofRadiology Guidance Document onMRSafePractices5.Someoftheaccessoriespackaged withpulsegenerators and\\n5.KanalE,Barkovich AJ,BellC,etal.ACRguidancedocument onMRsafepractices:2013.J.Magn.Reson.Imaging2013;37:501-530.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 38}), Document(page_content='36leads,includingthetorquewrenchandstyletwires,arenotMRConditional andshouldnotbebroughtintotheMRIscanner\\nroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nSYMBOLSONPACKAGING\\nThefollowing symbolsmaybeusedonpackaging andlabeling:\\nTable8.Symbolsonpackaging\\nSymbol Description\\nReferenceNumber\\nContents\\nPulsegenerator\\nTorquewrench\\nLiteratureenclosed\\nSerialNumber', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 39}), Document(page_content='37Table8.Symbolsonpackaging (continued)\\nSymbol Description\\nUseBy\\nLotNumber\\nDateofManufacture\\nNon-Ionizing Electromagnetic Radiation\\nSterilizedusingethyleneoxide.\\nSTERILIZE2\\nDoNotResterilize\\nSingleuse.Donotre-use.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 40}), Document(page_content='38Table8.Symbolsonpackaging (continued)\\nSymbol Description\\nDonotuseifpackageisdamaged.\\nDangerous Voltage\\nConsultinstructions foruseonthiswebsite:www.\\nbostonscientific -elabeling.com\\nTemperatur elimitation.\\nPlacetelemetry wandhere', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 41}), Document(page_content='39Table8.Symbolsonpackaging (continued)\\nSymbol Description\\n,\\nOpenHere\\nManufacturer\\nMRConditional\\nCRT-DRA,RV,LV\\nICDRA,RV\\nICDRV\\nUncoated device', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 42}), Document(page_content='40Table8.Symbolsonpackaging (continued)\\nSymbol Description\\nRFTelemetry\\nDoublesterilebarriersystem\\nCHARACTERISTICS ASSHIPPED\\nRefertothetableforpulsegenerator settingsatshipment (Table9Characteristics asshippedonpage40).\\nTable9.Characteristics asshipped\\nParameter Setting\\nTachyMode Storage\\nTachyTherapyavailable ATP,Shock\\nPacingMode Storage\\nPacingTherapyavailable DDDR(DRmodels)VVIR(VRmodels)\\nSensor Accelerometer', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 43}), Document(page_content='41Table9.Characteristics asshipped(continued)\\nParameter Setting\\nSensor Blend(AccelandMV)(MOMENTUM, RESONATE HFandPERCIVAHF\\nmodels)\\nPace/Sense Configuration RA:BI/BI(DRmodels)\\nPace/Sense Configuration RV:BI/BI\\nThepulsegenerator isshippedinapower-savingStoragemodetoextenditsshelflife.InStoragemode,allfeaturesare\\ninactiveexcept:\\n•Telemetry support,whichallowsinterrogation andprogramming\\n•Real-time clock\\n•Commanded capacitorre-formation\\n•STATSHOCKandSTATPACEcommands\\nThedeviceleavesStoragemodewhenoneofthefollowing actionsoccurs;however,programmingotherparameters willnot\\naffecttheStoragemode:\\n•STATSHOCKorSTATPACEiscommanded\\n•TachyModeisprogramm edto:\\n•Off\\n•MonitorOnly\\n•Monitor+Therapy', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 44}), Document(page_content=\"42Onceyouhaveprogramm edthepulsegenerator outofStoragemode,thedevicecannotbereprogrammedtothatmode.\\nX-RAYIDENTIFIER\\nThepulsegenerator hasanidentifierthatisvisibleonanx-rayorfluoroscopicimage.Thisidentifierprovidesnoninvasive\\nconfirmationofthemanufacturer andconsistsofthefollowing:\\n•Theletters,BSC,toidentifyBostonScientificasthemanufacturer .\\n•Thenumber,140,toidentifythepulsegenerators.\\nThex-rayidentifierisembedded intheheaderofthedevice.Foraleftsidepectoralimplant,theidentifierwillbevisiblebyx-\\nrayorfluorographyattheapproximate locationshown(Figure1X-rayidentifieronpage42).\\n1\\n2\\n3\\n[1]X-RayIdentifier[2]Header[3]PulseGeneratorCase\\nFigure1.X-rayidentifier\\nForinformation onidentifying thedeviceviatheProgrammer,refertotheProgrammerOperator's Manual.\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 45}), Document(page_content=\"43Thepulsegenerator modelnumberandserialnumberareaccessiblefromtheProgrammerSummary screenoncethepulse\\ngenerator isinterrogated. Additional information suchasdateofmanufacture canbeobtainedbycontactingBostonScientific\\nandproviding themodelnumberandserialnumber.\\nFEDERALCOMMUNICATIONS COMMISSION (FCC)\\nThisdevicecomplieswithTitle47,Part15oftheFCCrules.Operationissubjecttothefollowing twoconditions:\\n•Thisdevicemaynotcauseharmfulinterferenc e,and\\n•Thisdevicemustacceptanyinterferenc ereceived,includinginterferenc ethatmaycauseundesired operation.\\nForpulsegenerators operating withatransmitfrequency of402to405MHz:thistransmitter isauthorizedbyruleunderthe\\nMedicalDeviceRadiocommunication Service(inpart95oftheFCCRules)andmustnotcauseharmfulinterferenc etostations\\noperating inthe400.150–406.000 MHzbandintheMeteorological Aids(i.e.,transmitters andreceiversusedtocommunicate\\nweatherdata),theMeteorological Satellite,ortheEarthExploration SatelliteServicesandmustacceptinterferenc ethatmaybe\\ncausedbysuchstations,includinginterferenc ethatmaycauseundesired operation. Thistransmitter shallbeusedonlyin\\naccordancewiththeFCCRulesgoverning theMedicalDeviceRadiocomm unicationService.Analoganddigitalvoice\\ncommunications areprohibited. Although thistransmitterhasbeenapproved bytheFederalCommunications Commission,\\nthereisnoguarantee thatitwillnotreceiveinterferenc eorthatanyparticular transmission fromthistransmitter willbefree\\nfrominterference.\\nCAUTION: Changesormodifications notexpresslyapproved byBostonScientificcouldvoidtheuser'sauthoritytooperatethe\\nequipment.\\nRESONATE HF,RESONATE, PERCIVAHF,PERCIVA,VIGILANT, andMOMENTUM devicesoperateinthe402–405MHzbandusing\\nFSKmodulation withradiatedpowerconforming totheapplicable 25μWlimit.TheFCCIDisESCCRMG17912. Wandedtelemetry\\noperatesat57kHzandusesQPSKmodulation.\\nPULSEGENERATOR LONGEVITY\\nBasedonsimulated studies,itisanticipated thatthesepulsegenerators haveaveragelongevitytoexplantasshownbelow.\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 46}), Document(page_content='44RefertothePRMSummary andBatteryDetailSummary screensforanestimateofpulsegenerator longevityspecifictothe\\nimplanted device.\\nThelongevityexpectations, whichaccountfortheenergyusedduringmanufacture andstorage,applyattheconditions shown\\ninthetablesalongwiththefollowing:\\n•Assumes60ppmLRL,0.4mspacingpulsewidth;sensorsOn,HeartFailureSensorSuiteOn.\\nThefollowing longevity tablesandconditions ofuseapplytoRESONATE HF,RESONATE, PERCIVAHF,PERCIVA,VIGILANT,\\nandMOMENTUM devices.\\nProjectedlongevityiscalculated assuming 2maximum energychargingcyclesperyear,includingautomatic capacitorre-forms\\nandtherapeutic shocks.Thesecalculations alsoassume3-channel EGMOnsetisonandthatthepulsegenerator spends3\\nmonthsinStoragemodeduringshippingandstorage.\\nPaceSafeOnforRAATandRVATprovidesanoutputof2Xthethreshold withaminimum outputof2.0V.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 47}), Document(page_content='45Table10.RESONATE HFandExtended Longevity (EL)ICDpulsegenerator lifeexpectancy estimation (implantto\\nexplant)withENDURALIFE battery\\nAllModelsa\\nPacing\\nAmpli-\\ntudePacingLongevity (years)\\n500Ωwith\\nLATITUDEb700Ωwith\\nLATITUDEb900Ωwith\\nLATITUDEb700ΩNoLATITUDE,\\nMV/RS,orHFSSc\\nVR DR VR DR VR DR VR DR\\n2.0V 0% 15.4 14.2 15.4 14.2 15.4 14.2 17.5 16.0\\n2.0V15% 15.2 13.8 15.2 13.9 15.3 14.0 17.2 15.6\\n2.0V50% 14.6 13.0 14.8 13.2 14.9 13.4 16.7 14.8\\n2.0V100% 13.9 11.9 14.3 12.4 14.5 12.7 16.0 13.7\\n2.5V15% 15.0 13.6 15.1 13.7 15.2 13.8 17.1 15.4\\n2.5V50% 14.2 12.3 14.5 12.7 14.7 13.0 16.3 14.1\\n2.5V100% 13.2 10.9 13.7 11.5 14.0 12.0 15.3 12.7\\na.AssumesZIPtelemetry usefor1houratimplantandfor40minutesannuallyforin-clinicfollow-up checks.\\nb.AssumesstandarduseoftheLATITUDE Communicator asfollows:DailyDeviceCheckon,quarterlyscheduled remotefollowups,andother\\ntypicalinterrogations.\\nc.AssumesLATITUDE Communicator isnotused,MinuteVentilation (MV)/Respiratory SensorisOff,andHeartFailureSensorSuiteisOff.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 48}), Document(page_content='46Table11.PERCIVAICDpulsegenerator lifeexpectancy estimation (implanttoexplant)\\nAllModelsa\\nPacing\\nAmpli-\\ntudePacingLongevity (years)\\n500Ωwith\\nLATITUDEb700Ωwith\\nLATITUDEb900Ωwith\\nLATITUDEb700ΩNoLATITUDE,\\nRS,orHFSSc\\nVR DR VR DR VR DR VR DR\\n2.0V 0% 8.2 7.5 8.2 7.5 8.2 7.6 9.3 8.5\\n2.0V15% 8.1 7.3 8.1 7.4 8.1 7.4 9.1 8.3\\n2.0V50% 7.8 6.9 7.9 7.0 7.9 7.1 8.9 7.8\\n2.0V100% 7.4 6.3 7.6 6.6 7.7 6.7 8.5 7.3\\n2.5V15% 8.0 7.2 8.0 7.3 8.1 7.3 9.1 8.1\\n2.5V50% 7.5 6.5 7.7 6.8 7.8 6.9 8.7 7.5\\n2.5V100% 7.0 5.7 7.3 6.1 7.4 6.3 8.1 6.7\\na.AssumesZIPtelemetry usefor1houratimplantandfor40minutesannuallyforin-clinicfollow-up checks.\\nb.AssumesstandarduseoftheLATITUDE Communicator asfollows:DailyDeviceCheckon,quarterlyscheduled remotefollowups,andother\\ntypicalinterrogations.\\nc.AssumesLATITUDE Communicator isnotused,MinuteVentilation (MV)/Respiratory SensorisOff,andHeartFailureSensorSuiteisOff.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 49}), Document(page_content='47NOTE:Theenergyconsumptioninthelongevitytableisbasedupontheoretical electricalprinciples andverifiedviabench\\ntestingonly.\\nThepulsegenerator longevitymayincreasewithadecreaseinanyofthefollowing:\\n•Pacingrate\\n•Pacingpulseamplitude(s)\\n•Pacingpulsewidth(s)\\n•Percentageofpacedtosensedevents\\n•Chargingfrequency\\nForRESONATE HFandExtended Longevity (EL)devices,longevityisalsoaffectedinthefollowing circumstanc es:6\\n•Adecreaseinpacingimpedance mayreducelongevity.\\n•WhentheMV/Respiratory SensorisprogrammedOffforthelifeofthedevice,longevityisincreased byapproximately 6\\nmonths.\\n•WhenPatientTriggered MonitorisprogrammedtoOnfor60days,longevityisreducedbyapproximately 5days.\\n•WhentheLATITUDE Communicator isnotusedforthelifeofthedevice,longevityisincreasedbyapproximately 7\\nmonths.\\n•Onehourofadditional ZIPwandless telemetry reduceslongevitybyapproximately 11days.\\n•Fivepatient-initiatedLATITUDE Communicator interrogations perweekforayearreduceslongevitybyapproximately 52\\ndays.\\n•Anadditional maximum-energy shockreduceslongevitybyapproximate ly24days.\\n•SixhoursinMRIProtection Modereduceslongevitybyapproximately 4days.\\n•Anadditional 6monthsinStoragemodepriortoimplantwillreducelongevityby67days.\\n6.Assumesimplanted settingsof60ppmLRL;2.5VpacingpulseAmplitude and0.4mspacingPulseWidth;500ΩpacingImpedance; 50%\\npacing.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 50}), Document(page_content='48•WhentheHeartFailureSensorSuiteisprogrammedtoOffforthelifeofthedevice,longevityisincreasedby\\napproximately 1month.\\n•AHeartLogic subscription withdailyalertchecksandweeklyinterrogations willdecreaselongevitybyapproximately 3\\nmonthswhenusedforthelifeofthedevice.\\n•Dailyinterrogations torefreshHeartLogic following analertfor30dayseachyearwilldecreaselongevitybyanadditional\\n2months.\\n•ForDRdevices,whentheSignalArtifactMonitorisprogrammedOnforthelifeofthedevice,longevityisreducedby\\napproximately 4months.7\\n•ForVRdevices,whentheSignalArtifactMonitorisprogrammedOnforthelifeofthedevice,longevityisreducedby\\napproximately 6months.7\\nForPERCIVAdevices,longevityisalsoaffectedinthefollowing circumstanc es:8\\n•Adecreaseinpacingimpedancemayreducelongevity.\\n•WhentheMV/Respiratory SensorisprogrammedOffforthelifeofthedevice,longevityisincreased byapproximately 3\\nmonths.\\n•WhenPatientTriggeredMonitorisprogrammedtoOnfor60days,longevityisreducedbyapproximately 5days.\\n•WhentheLATITUDE Communicator isnotusedforthelifeofthedevice,longevityisincreased byapproximately4\\nmonths.\\n•Onehourofadditional ZIPwandless telemetry reduceslongevitybyapproximately 11days.\\n•Fivepatient-initiatedLATITUDE Communicator interrogations perweekforayearreduceslongevitybyapproximately 47\\ndays.\\n•Anadditional maximum-energy shockreduceslongevitybyapproximately 26days.\\n7.Assumessettingsof60min-1LRL;2.0VpacingpulseAmplitude and0.4mspacingPulseWidth;500ΩpacingImpedance; 0%pacing.\\n8.Assumesimplanted settingsof60ppmLRL;2.5VpacingpulseAmplitude and0.4mspacingPulseWidth;500ΩpacingImpedance; 50%\\npacing.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 51}), Document(page_content='49•SixhoursinMRIProtection Modereduceslongevitybyapproximately 4days.\\n•Anadditional 6monthsinStoragemodepriortoimplantwillreducelongevityby66days.\\n•WhentheHeartFailureSensorSuiteisprogrammedtoOffforthelifeofthedevice,longevityisincreased by\\napproximately 1month.\\n•AHeartLogic subscription withdailyalertchecksandweeklyinterrogations willdecreaselongevitybyapproximately2\\nmonthswhenusedforthelifeofthedevice.\\n•Dailyinterrogations torefreshHeartLogic following analertfor30dayseachyearwilldecreaselongevitybyanadditional\\n1month.\\n•ForDRdevices,whentheSignalArtifactMonitorisprogrammedOnforthelifeofthedevice,longevityisreducedby\\napproximately 2months.9\\n•ForVRdevices,whentheSignalArtifactMonitorisprogrammedOnforthelifeofthedevice,longevityisreducedby\\napproximately 3months.9\\nDevicelongevitymayalsobeaffectedby:\\n•Tolerancesofelectronic components\\n•Variations inprogrammedparameters\\n•Variations inusageasaresultofpatientcondition\\nWARRANTY INFORMATION\\nAlimitedwarrantycertificate forthepulsegenerator isavailableatwww.bostonscientific.com. Foracopy,contactBoston\\nScientificusingtheinformation onthebackcover.\\n9.Assumessettingsof60min-1LRL;2.0VpacingpulseAmplitude and0.4mspacingPulseWidth;500ΩpacingImpedance; 0%pacing.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 52}), Document(page_content=\"50PRODUCTRELIABILITY\\nItisBostonScientific's intenttoprovideimplantable devicesofhighqualityandreliability.However,thesedevicesmayexhibit\\nmalfunctions thatmayresultinlostorcompromisedabilitytodelivertherapy.Thesemalfunctions mayincludethefollowing:\\n•Prematurebatterydepletion\\n•Sensingorpacingissues\\n•Inabilitytoshock\\n•Errorcodes\\n•Lossoftelemetry\\nRefertoBostonScientific's CRMProductPerformance Reportonwww.bostonscientific.com formoreinformation aboutdevice\\nperformance, includingthetypesandratesofmalfunctions thatthesedeviceshaveexperiencedhistorically .Whilehistorical\\ndatamaynotbepredictive offuturedeviceperformance, suchdatacanprovideimportant contextforunderstanding theoverall\\nreliabilityofthesetypesofproducts.\\nSometimes devicemalfunctions resultintheissuanceofproductadvisories. BostonScientificdetermines theneedtoissue\\nproductadvisories basedontheestimated malfunction rateandtheclinicalimplication ofthemalfunction. WhenBoston\\nScientificcommunicates productadvisoryinformation, thedecisionwhethertoreplaceadeviceshouldtakeintoaccountthe\\nrisksofthemalfunction, therisksofthereplacementprocedure,andtheperformance todateofthereplacement device.\\nPATIENTCOUNSELING INFORMATION\\nThefollowing topicsshouldbediscussed withthepatientpriortodischarge:\\n•Externaldefibrillation—the patientshouldcontacttheirphysician tohavetheirpulsegenerator systemevaluated ifthey\\nreceiveexternaldefibrillation\\n•Beepingtones—the patientshouldcontacttheirphysician immediately iftheyheartonescomingfromtheirpulse\\ngenerator\\n•Signsandsymptoms ofinfection\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 53}), Document(page_content='51•Symptoms thatshouldbereported(e.g.,sustained high-rate pacingrequiringreprogramming)\\n•Protected environments—the patientshouldseekmedicalguidancebeforeenteringareasprotected byawarningnotice\\nthatpreventsentrybypatientswhohaveapulsegenerator\\n•MRIscanning—the physician following thepatient\\'sdevicemustbeconsultedtodetermine eligibilityforanMRIscan.\\nBeforeanMRIprocedureisperformed, aphysician andpatientshouldweighthebenefitoftheMRprocedureagainstthe\\nriskoflosingtheBeeper.\\nWARNING: Determine thebeepertypebeforeanMRIscan.TheArmature Beepermaynolongerbeusablefollowing anMRI\\nscan.Comingincontactwiththestrongmagnetic fieldofanMRIscannermaycauseapermanent lossoftheArmature Beeper\\nvolume.Thiscannotberecovered,evenafterleavingtheMRIscanenvironment andexitingMRIProtection Mode.Forthe\\nArmature Beeper,beforeanMRIscanisperformed, aphysician andpatientshouldweighthebenefitoftheMRIscanagainst\\ntheriskoflosingtheBeeper;aftertheMRIscan,performBeeperevaluation testtodetermine iftheBeeperisusable.Ifthe\\nBeeperisnotusable,itisstronglyrecommended thatpatientsarefollowedonLATITUDE NXTafteranMRIscaniftheyarenot\\nalready.Otherwise, anin-clinicfollow-up scheduleofeverythreemonthsisstronglyrecommended tomonitordevice\\nperformance.\\n•AvoidingpotentialsourcesofEMIinhome,work,andmedicalenvironments\\n•Personsadministering CPR—thepresenceofvoltage(tingling)onthepatient\\'sbodysurfacemaybeexperience dwhen\\nthepulsegenerator deliversashock\\n•Reliability oftheirpulsegenerator (\"ProductReliability\" onpage50)\\n•Activityrestrictions (ifapplicable)\\n•Minimum heartrate(lowerratelimitofthepulsegenerator)\\n•Frequency offollowup\\n•Travelorrelocation—follow-up arrangements shouldbemadeinadvanceifthepatientisleavingthecountryofimplant\\n•PatientIDcard—thepatientshouldbeadvisedtocarrytheirpatientIDcardatalltimes(atemporary patientIDcardis\\nprovidedwiththedevice,andapermanent IDcardwillbesenttothepatient4to6weeksaftertheimplantformis\\nreceivedbyBostonScientific)', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 54}), Document(page_content='52NOTE:PatientsshouldpresenttheirpatientIDcardbeforeenteringprotected environments suchasforMRI\\nscanning.\\nPatientHandbook\\nThePatientHandbook isprovidedforeachdevice.\\nItisrecommended thatyoudiscusstheinformation inthePatientHandbook withconcernedindividuals bothbeforeandafter\\nimplantation sotheyarefullyfamiliarwithpulsegenerator operation.\\nInaddition,forpatientswithanImageReady MRConditional Defibrillation System,anImageReady MRConditional Defibrillation\\nSystemMRIPatientGuideisavailable.\\nForadditional copies,contactBostonScientificusingtheinformation onthebackcover.\\nLEADCONNECTIONS\\nLeadconnections areillustrated below.\\nCAUTION: Priortoimplantation, confirmthelead-to-pulse generator compatibility.Usingincompatible leadsandpulse\\ngenerators candamagetheconnector and/orresultinpotentialadverseconsequenc es,suchasundersensing ofcardiacactivity\\norfailuretodelivernecessary therapy.\\nWhendeactivating alead,ensuretheleadisfullyinsulatedandelectricalnonactivebyusingleadcaps.Whendeactivating a\\nleadport,verifythattheplugandlabeledheaderportmatch.Verifywithaprogrammertheappropriate devicefunctionand\\nnewlyestablished configuration.Theabsenceofaleadorportplugmayaffectdeviceperformance andpotentially leavethe\\npatientwithouteffectivetherapy.\\nNOTE:UseofBostonScientificMRConditional leadsisrequiredforanimplanted systemtobeconsideredMRConditional.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnicalGuideformodelnumbersofpulsegenerators,\\nleads,accessories,andothersystemcomponentsneededtosatisfytheConditions ofUse.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 55}), Document(page_content='53\\n4\\n3\\n5DF4-LLHH\\nIS-1 \\nB\\nI\\nR\\nV\\nRA\\n1\\n2[1]RA:White[2]RV:Red[3]RA(-)[4]SutureHoles[5]RV(-)\\nFigure2.Leadconnections andsetscrewlocations, RA:IS-1,RV:DF4-LLHH\\n3\\n2\\nDF4-LLHH\\nRV\\n1\\n[1]RV:Red[2]RV(-)[3]SutureHoles\\nFigure3.Leadconnections andsetscrewlocations, RV:DF4-LLHH', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 56}), Document(page_content='54\\n9\\n5\\n6\\n7\\n8\\nIS-1 \\nBI\\nRV\\n–\\n+\\nR\\nA\\nDF-1\\nDF-1\\nIS-1 \\nBI\\n1\\n2\\n43[1]Defib(-):Red[2]Defib(+):Blue[3]RA:White[4]RV:White[5]Defib(+)[6]Defib(-)[7]RA(-)[8]RV(-)[9]SutureHole\\nFigure4.Leadconnections andsetscrewlocations, RA:IS-1,RV:IS-1/DF-1', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 57}), Document(page_content='55\\n7\\n4\\n5\\n6\\nIS-1 \\nBI\\nR\\nV\\n–\\n+\\nDF-1\\nDF-1\\n1\\n2\\n3[1]Defib(-):Red[2]Defib(+):Blue[3]RV:White[4]Defib(+)[5]Defib(-)[6]RV(-)[7]SutureHole\\nFigure5.Leadconnections andsetscrewlocations, RV:IS-1/DF-1\\nNOTE:Thepulsegenerator caseisusedasadefibrillating electrodeunlessthepulsegenerator hasbeenprogrammedtothe\\nDistalCoiltoProximalCoil(or“ColdCan”)ShockVector.\\nIMPLANTING THEPULSEGENERATOR\\nImplantthepulsegenerator byperforming thefollowing stepsinthesequence provided. Somepatientsmayrequirepacing\\ntherapies immediately uponconnecting theleadstothepulsegenerator.Insuchcases,considerprogrammingthepulse\\ngenerator beforeorinparallelwithimplanting theleadsystemandformingtheimplantation pocket.\\nWARNING: Implantofthesystemcannotbeperformed inanMRIsiteZoneIII(andhigher)asdefinedbytheAmerican\\nCollegeofRadiology Guidance Document onMRSafePractices10.Someoftheaccessoriespackaged withpulsegenerators and\\n10.KanalE,Barkovich AJ,BellC,etal.ACRguidancedocument onMRsafepractices:2013.J.Magn.Reson.Imaging2013;37:501-530.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 58}), Document(page_content='56leads,includingthetorquewrenchandstyletwires,arenotMRConditional andshouldnotbebroughtintotheMRIscanner\\nroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nStepA:CheckEquipment\\nItisrecommended thatinstrumentation forcardiacmonitoring, defibrillation, andleadsignalmeasurement shouldbeavailable\\nduringtheimplantprocedure.ThisincludesthePRMsystemwithitsrelatedaccessoriesandthesoftwareapplication. Before\\nbeginning theimplantation procedure,becomecompletely familiarwiththeoperation ofalltheequipment andtheinformation\\nintherespective operator\\'s anduser\\'smanuals.Verifytheoperational statusofallequipment thatmaybeusedduringthe\\nprocedure.Incaseofaccidental damageorcontamination, thefollowing shouldbeavailable:\\n•Sterileduplicates ofallimplantable items\\n•Sterilewand\\n•SterilePSAcables\\n•Torqueandnon-torque wrenches\\nDuringtheimplantation procedure,alwayshaveastandardexternaldefibrillator withexternalpadsorpaddlesavailableforuse\\nduringdefibrillation threshold testing.\\nStepB:InterrogateandCheckthePulseGenerator\\nThePRMcommunicates withthepulsegenerator usingatelemetry wand.Afterinitiatingcommunication withthewand,the\\nPRMcanusewandless ZIPtelemetry (two-way RFcommunication) tointerfacewithRFcapablepulsegenerators. Telemetry is\\nrequiredtodirectcommands fromthePRMsystem,modifydeviceparametersettingsandconductdiagnostics tests.\\nForadditional technicalspecifications regardingtelemetry function,referto\"FederalCommunications Commission (FCC)\"on\\npage43.\\nTomaintainsterility,testthepulsegenerator asdescribed belowbeforeopeningthesterileblistertray.Thepulsegenerator\\nshouldbeatroomtemperatur etoensureaccuratelymeasured parameters.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 59}), Document(page_content=\"571.Interrogate thepulsegenerator usingthePRM.Verifythatthepulsegenerator's TachyModeisprogrammedtoStorage.\\nIfotherwise, contactBostonScientificusingtheinformation onthebackcover.\\nTobeginaZIPtelemetry session,verifythattheZOOMWirelessTransmitter isconnectedtothePRMviatheUSBcable\\nandthatthegreenlightontopofthetransmitter isilluminated. Toinitiatecommunication withalldevices,positionthe\\nwandoverthePGandusethePRMtoInterrogate thepulsegenerator.Keepthetelemetry wandinpositionuntileithera\\nmessageappears,indicating thatthetelemetry wandmayberemovedfromproximity ofthepulsegenerator,ortheZIP\\ntelemetry lightilluminates onthePRMsystem.SelecttheEndSessionbuttontoquitatelemetry sessionandreturnto\\nthestartupscreen.Radiofrequency interferencemaytemporarily disruptZIPtelemetry communication. Increasing the\\ndistancefromthesourceofinterfering signalsorrepositioning theZOOMWirelessTransmitter mayimproveZIP\\ntelemetry performance. IfZIPtelemetry performance isnotsatisfactory ,theoptionofusingwandedtelemetry is\\navailable.\\n2.Performamanualcapacitorre-formation.\\n3.Reviewthepulsegenerator's currentbatterystatus.Countersshouldbeatzero.Ifthepulsegenerator batterystatusis\\nnotatfullcapacity,donotimplantthepulsegenerator.ContactBostonScientificusingtheinformation onthebackcover.\\nStepC:ImplanttheLeadSystem\\nThepulsegenerator requiresaleadsystemforsensing,pacing,anddelivering shocks.Thepulsegenerator canuseitscaseasa\\ndefibrillating electrode.\\nAfunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriat esensingandpacinginallchambers,\\nregardlessofprogrammedconfiguration,inconjunction withalltherapyrequiredleads.\\nSelectionofleadconfigurationandspecificsurgicalproceduresisamatterofprofessional judgment. Thefollowing leadsare\\navailableforusewiththepulsegenerator depending onthedevicemodel.\\n•Bipolarendocardial cardioversion/defibrillation andpacingleadsystem\\n•Ventricular endocardial bipolarlead\\n•Atrialbipolarlead\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 60}), Document(page_content='58•Superiorvenacavaleadcoupledwithaventricular patchlead\\n•Two-patch epicardial leadsconfiguration\\nNOTE:UseofBostonScientificMRConditional leadsisrequiredforanimplanted systemtobeconsideredMRConditional.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnicalGuideformodelnumbersofpulsegenerators,\\nleads,accessories,andothersystemcomponentsneededtosatisfytheConditions ofUse,andforwarningsandprecautions\\nregardingMRIscanning.\\nCAUTION: Theabsenceofaleadorpluginaleadportmayaffectdeviceperformance andpotentially leavethepatient\\nwithouteffectivetherapy.Ifaleadisnotused,verifythattheplugandlabeledheaderportmatch(i.e.,IS-1,DF-1,orDF4).Fully\\ninserttheplugintheunusedportandthentightenthesetscrewontotheplug.Verifyappropriate devicefunctionusingthe\\nprogrammer.\\n•Afunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriate sensingandpacinginall\\nchambers, regardlessofprogrammedconfiguration.ThisincludesdualchamberdevicesprogrammedtoAAI(R).\\n•Lackofafunctional RVleadmayresultinundersensing, and/oroversensing andleavethepatientwithouteffective\\ntherapy.\\nCAUTION: Donotsuturedirectlyovertheleadbody,asthismaycausestructural damage.Usethesuturesleevetosecure\\ntheleadproximaltothevenousentrysitetopreventleadmovement.\\nWhichever leadconfigurationisusedforbothpacing/sensing anddefibrillating, severalconsiderationsandcautionsshouldbe\\nheeded.Factorssuchascardiomegaly ordrugtherapymaynecessitate repositioning ofthedefibrillating leadsorsubstituting\\noneleadforanothertofacilitatearrhythmia conversion. Insomeinstances, noleadconfigurationmaybefoundthatprovides\\nreliablearrhythmia termination atenergylevelsavailablefromthepulsegenerator.Implantation ofthepulsegenerator isnot\\nrecommended inthesecases.\\nImplanttheleadsviathesurgicalapproach chosen.\\nNOTE:Shouldleadperformance changesoccurwhichcannotberesolvedwithprogramming,theleadmayneedtobe\\nreplacedifnoadapterisavailable.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 61}), Document(page_content='59NOTE:Useofadaptersisinconsistent withtheConditions ofUserequiredforMRConditional status.RefertotheImageReady\\nMRConditional Defibrillation SystemMRITechnicalGuideforwarnings, precautions, andotherinformation aboutMRIscanning.\\nStepD:TakeBaselineMeasurements\\nOncetheleadsareimplanted, takebaselinemeasurements. Evaluatetheleadsignals.Ifperforming apulsegenerator\\nreplacementprocedure,existingleadsshouldbereevaluated, (e.g.,signalamplitudes, pacingthresholds, andimpedance). The\\nuseofradiographymayhelpensureleadpositionandintegrity.Iftestingresultsareunsatisfactory ,leadsystemrepositioning or\\nreplacementmayberequired.\\n•Connectthepace/sense lead(s)toapacingsystemanalyzer(PSA).\\nWARNING: ForleadsthatrequiretheuseofaConnector Tool,usecautionhandlingtheleadterminalwhentheConnector\\nToolisnotpresentonthelead.Donotdirectlycontacttheleadterminalwithanysurgicalinstruments orelectricalconnections\\nsuchasPSA(alligator) clips,ECGconnections, forceps,hemostats, andclamps.Thiscoulddamagetheleadterminal,possibly\\ncompromisingthesealingintegrityandresultinlossoftherapyorinappropriatetherapy,suchasashortwithintheheader.\\n•Pace/sense leadmeasurements,measured approximately 10minutesafterinitialplacement (acute)orduringa\\nreplacementprocedure(chronic),arelistedbelow.Valuesotherthanwhataresuggested inthetablemaybeclinically\\nacceptableifappropriate sensingcanbedocumented withthecurrentlyprogrammedvalues.Considerreprogramming\\nthesensitivity parameter ifinappropriate sensingisobserved. Notethatthepulsegenerator measurements maynot\\nexactlycorrelatetothePSAmeasurements duetosignalfiltering.\\nTable12.Leadmeasurements\\nPace/senselead(acute) Pace/senselead(chronic)Shockinglead(acuteand\\nchronic)\\nR-WaveAmplitudeab>5mV >5mV >1.0mV\\nP-WaveAmplitudeab>1.5mV >1.5mV', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 62}), Document(page_content='60Table12.Leadmeasurements (continued)\\nPace/senselead(acute) Pace/senselead(chronic)Shockinglead(acuteand\\nchronic)\\nR-WaveDurationbcd<100ms <100ms\\nPacingThreshold (right\\nventricle)<1.5Vendocardial\\n<2.0Vepicardial<3.0Vendocardial\\n<3.5Vepicardial\\nPacingThreshold (atrium) <1.5Vendocardial <3.0Vendocardial\\nLeadimpedance (at5.0V\\nand0.5msatrium)e>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg\\nLeadimpedance (at5.0V\\nand0.5msrightventricle)e>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg>20Ω\\n<programmedHigh\\nImpedance Limit(125–200\\nΩ)\\na.Amplitudes lessthan2mVcauseinaccurate ratecountinginthechronicstate,andresultininabilitytosenseatachyarrhythmia orthe\\nmisinterpretation ofanormalrhythmasabnormal.\\nb.LowerR-waveamplitudes andlongerdurationmaybeassociated withplacement inischemicorscarredtissues.Sincesignalqualitymay', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 63}), Document(page_content=\"61Table12.Leadmeasurements (continued)\\ndeteriorate chronically ,effortsshouldbemadetomeettheabovecriteriabyrepositioning theleadstoobtainsignalswiththelargestpossible\\namplitude andshortestduration.\\nc.Durations longerthan135ms(thepulsegenerator's refractoryperiod)mayresultininaccuratecardiacratedetermination, inabilitytosensea\\ntachyarrhythmia, orinthemisinterpretation ofanormalrhythmasabnormal.\\nd.Thismeasurement isnotinclusiveofcurrentofinjury.\\ne.Changesinthedefibrillation electrode surfacearea,suchaschangingfromatriadconfigurationtoasinglecoilconfiguration,canaffectthe\\nimpedance measurements. Baselinedefibrillation impedance measurements shouldfallwithintherecommended valuesindicatedinthetable.\\nf.TheLowImpedance Limitisprogrammable between200–500Ω.\\ng.TheHighImpedance Limitisprogrammable between2000–3000 Ω.\\nIftheleadintegrityisinquestion, standardleadtroubleshooting testsshouldbeusedtoassesstheleadsystemintegrity.\\nTroubleshooting testsinclude,butarenotlimitedto,thefollowing:\\n•Electrogramanalysiswithpocketmanipulation\\n•X-rayorfluoroscopicimagereview\\n•Additional maximum-energy shocks\\n•ProgrammingtheShockLeadVector\\n•WirelessECG\\n•Invasivevisualinspection\\nStepE:FormtheImplantation Pocket\\nUsingstandardoperating procedurestoprepareanimplantation pocket,choosethepositionofthepocketbasedonthe\\nimplanted leadconfigurationandthepatient'sbodyhabitus.Givingconsiderationtopatientanatomyandpulsegenerator size\\nandmotion,gentlycoilanyexcessleadandplaceadjacenttothepulsegenerator.Itisimportant toplacetheleadintothe\\npocketinamannerthatminimizes leadtension,twisting,sharpangles,and/orpressure.Pulsegenerators aretypically\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 64}), Document(page_content='62implanted subcutaneously inordertominimizetissuetraumaandfacilitateexplant.However,deeperimplantation (e.g.,\\nsubpectora l)mayhelpavoiderosionorextrusioninsomepatients.\\nIfanabdominal implantissuitable,itisrecommended thatimplantation occurontheleftabdominal side.\\nNOTE:Anabdominal implantsiteisinconsistentwiththeConditions ofUseforMRConditional MRIscanning. Refertothe\\nImageReady MRConditional Defibrillation SystemMRITechnicalGuideforwarnings, precautions andotherinformation about\\nMRIscanning.\\nIfitisnecessarytotunnelthelead,considerthefollowing:\\nWARNING: ForleadsthatrequiretheuseofaConnector Tool,usecautionhandlingtheleadterminalwhentheConnector\\nToolisnotpresentonthelead.Donotdirectlycontacttheleadterminalwithanysurgicalinstruments orelectricalconnections\\nsuchasPSA(alligator) clips,ECGconnections,forceps,hemostats, andclamps.Thiscoulddamagetheleadterminal,possibly\\ncompromisingthesealingintegrityandresultinlossoftherapyorinappropriate therapy,suchasashortwithintheheader.\\nWARNING: DonotcontactanyotherportionoftheDF4–LLHH orDF4–LLHO leadterminal,otherthantheterminalpin,even\\nwhentheleadcapisinplace.\\n•Ifacompatibletunnelerisnotused,captheleadterminalpins.APenrosedrain,largechesttube,ortunneling toolmay\\nbeusedtotunneltheleads.\\n•ForDF4-LLHH orDF4-LLHO leads,ifacompatible tunneling tipand/ortunnelerkitisnotused,captheleadterminaland\\ngriponlytheterminalpinwithahemostat orequivalent.\\n•Gentlytunneltheleadssubcutaneously totheimplantation pocket,ifnecessary.\\n•Reevaluate allleadsignalstodetermine ifanyoftheleadshavebeendamaged duringthetunneling procedure.\\nIftheleadsarenotconnected toapulsegenerator atthetimeofleadimplantation, theymustbecappedbeforeclosingthe\\nincision.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 65}), Document(page_content='63StepF:ConnecttheLeadstothePulseGenerator\\nToconnectleadstothepulsegenerator,useonlythetoolsprovidedinthepulsegenerator steriletrayoraccessorykit.Failure\\ntousethesuppliedtorquewrenchmayresultindamagetothesetscrews, sealplugs,orconnector threads.Donotimplantthe\\npulsegenerator ifthesealplugsappeartobedamaged. Retainthetoolsuntilalltestingproceduresarecompleteandthepulse\\ngenerator isimplanted.\\nNOTE:Somepatientsmayrequirepacingtherapies immediately uponconnecting theleadstothepulsegenerator.Insuch\\ncases,considerprogrammingthepulsegenerator beforecontinuing.\\nLeadsshouldbeconnected tothepulsegenerator inthefollowing sequence (forpulsegenerator headerandsetscrewlocation\\nillustrations, referto\"LeadConnections\" onpage52):\\n1.Rightventricle. ConnecttheRVleadfirstbecauseitisrequiredtoestablishRV-based timingcyclesthatyield\\nappropriate sensingandpacinginallchambers, regardless oftheprogrammedconfiguration.\\n•InmodelswithanIS-1RVleadport,insertandsecuretheterminalpinofanIS-1RVpace/sense lead.\\n•InmodelswithaDF4-LLHH RVleadport,insertandsecuretheterminalpinofaDF4-LLHH orDF4-LLHO lead.\\n2.Rightatrium.\\n•InmodelswithanIS-1RAleadport,insertandsecuretheterminalpinofanIS-1atrialpace/sense lead.\\n3.Defibrillation lead.\\n•InmodelswithDF-1leadports,firstinsertandsecurethedefibrillation leadanode(+,proximal) intothe(+)DF-1\\nleadport.Theninsertandsecuretheleadcathode(–,distal)intothe(–)DF-1leadport.\\nCAUTION: ForIS-1/DF-1leads,neverchangetheshockwaveform polaritybyphysically switching theleadanodesand\\ncathodesinthepulsegenerator header—use theprogrammable Polarityfeature.Devicedamageornonconversion ofthe\\narrhythmia post-operatively mayresultifthepolarityisswitchedphysically.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 66}), Document(page_content='64Connecteachleadtothepulsegenerator byfollowing thesesteps(foradditional information aboutthetorquewrench,referto\\n\"BidirectionalTorqueWrench\"onpage77):\\n1.Checkforthepresenceofanybloodorotherbodyfluidsintheleadportsonthepulsegenerator header.Iffluid\\ninadvertently enterstheports,cleanthemthoroughly withsterilewater.\\n2.Ifapplicable, removeanddiscardthetipprotection beforeusingthetorquewrench.\\n3.Gentlyinsertthetorquewrenchbladeintothesetscrewbypassingitthroughthepreslit,centerdepression oftheseal\\nplugata90°angle(Figure6Insertingthetorquewrenchonpage65).Thiswillopenupthesealplug,relievingany\\npotentialpressurebuild-upfromtheleadportbyproviding apathwaytoreleasetrappedfluidorair.\\nNOTE:Failuretoproperlyinsertthetorquewrenchinthepreslitdepression ofthesealplugmayresultindamageto\\nthepluganditssealingproperties.\\nCAUTION: Donotinsertaleadintothepulsegenerator connector withouttakingthefollowing precautionstoensure\\nproperleadinsertion:\\n•Insertthetorquewrenchintothepreslitdepression ofthesealplugbeforeinsertingtheleadintotheport,to\\nreleaseanytrappedfluidorair.\\n•Visuallyverifythatthesetscrewissufficiently retractedtoallowinsertion. Usethetorquewrenchtoloosenthe\\nsetscrewifnecessary.\\n•Fullyinserteachleadintoitsleadportandthentightenthesetscrewontotheterminalpin.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 67}), Document(page_content='65\\nFigure6.Insertingthetorquewrench\\n4.Withthetorquewrenchinplace,fullyinserttheleadterminalintotheleadport.Theleadterminalpinshouldbeclearly\\nvisiblebeyondtheconnector blockwhenviewedthroughthesideofthepulsegenerator header.Placepressureonthe\\nleadtomaintainitspositionandensurethatitremainsfullyinsertedintheleadport.\\nCAUTION: Inserttheleadterminalstraightintotheleadport.Donotbendtheleadnearthelead-header interface.\\nImproperinsertioncancauseinsulation orconnectordamage.\\nNOTE:Ifnecessary,lubricatetheentireleadterminal(areashowninFigure7DF4LeadTerminalonpage65)sparingly\\nwithsterilewaterorsterilemineraloiltomakeinsertioneasier.\\nFigure7.DF4LeadTerminal\\nNOTE:ForIS-1leads,becertainthattheterminalpinvisiblyextendsbeyondtheconnector blockatleast1mm.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 68}), Document(page_content='66NOTE:ForDF4-LLHH orDF4-LLHO leads,theterminalpinmustbeinsertedbeyondthesetscrewblocktoenablea\\nproperconnection. Visualization oftheterminalpininsertionindicatorbeyondthesetscrewblockmaybeusedtoconfirm\\nthattheterminalpinisfullyinsertedintotheleadport.\\n5.Applygentledownward pressureonthetorquewrenchuntilthebladeisfullyengagedwithinthesetscrewcavity,taking\\ncaretoavoiddamagetothesealplug.Tightenthesetscrewbyslowlyturningthetorquewrenchclockwise, untilit\\nratchetsonce.Thetorquewrenchispresettoapplytheproperamountofforcetothecaptivesetscrew; additional\\nrotationandforceisunnecessary .\\n6.Removethetorquewrench.\\n7.Applygentletractiontotheleadtoensureasecureconnection.\\n8.Iftheleadterminalisnotsecure,attempttoreseatthesetscrew.Reinsertthetorquewrenchasdescribed above,and\\nloosenthesetscrewbyslowlyturningthewrenchcounterclockwise, untiltheleadisloose.Thenrepeatthesequence\\nabove.\\n9.Ifaleadportisnotused,insertaplugintotheunusedportandtightenthesetscrew.\\nCAUTION: Theabsenceofaleadorpluginaleadportmayaffectdeviceperformance andpotentially leavethe\\npatientwithouteffectivetherapy.Ifaleadisnotused,verifythattheplugandlabeledheaderportmatch(i.e.,IS-1,DF-1,\\norDF4).Fullyinserttheplugintheunusedportandthentightenthesetscrewontotheplug.Verifyappropriate device\\nfunctionusingtheprogrammer.\\n•Afunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriat esensingandpacingin\\nallchambers, regardlessofprogrammedconfiguration.ThisincludesdualchamberdevicesprogrammedtoAAI(R).\\n•Lackofafunctional RVleadmayresultinundersensing, and/oroversensing andleavethepatientwithout\\neffectivetherapy.\\nStepG:EvaluateLeadSignals\\n1.Takethepulsegenerator outofpower-savingStoragemodebyprogrammingtheTachyModetoOff.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 69}), Document(page_content=\"67CAUTION: Topreventinappropriate shocks,ensurethatthepulsegenerator's TachyModeisprogrammedtoOffwhennot\\ninuseandbeforehandlingthedevice.Fortachyarrhythmia detection andtherapy,verifythattheTachyModeisprogrammedto\\nMonitor+Therapy.\\n2.Insertthepulsegenerator intotheimplantation pocket.\\n3.Evaluatethepace/senseanddefibrillation leadsignalsbyviewingthereal-timeEGMsandmarkers.Thesignalfromthe\\nimplanted defibrillation leadsshouldbecontinuous andwithoutartifact,similartoabody-surface ECG.Adiscontinuous\\nsignalmayindicateapoorconnection, leadfractureorotherwise damaged lead,oraninsulation breakthatwould\\nnecessitate leadreplacement.Inadequate signalsmayresultinfailureofthepulsegenerator systemtodetectan\\narrhythmia, inabilitytodeliverprogrammedtherapy,orunnecessary deliveryoftherapy.Leadmeasurements should\\nreflectthoseabove(Table12Leadmeasurements onpage59).\\nCAUTION: Takecaretoensurethatartifactsfromtheventricles arenotpresentontheatrialchannel,oratrialoversensing\\nmayresult.Ifventricular artifactsarepresentintheatrialchannel,theatrialleadmayneedtoberepositioned tominimizeits\\ninteraction.\\n4.Evaluateallleadimpedances.\\nCAUTION: Iftotalshockingleadimpedance duringimplantislessthan20Ω,verifytheproximalcoilisnotincontactwith\\nthepulsegenerator surface.Ameasurement oflessthan20Ωisanindication ofashortsomewhere inthesystem.Ifrepeated\\nmeasurements showthetotalshockingleadimpedance islessthan20Ω,theleadand/orpulsegenerator mayneedtobe\\nreplaced.\\nTheHighImpedance Limitisnominally setto2000Ω,andisprogrammable between2000and3000Ωin250Ωincrements.\\nTheLowImpedanceLimitisnominally setto200Ω,andisprogrammable between200and500Ωin50Ωincrements.\\nConsiderthefollowing factorswhenchoosingavaluefortheimpedance limits:\\n•Forchronicleads,historicalimpedance measurements forthelead,aswellasotherelectricalperformance indicators such\\nasstabilityovertime\\n•Fornewlyimplanted leads,thestartingmeasured impedance value\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 70}), Document(page_content=\"68NOTE:Depending onleadmaturation effects,duringfollow-up testingthephysician maychoosetoreprogramthe\\nimpedancelimits.\\n•Pacingdependenc eofthepatient\\n•Recommended impedancerangeforthelead(s)beingused,ifavailable\\nTheShockLowImpedance Limitisfixedat20Ω.TheShockHighImpedance Limitisnominally setto125Ω,andis\\nprogrammable between125and200Ωin25Ωincrements. Considerthefollowing factorswhenchoosingavaluefortheHigh\\nImpedanceLimits:\\n•Forchronicleads,historicalimpedance measurements forthelead,aswellasotherelectricalperformance indicators such\\nasstabilityovertime\\n•Fornewlyimplanted leads,thestartingmeasured impedance value\\nNOTE:Depending onleadmaturation effects,duringfollow-up testingthephysician maychoosetoreprogramtheHigh\\nImpedanceLimits.\\n•Recommended impedancerangeforthelead(s)beingused,ifavailable\\n•Theimpedance valueofahighormaximum energyshockimpedance test\\nShockingleadimpedance readingsbetween20ΩandtheprogrammedHighImpedance Limitareconsideredin-range.Ifabrupt\\norlargeimpedance fluctuations orout-of-range conditions areobserved, considerthefollowing:\\n•Verifytheconfiguration—ensure theprogrammedShockVectormatchestheconfigurationoftheimplanted lead(e.g.,\\nuseRVCoiltoCanwithasingle-coil lead).\\n•Verifytheconnection—ensur etheshockinglead'sterminalpinsareplacedinthecorrectleadportsandverifyasecure\\nleadconnection.\\n•Verifythecontact—ensur ethedeviceisinsideawetimplantpocketsincethepulsegenerator caseservesasanactive\\nelectrode intheV-TRIADconfiguration.Avoidpocketmanipulation duringthetest.\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 71}), Document(page_content='69•Turnoffsourcesofexternalnoise(e.g.,electrocautery equipment, monitors).\\n•Useothertroubleshooting tools,asneeded,tofurtherassessleadsystemintegrity,includingelectrogramanalysis,X-ray\\norfluoroscopicimagereview,orinternalvisualinspection.\\nNOTE:Becausethisdeviceusesasubthreshold testpulsetoconductshockleadimpedance measurements, itcanbedifficult\\ntomeasureresponses totestsignalswhenelectricalinterferenc eor“noise”(e.g.,electrocautery orexternalmonitoring\\nequipment attacheddirectlytothepatient)ispresentduringthetest.Thismayresultinimpedance measurement variations,\\nparticularly atimplant.Intheabsenceofsuchelectricalinterferenc e,shockleadimpedance readingswillbemorestable.\\nStepH:ProgramthePulseGenerator\\n1.ChecktheProgrammerClockandsetandsynchroniz ethepulsegenerator asnecessary sothatthepropertimeappears\\nonprintedreportsandPRMstripchartrecordings.\\n2.ItmaybeusefultoprogramtheBeepDuringCapacitorChargefeaturetoOnduringconversion testingandimplantation\\ntohelprecognizewhenthepulsegenerator ischargingtodeliverashock.\\n3.Performamanualcapacitorre-formation ifnotalreadyperformed.\\n4.Programthepulsegenerator appropriately ifaleadport(s)isnotused.\\n5.Programthepulsegenerator todesiredparametersappropriat eforthepatientforconversion testing.\\nConsiderthefollowing whenprogrammingthepulsegenerator:\\n•Theminimum 2Xvoltageor3Xpulsewidthsafetymarginisrecommended foreachchamberbasedonthecapture\\nthresholds, whichshouldprovideanadequate safetymarginandhelppreservebatterylongevity.\\n•WhenSmartBlankingisused,itispossiblethatpolarization artifactsfollowing atrialpacingmaybedetectedasR-waves\\nandinhibitventricular pacing(aftertachytherapyorhigh-output ventricular pacing).Ifthepatientispacemaker-\\ndependent, testforpropersensingaftershocktherapy.Ifoversensing isoccurringpost-shock,bepreparedtousethe\\nSTATPACEcommand.\\n•Programmingalongerblankingperiodmayincreasethelikelihood ofundersensing R-waves.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 72}), Document(page_content='70•Programmingashorterblankingperiodmayincreasethelikelihood forventricular oversensing ofanatrialpacedevent.\\n•Toreducetheriskofventricular undersensing duetoV-BlankafterA-Pace(whenadual-chamber pacingmodewithRate\\nSmoothing orRateAdaptivePacingisnecessary):\\n–ReducetheLRL\\n–ShortentheAVDelayoruseDynamicAVDelayandreducetheminimum DynamicAVDelaysetting\\n–ReducetheSearchAVDelayforAVSearch+\\n–IncreasetheDownRateSmoothing percentagetothelargestpossiblevalue\\n–DecreasetheRecoveryTimeforRateAdaptivePacingmodes\\n–ReducetheMTRorMPRifDownRateSmoothing ison\\n–ReducetheMSRifthepacingmodeisrateadaptive\\n•Whenreprogramming theRhythmMatch Threshold value,considerthefollowing:\\n–Reviewthemeasured RhythmMatch valuesforpreviousepisodesofVTandSVT(inducedorspontaneous)\\n–Toincreasethelikelihood ofappropriate treatment ofVT,theRhythmMatch Threshold shouldbeprogrammed\\nabovethemeasured RhythmMatch valuesofanyVTs\\n–Toincreasethelikelihood ofappropriate inhibition oftherapyforSVT,theRhythmMatch Threshold shouldbe\\nprogrammedbelowthemeasured RhythmMatch valuesofanySVTs\\n–Ingeneral,thesensitivity ofVTdetection declineswithlowerprogrammedRhythmMatch Threshold values,\\nthereforeformaximum sensitivity toVT,thehighestappropriate RhythmMatch Threshold valueshouldbe\\nprogrammed.\\n–Measured RhythmMatch valuesmayalsobeusefulforprogrammingotherRhythmIDparametersincludingAtrial\\nTachyarrhythmia Discrimination, AFibRateThreshold, andStability', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 73}), Document(page_content=\"71•WhenprogrammingMTR,considerthepatient’scondition, age,generalhealth,sinusnodefunction,andthatahighMTR\\nmaybeinappropriateforpatientswhoexperience anginaorothersymptoms ofmyocardial ischemiaathigherrates.\\n•WhenprogrammingMSR,considerthepatient’scondition, age,generalhealthandthatadaptive-rat epacingathigher\\nratesmaybeinappropriate forpatientswhoexperienceanginaorothersymptoms ofmyocardial ischemiaatthese\\nhigherrates.Anappropriate MSRshouldbeselectedbasedonanassessment ofthehighestpacingratethatthepatient\\ncantoleratewell.\\n•ProgramminglongAtrialRefractory periodsincombination withcertainAVDelayperiodscancause2:1blocktooccur\\nabruptlyattheprogrammedMTR.\\n•PriortoprogrammingRVATon,considerperforming aCommanded Ventricular Automatic Threshold Measurement to\\nverifythatthefeaturefunctionsasexpected.\\n•Inpacemaker-dependent patients,usecarewhenconsidering settingNoiseResponse toInhibitPacingaspacingwillnot\\noccurinthepresenceofnoise.\\n•Toresolvesuspected impedance-basedinteractions withtheMV/Respiratory Sensor,programthesensortoOff.\\nCAUTION: Topreventinappropriate shocks,ensurethatthepulsegenerator's TachyModeisprogrammedtoOffwhennot\\ninuseandbeforehandlingthedevice.Fortachyarrhythmia detection andtherapy,verifythattheTachyModeisprogrammedto\\nMonitor+Therapy.\\nStepI:TestforAbilitytoConvertVentricular Fibrillation andInducibleArrhythmias\\nAfterobtaining acceptablesignalsfromtheimplanted leads,thephysician maychoosetoperformVTandVFconversion testing\\ntodetermine (1)iftheconfigurationandpositionoftheimplanted leadsareappropriate forthepatientand(2)ifthepulse\\ngenerator’s programmedshockenergyormaximum-shock energywillbesufficienttoconvertarrhythmias reliablyand(3)if\\nAGCanddetection enhancements areprogrammedappropriately todetectVF/VT.Aconversion testconsistsofinducingthe\\narrhythmia andthenattempting toconvertthearrhythmia withapreselected energylevel.\\nDemonstrating conversion ofventricular fibrillation issuggested beforeimplanting apulsegenerator becauseashockdelivered\\nduringventricular tachycardia hasthepotentialtoacceleratethearrhythmia. Intraopera tivetestingmaybeminimized by\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 74}), Document(page_content=\"72performing onlyVFtestingattimeofimplantandperforming VTtestingpost-operatively intheelectrophysiology labpriorto\\nthepatient’sdischarge.\\nIftheconversion isunsuccessful,thepatientshouldberescuedusinganappropriate externaldefibrillator .Aspartoftheoverall\\nclinicalevaluation duringconversion testingandevaluation ofspontaneous episodesduringfollowup,ensurethereisnodelay\\norinterruption intachyarrhythmia detection andtherapydelivery.Performadditional evaluation ifanydiversionofcharging\\ncyclesorshockdeliveryisobserved.\\nIfconversion testingisperformed, thepermanently programmedparameters maybethesameasthoseusedduringtesting,or\\ntheymaybemodifiedtodifferentvalues.Thedevicecanbeprogrammedwiththeintendedfinalparameter settingsforallVT/\\nVF(multiplezones),orwithasinglezoneVFsettingwitharatethreshold belowthatofanyknownarrhythmia. Whenno\\nconversiontestingisperformed inpatientswithprimaryprevention indications, aphysician shouldconsiderthathighdetection\\nratescanlimittheabilityofthedevicetoaccuratelydetectandtreatpolymorphic tachyarrhythmias. Itisimportant toevaluate\\nthedevice'sstoreddiagnostic dataandEGMs,includingtheintervalplot,afterconversion testing(referto“Tachyarrhythmia\\nProgramming Considerations”below).Programmingfinalratethresholds forVT/VFtohighervalues,orlesssensitiveAGC\\nsettings,thanthetestedparameters mayresultinunder-detection oflaterspontaneous tachyarrhythmias.\\nWARNING: Alwayshaveexternaldefibrillation equipment availableduringimplantandelectrophysiologic testing.Ifnot\\nterminated inatimelyfashion,aninducedventricular tachyarrhythmia canresultinthepatient'sdeath.\\nNOTE:Ifopenchestsurgeryisperformed andachestretractorisused,removeitbeforeconversion testingtobestsimulate\\ntheambulatory conditionsinwhichthepulsegenerator willoperateandtoavoidpotentialshuntingofenergy.\\nInducethePatient’sArrhythmia\\nAnarrhythmia canbeinducedbyusingtheinduction featuresofthepulsegenerator.\\nAllowthepatient’sbloodpressureandelectrophysiologic statustoreturntobaselinebetweenarrhythmia inductions, whether\\nsuccessfulorunsuccessful.Theminimum timebetweenconversion testsshouldbebasedontheclinical(hemodynamic and\\nmetabolic) stabilityofthepatientandthephysician’s discretion.\\nDuringeacharrhythmia induction, notetheheartratetodetermine theappropriate ratethreshold values.Ventricular cycle\\nlengthsthatoccurclosetobutbelowthelowestprogrammedratethresholdvaluemaybedetectedasnormalsinusrhythm.To\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 75}), Document(page_content='73providesufficientopportunity fordetection, theratethreshold value(s)shouldbeprogramm edatleast10bpmbelowtherate\\nofthearrhythmia(s) intendedtobetreated.\\nPerformtheInduction\\n1.Verifythepulsegenerator isintheimplantation pocket.Temporarily closethepocketenoughtoensurethatthepulse\\ngenerator willremaininpositionduringconversion testing.Makesurethepulsegenerator hasgoodcontactwith\\nsurrounding tissue;flushthepocketwithsalinesolution,ifnecessary,toavoidadrypocket.\\nCAUTION: Donotallowanyobjectthatiselectrically conductive tocomeintocontactwiththeleadordeviceduring\\ninduction becauseitmayshuntenergy,resultinginlessenergygettingtothepatient,andmaydamagetheimplanted system.\\n2.Verifymagnetfunctionandtelemetry toensurethepulsegenerator iswithinacceptablerange.\\n3.Programtheappropriate parameters andchangethepulsegenerator TachyModetoMonitor+Therapy.\\n4.Performtheinduction usingtheprogrammer.\\nTestingEnergyRequirements andThresholds forSuccessfulDefibrillation\\nDefibrillation energyrequirementsandthreshold testingforsuccessfuldefibrillation shouldbeperformed atimplant.\\nShocksintendedforVForpolymorphic VTtherapyshouldbeprogrammedwitha10Jsafetymarginabovetheshockenergy\\nlevelthatthephysician determines isrequiredforsuccessfulVFconversion. Insomesituations, analternative safetymargin\\n(abovetheshockenergylevelrequiredforsuccessfulVFconversion) maybedetermined bythephysician tobeadequate.\\nDifferenttestmethodsfordetermining defibrillation thresholds aredescribed inclinicalliteratureandinclude,butarenot\\nlimitedto:\\n•Steppingdowntofailuredefibrillation threshold testingtodetermine theDFTandverifyingthelastsuccessfulenergy\\neitheronce[1x(DFT+)]ortwice[2x(DFT++)].\\n•Selectingthedefibrillation energyrequirement testingbysubtracting theacceptedsafetymarginfromthedevice\\nmaximum output.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 76}), Document(page_content='74Defininganimplantation safetymarginandtherelationship totheprobabilityforsuccessisdescribed inclinicalliterature.Any\\nresultfromasingletestmethodmaybeanexampleofstatistical variation, andaone-timeconversion ofarhythmdisturbance\\nataparticular energyleveldoesnotguaranteeorensurethattheenergylevelisreliableforconversion.\\nAsasafetymarginwitha41Jsystem,itisrecommended thattheconversion testbeperformed attheDFTleveltwotimesif\\ntheDFTorselectedenergylevelis31J,oronetimeiftheDFTorselectedenergylevelis21Jwithnofailurestoconvert.\\nAlwayshaveastandardexternaldefibrillator withexternalpadsorpaddlesavailableforuseduringdefibrillation threshold\\ntesting.\\nIfimplantation safetymarginandinitialconversion at31Jisunsuccessful,consideracombination ofdifferentmethodsto\\noptimizethedefibrillation fieldandefficacy.Possibilities include,butarenotlimitedto:\\n•Optimizetheleadposition—placetheleadasapicalandseptalaspossibletodirectmostoftheenergytotheleft\\nventricular massasdescribed inclinicalliterature.\\n•Reversepolarity—useelectronic deviceprogrammingoptionstochangepolarity.Donotphysically switchthelead\\nanodesandcathodesinthepulsegenerator header.\\n•ReprogramtheShockLeadVectorconfigurationinthedevice(e.g.,removetheproximalcoilfromaTRIADconfiguration\\ntoasingleshockvectorsuchastheRVCoiltoCanconfiguration).\\n•Addadditional defibrillation coilsorleadstoincreasethedefibrillation surfacearea.\\nNOTE:RefertoTable12Leadmeasurements onpage59foracceptableleadmeasurements afterleadrepositioning or\\nreprogramming.\\nStepJ:Tachyarrhythmia Programming Considerations\\nDetection Zones\\nSelecttheappropriate numberoftherapyzones(VT-1,VT,VF)totreattheexpectedventricular tachyarrhythmias basedonthe\\ntachyarrhythmia hemodynamic stability,patientindications, andtheindividual patientclinicalcharacteris tics.Toprovide', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 77}), Document(page_content='75sufficientopportunity fordetection, theratethreshold value(s)shouldbeprogrammedatleast10bpmbelowtherateofknown\\narrhythmia(s) intendedtobetreated.\\nNOTE:Thedevicedetection andsubsequent therapymaybedifferentforthesameunderlying tachyarrhythmia depending on\\nthenumberofzonesandprogrammedparameters suchasratethreshold, detection time,anddetection enhancements (if\\napplied).\\nEpisodeStorageReview\\nDevicediagnostics arestoredinthepulsegenerator andareviewableviathePRMorLATITUDE NXT.Diagnostics enablea\\nreviewofdevicedetection andresponsetoinducedandspontaneous tachyarrhythmias. Storedelectrogramsincludeaninterval\\nplot.Evaluating theintervalplothelpstoidentifydetectedbeatsincludingthosebelowtheratethreshold. Beatsbelowthe\\nprogrammedratethreshold maydelayorinhibitdevicedetection ofatachyarrhythmia, andconsiderationshouldbegivento\\nreprogramtheratestoimprovedetection. Inspection ofthestoredelectrograms,withuseoftheon-screen calipersforEGM\\namplitude andtimingmeasurement, permitsthephysician tointerpretwhetherthereareventricular beatswhicharenot\\ndetected. Ifthereareunmarked beats,thenanassessment shouldoccurtodetermine ifprogrammingslowerratezoneswould\\nimprovedetection.\\nDetection andAutomatic GainControl(AGC)\\nTherightventricular AGCissettoanominalvalueof0.6mVandcanbeadjustedusingthePRM.Adjustment oftheAGCmay\\nbeconsideredforcaseswithlowamplitude EGMs,delayintimetotherapy,orperthephysician’s discretion inindividual cases.\\nAnyadjustment oftheAGCmustbeevaluated incombination withtheprogrammeddetection ratethresholds/z onestoensure\\nappropriate ratedetection oftheexpectedtachyarrhythmia. TheAGCmaynotreachitsprogrammedfloorwhen\\ntachyarrhythmia detection ratesarerapidandthearrhythmia ispolymorphic. Alwaysevaluatetherateofthedetection zones\\nandtheAGCsettingincombinationusingtheepisodestorageinformation. Ifaphysician examines theEGMsandbelievesthe\\ndeviceisnotdetecting ventricular beat(s)intheappropriat ezone,thenreprogrammingdetection ratethresholds toslowerrates\\nmayfacilitatetheoveralldetection behavior.Adjusting theAGCwithconversion testingmaybeconsidered.Changesinthe\\npatient’smetabolic state,alongwithprescription drugs,mayaffectthesizeofthewaveform ontheEGM.AGCreprogramming\\nmaynotbenecessary whenmarkersindicatedevicesensingisappropriate, butthesensedintervalsarebelowtheratecriteria.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 78}), Document(page_content='76Markers\\nMarkerssuchasVT-1,VT,andVF,includingthemeasured cyclelength,arerecordedandassociated withtheprogrammed\\ndetection zones.Thepresenceofmarkersindicatesthatthedevicehasdetectedacertainbeat.Fluctuating tachycardiarates\\nthatarecloseto,orjustbelow,thelowestratethreshold maybemarkedasVS(ventricular sense).Reviewoftheintervalplot\\nprovidesanoverviewoftheprogrammedratethresholds andintervaldistribution duringtheepisodes. Thisinformation enables\\nclinicaladjustment ofdetection parameters perthephysician’s discretion.\\nStepK:ImplantthePulseGenerator\\n1.ProgramtheTachyModetoOff.\\n2.Verifymagnetfunctionandwandedtelemetry toensurethepulsegenerator iswithinacceptablerangetoinitiate\\ninterrogation.\\n3.Ensurethatthepulsegenerator hasgoodcontactwithsurrounding tissueoftheimplantation pocket,andthensutureit\\ninplacetominimizedevicemigration(forsutureholelocationillustrations,referto\"LeadConnections\" onpage52).\\nGentlycoilexcessleadandplaceadjacenttothepulsegenerator.Flushthepocketwithsalinesolution,ifnecessary,to\\navoidadrypocket.\\nWARNING: Donotkink,twist,orbraidtheleadwithotherleadsasdoingsocouldcauseleadinsulation abrasion\\ndamageorconductor damage.\\n4.Closetheimplantation pocket.Considerationshouldbegiventoplacetheleadsinamannertopreventcontactwith\\nsuturematerials. Itisrecommended thatabsorbable suturesbeusedforclosureoftissuelayers.\\n5.Complete anyelectrocautery proceduresbeforereactivating thepulsegenerator.\\n6.ProgramtheTachyModetothedesiredsettingandconfirmfinalprogrammedparameters.\\nCAUTION: Following anysensingrangeadjustment oranymodification ofthesensinglead,alwaysverifyappropriate\\nsensing.Programming Sensitivity tothehighestvalue(lowestsensitivity) mayresultindelayeddetection or\\nundersensing ofcardiacactivity.Likewise,programmingtothelowestvalue(highestsensitivity) mayresultin\\noversensing ofnon-cardiac signals.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 79}), Document(page_content=\"777.UsethePRMtoprintoutparameter reportsandsaveallpatientdata.\\nStepL:Complete andReturntheImplantation Form\\nWithintendaysofimplantation, completetheWarrantyValidation andLeadRegistration formandreturntheoriginaltoBoston\\nScientificalongwithacopyofthepatientdatasavedfromthePRM.Thisinformation enablesBostonScientifictoregistereach\\nimplanted pulsegenerator andsetofleads,andprovideclinicaldataontheperformance oftheimplanted system.Keepacopy\\noftheWarrantyValidation andLeadRegistration formandprogrammerprintouts, andtheoriginalpatientdataforthepatient's\\nfile.\\nComplete thetemporary patientidentification cardandgiveittothepatient.Afterreceivingthevalidation form,Boston\\nScientificsendsthepatientapermanent identification card.\\nBIDIRECTIONAL TORQUEWRENCH\\nAtorquewrench(model6628)isincludedinthesteriletraywiththepulsegenerator,andisdesignedfortightening and\\nloosening #2-56setscrews, capturedsetscrews,andsetscrews onthisandotherBostonScientificpulsegenerators andlead\\naccessoriesthathavesetscrews thatspinfreelywhenfullyretracted(thesesetscrews typicallyhavewhitesealplugs).\\nThetorquewrenchisbidirectional, ispresettoapplyadequate torquetothesetscrew,andwillratchetwhenthesetscrewis\\nsecure.Theratchetreleasemechanism preventsovertightening thatcouldresultindevicedamage.Tofacilitatetheloosening of\\ntightextended setscrews,thiswrenchappliesmoretorqueinthecounterclockwise directionthanintheclockwise direction.\\nNOTE:Asanadditional safeguard, thetipofthetorquewrenchisdesignedtobreakoffifusedtoovertighten beyondpreset\\ntorquelevels.Ifthisoccurs,thebrokentipmustbeextractedfromthesetscrewusingforceps.\\nThistorquewrenchmayalsobeusedforloosening setscrews onotherBostonScientificpulsegenerators andleadaccessories\\nthathavesetscrews thattightenagainstastopwhenfullyretracted(thesesetscrews typicallyhaveclearsealplugs).However,\\nwhenretractingthesesetscrews,stopturningthetorquewrenchwhenthesetscrewhascomeincontactwiththestop.The\\nadditional counterclockwise torqueofthiswrenchmaycausethesesetscrews tobecomestuckiftightened againstthestop.\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 80}), Document(page_content='78Loosening StuckSetscrews\\nFollowthesestepstoloosenstucksetscrews:\\n1.Fromaperpendicular position,tiltthetorquewrenchtotheside20ºto30ºfromtheverticalcenteraxisofthesetscrew\\n(Figure8Rotatingthetorquewrenchtoloosenastucksetscrewonpage79).\\n2.Rotatethewrenchclockwise (forretractedsetscrew) orcounterclockwise (forextendedsetscrew) aroundtheaxisthree\\ntimes,suchthatthehandleofthewrenchorbitsthecenterline ofthescrew(Figure8Rotatingthetorquewrenchto\\nloosenastucksetscrewonpage79).Thetorquewrenchhandleshouldnotturnortwistduringthisrotation.\\n3.Asneeded,youmayattemptthisuptofourtimeswithslightlymoreangleeachtime.Ifyoucannotfullyloosenthe\\nsetscrew,usethe#2torquewrenchfromWrenchKitModel6501.\\n4.Oncethesetscrewhasbeenfreed,itmaybeextended orretractedasappropriate.\\n5.Discardthetorquewrenchuponcompletion ofthisprocedure.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 81}), Document(page_content='79\\n20°–30°[1]Clockwise rotationtofreesetscrews stuckintheretractedposition[2]Counterclockwise rotationtofreesetscrews stuckinthe\\nextended position\\nFigure8.Rotatingthetorquewrenchtoloosenastucksetscrew\\nFOLLOWUPTESTING\\nItisrecommended thatdevicefunctionsbeevaluated withperiodicfollow-up testingbytrainedpersonnel. Followupguidance\\nbelowwillenablethorough reviewofdeviceperformance andassociated patienthealthstatusthroughout thelifeofthedevice\\n(refertotheinformation withinthe“ProgramthePulseGenerator”stepin\"Implanting thePulseGenerator\" onpage55).\\nWARNING: Ensurethatanexternaldefibrillator andmedicalpersonnel skilledinCPRarepresentduringpost-implantdevice\\ntestingshouldthepatientrequireexternalrescue.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 82}), Document(page_content='80Predischar geFollowUp\\nThefollowing proceduresaretypicallyperformed duringthepredischar gefollowuptestusingPRMtelemetry:\\n1.Interrogate thepulsegenerator andreviewtheSummary screen.\\n2.Verifypacingthresholds,leadimpedance, andamplitude ofintrinsicsignals.\\n3.Reviewcountersandhistograms.\\n4.Whenalltestingiscomplete, performafinalinterrogation andsaveallthepatientdata.\\n5.PrinttheQuickNotesandPatientDatareportstoretaininyourfilesforfuturereference.\\n6.Clearthecountersandhistograms sothatthemostrecentdatawillbedisplayed atthenextfollowupsession.Counters\\nandhistograms canbeclearedbypressingResetontheHistogram screen,TachyCountersscreen,orBradyCounters\\nscreen.\\nRoutineFollowUp\\nYoushouldconductroutinefollowupexaminations onemonthafterthepredischar gecheckandeverythreemonthsthereafter\\ntoevaluatedeviceprogramming,therapyeffectiveness, leadstatus,andbatterystatus.Officevisitsmaybesupplemented by\\nremotemonitoring whereavailable.\\nNOTE:Becausethedurationofthedevicereplacementtimeristhreemonths(startingwhenExplantstatusisreached),three\\nmonthfollowupfrequency isparticularly important aftertheOneYearRemaining statusisreached.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 83}), Document(page_content='81Considerperforming thefollowing proceduresduringaroutinefollow-up test:\\n1.Interrogate thepulsegenerator andreviewtheSummary screen.\\n2.Verifypacingthresholds, leadimpedance, andamplitude ofintrinsicsignals.\\n3.PrinttheQuickNotesandPatientDatareportstoretaininyourfilesforfuturereference.\\n4.ReviewtheArrhythmia Logbookscreenandforepisodesofinterest,printepisodedetailsandstoredelectrogram\\ninformation.\\n5.Clearthecountersandhistograms sothatthemostrecentepisodedatawillbedisplayed atthenextfollow-up session.\\n6.Verifythatimportant programmedparameter values(e.g.,LowerRateLimit,AVDelay,RateAdaptivePacing,output\\nAmplitude, PulseWidth,Sensitivity ,Ventricular Zones,Detection Rate)areoptimalforcurrentpatientstatus.Refertothe\\nstepsabove(“TestforAbilitytoConvertVentricular Fibrillation andInducibleArrhythmias” and“Tachyarrhythmia\\nProgrammingConsiderations”) foradditional information onprogrammingtachyarrhythmia detection andtherapy\\n(\"Implanting thePulseGenerator\" onpage55).\\nNOTE:Echo-Doppler studiesmaybeusedtonon-invasively evaluateAVDelayandotherprogrammingoptionspost-implant.\\nCAUTION: SuccessfulVForVTconversion duringarrhythmia conversion testingisnoassurancethatconversion willoccur\\npost-operatively .Beawarethatchangesinthepatient\\'scondition, drugregimen,andotherfactorsmaychangetheDFT,which\\nmayresultinnonconversion ofthearrhythmia post-operatively .\\nEXPLANTATION ANDDISPOSAL\\nWARNING: Donotreuse,reprocess,orresterilize.Reuse,reprocessing,orresterilization maycompromisethestructural\\nintegrityofthedeviceand/orleadtodevicefailurewhich,inturn,mayresultinpatientinjury,illness,ordeath.Reuse,\\nreprocessing,orresterilization mayalsocreateariskofcontamination ofthedeviceand/orcausepatientinfectionorcross-\\ninfection, including, butnotlimitedto,thetransmission ofinfectious disease(s) fromonepatienttoanother.Contamination of\\nthedevicemayleadtoinjury,illness,ordeathofthepatient.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 84}), Document(page_content=\"82NOTE:Returnallexplanted devicestoBostonScientificregardlessofcondition. Examination ofexplanted devicescanprovide\\ninformation forcontinued improvement insystemreliabilityandwarrantyconsiderations.ForaReturnedProductKit,contact\\nBostonScientificusingtheinformation onthebackcover.\\nContactBostonScientificwhenanyofthefollowing occur:\\n•Whenaproductisremovedfromservice.\\n•Intheeventofpatientdeath(regardlessofcause),alongwithanautopsyreport,ifperformed.\\n•Forotherobservation orcomplication reasons.\\nConsiderthefollowing itemswhenexplanting andreturning devices:\\n•Interrogate thepulsegenerator andprintacomprehensivereport.\\n•Deactivate thepulsegenerator beforeexplantation.\\n•Disconnect theleadsfromthepulsegenerator.\\n•Ifleadsareexplanted,attempttoremovethemintact,andreturnthemregardless ofcondition. Donotremoveleads\\nwithhemostats oranyotherclampingtoolthatmaydamagetheleads.Resorttotoolsonlyifmanualmanipulation\\ncannotfreethelead.\\n•Wash,butdonotsubmerge, thedevicestoremovebodyfluidsanddebrisusingadisinfectant solution.Donotallow\\nfluidstoenterthepulsegenerator's headerport(s).\\n•UseaBostonScientificReturnedProductKittoproperlypackagethedevices,andsendittoBostonScientific.\\nCAUTION: Cleananddisinfectthedeviceusingstandardbiohazard handlingtechniques sinceallexplantedcomponents are\\nconsideredbiohazardous.\\nNOTE:Discolorationofthepulsegenerator mayhaveoccurredduetoanormalprocessofanodization, andhasnoeffecton\\nthepulsegenerator function.\\nCAUTION: Besurethatthepulsegenerator isremovedbeforecremation. Cremationandincineration temperatur esmight\\ncausethepulsegenerator toexplode.\", metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 85}), Document(page_content='83CAUTION: Beforeexplanting, cleaning,orshippingthedevice,completethefollowing actionstopreventunwanted shocks,\\noverwriting ofimportant therapyhistorydata,andaudibletones:\\n•Programthepulsegenerator TachyandBradyModestoOff.\\n•ProgramtheMagnetResponse featuretoOff.\\n•ProgramtheBeepwhenExplantisIndicatedfeaturetoOff.\\n•ProgramtheBeepWhenOut-of-Range featuretoOff.\\nAllitemsusedduringexplantation, suchasaccessories,consumables, andsharps,maybecontaminated withinfectious\\nsubstances. Considerthefollowing tominimizetheriskofinfection, microbialhazards,orphysicalharm:\\n•Biohazardous wasteshouldbedisposedinabiohazard containerthatislabeledwiththebiological hazardsymboland\\ntakentoadesignated facilityforbiohazardous wasteforpropertreatment inaccordancewithhospital,administrative,\\nand/orlocalgovernment policy.\\n•Biohazardous wasteshouldbetreatedwithanappropriate thermalorchemicalprocess.\\n•Sharpsshouldbedisposedofinasharpsdisposalcontainer.\\nNOTE:Disposalofexplanted devicesissubjecttoapplicable lawsandregulations.\\nNOTE:Untreatedbiohazardous wasteshouldnotbedisposedofinamunicipal wastesystem.', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 86}), Document(page_content='', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 87}), Document(page_content='', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 88}), Document(page_content='Foradditional referenceinformation, gotowww.\\nbostonscientific -elabeling.com.\\nBostonScientificCorporation\\n4100HamlineAvenueNorth\\nSt.Paul,MN55112–5798 USA\\nwww.bostonscientific.com\\n1.800.CARDIAC (227.3422)\\n+1.651.582.4000\\n©2021BostonScientificCorporation oritsaffiliates.\\nAllrightsreserved.\\n51114084-001 ENUS2021-08\\n*51114084-001*', metadata={'source': 'raw_data/51114084-001A_NG4 Tachy ICD_PTM_en_S.pdf', 'page': 89}), Document(page_content='REFERENCE GUIDE\\nRESONATE™HFCRT-D,\\nRESONATE™CRT-D,\\nRESONATE™X4CRT-D,\\nVIGILANT™CRT-D,\\nVIGILANT™X4CRT-D,\\nMOMENTUM™CRT-D,\\nMOMENTUM™X4CRT-D\\nCARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR\\nRREEFFG524,G525,G526,G528,G537,G547,G548,G424,G425,G426,G428,G437,\\nG447,G448,G224,G225,G228,G237,G247,G248,G124,G125,G126,G128,G138\\nCAUTION: Federal law(USA)\\nrestricts thisdevicetosalebyoron\\ntheorderofaphysician trained or\\nexperience dindeviceimplant and\\nfollow-up procedures.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 0}), Document(page_content='', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 1}), Document(page_content='ABOUTTHISMANUAL\\nThisliteratur eisintended forusebyprofessionals trainedorexperienc edindeviceimplant and/or follow-up\\nprocedures.\\nThesefamilies ofcardiacresynchr onization therapydefibrillators (CRT-Ds) provideventricular tachyarrhythmia therapy,\\nCardiacResynchron ization Therapy(CRT),bradycar diapacing, andavariety ofdiagnostic tools.\\nThePhysician Technical Manual, usedinconjunction withtheZOOMVIEW softwar e,isintended toprovideinformation\\nmostrelevantforimplanting thepulsegenerator.ThePhysician Technical Manual alsocontainsinformation suchas\\nwarnings/cautions, potential adverse events, mechanical specifications, longevity ,hyperbaric therapy,and\\nprogramming considerations. ThisReferenc eGuideprovidesfurther descriptions ofprogrammable features and\\ndiagnostics.\\nSummaries oftherelevant clinical studies supporting theseproducts areavailable asseparatedocuments. The\\nfollowing clinical summaries areapprovedasapplicable tosomeorallofthedevices described inthismanual:\\n•SMART MSP\\n•COMPANION\\n•DECREASE HF\\n•CRTOptimization Algorithm Validation Study\\n•MADIT CRT\\n•GDT1000 Sensing AcuteStudy\\n•CONTAK CD\\n•CONTAK RENEWAL\\n•VITALITY\\n•CONTAK RENEWAL 3AVT\\n•IVORY\\n•CAPTIVATE\\n•MADIT-RIT\\nForinformation aboutMRIscanning, refertotheImageReady MRConditional Defibrillation SystemMRITechnical\\nGuide.\\nToviewanddownload anyofthesedocuments, gotowww.bostonscientific -elabeling.c om.\\nRefertotheHeartLogic Technical Guideforinformation abouttheHeartLogic HeartFailureDiagnostic Service.\\nThisguidemaycontain referenceinformation formodelnumbers thatarenotcurrentlyapproved forsaleinall\\ngeographies. Foracomplet elistofmodelnumbers approved inyourgeography,consultwithyourlocalsales\\nrepresentative. Somemodelnumbers maycontainfewerfeatures; forthosedevices,disregar ddescriptions ofthe\\nunavailable features.Descriptions foundwithinthismanual applytoalldevicetiersunlessotherwisenoted.\\nReferencestonames ofnon-quadripolar devices alsoapplytothecorresponding quadripolar devices.\\nThescreenillustrationsusedinthismanual areintended tofamiliarize youwiththegeneralscreenlayout. Theactual\\nscreensyouseewheninterrogatingorprogramming thepulsegenerator willvarybasedonthemodeland\\nprogrammed paramet ers.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 2}), Document(page_content='LATITUDE NXTisaremotemonitoring system thatprovidespulsegeneratordataforclinicians. Allpulsegenerators\\ndescribed inthismanual aredesigned tobeLATITUDE NXTenabled; availability variesbyregion.\\nAcomplete listofprogrammable options isprovidedintheappendix (\"Programmable Options\" onpageA-1).The\\nactualvaluesyouseewheninterrogatingorprogramming thepulsegeneratorwillvarybasedonthemodeland\\nprogrammed parameters.\\nThetextconventions discussed belowareusedthroughout thismanual.\\nPRMKEYS Thenames ofProgrammer/Rec order/Monitor (PRM)\\nkeysappear incapital letters(e.g.,PROGRAM,\\nINTERROGATE).\\n1.,2.,3. Number edlistsareusedforinstructions thatshould be\\nfollowed intheordergiven.\\n• Bulleted listsareusedwhentheinformation isnot\\nsequential.\\nThefollowing acronyms maybeusedinthismanual:\\nA Atrial\\nAF AtrialFibrillation\\nAFib AtrialFibrillation\\nAFR AtrialFlutterResponse\\nAGC Automatic GainControl\\nAIVR AcceleratedIdioventricular Rhythm\\nAT AtrialTachycar dia\\nATP Antitachycardia Pacing\\nATR AtrialTachyResponse\\nAV Atrioventricular\\nBiV Biventricular\\nBCL BurstCycleLength\\nBPEG BritishPacing andElectrophysiology Group\\nBTR BradyTachyResponse\\nCPR Cardiopulmon aryResuscitation\\nCRT Cardiac Resynchr onization Therapy\\nCRT-D Cardiac Resynchr onization TherapyDefibrillator\\nDFT Defibrillation Threshold\\nEAS ElectronicArticleSurveillance\\nECG Electrocardiogr am\\nEF Ejection Fraction\\nEGM Electrogram\\nEMI Electromagnetic Interfere nce\\nEP Electrophysiology; Electrophysiologic\\nFCC FederalCommunications Commission\\nHE HighEnergy\\nHRV HeartRateVariability\\nIBP Indications-Based Programming\\nICD Implantable Cardioverter Defibrillator\\nLRL LowerRateLimit\\nLV LeftVentricular\\nLVAT LeftVentricular Automatic Threshold\\nLVPP LeftVentricular Protection Period\\nLVRP LeftVentricular RefractoryPeriod\\nMI Myocard ialInfarctio n\\nMICS Medical Implant Communication Service', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 3}), Document(page_content='MPR Maximum Pacing Rate\\nMRI Magnetic Resonanc eImaging\\nMSP MultiSite Pacing\\nMSR Maximum Sensor Rate\\nMTR Maximum TrackingRate\\nMV Minute Ventilation\\nNASPE NorthAmerican Society ofPacing andElectrophys iology\\nNSR Normal SinusRhythm\\nPAC Premature AtrialContraction\\nPAT Paroxysmal AtrialTachycardia\\nPES Programmed Electrical Stimulation\\nPMT Pacemaker-Mediated Tachycar dia\\nPRM Programmer/Rec order/Monitor\\nPSA Pacing System Analyze r\\nPTM Patient Triggere dMonitor\\nPOST Post-OperativeSystem Test\\nPVARP Post-Ventricular AtrialRefractoryPeriod\\nPVC Premature Ventricular Contract ion\\nRAAT RightAtrialAutomatic Threshold\\nRADAR RadioDetection andRanging\\nRF RadioFrequency\\nRV RightVentricular\\nRVAT RightVentricular Automatic Threshold\\nRVRP RightVentricular Refractory Period\\nSAM SignalArtifact Monitor\\nSCD Sudden Cardiac Death\\nSDANN Standar dDeviation ofAveraged Normal-to-Normal R-Rintervals\\nSRD Sustained RateDuratio n\\nSVT Supraventricular Tachycar dia\\nTARP TotalAtrialRefractoryPeriod\\nTENS Transcutaneous Electrical NerveStimulation\\nV Ventricular\\nVF Ventricular Fibrillation\\nVFib Ventricular Fibrillation\\nVRP Ventricular RefractoryPeriod\\nVRR Ventricular RateRegulation\\nVT Ventricular Tachycardia\\nVTR Ventricular Tachycardia Response\\nThefollowing aretrademarks ofBoston Scientific Corporat ionoritsaffiliates (allothertrademarks aretheproperty of\\ntheirrespective owners):\\nAcuShock, AVT,CONTAK, CONTAK RENEWAL, EASYVIEW,ENDURALIFE, HeartLogic, IMAGEREADY, LATITUDE,\\nMOMENTUM, Onset/Stability ,PaceSafe, QuickCapture,QuickConvert, QUICKNOTES,RESONATE, RHYTHM ID,\\nRHYTHMMATCH, RightRate, SafetyCore,SmartBlanking, SmartDelay ,VectorGuide, VIGILANT, VITALITY, ZIP,ZOOM,\\nZOOMVIEW.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 4}), Document(page_content='', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 5}), Document(page_content='TABLEOFCONTENTS\\nUSINGTHEPROGRAMMER .....................................................................................................1-1\\nCHAPTER 1\\nLATITUDE Programming System...............................................................................................1-2\\nSoftwar eTerminology andNavigation .......................................................................................1-2\\nMainScreen..................................................................................................................1-2\\nPRMModeIndicator ........................................................................................................1-3\\nECG/EGM Display ...........................................................................................................1-3\\nToolbar ........................................................................................................................1-5\\nTabs............................................................................................................................1-5\\nButtons ........................................................................................................................1-5\\nIcons...........................................................................................................................1-5\\nCommon Objects ............................................................................................................1-7\\nUseofColor..................................................................................................................1-7\\nDemonstra tionMode.............................................................................................................1-8\\nCommunicating withthePulseGenerator ...................................................................................1-8\\nZIPTelemetr y................................................................................................................1-9\\nStarting aWanded Telemetr ySession ..................................................................................1-9\\nStarting aZIPTelemetr ySession ........................................................................................1-9\\nEnding aTelemetr ySession ............................................................................................1-10\\nZIPTelemetr ySecurity ...................................................................................................1-10\\nIndications-Based Programming (IBP).......................................................................................1-11\\nManual Programming ...........................................................................................................1-13\\nDIVERT THERAPY .................................................................................................................1-14\\nSTATSHOCK.......................................................................................................................1-14\\nSTATPACE.........................................................................................................................1-15\\nDataManagement ...............................................................................................................1-15\\nPatient Information ........................................................................................................1-15\\nDataStorage ................................................................................................................1-16\\nDeviceMemory.............................................................................................................1-17\\nPrint..........................................................................................................................1-17\\nSafetyMode.......................................................................................................................1-17\\nBackup Pacemak er.........................................................................................................1-18\\nBackup Defibrillator ........................................................................................................1-18\\nTACHYARRHYTHMIA DETECTION .............................................................................................2-1\\nCHAPTER 2\\nDeviceMode......................................................................................................................2-2\\nVentricular TachyMode...................................................................................................2-2\\nElectrocautery Protection Mode.........................................................................................2-2\\nMRIProtection Mode......................................................................................................2-3\\nRateSensing ......................................................................................................................2-4', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 6}), Document(page_content='Calculating RatesandRefractoryPeriods .............................................................................2-4\\nVentricular RateThresholds andZones...............................................................................2-5\\nCRTDelivery ZoneandTachyarrhythmia Zones ....................................................................2-5\\nUseofAtrialInformation .................................................................................................2-6\\nVentricular Detection ............................................................................................................2-6\\nVentricular Detection Enhancemen tSuites............................................................................2-7\\nVentricular Redetection ..................................................................................................2-10\\nVentricular Post-shock Detection Enhance ments....................................................................2-11\\nVentricular Detection Details ...........................................................................................2-12\\nTACHYARRHYTHMIA THERAPY ...............................................................................................3-1\\nCHAPTER 3\\nVentricular Therapy..............................................................................................................3-2\\nVentricular TherapyPrescrip tion........................................................................................3-2\\nVentricular TherapySelection ...........................................................................................3-2\\nVentricular Redetection afterVentricular TherapyDelivery........................................................3-6\\nVentricular Redetection afterVentricular ATPTherapy.............................................................3-6\\nVentricular Redetection afterVentricular ShockTherapy...........................................................3-7\\nAntitachycar diaPacing TherapiesandParamet ers.........................................................................3-7\\nBurstParamet ers...........................................................................................................3-8\\nCoupling IntervalandCoupling IntervalDecremen t................................................................3-9\\nBurstCycleLength (BCL).................................................................................................3-10\\nMinimum Interval ..........................................................................................................3-11\\nBurstScheme ...............................................................................................................3-11\\nRampScheme ..............................................................................................................3-11\\nScanScheme ...............................................................................................................3-12\\nRamp/Scan Scheme ......................................................................................................3-12\\nATPPulseWidthandATPAmplitude .................................................................................3-13\\nVentricular ATPTime-out ................................................................................................3-13\\nQUICKCONVERT ATP.....................................................................................................3-14\\nVentricular ShockTherapyandParameters ................................................................................3-15\\nVentricular ShockVector.................................................................................................3-15\\nVentricular ShockEnergy................................................................................................3-15\\nCharge Time................................................................................................................3-15\\nWaveform Polarity ........................................................................................................3-16\\nCommitted Shock/Reco nfirmation oftheVentricular Arrhythmia ...............................................3-17\\nPACINGTHERAPIES ..............................................................................................................4-1\\nCHAPTER 4\\nPacing Therapies.................................................................................................................4-2\\nDeviceProgramming Recommendations ....................................................................................4-3\\nMaintaining CRT..................................................................................................................4-4\\nBasicParamete rs.................................................................................................................4-5\\nBradyMode.................................................................................................................4-6\\nLowerRateLimit(LRL)....................................................................................................4-8\\nMaximum TrackingRate(MTR)..........................................................................................4-9\\nMaximum Sensor Rate(MSR)............................................................................................4-11\\nRunaway Protection ......................................................................................................4-12\\nVentricular Pacing Chamber ............................................................................................4-12', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 7}), Document(page_content='PulseWidth................................................................................................................4-15\\nAmplitude ..................................................................................................................4-16\\nPaceSafe ....................................................................................................................4-16\\nSensitivity ...................................................................................................................4-27\\nPost-TherapyPacing ...........................................................................................................4-30\\nPost-Shock Pacing Delay................................................................................................4-31\\nPost-Therapy Period......................................................................................................4-31\\nTempora ryBradyPacing ......................................................................................................4-31\\nMinute Ventilation /Respiratory Sensor andSignalArtifact Monitor ................................................4-32\\nMinute Ventilation/Respirat orySensor (MV/Respiratory Sensor) ...............................................4-32\\nSignalArtifact Monitor Device Diagnostic ............................................................................4-35\\nRateAdaptive Pacing andSensor Trending...............................................................................4-39\\nRateAdaptive Pacing ....................................................................................................4-39\\nAccelerometer .............................................................................................................4-40\\nMinute Ventilation (MV).................................................................................................4-44\\nSensor Trending...........................................................................................................4-54\\nAtrialTachyResponse. .........................................................................................................4-56\\nATRModeSwitch.........................................................................................................4-56\\nVentricular RateRegulation (VRR).....................................................................................4-59\\nBiventricular Trigger ......................................................................................................4-60\\nAtrialFlutterResponse (AFR)...........................................................................................4-60\\nPMTTermination ..........................................................................................................4-61\\nRateEnhance ments............................................................................................................4-62\\nTracking Preference.......................................................................................................4-62\\nRateHysteresis............................................................................................................4-63\\nRateSmoothing ...........................................................................................................4-63\\nRateSmoothing Example BasedonaDual-Chamber TrackingMode..........................................4-66\\nLeadConfiguration .............................................................................................................4-67\\nLeftVentricular ElectrodeConfigurati on..............................................................................4-67\\nLeftVentricular MultiSite Pacing.............................................................................................4-71\\nAVDelay..........................................................................................................................4-73\\nPacedAVDelay............................................................................................................4-73\\nSensed AVDelay..........................................................................................................4-75\\nSmartDelay Optimization ................................................................................................4-76\\nRefractory.........................................................................................................................4-78\\nA-Refra ctory-PVARP ....................................................................................................4-79\\nARefractory-samechamber ...........................................................................................4-81\\nRV-Refractory (RVRP).....................................................................................................4-81\\nLV-Refracto ry(LVRP).....................................................................................................4-82\\nLeftVentricular ProtectionPeriod(LVPP) ............................................................................4-82\\nCross-Chamber Blanking .................................................................................................4-83\\nNoiseResponse .................................................................................................................4-87\\nVentricular TachySensing Interactions .....................................................................................4-89\\nSYSTEMDIAGNOSTICS ..........................................................................................................5-1', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 8}), Document(page_content='CHAPTER 5\\nSummary Dialog .................................................................................................................5-2\\nBattery Status.....................................................................................................................5-2\\nCapacitor Re-formation ...................................................................................................5-6\\nCharge TimeMeasur ement..............................................................................................5-6\\nLastDelivered Ventricular Shock........................................................................................5-6\\nLeadsStatus.......................................................................................................................5-7\\nPost-OperativeSystemTest(POST) ..........................................................................................5-11\\nLeadTests........................................................................................................................5-12\\nIntrinsic Amplitude Test.................................................................................................5-13\\nLeadImpedanc eTest....................................................................................................5-13\\nPaceThresholdTest......................................................................................................5-14\\nLVVectorGuide ............................................................................................................5-17\\nPATIENTDIAGNOSTICS ANDFOLLOWUP..................................................................................6-1\\nCHAPTER 6\\nTherapyHistory..................................................................................................................6-2\\nArrhythmia Logbook ............................................................................................................6-2\\nSnapshot ...........................................................................................................................6-8\\nHistograms ........................................................................................................................6-9\\nCounters ...........................................................................................................................6-9\\nVentricular TachyCounters ...............................................................................................6-9\\nBrady/CRT Counters ......................................................................................................6-10\\nHeartRateVariability (HRV)...................................................................................................6-10\\nTrends.............................................................................................................................6-13\\nPostImplant features ..........................................................................................................6-17\\nPatient TriggeredMonitor (PTM).......................................................................................6-17\\nBeeper Feature ............................................................................................................6-19\\nMagnet Feature ...........................................................................................................6-23\\nELECTROPHYSIOLOGIC TESTING...............................................................................................7-1\\nCHAPTER 7\\nEPTestFeatures...................................................................................................................7-2\\nTemporary EPMode........................................................................................................7-2\\nEPTestScreen...............................................................................................................7-2\\nInduction Methods ...............................................................................................................7-4\\nVFibInduction ..............................................................................................................7-4\\nShockonTInduction ......................................................................................................7-4\\nBackup Ventricular Pacing During AtrialEPTesting ..................................................................7-5\\nProgrammed Electrical Stimulation (PES)..............................................................................7-5\\n50Hz/Manual BurstPacing...............................................................................................7-7', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 9}), Document(page_content='Commanded TherapyMethods ...............................................................................................7-8\\nCommanded Shock........................................................................................................7-8\\nCommanded ATP..........................................................................................................7-8\\nPROGRAMMABLE OPTIONS...................................................................................................A-1\\nAPPENDIX A\\nSYMBOLSONPACKAGING ....................................................................................................B-1\\nAPPENDIX B\\nSymbols onPackaging ...........................................................................................................B-1', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 10}), Document(page_content='', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 11}), Document(page_content='1-1\\nUSINGTHEPROGRAMMER\\nCHAPTER 1\\nThischapter containsthefollowing topics:\\n•“LATITUDE Programming System” onpage1-2\\n•“Softwar eTerminology andNavigation” onpage1-2\\n•“Demonstr ationMode” onpage1-8\\n•“Communicating withthePulseGenerator” onpage1-8\\n•“Indications-Based Programming (IBP)”onpage1-11\\n•“Manual Programming” onpage1-13\\n•“DIVERT THERAPY” onpage1-14\\n•“STATSHOCK” onpage1-14\\n•“STATPACE”onpage1-15\\n•“DataManagement” onpage1-15\\n•“Safety Mode” onpage1-17', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 12}), Document(page_content='1-2UsingtheProgrammer\\nLATITUDE Programming System\\nLATITUDE PROGRAMMING SYSTEM\\nThesepulsegeneratorscanbeusedonlywiththeModel3300LATITUDE Programming System. TheLATITUDE\\nProgramming Systemistheexternalportion ofthepulsegeneratorsystem.\\nNOTE:The2868software application onthemodel3120LATITUDE Programming System isoutdated andshould\\nnotbeusedwiththepulsegenerators.Forassistanc e,call+1.651.582.4000 (worldwide) orcontactyourlocalBoston\\nScientific representative.\\nThe3300LATITUDE Programming Systemincludes:\\n•Model3300Programmer\\n•Model3868Softwar eApplication\\n•Model6395AccessoryTelemetr yWand\\nThesoftwar eprovidesadvance ddeviceprogramming andpatient monitoring technology .Itwasdesigned withthe\\nintentto:\\n•Enhance deviceprogramming capability\\n•Improvepatient anddevicemonitoring performanc e\\n•Simplify andexpedite programming andmonitoring tasks\\nYoucanusetheLATITUDE Programming System todothefollowing:\\n•Interrogatethepulsegenerator\\n•Programthepulsegeneratortoprovide avariety oftherapyoptions\\n•Accessthepulsegenerator’sdiagnostic features\\n•Perform noninvasive diagnostic testing\\n•Accesstherapyhistorydata\\n•Storea12second traceoftheECG/EGM display fromanyscreen\\n•AccessaninteractiveDemonstr ationModeorPatient DataModewithout thepresence ofapulsegenerator\\n•Printpatient dataincluding pulsegeneratortherapy options andtherapyhistory data\\n•Savepatient data\\nYoucanprogram thepulsegeneratorusingtwomethods: automatically usingIBPormanually .\\nFormoredetailed information aboutusingthePRMorZOOMWirelessTransmitter ,refertothePRMOperator’s\\nManual orZOOMWirelessTransmitt erReferenceGuide.\\nRefertothe3300Programming System’s familyofoperator’smanuals forspecific information aboutthe3300\\nProgrammer,itsPSA,patient datamanagement, andnetworking andconnectivity .\\nSOFTWARE TERMINOLOGY ANDNAVIGATION\\nThissection providesanoverview ofthePRMsystem.\\nMainScreen\\nThemainProgrammer screenisshown below,followed byadescription ofthecomponents (Figure1–1MainScreen\\nonpage1-3).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 13}), Document(page_content='UsingtheProgrammer\\nPRMModeIndicator1-3\\n1\\n2\\n3\\n4\\n5\\n6\\n7\\n8\\nxxxxxxxxx xxxxxxxxx\\nxxxxxx xxx\\nxxxxxxxxxxxxx\\nxxxx\\n[1]Patient name,[2]PRMModeIndicator ,[3]devicename,[4]Details button, [5]tabs,[6]toolbar,[7]devicemodel, [8]ECG/EGM display\\nFigure1–1.MainScreen\\nPRMModeIndicator\\nThePRMModeIndicator displays atthetopofthescreentoidentify thecurrent PRMoperationalmode.\\nPatient—indicates thatthePRMisdisplaying data\\nobtained bycommunicating withadevice.\\nPatient Data—indicates thatthePRMisdisplaying\\nstoredpatient data.\\nDemoMode—indicates thatthePRMisdisplaying\\nsample dataandoperatingindemonstratio nmode.\\nECG/EGM Display\\nTheWirelessECGfeature isavailable inRESONATE HF,RESONATE, andMOMENTUM devices.\\nTheECGareaofthescreenshowsreal-time statusinformation aboutthepatient andthepulsegeneratorthatcanbe\\nusefulinevaluating system performanc e.Thefollowing typesoftracescanbeselected:\\n•Surface ECGsaretransmittedfrombodysurface leadelectrodesthatareconnected tothePRM,andcanbe\\ndisplayed without interrogating thepulsegenerator.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 14}), Document(page_content='1-4 UsingtheProgrammer\\nECG/EGM Display\\n•Real-time EGMsaretransmitted fromthepace/sense orshocking electrodes, andareoftenusedtoevaluate lead\\nsystem integrity andhelpidentify faultssuchasleadfractures, insulation breaks,ordislodgments.\\nReal-time EGMscanonlybedisplayed uponinterrogationofthepulsegenerator.Because theyrelyonZIPor\\nwanded telemetry ,theyaresusceptible toradiofrequency interfer ence.Significant interfer encemaycausea\\nbreakordrop-outofreal-time EGMs(\"ZIPTelemetry Security\" onpage1-10).\\n•Atanytime,a12secondtraceoftheECG/EGM display canbestoredbypressingtheSnapshot button fromany\\nscreen.\\nNOTE:IfthePRMisleftidlefor15minutes (or28minutes ifthepulsegeneratorwasinStorageModeat\\ninterrogation) real-time EGMsareshutoff.ThePRMprovidesadialogboxallowing real-time EGMstobe\\nrestored.\\nNOTE:Real-time LVEGMsareavailable onallLVsenseconfigurations.\\nNOTE:Inthepresenceoftelemetr yinterfer ence,thereal-time intracardiacEGMtracesandmarkers may\\nbecomemisaligned fromthereal-timesurface ECGtraces.Whenthetelemetry linkhasimproved,re-selectanyof\\ntheintracardiac EGMtracestocausere-initialization.\\n•WirelessECGisaformofreal-timeEGMthatmimics asurface ECGbyusingashocking leadproximal coiltocan\\nvectorformeasuring heartactivity.Unless thedeviceisstillinStorage mode,thefirst(top)traceonthedisplay\\nwilldefault toWireless ECG.\\nCAUTION: WirelessECGissusceptible toRFinterferenc e,andmayhaveanintermittent orlostsignal. If\\ninterfere nceispresent,especially during diagnostic testing, consider usingasurface ECGinstead.\\nNOTE:WirelessECGsareonlyavailable withdual-coil shockleads.\\nYoucanselecttheDetails button toenlargetheECG/EGM screen. Thefollowing options areavailable:\\n•ShowDeviceMarkers—displays annotated eventmarkers,whichidentify certain intrinsic cardiacanddevice-\\nrelated events, andprovideinformation suchassensed/pac edevents, decision ofdetection criteria, andtherapy\\ndelivery\\n•Enable SurfaceFilter—minimizes noiseonthesurface ECG\\n•Display Pacing Spikes—sho wsdetected pacing spikes,annotated byamarker onthesurface ECGwaveform\\n•TraceSpeed—adjusts thespeedofthetrace(0,25,or50mm/s). Asthespeedisincreased, thetime/horizontal\\nscaleisexpanded\\n•Gain—adjusts theamplitude/vertical scale(AUTO, 1,2,5,10,or20mm/mV) foreachchannel. Asthegainis\\nincreased, theamplitude ofthesignalisenlarged\\nYoucanprintreal-time EGMs,whichinclude annotated eventmarkers, byperforming thefollowing steps:\\n1.PressoneoftheprintspeedkeysonthePRM(e.g.,speedkey25)tobeginprinting.\\n2.Pressthe0(zero)speedkeytostopprinting.\\n3.Pressthepaper-feedkeytofullyejectthelastprinted sheet.\\nYoucanprintdefinitions oftheannotated markersbypressing thecalibrat ionkeywhiletheEGMisprinting.\\nAlternatively youcanprintafullreportcontaining thedefinitions ofalloftheannotated markers byperforming the\\nfollowing steps:\\n1.Fromthetoolbar,clicktheReports button. TheReports window displays.\\n2.SelecttheMarkerLegend checkbox.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 15}), Document(page_content='UsingtheProgrammer\\nToolbar1-5\\n3.ClickthePrintbutton. TheMarkerLegend Report issenttotheprinter.\\nToolbar\\nThetoolbar allowsyoutoperform thefollowing tasks:\\n•Selectsystem utilities\\n•Genera tereports\\n•Interrogateandprogramthepulsegenerator\\n•Viewpending orprogrammed changes\\n•Viewattentions andwarnings\\n•EndyourPRMsession\\nTabs\\nTabsallowyoutoselectPRMtasks,suchasviewing summary dataorprogramming devicesettings. Selecting atab\\ndisplays theassociated screen.Manyscreens containadditional tabs,whichallowyoutoaccessmoredetailed\\nsettings andinformation.\\nButtons\\nButtons arelocated onscreensanddialogs throughout theapplication. Buttons allowyoutoperform various tasks,\\nincluding:\\n•Obtain detailed information\\n•Viewsetting details\\n•Setprogrammable values\\n•Loadinitialvalues\\nWhenabutton selection opensawindow infrontoftheMainScreen,aClosebutton displays intheupper-right\\ncornerofthewindow toallowyoutoclosethewindow andreturntotheMainScreen.\\nIcons\\nIconsaregraphic elements that,whenselected, mayinitiate anactivity,display listsoroptions, orchange the\\ninformation displayed.\\nDetails—opens awindow containing detailed\\ninformation.\\nPatient—opens awindow withpatient information\\ndetails.\\nLeads—opens awindow withdetails onleads.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 16}), Document(page_content='1-6UsingtheProgrammer\\nIcons\\nBattery—opens awindow withdetails onthepulse\\ngeneratorbattery.\\nCheck—indicates thatanoption isselected.\\nEvent—indicates thataneventhasoccurred. Whenyou\\nviewtheTrendstimeline ontheEvents tab,eventicons\\ndisplay whereverevents haveoccurred. Selecting an\\nevents icondisplays details abouttheevent.\\nInformation—indicates information thatisprovidedfor\\nreference.\\nActionIcons\\nRun—causes theprogrammer toperform anaction.\\nHold—causes theprogrammer topauseanaction.\\nContinue—causes theprogrammer tocontinue an\\naction.\\nSnapshot —causes theprogrammer tostorea12second\\ntraceoftheECG/EGM display fromanyscreen.\\nSliderIcons\\nHorizontalSlider—indicates thatasliderobjectcanbe\\nclickedanddragged leftorright.\\nVertical Slider—indicates thatasliderobjectcanbe\\nclickedanddragged upordown.\\nSortIcons\\nSortAscending—indicates thatAscending sortis\\ncurrentlyselected onatablecolumn sortbutton. (e.g.,1,\\n2,3,4,5)\\nSortDescending—indicates thatDescending sortis\\ncurrentlyselected onatablecolumn sortbutton. (e.g.,\\n5,4,3,2,1)', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 17}), Document(page_content='UsingtheProgrammer\\nCommon Objects1-7\\nIncrement andDecrement Icons\\nIncremen t—indicates thatanassociated valuecanbe\\nincremented.\\nDecremen t—indicates thatanassociated valuecanbe\\ndecremented.\\nScrollIcons\\nScrollLeft—indicates thatanassociated itemcanbe\\nscrolledleft.\\nScrollRight—indicates thatanassociated itemcanbe\\nscrolledright.\\nScrollUp—indicates thatanassociated itemcanbe\\nscrolledup.\\nScrollDown—indicates thatanassociated itemcanbe\\nscrolleddown.\\nCommon Objects\\nCommon objects suchasstatusbars,scrollbars,menus, anddialogs areusedthroughout theapplication. These\\noperatesimilarly totheobjects foundinwebbrowsers andothercomputer applications.\\nUseofColor\\nColorsandsymbols areusedtohighlight buttons, icons,andotherobjects, aswellascertain typesofinformation.\\nTheuseofspecific colorconventions andsymbols isintended toprovide amoreconsistent userexperience and\\nsimplify programming. Refertothetablebelowtounderstand howcolorsandsymbols areusedonthePRMscreens\\n(Table1–1PRMcolorconventions onpage1-7).\\nTable1–1.PRMcolorconventions\\nColor Meaning Examples Symbol\\nRed Indicates warning conditions Theselected parameter valueisnot\\nallowed; clicktheredwarning button\\ntoopentheParameter Interactions\\nscreen,whichprovides information\\naboutcorrectiveaction.\\nDevice andpatient diagnostic\\ninformation thatrequires serious\\nconsideration.\\nYellow Indicates conditionsrequiring your\\nattentionTheselected parameter valueis\\nallowed, butnotrecommended; click\\ntheyellowattention button toopen\\ntheParameter Interact ionsscreen,\\nwhichprovides information about\\ncorrectiveaction.\\nDevice andpatient diagnostic\\ninformation thatshould beaddressed.\\nGreen Indicates acceptable changes or\\nconditionsTheselected parameter valueis\\nallowed, butisstillpending.\\n', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 18}), Document(page_content='1-8UsingtheProgrammer\\nDemonstration Mode\\nTable1–1.PRMcolorconventions (continued)\\nColor Meaning Examples Symbol\\nThereisnodeviceorpatient\\ndiagnostic information requiringyour\\nspecific attention.\\nWhite Indicates thevaluethatiscurrently\\nprogrammed\\nDEMONSTRATION MODE\\nThePRMincludes aDemonstr ationModefeature,whichenables thePRMtobeusedasaself-teaching tool.When\\nselected, thismodeallowsyoutopracticePRMscreennavigation without interrogat ingapulsegenerator.Youcan\\nuseDemonstr ationModetofamiliarize yourself withmanyofthespecific screensequenc esthatwilldisplay when\\ninterrogatingorprogramming aspecific pulsegenerator.YoucanalsouseDemonstration Modetoexamineavailable\\nfeatures, parameters, andinformation.\\nToaccessDemonstra tionMode,selecttheappropriat ePGfromtheSelectPGscreen,andthenselectDemofromthe\\nSelectPGModedialog. WhenthePRMisoperatinginDemonstr ationMode,thePRMModeIndicator displays the\\nDemoModeicon.Thepulsegeneratorcannot beprogrammed whenthePRMisoperatinginDemonstr ationMode.\\nExittheDemonstration Modebefore attempting tointerrogate orprogramthepulsegenerator.\\nCOMMUNICATING WITHTHEPULSEGENERATOR\\nThePRMcommunicates withthepulsegeneratorusingatelemetr ywand.\\nAfterinitiating communication withthewand,thePRMcanusewandless ZIPtelemetr y(two-way RFcommunication)\\ntointerface withRFcapable pulsegenerator models.\\nTelemetr yisrequired to:\\n•Directcommands fromthePRMsystem, suchas:\\n–INTERROGATE\\n–PROGRAM\\n–STATSHOCK\\n–STATPACE\\n–DIVERT THERAPY\\n•Modify deviceparameter settings\\n•Conduct EPtesting\\n•Conduct diagnostic testsincluding thefollowing:\\n–Pacing impedance tests\\n–Pacing threshold tests\\n–Intrinsic amplitude tests\\n•Perform manual capacitor re-form', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 19}), Document(page_content='UsingtheProgrammer\\nZIPTelemetry1-9\\nZIPTelemetry\\nZIPtelemetr yoperates intheMICS(Medical Implant Communication Service) telemetr ybandwithatransmit\\nfrequency of402to405MHz(FCCID:ESCCRMG17912).\\nZIPtelemetr yisawandless, two-way RFcommunication option thatallowsthePRMsystem tocommunicate with\\ntheseRFcapable pulsegenerators.\\n•RFcommunication isenabled bytheZOOMWirelessTransmitter unitconnected tothePRM.Wheninitiating\\ncommunication, wanded telemetr yisneeded. WhenZIPtelemetr yisreadyforuse,amessage willdisplay onthe\\nPRMscreenindicating thatthewandcanberemoved.Otherwise,thesession willcontinuewithwanded\\ntelemetry .\\nZIPtelemetr yoffersthefollowing advantages overtradition alwanded telemetry:\\n•Thefasterdatatransmission speedmeans lesstimeisrequired fordeviceinterrogation\\n•Datatransmission overalongerdistance(within 3m[10ft])minimizes theneedtokeepthewandinthesterile\\nfieldduring implant, whichmayreducetheriskofinfection\\n•Continuous telemetr yispossible during theentireimplant procedure,allowing monitoring ofpulsegenerator\\nperformanc eandleadintegrity during implant\\n•Allows thephysician tocontinue withtheoperatingprocedurewhilethedeviceisbeingprogrammed forthe\\npatient\\nRegardlessofwhether ZIPtelemetr yisbeingused,wanded communication isstillavailable.\\nStartingaWandedTelemetry Session\\nFollow thisproceduretobeginawanded telemetr ycommunication session:\\n1.Makesurethetelemetry wandisconnected tothePRMsystem andisavailable throughout thesession.\\n2.Position thewandoverthepulsegeneratoratadistancenotgreater than6cm(2.4inches).\\n3.UsethePRMtoInterrogatethepulsegenerator.\\n4.Retainthewandposition whenever communication isrequired.\\nStartingaZIPTelemetrySession\\nFollow thisproceduretobeginaZIPtelemetry communication session:\\n1.VerifythattheZOOMWirelessTransmitter isconnecte dtothePRMviatheUSBcableandthatthegreenlighton\\ntopofthetransmitter isilluminated (indicating thetransmitter isreadyforuse).\\n2.Startawanded telemetry session. Verifythatthewandcordiswithinreachofthepulsegeneratortoenable the\\nuseofwanded telemetr yshould itbecomenecessary.\\n3.Keepthetelemetr ywandinposition untileitheramessage appears, indicating thatthetelemetry wandmaybe\\nremoved fromproximityofthepulsegenerator,ortheZIPtelemetry lightilluminates onthePRMsystem.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 20}), Document(page_content='1-10UsingtheProgrammer\\nEndingaTelemetry Session\\nEndingaTelemetry Session\\nSelecttheEndSession button toquitatelemetry session andreturntothestartup screen.Youcanchoose toendthe\\nsession orreturntothecurrentsession. Uponending asession, thePRMsystem terminates allcommunication with\\nthepulsegenerator.\\nZIPTelemetry Security\\nThepulsegenerator containsacompliant low-power transceiver.Thepulsegenerator canonlybeinterrogated or\\nprogrammed byRFsignals thatemploy theproprietaryZIPtelemetry protocol.Thepulsegeneratorverifies thatitis\\ncommun icating withaZOOMVIEW system beforeresponding toanyRFsignals. Thepulsegeneratorstores, transmits,\\nandreceivesindividually identifiable healthinformation inanencryptedformat.\\nZIPtelemetry ispossible whenallofthefollowing condition saremet:\\n•ZIPtelemetry forthePRMisenabled\\n•TheZOOMWireless Transmitt erisconnected tothePRMviatheUSBcable\\n•Theindicator lightontopoftheZOOMWirelessTransmitter isgreen; indicating thetransmitter isreadyforuse\\n•ThepulsegeneratoriswithinrangeofthePRMsystem\\n•Thepulsegeneratorhasnotreached Explant; notethatatotalof1.5hoursofZIPtelemetr ywillbeavailable after\\nthepulsegeneratorreaches Explant\\n•Thepulsegeneratorbattery capacity isnotdepleted\\n•PulsegeneratorisnotinMRIProtection Mode\\nInordertomeetlocalcommunications rulesandregulations, ZIPtelemetry should notbeusedwhenthepulse\\ngeneratorisoutside itsnormal operating temper atureof20°C–45°C (68°F–113°F).\\nCommunication canbesupported between multiple PRMsandpulsegeneratorsatatime,asindependent sessions.\\nSignals fromothersessions usingRFcommunication orinterfer encefromotherRFsourcesmayinterfer ewithor\\npreventZIPtelemetry communication.\\nCAUTION: RFsignals fromdevicesthatoperateatfrequencies nearthatofthepulsegenerator mayinterrupt ZIP\\ntelemetry whileinterrogating orprogramming thepulsegenerator.ThisRFinterfer encecanbereducedbyincreasing\\nthedistance between theinterfering deviceandthePRMandpulsegenerator .\\nRadiofrequencyinterfer encemaytempor arilydisrupt ZIPtelemetry communication. ThePRMwillnormally\\nreestablish ZIPcommunication whentheRFinterferenc eendsorsubsides. Because continued RFinterfer encemay\\npreventZIPtelemetry communication, thesystem isdesigned tousewanded telemetr ywhenZIPtelemetr yisnot\\navailable.\\nIfZIPtelemetr yisnotavailable duetointerferenc eoriftheZOOMWirelessTransmitter isunplugged ornot\\nfunctioning properly,wanded telemetry communication withthePRMcanbeestablished. Thesystem provides the\\nfollowing feedback toindicate thatZIPtelemetr yisnotavailable:\\n•TheZIPtelemetry indicator lightonthePRMturnsoff\\n•Thegreenindicator lightontheZOOMWirelessTransmitter isoff\\n•Ifeventmarkersand/or EGMsareactivated, transmission oftheeventmarkersand/or EGMswillbeinterrupted\\n•Ifacommand orotheractionhasbeenrequested, thePRMdisplays anotification indicating thewandshould be\\nplaced inrangeofthepulsegenerator', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 21}), Document(page_content='UsingtheProgrammer\\nZIPTelemetry Security1-11\\nZIPtelemetr yoperates consistentlywithwanded telemetr y—noprogramming stepcanbecompleted unlesstheentire\\nprogramming command hasbeenreceivedandconfirmed bythepulsegenerator.\\nThepulsegeneratorcannot bemisprogr ammed asaresultofinterrupted ZIPtelemetry .Interruptions ofZIPtelemetr y\\nmaybecaused byRFsignals thatoperateatfrequencies nearthatofthepulsegeneratorandarestrongenough to\\ncompete withtheZIPtelemetry linkbetween thepulsegeneratorandthePRM.Significant interfer encemayresultin\\nabreakordrop-outs ofreal-time EGMs.Ifcommands areinterrupted, thePRMdisplays amessage toplacethewand\\nonthepulsegenerator.Repeated displays ofthismessage mayindicate thepresenceofintermittent interfer ence.\\nThesesituations canberesolvedbyrepositioning theZOOMWirelessTransmitter attached tothePRMorbyusing\\nstandar dwanded telemetr y.Therewillbenointerruption ofdevicefunctionality ortherapyduring thisperiod.\\nNOTE:WhenbothZIPandwanded telemetr yarebeingused(forexample, switching fromZIPtowanded because\\nofthepresenc eofinterfer ence),thepulsegenerator willcommunicate withtheprogrammer byZIPtelemetr ywhen\\npossible. Ifwanded telemetr yonlyisdesired,settheCommunication Mode(accessedviatheUtilities button) touse\\nthewandforalltelemetr y.\\nNOTE:Toconservebattery longevity ,aZIPtelemetr ysession willbeterminated ifthepulsegenerator completely\\nlosescommunication withthePRMforacontinuous periodofonehour(or73minutes ifthedevicewasinStorage\\nModeatinterrogatio n).Wanded telemetry mustbeusedtore-establish communication withthepulsegeneratorafter\\nthisperiodhaselapsed.\\nConsiderations forReducing Interference\\nIncreasing thedistance fromthesourceofinterfering signals mayenable theuseoftheZIPtelemetry channel.\\nRepositioning theZOOMWirelessTransmitter mayimprove ZIPtelemetr yperformanc e.IfZIPtelemetry performanc e\\nisnotsatisfactory ,theoption ofusingwanded telemetry isavailable.\\nDepending ontheenvironment andPRMorientation relativetothepulsegenerator ,thesystem iscapable of\\nmaintaining ZIPtelemetry commun ication atdistances upto3m(10ft).Foroptimum ZIPtelemetr ycommunication,\\nposition theZOOMWirelessTransmitter within3m(10ft)ofthepulsegeneratorandremove anyobstruction\\nbetween theZOOMWirelessTransmitter andthepulsegenerator .\\nPositioning theZOOMWirelessTransmitter atleast1m(3ft)awayfromwallsormetalobjects andensuring thepulse\\ngenerator(priortoimplant) isnotindirectcontactwithanymetalobjects mayreducesignalreflection and/or signal\\nblocking.\\nAvoidplacing theZOOMWireless Transmitter incloseproximitytomonitors, high-frequency electrosur gical\\nequipment, orstrongmagnetic fieldssincethetelemetr ylinkmaybeimpaired .\\nEnsuring therearenoobstructions (e.g.,equipment, metalfurnitur e,people, orwalls)between theZOOMWireless\\nTransmitter andpulsegeneratormayimprovesignalquality.Personnel orobjects thatmomentarily movebetween\\ntheZOOMWireless Transmitt erandpulsegenerator during ZIPtelemetr ymaytempor arilyinterrupt commun ication,\\nbutwillnotaffectdevicefunctionality ortherapy.\\nChecking thetimerequired tocomplete aninterrogatio nafterZIPtelemetry isestablished canprovideanindication\\nofwhether interfer enceispresent.Ifaninterrogation usingZIPtelemetr ytakeslessthan20seconds,thecurrent\\nenvironment islikelyfreeofinterfer ence.Interroga tiontimeslongerthan20seconds(orshortintervalsofEGMdrop-\\nouts)indicate thatinterfere ncemaybepresent.\\nINDICATIONS-BASED PROGRAMMING (IBP)\\nIBPisatoolthatprovides specific programming recommendations basedonthepatient’s clinical needsandprimary\\nindications.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 22}), Document(page_content=\"1-12UsingtheProgrammer\\nZIPTelemetry Security\\nIBPisaclinical approachtoprogramming thatwasdeveloped basedonphysician consultation andcasestudies. The\\nintentofIBPistoenhance patient outcomes andsavetimebyproviding baseprogramming recommendations that\\nyoucancustomiz easneeded. IBPsystematically presents thespecific features intended forusewiththeclinical\\nconditions youidentify intheIBPuserinterfac e,andallowsyoutotakemaximum advantage ofthepulsegenerator's\\ncapabilities.\\nIBPcanbeaccessedfromtheSettings tabonthemainapplication screen(Figure1–2Indications-based Programming\\nscreenonpage1-12).\\nFigure1–2.Indications-based Programming screen\\nIndications areclustered ingeneralcategories asillustratedabove. Theintentforeachcategor yofindications is\\ndescribed below:\\n•SinusNode\\n–IfNormal isselected, theintentistoallowintrinsic atrialevents andprovideCRTpacing.\\n–IfChronotropically Incompetent isselected, theintentistoproviderate-adaptive CRTpacing.\\n–IfSickSinusSyndromeisselected, theintentistoprovide atrialpacing support andCRTpacing.\\n•AVNode\\n–Theintentistousenominal PacedAVDelayandSensed AVDelaysettings. TheSmartDelay optimization\\nfeature maybeusedtoadjusttheAVdelay.\\nNOTE:Theselected settings forAFandSinusNodemayaffectthesuggested valueforthesetting ofAVNode.\\n•AtrialArrhythmias\\n–IfParoxysmal/P ersistent isselected, theintentistoavoidtracking atrialarrhythmias byusingATRMode\\nSwitch whenadual-chamber pacing modeissuggested.\\n–IfPermanent/Chr onicAFisselected, theintentistoproviderate-adaptive CRTpacing.\\n•Ventricular Arrhythmias\\n–WhenHistory ofVF/SCD isselected, a2-zoneconfiguration withthefollowing ratethresholds andtherapies\\nisprovided:\\n–180bpmfortheVFzonewithQUICKCONVERT ATPandallshocks enabled andsettoMaximum Energy\\n–160bpmfortheVTzonewiththerapy disabled (Monitor Only)\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 23}), Document(page_content='UsingtheProgrammer\\nManualProgramming1-13\\n–WhenProphylaxis forVT/VFisselected, a2-zoneconfiguration withthefollowing ratethresholds and\\ntherapiesisprovided:\\n–200bpmfortheVFzonewithQUICKCONVERT ATPandallshocks enabled andsettoMaximum Energy\\n–170bpmfortheVTzonewiththerapydisabled (Monitor Only)\\n–WhenHistory ofVT/VFisselected, a2-zoneconfiguration withthefollowing ratethresholds andtherapiesis\\nprovided:\\n–200bpmfortheVFzonewithQUICKCONVERT ATPandallshocks enabled andsettoMaximum Energy\\n–160bpmfortheVTzonewithATPandallshocks enabled andsettoMaximum Energy\\n–Onset/Stability enabled\\n–WhenVFOnlyisselected, theintentistoprovideasingleVFzoneof220bpmwithonlyshocks enabled and\\nsettomaximum energy.\\nAfterchoosing appropriat epatient indications, selecttheViewRecommended Settings button toviewasummary of\\ntheprogramming recommen dations (Figure 1–3ProposedSettings Summary screenonpage1-13).\\nNOTE:Youmustviewtherecommended settings beforeyoucanprogramthem.Selecting theViewRecommen ded\\nSettings button allowsyoutoviewthesettings thatarerecommended basedontheindications thatyouselected.\\nViewing therecommended settings doesnotoverwrite anypending (i.e.,notyetprogrammed) parameter changes.\\nYoumustchoose toprogramorrejecttherecommended settings afterviewing them.Ifyouchoose torejectthe\\nrecommen dedsettings, allofyourpending settings willberestored.Ifyouchoose toprogram therecommended\\nsettings, anypending parameter changes willbeoverwritten.\\nFigure1–3.ProposedSettingsSummary screen\\nTheProposed Settings Summar yscreendisplays theprimary programming recommendations. Additional details\\naboutallchanged paramet ersareavailable byselecting theViewChanges button fromthetoolbar.Youhavethe\\noption toprogramtheproposed settings orrejectthem,aslongastelemetry isstillengaged:\\n•Program—select theProgramthisProfilebutton toaccepttheproposed settings.\\n•Reject—select theRejectthisProfilebutton torejectthepropose dsettings; thisactionwillreturnyoutothemain\\nIBPscreenwithnochanges made.\\nMANUAL PROGRAMMING\\nManual programming controlssuchasslidersandmenus areavailable toallowyoutoindividually adjustpulse\\ngeneratorprogramsettings.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 24}), Document(page_content='1-14 UsingtheProgrammer\\nDIVERTTHERAPY\\nManual programming controlsarelocated ontheSettings Summar ytab,whichcanbeaccessedfromtheSettings tab\\norbyselecting theSettings Summary button ontheSummary tab.Refertootherfeature descriptions inthismanual\\nforspecific manual programming information andinstructions. Referto\"Programmable Options\" onpageA-1for\\ndetailed listings ofavailable settings.\\nDIVERTTHERAPY\\nWhenthepulsegeneratorischarging todeliver ashock,theshockdelivery maybediverted fromthepatient. If\\ndiverted, theshockdoesnotcountasoneofthetotalnumber ofshocks thatmaybedeliveredduring anepisode. If\\nredetection occursandmoreshocktherapyisrequired,andifmoreshocks areavailable inthetherapyprescription,\\nthepulsegeneratorwillchargeagaintodeliver subsequent shocks.\\nAlso,theDIVERT THERAPY keycanbepressedtodivertATPtherapyinmidburst. Ifredetection occurs,theATP\\nscheme willnotbeusedagainandthenextprogrammed therapyinthesequence willbeinitiated.\\n1.Ifyouarenotalreadyinasession, position thetelemetry wandwithinrangeofthepulsegenerator andstarta\\ncommunication session.\\n2.PresstheDIVERT THERAPY key.Amessage window willappear indicating thatadivertattempt isbeingmade.\\n3.Ifusingwanded telemetry ,maintain thewandposition untilthemessage window disappears, indicating the\\nshockhasbeendiverted. Prematur elyremoving thewand(breaking thetelemetr ylink)mayallowthepulse\\ngenerator tocontinuechargingandtodeliver theshock.\\nNOTE:Thereisa500msdelaybetween theendofchargingandshockdelivery designed toprovide aminimum\\nperiodfortheDIVERT THERAPY command. Afterthistime,pressingDIVERT THERAPY maynotdiverttheshock.\\nTheDIVERT THERAPY keycanbeusedtoterminate anydiagnostic testinprogress, aswellasElectrocautery\\nProtectionMode(ifusingwanded telemetr y,maintain thetelemetr ywandposition untilthedivertfunction is\\ncomplet etoavoidinterruption tothedivertcommand).\\nTheDIVERT THERAPY keycanalsobeusedtoterminate MRIProtection Mode.\\nSTATSHOCK\\nAnonprogrammable, maximum-output STATSHOCK canbedelivered tothepatient atanytimeduring a\\ncommun ication session. TheSTATSHOCK canbedeliveredwhenthepulsegenerator’sTachyModeisprogrammed to\\nanymode.Thisfunction doesnotaffecttheprogrammed shocksequenc es(lower-energyshocks canbedelivered\\nfollowing aSTATSHOCK) anddoesnotcountasoneofthetotalnumber ofshocks inatherapysequenc eforagiven\\nepisode. Theoutput oftheSTATSHOCK isatthemaximum-output energy andattheprogrammed polarity and\\nwaveform; STATSHOCK isalways committe dregardless ofprogrammed paramet ers.\\n1.Ifyouarenotalreadyinasession, position thetelemetry wandwithinrangeofthepulsegenerator .\\n2.PresstheSTATSHOCK key.Amessage window appears withinformation abouttheshockandinstructions to\\ninitiate theshock.\\n3.Toinitiate theshock,presstheSTATSHOCK keyagain.Adifferentmessage window appears indicating thatSTAT\\nSHOCK isinprocess.Whentheshockhasbeendelivered,themessage window disappears.\\n4.Subsequent high-energ ySTATSHOCKS maybedeliveredbyrepeatingtheprevioussteps.\\nNOTE:TheSTATSHOCK maybediverted usingtheDIVERT THERAPY key.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 25}), Document(page_content='UsingtheProgrammer\\nSTATPACE1-15\\nNOTE:Following STATSHOCK delivery ,iftheTachyModeisprogrammed toMonitor OnlyorMonitor +Therapy,\\npost-shock redetectionisinitiated (initialdetection criteria andenhancements arenotused).IftheTachyModeis\\nprogrammed toMonitor +Therapyandredetection determines thatfurther therapyisrequired, theprogrammed\\nsequenc eoftherapywillberesumed orinitiated, including ATPand/or low-energy shocks.\\nNOTE:STATSHOCK willterminate ElectrocauteryProtection ModeandMRIProtectionMode.\\nSTATPACE\\nEmergencybradyca rdiapacing usingtheSTATPACEcommand setsthebradycar diaoperationtoparame tersintended\\ntoensure capture.\\n1.Ifyouarenotalready inasession, position thetelemetr ywandwithinrangeofthepulsegenerator.\\n2.PresstheSTATPACEkey.Amessage window displays theSTATPACEvalues.\\n3.PresstheSTATPACEkeyasecondtime.Amessage indicates thatSTATPACEisbeingperformed, followed by\\ntheSTATPACEvalues.\\n4.SelecttheClosebutton onthemessage window .\\n5.TostopSTATPACE,reprogramthepulsegenerator.\\nNOTE:STATPACEwillterminate Electrocautery ProtectionModeandMRIProtection Mode.\\nCAUTION: Whenapulsegeneratorisprogrammed toSTATPACEsettings, itwillcontinuetopaceatthehigh-\\nenergySTATPACEvaluesifitisnotreprogrammed. TheuseofSTATPACEparameters willlikelydecreasedevice\\nlongevity .\\nTheSTATPACEparametervaluesarelistedbelow(Table1–2STATPACEParameter Values onpage1-15).\\nTable1–2.STATPACEParameter Values\\nParameter Values\\nMode VVI\\nLowerRateLimit 60ppm\\nInterval 1000ms\\nPacing Chamber BiV\\nAmplitude 7.5V\\nPulseWidth 1.0ms\\nPacedRefractory 250ms\\nPost-shock Pacing VVI\\nDATAMANAGEMENT\\nThePRMsystem allowsyoutoview,print,store,orretrievepatient andpulsegenerator data.Thissection describes\\nthePRMdatamanagement capabilities.\\nPatientInformation\\nInformation aboutthepatient canbestoredinpulsegeneratormemory .Theinformation isaccessible fromthe\\nSummary screenbyselecting thePatient icon.Thisinformation includes, butisnotlimited to,thefollowing:', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 26}), Document(page_content=\"1-16UsingtheProgrammer\\nDataStorage\\n•Patient andphysician data\\n•Pulsegeneratorserialnumber\\n•Implant date\\n•Leadconfigurations\\n•Implant testmeasur ements\\nTheinformation canberetrieved atanytimebyinterrogating thepulsegenerator andviewing itonthePRMscreen\\norprinting itasareport.\\nNOTE:Ifthedataforpatient dateofbirth,gender,orfitness levelarechanged withinPatient Information, the\\ncorresponding valueinMinute Ventilation willautomatically change. Likewise,ifthedataforfitness levelischanged\\nwithinMinute Ventilation, thecorresponding valueinPatient Information willautomatically change.\\nNOTE:Thedataentered forpatient SleepSchedule isusedfortheSleepIncline trend.\\nDataStorage\\nThePRMsystem allowsyoutosavepulsegeneratordatatothePRMharddriveoraremovable floppydatadisk.Data\\nsavedtothePRMcanalsobetransferred toaremovabl eUSBpendrive.\\nSavedpulsegenerator dataincludes, butisnotlimited to,thefollowing:\\n•Therapyhistory\\n•Programmed parame tervalues\\n•Trending values\\n•HRV\\n•Histogram paced/sen sedcounters\\nSelecttheUtilities button, andthenselecttheDataStorage tabtoaccessthefollowing options:\\n•ReadDisk—allows youtoretrieve savedpulsegeneratordatafromafloppydisk.\\n•SaveAll—allows youtosavepulsegenerator datatoeitherafloppydisk(diskmustbeinserted) orthePRMhard\\ndrive(ifnofloppydiskisdetected). DatasavedtoafloppydiskcanberetrievedusingtheReadDiskoption\\ndescribed above. DatasavedtothePRMcanberead,deleted, orexported toaUSBpendrivefromthePRM\\nstartup screen.Reports areavailable inPDFformat. RefertothePRMOperator's Manual formoreinformation.\\nNOTE:Whilethedataisbeingsaved,amessage ontheright-handsideoftheSystemStatusscreenindicates\\nwherethedataisbeingsaved.\\nConsider thefollowing whenstoring andretrieving pulsegeneratordata:\\n•Nomorethan400unique patient recordsmaybesavedtothePRM.Whenapulsegenerator isinterrogated, the\\nPRMevaluates ifthereisalreadyarecordonfileforthispulsegenerator,orifanewrecordwillneedtobe\\ncreated.Ifanewrecordisneeded, andthePRMisatthe400recordcapacity ,theoldestrecordonfilewillbe\\ndeleted tocreatespaceforthenewpatient record.\\n•Whenperforming multiple patient checkups, besuretostartanewsession foreachpatient.\\n•BesuretosaveallpulsegeneratordatatoeitherafloppydiskorUSBpendrivebeforereturning aPRMtoBoston\\nScientific, asallpatient andpulsegeneratordatawillbeerasedfromthePRMwhenitisreturned.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 27}), Document(page_content='UsingtheProgrammer\\nDeviceMemory1-17\\n•Toprotect patient privacy,pulsegeneratordatacanbeencryptedbefore itistransferr edtoaUSBpendrive.\\nDeviceMemory\\nTheDeviceMemory utilityallowsyoutoretrieve, save,andprintpulsegeneratormemory data,whichisintended for\\nusebyaBoston Scientific representative forclinical andtroubleshooting purposes. Thisutilityshould onlybeused\\nwhendirected byaBoston Scientific representative. Digitalmediawithdevicememory datacontainsprotectedhealth\\ninformation andtherefo reshould behandled inaccordancewithapplicable privacy andsecurity policies and\\nregulations.\\nNOTE:UsetheDataStoragetabtoaccesspulsegenerator dataforclinician use(\"DataStorage\"onpage1-16).\\nPrint\\nYoucanprintPRMreports byusingtheinternal printer,orbyconnecting toanexternalprinter.Toprintareport,\\nselecttheReports button. Thenselectthereportyouwishtoprintfromthefollowing categories:\\n•Follow-up reports\\n•Episode reports\\n•Otherreports (includes devicesettings, patient data,andotherinformation)\\nSAFETYMODE\\nThepulsegeneratorisequipped withdedicated SafetyCorehardwarethatisintended toprovidelife-sustaining\\ntherapyifcertain nonrecoverable orrepeatfaultcondition soccurandcauseasystem reset.Thesetypesoffaults\\nindicate alossofcomponent integrity inthepulsegenerator\\'s centralprocessingunit(CPU),including the\\nmicroprocessor,program code,andsystem memory .Usingminimal hardware(i.e.,unipolar leadconfiguration), Safety\\nCoreoperatesindependently andactsasabackuptothesecomponents.\\nSafetyCorealsomonitors thedeviceduring normal pacing; ifnormal pacing doesnotoccur,SafetyCoredelivers an\\nescape pace,andasystem resetisinitiated.\\nIfthepulsegeneratorexperienc esthreeresetswithinapproximately 48hours,thedevicerevertstoSafetyModeand\\ndevicereplacement should beconsidered. Thefollowing willalsooccur:\\n•Thepulsegeneratorwillbeep16timesevery6hours.Thisbeeping isdisabled oncethedevicehasbeen\\ninterrogated withaPRM.\\nWARNING: Determine thebeeper typebeforeanMRIscan.TheArmature Beeper maynolongerbeusable\\nfollowing anMRIscan.Coming incontact withthestrongmagnetic fieldofanMRIscanner maycauseapermanent\\nlossoftheArmatur eBeeper volume. Thiscannot berecovered,evenafterleaving theMRIscanenvironment and\\nexitingMRIProtection Mode.FortheArmatur eBeeper,before anMRIscanisperformed, aphysician andpatient\\nshould weighthebenefit oftheMRIscanagainst theriskoflosingtheBeeper; aftertheMRIscan,perform Beeper\\nevaluation testtodetermine iftheBeeper isusable. IftheBeeper isnotusable, itisstronglyrecommended that\\npatients arefollowed onLATITUDE NXTafteranMRIscaniftheyarenotalready.Otherwise, anin-clinic follow-up\\nschedule ofeverythreemonths isstronglyrecommended tomonitor deviceperformance.\\nNOTE:Forinstructions onhowtodetermine thebeeper type,referencethe“Determine Beeper Type”subsection of\\n\"Beeper Feature\" onpage6-19.Forinstructions onperforming theBeeper evaluation test,see\"Beeper Feature\" on\\npage6-19.\\n•ZIPtelemetr yisunavailable forcommunicating withthePRMwhenSafetyModeisactive; wanded telemetry\\nmustbeusedinstead.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 28}), Document(page_content='1-18UsingtheProgrammer\\nBackupPacemaker\\n•LATITUDE NXTwillalertthatSafetyModehasbeenactivated.\\n•Uponinterrogation, awarning screenisdisplayed indicating thatthepulsegeneratorisinSafetyMode,and\\ndirectingyoutocontact Boston Scientific.\\nBackupPacemaker\\nSafetyModeprovides biventricular pacing, withthefollowing fixedparamet ers:\\n•BradyMode—VVI\\n•LRL—72.5 ppm\\n•PulseAmplitude—5.0 V\\n•PulseWidth—1.0 ms\\n•RVRefractoryPeriod(RVRP)—250 ms\\n•RVSensitivity—AGC 0.25mV\\n•RVleadconfiguration—Unipolar\\n•Ventricular Pacing Chamber—BiV\\n•LVOffset—0 ms\\n•LVleadconfigur ation—Unipolar (LVtiptoCan)\\n•NoiseResponse—VOO\\n•Post-Shock Pacing Delay—3 sec\\nWARNING: Intherareeventthatnon-rec overable orrepeatfaultconditions occurwhilethedeviceisprogrammed\\ninMRIProtection Mode,thesubsequent devicebehavior willbedetermined bytheMRIProtection BradyMode\\nsetting.\\n•IfMRIBradyModeissettoOff,thedevicewillenterSafetyMode(permanent VVIunipolar pacing andtachycard ia\\ntherapyenabled).\\n•IfMRIBradyModeissettoasynchron ouspacing (AOO,VOO,DOO),bothbradycardiatherapyandtachycard ia\\ntherapywillbepermanently disabled.\\nBackupDefibrillator\\nWhenSafetyModeisactivated, TachyModeisautomatically programmed toMonitor +Therapy toprovide single-\\nzonetachyarrhythmia detection andtherapy .TachyModemaystillbeprogrammed toOffwhileinSafetyMode.\\nNOTE:Ifadditional faultsaredetected whileinSafetyMode,tachyarrhythmia therapywillbedisabled.\\nWhileinSafetyMode,thetachyarrhythmia therapyislimited to5maximum-energy committe dshocks perepisode.\\nTachyarrhythmia detection andtherapyparamet ersarefixedasfollows:\\n•VFRateThreshold—165 ppm\\n•Duration—1 sec\\n•Shockpolarity—initial\\n•Shockwaveform—biphasic', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 29}), Document(page_content='UsingtheProgrammer\\nBackupDefibrillator1-19\\n•ShockVector—V-TRIAD\\nMagnet application willimmediately inhibittherapy,although charging maycontinue. Afterthemagnet hasbeen\\napplied for1second,therapyisdiverted anddetection isinhibited. Themagnet mustthenberemoved for2seconds\\ninordertoallowdetection tocontinue. Also,SafetyModedisables normal beeping behavior following magnet\\napplication.\\nWARNING: Intherareeventthatnon-rec overable orrepeatfaultconditions occurwhilethedeviceisprogrammed\\ninMRIProtection Mode,thesubsequent devicebehavior willbedetermined bytheMRIProtectionBradyMode\\nsetting.\\n•IfMRIBradyModeissettoOff,thedevicewillenterSafetyMode(permanent VVIunipolar pacing andtachycardia\\ntherapyenabled).\\n•IfMRIBradyModeissettoasynchr onouspacing (AOO,VOO,DOO),bothbradycar diatherapyandtachycard ia\\ntherapywillbepermanently disabled.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 30}), Document(page_content='1-20UsingtheProgrammer\\nBackupDefibrillator', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 31}), Document(page_content='2-1\\nTACHYARRHYTHMIA DETECTION\\nCHAPTER 2\\nThischapter containsthefollowing topics:\\n•“Device Mode” onpage2-2\\n•“RateSensing” onpage2-4\\n•“Ventricular Detection” onpage2-6', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 32}), Document(page_content='2-2Tachyarrhythmia Detection\\nDeviceMode\\nDEVICEMODE\\nTheDeviceModeallowsyoutoprogramthedevicetoprovide thetypeoftherapyanddetection desired.\\nVentricular TachyMode\\nTheVentricular TachyModecontrols theavailability ofthedetection andtherapy functions intheventricle (Table2–1\\nDevicefeature availability intheVentricular TachyModesettings onpage2-2).\\nYoucanprogram theVentricular TachyModetothefollowing modes:\\n•Off––disables ventricular tachyarrhythmia detection andautomatic ventricular therapy delivery .Thismodeis\\nusefulduring implant orexplant,whenconnecting theleadstoordisconnecting themfromthepulsegenerator.\\n•Monitor Only––enables ventricular tachyarrhythmia detection andepisode storage,butdoesnotautomatically\\ndeliver therapy tothepatient. Thismodeisusefulincontrolledenvironments, suchasduring EPtesting, exercise\\ntesting, andimmediately postoper ative,wherealternate therapy (e.g.,externaldefibrillation) isavailable.\\n•Monitor +Therapy––enables thefullrangeofventricular detection andventricular therapyoptions.\\nTable2–1.Devicefeatureavailability intheVentricular TachyModesettings\\nDevicefeatures Ventricular TachyMode\\nOff MonitorOnly Monitor+Therapy\\nRatesensing XaX X\\nBradycardia pacing X X X\\nVentricular Detection/Therapy History XbX X\\nSTATSHOCK X X X\\nSTATPACE X X X\\nReal-time annotated EGMs X X X\\nVentricular tachyarrhythmia detection X X\\nCommanded Ventricular ATP X Xc\\nCommanded Ventricular Shock X X\\nVentricular EPTest XdXd\\nAutomatic ventricular tachyarrhythmia therapy X\\na.Inordertoenable ventricular sensing whentheVentricular TachyModeisprogrammed toOff,youmustprogramtheBradyModetoamodewithventricular sensing.\\nb.Whileprogrammed toOffMode,thepulsegenerator willstoreonlySTATSHOCK inhistory.\\nc.WhentheVentricular TachyModeisMonitor +Therapy ,theEPTempVModemustbeprogramm edtoMonitor OnlyinordertousetheCommanded Ventricular ATP.\\nd.NotallformsofEPTestsareavailable inthismode.\\nElectrocauteryProtectionMode\\nElectrocauteryProtection Modeprovidesasynchron ouspacing attheprogrammed outputs andLRL.Tachyarrhythmia\\ndetection andtherapyfeaturesaredeactivated.\\nWhenElectrocauteryProtection isenabled, theBradyModeswitches toanXOOmode(whereXisdetermined bythe\\nprogrammed BradyMode). Otherpacing paramet ersremainattheprogrammed settings (including pacing output). If\\nBradyModeisOffpriortoenabling Electrocauter yProtection, itwillremainOffduring Electrocautery Protection. Once\\nenabled, Electrocautery Protectiondoesnotrequireconstant telemetry toremainactive.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 33}), Document(page_content='Tachyarrhythmia Detection\\nDeviceMode2-3\\nAftercancelling Electrocaute ryProtection, thefollowing modes willreverttothepreviously programmed settings:\\n•Ventricular TachyMode\\n•Brady/CRT Mode\\nAfterattempting toenable Electrocautery ProtectionMode,refertothemessage onthePRMscreenconfirming that\\nElectrocautery Protectionisactive.\\nExceptforSTATSHOCK andSTATPACE,nocommanded therapies,inductions, diagnostic tests,orprinting ofreports\\nwillbeallowed whileElectrocauteryProtection isenabled.\\nApplication ofamagnet whilethedeviceisinElectrocautery ProtectionhasnoeffectonTachyMode.\\nBiventricular pacing withLVOffsetprogrammed tozerowillbedelivere dwhileElectrocautery ProtectionModeis\\nenabled iftheprogrammed modeisaventricular pacing mode.\\nToenable anddisable Electrocautery Protection Mode,perform thefollowing steps:\\n1.SelecttheTachyModebutton fromthetopofthePRMscreen.\\n2.SelectthecheckboxtoEnable Electrocautery Protection.\\n3.SelecttheApplyChanges button toenable Electrocautery ProtectionMode.Adialogwindow willappear,\\nindicating thatElectrocautery Protectionisactive.\\n4.SelecttheCancelElectrocautery Protectionbutton onthedialogwindow toreturnthedevicetothepreviously\\nprogrammed mode.Electrocaute ryProtection canalsobecancelle dbyselecting STATSHOCK, STATPACE,or\\nDIVERT THERAPY onthePRM.\\nMRIProtectionMode\\nThisfeature isavailable inRESONATE HF,RESONATE, andMOMENTUM devicesexceptforthosewithanLV:LV-1lead\\nconnection, aswellasVIGILANT devices.\\nForacomplete description ofMRIProtection Mode,alistofMRConditional devices,andadditional information about\\ntheImageReady MRConditional Defibrillation System, refertotheImageReady MRConditional Defibrillation System\\nMRITechnical Guide.\\nWARNING: RESONATE HF,RESONATE, andMOMENTUM devices exceptforthosewithanLV:LV-1leadconnection\\nareconsidered MRConditional. VIGILANT devices areconsidered MRConditional. Forthesedevices, unlessallofthe\\nMRIConditions ofUsearemet,MRIscanning ofthepatient doesnotmeetMRConditional requirements forthe\\nimplanted system. Significant harmtoordeathofthepatient and/or damage totheimplanted system mayresult.Do\\nnotexposepatients withnon-MR Conditional devicestoMRIscanning. Strongmagnetic fieldsmaydamage thepulse\\ngeneratorand/or leadsystem, possibly resultingininjurytoordeathofthepatient.\\nForadditional warnings, precautions, Conditions ofUse,andpotential adverse events applicable whentheConditions\\nofUsearemetornotmet,refertotheImageReady MRConditional Defibrillation SystemMRITechnical Guide.\\nMRIProtectionModemodifies certain pulsegenerator functions inordertomitigate risksassociated withexposing\\nthedefibrillation system totheMRIenvironment.\\nMRIProtectionModeisaccessedviatheTachyModebutton. Choosing MRIProtection Modewillinitiate asequenc eof\\ndialogboxestoassesstheeligibility andreadiness ofthepatient andthepatient’s pacing system toundergoanMR\\nConditional MRIscan.Detailed programming instructions, theConditions forUse,andacomprehensive listofMRI-', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 34}), Document(page_content='2-4Tachyarrhythmia Detection\\nRateSensing\\nrelatedwarnings andprecautions areprovided intheImageReady MRConditional Defibrillation SystemMRITechnical\\nGuide.\\nInMRIProtection Mode:\\n•Pacing modeoptions include asynchr onouspacing (DOO,AOO,VOO)ornopacing (Off).Asynchr onouspacing\\nshould onlybeusedifthepatient ispacing-dependent. IfMRIProtection BradyModeisprogrammed toOff,the\\npatient willnotreceivetherapyuntilMRIProtectionModeisexited.Offshould onlybeusedifthepatient is\\njudged tobeclinically capable ofreceiving nopacing during thetimethepulsegeneratorisinMRIProtection\\nMode,including during thescan.\\n•Cardiac Resynchro nization Therapyissuspended ifMRIProtectionBradyModeisprogrammed toOff.\\n•Tachycardia therapyissuspended.\\n•Beeper isturned Off.\\n•ZIPTelemetr yissuspended.\\nMRIProtection Modeisterminated bymanual exitorbysetting theuser-programmed automatic MRIProtection\\nTime-out period(refertotheImageReady MRConditional Defibrillation SystemMRITechnical GuideforMRI\\nProtectionModeprogramming instructions). STATPACE,STATSHOCK andDIVERT THERAPY willalsoterminate MRI\\nProtectionMode.WhenMRIProtectionModeisexited,allparameters (exceptfortheArmature Beeper) returntothe\\npreviouslyprogrammed settings (see\"Beeper Feature\" onpage6-19toreferencethe“Determine Beeper Type”\\nsubsection).\\nNOTE:Itisrecommended toperform Beeper evaluation testaftereachMRIscan(\"Beeper Feature\" onpage6-19).\\nInsituations wheretheMRIscandidnotoccur,theArmatur eBeeper canbeturned backonafterexitingMRI\\nProtectionMode.\\nRATESENSING\\nRatesensing iscriticaltoalldetection decisions. Thepulsegeneratorreliesonthefollowing todetermine cardiac\\ncyclelength:\\n•Bipolar electrodes intheatrium andrightventricle.\\n•Automatic gain-controlled sensing circuitforratesensing. Thiscircuitensures properratesensing by\\ncompensati ngforchanging ordiminished signalamplitudes.\\nForCRTandbradycar diatherapydecisions, ratesensing isbasedonRVsensed andventricular pacedevents.\\nCalculating RatesandRefractory Periods\\nThepulsegenerator evaluates rateonaninterval-by-inter valbasis.Following asensed depolarization, acyclelength\\nismeasur edandcompar edtotheprogrammed detection parameters.\\nThepulsegenerator usesrefractory periods following pacedandsensed intrinsic events; intrinsic events thatfall\\nwithintheseperiods areignoredfordetection purposes. Therefractoryperiods, together withnoisewindows, may\\npreventthesensing ofnonphysiologic signals andthepotential delivery ofunwanted therapy.Thenonprogr ammable\\nrefractory periods areasfollows:\\n•85msatrialrefractory following anatrialsensed event\\n•150msatrialrefractory following anatrialpaceinDDD(R) andDDI(R)modes', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 35}), Document(page_content='Tachyarrhythmia Detection\\nCRTDeliveryZoneandTachyarrhythmia Zones2-5\\n•135msRVrefractory following anRVsensed event\\n•135msrefractory following acapacitor charge(sensing isignoredinallchambers)\\n•500msrefractoryfollowing shockdelivery (sensing isignored inallchambers)\\nVentricular RateThresholds andZones\\nThepulsegeneratorcompar eseachsensed RVcardiaccycleintervalagainst theprogrammed Ventricular\\nTachyarrhythmia RateThreshold.\\nAVentricular Tachyarrhythmia Zoneisarangeofheartratesdefined byatleastoneprogrammed Ventricular\\nTachyarrhythmia RateThreshold. Youcanprogramfrom1to3Ventricular Tachyarrhythmia Zones, eachofwhichcan\\nbetreated byaseparate therapy prescription (Table2–2Nominal valuesforVentricular RateThresholdconfigurations\\nonpage2-5,Figure2–1Ventricular TachyDetection settings onpage2-5).\\nTable2–2.NominalvaluesforVentricular RateThreshold configurations\\nVentricular ZoneConfiguration VT-1Zone VTZone VFZone\\n1Zone –– –– 200bpm\\n2Zones –– 170bpm 200bpm\\n3Zones 140bpm 170bpm 200bpm\\nFigure2–1.Ventricular TachyDetection settings\\n•Ratethresholds inadjacent zonesmustdifferbyatleast20bpm\\n•Thelowest Ventricular Tachyarrhythmia RateThreshold mustbeatleast5bpmhigherthantheMTR,MSR,and\\ntheMPR\\n•Thelowest Ventricular Tachyarrhythmia RateThreshold mustbeatleast15bpmhigherthantheLRL\\nCRTDeliveryZoneandTachyarrhythmia Zones\\nThedevicedivides therapydelivery intozonesbasedonheartrate.\\n•Theprogrammed LRLandMTR/MSR/MPR definetheCRTdelivery zone,ortherangeoverwhichCRTisdelivere d.\\n•Thetachyarrhythmia zonesarebounded bythelowerratethreshold ofthelowest tachyarrhythmia zone.Itisnot\\npossible toprogramtheCRTdelivery zoneandthetachyarrhythmia zonestooverlap. Aminimum 5bpm\\ndifferencemustexistbetween theupperlimitoftheCRTdelivery zoneandthelowerlimitofthetachyarrhythmia\\nzones.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 36}), Document(page_content='2-6Tachyarrhythmia Detection\\nUseofAtrialInformation\\nUseofAtrialInformation\\nTheatrialratemaybeusedto:\\n•Inhibitventricular therapyinthepresenc eofatrialfibrillation oratrialflutter\\n•Bypass ventricular therapyinhibitors iftheventricular rateisfasterthantheatrialrate\\nAtrialsensing canbeprogrammed toOnorOffinanydualorsinglechamber BradyMode.Thepulsegenerator will\\nrespondtoatrialsensing regardless ofwhether anatrialleadisimplanted.\\nTheremaybeclinical situations inwhichatrialleadinformation isnotuseful(e.g.,chronic atrialfibrillation, faultyor\\ndislodged atriallead,plugged atrialport).\\nCAUTION: Ifanatrialleadisnotimplanted (portisplugged instead), oranatrialleadisabandoned butremains\\nconnected totheheader,deviceprogramming should beconsistentwiththenumber andtypeofleadsactually in\\nuse.\\nIfanatrialleadwillnotbeused,usethefollowing programming recommendations toensure appropriatedevice\\nbehavior:\\n•ProgramtheatrialleadtoOff,toprevent atrialsensing andminimiz eaccrualofatrialcounters .\\nNOTE:AnatrialEPtestshould notbeperformed iftheatrialleadisprogrammed toOff.\\nCAUTION: Whenatrialsensing isprogrammed toOffinaDDI(R)orDDD(R) mode,anyatrialpacing thatoccurswill\\nbeasynchro nous.Additionally ,features thatrequireatrialsensing maynotfunction asexpected.\\n•ProgramtheBradyModetoVVIorVVI(R), topreventatrialpacing andensure thatatrialinformation isnotused\\ntodrivebradypacing.\\n•Programthefollowing ventricular detection enhancements toOff,toensure therapydecisions arenotbasedon\\natrialmeasurem ents:\\n–InitialandPost-Shock VRate>ARate(forOnset/Stability)\\n–InitialandPost-Shock AFibRateThreshold (forOnset/Stability)\\n–AtrialTachyarrhythmia Discrimination (forRhythm ID)\\nNOTE:Youshould alsoreviewand,ifnecessary,adjustStability settings.\\n•ProgramtheAtrialIntrinsic Amplitude andAtrialImpedanc edailyleadmeasur ements toOfftodisable atrial\\ndiagnostics (e.g.,atrialAmplitude andImpedanc e).\\n•During follow-up visits,consider deselecting theatrialreal-timeEGM.\\nIfanatrialleadisusedinthefuture, theseprogramming adjustments should bereevaluate d,andthepulsegenerator\\nshould beprogrammed appropr iatelyforusewithanatriallead.\\nVENTRICULAR DETECTION\\nVentricular detection consists ofthefollowing components:\\n•Initialventricular detection\\n•Reconfirmation/c ommitted shock', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 37}), Document(page_content=\"Tachyarrhythmia Detection\\nVentricular Detection Enhancement Suites2-7\\n•Redetection andpost-shockdetection\\nInitialventricular detection criteria consistoftheprogrammable paramet ersRateandDuration. Thedetection criteria\\nmayalsoinclude oneofthefollowing detection enhancemen tsuites,whichmaybeusedduring initialandpost-shock\\nventricular detection toaddspecificity beyond RateandDuration:\\n•Onset/Stability\\n•Rhythm ID\\nThepulsegeneratorinitiates ventricular therapywhenitdetermines thatdetection ismet.Ventricular detection ismet\\nwhenallofthefollowing occur:\\n•Aventricular zone’sdetection window becomesandremainssatisfied throughout Duration\\n•Theventricular zone’sDuration expires\\n•Ahigher ventricular zone'sdetection window isnotsatisfied\\n•Detection enhancemen ts(ifprogrammed toOn)indicate therapy\\n•Thelastdetected intervalisintheventricular zone\\nIftheabovecriteria arenotmet,therapyisnotinitiated andthepulsegeneratorcontinues toevaluate intervals.\\nWARNING: During MRIProtection Mode,Tachycar diatherapyissuspended. Thesystem willnotdetectventricular\\narrhythmias andthepatient willnotreceiveATPorshockdefibrillation therapyuntilthepulsegenerator is\\nprogrammed backtonormal operation.Onlyscanthepatient ifjudged tobeclinically capable oftolerating no\\nTachycar diaprotectionfortheentiredurationinwhichthepulsegenerator isinMRIProtectionMode.\\nVentricular Detection Enhancemen tSuites\\nOneofthefollowing ventricular detection enhancemen tsuitesmaybeprogrammed toprovide specificity beyond\\nRateandDuration (Table2–3Detection enhanceme ntsuitesavailable perzoneonpage2-7):\\n•Rhythm ID\\n•Onset/Stability\\nDetection enhance mentsuitesarenotavailable intheVFzone.\\nTable2–3.Detection enhancement suitesavailable perzone\\nVT-1Zone VTZone VFZone\\n3-zone configur ationaRhythm ID\\nOnset/StabilityRhythm ID\\nOnset/StabilitydNone\\n3-zone configur ation(withMonitor Onlyzone)bc None Rhythm ID\\nOnset/StabilityNone\\n2-zone configur ation Rhythm ID\\nOnset/StabilityNone\\n2-zone configur ation(withMonitor Onlyzone)b None None\\n1-zone configur ation None\\na.Ifthedetection enhancement suiteisenabled ina3-zoneconfiguration, itapplies toboththeVT-1andVTzones.\\nb.Detection enhancement suitesarenotavailable inthelowest zoneofamulti-zoneconfigur ationwhenthezoneisusedasaMonitor Onlyzone(notherapy programmed forthatzone).\\nc.Fordevices programmed toa3zoneconfigur ationwithVT-1programmed toMonitor Onlyanddetection enhancements OnintheVTzone,rhythm discrimination willbeapplied whena\\ntachycardia meetsInitialDetection intheMonitor Onlyzoneandtheratesubsequently accelerates totheVTzone.Inthiscase,InitialDetection isrestarted anddetection enhancements are\\navailable intheVTzone.\\nd.ShockifUnstable istheonlyOnset/Stability detection enhance mentavailable intheVTzoneofa3-zone configur ation(applies onlyto3-zone configur ationwithout aMonitor Onlyzone).\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 38}), Document(page_content='2-8Tachyarrhythmia Detection\\nVentricular Detection Enhancement Suites\\nNOTE:Thereisnoclinical datatosuggest thatonedetection enhancement suiteissuperior totheotherforany\\ngivenpatient indication. Therefore,individual programming andevaluation ofdetection enhancemen tspecificity is\\nrecommended.\\nRhythmID\\nRhythm IDusesVectorTiming andCorrelat ionanalysis inaddition toatrialandventricular intervalanalysis to\\ndetermine ifapatient\\'s rhythm should betreated (VT)oriftherapyshould beinhibited (SVT).\\nWithRhythm ID,thepulsegenerator performs avectortimingandcorrelation analysis usingtheshockEGMandrate\\nEGM.Basedonthisdata,itsavesareferencetemplate ofthepatient\\'s normal sinusrhythm.\\nDuring Rhythm IDanalysis, thepulsegenerator firstdetermines iftheventricular rateisgreaterthantheatrialrate.If\\nso,therapywillbeinitiated. Iftheventricular rateisnotgreater thantheatrialrate,Rhythm IDevaluates the\\nfollowing criteria todetermine iftherapyshould beinhibited orinitiated:\\n•VectorTiming andCorrelationanalysis during InitialDetection determines iftherhythm isSVTbycomparing itto\\nthepreviously storedreferencetemplate. Iftherhythm isdeclaredSVT,therapyisinhibited. Fordeviceswith\\nRhythmMatch Threshold, thecorrelation between thepatient\\'s rhythm andthereferencetemplate mustbeequal\\ntoorgreaterthantheprogrammed RhythmMatch Threshold fortherhythm tobedeclared SVTandtherapy\\ninhibited (\"Vector Timing andCorrelation\" onpage2-21).\\n•IfVectorTiming andCorrelation doesnotdeclare therhythm SVT,Stability andAFibRateThreshold determine if\\ntheventricular rhythm isunstable andtheatrialrateisfast.Iftheventricular rhythm isunstable andtheatrial\\nrateisfast,therhythm isdeclaredSVTandtherapyisinhibited.\\nRhythm IDdoesnotconsideratrialdetection criteria (VRate>ARateorAgreaterthanAFibRateThreshold) forthe\\nfollowing configurations:\\n•Dual-chamber devicesifAtrialTachyarrhythmia Discrimination isprogrammed toOff\\nWhenconfigured thisway,Stability isnotevaluated forInitialDetection. Thismaybeusefulininstanceswhereatrial\\nleadproblemshaveoccurred. Fortheseconfigurations, therapyisinhibited atInitialDetection iftherhythm is\\ndeclaredSVT(based onVectorTiming andCorrelatio n).Otherwise, therapyisinitiated.\\nTwomethods areavailable forthedevicetoautomatically acquireaRhythm IDreferencetemplate: passive and\\nactive.Theactivemethod maybeusefulforpatients whoarefrequently ventricular paced.\\nIfthepassive method isenabled, thepulsegeneratorwillattempt tocollecttheRhythm IDreferencetemplate every\\ntwohoursusingtheprogrammed bradysettings. Updates startbetween 2and4hoursafterthedevicehasbeen\\nremoved fromStorage mode.\\nIftheactivemethod isenabled andsevendayshavepassed sincethelastsuccessfulcollectionofareferenc e\\ntemplate, thenevery28hoursthedeviceautomatically analyzes thepatient\\'s intrinsic rhythm byadjusting thebrady\\nparamet ers.During aRhythm IDactivereferencetemplate update, thefollowing willoccur:\\n1.Thedeviceverifies thatthepatient isatrest(asmeasur edbytheaccelerometer input).\\n2.Thedeviceenables acontrolled pacing ratedecreasetotheprogrammed Rhythm IDFallback LRL.During this\\nfallback period, thefollowing occurs:\\n•Thedevicetempor arilyswitches thepacing modetoDDI,VDI,VVI,AAI,orOff(according totheprogrammed\\nbradymode)andextendstheAVDelayupto400ms.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 39}), Document(page_content=\"Tachyarrhythmia Detection\\nVentricular Detection Enhancement Suites2-9\\n•Biventricular Trigger,RateSmoothing, ATR,RateHysteresis,RateSearchHysteresis,anddynamic\\nprogramming (excluding dynamic VRP)aresuspended. Thepacing chamber issettoBiventricular; LVOffset\\nissetto0.\\n3.AftertheFallback period, pacing paramet ersarerestoredtonormal programmed parameters. Fallback periods\\noccurnomorethanonceperdayandwilltypically lastlessthanoneminute.\\nAmethod formanually commanding thedevicetoacquireaRhythm IDreferencetemplate isalsoavailable.\\nNOTE:IfRhythm IDisnotenabled, amanual referencetemplate update canstillbeperformed. Should an\\narrhythmia occur,thisallowsthedevicetoperform VectorTiming andCorrelationanalysis and,fordevices with\\nRhythmMatch Threshold, recordthemeasur edRhythmMatch valueofthearrhythmia intheepisode data.However ,\\ntheVectorTiming andCorrelation analysis resultwillnotbeusedtodetermine ifthepatient's rhythm isVTorSVT.\\nDuring amanual Rhythm IDreferenc etemplate update, thepulsegeneratorwillperform thefollowing tasks:\\n1.Enable acontrolledratedecreasetotheprogrammed Rhythm IDFallback LRL.During thefallback period, the\\nfollowing occurs:\\n•Thedevicetempor arilyswitches totheprogrammed Manual Rhythm IDBradyModeandextends theAV\\nDelayupto400ms.\\n•Biventricular Trigger,RateSmoothing, ATR,RateHysteresis,RateSearchHysteresis,anddynamic\\nprogramming (excluding dynamic VRP)aresuspended. Thepacing chamber issettoBiventricular; LVOffset\\nissetto0.\\n2.AftertheFallback interval, pacing parameters arerestored tonormal programmed parameters. Thisprocesswill\\ntypically lastlessthanoneminute.\\nNOTE:Rhythm IDFallback LRLsettings should beselected suchthatnormal sinusrhythms arepromoted(e.g.,\\nnormal AVnodeconduction). Caremustbeusedwhenselecting LRLlessthan50ppm(ratesthatapproac hthe\\npatient’s ventricular escape rates).Ventricular escape rhythms during Rhythm IDupdates mayresultininappropriate\\ntherapydecisions.\\nNOTE:AnacquiredRhythm IDreferenc etemplate willbeusedtoperform VectorTiming andCorrelat ionanalysis\\nuntilanewerreferencetemplate isacquired.\\nNOTE:Amanual Rhythm IDreferencetemplate update should notbecommanded immediately aftershock\\ntherapy.Itmaytakeseveral minutes forirregularities inEGMmorphology caused bytheshocktosubside.\\nConsider thefollowing whenusingRhythm ID:\\n•Rhythm IDdetermines whether therapy willbeinhibited ornotattheendofDuratio n.Ifthedecision istoinhibit\\ntherapy,thenRhythm ID(including VectorTiming andCorrelation, VRate>ARate,AFibRateThreshold, and\\nStability) continues tobereevaluated beat-by-beat. UseoftheSustained RateDuration (SRD)feature willlimit\\ninhibition oftherapybyRhythm IDtothelengthoftheprogrammed SRD.\\n•Rhythm IDwillnotinhibittherapyintheVFzone.Programming theVFratethreshold lowerthantherateoffast\\nrhythms willpreventRhythm IDfrominhibiting therapyforthoserhythms.\\n•Programming AtrialTachyarrhythmia Discrimination toOnpreventsRhythm IDfrominhibiting therapyifthe\\nventricular rateisfasterthantheatrialrate.\\n•IfnoRhythm IDreferencetemplate haseverbeenacquired,Rhythm IDusesonlyStability andAFibRate\\nThreshold todiscriminate between VTandSVT,because VectorTiming andCorrelation analysis cannot be\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 40}), Document(page_content=\"2-10Tachyarrhythmia Detection\\nOnset/Stability\\nperformed. Furthermor e,ifRhythm IDdoesnotconsideratrialdetection criteria, andnoreferencetemplate has\\nbeenacquired, nodetection enhancements willbeevaluated during InitialDetection.\\nOnset/Stability\\nTheOnset/Stability detection enhancement suiteanalyzes thecardiaccycleintervals todetermine ifapatient's\\nrhythm should betreated(VT)oriftherapyshould beinhibited (SVT).\\nOnset/Stability allowsyoutoprogramdetection enhanceme ntsbyidentifying thedesired typeofrhythm\\ndiscrimination: atrialtachyarrhythmia, sinustachycard ia,orpolymorphic VT(Table2–4Onset/Stability rhythm\\ndiscrimination available perzoneonpage2-10).\\nTable2–4.Onset/Stability rhythmdiscrimination available perzone\\nVT-1Zone VTZone VFZone\\n3-zone Configuration AtrialTachyarrhythmia Polymorphic VTa None\\nSinusTachycardia\\n3-zone Configuration\\n(withMonitor Onlyzone)bcNone AtrialTachyarrhythmia None\\nSinusTachycardia\\nPolymorphic VTa\\n2-zoneConfigura tion AtrialTachyarrhythmia None\\nSinusTachycardia\\nPolymorphic VTa\\n2-zoneConfigura tion(withMonitor Onlyzone)b None None\\n1-zone Configura tion None\\na.Polymorphic VTDiscrimination isonlyavailable intheVTzone.\\nb.Rhythm discrimination isnotavailable inthelowest zoneofamulti-zone configur ationifthezoneisusedasaMonitor Onlyzone(notherapy programmed forthatzone).\\nc.Fordevices programmed toa3zoneconfigura tionwithVT-1programmed toMonitor Onlyanddetection enhancements OnintheVTzone,rhythm discrimination willbeapplied whena\\ntachycardia meetsInitialDetection intheMonitor Onlyzoneandtheratesubsequently acceleratestotheVTzone.Inthiscase,InitialDetection isrestarted anddetection enhancements are\\navailable intheVTzone.\\nReconfirmation/Committed Shock\\nReconfirmation referstothemonitoring performed bythedeviceduring andimmediately following capacitor\\nchargingforashock.WhentheCommitted Shockparameter isprogrammed toOff,thedeviceisallowed toreconfirm\\nthatashockshould bedelivered.\\nVentricular Redetection\\nVentricular Redetection occursfollowing any:\\n•Ventricular therapydelivery\\n•Diverted therapyduetoreconfirmation analysis (diverted-rec onfirm)\\n•Manually diverted therapy\\n•Therapynotavailable atDetection Met(exceptwhentheVT-1zoneisprogrammed toMonitor Only,inwhichcase\\nInitialDetection isrestarted)\\nRedetection usesthesameventricular detection window processandprogrammed tachycard iaRatethresholds as\\nInitialDetection toidentify atachyarrhythmia.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 41}), Document(page_content=\"Tachyarrhythmia Detection\\nVentricular Post-shockDetection Enhancemen ts2-11\\nTheprimary differencesbetween InitialDetection andRedetection aretheDuration paramet ersusedandthe\\ndetection enhancements thatareavailable:\\n•Ifventricular shocktherapyisdelivere d,thefollowing willoccur:\\n–Theredetection durationtimeisdetermined bythevalueofthePost-shock Duration parameter\\n–Detection enhancement s(exceptforOnset, ShockifUnstable, andVectorTiming andCorrelation )are\\navailable during redetection\\n•Ifventricular ATPisdeliveredoriftherapyisdiverted orunavailable, thefollowing willoccur:\\n–Theredetection durationtimeisdetermined bytheRedetection Duration parameter\\n–Detection enhancement s(exceptforShockifUnstable) arenotavailable during redetection\\nWhichever durationisdetermined tobeappropriate, thattypeofduration(Redetection orPost-Shock) willbeineffect\\ninallzonesateachzone'sprogrammed durationvalue.\\nVentricular Post-shockDetection Enhancemen ts\\nWhenprogrammed toOn,thefollowing ventricular post-shockdetection enhancements willbeineffectfollowing the\\nPost-shock Duration:\\n•Post-shock VRate>ARate\\n•Post-Shock AFibRateThreshold\\n•Post-shock Stability\\n•Post-shock SRD\\n•Post-shock Rhythm ID(usesAFibRateThreshold, Stability, VRate>ARate,andSRD)\\nWiththeexceptionofRhythm ID,allpost-shockdetection enhance mentsperform thesameasthecorresponding\\nInitialDetection enhancement s(withRhythm ID,VectorTiming andCorrelationisnotavailable post-shock).\\nPost-shock Stability maybeusedtopreventshock-inducedAFfromcausing thepulsegeneratortodeliver undesir ed\\nadditional shocks (Figure2–2Post-shock Duration andPost-shock Stability analysis onpage2-11.)\\nTheAFibRateThreshold canbeprogrammed inconjunction withPost-shock Stability tofurther discriminate AFand\\npreventthepulsegenerator fromdelivering undesire dventricular shocktherapy.\\n0 s 5 s\\n20 s\\n0 s\\n15 s\\nLowest zone \\ndetection window \\nsatisfied.\\nPost-shock Duration = 5 s\\nPost-shock SRD = 15 sPost-shock \\nDuration starts in \\nlowest zone.\\nPost-shock Duration \\nexpires.\\nEvaluate Stability . If \\nstable, charge and \\nshock. If unstable, inhibit \\ntherapy . Post-shock \\nSRD timer starts.\\nContinue Pos t-shock Stabi\\nlity \\nanalysis thro ughout S\\nRD time \\nas long as th e detect\\nion \\nwindow rema ins satis\\nfied.\\nIf Stability indicates \\ntherapy , charge and \\nshock.\\nPost-shock SRD times out. \\nCharge and deliver shock if \\ntherapy had been inhibited \\nduring SRD.\\nShock\\nFigure2–2.Post-shockDuration andPost-shockStabilityanalysis\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 42}), Document(page_content='2-12Tachyarrhythmia Detection\\nVentricular Detection Details\\nVentricular Detection Details\\nThepulsegenerator usesthefollowing information todetermine appropriat etherapydelivery:\\n•Ventricular detection windows\\n•Duration parameter\\n•Redetection durationandpost-shockduration\\n•Ventricular episodes\\n•Ventricular detection enhance ments\\nVentricular Detection Windows\\nAppropriatetherapydelivery isdependent uponaccurately classifying apatient’s rhythm. Toensure thatappropriate\\ntherapyisdelivered,thepulsegenerator employs detection windows todifferen tiatetachycard ias.\\nEachventricular zonehasadetection window thatconsistsofthe10mostrecentRVR–Rintervals measur edbythe\\npulsegenerator.Aseachnewintervalismeasured, itiscompared toeachzone’sprogrammed ratethreshold and\\nclassified aseitherfastorslow(i.e.,aboveorbelowtheratethreshold) ineachdetection window .\\nThepulsegenerator prepares forapotential episode whenitcounts3consecutive fastintervals.Thedetection\\nwindow issatisfied andanepisode isdeclaredwhen8outof10fastintervalsarecounted.Thedetection window will\\nremainsatisfied aslongas6of10intervalsremain classified asfast.Ifthenumber offastintervals fallsbelow6,the\\nzone’sdetection window isnolongersatisfied. Thezone’sdetection window willonlybecomeresatisfiedwhen8of\\n10intervals areagainclassified asfast(Figure 2–3Ventricular detection window satisfied onpage2-12).\\n630 600 6\\n00 380 37\\n0 390 380\\n 370 600 \\n370 350 3\\n70 490 50\\n0 500 500\\n 500 370 \\nS \\nS S S F F\\n F F F F \\nF F S S S\\n S S F \\nF \\n6 of 10 i\\nntervals \\nare fast,\\n VF windo\\nw not sat\\nisfied. \\n8 of 10 i\\nntervals \\nare fast,\\n VF windo\\nw is sati\\nsfied. \\n7 of 10 i\\nntervals \\nare fast,\\n VF windo\\nw remains\\n satisfie\\nd. \\n7 of 10 i\\nntervals \\nare fast,\\n VF windo\\nw not sat\\nisfied. \\n6 of 10 i\\nntervals \\nare fast,\\n VF windo\\nw remains\\n satisfie\\nd. \\n5 of 10 i\\nntervals \\nare fast,\\n VF windo\\nw is no l\\nonger sat\\nisfied. \\n6 of 10 i\\nntervals \\nare fast,\\n VF \\nwindow is\\n not yet \\nresatisfi\\ned \\n7 of 10 i\\nntervals \\nare fast,\\n VF \\nwindow is\\n not yet \\nresatisfi\\ned \\n8 of 10 i\\nntervals \\nare fast,\\n VF \\nwindow is\\n resatisf\\nied \\nVF \\nwindow \\nIntervals\\n \\nin ms \\nVF Zone R\\nate = 150\\n min\\n-1 \\n(bpm) = 4\\n00 ms \\nS = Slow \\nF = Fast \\nOne-zone \\nconfigura\\ntion \\nRight \\nVentricle\\n \\nFigure2–3.Ventricular detection windowsatisfied\\nBecause RateThreshold inthehigherzonesmustbeprogrammed atavaluegreaterthanRateThreshold inlower\\nzones,anintervalclassified asfastinahigher window wouldalsobeclassified asfastinanylowerwindows (Figure\\n2–4Interacti onofventricular detection windows, 2-zone configuration onpage2-13).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 43}), Document(page_content=\"Tachyarrhythmia Detection\\nVentricular Detection Windows2-13\\n630 600 600 370 390 380 275 275 600 \\n275 250 250 \\nS S S S F F F F F \\nF F F \\n240 240 \\nF F \\nS S S S S S S F F \\nF F F F F \\n240 \\nF \\nF \\nVF Zone Rate = 200 min\\n-1 \\n(bpm) = 300 ms \\nVT Zone Rate = 150 min\\n-1 \\n(bpm) = 400 ms \\nS = Slow F = Fast \\nIntervals in ms \\n8 of 10 intervals are fast, VF window is satisfied. \\n7 of 10 intervals are fast, VF window not satisfied. \\n6 of 10 intervals are fast, VF window not satisfied. \\n8 of 10 intervals are fast, VT  window is satisfied. 7 of 10 intervals are fast, VT  window not satisfied. \\n6 of 10 intervals are fast, VT  window not satisfied. \\nVF window \\nVT window \\nFigure2–4.Interaction ofventricular detection windows, 2-zoneconfiguration\\nDuration Parameter\\nTheDuration parameter isatimerthatmeasur esthelengthoftimeineachzonethatarhythm mustbesustained\\nbeforetherapyisdelivered.\\nADuration timerbegins whenitsrespective zone’sdetection window issatisfied. Theprogrammed Duration timeis\\ncheckedfollowing everycardiac cycletodetermine ifithasexpired.\\nNOTE:SincetheDuration timerisexamined synchro nously withacardiaccycle,theprogrammed Duration maybe\\nexceededbyuptoonefullcardiaccycle.\\n•Aslongasthezone’sdetection window remains satisfied, theDurationtimercontinues toelapse. Ifthelast\\ndetected interval isinthezonewhenitsDuration timeexpires,detection isconsidered metandtherapyis\\ninitiated (assuming noprogrammed detection enhancemen tsinhibittherapydelivery) (Figure2–5Ventricular\\nDuratio ntimeronpage2-14).\\n•Ifthelastdetected intervalisnotinthezone,therapyisnotinitiated. Eachsubsequent intervalwillbechecked\\nuntilaninterval isintheoriginal zone,orthewindow isnolongersatisfied (Figure2–6Lastdetected intervalon\\npage2-14).\\n•Ifatanypointduring Durationazone’sdetection window detects fewerthan6of10fastintervals,thatzone's\\nDuratio nisresetto0(Figure 2–7Ventricular Duration resetonpage2-14).Duration willstartagainonlyifthe\\ndetection window becomes resatisfied.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 44}), Document(page_content='2-14Tachyarrhythmia Detection\\nVentricular Detection Windows\\nVT detection window remains satisfied during \\nVT Duration. \\nVT Duration expires and the \\nnext detected interval is in the \\nVT zone, detection is met. \\n ATP therapy is initiated. VT window satisfied. \\nVT Duration starts. \\nVT Duration 1-30 s \\nVT detected \\nRight V entricle \\nDuration startswhenawindow becomes satisfied andcontinues toelapse aslongastheventricular detection window remains satisfied. Detection ismetwhenDuration expiresandthenext\\ndetected interval isinthesameventricular zone.\\nFigure2–5.Ventricular Duration timer\\nVT detection window remains satisfied during \\nVT Duration.\\nVT Duration expires and the last \\ndetected interval is not in the \\nsame zone, detection in that \\nzone is not met. Therapy in that \\nzone is not initiated.VT window satisfied. \\nVT Duration starts.\\nVT detected VT Duration 1-30 s\\nRight ventricle\\nFigure2–6.Lastdetected interval\\nVT detection window is no longer satisfied; fewer \\nthan 6 of 10 intervals are classified as fast. \\nVT window satisfied. \\nVT Duration starts. VT Duration resets  to zero. VT  Duration will start \\nagain when the win dow becomes resatisfied. Need 8 of 10 intervals classified as fast to restart VT  Duration. VT Duration 1-30 seconds VT detected \\nRight ventricle \\nDuration resetswhenduring theDuration periodthewindow isnolongersatisfied.\\nFigure2–7.Ventricular Duration reset\\nADurationisprogrammed foreachventricular zone.Different valuesareavailable depending ontheconfigur ation\\nprogrammed (Table2–5Durationprogrammable rangesbyventricular zoneandconfiguration onpage2-15).The\\nDuration programmed inlowerventricular ratezonesmustbegreaterthanorequaltohigher ventricular zones.\\nLonger Duratio nsmaybeusedtopreventthedevicefrominitiating treatment ofnon-sustained arrhythmias.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 45}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Detection Windows2-15\\nTable2–5.Duration programmable rangesbyventricular zoneandconfiguration\\nConfiguration VT-1ZoneaVTZoneaVFZoneb\\n1Zone –– –– 1–15seconds\\n2Zones –– 1–30seconds 1–15seconds\\n3Zones 1–60seconds 1–30seconds 1–15seconds\\na.Themaximum redetect durationfortheVT-1andVTzonesis15seconds.\\nb.IntheVFzone,theredetect andpost-shock duration isfixedat1second.\\nDuration inaMulti-zone Configuration\\nDurationtimersrunindependently ofeachotherwithintheirrespective ventricular zones.\\n•Ifthearrhythmia isdetected inthehighest zone,thatzone’sDuration timertakesprecedenc eoverthelower\\nzones’timers; thelowerzones’Duratio ntimerscontinue toelapsebutareignored whilethehigherzone’s\\nDuratio ntimerruns.\\n•Ifthehigherzone’sDuration expiresanddetection ismet,therapyforthatzonewillbeinitiated regardlessof\\nwhether thelowerzones’Duration timershaveexpired.\\n•Ifthehigherzone’sdetection window doesnotremainsatisfied, thentheDuration timersforthelower\\nventricular zonesarenolongerignored.\\nProgrammed therapyforlowerventricular zoneswillbeinitiated whenalowerventricular zone’sdurationismetand\\nnohigher ventricular zone’swindow issatisfied (Figure2–8Interactionofventricular Duratio n,2-zone configuration,\\nchargingonpage2-15,Figure2–9Interactionofventricular Duration,2-zoneconfiguration, charging delayed onpage\\n2-15).\\nVF window satisfied. \\nVF Duration starts. \\nVF Duration 1 s \\nVF window remains satisfied. VF Duration expires \\nand detection is met. Charging begins. VT  Duration \\nexpires during charging, but is ignored. \\nCharging \\nVT window satisfied. \\nVT Duration starts. VT detected VT Duration 5 s \\nVF detected \\nFigure2–8.Interaction ofventricular Duration, 2-zoneconfiguration,charging\\nVF window satisfied. \\nVF Duration starts. \\nVF window does not remain satisfied. \\nVF Duration is not satisfied. \\nVT Detection is met. \\nVT window satisfied. \\n VT Duration starts. VT Duration expires. Detection is not met \\n because VF window is satisfied. VT detected \\nVF detected \\nVF Duration 1 s \\nVT Duration 5 s \\nCharging \\nFigure2–9.Interaction ofventricular Duration, 2-zoneconfiguration, chargingdelayed', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 46}), Document(page_content='2-16Tachyarrhythmia Detection\\nVentricular Detection Windows\\nVentricular Redetection Duration andPost-shockDuration\\nDuration parameters areusedtoidentify tachyarrhythmias during theventricular redetection process.\\n•Redetection Duration isapplied following delivery ofATPtherapy(exceptQUICKCONVERT ATP),adiverted-\\nreconfirm, manually diverted therapy,oriftherapyisunavailable atDetection Met(Figure 2–10Redetection\\nfollowing ventricular ATPdelivery onpage2-16).\\n•Post-shock Duration isapplied following shocktherapydelivery (Figure 2–11Redetection following ventricular\\nshockdelivery onpage2-16).\\nRedetection Duration isprogrammable inthelowerventricular zonesofamulti-zon econfiguration. Itis\\nnonprogrammable intheVFZone.Post-shock Duration canbeprogrammed inthesamemanner; thevalues\\nprogrammed inthelowerventricular ratezonesmustbegreaterthanorequaltothevaluesprogrammed inthe\\nhigherzones.\\nTohelpminimiz etimetopotential therapy ,itisrecommended thatRedetection Duration intheVT-1andVTzonesof\\nmulti-zone configur ationsbeprogrammed atlessthanorequalto5seconds.\\nItisrecommended thatPost-shock Duration intheVT-1andVTzonesofmulti-zo neconfigurations alsobe\\nprogrammed atlessthanorequalto5seconds. However ,youmayprogramforlongerdurationsifshock-induce d,\\nnon-sustained, high-raterhythms, suchasacceleratedidioventricular rhythm (AIVR)orAFareevident. Thelonger\\ndurationsmayallowtherhythm toreturntoalowerratebefore redetection ismet.\\n3 s\\n8 of 10 intervals are \\nfast, window satisfied\\nStart \\nRedetection \\nDuration\\nStart \\nRedetection\\nATP therapy programmed. \\nRedetection Duration programmed at 3 s.Initial Detection met\\nATP therapy ATP therapy\\nRedetection \\nDuration expires. \\nDetection met.\\nStart Redetection\\nLook for 8 of 10 fast intervals\\nIgnored Ignored\\nFigure2–10.Redetection following ventricular ATPdelivery\\n3 s\\nShock therapy programmed. Post-shock \\nDuration programmed at 3 s.Initial Detection met Start Redetection Start Post-shock \\nDuration\\nPost-shock \\nDuration expires. \\nDetection met.\\nStart Redetection\\nCharging\\n8 intervals are fast\\nCharging\\nLook for 8 of 10 fast intervals\\nShock Shock\\nIgnored Ignored\\nFigure2–11.Redetection following ventricular shockdelivery', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 47}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Episodes2-17\\nVentricular Episodes\\nIfthreeconsecutive fastventricular beatsaredetected, thenthepulsegeneratorstartsmonitoring foradetection\\nwindow tobesatisfied. Whenanyzone’sdetection window become ssatisfied, thepulsegeneratorperforms the\\nfollowing:\\n•Declaresthestartofaventricular episode\\n•Increments theepisode number\\n•Allocates memory forhistorydataandelectrogr amstorage\\n•Begins duratio ntimersinzoneswheredetection windows aresatisfied\\nTheventricular episode isdeclaredcomplete whenalldetection windows arenolongersatisfied andremain\\nunsatisfied foraspecified time.\\nEachventricular tachyepisode isclassified asTreatedorNon-Treated(Figure2–12Treatedepisode, ventricular mode\\nisMonitor +TherapyandATPisdelivere donpage2-18throughFigure2–16Treatedepisode, ventricular modeis\\nMonitor +TherapyandEnd-of-Episode timerisresetto0onpage2-19).\\n•ATreated episode isoneinwhichtherapy isdelivered\\n•ANon-Treated episode isoneinwhichnotherapyisdelivered\\nForaTreatedepisode, anEnd-of-Episode timerstartsaftertherapy isdelivered. ForaNon-Treatedepisode, anEnd-\\nof-Episode timerstartsatthepointthatthepulsegeneratorrecognizes thatalldetection windows arenolonger\\nsatisfied. TheEnd-of-Episode timeinterval isintended toallowthepatient tostabilize beforeInitialDetection and\\ninitialtherapy areusedagain.Theepisode isdeclaredcomplete ifnodetection window becomes satisfied fora\\nspecified timefollowing thelasttherapyattempt (Table2–6End-of-Episode Timeronpage2-17).Ifanywindow\\nbecomessatisfied whiletheEnd-of-Episode timeriselapsing, theEnd-of-Episode timerisresettozero.Itwillstart\\nagainwheneithertherapyisattempted orallwindows arenotsatisfied (Figure2–16Treatedepisode, ventricular\\nmodeisMonitor +TherapyandEnd-of-Episode timerisresetto0onpage2-19).\\nOnceanepisode hasbeendeclared complete, thepulsegeneratorwillapplyInitialDetection andtherapyto\\nsubsequent tachyarrhythmias.\\nTable2–6.End-of-Episode Timer\\nEpisodeClassification Ventricular End-of-Episode Timer\\n(elapsedtimerequired todeclareepisodeover)\\nNon-Treated (notherapy delivered) 10seconds\\nTreated (onlyATPtherapy delivered) 10seconds\\nTreated (anyshocktherapydelivered) 30seconds\\nNOTE:Theepisode isterminated immediately iftheTachyModeisreprogrammed, aninduction method orlead\\ntestisattempted before theEnd-of-Episode timeout,oranyventricular detection orventricular therapyparameters\\narereprogrammed.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 48}), Document(page_content='2-18Tachyarrhythmia Detection\\nVentricular Episodes\\nCoupling \\nInterval \\nDetection window does \\nnot become satisfied. \\nEnd-of-Episode times out. \\nEpisode is over . Detection met. \\nDeliver ATP. Start Duration. \\nStart episode. Start End-of -\\nEpisode timer .Detection window remains satisfied. \\nATP Burst \\n10 s \\nDetection window satisfied. \\nFigure2–12.Treatedepisode, ventricular modeisMonitor+TherapyandATPisdelivered\\nDetection window remains satisfied. \\nDetection met. \\nStart Charging. Start Duration. \\nStart episode. Detection window satisfied. \\nCharging \\nShoc k \\nEnd-of-Episode times out. \\nEpisode is over . Start End-of-Episode timer . \\n30 s \\nDetection window does not become satisfied. \\nFigure2–13.Treatedepisode, ventricular modeisMonitor+Therapyandshockisdelivered\\nStart Duration. \\nStart episode.\\nDuration did not expire. \\nDuration resets to zero. \\nStart End-of-Episode timer .End-of-Episode times out. \\nEpisode is over .\\nDetection window is no longer satisfied; fewer than 6 \\nof 10 intervals are classified as fast.\\nDetection window satisfied.\\n10 s\\nDetection window does not become satisfied.\\nFigure2–14.Non-Treated episode,ventricular modeisMonitor+TherapyorMonitorOnly,durationisnotexpired\\n10 s\\nTachyarrh\\nythmia sp\\nontaneous\\nly conver\\nts.\\nReconfirmation monitors rhythm for five of ten \\nslow intervals during charging.\\nEnd-of-Episode \\ntimes out. \\nEpisode is over .\\nReconfirmation indicates \\ntachyarrhythmia not present; \\nshock not delivered. Start \\nEnd-of-Episode timer .Start Duration. \\nStart episode.\\nDetection met. \\nStart Charging.\\nDetection window \\nsatisfied.\\nF = Fast\\nS = Slow\\nDetection window remains satisfied.\\nF\\nS SSS\\nS\\nCharging\\nRight V entricle\\nThisexample assumes Committed Shockisprogrammed toOff.\\nFigure2–15.Non-Treated episode, ventricular modeisMonitor+Therapyandchargingisstoppedpriortoshockdelivery', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 49}), Document(page_content=\"Tachyarrhythmia Detection\\nVentricular Detection Enhancemen ts2-19\\nDetection window \\nsatisfied. \\nStart End-of -\\nEpisode timer .\\nStart Post-shock \\nDuration \\nEnd-of-Episode \\ntimer resets to zero. Detection met. \\nStart Charging. \\nRestart End-of-Episode timer . End-of-Episode times \\nout. Episode is over . \\nCharging \\n30 s \\nShock Shock \\nVentricular rate \\nremains fast. \\nDetection window does not become satisfied. \\nRight V entricle \\nThisexample illustrates aTreated Episode whenVentricular ModeisMonitor +Therapy .TheEnd-of-Episode timerisresetto0whenaventricular detection window becomes satisfied after\\nventricular therapy delivery ,butpriortotheepisode time-out beingreached. Inthisexample, 2shocks weredelivered intheepisode.\\nFigure2–16.Treatedepisode, ventricular modeisMonitor+TherapyandEnd-of-Episode timerisresetto0\\nVentricular Detection Enhanceme nts\\nVentricular detection enhancement saddspecificity totheRateandDuration detection criteria. Youmayprogram\\nventricular detection enhancemen tstoperform thefollowing:\\n•Delayorinhibittherapydelivery\\n•Override therapyinhibition\\n•Bypass asequenc eofATPtherapy infavorofshocktherapy\\nVentricular detection enhancement smaybeprogrammed tooneofthefollowing:\\n•Rhythm ID\\n•Onset/Stability\\n•Off(i.e.,RateOnly)\\nIfOffisselected, onlytheventricular rateandduration areusedfortherapydecisions.\\nIfeitherRhythm IDorOnset/Stability isselected, enhanceme ntparamet ersareusedinaddition toventricular Rate\\nandDuration fortherapydecisions (Table2–7Enhanceme ntparamet ersavailable withdetection enhancemen tson\\npage2-20)asfollows:\\n•VectorTiming andCorrelation inhibits therapywhentheconduction vector(EGMmorphology andtiming) during\\ntachyarrhythmia matches areferenceconduction vectorofthepatient's normal sinusrhythm.\\n•VRate>ARatecanbeusedtooverride theinhibitdecision ofOnset, Stability, VectorTiming andCorrelation,\\nand/or AFibRateThreshold. VRate>ARatecanbeusedtodeliver ventricular therapyanytime theventricular\\nrateisgreaterthantheatrialrate.\\n•AFibRateThreshold canbeprogrammed (together withstability) toinhibitventricular therapyiftheatrialrhythm\\nisfast.\\n•Stability canbeprogrammed toinhibitventricular therapydelivery iftheventricular rhythm isunstable.\\n•ShockifUnstable canbeprogrammed tobypass theventricular ATPtherapyanddeliver shocktherapyifthe\\nventricular rhythm isdeclaredUnstable.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 50}), Document(page_content=\"2-20Tachyarrhythmia Detection\\nVentricular Detection Enhancements\\n•Onsetcanbeprogrammed toinhibitventricular therapyifthepatient's heartrateincreasesgradually .\\n•SRDenables thepulsegeneratortooverride theStability, Onset, VectorTiming andCorrelation, and/or AFibRate\\nThreshold paramete rs'decision toinhibitventricular therapyifthehighratecontinues throughout the\\nprogrammed timeperiod.\\nTable2–7.Enhancement parameters available withdetection enhancements\\nEnhancement Parameter RhythmID Onset/Stability\\nInitial Post-Shock Initial Post-Shock\\nVectorTiming andCorrelationa X –– –– ––\\nVRate>ARate(dual-chamber devices only) XbcXbcX X\\nAFibRateThreshold(dual-chamber devices only) XbdXbdXeXe\\nStability (toinhibit) XfXfX X\\nShockifUnstable –– –– X ––\\nOnset –– –– X ––\\nSRDgX X X X\\na.Thisenhancement isnotindividually programmable.\\nb.WhenRhythm IDisselected, thisenhance mentisautomatically enabled whenAtrialTachyarrhythmia Discrimination isprogrammed toOn.However ,itisnotavailable insinglechamber\\ndevices orwhentheAtrialTachyarrhythmia Discrimination isprogrammed toOffindualchamber devices.\\nc.Thisenhancement isnotindividually programmable whenRhythm IDisenabled.\\nd.WhenRhythm IDisselected, thisparameter usesthesamevalueforbothInitialandPost-Shock Detection. Itcannot beindependently enabled ordisabled forPost-Shock Detection.\\ne.WhenOnset/Stability isselected, thisparameter canbeenabled anddisabled independently forPost-Shock Detection. Ifenabled, itusesthesamevalueastheInitialDetection.\\nf.WhenRhythm IDisenabled andAtrialTachyarrhythmia Discrimination isprogrammed toOnindualchamber devices,thisenhancement usesthesamevalueforbothInitialandPost-Shock\\nDetection. Insinglechamber devices, orwhenAtrialTachyarrhythmia Discrimination isprogrammed toOff,thisenhancement isautomatically disabled forInitialDetection, butisstill\\nenabled forPost-Shock Detection.\\ng.SRDisavailable whendetection enhancements, whichinhibittherapy ,areprogrammed.\\nSomeofthesedetection enhancement parameters arealsoindependently programmable asPost-Shock paramet ers\\n(Table2–7Enhance mentparameters available withdetection enhanceme ntsonpage2-20).\\nTheindividual detection enhancement parameters thatareavailable depend onthenumber oftachyzonesthatare\\nprogrammed: 3,2,or1(Table2–8Individual Ventricular Detection Enhanc ements available inmultizone\\nconfigurations onpage2-20).\\nTable2–8.Individual Ventricular Detection Enhancements available inmultizone configurations\\nVT-1Zone VTZone VFZone\\n3-zone configuration VectorTiming andCorrelation\\nVRate>ARate\\nAFibRateThreshold\\nStability (toInhibit)\\nOnset\\nSRDVectorTiming andCorrelationa\\nVRate>ARatea\\nAFibRateThresholda\\nStability (toInhibit)a\\nShockifUnstable\\nSRDa––\\n3-zone configuration\\n(withMonitor Onlyzone)bc–– VectorTiming andCorrelation\\nVRate>ARate\\nAFibRateThreshold\\nStability (toInhibit)\\nShockifUnstabled\\nOnset\\nSRD––\\n2-zoneconfiguration VectorTiming andCorrelation\\nVRate>ARate\\nAFibRateThreshold\\nStability (toInhibit)\\nShockifUnstabled\\nOnset\\nSRD––\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 51}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Detection Enhancemen ts2-21\\nTable2–8.Individual Ventricular Detection Enhancementsavailable inmultizone configurations (continued)\\nVT-1Zone VTZone VFZone\\n2-zone configur ation(withMonitor Onlyzone)b –– ––\\n1-zone configur ation ––\\na.Enhancement isavailable inthemiddle zoneofa3-zone configura tiononlywhenRhythm IDisenabled.\\nb.Detection enhancements arenotavailable inthelowest zoneofamulti-zoneconfigura tionwhenitisusedasaMonitor Onlyzone(notherapy programmed forthatzone).\\nc.Fordevices programmed toa3zoneconfigur ationwithVT-1programmed toMonitor Onlyanddetection enhancements OnintheVTzone,rhythm discrimination willbeapplied whena\\ntachycardia meetsInitialDetection intheMonitor Onlyzoneandtheratesubsequently accelerates totheVTzone.Inthiscase,InitialDetection isrestarted anddetection enhancements are\\navailable intheVTzone.\\nd.ShockifUnstable cannot beprogrammed oninthesamezoneasotherdetection enhancements thatareprogrammed toinhibittherapy (Onset, Stability ,andAFibRateThreshold).\\nWhenaspecific rhythm discrimination isselected, youcanmodify thevaluesforthedetection enhancements thatare\\nsuitable fordiscriminating thatrhythm. Nominal valuesareshown inthefollowing table;however ,youcanusethose\\nvaluesatyourdiscretion.\\nTable2–9.Nominalvaluesforinitialdetection andredetection enhancements\\nOnset/Stability RhythmID\\nParameter Atrial\\nTachyarrhythmia\\nDiscriminationSinusTachycardia\\nDiscriminationPolymorphic VT\\nDiscriminationAtrial\\nTachyarrhythmia\\nDiscrimination OnAtrial\\nTachyarrhythmia\\nDiscrimination Off\\nVectorTiming andCorrelation –– –– –– OnaOna\\nVRate>ARate(dual-chamber models only) On On –– Onb ––\\nAFibRateThreshold (dual-chamber models\\nonly)170bpm –– –– 170bpm ––\\nStability (Inhibit) 20ms –– –– 20ms 30ms\\nOnset(InitialDetection only) –– 9% –– –– ––\\nSRDInitial 3:00minutes:\\nseconds3:00minutes:\\nseconds–– 3:00minutes:\\nseconds3:00minutes:\\nseconds\\nSRDRedetection 0:15minutes:\\nseconds–– –– 0:15minutes:\\nseconds0:15minutes:\\nseconds\\nShockifUnstable –– –– 30ms –– ––\\na.Parameter isnotindividually programmable.\\nb.Parameter isnotindividually programmable whenRhythm IDisenabled.\\nVectorTimingandCorrelation\\nVectorTiming andCorrelatio ncompar esEGMsignals foranunknown rhythm withastoredreferencetemplate ofthe\\nEGMsignals ofanormal sinusrhythm (NSR).Rhythms thatarenotsimilar (i.e.notcorrelated) tothestoredreference\\ntemplate areclassified asVT.Rhythms thatarecorrelatedwiththestoredreferencetemplate areclassified asSVT.\\nRhythm IDusesthisclassification during InitialDetection tomakeadecision totreatortoinhibittherapy.\\nWhenafastrhythm issensed, eachbeatoftherhythm iscompared tothestoredreferencetemplate. Thepulse\\ngeneratormeasur esthecorrelation ofthedetected waveform tothestoredreferencetemplate, andclassifies each\\nbeatascorrelatedoruncorrelated. AbeatintheVFzoneisalways countedasuncorrelated,evenifithasahigh\\nmeasur edcorrelation value.\\nThepulsegeneratorthenclassifies thedetected rhythm asSVTorVTbasedonthecalculations:\\n•Ifatleast3outof10beatsarecorrelated, therhythm isclassified asSVT,shown asRID+intheannotated\\nelectrograms', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 52}), Document(page_content='2-22Tachyarrhythmia Detection\\nVentricular Detection Enhancements\\n•Iffewerthan3outof10beatsarecorrelated, therhythm isclassified asVT,shown asRID-intheannotated\\nelectrogr ams\\nRhythmMatch Threshold\\nThisfeature isavailable inRESONATE HF,RESONATE, andMOMENTUM devices.\\nProgramming theRhythmMatch Threshold paramete rwilladjustthethreshold usedbyVectorTiming andCorrelation\\ntodetermine whether apatient\\'s rhythm correlates totheirnormal sinusrhythm template. Byadjusting the\\nRhythmMatch Threshold,youcanadjusthowthepulsegenerator discriminates between VTandSVT.\\nTheRhythmMatch Threshold isprogrammable between 70%and96%,withanominal valueof94%.During Vector\\nTiming andCorrelation analysis, thepulsegeneratorusestheprogrammed RhythmMatch Threshold asthecriteria for\\nclassifying thepatient\\'s rhythm aseitherVTorSVT(\"Vector Timing andCorrelatio n\"onpage2-21).\\nThepulsegenerator recordsaRhythmMatch scoreforthedetected rhythm basedonthecalculated correlation values\\nusedtoclassify therhythm asVTorSVT.Uptotwomeasured RhythmMatch valuesmayberecorded:oneifand\\nwhentherapyisfirstinhibited (byRhythm ID),andoneifandwhentherapy isattempted. Themeasured\\nRhythmMatch valuesarerecordedevenifRhythm IDisnotenabled, aslongasareferencetemplate hasbeen\\nacquired.\\nIfRhythm IDisenabled, eachbeat\\'smeasur edcorrelation value,aswellasanindication ofwhether thebeatwas\\nclassified ascorrelatedoruncorrelated,isrecordedinthestoredelectrograms during InitialDetection. These\\nmeasur edcorrelation valuesmaybehelpful indetermining thebestRhythmMatch Threshold valuetoprogramforthe\\npatient. Inaddition, measur edcorrelation valuesforVFbeatsmaybehelpful inprogramming theVFzonerate\\nthreshold.\\nNOTE:Undercertaincircumstanc es,therecordedcorrelation dataforsomeindividual beatsmaynotbedisplayed\\nontheprogrammer screen.\\nNOTE:Whenthememory allocated toEGMstorageisfull,thedeviceoverwritesolderEGMdatasegments inorder\\ntostorenewEGMdata.Events mustbesavedinordertopreservethecalculated RhythmMatch valuesandthe\\nmeasur edbeat-to-beat correlation valuesforfuturereference.\\nWhenreprogramming theRhythmMatch Threshold value,considerthefollowing:\\n•Results fromtheUSVITALITY clinical studyprovideevidenc eofthesafetyandeffectiveness oftheVITALITY with\\nRhythm ID.IntheUSVITALITY study,theRhythmMatch Threshold was94%1\\n•Review themeasur edRhythmMatch valuesforprevious episodes ofVTandSVT(induced orspontaneous)\\n•Toincreasethelikelihoodofappropriatetreatment ofVT,theRhythmMatch Threshold should beprogrammed\\nabovethemeasur edRhythmMatch valuesofanyVTs\\n•Toincreasethelikelihoodofappropriateinhibition oftherapyforSVT,theRhythmMatch Threshold should be\\nprogrammed belowthemeasured RhythmMatch valuesofanySVTs\\n•Ingeneral,thesensitivity ofVTdetection declines withlowerprogrammed RhythmMatch Threshold values,\\ntherefor eformaximum sensitivity toVT,thehighest appropr iateRhythmMatch Threshold valueshould be\\nprogrammed.\\n•Measure dRhythmMatch valuesmayalsobeusefulforprogramming otherRhythm IDparameters including Atrial\\nTachyarrhythmia Discrimination, AFibRateThreshold, andStability\\n1.TheUSVITALITY Clinical Summary canbefoundatwww.bostonscientific -elabeling.com.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 53}), Document(page_content=\"Tachyarrhythmia Detection\\nVentricular Detection Enhancemen ts2-23\\n•Bydecreasing theRhythmMatch Threshold, thefollowing willoccur(Figure2–17Programming theRhythmMatch\\nthreshold onpage2-23):\\n–Thepatient's rhythm ismorelikelytocorrelatetothestoredreferencetemplate\\n–Thepulsegenerator willbelesssensitive toVT\\n–Thepulsegenerator willbemorelikelytoclassify therhythm asSVTandinhibittherapy\\n–IftheRhythmMatch Threshold isprogrammed toolow,VTcouldgountreated\\n•Byincreasing theRhythmMatch Threshold, thefollowing willoccur(Figure 2–17Programming theRhythmMatch\\nthreshold onpage2-23):\\n–Thepatient's rhythm islesslikelytocorrelatetothestoredreferencetemplate\\n–Thepulsegenerator willbemoresensitive toVT\\n–Thepulsegenerator willbelesslikelytoclassify therhythm asSVTandinhibittherapy\\n–IftheRhythmMatch Threshold isprogrammed toohigh,therapymaynotbeinhibited forSVTepisodes\\nTherefore,itisimportant toreviewpastepisodes ofVTandSVTanddetermine whatRhythmMatch Thresholdis\\nsufficiently abovethepatient's correlation valuesforVT,butstillbelowthecorrelation valuesforSVT.Thismayallow\\nthepulsegeneratortomoreaccurately distinguish between VTandSVT,andpotentially reducedelivery of\\ninappropriate therapy .\\n94%\\n 96% 80% 90% 70%\\n[1]Nominal RhythmMatch Threshold value[2]Lesssensitive toVT,morespecific forSVT[3]Moresensitive toVT,lessspecific forSVT\\nFigure2–17.Programming theRhythmMatch threshold\\nSeeFigure2–18Relationship between sensitivity andspecificity usingRhythmMatch Threshold onpage2-24foran\\nillustrationoftherelationship between sensitivity andspecificity toVTatthepopulation levelastheRhythmMatch\\nThreshold valueisincreasedordecreased(RhythmMatch Threshold isprogrammable between 70%and96%,witha\\nnominal valueof94%).Ingeneral,astheRhythmMatch Threshold isincreased, sensitivity toVTincreases,and\\nspecificity forSVTdecreases.AstheRhythmMatch Thresholdisdecreased, sensitivity toVTdecreases,andspecificity\\nforSVTincreases. Thisrelationship canalsobestatedasfollows: athigherprogrammed RhythmMatch Threshold\\nvalues, anarrhythmia ismorelikelytobeclassified asVTandlesslikelytobeclassified asSVT,whileatlower\\nprogrammed RhythmMatch Thresholdvalues, anarrhythmia ismorelikelytobeclassified asSVTandlesslikelytobe\\nclassified asVT.\\nNotethattheUSVITALITY clinical studydemonstrated thatwiththeRhythmMatch Threshold valuepermanently\\nprogrammed to94%,observed sensitivity toVTwas100%andobserve dspecificity toSVTwas94%forspontaneous\\nepisodes.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 54}), Document(page_content='2-24Tachyarrhythmia Detection\\nVentricular Detection Enhancements\\n100%\\n65%\\n70 96\\n[1]Programmed RhythmMatch Threshold (%)[2]Sensitivity orspecificity percentage[3]Sensitivity toVT[4]Specificity forSVT\\nFigure2–18.Relationship between sensitivity andspecificity usingRhythmMatch Threshold\\nVRate>ARate\\nTheVRate>ARate(ventricular rategreaterthanatrialrate)enhance mentcompares theatrialandventricular ratesto\\nclassify thetypeoffastventricular rhythm. Whentheventricular rateisgreater thantheatrialrate,therapywillbe\\ninitiated regardless oftheanalysis oftheotherprogrammed detection enhancemen ts.\\nAnalysis ismadebycompar ingtheaveragerateofthelast10ventricular intervals priortotheendofDuration tothe\\naveragerateofthelast10atrialintervalspriortotheendofDuration (Figure 2–19VRate>ARateanalysis onpage2-\\n25).Iffewerthan10atrialintervalsareavailable, thoseintervalswillbeusedtocalculate theaverageatrialrate.This\\nanalysis isperformed usingthefollowing criteria:\\n•Iftheaverageventricular rateisgreaterthantheaverageatrialratebyatleast10bpm,theventricular rateis\\ndeclaredtobefasterthantheatrialrate(indicated asTrueontheEpisode DetailReport), andtherapywillbe\\ninitiated.\\n•Iftheaverageventricular rateisnotgreaterthantheaverage atrialratebyatleast10bpm(indicated asFalseon\\ntheEpisode DetailReport), therapymaycontinue tobeinhibited. TheEpisode DetailReport willindicate the\\nmeasur edvalueeventhough theparamete rmaybeprogrammed toOff.\\nIftherapyisinhibited, theVRate>ARateanalysis continues untileithertheventricular rateisgreaterthantheatrial\\nrateorotherenhancements indicate therapytreatment, atwhichtimetherapy willbeinitiated.\\nNOTE:VRate>ARateisnotevaluated during redetection following ATPtherapy.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 55}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Detection Enhancemen ts2-25\\n400 380 420 390 410 400 360 440 410 \\n390 \\n580 620 600 640 560 600 580 600 \\n620 \\n1 2 3 4 5 6 7 8 9 \\n1 2 3 4 5 6 7 8 \\nNumber of \\nIntervals \\nIntervals \\nin ms \\nThird fast interval (of the 8 out \\nof 10 that satisfy the detection \\nwindow) \\nStart Duration. \\nEvaluate Onset. \\nCompute the sum of 10 most recent ventricular \\nintervals. Average = 400 ms = 150 min\\n-1\\n (bpm).\\nDuration expired. \\nOnset is gradual. \\nAnalyze V Rate > A Rate. \\nDeliver therapy because V > A. Average ventricular rate (150 min\\n-1\\n \\n[bpm]) is greater than average \\natrial rate (100 min\\n-1\\n [bpm]) by at \\nleast 10 bpm, so delivery therapy .\\nCompu te the su m of the atrial intervals. \\nAverage = 600 ms = 100 min\\n-1\\n (bpm).\\nNumber of Intervals \\nIntervals in \\nms \\nAtrium \\nVentricle \\nVT detected \\nATP therapy \\nFigure2–19.VRate>ARateanalysis\\nVRate>ARatecanbeprogrammed tobypass inhibitors (Vector Timing andCorrelat ion,AFibRateThreshold,\\nStability, and/or Onset) andinitiate therapyintheeventthattheventricular rateisfasterthantheatrialrate.\\nNOTE:Referto\"UseofAtrialInformation\" onpage2-6foradditional information aboutdeviceperformance when\\ntheatrialleadisprogrammed toOff.\\nNOTE:InaRhythm IDconfiguration, theevaluation ofVRate>ARateislinkedtotheAFibRateThreshold. IfAtrial\\nTachyarrhythmia Discrimination isprogrammed toOff,theAFibRateThresholdandVRate>ARatedetection\\nenhanc ements arenotevaluated.\\nAFibRateThreshold\\nAFibRateThresholdanalysis identifies AFbycomparing theatrialratetotheprogrammed AFibRateThreshold.\\nAFibRateThresholdcannot beenabled without alsoenabling theStability detection enhancement .Thedevice\\nanalyzesbothparameters todetermine whether towithhold ordeliver therapy.\\nIftheintrinsic atrialrateisgreater thantheAFibRateThreshold andtheventricular rhythm isclassified asUnstable,\\ntheventricular rhythm isdeclaredtobeduetoAF.\\nTheintrinsic atrialrateisdeclaredtobeabovetheAFibRateThreshold inthefollowing manner (Figure 2–20\\nInteractionofAFibRateThreshold andStability onpage2-26):\\n•Atrialanalysis begins atinitiation ofventricular tachyarrhythmia detection. Eachatrialintervalisclassified as\\nfasterorslower thantheAFibRateThreshold Interval.\\n•When6ofthelast10intervalsareclassified asfasterthantheAFibRateThreshold, thedevicedeclaresAFtobe\\npresent.\\n•Ventricular stability isthenchecked.Ifunstable, therapyisinhibited.\\nIntheeventthatventricular therapyisnotdelivered, theatrialratecontinuestobeexamine d.Aslongas4of10\\nintervals remainclassified asfast,AFisconsider edpresent.Therapyisinhibited byAFibRateThreshold/Stability until\\nanyofthefollowing occur:\\n•TheatrialratedropsbelowtheAFibRateThreshold', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 56}), Document(page_content='2-26Tachyarrhythmia Detection\\nVentricular Detection Enhancements\\n•Theventricular rhythm becomes stable\\n•Ifprogrammed toOn,VRate>ARateistrue\\n•SRDtimesout\\n1 2 3 4 5\\n 6 7 8 \\nOnly 3 of 10 intervals are \\nabove the AFib Rate Threshold \\n4 of 10 > AFib Rate Threshold \\n4 of 10 intervals must remain \\n> AFib Ra\\nte Thresh\\nold \\n6 of 10 atrial intervals are greater \\nthan AFib Rate Threshold \\nThird fast interval (of the 8 \\nout of 10 that satisfy the \\ndetection window) \\nDetection satisfied. \\nStart duration. \\nStart episode. \\nStart Stability analysis. Atrial rate > \\nAFib Rate \\nThreshold. \\nDuration expires. \\nAtrial rate > AFib Rate Threshold. \\nRhythm declared unstable. \\nTherapy is inhibited. Rhythm remains unstable. \\nAtrial rate is less than \\nAFib Rate Threshold. \\nInitiate therapy . ATP thera\\npy \\nVT detect\\ned \\nVentricle\\nAtrium \\nFigure2–20.Interaction ofAFibRateThreshold andStability\\nWhenAFibRateThreshold andStability areusedalone,ventricular therapyisinitiated whenastablerhythm is\\ndeclared.Ventricular therapyisinitiated foranunstable rhythm whenitisdetermined thattheatrialrateislessthan\\ntheAFibRateThreshold(Table2–10AFibRateThreshold andStability combination sandresultingtherapyonpage2-\\n27).WhenAFibRateThreshold andStability areusedwithotherinhibitor enhancements ,ventricular therapyisnot\\nalways initiated whennolongerinhibited byAFibRateThreshold/Stability. Therapy maycontinue tobeinhibited by\\notherprogrammed detection enhancemen ts,suchasOnset(whentheOnset/Stability detection enhance mentsuiteis\\nenabled) orVectorTiming andCorrelation (whentheRhythm IDdetection enhancement suiteisenabled).\\nConsider thefollowing information during theseinteractions:\\n•TheAFibRateThreshold andVRate>ARatedetection enhanc ements arenotevaluated ifAtrialTachyarrhythmia\\nDiscrimination isprogrammed toOffinaRhythm IDconfiguration.\\n•Because theAFibRateThreshold isnotevaluated during redetection (following ventricular ATPtherapydelivery ,\\nanyaborted ventricular therapy ,ortherapynotavailable), theEpisode DetailReport willnotdisplay dataforthe\\nenhancement during redetection, eventhough theparameterisprogrammed On.\\n•TheAFibRateThreshold enhancement isnotevaluated forarrhythmia detection inthefollowing cases;however ,\\ntheEpisode DetailReport willstilldisplay thedatafortheAFibRateThreshold enhancement basedona\\nthreshold of170bpm:\\n–TheAFibRateThreshold isprogrammed toOff\\n–Ventricular Zonesisprogrammed to1\\n–Nodetection enhancement suiteisenabled\\n•Anatrialsenseeventwillonlybeclassified asAFwhiletheAFibRateThreshold isbeingevaluated forarrhythmia\\ndetection.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 57}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Detection Enhancemen ts2-27\\nTable2–10.AFibRateThreshold andStabilitycombinations andresulting therapy\\nDetected Ventricular RhythmaTherapyDecisionb\\nUnstable, A>AFibRateThreshold Inhibit\\nStable, A>AFibRateThreshold Treat\\nUnstable, A<AFibRateThreshold Treat\\nStable, A<AFibRateThreshold Treat\\na.Ifthedetected ventricular rhythm changes, thentheappropriate, corresponding rowinthetableisevaluated.\\nb.Decisions toinhibitcanbeoverridden byV>AorexpirationofSRD.\\nNOTE:Referto\"UseofAtrialInformation\" onpage2-6foradditional information aboutdeviceperformance when\\ntheatrialleadisprogrammed toOff.\\nStabilityAnalysis\\nStability analysis distinguishes Unstable (irregular) ventricular rhythms fromStable(regular) ventricular rhythms. This\\nisaccomplished bymeasuring thedegree ofvariability ofthetachycard iaR–Rintervals.\\nThisdegree ofvariability ,whenusedalone,mayallowthedevicetodistinguish conducted AF(which mayproduce\\ngreaterR–Rvariability) frommonomorphic VT(which istypically stable). Italsomaybeusedtodifferentiate MVTs\\n(which arepaceterminable) frompolymorphic VTsandVF(which aretypically notpaceterminable).\\nBasedonthepatient\\'s needs, youmaychoose toprogramStability asaninhibitor toprevent therapyforAF,oruse\\nstability analysis todirectthetypeoftherapytobedelivere d(Shock ifUnstable).\\nThestability algorithm calculates RVR–Rintervaldifferenc es.Thesedifferenc esarecalculated throughout Duration;\\nanaveragedifferen ceisalsocalculated. WhenDuration expires,rhythm stability isevaluated bycompar ingthe\\ncurrentaverage differenc etotheprogrammed Stability threshold and/or ShockifUnstable thresholds. Iftheaverage\\ndifferenceisgreater thantheprogrammed thresholds, therhythm isdeclaredUnstable. Independent thresholds are\\navailable fortheStability (toinhibit) orShockifUnstable functions; youcannot programbothinthesameventricular\\nzone.\\nThepulsegeneratorperforms stability calculations forallepisodes (evenwhenStability isprogrammed toOff)and\\nstorestheresultsinTherapyHistory.Thisstoreddatamaybeusedtoselectanappropr iatestability threshold.\\nStabilitytoInhibit\\nTheStability paramet ermayhelpyouidentify rapidrhythms originating intheatrium, suchasAF.Theserhythms may\\nresultinunstable ventricular rhythms whose rateexceedsthelowest ratethreshold andshould notbetreated.Ifa\\nrhythm isdeclaredstablewhenDuration expires,programmed therapywillbedelivered.Iftherhythm isdeclared\\nUnstable, ventricular therapywillbeinhibited.\\nAttheendofinitialDuration, ifatachycard iaisdeclaredUnstable andventricular therapyisinhibited, thepulse\\ngeneratorcontinues toevaluate forstability oneachnewdetected interval(Figure 2–21Stability evaluation when\\nDurationexpiresonpage2-28).Therapywillnotbeinhibited byStability if:\\n•VRate>ARatedeclarestheventricular rategreaterthantheatrialrate\\n•TheSRDhasexpired(ifprogrammed toOn)\\nVentricular therapyisnotalways initiated whennolongerinhibited byStability. Therapymaycontinuetobeinhibited\\nbyotherprogrammed detection enhancements, suchasOnset(whentheOnset/Stability detection enhancement\\nsuiteisenabled) orVectorTiming andCorrelation (whentheRhythm IDdetection enhancement suiteisenabled).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 58}), Document(page_content='2-28Tachyarrhythmia Detection\\nVentricular Detection Enhancements\\nNOTE:Ventricular Therapycanalsobeinhibited throughanalysis oftheStability algorithm asitisusedwiththe\\nAFibRateThreshold enhance ment.\\nUnstable  intervals \\nDetection window satisfied. \\nStart Duration. \\nStability analysis begins. \\nDuration expires. \\nRhythm declared unstable. \\nStart SRD. \\nTherapy inhibited until rhythm stabilizes, V is greater \\nthan A, or SRD times out. Stability analysis continues \\nFigure2–21.Stabilityevaluation whenDuration expires\\nShockifUnstable\\nWhenprogrammed toShockifUnstable, thestability analysis helpsdetermine ifventricular ATPtherapy should be\\nbypassed inpreferenceforthefirstprogrammed ventricular shocktherapy (which maybelow-orhigh-energ y)forthe\\nventricular zone(Figure 2–22ShockifUnstable onpage2-28).\\nDynamic ventricular arrhythmias suchaspolymorphic VTorVFmaybesensed ataratelowerthanthehighest\\nventricular ratethreshold andcanbeclassified asUnstable. Sincethesensed rhythm maybedetected inalower\\nventricular zoneinwhichATPmaybeprogrammed, thestability analysis maybeusedtoskipovertheprogrammed\\nventricular ATPtherapiesandinstead provideshocks tothepatient. Stability isevaluated oneachdetection/\\nredetection cycle,including evaluation between burstsofanATPscheme. Onceaventricular shockhasbeendelivered\\ninanepisode, theShockifUnstable function nolongeraffects therapyselection.\\nShockifUnstable maybeusedonlyintheVTzoneofa2-or3-zone configur ation.Youcannot program itina2-zone\\nconfiguration ifStability orOnsetisalready programmed toOn,orifPostVShockStability orAFibRateThreshold is\\nprogrammed toOn.\\nDetection window satisfied. \\nStart Duration. \\nStability analysis begins. \\nDuration expires. \\nRhythm declared stable. \\nDeliver programmed ATP \\ntherapy . \\nStart \\nRedetection. \\nDetection window \\nsatisfied. \\nStart Redetection \\nDuration. \\nReanalyze Stability . Redetection Duration expires. \\nRhythm declared unstable. \\nSkip remaining ATP and \\nproceed to the first \\nprogrammed shock therapy . Charging \\nShock \\nATP Burst \\nFigure2–22.ShockifUnstable\\nOnset\\nOnsetdifferentiates physiologic sinustachycard ias,whichtypically beginslowly,frompathologic tachycard ias,which\\ntypically beginabruptly .Itmeasur estherateoftransition intheventricular rhythm fromslowratestotachycard ia.If\\ntherateincrease isgradual, itenables thedevicetoinhibitventricular therapyinthelowest tachycard iaratezone.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 59}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Detection Enhancemen ts2-29\\nWhenadetection window becomessatisfied, thepulsegeneratorbegins calculating forsudden Onsetinatwo-stage\\nsequenc e.\\n•Stage1measur estheventricular intervalspriortothestartoftheepisode andlocates thepairofadjacent\\nintervals (pivotpoint)wherethecyclelengthdecreasedthemost.Ifthedecreaseincyclelengthisequaltoor\\ngreaterthantheprogrammed Onsetvalue,stage1declaressudden Onset.\\n•Stage2thencompar esadditional intervals.Ifthedifferencebetween theaverageintervalbefore thepivotpoint\\nand3outofthefirst4intervalsfollowing thepivotpointisequaltoorgreater thantheprogrammed Onset\\nThreshold, stage2declaressudden Onset.\\nIfbothstagesdeclaretherhythm sudden, therapywillbeinitiated. Ifeitherstageindicates agradual onset,initial\\nventricular therapywillbeinhibited inthelowest zone.Therapywillnotbeinhibited byOnsetif:\\n•Therateacceleratestoahigher ventricular zone\\n•Information fromtheatrialleaddetermines thattheRVrateisfasterthantheatrialrate(VRate>ARate\\nprogrammed toOn)\\n•TheSRDtimerexpires\\nOnsetismeasur edusingRVintervals only.Itcanbeprogrammed asapercentage ofcyclelengthorasaninterval\\nlength(inms).Itislimited tothelowest therapy zoneofamulti-zone configuration. Theselected Onsetvalue\\nrepresentstheminimum differenc ethatmustexistbetween intervalsthatareaboveandbelowthelowest\\nprogrammed ratethreshold. Thepulsegeneratorperforms Onsetcalculations (evenwhenthefeature isprogrammed\\ntoOff)forallepisodes exceptinduced orcommanded episodes. Themeasur edOnsetresults fromatwo-stage\\ncalculation arestoredinTherapyHistory.Thisstoreddatamaybeusedtoprogramanappropr iateOnsetvalue.\\nSustained RateDuration (SRD)\\nSustained RateDuratio nallowsdelivery oftheprogrammed ventricular therapywhenatachycard iaissustained fora\\nprogrammed periodbeyond Duration, buttheprogrammed therapy inhibitors (Vector Timing andCorrelat ion,AFib\\nRateThreshold, Onset, and/or Stability) indicate towithhold therapy(Figure2–23Combination ofOnsetORStability ,\\nSRDprogrammed ononpage2-29).\\n0 s 5 s 35 s\\n0 s\\n30 s\\nDuration = 5 seconds\\nSRD = 30 seconds\\nEvaluate programmed detection \\nenhancements. If enhancements \\nindicate to inhibit therapy , start \\nSRD timer; otherwise, deliver \\ntherapy .\\nContinue detection \\nenhancement \\nanalysis throughout \\nSRD time.\\nIf detection \\nenhancements \\nindicate therapy , \\ndeliver therapy .\\nSRD times out. \\nDeliver therapy .\\nDetection window \\nsatisfied\\nDuration starts. Start \\ndetection enhancement \\nanalysis.Duration expires.\\nFigure2–23.Combination ofOnsetORStability,SRDprogrammed on\\nSRDisavailable inazoneonlywhenaninhibitor enhance mentisprogrammed oninthatzone.WhentheRhythm ID\\ndetection enhancement suiteisenabled, SRDmaybeprogrammed separatelyfortheVTandVT-1zones.\\n•Aprogrammed SRDtimerbegins ifventricular therapyiswithheld whentheDuration expiresinazonewhere\\ndetection enhancements areprogrammed On.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 60}), Document(page_content='2-30Tachyarrhythmia Detection\\nVentricular Detection Enhancements\\n•Ifthedetection window inthelowest zoneismaintained fortheprogrammed SRDperiod, theprogrammed\\nventricular therapywillbedeliveredattheendoftheVT-1SRDperiodifVT-1SRDisprogrammed andtherhythm\\nisintheVT-1zone.Therapywillbedelivered attheendoftheVTSRDperiodifVTSRDisprogrammed andthe\\nrhythm isintheVTzone.\\n•Iftherateacceleratestoahigher ventricular zone,detection enhancements arenotprogrammed toOninthe\\nhigherzone,andtheDuration forthehigherzoneexpires,therapyisinitiated inthatzonewithout waiting for\\nSRDtime-out inalowerventricular zone.IfSRDisprogrammed toOff,anSRDtimerwillnotstartwhenDuration\\nexpires,thusallowing detection enhancements topotentially inhibittherapyindefinitely .\\nAnindependent Post-shock SRDvaluemaybeprogrammed.\\nCombinations ofAFibRateThreshold, Stability,andVectorTimingandCorrelation\\nThecombination ofAFibRateThreshold,Stability, andVectorTiming andCorrelatio naddspecificity toventricular\\ndetection beyond rateandduration. Inaddition tousingAFibRateThreshold andStability toidentify AF,this\\ncombinat ionofenhance mentsusesVectorTiming andCorrelat ionanalysis todifferentiate SVTrhythms fromVT\\nrhythms basedonconduction patterns withintheheart.\\nTheAFibRateThreshold, Stability, andVectorTiming andCorrelation detection enhancement combination also\\nincludes VRate>ARate;bothAFibRateThreshold andVRate>ARateareenabled whenAtrialTachyarrhythmia\\nDiscrimination isprogrammed toOn.Thiscombination isonlyavailable whentheRhythm IDdetection enhance ment\\nsuiteisenabled, andonlyforInitialDetection (Table2–11AFibRateThreshold, Stability ,andVectorTiming and\\nCorrelatio ncombination sandresultingtherapydecision ifAtrialTachyarrhythmia Discrimination isprogrammed toOn\\nonpage2-30).\\nIfVRate>ARateisprogrammed toOn(byprogramming AtrialTachyarrhythmia Discrimination toOn)andisTrue,it\\nwilltakeprecedenc eoverallinhibitor enhancements.\\nTable2–11.AFibRateThreshold, Stability,andVectorTimingandCorrelation combinations andresulting therapydecisionifAtrialTachyarrhythmia\\nDiscrimination isprogrammed toOn\\nDetected Ventricular RhythmabcTherapyDecisiond\\nCorrelated, Unstable, A>AFibRateThreshold Inhibit\\nCorrelated, Unstable, A<AFibRateThreshold Inhibit\\nUncorrelated, Unstable, A>AFibRateThreshold Inhibit\\nUncorrelated, Unstable, A<AFibRateThreshold Treat\\nCorrelated, Stable, A>AFibRateThreshold Inhibit\\nCorrelated, Stable, A<AFibRateThreshold Inhibit\\nUncorrelated, Stable, A>AFibRateThreshold Treat\\nUncorrelated, Stable, A<AFibRateThreshold Treat\\na.Ifthedetected ventricular rhythm changes, thentheappropriate, corresponding rowinthetableisevaluated.\\nb.IfaRhythm IDreferencetemplate isnotavailable, thedetected ventricular rhythm isconsider edtobeUncorre lated.\\nc.ForPost-Shock Detection (ifenabled), VectorTiming andCorrelation isconsider edtobeUncorrelated.\\nd.Decisions toinhibitcanbeoverridden byV>Aorexpiration ofSRD.\\nWhenAtrialTachyarrhythmia Discrimination isprogrammed toOff,thenVectorTiming andCorrelat ionisusedfor\\nInitialDetection andStability isusedforPost-Shock Detection. VRate>ARateandAFibRateThreshold arenolonger\\nused(Table2–12VectorTiming andCorrelat ionandStability combinations withresulting therapydecision ifAtrial\\nTachyarrhythmia Discrimination isprogrammed toOffonpage2-31).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 61}), Document(page_content='Tachyarrhythmia Detection\\nVentricular Detection Enhancemen ts2-31\\nTable2–12.VectorTimingandCorrelation andStabilitycombinationswithresulting therapydecisionifAtrialTachyarrhythmia Discrimination is\\nprogrammed toOff\\nDetectionabDetected Ventricular RhythmacTherapyDecision\\nInitial Correlated Inhibitd\\nInitial Uncorrelated Treat\\nPost-Shock Unstable Inhibitd\\nPost-Shock Stable Treat\\na.Ifthedetected ventricular rhythm changes, thentheappropriate, corresponding rowinthetableisevaluated.\\nb.IfAtrialTachyarrhythmia Discrimination isprogrammed toOff,thenVectorTiming andCorrelation isusedforInitialDetection, andStability isusedforPost-Shock Detection.\\nc.IfaRhythm IDreferenc etemplate isnotavailable, thedetected ventricular rhythm isconsideredtobeUncorrelated.\\nd.Decision toinhibitcanbeoverridden byexpirationofSRD.\\nCombinations ofAFibRateThreshold, Stability,andOnset\\nThecombination ofAFibRateThreshold, Stability, andOnsetaddspecificity toventricular detection beyond rateand\\nduration.Thiscombination ofdetection enhanceme ntsisavailable onlywhentheOnset/Stability detection\\nenhanc ementsuiteisenabled andisavailable onlyforInitialDetection. Whendetection enhancemen tsareenabled,\\ntheywillacttorecommend orinhibittherapyforaspecific zone.\\nIfAFibRateThreshold, Stability, andOnsetparamete rsareallprogrammed toOn,ventricular therapywillbeinitiated\\niftherhythm hasasudden onsetprovidedthateithertheventricular rateisstableortheatrialrateislessthanthe\\nAFibRateThreshold(Table2–13AFibRateThreshold, Stability ,andOnsetcombinations andresulting ventricular\\ntherapyonpage2-31).\\nTable2–13.AFibRateThreshold, Stability,andOnsetcombinations andresulting ventricular therapy\\nDetected Ventricular RhythmaTherapyDecisionb\\nGradual, Unstable, A>AFibRateThreshold Inhibit\\nGradual, Unstable, A<AFibRateThreshold Inhibit\\nSudden, Unstable, A>AFibRateThreshold Inhibit\\nSudden, Unstable, A<AFibRateThreshold Treatc\\nGradual, Stable, A>AFibRateThreshold Treat\\nGradual, Stable, A<AFibRateThreshold Inhibit\\nSudden, Stable, A>AFibRateThreshold Treat\\nSudden, Stable, A<AFibRateThreshold Treat\\na.Ifthedetected ventricular rhythm changes, thentheappropriate, corresponding rowinthetableisevaluated.\\nb.Decisions toinhibitcanbeoverridden byV>AorexpirationofSRD.\\nc.IfVRate>ARateisprogrammed toOnandisFalse,ventricular therapy willbeinhibited because therhythm isunstable.\\nIfVRate>ARateisprogrammed toOnandisTrue,itwilltakeprecedenceoverallinhibitor enhancement s.\\nCombinations ofOnsetandStability\\nWhenStability isprogrammed toinhibit, itmaybecombined withOnsettoprovide evengreaterspecificity in\\nclassifying arrhythmias.\\nThiscombination ofdetection enhanceme ntsisavailable onlywhentheOnset/Stability detection enhance mentsuite\\nisenabled andisavailable onlyforInitialDetection. Theenhancement scanbeprogrammed toinitiate ventricular', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 62}), Document(page_content='2-32Tachyarrhythmia Detection\\nVentricular Detection Enhancements\\ntherapyifthefollowing options areselected (Table2–14Combinations ofOnsetAndStability andresulting therapyon\\npage2-32):\\n•BothOnsetAndStability indicate totreat\\n•EitherOnsetOrStability indicates totreat\\nBasedontheseprogramming decisions, ventricular therapyisinhibited whenanyofthefollowing criteria ismet:\\n•Ifthecombinatio nprogrammed isOnsetAndStability, ventricular therapyisinhibited ifeitherparameter\\nindicates thattherapyshould bewithheld; thatis,therhythm isgradual Orunstable (theAndcondition totreatis\\nnotsatisfied).\\n•Ifthecombinatio nprogrammed isOnsetOrStability, ventricular therapyisinhibited immediately attheendof\\nDuration onlyifbothparameters indicate thattherapyshould bewithheld; thatis,therhythm isgradual and\\nunstable (theOrcondition totreatisnotsatisfied).\\nIneithercase,ventricular therapywillbeinitiated onlyiftheAnd/Or conditions totreataresatisfied. Whenthesetwo\\ncombinat ions(And/Or) areusedinconjunction withSRD,andtheAnd/Or conditions arenotsatisfied, ventricular\\ntherapywillbeinhibited untilVRate>ARateisTrueorSRDtimesout(Table2–14Combinations ofOnsetAnd\\nStability andresulting therapyonpage2-32).\\nTable2–14.Combinations ofOnsetAndStabilityandresulting therapy\\nDetection Rhythm OnsetAndStabilityCombinationabcOnsetOrStabilityCombinationc\\nGradual, Unstable Inhibit Inhibit\\nGradual, Stable Inhibit Treat\\nSudden, Unstable Inhibit Treat\\nSudden, Stable Treat Treat\\na.Ifthedetected ventricular rhythm changes, thentheappropriate, corresponding rowinthetableisevaluated.\\nb.TheAndcombination isthenominal setting whenbothareenabled.\\nc.Decisions toinhibitcanbeoverridden byV>AorexpirationofSRD.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 63}), Document(page_content='3-1\\nTACHYARRHYTHMIA THERAPY\\nCHAPTER 3\\nThischapter containsthefollowing topics:\\n•“Ventricular Therapy” onpage3-2\\n•“Antitachycar diaPacing Therapies andParameters” onpage3-7\\n•“Ventricular ShockTherapyandParamete rs”onpage3-15', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 64}), Document(page_content='3-2Tachyarrhythmia Therapy\\nVentricular Therapy\\nVENTRICULAR THERAPY\\nThepulsegenerator candeliver thefollowing typesoftherapy toterminate VTorVF:\\n•Antitachycardia pacing (ATP)\\n•Cardioversion/defibr illation shocks\\nATPpacing schemes areburstsofpacing pulsesdelivered between theventricular pace/sense electrodes. Shocks are\\nhigh-voltage biphasic pulsesdeliveredthroughtheshocking electrodessynchronously withdetected heartactivity.\\nNOTE:Tachycardia therapydecisions arebasedoncardiaccyclelengthbyusingRVsensed events only.\\nWARNING: During MRIProtection Mode,Tachycardia therapyissuspended. Thesystem willnotdetectventricular\\narrhythmias andthepatient willnotreceiveATPorshockdefibrillation therapyuntilthepulsegeneratoris\\nprogrammed backtonormal operation.Onlyscanthepatient ifjudged tobeclinically capable oftoleratin gno\\nTachycar diaprotection fortheentireduration inwhichthepulsegeneratorisinMRIProtection Mode.\\nVentricular TherapyPrescription\\nAventricular therapyprescription determines thetypeoftherapytobedeliveredinaparticular ventricular ratezone.\\nItconsists ofventricular ATPand/or shocks. Eachventricular zonemaybeprogrammed withindependent ventricular\\ntherapyprescriptions (Figure 3–1Ventricular therapyprescription, 3-zone configuration onpage3-2).\\nLowest strength Highest strength\\nWithin each zone, therapy strength must be  in ascending order .\\nZone\\nATP1\\n2\\nATP2\\n2\\nQUICK \\nCONVERT ATP\\nShock 1\\n1\\nShock 2\\n1\\nRemaining (Maximum) \\nShocks\\n1\\nVF\\nVT\\nVT-1\\nNot available\\nAll ATP type\\ns \\navailable\\nOn/Of f\\nN/A\\nN/A\\n0.1-max J\\n0.1-max J\\n0.1-max J\\n0.1-max J\\n0.1-max J\\n0.1-max J\\nmax J\\nmax J\\nmax J\\nAll ATP type\\ns \\navailable\\nAll ATP type\\ns \\navailable\\nAll ATP type\\ns \\navailable\\nBetween \\nzones, \\ntherapy \\nstrengths \\nare not \\nrestricted.\\n1 \\nIn the lowest zone of a multi-zone config uration, some or all of the shocks may be programmed to Of f, starting with the maximum shocks \\nfirst. If the maximum shocks are program med to Of f, then Shock 2 can be programmed to Of f. If Shock 2 is programmed to Of f, then \\nShock 1 can be programmed to Of f. If th e arrhythmia persists in the lowest zone when some or all of the shocks are programmed to Of f, \\nno further therapy will be delivered unle ss the arrhythmia accelerates to a higher zone. A Disab\\nle Therap\\ny button \\nis availa\\nble in th\\ne VT or \\nVT-1 zone\\ns’ therap\\ny window \\nto quickl\\ny disable\\n all ATP \\nand Shock\\n therapy \\nin that z\\none.\\n2\\n Ventricular ATP therapy can be programmed as Off, Burst, Ramp, Scan, or Ramp/Scan in VT-1 and VT zones.\\nFigure3–1.Ventricular therapyprescription, 3-zoneconfiguration\\nThetherapieswithinaventricular zonemustbeorderedinascending therapystrengths. Allventricular ATPtherapies\\nareconsider edtobeofequalstrength,butareoflowerstrengththananyshocktherapy.Thestrengthoftheshock\\ntherapiesisdetermined bytheprogrammed energy.Inamulti-zone configuration, therapiesinahigher ventricular\\nzonemaybeoflesser,greater,orequalstrength tothoseinalowerventricular zone;however ,withineachzonethe\\ntherapiesmustbeprogrammed inequalorincreasing energyoutput.\\nVentricular TherapySelection\\nThepulsegenerator determines whichventricular therapytodeliver basedonthefollowing rules:\\n•Eachsuccessivetherapydelivery mustbegreater thanorequaltothestrengthoftheprevioustherapyina\\nventricular episode. Whenever aventricular shocktherapyhasbeendelivered,nofurther ventricular ATPtherapy\\nisallowed inthatepisode sinceATPtherapyisoflowerstrengththanshocktherapy.Eachsubsequent ventricular', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 65}), Document(page_content='Tachyarrhythmia Therapy\\nVentricular TherapySelection3-3\\nshockdelivery mustbeofequalorgreater strengthregardless ofventricular zonechanges during aventricular\\nepisode.\\n•Eachventricular ATPscheme (which mayconsistofmultiple bursts) canonlybedeliveredonceduring a\\nventricular episode.\\n•Upto8shocks maybedeliveredinaventricular episode. Thefirst2shocks areprogrammable. Thefollowing\\nmaximum-ener gy,non-programmable shocks areavailable ineachzone:\\n–VT-1zone:3maximum-energy shocks\\n–VTzone:4maximum-energy shocks\\n–VFzone:6maximum-energy shocks\\nNOTE:Intheeventashockisdiverted withtheDIVERT THERAPY programmer command, bymagnet application or\\nduetoaDiverted-Rec onfirm, thediverted shockisnotcounted asoneoftheavailable shocks forthat\\ntachyarrhythmia episode. Also,commanded therapies andSTATSHOCK arenotcountedasoneoftheavailable\\nshocks foranepisode anddonotaffectsubsequent therapyselection.\\nBasedoninitialventricular detection criteria, thepulsegeneratorselects thefirstprescribed therapyintheventricular\\nzoneinwhichthetachyarrhythmia isdetected (i.e.,detection ismet;referto\"Ventricular Detection\" onpage2-6).\\nAfterdelivering theselected therapy,thepulsegeneratorbegins redetection todetermine whether thearrhythmia\\nhasbeenconverted.\\n•Ifthearrhythmia isconverted toaratebelowthelowest programmed threshold, thepulsegeneratorcontinues\\nmonitoring untiltheendoftheepisode isdeclared.Whentheepisode ends,thepulsegeneratorwillagainuse\\ninitialventricular detection criteria foranewepisode. Whenanewepisode isdeclared,thefirstprescribed\\ntherapywillbedeliveredagain.\\n•Ifthearrhythmia isnotconvertedandanarrhythmia isredetected inthesameventricular zone,thenext\\nprogrammed therapyinthatzoneisselected anddelivered(Figure 3–2Therapydelivery progression, arrhythmia\\nremains insamezoneasinitially detected onpage3-4),followed againbyredetection. Ifthearrhythmia persists\\ninthesamezone,thetherapywillprogressinthatzone.\\n•Ifanarrhythmia crossesventricular zones(acceleratesordeceler ates)following therapy delivery andisredetected\\ninahigherorlowerventricular zone,atherapyofequalorgreaterstrength thanthepreviously deliveredtherapy\\nisselected fromthedetected zoneanddelivered.Forshocktherapy,thepulsegenerator determines whichshock\\ntodeliver priortocapacitor charging basedonthedetected ratethreshold. Ifduring capacitor charging,the\\ntachyarrhythmia accelerates ordeceler atesfromtheinitialdetected rate,thepredetermined energywillstillbe\\ndelivered.\\nRefertoFigure3–3Therapy delivery progression, ATP1intheVTzoneandshock2intheVFzoneonpage3-4\\nthroughFigure3–10Therapy delivery progression, ATP1inVTzoneacceleratestherhythm, QUICKCONVERT ATP\\nisskipped inVFzoneonpage3-6.\\nRedetection isperformed aftereachtherapydeliver todetermine iffurther therapyisrequired. Usethefollowing\\ninformation wheninterpret ingthetherapyprogression figures:\\n•Aftereachredetection cycle,therapy delivery progressesinthedirection indicated bythecirclednumbers.\\n•Upward sloping linesindicate accelerationofthearrhythmia toahigher ventricular zone.\\n•Downwar dsloping linesindicate deceleration intoalowerventricular zone.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 66}), Document(page_content='3-4Tachyarrhythmia Therapy\\nVentricular TherapySelection\\n•Thelowest strengththerapyisintheATPcolumns; thetherapystrengths increaseasyoumovetotherightinthe\\ntable.\\nNOTE:IntheVT-1zoneofa3-zoneconfiguration ortheVTzoneofa2-zoneconfiguration, oneortwoATP\\nschemes maybeprogrammed astheonlytherapy,withallshocks inthelowest zoneprogrammed toOff.Ifthose\\npacing schemes donotterminate anarrhythmia detected inthelowest zone,nofurther therapywillbedeliveredin\\ntheepisode unlesstherateisredetected inahigherzone.\\n1 \\n3 \\n2 \\n4 \\n5 \\n6 \\n7 \\nZone ATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 \\nRemaining Shocks \\nVF \\nVT \\nVT-1 \\nOn/Of f \\nN/A \\nN/A \\n5 J \\n3 J \\n0.1 J \\n11 J \\n9 J \\n2 J \\nBurst Scan \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nFigure3–2.Therapydeliveryprogression, arrhythmia remainsinsamezoneasinitiallydetected\\n1 \\n3 \\n6 \\n7 \\n8 \\n9 \\n4 \\n5 \\n2 \\nZone \\nATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 \\nRemaining Shocks \\nVF \\nVT \\nVT-1 \\nOn/Of f \\nN/A \\nN/A \\n2 J \\n3 J \\n0.1 J \\n11 J \\n9 J \\n2 J \\nBurst Off \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nWhen the rhythm accelerates to the VF zone, Shock \\n2 in the VF zone is delivered since Shock 1 is a lower \\nenergy level than Shock 1 in the VT  zone. \\nATP1 in the VT  zone is delivered \\nbecause it is considered of equal \\nstrength to VT -1 ATP2 therapy . \\nFigure3–3.Therapydeliveryprogression, ATP1intheVTzoneandshock2intheVFzone\\n3 \\n1 \\n8 \\n9 \\n5 \\n4 \\n2 \\n6 \\n7 \\nZone \\nATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 \\nRemaining Shocks \\nVF \\nVT \\nVT-1 \\nOn/Of f \\nN/A \\nN/A \\n11 J \\n5 J \\n3 J \\n17 J \\n9 J \\n5 J \\nBurst Scan \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nWhen the rhythm accelerates back to the VT  \\nzone, ATP2 therapy is delivered because ATP1 \\nhas already been used during the episode. \\nFigure3–4.Therapydeliveryprogression, ATP2therapy', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 67}), Document(page_content='Tachyarrhythmia Therapy\\nVentricular TherapySelection3-5\\n3 \\n5 \\n2 \\n1 \\n4 \\n6 \\n8 \\n9 \\n7 \\nZone ATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 Remaining Shocks \\nVF \\nVT \\nVT-1 \\nOn/Of f \\nN/A \\nN/A \\n5 J \\n1.1 J \\n3 J \\n11 J \\n9 J \\n5 J \\nBurst Scan \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nThis is the thi rd shock, since \\ntwo programm able shocks \\nhave been de livered. \\nWhen the rhy thm decelerates to the VT -1 zone, ATP2 of the VT -1 zone is \\nnot delivered since a shock had already been delivered in the VT  zone. So \\nthe next highe r strength therapy (Shock 1 of the VT -1 zone) is delivered. \\nFigure3–5.Therapydeliveryprogression, shock1intheVT-1zone\\n3 \\n2 \\n1 \\n4 \\nZone \\nATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 \\nRemaining Shocks \\nVF \\nVT \\nVT-1 \\nOn/Of f \\nN/A \\nN/A \\n2 J \\n3 J \\n0.1 J \\n11 J \\n9 J \\n2 J \\nBurst Scan \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nOff Off Off \\nIf the arrhythm ia persists in the VT -1 zone after the second shock delivery , \\nno further shoc k therapy will be delivered unless the arrhythmia ac celerates \\nto a higher zon e sin ce Shocks 3-5 are programmed Of f in the VT -1 zone. \\nFigure3–6.Therapydeliveryprogression, shocks3to5programmed toOffintheVT-1zone\\n5 \\n6 \\n7 \\n3 \\n2 \\n1 \\n4 \\n10 \\n8 \\n9 \\nThe arrhythm ia accelerated back to the VF zone, the \\nseventh shoc k is delivered. The arrhythmia persists in \\nthe VF zone s o the eighth (and final) s hock is delivered. \\nA sixth shock  is delivered \\nsince the arrh ythmia is in \\nthe VF zone. \\nThe arrhythmia decelerated to a low er zone, an \\nadditional shock would not be delive red until the \\narrhythmia accelerated back to the V F zone. Zone ATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 Remaining Shocks \\nVF \\nVT \\nVT-1 \\nOn/Of f \\nN/A \\nN/A \\n2 J \\n3 J \\n0.1 J \\n11 J \\n9 J \\n2 J \\nBurst Off \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nFigure3–7.Therapydeliveryprogression, sixthshockdelivered', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 68}), Document(page_content='3-6Tachyarrhythmia Therapy\\nVentricular Redetection afterVentricular TherapyDelivery\\n1 \\n3 \\n2 \\nZone \\nATP1 ATP2 \\nIf reconfirmation indicates the arrhythmia persists \\nafter delivery of QUICK CONVER T ATP, the device \\nimmediately begins charging for Shock 1. \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 \\nRemaining Shocks \\nVF \\nVT \\nVT-1 \\nOn \\nN/A \\nN/A \\n11 J \\n3 J \\n0.1 J \\n21 J \\n9 J \\n2 J \\nBurst Scan \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nFigure3–8.Therapydeliveryprogression, QUICKCONVERT ATPandshockintheVFzone\\n2 \\n1 \\n4 \\n5 \\n3 \\nZone \\nATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 \\nRemaining Shocks \\nVF \\nVT \\nVT-1 \\nOn \\nN/A \\nN/A \\n2 J \\n3 J \\n0.1 J \\n11 J \\n9 J \\n2 J \\nBurst Scan \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nATP1 in the VT  zone is delivered because \\nit is considered of equal strength to QUICK \\nCONVER T ATP therapy. \\nFigure3–9.Therapydeliveryprogression, QUICKCONVERT ATPdeceleratestherhythm,ATP1andshockdelivered intheVTzone\\n1 \\n2 \\n3 \\nZone \\nATP1 ATP2 \\nQUICK \\nCONVERT ATP \\nShock 1 Shock 2 \\nRemaining Shocks \\nVF \\nVT \\nVT-1 \\nOn \\nN/A \\nN/A \\n11 J \\n3 J \\n0.1 J \\n21 J \\n9 J \\n2 J \\nBurst Scan \\nRamp Burst \\nmax max max max max max \\nmax max max max \\nmax max max \\nWhen the rhythm accelerates to the VF zone, Shock \\n1 is delivered because QUICK CONVER T ATP is \\nonly available as the first therapy in an episode. \\nFigure3–10.Therapydeliveryprogression, ATP1inVTzoneaccelerates therhythm,QUICKCONVERT ATPisskippedinVFzone\\nVentricular Redetection afterVentricular TherapyDelivery\\nAfterventricular therapydelivery ,thepulsegenerator usesredetectioncriteria toevaluate therhythm anddetermine\\nwhether moretherapyisappropriate. Whenredetection criteria aresatisfied, therulesfortherapyselection then\\ndetermine thetypeoftherapy todeliver.\\nVentricular Redetection afterVentricular ATPTherapy\\nVentricular Redetection afterventricular ATPtherapydetermines ifanarrhythmia hasbeenterminated.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 69}), Document(page_content='Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters3-7\\nAsaventricular ATPscheme isdelivered, thepulsegeneratormonitors thecardiacrateaftereachburstanduses\\nventricular detection windows (looking for8of10fastintervals) andtheVentricular Redetection Duratio nto\\ndetermine ifthearrhythmia hasterminated.\\nTheATPscheme willcontinue withthenextburstsinthesequenc euntilanyoneofthefollowing condition sis\\nsatisfied:\\n•Redetection declaresthatthetherapyhasbeensuccessful(end-of-episode)\\n•Thespecified number ofATPburstsinthescheme hasbeendelivered\\n•TheATPTime-out fortheventricular zonehasexpired\\n•Thedetected ventricular arrhythmia ratechanges toadifferentventricular ratezone,whereby adifferent therapy\\nisselected\\n•ShockIfUnstable forcesthedevicetoskiptheremainingATPtherapyandinitiate shocktherapy\\n•ADIVERT THERAPY command isreceivedfromthePRMduring delivery ofaburstofascheme\\n•Amagnet abortoccursduring delivery ofascheme\\n•Thetemporary TachyModehaschanged\\n•Acommanded therapyisrequested\\n•Theepisode endsduetoreprogrammed TachyMode,reprogrammed ventricular tachyparamet ers,orattempted\\ninduction method orleadtest\\nNOTE:Aborting anATPburstterminates theaffected ATPscheme. Iffurther therapyisrequired,thenext\\nprogrammed therapy(either ATPorshocks) intheprescription isinitiated.\\nVentricular Redetection afterVentricular ShockTherapy\\nVentricular Redetection afterventricular shocktherapydetermines ifanarrhythmia hasbeenterminated.\\nAsshocktherapyisdelivered,thepulsegeneratormonitors thecardiacrateaftereachshockandusesventricular\\ndetection windows (looking for8of10fastintervals)andpost-shockdetection enhance ments, ifapplicable, to\\ndetermine ifthearrhythmia hasbeenterminated. Shocktherapywillcontinueuntiloneofthefollowing condition sis\\nsatisfied:\\n•Redetection declaresthetherapyhasbeensuccessful(end-of-episode)\\n•Allavailable ventricular shocks havebeendeliveredforanepisode\\n•Therhythm isredetectedineithertheVTorVT-1zone,theavailable number ofprogrammed shock(s) inthose\\nzoneshasbeendelivered andthearrhythmia staysinoneoftheselowerzones\\nIfallavailable shocks havebeendeliveredforanepisode, nofurther therapyisavailable untilthepulsegenerator\\nmonitors aratebelowthelowest ratethreshold for30secondsandend-of-episode isdeclared.\\nANTITACHYCARDIA PACINGTHERAPIES ANDPARAMETERS\\nAntitachycar diaPacing (ATP)therapyandparameters enable thepulsegeneratortointerrupt thefollowing fast\\nrhythms bydelivering aseriesofcritically timedpacing pulses:', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 70}), Document(page_content='3-8Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters\\n•Monomorphic ventricular tachycardia\\n•Suprave ntricular tachycardias\\nATPTherapyisdelivered whenthelastsensed eventfulfillstheprogrammed detection criteria (Figure 3–11ATP\\ntherapybasicparameters areCoupling Interval, BurstCycleLength, Number ofBursts, andNumber ofPulseswithin\\neachburst.onpage3-8).\\nAnATPscheme maybecustomized withthefollowing paramet ers:\\n•Number ofBurstsdelivered\\n•Number ofpulseswithineachburst\\n•Coupling Interval\\n•BurstCycleLength\\n•Minimum pacing interval\\nTheseparameters canbeprogrammed toproducethefollowing ATPtherapyschemes:\\n•Burst\\n•Ramp\\n•Scan\\n•Ramp/Scan\\nTheATPAmplitude andPulseWidtharecommon toallschemes. Theyareindependently programmable fromthe\\nnormal pacing settings. TheATPAmplitude andPulseWidthsharethesameprogrammable valueasthepost-therap y\\npacing settings.\\nCoupling \\nInterval\\nCoupling \\nInterval\\nBurst Cycle Length\\nBurst 1\\nBurst 2\\nATP SchemeRedet ection\\nATP Pace Pulse\\nBurst Cycle Length\\nFigure3–11.ATPtherapybasicparameters areCoupling Interval,BurstCycleLength,NumberofBursts,andNumberofPulseswithineachburst.\\nBurstParameters\\nAburstisaseriesofcritically timedpacing pulsesdelivere dbythepulsegeneratorduring ATPtherapy.By\\nprogramming Burstparameters, youcanoptimize ATPtherapyforthepatient.\\nAllATPschemes haveseveral parameters incommon .Inaddition toprogramming thetypeofscheme (Off,Burst,\\nRamp,Scan,Ramp/Scan), thefollowing Burstparamete rsareprogrammable (Figure3–12InteractionofMaximum\\nNumber ofPulsesandNumber ofBurstsonpage3-9):', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 71}), Document(page_content=\"Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters3-9\\n•TheNumber ofBurstsparamete rdetermines thenumber ofburstsusedinanATPscheme andmaybe\\nprogrammed independently foreachATPscheme. Programming theparamet ertoOffwilldeactivate theATP\\nscheme.\\n•TheInitialPulseCountparameterdetermines thenumber ofpulsesdelivered inthefirstburstofascheme.\\n•ThePulseIncrement paramete rdetermines thenumber ofpulsesperbursttobeincreasedforeachsuccessive\\nburstinthescheme.\\n•TheMaximum Number ofPulsesparamete rdetermines thegreatestnumber ofpulsesusedinanATPburstand\\nmaybeprogrammed independently foreachATPscheme. Afterthemaximum number ofpulsesisreached ina\\nburst,eachadditional burstremaining inthescheme contains theprogrammed Maximum Number ofPulses. The\\nparameter isavailable onlyifthePulseIncrement isgreater thanzero.\\nCoupling \\nInterval\\nRedetect\\nRedetect Redetect\\nDetection \\nSatisfied\\nBurst 1; Initial \\npulse count at 3\\nBurst 2; Pulse count \\nincremented by 1\\nBurst 3; Pulse count \\nincremented by 1; \\nMaximum Number of \\nPulses reached\\nBurst 4; (programmed \\nnumber); Pulse count \\nremaining at Maximum \\nNumber of Pulses (5)\\nNumber of Bursts = 4\\nInitial Pulse Count = 3\\nPulse Increment = 1\\nMaximum Number of Pulses = 5\\nFigure3–12.Interaction ofMaximum NumberofPulsesandNumberofBursts\\nCoupling IntervalandCoupling IntervalDecrement\\nTheCoupling Intervalcontrolsthetimingofthefirstpulseinaburst.Itdefines thetimebetween thelastsensed\\neventthatfulfillsthedetection criteria anddelivery ofthefirstpulseinaburst.\\nTheCoupling Intervalisprogrammed independent fromtheBurstCycleLength. Thisallowsaggressiverampsand\\nscanstobeusedwithout compromising capture ofthefirstpacing pulseinaburst.TheCoupling Interval canbe\\nprogrammed asanyofthefollowing:\\n•Adaptive, withtimingspecified aspercentages ofthecomputed averageheartrate\\n•Afixedinterval, withtimingspecified inabsolute time(ms)independent ofthemeasur edaveragerate\\nWhenprogrammed asadaptive, theCoupling Interval adjusts tothepatient's rhythm basedonafour-cycleaverage\\n(Figure3–13Adaptive Coupling Interval,Coupling IntervalDecrement andScanDecrementprogrammed to0onpage\\n3-10).TheCoupling IntervalDecrement maybeprogrammed suchthattheCoupling Intervaldecreases fromoneburst\\ntothenextwithinamultiple-burst scheme (Figure 3–14Coupling Interval Decrementonpage3-10).\\nNOTE:Youcannot programanATPburstthatlastslongerthan15seconds. Thelengthofanadaptive burstis\\ncalculated basedontheintervaloftheventricular zoneinwhichtheATPisprogrammed, whichmeans itisbasedon\\nworst-casetiming.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 72}), Document(page_content='3-10Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters\\nCoupling Interval = 382 ms\\n4-Cycle A verage = 420 ms\\n400 \\nms\\n410 \\nms\\n420 \\nms\\n450 \\nms\\nCoupling Interval (C.I.) = 91%\\nFirst C.I. is 420 x 91% = 382 ms\\nSecond C.I. is 400 x 91% = 364 ms\\nThe 4-cycle average is calculated on the four cycles prior to each tachycardia therapy delivery \\nonly when no Decrement (Coupling Interval or Scan) is programmed.\\nCoupling Interval = 364 ms\\n4-Cycle A verage = 400 ms\\nFigure3–13.Adaptive Coupling Interval,Coupling IntervalDecrement andScanDecrement programmed to0\\nCoupling Interval = 91%\\nC.I. Decrement = 10 ms\\n4-Cycle A verage = 420 ms\\nCoupling \\nInterval = \\n382 ms\\nCoupling Interval Decrement\\n(4-cycle average is not recalculated)\\nCoupling \\nInterval = \\n372 ms\\nPaced PulsesLast sensed \\nR-wave that fulfills \\nredetection\\nRedetection \\nsatisfied\\nPaced PulsesLast sensed \\nR-wave that fulfills \\ndetection\\nDetection satisfied\\n400 \\nms\\n410 \\nms\\n420 \\nms\\n450 \\nms\\nFigure3–14.Coupling IntervalDecrement\\nThefollowing information should betakenintoconsideration whenprogramming theCoupling Interval andCoupling\\nInterval Decremen t:\\n•WhentheCoupling Interval Decrementisprogrammed toOn,theprogrammed ATPscheme iscalledaScan\\n•WhentheCoupling Interval isprogrammed asadaptive, theCoupling Interval willnotre-adapt following\\nredetection whenthefollowing areprogrammed toOn(greater thanzero):\\n–Coupling IntervalDecrement––the decrementvaluedetermines thetimingofthefirstpulseinsubsequent\\nbursts\\n–ScanDecrement––the decrement valuedetermines thetimingofthesecondpulseinsubsequent bursts\\nBurstCycleLength(BCL)\\nTheBurstCycleLength controls theintervalbetween pacing pulsesaftertheCoupling Interval.\\nThistimingiscontrolledinthesamefashion astheCoupling Interval: rateadaptive tothesensed tachycard iaorfixed\\ntimespecified inms.\\nNOTE:Anadaptive BCLisaffected inthesamemanner asanadaptive Coupling Interval; theaveragecyclelengthis\\nnotcontinually recalculated forsubsequent burstsiftheScanDecrementorCoupling Interval Decremen tare\\nprogrammed toOn.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 73}), Document(page_content=\"Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters3-11\\nThefollowing paramet ersmaybeprogrammed todecrement theburstcyclelengthduring anATPscheme:\\n•RampDecrement controlsthepulsetimingwithinagivenburst\\n•ScanDecremen tcontrolsthepulsetimingbetween bursts\\nMinimum Interval\\nTheMinimum IntervallimitstheCoupling Interval andtheBCLinBurst,Ramp,andScan.\\nIftheCoupling Intervalreaches thelimit,subsequent Coupling Intervalswillremainattheminimum value.Likewise, if\\ntheBCLreaches thelimit,subsequent BCLswillremainattheminimum value.TheCoupling IntervalandBCLmay\\nreachthelimitindependently .\\nBurstScheme\\nABurstscheme isasequenc eofcritically timedpacing pulsesintended tointerrupt areentrantloop,usually delivered\\nataratefasterthanthepatient's tachycard ia.\\nAnATPscheme isdefined asaBurst(asindicated onthePRMscreen)whenthetimingofallpacing intervalswithina\\nburstisthesame.ThefirstBCLofeachBurstisdetermined bytheprogrammed BCL.Whenthenumber ofpulses\\nprogrammed inaBurstisgreater thanone,youcanusetheBCLtocontrolthetimingbetween thesepacedpulses\\n(Figure3–15Adaptive-rate Burstscheme onpage3-11).\\nCoupling \\nInterval\\n400 \\nms\\n410 \\nms\\n420 \\nms\\n450 \\nms\\n315\\nms \\nBCL\\n315\\nms \\nBCL\\n315\\nms \\nBCL\\n315\\nms \\nBCL\\nCoupling \\nInterval\\n300\\nms \\nBCL\\n300\\nms \\nBCL\\n300\\nms \\nBCL\\n300\\nms \\nBCL\\nBurst\\n4-Cycle A verage = 400 ms\\nBurst\\n4-Cycle A verage = 420 ms\\nBCL = 75%\\n420 ms x .75 = 315 ms\\n400 ms x .75 = 300 ms\\nThe first BCL  of each burst is calculated by multiplying the 4-cycle average prior  to \\ndelivery of the first pacing pulse of the burst by the BCL  percentage.\\nFigure3–15.Adaptive-rate Burstscheme\\nRampScheme\\nARampscheme isaburstinwhicheachpaced-to-pac edinterval withintheburstisshortened (decremented).\\nToprogramaRampscheme, program(inms)theRampDecreme nttospecify howmuchthepaced-to-pac edinterval\\nshould beshortened, andtheScanDecrementandCoupling Interval Decrementeachto0ms.Aseachadditional\\npacedpulseinaburstisdelivered,itsintervalisshortened bytheprogrammed RampDecrement untileitherofthe\\nfollowing occur:\\n•Thelastpacedpulseoftheburstisdelivered\\n•TheMinimum Interval isreached\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 74}), Document(page_content='3-12Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters\\nIfsubsequent burstsarerequired,theprogrammed RampDecrementwillbeapplied basedonthecalculated BCLof\\nthatsubsequent burst(Figure3–16Adaptive RampScheme, Coupling Interval Decreme ntandScanDecrement\\nprogrammed to0onpage3-12).\\nBurst Cycle Length = 75%\\nRamp Decrement (R-R Within Burst) = 10 ms\\nScan Decrement (R-R Between Bursts) = 0 ms\\nC.I. Decrement = 0 ms\\nMinimum Interval = 265 ms\\n300 \\nms\\n290 \\nms\\n280 \\nms\\n270 \\nms\\n4-Cycle A verage \\n= 400 ms\\nRamp Ramp4-Cycle A verage \\n= 380 ms\\nReadapt 75%\\n285 \\nms\\n275 \\nms\\n265 \\nms\\n265\\nms\\nMinimum interval reached; \\nsubsequent interval is not \\ndecremented.\\nRedetect\\nFigure3–16.Adaptive RampScheme,Coupling IntervalDecrement andScanDecrement programmed to0\\nScanScheme\\nAScanscheme isaburstinwhichtheBCLofeachburstinascheme issystematically shortened (decremented)\\nbetween successive bursts.\\nYoucanprogram aScanscheme byprogramming theScanDecrementtospecify theBCLdecrem enttoavalue\\ngreaterthan0ms,whiletheRampDecrementisprogrammed to0ms.TheBCLofsubsequent burstsisdetermined\\nbysubtractingtheScanDecrementfromtheBCLoftheprevious burst(Figure3–17Scanscheme, nonadaptive BCLand\\nScanDecrement programmed ononpage3-12).\\nInitial BCL  is determined and then Scan \\nDecrement is applied on the next burst \\nBCL of previous Burst is determined and then Scan \\nDecrement is applied again on the next burst \\n300 \\nms \\n300 \\nms \\n300 \\nms \\n300 \\nms \\n290 \\nms \\n290 \\nms \\n290 \\nms \\n290 \\nms \\n280 \\nms \\n280 \\nms \\n280 \\nms \\n280 \\nms \\nBurst Cycle Length = 300 ms \\nScan Decrement = 10 ms \\nRamp Decrement = 0 ms \\nCoupling Interval Decrement = 0 ms Scan Scan \\nRedetect Redetect \\nScan \\nFigure3–17.Scanscheme,nonadaptive BCLandScanDecrement programmed on\\nRamp/Scan Scheme\\nARamp/Scan scheme isasequence ofbursts. Eachscheme containsaRampDecrement andaScanDecrement\\n(Figure 3–18Ramp/Scan scheme, interaction ofATPparamet ersonpage3-13).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 75}), Document(page_content='Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters3-13\\n290 \\nms\\n270 \\nms\\n280 \\nms\\n270 \\nms*\\n240 \\nms\\n250 \\nms\\n260 \\nms\\n240 \\nms\\n250 \\nms\\n220 \\nms\\n220 \\nms\\n230 \\nms\\nMinimum \\ninterval \\nreached\\n4-Cycle \\nAverage \\n= 370 ms\\nPARAMETER\\nNumber of Bursts\\nPulses per Burst:\\n    Initial\\n    Increment\\n    Maximum\\nCoupling Interval\\n    Decrement\\nBurst Cycle Length\\n    Ramp Decrement\\n    Scan Decrement\\nMinimum IntervalVALUE\\n3\\n4\\n1\\n6\\n81%\\n0 ms\\n78%\\n10 ms\\n20 ms\\n220 ms* When a Scan Decrement is programmed to On, the Coupling Interval and \\nBCL, if programmed as a percentage, will not re-adapt following redetection.\\nMaximum Number of Pulses \\nreached (6) and Maximum \\nNumber of Bursts reached (3)\\nNumber o f Pulses \\nincremen ted by 1\\nRamp Burst Ramp/Scan Burst Ramp/Scan Burst\\nRedetect\\nRedetect\\nC.I. 300 ms\\nScan Scan\\nC.I. 300 ms* C.I. 300 ms*\\nFigure3–18.Ramp/Scan scheme,interaction ofATPparameters\\nToprogramaRamp/Scan scheme, boththeScanDecrementandRampDecremen tareprogrammed tovaluesgreater\\nthan0ms.\\nATPPulseWidthandATPAmplitude\\nTheATPPulseWidthisthedurationofapacing pulse.TheATPAmplitude istheleading edgevoltage ofapacing\\npulse.\\nTheATPPulseWidthandATPAmplitude paramet erssharethesamevalueastheposttherapypacing PulseWidth\\nandAmplitude. Iftheprogrammable valueischanged foroneparameter ,thatvaluewillbereflected intheother\\nparameters.\\nTheprogrammed ATPPulseWidthandATPAmplitude aresharedforallATPschemes regardlessofzoneandposition\\ninaprescription. TheATPAmplitude andPulseWidthsharethesameprogrammable valueasthepost-therap y\\npacing settings.\\nVentricular ATPTime-out\\nTheVentricular ATPTime-out forcesthepulsegeneratortoskipoveranyremaining ATPtherapy inaventricular zone\\ntobegindelivering ventricular shocktherapy programmed inthesamezone.Thisparameter iseffective onlyfor\\nventricular therapydelivery .\\nTheATPTime-out maybeusedintheVTorVT-1zoneaslongasATPtherapyisprogrammed toOn.Timervaluesare\\nindependent, although VT-1ATPTime-out mustbeequaltoorgreaterthantheVTATPTime-out.\\nThetimerstartswhenthefirstburstisdeliveredandcontinuesuntilanyofthefollowing occur:\\n•Thetimerexpires(Figure 3–19ATPTime-out expiration onpage3-14)\\n•Aventricular shockisdelivered\\n•Theventricular episode ends', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 76}), Document(page_content='3-14Tachyarrhythmia Therapy\\nAntitachycardia PacingTherapies andParameters\\nThetime-out isexamined aftereachredetection sequence todetermine iffurther ATPburstscanbedelivere d.Ifthe\\ntime-out hasbeenreached orexceeded, further ATPtherapywillnotbeinitiated during thatventricular episode. The\\ntime-out willnotterminate aburstinprocess.\\nDetection window met.\\nStart episode.\\nStart Duration.\\nStart stability analysis.\\nDuration expires.\\nInitiate A TP therapy .\\nStart A TP Time-out.\\nRedetection Duration expires.\\nInitiate shock therapy .\\nCharge\\nRedetect Red\\netect\\nATP Time-out expires\\n30 s\\nFigure3–19.ATPTime-out expiration\\nNOTE:Onceaventricular shockhasbeendeliveredduring aventricular episode, ATPwillnolongerbeinvoked,\\nirrespective ofthetimeremaining ontheATPTime-out timer.\\nThetimeralonedoesnotinvoke therapy;therateandduration criteria anddetection enhancements muststillbe\\nsatisfied inorderforashocktherapytobedelivered.\\nIfthreezonesareprogrammed, youmayprogramATPTime-out settings ineachofthelowertwoventricular zones\\n(Figure 3–20ATPTime-outs, 3-zoneconfiguration onpage3-14).\\n0 s 10 s \\n20 s 30 s\\n 40 s \\nVF Zone \\nVT Zone \\nVT-1 Zone\\n \\nVT Detect\\nion \\nwindow sa\\ntisfied. \\nDuration \\nstarts. \\nStart epi\\nsode. \\nVT Detect\\nion met. \\nTherapy i\\nntitiated\\n. \\nStart ATP\\n Time-out\\n. \\nATP Time-\\nout \\nexpires i\\nn VT zone\\n.\\nVT-1 \\nTime-out \\nexpires. \\nVT\\n-1 Detect\\nion met. \\nInitiate \\nshock the\\nrapy. \\nProgramme\\nd therapy\\n for lowe\\nr zones: \\nVT-1 ATP \\nTime-out \\n= 40 s \\nVT ATP Ti\\nme-out = \\n30 s \\nATP is pr\\nogrammed \\nin VT-1 a\\nnd VT zon\\nes. \\nR\\nedetectio\\nn and \\nATP burst\\ns \\nATP Time-\\nout \\nATP 1 ATP\\n 1 \\nBurst 1 B\\nurst 5 \\nRedetect \\nCharging \\nRhythm changes to VT-1 zone \\nFigure3–20.ATPTime-outs, 3-zoneconfiguration\\nQUICKCONVERT ATP\\nQUICKCONVERT ATPprovidesanadditional option totreatafast,monomorphic VTthatisdetected intheVFzone,\\nbeforeadvancing toshocktherapy .', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 77}), Document(page_content=\"Tachyarrhythmia Therapy\\nVentricular ShockTherapyandParameters3-15\\nWhenQUICKCONVERT ATPisprogrammed toOn,thepulsegeneratordelivers oneburstofATPconsisting of8\\npacing pulseswithan88%Coupling Interval and88%BCL.\\nQUICKCONVERT ATPisusedonlyasthefirsttherapyattempted inanepisode. IntheeventthatQUICKCONVERT ATP\\nisunsuccessfulinconverting therhythm andshocktherapy isrequired,thefeature's algorithm minimize sthedelayto\\nbeginchargingbyusingreconfirmation toevaluate whether ATPtherapysuccessfullytreatedthearrhythmia:\\n•If2outof3intervalsfollowing delivery ofQUICKCONVERT ATParefasterthanthelowest ratethreshold, the\\nattempt isconsidered unsuccessfulandchargingbegins foranon-commi ttedshock.\\n•If2outof3intervalsareslow,shocktherapyisdiverted andthepulsegeneratorentersredetection. Ifredetection\\nissatisfied following adiverted shock,thenextshockwillbecommitt ed.\\nNOTE:QUICKCONVERT ATPisnotapplied toanyrhythm aboveamaximum rateof250bpm.\\nNOTE:QUICKCONVERT ATPisdeliveredBiV.TheLVPacewillbedeliveredsynchronous totheRVPaceregardless\\noftheLVOffset.\\nVENTRICULAR SHOCKTHERAPY ANDPARAMETERS\\nThepulsegeneratordelivers shocks synchro noustoasensed event.Theshockvector,energylevel,andpolarity of\\ntheshocks areprogrammable.\\nVentricular ShockVector\\nTheprogrammed Ventricular ShockVectorindicates thevectorofenergydelivery forventricular shocktherapy.\\nThefollowing programmable configur ationsareavailable:\\n•RVCoiltoRACoilandCan––this vectorisalsoknown astheV-TRIAD vector.Itusesthemetallic housing ofthe\\npulsegenerator asanactiveelectrode (“hotcan”)combined withatwo-electrode defibrillation lead.Energyis\\nsentviaadual-curr entpathway fromthedistalshocking electrode totheproximalelectrodeandtothepulse\\ngeneratorcase.\\n•RVCoiltoCan––this vectorusesthemetallic housing ofthepulsegeneratorasanactiveelectrode(“hotcan”).\\nEnergyissentfromthedistalshocking electrode tothepulsegeneratorcase.Thisconfiguration should be\\nselected whenusingasingle-coil lead.\\n•RVCoiltoRACoil––this vectorremoves thepulsegeneratorcaseasanactiveelectrodeandisalsoknown asa\\n“coldcan”vector.Energyissentfromthedistalshocking electrode totheproximalelectrode.Thisvectorshould\\nneverbeusedwithasingle-co illead,asashockwillnotbedelivered.\\nVentricular ShockEnergy\\nVentricular shockenergydetermines thestrengthofshocktherapydeliveredbythepulsegenerator.\\nShockoutput remains constantoverthelifetime ofthepulsegenerator,regardlessofchanges inleadimpedance or\\nbattery voltage. Theconstantoutput isaccomplished byvaryingpulsewidthtoadjusttochanges inleadimpedance.\\nThefirsttwoshocks ineachventricular zonecanbeprogrammed tooptimize chargetime,longevity ,andsafety\\nmargins.Theremaining shockenergiesineachzonearenonprogrammable atthemaximum-energy value.\\nChargeTime\\nChargeTimeisthetimethepulsegenerator requires tochargefordelivery oftheprogrammed shockenergy.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 78}), Document(page_content='3-16Tachyarrhythmia Therapy\\nVentricular ShockTherapyandParameters\\nCharge Timeisdependent onthefollowing:\\n•Programmed output energylevel\\n•Battery condition\\n•Condition oftheenergystoragecapacitors\\nCharge timesincreaseasthepulsegeneratorisprogrammed tohigherenergy output levelsandasthebattery\\ndepletes (Table3–1Typical charge timerequiredat37degrees Catthebeginning oflifeonpage3-16).Ifacharge\\ntimeisgreaterthan15seconds,thepulsegenerator schedules anautomatic capacitor re-formation foronehourlater.\\nIfthechargetimeduring re-formatio nalsoexceeds15seconds, battery statusischanged toExplant.\\nCapacitor deformation canoccurduring inactive periods andmayresultinaslightly longerchargetime.Toreducethe\\nimpact ofcapacitor deformation onchargetime,thecapacitors areautomatically reformed.\\nTable3–1.Typicalchargetimerequired at37degreesCatthebeginning oflife\\nEnergyStored(J)aEnergyDelivered (J)bChargeTime(seconds)c\\n11.0 10.0 2.0\\n17.0 15.0 3.2\\n26.0 22.0 5.1\\n41.0 35.0 8.4\\na.Values indicate theenergy levelstoredonthecapacitors andcorrespond tothevalueprogrammed forshockenergy parameters.\\nb.Theenergy delivered indicates theshockenergy leveldelivered through theshocking electrodes.\\nc.Charge timesshown areatbeginning oflifeaftercapacitor re-formation.\\nTable3–2.Typicalmaximum-ener gychargetimeoverthelifeofthepulsegenerators\\nChargeRemaining (Ah)aMaximum-ener gyChargeTimeRange(seconds)\\n2.1to1.0 8to10\\n1.0to0.4 9to12\\n0.4to0.2 10to14\\na.Atexplant, Charge Remaining istypically 0.18Ah,andresidual capacity is0.15Ah.Thesemayvarydepending ontheamount oftherapy deliveredoverthelifeofthepulsegenerator .\\nResidual capacity isusedtosupport devicefunction between Explant andBattery Capacity Depleted indicators.\\nNOTE:Themaximum-energy chargetimerangesabovearebasedupontheoretic alelectrical principles andverified\\nbenchtesting only.\\nWaveformPolarity\\nWaveform polarity reflects therelationship between theleading edgevoltages onthedefibrillating output electrodes.\\nAllshocks willbedelivered usingabiphasic waveform (Figure 3–21Biphasic waveform onpage3-17).\\n•Thepeakshockvoltage (V1)is728Vat41J,531Vat21J,and51Vat0.1J.\\nTheselection oftheshockpolarity applies toallshocks deliveredbythedevice. Ifthepreceding shocks inazoneare\\nunsuccessful,thelastshockofthatzonewillbeautomatically deliveredataninverted polarity totheprevious shock\\n(initialorreversed) (Figure 3–22Polarity ofshockdelivery onpage3-17).\\nCAUTION: ForIS-1/DF-1 leads,neverchange theshockwaveform polarity byphysically switching theleadanodes\\nandcathodes inthepulsegeneratorheader—use theprogrammable Polarity feature.Devicedamage or\\nnonconv ersionofthearrhythmia post-operatively mayresultifthepolarity isswitched physically .', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 79}), Document(page_content='Tachyarrhythmia Therapy\\nVentricular ShockTherapyandParameters3-17\\nBiphasic\\nV1\\nV2\\nPW1\\nPW2\\nV3\\nV4\\nPW = Pulse Widt\\nh\\nPW2 =  PW1 x 0.\\n66\\nV2 = V 3\\nFigure3–21.Biphasicwaveform\\n+\\n–\\n+\\n–\\n+\\n–\\nInitial polarity Reverse polarity\\nFigure3–22.Polarityofshockdelivery\\nCommitted Shock/Reconf irmationoftheVentricular Arrhythmia\\nCommitted Shock/Recon firmation referstothemonitoring performed bythepulsegenerator beforedelivery ofa\\nventricular shock.\\nIfthepatient issubject tonon-sustained arrhythmias, reconfirmation maybedesirable inordertopreventdelivery of\\nunnece ssaryshocks tothepatient.\\nThedevicemonitors tachyarrhythmias during andimmediately following capacitor charging.During thistime,it\\nchecks forthespontaneous conversion ofthetachyarrhythmia anddetermines whether ventricular shocktherapy\\nshould bedelivered;itdoesnotaffecttherapyselection.\\nVentricular shocktherapycanbeprogrammed ascommitted ornon-commi tted.IftheCommitted Shockfeature is\\nprogrammed toOn,theshockisdeliveredsynchronously withthefirstsensed R-wave following a500-ms delayafter\\nthecapacitors arecharged, whether thearrhythmia issustained ornot(Figure 3–23Committed Shockisprogrammed\\ntoOn,Reconfirmation isOffonpage3-18).The500-ms delayallowsaminimum timeforadivertcommand tobe\\nissuedfromthePRM,ifdesired.Ifthereisnosensed R-wave detected within2secondsfollowing theendof\\ncharging,theventricular shockisdelivere dasynchr onously attheendofthe2-secondinterval.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 80}), Document(page_content='3-18Tachyarrhythmia Therapy\\nVentricular ShockTherapyandParameters\\nShock\\n2 3 4 5 6 7 8 9 10\\n1112 1\\nF F F F F F F F F\\nF\\nShock is committed.\\nSynchronize with R-wave and deliver shock.\\nDuration complete. \\nStart charging.\\nRefractory \\nperiod\\nDivert window\\nCharging\\n500 ms\\n135 ms\\nRedetect ion starts.\\nDetection  window \\nsatisfied\\n.\\nPost-Sho ck Duratio\\nn starts.\\nNumber of intervals\\n(F = Fast)\\nFigure3–23.Committed Shockisprogrammed toOn,Reconfirmation isOff\\nNOTE:Thereisaforced135-ms refractory periodfollowing theendofcharging;events thatoccurduring thefirst\\n135msofthe500-ms delayareignored.\\nIftheCommitted Shockfeature isprogrammed toOff,Reconfirmation consists ofthefollowing steps:\\n1.During capacitor charging,thepulsegeneratorcontinues tosensethearrhythmia. Sensed andpacedbeatsare\\nevaluated. If5slowbeats(sensed orpaced)arecountedina10-beat detection window (or4consecutive slow\\nbeatsafteranunsuccessfulQUICKCONVERT ATPattempt), thepulsegeneratorstopschargingandconsiders this\\naDiverted-Recon firm.\\n2.If5of10beatsarenotdetected asslow(orlessthan4consecutive slowbeatsafteranunsuccessfulQUICK\\nCONVERT ATPattempt) andcharging completes, post-chargereconfirmation isperformed afterchargingends.\\nAfterthepost-chargerefractoryandthefirstsensed event,thepulsegenerator measures upto3intervals\\nfollowing chargingandcompar esthemtothelowest ratethreshold.\\n•If2ofthe3intervalsfollowing chargingarefasterthanthelowest ratethreshold, theshockwillbedelivered\\nsynchronously withthesecondfastevent.\\n•If2ofthe3intervalsfollowing chargingareslower thanthelowest ratethreshold, theshockwillnotbe\\ndelivered. Ifnobeatsaresensed, pacing willbeginattheprogrammed LRLfollowing the2-second no-sense\\nperiod. Ifashockisnotdelivere d,orifpacing pulsesaredelivered, thisisalsoconsidered aDiverted-\\nReconfirm.\\nIfashockisrequiredafterredetection, thecharge timefortheshockmaybeshort.\\nThereconfirmation algorithm willnotallowtwoconsecutive Diverted-Recon firmcycles.Ifthearrhythmia isdetected\\nafteraDiverted-Rec onfirm, thenextshockintheepisode isdelivered asifCommitted Shockwereprogrammed toOn.\\nOnceashockhasbeendelivered,thereconfirmation algorithm canbeapplied again(Figure3–24Committed Shockis\\nprogrammed toOff,reconfirmation isOnonpage3-19).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 81}), Document(page_content='Tachyarrhythmia Therapy\\nVentricular ShockTherapyandParameters3-19\\n2 3 4 5 6 7 8 1\\n2 3 4 5\\n1\\n2 3 1\\nIntervals are measured and compared to the lowest Rate threshold. If 2 of 3 are slow , \\nthe shock will not be delivered. If 2 of 3 are fast, the shock will be delivered.\\nReconfirmation  determi\\nnes arrhyth\\nmia \\nis no longer pre sent. Sho\\nck is not \\ndelivered. If no  beats are\\n sensed, \\npacing will star t.\\nDuration complete. \\nStart charging.Refractory \\nperiodDivert \\nwindowIntervals are measured \\nduring charging.\\nCharging\\n500 ms\\n135 ms\\nFigure3–24.Committed Shockisprogrammed toOff,reconfirmation isOn', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 82}), Document(page_content='3-20Tachyarrhythmia Therapy\\nVentricular ShockTherapyandParameters', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 83}), Document(page_content='4-1\\nPACINGTHERAPIES\\nCHAPTER 4\\nThischapter containsthefollowing topics:\\n•“Pacing Therapies”onpage4-2\\n•“Device Programming Recommendations” onpage4-3\\n•“Maintaining CRT”onpage4-4\\n•“BasicParamet ers”onpage4-5\\n•“Post-TherapyPacing” onpage4-30\\n•“Tempor aryBradyPacing” onpage4-31\\n•“Minute Ventilation /Respiratory Sensor andSignalArtifact Monitor” onpage4-32\\n•“RateAdaptive Pacing andSensor Trending” onpage4-39\\n•“AtrialTachyResponse” onpage4-56\\n•“RateEnhancements” onpage4-62\\n•“LeadConfigurati on”onpage4-67\\n•“LeftVentricular MultiSite Pacing” onpage4-71\\n•“AVDelay” onpage4-73\\n•“Refractory”onpage4-78\\n•“Noise Response” onpage4-87\\n•“Ventricular TachySensing Interactions” onpage4-89', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 84}), Document(page_content='4-2Pacing Therapies\\nPacingTherapies\\nPACINGTHERAPIES\\nCRT-Ds providebothatrialandbiventricular normal andpost-therap ybradycardiapacing, including adaptive-rate\\nmodes.\\nWARNING: During MRIProtection Mode,ifBradyModeisprogrammed toOff,Bradycardia therapyandCardiac\\nResynchron ization Therapy(CRT)aresuspended. Thepatient willnotreceivepacing untilthepulsegenerator is\\nprogrammed backtonormal operation.OnlyprogramBradyModetoOffduring MRIProtection Modeandscanthe\\npatient ifjudged tobeclinically capable oftolerating noBradycar diatherapy(including pacing-dependenc eorneed\\nforoverdrivepacing) andnoCRTfortheentireduration inwhichthepulsegeneratorisinMRIProtection Mode.\\nThebradycardia pacing function isindependent ofthetachycard iadetection andtherapy functions ofthedevice,with\\ntheexceptionofinterval-to-inter valsensing.\\nThepulsegenerator providesthefollowing typesoftherapies:\\nCRT\\n•Whenthepatient\\'s intrinsic atrialrateisbelowtheMTRandtheprogrammed AVDelayislessthantheintrinsic\\nintracardiac AVinterval,thedevicedelivers pacing pulsestotheventricles attheprogrammed settings inorderto\\nsynchron izeventricular contractions.\\n•Independent programmability oftheRVandLVleadsallowstherapeuticflexibilityforrestoring mechanical\\ncoordination.\\nNOTE:ForCRTandbradycardia therapydecisions, thecardiac cycleisdetermined byRVsensed andpaced\\nevents orLVpacedevents whenthepacing chamber isprogrammed toLVOnly.ItisnecessarythatanRVlead\\nbeimplanted evenwhenprogrammed toLV-only pacing because allofthedevicetimingcyclesrelyontheRV.\\nLVsensed events inhibitinappropriate LVpacing anddonotmodify thetimingcycle.\\nCAUTION: Toensure ahighpercentage ofbiventricular pacing, theprogrammed AVDelaysetting mustbeless\\nthanthepatient’s intrinsic PRinterval.\\nNormalBradycardia Pacing\\n•Iftheintrinsic heartratefallsbelowtheprogrammed pacing rate(i.e.,LRL),thedevicedelivers pacing pulsesat\\ntheprogrammed settings.\\n•Adaptive-rate pacing allowsthepulsegeneratortoadaptthepacing ratetothepatient\\'s changing activity levels\\nand/or physiologic needs.\\nPost-Therapy Pacing—alternative bradycardia pacing therapymaybedeliveredforaprogrammed periodtoensure\\ncapture afterdelivery ofashock.\\nAdditional Options\\n•Temporary Bradycard iaPacing—allows theclinician toexamine alternate therapieswhilemaintaining the\\npreviously programmed normal pacing settings inthepulsegeneratormemory (\"Tempor aryBradyPacing\" on\\npage4-31).\\n•STATPACE—initiates emergency ventricular pacing athighoutput settings whencommanded viatheProgrammer\\nusingtelemetry communication (\"STAT PACE\"onpage1-15).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 85}), Document(page_content='Pacing Therapies\\nDeviceProgramming Recommendations4-3\\nDEVICEPROGRAMMING RECOMMENDATIONS\\nItisimportant toprogramdeviceparamete rstotheappropriatesettings toensure optimal CRTdelivery .Please\\nconsider thefollowing guidelines inconjunction withthepatient\\'s specific condition andtherapyneeds.\\nNOTE:AlsoconsiderusingIndications-Based Programming (IBP),atoolthatprovidesspecific programming\\nrecommen dations basedonthepatient\\'s clinical needsandprimary indications (\"Indications-Based Programming\" on\\npage1-11).\\nCAUTION: Programming thedevicetoprovide RV-only pacing isnotintended forthetreatment ofheartfailure.The\\nclinical effects ofRV-only pacing forthetreatment ofheartfailurehavenotbeenestablished.\\nPacing mode––Progr amadual-chamber trackingmode[VDD(R) orDDD(R)]. Adaptive-rate pacing modes areintended\\nforpatients whoexhibitchronot ropicincompetence andwhowouldbenefit byincreasedpacing ratesconcurrent with\\nphysical activity (\"BradyMode\" onpage4-6).\\nPacing chamber ––Progr amtoBiV(nominal) unlessmedical discretiondictates theselection ofadifferentpacing\\nchamber (\"Ventricular Pacing Chamber\" onpage4-12).\\nBiVTrigger––Pro gramtoOntoprovidebiventricular pacing uptotheapplicable upperratelimit.\\nLeftVentricular MultiSite Pacing––Progr amtoOntoprovideLeftVentricular MultiSite Pacing (LVMSP)(\"Left\\nVentricular MultiSite Pacing(LVMSP)\"onpage4-71).\\nLRL––Pr ogram belowasinusratenormally reached whilestillprovidinganappropriate rateforbradycardia support\\n(\"Lower RateLimit\"onpage4-8).Ifthepulsegenerator isprogrammed toVVI(R)modeandthepatient hasAV\\nconduction during atrialtachyarrhythmias, resulting ininhibition ofbiventricular pacing (lossofCRT),consider\\nprogramming anelevated LRLtoincreasethedelivery ofbiventricular pacing.\\nMTR––Pr ogram highenough toensure 1:1AVsynchron y.AMTRat130ppmisrecommended unlessmedical\\ndiscretiondictates otherwise(\"Maximum TrackingRate\"onpage4-9).\\nPacing Output––The programmed Amplitude isrecommen dedtobeaminimum of2Xthecapture threshold to\\nprovideadequate safetymargin.Lowerpaceamplitudes willpreserve/extend longevity .Theprogrammed Amplitude\\nshould beabalanceofadequate safetymargin andeffectuponbattery longevity .IfPaceSafe isprogrammed On,it\\nwillautomatically provide anadequate safetymargin andmayhelpextendbattery longevity (\"PaceSafe \"onpage4-\\n16).\\nPacedAVDelay––The PacedAVDelaysetting should beindividualized foreachpatient toensure consistent CRT\\ndelivery .Several methods areavailable todetermine thePacedAVDelaysetting, including:\\n•Intrinsic QRSdurationassessment\\n•Echocard iogram\\n•Pulsepressuremonitoring\\n•SmartDelay optimization, whichwillrecommend AVDelaysettings (\"SmartDelay Optimization\" onpage4-76)\\nSinceoptimizing thePacedAVDelaycansignificantly influence CRTeffectiveness, considerusingmethods that\\ndemonstrat ethehemodynamic impact ofdifferentPacedAVDelaysettings, suchasechocar diography orpulse\\npressuremonitoring.\\nAtrialpacing mayprolongtheinteratrialdelay;therefore,itmaybenecessarytoprogramdifferent PacedAVDelay\\nsettings tooptimize CRTduring normal sinusrhythm andatrialpacing.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 86}), Document(page_content='4-4 Pacing Therapies\\nMaintaining CRT\\nSensed AVDelay––Sensed AVDelayisusedtoachieve ashorter AVDelayfollowing sensed atrialevents whilethe\\nlonger,programmed PacedAVDelayisusedfollowing pacedatrialevents. Whenprogrammed totheDDD(R) mode,it\\nisrecommended thatthepatient betestedtodetermine theoptimal Sensed AVDelayduring atrialsensing and\\npacing.\\nDynamic AVDelay––Dynamic AVDelayissetautomatically basedonthefollowing (\"Paced AVDelay\"onpage4-73):\\n•Iftheminimum andmaximum PacedAVDelays areequal,thenAVDelayisfixed.\\n•Iftheminimum PacedAVDelayislessthanthemaximum, thenAVDelayissettoDynamic.\\nPVARP––Pro gramPVARP to280ms.Forheartfailurepatients withintactAVconduction, alongintrinsic intracardiac\\nAVintervalandalongprogrammed PVARP cancausealossofatrialtrackingbelowtheMTR,resultinginalossofBiV\\nstimulation (CRT).IflossofatrialtrackingbelowtheMTRisoccurring, program TrackingPreferencetoOn(nominal)\\n(\"A-Refr actory-PVARP\" onpage4-79).\\nPVARP afterPVC––Pro gramPVARP afterPVCto400ms(nominal) topotentially reducethenumber ofPMTsathigh\\nrates.TheoccurrenceofPMTsmayalsobeduetootherfactors (\"PVARP afterPVC\"onpage4-80).\\nATR––If ATRisused,EntryandExitCounts should beprogrammed toensure appropriat eandtimelymodeswitching\\n(\"ATRModeSwitch\" onpage4-56).\\nNotethatVRRandBiVTrigger havethepotential toincreaseCRTdelivery during atrialtachyarrhythmias. BiVTrigger\\nshould beprogrammed toOn,andVRRshould beprogrammed toOnatthemaximum setting toincreasethepercent\\nofventricular pacing andmaximize consistent CRTdelivery during conducted atrialtachyarrhythmias.\\nPMTTermination––Pro gramtoOn(nominal) toterminate PMTsathighrates(\"PMTTermination\" onpage4-61).\\nLVPP––Pr ogram to400ms(nominal) toprevent thedevicefrompacing intheLVvulnerable period(\"LeftVentricular\\nProtectionPeriod\" onpage4-82).\\nTrackingPreference––Progr amtoOn(nominal) tosupport CRTdelivery foratrialratesbelow,butnear,theMTR.Use\\nthisfeaturewhenPVARP andthepatient’s intrinsic intracardiac AVinterval arelongerthantheprogrammed MTR\\ninterval(\"Tracking Preference\"onpage4-62).\\nLVLeadConfigur ation––For devices withanIS-1orLV-1leftventricular leadport,programinaccordancewiththe\\nnumber ofelectrodesontheLVlead(\"LeftVentricular ElectrodeConfigurati on\"onpage4-67).\\nMAINTAINING CRT\\nCertain conditions maycausethetemporary lossofCRTorAVsynchro nyduetoWenckebac h-likebehavior ,andheart\\nfailurepatients maybecome symptomatic ifCRTiscompromised. Pleaseconsider thefollowing whenyouare\\nprogramming thedevice.\\nMTR\\nRapidatrialrateswithafastventricular response aboveMTRcancause:\\n•Temporary inhibition ofCRTifAVconduction isintact\\n•Wenckebac h-likebehavior ifsecond- orthird-degree AVblockispresent\\nCRTdeliveryandprogrammed AVsynchron yreturnwhennormal sinusratesarerestored.\\nMTRshould beprogrammed sufficiently hightomaintain CRTatfastatrialrates.Inaddition, please consider the\\nfollowing formaintaining CRT:', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 87}), Document(page_content=\"Pacing Therapies\\nBasicParameters4-5\\n•RateSmoothing maybeusedtopreventsudden changes inrate\\n•VRRmayhelppromoteCRTbyincreasing thepercentofventricular pacing during conducted atrialarrhythmias\\n•SVTsmayrequiremedical management topreserveCRTaswellasprotect thepatient fromthepotential\\nhemodynamic compromise associated withfastrates\\n•Medical management offastatrialratescanmaximize theamount oftimethatthepatient remains belowMTR\\nandhelpensure consistent CRTdelivery\\nNOTE:Ifapatient hasslowVT,theabilitytoprogramhigherMTRvaluesislimited bythelowerratethreshold of\\nthelowest tachyarrhythmia zone.\\nForCRTdelivery atheartratesthatcorrespond totheslowVTrate,considermanaging theslowVTbyalternate\\nmeans suchasantiarrhythmic drugsorcatheter ablation toensure consistent CRT.\\nAFR\\nAFRmaydelayorinhibitanatrialpacedeventandprevent pacing intotheatrialvulnerable periodandprovide\\nimmediate cessation oftrackingofatrialrateshigherthantheAFRprogrammable rate.Thischanges theAVDelay\\nandmayimpact CRTeffectiveness iftheAFRrateisprogrammed slower thanthepatient's sinusrate.\\nRateSmoothing\\nWhenRateSmoothing Upisprogrammed toOn,CRTiscompromised during episodes ofatrialrateincreases\\nexceedingtheprogrammed RateSmoothing Uppercentage. Forpatients withAVblock,thisoccursbecause Rate\\nSmoothing UpprolongsAVDelayfromtheoptimal setting (controlsthebiventricular pacing ratewhiletheatrialrate\\nincreases).\\nFeaturesthatSwitchtoVVIorVVI-likeBehavior\\nVTR/ATR mayresultinWenckebach-lik ebehavior orthetemporary lossofCRT.CRTdelivery withprogrammed AV\\nsynchronywillreturnwhentheSVT/VT/VF eventisresolvedandanormal sinusrhythm isrestored.\\nForpatients programmed toVDD(R) withsinusratesbelowLRL,CRTwillnotbesynchro nizedwithatrialevents and\\nlossofAVsynchro nywillresult.Consider programming alowerLRLorenabling apacing modethatprovidesatrial\\npacing withsynchronous ventricular pacing [e.g.,DDD(R)], asmedically appropr iate.\\nSTATPACEdelivers CRTinVVImodewithalossofAVsynchron y.Thepermanent, programmed settings resumewhen\\nthepulsegeneratorisprogrammed outofSTATPACE.\\nBASICPARAMETERS\\nByprogramming deviceparamet ers,thepulsegeneratorprovidesCRTfortheintentofprovidingmechanical\\nsynchronization. Theprogramming options usedforCRTinclude thoseusedforbradycar diapacing therapy .\\nLVstimulation isdeliveredusingaunipolar orbipolar LVlead.Thedeviceusesatrialpacing andsensing tocoordinate\\nAVcontractions withCRT.\\nNormal Settings include thefollowing:\\n•Pacing parameters, whichareindependently programmable frompost-therapy andtempor arypacing parameters\\n•Pacing andSensing\\n•Leads\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 88}), Document(page_content='4-6Pacing Therapies\\nBasicParameters\\n•Sensors andTrending\\nPost-TherapySettings include thefollowing:\\n•Pacing paramete rs,whichareindependently programmable fromnormal andtempor arypacing parameters\\n•Post-ventricular shock\\nInteractive Limits\\nBecause manyfeatures withprogrammable paramete rsinteract,programmed valuesmustbecompatible acrosssuch\\nfeatures. Whenvaluesrequested bytheuserareincompatible withexisting parame ters,theProgrammer screen\\ndisplays analertdescribing theincompatibility andeitherprohibitstheselection orinstructs theusertoproceedwith\\ncaution (\"UseofColor\"onpage1-7).\\nBradyMode\\nBradymodes provideprogrammable options tohelpindividualize patient therapy.\\nThispulsegeneratorincludes thepacing modes identified intheProgrammable Options appendix.\\nCRTModes\\nTheobjective ofCRTistodeliver continuous pacing totheventricles. CRTcanonlybedeliveredinmodes thatprovide\\nventricular pacing.\\nThemaximal CRTbenefit canbeachieved whenbiventricular stimulation isdelivered.Atrialpacing andadaptive-r ate\\nmodes maybeappropriateforpatients whoalsoexperienc ebradycardia.\\nWARNING: Donotuseatrial-only modes inpatients withheartfailurebecause suchmodes donotprovide CRT.\\nNOTE:Thesafetyandeffectiveness ofCRTwasevaluated inclinical studies usingtheVDDmode.Usemedical\\ndiscretionwhenprogramming thepulsegenerator topacing modes otherthanVDD.\\nNOTE:Atrialpacing mayprolonginteratrialconduction, desynchro nizingrightandleftatrialcontractions. Theeffect\\nofatrialpacing onCRThasnotbeenstudied.\\nDDDandDDDR\\nIntheabsenceofsensed P-andR-waves, pacing pulseswillbedelivered totheatrium andtheventricle attheLRL\\n(DDD)orthesensor-indicated rate(DDDR), separated bytheAVDelay.Asensed P-wave willinhibitanatrialpaceand\\nstarttheAVDelay.AttheendoftheAVDelay,aventricular pacewillbedeliveredunlessinhibited byasensed R-\\nwave.\\n•Couldbeappropr iateforheartfailurepatients withsinusbradycardiasinceDDD(R) canprovideatrial-synchronous\\nbiventricular pacing atratesabovetheLRLandAV-sequential biventricular pacing attheLRLorsensor-indicated\\nrate—DDDR\\n•DDDmodemaybepreferredoverVDDmodeforpatients withsinusbradycar diaoratrialratesbelowtheLRLto\\npreserve AVsynchro nywithCRTdelivery', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 89}), Document(page_content='Pacing Therapies\\nBasicParameters4-7\\nDDIandDDIR\\nIntheabsence ofsensed P-andR-waves, pacing pulseswillbedeliveredtotheatrium andtheventricle attheLRL\\n(DDI)orthesensor-indicated rate(DDIR), separatedbytheAVDelay.Asensed P-wave willinhibitanatrialpacebut\\nwillnotstarttheAVDelay.\\n•Maynotbeappropr iateforheartfailurepatients withnormal sinusactivity\\n•Couldbeappropriate forheartfailurepatients whohavenounderlying intrinsic sinusrhythm butmight\\nexperience episodes ofatrialtachyarrhythmias suchasbrady-tachy syndrome\\n•ProvideAV-sequential biventricular pacing onlyattheLRL(DDI)orsensor-indicated rate(DDIR)intheabsenceof\\nsinusactivity\\n•During periods ofintrinsic atrialactivity abovetheLRLandintheabsence ofsensed R-waves, non-atrial-\\nsynchronousbiventricular pacing isdeliveredattheLRLorsensor-indicated rate\\nVDDandVDDR\\nIntheabsence ofsensed P-andR-waves, pacing pulseswillbedeliveredtotheventricle attheLRL(VDD)orthe\\nsensor-indicated rate(VDDR). Asensed P-wave willstarttheAVDelay.AttheendoftheAVDelay,aventricular pace\\nwillbedeliveredunlessinhibited byasensed R-wave. Asensed R-wave orapacedventricular eventwilldetermine\\nthetimingofthenextventricular pace.\\n•VDDisappropr iateforheartfailurepatients withnormal sinusactivity,sinceVDDdelivers atrial-synchron ous\\nbiventricular pacing butnoatrialpacing\\n•VDDRmaynotbeappropriat eforheartfailurepatients withnormal sinusactivity duetotheincreasedpotential\\nforlossofAVsynchrony\\n•WhileVDDRcanprovideatrial-synchronous biventricular pacing during normal sinusactivity,sensor-driven\\nventricular pacing willresultinthelossofAVsynchron yifthesensor-indicated rateexceedsthesinusrate\\n•Consider programming alowLRLforbradyca rdiasupport sincelossofAVsynchrony islikelytooccurduring LRL\\nventricular pacing\\n•Iffrequentpacing attheLRLisanticipated orobserve d,consider programming aDDD(R) modetomaintain AV\\nsynchronyduring LRLpacing\\nVVIandVVIR\\nInVVI(R)mode,sensing andpacing occuronlyintheventricle. Intheabsence ofsensed events, pacing pulseswillbe\\ndeliveredtotheventricle attheLRL(VVI)orthesensor-indicated rate(VVIR). Asensed R-wave orapacedventricular\\neventwilldetermine thetimingofthenextventricular pace.\\n•Maybedetrimental forheartfailurepatients withnormal sinusactivity\\n•Couldbeappropriate forheartfailurepatients withchronicatrialtachyarrhythmias orduring episodes ofatrial\\ntachyarrhythmia sincetheyprovidebiventricular pacing attheLRLorsensor-indicated rate—VVI(R)\\n•Ifpatients haveAVconduction during atrialtachyarrhythmias thatresultsininhibition ofbiventricular pacing (loss\\nofCRT),consider programming anelevated LRLinanattempt toincreasethedelivery ofbiventricular pacing and/\\nortoVVI(R), ifnotalreadyprogrammed', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 90}), Document(page_content='4-8Pacing Therapies\\nBasicParameters\\nAAIandAAIR\\nInAAI(R)mode,sensing andpacing occuronlyintheatrium. Intheabsenceofsensed events, pacing pulseswillbe\\ndeliveredtotheatrium attheLRL(AAI)orthesensor-indicated rate(AAIR). Asensed P-wave orapacedatrialevent\\nwilldetermine thetimingofthenextatrialpace.\\nDual-Chamber Modes\\nDonotuseDDD(R) andVDD(R) modes inthefollowing situations:\\n•Inpatients withchronic refractoryatrialtachyarrhythmias (atrialfibrillation orflutter), whichmaytrigger\\nventricular pacing\\n•Inthepresenceofslowretrograde conduction thatinducesPMT,whichcannot becontrolled byreprogramming\\nselective parametervalues\\nAtrialPacingModes\\nInDDD(R), DDI(R), andAAI(R)modes, atrialpacing maybeineffective inthepresenc eofchronicatrialfibrillation or\\nflutterorinanatrium thatdoesnotrespond toelectrical stimulation. Inaddition, thepresenc eofclinically significant\\nconduction disturbances maycontraindicate theuseofatrialpacing.\\nWARNING: Donotuseatrialtrackingmodes inpatients withchronic refractory atrialtachyarrhythmias. Trackingof\\natrialarrhythmias couldresultinventricular tachyarrhythmias.\\nNOTE:Referto\"UseofAtrialInformation\" onpage2-6foradditional information aboutdeviceperformanc ewhen\\ntheatrialleadisprogrammed toOff.\\nIfyouhaveanyquestions regarding theindividualization ofpatient therapy ,contactBoston Scientific usingthe\\ninformation onthebackcover.\\nLowerRateLimit(LRL)\\nLRListhenumber ofpulsesperminute atwhichthepulsegeneratorpacesintheabsenceofsensed intrinsic activity.\\nAslongastheventricle isbeingpaced(orifaPVCoccurs),theintervalistimedfromoneventricular eventtothenext.\\nWhenever aneventissensed intheventricle (e.g.,intrinsic AVconduction occursbefore theAVDelayelapses), the\\ntimingbaseswitches fromventricular -based timingtomodified atrial-based timing(Figure 4–1LRLtimingtransitions\\nonpage4-9).Thisswitching oftimingbaseensures accuratepacing ratessincethedifferencebetween theintrinsic\\nAVconduction andprogrammed AVDelayisapplied tothenextV–Ainterval.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 91}), Document(page_content=\"Pacing Therapies\\nBasicParameters4-9\\nAV\\nAV\\nAV\\nAV AV\\nVA\\nVA\\nVA VA\\nVA\\nAA\\nAA\\nAA\\nAA\\nVA + d\\nd\\nTransitio\\nn from V-\\nV timing \\nto A-A ti\\nming\\nTransition from A-A timing to V-V timing\\nIllustrationoftiming transitions (d=thedifferencebetween AVDelayandtheAVinterval inthefirstcycleduring whichintrinsic conduction occurs.Thevalueofdis\\napplied tothenextV–Ainterval toprovide asmooth transition without affecting A–Aintervals).\\nFigure4–1.LRLtimingtransitions\\nMaximum TrackingRate(MTR)\\nTheMTRisthemaximum rateatwhichthepacedventricular ratetracks1:1withnonrefr actorysensed atrialevents in\\ntheabsenceofasensed ventricular eventwithintheprogrammed AVDelay.MTRapplies toatrialsynchronouspacing\\nmodes, namely DDD(R) andVDD(R).\\nConsider thefollowing whenprogramming MTR:\\n•Thepatient's condition, age,andgeneralhealth\\n•Thepatient's sinusnodefunction\\n•AhighMTRmaybeinappropriate forpatients whoexperience angina orothersymptoms ofmyocardi alischemia\\nathigherrates\\nNOTE:Ifthepulsegenerator isoperatinginDDDRorVDDRmode,theMSRandMTRmaybeprogrammed\\nindependently todifferen tvalues.\\nUpperRateBehavior\\nForheartfailurepatients withnormal AVconduction, biventricular stimulation (CRT)maynotbedeliveredwhenthe\\natrialrateexceedstheMTR.ThiscanoccuriftheAVDelaylengthens beyond thepatient's intrinsic intracar diacAV\\ninterval andAVconduction occurs,whichinhibits ventricular pacing. Inbothsituations (AVblockandAVconduction)\\nCRTiscompromised whentheatrialrateexceedstheMTR,eitherbecause ofthesuboptimal, prolonged AVDelayora\\nlossofbiventricular pacing, orboth.\\nIfthepatient's normal atrialrateexceedstheMTR,considerprogramming ahigherMTRtoensure 1:1atrial\\nsynchronous, biventricular pacing attheprogrammed AVDelay.Ifreprogramming ahigherMTRislimited bythe\\ncurrentTARP(AVDelay+PVARP =TARP), attempt toshorten thePVARP beforeshortening theAVDelayinorderto\\navoidasuboptimal AVDelayforCRT.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 92}), Document(page_content=\"4-10Pacing Therapies\\nBasicParameters\\nWhenthesensed atrialrateisbetween theprogrammed LRLandMTR,1:1ventricular pacing willoccurintheabsence\\nofasensed ventricular eventwithintheprogrammed AVDelay.Ifthesensed atrialrateexceedstheMTR,thepulse\\ngeneratorbegins aWenckebac h-likebehavior topreventthepacedventricular ratefromexceeding theMTR.This\\nWencke bach-like behavior ischaracteriz edbyaprogressivelengthening oftheAVDelayuntilanoccasional P-wave is\\nnottrackedbecause itfallsintothePVARP. Thisresults inanoccasional lossof1:1trackingasthepulsegenerator\\nsynchro nizesitspacedventricular ratetothenextsensed P-wave. Should thesensed atrialratecontinuetoincrease\\nfurther abovetheMTR,theratioofsensed atrialevents tosequentially pacedventricular events becomes loweruntil,\\neventually ,2:1blockresults(e.g.,5:4,4:3,3:2,andfinally2:1).\\nThesensing window should bemaximized byprogramming theappropriateAVDelayandPVARP. Atratescloseto\\ntheMTR,thesensing window canbemaximized byprogramming Dynamic AVDelayandDynamic PVARP, and\\nWencke bachbehavior willbeminimized.\\nHighrateatrialtrackingislimited bytheprogrammed MTRandthetotalatrialrefractoryperiod(TARP) (AVDelay+\\nPVARP =TARP). Inordertoavoidcomplete closure ofthesensing window atMTR,thePRMwillnotallowaTARP\\nintervalthatislonger(lowerpacing rate)thantheprogrammed MTRinterval.\\nIftheTARPintervalisshorter (higher pacing rate)thantheintervaloftheprogrammed MTR,thenthepulse\\ngenerator'sWenckebach-lik ebehavior limitstheventricular pacing ratetotheMTR.IftheTARPintervalisequaltothe\\nintervaloftheprogrammed MTR,2:1blockmayoccurwithatrialratesabovetheMTR.\\nRapidchanges inthepacedventricular rate(e.g.,Wenckebac h-like,2:1block)caused bysensed atrialratesabovethe\\nMTRmaybedampened oreliminated bytheimplementation ofanyofthefollowing:\\n•AFR\\n•ATR\\n•RateSmoothing parameters andsensor input\\nNOTE:Forthepurpose ofatrialtachycard iadetection andhistogramupdates, atrialevents aredetected throughout\\nthecardiac cycle(exceptduring atrialblanking), including AVDelayandPVARP.\\nExamples\\nIftheatrialrateexceedstheMTR,theAVDelaywillbeprogressively lengthened (AV')untilanoccasional P-wave is\\nnottrackedbecause itfallsintotheatrialrefractoryperiod(Figure 4–2Wenckebachbehavior atMTRonpage4-10).\\nThisresultsinoccasional lossof1:1trackingasthepulsegeneratorsynchroniz esitspacedventricular ratetothenext\\ntrackedP-wave (pacemakerWenckebac h).\\nAVPVARPAV PVARPAV’P VARP AVPVA RPAV’PVAR P MTR MTR MTR\\nMTR MTR\\nFigure4–2.Wenckebach behavior atMTR\\nAnother typeofpulsegeneratorupperratebehavior (2:1block)canoccurwhentrackinghighatrialrates.Inthistype\\nofbehavior ,everyotherintrinsic atrialeventoccursduring PVARP and,thus,isnottracked(Figure 4–3Pacemak er2:1\\nblockonpage4-11).Thisresultsina2:1ratioofatrial-to-ventricular events orasudden dropintheventricular paced\\nratetohalfoftheatrialrate.Atfasteratrialrates,severalatrialevents canfallintheTARPperiod, resulting inthe\\npulsegeneratortrackingonlyeverythirdorfourthP-wave. Theblockthenoccursatratessuchas3:1or4:1.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 93}), Document(page_content=\"Pacing Therapies\\nBasicParameters4-11\\nAVPVA RP AVPVA RP AVPVA RP AVPVA RP\\nIllustrationofpacemak er2:1block,inwhicheveryotherP-wave fallsinsidethePVARP interval.\\nFigure4–3.Pacemaker2:1block\\nMaximum SensorRate(MSR)\\nMSRisthemaximum pacing rateallowed asaresultofrate-adaptive sensor control.\\nConsider thefollowing whenprogramming MSR:\\n•Patient's condition ,age,andgeneralhealth:\\n–Adaptive-rate pacing athigherratesmaybeinappropr iateforpatients whoexperienc eangina orother\\nsymptoms ofmyocardi alischemia atthesehigherrates\\n–Anappropriate MSRshould beselected basedonanassessment ofthehighest pacing ratethatthepatient\\ncantolerate well\\nNOTE:Ifthepulsegeneratorisoperating inDDDRorVDDRmode,theMSRandMTRmaybeprogrammed\\nindependently todifferentvalues.\\nMSRisindependently programmable at,above, orbelowtheMTR.IftheMSRsetting ishigherthantheMTR,pacing\\nabovetheMTRmayoccurifthesensor rateexceedstheMTR.\\nPacing abovetheMSR(whenprogrammed lowerthantheMTR)canonlyoccurinresponse tosensed intrinsic atrial\\nactivity.\\nCAUTION: Adaptive-rate pacing isnotlimited byrefractory periods. Alongrefractory periodprogrammed in\\ncombination withahighMSRcanresultinasynchron ouspacing during refractoryperiods sincethecombination can\\ncauseaverysmallsensing window ornoneatall.UseDynamic AVDelayorDynamic PVARP tooptimize sensing\\nwindows. Ifyouareprogramming afixedAVDelay,considerthesensing outcomes.\\nWithintrinsic conduction, thepulsegenerator maintains theA–Apacing ratebyextending theV–Ainterval.This\\nextension isdetermined bythedegreeofdifferencebetween theAVDelayandtheintrinsic ventricular conduction—\\noftenreferredtoasmodified atrial-based timing (Figure4–4VAinterval extension andMSRonpage4-12).\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 94}), Document(page_content=\"4-12Pacing Therapies\\nBasicParameters\\nPacing wi\\nthout mod\\nified \\natrial-ba\\nsed timin\\ng\\nPacing wi\\nth modifi\\ned \\natrial-ba\\nsed timin\\ng\\n1\\n50 ms 200 \\nms\\nA\\nV\\nVA\\nAV + VA\\nForced VA\\n extensio\\nn\\n150 ms 250\\n ms\\nAV\\nVA\\nAV + VA +\\n extensio\\nn\\nMSR 400 m\\ns (150 mi\\nn\\n-1\\n [ppm])\\nAV 150 ms\\n (conduct\\ned event)\\nVA 200 ms\\nPacing in\\nterval = \\nAV + VA =\\n 350 ms\\nMSR 400 m\\ns (150 mi\\nn\\n-1\\n [ppm])\\nAV 150 ms\\n (conduct\\ned event)\\nVA 200 ms\\nVA Ext. 5\\n0 ms\\n Pacing in terval = AV + VA +  VA exten sion = 40 0 ms\\nThepulsegenerator's timing algorithm provides effective pacing attheMSRwithintrinsic ventricular conduction. Extending theVAinterval prevent stheApacefromexceeding theMSRathigh\\nrates.\\nFigure4–4.VAintervalextension andMSR\\nRunaway Protection\\nRunaway protectionisdesigned topreventpacing rateaccelerationsabovetheMTR/MSR formostsingle-component\\nfailures.Thisfeature isnotprogrammable andoperatesindependently fromthepulsegenerator'smainpacing\\ncircuitry.\\nRunaway protectionprevents thepacing ratefromincreasing above205ppm.\\nNOTE:Magnet application doesnotaffectthepacing rate(pulseinterval).\\nNOTE:Runaway Protection isnotanabsolute assurancethatrunaways willnotoccur.\\nDuring PES,Manual BurstPacing, andATP,runaway protectionistemporarily suspended toallowforhigh-rate\\npacing.\\nVentricular PacingChamber\\nWiththeVentricular Pacing Chamber option, youcanchoose whichchamber(s) willreceivepacing pulses.\\nThefollowing options areavailable:\\n•RVOnly\\n•LVOnly—Available onlyinRESONATE HF(G547,G548), RESONATE X4(G447,G448), VIGILANT X4(G247,G248),\\nandMOMENTUM X4(G138)\\n•BiV(bothRVandLV)—when selected, LVOffsetbecomesavailable\\nNOTE:ItisnecessarythatanRVleadbeimplanted evenwhenprogrammed toLV-only pacing because allofthe\\ndevicetiming cyclesrelyontheRV.\\nFordevices withanIS-1orLV-1leftventricular leadport,thenominal LVElectrode Configur ationisNone.Thisresults\\ninaparameter interaction whencombined withthenominal Ventricular Pacing Chamber setting ofBiV.Thisis\\nintended toensure thatanappropriateLVElectrode Configur ation(dualorsingle) ischosen basedontheimplanted\\nLVlead.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 95}), Document(page_content='Pacing Therapies\\nBasicParameters4-13\\nFordeviceswithanIS4leftventricular leadport,theLVElectrodeConfiguration isautomatically settoQuadripolar.\\nCAUTION: Programming thedevicetoprovide RV-only pacing isnotintended forthetreatment ofheartfailure.The\\nclinical effects ofRV-only pacing forthetreatment ofheartfailurehavenotbeenestablished.\\nLV-OnlyPacing\\nAdequate fusionofLVpacing andnaturalconduction, basedonappropriate AVDelayprogramming, isnecessaryfor\\nLV-only pacing toprovideoptimal cardiacresynchronization therapyresponse.\\nLV-only pacing maynotbeoptimal forpatients withlargefluctuations inPRintervals orwithconditions suchas\\nfrequent prematur eatrialcontractions andfrequent prematur eventricular contractions. Itisalsonotrecommended for\\npatients withsecond-orthird-degr eeheartblock.\\nOptimal CRTdelivery requires near100%delivery ofpacing. Whenprogramming LV-only pacing, consider the\\nfollowing inconjunction withthepatient\\'s specific condition andtherapyneeds:\\n•Tomaximize thepercentCRTdelivery ,periodically review LVpacing counters andenable the%CRTPacing alertin\\nLATITUDE.\\n•Tomaximize thechance thatLVpacing willfusewithRVactivation, consider adjusting theAVDelayovertime,\\nbasedonperiodic reviewofmeasur edPRintervals, usingstoredEGMsindevicememory ,orusingambulator yor\\nrestECGs.\\nNOTE:Whilethedevicecanmonitor thepercentage ofventricular pacing, thisvaluemaynotreflectwhether\\nLV-only pacing isassociated withfusionwithRVactivation.\\nTheclinician mayalsoconsider usingDynamic AVDelay,whichprovidesamorephysiologic AVDelayinresponseto\\nratechanges (\"PacedAVDelay\"onpage4-73).\\nLVOffset\\nWhenthePacing Chamber issettoBiV,theLVOffsetfeatureisavailable andallowsyoutoadjustthedelaybetween\\ndelivery oftheleftventricular pacing pulseandtherightventricular pacing pulse.LVOffsetisdesigned toenhance\\nprogramming flexibilitytocoordinate themechanical response oftheventricles.\\nThedeviceautomatically accommodates theLVOffsetforhighpacing ratesandforthelowest programmed tachy\\nratethreshold whenbiventricular pacing occursneartheupperratelimit.\\nAV Delay PVARP\\nAtrial Sense or Pace RV Pace\\n-100 ms\\nProgrammable L V Pace Range0 ms\\nFigure4–5.Programmable LVpacerange\\nNOTE:Theprogrammed AVDelayisbasedonRVtiming; therefore,itisnotaffected byLVOffset.\\nNOTE:WhenLVMSPisprogrammed On,theindependently programmable LVMSPdelayssupersede theLVOffset\\nfield,whichbecomes unavailable.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 96}), Document(page_content='4-14 Pacing Therapies\\nBasicParameters\\nTodetermine theLVOffsetvalue,followthesesteps:\\nNOTE:TheLVOffsetselection isavailable onlyifthePacing Chamber option isprogrammed toBiV.\\n1.Identify theinterval byusingTempBradyModetoprogramthedevicetoalowerpacing rateand/or toextend\\ntheAVDelayinordertoassessintrinsic ventricular signals. Obtain andprintareal-time EGMandstopTemp\\nBradyafterapproximately tenintervals. Identify arepresentative (averaged )rightventricular sense(RVS)toleft\\nventricular sense(LVS)interval(Figure4–6LVOffsetEGMonpage4-14).\\nFigure4–6.LVOffsetEGM\\n2.Findthecorresponding Intervalvalueinthetablebelowtodetermine therecommended LVOffsetvalue.Ifthe\\nLVSprecededtheRVSontheEGM,programtheLVOffsetto0ms.\\nTable4–1.Recommended LVOffsetvalues\\nRVStoLVSInterval(ms) Recommended LVOffset(ms)\\n0–15 -20\\n16–45 -30\\n46–75 -40\\n76–105 -50\\n106–135 -60\\n136–165 -70\\n>166 -80\\nNOTE:TheDECREASE HFstudyevaluated theLVOffsetfeature usingthistable.\\n3.Asdescribed indetailbelow,selecttherecommended LVOffsetfromthechoices providedbytheprogrammer\\nandlengthen theAVDelaybytheabsolute valueoftheLVOffset(e.g.,AVDelay=70+[-40]=70+40=110).\\nProgramthedevice.\\nNOTE:Ifsubsequently usingSmartDelay todetermine optimal AVDelay,SmartDelay willautomatically adjust\\nfortheprogrammed LVOffset. Refertothedescription ofLVOffsetprogramming withSmartDelay (\"SmartDelay\\nOptimization\" onpage4-76).\\nSelecttherecommended LVOffsetfromthechoices provided bytheprogrammer .', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 97}), Document(page_content='Pacing Therapies\\nBasicParameters4-15\\nModify theAVDelayusingthefollowing formula andprogram thedevice:\\n•AVDelaynew=AVDelaypresent–[LVOffsetrecommended–LVOffsetpresent]\\nWhere:\\n•AVDelaypresent=currentlyprogrammed AVDelay\\n•LVOffsetpresent=currentlyprogrammed LVOffset[nominal value=0]\\n•LVOffsetrecommended=recommended LVOffsetvaluefromthetablebasedonstep2.\\nExample1\\nPatient currently hasprogrammed LVOffsetvalue=0,AVDelay=120ms\\nTherecommended LVOffsetvalueforthepatient is-20ms\\nUsingtheaboveformula, AVDelay(new)=120–[-20–0]=140ms\\nExample2\\nPatient currently hasprogrammed LVOffsetvalue=-20,AVDelay=140ms\\nTherecommended LVOffsetvalueforthepatient is-40ms\\nUsingtheaboveformula, AVDelay(new)=140–[-40–(-20)]=140ms–[-20]=160ms\\nExample3\\nPatient currently hasprogrammed LVOffsetvalue=-40,AVDelay=160ms\\nTherecommended LVOffsetvalueforthepatient is-20ms\\nUsingtheaboveformula, AVDelay(new)=160–[-20–(-40)]=160–[20]=140ms\\nPulseWidth\\nPulseWidth, alsoreferredtoaspulseduration,determines howlongtheoutput pulsewillbeapplied between the\\npacing electrodes.\\nConsider thefollowing whenprogramming PulseWidth:\\n•PulseWidths areindependently programmable foreachchamber .\\n•IfaPulseWidthThreshold Testisperformed, aminimum 3Xpulsewidthsafetymarginisrecommended.\\n•Theenergy delivered totheheartisdirectly proportional tothePulseWidth; doubling thePulseWidthdoubles\\ntheenergydelivere d.Therefor e,programming ashorter PulseWidthwhilemaintaining anadequate safety\\nmarginmayincreasebattery longevity .Topreventlossofcapture, exercisecaution whenprogramming\\npermanent PulseWidthvaluesoflessthan0.3ms(Figure4–7Pulsewaveform onpage4-16).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 98}), Document(page_content=\"4-16Pacing Therapies\\nPaceSafe\\nPulse Width (ms)\\nAmplitude (V)\\nFigure4–7.Pulsewaveform\\nAmplitude\\nThepulseAmplitude, orvoltage oftheoutput pulse,ismeasur edattheleading edgeoftheoutput pulse(Figure4–7\\nPulsewaveform onpage4-16).\\nConsider thefollowing whenprogramming Amplitude:\\n•Amplitudes areindependently programmable foreachchamber .\\n•BradyModemaybeprogrammed toOffviapermanent ortempora ryprogramming. Ineffect,thisturns\\nAmplitude Offtomonitor thepatient's underlying rhythm.\\n•Theprogrammed Amplitude isrecommended tobeaminimum of2Xthecapture threshold toprovideadequate\\nsafetymargin. Lowerpaceamplitudes willpreserve/e xtendlongevity .Theprogrammed Amplitude should bea\\nbalance ofadequate safetymarginandeffectuponbattery longevity .IfPaceSafe isprogrammed On,itwill\\nautomatically provideanadequate safetymargin andmayhelpextend battery longevity .\\n•Theenergydeliveredtotheheartisdirectlyproportiona ltothesquare oftheAmplitude; doubling theAmplitude\\nquadruples theenergydelivered.Therefor e,programming toalowerAmplitude whilemaintaining anadequate\\nsafetymargin mayincreasebattery longevity .\\nPaceSafe\\nPaceSafeRightAtrialAutomatic Threshold (RAAT)\\nPaceSafe RAATisdesigned todynamically adjusttheatrialpacing output toensure capture oftheatrium by\\noptimizing theoutput voltage to2Xthecapture threshold toprovide adequate safetymargin (forthresholds lessthan\\norequalto2.5V).RAATwillmeasure pacing thresholds between 0.2Vand4.0Vat0.4msandtheoutput willbea\\nminimum of2.0Vandamaximum of5.0Vwithafixedpulsewidthof0.4ms.\\nNOTE:Tofunction properly,RAATrequiresafunctional RVleadandabipolar atriallead.\\nNOTE:RAATisonlyavailable inpulsegenerators programmed toDDD(R) andDDI(R)modes aswellasDDI(R)\\nFallback Mode.\\nRAATcanbeprogrammed onbyselecting AutofromtheAtrialAmplitude paramete roptions. Programming theatrial\\noutput toAutowillautomatically adjustthePulseWidthto0.4msandsettheatrialvoltage output toaninitialvalue\\nof5.0Vunlessthereisasuccessful testresultwithinthelast24hours.\\nNOTE:Priortoprogramming RAATon,considerperforming aCommanded AtrialAutomatic Threshold\\nMeasur ementtoverifythatthefeature functions asexpected. RAATtesting isperformed inaunipolar configuration\\nandtheremaybeadiscrepancy between unipolar andbipolar thresholds. Ifthebipolar threshold isgreaterthanthe\\nunipolar threshold bymorethan0.5V,consider programming afixedAtrialAmplitude.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 99}), Document(page_content='Pacing Therapies\\nPaceSafe4-17\\nRAATisdesigned toworkwithtypicalleadimplant criteria andanatrialthreshold between 0.2Vand4.0Vat0.4ms.\\nTheRAATalgorithm thenmeasur estheatrialpacing threshold eachdayandadjusts thevoltage output. During\\ntesting, RAATmeasur esanevoked responsesignaltoconfirm thateachatrialpacing output capture stheatrium. If\\nthedeviceisunable torepeatedly measure anevoked response signalofsufficient amplitude, a“LowER”or“Noise”\\nmessage maybedisplayed andthealgorithm willdefault to5.0Vpacing amplitude. Consider programming afixed\\natrialpacing amplitude inthesesituations andre-check withaCommanded RAATtestatalaterfollow-up; maturation\\nofthelead-tissue interfac emayimprovetheperformanc eofRAAT.\\nIftesting issuccessful,theAtrialAmplitude isadjusted to2Xthehighest measur edthreshold ofthelast7successful\\nambulatory tests(output Amplitude between 2.0Vand5.0V).Seventestsareusedtoaccountforcircadian cycle\\neffects onthreshold andensure anadequate safetymargin. Thisalsoallowsforarapidincrease inoutput duetoa\\nsudden riseinthreshold whilerequiring consistently lowerthreshold measur ements todecreaseoutput (i.e.,onelow\\nthreshold measur ementwillnotcauseadecrease inoutput) (Figure 4–8Effectofthreshold change onRAATpacing\\noutput onpage4-17).\\nNOTE:Sinceoutput issetto2Xthecapture threshold toprovideadequate safetymarginandRVpacing occurs\\nshortly afteratrialpacing, thereisnobeat-to-beat capture verification orbackupatrialpacing atanytime.\\nWhenDailyTrendisselected alongwithafixedAmplitude, automatic atrialthreshold measur ements willoccurevery\\n21hourswithnochange toprogrammed output.\\nTheRAATfeature isdesigned tooperatewithalargerangeofpacing leads(e.g.,highimpedance ,lowimpedance,\\ntinedfixation, orpositive fixation).\\n6.0\\n5.0\\n4.0\\n3.0\\n2.0\\n1.0\\n0.\\n0\\nV\\na\\nl\\nu\\ne\\n \\n(\\nV\\n)\\nDay\\n5 10 15 20 25\\n70 30 35 40 4\\n5 50 55 60 65\\nThreshold\\nPace Outp\\nut\\nOne high \\nthreshold\\n causes a\\nn \\nimmediate\\n rise in \\npacing ou\\ntput\\nOne low t\\nhreshold \\ndoes not \\n change th e pacing output Lead aler\\nt trigger\\ned on \\n 4th day o f failed testing\\nFigure4–8.Effectofthreshold changeonRAATpacingoutput\\nAmbulatory AtrialAutomatic Threshold Measurement\\nTesting usesanRAtip>>can(unipolar) pacing vectorandanRAring>>can(unipolar) sensing vectoreventhough\\ntheatrialleadisprogrammed toanormal bradyBipolar Pace/Sense configurat ion.\\nWhenRAATissettoAutoorDailyTrend,ambulator yatrialautomatic threshold measurements areconducted every\\n21hoursandthefollowing parameters areadjusted toensure avalidmeasur ementisobtained:\\n•Starting atrialpacing amplitude istheoutput thatRAATiscurrentlyusing.IfthatAmplitude valuefailsorifno\\npreviousresultsareavailable, thestarting Amplitude is4.0V.\\n•Thepacing amplitude willdecrement in0.5Vstepsabove3.5Vandin0.1Vstepsatorbelow3.5V.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 100}), Document(page_content='4-18Pacing Therapies\\nPaceSafe\\n•PacedAVDelayisfixedat85ms.\\n•Sensed AVDelayisfixedat55ms.\\n•Initialpacing rateissettotheaverageatrialrate,theLRLorsensor-indicated rate,whichever isfaster.\\n•Ifthereareaninsufficient number ofatrialpacesoriffusionoccurs, theatrialpacing ratewillbeincreasedby\\n10ppm(itmaybeincreasedasecond time),butwillnotexceedthelowest oftheMTR,MSR,MPR,110bpm,or\\n5bpmbelowthelowest VTDetection Rate.\\n•TheVentricular Pacing Chamber isnotchanged; however ,ifventricular pacing issettoBiVandLVOffsetis\\nnegative, theoffsetwillbesettozeroduring testing.\\nFollowing initialization paces,thepulsegeneratorwilldecrement theatrialoutput every3pacesuntilathreshold is\\ndetermined. Iflossofcapture occurstwiceataparticular output level,threshold isdeclaredasthepreviousoutput\\nlevelthatdemonstrated consistentcapture. If3capture dbeatsoccuratanyparticular output level,output decrements\\ntothenextlevel.\\nNOTE:Toensure thatlossofcapture during RAATdoesnotencouragePMT(andalsoendthetestprematu relydue\\ntotoomanyatrialsenses), thepulsegeneratorusesaPMTalgorithm. Following thelossofcapture ofanyatrialbeat,\\nthePVARP following thatventricular eventisextended to500mstopreventtrackingofasubsequent P-wave.\\nIfdailytesting isunsuccessful,RAATwillreturntothepreviously determined output andthepulsegenerator will\\nperform upto3re-attempts athourlyintervals. Ifasuccessfultestdoesnotoccurfor4days,aLeadAlertwillbe\\ntriggeredandRAATwillenterSuspension.\\nRightAtrialAutomatic Threshold Suspension\\nIfambulatory testing failsinAutomodefor4consecutive days,RAATwillgointoaSuspension modeandthepacing\\noutput willoperateat5.0Vand0.4ms.Testing willcontinueeachdaywithupto3re-attempts toevaluate\\nthresholds andthepulsegeneratorwilladjusttoaloweroutput setting whenindicated byasuccessfultest.\\nAlthough RAATisdesigned toworkwithawiderangeofleads,insomepatients theleadsignals mayhinder\\nsuccessfuldetermination oftheatrialthreshold. Intheseinstances, RAATwillcontinually operateintheSuspension\\nmodeat5.0V.Insituations whereSuspension modepersists foranextended periodoftime,itisrecommended to\\nturnRAAToffbyprogramming afixedatrialoutput.\\nCommanded AtrialAutomatic Threshold Measurement\\nAnautomatic threshold measur ementcanbecommanded viatheThreshold Testsscreenbyselecting AutoAmplitude\\nastheTestType.Iftesting completes successfullyandRAATisprogrammed on,theoutput willautomatically beset\\nto2Xthattest’smeasur edthreshold (between 2.0Vand5.0V).Thelast7successfuldailymeasurem entsarecleared\\nandthecurrentcommanded testresultisusedasthefirstsuccessfultestofanew7testcycle.Thisistoensure that\\ntherewillbeanimmediate output adjustment basedonthecurrentcommanded testresultratherthanonolder\\nambulator ytestdata.Thiscanbeconfirmed byobserving theoutput voltage ontheBradySettings screen,whichwill\\nshowtheactualoperatingvoltage oftheRAATalgorithm.\\nIftesting isunsuccessful,theThreshold Testsscreenwilldisplay afailurecodeindicating thereasonthetestwasnot\\nsuccessful,andtheoutput willreturntothepreviously setlevel(Table4–2ThresholdTestCodesonpage4-19).\\nNOTE:FortheinitialAtrialThreshold testafterthepulsegeneratorisimplanted, theTestTypefieldisseeded to\\nAuto.Choose thedesired testtypefromtheTestTypefieldoptions, andadjustanyotherprogrammable valuesas\\nappropr iate.\\nNOTE:Commanded testing requiresafunctional bipolar atrialleadandmaybeperformed inAAImode.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 101}), Document(page_content='Pacing Therapies\\nPaceSafe4-19\\nTestResultsandLeadAlerts\\nAstoredEGMforthemostrecentsuccessfulambulator ytestwillbestoredintheArrhythmia Logbook (\"Arrhythmia\\nLogbook\" onpage6-2).RefertotheDailyMeasure mentsscreenfortheresulting threshold value.Ifdesired, the\\nstoredEGMcanbereviewed todetermine wherelossofcapture occurred.\\nUpto12months ofAmbulatory ThresholdTestresults,aswellastestfailurecodesandleadalerts,canbefound\\nwithintheDailyMeasurement andTrendsscreens.Toprovidefurther information onthereasonfortestfailure,a\\nfailurecodeisprovided foreachdayinwhichtesting fails.Additionally ,failurecodesareprovidedontheThreshold\\nTestscreenifacommanded automatic threshold testdoesnotcomplete successfully .ThresholdTestFailureCodesare\\nlistedbelow(Table4–2Threshold TestCodesonpage4-19).\\nThefollowing scenarioswilltrigger theCheckAtrialLeadalert:\\n•Threshold >Programmed Amplitude willbedisplayed ifRAATisinDailyTrendmodeandtheambulatory test\\nresultsofthelast4consecutive daysexceedthemanually programmed fixedoutput.\\n•Automatic ThresholdSuspension willbedisplayed ifnosuccessfultestsareperformed for4consecutive daysin\\nAutoorDailyTrendmode.\\nTable4–2.Threshold TestCodes\\nCode Reason\\nN/R:devicetelem. Telemetry started during anambulatory test\\nN/R:comm. lost Telemetry waslostduring acommanded test\\nN/R:nocapture Capturewasnotobtained atthestarting amplitude foracommandedtestor\\ncapture is>4.0Vforanambulator ytest\\nN/R:modeswitch ATRmodeswitcheitherstarted orstopped\\nN/R:fusionevents Toomanyconsecutiveortoomanytotalfusionevents occurred\\nNodatacollected Minimum pacing amplitude wasreached without losingcapture foran\\nambulatory test,orneither AutonorDailyTrendisturned ontoobtainan\\nambulatory result\\nN/R:battery low Testwasskipped duetoBattery Capacity Depleted\\nN/R:noise Toomanyconsecutivesensechannel noiseorEvoked Response noisecycles\\noccurred\\nN/R:incompa t.mode Incompatible Bradymodewaspresent(e.g.VDIFallback Mode)\\nN/R:ratetoohigh Ratewastoohighatthestartofthetest,arateincreasewouldraisetheratetoo\\nhighormorethan2rateincreases wererequired\\nN/R:usercancelled Commanded testwasstopped bytheuser\\nN/R:intrinsic beats Toomanycardiaccyclesoccurredduring thetest\\nN/R:testdelayed Testwasdelayed duetotelemetry beingactive,VTepisode alreadyinprogress,\\nElectrocauterymode,MRIProtection Mode,orRAATwasturned onwhilethe\\ndeviceremained inStorage mode.Codedisplayed regardlessofwhether Autoor\\nDailyTrendisturned onoroff.\\nN/R:vent.episode AVentricular Episode started during testing\\nN/R:respiration Respirato ryartifact wastoohigh\\nN/R:lowER TheEvoked Response signalcouldnotbeassessed adequately', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 102}), Document(page_content='4-20Pacing Therapies\\nPaceSafe\\nTable4–2.Threshold TestCodes(continued)\\nCode Reason\\nAutoN/R Minimum pacing amplitude wasreached without losingcapture fora\\ncommanded test,ortelemetry ismanually cancelled during acommande dtest\\nN/R:recentshock Ventricular shocktherapywasdelivered lessthan60minutes priortothe\\nscheduled startofanambulator ytest\\nPaceSafeRightVentricular Automatic Threshold (RVAT)\\nPaceSafe RVATisdesigned todynamically adjusttherightventricular pacing output toensure capture oftheventricle\\nbyoptimizing theoutput voltage to2Xthecapture threshold toprovide adequate safetymargin (forthresholds less\\nthanorequalto2.5V).RVATwillmeasur epacing thresholds between 0.2Vand5.0Vat0.4ms,andtheoutput will\\nbeaminimum of2.0Vandamaximum of5.0VwithafixedPulseWidthof0.4ms.\\nNOTE:RVATisavailable inDDD(R), DDI(R), VDD(R), andVVI(R)modes, aswellasduring VDI(R)andDDI(R)Fallback\\nModes.\\nRVATcanbeprogrammed onbyselecting AutofromtheVentricular Amplitude paramet eroptions. Ifstarting froma\\nfixedamplitude greater than5.0V,program afixedamplitude of5.0Vpriortoselecting Auto.Programming the\\nventricular output toAutowillautomatically adjustthePulseWidthto0.4msandsettheventricular voltage output\\ntoaninitialvalueof5.0Vunlessthereisasuccessfultestresultwithinthelast24hours.\\nNOTE:Priortoprogramming RVATon,considerperforming aCommanded Ventricular Automatic Threshold\\nMeasur ementtoverifythatthefeature functions asexpected.\\nRVATisdesigned toworkwithtypicalleadimplant criteria andmeasur eaventricular threshold between 0.2Vand\\n5.0Vat0.4ms.\\nTheRVATalgorithm thenmeasur estheventricular pacing threshold eachdayandadjusts thevoltage output. During\\ntesting, RVATusesanevoked respons esignaltoconfirm thateachventricular pacing output captures theventricle.\\nTheevokedresponse issensed between theRVcoilandcan.Thisconfiguration provides ahighelectrode surface area\\nwhichresultsinasmallafterpotential, smaller pacing artifact, andimproves sensing oftheevoked response.\\nIftesting issuccessful,theVentricular Amplitude isadjusted to2Xthehighest measur edthreshold ofthelast7\\nsuccessfulambulatory testsbetween 2.0Vand5.0V.Seventestsareusedtoaccountforcircadiancycleeffects on\\nthreshold andensure anadequate safetymargin.Thisalsoallowsforarapidincreaseinoutput duetoasudden rise\\ninthreshold whilerequiring consistently lowerthreshold measurements todecrease output (i.e.onelowthreshold\\nmeasur ementwillnotcauseadecreaseinoutput) (Figure4–9Effectofthreshold changes onRVATpacing output on\\npage4-21).\\nNOTE:Sinceoutput issetto2Xthecapture threshold toprovideadequate safetymargin, thereisnobeat-to-beat\\ncapture verification.\\nWhenDailyTrendisselected alongwithafixedAmplitude, automatic ventricular threshold measur ements willoccur\\nevery21hourswithnochange toprogrammed output.\\nTheRVATfeature isdesigned tooperatewithalargerangeofpacing leads(e.g.,highimpedance, lowimpedance,\\nintegratedbipolar,dedicated bipolar).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 103}), Document(page_content='Pacing Therapies\\nPaceSafe4-21\\n6.0\\n5.0\\n4.0\\n3.0\\n2.0\\n1.0\\n0.\\n0\\nV\\na\\nl\\nu\\ne\\n \\n(\\nV\\n)\\nDay\\n5 10 15 20 25\\n70 30 35 40 4\\n5 50 55 60 65\\nThreshold\\nPace Outp\\nut\\nOne high \\nthreshold\\n causes a\\nn \\nimmediate\\n rise in \\npacing ou\\ntput\\nOne low t\\nhreshold \\ndoes not \\n change th e pacing output Lead aler\\nt trigger\\ned on \\n 4th day o f failed testing\\nFigure4–9.Effectofthreshold changesonRVATpacingoutput\\nAmbulatory RightVentricular Automatic Threshold Measurement\\nWhenRVATissettoAutoorDailyTrend,ambulatory ventricular automatic threshold measur ements areconducted\\nevery21hours.\\nInatrialtrackingmodes, theautomatic threshold measur ementadjusts thefollowing parameters tohelpensure a\\nvalidmeasurement isobtained:\\n•PacedAVDelayisfixedat60ms.\\n•Sensed AVDelayisfixedat30ms.\\n•RV-Blank AfterA-Pace isfixedat85ms.\\n•LVpacing istempor arilysuspended inordertoevaluate anRV-only evoked response.\\n•Starting ventricular pacing output amplitude istheoutput whichRVATiscurrentlyusing(orwouldbeusingwhen\\nRVATissettoDailyTrendonly).Ifthatamplitude failsorifnopreviousresultsareavailable, thestarting\\namplitude is5.0V.\\n•Thepacing amplitude willdecrement in0.5Vstepsabove3.5Vandin0.1Vstepsatorbelow3.5V.\\n•Abackup pulseisdelivered approximately 90msaftertheprimary pacing pulsewhenlossofcapture isdetected.\\nInnontrac kingmodes, theautomatic threshold measurement adjusts thefollowing parameters tohelpensure avalid\\nmeasur ementisobtained:\\n•PacedAVDelayisfixedat60ms.\\n•RV-Blank AfterA-Pace isfixedat85ms.\\n•LVpacing istempor arilysuspended inordertoevaluate anRV-only evoked response.\\n•Starting ventricular pacing output amplitude istheoutput whichRVATiscurrentlyusing(orwouldbeusingwhen\\nRVATissettoDailyTrendonly).Ifthatamplitude failsorifnopreviousresultsareavailable, thestarting\\namplitude is5.0V.\\n•Thepacing amplitude willdecrement in0.5Vstepsabove3.5Vandin0.1Vstepsatorbelow3.5V.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 104}), Document(page_content='4-22Pacing Therapies\\nPaceSafe\\n•Abackuppulseisdeliveredapproximately 90msaftertheprimarypacing pulsewhenlossofcapture isdetected.\\n•Theventricular pacing ratewillbeincreasedby10ppmabovethecurrent rate(paced orintrinsic) andiscapped\\natthelowest oftheMPR,MSR,110bpm,or5bpmbelowthelowest VTDetection Rate.\\nNOTE:Iffusion(which couldpotentially beanoisebeat)isdetected, theamplitude ofthenextpacewillbeat5.0V\\nifthetesting voltage isabove1.0V;otherwise, theamplitude ofthenextpacewillbeat2.5V.\\nFollowing initialization paces,thepulsegeneratorwilldecrement theventricular output every3pacesuntila\\nthreshold isdetermined. Additional pacing pulseswillbeissuedifthereisfusionorintermittent lossofcapture .\\nThresholdisdeclaredastheprevious output levelthatdemonstrated consistent capture.\\nIfdailytesting isunsuccessful,RVATwillreturntothepreviously determined output andthedevicewillperform upto\\n3re-attempts athourlyintervals. Ifasuccessfultestdoesnotoccurfor4days,aLeadAlertwillbetriggered andRVAT\\nwillenterSuspension.\\nRightVentricular Automatic Threshold Suspension\\nIfambulatory testing failsinAutomodefor4consecutive days,RVATwillgointoaSuspension modeandthepacing\\noutput willoperateat5.0Vand0.4ms.Testing willcontinueeachdaywithupto3re-attempts toevaluate\\nthresholds andthepulsegeneratorwilladjusttoaloweroutput setting whenindicated byasuccessfultest.\\nAlthough RVATisdesigned toworkwithawiderangeofleads,insomepatients theleadsignals mayhinder\\nsuccessfuldetermination oftheventricular threshold. Intheseinstances,RVATwillcontinually operate inthe\\nSuspension modeat5.0V.Insituations whereSuspension modepersists foranextendedperiodoftime,itis\\nrecommended toturnRVAToffbyprogramming afixedventricular output.\\nCommanded RightVentricular Automatic Threshold Measurement\\nAnautomatic threshold measur ementcanbecommanded viatheThreshold Testsscreenbyselecting AutoAmplitude\\nastheTestType.Iftesting completes successfullyandRVATisprogrammed on,theoutput willautomatically beset\\nto2Xthattest’smeasur edthreshold (between 2.0Vand5.0V).Thelast7successfuldailymeasurem entsarecleared\\nandthecurrentcommanded testresultisusedasthefirstsuccessfultestofanew7testcycle.Thisistoensure that\\ntherewillbeanimmediate output adjustment basedonthecurrentcommanded testresultratherthanonolder\\nambulator ytestdata.Thiscanbeconfirmed byobserving theoutput voltage ontheBradySettings screen,whichwill\\nshowtheactualoperatingvoltage oftheRVATalgorithm.\\nBackup pacing isdeliveredapproximately 90msaftertheprimary paceforeverylossofcapture beatduring\\ncomman dedtesting.\\nIftesting isunsuccessful,theThreshold Testsscreenwilldisplay thereasonthetestwasnotsuccessful,andthe\\noutput willreturntothepreviously setlevel(Table4–3Threshold TestFailureCodesonpage4-23).\\nNOTE:FortheinitialVentricular Threshold Testafterthepulsegeneratorisimplanted, theTestTypefieldisseeded\\ntoAuto.Choose thedesired testtypefromtheTestTypefieldoptions, andadjustanyotherprogrammable valuesas\\nappropr iate.\\nTestResultsandLeadAlerts\\nAstoredEGMforthemostrecentsuccessfulambulatory testwillbestoredintheArrhythmia Logbook (\"Arrhythmia\\nLogbook\" onpage6-2).RefertotheDailyMeasur ements screenfortheresulting threshold value.Ifdesired, the\\nstoredEGMcanbereviewedtodetermine wherelossofcapture occurred.\\nUpto12months ofAmbulator yThreshold Testresults,aswellastestfailurecodesandleadalerts,canbefound\\nwithintheDailyMeasur ementandTrendsscreens.Toprovide further information onthereasonfortestfailure, a', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 105}), Document(page_content='Pacing Therapies\\nPaceSafe4-23\\nfailurecodeisprovided foreachdayinwhichtesting fails.Additionally ,failurecodesareprovidedontheThreshold\\nTestscreenifacommanded automatic threshold testdoesnotcomplete successfully .ThresholdTestFailureCodesare\\nlistedbelow(Table4–3Threshold TestFailure Codesonpage4-23).\\nThefollowing scenarioswilltrigger theCheckRVLeadalert:\\n•Threshold >Programmed Amplitude willbedisplayed ifRVATisinDailyTrendmodeandtheambulator ytest\\nresultsofthelast4consecutive daysexceedthemanually programmed fixedoutput.\\n•Automatic ThresholdSuspension willbedisplayed ifnosuccessfultestsareperformed for4consecutive daysin\\nAutoorDailyTrendmode.\\nTable4–3.Threshold TestFailureCodes\\nCode Reason\\nN/R:devicetelem. Telemetry started during anambulatory test\\nN/R:comm. lost Telemetry waslostduring acommanded test\\nN/R:nocapture Capturewasnotobtained atthestarting amplitude foracommandedtest\\nN/R:modeswitch ATReitherstarted orstopped (testing willnotfailifATRisalready activeand\\nstaysactiveduring testing)\\nNodatacollected Minimum pacing amplitude wasreached without losingcapture, neither Auto\\nnorDailyTrendwasturned ontoobtainanambulatory testresult,lossof\\ncapture occurredat5.0V,oraninadequate number ofinitialization paces\\noccurred\\nN/R:battery low Testwasskipped duetoBattery Capacity Depleted\\nN/R:noise Toomanyconsecutivesensechannel noisecyclesoccurred\\nN/R:ratetoohigh Ratewastoohighatthestartofthetest,orduring testing\\nN/R:usercancelled Commanded testwasstopped bytheuser\\nN/R:intrinsic beats Toomanycardiaccyclesoccurredduring thetestorinitialization restartedtoo\\nmanytimes\\nN/R:testdelayed Testwasdelayed duetotelemetry beingactive,VTepisode alreadyinprogress,\\nElectrocauterymode,MRIProtection Mode,orRVATwasturned onwhilethe\\ndeviceremained inStorage mode.Codedisplayed regardlessofwhether Autoor\\nDailyTrendisturned onoroff.\\nN/R:vent.episode AVentricular Episode started during testing\\nAutoN/R Minimum pacing amplitude wasreached without losingcapture fora\\ncommandedtestortelemetry ismanually cancelledduring acommanded test\\nN/R:fusionevents Testfailedduetotoomanyconsecutive fusionbeats\\nN/R:recentshock Ventricular shocktherapy wasdeliveredlessthan60minutes priortothe\\nscheduled startofanambulatory test\\nPaceSafeLeftVentricular Automatic Threshold (LVAT)\\nPaceSafeLVATisdesigned todynamically adjusttheleftventricular pacing output toensure capture oftheleft\\nventricle usingaprogrammable SafetyMargin.LVATwillmeasur epacing thresholds from0.2Vuptothe\\nprogrammable Maximum Amplitude (7.5Vmaximum). Theoutput willbeataminimum amplitude of1.0Vuptothe\\nprogrammable Maximum Amplitude of7.5V(withaprogrammable pulsewidth).\\nNOTE:LVATisavailable inDDD(R), DDI(R), VDD(R), andVVI(R)modes, aswellasduring VDI(R)andDDI(R)Fallback\\nModes.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 106}), Document(page_content='4-24Pacing Therapies\\nPaceSafe\\nNOTE:LVATisavailable onlyontheLVapacevectorwhenLVMSPisenabled.\\nLVATisavailable inallLVpacing configurations andcanbeprogrammed onbyselecting AutofromtheLeft\\nVentricular Amplitude paramete roptions. TheMaximum Amplitude andSafetyMargin canbeprogrammed viathe\\nPacing andSensing Details button. Theprogrammable Maximum Amplitude andSafetyMargin areintended toallow\\ntheclinician tooptimiz ethesafetymarginwhilealsoavoiding diaphragmatic stimulation. Todetermine an\\nappropr iatecombinatio n,itisrecommended thattesting beperformed inmultiple LVpacing configurations.\\nIfstarting fromafixedamplitude greaterthantheprogrammable maximum, programaloweramplitude priorto\\nselecting Auto.Programming theleftventricular output toAutowillautomatically settheleftventricular voltage\\noutput totheprogrammable Maximum Amplitude unlessthereisasuccessfultestresultwithinthelast24hours.\\nNOTE:Priortoprogramming LVATon,consider performing aCommanded LeftVentricular Automatic Threshold\\nMeasur ementtoverifythatthefeature functions asexpected.\\nLVATisdesigned toworkwithtypicalleadimplant criteria andaleftventricular threshold between 0.2Vandthe\\nprogrammable Maximum Amplitude.\\nTheLVATalgorithm thenmeasur estheleftventricular pacing threshold eachdayandadjusts thevoltage output.\\nDuring testing, LVATusesanevoked response signaltoconfirmthateachleftventricular pacing output captures the\\nleftventricle. Ifthedeviceisunable torepeatedly measur eanevoked response signalofsufficient quality,an\\n“Intrinsic Beats”or“Fusion Events” message maybedisplayed andthealgorithm willdefault totheprogrammed\\nMaximum Amplitude. Consider programming afixedpacing amplitude inthesesituations andre-chec kwitha\\nCommanded LVATtestatalaterfollow-up; maturation ofthelead-tissue interface mayimprove theperformanc eof\\nLVAT.\\nIftesting issuccessful,theLeftVentricular Amplitude isadjusted byadding theprogrammable SafetyMargin tothe\\nhighest measured threshold ofthelast7successfulambulator ytests(between 1.0Vandtheprogrammable\\nMaximum Amplitude). Seventestsareusedtoaccountforcircadian cycleeffects onthreshold andensure an\\nadequate safetymargin.Thisalsoallowsforarapidincreaseinoutput duetoasudden riseinthreshold while\\nrequiring consistentlylowerthreshold measur ements todecreaseoutput (i.e.onelowthreshold measurement willnot\\ncauseadecreaseinoutput) (Figure4–10Effectofthreshold changes onLVATpacing output (withaprogrammable\\nMaximum Amplitude of5.0VandSafetyMargin of1.0V)onpage4-25).\\nNOTE:Sinceoutput issetwithaprogrammable SafetyMargin,thereisnobeat-to-beat capture verification.\\nWhenDailyTrendisselected alongwithafixedAmplitude, automatic leftventricular threshold measur ements will\\noccurevery21hourswithnochange toprogrammed output.\\nTheLVATfeature isdesigned tooperatewithalargerangeofpacing leads(e.g.,highimpedance ,lowimpedance).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 107}), Document(page_content='Pacing Therapies\\nPaceSafe4-25\\n6.0\\n5.0\\n4.0\\n3.0\\n2.0\\n1.0\\n0.0\\nV\\na\\nl\\nu\\ne\\n \\n(\\nV\\n)\\nDay\\n5 10 15 20 25\\n70 30 35 40 4\\n5 50 55 60 65\\nThreshold\\nPace Output\\nOne high threshold causes an \\nimmediate rise in pacing output\\nOne low threshold does not \\nchange the pacing outputLead alert triggered on \\n4th day of failed testing\\nFigure4–10.Effectofthreshold changesonLVATpacingoutput(withaprogrammable Maximum Amplitude of5.0VandSafetyMarginof1.0V)\\nAmbulatory LeftVentricular Automatic Threshold Measurement\\nWhenLVATissettoAutoorDailyTrend,ambulator yleftventricular automatic threshold measur ements are\\nconducted every21hours.\\nInatrialtrackingmodes, theautomatic threshold measur ementadjusts thefollowing parameters tohelpensure a\\nvalidmeasurement isobtained:\\n•PacedAVDelayisfixedat140ms.\\n•Sensed AVDelayisfixedat110ms.\\n•RVpacing isprovided asbackupthroughout LVtesting withanapplied LVOffsetof-80ms.\\n•Starting leftventricular pacing output amplitude istheprogrammable Maximum Amplitude.\\n•Thepacing amplitude willdecrement in0.5Vstepsabove3.5Vandin0.1Vstepsatorbelow3.5V.\\nInnontrac kingmodes, theautomatic threshold measurement adjusts thefollowing parameters tohelpensure avalid\\nmeasur ementisobtained:\\n•PacedAVDelayisfixedat140ms.\\n•RVpacing isprovided asbackupthroughout LVtesting withanapplied LVOffsetof-80ms.\\n•Starting leftventricular pacing output amplitude istheprogrammable Maximum Amplitude.\\n•Thepacing amplitude willdecrement in0.5Vstepsabove3.5Vandin0.1Vstepsatorbelow3.5V.\\n•Theventricular pacing ratewillbeincreasedby10ppmabovethecurrentrate(paced orintrinsic) andiscapped\\natthelowest oftheMPR,MSR,110bpm,or5bpmbelowthelowest VTDetection Rate.\\nFollowing initialization paces,thepulsegenerator willdecrementtheleftventricular output every3pacesuntila\\nthreshold isdetermined. Additional pacing pulseswillbeissuedifthereisfusionorintermittent lossofcapture.\\nThreshold isdeclaredasthepreviousoutput levelthatdemonstrated consistentcapture.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 108}), Document(page_content='4-26Pacing Therapies\\nPaceSafe\\nIfdailytesting isunsuccessful,LVATwillreturntothepreviouslydetermined output andthedevicewillperform upto\\n3re-attempts athourlyintervals. Ifasuccessfultestdoesnotoccurfor4days,aLeadAlertwillbetriggered andLVAT\\nwillenterSuspension.\\nLeftVentricular Automatic Threshold Suspension\\nIfambulatory testing failsinAutomodefor4consecutive days,LVATwillgointoaSuspension modeandthepacing\\noutput willoperateattheprogrammable pulsewidthandMaximum Amplitude. Testing willcontinue eachdaywith\\nupto3re-attempts toevaluate thresholds andthepulsegeneratorwilladjusttoaloweroutput setting when\\nindicated byasuccessfultest.\\nAlthough LVATisdesigned toworkwithawiderangeofleads,insomepatients theleadsignals mayhinder\\nsuccessfuldetermination oftheleftventricular threshold. Intheseinstances,LVATwillcontinually operate inthe\\nSuspension modeattheprogrammable Maximum Amplitude. Insituations whereSuspension modepersists foran\\nextended periodoftime,itisrecommended toturnLVAToffbyprogramming afixedleftventricular output.\\nCommanded LeftVentricular Automatic Threshold Measurement\\nAnautomatic threshold measur ementcanbecommanded viatheThreshold Testsscreenbyselecting AutoAmplitude\\nastheTestType.Iftesting completes successfullyinthecurrently programmed pacing leadconfigur ationandLVATis\\nprogrammed on,theoutput willautomatically besetbyadding theprogrammable SafetyMargintothattest’s\\nmeasur edthreshold (between 1.0Vandtheprogrammable Maximum Amplitude). Thelast7successfuldaily\\nmeasur ements arecleared andthecurrentcommanded testresultisusedasthefirstsuccessful testofanew7test\\ncycle(ifthetestisperformed inthecurrentlyprogrammed pacing leadconfiguration). Thisistoensure thattherewill\\nbeanimmediate output adjustment basedonthecurrentcommanded testresultratherthanonolderambulator y\\ntestdata.Thiscanbeconfirmed byobservin gtheoutput voltage ontheBradySettings screen,whichwillshowthe\\nactualoperatingvoltage oftheLVATalgorithm.\\nRVpacing isprovidedasbackup throughout LVtesting withanapplied LVOffsetof-80ms.\\nIftesting isunsuccessful,theThreshold Testsscreenwilldisplay thereasonthetestwasnotsuccessful,andthe\\noutput willreturntothepreviously setlevel(Table4–4Threshold TestFailureCodesonpage4-27).\\nNOTE:Whenaccessed fromtheLeadTestsscreen, theinitialLeftVentricular Threshold TestTypefieldisseeded to\\nAutoafterimplant. Choose thedesired testtypefromtheTestTypefieldoptions, andadjustanyotherprogrammable\\nvaluesasappropr iate.\\nTestResultsandLeadAlerts\\nAstoredEGMforthemostrecentsuccessfulambulatory testwillbestoredintheArrhythmia Logbook (\"Arrhythmia\\nLogbook\" onpage6-2).RefertotheDailyMeasur ements screenfortheresulting threshold value.Ifdesired, the\\nstoredEGMcanbereviewedtodetermine wherelossofcapture occurred.\\nUpto12months ofAmbulator yThreshold Testresults,aswellastestfailurecodesandleadalerts,canbefound\\nwithintheDailyMeasur ementandTrendsscreens.Toprovide further information onthereasonfortestfailure, a\\nfailurecodeisprovidedforeachdayinwhichtesting fails.Additionally ,failurecodesareprovided ontheThreshold\\nTestscreenifacomman dedautomatic threshold testdoesnotcomplete successfully.Threshold TestFailure Codesare\\nlistedbelow(Table4–4ThresholdTestFailureCodesonpage4-27).\\nThefollowing scenarios willtrigger theCheckLVLeadalert:\\n•Threshold >Programmed Amplitude willbedisplayed ifLVATisinDailyTrendmodeandtheambulatory test\\nresultsofthelast4consecutive daysexceedthemanually programmed fixedoutput.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 109}), Document(page_content='Pacing Therapies\\nPaceSafe4-27\\n•Automatic ThresholdSuspension willbedisplayed ifnosuccessfultestsareperformed for4consecutive daysin\\nAutoorDailyTrendmode.\\nTable4–4.Threshold TestFailureCodes\\nCode Reason\\nN/R:devicetelem. Telemetry started during anambulatory test\\nN/R:comm. lost Telemetry waslostduring acommanded test\\nN/R:nocapture Capturewasnotobtained atthestarting amplitude\\nN/R:modeswitch ATReitherstarted orstopped (testing willnotfailifATRisalready activeand\\nstaysactiveduring testing)\\nNodatacollected Minimum pacing amplitude wasreached without losingcapture, neither Auto\\nnorDailyTrendisturned ontoobtainanambulatory testresult,oran\\ninadequate number ofinitialization pacesoccurred\\nN/R:battery low Testwasskipped duetoBattery Capacity Depleted\\nN/R:noise Toomanyconsecutivesensechannel noisecyclesoccurred\\nN/R:ratetoohigh Ratewastoohighatthestartofthetest,orduring testing\\nN/R:usercancelled Commanded testwasstopped bytheuser\\nN/R:intrinsic beats Toomanycardiaccyclesoccurredduring thetestorinitialization restartedtoo\\nmanytimes\\nN/R:testdelayed Testwasdelayed duetotelemetry beingactive,VTepisode alreadyinprogress,\\nElectrocauterymode,MRIProtection Mode,orLVATwasturned onwhilethe\\ndeviceremained inStorage mode.Codedisplayed regardlessofwhether Autoor\\nDailyTrendisturned onoroff.\\nN/R:vent.episode AVentricular Episode started during testing\\nAutoN/R Minimum pacing amplitude wasreached without losingcapture fora\\ncommandedtestortelemetry ismanually cancelledduring acommanded test\\nN/R:fusionevents Testfailedduetotoomanyconsecutive fusionbeats\\nN/R:recentshock Ventricular shocktherapy wasdeliveredlessthan60minutes priortothe\\nscheduled startofanambulatory test\\nSensitivity\\nTheSensitivity feature allowsthepulsegeneratortodetectintrinsic cardiacsignals thatexceedtheprogrammed\\nsensitivity value.Adjusting theSensitivity valueallowsyoutoshifttheatrialand/or ventricular sensing rangeto\\nhigherorlowersensitivity .Alldetection andtimingdecisions arebasedonthesensed cardiac signals. Atrialand\\nventricular Sensitivity valuesareindependently programmable.\\n•HighSensitivity (lowprogrammed value)—when Sensitivity isprogrammed toaverysensitive setting, thepulse\\ngeneratormaydetectsignals unrelatedtocardiacdepolarization (oversensing, suchassensing ofmyopotentials)\\n•LowSensitivity (highprogrammed value)—when Sensitivity isprogrammed toalesssensitive setting, thepulse\\ngeneratormaynotdetectthecardiac depolarization signal(undersensing)\\nItisrecommended thattheSensitivity parametersettings beleftatthenominal valuesunlesstroubleshooting\\ndetermines thatanother valuemaybemoreappropr iate.Whilethenominal valueisprimarily indicated forbothatrial\\nandventricular sensing, anadjustment canbemadeif,inararesituation, atrialorventricular oversensing/\\nundersensing hasbeenobserved (e.g.,inhibition ofbradycar diapacing orinappropriate therapy)', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 110}), Document(page_content='4-28Pacing Therapies\\nPaceSafe\\nWARNING: Leftventricular leaddislodgement toaposition neartheatriacanresultinatrialoversensing andleft\\nventricular pacing inhibition.\\nShould itbecome necessarytoadjusttheSensitivity parameterinachamber ,always choose thesetting thatprovides\\nappropr iatesensing ofintrinsic activity andbestresolves oversensing/undersensing.\\nIfpropersensing cannot berestored withanadjustment orifanyundersensing oroversensing isobserved after\\nmaking achange, consider anyofthefollowing (taking intoaccountindividual patient characteristic s):\\n•Reprogr amtheAGCsensitivity value\\n•Reprogr amtheRefractoryorcross-chamber blanking periodappropriat elytoaddress theobserved undersensing\\noroversensing\\n•Reposition thelead\\n•Implant anewsensing lead\\nAfteranychange toSensitivity, evaluate thepulsegeneratorforappropriat esensing andpacing.\\nCAUTION: Following anysensing rangeadjustment oranymodification ofthesensing lead,always verify\\nappropr iatesensing. Programming Sensitivity tothehighest value(lowest sensitivity) mayresultindelayed detection\\norundersensing ofcardiacactivity.Likewise,programming tothelowest value(highest sensitivity) mayresultin\\noversensing ofnon-cardiac signals.\\nAutomatic GainControl\\nThepulsegenerator usesdigitalAutomatic GainControl (AGC)todynamically adjustthesensitivity inboththeatrium\\nandtheventricle. Thepulsegeneratorhasindependent AGCcircuits foreachchamber .\\nCardiac signals canvarywidely insizeandrate;therefo rethepulsegeneratorneedstheabilityto:\\n•Senseanintrinsic beat,regardless ofrateorsize\\n•Adjusttosensevaryingamplitude signals, butnotoverreacttoaberrant beats\\n•Senseanyintrinsic activity afterapacedbeat\\n•IgnoreT-waves\\n•Ignorenoise\\nTheprogrammable AGCvalueistheminimum sensitivity value(floor)thatcouldbereached between onebeatand\\nthenextbeat.Thisprogrammable valueisnotafixedvaluepresent throughout thecardiaccycle;rather,the\\nsensitivity levelbegins atahigher value(based onthepeakofasensed eventorafixedvalueforapacedevent)and\\ndecrements towardstheprogrammed floor(Figure 4–11AGCsensing onpage4-30).\\nAGCwilltypically reachtheprogrammable floorduring pacing (orwithlowamplitude signals). Butwhenmoderateor\\nhighamplitude signals aresensed, AGCwilltypically belesssensitive andnotreachtheprogrammable floor.\\nTheAGCcircuitineachrespective chamber processesanelectrogram signalviaatwostepprocesstooptimiz e\\nsensing ofpotentially rapidly changing cardiac signals. Theprocessisillustratedinthefigurebelow(Figure4–11AGC\\nsensing onpage4-30):\\n•Firststep\\n1.AGCusesarollingaverageofprevioussignalpeakstocalculate asearchareawherethenextpeakwill\\nlikelyoccur.\\n–Iftheprevious beatissensed, itisincorpor atedintotherollingpeakaverage.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 111}), Document(page_content='Pacing Therapies\\nPaceSafe4-29\\n–Ifthepreviousbeatispaced,thepeakaverageiscalculated usingtherollingaverage andapaced\\npeakvalue.Thepacedpeakvaluedepends onthesettings:\\n–Fornominal ormoresensitive settings, itisafixedvalue(initialvalue4.8mVintheRV,8mV\\nintheLV,2.4mVintheRA).\\n–Forlesssensitive settings, itisahigher valuecalculated usingtheprogrammed AGCfloor\\nvalue(forexample, ifRVsensitivity isprogrammed totheleastsensitive setting orthehighest\\nvalueof1.5mV,thepacedpeakvalue=12mV).\\nThepeakaverageisthenusedtobound anareawithMAX(maximum) andMIN(minimum) limits.\\n•Secondstep\\n2.AGCsenses thepeakoftheintrinsic beat(orusesthecalculated peakforapacedbeatasdescribed above)\\n3.Itholdsthesensitivity levelatthepeak(orMAX)throughtheabsolute refractory period+15ms.\\n4.Itdropsto75%ofthesensed peakorcalculated peakaverageforpacedevents (ventricular pacedevents\\nonly).\\n5.AGCbecomes moresensitive by7/8ofthepreviousstep.\\n6.Sensed beatstepsare35msfortheRVandLVand25msfortheatrium. Pacedbeatstepsareadjusted\\nbasedonthepacing intervaltoensure anapproximately 50mssensing window attheMINlevel.\\n7.ItreachestheMIN(orprogrammed AGCFloor).\\n–Theprogrammed AGCFloorwillnotbereachediftheMINvalueishigher.\\n8.TheAGCremainsattheMIN(orprogrammed AGCfloor)untilanewbeatissensed, orthepacing interval\\ntimesoutandapaceisdelivered.\\nNOTE:Ifanewbeatissensed asthesensitivity levelstepsdown,AGCstartsoveratStep1.\\nNOTE:Iftheamplitude ofasignalisbelowthesensitivity threshold ineffectatthetimethesignaloccurs,\\nitwillnotbesensed.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 112}), Document(page_content='4-30Pacing Therapies\\nPost-Therapy Pacing\\nSensed Ev ent Programme\\nd AGC \\nfloor val\\nue\\nMIN\\nMAX\\nPeak\\nAbsolute \\nsensing \\nlimit (32\\n mV)\\nFigure4–11.AGCsensing\\nAnonprogrammable Dynamic NoiseAlgorithm isactiveinratechannels whereAGCsensing isused.TheDynamic\\nNoiseAlgorithm isintended tohelpfilteroutpersistent noise.TheDynamic NoiseAlgorithm isaseparat enoise\\nchannel foreachchamber thatcontinuously measures thebaseline signalthatispresent andisdesigned toadjust\\nthesensitivity floortominimiz etheeffects ofnoise.\\nThealgorithm usesthecharacteristics ofasignal(frequency andenergy)toclassify itasnoise.Whenpersistent noise\\nispresent,thealgorithm isdesigned tominimize itsimpact, whichmayhelptopreventoversensing myopotentials\\nandtheassociated inhibition ofpacing. Noisethataffects thesensing floormaybevisibleontheintracar diacEGMs,\\nbutwouldnotbemarked assensed beats.However ,ifthenoiseissignificant, thefloormayrisetoalevelabovethe\\nintrinsic electrogramandtheprogrammed NoiseResponse behavior (asynchronous pacing orInhibitPacing) willoccur\\n(\"Noise Response\" onpage4-87).\\nNOTE:TheDynamic NoiseAlgorithm doesnotensure thatAGCwillalways accurately distinguish intrinsic activity\\nfromnoise.\\nPOST-THERAPY PACING\\nPost-therap ypacing providesalternate pacing therapyfollowing thedelivery ofanyshock.\\nThepacing modeandpacing therapiesusedfollowing ashockarethesameastheprogrammed Normal pacing\\nsettings.\\nThefollowing pacing parameters canbeprogrammed independently fromtheNormal pacing settings:\\n•Pacing Paramete rs—LRL, Amplitude, andPulseWidth\\n•PostTherapyPeriod', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 113}), Document(page_content='Pacing Therapies\\nPost-Therapy Pacing4-31\\nPost-ShockPacingDelay\\nThePost-Shock Pacing Delaydetermines theearliest possible startofpost-shock pacing following thedelivery ofa\\nventricular shockandisfixedat2.25seconds.\\nThetimingoftheinitialpacing pulseinthePostTherapy Perioddepends onthecardiac activity during thePost-\\nShockPacing Delay.\\n•IfR-waves (and/or P-waves fordual-chamber pacing modes) aresensed during thePost-Shock Pacing Delay,the\\ndevicepacesonlywhenthesensed rateisslower thanthepost-therap yLRL.\\n•IfnoR-waves (and/or P-waves fordual-chamber pacing modes) aresensed during thePost-Shock Pacing Delay\\noriftheintervalsincetheprecedingP-orR-wave wasgreaterthantheescape interval,apacing pulseis\\ndeliveredattheendofthePost-Shock Pacing Delay.\\nSubsequent pacing pulsesaredeliveredasrequired, depending onthepacing prescription.\\nPost-Therapy Period\\nThePostTherapyPerioddetermines howlongthepulsegeneratoroperatesusingthepost-therap yparamet ervalues.\\nThePostTherapyPeriodfunctions asfollows:\\n•TheperiodstartswhenthePost-Shock Pacing Delayexpires\\n•Oncompletio nofthispacing period, thepulsegeneratorrevertstotheprogrammed Normal pacing values\\n•Whileinprocess,thepacing periodisnotaffected bytheendofthecurrentepisode\\nTEMPORAR YBRADYPACING\\nThepulsegeneratorcanbeprogrammed withtempora rypacing parameter valuesthatdifferfromtheprogrammed\\nNormal Settings. Thisallowsyoutoexaminealternate pacing therapieswhilemaintaining thepreviously programmed\\nNormal Settings inthepulsegenerator memory .During theTempor aryfunction, allotherbradycardiafeatures not\\nlistedonthescreenaredisabled.\\nNOTE:Post-therap yvaluesarenotaffected.\\nTousethisfunction, followthesesteps:\\n1.FromtheTeststab,selecttheTempBradytabtodisplay thetemporary parameters.\\nNOTE:Post-therap yvaluesarenotshown evenifpost-therap yispresentlyineffect.\\n2.Selectthedesired values; thesevaluesareindependent fromotherpacing functions.\\nNOTE:Temporary Bradyinteractivelimitsmustbecorrected beforeTempor arypacing canoccur.\\nNOTE:IfOffisselected astheTemporary BradyMode,thepulsegeneratorwillnotsenseorpacewhile\\nTempor arypacing modeisineffect.\\n3.Establish telemetr ycommunication, thenselecttheStartbutton. Pacing begins atthetemporary values. Adialog\\nboxindicates thattempor aryparamet ersarebeingused,andaStopbutton isprovided.\\nNOTE:Tempora rypacing cannot bestarted whileatachyarrhythmia episode isinprogress.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 114}), Document(page_content='4-32Pacing Therapies\\nMinuteVentilation /Respiratory SensorandSignalArtifactMonitor\\nNOTE:Emergency therapyistheonlyfunction thatcanbeinitiated untiltheTemporary function isstopped.\\n4.TostoptheTemporary pacing mode,selecttheStopbutton. TheTemporary pacing modealsostopswhenyou\\ncommand emergencytherapyfromthePRM,whenyouselectDIVERT THERAPY, oriftelemetry islost.\\nOnceTemporary pacing modeisstopped, pacing revertstothepreviously programmed Normal/Post -Therapy\\nsettings.\\nMINUTEVENTILATION /RESPIRATOR YSENSORANDSIGNALARTIFACT MONITOR\\nMinuteVentilation/Respirator ySensor(MV/Respiratory Sensor)\\nThePGusestheMinute Ventilation (MV)/Respirato rySensor tomeasur etransthorac icimpedance. Theresulting\\ntransthoracic impedance measur ements areusedfortwopurposes:\\n•Tocollectrespiration -related dataforuseingeneratingtrends,suchastheRespiratory Ratetrend.\\n•Tomeasur eminute ventilation (MV),theproductofrespiration rateandtidalvolume. MVcanbeusedtoincrease\\nthepacing ratetomeetthepatient’s corresponding physiologic need.RefertoMinute Ventilation (\"Minute\\nVentilation \"onpage4-44)formoreinformation.\\nWhentheMV/Respiratory Sensor isprogrammed toOnorPassive (MV),approximately every50ms(20Hz),the\\ndevicewilldeliver asubthreshold excitation currentwaveform between theRARingelectrode orRVCoilandCan(the\\nMV/Respir atorySensor signal). Theapplication ofcurrentbetween theRARingelectrode orRVCoilandtheCanwill\\ncreateanelectrical fieldacrossthethorax, modulated byrespiration.During inspiratio nthetransthor acicimpedance is\\nhigh,andduring expirationitislow.Thedevicemeasur estheresultingvoltage modulations between theleadtip\\nelectrodeandtheCan.\\nNOTE:IfanRAleadisnotused,onlytheRVvectorisavailable.\\nNOTE:Leadsmaybeprogrammed toUnipolar orBipolar,butafunctioning bipolar leadmustbepresent.\\nirepresents excitation output (current), Vrepresents measurement ofresulting voltage (volts)\\nFigure4–12.Measurement oftransthoracic impedance usingtheRVlead\\nWhentheRA/RV leadsandleadterminal connections areoperating asintended, theMV/Respir atorySensor signalis\\nappropr iatelyfilteredandtherefo reisnotdetected bythedeviceordisplayed onelectrogr ams(EGMs). However ,\\nintermittency relatedtointegrity oftheleadordevice-leadconnection hasthepotential tocreateatransient high\\nimpedance condition. Ahighimpedance conditionmayresultintheMV/Respir atorySensor signalbecomingvisible\\nonEGMsandpotentially subject tooversensing ontheRAand/or RVchannels.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 115}), Document(page_content='Pacing Therapies\\nMinuteVentilation /Respiratory SensorandSignalArtifactMonitor4-33\\nTheMV/Respir atorySensor providestwomechanisms formeasuring theintegrity ofthesensor vectors:\\n•WhentheSignalArtifact Monitor (SAM)devicediagnostic isprogrammed toOn,theSAMcontinually monitors the\\nEGMforsensor artifacts. Fordetails, see\"DeviceBehavior whenSAMisOn\"onpage4-35.\\n•WhentheSAMisprogrammed toOff,thedeviceperforms MV/Respir atorySensor vectorimpedance\\nmeasur ements approximately everyhourtoassessleadandleadconnection integrity .Fordetails, see\"Device\\nBehavior whenSAMisOff\"onpage4-36.\\nCAUTION: Formaximum sensitivity indetecting andpreventing potential signalartifact-generated oversensing, itis\\nrecommen dedthattheSignalArtifact Monitor (SAM)isprogrammed OnanytimetheMV/Respir atorySensor is\\nprogrammed toOnorPassive. Turning theSignalArtifact Monitor Offmayputthepatient atincreasedriskof\\noversensing, unlesstheMV/Respir atorySensor isalsoprogrammed Off.\\nMV/Respiratory SensorProgrammable Parameters\\nThefollowing paramet ersfortheMV/Respir atorySensor areprogrammable.\\nFordeviceswhereMVrateresponsive pacing isavailable, theMVSensor canbeprogrammed toOn,Passive, Off,or\\nATROnly:\\n•On:enables RightRate pacing andrespiration-relat edtrending. Ifthedeviceisprogrammed toanon-rate\\nadaptive mode,theOnsetting isnotavailable.\\n•Passive: enables respiration-r elatedtrending only.\\n•ATROnly:enables rateresponsive pacing onlyduring ATRFallback. Ifthepulsegenerator ispermanently\\nprogrammed toanon-rateadaptive mode,butarateadaptive ATRFallback modeisselected, theMVfieldwill\\ndisplay ATROnly.\\n•Off:norate-responsive pacing orrespiration -related trending isavailable.\\nExcitation Currentcontrolstheamplitude oftheMV/Respir atorySensor signalandcanbesetto80uAor320uA.\\nVectorSelection controls howtheactiveMV/Respir atorySensor vectorisdetermined bythedevice, andcanbesetto:\\n•AOnly:theMV/Respir atorySensor isrestricted toRAvectors.\\n•RVOnly:theMV/Respiratory Sensor isrestrictedtoRVvectors.\\n•AutoSelect: eitherAorRVwillbeautomatically determined bythedevice.Thevectorselection behavior when\\nsettoAutoSelectdepends onwhether theSignalArtifact Monitor isOnorOff.RefertoSAMDeviceDiagnostic\\n(\"Signal Artifact Monitor DeviceDiagnostic\" onpage4-35)formoredetails.\\nNOTE:WhentheSAMisON,itmonitors boththeRAandtheRVEGMforsignalartifacts, regardless ofhowVector\\nSelection isprogrammed. VectorSelection onlydetermines whichvectorisusedtomeasur etheMV/Respir atory\\nSensor signal.\\nCAUTION: ProgramtheMV/Respir atorySensor toOffduring mechanical ventilation. Otherwise,thefollowing may\\noccur:\\n•Inappropriate MVSensor-driven rate\\n•Misleading respiration-based trending', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 116}), Document(page_content='4-34Pacing Therapies\\nMinuteVentilation /Respiratory SensorandSignalArtifactMonitor\\nCAUTION: Anymedical equipment, treatment, therapy ,ordiagnostic testthatintroduc eselectrical currentintothe\\npatient hasthepotential tointerfer ewithpulsegeneratorfunction.\\n•External patient monitors (e.g.,respiratory monitors, surfaceECGmonitors, hemodynamic monitors) maycause:\\n–Inappropriate MVSensor-driven rate(uptomaximum sensor-driven rate)\\n–Misleading respiration-based trending\\nToresolvesuspected interactions withRespirato rySensor-based diagnostics, deactivate thepulsegenerator\\'s\\nRespiratory Sensor byprogramming ittoOff.\\nMV/Respiratory SensorStatus\\nTheMV/Respir atorySensor initiates calibrationwheninitially activated afterdeviceimplant andaftersensor\\nsuspension duetonoiseorotherconditions. Refertoadditional information aboutcalibration in\"Minute Ventilation \"\\nonpage4-44.Thestatusofthesensor isindicated bytheappropr iateMV/Respir atorySensor statusmessage, as\\nsummarized inMV/Respir atorySensor StatusMessages (Table4–5MV/Respir atorySensor StatusMessages onpage\\n4-34).Sensor statusisreported ontheMinute Ventilation Sensor Details screen(devices withMVrateresponsive\\npacing (Figure4–13Minute Ventilation Sensor Details onpage4-35))orRespiratory Sensor Details screen(devices\\nwithout MVrateresponsive pacing).\\nIfaVentricular Tachyepisode isdeclared(8outof10fastbeats), thesensor willbesuspended forthedurationofthe\\nepisode. Oncetheepisode hasended, MVdrivenpacing willresumeunlessanautomatic 6-hour calibrat ionoccurs\\nduetoalongepisode oroutofrangeleadimpedances (testperformed atendofepisode).\\nTable4–5.MV/Respiratory SensorStatusMessages\\nSensorStatus MVSensorDrivenPacing MV/Respiratory SensorDataCollection for\\nTrendinga\\nOff No No\\nInitializing No No\\nAutoCalibration inProgress No Yes\\nCalibrated YesbYes\\nSuspended No No\\nSuspended: NoValidLead No No\\nSuspended: NoiseDetected No Yes\\nSuspended: Telemetry NocYes\\nSuspended: TachyEpisode No No\\nDisabled bydevicediagnostic No No\\nRateHold:Telemetry NocdeYes\\nManual Calibrati oninProgress NoeYes\\na.Individual Trends determine ifdatacollectedduring Suspension isvalidandincorpora tedintoTrendresults.\\nb.IftheMV/Respiratory Sensor isprogrammed toPassive, MV/Respir atorySensor-driven pacing willnotoccur.\\nc.Inductive (wanded) telemetry mayinterfere withthedevice\\'s MV/Respiratory sensor function. MVdrivenpacing ratesmayholdatthecurrent rateandRespiratory\\nRateTrenddatacollection issuspended forapproximately oneminute immediately following anyinterrogation orprogramming command (RateHold).Longer\\ndelays(uptoseveral minutes) willbeindicated byastatusofSuspended: Telemetry .IfMVdrivenratechanges aredesired priortotherateholdorsuspension\\nperiods, allowtheMVdrivenratetoreachthedesired ratepriortousinginductive telemetry ,oruseRFtelemetry tocommunicate withthedevice.\\nd.Ratewillholdatthecurrent MVindicated valueforuptooneminute; further MVbasedratechanges willnotoccurwiththissensor status.\\ne.Statusapplies toMVrateresponsive pacing devices only.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 117}), Document(page_content='Pacing Therapies\\nMinuteVentilation /Respiratory SensorandSignalArtifactMonitor4-35\\nSignalArtifactMonitorDeviceDiagnostic\\nTheSignalArtifact Monitor (SAM)isadevicediagnostic thatmonitors theEGMforMV/Respir atorySensor signal\\nartifacts andmeasur esMV/Respir atorySensor vectorleadimpedance values. Ifartifacts aredetected oraMV/\\nRespirat orySensor vectorleadimpedance valueisoutofrange,SAMeitherswitches theMV/Respir atorySensor\\nvector,ordisables thesensor (Figure4–13Minute Ventilation Sensor Details onpage4-35).Inaddition, anepisode is\\ncreatedthatincludes EGMsanddiagnostic leadimpedance data.\\nTheSAMisnominally OnwhenMV/Respir atorySensor isprogrammed toOnorPassive (MV).Signalartifacts canbe\\ngeneratedwhentheMV/Respir atorySensor issettoanyvalueexceptOff.Therefor e,itisrecommended tokeepSAM\\nOnunlesstheMV/Respir atorySensor isprogrammed toOff.Recommended SAMSettings arelistedbelow(Table4–6\\nRecommended SignalArtifact Monitor (SAM)Settings onpage4-35).\\nCAUTION: Turning theSignalArtifact Monitor Offmayputthepatient atincreasedriskofoversensing, unlessthe\\nMV/Respir atorySensor isalsoprogrammed toOff.\\nTable4–6.Recommended SignalArtifactMonitor(SAM)Settings\\nMVSensorSetting Possibletogenerate SignalArtifact Recommend edSAMSetting\\nOn Yes On\\nPassive Yes On\\nATROnly Yes On\\nOff No N/A\\nRespiratory SensorSetting Possibletogenerate SignalArtifact Recommend edSAMSetting\\nOn Yes On\\nOff No N/A\\nFigure4–13.MinuteVentilation SensorDetails\\nDeviceBehavior whenSAMisOn\\nTheSAMcontinuously monitors theEGMforMV/Respir atorySensor signalartifacts thatmayresultinoversensing. At\\nthetimeofartifact detection, impedance valuesfortheMV/Respir atorySensor vectors aremeasur ed,andpacedlead\\nimpedanc esarealsomeasur ed.ASAMepisode iscreatedthatrecordstheEGMwithartifact andallassociated vector\\nandleadimpedance values.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 118}), Document(page_content='4-36Pacing Therapies\\nMinuteVentilation /Respiratory SensorandSignalArtifactMonitor\\nDepending onthesetting oftheMV/Respir atorySensor VectorSelection parameter,twooutcome sarepossible (as\\ndescribed inTable4–7ResultofEGMartifact detection bySAMonpage4-36):\\n•Theactivesensor vectors switchfromAtoV,or\\n•Thesensor isdisabled bySAM.\\nNOTE:TheSAMisaninterval basedalgorithm, therefor e,thealgorithm mayidentify othersignals (including atrial\\narrhythmias) asMV/Respir atorySensor signalartifacts, iftheymeetthealgorithm’s criteria.\\nNOTE:Impedance measur ements recordedbySAMareindependent ofdailyleadimpedance measur ements. They\\ndonotappear onthedailyleadimpedance trendgraphsandwillnottrigger LeadSafetySwitch.\\nTable4–7.ResultofEGMartifactdetection bySAM\\nIfMV/Respiratory SensorVectorSelection\\nissettoAndtheactivevector\\nwasDeviceresponse toEGMartifactbeingdetected\\nAutoSelect ASAMepisode created\\nMeasure MV/Respiratory Sensor RVvector’s impedance values:\\n•Ifinrange: Switch theactivesensor vectortoRVab\\n•Ifoutofrange: second SAMepisode createdandMV/\\nRespirato rySensor isDisabled\\nAutoSelect RV\\nSAMepisodecreatedandMV/Respiratory SensorDisabled AOnly A\\nRVOnly RV\\na.IfaMV/Respiratory Sensor vectorswitchoccurs, anautomatic 6-hour calibration willoccur(noMVrateresponsive pacing occursduring the6-hour calibration\\nperiod).\\nb.AcceptableMV/Respiratory Sensor vectorimpedanc evaluesare100-1500 ΩfortheringtoCanvector,200-2000 ΩforthetiptoCanvector,and20–200 Ωforthe\\ncoiltocanvector.Thesevaluesarenotaffected byimpedance alertlimitsprogrammed forDailyleadimpedanc emeasurements.\\nDuring aprogrammer session, activemonitoring forartifacts isnotperformed. However ,programming theMV/\\nRespiratory Sensor settings maytrigger asensor vectorimpedance measurement. Iftheresulting MV/Respir atory\\nSensor vectorimpedance isoutofrange,aSAMepisode iscreated,andthesensor vectormaybeswitched orthe\\nsensor maybedisabled depending onvectorselection settings.\\nAdisabled MV/Respir atorySensor willremain inthatstateuntilmanually reprogrammed fromtheMVSensor Details\\nscreen(Figure4–13Minute Ventilation Sensor Details onpage4-35).NoMVrate-responsive pacing andno\\nrespiratory-related trendingwilloccurwhilethesensor isdisabled.\\nDeviceBehavior whenSAMisOff\\nIfSAMisprogrammed toOff,MV/Respir atorySensor vectorimpedance measurements areperformed hourly(Table\\n4–8Deviceresponsetoout-of-rang eimpedance valuefoundduring hourlyleadcheckonpage4-37).Whenthe\\nVectorSelection paramet erissettoAutoSelect, ifthemeasur edimpedance forthecurrentlyutilized vector(for\\nexample, RA)isoutofrange,theimpedance forthealternate vector(forexample, RV)isevaluated todetermine if\\nthatvectorcanbeutilized. Ifthemeasur edimpedance forthealternate vectorisinrange,thenthealternate vector\\nbecomes theactivevector.Ifbothvectors areoutofrange,thesensor issuspended foronehour.Leadintegrity will\\ncontinuetobetestedeveryhourtoevaluate iftheMV/Respiratory Sensor canresumeusingoneofthevectors or\\nremainsuspended. IfaMV/Respiratory Sensor vectorswitchoccurs,anautomatic 6-hour calibrationwilloccur(noMV\\nrateresponsivepacing occursduring the6-hour calibrationperiod).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 119}), Document(page_content='Pacing Therapies\\nMinuteVentilation /Respiratory SensorandSignalArtifactMonitor4-37\\nTable4–8.Deviceresponse toout-of-range impedance valuefoundduringhourlyleadcheck\\nIfMV/Respiratory SensorVectorSelection\\nissettoAndtheactivevector\\nisThenthedeviceresponse toanout-of-range impedance is\\nAutoSelect AorRV Switch tothealternate vectorifalternate vectorimpedance isin\\nrangea\\nIfthealternate vectorimpedance isoutofrange,theMV/\\nRespiratory Sensor issuspended, re-test afteronehour\\nAOnly A\\nMV/Respiratory Sensor suspended, re-testafteronehour\\nRVOnly RV\\na.IfaMV/Respiratory Sensor vectorswitchoccurs, anautomatic 6-hour calibration willoccur(noMVrateresponsive pacing occursduring the6-hour calibration\\nperiod).\\nUnlikewhenSAMisprogrammed toOn,nomonitoring forEGMartifacts occursandnoSAMepisodes arecreated.\\nSignalArtifactMonitorEpisodes\\nSAMepisode details arerecordedintheArrhythmia Logbook (\"Arrhythmia Logbook\" onpage6-2).ToviewSAM\\nepisode details, selectthedesired episode ontheArrhythmia Logbook screen. TheEventSummary screendisplays\\ndetails abouttheSAMepisode (Figure4–14SignalArtifact Monitor Episode Summar yonpage4-37).\\nTheSummary tabprovidesalinktothescreenwheresensor details arefound(thebutton willbelabeled ‘MVSensor\\nDetails’ or‘Respirato rySensor Details’, depending onthedevicemodelandavailability ofMVrateresponsive pacing).\\nThescreendisplays programming options fortheMV/Respiratory Sensor andSAM(Figure4–13Minute Ventilation\\nSensor Details onpage4-35).RefertoMV/Respir atorySensor Programmable Paramete rs(\"MV/Respir atorySensor\\nProgrammable Paramete rs\"onpage4-33)formoreinformation onprogramming options.\\nFigure4–14.SignalArtifactMonitorEpisodeSummary', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 120}), Document(page_content='4-38Pacing Therapies\\nMinuteVentilation /Respiratory SensorandSignalArtifactMonitor\\nTwotypesofSAMepisodes canbegenerated; MV/Respiratory Sensor Disabled, orMV/Respir atorySensor Vector\\nSwitched. Bothtypesinclude anEGM,aswellasimpedance valuesrecordedatthetimeofepisode creationfor:\\n•Available MV/Respiratory Sensor vectors\\n•Pacing Leads\\nTheEGMtabdisplays theEGMrecordedatthetimeofSAMepisode creation. Whendeviceconditions resultinthe\\nsensor excitation signalbeingdetected onthesensechannel, thesignalartifact isvisibleonthecorresponding trace\\nasaregular,rapidlyrepeating (20Hz)pattern ofpeaksthatmayresemblenon-physiologic noise(Figure4–15Signal\\nArtifact Monitor Episode EGMonpage4-38).Theamplitude andduration ofthesensor signalartifact ontheEGMcan\\nbevariable, andmaybemodulated bypostural,respiratory,orcardiacmotion.\\nSomeSAMepisodes maygenerate EGMswithnovisiblesignalartifact. Thisistheexpected behavior whenthesensor\\nvectorimpedance measur ementwastriggeredbysomething otherthanadetected signalartifact. Forexample, when\\nSAMisOnandtheMV/Respir atorySensor setting ischanged fromOfforDisabled toOnorPassive, asensor vector\\nimpedance measur ementistriggered. Ifout-of-rangeimpedance( s)aredetected, aSAMepisode willbecreated.\\nFigure4–15.SignalArtifactMonitorEpisodeEGM\\nSignalArtifactMonitorEpisodeDataandProgramming Considerations\\nSAMepisode data(impedanc evaluesfortheindividual sensor vectors) mayhelpindetermining thesourceof\\ntransient highimpedance condition s.Ingeneral,transient highimpedance conditions maybecaused byalead\\nconductorfracture, under-insertion oftheleadterminal, oraxial/radial motion oftheleadterminal’s ringelectrode\\nwithinthedeviceheader.\\nWhentheMV/Respiratory Sensor isdisabled bytheSAM:\\n•FromtheLeadsStatusSummary screen(\"Leads Status\" onpage5-7),checkfortransient highimpedance\\ncondition sorsignificant changes overtimeinthedailyleadimpedance measur ements.\\n•Perform leadtesting fromtheLeadTestsscreen(\"LeadTests\"onpage5-12).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 121}), Document(page_content=\"Pacing Therapies\\nRateAdaptive PacingandSensorTrending4-39\\nIfaproblemwiththeleadissuspected, toreducethepotential forMV/Respir atorySensor signalartifact-generated\\noversensing, considerprogramming totheopposite VectorSelection paramet er,orprogramming theMV/Respiratory\\nSensor toOff.\\nIfdailyleadimpedance measur ements andleadimpedance trendslooknormal, consider thepatient’s needforMV/\\nRespirat orySensor-associated trendsand/or MVrateresponsive pacing. Ifnotneeded, turntheMV/Respir atory\\nSensor Offandcontinue tomonitor thelead.\\nIfrespiration-r elatedtrenddataand/or MVrateresponsivepacing isdesired, keeptheSAMprogrammed toOn.The\\nMinute Ventilation Sensor Details screenmaybeusedtoadjusttheMV/Respir atorySensor VectorSelection\\nparameter tousetheopposite lead(Figure 4–13Minute Ventilation Sensor Details onpage4-35).TheExcitation\\nCurrentcontrolstheamplitude oftheMV/Respiratory Sensor signalandcanalsobeadjusted. Programming the\\nExcitation Currentto80uAmayreducetheamplitude ofexcitationpulsesiftheyappear ontheEGM,thereby\\ndecreasing thelikelihoodofartifacts beingoversensed. However ,alowerexcitation pulseamplitude hasthepotential\\ntoresultinmorefrequentsuspension oftheMV/Respir atorySensor duetoexternalnoiseinterfering withthe\\nsensor’s function.\\nForamoredetailed discussion ofVectorSelection andExcitation Current programming, please contactBoston\\nScientific usingtheinformation onthebackcover.\\nAllprogramming decisions should bebasedontheindividual patient’s condition, indications andtherapyneeds.\\nRATEADAPTIVE PACINGANDSENSORTRENDING\\nRateAdaptive Pacing\\nInrateadaptive pacing modes (i.e.,anymodeending withR),sensors areusedtodetectchanges inthepatient's\\nactivity leveland/or physiologic demand andincreasethepacing rateaccordingly.Rateadaptive pacing isintended\\nforpatients whoexhibitchronot ropicincompetence andwhowouldbenefit fromincreasedpacing ratesthatare\\nconcurrent withincreasedactivity leveland/or physiologic need.\\nThedevicecanbeprogrammed tousetheAccelerometer, Minute Ventilation, orablendofboth.Theclinical benefit\\nofrateadaptive pacing usingeitherofthesesensors hasbeenshown inpreviousclinical studies.\\nCAUTION: Rateadaptive pacing should beusedwithcareinpatients whoareunable totolerate increased pacing\\nrates.\\nWhenrateadaptive parameters areprogrammed, thepacing rateincreasesinresponse toincreasedactivity level\\nand/or physiologic need,thendecreasesasappropriat e.\\nNOTE:Activity involving minimal upperbodymotion, suchasbicycling, mayresultinonlyamoderatepacing\\nresponse fromtheaccelerometer.\\nNOTE:RateAdaptive Pacing hasbeenshown tobepotentially proarrhythmic. Usecaution whenprogramming\\nadaptive-r atefeatures.\\nCAUTION: Theclinical benefit ofRateAdaptive Pacing inheartfailurepatients hasnotbeenstudied. RateAdaptive\\nPacing should beusedwithmedical discretion ifthepatient develops anindication suchaschronot ropic\\nincompetence. Patients withheartfailuremayhavehemodynamic compromise atrapidsensor-driven rates,andthe\\nphysician maywishtoprogramlessaggressive rateadaptive parameters inaccordancewithpatient condition.Heart\\nfailure-relatedrespiratory changes inpatient’s minute ventilation (MV)mayinappro priately increase pacedratetothe\\nupperrate(MSR),forinstance during heartfailureatrest.Ifthisoccurs,physicians mayconsiderturning offrate\\nresponsive pacing ormodifying theRateAdaptive Pacing settings. RateAdaptive Pacing maybehelpful forheart\\nfailurepatients withcoexisting bradyar rhythmic conditions.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 122}), Document(page_content=\"4-40Pacing Therapies\\nRateAdaptive PacingandSensorTrending\\nAccelerometer\\nTheaccelerometer detects motion thatisassociated withapatient's physical activity andgenerates anelectronic\\nsignalthatisproportional totheamount ofbodymotion. Basedonaccelerometer input,thepulsegenerator\\nestimates thepatient's energyexpenditu reasaresultofexercise,thentranslates itintoarateincrease.\\nThepulsegenerator senses bodymotion bymeans ofanintegratedcircuitaccelerometer.Theaccelerometer sensor\\nresponds toactivity inthefrequency rangeoftypicalphysiologic activity (1–10Hz).Theaccelerometer evaluates both\\nthefrequency andtheamplitude ofthesensor signal.\\n•Frequencyreflectshowoftenanactivity occurs(e.g.,thenumber ofstepstakenperminute during abriskwalk)\\n•Amplitude reflectstheforceofmotion (e.g.,themoredeliberatestepstakenwhilewalking)\\nOncedetected, analgorithm translates themeasur edacceleration intoarateincrease abovetheLRL.\\nBecause theaccelerometer isnotincontactwiththepulsegeneratorcase,itdoesnotrespond tosimple static\\npressureonthedevicecase.\\nTherearethreeAccelerometer settings: Off,On,andATROnly.Whenyouprogramtherespective rate-responsive\\nmodes forNormal Settings andATRFallback, thatactionautomatically updates theAccelerometer setting. Ifthepulse\\ngeneratorispermanently programmed toanon–rat eadaptive mode,itispossible toprogramtheATRFallback mode\\ntoanadaptive-ra temodeusingtheaccelerometer sensor.Inthiscase,theAccelerometer fieldwilldisplay ATROnly.\\nThefollowing programmable paramet erscontrolthepulsegenerator'sresponse tothesensor valuesgeneratedby\\ntheAccelerometer:\\n•Response Factor\\n•Activity Threshold\\n•Reaction Time\\n•RecoveryTime\\nResponse Factor(Accelerometer)\\nResponse Factor(accelerometer) determines thepacing rateincrease thatwilloccurabovetheLRLatvarious levelsof\\npatient activity (Figure 4–16Response Factorandpacedrateonpage4-41).\\n•HighResponse Factor––r esultsinlessactivity requiredforthepacing ratetoreachtheMSR\\n•LowResponse Factor––r esultsinmoreactivity requiredforthepacing ratetoreachtheMSR\\nNOTE:Programming Response FactorforNormal Settings alsochanges thecorresponding selection forPost-\\nTherapySettings.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 123}), Document(page_content=\"Pacing Therapies\\nRateAdaptive PacingandSensorTrending4-41\\nRate Res pons e Slopes \\n16 14 12 10 8 6 4 2 1 \\nMSR \\nLRL \\nLow High \\nActivity \\nPaced rate \\nN\\no\\nm\\ni\\nn\\na\\nl\\n \\nFigure4–16.Response Factorandpacedrate\\nThepacing rateachieved canbelimited eitherbythedetected activity levelortheprogrammed MSR.Ifthedetected\\nactivity levelresultsinasteady-state ratebelowtheMSR,thepacing ratecanstillincrease whenthedetected activity\\nlevelsincrease(Figure 4–17Response Factorinexercisetestonpage4-41).Thesteady-state responseisindependent\\noftheprogrammed reactionandrecoverytimes.\\nResponse Factor \\nMSR \\nPaced rate \\nLRL \\nRest Stage 1 Rest Stage 2 \\nTime Higher Response \\nSetting \\nLower Response \\nsetting \\nNominal \\nResponse Setting \\nLower \\nHigher \\nThisfigureshowstheeffectofhigherandlowersettings during atheoretical two-stage exercisetest.\\nFigure4–17.Response Factorinexercisetest\\nProgramming theLRLupordownmoves theentireresponse upordownwithout changing itsshape.\\nActivityThreshold\\nActivity Thresholdpreventsrateincreasesduetolow-intensity ,extraneous motion (e.g.,motion caused byrespiration,\\nheartbeat,orinsomecasestremorassociated withParkinson's disease).\\nActivity Thresholdrepresentstheactivity levelthatmustbeexceeded beforethesensor-driven pacing ratewill\\nincrease.Thepulsegenerator willnotincreasethepacedrateabovetheLRLuntiltheactivity signalincreasesabove\\ntheActivity Threshold. AnActivity Threshold setting should allowarateincrease withminoractivity,suchaswalking,\\nbutbehighenough sothepacing ratewillnotincreaseinappro priately whenthepatient isinactive (Figure 4–18\\nActivity Thresholdandrateresponseonpage4-42andFigure4–19Activity Threshold inexercisetestonpage4-42).\\n•Lowersetting––less motion isrequiredtoincreasethepacing rate\\n•Higher setting––more motion isrequired toincrease thepacing rate\\nNOTE:Programming theActivity Threshold forNormal Settings alsochanges thecorresponding selection forPost-\\nTherapySettings.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 124}), Document(page_content='4-42Pacing Therapies\\nRateAdaptive PacingandSensorTrending\\nActivity Threshold\\nMSR\\nLRL\\nLow High\\nActivityLow\\nM\\ned\\ni\\num\\nM\\ned-\\nLo\\nM\\ned-\\nHi\\nHigh\\nV\\n-\\nHigh\\nV\\n-\\nLow\\nPa\\nced r\\na\\nte\\nFigure4–18.ActivityThreshold andrateresponse\\nActivity Threshold\\nMSR\\nPa\\nced r\\na\\nte\\nLRL\\nRest Stage 1 Rest Stage 2\\nTimeLower threshold \\nsetting\\nHigher threshold\\n \\nsetting\\nNomin al threshold \\nsetting\\nThisfiguredemonstrates theeffectofincreased ordecreased Activity Threshold settings inresponse toatheoretical two-stage exercisetest.\\nFigure4–19.ActivityThreshold inexercisetest\\nReactionTime\\nReaction Timedetermines howquickly thepacing ratewillrisetoanewlevelonceanincrease inactivity levelis\\ndetected.\\nReaction Timeaffects onlythetimerequiredforarateincreasetooccur.Thevalueselected determines thetime\\nrequiredforthepacedratetomovefromtheLRLtotheMSRforamaximum levelofactivity (Figure 4–20Reaction\\nTimeandpacedrateonpage4-43andFigure4–21Reaction Timeinexercisetestonpage4-43).\\n•ShortReaction Time:resultsinarapidincreaseinthepacing rate\\n•LongReaction Time:resultsinaslower increaseinthepacing rate\\nNOTE:Programming Reaction TimeforNormal Settings alsochanges thecorresponding selection forPost-Therapy\\nSettings.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 125}), Document(page_content='Pacing Therapies\\nRateAdaptive PacingandSensorTrending4-43\\nReaction Slopes\\nMSR\\nLRL\\n0 10 20 30 40 50\\nSeconds\\nP\\nace\\nd\\n \\nr\\nate\\nS\\nh\\no\\nr\\nt\\nN\\no\\nm\\ni\\nn\\na\\nl\\nL\\no\\nn\\ng\\nFigure4–20.ReactionTimeandpacedrate\\nReaction T ime\\nMSR\\nLRL\\nRest Stage 1 Rest Stage 2\\nTimeShorter\\nLonger\\nP\\nace\\nd\\n \\nr\\nate\\nShorter \\nReaction Tim\\ne\\nLonger \\nReaction Tim\\ne\\nNominal \\nReaction Tim\\ne\\nFigure4–21.ReactionTimeinexercisetest\\nRecoveryTime\\nRecoveryTimedetermines thetimerequiredforthepacedratetodecrease fromtheMSRtotheLRLintheabsenceof\\nactivity.Whenpatient activity concludes, RecoveryTimeisusedtopreventanabrupt decreaseinpacing rate(Figure\\n4–22RecoveryTimeandpacedrateonpage4-44andFigure4–23Recovery Timeinexercisetestonpage4-44).\\n•ShortRecoveryTime––resu ltsinafasterdecreaseinpacing rateafterpatient activity lowers orstops\\n•LongRecoveryTime––results inaslower decreaseinpacing rateafterpatient activity lowers orstops\\nNOTE:Programming Recovery TimeforNormal Settings alsochanges thecorresponding selection forPost-\\nTherapy Settings.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 126}), Document(page_content='4-44 Pacing Therapies\\nRateAdaptive PacingandSensorTrending\\nRecovery Curves\\nMSR\\nPa\\nce\\nd\\n r\\nat\\ne\\nLRL\\n0246 161412108\\nMinutes\\nThereare15settings available; onlytheeven-numbered settings areshown.\\nFigure4–22.Recovery Timeandpacedrate\\nRecovery T ime\\nMSR\\nPa\\nce\\nd\\n r\\nat\\ne\\nLRL\\nRest Stage 1 Rest Stage 2\\nTimeLonger \\nRecovery Tim\\ne\\nNomin al \\nRecovery Tim\\ne\\nThefigureshowstheeffectoflongerandshorter settings during atheoretical two-stage exercisetest.\\nFigure4–23.Recovery Timeinexercisetest\\nMinuteVentilation (MV)\\nThisfeature isavailable inRESONATE HFandMOMENTUM devices.\\nThepulsegenerator’s Minute Ventilation/Respirato rySensor usestransthoracic impedance toevaluate andmeasur e\\nminute ventilation (MV),whichistheproductofrespirationrateandtidalvolume. BasedontheMVmeasur ement, the\\npulsegeneratorcalculates thesensor-indicated pacing rate.\\nForadetailed description ofMinute Ventilation/Respirato rySensor function, refertoMinute Ventilation/Respiratory\\nSensor (\"Minute Ventilation/Respiratory Sensor\" onpage4-32).Toenable MV-driven pacing, thepacing modemust\\nbesettoarate-adaptive mode(anymodeending inR),andtheMinute Ventilation/Respiratory Sensor mustbe\\nprogrammed toOn.\\nCAUTION: DonotprogramtheMVSensor toOnuntilafterthepulsegeneratorhasbeenimplanted andsystem\\nintegrity hasbeentestedandverified.\\nCAUTION: Forpatients withrespiratorydisorder sorabnormal breathingpatterns, thephysician should usemedical\\njudgment whenprogramming theMVSensor toOn.Tomitigate inappropriat esensor-driven rates,thephysician may\\nevaluate therateresponseandconsideralowerResponse Factor.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 127}), Document(page_content=\"Pacing Therapies\\nRateAdaptive PacingandSensorTrending4-45\\nCAUTION: ProgramtheMV/Respir atorySensor toOffduring mechanical ventilation. Otherwise,thefollowing may\\noccur:\\n•Inappropriate MVSensor-driven rate\\n•Misleading respiration-based trending\\nCAUTION: Anymedical equipment, treatment, therapy,ordiagnostic testthatintroduces electrical currentintothe\\npatient hasthepotential tointerfere withpulsegenerator function.\\n•External patient monitors (e.g.,respiratorymonitors, surface ECGmonitors, hemodynamic monitors) maycause:\\n–Inappro priateMVSensor-driven rate(uptomaximum sensor-driven rate)\\n–Misleading respiration-based trending\\nToresolvesuspected interactions withRespiratory Sensor-based diagnostics, deactivate thepulsegenerator's\\nRespirat orySensor byprogramming ittoOff.\\nMVRateResponse Algorithm\\nThepulsegeneratorkeepsalong-term moving average(baseline) oftheseMVmeasur ements (updated every4\\nminutes) aswellasashort-term(approximately 30-second) moving average,whichisupdated every7.5seconds.The\\ndifferencebetween theshort-termaverageandlong-term baseline isusedtodetermine themagnitude oftherate\\nincreaseovertheLRL,ordecreasedowntotheLRL.Following aperiodofexertionandhighMVratedrive,the\\npatient’s short-termaveragewilldecreaseandeventually dropbelowthebaseline. Asitdecreases,theMVSensor-\\nindicated ratedecreases downtotheLRL.Theincreaseordecreaseinthesensor-indicated rateoccursatamaximum\\nof2ppmpercycle(Figure 4–24Differen cebetween MVshort-termaverageandMVbaseline onpage4-45).The\\nalgorithm supports breathingratesupto72bpm.\\nM\\nV\\n∆\\n \\nM\\nV\\nTime (app\\nroximatel\\ny 24 hour\\ns)\\n Time (app roximatel y 24 hour s) Short-ter\\nm average\\nBaseline\\nTop:Thebaseline (long-term average) follows thedriftoftheshort-termaverage. Bottom: Thedifferenc ebetween theshort-andlong-term average isusedfor\\nincreasing thesensor-driven rateuponexertion.\\nFigure4–24.Differencebetween MVshort-term averageandMVbaseline\\nNOTE:Whenever amagnet isapplied andtheMagnet Response hasbeenprogrammed toPaceAsync,thedevice\\nwillpaceasynchr onously atthemagnet rateandwillnotrespond toMVdata.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 128}), Document(page_content='4-46Pacing Therapies\\nRateAdaptive PacingandSensorTrending\\nToactivate theMVSensor,thesystem needsameasure ofthebaseline orrestingMV(Sensor calibrat ion).Methods\\nforcalibrat ioninclude:\\n•Automatic Calibration. Anautomatic, 6-hour calibrationwilloccurwhenever MVisprogrammed toOnor\\nPassive. NoMV-driven rateresponseorhourlyleadintegrity checks willoccurduring the6-hour calibration time.\\nIfMVisprogrammed toOnatimplant, thefirsthourlyleadcheckwithacceptable leadimpedance valueswill\\nbegina2-hour waitperiodfollowed bythe6-hour calibration.This2-hour periodwillbeindicated byasensor\\nstatusofInitializing andisintended toallowtheimplantation proceduretobecompleted.\\nNOTE:IfMVisprogrammed toOnorPassive atthetimeofentryintoMRIProtectionMode,uponexitfrom\\nMRIProtectionMode,anautomatic 6–hour calibrat ionwillbegin.IfMV-driven rateresponse isdesiredsooner,a\\nmanual calibrat ioncanbeperformed.\\n•ManualCalibration. Whenever MVisprogrammed On,(including during the2-hour periodfollowing lead\\nattachment) thesensor canbecalibratedmanually .Ifthecalibrationissuccessful,MV-driven rateresponse takes\\neffectwithinoneminute. FromtheRightRate Pacing Details screen,selecttheStartSensor Calibration button to\\ninitiate themanual calibration process.Manual calibrationmaytakeaslittleas2minutes orasmuchas5minutes\\ntocomplete, depending onwhether noiseisencountered during datacollection. Thepatient should beresting\\nquietly andbreathing normally forafewminutes priortoandduring themanual calibration.WhenManual\\ncalibrat ionisinitiated, asensor leadintegrity checkisperformed. IfanMVvectorwithin-range impedance s\\ncannot befound, Manual calibrationfailsduetonovalidMVleadvector.Ifthemanual calibrationfailsdueto\\nnoise,itwillbeindicated byaSuspended: NoiseDetected sensor statusandthe6-hour automatic calibrationwill\\nautomatically begin.\\nIfasensor leadintegrity checkisperformed, Manual calibration startsonthefirstMVvectorwithin-range\\nimpedances. IfanMVvectorwithin-rangeimpedances cannot befound, Manual calibrationfailsduetonovalidMV\\nleadvector.\\nThepossible resultsoftheManual calibrationandthecorresponding MVbehavior aredescribed inTable4–9Manual\\nCalibration Results onpage4-46asfollows:\\nTable4–9.ManualCalibration Results\\nManualCalibration Result MVBehavior\\nSuccessfulcalibrationMV-driven rateresponse takeseffectwithinoneminute.\\nCalibration failsduetonovalidMVleadvectorIfSAMisOn:\\n•SAMepisode(s) arecreated.\\n•TheMVSensor isdisabled.\\n•Thesensor statusisDisabled bydevicediagnostic.\\nIfSAMisOff:\\n•Thepulsegenerat orchecks hourlyforavalidvectorandstartsthe6-hour\\ncalibration ifavalidvectorisdetected.\\nCalibration failsduetonoiseThesensor statusisSuspended: NoiseDetected.\\nThe6-hour calibration automatically begins whennoiseisnolongerdetected.\\nNOTE:TheManual Calibrat ionmethod willnotbeavailable uponinitialinterrogationwhileinformation suchas\\nArrhythmia Logbook episodes areretrieved fromthedevice. Thiswillbeindicated byadimmed StartSensor\\nCalibration iconandmayoccurforsecondstominutes depending ontheamount ofdatabeingretrieved.\\nThereisnoclinical differencebetween theAutomatic andtheManual calibrationmethods. AsuccessfulManual\\ncalibrationsimply allowsabaseline tobeobtained andMV-driven rateresponse tobeginuponcompletion of\\ncalibration.Neither calibrationmethod requiresthattelemetr ycommunication bemaintained forthedurationofthe\\ncalibration.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 129}), Document(page_content='Pacing Therapies\\nRateAdaptive PacingandSensorTrending4-47\\nCAUTION: ToobtainanaccurateMVbaseline following anysurgicalprocedureinvolving thepulsegenerator or\\nleads,anew,manual calibrationshould beperformed. Leadmaturation, airentrapmentinthepocket, pulse\\ngeneratormotion duetoinadequate suturing, externaldefibrillation orcardioversion, orotherpatient complications\\n(e.g.,pneumothorax) requireanewMVbaseline forappropriateMVbehavior .\\nForoptimal rateresponse, avariety ofMinute Ventilation paramet erscanbeprogrammed viatheRightRate Pacing\\nareaontheRightRate Pacing Settings screen.Theseinclude:\\n•Response Factor\\n•Ventilatory Threshold\\n•Ventilatory Threshold Response\\n•Fitness Level\\nResponse Factor(MinuteVentilation)\\nAnincreaseinMVoverbaseline duetoanincreaseinmetabolic demand willbedetected bythepulsegenerator and\\nconverted byitsalgorithm intoanincreasedpacing rate.Therelationship between thedetected increaseinMVand\\ntheresulting increaseinthesensor-indicated rateisestablished bytheMVResponse Factor.\\nTheResponse Factorparamete rdetermines thepacing ratethatwilloccurabovetheLRLatvarious elevated levelsof\\nMV.Largerresponsefactorvalueswillresultinhighersensor ratesforagivenMVlevel(Figure4–25Relationship\\nbetween theprogrammed Response Factorsetting andrateresponse onpage4-47).Theeffects ofhigherandlower\\nResponse Factorsettings onsensor-driven pacing rateduring atheoretic altwo-stage exercisetestareillustrated\\nbelow(Figure4–26Effects ofResponse Factorsettings inatwo-stage exercisetestonpage4-47).\\nResponse \\nFactor\\n161412108\\n6421\\nMSR\\nLRL\\nLow High\\n ∆ MV\\nP\\na\\nc\\ne\\nd\\n \\nr\\na\\nt\\ne\\n5\\nFigure4–25.Relationship between theprogrammed Response Factorsettingandrateresponse\\nResponse Factor \\nMSR \\nPaced rate \\nLRL \\nRest Stage 1 Rest Stage 2 \\nTime Higher Response \\nSetting \\nLower Response \\nsetting \\nNominal \\nResponse Setting \\nLower \\nHigher \\nFigure4–26.EffectsofResponse Factorsettingsinatwo-stage exercisetest', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 130}), Document(page_content=\"4-48Pacing Therapies\\nRateAdaptive PacingandSensorTrending\\nVentilator yThreshold andVentilatory Threshold Response\\nVentilatory Threshold isaphysiologic termdescribing thepointduring exercisewhenthebreathingrateincreases\\nfasterthantheheartrate(sometimes referredtoasAnaerobic orLactate Threshold).\\nTheResponse Factorcontrols theMVrateresponse forsensor ratesbetween theLRLandtheVentilatory Threshold.\\nTheVentilatory Threshold Response controlstheMVrateresponsewhenthesensor rateisabovetheVentilatory\\nThreshold.\\nTheVentilatory Threshold andVentilator yThreshold Response canbeeithermanually programmed orautomatically\\nderived frompatient information. Theclinician canselectDerivefromPatient Attributes fromtheRightRate Pacing\\nDetails screentoobtainsettings basedonthepatient's ageandgender (andFitness Level,seebelow). Asparameters\\narechanged, thegraphwilllikewise adjusttodemonstrate theeffectofthenewprogramming onoverall rate\\nresponse (Figure 4–27Ventilatory Threshold andVentilatory Threshold Response onpage4-48).IftheDateofBirthor\\nGender isadjusted onthePatient Information screen,thenewvalueswillalsobereflectedontheRightRate Pacing\\nDetails screen.\\nFigure4–27.Ventilatory Threshold andVentilatory Threshold Response\\nThephysiologic relationship between MVandrateisapproximately bilinear asshown (Figure 4–28Typical physiologic\\nrelationship between MVandheartrateonpage4-49).During exerciselevelsuptotheVentilatory Threshold,this\\nrelationship canbeapproximated byalinearrelationship. Atexertion levelsabovetheVentilatory Threshold, the\\nrelationship isstillapproximately linear,butatareducedslope.Therelationship between thetwoslopesvariesfrom\\nperson toperson anddepends onseveral factors suchasgender,age,andexercisefrequency andintensity .Thepulse\\ngeneratorsallowprogramming ofaslopeabovetheVentilatory Threshold thatislesssteepandthusdesigned to\\nmimicthephysiologic relationship between respirationrateandheartrate.TheVentilatory Threshold Response is\\nprogrammed asapercentage oftheResponse Factor. Ventilatory Threshold Response isineffectatratesabovethe\\nVentilatory Threshold andwillresultinalessaggressiveresponse toMVathigherrates(Figure 4–29Ventilator y\\nThresholdResponse onpage4-49).\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 131}), Document(page_content='Pacing Therapies\\nRateAdaptive PacingandSensorTrending4-49\\nMinute VentilationVentilato\\nry \\nThreshold\\nR\\ne\\ns\\np\\no\\nn\\ns\\ne\\n \\nF\\na\\nc\\nt\\no\\nr\\nResting \\nheart rat\\ne\\nMV\\n0\\nMV\\nT\\nH\\ne\\na\\nr\\nt\\n \\nR\\na\\nt\\ne\\nMV0=restingMV;MVT=MVattheVentilatory Threshold\\nFigure4–28.Typicalphysiologic relationship between MVandheartrate\\nOff\\n85%\\n70%\\n55%\\nH\\ne\\na\\nr\\nt\\n \\nR\\na\\nt\\ne\\n Relative MV MV\\n0\\nMV\\nT\\nLRL\\nVentilato\\nry Thresh\\nold\\nV\\nentilator\\ny Thresho\\nld Respon\\nse\\nTheResponse FactorislinearfromtherestingstateuptotheVentilatory Threshold (MV0=restingMV;MVT=MVattheVentilatory Threshold).\\nFigure4–29.Ventilator yThreshold Response\\nFitnessLevel\\nTheselected Fitness Levelwillautomatically determine anappropr iateVentilatory Threshold Response factorandrate\\natwhichtheMVbaseline willbefixed.\\nTable4–10.Recommended FitnessLevelsettings\\nRecommended FitnessLevelsetting Patientactivitylevel\\nSedentary Littletonophysical activity\\nActive Regular walking andlowimpact activities\\nAthletic Moderateintensity ,non-competitive jogging/biking\\nEnduranc eSports Strenuous, competitive activities suchasmarathons\\nThebaseline (long-term average) isfixedforupto4.5hours.Thisallowsactivepatients whoexerciseforalong\\nduration(e.g.,long-distance runners) tomaintain anadequate sensor-driven ratethroughout theexerciseperiod. The\\nbaseline willbefixedwhenthesensor indicated rateisabove110ppmfortheFitness Levelsetting ofEnduranc e\\nSportsor90ppmfortheotherthreeFitness Levelsettings (Table4–10Recommended Fitness Levelsettings onpage\\n4-49).After4.5hours,orwhenthesensor ratefallsbelow90ppmor110ppmasdefined above, baseline adaptation\\nwillbere-enabled.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 132}), Document(page_content='4-50Pacing Therapies\\nRateAdaptive PacingandSensorTrending\\nPhysicalActivityEvaluation\\nFollowing medical judgment, healthcareprofessionals mayaskpatients toengage inlighttomoderatephysical\\nactivity,suchasahallwalkorwalking upanddownsteps,toassessthepulsegenerator’srateresponse. This\\nevaluation isusedtoinform theprogramming ofrateadaptive pacing forthepatient\\'s detected activity level.For\\npatients whoengage inendurancesports, strenuous physical activity mayresultinamoreaccurateassessment of\\nrateresponse.\\nPriortostarting thephysical activity evaluation:\\n•Ensure thatpatients arehealthy enough toparticipate.\\n•Review andconsider printing thepatient’s previous 25-hour Sensor Trending data.Formoreinformation, referto\\nSensor Trending(\"Sensor Trending\" onpage4-54).\\n•TheBeattoBeatRecordingMethod (asdescribed in\"Sensor Trending\" onpage4-54)isrecommended during\\nphysical activity evaluations tomanually optimiz esensor rates.\\nNOTE:Sensor Trending resultsmaybeprinted viatheReports tab.\\nAfterthephysical activity evaluation, interrogatethepatient’s deviceasdescribed in“Working withTrending Data”\\nandreviewtherateresponse data.Thisrateresponse datacanbecompared totheprevious25-hour dataprinted\\npriortothetest.Itisrecommen dedtoresettheRecordingMethod tothemodeusedpriortothephysical activity\\nevaluation (e.g.,30-Second Average).\\nOptimizing RateResponse forPhysicalActivity\\nSensor Trendingprovidesagraphic aldisplay ofthepulsegenerator\\'srateresponse tothepatient\\'s detected activity\\nlevelduring exercise(\"Sensor Trending\"onpage4-54).TheSensor Trendinggraphasshown (Figure4–30Rate\\nResponse beforeMVSensor programmed toOnonpage4-50)displays rateresponsedataforapatient before\\nprogramming theMVSensor toOn.TheActualRate(blackline)representsthepatient’s heartratedatainDDDmode\\nwhenMVSensor isprogrammed toPassive; thepatient’s heartratewasapproximately 85bpmafterengaging in\\nphysical activity.\\nFigure4–30.RateResponse beforeMVSensorprogrammed toOn\\nThesecondSensor Trendinggraph(Figure 4–31RateResponse afterMVSensor programmed toOnonpage4-51)\\ndisplays theheartrateresponse forthesamepatient aftertheMVSensor wasprogrammed toOn.TheSensor replay', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 133}), Document(page_content='Pacing Therapies\\nRateAdaptive PacingandSensorTrending4-51\\n(orangeline)depicts thesensor-driven heartrateresponse thatwasapproximately 105bpmafterthepatient\\nengaged inphysical activity.\\nFigure4–31.RateResponse afterMVSensorprogrammed toOn\\nForpatients whoarechronot ropically incompetent, considerprogramming thedevicetorateresponsivemode(e.g.,\\nDDDR) withtheMVSensor toOn.Forexample, chronotropically incompetent patients, suchasthosewhose heartrate\\nis<100bpmduring physical activity andtheprevious 24-hours, maybenefit fromdeviceoptimization forrate\\nadaptive pacing.\\nAftersetting theMVSensor toOn,therateresponsecanbeoptimized toachieve anappropriateheartrateduring\\nfutureexercise.Consider programming therateresponse factortotargetamaximum Sensor Replay rateas\\nappropriate basedonthepatient’s clinical condition (e.g.,70%to80%ofthepatient’s agepredictedmaximal heart\\nrate(APMHR)). Thisprogramming canbedoneincrementally accordingtothepatient’s clinical conditionduring\\nclinical follow-up. Notethatthesensor rateislimited byMSRandLRL.Therefore,whenreprogramming thedevice,\\nconsider re-optimizing usingthesefeatures.\\nDual-Sensor Blending\\nWhenever boththeAccelerometer andtheMVsensor areprogrammed Onforrateadaptive pacing, thetwosensor-\\nindicated ratesareblended toproducearate-dependent, weighted averageresponse. Asaresult,theblended\\nresponse willalways beequaltooneoftheratesorbetween thetworates.Whenever theAccelerometer responseis\\nlessthantheMVresponse, thesensor blending willbe100%MV-based. IftheAccelerometer responseisgreaterthan\\ntheMVresponse, theblending willrangefromapproximately 80%Accelerometer and20%MVwhenthe\\nAccelerometer rateisatLRL,toapproximately 40%Accelerometer and60%MVwhentheAccelerometer rateisat\\nMSR.\\nThefollowing examples illustrate theblending algorithm operation.\\nExample1\\nTheAccelerometer detects motion withasimultaneous MVincrease(Figure 4–32Blended response withan\\nAccelerometer Reaction Timeof30secondsonpage4-52).Uponexercise,theblended response willpromptly (within\\n4seconds)increasetheratebasedontheAccelerometer response. Astheratecontinues toincrease,theblended\\nresponse willbemoving towardtheMVresponse, butwillalways remainbetween theAccelerometer andMV\\nresponses. Athigherrates,thechanges inAccelerometer inputwillhavealessereffectontheblended response (only\\n40%atMSR),whereas changes inMVwillhaveamoresignificant effect.Atcessation ofexercise,theAccelerometer\\nratewilldecreaseasprescribed bytheRecoveryTimeparameter and,inthisexample, willdropbelowtheMV\\nresponse. Asaresult,thealgorithm willswitchovertoa100%MVblendduring therecovery phaseforaslongasthe', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 134}), Document(page_content='4-52Pacing Therapies\\nRateAdaptive PacingandSensorTrending\\nAccelerometer responseremains belowtheMVresponse.Whenusingdual-sensor blending, retainthenominal\\nAccelerometer valueof2minutes. Thisallowsthephysiologic MVsignaltocontrolrateadaptive pacing intheexercise\\nrecoveryphase.\\nAccelerom\\neter\\nB\\nlend\\nMinute Ve\\nntilation\\n100\\n50\\n0\\n Time (sec onds)\\nS\\ne\\nn\\ns\\no\\nr\\n \\nr\\na\\nt\\ne\\n \\ni\\nn\\nc\\nr\\ne\\na\\ns\\ne\\n \\n(\\nm\\ni\\nn\\n-\\n1\\n \\n(\\np\\np\\nm\\n)\\n)\\n0 250 200 15\\n0 100 50\\nFigure4–32.Blendedresponse withanAccelerometerReactionTimeof30seconds\\nTheaggressiveness ofresponseattheonsetofexercisecanbecontrolledbyprogramming ashorter Accelerometer\\nReaction Time(Figure 4–33Blended response withanAccelerometer Reaction Timeof20secondsonpage4-52).\\nAccelerom\\neter\\nB\\nlend\\nMinute Ve\\nntilation\\n100\\n50\\n0\\n Time (sec onds)\\nS\\ne\\nn\\ns\\no\\nr\\n \\nr\\na\\nt\\ne\\n \\ni\\nn\\nc\\nr\\ne\\na\\ns\\ne\\n \\n(\\nm\\ni\\nn\\n-\\n1\\n \\n(\\np\\np\\nm\\n)\\n)\\n0 250 200 15\\n0 100 50\\nFigure4–33.Blendedresponse withanAccelerometerReactionTimeof20seconds\\nExample2\\nTheAccelerometer detects motion withlittleMVincrease(Figure4–34Blended response: Accelerometer detects\\nmotion withlittleornoincrease inMVonpage4-52).Theresponseoftheblended sensor willbelimited to\\napproximately 60%oftheAccelerometer response.OncetheAccelerometer response dropsbelowtheMVresponse\\nduring recovery ,theblended response willbe100%MV-driven.\\nAccelerom\\neter\\nB\\nlend\\nMinute Ve\\nntilation\\n100\\n50\\n0\\n Time (sec onds)\\nS\\ne\\nn\\ns\\no\\nr\\n \\nr\\na\\nt\\ne\\n \\ni\\nn\\nc\\nr\\ne\\na\\ns\\ne\\n \\n(\\nm\\ni\\nn\\n-\\n1\\n \\n(\\np\\np\\nm\\n)\\n)\\n0 250 200 15\\n0 100 50\\nFigure4–34.Blendedresponse: AccelerometerdetectsmotionwithlittleornoincreaseinMV', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 135}), Document(page_content='Pacing Therapies\\nRateAdaptive PacingandSensorTrending4-53\\nExample3\\nMVincreaseswithlittleAccelerometer rateincrease(Figure4–35Blended response: MVincreasewithlittleorno\\nmotion detected bytheAccelerometer onpage4-53).Theblended response willinitially increasewiththe\\nAccelerometer response, butastheMVresponse increasesovertheAccelerometer response, theblended response\\nwillbe100%MV-driven. Thisprovidesadequate response during increasesinmetabolic demand underconditions of\\nlittleornoupperbodymovement.\\nAccelerom\\neter\\nBlend\\nMinute Ve\\nntilation\\n100\\n50\\n0\\n Ti me (secon ds)\\nS\\ne\\nn\\ns\\no\\nr\\n \\nr\\na\\nt\\ne\\n \\ni\\nn\\nc\\nr\\ne\\na\\ns\\ne\\n \\n(\\nm\\ni\\nn\\n-\\n1\\n \\n(\\np\\np\\nm\\n)\\n)\\n0 250 200 15\\n0 100 50\\nFigure4–35.Blendedresponse: MVincreasewithlittleornomotiondetected bytheAccelerometer\\nFollow-up DeviceAssessments\\nAfterprogramming theMVSensor orAccelerometer, parameters associated withrateresponsecanbeadjusted at\\nsubsequent devicechecks. Consider checking histogramsandadjusting paramete rsifpatients complain ofshortness\\nofbreathortiredness whileexercising,orreportahighheartrateforprolonged periods oftime.Also,consider\\nresetting theHistograms whenever parameters associated withrate-response areadjusted (referto\"Histograms\" on\\npage6-9).\\nLowandHighResponse Factor\\nHistogr amsmayprovideanindication thatparameters associated withrateresponse (e.g.Response Factor, MSR,etc.)\\ncanbeadjusted toachieve thedesired heartrate.Anincreasedamount ofpacing atMSRmayindicate thatthe\\nResponse Factorissettoohigh(Figure 4–36HighResponse Factoronpage4-53)ortheMSRissettoolowasshown\\n(Figure4–37LowResponse Factoronpage4-54).Inthehistogramasshown inFigure4–36HighResponse Factoron\\npage4-53,consider whether itisappropriat etolowertheResponse FactororraisetheMSR.\\nFigure4–36.HighResponse Factor\\nInthehistograms asshown inFigure4–37LowResponse Factoronpage4-54,theResponse Factormaybetoolow\\nasindicated byalargepercentage ofbeatsinasinglebin,e.g.,>70%.Inthiscase,consider progressively increasing\\ntheprogrammed Response Factor.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 136}), Document(page_content=\"4-54 Pacing Therapies\\nRateAdaptive PacingandSensorTrending\\nFigure4–37.LowResponse Factor\\nSensorTrending\\nSensor Trendingprovidesagraphic aldisplay ofthepulsegenerator'srateresponse tothepatient's detected activity\\nleveland/or physiologic needandprovides usefulinformation during exercisetesting. Thisdataallowstheclinician to\\nadaptthesensor-driven pacing ratetocorrespond tothepatient's actualneed.\\nTheSensor Trending graphandSensor Trending Setupparamet ersareviewable viatheRateAdaptive Pacing screen\\n(Figure 4–38Sensor Trending graphonpage4-54).\\nFigure4–38.SensorTrending graph\\nSetupofSensor Trendingincludes thefollowing options:\\n•RecordingMethod—pro grammable:\\n–30-Second Average—r ecordsandplotstheaveragerateevery30seconds.\\n–BeattoBeat—rec ordsandplotstherateofeverybeat.\\nNOTE:BeattoBeatisrecommen dedwhenusinghallwalksorshorter periods ofactivity tomanually\\noptimize sensor rates.\\n–Off—no trending dataisgathered.\\n•Duration––no n-progr ammable andbasedontheselected RecordingMethod:\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 137}), Document(page_content=\"Pacing Therapies\\nRateAdaptive PacingandSensorTrending4-55\\n–WhenRecordingMethod issettoOffor30-SecondAverage––Du rationisapproximately 25hours.\\n–WhenRecordingMethod issettoBeattoBeat––Dur ationisapproximately 40minutes at75bpm.\\n•DataStorage—progr ammable:\\n–Continuous—con tainsthemostrecentdataavailable. Storagestartswhensetupisconfirmed and\\ncontinuously recordsthelatestinformation, overwriting theoldestdatauntiltheinformation isretrieved.\\nThisoption allowsyoutoviewdatafortherecordingduration immediately priortodataretrieval.\\n–Fixed—storage startswhensetupisconfirmed andcontinues untildevicememory storageisfull.Thisallows\\nyoutoviewdatafrominitialsetupforafixedamount oftime.\\nThepulsegeneratorcollects andstoresrateandsensor datawhichisthendisplayed onthePRMinagraphic alformat\\nasthepatient's ActualRateandSensor Replay during therecordingtime.\\nTheActualRate(blackline)indicates thepatient's heartrateduring activity (whether pacedorsensed). TheSensor\\nReplay (orangeline)depicts thesensor-driven heartrateresponse withthecurrentsensor parameter settings.\\nAstheslideralongthehorizontalaxisofthegraphismoved, actualandsensor-indicated heartratesaredisplayed for\\nparticular datapoints. Additionally ,theatrialevents represented byaparticular datapoint(single beator30-second\\naverage)areclassified anddisplayed nexttotheActualRate.Events areclassified anddisplayed asoneormoreof\\nthefollowing: Paced, Sensed, Sensed inATR,VT.Thiseventtypewillreflectventricular events inVVI(R)modes.\\nCurrentsensor parameters canbeadjusted toviewtheresultingchange tosensor ratebehavior without having to\\nrepeatanexercisetest.\\nThepulsegeneratorcancollectandstoredatainrateadaptive andnon-rate adaptive modes:\\n•Innon-rate adaptive modes, thetrending iscollected viathePassive sensor setting. Passive allowsforsensor\\ndatacollection thatcanbeusedtooptimize thesensors intheabsenceofthesensor-driven rateresponse.\\nHowever ,whenthesensor setting isPassive, Sensor Replay datawillnotbedisplayed onthegraphuntilarate\\nresponsive modeisselected.\\nThepulsegeneratorwillrecordSensor Trendingdatawhilewanded orRFtelemetr yisactive.\\nWhentheheartrateiscompletely sensor-driven, smalldifferencesbetween theActualRateandSensor Replay may\\nstillbeobserve dbecause theyarecalculated independently byslightly differentmethods.\\nWorkingwithSensorTrending Data\\nTousetheSensor Trendingfunction, followthesesteps:\\n1.Following anexercisesession, navigate totheSensor TrendinggraphandpressInterrogatetoupdate trending\\ninformation. Trending dataisretrieved oninitialinterrogation. Ifasession remainsactivewhilethepatient\\nengages inlighttomoderatephysical activity,pressInterrogateagaintoupdate thetrending information.\\n2.SelecttheViewbutton toexpandorcompress theamount ofdataviewed atonetime.Thestartandenddates\\nandtimesatthebottom ofthegraphwillchange toreflectthetimeperiodrepresented onthegraph.The30\\nSecondAverage RecordingMethod hasoptions for1to25hours,andtheBeattoBeatRecordingMethod has\\noptions for5to40minutes.\\n3.Toadjustwhichdataisdisplayed onthegraphortoviewparticular datapoints, movetheslider(s) alongthe\\nhorizontalaxesatthebottom ofthedisplay windows.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 138}), Document(page_content=\"4-56Pacing Therapies\\nAtrialTachyResponse\\n4.Adjustthesensor paramet erstotherightofthegraphtoseehowadjustments intherateadaptive pacing\\nparameters willaffectthesensor response(orangeline).Astheseparameters and/or theMSRandLRLare\\nchanged onthescreen,theapplication willmodify thegraphtoillustratetheresulting effects. Ifthepatient's\\nheartrateisappropriat efortheactivity performed, nosensor optimization isnecessary.\\n5.Whenapatient's heartrateiswithinthedesired rangefortheactivity performed, selectProgram.\\nNOTE:Sensor Trending resultsmaybeprinted viatheReports tab.BoththePresent (currentlyprogrammed) and\\nReplay (clinician adjusted) parameters areprovided inaddition tothecurrentgraphasrepresented onthe\\nprogrammer screen.\\nNOTE:Sensor adjustments should notbebasedondatawhichiscollected during theMVcalibrat iontimeperiod.\\nATRIALTACHYRESPONSE\\nATRModeSwitch\\nATRisdesigned tolimittheamount oftimethattheventricular pacedrateisattheMTRorexhibits upper-rate\\nbehavior (2:1blockorWenckebac h)inresponse toapathological atrialarrhythmia.\\nATRalsolimitstheamount oftimethatCRTisinhibited duetopathological atrialtachycardia.\\nInthepresenceofdetected atrialactivity thatexceedstheATRTrigger Rate,thepulsegeneratorswitches thepacing\\nmodefromatrackingmodetoanontrackingmodeasfollows:\\n•FromDDD(R) toDDI(R)orVDI(R)\\n•FromVDD(R) toVDI(R)\\nAnexample ofATRbehavior isshown (Figure4–39ATRbehavior onpage4-56).\\nATR Count\\ner\\nDurati\\non Counte\\nr\\n0 8\\nDetect Dur\\nation Fall\\nback Reset\\n0 8\\nExit Coun\\nt = 8\\n8 atr\\nial cycle\\ns < \\nATR\\n Trigger \\nRate\\nN\\nE\\nntry Coun\\nt = 8\\n8 atrial \\ncycles > \\nATR Trig\\nger Rate\\nRate\\nAtrial \\ntachycard\\nia \\nstarts\\nRate Smoo\\nthing \\n applied h ere Atrial \\ntachycard\\nia \\nconfirmed\\nATR Durat\\nion \\nfulfilled\\nAtrial \\ntachycard\\nia \\nterminate\\ns\\nMODE SWIT\\nCHING\\nDDDR VDIR\\nDDDR\\nAtrial \\ntachycard\\nia \\nterminati\\non \\nconfirmed\\nRate \\nSmoothing\\n \\napplied \\nhereATR Trigg\\ner Rate =\\n \\n170 min\\n-1\\n (ppm)\\nMTR = \\n120 \\nmin\\n-1\\n (pp\\nm)\\nAtrial Ra\\nte\\nRight Ven\\ntricular \\nRate\\nSensor Ra\\nte\\nATR/VTR F\\nallback \\nLRL = 70 \\nmin\\n-1 \\n (ppm)\\nLRL\\n = 60 min\\n-1\\n (p\\npm)\\nFigure4–39.ATRbehavior\\nCAUTION: ATRshould beprogrammed toOnifthepatient hasahistory ofatrialtachyarrhythmias. Thedeliveryof\\nCRTiscompromised because AVsynchrony isdisrupted iftheATRmodeswitchoccurs.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 139}), Document(page_content='Pacing Therapies\\nAtrialTachyResponse4-57\\nWhenaheartfailurepatient hasanatrialtachyarrhythmia episode, theeffectiveness ofCRTiscompromised because\\nAVsynchro nyisdisrupted. WhileATRcannot resolveAVasynchr ony,itcanquickly bringthebiventricular pacedrate\\nfromtheMTRtotheATR/VTR Fallback LRL,VRRrateorsensor-indicated rate(DDIRorVDIR).Programming ashort\\nATRDuration andATRFallback Timeallowsaquickermodeswitchandfasterdecrease inthebiventricular pacing\\nrate.\\nPatients withintactAVconduction mayhaveconducted ventricular ratesduring ATRepisodes. Iftheintrinsic\\nventricular rateexceedsthebiventricular pacing rateduring theATRepisode, biventricular pacing willbeinhibited.\\nForthesepatients, considerprogramming theVRRandBiVTrigger features toOn.\\nNOTE:InATR,thepacing chamber isalways biventricular ,regardless ofthepermanently programmed Ventricular\\nPacing Chamber .\\nNOTE:Paramet ersettings thatreducetheatrialsensing window mayinhibitATRtherapy.\\nATRTriggerRate\\nTheATRTrigger Ratedetermines therateatwhichthepulsegeneratorbegins todetectatrialtachycard ias.\\nThepulsegeneratormonitors atrialevents throughout thepacing cycle,exceptduring theatrialblanking periodand\\nthenoiserejection intervals. Atrialevents fasterthantheTrigger Rateincrease theATRdetection counter;atrial\\nevents slower thantheTrigger Ratedecreasethecounter.\\nWhentheATRdetection counter reachestheprogrammed entrycount,theATRDuration begins. WhentheATR\\ndetection counter countsdownfromtheprogrammed ExitCountvaluetozeroatanypointintime,ATRDuratio n\\nand/or fallback areterminated, andtheATRalgorithm isreset.Aneventmarker isgenerated whenever theATR\\ndetection counter isincremented ordecremented.\\nNOTE:During post-therap ypacing, ATRfunctions thesameasinnormal pacing.\\nATRDuration\\nATRDuration isaprogrammable valuethatdetermines thenumber ofventricular cyclesduring whichtheatrialevents\\ncontinue tobeevaluated afterinitialdetection (entrycount)ismet.Thisfeature isintended toavoidmodeswitching\\nduetoshort,nonsustained episodes ofatrialtachycard ia.IftheATRcounterreacheszeroduring ATRDuration,the\\nATRalgorithm willbereset,andnomodeswitchwilloccur.\\nIftheatrialtachycardia persists fortheprogrammed ATRDuration, thenmodeswitching occursandtheFallback\\nModeandFallback Timebegin.\\nEntryCount\\nTheEntryCountdetermines howquickly anatrialarrhythmia isinitially detected.\\nThelowertheprogrammable value,thefewerthefastatrialevents requiredtofulfillinitialdetection. Oncethe\\nnumber offastatrialevents detected equals theprogrammable EntryCount,ATRDuration begins, andtheExitCount\\nisenabled.\\nCAUTION: Exercisecarewhenprogramming theEntryCounttolowvaluesinconjunction withashortATRDuration.\\nThiscombination allowsmodeswitching withveryfewfastatrialbeats.Forexample, iftheEntryCountwas\\nprogrammed to2andtheATRDuration to0,ATRmodeswitching couldoccuron2fastatrialintervals.Inthese\\ninstances,ashortseriesofpremature atrialevents couldcausethedevicetomodeswitch.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 140}), Document(page_content='4-58Pacing Therapies\\nAtrialTachyResponse\\nExitCount\\nTheExitCountdetermines howquickly theATRalgorithm isterminated oncetheatrialarrhythmia isnolonger\\ndetected.\\nThelowertheprogrammed value,themorequickly thepulsegeneratorwillreturntoanatrialtrackingmodeoncean\\natrialarrhythmia terminates. Oncethenumber ofslowatrialevents detected equals theprogrammable ExitCount,\\nATRDuration and/or Fallback willbeterminated, andtheATRalgorithm willbereset.TheATRExitCountis\\ndecremented byatrialevents slower thantheATRTrigger Rateorbyanyventricular eventthatoccursmorethantwo\\nsecondsafterthelastatrialevent.\\nCAUTION: Exercisecarewhenprogramming theExitCounttolowvalues. Forexample, iftheExitCountwas\\nprogrammed to2,afewcyclesofatrialundersensing couldcausetermination ofmodeswitching.\\nFallbackMode\\nFallback Modeisthenontracking pacing modethatthepulsegeneratorautomatically switches towhenATRDuratio n\\nisfulfilled.\\nAfterswitching modes, thepulsegeneratorgradually decreasestheventricular pacedrate.Thisdecrease iscontrolled\\nbytheFallback Timeparameter .\\nNOTE:Dual-chamber pacing fallback modevaluesareonlyavailable whentheNormal pacing modeisalsosetto\\ndual-chamber .\\nNOTE:ATRFallback modemaybeprogrammed rateresponsive evenifthepermanent bradymodeisnon-rate\\nresponsive. Inthisscenario,thesensor parameters willindicate “ATROnly”.\\nFallbackTime\\nFallback Timecontrolshowquickly thepacedratewilldecreasefromtheMTRtotheATR/VTR Fallback LRLduring\\nfallback. Thepacedratewilldecreasetothehighest ofthesensor-indicated rate,VRRrate,ortheATR/VTR Fallback\\nLRL.\\nDuring fallback, thefollowing features aredisabled:\\n•RateSmoothing—disabled untilfallback reaches theATR/VTR Fallback LRLorthesensor-indicated rate.IfVRRis\\nenabled, thenRateSmoothing isdisabled throughout themodeswitch\\n•RateHysteresis\\n•PVARP Extension\\nFallbackLRL\\nTheATR/VTR Fallback LRListheprogrammed lowerratetowhichtheratedecreases during modeswitching. The\\nATR/VTR Fallback LRLmaybeprogrammed higherorlowerthanthepermanent bradyLRL.\\nTheratewilldecrease tothehighest among thesensor-indicated rate(whenapplicable), theVRRrate(ifenabled),\\nandtheATR/VTR Fallback LRL.\\nTheATR/VTR Fallback LRLisalsotheBackup VVIpacing rateduring backuppacing inthepresenceofdetected\\nventricular arrhythmias.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 141}), Document(page_content='Pacing Therapies\\nAtrialTachyResponse4-59\\nEndofATREpisode\\nTheEndofATREpisode identifies thepointwhenthepulsegeneratorrevertstoAV-synchr onousoperationbecause\\ntheatrialarrhythmia isnolongerdetected.\\nWiththetermination ofthearrhythmia, theATRExitCountdecrements fromitsprogrammed valueuntilitreaches 0.\\nWhentheATRExitCountreaches 0,thepacing modeautomatically switches totheprogrammed trackingmode,and\\nAV-synchr onousoperationisrestored.\\nVentricular TachyResponse (VTR)\\nVTRservesasanautomatic modeswitchforbackupVVIpacing inthepresenceofdetected ventricular\\ntachyarrhythmias.\\nWhendetection issatisfied inaventricular tachycardia zone,thepacing modeswitches toVVI(BiV)ortoOffifthe\\ncurrentmodeisAAI(R)orOff.\\nWhenthemodeswitches, backup pacing occursattheprogrammed ATR/VTR Fallback LRLandusestheprogrammed\\nATPventricular PulseWidthandAmplitude values.\\nVentricular RateRegulation (VRR)\\nVRRisdesigned toreducetheV–Vcyclelengthvariability during partially conducted atrialarrhythmias bymodestly\\nincreasing theventricular pacing rate.Inaddition, VRRpreservesCRTdelivery during conducted atrialarrhythmias.\\nTheVRRalgorithm calculates aVRR-indicated pacing interval basedonaweighted sumofthecurrent V–Vcycle\\nlengthandthepreviousVRR-indicated pacing intervals.\\n•Pacedintervals havemoreinfluence thansensed intervalssuchthatpacedevents causeadecreaseintheVRR-\\nindicated rate.\\n•Forsensed intervals,theVRR-indicated ratemaybeincreased; however ,theinfluence istempered bythe\\nprevioushistory.\\n•TheVRR-indicated rateisfurther bound bytheLRLandtheVRRMPR.\\nTheprogrammable valuesforVRRareMin(Minimum), Med(Medium), andMax(Maximum). Theprogrammed value\\nwillaffectthedegree ofrateregulation asfollows:\\n•Ahighersetting willincrease CRTpacing morethanalowersetting (i.e.,Maxvs.Med).\\n•Ahighersetting willdecrease V–Vvariability morethanalowersetting.\\n•Alowersetting willresultinawiderrangeofV–Vvariability andlessventricular CRTpacing.\\nNOTE:VRRhasthepotential toincreaseCRTdelivery during atrialtachyarrhythmias andshould beprogrammed on\\natthemaximum setting toincreasetheventricular pacing percentandmaximize CRTdelivery during conducted atrial\\ntachyarrhythmias.\\nWhenVRRisprogrammed onintrackingmodes, itisonlyactivewhenanATRmodeswitchhasoccurred.Oncethe\\ntrackingmodeoperationresumes atthetermination oftheatrialarrhythmia, VRRbecomesinactive. Intracking\\nmodes wherebothRateSmoothing andVRRareprogrammed on,RateSmoothing isdisabled whenVRRisactive\\nduring ATRandre-enabled oncetheATRterminates.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 142}), Document(page_content='4-60Pacing Therapies\\nAtrialTachyResponse\\nWhenprogrammed oninnontrac kingmodes, VRRiscontinually activeandupdates theVRR-indicated pacing rate\\nandthesmoothed average oneachcardiaccycle.\\nVentricular RateRegulation Maximum PacingRate(VRRMPR)\\nTheVRRMPRlimitsthemaximum pacing rateforVRR.\\nVRRoperates between theLRLandtheMPR.\\nBiventricular Trigger\\nBiventricular Trigger (BiVTrigger) isdesigned topromotesynchro nizedRVandLVcontractions inthepresenceofRV\\nsensed events. Itdoesthisbypacing theleftandrightventricles immediately afteranysensed RVevent,including\\nanyPVCs.Whenusedinconjunction withVRR,BiVTrigger isdesigned toprovideadditional CRTsupport during atrial\\ntachycard ias.\\nBiventricular Trigger operatesbetween theLRLandtheMPR.PacesthatoccurasaresultofBiVTrigger aremarked as\\nRVP-Tr andLVP-Tr withnoLVOffsetapplied. Thesetriggeredevents arecounted toward RVSandLVPcounters.\\nBiventricular Trigger isseparatelyprogrammable fornormal pacing andATRFallback.\\nNOTE:Ifthepulsegeneratorisprogrammed toRVorLVOnly,pacing inbothchambers willoccurifBiVTrigger is\\nenabled.\\nBiventricular TriggerMaximum PacingRate(MPR)\\nTheBiventricular Trigger MPRlimitsthemaximum pacing ratethatBiventricular Trigger canreach.\\nAtrialFlutterResponse (AFR)\\nAtrialFlutterResponse isdesigned to:\\n•Preventpacing intothevulnera bleperiodfollowing anatrialsense.Pacing intothevulnerableperiodcouldoccur\\nifanatrialpaceisscheduled soonafterarefractory atrialsense.\\n•Provide immediate nontrackingofatrialrateshigherthantheAFRTrigger Rate.\\nThenontrackingbehavior ismaintained foraslongasatrialevents continually exceedtheAFRTrigger Rate.\\nExample: WhenAFRisprogrammed to170ppm,adetected atrialeventinsidethePVARP orapreviously triggered\\nAFRinterval startsanAFRwindow of353ms(170ppm).Atrialdetection insidetheAFRisclassified asasensewithin\\ntherefractoryperiodandisnottracked.AtrialtrackingmayonlyoccurafterbothPVARP andtheAFRwindow expire.\\nPacedatrialevents scheduled insideanAFRwindow aredelayed untiltheAFRwindow expires.Iftherearefewerthan\\n50msremaining beforethesubsequent ventricular pace,theatrialpaceisinhibited forthecycle.\\nNOTE:Thisfeature mayoverride theprogrammed AVDelayandtempor arilyaltertheeffectiveness ofCRTdueto\\ntheeffectonAVsynchro ny.\\nVentricular pacing isnotaffected byAFRandwilltakeplaceasscheduled. Thewideprogrammable rangeforAFR\\nTrigger ratesallowsforappropriatesensing ofslowatrialflutters. High-rate atrialsensing maycontinuously retrigger\\ntheAFRwindow ,effectively resulting inbehavior similar totheVDI(R)fallback mode.\\nNOTE:Foratrialarrhythmias thatmeettheprogrammed AFRratecriteria, usingtheAFRfeature willresultinslower\\nventricular pacing rates.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 143}), Document(page_content=\"Pacing Therapies\\nAtrialTachyResponse4-61\\nNOTE:WhenbothAFRandATRareactiveinthepresenceofatrialarrhythmias, nontracking ventricular paced\\nbehavior mayoccursooner,buttheATRModeSwitchmaytakelonger.Thisisbecause theATRDuration feature\\ncountsventricular cyclesformeeting duration andtheAFRfeatureslowstheventricular pacedresponse tofastatrial\\narrhythmias.\\nPMTTermination\\nPMTTermination detects andattempts tointerrupt pacemak er-mediated tachycard ia(PMT)conditions.\\nAVsynchro nymaybelostformanyreasons, including atrialfibrillation, PVCs,PACs,atrialoversensing, orlossofatrial\\ncapture.Ifthepatient hasanintactretrogradeconduction pathway whenAVsynchronyislost,theunsynchroniz ed\\nbeatmayconductretrogradetotheatrium, resultinginprematu reatrialdepolarization. InDDD(R) andVDD(R) pacing\\nmodes, thedevicemaydetectandtrackretrogradeconducted P-waves thatfalloutside ofPVARP. Therepeated cycle\\nofsensing andtrackingretrogradeconduction isknown asPMT,whichcanresultintriggered ventricular pacing rates\\nashighastheMTR.Programming certainrefractoryperiods (e.g.,PVARP afterPVC)canreducethelikelihoodof\\ntrackingretrogradeevents. RateSmoothing canalsobeusefulincontrollingthepulsegenerator'sresponseto\\nretrograde conduction.\\nWhenthepulsegenerator'sresponse toretrograde conduction hasnotbeencontrolled bydeviceprogramming, PMT\\nTermination (whenprogrammed toOn)isusedtodetectandterminate PMTwithin16cyclesofonsetwhenthe\\nfollowing conditions havebeenmet:\\n•16successive ventricular pacesarecountedattheMTRfollowing atrialsensed events\\n•All16V–Aintervalsarewithin32ms(precedingorfollowing) ofthesecond V–Ainterval measur edatMTRduring\\nthe16ventricular pacedevents (todistinguish Wenckebachbehavior fromPMT)\\nWhenbothconditions aremet,thepulsegeneratorsetsthePVARP toafixedsetting of500msforonecardiac cycle\\ninanattempt tobreakthePMT.Ifbothconditions arenotmet,thepulsegeneratorcontinues tomonitor successive\\nventricular pacesforthepresenceofaPMT.\\nWhenPMTTermination isprogrammed toOn,thepulsegeneratorstoresPMTepisodes intheArrhythmia Logbook.\\nNOTE:Although theV–Aintervalevaluation helpsdiscriminate truePMT(stable V–Aintervals)fromupperrate\\nbehavior duetosinustachycardia ornormal exerciseresponse(typically unstable V–Aintervals), itispossible thata\\npatient’s intrinsic atrialratecanmeetPMTdetection criteria. Insuchcases,ifPMTTermination isprogrammed On,the\\nalgorithm willdeclaretherhythm aPMTandextend PVARP onthe16thcycle.\\nNOTE:Because retrograde conduction timesmayvaryoverapatient's lifetime duetotheirchanging medical\\ncondition, occasional programming changes maybenecessary.\\nIfretrogradeconduction isevident inastoredEGM,youcanevaluate theelectrogr amand/or perform athreshold test\\ntoconfirmappropr iateatrialpacing andsensing. IfstoredEGMsarenotavailable forreview,followthesestepstouse\\nthePRMtoassistinV–Aintervalevaluation:\\n1.FromtheTestsscreen,selecttheTempBradytab.\\n2.Programanappropr iateatrialsensing modethatprovidesatrialmarkers (VDD,DDD,orDDI).\\n3.Programthemaximum PVARP toavalueshorter thantheaverageretrogradeconduction time.\\nNOTE:Scientific literaturesuggests thattheaverageretrogradeconduction timeis235±50ms(witharange\\nof110–450 ms).1\\n1.Furman S,HayesD.L.,Holmes D.R.,APracticeofCardiac Pacing. 3rded.Mount Kisco,NewYork:FuturaPublishing Co.;1993:74-75.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 144}), Document(page_content='4-62Pacing Therapies\\nRateEnhancements\\n4.ProgramtheLRLtoensure pacing abovetheintrinsic atrialrate(e.g.,90,100,110…).\\n5.Beginprinting thereal-time ECG.\\n6.SelecttheStartbutton toactivate thetemporary parameters.\\n7.Whentesting iscomplete forthespecified LRLvalue,selecttheStopbutton.\\n8.Stopprinting thereal-time ECG.\\n9.Evaluate theECGstripforV–Aconduction (VPfollowed byanAS).Lookforstableandconsistent intervals\\nsuggestive ofretrograde conduction.\\n•Ifretrogradeconduction wasidentified, comparetheretrograde V–Aintervaltimetotheprogrammed\\nrefractoryperiod. Consider programming PVARP totheappropriate valuesothattheretrogradeeventisnot\\ntracked.\\n•Ifretrogradeconduction wasnotidentified, thePMTepisode maybearesultofnormal upperratebehavior .\\nReview Histograms toseehowoftentherateisattheMTR,andconsider raising theMTR(ifclinically\\nappropriate).\\n10.Ifnecessary,repeatthisprocedurewithdifferen tLRLvalues, asretrograde conduction mayoccuratdifferent\\nrates.\\nRATEENHANCEMENTS\\nTrackingPreference\\nTrackingPreferenceisdesigned tomaintain atrial-track edventricular pacing inDDD(R) andVDD(R) modes by\\nidentifying atrialevents fortrackingthatshould betrackedbutfallwithinPVARP. Thisfeature supports CRTdelivery\\nforatrialratesbelowbutneartheMTR;otherwise,therapymightbeinhibited.\\nAtrialevents canfallwithinPVARP whenapatient hasacombination ofalongintrinsic intracardiacAVintervalanda\\nlongPVARP. Iftwosuccessivecyclesoccurinwhichasensed RVeventisprecededbyanatrialsensed eventin\\nPVARP, thepulsegenerator shortens PVARP untilnormal atrial-tr ackedventricular pacing isestablished. ThePVARP is\\nshortened enough fortrackingtooccuronanyatrialeventthatoccursaftertheA-Blank afterRV-Sense cross-chamber\\nblanking periodends.Whenatrialtrackingisre-established, theAVDelaymaybeextendedtopreventviolation of\\ntheMTR.Theshortened PVARP remains ineffectuntilaventricular paceoccursattheprogrammed AVDelay.By\\nprogramming TrackingPreferencetoOn,continuous CRTisdeliveredatratesbelowMTR-rateswhichotherwisemight\\nbeinhibited whenthesumofPVARP andtheintrinsic intracardiac AVinterval islongerthantheMTRinterval.\\nTheeffectofTrackingPreferenceonatrialratesisillustratedbelow(Figure4–40TrackingPreferenceonatrialevents\\nthatshould betrackedbutfallwithinPVARP onpage4-63).\\nNOTE:Tracking Preferenceisinhibited iftheatrialrateintervalisgreaterthanorequaltotheMTRinterval.This\\npreventsthetrackingofpotentially pathological atrialratesandPMT.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 145}), Document(page_content=\"Pacing Therapies\\nRateHysteresis4-63\\nPVARP + intrinsic \\nintracardiac AV interval \\nPacing rate reaches MTR, \\nVentricular events are sensed. \\nVentricular sens e \\nMTR \\nPacing if Tracking Preference \\nis On; No pacing if Tracking \\nPreference is Of f. \\nVentricular pac e \\nTime Ventricular pac e \\nRate \\nFigure4–40.TrackingPreferenceonatrialeventsthatshouldbetrackedbutfallwithinPVARP\\nRateHysteresis\\nRateHysteresis canimprovedevicelongevity byreducing thenumber ofpacing stimuli. Thisfeature isavailable in\\nDDDandAAImodes andisactivated byasinglenonrefractory ,atrialsensed event.\\nInDDDandAAImodes, Hysteresisisdeactivated byasingleatrialpaceattheHystere sisRate.InDDDmode,\\nHysteresisisdeactivated byanatrialrateabovetheMTR.\\nWhenRateSmoothing Downisenabled, RateHysteresisremains ineffectuntilpacing occursattheHysteresisRate.\\nThisallowsRateSmoothing tocontrolthetransition totheHysteres isRate.\\nHysteresis Offset\\nHysteresisOffsetisusedtolowertheescape ratebelowtheLRLwhenthepulsegeneratorsenses intrinsic atrial\\nactivity.\\nIfintrinsic activity belowtheLRLoccurs,thenHystere sisOffsetallowsinhibition ofpacing untiltheLRLminus\\nHysteresisOffsetisreached. Asaresult,thepatient mightbenefit fromlongerperiods ofsinusrhythm.\\nSearchHysteresis\\nWhenSearchHysteresis isenabled, thepulsegenerator periodically lowers theescape ratebytheprogrammed\\nHysteresisOffsetinordertorevealpotential intrinsic atrialactivity belowtheLRL.Theprogrammed number ofsearch\\ncyclesmustbeconsecutively atrialpacedforasearchtooccur.\\nExample: Atarateof70ppmandasearchinterval of256cycles,asearchforintrinsic atrialactivity wouldoccur\\napproximately every3.7minutes (256÷70=3.7).\\nDuring SearchHysteresis, thepacing rateisloweredbytheHysteresisOffsetforupto8cardiaccycles.Ifintrinsic\\nactivity issensed during thesearchperiod, Hystere siswillremainactiveuntilanatrialpaceoccursatthehysteresis\\noffsetrate.\\nRateSmoothing isdisabled during thesearchcycles.Ifnointrinsic atrialactivity isdetected during the8-cycle search,\\nthepacing rateisbroughtuptotheLRL.RateSmoothing Up,ifenabled, controlsthepacing rateincrease.\\nRateSmoothing\\nRateSmoothing controls thepulsegenerator'sresponse toatrialand/or ventricular ratefluctuations thatcause\\nsudden changes inpacing intervals.RateSmoothing isanimportant enhancement toATRbecause itcansignificantly\\nreducetheratefluctuations associated withtheonsetandcessation ofatrialarrhythmias.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 146}), Document(page_content='4-64Pacing Therapies\\nRateHysteresis\\nWithout RateSmoothing, asudden, largeatrialrateincreasewillcauseasimultaneous sudden increaseinthepaced\\nventricular rateashighastheprogrammed MTR.Patients whoexperienc elargevariations intheirventricular paced\\nratecanfeelsymptomatic during theseepisodes. RateSmoothing canpreventthesesudden ratechanges andthe\\naccompanying symptoms (suchaspalpitations, dyspnea, anddizziness).\\nInanormal conduction system, limited cycle-to-cycle ratevariations occur.However ,thepacedratecanchange\\ndramatic allyfromonebeattothenextinthepresenc eofanyofthefollowing:\\n•Sinoatrial disease suchassinuspauseorarrest,sinoatrial block,andbrady-tachy syndrome\\n•PACsand/or PVCs\\n•Pacemak erWencke bach\\n•Intermittent, brief,self-terminating SVTs,andatrialflutter/fibrillation\\n•Retrogr adeP-waves\\n•Pulsegeneratorsensing ofmyopotential signals, EMI,crosstalk, etc.\\nInsingle-chamber modes, RateSmoothing operates between:\\n•TheLRLandtheMPRwhenprogrammed VVIorAAI\\n•TheLRLandtheMSRwhenprogrammed VVIRorAAIR\\nIndual-chamber modes, RateSmoothing operatesbetween:\\n•TheLRLandthegreateroftheMSRorMTRwhenprogrammed DDD(R) orVDD(R)\\n•TheLRLandMPRwhenprogrammed toDDI\\n•TheLRLandMSRwhenprogrammed toDDIR\\nRateSmoothing isalsoapplicable between theHysteresisRateandLRLwhenHysteresisisactive,exceptduring\\nSearchHysteresis.\\nWhenRateSmoothing isprogrammed toOn,itisfunctional except:\\n•During the8cyclesofrateSearchHysteresis\\n•During ATRFallback untilfallback reaches theATRLRL,thesensor-indicated rate,ortheVRRinterval\\n•During VRRwhenactive\\n•Upontriggering PMTTermination\\n•Immediately following programmed LRLincreases\\n•Whentheintrinsic rateisabovetheMTR\\n•WhenTracking Preferenceisactive', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 147}), Document(page_content=\"Pacing Therapies\\nRateHysteresis4-65\\nProgrammable Values\\nRateSmoothing valuesareapercentage oftheRVR–Rinterval(3%to25%in3%increments) andcanbe\\nindependently programmed for:\\n•Increase—Rate Smoothing Up\\n•Decrease—Rate Smoothing Down\\n•Off\\nThepulsegeneratorstoresthemostrecentR–Rintervalinmemor y.R-waves maybeeitherintrinsic orpaced. Based\\nonthisR–Rintervalandtheprogrammed RateSmoothing value,thedevicelimitsthevariation inpacedrateona\\nbeattobeatbasis.\\nItisimportant toascertain thepatient's physiologic cycle-to-cycle variation andprogramtheRateSmoothing\\nparameter toavaluethatprotectsagainst pathologic intervalchanges, yetallowsphysiologic intervalchanges in\\nresponse toincreasesinactivity orexercise.\\nRateSmoothing Up\\nRateSmoothing Upcontrols thelargest pacing rateincrease allowed whentheintrinsic orsensor rateisincreasing.\\nNOTE:RateSmoothing Upwilltransiently modify theprogrammed AVDelay.Thiscouldchange theeffectiveness of\\ntheAVDelayrecommended withSmartDelay optimization.\\nWhenRateSmoothing Upisprogrammed On,CRTiscompromised during episodes ofatrialrateincreasesthat\\nexceedtheprogrammed value.\\n•Forpatients withAVblock,thisoccursbecause RateSmoothing prolongstheAVDelayfromtheoptimal setting\\nasitcontrolsthebiventricular pacing ratewhiletheatrialrateincreases.\\n•Forpatients withnormal AVconduction, biventricular stimulation (CRT)maybeinhibited inoneormorecycles\\nduring theRateSmoothing operationbecause intrinsic AVconduction mayoccurduring theprolonged AVDelay\\nandinhibitventricular pacing.\\nWhiletheeffectoftheRateSmoothing Upoperationmayonlybetransient anditsimpact onCRTminimal, consider\\nthefollowing recommendations whenprogramming thisparamete rOn:\\n•Addressonlypatient-specific, sudden atrialrateincreases\\n•Usethehighest valuethatcanachieve thedesiredcontrolbecause thehigherthevalue,thelesstheimpact on\\ntheAVDelayextension\\nRateSmoothing Down\\nRateSmoothing Downcontrolsthelargest pacing ratedecrease allowed whentheintrinsic orsensor rateis\\ndecreasing.\\nCRTdelivery isnotaltered byprogramming RateSmoothing DownOn.However ,itisimportant toconsider thatwhen\\nRateSmoothing DownisOninDDD(R) mode,atrialpacing willoccurduring thedownward RateSmoothing\\noperation.TheAVDelayforoptimal CRTmaybedifferentduring atrialpacing thanduring intrinsic sinusrhythm.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 148}), Document(page_content='4-66Pacing Therapies\\nRateSmoothing ExampleBasedonaDual-Chamber TrackingMode\\nNOTE:WhenRateSmoothing Downisprogrammed OnandRateSmoothing Upisprogrammed Off,thepulse\\ngeneratorwillautomatically preventfastintrinsic beats(e.g.,PVCs)fromresetting theRateSmoothing Downescape\\nrateanyfasterthan12%percycle.\\nRateSmoothing Maximum PacingRate(MPR)\\nTheRateSmoothing Maximum Pacing Rateplacesalimitonthemaximum pacing ratethatRateSmoothing can\\nreach.\\nTheRateSmoothing Downparameter requiresaprogrammed MPRwheninAAI,VVI,orDDI.RateSmoothing will\\nthenbeusedonlybetween theMPRandtheLRLortheHysteresis Rate(ifapplicable).\\nWhenbothVRRandRateSmoothing areprogrammed onintheVVI(R)orDDI(R)mode,VRRwillhavepriority.\\nRateSmoothing ExampleBasedonaDual-Chamber TrackingMode\\nBasedonthemostrecentR–Rintervalstoredinmemory andtheprogrammed RateSmoothing value,thepulse\\ngeneratorsetsupthetwosynchro nization windows forthenextcycle:onefortheatrium andonefortheventricle.\\nThesynchronization windows aredefined below:\\nVentricular synchron ization window: previousR–Rinterval±RateSmoothing value\\nAtrialsynchronization window: (previousR–Rinterval ±RateSmoothing value)-AVDelay\\nThefollowing example explainshowthesewindows arecalculated (Figure 4–41Ratesmoothing synchronization\\nwindow onpage4-67):\\n•Previou sR–Rinterval=800ms\\n•AVDelay=150ms\\n•RateSmoothing Up=9%\\n•RateSmoothing Down=6%\\nThewindows wouldbecalculated asfollows:\\nVentricular Synchronization Window =800-9%to800+6%=800ms-72msto800ms+48ms=728msto\\n848ms\\nAtrialSynchronization Window =Ventricular Synchronization Window -AVDelay=728ms-150msto848ms-\\n150ms=578msto698ms\\nThetimingforbothwindows isinitiated attheendofeveryR–Rinterval(RVeventorLVpaceswhenthePacing\\nChamber isprogrammed toLVOnly).\\nIfpacedactivity istooccur,itmustoccurwithintheappropriatesynchronization window .', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 149}), Document(page_content='Pacing Therapies\\nLeadConfiguration4-67\\nPaced A V Delay (150 ms)\\nAtrial \\nEvent\\nAtrial \\nEvent\\nR-R Interval (800 ms)\\nRV Event\\nAtrial Smoothing Window\\n578 ms 650 ms 698 ms\\nRV Smoothing Window728 ms 800 ms 848 ms RV Event\\nFigure4–41.Ratesmoothing synchronization window\\nLEADCONFIGURATION\\nThepulsegeneratorhasindependently programmable leadconfigurations forthefollowing:\\n•Atrium\\n•RightVentricle\\n•LeftVentricle\\nTheatrialandRVleadsaresettoBipolar pacing andsensing. Theatrialleadhastheoption ofbeingprogrammed\\nOff.\\nTheinputimpedance is>100KΩforeachsense/pac eelectrode pair.\\nCAUTION: IftheLeadConfiguration isprogrammed toBipolar whenaunipolar leadisimplanted, pacing willnot\\noccur.\\nLeftVentricular ElectrodeConfiguration\\nTheLVElectrodeConfigur ationprovidesprogrammable options forLVleadpacing andsensing viatheLeadSettings\\nscreen(accessible fromtheNormal Settings screen).\\nCAUTION: Proper programming oftheLVcoronaryvenous LeadConfiguration isessential forproper LVlead\\nfunction. ProgramtheLeadConfiguration inaccordancewiththenumber ofelectrodesontheLVlead;otherwise,\\nerraticLVsensing, lossofLVpacing, orineffective LVpacing mightoccur.\\nThefollowing programming options areavailable fordevices withanIS-1orLV-1leftventricular leadport:\\n•Dual—used whenanLVleadwithtwoelectrodesisimplanted\\n•Single—used whenanLVleadwithonlyoneelectrode isimplanted\\n•None—used whenanLVleadisnotimplanted\\nNOTE:Thenominal LVElectrodeConfigur ationisNone,which,alongwiththenominal Ventricular Pacing\\nChamber ofBiV,resultsinaparame terinteraction. Thisisintended behavior toensure theclinician selects an\\nappropriateLVElectrodeConfiguration (dualorsingle) fortheimplanted LVlead.\\nFordeviceswithanIS4leftventricular leadport,theLVElectrodeConfiguration isautomatically settoQuadripolar.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 150}), Document(page_content='4-68Pacing Therapies\\nLeadConfiguration\\nThesepulsegeneratorsareintended forusewithanLVlead;however ,theremaybeclinical situations suchasthose\\ndescribed belowinwhichanLVleadisnotused:\\n•TheLVleadcannot bepositioned, andadecision ismadetotempor arilyusethepulsegeneratorwithout anLV\\nlead(plugtheunused LVport).\\n•TheLVleaddislodges toasuboptimal position, andadecision ismadetoleavetheleadimplanted and\\nconnecte dbutnotuseit.\\nThepulsegenerator cannot detectwhether anLVleadispresent orabsent. Therefore,ifanLVleadisnotused,\\nconsiderthefollowing programming adjustments, whichcanhelptopreventreportingofirrelevant LVdiagnostic\\ninformation, minimize storageofLVinformation (e.g.,counters,EGMs,markers,intervals),minimize diaphra gm\\nstimulation, andimprovedevicelongevity:\\nNOTE:Ifthesestepsareperformed inadifferent sequence, thePRMmaydisplay warning messages andcertain\\nstepsmaynotbeavailable.\\n1.ProgramBiVTrigger toOffunderboththeATRsection andtheVentricular Regulation section oftheAtrialTachy\\nTherapy Settings screen.\\n2.ProgramLVAmplitude andLVPulseWidthtotheminimum valueforbothNormal BradyandPost-Therapy\\npacing.\\n3.ProgramtheVentricular Pacing Chamber toRVOnly.\\n4.TurnoffLVsensing:\\na.FordeviceswithanIS-1orLV-1leftventricular leadport:\\ni.Change theLVElectrode Configur ationtoSingleorDual.\\nii.ProgramLVSensetoOff.\\niii.ProgramtheLVElectrode Configur ationtoNone.\\nb.FordeviceswithanIS4leftventricular leadport:\\ni.SelecttheDisable Sensing checkbox ontheLVSenseselection screen.\\nii.SelecttheAcceptbutton.\\niii.Programthedevice.\\n5.Programthedailyleadmeasur ements forLVIntrinsic Amplitude andLVImpedance toOff.\\nWhenthisprogramming sequence isfollowed, LVpacing andsensing areturned Off,andthefollowing are\\nunavailable:\\n•LVelectrograms\\n•LVmarkers\\n•LVintervals\\n•LVOffset\\n•LV-Blank afterA-Pace cross-chamber blanking period', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 151}), Document(page_content='Pacing Therapies\\nLeadConfiguration4-69\\n•SmartDelay optimization (non-Quadripolar devices)\\n•LVdailymeasur ements\\nNOTE:Somefeatures(e.g.,ATRModeSwitch, ATP,andElectrocautery ProtectionMode)tempor arilyuseBiVpacing\\n(regardless ofLVLeadConfigur ation),whichwilladdLVdatatothecounters, electrograms, markers, andintervals.\\nAnytimeachange ismadetotheElectrode Configur ation,itisimportant toverifyleadsystem baseline\\nmeasur ements toensure optimal functioning.\\nTheprogrammed selections arereflected intheElectrode Configur ationillustration ontheprogrammer LeadsSetting\\nscreen(Figure 4–42HeartLV,andRVleadinsituonpage4-69).Illustrations willdynamically adjustonthe\\nprogrammer screentoreflectthecurrently selected LVPaceandLVSenseconfigurations.\\nLV Pace\\nRV TipRV Coil\\nPulse \\nGenerator\\n \\nCan\\nAtrial Le\\nad\\nLV Lead\\nLV Ring\\nLV Tip\\nRV Lead\\nHeart\\nLeftillustration: heartwithLVandRVleads.Rightillustration: leadsontheprogrammer screen.\\nFigure4–42.HeartLV,andRVleadinsitu\\nLVPaceandSenseConfigurations\\nMultiple LVpaceandsenseconfigurations areavailable forthelead,allowing youtochange thepacing orsensing\\nvectors forincreasedsignalselection. Fordevices withanIS-1orLV-1leftventricular leadport,additional\\nprogramming options areavailable whenadual-electro deLVleadisimplanted andthecorresponding Electrode\\nConfigur ationisprogrammed toDual.Additionally ,LVsensing canbedisabled byselecting OffastheLVSense\\nconfiguration.\\nIllustrationsofpaceandsenseconfigurations areshown ontheprogrammer LeadsSetting screen.\\nQuadripolar Devices\\nFordeviceswithanIS4leftventricular leadport,17pacing configurations and8sensing configurations areavailable.\\nAtableofprogrammable options isprovidedwithintheLVSenseandLVPaceselections.\\nAdditionally ,theLVVectorGuide feature isavailable tostreamline thetesting required todetermine theoptimal LV\\nPacing LeadConfigur ationforeachindividual patient. Theclinician canquickly evaluate multiple Quadripolar LV\\npacing vectors andthenprogramthedesired configuration (\"LVVectorGuide\" onpage5-17).\\nFortheLVPaceconfiguration, thepacing stimulus travelsbetween thecathode (negative [-]electrode) andtheanode\\n(positive [+]electrode).Follow thesestepstoprogramtheLVPaceconfiguration:\\n1.Determine thedesiredCathode (-)whichislistedontheleft-handsideofthetable.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 152}), Document(page_content='4-70Pacing Therapies\\nLeadConfiguration\\n2.Determine thedesired Anode (+)whichislistedatthetopofthetable.\\n3.Selecttheoption inthetablewhichcorresponds tothedesired Cathode andAnode combinatio n.\\nTheillustrationtotherightofthetablewilldynamically adjusttoreflectthecurrentlyselected LVconfiguration. For\\nexample, ifLVTip1isselected astheCathode andRVisselected astheAnode, thisconfiguration willbereflected in\\ntheassociated illustration totherightofthetable(Figure4–43Pacing leadconfiguration screenforQuadripolar\\ndevices onpage4-70).\\nFigure4–43.Pacingleadconfiguration screenforQuadripolar devices\\nFortheLVSenseconfigur ation,thepatient’s intrinsic cardiacsignals willbesensed between Electrode1andElectrode\\n2.Selecttheoption inthetablewhichcorresponds tothedesired Electrode1andElectrode2combination. The\\nillustrationtotherightofthetablewilldynamically adjusttoreflectthecurrentlyselected LVconfiguration. For\\nexample, ifLVTip1isselected asElectrode1andLVRing2 isselected asElectrode2,thisconfiguration willbereflected\\nintheassociated illustrationtotherightofthetable(Figure4–44Sensing leadconfiguration screenforQuadripolar\\ndevices onpage4-70).Additionally ,LVsensing canbeturned offbyselecting theDisable Sensing checkbox.\\nFigure4–44.Sensingleadconfiguration screenforQuadripolar devices\\nLVElectrograms\\nReal-time LVEGMscanbeusedtoassessLVleadperformanc eandtoassistinoptimizing someprogrammable\\nparamet ers(e.g.,AVDelay,LVOffset).\\nLVEGMsandassociated LVeventmarkers areavailable fordisplay orprinting inallsenseconfigur ations.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 153}), Document(page_content='Pacing Therapies\\nLeftVentricular MultiSite Pacing4-71\\nLEFTVENTRICULAR MULTISITE PACING\\nLeftVentricular MultiSite Pacing (LVMSP)isavailable indevices thatsupport anIS4leftventricular lead.\\nLVMSPisassociated withincreasedcardiacresynchroni zationtherapyresponse innon-respon dersbydelivering two\\nLVpulsesperpacing cycle.\\nActivating anadditional LVelectrodewillcauseadditional battery consumption. Itisrecommen dedthatthisbe\\nconsidere dagainst thebenefits ofLVMSP.Estimated battery lifeisreflected ontheprogrammer System Summar y\\nscreen.LVMSPmaybedisabled inordertopreservedevicelongevity (seelongevity information inthePhysician\\'s\\nTechnical Manual).\\nTodetermine whether apatient isaresponder ornon-responder toconventional cardiacresynchronization therapy\\nwithsingle-site LVpacing orLVMSP,assessthefollowing criteria, individually orincombination, afteraseveral\\nmonth periodofthetherapy:\\n•Echocard iographic Parameters, e.g.,LeftVentricular End-Systolic Volume (LVESV)\\n•Quality ofLife,e.g.,Patient GlobalAssessment\\n•NewYorkHeartAssociation (NYHA) classification\\n•HeartFailurehospitalization\\nLVMSPisavailable inNormal BradyMode.WhenLVMSPisenabled, itwillalsobedeliveredwithBiVTrigger and\\nduring ATRModeSwitch.\\nWhenLVMSPisprogrammed On,thefirstLVpaceisdesignated asLVa,andthesecond paceasLVb.LVbalways\\nfollows LVabyaprogrammable delay.\\nNOTE:WhenLVMSPisprogrammed On,leadimpedances willbemeasur edanddisplayed forboththeLVaand\\ntheLVbpacevectors.\\nThefollowing pacing sequenc es,alongwithassociated independently programmable delays, areavailable fortherapy\\ndelivery:\\n•LVa>>LVb\\n•LVa>>LVb>>RV\\nSinceoptimizing theAVDelaycansignificantly influence CRTeffectiveness, considerrunning SmartDelay withLV\\nOffsetprogrammed to0mspriortoconfiguring MultiSite pacing vectors andoffsets. See\"SmartDelay Optimization\"\\nonpage4-76forinstructions andrecommen dations onrunning SmartDelay .\\nTwoadditional features, SmartVector andSmartOffset, canbeusedtofacilitate programming LVMSPusingdatafrom\\nLVVectorGuide. Thesefeatures relyoninputfromLVVectorGuide andneedsufficient data(i.e.,vectors fromatleast\\ntwodifferent cathodes, including LVTip1; vectors fromallfourcathodes arepreferable) tomakerecommendations. For\\nmoreinformation aboutLVVectorGuide, see\"LVVectorGuide\" onpage5-17.SmartVector andSmartOffset are\\nprogrammed viatheLVMSPConfigura tionSettings screen(Figure 4–45LVMultiSite Pacing Configur ationSettings\\nscreenonpage4-73),whichalsoprovidesaccesstotheLVVectorGuide settings.\\nSmartVector\\nTheSmartVector feature provides recommendations fortheLVMSPpacing sequence, pacing vectors, andpacing\\ncharacteristics (amplitude andpulsewidth)basedonRVS-LVS delayandelectrodeseparation distance.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 154}), Document(page_content='4-72Pacing Therapies\\nLeftVentricular MultiSite Pacing\\nNOTE:SmartVector isoptimiz edforBSCquadripolar spiralleads.Ifadifferentleadisused,theusermayoverride\\ntherecommendations ifdesired.\\nForLVa,SmartVector generallyrecommends thevectorwiththelongest RVS-LVS delaythathasacceptable threshold,\\nimpedance, andnophrenicnervestimulation (PNS).ForLVb,SmartVector recommends thevectorthatisphysically\\nfarthest fromtheLVarecommendation, hasanacceptable threshold, impedance, andnoPNS.LVaandLVbcannot\\nsharethesamecathode.\\nNOTE:Ifyoumanually selectavectorpriortorunning SmartVector ,SmartVector mayoverride thevector.\\nSmartVector isunable tomakearecommendation inthefollowing circumstanc es:\\n•Ifthereisinsufficient ormissing data,amessage appears tosuggest thattheuserassessadditional vectors or\\ncomplete alltestsfortheselected vectors.\\n•Ifnoacceptable combination oftwopacing vectors isavailable, amessage appears tosuggest theuserre-run\\nvectors withalowerPNSThreshold orhigherQuickCaptureThreshold.\\nSmartOffset\\nTheSmartOffset feature providesrecommendations fortheprogrammed delaysbetween theventricular paces.The\\nmaximum totaldelayfromthefirstventricular pacetothelastventricular paceofthepacing sequenc eis100ms.\\nSmartOffset isunable tomakearecommendation inthefollowing circumstances:\\n•IfRVS-LVS Delaytestshavenotbeenrunfortheselected vector(s), amessage appears tosuggest thattheuser\\ncomplete theRVS-LVS Delaytestforthevectors chosen.\\n•IftheRVS-LVS Delaymeasur ementfortheselected vectors isinvalid, amessage appears tosuggest theuserre-\\nruntheRVS-LVS Delaytestsagainforthevectors chosen, ormanually selectoffsets.\\nNOTE:WhenLVMSPisprogrammed On,theindependently programmable delayssupersede theLVOffsetfield,\\nwhichbecomesunavailable.\\nUsersarenotrequiredtousetheSmartVector andSmartOffset values; theycanbemodified atthediscretionofthe\\nphysician basedontheirinterpret ationoftheLVVectorGuide dataorotheravailable data.\\nNOTE:Theprogrammed LVa>>LVb intervalisnotdisplayed oneitherReal-time EGMsorStoredEGMs.The\\nLVa>>LVb intervalcanbedetermined fromtheNormal Brady/CRT Settings onthePRMUserInterfac e,DeviceSettings\\nReport, orDevice Follow-up Report.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 155}), Document(page_content=\"Pacing Therapies\\nAVDelay4-73\\nFigure4–45.LVMultiSite PacingConfiguration Settingsscreen\\nAVDELAY\\nAVDelayistheprogrammable timeperiodfromtheoccurrenc eofeitherapacedorsensed rightatrialeventtoa\\npacedRVeventwhentheVentricular Pacing Chamber isprogrammed toBiVorRVOnly.\\nWhenthePacing Chamber isprogrammed toLVOnly,AVDelayistheperiodfromapacedorsensed atrialeventtoa\\npacedLVevent.\\nAVDelayisdesigned tohelppreservetheheart's AVsynchrony .Ifasensed rightventricular eventdoesnotoccur\\nduring theAVDelayfollowing anatrialevent,thepulsegeneratordelivers aventricular pacing pulsewhentheAV\\nDelayexpires.\\nAVDelaycanbeprogrammed tooneorbothofthefollowing operations:\\n•PacedAVDelay\\n•Sensed AVDelay\\nCAUTION: Toensure ahighpercentage ofbiventricular pacing, theprogrammed AVDelaysetting mustbelessthan\\nthepatient’s intrinsic PRinterval.\\nAVDelayisapplicable inDDD(R), DDI(R), DOOorVDD(R) modes.\\nPacedAVDelay\\nPacedAVDelaycorresponds totheAVDelayfollowing anatrialpace.\\nThePacedAVDelaysetting should beindividualiz edforeachpatient toensure consistent CRTdelivery .Several\\nmethods areavailable todetermine thePacedAVDelaysetting, including:\\n•Intrinsic QRSdurationassessment\\n•Echocard iogram evaluation\\n•Pulsepressuremonitoring\\n•SmartDelay optimization\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 156}), Document(page_content='4-74 Pacing Therapies\\nAVDelay\\nSinceoptimization ofthePacedAVDelaycansignificantly influence CRTeffectiveness, considerusingmethods that\\ndemonstrate thehemodynamic impact ofdifferen tPacedAVDelaysettings, suchasechocar diography orpulse\\npressuremonitoring.\\nWhentheminimum AVDelayvalueislessthanthemaximum AVDelayvalue,thenthePacedAVDelayisscaled\\ndynamically accordingtothecurrentpacing rate.Dynamic AVDelayprovidesamorephysiologic response torate\\nchanges byautomatically shortening thePacedAVDelayorSensed AVDelaywitheachinterval during anincrease in\\natrialrate.Thishelpsminimiz etheoccurrenceoflargeratechanges attheupperratelimitandallowsone-to-one\\ntrackingathigherrates.\\nWhenusingDynamic AVDelay,consider evaluating thePacedAVDelayineffectwhenthepatient hasanelevated\\nheartratetoensure thatCRTisstilleffective.\\nThepulsegenerator automatically calculates alinearrelationship basedontheintervallengthofthepreviousA–Aor\\nV–Vcycle(depending onthepreviouseventtype)andtheprogrammed valuesforthefollowing:\\n•Minimum AVDelay\\n•Maximum AVDelay\\n•LRL\\n•MTR\\n•MSR\\n•MPR\\nTheDynamic AVDelayisnotadjusted following aPVCorwhenthepreviouscardiaccyclewaslimited bytheMTR.\\nIftheatrialrateisatorbelowtheLRL(e.g.,hystere sis),themaximum AVDelayisused.Iftheatrialrateisatorabove\\nthehigheroftheMTR,MSR,orMPR,theprogrammed minimum AVDelayisused.\\nWhentheatrialrateisbetween theLRLandthehigheroftheMTR,MSR,andMPR,thepulsegeneratorcalculates the\\nlinearrelationship todetermine theDynamic AVDelay.\\nMaximum \\nAV Delay\\nMinimum \\nAV Delay\\nShorter o\\nf MTR int\\nerval \\nor\\n MSR inte\\nrval\\nLRL Inter\\nval\\nDynamic A\\nV Delay\\nHysteresi\\ns \\n rate inte rval\\nFigure4–46.DynamicAVDelay\\nTheAVDelaymaybeprogrammed toeitherafixedordynamic valueasfollows:\\n•FixedAVDelay—occurs whenPacedAVDelayminimum andmaximum valuesareequal\\n•Dynamic AVDelay—occ urswhenPacedAVDelayminimum andmaximum valuesarenotequal', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 157}), Document(page_content='Pacing Therapies\\nAVDelay4-75\\nSensedAVDelay\\nSensed AVDelaycorresponds totheAVDelayafterasensed atrialevent.\\nSensed AVDelaymaybeprogrammed toavalueshorter thanorequaltothePacedAVDelay.Ashorter valueis\\nintended tocompensate forthedifferenceintiming between pacedatrialevents andsensed atrialevents (Figure4–\\n47Sensed AVDelayonpage4-75).\\nSAV \\nPAV \\nAp As Vp Ap = Paced atrial event \\nAs = Sensed atrial event \\nVp = Paced ventricular event \\n \\nSAV = Sensed AV Delay (As-Vp interval) \\nPAV = Paced AV Delay (Ap-Vp interval) \\nFigure4–47.SensedAVDelay\\nThehemodynamic impact oftheSensed AVDelaydepends ontheappropr iateness ofthetiming between theatrial\\nandventricular contractions. Atrialpacing initiates atrialelectrical excitation, whereas atrialsensing canonlyoccur\\naftertheonsetofspontaneous atrialexcitation. Thedelaybetween initiation andsensing depends onthelead\\nlocation andconduction. Asaresult,whenSensed AVDelayisprogrammed tothesamevalueasPacedAVDelay,the\\nhemodynamic AVintervalwilldifferbetween pacedandsensed atrialevents.\\nWhentheDDD(R) modeisusedtodeliver biventricular stimulation (CRT),itmaybenecessarytoprogram different\\nPacedandSensed AVDelaysettings tooptimiz eCRTduring normal sinusrhythm andduring atrialpacing because\\natrialpacing mayprolong theinteratrialdelay.Theprolonge dinteratrialdelaymayrequirealongerPacedAVDelay\\ntoachieve anoptimal timingrelationship between leftatrialactivation andbiventricular pacing. Theinteratrialdelay\\nmaybeestimated bythelongest P-wave duration.\\nWhenthedeviceisprogrammed toDDD(R), itisrecommended thatthepatient betestedtodetermine theoptimal\\nAVDelayduring atrialsensing andatrialpacing. Iftheoptimal AVDelays aredifferent,thiscanbereflected by\\nprogramming differen tPacedAVDelayandSensed AVDelayparame tersettings.\\nUsingSensedAVDelaywithPacedAVDelay—Fixed\\nWhenPacedAVDelayisprogrammed toafixedvalue,thentheSensed AVDelaywillbefixedattheprogrammed\\nSensed AVDelayvalue.\\nUsingSensedAVDelaywithPacedAVDelay—Dynamic\\nWhenPacedAVDelayisprogrammed asdynamic, thentheSensed AVDelaywillalsobedynamic.\\nDynamic Sensed AVDelayandPacedAVDelayarebasedontheatrialrate.Toreflecttheshortening ofthePR\\ninterval during periods ofincreasedmetabolic demand, theAVDelayshortens linearly fromtheprogrammed\\n(maximum) valueattheLRL(orhysteresis rate)toavaluedetermined bytheratioofminimum andmaximum AV\\nDelayatthehigheroftheMTR,MSR,orMPR(Figure 4–48Dynamic andSensed AVDelayfunction onpage4-76).\\nWhenDynamic AVDelayisused,ifthemaximum Sensed AVDelayvalueisprogrammed asshorter thanthe\\nmaximum PacedAVDelayvalue,thentheminimum Sensed AVDelayvaluewillalsobeshorter thantheminimum\\nPacedAVDelayvalue.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 158}), Document(page_content='4-76Pacing Therapies\\nAVDelay\\nNOTE:Theminimum Sensed AVDelayvalueisprogrammable onlyinVDD(R) mode.\\nMaximum \\nPaced A V \\nDelay\\nMinimum \\nPaced A V \\nDelay\\nShorter of MTR \\nor MSR Interval\\nLRL Interval Hysteresis Rate \\nInterval\\nPaced A V Delay\\nSensed A V Delay\\nFigure4–48.DynamicandSensedAVDelayfunction\\nSmartDelayOptimization\\nTheSmartDelay optimization feature quickly (<2.5minutes) provides recommen dedsettings forprogramming paced\\nandsensed AVDelaybasedonthemeasur ementofintrinsic AVintervals.Theobjective ofthefeature isto\\nrecommend AVdelaysthatprovide optimally timedCRT,whichmaximizes contractilefunction.\\nClinical datafromtheCRTAVOstudyregardinghemodynamic performanc eofthisfeature relative tootherAVDelay\\noptimization methods showsthattheSmartDelay optimization algorithm recommen dedAVdelaysthatmaximized\\nglobalcontractile function asmeasur edindependently byLVdP/dtmax.LVdP/dtmaxisconsidered anindexforglobal\\nventricular contractile function andpumping efficiency .\\nTheSmartDelay optimization testevaluates rightandleftventricular response tobothatrialsensed andpacedevents\\ntodetermine suggested settings forthefollowing:\\n•PacedAVDelay\\n•Sensed AVDelay\\n•Pacing Chamber\\nThesesuggested settings canbeusedwhenprogramming thepulsegeneratorforCRT.Inaddition totheparamet ers\\nsuggested bySmartDelay ,thefollowing paramete rsarealsodisplayed onthePRM:\\n•LVOffset(whenapplicable) andLVMultiSite Pacing (MSP)SmartOffset (whenapplicable) areseparately\\nprogrammable featuresthatyoucanentermanually .IfLVOffsetorMSP’sSmartOffset valueshavebeenmodified\\nafterrunning SmartDelay optimization, consideradjusting theAVDelayeitherbyrunning SmartDelay\\noptimization againormanually reprogramming theAVDelay.SmartDelay takestheLVOffsetorMSP’s\\nSmartOffset valuesintoaccountasfollows:\\n–WhenLVMultiSite Pacing isOff:\\n–SmartDelay usessimple arithmetic toaccountfortheprogrammed LVOffsetinthePacedandSensed\\nAVDelayrecommendations itprovides.Forexample, iftheSmartDelay suggested AVDelay(which\\nstartsattheatrialeventandendsattheleftventricular pace)is150msandtheprogrammed LVOffset', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 159}), Document(page_content='Pacing Therapies\\nAVDelay4-77\\nis-20ms,thentheSmartDelay feature willadjustitsrecommendation to170ms,sincetheAVDelay\\nfeature isprogrammed fromtheatrialeventtotherightventricular pace.\\n–SmartDelay maintains thecurrentlyprogrammed LVOffsetwiththefollowing exception s:(1)If\\nSmartDelay cannot collectsufficient intrinsic events, nominal settings thatinclude anLVOffsetofzero\\naresuggested. (2)IfSmartDelay recommen dsanAVDelayandLVOffsetthattogether exceedthe\\nmaximum programmable AVDelayof300ms,SmartDelay willsuggest areducedLVOffset.\\n–WhenLVMultiSite Pacing isOn:\\n–SmartDelay usessimple arithmetic toaccountfortheprogrammed SmartOffset valuesinthePacedand\\nSensed AVDelayrecommen dations itprovides.Forexample, iftheSmartDelay-suggested AVDelay\\n(which startsattheatrialeventandendsatthefirstleftventricular pace)is150msandthe\\nprogrammed SmartOffset valuesare10msfortheLVatoLVbdelayand10msfortheLVbtoRVdelay,\\nthentheSmartDelay feature willadjustitsrecommendation to170ms,sincetheAVDelayfeature is\\nprogrammed fromtheatrialeventtotherightventricular pace.\\n–SmartDelay maintains thecurrentSmartOffset values. Toensure theSmartOffset valuesareappropriate,\\nreview theminthefollowing circumstanc es:\\n–Ifnominal settings forAVDelayarerecommended because SmartDelay couldnotcollectsufficient\\nintrinsic events\\n–Iftherecommended AVDelayis300ms\\n–IfaninteractivelimiterroroccursasaresultoftheSmartOffset values\\nNOTE:Before making aprogramming change, itisimportant toassesswhether thesuggested settings are\\nappropriate forthepatient.\\nTheSmartDelay optimization screenisshown below(Figure4–49SmartDelay optimization screenonpage4-77).\\nFigure4–49.SmartDelay optimization screen\\nNOTE:Tachytherapyisdisabled whilethetestisinprogress.\\nSmartDelay optimization automatically switches toaunipolar sensing configur ationfortheduratio nofthetest.The\\ntestrunsautomatically whenStartTestispressed.TheSmartDelay optimization testwillnotrununderthefollowing\\nconditions:\\n•During thepost-therap yperiod', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 160}), Document(page_content='4-78Pacing Therapies\\nRefractory\\n•WhentheLVElectrodeConfiguration isprogrammed toNonefordeviceswithanIS-1orLV-1leftventricular lead\\nport\\n•During anATRModeSwitch\\n•During atachycard iaepisode asdetermined bythepulsegenerator detection criteria\\nNOTE:Whencollecting atrialsensed events during thetest,backupDDDpacing isprovided at40ppm.\\nNOTE:Whencollecting atrialpacedevents, backup DDDpacing isprovided atthetempor aryLRL,whichcanbe\\nselected fromtheSmartDelay optimization screen.Thistempora ryLRLisnominally setto80ppm.\\nNOTE:Itisnecessarytoincreasetempora rypacedLRL10to15bpmhigherthantheintrinsic atrialratetoachieve\\npacedAVintervalmeasur ements.\\nFollow thesestepstoruntheSmartDelay optimization test.\\n1.FromtheNormal Settings screen,selecttheMode.\\n•InDDD(R) mode,therecommendation isforbothPacedAVDelayandSensed AVDelay.\\n•InVDD(R) mode,therecommended AVDelayistheSensed AVDelay;thePacedAVDelaydoesnotapply.\\nWhenchanging modes fromDDD(R) toVDD(R) orviceversa,itisimportant toreruntheSmartDelay optimization\\ntest.\\n2.SelecttheSmartDelay optimization button.\\n3.Enterthetemporary pacedLRLvalueorusethedefault valueof80ppm.\\n4.Maintain telemetry throughout thetest.\\n5.Before beginning thetest,advisethepatient toremain stillandtoavoidtalking during thetest.\\n6.PresstheStartTestbutton. Anotification window indicates thatthetestisinprogress.Ifitisnecessarytocancel\\nthetest,selecttheCancelTestbutton.\\nNOTE:Thetestisautomatically cancelledifaSTATPACE,STATSHOCK, orDIVERT THERAPY command is\\nselected.\\n7.Whenthetestiscomplete ,thesuggested settings appear.Foreaseinprogramming, selecttheCopySuggested\\nSettings button totransfer thesuggested settings totheNormal BradyandCRTSettings screen.\\nNOTE:Iftesting fails,thereason fortestfailurewillbeprovided.\\nREFRACTORY\\nRefractoryperiods aretheintervalsfollowing pacedorsensed events during whichthepulsegeneratorisnot\\ninhibited ortriggere dbydetected electrical activity.Theysuppress(orprevent) oversensing ofpulsegenerator\\nartifacts andevoked responsesfollowing apacing pulse.Theyalsopromot eappropriate sensing ofasingle, wide,\\nintrinsic comple xandpreventthesensing ofotherintrinsic signalartifacts (e.g.,aT-wave orfar-fieldR-wave).\\nRefertomoreinformation aboutrefractory periods (\"Calculating RatesandRefractoryPeriods\" onpage2-4).\\nNOTE:RateAdaptive Pacing isnotinhibited during refractoryperiods.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 161}), Document(page_content=\"Pacing Therapies\\nRefractory4-79\\nA-Refractory -PVARP\\nPVARP isdefined accordingtothepacing mode:\\n•Single-chamber atrialmodes: AAI(R)—the timeperiodafterasensed orpacedatrialeventwhenanatrialsense\\neventdoesnotinhibitanatrialpace.\\n•Dual-chamber modes: DDD(R), DDI(R), VDD(R)—the timeperiodafterasensed orpacedRVevent(orLVpace\\nwhenthePacing Chamber isprogrammed toLVOnly)whenanatrialeventdoesnotinhibitanatrialpaceor\\ntrigger aventricular pace.TheAtrialRefractory periodpreventsthetrackingofretrogradeatrialactivity initiated in\\ntheventricle.\\nPVARP canbeprogrammed toafixedvalueortoadynamic valuecalculated basedontheprevious cardiac cycles.To\\nprogram afixedPVARP, settheminimum andmaximum tothesamevalue.PVARP willautomatically bedynamic if\\ntheminimum valueislessthanthemaximum value.\\nForheartfailurepatients withintactAVconduction, alongintrinsic intracardiac AVinterval andalongprogrammed\\nPVARP cancausethelossofatrialtrackingbelowtheMTR,resulting inthelossofbiventricular stimulation (CRT).Ifan\\natrialevent,suchasaPACoraP-wave thatimmediately follows aPVC,fallsintoPVARP, itwillnotbetracked.This\\nallowsforAVconduction ofanintrinsic ventricular event,whichrestarts PVARP. Unless thenextatrialeventoccurs\\noutside ofPVARP, ittoowillnotbetracked,andanother intrinsic AV-conducted ventricular eventwilloccur,again\\nrestarting PVARP. Thispattern cancontinue untilanatrialeventisfinallysensed outside ofPVARP (Figure 4–50Atrial\\nsensed eventinPVARP onpage4-79).\\nAVPVARPAVPVARP PR\\nPVARP PRPVARP\\nPVARP PRPVARPAs\\nVp\\nAs\\nVp\\n(As)PVC\\nVs\\n(As)\\nVs\\n(As)\\nVs\\nFigure4–50.AtrialsensedeventinPVARP\\nIfyoubelieve alossofatrialtrackingbelowtheMTRisoccurring, program TrackingPreferencetoOn.Ifthelossof\\nCRTbelowMTRcontinues tobeaproblemorifTracking Preferenceisnotused,consider reprogramming ashorter\\nPVARP.\\nForheartfailurepatients withsecond-andthird-degree AVblock,programming longAtrialRefractoryperiods in\\ncombination withcertainAVDelayperiods cancause2:1blocktooccurabruptly attheprogrammed MTR.\\nInDDD(R) andVDD(R) pacing modes, thepulsegeneratormaydetectretrogradeconduction intheatrium, causing\\ntriggeredventricular pacing ratesashighastheMTR(i.e.,PMT).Retrograde conduction timesmayvaryovera\\npatient's lifetime asafunction ofchanging autonomic tone.Iftesting doesnotrevealretrogradeconduction at\\nimplantation, itmaystilloccuratalatertime.Thisproblemcanusually beavoided byincreasing theatrialrefractory\\nperiodtoavaluethatexceedstheretrogradeconduction time.\\nIncontrolling thepulsegenerator'sresponse toretrograde conduction, itmayalsobeusefultoprogramthe\\nfollowing:\\n•PVARP afterPVC\\n•PMTTermination\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 162}), Document(page_content='4-80Pacing Therapies\\nRefractory\\n•RateSmoothing\\nDynamicPVARP\\nProgramming ofDynamic PVARP andDynamic AVDelayoptimizes thesensing window athigherrates,allowing\\nupperratebehavior (e.g.,2:1blockandpacemak erWenckebach) inDDD(R) andVDD(R) modes tobesignificantly\\nreduced, evenathigherMTRsettings. Atthesametime,Dynamic PVARP reducesthelikelihoodofPMTsatlower\\nrates.Dynamic PVARP alsoreducesthelikelihood ofcompetit iveatrialpacing.\\nThepulsegenerator automatically calculates theDynamic PVARP usingaweighted averageofthepreviouscardiac\\ncycles.Thisresultsinashortening ofthePVARP inalinearfashion astherateincreases. Whentheaverage rateis\\nbetween theLRLandtheMTRorapplicable upperratelimit,thepulsegenerator calculates theDynamic PVARP\\naccording tothelinearrelationship shown (Figure4–51Dynamic PVARP onpage4-80).Thisrelationship is\\ndetermined bytheprogrammed valuesforMinimum PVARP, Maximum PVARP, theLRL,andtheMTRorapplicable\\nupperratelimit.\\nCAUTION: Programming minimum PVARP lessthanretrogradeV–Aconduction mayincrease thelikelihood ofa\\nPMT.\\nMaximum \\nPVARP\\nMinimum \\nPVARP\\nMTR Inter\\nval\\nLRL Inter\\nval\\nDynamic P\\nVARP\\nHysteresi\\ns \\n rate inte rval\\nFigure4–51.DynamicPVARP\\nMaximum PVARP\\nIftheaveragerateisequaltoorlowerthantheLRL(e.g.,hysteresis),theMaximum PVARP isused.\\nMinimum PVARP\\nIftheaveragerateisequaltoorhigherthantheMTRinterval, theprogrammed Minimum PVARP isused.\\nPVARPafterPVC\\nPVARP afterPVCisdesigned tohelppreventPMTduetoretrogradeconduction, whichcanoccurduetoaPVC.\\nWhenthepulsegeneratordetects asensed RVeventwithout detecting aprecedingatrialsensed event(refractoryor\\nnon-refr actory)ordelivering anatrialpace,theAtrialRefractoryperiodautomatically extends totheprogrammed\\nPVARP afterPVCvalueforonecardiaccycle.AfteraPVCisdetected, thetimingcyclesresetautomatically .PVARP\\nextendsnomorefrequently thaneveryothercardiaccycle.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 163}), Document(page_content='Pacing Therapies\\nRefractory4-81\\nThepulsegeneratorautomatically extendsthePVARP tothePVARP afterPVCvalueforonecardiac cycleinthese\\nadditional situations:\\n•Ifanatrialpaceisinhibited duetoAtrialFlutterResponse\\n•Afteraventricular escape pacethatisnotprecededbyanatrialsenseinVDD(R) mode\\n•Whenthedevicetransitions fromanon-atrial trackingmodetoanatrialtracking mode(e.g.,exitsATRFallback,\\ntransitions fromtempor arynon-atrial tracking modetopermanent atrialtrackingmode)\\n•WhenthedevicereturnsfromElectrocaute ryProtection ModeorMRIProtection Modetoanatrialtrackingmode\\nForheartfailurepatients withintactAVconduction, PVARP afterPVChasthepotential tocauseinhibition ofCRTifthe\\natrialcyclelengthisshorter thantheintrinsic intracar diacAVinterval(PRinterval) +PVARP. Ifthisoccurs, program\\nTrackingPreferencetoOninconjunction withthePVARP afterPVCfeature.\\nARefractory -samechamber\\nDual-chamber Modes\\nAtrialRefractory provides anintervalfollowing anatrialpacedorsensed eventwhenadditional atrialsensed events\\ndonotimpact thetimingofpacing delivery .\\nThefollowing arenonprogr ammable intervalsfordual-chamber modes:\\n•85msAtrialRefractoryfollowing anatrialsensed event\\n•150msAtrialRefractoryfollowing anatrialpaceinDDD(R) andDDI(R)modes\\nRV-Refractory (RVRP)\\nTheprogrammable RVRPprovides anintervalfollowing anRVpaceevent,orleading ventricular paceeventwhenLV\\nOffsetisnotprogrammed tozero,during whichRVsensed events donotimpact thetiming ofpacing delivery .\\nAdditionally ,a135msnonprogr ammable refractoryperiodprovidesanintervalfollowing anRVsensed eventduring\\nwhichfurther RVsensed events donotimpact thetimingofpacing delivery.\\nAnyeventwhichfallsintoVRPisnotdetected ormarked (unless itoccurswithinthenoisewindow), anddoesnot\\nimpact timingcycles.\\nRVRPisavailable inanymodewhereventricular sensing isenabled, andRVRPcanbeprogrammed toafixedor\\ndynamic interval(Figure 4–52Relationship between ventricular rateandrefractoryinterval onpage4-82):\\n•Fixed—RVRP remains attheprogrammed, fixedRVRPvaluebetween theLRLandtheapplicable upperratelimit\\n(MPR,MTRorMSR).\\n•Dynamic—RVRP shortens asventricular pacing increasesfromtheLRLtotheapplicable upperratelimit,allowing\\nadequate timeforRVsensing.\\n–Maximum—if thepacing rateislessthanorequaltotheLRL(i.e.,hysteresis), theprogrammed Maximum\\nVRPisusedastheRVRP.\\n–Minimum—if thepacing rateisequaltotheapplicable upperratelimit,theprogrammed Minimum VRPis\\nusedastheRVRP.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 164}), Document(page_content=\"4-82Pacing Therapies\\nRefractory\\nDy\\nnami\\nc VRP \\ns\\nhort\\nens\\nSensing w\\nindow \\nis optimi zed\\nFigure4–52.Relationship between ventricular rateandrefractory interval\\nToprovideanadequate sensing window ,thefollowing Refractory value(fixedordynamic) programming is\\nrecommended:\\n•Single-chamber modes—less thanorequaltoone-half theLRLinms\\n•Dual-chamber modes—less thanorequaltoone-half theapplicable upperratelimitinms\\nTheuseofalongRVRPshortens theventricular sensing window .\\nProgramming theVentricular RefractoryPeriodtoavaluegreaterthanPVARP canleadtocompetitive pacing. For\\nexample, iftheVentricular RefractoryislongerthanPVARP, anatrialeventcanbeappropriately sensed following\\nPVARP andintrinsic conduction totheventricle fallsintotheVentricular RefractoryPeriod. Inthiscase,thedevicewill\\nnotsensetheventricular depolarization andwillpaceattheendoftheAVDelay,resulting incompetitive pacing.\\nLV-Refractor y(LVRP)\\nTheLVRPpreventssensed electrical events fromcausing aninappropriate lossofCRTfollowing asensed orpaced\\nevent,suchasaleft-sidedT-wave. Properprogramming ofthisfeaturewillhelpmaximize CRTdelivery while\\nreducing theriskofacceleratingthepatient's rhythm toaventricular tachyarrhythmia.\\nCRTshould bedeliveredcontinuously tomaximize thepatient benefit; however ,therearecircumstanc eswhenitmay\\nbeappropr iatetoinhibittherapy delivery.LVRPprovidesanintervalfollowing anLVsenseorpaceevent,orleading\\nventricular paceeventwhenLVOffsetisnotprogrammed tozero,during whichLVsensed events donotimpact the\\ntimingoftherapydelivery .UseofalongLVRPshortens theLVsensing window .\\nLVRPisavailable inanymodewhereLVsensing isenabled. TheLVintervalremains attheprogrammed fixedvalue\\nbetween theLRLandtheapplicable upperratelimit.\\nLVoversensing ofaT-wave mayinhibitLVpacing. Topreventinappro priateinhibition ofLVpacing, programLVRPto\\nadurationsufficiently longtoinclude theT-wave.\\nLeftVentricular ProtectionPeriod(LVPP)\\nTheLVPPpreventsthepulsegeneratorfrominadvertently delivering apacing stimulus during theLVvulnerable\\nperiodif,forexample, aleft-sidedPVCoccurs. Proper programming ofthisfeature willhelpmaximize CRTdelivery\\nwhilereducingtheriskofacceleratingthepatient's rhythm toaventricular tachyarrhythmia.\\nCRTshould bedeliveredcontinuously tomaximize thepatient benefit; however ,therearecircumstanc eswhenitmay\\nbeappropr iatetoinhibittherapy delivery.LVPPistheperiodafterapacedorsensed LVeventwhenthepulse\\ngeneratorwillnotpacetheleftventricle. LVPPprevents thepulsegeneratorfrompacing intotheLVvulnera ble\\nperiod.\\nCAUTION: UseofalongLVPPreducesthemaximum LVpacing rateandmayinhibitCRTathigherpacing rates.\\nNOTE:IfLVPPinhibits inLVOnly,thepulsegeneratorwillissueanRVpaceforbradycardiasupport.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 165}), Document(page_content='Pacing Therapies\\nRefractory4-83\\nLVPPisavailable inanymodewhereventricular sensing andLVpacing areenabled.\\nCross-Chamber Blanking\\nCross-chamber blanking periods aredesigned topromoteappropr iatesensing ofin-chamber events andprevent\\noversensing ofactivity inanother chamber (e.g.,cross-talk, far-fieldsensing).\\nCross-chamber blanking periods areinitiated bypacedand/or sensed events inanadjacen tchamber .Forexample, a\\nblanking periodisinitiated intherightventricle eachtimeapacing pulseisdelivere dtotherightatrium; this\\nprevents thedevicefromdetecting theatrialpacedeventintherightventricle.\\nCross-chamber Blanking canbeprogrammed toSmartorafixedvalue.SmartBlanking isdesigned topromote\\nappropriate sensing ofin-chamber events byshortening thecross-chamber blanking period(37.5msfollowing paced\\nevents and15msfollowing sensed events) andpreventoversensing ofcross-chamber events byautomatically raising\\ntheAGCthreshold forsensing attheexpiration oftheSmartBlanking period.\\nSmartBlanking doesnotchange theprogrammed AGCSensitivity settings.\\nNOTE:SmartBlanking periods willbelengthened to85msifasame-chamber blanking periodoraretrigger able\\nnoisewindow isactivewhentheSmartBlanking periodbegins. Forexample, ifanRVsenseoccurswithintheatrial\\nrefractoryperiod, theA-Blank afterRV-Sense crosschamber blankwillbe85ms.\\nCAUTION: Sensitivity adjustments associated withSmartBlanking maynotbesufficient toinhibitdetection ofcross-\\nchamber artifacts ifthecross-chamber artifacts aretoolarge.Consider otherfactors thatimpact thesize/amplitude of\\ncross-chamber artifacts including lead-placement, pacing output, programmed Sensitivity settings, shockoutput, and\\ntimesincelastdelivere dshock.\\nRV-Blank afterA-Pace\\nRV-Blank afterA-Pace isacross-chamber blanking perioddesigned topromotetheappropriate sensing ofRVevents\\nandprevent oversensing ofcross-chamber events following anatrialpace.\\nIfRV-Blank afterA-Paceisprogrammed toafixedperiod, thepulsegeneratorwilldisregar dRVevents forthe\\ndurationselected following anatrialpace.Ifafixedperiodischosen, thenthereistheincreasedpotential for\\nundersensing ofR-waves (e.g.,PVCs)inthecross-chamber blanking periodafteratrialpacing.\\nIfthevalueisprogrammed toSmart,thepulsegeneratorautomatically raisestheAGCthreshold forsensing atthe\\nexpiration oftheSmartBlanking periodinordertoaidrejection ofcross-chamber atrialevents. Thispromot essensing\\nofR-waves thatmayhaveotherwisefallenintothecross-chamber Blanking period. SmartBlanking doesnotchange\\ntheprogrammed Sensitivity settings.\\nSmartBlanking isdesigned topromote sensing ofR-waves, andshould onlybeconsideredwhenPVCsoccurduring\\nthecross-chamber blanking periodfollowing anatrialpaceandarenotproperly sensed.\\nWhenSmartBlanking isused,itispossible thatpolarization artifacts following atrialpacing maybedetected asR-\\nwaves. Theseartifacts arelikelyaresultofvoltage build-up ontheventricular sensing leadfollowing tachytherapyor\\nhigh-output ventricular pacing, andmayinhibitventricular pacing.\\nWhenadjusting Blanking, consider thefollowing:\\n•Ifthepatient ispacemak er-dependent, testforproper sensing aftershocktherapy.Ifoversensing isoccurring\\npost-shock, bepreparedtousetheSTATPACEcommand.\\n•Topromote continuous pacing forpacemaker-dependent patients, itmaybepreferabletolessenthepotential for\\nventricular oversensing ofatrialpacedartifacts byprogramming alongerblanking period. However ,programming', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 166}), Document(page_content='4-84Pacing Therapies\\nRefractory\\nalongerblanking periodmayincreasethelikelihoodofundersensing R-waves (e.g.,PVCs,should theyoccur\\nwithintheRV-Blank afterA-Pace cross-chamber blanking period).\\n•Forpatients withahighpercentage ofatrialpacing andfrequent PVCswhoarenotpacemak er-dependent, itmay\\nbepreferabletoshorten theblanking periodtolessenthepotential forundersensing aPVC(should itoccurinthe\\ncross-chamber blanking periodfollowing anatrialpacedevent). However ,ashorter blanking periodmayincrease\\nthelikelihood forventricular oversensing ofanatrialpacedevent.\\nLV-Blank afterA-Pace\\nLV-Blank afterA-Pace isacross-chamber blanking perioddesigned topromotetheappropriat esensing ofLVevents\\nandpreventoversensing ofcross-chamber events following anatrialpace.ThepulsegeneratorwillnotrespondtoLV\\nevents fortheduration selected following anatrialpace.\\nIfthevalueisprogrammed toSmart,thepulsegenerator automatically raisestheAGCthreshold forsensing atthe\\nexpiration oftheSmartBlanking periodinordertoaidrejection ofcross-chamber atrialevents. Thispromotessensing\\nofLVevents thatmayhaveotherwisefalleninthecross-chamber blanking period. SmartBlanking doesnotchange\\ntheprogrammed Sensitivity settings.\\nA-BlankafterV-Pace\\nA-Blank afterV-Pace isacross-chamber blanking perioddesigned topromot etheappropriate sensing ofP-waves\\nandpreventoversensing ofcross-chamber events following eitheranRVorLVpace.\\nIfthevalueisprogrammed toSmart,thepulsegenerator automatically raisestheAGCthreshold forsensing atthe\\nexpiration oftheSmartBlanking periodinordertoaidrejection ofcross-chamber ventricular events. Thispromotes\\nsensing ofP-waves thatmayhaveotherwise falleninthecross-chamber blanking period. SmartBlanking doesnot\\nchange theprogrammed Sensitivity settings.\\nA-BlankafterRV-Sense\\nA-Blank afterRV-Sense isacross-chamber blanking perioddesigned topromot eappropriat esensing ofP-waves and\\npreventoversensing ofcross-chamber events following anRV-sensed event.\\nIfthevalueisprogrammed toSmart,thepulsegenerator automatically raisestheAGCthreshold forsensing atthe\\nexpiration oftheSmartBlanking periodinordertoaidrejection ofcross-chamber RVevents. Thispromotes sensing\\nofP-waves thatmayhaveotherwise falleninthecross-chamber blanking period. SmartBlanking doesnotchange the\\nprogrammed Sensitivity settings.\\nRefertothefollowing illustrations:', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 167}), Document(page_content='Pacing Therapies\\nRefractory4-85\\nAV Delay \\nafter pac\\ned atrial\\n event (p\\nrogrammab\\nle, \\nincludes \\n150 ms ab\\nsolute re\\nfractory)\\nAV Delay \\nafter sen\\nsed atria\\nl event (\\nprogramma\\nble, \\nincludes \\n85 ms abs\\nolute ref\\nractory)\\nAtrial Re\\nfractory-\\nPVARP (pr\\nogrammabl\\ne; includ\\nes \\npro\\ngrammable\\n atrial c\\nross cham\\nber blank\\n)\\nV-A inter\\nval (may \\nbe length\\nened \\nby modifi\\ned atrial\\n timing)\\nRV Sensed\\n Refracto\\nry (135 m\\ns)\\nRV Refrac\\ntory (pro\\ngrammable\\n)\\nVentricul\\nar Cross \\nChamber B\\nlank \\n(programm\\nable)\\nLV RefractoryA sensed\\nRV sensed\\nA sensed\\nRV paced\\nA paced\\nRV sensed\\nLV sensed\\nA paced\\nRV paced\\nECG\\nAtrial Ch\\nannel\\nRV Channe\\nl\\nLV Channe\\nl\\nFigure4–53.Refractory periods,dual-chamber pacingmodes;RVonly\\nAV Delay \\nafter pac\\ned atrial\\n event (p\\nrogrammab\\nle, \\nincludes \\n150 ms ab\\nsolute re\\nfractory)\\nAV Delay \\nafter sen\\nsed atria\\nl event (\\nprogramma\\nble, \\nincludes \\n85 ms abs\\nolute ref\\nractory)\\nAtrial Re\\nfractory-\\nPVARP (pr\\nogrammabl\\ne; includ\\nes \\npr\\nogrammabl\\ne atrial \\ncross cha\\nmber blan\\nk)\\nV-A inter\\nval (may \\nbe length\\nened \\nby modifi\\ned atrial\\n timing)\\nRV Sensed\\n Refracto\\nry (135 m\\ns)\\nRV Refrac\\ntory (pro\\ngrammable\\n)\\nVentricul\\nar Cross \\nChamber B\\nlank \\n(programm\\nable)\\nLV Refractory (programmable)A sensed\\nRV sensed\\nA sensed\\nBiV paced\\nA paced\\nRV sensed\\nLV sensed\\nA paced\\nBiV paced\\nECG\\nAtrial Ch\\nannel\\nRV Channe\\nl\\nLV Channe\\nl\\nFigure4–54.Refractory periods,dual-chamber pacingmodes;BiV', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 168}), Document(page_content='4-86Pacing Therapies\\nRefractory\\nAV Delay \\nafter pac\\ned atrial\\n event (p\\nrogrammab\\nle, \\nincludes \\n150 ms ab\\nsolute re\\nfractory)\\nAV Delay \\nafter sen\\nsed atria\\nl event (\\nprogramma\\nble, \\nincludes \\n85 ms abs\\nolute ref\\nractory)\\nAtrial Re\\nfractory-\\nPVARP (pr\\nogrammabl\\ne; includ\\nes \\npro\\ngrammable\\n atrial c\\nross cham\\nber blank\\n)\\nV-A inter\\nval (may \\nbe length\\nened \\nby modifi\\ned atrial\\n timing)\\nRV Sensed\\n Refracto\\nry (135 m\\ns)\\nRV Refrac\\ntory (pro\\ngrammable\\n)\\nVentricul\\nar Cross \\nChamber B\\nlank \\n(programm\\nable)\\nLV Refractory (programmable)A sensed\\nRV sensed\\nA sensed\\nLV paced\\nA paced\\nRV sensed\\nLV sensed\\nA paced\\nLV paced\\nECG\\nAtrial Ch\\nannel\\nRV Channe\\nl\\nLV Channe\\nl\\nFigure4–55.Refractory periods,dual-chamber pacingmodes;LVonly\\nA sensed*\\nRV paced\\nA sensed*\\nRV sensed\\nA sensed*\\nBiV paced\\nECG\\nAtrial Ch\\nannel\\nRV Channe\\nl\\nAtrial Se\\nnsed Refr\\nactory (8\\n5 ms)\\nRV Sensed\\n Refracto\\nry (135 m\\ns)\\nRV Refrac\\ntory (pro\\ngrammable\\n)\\nAtrial Cr\\noss Chamb\\ner Blank \\n(programm\\nable)\\n* An RA s\\nense occu\\nrs during\\n VVI \\npacing du\\ne to the \\ntachycard\\nia \\nfunction \\nof the pu\\nlse gener\\nator.\\nLV Channe\\nl\\nLV Refractory (programmable)\\nFigure4–56.Refractory periods,VVIpacingmode;RVandBiV', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 169}), Document(page_content='Pacing Therapies\\nRefractory4-87\\nA sensed*\\nRV paced\\nLV sensed\\n (Inh-LVP\\n)\\nA sensed*\\nRV sensed\\nECG\\nAtrial Ch\\nannel\\nRV Channe\\nl\\nAtrial Se\\nnsed Refr\\nactory (8\\n5 ms)\\nRV Sensed\\n Refracto\\nry (135 m\\ns)\\nRV Refrac\\ntory (pro\\ngrammable\\n)\\nAtrial Cr\\noss Chamb\\ner Blank \\n(programm\\nable)\\n* An RA s\\nense occu\\nrs during\\n VVI \\npacing du\\ne to the \\ntachycard\\nia \\nfunction \\nof the pu\\nlse gener\\nator.\\nLV Channe\\nl\\nLV Refractory (programmable)A sensed*\\nRV sensed\\nLV sensed\\nA sensed*\\nLV paced\\nFigure4–57.Refractory periods,VVIpacingmode;LVonly\\nSensed Atrial Refractory-PV ARP (programmable; \\nincludes 85 ms absolute refractory) \\nRV Sensed Refractory (135 ms) \\nCross Chamber Blank (programmable \\natrial and R V) \\nPaced Atrial Refractory-PV ARP (programmable; \\nincludes 150 ms absolute refractory) ECG \\nAtrial Sensing \\nVentricular Sensing \\nA sensed \\nRV sensed* \\nA paced \\nRV sensed* \\n* An RV sense occurs during AAI \\npacing due to the tachycardia \\nfunction of the pulse generator . \\nFigure4–58.Refractory periods,AAIpacingmode;DR\\nNOISERESPONSE\\nNoisewindows andblanking periods aredesigned topreventinappro priatetherapyorpacing inhibition duetocross-\\nchamber oversensing.\\nNoiseResponse allowstheclinician tochoose whether topaceorinhibitpacing inthepresenceofnoise.\\nAretriggerable, 40-msnoisewindow existswithineachrefractory andfixed(non-smart) cross-chamber blanking\\nperiod. Thewindow isinitiated byeitherasensed orpacedevent.Boththenoisewindow andtherefractory period\\nmustbecomplet edforeachcardiaccycleinonechamber beforethenexteventrestartsthetiminginthesame\\nchamber .Recurre ntnoiseactivity maycausethenoisewindow torestart,extending thenoisewindow andpossibly\\ntheeffective refractoryperiodorblanking period.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 170}), Document(page_content='4-88Pacing Therapies\\nRefractory\\nTheNoiseResponse paramete rcanbeprogrammed toInhibitPacing oranasynchr onousmode.Theavailable\\nasynchro nousmodewillautomatically correspond tothepermanent BradyMode(i.e.,VVIpermanent modewillhave\\nVOOnoiseresponse). IfNoiseResponse isprogrammed toanasynchro nousmodeandthenoisepersists sothatthe\\nnoisewindow isextendedlongerthantheprogrammed pacing interval,thepulsegeneratorpacesasynchr onously at\\ntheprogrammed pacing rateuntilthenoiseceases.IfNoiseResponse isprogrammed toInhibitPacing andpersistent\\nnoiseoccurs, thepulsegeneratorwillnotpaceinthenoisychamber untilafterthenoiseceases.TheInhibitPacing\\nmodeisintended forpatients whose arrhythmias maybetriggered byasynchr onouspacing.\\nRefertothefollowing illustrations.\\nECG \\nRV Sensing \\nRV Paced \\nevent \\nRV Sensed \\nevent \\nNoise window (40 ms) \\nRV Refractory: \\nsensed = nonprogrammable \\npaced = programmable \\nFigure4–59.Refractory periodsandnoisewindows, RV\\nECG \\nLV Sensing \\nLV Paced \\nevent \\nLV Sensed \\nevent \\nNoise window (40 ms) \\nLV Refractory \\n(programmable) \\nFigure4–60.Refractory periodsandnoisewindows, LV\\nECG\\nA Sensing\\nA Paced \\nevent\\nA Sensed \\nevent\\nNoise win\\ndow (40 m\\ns)\\nA Refract\\nory:\\nsensed\\npaced\\nFigure4–61.Refractory periodsandnoisewindows, RA\\nInaddition, anonprogrammable Dynamic NoiseAlgorithm isactiveinallratechannels.\\nTheDynamic NoiseAlgorithm usesaseparatenoisechannel tocontinuously measure thebaseline signalandadjust\\nthesensing floortoavoidnoisedetection. Thisalgorithm isintended tohelppreventoversensing ofmyopotential\\nsignals andtheproblems associated withoversensing.\\nIfeventmarkers arebeingtransmitted,depending onthechamber wherenoiseisoccurring, themarker [AS],[RVS],\\nor[LVS]occurswhenthenoisewindow isinitially triggered following apace.Ifthenoisewindow isretriggered for\\n340ms,themarkersAN,RVN,orLVNoccur.Withcontinuous retrigge rs,theAN,RVN,orLVNmarkerswilloccur\\nfrequently .Ifasynchr onouspacing occursduetocontinuous noise,themarkersAP-Ns, RVP-Ns, orLVP-Ns willoccur.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 171}), Document(page_content='Pacing Therapies\\nVentricular TachySensingInteractions4-89\\nNOTE:Inpacer-dependent patients, usecarewhenconsidering setting NoiseResponse toInhibitPacing aspacing\\nwillnotoccurinthepresenceofnoise.\\nNOTE:Ifnoiseinhibits inLVOnly,thedevicewillissueanRVpaceforbradycar diasupport providedthereisno\\nnoiseintheRVchannel.\\nNoiseResponse example\\nCross-chamber sensing thatoccursearlyintheAVDelaymaybedetected bytheRVsenseamplifiers during thefixed\\nblanking period, butisnotresponded toexcepttoextendthenoiserejection interval.The40msnoiserejection\\ninterval continues toretriggeruntilthenoiseisnolongerdetected, uptothelengthoftheAVDelay.Ifnoise\\ncontinues throughout thedurationoftheAVDelay,thedevicewilldeliver apacing pulsewhentheAVDelaytimer\\nexpires,preventing ventricular inhibition duetonoise.Ifaventricular pacing spikeisdeliveredunderconditions of\\ncontinuous noise,aVP-Nsmarker notation appears ontheintracardiacelectrogr am(Figure 4–62NoiseResponse\\n(fixedblanking) onpage4-89).\\nIfnoiseceases priortotheexpirationoftheAVDelay,thedevicecandetectanintrinsic beatthatoccursatanytime\\nbeyond the40msretriggerable noiseintervalandinitiate anewcardiaccycle.\\n65 ms\\n40 ms\\n40 ms\\n40 ms\\n40 ms\\n40 ms\\n40 ms\\n120 ms\\nS\\nurface el\\nectrogram\\nProgramma\\nble AV De\\nlay\\nProgramma\\nble V-Bla\\nnk after \\nA-Pace\\n40 ms ret\\nriggerabl\\ne noise w\\nindow\\nAP\\nVP-Ns ann\\notation a\\nt end \\nof the AV DelayNoise sti\\nll presen\\nt even \\nafter AV \\nDelay exp\\nires\\nVentricul\\nar pace \\ndelivered\\n in the \\npresence \\nof noise\\nNoise int\\nerval ext\\nended \\nfor durat\\nion of AV\\n Delay\\nFigure4–62.NoiseResponse (fixedblanking)\\nVENTRICULAR TACHYSENSINGINTERACTIONS\\nRefractoryperiods andblanking intervalsareanintegralpartofthepulsegeneratorsensing system. Theyareusedto\\nefficiently suppress detection ofpulsegeneratorartifacts (e.g.,apaceorshock)andcertain intrinsic signalartifacts (e.\\ng.,aT-wave orfar-fieldR-wave). Thepulsegeneratordoesnotdiscriminate between events thatoccurduring\\nRefractoryperiods andblanking intervals.Asaresult,allevents (pulsegeneratorartifacts, intrinsic artifacts, and\\nintrinsic events) thatoccurduring arefractoryperiodorblanking interval areignoredforpurposes ofpacing timing\\ncyclesandVentricular TachyDetection.\\nCertain programmed combinatio nsofpacing parameters areknown tointerfere withventricular tachydetection.\\nWhenanintrinsic beatfromaVToccursduring apulsegeneratorrefractoryperiod, theVTbeatwillnotbedetected.\\nAsaresult,detection andtherapy ofthearrhythmia maybedelayed untilenough VTbeatsaredetected tosatisfythe\\ntachydetection criteria (\"Ventricular Detection Windows\" onpage2-12).\\nPacingParameter Combination Examples\\nThefollowing examples illustrate theeffects ofcertainpacing paramete rcombinations onventricular sensing. When\\nprogramming pulsegeneratorpacing andtachydetection parameters, considerthepossible interactions ofthese\\nfeaturesinlightoftheexpected arrhythmias. Ingeneral,thePRMscreendisplays Parameter InteractionAttentions\\nandadvisory messages toinform youaboutprogramming combinations thatcouldinteracttocausethesescenarios;\\ntheinteractions canberesolvedbyreprogramming thepacing Rate,AVDelayand/or refractory/blanking periods.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 172}), Document(page_content='4-90Pacing Therapies\\nVentricular TachySensingInteractions\\nExample1:Ventricular Undersensing DuetoVentricular Refractory Period\\nIfthepulsegeneratorisprogrammed asfollows, aVTthatoccurssynchro nouswiththepacing willnotbedetected:\\n•BradyMode=VVI\\n•LRL=75ppm(800ms)\\n•VRP=500ms\\n•VTZone=150bpm(400ms)\\nInthisscenario,thepulsegeneratorisVVIpacing atLRL(800ms).A500msVRPfollows eachventricular pace.VT\\nbeatsthatoccurduring VRPareignoredforpurposes ofpacemak ertimingandVentricular TachyDetection/Therapy.\\nIfastableVTof400msstartssimultaneously withaventricular pace,theVTwillnotbedetected because everybeat\\nwilloccurduring the500msVRP,eitherconcurrent withaventricular paceor400msafterapace(Figure 4–63\\nVentricular undersensing duetoVRPonpage4-90).\\nNOTE:ItisnotrequiredfortheVTtostartconcurrently withapaceforundersensing tooccur.Inthisexample, all\\npacing willbeinhibited andtachydetection willsubsequently occur,assoonasasingleVTbeatisdetected.\\nVP VP VP VP\\n(VT) (VT) (VT) (VT) (VT) (VT) (VT)\\nVRP = 500 ms\\n400 ms\\n LRL = 800 ms\\nFigure4–63.Ventricular undersensing duetoVRP\\nWhentheprogramming interactiondescribed inthisscenario ispresent,amessage willdescribe theinteraction of\\nVRPwithLRL.Inrate-responsive ortrackingmodes (e.g.,DDDR), similar messages maydescribe theinteraction of\\nVRPwithMTR,MSR,orMPR.Alongwitheachmessage, thepertinent programmable parameters aredisplayed to\\nassistyouinresolving theinteraction. Programming Dynamic VRPcanbeusefulinresolving thesetypesof\\ninteractions.\\nExample2:Ventricular Undersensing DueToV-BlankAfterA-Pace\\nCertain programmed combinations ofdual-chamber pacing parame tersmayalsointerfer ewithVentricular Tachy\\nDetection. Whendual-chamber pacing occurs,pulsegeneratorrefractory periods areinitiated bybothatrialand\\nventricular paces.Theventricular refractoryperiodfollowing aventricular paceiscontrolled bytheVRPparamete r;the\\nventricular refractoryperiodfollowing anatrialpaceiscontrolled bytheV-Blank AfterA-Pace parame ter.\\nUndersensing ofaVTduetothepulsegenerator refractoryperiods mayoccurwhenthepulsegeneratorispacing at\\noraboveLRL.Forexample, ifthepulsegeneratorisrate-adaptive pacing at100ppm(600ms)andisprogrammed as\\nfollows, thenaVTthatoccurssynchro nouswiththepacing maynotbedetected:\\n•LRL=90ppm(667ms),MTR/MSR =130ppm(460ms)\\n•BradyMode=DDDR,FixedAVdelay=300ms\\n•VRP=230ms\\n•V-Blank AfterA-Pace =65ms\\n•VTZone=150bpm(400ms)\\nInthisscenario,thepulsegeneratorisDDDRpacing at600ms.AVRPof230msfollows eachventricular pace;a\\nVentricular RefractoryPeriodof65ms(V-Blank afterA-Pace) follows eachatrialpace;anatrialpaceoccurs300ms', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 173}), Document(page_content='Pacing Therapies\\nVentricular TachySensingInteractions4-91\\naftereachventricular pace.VTbeatsthatoccurduring eitherrefractoryperiodareignored forpurposes ofpacemaker\\ntimingandVentricular TachyDetection/Therapy. IfastableVTof350msstarts,thentheVTwillnotbedetected\\nbecause mostbeatswilloccurduring aventricular refractory period, eitherV-Blank afterA-PaceorVRP.SomeVT\\nbeatswillbedetected, butnotenough tosatisfythe8of10tachydetection criteria (\"Ventricular Detection Windows\"\\nonpage2-12).\\nNOTE:Itisnotrequired fortheVTtostartconcurrently witharefractoryperiodorblanking intervalfor\\nundersensing tooccur.Inthisexample, itislikelythattheVTwillnotbedetected untileithertheVTaccelerates to\\nfasterthan350msorthesensor-driven pacing ratechanges from600ms.\\nVT (VT) (VT) VT VS*\\nAP AP\\nAV = 300 ms\\nVRP\\n230 ms\\nVP\\n600 ms\\n350 ms\\n 350 ms 700 ms 600 ms 450 ms\\nRepeat pattern\\nAP, VP, AP, VS, VT\\nFigure4–64.Ventricular undersensing duetoV-BlankafterA-Pace\\nWhentheprogramming interactiondescribed inthisscenarioispresent, amessage willdescribe theinteractionof\\nTachyRateThreshold withLRLandAVDelay.Similar messages maydescribe theinteraction ofV-Blank afterA-Pace\\nwithMTR,MPR,orLRL.Alongwitheachmessage, thepertinent programmable parameters aredisplayed toassist\\nyouinresolving theinteraction. Programming Dynamic VRPcanbeusefulinresolving thesetypesofinteractions.\\nProgramming Considerations\\nCertain programmed combinatio nsofpacing parameters areknown tointerfere withVentricular TachyDetection. The\\nriskofventricular tachyundersensing duetodevicerefractory periods isindicated bytheinteractivewarnings onthe\\nparameter screen.\\nAswithalldeviceprogramming, youshould evaluate thebenefits andtherisksoftheprogrammed features foreach\\npatient (forexample, thebenefit ofRateSmoothing withalongAVDelayversustheriskofventricular tachy\\nundersensing).\\nThefollowing programming recommendations areprovided toreducetheriskofventricular undersensing duetothe\\nrefractoryperiodcaused byanatrialpace(V-Blank afterA-Pace):\\n•Ifadual-chamber pacing modewithRateSmoothing orRateAdaptive Pacing isnecessary:\\n–Reduce theLRL\\n–Shorten theAVDelayoruseDynamic AVDelayandreducetheminimum Dynamic AVDelaysetting\\n–IncreasetheDownRateSmoothing percentage tothelargest possible value\\n–Decreas etheRecoveryTimeforRateAdaptive Pacing modes', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 174}), Document(page_content='4-92Pacing Therapies\\nVentricular TachySensingInteractions\\n–Reduce theMTRorMPRifDownRateSmoothing ison\\n–Reduce theMSRifthepacing modeisrateadaptive\\n•IfRateSmoothing orRateAdaptive Pacing arenotrequired forthepatient, considerprogramming thesefeatures\\nOff.Programming thesefeatures Offcanreducethelikelihoodofatrialpacing atelevated rates.\\n•Ifatrialpacing isnotrequiredforthepatient, considerusingVDDratherthanDDDpacing mode.\\n•Incertainusagescenarios,youmayelecttoprogramlongAVDelays toreduceventricular pacing forpatients with\\nlongPRintervals,whileprovidingsensor pacing orRateSmoothing toaddress otherpatient needs.\\n•Incertainusagescenarios,ifapattern ofatrialpacing andVTbeatsisdetected, theBradyTachyResponse (BTR)\\nfeature willautomatically adjusttheAVDelaytofacilitate confirmation ofasuspected VT.IfnoVTispresent,the\\nAVDelayisreturned totheprogrammed value.Forprogramming scenarios wheretheautomatic AVDelay\\nadjustment mayoccur,aspecific Parameter InteractionAttention willnotbedisplayed.\\nFordiscussion ofdetails andadditional information regarding theseorotherprogrammed settings, please contact\\nBoston Scientific usingtheinformation onthebackcover.\\nInsummar y,whenprogramming thepulsegeneratorpacing andtachydetection paramete rs,itisusefultoconsider\\nthepossible interactions ofthesefeatures inlightoftheexpected arrhythmias ofaparticular patient. Ingeneral,the\\ninteractions willbebroughttoyourattention throughParameter Interaction Attention messages onthePRMscreen\\nandcanberesolvedbyreprogramming thepacing Rate,AVDelay,and/or refractory/blanking periods.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 175}), Document(page_content='5-1\\nSYSTEMDIAGNOSTICS\\nCHAPTER 5\\nThischapter containsthefollowing topics:\\n•“Summary Dialog” onpage5-2\\n•“Battery Status” onpage5-2\\n•“Leads Status” onpage5-7\\n•“Post-OperativeSystemTest(POST)” onpage5-11\\n•“LeadTests”onpage5-12', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 176}), Document(page_content='5-2System Diagnostics\\nSummary Dialog\\nSUMMARY DIALOG\\nUponinterrogation, aSummar ydialogisdisplayed. Itincludes LeadsandPOSTinformation, Battery status\\nindications, approximatetimetoexplant, andanEvents notification foranyepisodes sincethelastreset.Inaddition,\\namagnet notification willappear ifthepulsegeneratordetects thepresenc eofamagnet.\\nFigure5–1.Summary dialog\\nPotential statussymbols include OK,Attention, orWarning (\"UseofColor\"onpage1-7).Potential messages are\\ndescribed inthefollowing sections:\\n•Leads—\"Leads Status\" onpage5-7\\n•Battery— \"Battery Status\" onpage5-2\\n•Events—\"Therapy History\" onpage6-2\\nOncetheClosebutton isselected, theWarning orAttention symbols forLeadsandBattery willnotappear on\\nsubsequent interrogatio nsuntiladditional events triggering analertconditionoccur.Events willcontinuetoappear\\nuntilanyhistorycounter Resetbutton isselected.\\nBATTERYSTATUS\\nThepulsegenerator automatically monitors battery capacity andperformance. Batterystatusinformation isprovided\\nviaseveral screens:\\n•Summary dialog—displays abasicstatusmessage aboutremaining battery capacity (\"Summary Dialog\" onpage\\n5-2).\\n•Summary tab(ontheMainScreen)—displays thesamebasicstatusmessage astheSummary dialog, alongwith\\nthebattery statusgauge(\"MainScreen\"onpage1-2).\\n•Battery StatusSummar yscreen(accessedfromtheSummary tab)—displays additional battery statusinformation\\naboutremaining battery capacity andChargeTime(\"Battery StatusSummar yScreen\" onpage5-3).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 177}), Document(page_content='System Diagnostics\\nBatteryStatusSummary Screen5-3\\n•Battery Detailscreen(accessed fromtheBatteryStatusSummary screen)—pr ovidesdetailed information about\\nbattery use,capacity ,andperformanc e(\"Battery DetailSummar yScreen\"onpage5-5).\\nBatteryStatusSummaryScreen\\nTheBattery StatusSummar yscreenprovides thefollowing keyinformation aboutbattery capacity andperformance.\\nTimeRemaining\\nThissection ofthescreendisplays thefollowing items:\\n•Battery statusgauge—displays avisualindication ofthetimeremaining toexplant.\\n•Approximate timetoexplant––displays theestimate ofcalendar timeremaining untilthepulsegeneratorreaches\\ntheExplant status.\\nThisestimate iscalculated usingbattery capacity consumed, chargeremaining, andpowerconsumption at\\ncurrentprogrammed settings.\\nWheninsufficient usagehistoryisavailable, Approxim atetimetoexplantmaychange between interrogation\\nsessions. Thisfluctuation isnormal, andoccursasthepulsegeneratorcollects newdataandcancalculate amore\\nstableprediction. Approxim atetimetoexplant willbemorestableafterseveral weeksofusage. Causes of\\nfluctuation mayinclude thefollowing:\\n–Ifcertain bradyfeatures thataffectpacing output arereprogrammed, theApproxim atetimetoexplantwill\\nbeforecasted basedontheexpected changes inpowerconsumption fromthereprogrammed features. The\\nnexttimethepulsegeneratorisinterrogat ed,thePRMwillresumedisplaying Approximate timetoexplant\\nbasedonrecentusagehistory.Asnewdataiscollected, Approximate timetoexplantwilllikelystabilizenear\\ntheinitialforecast.\\n–Forseveral dayspost-implant, thePRMwilldisplay astaticApproximate timetoexplant basedonmodel-\\ndependent data.Onceenough usagedatahasbeencollected,device-specific predictions willbecalculated\\nanddisplayed.\\nChargeTime\\nThissection ofthescreendisplays theamount oftimeittookthepulsegenerator tochargeforthemostrecent\\nmaximum-ener gyshockorcapacitor re-formation.\\nBatteryDetailicon\\nWhenselected, thisicondisplays theBattery DetailSummar yscreen(\"Battery DetailSummar yScreen\" onpage5-5).\\nBatteryStatusIndicators\\nThefollowing battery statusindicators appear inthebattery statusgauge. Theindicated Approxim atetimetoexplant\\niscalculated basedonthepulsegenerator\\'scurrentprogrammed parameters.\\nOneYearRemaining—appr oximately oneyearoffullpulsegeneratorfunction remains(Approximate timetoexplant\\nisoneyear).\\nExplant—the battery isnearing depletion, andpulsegeneratorreplacement mustbescheduled. OnceExplant statusis\\nreached thereissufficient battery capacity tomonitor andpace100%underexistingconditions forthreemonths and\\ntodeliver threemaximum-energy shocks, ortodeliver sixmaximum energyshocks withnopacing. WhenExplant\\nstatusisreached, 1.5hoursofZIPtelemetry remain.Consider usingwanded telemetry .', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 178}), Document(page_content='5-4 System Diagnostics\\nBatteryStatusIndicators\\nNOTE:Whenthe1.5hoursoftelemetry areexhausted, aLATITUDE alertisgenerated.\\nBattery Capacity Depleted—pulse generatorfunctionality islimited, andtherapiescannolongerbeguaranteed.This\\nstatusisreached threemonths afterExplant statusisreached. Thepatient should bescheduled forimmediate device\\nreplacement. Uponinterrogation, theLimited DeviceFunctionality screenisdisplayed (allotherscreens aredisabled).\\nThisscreenprovidesbattery statusinformation andaccesstoremaining devicefunctionality .ZIPtelemetr yisno\\nlongeravailable.\\nNOTE:ALATITUDE alertisgenerated,afterwhichLATITUDE NXTceasesinterrogations ofthedevice.\\nWhenthedevicereachesBattery Capacity Depleted status, functionality islimited tothefollowing:\\n•BradyModewillbechanged asdescribed below:\\nBradyModepriortoBattery Capacity Depleted Indicator BradyModeafterBatteryCapacity Depleted Indicator\\nDDD(R), DDI(R), VDD(R), VVI(R) VVI/BiV\\nAAI(R) AAI\\nOff Off\\n•BradyModeandVentricular TachyModecanbeprogrammed toOff;nootherparame tersareprogrammable\\n•Oneventricular zone(VF)witharatethreshold of165bpm\\n•Wanded telemetry only(RFtelemetr yisdisabled)\\n•Maximum-energy shocks andmanual capacitor reformatio nsonly(ATPtherapy andlow-energy shocks are\\ndisabled)\\n•AnLRLof50ppm\\nAtBatteryCapacity Depleted status, thefollowing features aredisabled:\\n•DailyMeasur ementtrends\\n•Bradyenhancements (e.g.,rateresponse, RateSmoothing)\\n•PaceSafe RVAutomatic Threshold (theoutput isfixedatthecurrentoutput value)\\n•PaceSafe RAAutomatic Threshold(theoutput isfixedatthecurrentoutput value)\\n•PaceSafe LVAutomatic Threshold (theoutput isfixedatthecurrentoutput value)\\n•Episode storage\\n•Diagnostic andEPTests\\n•Real-time EGMs\\n•MVsensor\\n•Accelerometer\\n•LeftVentricular MultiSite Pacing\\nIfthedevicereaches apointwhereinsufficient battery capacity isavailable forcontinued operation,thedevicewill\\nreverttoStorageMode.InStorage Mode,nofunctionality isavailable.\\nWARNING: MRIscanning afterExplant statushasbeenreached mayleadtopremature battery depletion, a\\nshortened devicereplacement window ,orsudden lossoftherapy.Afterperforming anMRIscanonadevicethathas\\nreachedExplant status, verifypulsegeneratorfunction andschedule devicereplacement.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 179}), Document(page_content=\"System Diagnostics\\nBatteryDetailSummary Screen5-5\\nNOTE:Thedeviceusestheprogrammed parameters andrecentusagehistorytopredict Approximate timeto\\nexplant.Greaterthannormal battery usagemayresultinthesubsequent day'sApproxim atetimetoexplant to\\nappear lessthanexpected.\\nNOTE:Asabackup method, Explant isdeclaredwhentwoconsecutive chargetimesexceed15secondseach.Ifa\\nChargeTimeisgreaterthan15seconds, thepulsegeneratorschedules anautomatic capacitor re-formation forone\\nhourlater.IftheChargeTimeduring re-formation alsoexceeds15seconds,thebattery statusischanged toExplant.\\nBatteryDetailSummaryScreen\\nTheBattery Detailsummar yscreenprovidesthefollowing information aboutpulsegenerator battery status(Figure 5–\\n2Battery Detailscreenonpage5-6):\\n•LastDelivered Shock––date, Energy,Charge Time,andShockImpedance data.\\n•BeepwhenExplant IsIndicated––if thisfeature isprogrammed toOn,thepulsegenerator emits16beeping tones\\neverysixhoursafteritreachestheExplant indicator .Thetonecanthenbeprogrammed toOff.Evenwhenthis\\nfeature isprogrammed toOff,itisautomatically reactivated whentheBatteryCapacity Depleted indicator is\\nreached.\\nCAUTION: Patients should beadvised tocontacttheirphysician immediately iftheyheartonescoming from\\ntheirdevice.\\n•LastCapacitor Re-form—date andChargeTime.\\n•Manual Re-form Capacitor—this feature isusedtocommand acapacitor re-formation whenneeded.\\n•ChargeRemaining (measured inampere-hours)—the amount ofchargeremaining basedonthepulsegenerator's\\nprogrammed paramete rsuntilthebattery isdepleted.\\n•PowerConsumption (measured inmicrowatts)—the average dailypowerbeingusedbythepulsegenerator,\\nbasedoncurrentlyprogrammed parameters. Powerconsumption isincluded inthecalculations thatdetermine\\nApproximate timetoexplantandtheneedle position onthebattery statusgauge.\\n•PowerConsumption Percentage—compar esthepowerconsum ptionatthepulsegenerator'scurrently\\nprogrammed paramete rswiththepowerconsumption ofthestandar dparameters usedtoquotedevice\\nlongevity .\\nIfanyofthefollowing paramete rs(which affectpacing output) arereprogrammed, thePowerConsumption and\\nPowerConsumption Percentage valuesareadjusted accordingly:\\n•Amplitude\\n•PulseWidth\\n•BradyMode\\n•LRL\\n•MSR\\n•PaceSaf e\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 180}), Document(page_content=\"5-6System Diagnostics\\nCapacitor Re-formation\\nFigure5–2.BatteryDetailscreen\\nCapacitor Re-formation\\nAutomatic Capacitor Re-form.Capacitor deformation mayoccurduring periods whennoshocks aredelivered,\\nresulting inlongerchargetimes.Toreducetheeffectofcapacitor deformation onChargeTime,thecapacitors are\\nautomatically re-formed. Toneswillnotbeemitted fromthepulsegeneratorduring automatic capacitor re-formations\\n(eveniftheBeepDuring Capacitor Chargefeature isprogrammed toOn).During acapacitor re-formation, theCharge\\nTimeismeasur edandstoredforlaterretrieval.\\nManualCapacitor Re-form. Manual capacitor re-formsarenotnecessary,butmaybecommanded viathePRMas\\nfollows:\\n1.SelecttheManual Re-form Capacitor button ontheBatteryDetailscreenandensure thattelemetr y\\ncommunication isestablished. Amessage willappear indicating thatthecapacitors arecharging. Warbling tones\\nfromthepulsegenerator(iftheBeepDuring Capacitor Charge feature isprogrammed toOn)willsoundwhilethe\\ncapacitors arecharging.\\n2.Theentirere-formcycletypically takeslessthan15seconds.Aftercompletion ofthecycle,thecapacitor energy is\\ndelivered tothepulsegenerator'sinternal testload.TheinitialChargeTimeisdisplayed ontheBatteryDetail\\nscreen.\\nChargeTimeMeasurement\\nThepulsegenerator measur estheChargeTimewhenever itscapacitors charge. Thelastmeasured valueisstoredin\\npulsegeneratormemory anddisplayed bythePRMsystem ontheBatteryDetailscreen.\\nLastDelivered Ventricular Shock\\nWhenashockhasbeendeliveredtothepatient, thefollowing information fromthelastshockdeliveredisstoredin\\nthepulsegenerator'smemory anddisplayed ontheBattery Detailscreen:\\n•Date\\n•Energylevel\\n•Charge Time\\n•Shocking leadImpedanc e\\nThisdoesnotinclude autocapacitor re-forms orshocks thatmayhavebeendiverted. Ifafaultcondition is\\nencountered (i.e.,HighorLowImpedance ),thefaultwillbeindicated sothatcorrective actionmaybetaken.\\nNOTE:Forshocks of1.0Jorless,theaccuracyoftheimpedance measurem entdecreases.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 181}), Document(page_content='System Diagnostics\\nLeadsStatus5-7\\nLEADSSTATUS\\nDailyMeasurements\\nThedeviceperforms thefollowing measurements every21hoursandreports themdaily:\\n•DailyIntrinsic Amplitude measur ement: thedevicewillautomatically attempt tomeasure theintrinsic P-andR-\\nwaveamplitudes foreachcardiacchamber inwhichtheDailyIntrinsic Amplitude measur ementisenabled\\nregardless ofthepacing mode.Thismeasur ementwillnotaffectnormal pacing. Thedevicewillmonitor upto\\n255cardiaccyclestofindasensed signaltoobtainasuccessfulmeasur ement.\\n•Dailylead(PaceImpedanc e)measur ement:\\n–Pacelead(s)—the devicewillautomatically attempt tomeasur ethepaceleadimpedance foreachchamber in\\nwhichtheDailyPaceImpedance testisenabled, regardless ofthepacing mode.ToconducttheLead\\nImpedance Testthedeviceutilizes asub-pacing threshold signalthatwillnotinterfer ewithnormal pacing or\\nsensing.\\n–TheHighImpedance Limitisnominally setto2000Ω,andisprogrammable in250Ωincrements between\\n2000Ωand3000Ω.TheLowImpedanc eLimitisnominally setto200Ω,andisprogrammable between 200\\nand500Ωin50Ωincrements.\\nConsider thefollowing factors whenchoosing avaluefortheImpedance Limits:\\n–Forchronicleads,historical impedance measur ements forthelead,aswellasotherelectrical\\nperformance indicators suchasstability overtime\\n–Fornewlyimplanted leads,thestarting measured impedance value\\nNOTE:Depending onleadmaturation effects, during follow-up testing thephysician maychoose to\\nreprogramtheImpedance Limits.\\n–Pacing dependence ofthepatient\\n–Recommended impedance rangeforthelead(s) beingused,ifavailable\\n•Dailylead(Shock Impedanc e)measur ement:\\n–Shocklead—the devicewillautomatically attempt tomeasure theshockleadimpedance. During ashock\\nLeadImpedanc eTest,thepulsegenerator delivers asubthreshold energy pulsethrough theshocking\\nelectrodes.Theseimpedance measur ements mayshowsomevariation overtime,sincetheyaretakenevery\\n21hoursand,thus,atdifferenttimesoftheday.\\n–TheShockLowImpedance Limitisfixedat20Ω.TheShockHighImpedance Limitisnominally setto125Ω,\\nandisprogrammable between 125and200Ωin25Ωincrements. Consider thefollowing factors when\\nchoosing avaluefortheHighImpedanc eLimit:\\n–Forchronicleads,historical impedance measur ements forthelead,aswellasotherelectrical\\nperformance indicators suchasstability overtime\\n–Fornewlyimplanted leads,thestarting measured impedance value\\nNOTE:Depending onleadmaturation effects, during follow-up testing thephysician maychoose to\\nreprogramtheHighImpedanc eLimit.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 182}), Document(page_content='5-8System Diagnostics\\nLeadsStatus\\n–Recommen dedimpedance rangeforthelead(s) beingused,ifavailable\\n–Theimpedance valueofahighormaximum energy ShockImpedance test\\nNOTE:Whenacommanded ordailyshockLeadImpedanc eTestresultisabove125Ωandthe\\nprogrammed ShockHighImpedance Limitisgreaterthan125Ω,confirmproper system operation by\\ndelivering ahigh-energ yshock.\\n–Thepulsegeneratorcontains abeeper thatemitsaudible tonestocommun icatestatusinformation. The\\nbeeper includes aprogrammable feature that,whenprogrammed On,willcausethepulsegeneratorto\\nemittoneswhenDailyImpedance valuesareoutofrange.TheBeepWhenOut-of-Range indicator\\nconsistsof16tonesrepeated everysixhours.Whenthisfeature isprogrammed Off,thereisnoaudible\\nindication ofoutofrangeDailyImpedance values. Referto\"Beeper Feature\" onpage6-19.\\n•PaceSafe dailythreshold measurements—when PaceSafe isprogrammed toAutoorDailyTrend,thedevicewill\\nautomatically attempt tomeasure thepacing threshold inthechamber forwhichPaceSafe isprogrammed. To\\nconduct thetest,thedeviceadjusts thenecessary parameters tofacilitate thetest.\\nBasicleadstatusinformation isdisplayed ontheSummary screen.Detailed dataaredisplayed inagraphicalformat\\nontheLeadsStatussummary screen,whichcanbeaccessedbyselecting theleadsiconontheSummary screen\\n(Figure 5–3LeadsStatussummary screenonpage5-9).\\nPossible leadsstatusmessages areasfollows (Table5–1Leadmeasurem entreporting onpage5-8):\\n•Leadmeasur ements arewithinrange.\\n•CheckLead(message willspecify whichlead)—indicates dailyleadmeasur ement(s) areoutofrange.To\\ndetermine whichmeasur ementisoutofrange,evaluate thecorresponding lead\\'sdailymeasur ementresults.\\nNOTE:Adetailed description ofPaceSafe–spec ificmessages including notification ofleadtestfailuresandlead\\nalertsisavailable (\"PaceSafe\" onpage4-16).\\nTable5–1.Leadmeasurement reporting\\nLeadMeasurement Reported Values Out-of-Range Limits\\nAPaceImpedance (Ω) 200to3000 Low:≤programmed AtrialLowImpedance Limit\\nHigh:≥programmed AtrialHighImpedance Limit\\nRVPaceImpedance (Ω) 200to3000 Low:≤programmed RightVentricular Low\\nImpedance Limit\\nHigh:≥programmed RightVentricular High\\nImpedance Limit\\nLVPaceImpedance (Ω) 200to3000 Low:≤programmed LeftVentricular LowImpedance\\nLimit\\nHigh:≥programmed LeftVentricular High\\nImpedance Limit\\nShockImpedance (Ω) 0to200 Low:≤20\\nHigh:≥programmed ShockHighImpedance Limit\\nP-Wave Amplitude (mV) 0.1to25.0 Low:≤0.5\\nHigh:none\\nR-Wave (RV)Amplitude (mV) 0.1to25.0 Low:≤3.0\\nHigh:none\\nR-Wave (LV)Amplitude (mV) 0.1to25.0 Low:≤3.0\\nHigh:none', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 183}), Document(page_content=\"System Diagnostics\\nLeadsStatus5-9\\nTheLeadsStatussummary screenprovides dailymeasur ementdetails forapplicable leads(Figure 5–3LeadsStatus\\nsummary screenonpage5-9):\\n•Thegraphshowsdailymeasur ements fromthepast52weeks.\\n•Usethetabsacrossthetopofthescreentoviewdataforeachlead.SelecttheSetuptabtoenable ordisable\\nspecific dailyleadmeasur ements ortosettheImpedance Limitvalues.\\n•Eachdatapointrepresents thedailymeasur ementorPOSTresultsforagivenday.Toviewspecific resultsfora\\nday,movethehorizontalslideroverthecorresponding datapointorgap.\\n•Anout-of-rangemeasur ementwillplotapointatthecorresponding maximum orminimum value.\\n•Agapwillbegeneratedifthedeviceisunable toobtainavalidmeasur ementforthatday.\\n•Themostrecentdailymeasurements orPOSTresults aredisplayed atthebottom ofthescreen.\\n[1]Usetabstoselecttheappropriate lead[2]Results fortheselected day[3]Results formostrecentday[4]Y-axisadjusts basedonmeasured results [5]Usehorizontal slidertoviewdatafora\\nspecific day\\nFigure5–3.LeadsStatussummaryscreen\\nIfthedeviceisunable toobtainoneormoredailymeasur ements atthescheduled time,uptothreere-attempts will\\nbeperformed atone-hour intervals.Re-attempts donotchange thetiming ofdailymeasur ements. Thenextday's\\nmeasur ementwillbescheduled 21hoursfromtheinitialattempt.\\nIfavalidmeasur eisnotrecordedaftertheinitialattempt plusthreere-attempts, orisnotrecordedattheendofa\\n24-hour timeblock,themeasurement willbereported asInvalid DataorNodatacollected (N/R).\\nBecause eightmeasur ements arerecordedinsevendays,onedaywillcontaintwomeasur ements:\\n•Ifoneofthemeasurements isvalidandoneinvalid forAmplitude andImpedance, theinvalid measur ementwill\\nbereported. Ifbothmeasurements arevalid,themostrecentvaluewillbereported. ForThreshold, ifone\\nmeasur ementisvalidandoneinvalid, thevalidmeasurement willbereported. Ifbothmeasur ements arevalid,\\nthehighest valuewillbereported.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 184}), Document(page_content='5-10System Diagnostics\\nLeadsStatus\\nIftheSummary screenindicates thataleadshould bechecked andtheIntrinsic Amplitude andImpedanc egraphs do\\nnotshowanyout-of-range valuesorgaps,thetestthatresultedintheout-of-rangevaluemeetsoneofthefollowing\\nconditions:\\n•Testoccurredwithinthecurrent24hoursandhasnotyetbeensavedwiththedailymeasur ements\\nTable5–2.IntrinsicAmplitude: DailyMeasurement Conditions, Programmer Display,andGraphical Representation\\nCondition Programmer Display Graphical Representation\\nIn-range amplitude measurement Measur ementvalue Plotted point\\nElectrode configur ationisprogrammed toOff/None Nodatacollected Gap\\nAllevents during thetestperiodarepaced Paced Gap\\nNoisedetected during thetestperiod Noise Gap\\nSensed events defined asaPVC PVC Gap\\nSensed events defined asaPAC PAC Gap\\nOut-of-range amplitude measurements (mV) 0.1,0.2,...,0.5(RAlead)withattention icon\\n0.1,0.2,...,3.0(ventricular lead)withattention iconPlotted point\\n<0.1withattention icon Plotted pointatcorresponding minimum\\n>25withattention icon Plotted pointatcorresponding maximuma\\na.Whenthevaluemeasured is>25mV,anattention symbol isdisplayed onthegrapheventhough noalertisgenerated onthesummary screens.\\nTable5–3.LeadImpedance: DailyMeasurement Conditions, Programmer Display,andGraphical Representation\\nCondition Programmer Display Graphical Representation\\nIn-range impedance measurement Measur ementvalue Plotted point\\nElectrode Configuration isprogrammed Off/None Invalid Data Gap\\nNoisedetected during thetestperiod Noise Gap\\nOut-of-range impedance measurements (paceleads)\\n(Ω)Measur edvaluegreater thanorequaltothePace\\nHighImpedance Limitwithattention icon\\nMeasur edvaluelessthanorequaltothePaceLow\\nImpedance Limitwithattention iconPlotted point\\n>Maximum PaceHighImpedance Limitwith\\nattention icon\\n<Minimum PaceLowImpedance Limitwith\\nattention iconPlotted pointatcorresponding minimum or\\nmaximuma\\nOut-of-range impedance measurements (shocklead)\\n(Ω)Measur edvaluegreater thanorequaltothe\\nprogrammed ShockHighImpedance Limit(125–200)\\nwithattention icon\\n0;attention icongenerated at≤20Plotted point\\n>200;attention icongenerated Plotted pointatcorresponding maximumb\\na.Selecting thesepointswillnotdisplay thenumerical value,butwillindicate thatthevalueisabovetheupperrangelimitorbelowthelowerrangelimit,asappropriate.\\nb.Selecting thesepointswillnotdisplay thenumerical value,butwillindicate thatthevalueisabovetheupperrangelimit.\\nTable5–4.PaceSafeAutomatic Threshold: DailyMeasurement Conditions, Programmer Display,andGraphical Representation\\nCondition Programmer Display Graphical Representation\\nIn-range threshold measurement Measur ementvalue Plotted point\\nFeature isnotenabled Nodatacollected Gap\\nTestfailures oroutofrangemeasureme nts Various Gap', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 185}), Document(page_content='System Diagnostics\\nLeadsStatus5-11\\nNOTE:Seeadetailed listoffailurecodesforPaceSafe Threshold tests(\"PaceSaf e\"onpage4-16).\\nUnderthefollowing conditions, Intrinsic Amplitude andLeadImpedance measurements willnotbeattempted. The\\nprogrammer display willindicate NodatacollectedorInvalid Data,andtherewillbeagapinthegraphical\\nrepresentation:\\n•Tachyepisode isinprogress\\n•Tachytherapyisactive\\n•Telemetry isactive\\n•Post-Therapyparamete rsareineffect\\n•Devicebattery capacity isdepleted\\n•LATITUDE interrogationisinprogress\\n•PulsegeneratorisinElectrocautery ProtectionMode\\n•PulsegeneratorisinMRIProtectionMode\\nSeeadetailed description ofcondition sunderwhichPaceSafe measurements willnotbeattempted (\"PaceSafe\" on\\npage4-16).\\nPOST-OPERATIVE SYSTEMTEST(POST)\\nThePOSTfeature providesanautomatic device/leadcheckatapre-dete rmined timeafterPOSTisinitiated. Thishelps\\ndocument proper system functionality without requiring manual system testing, whichhelpsfacilitate same-day\\ndischarge.Theusercanselecttheamount oftimeafterPOSTisinitiated whenautomatic leadtestresultsaredesired.\\nAnyadjustments tothenominal testresults timemustbeprogrammed priortoinitiating POST.\\nPOSTisinitiated automatically uponexiting MRIProtectionModewithafixeddesiredresultstimeofonehour.\\nIfenabled, automatic Intrinsic Amplitude, Impedance, andPaceThreshold testing willbeattempted onehourpriorto\\nthedesiredtestresultstime.Uponinterrogation, statusofthetesting (scheduled torun,in-progress,complete) will\\nbeprovided ontheSummary dialog, Summar yscreen, andPOSTscreenforthefirst48hoursafterPOSTwas\\ninitiated. Testresultsareavailable onthePOSTscreenandcanbeprinted onQuickNotesandFollow-Up Reports.\\nNOTE:Pacing parame tersmaybetempora rilyadjusted tohelpensure avalidmeasurement isobtained.\\nIfthedeviceisunable toobtainoneormorevalidmeasur ements ontheinitialattempt, re-attempts willbe\\nperformed tohelpfacilitate ameasur ement. Testing maycomplete uptoonehourafterthetestresultstimeifre-\\nattempts arerequired.Ifavalidmeasur ementisnotobtained, and/or ifautomatic dailymeasur ements occurpriorto\\nprinting thereport, thedailymeasurement resultmayberecorded(\"Leads Status\" onpage5-7).\\nOncetesting iscomplet e,resultswillbedisplayed onthePOSTscreenforthefirst48hoursafterPOSTwasinitiated\\n(Figure5–4POSTScreen onpage5-12).Results aredisplayed similarly todailymeasur ements ontheLeadsStatus\\nscreen(\"Leads Status\" onpage5-7).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 186}), Document(page_content='5-12System Diagnostics\\nLeadTests\\nFigure5–4.POSTScreen\\nLEADTESTS\\nThefollowing leadtestsareavailable (Figure 5–5LeadTestsscreenonpage5-12):\\n•PaceImpedance\\n•ShockImpedanc e\\n•Intrinsic Amplitude\\n•PaceThreshold\\nFigure5–5.LeadTestsscreen\\nLeadTestscanbeaccessedbyusingthefollowing steps:\\n1.Fromthemainscreen,selecttheTeststab.\\n2.FromtheTestsscreen,selecttheLeadTeststab.\\nAllleadtestsmaybeperformed following threedifferentprocesses:\\n•ViatheLeadTestsscreen––allows youtoperform thesameleadtestsacrossallchambers\\n•Byselecting thedesired chamber button––allows youtoperform alltestsonthesamelead', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 187}), Document(page_content=\"System Diagnostics\\nLeadTests5-13\\n•Byselecting theRunAllTestsbutton––automatically performs Intrinsic Amplitude andLeadImpedance testsand\\nallowsyoutoperform PaceThreshold tests\\nIntrinsicAmplitude Test\\nTheIntrinsic Amplitude Testmeasur estheintrinsic P-andR-wave amplitudes fortherespective chambers.\\nAnIntrinsic Amplitude Testcanbeperformed fromtheLeadTestsscreenbycompleting thefollowing steps:\\n1.Youmaychange thefollowing presele ctedvaluesasnecessarytoelicitintrinsic activity inthechamber(s) being\\ntested:\\n•Programmed Normal BradyMode\\n•LRLat30ppm\\n•AVDelayat300ms\\n2.SelecttheIntrinsic Amplitude button. During thetest,awindow willdisplay thetest'sprogress.Selecting and\\nholding theIntrinsic Amplitude Button willcausemeasur ements toberepeated forupto10seconds oruntilthe\\nbutton isreleased. Whenthewindow closes, thesametestcanbeperformed againbyselecting theIntrinsic\\nAmplitude button. Tocancelthetest,selecttheCancelbutton orpresstheDIVERT THERAPY keyonthePRM.\\n3.Whenthetestiscomplete, theIntrinsic Amplitude measur ementwillbedisplayed astheCurrent measur ement\\n(notinparentheses). Ifthetestisrepeated during thesamesession, theCurrent measurement willbeupdated\\nwiththenewresult.NotethatthePrevious Session measur ement(displayed inparentheses) isfromthemost\\nrecentpastsession during whichthistestwasperformed.\\nNOTE:Thetestresultsfromthelastmeasur ementarestoredinpulsegeneratormemory ,retrieved during the\\ninitialinterrogation, anddisplayed ontheLeadTestsscreen.Themeasurements arealsoprovidedontheQuickNotes\\nreport.\\nLeadImpedanc eTest\\nALeadImpedanc eTestcanbeperformed andusedasarelative measur eofleadintegrity overtime.\\nIftheleadintegrity isinquestion, standar dleadtroubleshooting testsshould beusedtoassesstheleadsystem\\nintegrity .\\nTroubleshooting testsinclude, butarenotlimited to,thefollowing:\\n•Electrogram analysis withpocket manipulation and/or isometrics\\n•X-rayorfluoroscopicimagereview\\n•Additional maximum-energy shocks\\n•Programming theShockLeadVector\\n•WirelessECG\\n•Invasive visualinspection\\nAShockImpedanc etestisausefultoolindetecting shocking leadintegrity changes overtime.Evaluating this\\ninformation together withtheLastDelivered ShockImpedance (displayed ontheBattery Detailscreen)ora\\nsubsequent high-energ yShockImpedance andothernon-invasive diagnostic techniques mayhelptroubleshoot\\npotential leadsystem conditions.\\nAtestresultofNOISEisreported ifavalidmeasur ementcouldnotbeobtained (likelyduetoEMI).\\nShorted andopenshockleadfailureswillbereported as0Ωand>200Ω,respectively .\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 188}), Document(page_content='5-14 System Diagnostics\\nLeadTests\\nNOTE:TheShockImpedanc etestmayresultinslightly higher valuesthandeliveredShockImpedance\\nmeasur ements.\\nBothlow-ener gyandhigh-energ yimpedance testshavethefollowing clinical limitations:\\n•Ahigh-ormaximum-energy shocktestdoesnotexpose allformsofopenleadcondition s.Shockleadimpedance\\nmeasur edduring acommanded maximum-energy shockmayappear normal whencertaintypesofopenlead\\ncondition sexist(e.g.,leadconductorfractureoraloosesetscrew), astheenergy deliveredcouldjumporarc\\nacrosssmallgaps.Acommanded low-ener gyimpedance testisamorerobusttoolforidentifying andverifying a\\npotential openshocking leadcondition.\\n•Alow-ener gyLeadImpedanc eTestdoesnotexpose allformsofshorted leadconditions. Alow-energy\\nimpedance testmayappear normal whencertain typesofshorted leadconditions exist(e.g.,abradedleadbody\\ninsulation orleadcrushed between clavicle andfirstrib),astestenergyisinsufficient tojumporarcacrosssmall\\ngapsbetween exposedconductors. Amaximum-energy shockisamorerobusttoolforidentifying andverifying a\\npotential shorted shocking leadcondition.\\nPaceandShockleadimpedance testscanbeperformed fromtheLeadTestsscreenbycompleting thefollowing\\nsteps:\\n1.Selectthedesiredleadimpedance testbutton. Selecting andholding abutton willcausemeasur ements tobe\\nrepeated forupto10secondsoruntilthebutton isreleased.\\n2.During thetest,awindow willdisplay thetestprogress.Whenthewindow closes, thesametestcanbe\\nperformed byonceagainselecting thedesired leadimpedance testbutton. Tocancelthetest,selecttheCancel\\nbutton orpresstheDIVERT THERAPY keyonthePRM.\\n3.Whenthetestiscomplete ,theimpedance measurement willbedisplayed astheCurrentmeasur ement(notin\\nparentheses). Ifthetestisrepeated during thesamesession, theCurrent measur ementwillbeupdated withthe\\nnewresult.NotethatthePrevious Session measur ement(displayed inparentheses) isfromthemostrecentpast\\nsession during whichthistestwasperformed.\\n4.SelecttheIndividual VectorBreakdownbutton toviewadditional outofrangeShockImpedanc etestinformation.\\nThePreviousandCurrent Session resultsforindividual shockvectors willbeprovided.\\n5.Ifthetestresults inNOISE, consider thefollowing mitigation options:\\n•Repeat thetest\\n•Switch telemetr ymodes\\n•Remove othersourcesofelectromagnetic interfer ence\\nNOTE:Thetestresults fromthelastmeasurement arestoredinpulsegeneratormemory ,retrieved during the\\ninitialinterrogation, anddisplayed ontheLeadTestsscreen.Themeasur ements arealsoprovided ontheQuickNotes\\nreport.\\nNOTE:WhenLVMSPisprogrammed On,leadimpedances willbemeasur edanddisplayed forboththeLVaand\\ntheLVbpacevectors.\\nPaceThreshold Test\\nThePaceThreshold Testdetermines theminimum output needed forcapture inaspecific chamber .\\nTheventricular andatrialpaceamplitude threshold testscanbeperformed manually orautomatically .WhenPaceSafe\\nisprogrammed toAuto,theresults ofthecommanded automatic amplitude testsmaybeusedtoadjustthePaceSaf e\\noutput levels.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 189}), Document(page_content='System Diagnostics\\nLeadTests5-15\\nVentricular andatrialpulsewidththreshold testsareperformed manually byselecting thePulseWidthoption onthe\\nPaceThreshold details screen.\\nManualPaceThreshold Test\\nAminimum 2Xvoltage capture threshold or3Xpulsewidthcapture threshold foreachchamber isrecommended to\\nprovideanadequate safetymargin andhelppreservebattery longevity .Thestarting parame tervaluesare\\nautomatically calculated priortotesting. Thetestbegins ataspecified starting valueandstepsthatvaluedown\\n(Amplitude orPulseWidth) asthetestprogresses.ThePRMbeepswitheachdecrement. Thevaluesusedduring the\\nthreshold testareprogrammable. Theparame tersareonlyineffectduring thetest.\\nNOTE:IfDDDmodeischosen, selecting eithertheatrialorventricular testwillcausethepacing output todecrease\\nonlyinthechamber selected.\\nCAUTION: During manual LVThreshold andQuickCapture tests,RVBackupPacing isunavailable.\\nNOTE:Whenaventricular testisselected, onlythepacing output oftheselected ventricular chamber decreases;\\ntheotherventricular chamber isnotpaced.\\nOncethetestisstarted, thedeviceoperateswiththespecified bradyparameters. Usingtheprogrammed number of\\ncyclesperstep,thedevicethendecrements (stepsdown)theselected testtypeparameter(Amplitude orPulseWidth)\\nuntilthetestiscomplete. Real-time electrograms andannotated eventmarkers, whichinclude theLVpacing lead\\nconfiguration andvaluesbeingtested, continue tobeavailable during threshold testing. Thedisplay will\\nautomatically adjusttoreflectthechamber beingtested.\\nDuring thethreshold test,theprogrammer displays thetestparamet ersinawindow whilethetestisinprogress.To\\npausethetestorperform amanual adjustment, selecttheHoldbutton onthewindow .Selectthe+or−button to\\nmanually increaseordecreasethevaluebeingtested. Tocontinue thetest,selecttheContinue button.\\nThethreshold testiscomplete andallparamet ersarereturned tothenormal programmed valueswhenanyofthe\\nfollowing occur:\\n•Thetestisterminated viaacomman dfromthePRM(e.g.,pressingtheEndTestbutton orDIVERT THERAPY key).\\n•Thelowest available setting forAmplitude orPulseWidthisreached andtheprogrammed number ofcycleshas\\ncompleted.\\n•Telemetry communication isinterrupted.\\nApacethreshold testcanbeperformed fromtheLeadTestsscreenusingthefollowing steps:\\n1.Selectthedesired chamber tobetested.\\n2.SelectthePaceThresholddetails button.\\n3.Selectthetesttype.\\n4.Change thefollowing parameter valuesasdesired toelicitpacing inthechamber(s) beingtested:\\n•Mode\\n•LRL\\n•PacedAVDelay\\n•Pacing LeadConfiguration (programmable onlyforLVThreshold test)\\n•Amplitude\\n•PulseWidth', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 190}), Document(page_content='5-16System Diagnostics\\nLeadTests\\n•CyclesperStep\\n•LVProtectionPeriod(programmable onlyforLVThresholdtest)\\nForDDDmode,theNormal BradyMTRisused.\\nNOTE:AlongLVPPmayinhibitleftventricular pacing athigherpacing rates.LVPPcanbetempora rilyprogrammed\\n(forexample,toashorter LVPPorOff)throughthePaceThreshold Testscreen.\\n5.WatchtheECGdisplay andstopthetestbyselecting theEndTestbutton orpressing theDIVERT THERAPY key\\nwhenlossofcapture isobserve d.Ifthetestcontinues untiltheprogrammed number ofcyclesatthelowest\\nsetting haveoccurred,thetestisautomatically terminated. Thefinalthreshold testvaluewillbedisplayed (the\\nvalueisonestepabovethevaluewhenthetestwasterminated). A10secondtrace(priortolossofcapture) is\\nautomatically storedandcanbedisplayed andanalyzed byselecting theSnapshot tab(\"Snapshot\" onpage6-8).\\nNOTE:Thethreshold testresultcanbeeditedbyselecting theEditToday\\'s Testbutton ontheThreshold Test\\nscreen.\\n6.Whenthetestiscomplete ,thethreshold measurement willbedisplayed astheCurrentmeasur ement(notin\\nparentheses). Ifthetestisrepeated during thesamesession, theCurrent measur ementwillbeupdated withthe\\nnewresult.NotethatthePrevious Session measur ement(displayed inparentheses) isfromthemostrecentpast\\nsession during whichthistestwasperformed.\\n7.Toperform another test,makechanges tothetestparamet ervaluesifdesired, thenbeginagain.Results ofthe\\nnewtestwillbedisplayed.\\nNOTE:Thetestresults fromthemostrecentmeasur ementarestoredinpulsegeneratormemory ,retrieved during\\ninitialinterrogation, anddisplayed ontheLeadTestsscreenandontheLeadsStatusscreen.Themeasur ements are\\nalsoprovided ontheQuickNotesreport.\\nCommanded Automatic PaceThreshold Test\\nCommanded automatic threshold testsdifferfromthemanual testsinthefollowing ways:\\n•Commanded automatic threshold testsareavailable forAmplitude, butnotPulseWidth.\\n•Thefollowing parameters arefixed(vs.programmable inmanual tests):\\n–PacedAVDelay\\n–PulseWidth(RAATandRVAT)\\n–Cyclesperstep\\n–LVProtectionPeriod(LVAT)\\nNOTE:Change theprogrammable paramet ersasdesired toelicitpacing inthechamber beingtested.\\n•IfWirelessECGisenabled foraQuadripolar device, theECGwilltempor arilybesettoLeadIIduring commanded\\nLVATtesting.\\n•Additional eventmarkersareavailable including lossofcapture, fusion, andbackup pacing (where backuppacing\\nisavailable).\\n•Oncestarted, acommanded automatic threshold testcannot bepaused, onlycancelled.\\n•PaceSafe automatically determines whenthetestiscompleted andautomatically stopsthetest.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 191}), Document(page_content='System Diagnostics\\nLeadTests5-17\\n•Whencomplete, thetestautomatically stopsanddisplays thethreshold, whichisthelastoutput levelthat\\ndemonstrat edconsistent capture. A10secondtrace(priortolossofcapture)isautomatically storedandcanbe\\ndisplayed andanalyzedbyselecting theSnapshot tab(\"Snapshot\" onpage6-8).\\n•Testresultscannot beedited.\\nNOTE:Nobackupatrialpacing isprovidedduring acommanded automatic rightatrialthreshold test.RVpacing is\\nprovided asbackupduring acommanded automatic leftventricular threshold testwithanapplied LVOffsetof-80\\nms.\\nLVVectorGuide\\nThisfeature isavailable inRESONATE HF,RESONATE X4,VIGILANT X4,andMOMENTUM X4devices.\\nLVVectorGuide streamlines thetesting required todetermine theoptimal LVPacing LeadConfiguration foreach\\nindividual patient. Theclinician canquickly evaluate multiple Quadripolar LVpacing vectors andthenprogramthe\\ndesiredconfiguration.\\nThefollowing testsareavailable withintheLVVectorGuide screen(Figure5–6LVVectorGuide screenonpage5-18)\\nwhichisaccessedfromtheLeadTeststab:\\n•RVS-LVS Delay:TheLVelectrodewiththesiteoflatestactivation canbedetermined byperforming theRVS-LVS\\ntest,whichmeasur esthetimebetween anRVsensed andanLVsensed event.LVevents aresensed between the\\nselected LVelectrode(cathode) andCan.\\n•LVLeadImpedanc e:LVleadimpedance testing usesthesametesting methods andresultsasimpedance tests\\nrunviatheLeadTestsscreen(\"LeadImpedance Test\"onpage5-13).\\n•PhrenicNerveStimulation (PNS):Diaphragmatic stimulation fromtheLVleadcanbetestedusingtempor ary\\nparameters onthePhrenic NerveStimulation test.\\n•LVPaceThreshold: LVPaceThresholdtesting accessed fromtheLVVectorGuide usesthesametesting methods\\nandresultsasthreshold testsrunviatheLeadTestsscreen(\"PaceThreshold Test\"onpage5-14).\\n•Inaddition tothemanual andcommanded threshold tests,theQuickCapture featureisavailable asaTestType\\nwhenLVThreshold Testing isaccessed fromtheLVVectorGuide screen.Thisfeature allowstheclinician toquickly\\nevaluate capture inmultiple vectors atafixedpacing output. Manual orCommanded threshold testing canthen\\nbeperformed inthepacing vectors whichhaveacapture threshold belowtheoutput usedforQuickCapture.This\\nreduces thenumber ofvectors whichundergoregularthreshold testing andtestscanbeginatalowerstarting\\namplitude.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 192}), Document(page_content=\"5-18System Diagnostics\\nLeadTests\\nFigure5–6.LVVectorGuide screen\\nUsethefollowing stepstoperform LVVectorGuide testing (Figure 5–6LVVectorGuide screenonpage5-18):\\n1.Selectvectors tobetested.\\nThescrollbarcanbeusedtoviewallavailable vectors. Multiple methods areavailable tocontrolwhichvectors\\nwillbetested:\\n•UsetheSelectAllbutton intheSelectVectors areatotestallavailable vectors. Thecheckboxes nexttoall\\navailable vectors willautomatically populate intheRunTestsarea.\\n•Selectoneormoreofthecathodes orUnipolar vectors listedintheSelectVectors area.Thecheckboxes next\\ntothosecorresponding vectors willautomatically populate intheRunTestsarea.\\n•Individually selectthecheckbox nexttodesired vectors intheRunTestsarea.\\n•UsetheDeselect Allbutton ordeselect individual checkboxes toexcludevectors fromtesting.\\n2.RunTest(s).\\nSelecttheRunbutton abovethecolumn ofthedesired test.Whereapplicable, adjustthetempora ryparameters\\nonthetesting screenbasedonindividual patient characteristic s.Anotification willbeprovidedifaparticular test\\ncannot beattempted.\\nTestswillrunsequentially ineachoftheselected vectors. SelecttheCancelbutton orfollowtheon-screen\\ninstructions tostoptesting andreturntotheLVVectorGuide screen. Alternatively ,pressing theSTATPACE,STAT\\nSHOCK, orDIVERT THERAPY keyonthePRMwillcancelanytesting inprogress.\\nOncetesting iscomplete inallselected vectors, resultswillbedisplayed inthecorresponding test'scolumn. If\\nthesametestisperformed multiple timesinaparticular vector,onlythemostrecentresultwillbedisplayed. LV\\nVectorGuide results canbeprinted viatheReports tab.\\nTesting details aredescribed below:\\n•RVS-LVS Delay:\\nCAUTION: Ensure thepatient isclinically capable oftoleratinglowrateRVBackupPacing andlackofLV\\npacing during anRVS-LVS Delaytest.\\n–Thepatient musthaveRVandLVsensed beatsinorderfortesting tobesuccessful.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 193}), Document(page_content='System Diagnostics\\nLeadTests5-19\\n–Whentesting iscomplete foraparticular cathode, theresultwillbedisplayed forallvectors whichuse\\nthatsamecathode.\\n–Iftesting isunsuccessfulforaparticular vector,oneofthefollowing failurecodeswillbedisplayed in\\ntheRVS-LVS Delaycolumn:\\n–“N/R”: Displayed iftoomanypacedbeats,PVCsornoisebeatsoccurredduring testing. Thiswill\\nalsobedisplayed iftheRVsensed rateiseither<40bpmor>110bpm.\\n–“N/R:Unstable RV-LV”\\n–“N/R:Unstable RV-RV”\\n•LVLeadImpedanc e:\\n–Impedance resultsfromLVVectorGuide willnotoverwriteexisting resultsontheLeadTestsscreen.\\n•PhrenicNerveStimulation:\\n–Selecteither“YesPNS\"or\"NoPNS\"asappropriatetostopthecurrenttestandproceedtothenext\\npacing vector.Perform additional testing atdifferent outputs, asnecessary.PNSresults willdisplay as\\n\"PNS\"or\"NoPNS\"atthetestedpacing output.\\n•LVPaceThreshold:\\nCAUTION: During manual LVThreshold andQuickCapturetests,RVBackup Pacing isunavailable.\\n–ForQuickCapturetesting, pacing output willremainconstantandnotstep-down aswithother\\nthreshold testselections. Selecteither\"Captur e\"or\"NoCapture\" asappropriate tostopthecurrenttest\\nandproceedtothenextpacing vector.Results willbedisplayed as\"Cap.\"or\"NoCap.\"atthetested\\npacing output.\\n–Manual orCommanded LVThreshold testresultsfromLVVectorGuide willoverwri tetheexisting result\\nontheLeadTestsscreen.Butanautomatic Snapshot willnotoccurforLVThresholdtestsaccessedfrom\\ntheLVVectorGuide screen.\\nReduce thenumber ofvectors tobetestedandperform additional testsasnecessary.\\nTesting resultswillbedisplayed intheappropriate column. Selectacolumn header button tosortthedataby\\nthatcolumn\\'svalues. Vectors withapopulated checkbox willbesortedatthetopofthelist.\\nDeselect thecheckbox foranyvectors thatwillbeexcluded fromconsideration andrequirenofurther evaluation.\\nPerform additional testsontheremaining vectors asdescribed above.\\n3.Programthedevice.\\nOncetheevaluation iscomplete, usetheLVVectorGuide results toselectthedesired Pacing LeadConfigura tion,\\nAmplitude, andPulseWidthatthebottom ofthescreenandselectProgram.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 194}), Document(page_content='5-20System Diagnostics\\nLeadTests', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 195}), Document(page_content='6-1\\nPATIENTDIAGNOSTICS ANDFOLLOWUP\\nCHAPTER 6\\nThischapter containsthefollowing topics:\\n•“TherapyHistory” onpage6-2\\n•“Arrhythmia Logbook” onpage6-2\\n•“Snapshot” onpage6-8\\n•“Histogra ms”onpage6-9\\n•“Counters” onpage6-9\\n•“HeartRateVariability (HRV)” onpage6-10\\n•“Trends”onpage6-13\\n•“PostImplant features” onpage6-17', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 196}), Document(page_content='6-2Patient Diagnostics andFollow Up\\nTherapyHistory\\nTHERAPY HISTORY\\nThepulsegenerator automatically recordsdatathatcanbehelpful whenevaluating thepatient\\'s condition andthe\\neffectiveness ofpulsegeneratorprogramming.\\nTherapyhistorydatacanbereviewed atvarious levelsofdetailusingtheProgrammer:\\n•Arrhythmia Logbook—provides detailed information foreachdetected episode (\"Arrhythmia Logbook\" onpage6-\\n2)\\n•Histograms andCounters—displays thetotalnumber andpercentage ofpacedandsensed events during a\\nparticular recordingperiod(\"Histograms\" onpage6-9and\"Counters\" onpage6-9)\\n•HeartRateVariability (HRV)—measur eschanges inthepatient\\'s intrinsic heartratewithina24-hour collection\\nperiod(\"Heart RateVariability\" onpage6-10)\\n•Trends—pr ovidesagraphical viewofspecific patient, pulsegenerator,andleaddata(\"Trends\"onpage6-13)\\nNOTE:TheSummary dialogandSummary tabdisplay aprioritize dlistofevents thathaveoccurredsincethelast\\nreset.Thislistwillonlyinclude VF,andVT/VT-1 andATR(ifitlastedmorethan48hours)episodes, andMRI\\nProtectionModeevents.\\nARRHYTHMIA LOGBOOK\\nTheArrhythmia Logbook provides accesstothefollowing detailed information aboutepisodes ofalltypes(Figure 6–1\\nArrhythmia Logbook screenonpage6-3):\\n•Thenumber ,date,andtimeoftheevent\\n•Thetypeofeventwithtachyarrhythmia zone\\n•Asummary oftherapydelivere dorattempted (ifapplicable)\\n•Duration oftheevent(whenapplicable)\\n•Electrogr amswithannotated markers\\n•Intervals\\nNOTE:Thedatainclude information fromallactiveelectrodes.Thedevicecompressesthehistorydatatostorea\\nmaximum of17minutes ofelectrogramdata(13minutes withPatient Triggered Monitor enabled). However ,the\\namount oftimeactually storedmayvarybasedonthedatabeingcompressed (e.g.,noiseontheEGMoranepisode\\nofVF).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 197}), Document(page_content='Patient Diagnostics andFollow Up\\nArrhythmia Logbook6-3\\nFigure6–1.Arrhythmia Logbook screen\\nThepriority,maximum number ,andminimum number ofepisodes thatthepulsegeneratorstoresundernormal\\nconditions variesbyepisode type(Table6–1Episode Priority onpage6-4).Aslongasdevicememory allocated for\\nepisode dataisnotfull,thepulsegeneratorstoresuptothemaximum number ofepisodes allowed foreachepisode\\ntype.Theminimum number ofepisodes foreachepisode typeensures thatallepisode typesarerepresented by\\nprotecting afewlowpriority episodes frombeingoverwritten byhighpriority episodes whendevicememory isfull.\\nOncedevicememory isfull,thepulsegeneratorattempts toprioritiz eandoverwrite storedepisodes according tothe\\nfollowing rules:\\n1.Ifdevicememory isfull,andthereareepisodes olderthan18months, thentheoldestofthelowest priority\\nepisodes fromtheseepisode typeswillbedeleted (regardless iftheminimum number ofepisodes arestored).\\n2.Ifdevicememory isfull,andthereareepisode typesthathavemorethantheminimum number ofepisodes\\nstored,thentheoldestofthelowest priority episodes fromtheseepisode typeswillbedeleted. Inthiscase,the\\nlowpriority episodes arenotdeleted iftheirnumber ofstoredepisodes islessthantheminimum number .\\n3.Ifdevicememory isfull,andtherearenoepisode typesthathavemorethantheminimum number ofepisodes\\nstored,thentheoldestofthelowest priority episodes ofallepisode typeswillbedeleted.\\n4.Ifthemaximum number ofepisodes hasbeenreached withinanepisode type,theoldestepisode ofthattype\\nwillbedeleted.\\n•Fornon-commanded episodes, theepisode typeforVT-1,VT,andVFepisodes isdetermined accordingtothe\\nzoneDuration thatexpiresfirst.IfnozoneDuration expiresduring anepisode, theepisode typeisNonsustained.\\n•Anepisode inprogresshasthehighest priority untilitstypecanbedetermined.\\nNOTE:Oncehistorydataissaved,itcanbeaccessedatanytimewithout deviceinterrogation.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 198}), Document(page_content='6-4Patient Diagnostics andFollow Up\\nArrhythmia Logbook\\nTable6–1.EpisodePriority\\nEpisodeType Priority Maximum numberof\\nstoredepisodesMinimum numberof\\nstoredepisodes with\\ndetailedreportsMaximum numberof\\nstoredepisodes with\\ndetailedreports\\nVF/VT/VT-1 withshocka 1 50 5 30\\nPTM(Patient Triggered\\nMonitor)1 5 1 1\\nVF/VT/VT-1 withATPb2 30 2 15\\nVF/VT/VT-1 withno\\ntherapy(Duration Met)c3 20 1 10\\nCmdV 4 2 0 2\\nNonSustV (Durationnot\\nmet)4 10 0 2\\nRAAuto 4 1 1 1\\nRVAuto 4 1 1 1\\nLVAuto 4 1 1 1\\nATR 4 10 1 3\\nPMT 4 5 1 3\\nAPMRTd4 1 1 1\\na.Mayalsoinclude ATPtherapy .\\nb.ATPwithout shocktherapy\\nc.Notherapy defined asDurationMetwith:anInhibitdecision, detection intheMonitor Onlyzone,thelastsensed interval notinthezone,oraDivert-Reconfirm.\\nd.Advanced Patient Management realtime(APMRT)events arepresenting EGMs,captured andstoredonthepulsegenerator during LATITUDE Communicator follow-\\nups.\\nTodisplay Arrhythmia Logbook data,usethefollowing steps:\\n1.FromtheEvents tab,selectArrhythmia Logbook. Ifnecessary,thepulsegeneratorwillbeautomatically\\ninterrogated andcurrentdatawillbedisplayed. Savedpatient dataalsocanbedisplayed (\"DataStorage\"on\\npage1-16).\\n2.Whileretrieving thedata,theprogrammer willdisplay awindow indicating theprogressoftheinterrogation. No\\ninformation willbedisplayed ifyouselecttheCancelbutton before allofthestoreddataareretrieved.\\n3.UsethesliderandViewbutton tocontroltherangeofdatesfortheevents youwanttodisplay inthetable.\\n4.SelecttheDetails button ofaneventinthetabletodisplay theeventdetails. Eventdetails, available ifthe\\ndetails button ispresent,areusefulinevaluating eachepisode. TheStoredEventscreenwillappear,andyoucan\\nbrowse between thefollowing tabsformoreinformation abouttheevent:\\n•Events Summar y\\n•EGM\\n•Intervals\\n5.Selectacolumn header button tosorttheevents bythatcolumn. Toreversetheorder,selectthecolumn header\\nagain.\\n6.Tosavespecific events, selecttheeventandchoose theSavebutton. Toprintspecific events, selecttheevent\\nandchoose Reports fromthetoolbar.Choose theSelected Episodes reportandselectthePrintbutton.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 199}), Document(page_content='Patient Diagnostics andFollow Up\\nArrhythmia Logbook6-5\\nNOTE:An“in-progress”episode willnotbesaved; anepisode mustbecomplete before itwillbesavedbythe\\napplication.\\nToviewepisode details, selecttheDetails button nexttothedesired episode ontheArrhythmia Logbook screen. The\\nStoredEventscreenwillappear,andyoucanbrowse between theSummary, EGM,andIntervals tabs.\\nEventsSummary\\nTheEvents Summary screendisplays additional details abouttheselected episode corresponding totheArrhythmia\\nLogbook.\\nThesummary datamayinclude thefollowing:\\n•Episode number ,date,time,type(e.g.,VF,VT,VT-1,spontaneous/Induce d,orPTM)\\n•Averageatrialandventricular rates\\n•Typeoftherapydelivere d\\n•ForATPtherapy,thetimeoftherapydelivery andthenumber ofbursts\\n•Forshocktherapy ,thestarttimeofcharging, chargetime,impedance, andenergylevel\\n•Duratio n\\n•AtrialrateatPMTstart(PMTevents only)\\nStoredElectrogramswithAnnotated Markers\\nThepulsegeneratorcanstoreannotated electrogr amssensed fromthefollowing leadspriortotheonsetofan\\nepisode, around duration met,andaroundtherapystartandend:\\n•Shocklead\\n•RVpace/senselead\\n•LVpace/sen selead\\nNOTE:LVelectrogr amsareonlystoredforPTMandAPMRTepisodes. LVmarkersarealways storedwhen\\navailable, regardlessofepisode type.\\n•Atrialpace/sense lead\\n•PaceSaf eEvoked Response (ER)(PaceSafe episodes only)\\nTheparticular annotated electrogr amsstoreddepend upontheepisode type.Inthissection, EGMreferstoboth\\nelectrograms andtheassociated annotated markers.TheEGMstorage capacity variesdepending onEGMsignal\\ncondition andheartrate.Thetotalamount ofstoredEGMdataassociated withanepisode maybelimited; EGMsfrom\\nthemiddle oftheepisode mayberemoved forepisodes greaterthan4minutes induration.\\nWhenthememory allocated toEGMstorageisfull,thedeviceoverwritesolderEGMdatasegments inordertostore\\nthenewEGMdata.TheEGMisrecordedinsegments consisting ofepisode Onset,Attempt, andEndEGMStorage.\\nEachsegment ofdataisvisiblewhentheleftcaliper isinthespecific section.\\nThefollowing information isretained:\\n•Onsetretainsupto25seconds ofdatapriortoDuration expiring', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 200}), Document(page_content='6-6Patient Diagnostics andFollow Up\\nArrhythmia Logbook\\n•Reconfirmation retainsupto20seconds ofdatapriortotherapy delivery\\n•Therapydataisdisplayed. InthecaseofATPtherapy,upto20seconds ofatleastthefirstandlastburstforeach\\nscheme willberetained\\n•Post-therapy ordiverted therapyretainsupto10secondsofdata\\nEpisode Onsetreferstotheperiodoftime(measured inseconds)ofEGMpriortothefirstattempt.\\nOnsetincludes thefollowing information:\\n•Typeofevent\\n•Average RARateatthestartofEvent\\n•Average RVRateatthestartofEvent\\n•Programming ofDetection Enhance ments(RateOnly,Rhythm ID,orOnset/Stability)\\n•Acquisition timestamp ofRhythm IDreferencetemplate\\n•RhythmMatch Threshold (asprogrammed) (RESONATE HF,RESONATE, andMOMENTUM devices)\\n•Measure dRhythmMatch value(ifareferencetemplate hasbeenacquired,theeventhasnoattempts, andthe\\npulsegeneratorinhibited therapy)(RESONATE HF,RESONATE, andMOMENTUM devices )\\nAttempt information maybedisplayed asAttempt orInProgress,ifanattempt isinprogress.Attempt includes the\\nfollowing information:\\n•Detection information:\\n–Average RARateatstartofAttempt\\n–Average RVRateatstartofAttempt\\n–RateZone\\n•Measure dValues ofDetection Enhanc ements\\n•TherapyAttempt Information:\\n–Attempt Number\\n–Type(aborted, commanded, orinhibited)\\n–Number ofbursts(ATPattempt)\\n–Charge Time(shockattempt)\\n–Leadimpedance (shockattempt)\\n–LeadPolarity (shockattempt)\\n–Shockfaults(shockattempt)\\n–Reason forNoTherapy\\nTheEndEGMStoragestartsfollowing therapydelivery andstoresupto10seconds ofEGM.Thefollowing figure\\nshowstherelationship between theventricular tachyepisode EGMstorageandsurface ECGstripchartrecording\\n(Figure 6–2Relationship between ventricular tachyepisode EGMstorageandsurfaceECGstripchartrecordingon\\npage6-7).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 201}), Document(page_content='Patient Diagnostics andFollow Up\\nArrhythmia Logbook6-7\\nDuration expires Charging begins Start End-of -\\nEpisode timer\\nEnd-of-Episode \\ntimes out. \\nEpisode is over . \\n5 s 10 s 10 s\\n10 s \\n10 s 10 s 10 s 10 s \\nNote: Charging may begin \\nwhen duration expires. Shock \\n10 s\\n5 s\\nDetection window\\nsatisfied 8 of 10\\nfast beats\\nFigure6–2.Relationship between ventricular tachyepisodeEGMstorageandsurfaceECGstripchartrecording\\nNOTE:Referto\"UseofAtrialInformation\" onpage2-6foradditional information aboutdeviceperformance when\\ntheatrialleadisprogrammed toOff.\\nToviewtheEGMdata,selecttheDetails button ofthedesiredepisode ontheArrhythmia Logbook screen.\\nUsethefollowing stepstoviewspecific details abouteachepisode:\\n1.SelecttheEGMtab.\\n•EGMstripsfortheappropriatesourcesaredisplayed. Eachstripincludes theEGMssensed during the\\nepisode withthecorresponding annotated markers.Bluevertical barsindicate thesegment (Onset, Attempt,\\nEnd)boundaries.\\nNOTE:Formarker definitions, selecttheReports button onthePRMandviewtheMarkerLegend Report.\\n•Usethesliderundertheupperdisplay window toviewdifferentsections ofthestoredEGM.\\n•AdjustthetraceSpeedasneeded (10,25,50,100mm/s). AstheSpeedisincreased, thetime/horiz ontal\\nscaleisexpanded.\\nNOTE:Adjusting thetraceSpeedisforon-screen viewing only;theprintspeedofastoredEGMissetto25\\nmm/s.\\n•Usetheelectroniccaliper (sliderbar)tomeasur ethedistance/time between signals aswellasmeasur ethe\\namplitude ofsignals.\\n–Thedistance between signals canbemeasur edbymoving eachcaliper tothedesired pointsonthe\\nEGM.Thetime(inmilliseconds orseconds)between thetwocalipers willbedisplayed.\\n–Theamplitude ofthesignalcanbemeasur edbymoving theleft-handcaliper overthepeakofthe\\ndesired signal. Thevalue(inmillivolts) ofthesignalwillbedisplayed ontheleftsideoftheEGM.The\\nsignalismeasur edfrombaseline topeak,eitherpositive ornegative. AdjustthetraceSpeedand/or\\namplitude scaleasneeded tohelpfacilitate anamplitude measurement.\\n•Adjusttheamplitude/vertical scaleasneeded (0.2,0.5,1,2,5,10,20mm/mV) foreachchannel usingthe\\nup/down arrowbuttons located ontherightsideofthetracedisplay.Asthegainisincreased, theamplitude\\nofthesignalisenlarged.\\n2.SelectthePrevious EventorNextEventbutton todisplay adifferen teventstrip.\\n3.Toprinttheentireepisode report, selectthePrintEventbutton. Tosavetheentireepisode report,selectthe\\nSavebutton.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 202}), Document(page_content='6-8Patient Diagnostics andFollow Up\\nArrhythmia Logbook\\nIntervals\\nThepulsegenerator storeseventmarkers andassociated timestamps. ThePRMderives eventintervals fromthe\\neventmarkersandtimestamps.\\nToviewtheepisode intervals,usethefollowing steps:\\n1.FromtheStoredEventscreen,selecttheIntervals tab.Ifalloftheepisode dataisnotvisibleinthewindow ,use\\nthescrollbartoviewmoredata.\\n2.SelectthePreviousEventortheNextEventbutton todisplay apreviousormorecurrentepisode, oneepisode at\\natime.\\n3.SelectthePrintEventbutton toprinttheentireepisode report.\\n4.SelecttheSavebutton tosavetheentireepisode report.\\nSNAPSHO T\\nA12-secondtraceoftheECG/EGM display canbestoredatanytimebypressingtheSnapshot button fromany\\nscreen.Atraceisalsoautomatically storedfollowing aPaceThreshold Test.Afteratracehasbeenstored,itcanbe\\ndisplayed andanalyzed byselecting theSnapshot tab.\\nThetraceswhicharecurrentlyselected ontheECG/EGM display aswellasannotated markers willbecaptured forup\\nto10secondsbefore andupto2secondsaftertheSnapshot button wasselected. IfaSnapshot wasautomatically\\nstoredduring aPaceThreshold Test,itwillbe10secondslong,ending withthetermination ofthetest.\\nNOTE:TheSnapshot lengthwillbereducedifthetracesontheECG/EGM display arechanged orthesession\\nstarted within10secondsofpressing theSnapshot button.\\nUpto6time-stamped Snapshots willbestoredintheProgrammer memory forthecurrentsession only.Oncethe\\nsession hasbeenterminated byexiting theapplication softwar eorbyinterrogatinganewpatient, thedatawillbe\\nlost.Ifmorethan6Snapshots arestoredinoneProgrammer session, theoldestwillbeoverwritten.\\nUsethefollowing stepstoviewastoredSnapshot:\\n1.FromtheEvents tab,selecttheSnapshot tab.\\n2.SelectthePreviousSnapshot orNextSnapshot button todisplay adifferenttrace.\\n3.Usethesliderundertheupperdisplay window toviewdifferen tsections ofthestoredSnapshot.\\n4.AdjusttheSpeedasneeded (10,25,50,100mm/s). AstheSpeedisincreased, thetime/horizontal scaleis\\nexpanded.\\n5.Usetheelectron iccaliper (sliderbar)tomeasur ethedistance /timebetween, signals aswellasmeasure the\\namplitude ofsignals.\\n•Thedistance between signals canbemeasured bymoving eachcaliper tothedesired pointsonthe\\nSnapshot. Thetime(inmilliseco ndsorseconds)between thetwocalipers willbedisplayed.\\n•Theamplitude ofthesignalcanbemeasur edbymoving theleft-handcaliper overthepeakofthedesired\\nsignal. Thevalue(inmillivolts) ofthesignalwillbedisplayed ontheleftsideoftheSnapshot. Thesignalis\\nmeasured frombaseline topeak,eitherpositive ornegative. AdjusttheSpeedand/or amplitude scaleas\\nneeded tohelpfacilitate anamplitude measur ement.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 203}), Document(page_content=\"Patient Diagnostics andFollow Up\\nCounters6-9\\n6.Adjusttheamplitude/vertical scaleasneeded (0.2,0.5,1,2,5,10,20mm/mV) foreachchannel usingtheup/\\ndownarrowbuttons located ontherightsideofthetracedisplay.Asthegainisincreased, theamplitude ofthe\\nsignalisenlarged.\\n7.ToprinttheSnapshot thatiscurrentlybeingviewed, selectthePrintbutton. TosavetheSnapshot thatis\\ncurrentlybeingviewed, selecttheSavebutton. SelectSaveAllSnapshots tosaveallstoredSnapshot traces.\\nHISTOGRAMS\\nTheHistograms feature retrieves information fromthepulsegeneratoranddisplays thetotalnumber andpercentage\\nofpacedandsensed events forthechamber .\\nHistogr amsdatacanprovide thefollowing clinical information:\\n•Thedistribution ofthepatient's heartrates\\n•Howtheratioofpacedtosensed beatsvariesbyrate\\n•Howtheventricle responds topacedandsensed atrialbeatsacrossrates\\nWhencombined withverified biventricular capture, Histograms canbeusedtodetermine theamount ofCRTdelivery .\\nThepercentage ofpacedandsensed ventricular events indicates thepercentage ofBiVpacing delivered.\\nUsethefollowing stepstoaccesstheHistograms screen:\\n1.FromtheEvents screen, selectthePatient Diagnostics tab.\\n2.Theinitialdisplay showsthepacedandsensed datasincethelasttimethecounter swerereset.\\n3.SelecttheDetails button todisplay thedatatypeandtimeperiod.\\n4.SelecttheRateCounts button ontheDetails screentoviewratecountsbychamber .ForRESONATE HF,\\nRESONATE, andMOMENTUM devices, thiscanbeusedtoviewRVratecountsduring AT/AFevents.\\nAllHistograms canberesetbyselecting theResetbutton fromanyPatient Diagnostics Details screen.Histogram data\\ncanbesavedtothePRMandprinted viatheReports tab.\\nCOUNTERS\\nThefollowing countersarerecordedbythepulsegenerator anddisplayed onthePatient Diagnostics screen:\\n•Ventricular Tachy\\n•Brady/CRT\\nVentricular TachyCounters\\nInformation aboutVentricular TachyCounters isavailable byselecting theVentricular TachyCounters Details button.\\nThisscreendisplays Ventricular Episode, Ventricular Therapy,andClinical counters. Foreachcounter,thenumber of\\nevents sincelastresetanddevicetotalsaredisplayed. Ventricular TachyEpisode counterscontainsthefollowing data:\\n•TotalEpisodes\\n•Treated––VF, VT,VT-1,andCommanded\\n•Non-Treated––No TherapyProgrammed, Nonsustained, andOtherUntreated Episodes\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 204}), Document(page_content=\"6-10Patient Diagnostics andFollow Up\\nCounters\\nVentricular TachyTherapycountersconsist ofventricular shockandATPtherapyattempts. Theycanprovideuseful\\ndataabouttheeffectiveness ofapatient's therapy prescription. Thesecounters include thefollowing information:\\n•ATPDelivered\\n•ATP%Successful––the percentoftimethatthearrhythmia isconverted andtheepisode endswithout delivery of\\naprogrammed shock\\n•Shocks Delivere d\\n•FirstShock%Successful––the percentoftimethatthearrhythmia isconvert edandtheepisode endswithout\\nrequiringasecond programmed shock\\n•Shocks Diverted\\nTheventricular ATPcounter isincremented atthestartofthedelivery ofthefirstburstofanATPscheme. Subsequent\\nATPburstsinthesamescheme arenotcountedindividually during thesameepisode. AnATPscheme iscounted as\\ndiverted onlyifitisdiverted priortodelivery ofthefirstburst.\\nTheMRICounters withintheClinical Counters section displays thenumber oftimesthedevicewasprogrammed into\\nMRIProtection Mode,regardless ifanMRIscanwasperformed (available onlyinMRConditional devices).\\nBrady/CRT Counters\\nInformation aboutBrady/CRT Counters aredisplayed byselecting theBrady/CRT Counters Details button. Thisscreen\\ndisplays theBrady/CRT episode counters.Foreachcounter,thenumber ofevents sincelastresetandresetbefore last\\naredisplayed. Brady/CRT Counters containsthefollowing details:\\n•Percentofatrialpaced\\n•PercentofRVpaced\\nNOTE:TheRVpaceeventforaBiVentricular Trigger pacewillbecounted asanRVsense.\\n•PercentofLVpaced\\n•Intrinsic Promotion––includes RateHysteresis%Successful\\n•AtrialArrhythmia––includes percentage oftimeinAT/AF, TotalTimeinAT/AF(min,hr,ordays),Episodes by\\nDuration andTotalPACs.Inaddition, forRESONATE HF,RESONATE, andMOMENTUM devices, whenatleastone\\nATReventhasbeenstoredsincethelastreset,datafortheLongest AT/AFandFastest VSRateinAT/AFis\\npresentedontheSummary screenandonprinted reports.\\nNOTE:AT/AF%andTotalTimeinAT/AFrecordsanddisplays dataforamaximum ofoneyear.\\n•Ventricular Counters––includes TotalPVCsandThreeorMorePVCs\\nAllCounters canberesetbyselecting theResetbutton fromanyPatient Diagnostics Details screen.Counter datacan\\nbesavedtothePRMandprinted viatheReports tab.\\nHEARTRATEVARIABILITY (HRV)\\nHeartRateVariability (HRV)isameasure ofthechanges inapatient’s intrinsic heartratewithina24-hour collection\\nperiod.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 205}), Document(page_content='Patient Diagnostics andFollow Up\\nCounters6-11\\nThisfeature canassistinevaluating theclinical statusofheartfailurepatients.\\nHRV,asmeasur edbySDANN andHRVFootprint, isanobjective, physiological measure thatcanidentify heartfailure\\npatients athigherriskofmortality .Specifically ,depressed HRVcanbeusedasapredicto rofriskofmortality afteran\\nacutemyocardial infarction.1Anormal SDANN valueis127plusorminus35ms.1Higher SDANN values(indicating\\ngreatervariability ofheartrate)havebeenassociated withlowerriskofmortality .234Similarly ,alargerHRVFootprint\\nalsoindicates greater heartratevariability andhasbeenassociated withlowermortality risk.234\\nTheHRVmonitor feature providesthefollowing information usingtheintrinsic intervaldatafromthe24-hour\\ncollection periodthatmeetstheHRVcollection criteria (Figure6–3HeartRateVariability display onpage6-11):\\n•Dateandtimethe24-hour collection periodwascomplete d.\\n•%ofTimeUsed—displays thepercentageoftimeduring the24-hour collection periodinwhichtherearevalid\\nintrinsic beats.Ifthe%ofTimeUsedfallsbelow67%,datawillnotbedisplayed forthatcollection period.\\n•HRVFootprint plot—shows thepercentage ofthegraphareausedbytheHRVplot.Thegraphareaportrays an\\n“at-a-glanc esnapshot” ofthedistribution ofvariability versusheartrateovera24-hour period. Thetrended\\npercentage isanormalized scorebasedonthefootprint inthegraph.\\n•Standar dDeviation ofAveraged Normal RtoRintervals (SDANN)—the HRVcollection periodcomprises 2885-\\nminute segments (24-hours) ofintrinsic intervals.TheSDANN isthestandar ddeviation oftheaveragesofintrinsic\\nintervals inthe2885-minute segments. Thismeasur ementisalsoavailable intheTrends.\\n•CurrentNormal Brady/CRT paramete rs––Mode, LRL,MTR,Sensed AVDelay,andPacing Chamber withLVOffset.\\n•AnHRVplotforcurrent andpreviouscollectionperiods including alinethatshowsthemeanheartrate.TheHRV\\nplotsummarizes thecardiacvariation onacycle-to-cycle basis.Thex-axisshowstheheartraterange; they-axis\\nshowsthebeat-to-beat variability displayed inmilliseconds. Thecolorindicates thefrequency ofbeatsatany\\nparticular heartrateandheartratevariability combination.\\nFigure6–3.HeartRateVariability display\\nConsider thefollowing information whenusingHRV:\\n1.Electrophysiology TaskForceoftheEuropean Society ofCardiology andtheNorthAmerican Society ofPacing andElectrophysiology .\\nCirculation,93:1043-1065, 1996.\\n2.F.R.Gilliam etal.,Journal ofElectrocar diology ,40:336-342, 2007.\\n3.F.R.Gilliam etal.,PACE,30:56-64, 2007.\\n4.J.P.Singhetal.,Europac e,12:7–8, 2010.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 206}), Document(page_content='6-12Patient Diagnostics andFollow Up\\nCounters\\n•Thecardiaccycle(R–Rinterval)inHRVisdetermined byRVsensed andpacedevents (LVpacedevents whenthe\\nPacing Chamber isprogrammed toLVOnly).\\n•Programming thepacing paramete rscauses thedataacquiredforthecurrent24-hour collection periodtobe\\ninvalid.\\n•Thedevicesavesonlyonesetofvaluesandcorresponding HRVplotfortheReferenc eportion ofthescreen.Once\\nthevaluesarecopied fromLastMeasured toReferenc e,olderdatacannot beretrieved.\\n•ThefirsttimetheHRVfeatureisused,theReferenc escreenwillshowthedatafromthefirstvalid24-hour\\ncollectionperiod.\\nFollow thestepsbelowtoviewHRV:\\n1.ToaccesstheHRVmonitor screen,selecttheEvents tab.\\n2.FromtheEvents screen,selectthePatient Diagnostics tab.\\n3.SelecttheHeartFailureManagement Details button.\\n4.SelecttheHRVtabtoviewtheLastMeasure dandReferenc edata.\\n5.TocopytheLastMeasure dHRVmeasur ements intotheReferenc esection, selecttheCopyFromLastto\\nReferenc ebutton.\\nTheHRVmonitor screendisplays asetofmeasur ements andaHRVplotbasedonthemostrecent24-hour collection\\nperiodintheLastMeasur edportion ofthescreen;measur ements fromapreviously savedcollection periodare\\ndisplayed intheReferenc eportion ofthescreen.Bothcollection periods canbeviewed simultaneously tocompare\\ndatathatcouldshowtrendsinthepatient’s HRVchanges overaperiodoftime.BysavingtheLastMeasur edvalues\\ntotheReferenceportion ofthescreen, youcanviewthelastmeasur eddataduring alatersession.\\nHRVCollection Criteria\\nOnlyvalidsinusrhythm intervals areusedintheHRVdatacalculations. ForHRV,validintervalsarethosewhich\\ninclude onlyvalidHRVevents.\\nValidHRVevents arelistedbelow:\\n•ASwithaninterval notfasterthanMTR,followed byaVS\\n•ASfollowed byVPattheprogrammed AVDelay\\nInvalid HRVevents areasfollows:\\n•AP/VSorAP/VP\\n•ASwithaninterval fasterthanMTR\\n•Non-trackedVPevents\\n•Consecutive ASevents (nointerveningVevent)\\n•VP-Ns\\n•RateSmoothing events (e.g.,RVP↑)', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 207}), Document(page_content='Patient Diagnostics andFollow Up\\nTrends6-13\\n•PVC\\nHRVdatamaynotbereported foravariety ofreasons; themostcommon areasfollows:\\n•Lessthan67%ofthe24-hour collectionperiod(approxi mately 16hours)contains validHRVevents\\n•BradyParamet erswereprogrammed withinthelast24hours\\nAnexampleofhowHRVdataisrecordedisshown (Figure6–4Example ofHRVdatacollectiononpage6-13).Inthis\\nexample, theHRVdatainthefirstcollection periodisinvalid because theBradyParameters wereprogrammed after\\nthedevicewastakenoutofStorage.HRVdataissuccessfullycalculated andreported attheendofthesecond24-\\nhourcollection period. Subsequent HRVdataisnotreported untiltheendofCollection Period5.\\nInvalid\\nValid\\nValid Invalid\\nInvalid\\n24-hour \\nCollection \\nPeriod 1\\nCollection Period 1:\\nInvalid HR V due to Brady \\nparameters modification \\n(programming)Collection Period 2:\\nValid HR V; greater than 67% \\nof collection criteria met; HR V \\nfootprint created\\nCollection Period 3:\\nInvalid HR V due to Brady \\nparameter modifications \\n(programming)Collection Period 4:\\nInvalid HR V; less than 67% \\nof daily intervals were valid\\nCollection Period 5:\\nValid HR V; greater than 67% \\nof collection criteria met\\n24-hour \\nCollection \\nPeriod 2\\n24-hour \\nCollection \\nPeriod 3\\n24-hour \\nCollection \\nPeriod 4\\n24-hour \\nCollection \\nPeriod 5\\n24 hour \\ncollection \\nperiod begins\\nFigure6–4.ExampleofHRVdatacollection\\nTRENDS\\nTrendsprovideagraphical viewofspecific patient, device, andleaddata.Thisdatacanbeusefulwhenevaluating\\nyourpatient\\'s condition andtheeffectiveness ofprogrammed parameters. Unless otherwise notedbelow,dataforall\\ntrendsisreported every24hoursandisavailable forupto1year.Formanytrends,avalueof“N/R”isreported if\\nthereisinsufficient orinvalid dataforthecollectionperiod.\\nThefollowing trendsareavailable:\\n•Events––displays bothatrialandventricular events storedintheArrhythmia Logbook, organizedbydateandtype\\n(\"Arrhythmia Logbook\" onpage6-2).Thistrendisupdated whenever anepisode iscomplete d,andmaycontain\\ndatathatisolderthan1year.\\n•Activity Level––displays ameasure ofthepatient\\'s dailyactivity represented bythe“PercentofDayActive”.\\n•AT/AFBurden––displays atrendofthetotalnumber ofATRModeSwitch events andthetotalamount oftime\\nspentinanATRModeSwitch perday.\\n•RVRateduring AT/AF(RESONATE HF,RESONATE, andMOMENTUM devices)—displays atrendofthepatient’s\\nMeanandMaximum RVrateduring ATRevents. TheMeanrateiscalculated usingbothpacedandsensed beats\\nwhiletheMaximum rateisarollingaverage ofsensed beats.Insomecases,theMeanratemaybehigherthan\\ntheMaximum rate.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 208}), Document(page_content='6-14Patient Diagnostics andFollow Up\\nTrends\\n•Pacing Percent(RESONATE HF,RESONATE, andMOMENTUM devices) —displays thepercentage ofpacedevents for\\neachchamber .\\n•Respiratory Rate––displays atrendofthepatient\\'s dailyminimum, maximum, andmedian respiratory ratevalues\\n(\"Respiratory RateTrend\"onpage6-15).\\n•HeartRate––displays atrendofthepatient\\'s dailymaximum, mean,andminimum heartrate.\\n•SDANN (Standar dDeviation ofAveragedNormal-to-Normal R-Rintervals)—displays atrendofthestandar d\\ndeviation oftheaverages ofintrinsic intervals overthe24-hour collection period(which iscomprised of2885-\\nminute segments). OnlyintervalsthatmeettheHRVcollection criteria areconsidered valid.\\nAnormal SDANN valueis127plusorminus35ms.5\\n•HRVFootprint––displays thepercentage ofthegraphareausedbytheHRVFootprint plot,illustrating the\\ndistribution ofvariability versusheartrateovera24-hour period. Thetrendedpercentage isanormaliz edscore\\nbasedonthefootprint inthegraph.Refertoadditional information aboutHRV(\"Heart RateVariability\" onpage\\n6-10).\\n•Leadimpedance andamplitude—displays trendsofthedailyintrinsic amplitude andleadimpedance\\nmeasur ements (\"Leads Status\" onpage5-7).\\n•APaceThreshold—displays atrendofthedailyrightatrialpacing thresholds.\\n•RVPaceThreshold—displays atrendofthedailyrightventricular pacing thresholds.\\n•LVPaceThreshold—displays atrendofthedailyleftventricular pacing thresholds.\\n•S1heartsound—displays atrendofthepatient’s device-measured S1heartsound. S1heartsoundisviewable only\\nontheHeartFailure Management screen.Refertoadditional information aboutS1andS3HeartSounds (\"S1and\\nS3HeartSounds\" onpage6-15).\\n•S3heartsound—displays atrendofthepatient’s device-measured S3heartsound. S3heartsoundisviewable\\nonlyontheHeartFailureManagement screen.Refertoadditional information aboutS1andS3HeartSounds (\"S1\\nandS3HeartSounds\" onpage6-15).\\n•HeartLogic Index—displays atrendofthepatient’s HeartLogic Index.HeartLogic Indexisviewable onlyonthe\\nHeartFailure Management. Refertoadditional information aboutHeartLogic Index(\"HeartLogic Index\"onpage6-\\n16).\\n•ThoracicImpedanc e—displays atrendofthepatient’s dailyaveragethoracicimpedance. Viewable onlyonthe\\nHeartFailure Management screen.See\"Thoracic Impedanc e\"onpage6-16fordetails.\\n•NightHeartRate—displays atrendofthepatient’s averageheartratebetween midnight and6am.Viewable\\nonlyontheHeartFailureManagement screen.See\"NightHeartRate\"onpage6-16fordetails.\\n•SleepIncline—displays atrendofthepatient’s averageinclineduring sleeptime.Viewable onlyontheHeart\\nFailure Management screen.See\"SleepIncline\" onpage6-16fordetails.\\nFollow thestepsbelowtoaccessTrends:\\n1.FromtheEvents screen,selecttheTrendsTab.\\n5.Electrophysiology TaskForceoftheEuropean Society ofCardiology andtheNorthAmerican Society ofPacing andElectrophysiology .\\nCirculation, 93:1043-1065, 1996.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 209}), Document(page_content='Patient Diagnostics andFollow Up\\nTrends6-15\\n2.Choose theSelectTrends button tospecify thetrendsyouwanttoview.Youcanchoose fromthefollowing\\ncategories:\\n•HeartFailure––includes HeartRate,SDANN, andHRVFootprint trends.\\n•AtrialArrhythmia––includes AT/AFBurden, RVRateduring AT/AF, andRespirato ryRate(RESONATE HF,\\nRESONATE, andMOMENTUM devices).Forothermodels, theAtrialArrhythmia category includes Events,\\nHeartRate,andAT/AFBurdentrends.\\n•Activity––includes HeartRate,Activity Level,andRespiratory Ratetrends.\\n•Custom––allows youtoselectvarious trendstocustomiz etheinformation displayed ontheTrendsscreen.\\nThedisplay onthescreencanbeviewed inthefollowing manner:\\n•Selectthedesired timeontheViewbutton tochoose thelengthofvisibletrenddata.\\n•Adjustthestartandenddatesbymoving thehorizontalslideratthetopofthewindow .Youcanalsoadjust\\nthesedatesusingthescrollleftandscrollrighticons.\\n•Movethevertical axisacrossthegraphbymoving thehorizontal slideratthebottom ofthedisplay window .\\nInaddition, thefollowing trendisavailable onLATITUDE NXT:\\n•VTherapy––displays anindication ofshockorATPtherapy foreachday.IfbothshockandATPtherapyare\\ndeliveredforagivenday,ashockwillbeindicated forthatday.\\nRespiratory RateTrend\\nTheRespiratory Ratetrenddisplays agraphofthepatient\\'s dailyminimum, maximum, andmedian respiratoryrate\\nvalues. Thesedailyvaluesarestoredforuptooneyeartocreatealongitudinal display ofphysiological data.\\nNOTE:TheAmerican College ofCardiology (ACC)/American HeartAssociation (AHA)guidelines recommend the\\nmeasur ementanddocumentation ofphysiological vitalsignsincluding respiratory rateforcardiac patients.6\\nEnsuretheMV/Respir atorySensor isprogrammed toOn(orPassive fortheMVSensor) forRespirato ryRatetrend\\ndatatobecollected anddisplayed (\"Minute Ventilation/Respirato rySensor\" onpage4-32).\\nMovethehorizontal slideroveradatapointtoviewthevaluesforagivendate.Atleast16hoursofdatamustbe\\ncollected forvaluestobecalculated andplotted totheRespiratory Ratetrend.Ifinsufficient datawascollected,no\\ndatapointwillbeplotted andtherewillbeagapinthetrendline.Thisgapwillbelabeled asN/Rtoindicate that\\ninsufficient ornodatawascollected.\\nS1andS3HeartSounds\\nTheS1andS3HeartSounds sensor usesthepulsegenerator’saccelerometer todetectcardiacvibrations, whichare\\nusedtodetermine thedevice-mea suredintensities ofS1andS3.Thedailyvalueofeachtrendisaggregated from\\nmultiple samples eachday.Aheartsoundsample cannot betakenifthepatient’s heartrateistoohighortoo\\nvariable. Ifaminimum number ofvalidsamples arenotcollected, thenadailyvaluewillnotbeavailable forthatday.\\n6.ACC/AHA HeartFailure Clinical DataStandar ds.Circulation,Vol.112(12),September 20,2005.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 210}), Document(page_content=\"6-16Patient Diagnostics andFollow Up\\nTrends\\nHeartLogicIndex\\nTheHeartLogic Indexaggregates measur ements frommultiple device-based sensors (HeartSounds, Thoracic\\nImpedance ,Respiration, andNightHeartRate)andreflects changes overtimeinthepatient’s sensor trenddatafrom\\ntheirrespective baseline values. HeartLogic providesadditive information forclinicians touseincontextwith\\nstandar d-of-care patient treatment andshould notreplacestandar d-of-care treatment.\\nNOTE:Thenominal HeartLogic Thresholdis16.Aspecific patient’s HeartLogic Thresholdcanbeconfirmed in\\nLATITUDE NXT.\\nThoracicImpedance\\nTheThoracicImpedance sensor measur esimpedance between electrodesontheRVleadandthepulsegenerator\\n(PG)can.ThoracicImpedance maybeassociated withthefluidlevelinthepatient’s chestandmaytrackfluidlevel\\nchanges. Whenapatient’s fluidlevelincreases, thoracic impedance decreases.\\nNightHeartRate\\nTheNightHeartRatesensor measur esapatient’s heartratebetween thehoursofmidnight and6am.Thisperiodis\\nnon-programmable. Thedatafromthistrendcanbeaffected ifapatient travelstoanother timezoneorifthepulse\\ngenerator(PG)clockisincorrect.ThePGclockcanbeprogrammed bysynchron izingittotheprogrammer clockatthe\\ntimeofdeviceinterrogation. ForaccuratePGclockprogramming, itisimportant toensure thattheprogrammer clock\\niscorrect.\\nSleepIncline\\nTheSleepInclinesensor measur esthepatient's averagenighttime elevation angles (sleepincline).\\nInitialization andcalibrationmustbecompleted beforeSleepInclinetrending occurs.Initialization isautomatic;\\ncalibrationrequires clinician andpatient action.\\n•Initialization\\nTheinitialization oftheSleepIncline sensor occursautomatically afterimplant andtypically takes5-7days.\\nInitialization maytakelongerifapatient lacksdiversity intheirbodyorientations during thisperiod.\\nOncetheinitialization iscomplet e,calibrat ioncantakeplace.\\n•Calibration\\nCalibration isperformed viatheprogrammer during apatient follow-up visit,afterimplant andinitialization are\\ncomplete .Calibration determines PGorientation withinthepatient’s body.Toperform calibration, thepatient\\nmustadoptanupright posture,eithersittingorstanding, beforethephysician pressestheCalibrate button on\\ntheprogrammer .TheCalibrate button isshown inFigure6–5HeartFailureManagement Setupscreenonpage6-\\n17.\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 211}), Document(page_content='Patient Diagnostics andFollow Up\\nPostImplantfeatures6-17\\nFigure6–5.HeartFailureManagement Setupscreen\\nTheprogrammer notifies theclinician ofthecompletion ofcalibrat ionfortheparticular posture.Ifnotenough\\nstabledatawascollected, theprogrammer willindicate thisandaskfortheposturetoberepeated.\\nWhileanupright postureistheonlyrequired postureforcalibrat ingtheSleepInclinesensor,accuracyisincreased\\nbyperforming asecond calibrationusingasupine posture.Repeat theaboveprocesstocollectreadings forthe\\nsecondposture.\\nTheaccuracyofthesleepinclinetrenddepends onaproperbodycalibration.Ifthepatient isnotfullyvertical or\\nhorizontalwhentheprogrammer capture stheupright andsupine posturesrespectively ,thenthetrendvalueswill\\nbedistorted.\\nCalibrat ioncanberepeatedasoftenastheclinician desires.\\n•Trending\\nTheSleepIncline Trendaggregatesperiodic measurem entsoverthepatient’s sleepschedule. Toprogramthe\\npatient’s sleepschedule, accesstheGeneral tabofthePatient Information screen.\\nThefirstsample istaken1houraftertheprogrammed SleepStartandthelastsample istaken1hourpriortothe\\nendoftheprogrammed SleepDuration .Forameasurement tobesuccessful,thepatient mustbeatlowactivity.\\nPOSTIMPLANT FEATURES\\nPatientTriggered Monitor(PTM)\\nPatient Triggere dMonitor allowsthepatient totrigger thestorageofEGMs,intervals,andannotated marker data\\nduring asymptomatic episode byplacing amagnet overthedevice. Instruct thepatient toplacethemagnet onthe\\ndevicebrieflyandonetimeonly.\\nPatient Triggere dMonitor isenabled byselecting StoreEGMasthedesired Magnet Response. Thiscanbefoundin\\ntheMagnet andBeeper section ontheV-Tachy TherapySetupscreen.\\nWhenPTMisenabled, thepatient cantrigger datastoragebyholding amagnet overthedeviceforatleast2\\nseconds.Thedevicewillstoredataforupto2minutes priortoandupto1minute aftermagnet application. The\\nstoreddatainclude theepisode number ,ratesatmagnet application, andstarttimeanddateofmagnet application.\\nAfteroneEGMisgenerated andstored,PTMisdisabled. Tostoreanother EGM,thePTMfeature mustbere-enabled\\nusingtheprogrammer .If60dayselapseandthepatient didnottrigger datastorage,PTMisautomatically disabled.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 212}), Document(page_content='6-18Patient Diagnostics andFollow Up\\nPostImplantfeatures\\nWhendataarestored,thecorresponding episode typeisrecordedasPTMintheArrhythmia Logbook.\\nCAUTION: UsecarewhenusingPatient Triggered Monitor, because thefollowing conditions willexistwhileitis\\nenabled:\\n•Allothermagnet features ,including inhibiting therapy,aredisabled. TheMagnet/Beeper featurewillnotindicate\\nmagnet position.\\n•Devicelongevity isimpacted. Tohelpreducethelongevity impact, PTMonlyallowsstorage ofoneepisode, and\\nPTMisautomatically disabled after60daysifdatastorage wasnevertriggere d.\\n•OncetheEGMisstored(or60dayselapses), PTMisdisabled andthedeviceMagnet Response automatically will\\nbesettoInhibitTherapy.However ,thepulsegeneratorwillnotinhibittherapyuntilthemagnet isremoved for3\\nseconds andplaced onthedeviceagain.\\nToprogramthePatient Triggered Monitor feature,followthesesteps:\\n1.FromtheSettings tabonthemainscreen,selectSettings Summary.\\n2.FromtheSettings Summary tab,selectVentricular TachyTherapy.\\n3.FromVentricular TachyTherapy,selecttheV-Tachy TherapySetupdetails button.\\n4.ProgramtheMagnet Response toStoreEGM.\\n5.Determine ifthepatient iscapable ofactivating thisfeature priortobeinggiventhemagnet andpriorto\\nenabling Patient TriggeredMonitor. Remind thepatient toavoidstrongmagnetic fieldssothefeature isnot\\ninadvertently triggered.\\n6.Consider having thepatient initiate astoredEGMatthetimePatient Triggered Monitor isenabled toassistwith\\npatient education andfeature validation. Verifytheactivation ofthefeature ontheArrhythmia Logbook screen.\\nWARNING: Ifdesired, ensure thatPatient TriggeredMonitor isenabled priortosending thepatient homeby\\nconfirming theMagnet Response isprogrammed toStoreEGM.Ifthefeature isinadvertently leftintheInhibit\\nTherapy setting, thepatient couldpotentially disable tachyarrhythmia detection andtherapy.\\nWARNING: OncethePatient TriggeredMonitor feature hasbeentriggeredbythemagnet andanEGMhas\\nbeenstored,orafter60dayshaveelapsed fromthedaythatStoreEGMwasenabled, theMagnet Response\\nprogramming automatically willbesettoInhibitTherapy. Whenthishappens, thepatient should notapplythe\\nmagnet because tachyarrhythmia therapycouldbeinhibited.\\nNOTE:WhentheMagnet Response programming hasautomatically beensettoInhibitTherapy ,magnet\\napplication willcausethedevicetoemitbeeping tones.Inform thepatient thatiftheyheartonescoming from\\ntheirdeviceafterapplying themagnet, theyshould remove themagnet.\\n7.Patient TriggeredMonitor canonlybeenabled fora60-day periodoftime.Todisable thefeature withinthe60-\\ndaytimeperiod, reprogramtheMagnet Response toasetting otherthanStoreEGM.When60dayshavepassed\\nsinceenabling Patient Triggered Monitor, thefeature willautomatically disable itselfandtheMagnet Response\\nwillreverttoInhibitTherapy.Tore-enablethefeature, repeatthesesteps.\\nForadditional information, contact Boston Scientific usingtheinformation onthebackcover.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 213}), Document(page_content='Patient Diagnostics andFollow Up\\nPostImplantfeatures6-19\\nBeeperFeature\\nTheBeeper includes bothprogrammable andnonprogrammable features(referto“Programmable Features”\\nsubsection of\"Beeper Feature \"onpage6-19).\\nProgrammable Features\\nThefollowing Beeper featuresareprogrammable:\\n•BeepDuring Capacitor Charge—Wh enprogrammed toOn,regardlessoftheTachyMode,awarbling tonewill\\nsoundcontinuously whilethepulsegenerator ischarging(exceptwhenchargingduring anautocapacitor re-\\nform).Thetonewillcontinueuntilchargingiscomplete .Whenthisfeature isprogrammed toOff,thereisno\\naudible indication thatthepulsegeneratorischarging. Thisfeatureisusefulduring EPtesting.\\n•BeepwhenExplant isIndicated—When thisfeature isprogrammed toOn,thepulsegeneratoremitstonesupon\\nreaching Explant. TheExplant indicator consists of16tonesrepeated everysixhoursafterthepulsegenerator\\nreaches Explant untilthefeature isturned offviatheprogrammer .Whenthisfeature isprogrammed toOff,there\\nisnoaudible indication ofExplant.\\n•BeepWhenOut-of-Range—When thisfeatureisprogrammed toOn,thepulsegeneratoremitstoneswhenDaily\\nImpedanc evaluesareoutofrange.Itisseparat elyprogrammable foreachpacing leadimpedance aswellas\\nshockimpedance. TheOut-of-Range indicator consistsof16tonesrepeated everysixhours.Whenthisfeature is\\nprogrammed toOff,thereisnoaudible indication ofDailyImpedanc evalues.\\nPerform thefollowing stepstoprogramtheMagnet andBeeper features :\\nMagnetandBeeperResponse\\n1.SelecttheSettings tab.\\n2.FromVentricular Tachy,selecttheTherapy button.\\n3.SelecttheV-Tachy Therapy Setupbutton.\\n4.Enterthedesiredvalues.\\nBeepwhenExplantisIndicated\\n1.SelecttheSummar ytab.\\n2.SelecttheBattery button.\\n3.FromtheBattery Statussummary screen,selecttheBattery Detailbutton.\\n4.FromtheBattery Detailsummary screen,selectthedesiredvalueforBeepwhenExplant isIndicated.\\nBeepWhenOut-of-Range\\n1.SelecttheSummar ytab.\\n2.SelecttheLeadsbutton.\\n3.FromtheLeadsStatussummary screen,selecttheSetuptab.\\n4.Selectthedesired valuesforBeepWhenOut-of-Range.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 214}), Document(page_content='6-20Patient Diagnostics andFollow Up\\nPostImplantfeatures\\nNOTE:WhentheMagnet Response isprogrammed toInhibitTherapy,magnet application willcauseothertypesof\\nbeeping tonestobeemitted, depending onthedevicemode.Referto\"Magnet Feature\" onpage6-23formore\\ninformation.\\nNonprogrammable Features\\nThefollowing Beeper features arenonprogrammable:\\n•Battery capacity depleted—Regard lessofwhether BeepwhenExplant IsIndicated isprogrammed toOnorOff,\\noncethebattery capacity isdepleted, thepulsegeneratorwillemittheexplantindicator tones\\n•Faultcodetones—For certainfaultcodesorwhenSafetyModeisentered, thepulsegeneratorwillbeep16times\\nevery6hours.\\nNOTE:Beeping tonesmayemitundernonprogrammable scenarios inresponse todeviceself-diagnostic testing.\\nAdvise patients tohavetheirpulsegeneratorcheckedwhenever theyheartonescoming fromthedevice.\\nConfigure BeeperSettings\\nPerform thefollowing stepstoprogramtheConfigur eBeeper Settings:\\n1.SelecttheSettings tab.\\n2.SelecttheBeeper tab.\\n3.SelectthedesiredvalueforBeeper.\\n4.Beeper evaluation test:Afterturning ontheBeeper, ensure itisaudible byplacing amagnet overthedeviceand\\nlistening forbeeps. IftheBeeper isaudible, leavetheBeeper On.IftheBeeper isnotaudible, consider\\nprogramingtheBeeper toOff.\\nHearing capability ofthepatient andthecaregiver(s) mayvary.Itisrecommended toperform Beeper evaluation test\\nduring eachfollowup.\\nWARNING: IftheBeeper isinaudible orprogrammed Off,itisstronglyrecommended thatthepatient isfollowed\\nonLATITUDE NXT,and/or maintains anin-clinic follow-up schedule ofevery3months.\\nThefollowing aresituations thatwillnolongertrigger theBeeper toemitaudible tonesoncetheBeeper isturned\\nOff.\\nTable6–2.Situations thatwillnolongertriggeraudibleBeepertonesoncetheBeeperisturnedOff\\nProgrammable Beeper options•BeepDuring Capacitor Charge\\n•BeepWhenOut-of-Range\\n•BeepwhenExplant isIndicated\\nNon-Pro grammable Beeper options•Application ofthepatient magnet overthepulsegenerator in\\ncertainsituations (e.g.confirming Tachycard iaMode)\\n•Battery capacity depleted (EndofLife(EOL))\\n•Battery faultalert\\n•Highvoltage faultalert\\nTheBeeper willemittonesfollowing reversion ofthepulsegeneratortoSafetyModeOperationordevicereseteven\\naftertheBeeper isturned Off.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 215}), Document(page_content='Patient Diagnostics andFollow Up\\nPostImplantfeatures6-21\\nOnceturned Off,anotification thattheBeeper isturned Offappears ontheSummar ydialog(Figure 6–6Beeper Off\\nSummary dialogonpage6-21).\\nFigure6–6.BeeperOffSummary dialog\\nWhentheBeeper isprogrammed fromOfftoOn,allprogrammable andnon-programmable Beeper features willbe\\nreverted totheirnominal values(\"Magnet andBeeper Functions PgmOp\" onpageA-12).\\nDetermine BeeperType\\nThepulsegeneratorcontainseitheranArmatur eorPiezobeeper.\\n•TheArmature Beeper contains amagnetic component andmaybedamaged bythestrongmagnetic fields\\nassociated withMRIscanners. Before undergoinganMRIscan,thepatient andphysician should weighthe\\nbenefit oftheMRIscanagainst theriskoflosingbeeper function. TheBeeper maybeinaudible duetoMRIscan,\\nandshould betestedpostMRIscan.\\n•ThePiezoBeeper doesnotcontainanymagnetic components, andisdesigned towithstand thestrongmagnetic\\nfieldsassociated withMRIscanners without beingdamaged.\\nTodetermine theBeeper type,ensure theModel3868Programmer Softwar eApplication isversion 1.08oraboveand\\ninterrogatethedeviceusingtheModel3300Programmer.TheBeeper typeisdisplayed ontheBeeper tab(Figure 6–7\\nBeeper Tabonpage6-22).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 216}), Document(page_content='6-22Patient Diagnostics andFollow Up\\nPostImplantfeatures\\nFigure6–7.BeeperTab\\nNOTE:Screens willdifferdepending onbeeper typeandMRIProtectionModeavailability .\\nImpactofMRIScanonArmature Beeper\\nTheArmatur eBeeper maynolongerbeusable following anMRIscan.Coming incontact withthestrongmagnetic\\nfieldofanMRIscanner maycauseapermanent lossoftheArmatur eBeeper volume. Thiscannot berecovered, even\\nafterleaving theMRscanenvironment andexitingMRIProtection Mode.Thesystem proactively turnsoffthe\\nprogrammable andnon-progr ammable Beeper features whenMRIProtection Modeisprogrammed. TheArmature\\nBeeper willremain Offuponexiting MRIProtection Mode.Uponinterrogation, anotification willbeprovided onthe\\nSummary dialogthattheBeeper isoff.AfterexitingfromMRIProtectionMode,theBeeper canbeturned backon\\nusingtheConfigure Beeper Settings option ontheBeeper tabifdesired. Afterturning theBeeper backon,ensure itis\\nstillaudible bychecking theaudible tonesusingthemagnet. IftheBeeper isinaudible, considerreprogramingthe\\nBeeper toOff.\\nWARNING: Determine thebeeper typebeforeanMRIscan.TheArmatur eBeeper maynolongerbeusable\\nfollowing anMRIscan.Coming incontactwiththestrongmagnetic fieldofanMRIscanner maycauseapermanent\\nlossoftheArmature Beeper volume. Thiscannot berecovered,evenafterleaving theMRIscanenvironment and\\nexitingMRIProtection Mode.FortheArmatur eBeeper,beforeanMRIscanisperformed, aphysician andpatient\\nshould weighthebenefit oftheMRIscanagainst theriskoflosingtheBeeper; aftertheMRIscan,perform Beeper\\nevaluation testtodetermine iftheBeeper isusable. IftheBeeper isnotusable, itisstronglyrecommended that\\npatients arefollowed onLATITUDE NXTafteranMRIscaniftheyarenotalready .Otherwise,anin-clinic follow-up\\nschedule ofeverythreemonths isstronglyrecommended tomonitor deviceperformanc e.\\nNOTE:Forinstructions onhowtodetermine thebeeper type,referencethe“Determine Beeper Type”subsection of\\n\"Beeper Feature\" onpage6-19.Forinstructions onperforming theBeeper evaluation test,see\"Beeper Feature \"on\\npage6-19.\\nNOTE:Itisrecommended toperform Beeper evaluation testaftereachMRIscan.Insituations wheretheMRIscan\\ndidnotoccur,theArmatur eBeeper canbeprogrammed Onafterexiting MRIProtectionMode.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 217}), Document(page_content='Patient Diagnostics andFollow Up\\nPostImplantfeatures6-23\\nMagnetFeature\\nThemagnet feature allowscertain devicefunctions tobetriggered whenamagnet greaterthan60gaussisplaced in\\ncloseproximity tothepulsegenerator(Figure 6–8Proper position ofmagnet toactivate thepulsegeneratormagnet\\nfeatureonpage6-23).\\nPosition the magnet over the \\npulse generator as shown.\\nMagnet\\n3.0 cm\\nPulse generator\\nTop View\\nFigure6–8.Properpositionofmagnettoactivatethepulsegenerator magnetfeature\\nThepulsegeneratorMagnet Response settings canbeprogrammed tocontrolthebehavior ofthepulsegenerator\\nwhenamagnet isdetected. TheMagnet Response settings arelocated intheMagnet andBeeper section oftheV-\\nTachyTherapySetupscreen.\\nThefollowing Magnet Response settings areavailable:\\n•Off—no response\\n•StoreEGM—patient monitoring datawillbestored\\n•InhibitTherapy—therapy willbestopped\\nOff\\nWhentheMagnet Response isprogrammed toOff,application ofthemagnet willhavenoeffectonthepulse\\ngenerator.\\nStoreEGM\\nWhentheMagnet Response isprogrammed toStoreEGM,application ofthemagnet willactivate thePatient\\nTriggeredMonitor functionality (\"Patient TriggeredMonitor\" onpage6-17).\\nInhibitTherapy\\nWhentheMagnet Response isprogrammed toInhibitTherapy,application ofthemagnet willinhibitand/or divert\\nchargingforashock,divertashockthatisabouttobedelivered,orinhibitand/or divertfurther ATPtherapy.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 218}), Document(page_content='6-24Patient Diagnostics andFollow Up\\nPostImplantfeatures\\nWhenMagnet Response isprogrammed toInhibitTherapy,initiation oftachyarrhythmia therapy andarrhythmia\\ninduction isinhibited anytimethemagnet isproperlypositioned overthepulsegenerator.Thetachyarrhythmia\\ndetection processcontinues, buttherapyorinduction cannot betriggered.Whenamagnet isplacedoverthepulse\\ngenerator,thefollowing willoccur:\\n•IftheTachyModeisMonitor +Therapywhenthemagnet isapplied, theTachyModechanges tempor arilyto\\nMonitor OnlymodeandwillremaininMonitor Onlymodeaslongasthemagnet isapplied. Threesecondsafter\\nthemagnet isremoved,themodewillreturntothepreviouslyprogrammed mode.\\n•Ifthepulsegeneratorischargingtodeliver shocktherapy whenthemagnet isapplied, thechargingcontinues\\nbutisthenterminated withinonetotwosecondsofmagnet application, andthechargeisdiverted. (Thisdelay\\noccursincasethemagnet isinadvertently passed overthedevicewhentherapyinhibition isnotdesired.) The\\npulsegeneratorremains intemporary Monitor Onlymodewhilethemagnet isapplied. Nofurther therapyis\\ninitiated untilthemagnet isremoved; however ,detection willcontinue.\\n•Ifchargingiscomplet eorcompletes withinthe1–2second delayperiod, holding themagnet overthepulse\\ngeneratorformorethantwosecondswilldiverttheshock.(Ifthemagnet isremoved during thedelayperiod, the\\nshockcouldstillbedelivered.)Shocks willnotbedeliveredwiththemagnet inplace.\\n•Ifthepulsegeneratorisinitiating fibrillation induction orATPpulses, itterminates thedelivery afteronetotwo\\nseconds ofmagnet application. Nofurther induction orATPpulsesequenc esareinitiated untilthemagnet is\\nremoved.\\n•IftheTachyModeisMonitor OnlyorOff,magnet application willproduceaconstant tonetoindicate thatthe\\ndeviceisinanon-therapy mode.\\n•IftheTachyModeisMonitor +Therapy,magnet application willcausethepulsegeneratortobeeponceper\\nsecond toindicate thatthedeviceisinatherapymode.\\n•IfthepulsegeneratorisinElectrocautery Protection Mode,magnet application willproducebeeping consistent\\nwithwhichever TachyModewasactivewhenthepulsegenerator wasplacedintoElectrocautery Protection Mode.\\nForexample, ifElectrocautery ProtectionModewasenabled whentheTachyModewassettoMonitor +Therapy,\\nmagnet application willcausethepulsegeneratortobeeponcepersecond.\\nNOTE:Iftachydetection occurswhilethemagnet isinplace,detailed therapyhistorywillindicate thattherapywas\\nnotdelivered because thedevicewasinMonitor Onlymode.\\nNOTE:Themagnet featureissuspended whenthepulsegeneratorisinMRIProtection Mode.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 219}), Document(page_content='7-1\\nELECTROPHYSIOLOGIC TESTING\\nCHAPTER 7\\nThischapter containsthefollowing topics:\\n•“EPTestFeatures” onpage7-2\\n•“Induction Methods” onpage7-4\\n•“Commanded TherapyMethods” onpage7-8', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 220}), Document(page_content=\"7-2Electrophysiologic Testing\\nEPTestFeatures\\nEPTESTFEATURES\\nElectrophysiologic (EP)Testing features enable youtoinduce andterminate arrhythmias noninvasively inorderto\\nmonitor andtesttheeffectiveness ofselected detection criteria andtherapies.TheEPTestfeatures canbeusedin\\nconjunction withtheECGdisplay sothatreal-timetracesmaybeviewed. Thestatusofthepulsegenerator/patient\\ninteractionisalsodisplayed.\\nWARNING: Always haveexternal defibrillation equipment available during implant andelectrophy siologic testing. If\\nnotterminated inatimelyfashion, aninduced ventricular tachyarrhythmia canresultinthepatient's death.\\nThefeaturesallowing noninvasive EPtesting ofarrhythmias include thefollowing:\\n•VFibinduction\\n•ShockonTinduction\\n•Programmed electrical stimulation (PES)induction/termination\\n•50Hz/Manual Burstpacing induction/termination\\n•Commanded Shocktherapy\\n•Commanded ATPtherapy\\nTemporary EPMode\\nTemporary EPModeallowsyoutoprogramthedevicemodetoatempor aryvalueforEPtestdelivery ,andensures\\nthatthenormal devicemoderemains unchanged.\\nEPTestScreen\\nTheEPTestscreendisplays thereal-time statusofthedetection andtherapyprocessofthepulsegeneratorwhen\\ntelemetry communication isoccurring. Viewing thisdisplay allowsyoutoinduceandtesteitheraprogrammed\\ndetection/therapy prescription oroptional therapieswhilemonitoring thepulsegenerator'sprogress.\\nRefertotheEPTestscreen(Figure 7–1EPTestScreen onpage7-2):\\nFigure7–1.EPTestScreen\\nThescreenprovides thefollowing information:\\n•Statusmessages indicate detection andtherapystatusandaredescribed below:\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 221}), Document(page_content='Electrophysiologic Testing\\nEPTestFeatures7-3\\n–Ventricular episode status—if anepisode isoccurring, thedurationoftheepisode isdisplayed. (Ifitisgreater\\nthan10minutes, thenitisdisplayed as>10:00m:s).\\n–Ventricular detection status—if anepisode isoccurring, itindicates whether ventricular detection isinInitial\\nDetection, Redetection, orthezoneinwhichthatdetection ismet.Ifnoepisode isoccurring, the\\nprogrammer willalsodisplay thetime(inminutes) sincethelastventricular therapy(upto10minutes).\\n–Bradypacing andSRDstatus.\\n–Thetypeoftherapyinitiated andthezone.\\n–ThestatusofthetherapysuchasInProgress,Diverted, orDelivered.\\n•Duratio ntimer—Pro gression ofthedurationtimerisgraphic allydisplayed usingascale.Thebarinthescale\\nmoves fromlefttorighttoshowthepercentcomplete ofprogrammed duration. Whenduration isexpiredand\\ntherapydelivery begins, thebarisremoved.\\n•Detection status—The statusforeachprogrammed detection enhance mentisdisplayed. Whenenhancement\\ncriteria aremet,amarkappears intheadjacent box.\\n•Therapyprescriptions—Only thosetherapyprescriptions thatareprogrammed aredisplayed. Aseachtherapyis\\ndelivered,acheckmarkornumber willappear intheboxadjacen ttotherespective therapy.ATPtherapies\\nindicate thescheme typeaswellastheprogrammed number ofburstsinthescheme. Anumber willappear and\\nincrement(1,2,etc.)intheATPtherapyboxeachtimeanATPburstisdelivered. Shocktherapie sindicate the\\nprogrammed energy levelfortheprogrammable shocks. Anumber willappear andincrement (1,2,etc.)inthe\\nMaxboxeachtimeamaximum-energy shockisdelivered.\\nFollow thestepsbelowtoperform EPTestfunctions:\\n1.SelecttheTeststab,thenselecttheEPTeststab.\\n2.Establish telemetr ycommunication. Telemetr ycommunication between theprogrammer andthepulsegenerator\\nshould bemaintained throughout allEPtestprocedures.\\n3.SetBackup Pacing andEPTestPacing Outputs asdesired.\\n4.ProgramtheEPTempVModeappropriatetotheEPTestmethod (Table7–1EPTempVModeforEPTest\\nFunctions onpage7-3).\\nTable7–1.EPTempVModeforEPTestFunctions\\nEPTempVMode\\nEPTestMethodaMonitor+TherapydMonitorOnlyeOff\\n50Hz/Manual Burstb X\\nPESbX\\nVFibc X\\nShockonTc X\\nCommanded ATPc X\\nCommanded Shockc X X\\na.EPfunctions cannot beperformed ifthepulsegenerator isinStorage Mode.\\nb.Available method forbothatrialandventricular induction.\\nc.Available method onlyforventricular induction.\\nd.TheVentricular TachyModemustbeprogrammed toMonitor +Therapy .\\ne.TheVentricular TachyModemustbeprogrammed toMonitor OnlyorMonitor +Therapy .', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 222}), Document(page_content='7-4 Electrophysiologic Testing\\nInduction Methods\\nINDUCTION METHODS\\nEachEPTestmethod available fromtheEPTestscreenisdescribed belowwithinstructions. During anytypeof\\ninduction/termination, thepulsegeneratorperforms nootheractivity untilthetesthasceased, atwhichtimethe\\nprogrammed modewilltakeeffectandthepulsegeneratorwillrespondaccordingly.\\nConsider thefollowing information whenusingthesemethods:\\n•Ventricular PES,ShockonTwave,andVentricular ATPareBiV\\n•Ventricular Manual Burstand50HzBurstareRVOnly\\n•Allinductions andtachycardia therapydelivery areinhibited whenamagnet ispositioned overthepulse\\ngenerator(ifmagnet response issettoInhibitTherapy)\\n•Pacing pulsesduring induction aredeliveredattheprogrammed EPTestpacing paramet ers\\nVFibInduction\\nVFibinduction usestheshocking electrodestostimulate therightventricle atveryfastrates.\\nThefollowing settings areavailable toallowuseoftheminimum energynecessaryforinduction:\\n•VFibLowdelivers astimulation waveform of9volts\\n•VFibHighdelivers astimulation waveform of15volts\\nPerforming VFibInduction\\nNOTE:Thepatient should besedated priortodelivery offibrillation induction pulses. Thelargesurface areaofthe\\nshocking electrodestendstostimulate thesurrounding muscle andcanbeuncomfortable.\\n1.SelecttheVFiboption. Buttons foreachtestandanEnable checkbox aredisplayed.\\n2.SelecttheEnable checkbox.\\n3.SelectthedesiredHoldforFibbutton toinitiate delivery ofthefibrillation induction train.Theinduction trainis\\ndelivered upto15secondsaslongasthebutton isheldandthetelemetry linkismaintained.\\nDuring induction thepulsegenerator isautomatically disabled fromdetecting, andautomatically re-enabled\\nfollowing induction delivery .IfVFibinduction isinitiated during anepisode, theend-of-episode isdeclared\\nbefore theVFibinduction pulsesarestarted. Anewepisode (withinitialdetection andtherapy) canbedeclared\\naftertheVFibinduction iscompleted. EventmarkersandEGMsareinterrupted during VFibinduction andwill\\nautomatically restartfollowing induction.\\n4.Tostoptheinduction train,releasethebutton (thebutton willbecome dimmed again). Following theinduction,\\nthepulsegenerator automatically restartsdetection andPost-shock Pacing isactivated.\\n5.Todeliver another fibrillation induction, repeatthesesteps.\\nShockonTInduction\\nAShockonTwaveinduction method allowsthedevicetodeliver adrivetrain(upto30equally timedpacing pulses,\\norS1pulses) through theventricular pace/sen seelectrodes followed byshockdelivery throughtheshocking\\nelectrodes(Figure 7–2ShockonTinduction drivetrainonpage7-5).', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 223}), Document(page_content='Electrophysiologic Testing\\nInduction Methods7-5\\n400 400 400 400 400 400 \\nS1 S1 S1 S1 S1 S1 \\nLast sensed or \\npaced beat \\nCoupling \\nInterval \\nDrive Pulses Shock \\nS1 Interval \\nFigure7–2.ShockonTinduction drivetrain\\nTheinitialS1pulsefollows thelastsensed orpacedeventattheS1Interval.Theshockiscoupled tothelastS1pulse\\nofthedrivetrain.\\nPerforming ShockonTInduction\\n1.SelecttheShockonToption. Theprogrammable induction paramet erswillbedisplayed.\\n2.Selectthedesired valueforeachparameter .\\n3.SelecttheEnable checkbox. TheInducebutton willnolongerbedimmed.\\n4.SelecttheInduce button tobegindelivery ofthedrivetrain.Thepulsesaredeliveredinsequenc euntilthe\\nprogrammed number ofpulsesisreached. Onceinduction isinitiated, thedrivetraindelivery willnotstopifyou\\ninterrupt telemetr ycommunication. Whiletelemetr yisactive,pressing theDIVERT THERAPY keywillstop\\ninduction delivery .\\n5.ShockonTinduction iscomplete whenthedrivetrainandshockaredelivered,atwhichtimethepulsegenerator\\nautomatically restartsdetection andPost-shock Pacing isthenactivated.\\nNOTE:Priortodrivetraindelivery ,toneswillbeheardindicating capacitor charginginpreparationforshock\\ndelivery .\\nNOTE:Theshockdelivere dduring ShockonTinduction doesnotincrementepisode ortherapycounters.\\nBackupVentricular PacingDuringAtrialEPTesting\\nBackupbiventricular pacing isavailable during atrialEPtesting (PES,50Hz/Manual Burst)regardless ofthe\\nprogrammed Normal orPost-therap ypacing modes.\\nNOTE:BackupPacing isperformed inVOOmode.\\nProgramthebackup pacing parameters byselecting theEPTestPacing button. Backup Pacing parame tersare\\nindependently programmable fromthepermanent pacing parameters. Backup Pacing canalsobedisabled by\\nprogramming theBackupPacing ModetoOff.\\nProgrammed Electrical Stimulation (PES)\\nPESinduction allowsthepulsegeneratortodeliver upto30equally timedpacing pulses(S1)followed byupto4\\npremature stimuli (S2–S5) toinduceorterminate arrhythmias. Drivepulses, orS1pulses, areintended tocapture and', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 224}), Document(page_content='7-6Electrophysiologic Testing\\nInduction Methods\\ndrivetheheartatarateslightly fasterthantheintrinsic rate.Thisensures thatthetimingoftheprematu reextra\\nstimuli willbeaccuratelycoupled withthecardiaccycle(Figure 7–3PESinduction drivetrainonpage7-6).\\nTheinitialS1pulseiscoupledtothelastsensed orpacedbeatattheS1Interval. Allpulsesaredelivere dinXOO\\nmodes (whereXisthechamber) attheprogrammed EPTestpacing parameters.\\nForAtrialPES,backuppacing paramete rsareprovided.\\nS1 S1 S1 S1 S1 S2 S3\\n600 400 600 600 600 600 450\\nCoupling \\nInterval\\nCoupling \\nIntervalExtra \\nStimuliDrive Pulses\\nFigure7–3.PESinduction drivetrain\\nPerforming PESInduction\\n1.Choose theAtrium orVentricle tab,depending onwhichchamber youwanttopace\\n2.SelectthePESoption. Buttons fortheS1–S5pulsesandthecorresponding burstcyclelengths aredisplayed.\\n3.SelectthedesiredvaluefortheS1–S5intervals (Figure 7–4PESinduction options onpage7-6).Youcaneither\\nselectavalueboxforthedesired Sinterval andchoose avaluefromtheboxorusetheplusorminussymbols to\\nchange thevaluevisibleinthevaluebox.\\nFigure7–4.PESinduction options\\n4.SelecttheEnable checkbox.\\n5.Select(donothold)theInduce button tobegindelivery ofthedrivetrain.Whentheprogrammed number ofS1\\npulsesisdelivered,thepulsegenerator willthendeliver theprogrammed S2–S5pulses. Thepulsesaredelivered\\ninsequenc euntilapulseisencountered thatissettoOff(e.g.,ifS1andS2aresetto600ms,andS3isOff,then\\nS3,S4,andS5willnotbedelivered).Onceinduction isinitiated, thePESdelivery willnotstopifyouinterrupt\\ntelemetr ycommunication. (Whiletelemetr yisactive,pressing theDIVERT THERAPY keywillstopinduction\\ndelivery .)\\n6.PESinduction iscomplete whenthedrivetrainandextrastimuli aredelivere d,atwhichtimethepulsegenerator\\nautomatically restarts detection.\\nNOTE:Ensure thePESinduction iscomplete beforebeginning another induction.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 225}), Document(page_content='Electrophysiologic Testing\\n50Hz/Manual BurstPacing7-7\\nNOTE:WhenPESisusedtoterminate anarrhythmia thathasbeendetected (andanepisode declared),the\\nepisode isterminated whenthePESiscommanded regardless ofwhether itissuccessfulornot.Anewepisode\\ncanbedeclared afterthePESinduction iscompleted. ThePESitselfisnotrecordedintherapyhistory; thismay\\nresultinseveral episodes beingcountedintherapyhistory.\\nNOTE:Real-time EGMsandannotated eventmarkerswillcontinue tobedisplayed during theentiretest\\nsequenc e.\\n50Hz/Manual BurstPacing\\n50Hzpacing andManual Burstpacing arebothusedtoinduce orterminate arrhythmias whendeliveredtothe\\ndesiredchamber .Pacing parameters areprogrammable forManual Burstbutarefixedfor50Hzpacing.\\nManual Burstand50Hzpacing pulsesaredelivered inXOOmode(where Xisthechamber) attheprogrammed EP\\nTestpacing paramet ers.ForAtrialManual Burstand50Hz,backup pacing parameters areprovided.\\nPerforming ManualBurstPacing\\n1.Choose theAtrium orVentricle tab,depending onwhichchamber youwanttopace.\\n2.Selectthe50Hz/Manual Burstoption.\\n3.Selectthedesired valuefortheBurstInterval,Minimum, andDecrement. Thisindicates thecyclelengthofthe\\nintervals inthedrivetrain.\\n4.SelecttheEnable checkbox.\\n5.Todeliver theburst,selectandholdtheHoldforBurstbutton.\\nTheventricular Manual Burstwillbedeliveredupto30secondsaslongastheHoldforBurstbutton isheldand\\nthetelemetr ylinkismaintained.\\nTheatrialManual Burstwillbedelivere dupto45seconds aslongastheHoldforBurstbutton isheldandthe\\ntelemetry linkismaintained.\\nTheintervalswillcontinue tobedecremented untiltheMinimum intervalisreached, thenallfurther pulseswill\\nbeattheMinimum interval.\\n6.Tostoptheburstdelivery ,releasetheHoldforBurstbutton. TheHoldforBurstbutton willbecome dimmed\\nagain.\\n7.Todeliver additional Manual Burstpacing, repeatthesesteps.\\nPerforming 50HzBurstPacing\\n1.Choose theAtrium orVentricle tab,depending onwhichchamber youwanttopace.\\n2.Selectthe50Hz/Manual Burstoption.\\n3.SelecttheEnable checkbox.\\n4.Todeliver theburst,selectandholdtheHoldfor50HzBurstbutton.\\nTheventricular 50HzBurstwillbedeliveredupto30seconds aslongastheHoldforBurstbutton isheldand\\nthetelemetr ylinkismaintained.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 226}), Document(page_content='7-8Electrophysiologic Testing\\nCommanded TherapyMethods\\nTheatrial50HzBurstwillbedeliveredupto45seconds aslongastheHoldforBurstbutton isheldandthe\\ntelemetr ylinkismaintained.\\nNOTE:During Holdfor50HzBurstpacing, theS1Interval isautomatically setto20msandtheDecreme ntto\\n0.Thesevalueswillnotbedisplayed onthescreen.\\n5.Tostoptheburstdelivery ,releasetheHoldfor50HzBurstbutton. TheHoldfor50HzBurstbutton willbecome\\ndimmed again.\\n6.Todeliver additional 50HzBurstpacing, repeatthesesteps.\\nNOTE:Real-time EGMsandannotated eventmarkers willcontinuetobedisplayed during theentiretestsequenc e.\\nCOMMANDED THERAPY METHODS\\nThecommanded EPtestmethods, Commanded ShockandCommanded ATP,maybedeliveredindependently ofthe\\nprogrammed detection andtherapyparamete rs.Ifthepulsegenerator isintheprocessofdelivering therapywhena\\ncomman dedmethod isinitiated, theEPTestfunction overrides andabortsthetherapyinprocess.Ifanepisode isnot\\ninprogress,thenaCommanded Ventricular Episode willberecordedintheArrhythmia Logbook. Commanded Shock\\nandCommanded ATPdelivery isinhibited whentheDIVERT THERAPY keyispressedorwhenamagnet ispositioned\\noverthepulsegenerator,ifitisprogrammed toInhibitTherapy.\\nCommanded Shock\\nTheCommanded Shockfeature allowsdelivery ofashockwithprogrammable EnergyandCoupling Interval.\\nAllCommanded Shocks areCommitted anddeliveredR-Wave synchro nously whentheCoupling Interval is\\nprogrammed toSync.ShockWaveform andPolarity areidentical todetection-initiated shocks butaprogrammed\\nCoupling Interval maybespecified. TheCoupling Intervalisinitiated atthepointwheretheshockwouldhavebeen\\ndeliveredinSyncmode,butisinstead deliveredattheprogrammed Coupling Interval. Following anyCommanded\\nShockdelivery ,Post-Shock Redetection isusedandPost-shock Pacing isactivated.\\nPerforming Commanded ShockDelivery\\n1.SelecttheCommanded Shockoption.\\n2.SelectthedesiredvaluesfortheCoupling Interval andShockEnergy.\\n3.SelecttheEnable checkbox. TheDeliver Shockbutton willbecome available.\\n4.SelecttheDeliver Shockbutton toinitiate shockdelivery .TheCommanded Shockisrecordedintherapyhistory.\\n5.Todeliver subsequent shocks, repeatthesesteps.\\nCommanded ATP\\nCommanded ATPallowsyoutomanually deliver ATPschemes, independent oftheprogrammed detection and\\ntherapyparamet ers.YoucanconfiguretheCommanded ATPbyeitherselecting thetypeofATPscheme orby\\nprogramming ATPparameters ontheDetails screeninordertodeliver Commanded ATP.\\nTheEPTempVModemustbeprogrammed toMonitor Onlytoensure theCommanded ATPdoesnotinterfer ewith\\ndetection-initiated ATP.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 227}), Document(page_content='Electrophysiologic Testing\\nCommanded TherapyMethods7-9\\nPerforming Commanded ATP\\n1.Ifthepulsegenerator Ventricular TachyModeisnotcurrentlyprogrammed toMonitor Only,selecttheMonitor\\nOnlyEPTempVModeoption.\\n2.SelectthetypeofATPscheme andselectthevalueforNumber ofBursts.\\n3.SelecttheStartVentricular ATPbutton toinitiate thefirstburstintheselected ATPscheme. TheBursts\\nRemaining counterwilldecrement aseachburstiscomplete d.\\n4.SelecttheContinue button foreachadditional burstdelivery desired. Ifallburstsinascheme havebeen\\ndelivered,theBurstsRemaining counter willreturntotheinitialcount,andtheContinue button willbedimmed.\\n5.OtherATPschemes maybeselected atanytime;selectthedesired scheme andrepeattheabovesequenc e.The\\nCommanded ATPisrecordedasaphysician-commanded therapy counter anddisplayed onthecountersscreen.\\n6.AfterusingCommanded ATP,remember toprogram theEPTempVModetoMonitor +Therapy orleavethe\\nscreensothattheEPTempVModeisendedandthepermanent TachyModeisresumed.\\nNOTE:Ifanybutton otherthantheContinue button isselected during delivery ofaCommanded ATPscheme, the\\nscheme willberesetandtheBurstsRemaining boxwillberestored toitsinitialvalue.TheStartVentricular ATP\\nbutton mustbereselectedtoinitiate thescheme again.', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 228}), Document(page_content='7-10Electrophysiologic Testing\\nCommanded TherapyMethods', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 229}), Document(page_content='A-1\\nPROGRAMMABLE OPTIONS\\nAPPENDIX A\\nTableA–1.ZIPTelemetry settings\\nParameter Programmable Values Nominala\\nCommunication Mode Enable useofZIPtelemetry (Mayrequirelimited use\\nofwand); Usewandforalltelemetr yEnable useofZIPtelemetry (Mayrequirelimited use\\nofwand)\\na.IftheCommunication Modeisselected viatheUtilities button onthePRMStartup screen, theNominal setting withintheZOOMVIEW Programmer software application willcorrespond to\\nthevaluechosen ontheStartup screen.\\nTableA–2.TachyModeparameter\\nParameter Programmable Values Nominal\\nTachyMode Off;Monitor Only;Monitor +Therapy; Enable\\nElectrocautery Protection; Enable MRIProtectionaStorage\\na.Available inmodels withtheMRIProtection Modefeature.\\nTableA–3.Ventricular Zonesparameter\\nParameter Programmable Values Nominal\\nVentricular Zones 1;2;3 1\\nTableA–4.Detection parameters for1-zone,2-zone,and3-zoneconfigurations\\nParameter VT-1Zone VTZone VFZone Nominal\\nRatea(bpm)3zones\\n(interval sinms)90;95;...;200(667–300) 110;115;...;210(545–286);\\n220(273)130;135;...;210(462–286);\\n220;230;240;250(273–240)140(Toleranc e±5ms)forVT-\\n1Zone\\n170(Toleranc e±5ms)forVT\\nZone\\n200(Toleranc e±5ms)forVF\\nZone\\nRatea(bpm)2zones\\n(interval sinms)–– 90;95;...;210(667–286); 220\\n(273)110;115;...;210(545–286);\\n220;230;240;250(273–240)170(Toleranc e±5ms)forVT\\nZone\\n200(Toleranc e±5ms)forVF\\nZone\\nRatea(bpm)1zone(intervals\\ninms)–– –– 90;95;...;210(667–286);220\\n(273)200(Toleranc e±5ms)\\nInitialDuratio nb(sec)3zones 1.0;1.5;...;5.0;6.0;7.0;...;\\n15.0;20.0;25.0;...;60.01.0;1.5;...;5.0;6.0;7.0;...;\\n15.0;20.0;25.0;30.01.0;1.5;...;5.0;6.0;7.0;...;\\n15.02.5(Toleranc e±1cardiac\\ncycle)forVT-1Zone\\n2.5(Toleranc e±1cardiac\\ncycle)forVTZone\\n2.5(Toleranc e±1cardiac\\ncycle)forVFZone\\nInitialDuratio nb(sec)2zones –– 1.0;1.5;...;5.0;6.0;7.0;...;\\n15.0;20.0;25.0;30.01.0;1.5;...;5.0;6.0;7.0;...;\\n15.02.5(Toleranc e±1cardiac\\ncycle)forVTZone\\n2.5(Toleranc e±1cardiac\\ncycle)forVFZone\\nInitialDuratio n(sec)1zone –– –– 1.0;1.5;...;5.0;6.0;7.0;...;\\n15.02.5(Toleranc e±1cardiac\\ncycle)\\nRedetection Durationb(sec)3\\nzones1.0;1.5;...;5.0;6.0;7.0;...;\\n15.01.0;1.5;...;5.0;6.0;7.0;...;\\n15.01.0(nonprog rammable) 1.0(Toleranc e±1cardiac\\ncycle)forallzones', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 230}), Document(page_content='A-2Programmable Options\\nTableA–4.Detection parameters for1-zone,2-zone,and3-zoneconfigurations (continued)\\nParameter VT-1Zone VTZone VFZone Nominal\\nRedetection Duration(sec)2\\nzones–– 1.0;1.5;...;5.0;6.0;7.0;...;\\n15.01.0(nonprogr ammable) 1.0(Toleranc e±1cardiac\\ncycle)forallzones\\nRedetection Duration(sec)1\\nzone–– –– 1.0(nonprogr ammable) 1.0(Toleranc e±1cardiac\\ncycle)\\nPost-shock Durationb(sec)3\\nzones1.0;1.5;...;5.0;6.0;7.0;...;\\n15.0;20.0;25.0;...;60.01.0;1.5;...;5.0;6.0;7.0;...;\\n15.0;20.0;25.0;30.01.0(nonprogr ammable) 1.0(Toleranc e±1cardiac\\ncycle)forallzones\\nPost-shock Duration (sec)2\\nzones–– 1.0;1.5;...;5.0;6.0;7.0;...;\\n15.0;20.0;25.0;30.01.0(nonprogr ammable) 1.0(Toleranc e±1cardiac\\ncycle)forallzones\\nPost-shock Duration (sec)1\\nzone–– –– 1.0(nonprogr ammable) 1.0(Toleranc e±1cardiac\\ncycle)\\na.TheRatedifferencebetween eachtachyzonemustbeatleast20bpm.Thelowest TachyRateThreshold mustbe≥5bpmhigherthantheMaximum Tracking Rate,Maximum Sensor Rate,\\nandtheMaximum Pacing Rate;andthelowest TachyRateThreshold mustbe≥15bpmhigherthantheLowerRateLimit.\\nb.TheDuration inazonemustbeequaltoorgreater thantheDuration inthenexthighest zone.\\nTableA–5.Ventricular Detection EnhancementTypefor2-zoneand3-zoneconfigurations\\nParameter Programmable Values Nominal\\nDetection Enhanc ementType Off;Rhythm IDa;Onset/Stability Onset/Stability\\na.Available inmodels withtheRhythm IDfeature.\\nTableA–6.Onset/Stability detection enhancement parameters for2-zoneand3-zoneconfigurations\\nParameter VT-1Zone VTZone VFZone Nominal\\nDetection Enhanc ement3\\nzonesOff;On Off;On –– On(VT-1);Off(VT)\\nDetection Enhanc ement2\\nzones–– Off;On –– On\\nVRate>ARate3zonesaOff;On –– –– On\\nVRate>ARate2zones –– Off;On –– On\\nAFibRateThreshold(bpm)3\\nzonesabOff;100;110;...;300 –– –– 170(Toleranc e±5ms)\\nAFibRateThreshold(bpm)2\\nzonesb–– Off;100;110;...;300 –– 170(Toleranc e±5ms)\\nStability (ms)3zonesa Off;6;8;...;32;35;40;...;\\n60;70;80;...;120–– –– 20(Toleran ce±5ms)\\nStability (ms)2zones –– Off;6;8;...;32;35;40;...;\\n60;70;80;...;120–– 20(Toleran ce±5ms)\\nShockIfUnstable (ms)3zones –– Off;6;8;...;32;35;40;...;\\n60;70;80;...;120–– 30(Toleranc e±5ms)\\nShockIfUnstable (ms)2zones –– Off;6;8;...;32;35;40;...;\\n60;70;80;...;120–– Off(Toleranc e±5ms)\\nOnset(%orms)3zonesa Off;9;12;16;19;...;3741;44;\\n47;50%or50;60;...;250ms–– –– 9%(Toleranc e±5ms)\\nOnset(%orms)2zones –– Off;9;12;16;19;...;37;41;\\n44;47;50%or50;60;...;250\\nms–– 9%(Toleranc e±5ms)\\nStability And/Or Onset3\\nzonesaAnd;Or –– –– And\\nStability And/Or Onset2\\nzones–– And;Or –– And', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 231}), Document(page_content='Programmable Options A-3\\nTableA–6.Onset/Stability detection enhancem entparameters for2-zoneand3-zoneconfigurations (continued)\\nParameter VT-1Zone VTZone VFZone Nominal\\nSustained RateDuration(min:\\nsec)3zonesaOff;00:10;00:15;...;00:55;\\n01:00;01:15;...;02:00; 02:30;\\n03:00; ...;10:00;15:00;\\n20:00; ...;60:00–– –– 03:00(Toleranc e±1cardiac\\ncycle)\\nSustained RateDuration(min:\\nsec)2zones–– Off;00:10;00:15;...;00:55;\\n01:00;01:15;...;02:00; 02:30;\\n03:00; ...;10:00;15:00;\\n20:00; ...;60:00–– 03:00(Toleranc e±1cardiac\\ncycle)\\nAtrialTachyarrhythmia\\nDiscrimination 3zonesaOff;On –– –– On\\nAtrialTachyarrhythmia\\nDiscrimination 2zones–– Off;On –– On\\nSinusTachycardia\\nDiscrimination 3zonesaOff;On –– –– On\\nSinusTachycardia\\nDiscrimination 2zones–– Off;On –– On\\nPolymorphic VTDiscrimination\\n3zones–– Off;On –– On\\nPolymorphic VTDiscrimination\\n2zones–– Off;On –– Off\\na.IfallVT-1therapy isprogramm edtoOff,detection enhancements willapplyintheVTzone,nottheVT-1zone.\\nb.AlloftheAFibRateThresholds arelinkedtotheATRTrigger RateandAtrialFlutterResponse Rate.Ifanyoneoftheseratesisreprogrammed, theotherswillautomatically change tothe\\nsamevalue.\\nTableA–7.RhythmIDdetection enhancement parameters for2-zoneand3-zoneconfigurations\\nParameter VT-1Zone VTZone VFZone Nominal\\nInitialDetection Enhanc ement\\n3zonesOff;On Off;On –– On(VT-1);Off(VT)\\nInitialDetection Enhanc ement\\n2zones–– Off;On –– Off\\nSustained RateDuration(min:\\nsec)3zonesOff;00:10;00:15;...;01:00;\\n01:15;...;02:00; 02:30;...;\\n10:00;15:00;...;60:00Off;00:10;00:15;...;01:00;\\n01:15;...;02:00; 02:30;...;\\n10:00;15:00;...;60:00–– 03:00(VT-1andVT)\\n(Toleranc e±1cardiac cycle)\\nSustained RateDuration(min:\\nsec)2zones–– Off;00:10;00:15;...;01:00;\\n01:15;...;02:00; 02:30;...;\\n10:00;15:00;...;60:00–– 03:00(Toleranc e±1cardiac\\ncycle)\\nPassive Method 3zones(one\\nvalueforallzones)Off;On Off;On –– On\\nPassive Method 2zones –– Off;On –– On\\nActiveMethod 3zones(one\\nvalueforallzones)Off;On Off;On –– On\\nActiveMethod 2zones –– Off;On –– On\\nRhythmMatch Threshold (%)3\\nzones(onevalueforallzones)70;71;...;96 70;71;...;96 –– 94\\nRhythmMatch Threshold (%)2\\nzones–– 70;71;...;96 –– 94\\nTemporary LRL(ppm)3zones\\n(onevalueforallzones)UseNormal BradyLRL;30;35;\\n...;105UseNormal BradyLRL;30;35;\\n...;105–– UseNormal BradyLRL\\n(Toleranc e±5ms)\\nTemporary LRL(ppm)2zones –– UseNormal BradyLRL;30;35;\\n...;105–– UseNormal BradyLRL\\n(Toleranc e±5ms)', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 232}), Document(page_content='A-4 Programmable Options\\nTableA–7.RhythmIDdetection enhancement parameters for2-zoneand3-zoneconfigurations (continued)\\nParameter VT-1Zone VTZone VFZone Nominal\\nAtrialTachyDiscrimination 3\\nzones(onevalueforallzones)Off;On Off;On –– On\\nAtrialTachyDiscrimination 2\\nzones–– Off;On –– On\\nAFibRateThreshold(bpm)3\\nzones(onevalueforallzones)\\nab100;110;...;300 100;110;...;300 –– 170(Toleranc e±5ms)\\nAFibRateThreshold(bpm)2\\nzonesab–– 100;110;...;300 –– 170(Toleranc e±5ms)\\nStability (ms)3zones(one\\nvalueforallzones)a6;8;...;32;35;40;...;60;70;\\n...;1206;8;...;32;35;40;...;60;70;\\n...;120–– 20(Toleran ce±5ms)\\nStability (ms)2zonesa –– 6;8;...;32;35;40;...;60;70;\\n...;120–– 20(Toleran ce±5ms)\\na.Thisparameter isusedininitialdetection andPost-shock Detection. Changing thevalueforinitialdetection willchange thevalueforPost-Therapy Brady.\\nb.AlloftheAFibRateThresholds arelinkedtotheATRTrigger RateandAtrialFlutterResponse Rate.Ifanyoneoftheseratesisreprogrammed, theotherswillautomatically change tothe\\nsamevalue.\\nTableA–8.Post-shockOnset/Stability detection enhancement parameters for2-zoneand3-zoneconfigurations\\nParameter VT-1Zone VTZone VFZone Nominal\\nPost-shock VRate>ARate3\\nzonesaOff;On –– –– On\\nPost-shock VRate>ARate2\\nzones–– Off;On –– On\\nPost-shock AFibRate\\nThreshold (bpm)3zonesabOff;100;110;...;300 –– –– 170(Toleranc e±5ms)\\nPost-shock AFibRate\\nThreshold (bpm)2zonesb–– Off;100;110;...;300 –– 170(Toleranc e±5ms)\\nPost-shock Stability (ms)3\\nzonesaOff;6;8;...;32;35;40;...;\\n60;70;80;...;120–– –– 20(Toleran ce±5ms)\\nPost-shock Stability (ms)2\\nzones–– Off;6;8;...;32;35;40;...;\\n60;70;80;...;120–– 20(Toleran ce±5ms)\\nPost-shock Sustained Rate\\nDuratio n(min:sec) 3zonesaOff;00:10;00:15;...;00:55;\\n01:00;01:15;...;02:00; 02:30;\\n03:00; ...;10:00;15:00;\\n20:00; ...;60:00–– –– 00:15(Toleran ce±1cardiac\\ncycle)\\nPost-shock Sustained Rate\\nDuratio n(min:sec) 2zones–– Off;00:10;00:15;...;00:55;\\n01:00;01:15;...;02:00; 02:30;\\n03:00; ...;10:00;15:00;\\n20:00; ...;60:00–– 00:15(Toleran ce±1cardiac\\ncycle)\\na.IfallVT-1therapy isprogrammed toOff,detection enhancements willapplyintheVTzone,nottheVT-1zone.\\nb.AlloftheAFibRateThresholds arelinkedtotheATRTrigger RateandAtrialFlutterResponse Rate.Ifanyoneoftheseratesisreprogrammed, theotherswillautomatically change tothe\\nsamevalue.\\nTableA–9.Post-shockRhythmIDdetection enhancement parameters for2-zoneand3-zoneconfigurations\\nParameter VT-1Zone VTZone VFZone Nominal\\nPostShockDetection\\nEnhance ment3zonesOff;On Off;On –– Off\\nPostShockDetection\\nEnhance ment2zones–– Off;On –– Off', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 233}), Document(page_content='Programmable Options A-5\\nTableA–9.Post-shockRhythmIDdetection enhancement parameters for2-zoneand3-zoneconfigurations (continued)\\nParameter VT-1Zone VTZone VFZone Nominal\\nPostShockSustained Rate\\nDuration (min:sec) 3zonesOff;00:10;00:15;...;00:55;\\n01:00;01:15;...;02:00; 02:30;\\n...;10:00;15:00;...;60:00Off;00:10;00:15;...;00:55;\\n01:00;01:15;...;02:00; 02:30;\\n...;10:00;15:00;...;60:00–– 0:15(Toleranc e±1cardiac\\ncycle)\\nPostShockSustained Rate\\nDuration (min:sec) 2zones–– Off;00:10;00:15;...;00:55;\\n01:00;01:15;...;02:00; 02:30;\\n...;10:00;15:00;...;60:00–– 0:15(Toleranc e±1cardiac\\ncycle)\\nAFibRateThreshold (bpm)3\\nzones(onevalueforallzones)\\nab100;110;...;300 100;110;...;300 –– 170(Toleranc e±5ms)\\nAFibRateThreshold (bpm)2\\nzonesab–– 100;110;...;300 –– 170(Toleranc e±5ms)\\nStability (ms)3zones(one\\nvalueforallzones)a6;8;...;32;35;40;...;60;70;\\n...;1206;8;...;32;35;40;...;60;70;\\n...;120–– 20(Toleranc e±5ms)\\nStability (ms)2zonesa –– 6;8;...;32;35;40;...;60;70;\\n...;120–– 20(Toleranc e±5ms)\\na.Thisparameter isusedininitialdetection andPost-shock Detection. Changing thevalueforinitialdetection willchange thevalueforPost-Therapy Brady.\\nb.AlloftheAFibRateThresholds arelinkedtotheATRTrigger RateandAtrialFlutterResponse Rate.Ifanyoneoftheseratesisreprogrammed, theotherswillautomatically change tothe\\nsamevalue.\\nTableA–10.Ventricular ATPparameters (specified intoa750Ωload)\\nParameter VT-1Zone VTZone VFZone Nominal\\nATPType3zones Off;Burst;Ramp; Scan;\\nRamp/ScanOff;Burst;Ramp; Scan;\\nRamp/Scan–– Off(VT-1);Burst(VTATP1);\\nRamp(VTATP2)\\nATPType2zones –– Off;Burst;Ramp; Scan;\\nRamp/Scan–– Off(VTATP1andVTATP2)\\nNumber ofBursts(per\\nscheme) 3zonesOff;1;2;...;30 Off;1;2;...;30 –– Off(VT-1);2(VTATP1);1(VT\\nATP2)\\nNumber ofBursts(per\\nscheme) 2zones–– Off;1;2;...;30 –– Off(VTATP1andVTATP2)\\nInitialPulse(pulses) 3zones 1;2;...;30 1;2;...;30 –– 4(VT-1);10(VT)\\nInitialPulse(pulses) 2zones –– 1;2;...;30 –– 10\\nPulseIncrement (pulses) 3\\nzones0;1;...;5 0;1;...;5 –– 0\\nPulseIncrement (pulses) 2\\nzones–– 0;1;...;5 –– 0\\nMaximum Number ofPulses3\\nzones1;2;...;30 1;2;...;30 –– 4(VT-1);10(VT)\\nMaximum Number ofPulses2\\nzones–– 1;2;...;30 –– 10\\nCoupling Interval(%orms)3\\nzones50;53;56;59;63;66;...;84;\\n88;91;94;97%or120;130;\\n...;750ms50;53;56;59;63;66;...;84;\\n88;91;94;97%or120;130;\\n...;750ms–– 81%(Toleranc e±5ms)\\nCoupling Interval(%orms)2\\nzones–– 50;53;56;59;63;66;...;84;\\n88;91;94;97%or120;130;\\n...;750ms–– 81%(Toleranc e±5ms)\\nCoupling IntervalDecrement\\n(ms)3zonesd0;2;...;30 0;2;...;30 –– 10(Toleranc e+/-5ms)when\\nATPtypeisScanandRamp/\\nScan;otherwise 0(Toleranc e\\n+/-5ms)', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 234}), Document(page_content='A-6Programmable Options\\nTableA–10.Ventricular ATPparameters (specified intoa750Ωload)(continued)\\nParameter VT-1Zone VTZone VFZone Nominal\\nCoupling Interval Decrement\\n(ms)2zonesd–– 0;2;...;30 –– 10(Toleranc e+/-5ms)when\\nATPtypeisScanandRamp/\\nScan;otherwise0(Toleranc e\\n+/-5ms)\\nBurstCycleLength (BCL)(%or\\nms)3zones50;53;56;59;63;66;...;84;\\n88;91;94;97%or120;130;\\n...;750ms50;53;56;59;63;66;...;84;\\n88;91;94;97%or120;130;\\n...;750ms–– 81%(Toleranc e±5ms)\\nBurstCycleLength (BCL)(%or\\nms)2zones–– 50;53;56;59;63;66;...;84;\\n88;91;94;97%or120;130;\\n...;750ms–– 81%(Toleranc e±5ms)\\nRampDecrement (ms)3\\nzonese0;2;...;30 0;2;...;30 –– 10(Toleranc e+/-5ms)when\\nATPtypeisRampandRamp/\\nScan;otherwise0(Toleranc e\\n+/-5ms)\\nRampDecrement (ms)2\\nzonese–– 0;2;...;30 –– 10(Toleranc e+/-5ms)when\\nATPtypeisRampandRamp/\\nScan;otherwise0(Toleranc e\\n+/-5ms)\\nScanDecrement (ms)3\\nzonesd0;2;...;30 0;2;...;30 –– 10(Toleranc e+/-5ms)when\\nATPtypeisScanandRamp/\\nScan;otherwise0(Toleranc e\\n+/-5ms)\\nScanDecrement (ms)2\\nzonesd–– 0;2;...;30 –– 10(Toleranc e+/-5ms)when\\nATPtypeisScanandRamp/\\nScan;otherwise0(Toleranc e\\n+/-5ms)\\nMinimum Interval (ms)3\\nzones120;130;...;400 120;130;...;400 –– 220(Toleran ce±5ms)\\nMinimum Interval (ms)2\\nzones–– 120;130;...;400 –– 220(Toleran ce±5ms)\\nRightVentricular ATPPulse\\nWidtha(ms)3zones(one\\nvalueforallzones)0.1;0.2;...;2.0 0.1;0.2;...;2.0 –– 1.0(Toleranc e±0.03msat<\\n1.8ms;±0.08msat≥1.8ms)\\nRightVentricular ATPPulse\\nWidtha(ms)2zones(one\\nvalueforallzones)–– 0.1;0.2;...;2.0 –– 1.0(Toleranc e±0.03msat<\\n1.8ms;±0.08msat≥1.8ms)\\nLeftVentricular ATPPulse\\nWidtha(ms)3zones(one\\nvalueforallzones)0.1;0.2;...;2.0 0.1;0.2;...;2.0 –– 1.0(Toleranc e±0.03msat<\\n1.8ms;±0.08msat≥1.8ms)\\nLeftVentricular ATPPulse\\nWidtha(ms)2zones(one\\nvalueforallzones)–– 0.1;0.2;...;2.0 –– 1.0(Toleranc e±0.03msat<\\n1.8ms;±0.08msat≥1.8ms)\\nRightVentricular ATP\\nAmplitudea(V)3zones(one\\nvalueforallzones)0.1;0.2;...;3.5;4.0;...;7.5 0.1;0.2;...;3.5;4.0;...;7.5 –– 5.0(Toleranc e±15%or±100\\nmV,whichever isgreater)\\nRightVentricular ATP\\nAmplitudea(V)2zones(one\\nvalueforallzones)–– 0.1;0.2;...;3.5;4.0;...;7.5 –– 5.0(Toleranc e±15%or±100\\nmV,whichever isgreater)\\nLeftVentricular ATP\\nAmplitudea(V)3zones(one\\nvalueforallzones)0.1;0.2;...;3.5;4.0;...;7.5 0.1;0.2;...;3.5;4.0;...;7.5 –– 5.0(Toleranc e±15%or±100\\nmV,whichever isgreater)\\nLeftVentricular ATP\\nAmplitudea(V)2zones(one\\nvalueforallzones)–– 0.1;0.2;...;3.5;4.0;...;7.5 –– 5.0(Toleranc e±15%or±100\\nmV,whichever isgreater)', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 235}), Document(page_content='Programmable Options A-7\\nTableA–10.Ventricular ATPparameters (specified intoa750Ωload)(continued)\\nParameter VT-1Zone VTZone VFZone Nominal\\nATPTime-outb(min:sec) 3\\nzonesOff;00:10;00:15;…;01:00;\\n01:15;…;02:00; 02:30;\\n..;10:00; 15:00;..;60:00Off;00:10;00:15;…;01:00;\\n01:15;…;02:00; 02:30;\\n..;10:00; 15:00;..;60:00–– 01:00\\nATPTime-out (min:sec) 2\\nzones–– Off;00:10;00:15;…;01:00;\\n01:15;…;02:00; 02:30;\\n..;10:00; 15:00;..;60:00–– 01:00\\nQUICKCONVERT ATP(VFOnly)\\n1,2,or3zones–– –– Off;On On\\na.Theprogrammed Amplitude andPulseWidthvaluesaffectPostTherapy BradyPacing, butareseparately programmable fromNormal BradyPacing, Temporary BradyPacing, andEPTest.\\nb.TheVT-1ATPTime-out mustbegreater thanorequaltotheVTATPTime-out.\\nc.Values applyifBurstisselected fortheVT-1ATPparameter.\\nd.Values applyonlyifATPtypeisScanorRamp/Scan\\ne.Values applyonlyifATPtypeisRamporRamp/Scan\\nTableA–11.Ventricular ShockParameters\\nParameter Programmable Values Nominal\\nShocks 1and2energy,2zonesabcOff;0.1;0.3;0.6;0.9;1.1;1.7;2;3;5;6;7;9;11;14;\\n17;21;23;26;29;31;36;41Off(VT)\\n41J(VF)(Toleran ce+150/-60% for0.1J;±60%for\\n0.3J;±40%for0.6–3J;±20%for5–36J;±10%for\\n41J)\\nShocks 1and2energy,3zonesabcOff;0.1;0.3;0.6;0.9;1.1;1.7;2;3;5;6;7;9;11;14;\\n17;21;23;26;29;31;36;41Off(VT-1)\\n41J(VTandVF)(Toleranc e+150/-60% for0.1J;±\\n60%for0.3J;±40%for0.6–3J;±20%for5–36J;\\n±10%for41J)\\nEnergy ofRemaining Shocks, 2zonesacOff;41 Off(VT)\\n41J(VF)(Toleran ce±10%for41J)\\nEnergy ofRemaining Shocks, 3zonesacOff;41 Off(VT-1)\\n41J(VTandVF)(Toleranc e±10%for41J)\\nLeadPolaritydInitial;Reversed Initial\\nCommitted Shock Off;On Off\\nShockLeadVector RVCoiltoRACoilandCan;RVCoiltoCan;RVCoilto\\nRACoilRVCoiltoRACoilandCan\\na.Biphasic energy isspecified.\\nb.TheShock2energy levelmustbegreaterthanorequaltotheShock1energy level.\\nc.InaVT-1zoneofa3-zone configur ationoraVTzoneofa2-zone configur ation,allorsomeoftheshocks maybeprogrammed toOffwhileothershocks inthatzoneareprogrammed in\\njoules.\\nd.Acommanded STATSHOCK isdelivered attheprogrammed Polarity .\\nTableA–12.Pacingtherapyparameters (Normal,Post-Therapy,andTemporar y)(specified intoa750Ωload)\\nParameter Programmable Values Nominal\\nModeaeDDD(R); DDI(R); VDD(R); VVI(R); AAI(R); Off;\\nTemporary: DDD;DDI;DOO;VDD;VVI;VOO;AAI;\\nAOO;OffDDD\\nLowerRateLimit(LRL)abc(ppm) 30;35;...;185 45(Toleranc e±5ms)\\nMaximum Tracking Rate(MTR)e(ppm) 50;55;...;185 130(Toleranc e±5ms)', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 236}), Document(page_content=\"A-8Programmable Options\\nTableA–12.Pacingtherapyparameters (Normal, Post-Therapy,andTemporary) (specified intoa750Ωload)(continued)\\nParameter Programmable Values Nominal\\nMaximum Sensor Rate(MSR)eh(ppm) 50;55;...;185 130(Toleranc e±5ms)\\nPulseAmplitudeacd(atrium) (V) Auto;0.1;0.2;...3.5;4.0;...;5.0;\\nTempor ary:0.1;0.2;...;3.5;4.0;...;5.03.5(5.0post-therapy) (Toleranc e±15%or±100mV,\\nwhichever isgreater)\\nPulseAmplitudeacd(rightventricle) (V) Auto;0.1;0.2;...;3.5;4.0;...;7.5;\\nTempor ary:0.1;0.2;...;3.5;4.0;...;7.53.5(5.0post-therapy) (Toleranc e±15%or±100mV,\\nwhichever isgreater)\\nPulseAmplitude DailyTrendk(independently\\nprogrammable ineachchamber)Disabled; Enabled Enabled\\nPulseWidthacdi(atrium, rightventricle) (ms) 0.1;0.2,...,2.0 0.4(1.0post-therapy) (Toleran ce±0.03msat<1.8\\nms;±0.08msat≥1.8ms)\\nAtrialPace/Sense Configura tionaeBipolar; Off Bipolar\\nAccelerometerehOn;Passive Passive\\nAccelerometer Activity ThresholdehVeryHigh;High;Medium High;Medium; Medium\\nLow;Low;VeryLowMedium\\nAccelerometer Reaction Timeeh(sec) 10;20;...;50 30\\nAccelerometer Response Factoreh1;2;...;16 8\\nAccelerometer Recovery Timeeh(min) 2;3;...;16 2\\nMinute VentilationehOn;Passive; Off Passive\\nMinute Ventilation Response Factoreh1;2;...;16 8\\nMinute Ventilation Fitness Level Sedentary; Active; Athletic; Enduranc eSports Active\\nPatient's Agej≤5;6–10;11–15;...;91–95;≥96 56–60\\nPatient's GenderjMale;Female Male\\nVentilatory Threshold (ppm) 30;35;...;185 115(Toleranc e±5ms)\\nVentilatory Threshold Response (%) Off;85;70;55 70\\nMaximum PVARPae(ms) 150;160;...;500 280(Toleran ce±5ms)\\nMinimum PVARPae(ms) 150;160;...;500 240(Toleran ce±5ms)\\nPVARP AfterPVCae(ms) Off;150;200;...;500 400(Toleranc e±5ms)\\nRV-Blank AfterA-Paceaf(ms) 45;65;85;Smart 65(Toleranc e±5ms)\\nA-Blank AfterV-Paceaf(ms) 85;105;125;Smart Smart(Toleranc e±5ms)\\nA-Blank AfterRV-Senseaf(ms) 45;65;85;Smart Smart(Toleranc e±5ms)\\nMaximum VRP(rightventricle)ae(ms) 150;160;...;500 250(Toleranc e±5ms)\\nMinimum VRP(rightventricle)ag(ms) 150;160;...;500 230(Toleranc e±5ms)\\nMaximum PacedAVDelayae(ms) 30;40;...;300 180(Toleranc e±5ms)\\nMinimum PacedAVDelayae(ms) 30;40;...;300 180(Toleranc e±5ms)\\nMaximum Sensed AVDelayae(ms) 30;40;...;300 120(Toleranc e±5ms)\\nMinimum Sensed AVDelayae(ms) 30;40;...;300 120(Toleranc e±5ms)\\nRespiratory SensoraeOff;On Off\\nRespirati on-related TrendslmOff;On On\", metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 237}), Document(page_content='Programmable Options A-9\\nTableA–12.Pacingtherapyparameters (Normal,Post-Therapy,andTemporar y)(specified intoa750Ωload)(continued)\\nParameter Programmable Values Nominal\\nTracking Preferenc eehOff;On On\\nRateHysteresis Hysteresis Offseteh(ppm) -80;-75;...;-5;Off Off(Toleran ce±5ms)\\nRateHysteresis Search Hysteresiseh(cycles) Off;256;512;1024;2048;4096 Off(Toleran ce±1cycle)\\nRateSmoothing (up,down)eh(%) Off;3;6;9;12;15;18;21;25 Off(Toleran ce±1%)\\nRateSmoothing Maximum Pacing Rate(MPR)e(\\nppm)50;55;...;185 130(Toleranc e±5ms)\\nNoiseResponseaeAOO;VOO;DOO;InhibitPacing DOOforDDD(R) andDDI(R)modes; VOOforVDD(R)\\nandVVI(R)modes; AOOforAAI(R)mode\\nPostTherapy Pacing Period(min:sec) (available post-\\nshockonly)00:15;00:30; 00:45; 01:00;01:30;02:00; 03:00;\\n04:00; 05:00; 10:00;15:00;30:00; 45:00; and\\n60:0000:30(Toleranc e±1cardiac cycle)\\na.Theprogrammed Normal Bradyvalueswillbeusedasthenominal valuesforTemporary Bradypacing.\\nb.Thebasicpulseperiod isequaltothepacing rateandthepulseinterval (nohysteresis). Runaway protection circuitry inhibits bradycar diapacing above205ppm.Magnet application does\\nnotaffectpacing rate(testpulseinterval).\\nc.Separately programm ableforATP/Post -shock, Temporary Brady,andEPTest.\\nd.Values arenotaffected bytemperatur evariation withintherange20°–43°C.\\ne.Thisparameter isusedglobally inNormal Bradypacing andPost-Therapy Bradypacing. Changing thevalueforNormal Bradywillchange thevalueforPost-Therapy Brady.\\nf.Thisparameter isautomatically settoatleast85msforPost-Therapy Brady.\\ng.Thisparameter isautomatically adjusted inPost-Therapy Bradytoallowappropriate sensing.\\nh.Thisparameter isdisabled during Temporary Brady.\\ni.WhenthePulseAmplitude issettoAutoorPulseAmplitude DailyTrendisenabled thePulseWidthisfixedat0.4ms.\\nj.Thisparameter isusedforcalculating Ventilatory Threshold Response.\\nk.Thisparameter isautomatically enabled ifAutoisselected forthePulseAmplitude.\\nl.Thisvalueislocated ontheLeadSetupscreen.\\nm.Thisparameter isusedtocontroltheRespiratory Sensor.\\nTableA–13.Brady/CRT leftventricular pacingparameters (specified intoa750Ωload)\\nParameter Programmable Values Nominal\\nVentricular Pacing ChamberabRVOnly;BiV;LVOnly BiV\\nLVOffsetab(ms) -100;-90;...;0 0(Toleranc e±5ms)\\nLVOffsetab(formodels withLVMSP)(ms) -100;-95;-90;…;0 0(Toleranc e±5ms)\\nPulseAmplitudeacd(leftventricle) (V) Auto;0.1;0.2;...;3.5;4.0;...;7.5;\\nTemporary: 0.1;0.2;...;3.5;4.0;...;7.53.5(5.0posttherapy) (Toleranc e±15%or±100mV)\\n(whichever isgreater)\\nPulseAmplitude DailyTrendg(leftventricle) Disabled; Enabled Enabled\\nPulseWidthacd(leftventricle) (ms) 0.1;0.2;...;2.0 0.4(1.0posttherapy)(Toleranc e±0.03msat<1.8\\nms;±0.08msat≥1.8ms)\\nLV-Blank AfterA-Paceae(ms) 45;65;85;Smart Smart(Toleranc e±5ms)\\nLVRPab(ms) 250;260;...;500 250(Toleranc e±7.5ms)\\nLVPPab(ms) 300;350;...;500 400(Toleranc e±5ms)\\nBiVTriggerbhOff;On Off\\nBiV/VRR Maximum Pacing Ratebf(ppm) 50;55;...;185 130(Toleranc e±5ms)\\nLeftVentricular Electrode ConfigurationabDual;Single; None None\\nLeftVentricular Electrode ConfigurationabQuadripolar (Non-progr ammable) Quadripolar\\nLeftVentricular PaceConfigurationabSingleorDual:\\nLVtip>>Can\\nLVtip>>RV\\nDualOnly:Single: LVtip>>RV\\nDual:LVtip>>RV', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 238}), Document(page_content='A-10Programmable Options\\nTableA–13.Brady/CRT leftventricular pacingparameters (specified intoa750Ωload)(continued)\\nParameter Programmable Values Nominal\\nLVring>>Can\\nLVring>>RV\\nLVtip>>LVring\\nLVring>>LVtip\\nLeftVentricular PaceConfigura tionabQuadripolar:\\nLVTip1>>LVRing2\\nLVTip1>>LVRing3\\nLVTip1>>LVRing4\\nLVTip1>>RV\\nLVTip1>>Can\\nLVRing2>>LVRing3\\nLVRing2>>LVRing4\\nLVRing2>>RV\\nLVRing2>>Can\\nLVRing3>>LVRing2\\nLVRing3>>LVRing4\\nLVRing3>>RV\\nLVRing3>>Can\\nLVRing4>>LVRing2\\nLVRing4>>LVRing3\\nLVRing4>>RV\\nLVRing4>>CanLVRing2>>RV\\nLeftVentricular SenseConfigurationabSingleorDual:\\nLVtip>>Can\\nLVtip>>RV\\nOff\\nDualOnly:\\nLVring>>Can\\nLVring>>RV\\nLVtip>>LVringSingle: LVtip>>RV\\nDual:LVtip>>LVring\\nLeftVentricular SenseConfigurationabQuadripolar:\\nLVTip1>>LVRing2\\nLVTip1>>LVRing3\\nLVTip1>>LVRing4\\nLVTip1>>RV\\nLVTip1>>Can\\nLVRing2>>LVRing3\\nLVRing2>>RV\\nLVRing2>>Can\\nOff(Disable Sensing)LVTip1>>LVRing2\\nPaceSaf eLVAutomatic Threshold Maximum\\nAmplitude (V)2.5;3.0;...;7.5 5.0\\nPaceSaf eLVAutomatic Threshold SafetyMargin(V) 0.5;1.0;...;2.5 1.0\\nLVMSPPacing Order/OffjLVa>>LVb>>RV\\nLVa>>LVb\\nOffOff\\nLVaPaceConfigurationabinLVTip1>>LVRing2\\nLVTip1>>LVRing3\\nLVTip1>>LVRing4\\nLVTip1>>RV\\nLVTip1>>Can\\nLVRing2>>LVRing3\\nLVRing2>>LVRing4\\nLVRing2>>RV\\nLVRing2>>Can\\nLVRing3>>LVRing2\\nLVRing3>>LVRing4\\nLVRing3>>RV\\nLVRing3>>Can\\nLVRing4>>LVRing2\\nLVRing4>>LVRing3\\nLVRing4>>RV\\nLVRing4>>CanLVRing2>>RV', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 239}), Document(page_content='Programmable Options A-11\\nTableA–13.Brady/CRT leftventricular pacingparameters (specified intoa750Ωload)(continued)\\nParameter Programmable Values Nominal\\nLVaPulseAmplitudeacdin(V) Auto;0.1;0.2;...;3.5;4.0;...;7.5 3.5(5.0posttherapy) (Toleranc e±15%or±100mV)\\n(whichever isgreater)\\nLVaPulseWidthacdin(ms) 0.1;0.2;...;2.0 0.4(1.0posttherapy)(Toleranc e±0.03msat<1.8\\nms;±0.08msat≥1.8ms)\\nLVbPaceConfigurationjlLVTip1>>LVRing2\\nLVTip1>>LVRing3\\nLVTip1>>LVRing4\\nLVTip1>>RV\\nLVTip1>>Can\\nLVRing2>>LVRing3\\nLVRing2>>LVRing4\\nLVRing2>>RV\\nLVRing2>>Can\\nLVRing3>>LVRing2\\nLVRing3>>LVRing4\\nLVRing3>>RV\\nLVRing3>>Can\\nLVRing4>>LVRing2\\nLVRing4>>LVRing3\\nLVRing4>>RV\\nLVRing4>>CanLVTip1>>RV\\nLVbPulseAmplitudedj(V) 0.1;0.2;...;3.5;4.0;...;7.5 3.5(Toleranc e±15%or±100mV) (whichever is\\ngreater)\\nLVbPulseWidthdj(ms) 0.1;0.2;...;2.0 0.4(Toleranc e±0.03msat<1.8ms;±0.08msat≥\\n1.8ms)\\nLVMSPDelaysjkmforLVa>>LVb>>RV LVa>>LVb: 0;5;…;95\\nLVb>>RV: 5;10;…;1000ms\\n5ms\\nLVMSPDelaysjkmLVa>>LVb LVa>>LVb: 0;5;…;100 0ms\\na.Theprogrammed Normal Bradyvalueswillbeusedasthenominal valuesforTemporary Bradypacing.\\nb.Thisparameter isusedglobally inNormal Bradypacing andPost-Therapy Bradypacing. Changing thevalueforNormal Bradywillchange thevalueforPost-Therapy Brady.\\nc.Separately programm ableforATP/Post -shock, Temporary Brady,andEPTest.\\nd.Values arenotaffected bytemperatur evariation withintherange20°–43°C.\\ne.Thisparameter isautomatically settoatleast85msforPost-Therapy Brady.\\nf.TheBiV/VRR Maximum Pacing Rateisshared byBiVTrigger andVRR,changing thevalueforBiVMPRwillalsochange thevalueforVRRMPR.\\ng.Thisparameter isautomatically enabled ifAutoisselected forPulseAmplitude.\\nh.Thisparameter isdisabled during Temporary Brady.\\ni.Theseparameters areusedforLVwhennotinNormal Brady.\\nj.Programmed LVMSPvaluesareusedonlyduring Normal Brady.\\nk.Theseparameters areavailable forprogramm ingonlywhenthePacing Sequence isnotsettoOffandwhenLVOffsetisunavailable.\\nl.LVaandLVbcannot sharethesamecathode.\\nm.Totaldelaycannot begreater than100ms.\\nn.Theseparameters inherit thecorresponding LVvalues, iftheLVPacevaluesarealready programmed.\\nTableA–14.AtrialTachyParameters\\nParameter Programmable Values Nominal\\nATRModeSwitchabOff;On On\\nATRTrigger Rateabf(bpm) 100;110;...;300 170(Toleranc e±5ms)\\nATRDurationab(cycles) 0;8;16;32;64;128;256;512;1024;2048 8(Toleranc e±1cardiac cycle)\\nATREntryCountab(cycles) 1;2;...;8 8\\nATRExitCountab(cycles) 1;2;...;8 8\\nATRFallback Modebg VDI;DDI;VDIR;DDIR DDI\\nATRFallback Timeab(min:sec) 00:00; 00:15;00:30; 00:45; 01:00;01:15;01:30;\\n01:45;02:0000:30', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 240}), Document(page_content='A-12Programmable Options\\nTableA–14.AtrialTachyParameters (continued)\\nParameter Programmable Values Nominal\\nATR/VTR Fallback LRLab(ppm) 30;35;...;185 70(Toleranc e±5ms)\\nATRVentricular RateRegulation (VRR)ab Off;Min;Med;Max Min\\nATRBiVTriggerabOff;On On\\nATRMaximum Pacing Rate(MPR)abe(ppm) 50;55;...;185 130(Toleranc e±5ms)\\nAtrialFlutterResponsebcOff;On Off\\nAtrialFlutterResponse Trigger Ratebcf(bpm) 100;110;...;300 170(Toleran ce±5ms)\\nPMTTerminationbcOff;On On\\nVentricular RateRegulation (VRR)bc Off;Min;Med;Max Off\\nBiV/VRR Maximum Pacing Rate(MPR)bcd(ppm) 50;55;...;185 130(Toleranc e±5ms)\\na.Theprogrammed Normal Bradyvalueswillbeusedasthenominal valuesforTemporary Bradypacing.\\nb.Thisparameter isusedglobally inNormal Bradypacing andPost-Therapy Bradypacing. Changing thevalueforNormal Bradywillchange thevalueforPost-Therapy Brady.\\nc.Thisparameter getsdisabled during Temporary Brady.\\nd.TheBiV/VRR MPRisshared byVRRandBiVTrigger.Changing thisparameter forVRRwillalsochange theMPRvalueforBiVTrigger.\\ne.TheATRMPRisshared byATRVRRandATRBiVTrigger.Changing thisparameter forATRVRRwillalsochange theMPRvalueforATRBiVTrigger.\\nf.ATRTrigger RateandAtrialFlutterResponse RatearelinkedtoalltheAFibRateThresholds. Ifanyoneoftheseratesisreprogrammed, theotherswillautomatically change tothesame\\nvalue.\\ng.IfNormal BradyATRFallback ModeisDDIRorDDI,thenTemporary BradyATRFallback ModeisDDI.IfNormal BradyATRFallback ModeisVDIRorVDI,thenTemporary BradyATRFallback\\nModeisVDI.\\nTableA–15.MRIProtectionparameters\\nParameter Programmable Values Nominal\\nMRIBradyMode Off;VOO;AOO;DOO ––\\nMRILowerRateLimit(LRL)(ppm) 30;35;...;100 20ppmabovethenormal modeLRL\\nMRIVentricular Pacing Chamber RVOnly;BiV Ifnormal modePacing Chamber isRVOnlyorBiV,\\nsameasnormal modePacing Chamber;\\nIfnormal modePacing Chamber isLVOnly,BiV\\nMRIAtrialAmplitude (V) 2.0;2.1;…;3.5;4.0;…;5.0 5.0(Toleranc e±15%or±100mV,whichever is\\ngreater)a\\nMRIRightVentricular Amplitude (V) 2.0;2.1;…;3.5;4.0;…;5.0 5.0(Toleranc e±15%or±100mV,whichever is\\ngreater)a\\nMRILeftVentricular Amplitude (V) 2.0;2.1;…;3.5;4.0;…;5.0 Sameasthenormal modeLVAmplitude, capped\\nbetween 2.0and5.0\\n(Toleran ce±15%or±100mV,whichever isgreater)a\\nMRILeftVentricular PulseWidth(ms) 0.1;0.2;…;2.0 Sameasthenormal modeLVPulseWidth(Toleranc e\\n±0.03msat<1.8ms;±0.08msat≥1.8ms)\\nMRIProtection Time-out (hours) Off;3;6;9;12 6\\na.During thetransition intotheMRIProtection Mode,itmaytakeupto6cardiac pacing cyclesforthepaceamplitude tomeetthespecified tolerancerange.\\nTableA–16.MagnetandBeeperfunctions\\nParameter Programmable Values Nominal\\nMagnet Response Off;StoreEGM;InhibitTherapy InhibitTherapy\\nBeepDuring Capacitor Charge Off;On Off\\nBeepWhenExplant isIndicated Off;On On\\nAtrialBeepWhenOut-of-Range Off;On Off', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 241}), Document(page_content='Programmable Options A-13\\nTableA–16.MagnetandBeeperfunctions (continued)\\nParameter Programmable Values Nominal\\nRightVentricular BeepWhenOut-of-Range Off;On Off\\nLeftVentricular BeepWhenOut-of-Range Off;On Off\\nShockBeepWhenOut-of-Range Off;On Off\\nBeeper Off;On On\\nTableA–17.Sensitivity Adjustment\\nParameter Programmable Values Nominal\\nAtrialSensitivitya(mV) AGC0.15;AGC0.2;AGC0.25;AGC0.3;AGC0.4;…;\\nAGC1.0;AGC1.5AGC0.25\\nRightVentricular Sensitivitya(mV) AGC0.15;AGC0.2;AGC0.25;AGC0.3;AGC0.4;…;\\nAGC1.0;AGC1.5AGC0.6\\nLeftVentricular Sensitivitya(mV) AGC0.15;AGC0.2;AGC0.25;AGC0.3;AGC0.4;…;\\nAGC1.0;AGC1.5AGC1.0\\na.WithCENELEC waveform, perEN45502-2-2:2008.\\nTableA–18.DailyLeadMeasurements\\nParameter Programmable Values Nominal\\nAtrialDailyIntrinsic Amplitude On;Off On\\nRightVentricular DailyIntrinsic Amplitude On;Off On\\nLeftVentricular DailyIntrinsic Amplitude On;Off On\\nAtrialDailyImpedance On;Off On\\nRightVentricular DailyImpedance On;Off On\\nLeftVentricular DailyImpedance On;Off On\\nShockDailyImpedance On;Off On\\nAtrialLowImpedance Limit(Ω) 200;250;...;500 200\\nAtrialHighImpedance Limit(Ω) 2000;2250;...; 3000 2000\\nRightVentricular LowImpedance Limit(Ω) 200;250;...;500 200\\nRightVentricular HighImpedance Limit(Ω) 2000;2250;...; 3000 2000\\nLeftVentricular LowImpedance Limit(Ω) 200;250;...;500 200\\nLeftVentricular HighImpedance Limit(Ω) 2000;2250;...; 3000 2000\\nShockHighImpedance Limit(Ω) 125;150;175;200 125\\nPost-Operative SystemTest(POST) (hours) 2;3;...;24 12\\nTableA–19.Ventricular Commanded ATP\\nParameteraProgrammable Values Nominal\\nCommanded Ventricular ATP(Type) Burst;Ramp; Scan;Ramp/Scan Burst\\nNumber OfBursts 1;2;...;30 30\\nInitialPulsesperBurst(pulses) 1;2;...;30 4', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 242}), Document(page_content='A-14 Programmable Options\\nTableA–19.Ventricular Commanded ATP(continued)\\nParameteraProgrammable Values Nominal\\nPulseIncrement (pulses) 0;1;..;5 0\\nMaximum Number ofPulses 1;2;...;30 4\\nCoupling Interval (%orms) 50;53;56;59;63;66;...;84;88;91;94;97%or120;\\n130;...;750ms81%(Toleranc e±5ms)\\nCoupling Interval Decrement(ms) 0;2;...;30 0(Toleranc e±5ms)\\nBurstCycleLength (BCL)(%orms) 50;53;56;59;63;66;...;84;88;91;94;97%or120;\\n130;...;750ms81%(Toleranc e±5ms)\\nRampDecrement (ms) 0;2;...;30 0(Toleranc e±5ms)\\nScanDecrement (ms) 0;2;...;30 0(Toleranc e±5ms)\\nMinimum Interval (ms) 120;130;...;400 200(Toleranc e±5ms)\\na.Theventricular Commanded ATPPulseWidthandAmplitude valuesarethesameasprogrammed forventricular ATPtherapy.\\nTableA–20.50Hz/Manual BurstPacing\\nParameteraProgrammable Values Nominal\\nBurstInterval (ms) 20;30;...;750 600(Toleran ce±5ms)\\nMinimum Interval (ms) 20;30;...;750 200(Toleranc e±5ms)\\nDecrement (ms) 0;10;...;50 50(Toleranc e±5ms)\\na.Applied totheatrium orventricle depending onthechamber selected.\\nTableA–21.Ventricular Commanded Shock\\nParameter Programmable Values Nominal\\nShock(J)(stored energy) 0.1;0.3;0.6;0.9;1.1;1.7;2;3;5;6;7;9;11;14;17;\\n21;23;26;29;31;36;4141J(Toleran ce+150/-60% for0.1J;±60%for0.3J;±\\n40%for0.6–3J;±20%for5–36J;±10%for41J)\\nCoupling Interval (ms) SYNC;50;60;...;500 SYNC\\nTableA–22.VFib(Ventricular Fibrillation) Induction\\nParameter Values\\nVFibHigh 15V(nonprog rammable) (Toleranc e±10V)\\nVFibLow 9V(nonprog rammable) (Toleranc e±7V)\\nTableA–23.ShockonTInduction\\nParameter Programmable Values Nominal\\nShock(J)(stored energy) 0.1;0.3;0.6;0.9;1.1;1.7;2;3;5;6;7;9;11;14;17;\\n21;23;26;29;31;36;411.1J(Toleranc e+150/-60% for0.1J;±60%for0.3J;\\n±40%for0.6–3J;±20%for5–36J;±10%for41J)\\nNumber ofS1Pulses 1;2;...;30 8\\nS1Interval (ms) 120;130;...;750 400\\nCoupling Interval (ms) SYNC;10;20;...;500 310', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 243}), Document(page_content='Programmable Options A-15\\nTableA–24.SensorTrending\\nParameter Programmable Values Nominal\\nRecordingMethod BeatToBeat;Off;30Second Average 30Second Average\\nDataStorage Continuous; Fixed Continuous\\nTableA–25.BackupEPTest\\nParameter Programmable Values Nominal\\nBackup Pacing ModeaOff;On On\\nBackup Pacing LowerRateLimitab(ppm) 30;35;…;185 45(Toleranc e±5ms)\\nBackup Pacing RVRefractoryab(ms) 150;160;…;500 250(Toleranc e±5ms)\\nBackup Pacing Ventricular Pacing ChamberaBiV(nonprogr ammable) BiV\\nEPTestPacing Outputs AtrialAmplitude (whentest\\nisintheatrium) (V)Off;0.1;0.2;…;3.5;4.0;…;5.0 5.0(Toleranc e±15%or100mV,whichever is\\ngreater)\\nEPTestPacing Outputs RVAmplitude (V) Off;0.1;0.2;…;3.5;4.0;…;7.5 7.5(Toleranc e±15%or100mV,whichever isgreater)\\nEPTestPacing Outputs LVAmplitude (V) Off;0.1;0.2;…;3.5;4.0;…;7.5 7.5(Toleranc e±15%or100mV,whichever isgreater)\\nEPTestPacing Outputs AtrialPulseWidth(whentest\\nisintheatrium) (ms)0.1;0.2;…;2.0 1.0(Toleranc e±0.03msat<1.8ms;±0.08msat≥\\n1.8ms)\\nEPTestPacing Outputs RVPulseWidth(ms) 0.1;0.2;…;2.0 1.0(Toleranc e±0.03msat<1.8ms;±0.08msat≥\\n1.8ms)\\nEPTestPacing Outputs LVPulseWidth(ms) 0.1;0.2;…;2.0 1.0(Toleranc e±0.03msat<1.8ms;±0.08msat≥\\n1.8ms)\\na.Thisparameter onlyapplies whenthetestisintheatrium.\\nb.Theprogrammed Normal Bradyvaluewillbeusedasthenominal value.\\nTableA–26.PES(Programmed Electrical Stimulation)\\nParameteraProgrammable Values Nominal\\nNumber ofS1Intervals (pulses) 1;2;...;30 8\\nS2Decrement (ms) 0;10;...;50 0\\nS1Interval (ms) 120;130;...;750 600(Toleranc e±5ms)\\nS2Interval (ms) Off;120;130;...;750 600(Toleranc e±5ms)\\nS3Interval (ms) Off;120;130;...;750 Off(Toleran ce±5ms)\\nS4Interval (ms) Off;120;130;...;750 Off(Toleran ce±5ms)\\nS5Interval (ms) Off;120;130;...;750 Off(Toleran ce±5ms)\\na.Applied totheatrium orventricle ascommandedbytheprogrammer.\\nTableA–27.MVSensorSettings\\nParameter Programmable Values Nominal\\nSignalArtifact Monitor (SAM) On,Off On\\nExcitation Current 80uA,320uA 320uA\\nVectorSelection AutoSelect,RAOnly,RVOnly AutoSelect', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 244}), Document(page_content='A-16Programmable Options', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 245}), Document(page_content='B-1\\nSYMBOLSONPACKAGING\\nAPPENDIX B\\nSYMBOLSONPACKAGING\\nThefollowing symbols maybeusedonpackaging andlabeling:\\nTableB–1.Symbolsonpackaging\\nSymbol Description\\nReferenc eNumber\\nContents\\nPulsegenerator\\nTorque wrench\\nLiteratur eenclosed\\nSerialNumber\\nUseBy\\nLotNumber\\nDateofManufacture\\nNon-Ionizing Electromagne ticRadiation\\nSterilized usingethylene oxide.\\nSTERILIZE2\\nDoNotResterilize\\nSingleuse.Donotre-use.\\nDonotuseifpackage isdamaged andconsult instructions foruse.\\nDangerous Voltage\\nConsult instructions foruseonthiswebsite: www.bostonscientific -elabeling.c om\\nTemperatur elimitation.\\nPlacetelemetry wandhere', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 246}), Document(page_content='B-2Symbols onPackaging\\nTableB–1.Symbolsonpackaging (continued)\\nSymbol Description\\n,\\nOpenHere\\nManufacturer\\nMRConditional\\nCRT-DRA,RV,LV\\nICDRA,RV\\nICDRV\\nImplantable device\\nRFTelemetry\\nDouble sterilebarrier system\\nUnique Device Identifier', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 247}), Document(page_content='INDEX\\nSymbols\\n50Hz/manual burstpacing 7-7\\nA\\nA-blank\\nafterRV-sense 4-84\\nafterV-pace 4-84\\nA-tachy response(ATR)\\nmodeswitch4-56\\nAccelerate,inzone3-2\\nAccelerometer 4-40\\nactivity threshold 4-41\\nreaction time4-42\\nrecoverytime4-43\\nresponsefactor4-40\\nActivity threshold 4-41\\nAdaptive-rat epacing 4-39\\nAFibratethreshold 2-25,2-30–2-31\\nAGC(automatic gaincontrol) 4-28\\nAmplitude 4-16\\nATP(antitachycardia pacing) 3-13\\nintrinsic test5-13\\nApplication screen1-2\\nArrhythmia logbook 6-2\\nepisode detail6-5\\nevents summary 6-5\\ninterval6-8\\nstoredEGM6-5\\nATP(antitachycar diapacing) 3-7\\namplitude 3-13\\nburstcyclelength(BCL)3-10\\nburstscheme 3-11\\ncommanded, EPtest7-8\\ncoupling interval 3-9\\nminimum interval3-11\\nnumber ofbursts3-8\\npulsecount3-8\\npulsewidth3-13\\nrampscheme 3-11\\nramp/scan scheme 3-12\\nredetection afterATP2-16\\nscanscheme 3-12\\ntime-out 3-13\\nATR(atrialtachyresponse)\\natrialflutterresponse 4-60\\nbiventricular trigger 4-60\\nduratio n4-57\\nendofATRepisode 4-59\\nentrycount4-57\\nexitcount4-58\\nLRL,fallback 4-58\\nmaximum pacing rate4-60\\nmodeswitch4-56\\nmode,fallback 4-58PMTtermination 4-61\\nratethreshold 4-57\\ntime,fallback 4-58\\nventricular rateregulati on4-59\\nVTR(ventricular tachyresponse) 4-59\\nATRTrigger Rate4-57\\nAtrial\\nrefractoryperiod, postventricular atrial(PVARP) 4-79\\nrefractoryperiod, samechamber 4-81\\nuseofatrialinformation 2-6\\nAtrialflutterresponse4-60\\nAtrialtachy\\nATRmodeswitch4-56\\natrialflutterresponse4-60\\nPMTtermination 4-61\\nventricular rateregulati on4-59\\nAttention conditions, yellow1-7\\nAutomatic Intrinsic Rhythm ID2-8\\nAutomatic threshold\\nLVAT4-23\\nRAAT4-16\\nRVAT4-20\\nAVdelay4-73\\npaced4-73\\nsensed 4-75\\nB\\nBackupventricular pacing during atrialstimulation, EPtest7-5\\nBattery\\nExplant status5-3\\nicon1-6\\nindicator 5-3\\nstatus5-2\\nBeep\\nduring capacitor charge5-6\\nfeaturesetup6-19\\nBiventricular trigger 4-60\\nmaximum pacing rate4-60\\nBlanking 4-83\\nA-blank afterRV-sense 4-84\\nA-blank afterV-pace 4-84\\nLV-blank afterA-pace 4-84\\nRV-blank afterA-pace4-83\\nBlended Sensors 4-51\\nBradyTachyResponse (BTR)4-92\\nBurst\\nATP(antitachycar diapacing) 3-8\\ncyclelength(BCL)3-10\\nminimum interval 3-11\\nnumber ofbursts3-8–3-9\\npacing, 50Hz/manual burst7-7\\nparameter 3-8\\npulsecount3-8\\nscheme 3-11', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 248}), Document(page_content='Buttons, softwar e1-5\\nC\\nCapacitor\\ndeformation 3-16,5-6\\nre-formatio n5-6\\nChargetime3-15\\nmeasur ement5-6\\nCheck\\nicon1-6\\nCommanded\\nATP,EPtest7-8\\nshock,EPtest7-8\\ntherapy,EPtest7-8\\nCommitted shock2-10,3-17\\nCommunication, telemetr y\\nRadiofrequency (RF)1-9\\nContinue\\nicon1-6\\nCounter\\nbrady/CRT 6-10\\ntherapyhistory6-9\\nventricular 6-9\\nCoupling interval3-9\\ndecrem ent3-9\\nCRT(cardiacresynchronization therapy)delivery zone2-5\\nD\\nDailymeasur ements 5-7\\nData\\ndisk1-16\\npatient 1-15\\nstorage 1-16\\nUSB1-16\\nDecelerate,inzone3-2\\nDecrement\\ncoupling interval 3-9\\nrampscheme 3-11\\nscanscheme 3-12\\nDefibrillation\\nbackup defibrillator ,safetymode1-18\\nDemonstr ation\\nProgrammer/rec order/monitor (PRM)mode1-3,1-8\\nDetailicon1-5\\nDetection\\nAFibratethreshold 2-25\\nduratio n2-13\\nenhancement 2-7,2-19\\nepisode 2-17\\nonset2-28\\nratesensing 2-4\\nratethreshold 2-5\\nreconfirmation/c ommitted shock3-17redetection 2-10\\nRhythmMatch Threshold 2-22\\nstability 2-27\\nsustained rateduration(SRD)2-29\\ntachyarrhythmia 2-2\\ntachyarrhythmia, safetymode1-18\\nVrate>Arate2-24\\nvectortimingandcorrelation 2-21\\nventricular ,initial2-7\\nwindow 2-12\\nDevice\\nmemory 1-17\\nmode2-2\\nprogramming recommendation 4-3\\nDevicebehavior whenSAMisOff4-36\\nDevicebehavior whenSAMisOn4-35\\nDiagnostic\\nbattery status5-2\\nheartratevariability (HRV)6-10\\nhistogram6-9\\nleadtest5-12\\npatient triggeredmonitor 6-17\\nDisk\\ndata1-16\\nread1-16\\nsave1-16\\nDIVERT THERAPY 1-14\\nDual-Sensor Blending 4-51\\nDuration 2-13\\nATR(atrialtachyresponse) 4-57\\npost-shock 2-16\\nredetection 2-16\\nDynamic NoiseAlgorithm 4-30,4-88\\nE\\nECG(electrocar diogram)\\ndisplay 1-3\\nsurface1-3\\nwireless1-4\\nEGM(electrogram)\\ndisplay 1-3\\nleftventricular (LV)4-67\\nreal-time 1-3\\nElectrocautery\\nmode2-2\\nElectrode,leadconfiguration 4-67\\nEndofATRepisode 4-59\\nEnergy\\nshock3-15\\nEnhance ment\\ndetection 2-7,2-19\\nEntrycount4-57\\nEPtest(electro physiologic test)7-2\\nATP,commanded 7-8\\nbackupventricular pacing during atrialstimulation 7-5\\nburstpacing, 50Hz/manual 7-7\\ncommanded therapy7-8', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 249}), Document(page_content='fibrillation 7-4\\ninduction 7-4\\nmode,tempor ary7-2\\nprogrammed electrical stimulation (PES)7-5\\nshockonT7-4\\nshock,commanded 7-8\\nVFib7-4\\nEpisode 2-17\\nendofATR4-59\\nNon-Trea ted2-17\\nnontreate d6-9\\ntreated6-9\\nTreated2-17\\nventricular 2-17\\nEvent\\ncounter 6-9\\nicon1-6\\nsummary 6-5\\ntherapyhistory6-2\\nExitcount4-58\\nF\\nFallback, atrialmodeswitch\\nLRL4-58\\nmode4-58\\ntime4-58\\nFibrillation\\nVFibinduction 7-4\\nFitness Level4-49\\nFollow-up\\nLeadstatus5-7\\nFollow-up DeviceAssessments 4-53\\nH\\nHeartfailure4-3\\nHeartratevariability (HRV)6-10\\nHeartLogic Index6-16\\nHistogr am6-9\\nHold\\nicon1-6\\nHorizontalslider\\nicon1-6\\nHysteresis,rate4-63\\nI\\nIcon\\nbattery 1-6\\ncheck1-6\\ncontinue 1-6\\ndetails 1-5event1-6\\nhold1-6\\nhorizontalslider1-6\\nincrementanddecrement1-7\\ninformation 1-6\\nlead1-5\\npatient 1-5\\npatient information 1-15\\nProgrammer/r ecorder/monitor (PRM)modeindicator 1-3\\nrun1-6\\nscrolling1-7\\nsnapshot 1-6\\nsorting 1-6\\nvertical slider1-6\\nImpedanc etest,lead5-13\\nImplant\\npost,information 6-17\\nIncrementanddecrement\\nicon1-7\\nIndications BasedProgramming (IBP)1-11\\nInduction, EPtest7-4\\nInformation\\nicon1-6\\nimplant 1-15\\nlead1-15\\npatient 1-15\\nInterrogate1-9\\nInterval\\narrhythmia logbook 6-8\\ncoupling, ATP3-9\\nminimum, burstcyclelength3-11\\nIntrinsic amplitude test5-13\\nL\\nLastdeliveredshock5-6\\nLATITUDE Programming System\\ncomponents 1-2\\nLead\\nconfiguration 4-67\\nDailymeasur ements 5-7\\nicon1-5\\nimpedance 5-13\\nintrinsic amplitude 5-13\\nLeadstatus5-7\\npacethreshold 5-14\\ntest5-12\\nLeftventricular protection period(LVPP)4-82\\nLeftventricular refractoryperiod(LVRP) 4-82\\nLogbook 6-2\\nLowerratelimit(LRL)4-8\\nLVoffset4-13\\nLVVectorGuide 5-17\\nLV-blank afterA-pace 4-84\\nLV-only pacing 4-13\\nLVAT(leftventricular automatic threshold) 4-23', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 250}), Document(page_content='M\\nMagnet\\nfeature setup6-23\\ninhibittachytherapy6-23\\nMaintaining cardiac resynchr onization therapy\\nmaintaining CRT4-4\\nManual programming 1-13\\nManual/50 Hzburstpacing 7-7\\nMaximum\\npacing rate4-60\\nsensor rate(MSR)4-11\\ntracking rate(MTR)4-9\\nMaximum pacing rate\\nratesmoothing 4-66\\nMemory ,device1-17\\nMinimum\\ninterval3-11\\nMinute Ventilation 4-44\\nfitness level4-49\\nresponsefactor4-47\\nVentilatory Threshold 4-48\\nVentilatory Threshold Response 4-48\\nMode\\nDemonstration 1-8\\ndevice2-2\\nelectrocautery 2-2\\nfallback ATR(atrialtachyresponse) 4-58\\npacing 4-6\\nProgrammer/rec order/monitor (PRM)1-3\\ntempora ry,EPtest7-2\\nventricular tachy2-2\\nMRIProtectionMode2-3\\nMTR(maximum trackingrate)4-4\\nMV/Respir atorySensor Programmable Parame ters4-33\\nMV/Respir atorySensor Status4-34\\nN\\nNightHeartRate6-16\\nNoise\\nblanking andnoiserejection 4-83\\nDynamic NoiseAlgorithm 4-30,4-88\\nresponse4-87\\nNominal parameter setting A-1\\nNumber ofbursts3-8\\npulsecount3-9\\nO\\nOnset2-10,2-28,2-31\\nOptimizing rateresponse forphysical activity 4-50P\\nPace\\nSTATPACE1-15\\nPacethreshold test5-14\\nPaceSafe\\nLVAT4-23\\nRAAT4-16\\nRVAT4-20\\npacing\\nCRT(cardiacresynchronization therapy)4-4\\nPacing\\nadaptive-r ate4-39\\namplitude 4-16\\nATRmodeswitch4-56\\nAVdelay4-73\\nbackupduring atrialstimulation 7-5\\nbackuppacemak erinsafetymode1-18\\nburst,50Hz/manual 7-7\\nchamber ,ventricular 4-12\\nIndications BasedProgramming (IBP)1-11\\nlowerratelimit(LRL)4-8\\nLVoffset4-13\\nLV-only 4-13\\nmaximum sensor rate(MSR)4-11\\nmaximum trackingrate(MTR)4-9\\nmode4-6\\nnoiseresponse 4-87\\nPaceSafeLVAT4-23\\nPaceSafeRAAT4-16\\nPaceSafeRVAT4-20\\nparameter,basic4-5\\nposttherapy4-31\\npost-therap y4-30\\nprogramming recommendation 4-3\\npulsewidth4-15\\nrefractory4-78\\nrunaway protection 4-12\\nsensitivity 4-27\\nsensor 4-54\\nSmartDelay optimization 4-76\\ntempor ary4-31\\ntherapy4-2\\nPackage\\nsymbol onB-1\\nPatient\\ninformation icon1-5\\nPatient Information 1-15\\nPatient triggered monitor 6-17\\nPES(programmed electrical stimulation) 7-5\\nPhysical activity evaluation 4-50\\nPMT(pacemak er-mediated tachycardia) termination 4-61\\nPolarity\\nshock3-16\\nPOST5-11\\nPostimplant information 6-17\\nbeeper feature 6-19\\nmagnet feature 6-23\\nPost-Operative\\nSystemTest5-11', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 251}), Document(page_content='Post-shock\\ndetection paramet er2-11\\nduratio n2-16\\npacing 4-31\\nPost-therap ypacing 4-30\\nPremature ventricular contraction (PVC)4-80\\nPrescription\\ntherapy3-2\\nPrint\\nreport1-17\\nPrinter\\nexternal1-17\\nProgram1-11\\nProgrammable option, parameter A-1\\nProgrammer/r ecorder/monitor (PRM)1-2\\ncontrols1-2,1-13\\nDemonstration mode1-8\\nmodes 1-3\\nsoftware terminology 1-2\\nuseofcolor1-7\\nProgramming recommendation 1-11,1-13,4-3\\nProtection\\nperiod, leftventricular (LVPP)4-82\\nrunaway 4-12\\nPulseamplitude 4-16\\nPulsecount3-8\\nPulsegenerator (PG)\\nmemory 1-17\\nreplacementindicators 5-3\\nPulsewidth4-15\\nATP(antitachycardia pacing) 3-13\\nPVARP (postventricular atrialrefractoryperiod) 4-79\\nafterPVC(prematu reventricular contraction) 4-80\\ndynamic PVARP 4-80\\nPVC(premature ventricular contraction) 4-80\\nQ\\nQUICKCONVERT ATP3-14\\nQuit\\nending atelemetry session 1-10\\nR\\nRAAT(rightatrialautomatic threshold) 4-16\\nRadiofrequency (RF)\\noperating temperatur e,telemetry 1-10\\nstarting telemetr y1-9\\ntelemetr y1-9\\nRampscheme 3-11\\nRamp/Scan scheme 3-12\\nRate\\nadaptive 4-39\\nAFibthreshold 2-25\\ncalculation 2-4lowerlimit(LRL)4-8\\nmaximum sensor 4-11\\nmaximum tracking4-9\\nsensing 2-4\\nsustained rateduration(SRD)2-29\\nthreshold, ventricular 2-5\\nVrate>Arate2-24\\nventricular 2-5\\nzone2-5\\nRateadaptive pacing 4-39\\nRateenhance ment,pacing\\nratehystere sis4-63\\nratesmoothing 4-63\\ntrackingpreference4-62\\nRateHysteresis4-63\\nhysteresisoffset4-63\\nsearchhysteresis 4-63\\nRatesmoothing 4-63\\ndown4-65\\nMaximum pacing rate4-66\\nup4-65\\nRatethreshold, ATR4-57\\nReaction time4-42\\nReaddata1-16\\nReconfirmation 2-10,3-17\\nRecoverytime4-43\\nRedwarning conditions 1-7\\nRedetection 2-10\\nafterATPdelivery 2-16,3-6\\naftershockdelivery 2-16,3-7\\nduration2-16\\nventricular 3-6\\nReform, capacitor 5-6\\nRefractory\\natrial,postventricular (PVARP) 4-79\\natrial,samechamber 4-81\\nblanking andnoiserejection 4-83\\nleftventricular (LVRP) 4-82\\nleftventricular protection period4-82\\nPVARP afterPVC4-80\\nrightventricular (RVRP) 4-81\\nRefractory;pacing\\nrefractory4-78\\nReplacemen tIndicators 5-3\\nReport, printed 1-3,1-15\\nECG/EGM 1-3\\nRespirato rySensor 4-32\\nResponse factor,accelerometer 4-40\\nResponse Factor,Minute Ventilation 4-47\\nRhythm\\nID,automatic intrinsic 2-8\\nRhythmMatch Threshold 2-22\\nRightventricular refractory(RVRP) 4-81\\nRightRate Pacing 4-44\\nRun\\nicon1-6\\nRunaway protection 4-12\\nRV-blank afterA-pace 4-83\\nRVAT(rightventricular automatic threshold) 4-20', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 252}), Document(page_content='S\\nS1andS3HeartSounds 6-15\\nSafetycore1-17\\nSafetymode1-17\\nSafetyTachyMode1-18\\nSavedata1-16\\nScanscheme 3-12\\nScreen,programmer application 1-2\\nScrolling\\nicon1-7\\nSecurity\\nZIPtelemetry 1-10\\nSensing, rate2-4\\nSensitivity 4-27\\nAGC(automatic gaincontrol)4-28\\nSensor andtrending, pacing 4-54\\naccelerometer 4-40\\nadaptive-rate 4-39\\nmaximum sensor rate(MSR)4-11\\nminute ventilation 4-44\\nSmartDelay optimization 4-76\\nSetting\\nparamete rvalueA-1\\nzoneconfiguration 2-5\\nShock\\nchargetime,energy3-15,5-6\\ncommanded, EPtest7-8\\ncommitted 3-17\\ndiverting 1-14\\nenergy 3-15\\nimpedance 5-13\\nlastdelivered5-6\\nonTinduction 7-4\\npolarity 3-16\\npost-shock pacing 4-31\\nredetection 2-16\\nselection 3-2\\nsequenc e3-2\\nSTATSHOCK 1-14\\ntherapy3-15\\nventricular therapy3-15\\nwaveform 3-16\\nShockifunstable 2-28\\nShockonTinduction 7-4\\nSignalArtifact Monitor DeviceDiagnostic 4-35\\nSignalArtifact Monitor episode dataandprogramming\\nconsider ations4-38\\nSignalArtifact Monitor Episodes 4-37\\nSleepIncline 6-16\\nSmartDelay optimization 4-76\\nSnapshot 6-8\\nicon1-6\\nSoftwar eApplication 1-2\\npurpose 1-2\\nSoftwar eterminology 1-2\\nSorting\\nicon1-6\\nStability 2-10,2-27,2-30–2-31\\nSTATPACE1-15STATSHOCK 1-14\\nStimulation, PESinduction 7-5\\nStoredEGM\\narrhythmia logbook 6-5\\nSustained rateduration (SRD)2-29\\nSymbol\\nonpackage B-1\\nSystemTest\\nPost-Operative5-11\\nT\\nTabs,softwar e1-5\\nTachymode2-2\\nSafetyMode1-18\\nTachyarrhythmia\\ndetection 2-2\\ndetection insafetymode1-18\\nIndications BasedProgramming (IBP)1-12\\ntherapy3-2\\ntherapyinsafetymode1-18\\nzone2-5\\nTelemetr y\\nending atelemetr ysession 1-10\\noperatingtemper ature,ZIP1-10\\nstarting ZIP1-9\\nwand1-8\\nwanded 1-9\\nZIP1-9\\nTempor ary\\npacing 4-31\\nTest\\nEP(electrophysiologic) 7-2\\nintrinsic amplitude 5-13\\nlead5-12\\nleadimpedance 5-13\\npacethreshold 5-14\\nTherapy\\nATP(antitachycar diapacing) 3-7\\npacing 4-2\\npost-shock pacing 4-31\\nprescription 3-2\\nselection 3-2\\nshock3-15\\ntachyarrhythmia 3-2\\ntachyarrhythmia, safetymode1-18\\nTherapyhistory6-2\\narrhythmia logbook 6-2\\ncounter 6-9\\nheartratevariability (HRV)6-10\\nhistogram6-9\\npatient triggeredmonitor 6-17\\nThoracicImpedance 6-16\\nThreshold\\nAFibrate2-25\\nrate2-5\\nThreshold, activity 4-41\\nTime-out, ATP3-13', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 253}), Document(page_content='Timing\\nblanking 4-83\\nleftventricular protectionperiod(LVPP)4-82\\nPVARP afterPVC4-80\\nTiming, pacing 4-78\\nToolbar 1-5\\nTrackingpreference4-62\\nTrending\\nsensor 4-54\\nTrends6-13\\nHeartLogic Index6-16\\nNightHeartRate6-16\\nrespiratoryrate6-15\\nS1andS3HeartSounds 6-15\\nSleepIncline 6-16\\nThoracicImpedanc e6-16\\nU\\nUpperRateBehavior 4-9\\nUSB1-16\\nV\\nVrate>Arate2-24\\nVectortimingandcorrelation 2-21,2-30\\nRhythmMatch Threshold 2-22\\nVectorGuide (LV)5-17\\nVentilatory Threshold 4-48\\nVentilatory Threshold Response 4-48\\nVentricular\\nATP(antitachycardia pacing) 3-7\\ndetection, tachyarrhythmia 2-7\\nredetection afterventricular ATPtherapy3-6\\nredetection afterventricular shocktherapy3-7\\nredetection afterventricular therapydelivery 3-6\\nshocktherapy3-15\\ntachymode2-2\\ntachyarrhythmia therapy 3-2\\nVentricular pacing chamber 4-12\\nVentricular rateregulation 4-59\\nmaximum pacing rate4-60\\nVentricular shockvector3-15\\nVertical slider\\nicon1-6\\nVFibinduction 7-4\\nVTR(ventricular tachyresponse) 4-59\\nW\\nWand,telemetry 1-2,1-8–1-9\\nWarning conditions, red1-7\\nWaveform, shock3-16Wenckebach4-4,4-64\\nWindow\\ndetection 2-12\\nY\\nYellow attention conditions 1-7\\nZ\\nZIPtelemetr y1-9\\nadvantages 1-9\\nindicator light1-9\\noperatingtemper ature1-10\\nradiofrequency (RF)1-9\\nsecurity 1-10\\nsession 1-9\\nZone\\ncardiacresynchro nization therapy(CRT)delivery 2-5\\nconfiguration 2-5\\nventricular 2-5\\nventricular tachyarrhythmia 2-5\\nZOOMVIEW Software Application\\nscreensandicons1-2\\nuseofcolor1-7', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 254}), Document(page_content='', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 255}), Document(page_content='', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 256}), Document(page_content='Boston Scientific Corporation\\n4100Hamline Avenue North\\nSt.Paul,MN55112-5798 USA\\nwww.bostonscientific.com\\n1.800.CARDIAC (227.3422)\\n+1.651.582.4000\\n©2021Boston Scientific Corporation oritsaffiliates.\\nAllrightsreserved.\\n51114086-002 ENUS2021-11\\n*51114086-002*', metadata={'source': 'raw_data/51114086-002_NG4_Tachy_CRT-D_RG_en_S.pdf', 'page': 257}), Document(page_content='OPERATOR’S MANUAL\\nEMBLEM™S-ICD\\nAPPLICATION\\nfortheLATITUDE™ Programming System\\nREF3877S-ICDProgramming Application,\\n3300LATITUDE™ Programming System\\nCAUTION: Federal law(USA)restricts this\\ndevice tosalebyorontheorderofaphysician\\ntrained orexperienc edindevice implant and\\nfollow-up procedures.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 0}), Document(page_content='', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 1}), Document(page_content='Table ofContents\\nINFORMATION FORUSE..........................................................................1\\nTrademar kStatement ............................................................................1\\nDescription andUse.............................................................................1\\nIntended Use.....................................................................................1\\nIntended Audience ...............................................................................1\\nRequired Expertise andKnowledge ............................................................1\\nListofAcrony ms.................................................................................1\\nContraindicatio ns.................................................................................2\\nRelated Information .............................................................................2\\nWarnings. .........................................................................................3\\nS-ICDPrecautions ................................................................................5\\nAdverse Effects ...................................................................................7\\nUSING THES-ICD APPLICATION ..................................................................7\\nS-ICDApplication SetupOverview..............................................................7\\nPowering theModel 3300Programmer ......................................................8\\nPowering theProgrammer OnandOff......................................................10\\nUsingtheProgrammer Touch Screen.......................................................10\\nS-ICDApplication Navigation .................................................................11\\nS-ICDApplication Screen Header ............................................................11\\nS-ICDApplication Navigation Bar............................................................11\\nConfiguring theS-ICDApplication .............................................................12\\nStarting theModel 3300Programmer. ......................................................12\\nSettheLanguage andTimeZone...........................................................12\\nEnable Bluetooth®Communications .........................................................14\\nStarttheS-ICDApplication ...................................................................15\\nDateandTimeFormat ........................................................................17\\nSetNoiseFilterConfiguration ................................................................18\\nPrinter Selection ...............................................................................19\\nModel 3877S-ICDApplication Software Version ............................................20\\nBluetooth®DataExport .......................................................................20\\nApplication Modes ofOperat ion...............................................................22\\nOnline Behavior ...............................................................................22\\nOffline Behavior ...............................................................................22\\nStored Patient Sessions. ......................................................................22\\nModes ofOperationforthePulseGenerat or.................................................23\\nShelfMode....................................................................................23\\nTherapy OnMode.............................................................................23\\nTherapy OffMode.............................................................................23\\nMRIProtection Mode.........................................................................23\\nConnecting andDisconnecting fromtheS-ICDPulseGenerator ............................25', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 2}), Document(page_content='Scanning forPulseGenerators ...............................................................25\\nConnecting toaPulseGenerator............................................................26\\nConnecting toaPulseGeneratorinShelfMode............................................26\\nConnecting toanImplanted PulseGenerator ..............................................26\\nEnding aPatient Session .....................................................................26\\nProgramming thePulseGeneratoratImplant ................................................28\\nEntering ElectrodeInformation ..............................................................29\\nCreating thePatient Chart....................................................................29\\nAutomatic Setup..............................................................................30\\nProgrammi ngTherapy Parameters ..........................................................33\\nDefibrillation Testing .........................................................................35\\nPerforming aFollow-up ........................................................................38\\nSensing Configuration andAutomatic Setup...............................................38\\nViewing PulseGenerator Status .............................................................39\\nViewing StoredEpisodes .....................................................................40\\nPrinting Reports fromtheS-ICDApplication ..................................................42\\nPrinting Reports ...............................................................................42\\nSummary Report ..............................................................................43\\nCapture dS-ECG Report .......................................................................44\\nEpisode Reports ...............................................................................45\\nExport Patient Data.............................................................................45\\nS-ECG Features..................................................................................46\\nS-ECG Rhythm StripMarkers,Indicators, andDiscontinuities .............................46\\nS-ECG ScaleSettings ..........................................................................47\\nCapture andViewS-ECG Strips..............................................................48\\nViewpreviously-captured S-ECGs ............................................................49\\nUtilities Screen ..................................................................................49\\nAcquireReferenceS-ECG .....................................................................50\\nCapture AllSense Vectors ....................................................................50\\nBeeper Control ................................................................................51\\nManual Setup. .................................................................................52\\nSMART Settings ...............................................................................54\\nAFMonitor .....................................................................................56\\nAdditional S-ICDApplication Features .........................................................56\\nRescue Shock..................................................................................56\\nManual Shock .................................................................................58\\nS-ICDSystem Magnet Use....................................................................58\\nMAINTENANCE, TROUBLESHOO TING, HANDLING, STANDARDS, AND\\nSPECIFICATIONS ............................................................................59\\nWARRANTY INFORMATION .....................................................................59', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 3}), Document(page_content='1INFORMATION FORUSE\\nTrademark Statement\\nThefollowing aretrademarks ofBoston Scientific Corporat ionoritsaffiliates: AFMonitor,\\nEMBLEM, ImageReady, LATITUDE, LATITUDE NXT,QuickStart,ZIP,andZOOM.\\nBluetooth®isaregisteredtrademark ofBluetooth SIG.\\nDisplayPort isatrademark oftheVideoElectronics Standards Association (VESA).\\nDescription andUse\\nThefollowing Operator’s Manuals describe theLATITUDE Programming System foruse\\nwithS-ICDpulsegenerators:\\n1.LATITUDE™ Programming System Operator’s Manual (Model 3300)\\n2.EMBLEM™ S-ICDApplication Operator’sManual (Model 3877)\\nThese manuals arealsoavailable online at:\\nwww.bostonscientific -elabeling.com.\\nTheModel 3300Programmer istheprogramming device oftheLATITUDE Programming\\nSystem, which isaportable cardiac rhythm management system designed tobeusedwith\\nspecific Boston Scientific systems, i.e.,implantable pulsegenerat ors(PGs),electro des,and\\nleads.\\nIntended Use\\nTheLATITUDE Programming System isintended foruseinhospital andclinical\\nenvironments tocommunicate withBoston Scientific implantable systems. Thesoftwar ein\\nusecontrolsallcommunication functions forthePG.Fordetailed software application\\ninstructions, refertotheassociated product literatur eforthePGbeinginterrog ated.\\nIntended Audienc e\\nThisliteratu reisintended forusebyhealth careprofessionals trained orexperienc edin\\ndeviceimplant and/or follow-up procedures.\\nRequired Exper tiseandKnowledge\\nUsersmustbethoroug hlyfamiliar withelectrother apyoftheheart.Onlyqualified medical\\nspecialists having thespecial knowledge required fortheproperuseofthedevice are\\npermitted touseit.\\nPhysician Super vision\\nTheLATITUDE Programming System mayonlybeoperated under theconstant supervision\\nofaphysician. During aprocedure, thepatient mustbecontinuously monitored bymedical\\npersonnel withtheaidofasurface ECGmonitor .\\nListofAcronyms\\nThefollowing listofacrony msisusedthroughout thismanual.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 4}), Document(page_content='2AC Alternating current MRI Magnetic resonanc eimaging\\nAF AtrialFibrillation NSR Normal sinusrhythm\\nATP Anti-tachycard iapacing RF RadioFrequency\\nCRT Cardiac resynch ronization\\ntherapyRFI RadioFrequency Interferenc e\\nCPR Cardiopulmonary resuscitation RFID RadioFrequency Identification\\nECG Electro cardiogr am S-ECG Subcutaneous electrocar diogram\\nEMI Electro magnetic interferenc e S-ICD Subcutaneous implantable\\ncardioverter defibrillator\\nEOL Endoflife USB Universal serialbus\\nERI Elective replacement indicator VAC Voltage alternating current\\nESD Electro staticdischar ge VF Ventricular fibrillation\\nGUI Graphicuserinterface VT Ventricular tachycardia\\nLCD Liquid crystaldisplay\\nContraindications\\nTheLATITUDE Programmi ngSystem iscontraindicated forusewithanyPGotherthana\\nBoston Scientific PG.Forcontraindications foruserelated tothePG,refertotheassociated\\nproductliteratu reforthePGbeinginterrog ated.\\nTheModel 3877S-ICDapplication iscontraindicated forusewithanyprogramming system\\notherthantheBoston Scientific Model 3300LATITUDE Programming System.\\nUnipolar stimulation andimpedance-based features arecontraindicated forusewiththeS-\\nICDSystem.\\nRelated Information\\nBefore usingtheS-ICDsystem, readandfollow allinstructions, warnings, andprecautions\\nprovidedinthismanual, theLATITUDE Programming System Operat or’sManual (Model\\n3300), andinthemanuals fortheothersystem components, including theapplicable S-\\nICDpulsegenerat or,subcutaneous electrode, andelectrode implant toolsuser’s manuals.\\nThismanual maycontain referenc einformation forpulsegenerator model numbers that\\narenotcurrently approved forsaleinallgeographies. Foracomplete listofmodel\\nnumbers approved inyourgeography,consultwithyourlocalsalesrepresentative. Some\\nmodel numbers maycontain fewerfeatures; forthosedevices, disregar ddescriptions of\\ntheunavailable features. Descriptions found within thismanual applytoalldevice tiers\\nunless otherwise noted.\\nRefertotheImageReady™ MRConditional S-ICDSystem -MRITechnical Guide (hereafter\\nreferred toastheS-ICDMRITechnical Guide) forinformation aboutMRIscanning. This\\nmanual isalsoavailable online atwww.bostonscientific -elabeling.c om.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 5}), Document(page_content='3WARNINGS\\nAdditional warnings specific totheModel 3300Programmer aredescribed intheLATITUDE\\nProgrammi ngSystem Operator’sManual ,Model 3300.\\nAdditional warnings specific totheS-ICDpulsegenerat oraredescribed intheS-ICD\\nPhysician Technical Manuals.\\nS-ICD SystemWarnings General\\n• Connector contacts.\\n!\\nDonotsimultaneously touchthepatient andanyaccessible LATITUDE Programming\\nSystem connectororexposedconducto r.\\n• Physiological signals.\\n!\\nOperation oftheLATITUDE Programming Systemwithphysiological signals thatare\\nlowerthantheminimum detectable amplitude maycauseinaccurateresults.\\n• LATITUDE Programming Syste mmust remain outside sterile field.\\n!\\nTheProgrammer isnon-sterile andcannot besterilized. Donotallowthedevice to\\nenterasterile zoneinanimplant environment.\\n• LATITUDE Programming Syste mlocation.\\n!\\nUseoftheModel 3300Programmer adjacenttoorstacked withotherequipment\\nshould beavoided because itcouldresultinimproperoperation. Ifsuchuseis\\nnecessary ,thisequipment andtheotherequipment should beobservedtoverify\\nthattheyareoperating normally .\\n• LATITUDE Programming Syste misMRunsafe.\\n!\\nTheLATITUDE Programming System isMRUnsafe andmustremain outside theMRI\\nsiteZoneIII(andhigher) asdefined bytheAmerican College ofRadiology Guidance\\nDocument forSafeMRPractices1.Under nocircumstanc esshould theLATITUDE\\nProgramming System bebrought intotheMRIscanner room, thecontrolroom, or\\ntheMRIsiteZoneIIIorIVareas.\\n• Backup defibrillation protection.\\n!\\nAlways haveexternal defibrillation equipment andmedical personnel skilled inCPR\\navailable during implant andfollow uptesting. Ifnotterminated inatimely fashion,\\naninduced ventricular tachyarrhythmia canresultinthepatient’s death.\\n• Component compatibility .\\n!\\nAllBoston Scientific S-ICDimplantable components aredesigned forusewiththe\\nBoston Scientific orCameron Health S-ICDSystem only.Connection ofanyS-ICD\\nSystem compon entstoanon-compatible compon enthasnotbeentested andcould\\nresultinfailure todeliver life-saving defibrillation therapy .\\n1. KanalE,etal.,American Journal ofRoentgenology 188:1447-74, 2007.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 6}), Document(page_content='4• Pulse generator interaction.\\n!\\nUsingmultiple pulsegenerators couldcausepulsegenerator interaction, resulting in\\npatient injuryoralackoftherapy delivery .Testeachsystem individually andin\\ncombination tohelpprevent undesirab leinteract ions.RefertotheappropriateS-ICD\\npulsegenerator manual formoreinformation.\\nClinical Considerations\\n• Myopotentials.\\n!\\nTheS-ICDSystemmaysensemyopotentials which mayresultinover/under sensing.\\nImplantation\\n• High shocking electr odeimpedance.\\n!\\nHighshocking electrode impedance mayreduceVT/VF conversion success.\\n• Upper extremity injury .\\n!\\nDuring arrhythmia induction, theinduction current andsubsequent shockmayresult\\ninforcefulcontraction ofthepectoral ismajormuscle which canexertsignificant\\nacuteforcesontheglenohumeral jointaswellasontheclavicle. This,inconjunction\\nwithatightly restrained arm,mayresultininjurytotheclavicle, shoulder ,andarm,\\nincluding dislocation andfracture.\\n• Avoid shock atimplant.\\n!\\nVerifythedevice isinShelfmodeorTherap yOfftoprevent thedelivery ofunwanted\\nshocks tothepatient ortheperson handling thedevice during theimplant\\nprocedure.\\nDevic eProgramming\\n• Sensing adjustment.\\n!\\nFollowing anysensing parameter adjustment oranymodification ofthe\\nsubcutaneous electro de,always verifyappropriatesensing.\\n• Programming forsupraventricular tachyarrhythmias (SVTs).\\n!\\nDetermine ifthedevice andprogrammed parameters areappropriate forpatients\\nwithSVTsbecause SVTscaninitiate unwanted device therapy .\\n• Device software update.\\n!\\nDuring adevice software update, tachycardia therapy issuspended. Always monitor\\nthepatient andhaveexternaldefibrillation equipment available during\\ninterrogation.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 7}), Document(page_content=\"5Post-Implant\\n• Beeper volume after MRI.\\n!\\nTheBeeper maynolonger beusable following anMRIscan.Coming incontact with\\nthestrong magnetic fieldofanMRIscanner maycauseapermanent lossofthe\\nBeeper volume. Thiscannot berecovered, evenafterleaving theMRscan\\nenvironment andexitingMRIProtection Mode. BeforeanMRIprocedureis\\nperformed, aphysician andpatient should weigh thebenefit oftheMRprocedure\\nagainst theriskoflosing theBeeper .Itisstrongly recommended thatpatients are\\nfollowed onLATITUDE NXT(aremote patient management system) afteranMRIscan\\niftheyarenotalready .Otherwise, anin-clinic follow-up schedule ofeverythree\\nmonths isstrongly recommended tomonitor device performance.\\n• Magnet Response with Deep Implant Placement (S-ICD only).\\n!\\nInpatients withanS-ICDpulsegenerat ordeepimplant placement (greater distance\\nbetween themagnet andthepulsegenerat or)magnet application mayfailtoelicit\\nthemagnet response. Inthiscasethemagnet cannot beusedtoinhibit therapy.\\n• Magnet Response (S-ICD only).\\n!\\nUsecaution whenplacing amagnet overtheS-ICDpulsegenerat orbecause it\\nsuspends arrhythmia detection andtherapy response. Removing themagnet\\nresumes arrhythmia detection andtherapy response.\\nPRECAUTIONS\\nAdditional precautions specific totheModel 3300Programmer aredescribed inthe\\nLATITUDE Programming System Operat or'sManual ,Model 3300.\\nAdditional precautions specific totheS-ICDpulsegenerator aredescribed intheS-ICD\\nPhysician Technical Manuals.\\n•Implantation\\n• Operating temperature. Allowthepulsegenerator toreachanoperating\\ntemperatur erangeof25°C-45°C(77°F-113°F)before usingtelemetry\\ncommunication capabilities, programming, orimplanting thepulsegenerat or\\nbecause temperatur eextremesmayaffectinitialdevicefunction.\\n• Atimplant, confirmcommunication with thePG.Confirm thatthe\\nProgrammer isincommunication withtheintended S-ICDpulsegenerator .\\n•Device Programming\\n• Programming System. Useonlytheappropriate LATITUDE Programming\\nSystem equipped withtheappropr iatesoftware toprogramspecific Boston\\nScientific PGs.\\n• Programmer must remain outside thesterile field.TheProgrammer isnon-\\nsterile andcannot besterilized .Itmustremain outside thesterile field.\\n• Model 3203 S-ICD Telemetry Wand use.ForS-ICDPGtelemetry ,useonlythe\\nModel 3203S-ICDTelemetr yWandwiththeLATITUDE Programming System.\", metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 8}), Document(page_content='6• Date andtime accuracy .Inability toaccessaremotetimeserver couldleadto\\ndiscrepancies intheProgrammer time.Asabackup, contact yourBoston\\nScientific representative tohavethetimeanddatesetmanually .\\n• Patient data (S-ICD). Datafilesforuptofifty(50)patients maybestored onthe\\nProgrammer andappropriate precautions should betakentosecure the\\nProgrammer fromunauthoriz edaccess.\\n–Delete allS-ICDpatient datafromtheProgrammer byselecting thePurge\\nAllDatabutton ontheStored Patient Sessions screen before shipping the\\nProgrammer oratanytimewhentheProgrammer leaves yourdirect\\ncontrol.\\n–Onlyconnect toknown Bluetooth®devices toreducethepotential of\\ntransmitting patient datatoinappropriate printers ordevices.\\n• Stylus use.Ifyouwanttouseastylus, ensure thatitisaprojected capacitance\\nstylus. Theuseofanyotherobject coulddamage thetouchscr een.\\n• USBdevice s.USBdevices connected totheProgrammer should beencrypted\\nandcontrolledtolimitthepotential introduction ofmalwar e.\\n• Software. Ensure thatyouhavethelatestsoftwar eversions installed. Referto\\ntheLATITUDE Programming System Operat or’sManual (Model 3300)for\\ninformation aboutperforming asoftware update. Asabackup, yourlocalBoston\\nScientific representative canprovidesoftwar eupdates usingaUSBpendrive.\\n• Magnet handling. Donotplaceamagnet ontheProgrammer .\\n• Patients hear tones coming fromtheir S-ICD device .Patients should be\\nadvised tocontact theirphysician immediately whenever theyheartones\\ncoming fromtheirS-ICDdevice.\\n• Conversion testing. SuccessfulVForVTconversion during arrhythmia\\nconversion testing isnoassurancethatconversion willoccurpost-operativ ely.Be\\naware thatchanges inthepatient’s condition, drugregimen, andotherfactors\\nmaychange theDFT,which mayresultinnonconve rsionofthearrhythmia post-\\noperatively .Verifywithaconversion testthatthepatient’s tachyarrhythmias can\\nbedetected andterminated bythepulsegeneratorsystem ifthepatient’s\\nstatus haschanged orparameters havebeenreprogrammed .\\n• High shock impedance. Areported shockimpedance valueofgreater than110\\nohmsfromadelivered shockcouldindicate sub-optimal system placeme nt.Care\\nshould betakentoplaceboththepulsegenerator andelectrode directlyonthe\\nfasciawithout underlying adipose tissue. Adipose tissuecanaddsignificant\\nimpedance tothehighvoltage shockcurrent pathway .\\n• Low shock impedance. Areported shockimpedanc evalueoflessthan25ohms\\nfromadelivered shockcouldindicate aproblem withthedevice. Thedelivered\\nshockmayhavebeencompromised, and/or anyfuture therapy fromthedevice\\nmaybecompromised. Ifareported impedanc evalueoflessthan25ohmsis\\nobserved,correctfunctioning ofthedeviceshould beverified.\\n• Impact ofDisable Beeper button. IntheProgrammer stepstoprogramand\\ntesttheBeeper ,selecting No,Disable Beeper willdisable beeping functionality\\nforalertconditions, whenamagnet isplaced overthedevice,andwhentheS-\\nICDapplication connects tothedevice.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 9}), Document(page_content='7•Environmental andMedical Therapy Hazards\\n• Electr ocautery .Electrocautery mayinduce ventricular arrhythmias and/or\\nfibrillation andmaycauseinapprop riateshocks andinhibition ofpost-shock\\npacing andmayproduc eunexpected behavior intheProgrammer display or\\noperation. Ifelectrocautery ismedically necessary ,maintain adistanc eofat\\nleast30cm(12in)between electrocautery equipment andtheProgrammer and\\nitsassociated components. Similarly ,maintain thisdistanc ebetween the\\nProgrammer anditsassociated components andthepatient during these\\nprocedures.\\n• Model 3203 S-ICD Telemetry Wand shipped non-sterile. TheModel 3203S-\\nICDTelemetry Wandisshipped non-sterile. Remove thewandfromall\\npackaging material beforeuse.Ifthewandistobeusedinasterile field,it\\nmustbeenclosed inasterile intraoper ativeprobe cover(Model 3320)during\\nuse.RefertotheLATITUDE™ Programming System Operator’s Manual (Model\\n3300)forcleaning information.\\nAdverse Effects\\nThefollowing arethepossible adverse effects associated withprogramming thepulse\\ngeneratorsdescribed inthismanual.\\n•Asystole\\n•Atrialarrhythmia\\n•Bradycardia\\n•Tachycardi a\\n•Ventricular arrhythmia\\nUSING THES-ICD APPLICATION\\nS-ICD Application Setup Overview\\nThissection describes thewandandpower connection stotheModel 3300Programmer\\nandbasicnavigation oftheS-ICDApplication.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 10}), Document(page_content='8\\n7\\n5\\n4\\n3\\n2\\n1\\n6\\n8[1]Power (on/off )button (lightgray)[2-4]USB2.0ports(darkgray)[5]USB3.0port(blue)[6]Ethernet port(orange)\\n[7]DisplayPort Out(red-or ange)[8]DCpower connection forModel 6689power adapter (green)\\nFigure 1.LeftSide Panel oftheProgrammer\\nInFigure 1LeftSidePaneloftheProgrammer onpage8,callout 8identifies theDCpower\\nconnection, andcallout 1identifies theProgrammer On/Off power button.\\n5\\n4\\n3\\n2\\n1\\n6\\nA\\n/\\nR\\nV\\nL\\nV\\n[1]Model 6763PSACableforLV(green) [2]Model 6763PSACableforA/RV(lightgray)[3]Model 3153ECGCable\\n(darkgray)[4]connection portforfuture use(brown) [5]Model 3203 S-ICD Telemetry Wand (black) [6]Model 6395\\nTelemetry Wand(blue)\\nFigure 2.Right Side Panel oftheProgrammer\\nInFigure 2RightSidePaneloftheProgrammer onpage8,callout 5identifies theModel\\n3203S-ICDTelemetry Wandconnection.\\nPowering theModel 3300 Programmer\\nTheModel 3300Programmer isprimarily intended tobeoperatedwhileconnected tothe\\nAC-powered externalpower supply ,butmayalsobeoperated onbattery power provided', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 11}), Document(page_content='9thattheinternal battery isadequately charged.TheProgrammer isrechargedwhenever it\\nisconnected totheAC-powered external power supply .Whennotinuse,itis\\nrecommended thattheProgrammer remainconnected totheexternal power supply in\\nordertomaintain anadequate batterycharge.\\nNOTE:RefertotheLATITUDE™ Programming System Operat or’sManual (Model 3300)\\nforcomplete startup andbatterycharginginformation.\\nNOTE:Current S-ICDsession datamaybelostifa45minute period ofinactivity occurs\\nandtheProgrammer isnotconnected toACpower.\\nWhentheProgrammer ispowere dOnandtheS-ICDApplication isrunning, thebattery\\nstatus indicator displays intheupper rightcorner ofthescreen indicating theapproximate\\nchargestatus oftheProgrammer battery .SeeFigure 3S-ICDApplication startupscreen\\nwithbatterystatus icononpage10.\\n•Allfourbarsareilluminated (green) –Thebatteryis100%charged\\n•Threebarsareilluminated (green)–Thebattery is75%charged\\n•Twobarsareilluminated (yellow) –Thebatteryis50%charged\\n•Onebarisilluminated (red)–Thebatteryis25%charged\\nTheS-ICDApplication displays thefollowing alertscreens andtextastheProgrammer\\nbattery power getsprogressively lower.\\n•Programmer Battery Caution Screen—“Programmer Battery ≤25%—Battery capacity\\nisatxx%.2Itisrecommended youfindanACPower source.”\\n•Programmer Battery Warning Screen —”Programmer Battery ≤10%—Battery capacity\\nisatxx%.PlugtheProgrammer intoACPower immediately toensure system\\nfunctionality.”\\n•Programmer Battery Critical Screen —“Programmer Battery ≤5%—Battery capacity is\\natxx%.PlugtheProgrammer intoACPower immediately toensure system\\nfunctionality .Programmer willautomatically shutoffwithin 60seconds.”\\n2. “xx”isreplacedbytheactual battery charge remaining percentage.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 12}), Document(page_content='10\\n1[1]Battery Status (barsvisible whenonbattery power).\\nFigure 3.S-ICD Application start upscreen with battery status icon\\nNOTE:Thescreenimages inthismanual arerepresentative andmaynotexactlymatch\\nyourscreens.\\nPowering theProgrammer OnandOff\\nTheProgrammer’s power button islocated ontheleftsideoftheProgrammer (seeFigure\\n1LeftSidePaneloftheProgrammer onpage8).Pressthebutton andrelease ittopower\\ntheProgrammer OnorOff.3\\nNOTE:ToendtheS-ICDapplication, selecttheQuitbutton fromtheS-ICDmain\\napplication screen (Figure 3S-ICDApplication startupscreen withbattery status iconon\\npage10).Thisreturns theusertotheProgrammer mainmenuFigure 4Model 3300\\nProgrammer MainMenuonpage12.\\nNOTE:TheModel 3300Programmer canoperate onbatteryorACpower.Refertothe\\nLATITUDE Programming System Operat or’sManual, Model 3300forinstructions on\\nchargingthebattery andoperating onlyonbatterypower.\\nUsing theProgrammer Touch Screen\\nTheProgrammer isequipped withanLCDtouchscreen. Allinteraction withthe\\nprogrammer isconducted usingthefingers totouchtheappropriate areasonthescreen.\\nScrollon-screenlistsbysliding afinger upanddownthelist.Anon-screenkeyboar dis\\npresented whenever textentryisrequired.\\nNOTE:Useonlyfingers oraprojectedcapacitanc estylusontheProgrammer touch\\nscreen.\\n3. EndtheS-ICDsession before powering offtheProgrammer .', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 13}), Document(page_content=\"11S-ICD Application Navigation\\nTheapplication's graphical userinterface (GUI)facilitates management andcontrolofthe\\nS-ICDSystem. TheNavigation Barandon-screeniconsatthetopofthescreen allowthe\\nusertonavigate programming software screens. Inaddition, acontinuous subcutaneous\\nelectro cardiogr am(S-ECG) isdisplayed alongthebottom ofthescreen during Online\\n(active) communication withthepulsegenerator.\\nS-ICD Application Screen Header\\nWhentheS-ICDApplication isOffline (inactive communication), thescreenheader displays\\ntheProgrammer battery status indicator .\\nWhenviewing Offline Stored Sessions, thescreen header displays:\\n•Patient name\\n•Therapy On/Off\\n•Programmer batterystatus indicator\\nWhentheS-ICDApplication isOnline (active communication), thescreen header displays:\\n•Therapy On/Off\\n•Patient name\\n•Patient heartrate\\n•Programmer batteryandtelemetry status indicator\\n•Screentitle\\n•Rescue shockicon\\nS-ICD Application Navigation Bar\\nTheNavigation Baristheprimary method fornavigating theOnline application screens.\\nThebarislocated alongthetopedgeoftheapplication screen andchosen screensappear\\nwiththeirselection iconhighlighted. Thefollowing tableprovidesalistoftheiconsand\\ntheircorresponding descriptions.\\nTable 1.Icon descriptions\\nIcon Description User Application\\nS-ICDApplication Main\\nMenuIconAllows usertoreturn tothemainmenu.\\nBattery &Telemetry\\nMeterLeftsideofthemeter allows usertoviewtheProgrammer’s\\nbatterystatus. Therightsideofthemeter allows viewing of\\ntelemetry signal strength\\nCaptureS-ECG Allows usertocapture aliveS-ECG.\\nDetails Opens awindow containing detailed information.\\nHeartRateIcon Allows usertoviewcurrent heartrate.\", metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 14}), Document(page_content='12Table 1.Icon descriptions (continued)\\nIcon Description User Application\\nShock!\\nRescue ShockIcon Allows usertoadminister arescueshock.\\nOption Selection Switch Allows usertoselectoneoftwooptions, e.g.AorB.\\nConfiguring theS-ICD Application\\nStarting theModel 3300 Programmer\\nPower ontheProgrammer todisplay theMainMenu.\\n21\\n[1]S-ICDApplications button [2]Utilities button\\nFigure 4.Model 3300 Programmer Main Menu\\nSettheLanguage andTime Zone\\nBefore starting theS-ICDApplication, thelanguage andtimezoneareset.These settings\\narepersistent anddonotneedtobere-enter edforsubsequent S-ICDprogramming\\nsessions orusesoftheModel 3300Programmer .\\nNOTE:Theformats forthedate(mm/dd/yyyy ordd/mm/yyyy) andthetime(12houror\\n24hour)aresetintheS-ICDApplication itself.See\"DateandTimeFormat\" onpage17.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 15}), Document(page_content='131. SettheLanguage\\na.FromtheModel 3300Programmer MainMenu, selecttheUtilities button inthe\\nlowerleftofthescreen.\\nb.Select theSetuptab.\\nc.Select thelanguage bar,thenselectthedesiredlanguage. asillustrated inthe\\nfollowing figure.\\nFigure 5.Utilities\\n2. SettheTime Zone\\na.FromtheModel 3300Programmer MainMenu, selecttheUtilities button inthe\\nlowerleftofthescreen.\\nb.Select theDateandTimetab.\\nc.Select thetimezonebar,thenselectthedesired timezoneasillustratedinthe\\nfollowing figure.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 16}), Document(page_content='14\\nFigure 6.Utilities —Setup time zone\\nEnable Bluetooth®Communications\\nTouseBluetooth®communications forprinting orexporting patient data,itmustbe\\nenabled usingtheUtilities menuoftheModel 3300Programmer .\\nNOTE:Printers thataredirectly connected totheProgrammer byaUSBcabledonot\\nrequire Bluetooth®communications.\\nNOTE:Exporting patient datausingBluetooth®requires thatBluetooth®communications\\nbeenabled.\\n1.Select theUtilities tabfromthemainmenuoftheProgrammer .\\n2.FromtheUtilities menu, selecttheBluetooth®tabandthenselecttheEnable\\nBluetooth checkboxasillustrated inFigure 7Utilities menu-Enable Bluetooth®check\\nboxselected onpage15.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 17}), Document(page_content='15\\n1[1]Enable Bluetooth®checkbox selection\\nFigure 7.Utilities menu -Enable Bluetooth®check boxselected\\n3.TheProgrammer begins ascanofBluetooth®enabled computers4within rangeand\\nliststhemintheUnauthorized Computers Nearby column.\\nThese stepsenable Bluetooth®communications andallowyoutoconfigur eaBluetooth\\nprinter andexport patient datafromwithin theS-ICDApplication.\\nReferto\"Printer Selection\" onpage19toconfigure aBluetooth®printer .Referto\\n\"Bluetooth®DataExport\" onpage20toauthorize acomputer toreceiveexported patient\\ndatausingBluetooth®.\\nNOTE:Printers canbeconfigured fromeithertheProgrammer Utilities taborfromtheS-\\nICDPrinter Setupscreen.\\nStart theS-ICD Application\\n1.WiththeModel 3203Telemetry Wandconnected andtheModel 3300Programmer\\npowered on,selecttheS-ICDApplications button fromthemainmenu. SeeFigure 4\\nModel 3300Programmer MainMenuonpage12.\\n2.WhentheS-ICDApplications paneldisplays, selecttheS-ICDDevice Programmer\\nApplication icon.\\n3.AstartApplication dialogue displays whiletheapplication loads, thentheEMBLEM™\\nS-ICDSystem start-upscreen displays.\\nNOTE:Itcantakeapproximately 30secondsfortheS-ICDApplication toload.\\nDuring thistime,thescreendisplays theStartApplication message andhourglass\\niconfollowed byalargetextdisplay ofBoston Scientific.\\nThefollowing figure illustratesthestartup sequence .\\n4. The3300Progra mmer onlyrecognizes Bluetooth®enabled computers andprinters.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 18}), Document(page_content='16\\n1\\n2\\n3\\n4\\n5\\n[1]Model 3300MainMenu[2]S-ICDApplications button [3]S-ICDApplications selection screen [4]StartS-ICD\\nApplication dialog [5]S-ICDApplication mainscreen\\nFigure 8.S-ICD Application startup sequence\\nToconfigure theS-ICDApplication settings:\\n1.Select theProgrammer Settings button ontheEMBLEM S-ICDstart-upscreen (Figure\\n9S-ICDprogramming application start-upscreen onpage17)todisplay the\\nProgrammer Settings screen (Figure 10S-ICDProgrammer Settings screen onpage\\n17).', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 19}), Document(page_content='17\\nFigure 9.S-ICD programming application start-upscreen\\nFigure 10. S-ICD Programmer Settings screen\\n2.Select thecorresponding linetoaccesseachsetting. Thesettings thatcanbe\\nconfigured include:\\n•DateandTimeformat\\n•NoiseFilterConfigurat ion\\n•Printer Setup\\nDate andTime Format\\nNOTE:Before setting thedateandtimeformats, ensure thattheTimeZonehasbeenset\\nfortheProgrammer .See\"SettheLanguage andTimeZone\" onpage12.\\nTosetthedateandtimeformat:', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 20}), Document(page_content=\"181.Select SetDateandTimeFormat ontheProgrammer Settings screen (Figure11Set\\nDateandTimeFormat screenonpage18).TheDateandTimeSettings screen\\nappears.\\n2.Select thedesired timeformat (12or24hour).5\\n3.Select thedesired dateformat (mm/dd/yyyy ordd/mm/yyyy).\\n4.Select theSavebutton tosavethechanges andreturn totheProgrammer Settings\\nscreen, orselectCanceltoreturn totheProgrammer Settings screen without saving\\nthechanges.\\nFigure 11. SetDate andTime Format screen\\nSetNoise Filter Configuration\\nTheNoiseFilterConfigurat ionsetting controlstheelectro nicfilterinthepulsegenerat or\\nthatisintended tominimize electromagnetic interfer ence(EMI).Specifically ,thepulse\\ngeneratorlinefrequency filterisautomatically programmed toeither50Hzor60Hz,\\nbased ontheNoiseFiltersetting.\\nTheNoiseFilterisfactory settomatch yourcountry's electrical grid.So,donotchange it\\nunless youchange countries.\\nNOTE:Changing theNoiseFilterConfiguration setting ontheProgrammer willresultin\\nthe50/60 Hzlinefrequency filterbeingconfigur edtothechosen setting (50Hzor60Hz)\\ninallsubsequent pulsegenerators interrog ated.\\nTosettheS-ICDapplication NoiseFilter:\\n1.Select SetNoiseFilterConfiguration ontheS-ICDProgrammer Settings screen (Figure\\n12SetNoiseFilterConfigurat ionscreenonpage19).todisplay thenoisefilter\\nconfigur ationscreen.\\n2.Select either50Hzor60Hz.\\n5. Thisonlyaffects theS-ICDapplication dateandtimeformat. TheModel 3300Programmer dateandtime\\nformat isnotaffected.\", metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 21}), Document(page_content='193.Select theSavebutton tosavethechanges andreturn totheS-ICDProgrammer\\nSettings screen,orselectCancel toreturn totheProgrammer Settings screen without\\nsaving thechanges.\\nIntherarecaseswherethereareregional power linefrequency differenc es,choose the\\noption withthecorrectfrequency fortheregionwheretheProgrammer islocated. Be\\nawarethattravelling patients whose devices areinterrogated inregions orcountri esother\\nthantheoneinwhichtheyreside mayneedtohavetheirNoiseFilterresetuponreturning\\nhome.\\nFigure 12. SetNoise Filter Configuration screen\\nPrinter Selection\\nTheModel 3300Programmer provides USBandBluetooth®support forprinters.\\n1.Ensure theprinter isonand,depending onyourspecific printer ,connect ittothe\\nProgrammer viaUSBcableorBluetooth®.\\n•ForaUSBprinter ,connect theprinter toaUSBportontheleftsideofthe\\nProgrammer .\\n•Bluetooth®communications mustbeenabled before selecting aBluetooth®\\nprinter intheS-ICDapplication. See\"Enable Bluetooth®Communications\" on\\npage14toenable Bluetooth®communications.\\n2.Select Printer SetupontheProgrammer Settings screen.ThePrinter Setupscreen\\n(Figure13Printer Setupscreen onpage20)displays withaUSBprinter whether one\\nisconfigur edornot.Ifadefault printer hasalready beenselected andconfigur ed,the\\nscreen willdisplay it.Select theScanAgainbutton andtheProgrammer scansthe\\nareatolocate Bluetooth®printers. AScanProgressBardisplays informing theuser\\nthattheProgrammer iscurrently scanning forprinters.\\nAdditionally ,whentheprinter setupscreenisloaded, allprinters already pairedwill\\nbedisplayed.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 22}), Document(page_content='20\\nFigure 13. Printer Setup screen\\n3.Select theprinter ofchoicefromamong thosefound during thescan.Ifnonewere\\nfound, awindow displays stating thattherearenoprinters. Select theScanAgain\\nbutton ortheCancel button toreturn totheProgrammer Settings screen.\\n4.Select thedesired printer fromthelistandenterthenameusingtheon-screen\\nkeyboard (upto15characte rs).Aunique printer identifier should appear withthe\\nprinter selection.\\n5.Select theSavebutton tosavethechanges andreturn totheProgrammer Settings\\nscreen, orselectCanceltoreturn totheProgrammer Settings screen without saving\\nthechanges. Aconfirmation screen displays whentheprinter setupiscompleted.\\nNOTE:Refertothe“Troubleshooting” section oftheModel 3300Operator’s Manual for\\ninformation aboutprinter problems.\\nModel 3877 S-ICD Application Software Version\\nToviewtheS-ICDApplication’s softwar eversion:\\n1.Select About Programmer ontheProgrammer Settings screen. TheProgrammer\\nSoftware Version information screen appears.\\n2.TheProgrammer Softwar eVersion information screendisplays thecurrentversion of\\ntheProgrammer software andrelease notesforthelastmajorupdate. Select the\\nContinue button toreturn totheProgrammer Settings screen.\\nNOTE:Theprinted reports alsocontain Programmer software version information.\\nBluetooth®Data Export\\nTheProgrammer canbeconfigur edtowirelesslyexport patient datatodesktop or\\nnotebook computers thatareequipped withBluetooth®wirelesstechnology .The\\nProgrammer andeachcomputer mustbeindividually pairedinordertousethewireless\\ndataexport function. Theprocedureforpairing theProgrammer withacomputer is\\ndifferentfromtheprocedureusedtopairtheProgrammer withtheprinter .', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 23}), Document(page_content='21NOTE:Datatransfer issupported forcomputers running Windows. Thedatatransfer\\nfeature isnotavailable fortablets orsmartphones.\\nNOTE:InWindows 10,theBluetooth®\"Receiv eaFile\"window mustbeopentotransfer\\nfilestothatPC.\\n1.Bluetooth®communications mustbeenabled intheModel 3300Programmer before\\ntheS-ICDapplication canexportpatient date.See\"Enable Bluetooth®\\nCommunications\" onpage14forinstructions toenable Bluetooth®communications.\\n2.Ensure thecomputer tobepairedhasbeenmadediscover able,sincetheProgrammer\\nsearches fornearby computers during thepairing process.\\nNOTE:Detailed instructions foraccomplishing thisarefound intheMicrosoft\\nWindows helpfilesunder thegeneral heading of“Whycan’tIconnect myBluetooth\\ndevicetomycomputer? ”\\n3.Oncethetargetcomputer hasbeenmadediscover able,selecttheExport Programmer\\nDatabutton ontheS-ICDapplication start-upscreen. TheExport Programmer Data\\nOverBluetooth screen willappear .Select theSetUpAuthorized Computers button to\\nscanfornearby computers andbeginthepairing process.\\n4.Whilescanning, discover edcomputers display under theheading Unauthorized\\nComputers Nearby asillustratedinFigure 14Choosing acomputer toauthorize for\\nBluetooth®datatransfer onpage22.Choose thecomputer youwishtopairwithand\\npresstheplusbutton nexttoittocomplete thepairing process.Youcancancel any\\ntimeafteryouseethePCyouwishtopair.\\n5.During thepairing process,boththeProgrammer andthecomputer willpresent\\nidentical numeric passkeysandbothmachines willaskyoutoconfirm thatthetwo\\nnumbers arethesame. Thepasskey isonlypresente dwhilepairing andisusedto\\nverifythatthecorrectmachines arebeingpaired.\\n6.Successfulpairing isindicated whenthelisting forthesubject computer appears in\\ntheAuthorized Computers column instead oftheUnauthorized Computers Nearby\\ncolumn.\\n7.Authorized computers mayberenamed ifdesired. Pressandholdthelisting forthe\\ncomputer untiltheRename anAuthorized Computer popup appears.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 24}), Document(page_content='22\\nXXXXXXXXXX\\nXXXXXXXXXX\\nXXXXXXXXXXFigure 14. Choosing acomputer toauthorize forBluetooth®data transfer\\nApplication Modes ofOperation\\nOnline Behavior\\nTheapplication’s interface variesaccordingtowhether theProgrammer isOnline (actively\\ncommunicating) orOffline (notcommunicating) withaselected pulsegenerator .\\nAnOnline session begins whentheProgrammer establishes atelemetry linkwithaspecific\\npulsegenerat or.Ayellow alertscreen isdisplayed ifthetelemetry signal islostbetween\\ntheProgrammer andthepulsegeneratorformorethanfiveseconds during active\\ncommunication. Thismayoccurifthewandismoved outofthetelemetry communications\\nrangeorifnoiseorinterfering objects inhibit communication. Programming commands,\\nincluding Rescue Shocks, willnotbeavailable untiltelemetry isreestablished.\\nTelemetry reconnection mayoccurautomatically ifthereasonforthetelemetry losshas\\nbeenremedied, e.g.moving thewandbackintotelemetry rangeofthepulsegeneratoror\\nremoving thesourceofinterfere nceornoise. Restart thesession ifthetelemetry linkdoes\\nnotresume within oneminute.\\nNOTE:Wheninactivecommunication withapulsegenerat or,theProgrammer emitsan\\naudible notification toindicate thatthepulsegenerator ispreparing todeliver ashock,\\nwhether thatshockiscommanded orisinresponse toadetected arrhythmia. The\\nnotification continues untiltheshockiseitherdeliver edoraborted.\\nOffline Behavior\\nTheProgrammer isOffline whenitisnotactively communicating withapulsegenerator.\\nProgrammer settings canbeaccessedandstoredpatient sessions canbeviewed and/or\\nprinted during Offline sessions.\\nStored Patient Sessions\\nDuring apatient follow-up visit,theProgrammer willretrieve datafromthepulse\\ngeneratormemory .TheProgrammer canstoreupto50patient sessions or90daysof\\npatient session data.Whenthe51stsession occurs, theProgrammer willautomatically', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 25}), Document(page_content='23replace theoldest storedsession withthenewdata.Additionally ,whenthe90thday\\npasses afterapatient session wasstored, theProgrammer willautomatically delete that\\npatient session whentheS-ICDapplication isstarted. Astored session includes the\\nfollowing information:\\n•Captured S-ECG Reports (including Induction S-ECGs)\\n•Episode History (including anydownloaded episodes)\\n•Patient Data\\n•Programmed Device Settings\\nToview stored patient sessions:\\n1.FromtheS-ICDapplication start-upscreen,selectStored Patient Sessions.\\n2.Select thedesired patient session.\\nModes ofOperation forthePulse Generator\\nThepulsegenerator hasthefollowing modes ofoperation:\\n•Shelf\\n•Therapy On\\n•Therapy Off\\n•MRIProtection Mode\\nShelf Mode\\nTheShelfmodeisalowpower consumption stateintended forstorage only.Whenapulse\\ngeneratorinShelfmodeisinterrog atedbytheProgrammer ,afull-energy capacitor\\nreformation isperformed andthepulsegenerator isprepar edforset-up.WhenShelf\\nmodeisexited, theS-ICDapplication defaults toTherapy Offmode. Thepulsegenerator\\ncannot bereprogrammed backintoShelfmode.\\nTherapy OnMode\\nTheTherapy Onmodeistheprimary operating modeofthepulsegenerator,allowing\\nautomatic detection of,andresponse to,ventricular tachyarrhythmias.\\nTherapy OffMode\\nTheTherapy Offmodedisables automatic therapy delivery whilestillallowing manual\\ncontrol ofshockdelivery .Programmable parame tersmaybeviewed andadjusted viathe\\nProgrammer .Thesubcutaneous electrogr am(S-ECG) maybedisplayed orprinted fromthis\\nmode.\\nThepulsegenerator defaults toTherapy OffmodewhenitistakenoutofShelfmode.\\nNOTE:Manual andrescueshocktherapyareavailable whenthedeviceissettoTherapy\\nOnorTherapy Offmodeandisactively communicating withapulsegenerator ,butonly\\naftertheinitialSetupprocessiscomplete .Referto\"Automatic Setup\" onpage30.\\nMRIProtection Mode\\nMRIProtection Modeisavailable inEMBLEM S-ICDdevices.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 26}), Document(page_content='24MRIProtection Modemodifies certain pulsegenerat orfunctions inordertomitigate risks\\nassociated withexposingtheS-ICDsystem totheMRIenvironment. Choosing MRI\\nProtection Modewillinitiate asequence ofscreenstoassess thepatient’s eligibility and\\nreadiness toundergo anMRConditional MRIscan.RefertotheSummar yReport tofind\\noutwhether thedevicehasbeeninMRIProtection Mode. Foracomplete description of\\nMRIProtection Mode, alistofMRConditional devices, andadditional information about\\ntheImageReady S-ICDSystem, refertotheS-ICDMRITechnical Guide.\\nPriortothepatient undergoing anMRIscan,anImageReady S-ICDSystem mustbe\\nprogrammed totheMRIProtection ModeusingtheProgrammer .InMRIProtection Mode:\\n•Tachycardia therapy issuspended\\n•ATime-out feature isnominally setto6hours, withprogrammable values of6,9,12,\\nand24hours\\n•Beeper isdisabled\\nNOTE:TheBeeper remains disabled untiltheuserreprogramsitOn(\"Beeper Control\"on\\npage51).\\nMonitor thepatient continuously bypulseoximetry andelectro cardiogr aphy(ECG)until\\nscaniscomplete dandfortheentireduration inwhichthesystem isinMRIProtection\\nMode. External defibrillator andmedical personnel mustbepresent.\\nMRIProtection Modeisterminated bymanual exitusingtheProgrammer orthroughthe\\nuser-programmed automatic MRIProtection Time-out period (refertotheS-ICDMRI\\nTechnical Guide forMRIProtection Modeprogramming instructions.) Rescue Shockwill\\nalsoterminate MRIProtection Mode. WhenMRIProtectio nModeisexited,allparame ters\\n(exceptfortheBeeper) returntothepreviously programmed settings.\\nWARNING:\\n!\\nTheLATITUDE Programming System isMRUnsafe andmustremain outside theMRIsite\\nZoneIII(andhigher) asdefined bytheAmerican College ofRadiology Guidance Document\\nforSafeMRPractices6.Under nocircumstanc esshould theLATITUDE Programming System\\nbebrought intotheMRIscanner room, thecontrolroom, ortheMRIsiteZoneIIIorIV\\nareas.\\nWARNING:\\n!\\nTheS-ICDpulsegenerator Beeper maynolonger beusable following anMRIscan.\\nExposur etothestrongmagnetic fieldofanMRIscanner maycauseapermanent lossof\\ntheBeeper volume. Thiscannot berecovered, evenafterleaving theMRscanenvironment\\nandexiting MRIProtection Mode. Before anMRIprocedureisperformed, aphysician and\\npatient should weigh thebenefit oftheMRprocedureagainst theriskoflosing the\\nBeeper .Itisstrongly recommended thatpatients arefollowed onLATITUDE™ NXT(a\\nremote patient management system) afteranMRIscaniftheyarenotalready .Otherwise,\\nanin-clinic follow-up schedule ofeverythreemonths isstronglyrecommended tomonitor\\ndevice performance.\\n6. KanalE,etal.,American Journal ofRoentgenology 188:1447-74, 2007.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 27}), Document(page_content='25Connecting andDisconnecting fromtheS-ICD Pulse Generator\\nThissection provides theinformation necessaryforselecting, connecting to,and\\ndisconnecting fromthepulsegenerator .\\nScanning forPulse Generators\\n1.Select theScanForDevices button ontheProgrammer start-upscreen (Figure9S-ICD\\nprogramming application start-upscreen onpage17).TheScanProgressBaris\\ndisplayed during thescanning process,attheconclusion ofwhich theDevice List\\nscreen appears. Select theCancel button atanytimetoendthescanning process.\\n2.Whenthescanning processiscomplete, alistofallS-ICDpulsegenerators detected\\n(upto16)willbedisplayed ontheDeviceListscreen(Figure 15Device Listscreen\\n(scrollable list)onpage25).ThedevicesthatareinShelfmodewillbedisplayed as\\n“NOTIMPLANTED”. Anydevices thatwerepreviously takenoutofShelfmodeare\\ndisplayed eitheras“IMPLANTED” orwiththestoredpatient name.\\nFigure 15. Device Listscreen (scrollable list)\\n3.Ifthedesired pulsegeneratorisnotlisted, selecttheScanAgainbutton tore-initiate\\nthescanning process.Select theCancel button toreturntotheS-ICDProgramming\\napplication start-upscreen.\\nIftheProgrammer isunable tocommunicate withthepulsegenerator ,follow thesteps\\nbelow:\\n1.Ensure theProgrammer isconnected toACpower,whichimproves telemetry\\nperformance .\\n2.Attempt toreposition thewand.\\n3.Select ScanForDevicesfromtheS-ICDProgramming application start-upscreen or\\nselectScanAgainfromtheDevice Listscreen tolocate thedesireddevice.\\n4.Moveanyequipment andassociated cables thatmaybeinterfering withRF\\ncommunication.\\n5.Ifavailable, attempt tocommunicate usingadifferent Programmer and/or wand.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 28}), Document(page_content='266.Applyapulsegeneratormagnet tothepulsegenerator toelicitbeeper tones.\\nRemove themagnet andre-attempt communication.\\nConnecting toaPulse Generator\\nSelect thedesiredpulsegenerator fromtheDevice Listscreen(Figure15DeviceListscreen\\n(scrollable list)onpage25)toinitiate thecommunication session.\\nNOTE:Regardless ofhowmanypulsegenerators arelocated byascan,theusermust\\nselectaspecific pulsegenerat orfromthelistinordertobeginactivecommunication.\\nConnecting toaPulse Generator inShelf Mode\\nIfapulsegeneratorinshelfmodeischosen fromtheDeviceListscreen,thefollowing\\nconnection sequence occurs:\\n1.TheProgrammer connects totheselected pulsegenerat oraftertheselection ismade.\\nAwindow willappear indicating connection isinprocess.\\n2.TheDeviceIdentification screen displays oncecommunication isestablished withthe\\npulsegenerator .\\nNOTE:TheDevice Identification screenisvisible onlywhileconnecting toapulse\\ngenerat orinShelfmode.\\n3.Thedevicemodel andserialnumbers areautomatically acquired anddisplayed\\nduring theinitialscanning process.Select ExitShelfModetoremove thedevicefrom\\nShelfmodeandprepareforimplantation, orselectCanceltoreturn totheDevice List\\nscreen.\\nNOTE:Whenapulsegenerat oristakenoutofshelfmode, itcannot bereprogrammed\\nbackintoShelfmode.\\nNOTE:Eachtimeapulsegenerat orinshelfmodeisinterrogated, afull-ener gycapacitor\\nreformation isperformed\\nConnecting toanImplanted Pulse Generator\\nIfanimplanted pulsegenerator ischosen fromtheDevice Listscreen,thefollowing\\nconnection sequence occurs:\\n1.TheProgrammer connects totheselected pulsegenerat oraftertheselection ismade.\\nAwindow willappear indicating connection isinprocess.\\nDuring theconnection process,informational messages andwarning messages may\\ndisplay ,e.g.SMART Passhasbeendisabled.\\n2.TheDeviceStatus screen appears oncecommunication isestablished withthepulse\\ngenerat or(Figure 27DeviceStatus screen onpage40).\\nWARNING:\\n!\\nDuring adevice software update, tachycardia therapy issuspended. Always monitor the\\npatient andhaveexternal defibrillation equipment available during interrogati on.\\nEnding aPatient Session\\nToendanOnline patient session andreturn theProgrammer toitsOffline operation\\nmode:', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 29}), Document(page_content='271.Select theMainMenuicon\\n ontheNavigation Bar.TheMainMenuscreen appears.\\n2.Select theEndSession button.\\n1\\n[1]Return toMainMenuicon\\nFigure 16. S-ICD Online —Main Menu screen\\n3.Warning messages (Figure 17Session Incomplete message example sonpage28)will\\nbedisplayed totheuserifanyofthefollowing conditions exists:\\n•Therapy modeisprogrammed toOff\\n•Referenc eS-ECG hasnotbeenacquired\\n•Automatic SetuporManual Setuphasnotbeencompleted\\n•Optimization hasnotbeencompleted. Thismessage isdisplayed ifAutomatic\\nSetupOptimization wasnotperformed during theAutomatic Setupprocess\\n•SMART Passisnotenabled', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 30}), Document(page_content='28\\nFigure 17. Session Incomplete message examp les\\n4.Select theContinue button toendthepatient session andreturntotheProgrammer\\nstart-upscreen, orselectCanceltoremain Online andreturntotheMainMenu\\nscreen.\\nNOTE:OncetheContinue button isselected, thesession isstoredand\\ncommunication isterminated.\\nNOTE:Atelemetry session mustbeterminated usingtheEndSession processas\\ndescribed insteps1through4above inorderfordataobtained during thatsession to\\nbesaved. IftheProgrammer ispoweredoffduring asession, session datawillnotbe\\nsaved.\\nNOTE:Inordertoconfirm thatTherapy ModeissettoOnupondisconnection,\\nalways usetheEndSession processandreview alldisplayed warning messages.\\nProgramming thePulse Generator atImplant\\nThissection provides theinformation necessary forprogramming thepulsegenerat or\\nduring animplant.\\nCAUTION: Allowthepulsegenerator toreachanoperating temperatur erangeof25°C-\\n45°C(77°F-113°F)before usingtelemetry communication capabilities, programming, or\\nimplanting thepulsegenerat orbecause temperatur eextremesmayaffectinitialdevice\\nfunction.\\nCAUTION: ForS-ICDPGtelemetry ,useonlytheModel 3203S-ICDTelemetry Wandwith\\ntheLATITUDE Programming System.\\nCAUTION: TheModel 3203S-ICDTelemetry Wandisshipped non-sterile. Remove the\\nwandfromallpackaging material before use.Ifthewandistobeusedinasterile field,it\\nmustbeenclosed inasterile intraop erative probe cover(Model 3320)during use.Referto\\ntheLATITUDE™ Programming System Operator’s Manual (Model 3300)forcleaning\\ninformation.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 31}), Document(page_content='29CAUTION: TheProgrammer isnon-sterile andcannot besterilized .Itmustremain\\noutside thesterile field.\\nCAUTION: Confirm thattheProgrammer isincommunication withtheintended S-ICD\\npulsegenerator.\\nEntering Electr odeInformation\\nTheProgrammer maintains information ontheimplanted electro de.Torecordthis\\ninformation forapatient’s neworreplacement electro de:\\n1.WiththeProgrammer connected toanS-ICDpulsegenerator,selecttheMainMenu\\nicon.\\n2.Select theImplant button.\\n3.Select theAutoSetupbutton intheNavigation Bar.TheAutomatic Setupscreen\\nappears (Figure21Measuring electro deimpedance onpage32).\\n4.Select SetElectrode IDbutton.\\nFigure 18. Select theSetElectr odeIDbutton toenter electr odeinformation\\nNOTE:ECGandheartrateinformation arenotpresent ontheAutomatic Setupand\\nElectrodeIDsetupscreensuntiltheelectrode hasbeenconnected tothepulse\\ngenerat or.\\n5.Entertheelectrode model andserialnumber .\\n6.Select theProgrambutton tosavetheinformation. Aconfirmation screen willappear\\nduring communication withthedevice. Select Cancel tocancel information storage\\nandreturntotheAutomatic Setupscreen.\\nCreating thePatient Chart\\nThischartcontains referenc einformation forthepatient. Tosetupthepatient chart:\\n1.Select theMainMenuiconontheNavigation Bar.\\n2.Select theImplant button.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 32}), Document(page_content='303.Select thePatient Infobutton toaccessthePatient Viewscreen (Figure 19Patient\\nViewscreen onpage30).\\n4.Thepulsegeneratormodel andserialnumbers appear onthefirstlineofthechart.\\nTheelectro demodel andserialnumbers appear onthesecond lineofthechart.The\\nimplant dateappears onthethirdlineofthechart.Usingtheon-screen keyboar d,\\nenterthefollowing patient information:\\n•Patient Name: upto25characters\\n•Doctor Name: upto25characters\\n•Doctor Info:upto25characters\\n•Notes: upto100characters\\nFigure 19. Patient View screen\\nNOTE:TheNotesfieldwillautomatically wrapthetextwiththepresenc eofaspace\\nbetween anycharacters within thefirstline.\\n5.Select theSavebutton toupdate thepulsegenerat orwiththepatient information.\\nNOTE:Failure tosavethenewpatient information willresultinlossoftheentered\\ndata.\\nAutomatic Setup\\nBefore theS-ICDdevicecanbeactivated, itmustgothrough aninitialAutomatic Setup\\nprocessatthetimeoftheimplant.\\nTheAutomatic Setupprocessisinitiated asfollows:\\n1.Select theMainMenuicon.\\n2.Select theImplant button.\\n3.Select theAutoSetupbutton onthenavigation bar.TheAutomatic Setupscreen\\nappears. Select theAutoSetupbutton onthisscreentoadvanc etothenextscreen.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 33}), Document(page_content='314.Select Continue ifthepatient’s heartrateislessthan130bpm(Figure20Automatic\\nSetupscreenonpage31).Forratesgreaterthan130bpm,selecttheCancel button\\nandreferto\"Manual Setup\" onpage52.\\nFigure 20. Automatic Setup screen\\n5.Oncestarted theAutomatic Setupwill:\\n•Perform theshockelectro deintegrity checktomeasure electrode impedance.\\nNormal sub-threshold impedance rangeis<400Ohms.\\n•Select thebestsensing configur ation.SMART Passwillbeautomatically\\nconfigur edbased ontheamplitude oftheECGsignals intheselected vector.\\nThesenseelectrode configuration isdisplayed attheendoftheAutomatic\\nSetupProcess.Italsoappears ontheprinted reportandcanbeviewed viathe\\nManual Setupprocess.Thestatus ofSMART Pass(On/Off )isdisplayed onthe\\nSMART Settings Programmer screen andSummary Report (formoreinformation\\nonSMART Charge andSMART Pass,see\"SMART Settings\" onpage54).\\n•Select theappropriate gainsetting. Theselected sensegainappears onthe\\nPrinted Report andcanbeviewed viatheManual Setupprocess.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 34}), Document(page_content='32\\nFigure 21. Measuring electr odeimpedance\\nTheoverall progressoftheAutomatic Setupprocessisshown inthestatus bar\\n(Figure 21Measuring electro deimpedanc eonpage32).Wheneachfunction is\\ncomplete, thearrownexttothefunction moves toadownposition.\\n6.TheAutomatic Setupoptimization processwillbeinitiated. TheProgrammer will\\ndisplay amessage requesting thatthepatient situp.IfAutomatic Setupisbeing\\nperformed during implant, orifthepatient isunable tositupforsomeotherreason,\\nthisstepcanbeomitted byselecting theSkipbutton. Ifdesired,Automatic Setupcan\\nberepeated during afollow-up session toinclude theoptimization step.\\n7.Select theContinue button tofinishtheAutomatic Setupprocess.Aconfirmation\\nscreen willappear whenAutomatic Setupiscomplete. Thisscreen displays theresults\\nofeachvector andpostureandtheselected sensing vector.Ifavector andposturedo\\nnotmeettheminimum selection criteria, further information regarding thereason is\\navailable totheuser.SeeFigure 22Automatic SetupResults screen onpage33.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 35}), Document(page_content='33\\nFigure 22. Automatic Setup Results screen\\n8.Following theoptional optimization process,theAcquireReferenc eS-ECG screenis\\ndisplayed. Select theContinue button toacquireareferenceS-ECG.\\nNOTE:WhentheContinue button ispressed, ifaReferenceS-ECG iscurrently\\nstoredinthepulsegenerator,itwillbedeleted andcannot berecovered.\\n9.OncetheReferenceS-ECG acquisition processbegins, astatus screen appears. The\\nprocessmaytakeuptooneminute, during whichthepatient should remain still.\\nDuring thisprocess,atemplate ofthepatient’s baseline QRScomplex isstoredinthe\\npulsegenerat or.Select CancelatanytimetoendReferenceS-ECG acquisition. When\\nacquisition iscomplete, selecttheContinue button.\\nProgramming Therapy Parameters\\nOnceAutomatic Setuphasbeencompleted, thepulsegenerator therapyparameters may\\nbeselected.\\nTosetthetherapyparameters:\\n1.Select theMainMenuiconontheNavigation Bar.\\n2.Select theImplant button.\\n3.Select theSettings button ontheNavigation Bartodisplay theDeviceSettings screen\\n(Figure23Device Settings screenonpage34).', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 36}), Document(page_content='34\\nFigure 23. Device Settings screen\\n4.Select theShocktabtonavigate totheShockSettings tab.\\n5.Select thedesired therapy modeusingtheOn/Off Therapy toggle button.\\n6.Select anddragtheConditional ShockZone(yellow) andShockZone(red)sliderbars\\ntosetthedesiredzoneconfiguration.\\nNOTE:Clinical testing ofthefirstgeneration S-ICDSystem demonstrated a\\nsignificant reduction ininappropriate therapywiththeactivation oftheConditional\\nShockZonepriortohospital discharge.7\\n•TheShockZoneisprogrammable between 170and250bpminstepsof10bpm.\\n•TheConditional ShockZoneisprogrammable between 170and240bpmin\\nstepsof10bpm.Enhanced detection criteria areautomatically enabled when\\ntheConditional ShockZoneisprogrammed.\\n•Whenprogramming boththeShockZoneandConditional ShockZone,maintain\\natleasta10bpmdifferenc ebetween thetwozones.IftheConditional Shock\\nZoneslider(yellow) isdraggedovertheShockZoneslider(red),thetwosliders\\nwillmerge tocreateasingle ShockZone.\\n7.Ifpost-shock pacing isdesired, setthePostShockPacing toggle button totheON\\nposition. (Post-shock bradycar diapacing occurs atanon-progr ammable rateof50\\nbpmforupto30seconds. Pacing isinhibited iftheintrinsic rateisgreaterthan50\\nbpm.)\\n8.Select theProgrambutton toapplythechanges andprogramthepulsegenerator .A\\nmessage confirming thatthepulsegenerator settings weresuccessfully programmed\\nwillappear .Select theContinue button toreturntotheDevice Settings screen.\\n7. WeissR,Knight BP,GoldMR,LeonAR,HerreJM,HoodM,Rashtian M,Kremers M,CrozierI,LeeKl,SmithW,\\nBurkeMC.Safety andefficacy ofatotally subcutaneous implantable-cardioverte rdefibrillator .Circulation.\\n2013;128:944–953.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 37}), Document(page_content='359.Ifthepulsegenerator doesnotaccepttheprogramming, amessage withinstructions\\nwillappear ontheDeviceSettings screen.PresstheContinue button afterfollowing\\ntheinstructions.\\n10.Onceprogramming isconfirmed, selecttheContinue button toproceedtothenext\\noperation .\\nNOTE:ThePending ProgramChanges screenwillappear ifchanges madetopulse\\ngenerat orsettings ontheDevice Settings screen werenotsuccessfully applied tothe\\npulsegenerat or.Select Canceltoreturn totheDevice Settings screen andsaveall\\nsettings changes, orContinue toabandon allpulsegeneratorsetting changes.\\nDefibrillation Testing\\nOncethepulsegenerat orisimplanted andTherapy Modeisprogrammed On,defibrillation\\ntesting maybeconducted. Priortoarrhythmia induction during implant procedure, the\\nfollowing recommendations forarmpositioning areintended toreduce thepotential for\\ninjuryoftheclavicle, armandshoulder intheeventofforcefulmuscle contraction:\\n•Avoidtightstrapping ofthearmtothearmboard andconsider loosening arm\\nrestraints.\\n•Remove anywedge elevation below thetorso,ifusedduring theimplant procedure,\\ntaking caretopreserve thesterile field.\\n•Createasmaller angleofarmabduction fromthetorsobyadducting thearmasclose\\ntothetorsoasfeasible, taking caretopreserve thesterile field.Temporar ilyplacethe\\nhandinaneutralposition whilethearmisinamoreadducted position, reverting to\\nasupinated position ifthearmneeds tobeabducted again.\\nWARNING:\\n!\\nDuring arrhythmia induction withS-ICDpulsegenerator s,theinduction current and\\nsubsequent shockmayresultinforcefulcontraction ofthepectoralis majormuscle\\nwhich canexertsignificant acuteforcesontheglenohumeral jointaswellasonthe\\nclavicle. This,inconjunction withatightly restrainedarm,mayresultininjurytothe\\nclavicle, shoulder ,andarm,including dislocation andfracture.\\nWARNING:\\n!\\nAlways haveexternal defibrillation equipment andmedical personnel skilled inCPR\\navailable during implant andfollow uptesting. Ifnotterminated inatimely fashion,\\naninduced ventricular tachyarrhythmia canresultinthepatient’s death.\\nCAUTION: SuccessfulVForVTconversion during arrhythmia conversion testing is\\nnoassurancethatconversion willoccurpost-operatively .Beaware thatchanges in\\nthepatient’s condition, drugregimen, andotherfactors maychange theDFT,which\\nmayresultinnonconversi onofthearrhythmia post-operatively .Verifywitha\\nconversion testthatthepatient’s tachyarrhythmias canbedetected andterminated\\nbythepulsegenerator system ifthepatient’s status haschanged orparame tershave\\nbeenreprogrammed .\\nNOTE:Defibrillation testing isrecommended atimplant, replacement, and\\nconcomitant deviceimplants toconfirm theability oftheS-ICDSystem tosenseand\\nconvert VF.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 38}), Document(page_content='36NOTE:WhentheHoldtoInduce button ispressed during defibrillation testing, the\\nProgrammer begins capturing theepisode datagenerated during thetest.Thisdata\\nisavailable forviewing andprinting (see\"Capture andViewS-ECG Strips\" onpage48\\nand\"Captured S-ECG Report\" onpage44.)\\nToinduceVFandtesttheS-ICDSystem:\\n1.Select theMainMenuiconontheNavigation BartoaccesstheMainMenu.\\n2.Select theShockTestbutton. Ashocktestselection screenisdisplayed (seeFigure 24\\nShockTestSelection screenonpage36).Select VFInduction tosetuptheVF\\ninduction test.\\nFigure 24. Shock Test Selection screen\\n3.Select eitherstandard (STD)orreverse(REV)polarity .\\n4.Select anddragtheredmarkertosetthedesiredshockenergy forthefirstdeliver ed\\nshock. Theshockenergymaybeprogrammed from10to80J.A15Jsafety margin is\\nrecommended fordefibrillation testing. See(Figure25Setting thedesiredfirstshock\\nenergy fordefibrillation testing onpage37).', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 39}), Document(page_content='37\\nFigure 25. Setting thedesired first shock energyfordefibrillation testing\\n5.Select theContinue button todisplay thenextInduction Testscreenorselectthe\\nCancelbutton toreturn totheMainMenuscreen.\\nNOTE:Ensure thatnoisemarkers (“N”)arenotpresent ontheS-ECG priorto\\ninduction. Thepresenc eofnoisemarkers maydelaydetection andtherapydelivery .\\n6.OntheInduction Testscreen, selectthecheckboxtoenable theHoldtoInduce\\nbutton.\\nFigure 26. Induction Test —Hold toInduce screen\\n7.Select andholdtheHoldToInduce button forthedesired duration.\\nThefollowing functions occurduring thetest:', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 40}), Document(page_content='38•TheS-ICDSystem induces ventricular fibrillation using200mAalternating\\ncurrent (AC)at50Hz.Induction continues untiltheHoldToInduce button is\\nreleased (uptoamaximum of10seconds perattempt).\\nNOTE:Ifnecessary ,theinduction canbeterminated bydisconnecting the\\nwandfromtheProgrammer .\\n•Arrhythmia detection andtheLiveS-ECG aresuspended during induction. Once\\ntheHoldtoInduce button isreleased, theProgrammer displays thepatient’s\\nrhythm.\\n•Upondetection andconfirmation ofaninduced arrhythmia, theS-ICDSystem\\nautomatically delivers ashockattheprogrammed energy output andpolarity .\\nNOTE:Wheninactivecommunication withapulsegenerat or,theProgrammer\\nemitsanaudible notification toindicate thatthepulsegenerator isprepar ingto\\ndeliver ashock, whether thatshockiscommanded orisinresponse toa\\ndetected arrhythmia. Thenotification continues untiltheshockiseither\\ndelivered oraborted.\\n•Iftheshockfailstoconvert thearrhythmia, re-detection occursandsubsequent\\nshocks aredelivered atthepulsegenerat or’smaximum energy output (80J).\\nNOTE:Evaluate thesensing markers during theinduced rhythm thatfollows\\ntherelease oftheHoldToInduce button. TheS-ICDSystem usesalengthened\\nrhythm detection period. Consistent tachy“T”markers indicate that\\ntachyarrhythmia detection isoccurring, andthatcapacitor charging isimminent.\\nIfahighdegree ofamplitude variation isnoted during thearrhythmia, aslight\\ndelaymaybeexpectedpriortocapacitor chargingorshockdelivery .\\nNOTE:Thepulsegenerat orcandeliver amaximum offiveshocks perepisode.\\nAn80Jrescueshockcanbedeliver edatanytimepriortotherapy delivery by\\npressing theRescue ShockiconortheredSTATbutton ontheProgrammer .\\n•TheProgrammer willstartcapturing S-ECG datawhentheHoldtoInduce button\\nispressed. TheCaptured S-ECG willcoverthetimeperiod sixsecondsbefore the\\nbutton ispressed andupto102secondsafterwards, foramaximum totalof108\\nseconds. TheInduction S-ECGs willbeviewable andprintable fromtheCaptured\\nS-ECG screen,labeled as“Induction S-ECG”.\\n8.Atanytimepriortotherapy delivery ,theprogrammed energy maybeaborted by\\nselecting theredABORT button.\\n9.Select theExitbutton toreturn totheMainMenuscreen.\\nPerforming aFollow-up\\nForacomplete guideonclinical follow-up, seethesection onpostimplant follow-up\\nproceduresintheS-ICDpulsegeneratoruser’s manual.\\nSensing Configuration andAutomatic Setup\\nItisnotnecessary toperform Automatic Setupateachfollow-up. IfSensing Optimization\\nwasskipped during theoriginal implant setup, itmaybeperformed during afollow-up.\\nSensing should bere-evaluated ifAutomatic Setupisperformed andresults inavector\\nchange oriftheS-ECG signal quality indicates anyprogressive orsudden changes in\\nsensing amplitude ormorphology sinceimplant orlastfollow-up examwhichcouldimpact', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 41}), Document(page_content='39thedevice’sperformanc e.Afterthesetupprocessiscomplete, evaluate thestreaming S-\\nECGduring apectoral exercise.Sensing performance whilebending atthewaistorduring\\nhigh-rateexercisescanalsobeevaluated. Acceptable sensing willyield“S”markers\\nsynchronous toallQRScomplexes. Ifothermarkers arenoted, usetheManual Setup\\nprocesstoevaluate othersensing configurations.\\nWARNING:\\n!\\nTheS-ICDSystem maysensemyopotentials which mayresultinover/under sensing.\\nWARNING:\\n!\\nFollowing anysensing parameter adjustment oranymodification ofthesubcutaneous\\nelectro de,always verifyappropriatesensing.\\nNOTE:IfManual Setupwaspreviously usedtooverride asensing configuration, careful\\nconsideration should betakenwhenselecting Automatic Setup.\\nIfanupdate tothereferenceS-ECG isdesiredduetoachange inthepatient’s restingECG,\\nfollow theAcquireReferenc eS-ECG instructions.\\nViewing Pulse Generator Status\\nOncecommunication isestablished, theProgrammer displays theDevice Status screen\\nwhichcontains information regardingthecurrentepisodes andbatterystatus ofthepulse\\ngenerator.\\nTonavigate tothisscreen fromanother location:\\n1.Select theMainMenuicon.\\n2.Select theFollow Upbutton.\\n3.TheDevice Status screen willappear showing anoverviewofallpulsegenerator\\nactivity sincethelastcommunic ationsession (Figure27Device Status screenonpage\\n40).', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 42}), Document(page_content='40\\nFigure 27. Device Status screen\\nTheDevice Status overview reports:\\n•Dateofthelastfollow-up session\\n•Totalnumber ofshocks deliver edsincethelastfollow-up session\\n•Remaining pulsegenerat orbattery life\\n•Mostrecentsub-thr eshold system impedance\\n•Beeper status andTestbutton. Thisfieldisdisplayed following anMRIscanorafter\\nexitingMRIProtection Mode.\\n•Totalnumber ofepisodes sincethelastfollow-up session. Thistotalincludes treated\\nepisodes, untreatedepisodes, AFepisodes, anduptooneSMART Passdisable\\nepisode (only1ispossible sincelastfollow-up).\\nNOTE:Choosing the“View” button intheEpisodes rowallows navigation directly to\\nthelistofstoredepisodes (Figure 28Episodes screen (scrollable list)onpage41\\n•Totalnumber oftreatedepisodes sincethelastfollow-up session\\n•Totalnumber ofuntreatedepisodes sincethelastfollow-up session\\n•Whether ornotstoredAFepisodes sincethelastfollow-up session areavailable for\\nreview(Model A219only)\\nViewing Stored Episodes\\nThepulsegenerator stores episodes, whichcanbeviewed during apatient’s follow-up\\nsession. EMBLEM S-ICD(Model A209) andCameron Health (Model 1010)pulsegenerators\\nstoreupto25treated and20untreated tachycar diaepisodes. EMBLEM MRIS-ICD(Model\\nA219)pulsegenerators storeS-ECGs forupto20treatedand15untreated tachycardia\\nepisodes, aswellasupto7AFepisodes. Inthepulsegenerator ,SMART Passdisable\\nepisodes usethesamestorage spaceasuntreatedepisodes. Whenthemaximum number\\nofepisodes isreached, themostrecentepisode replacestheoldest stored episode ofthe\\nsametype.Thefirsttreated episode isneveroverwr itten.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 43}), Document(page_content='41NOTE:Spontaneous episodes thatoccurwhilethepulsegenerator iscommunicating\\nwiththeProgrammer willnotbestored.\\nToviewstored episodes:\\n1.Select theMainMenuicon.\\n2.Select theFollow Upbutton.\\n3.Select theEvents button fromtheNavigation Bar.\\n4.Select theEpisodes tabtoaccesstheEpisodes screen (Figure28Episodes screen\\n(scrollable list)onpage41).\\n5.Select anepisode fromthelist.Theselected episode willbedownloaded fromthe\\npulsegenerat oranddisplayed.\\nNOTE:Tobeavailable forprinting, allepisodes exceptSMART Passdisable\\nepisodes mustfirstbeindividually selected andviewed fromtheEpisodes screen.\\nFigure 28. Episodes screen (scrollable list)\\n6.Thedisplay screen foreachselected episode alsodisplays theprogrammed\\nparamet ersandthestored S-ECG dataatthetimeofepisode declaratio n.\\n7.Select theContinue button onthedisplay screen fortheselected episode toreturnto\\ntheEpisodes screen.\\nThefollowing details areavailable foreachepisode:\\nTreated Episodes\\nUpto128seconds ofS-ECG dataisstored foreachTreatedEpisode:\\n• Pre-episode S-ECG: Upto44seconds\\n• First shock: Upto24seconds ofpre-shockS-ECG andupto12seconds ofpost-shock\\nS-ECG\\n• Subsequent shocks: 6secondsofpre-shock and6secondspost-shock S-ECG\\nUntreated Episodes', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 44}), Document(page_content='42AnUntreated Episode isdefined asanyhigh-rat eepisode thatspontaneously terminates\\nduring thechargingprocess,before ashockisdeliver ed.\\nUpto128seconds ofS-ECG dataisstored foreachUntreatedEpisode:\\n• Pre-episode S-ECG: 44secondsofpre-episode S-ECG\\n• Episode S-ECG: Upto84seconds oftachycardia S-ECG data\\n• AFepisode S-ECG: EMBLEM MRIS-ICD(Model A219)withAFMonitor stores upto\\noneAFepisode foreachdayinwhichanatrialarrhythmia isdetected. 44secondsof\\nS-ECG dataisstored foreachAFEpisode.\\n• SMART Pass disable episode S-ECG: ForEMBLEM pulsegenerat ors,SMART Pass\\nDisabled Episodes arestored whenSMART Passisautomatically disabled bythe\\ndeviceduetosuspected under-sensing. 44seconds ofS-ECG dataisstored foreach\\nSMART PassDisabled Episode:\\n– Pre-disable S-ECG: 20seconds ofS-ECG priortoSMART Passdisable.\\n– Post-disable S-ECG: 24secondsofS-ECG afterSMART Passdisable.\\nPrinting Repor tsfromtheS-ICD Application\\nPrinting Report s\\nPatient reports canbeprinted before orafterapatient session isended. Itis\\nrecommended thatafinalreportbeprinted immediately following theimplant procedure.\\nTherearethreepatient reports:\\n•Summary Report\\n•Captured S-ECG Report\\n•Episode Reports\\nToprintpatient reports fromeitheranOnline orOffline session:\\n1.Select theS-ICDMainMenuicontodisplay theMainMenuscreen.\\n2.Select thePrintReports button todisplay thePrintReports screen (Figure29Print\\nReports screen onpage43).', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 45}), Document(page_content='43\\nFigure 29. Print Reports screen\\n3.Select thedesired report type.Acheckmark willappear nexttotheselected report.\\nReport typesaredescribed below.\\nSelect thePrintbutton toprinttheselected report.\\n4.Select theCancel button toreturntothepreviously accessed screen.\\nSummary Report\\nToprintasummar yreport, selecttheSummary Report option onthePrintReports screen\\nandpressthePrintbutton. Thereport willprintforeitherthecurrentactivesession (ifthe\\nProgrammer isOnline) orforthechosen stored session (iftheProgrammer isOffline.)\\nTheSummary Report includes thefollowing information:\\n•Printed Report Date\\n•Programmer Software Version\\n•Pulsegenerator Softwar eVersion\\n•Patient Name\\n•DateofLastFollow-Up\\n•DateofCurrent Follow-Up\\n•Implant Date\\n•Pulsegenerator Model/Serial Number\\n•ElectrodeModel/Serial Number\\n•Therapy Paramete rs\\n•SMART Charge Delay\\n•SMART Passstatus (On/Off )[Models A209andA219only]\\n•Programmed GainSettings andSensing Configuration\\n•Pulsegenerator Integrity Check, ifapplicable', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 46}), Document(page_content='44•InitialShockPolarity Configuration\\n•Dayswithmeasured AF[Model A219only]\\n•Estimate ofmeasure dAF[Model A219only]\\n•Beeper Status (ifdisabled)\\n•MRIInformation\\n•Episode Summary: SinceLastFollow-Up andSinceInitialImplant\\n•Pulsegenerator Battery Status\\n•ElectrodeImpedance Measur ement\\n•System alerts, ifapplicable\\nCaptured S-ECG Report\\nToprintaCaptured S-ECG Report:\\n1.Select theCaptured S-ECG Reports option fromthePrintReports screen.\\n2.Ascrollable listcontaini ngbothCaptured S-ECG andInduction S-ECG stripsis\\ndisplayed (Figure30Captured S-ECG list(scrollable) onpage44).Select thedesired S-\\nECG(s) tobeprinted byplacing acheckmark nexttotheselection(s). Thecheckbox at\\nthetopoftheselection column canbeusedtoselectordeselect allS-ECGs.\\n1\\n[1]Select/deselect allcheckbox\\nFigure 30. Captured S-ECG list(scrollable)\\n3.Select Continue toreturntothePrintReports screen.\\n4.Select thePrintbutton toprinttheselected report andreturntothepreviously\\naccessedscreen.\\n5.Select theCancel button toreturntothepreviouslyaccessedscreen without printing\\nthereport.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 47}), Document(page_content='45Episode Report s\\nToprintanEpisode Report:\\n1.Select theEpisode Reports option onthePrintReports screen.\\n2.TheSelect Episode Reports screen appears showing alistofthestored episodes\\n(Figure31Select Episode Reports screen (scrollable) onpage45).Select theepisode(s)\\ntobeprinted. Acheckmark appears nexttotheselected episode(s). Thecheckbox at\\nthetopoftheselection column canbeusedtoselectordeselect allepisodes.\\nNOTE:Inordertobeavailable forprinting, episodes musthavebeenindividually\\nselected andviewed fromtheEpisodes Screen (Figure 28Episodes screen (scrollable\\nlist)onpage41.\\n1\\n[1]Select/deselect allcheckbox\\nFigure 31. Select Episode Reports screen (scrollable)\\n3.Select Continue toreturntothePrintReports screen. Either12seconds or44seconds\\nofpre-episode S-ECG datamaybeselected usingtheradiobuttons below the\\nEpisode Reports row.Thedefault valueforEpisode Report Onset is12seconds.\\n4.Select thePrintbutton toprinttheselected report andreturntothepreviously\\naccessed screen.\\n5.Select theCancel button toreturntothepreviously accessed screen without printing\\nthereport.\\nExport Patient Data\\nPatient datasavedintheS-ICDapplication maybeexportedtoadesktop orlaptop\\ncomputer usingapre-configured Bluetooth®pairing. Forinformation aboutBluetooth®\\npairing between theS-ICDapplication andadesktop orlaptop computer ,see\"Bluetooth®\\nDataExport\" onpage20.\\nBefore configuri ngBluetooth®capable printers andcomputers, Bluetooth®connectivity\\nmustbeturned onusingtheUtilities function oftheProgrammer .RefertotheLATITUDE', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 48}), Document(page_content='46Programming System, Network andConnectivity Operator’s Manual (Model 3924)for\\ncomplete instructions.\\nEnsure thattheProgrammer andtheintended recipient computer arewithin 10meters (33\\nfeet)ofeachotherbefore attempting aBluetooth®wireless datatransfer .\\n1.Select theExport Programmer Databutton ontheS-ICDapplication start-upscreen.\\nTheExport Programmer DataOverBluetooth®screenwillappear .\\n2.Select oneofthethreeexport options (Export Today’s Data,Export LastSeven Days,\\nExport All).The“Select areceiving computer” pop-up window willappear .\\nNOTE:TheExport Today’s DataandExport LastSeven Daysoptions typically take\\nlesstimetocomplete thantheExport Alloption.\\n3.Thepop-up contains ascrollable listofallcomputers paired totheProgrammer .\\nSelect theintended receiving computer fromthelisttobeginthetransfer.\\nNOTE:Although everypairedcomputer islistedinthescrollablebox,onlythose\\nwithin 10meters (33feet)oftheProgrammer canparticipate inafiletransfer.Once\\noneofthethreeexport options hasbeenselected, theS-ICDapplication prepar esthe\\nfiletransfer package andattempts thewirelesstransfer .Anerrormessage appears if\\nthetransfer cannot becompleted. Should thisoccur,movetheProgrammer towithin\\n10meters oftheintended receiving computer orchoose another computer within\\nthatdistanc e.Restart theexport processbyselecting oneofthethreeexportoptions\\nontheExport Programmer DataOverBluetooth screen.\\nS-ECG Features\\nTheProgrammer provides thecapability toview,adjust, andcapture thestreaming S-ECG\\nfromthepulsegenerator .\\nS-ECG Rhythm Strip Markers, Indicators, andDiscontinuities\\nThesystem provides annotations toidentify specific events ontheS-ECG. These markers,\\nindicators, anddiscontinui tiesaredescribed inthefollowing tables:\\nTable 2.S-ECG Marker sonProgrammer Display Screens andPrinted Reports\\nDescription Marker\\nCharginga C\\nATP(clinical devices only) A\\nSensed Beat S\\nNoisyBeat N\\nPaced Beat P\\nTachyDetection T', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 49}), Document(page_content='47Table 2.S-ECG Marke rsonProgrammer Display Screens andPrinted Reports (continued)\\nDescription Marker\\nDiscard Beat •\\nReturn toNSRa\\na.Marker ispresent onprinted report butnotontheProgrammer display screen.\\nTable 3.S-ECG Indicators andDiscontinuities onProgrammer Display Screens andPrinted\\nReports\\nDescription Indicator /Discontinuity\\nATPdiscontinuity (clinical devices only)\\nShockdiscontinuity\\nEpisode datacompressed ornotavailable\\n(display only)\\nS-ECG Scale Settings\\nToadjust thereal-time S-ECG amplitude anddisplay speed scalesettings:\\n1.Select theDetails (magnifying glass)iconlocated totherightoftheLiveS-ECG\\nwindow .TheS-ECG Display Settings screenisdisplayed.\\n2.Select anddragtheGainorSweep Speed Scalebarsasdesired(Figure32Adjusting\\nGainandSweep Speed onpage48).TheS-ECG scalewillchange accordingtothe\\nselected setting. Thegainsetting controls thevisualgain.TheProgrammer defaults\\ntoFullRange forpulsegenerators withagainsetting of1xandto1/2Range for\\npulsegenerat orswithagainsetting of2x.TheSweep Speed slidercontrolsthe\\ndisplay speed ofthescrolling LiveS-ECG. Thenominal sweep speed setting is25\\nmm/sec.\\nNOTE:Amplitude settings anddisplay speed adjustments onscrolling real-time S-\\nECGandCaptured S-ECGs affectthedisplay screen settings onlyandhavenoimpact\\nonthepulsegenerat orsettings forsensing.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 50}), Document(page_content='48\\nFigure 32. Adjusting Gain andSweep Speed\\nCapture andView S-ECG Strips\\nTheProgrammer candisplay andstorereal-time S-ECG rhythm strips. TheProgrammer\\nsavesamaximum of50recordingsgeneratedby:\\n1.Manually-captured twelve-sec ondS-ECGs usingtheCapture S-ECG button which\\ninclude:\\n•8.5secondsbefore activation oftheCapture S-ECG button\\n•3.5seconds afteractivation oftheCapture S-ECG button\\n2.S-ECGs captured automatically during induction testing whichinclude:\\n•6secondsbefore theinduce button ispressed\\n•upto102secondsaftertheinduce button ispressed\\nNOTE:TheS-ICDsuspends detection ofsensed events for1.6seconds afterashockhas\\nbeendelivered. Asaresult,theS-ECG rhythm stripwillnotcontain eventmarkersduring\\nthis1.6secondpost-shock interval.\\nIfanadditional recordingisrequired, thentheoldest previous recording isreplaced with\\nthenewrecording.\\nManually Capture New S-ECG Rhythm Strips\\nTomanually capture anewS-ECG rhythm strip:\\n1.Select theCapture S-ECG button located totheleftoftheLiveS-ECG window .TheS-\\nECGwillscrollacross thedisplay screen. Calipers appear below theCapture dS-ECG\\nrhythm strip.Each12-second recordingisdateandtimestamped accordingtothe\\nProgrammer’s dateandtimesetting.\\nNOTE:Induction S-ECGs areautomatically generatedduring induction testing\\nwithout additional userinput.\\n2.Select andmovethecalipers across theS-ECG striptomeasure intervalsasdesired.\\n3.Select theContinue button toreturntothepreviously accessed screen.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 51}), Document(page_content='49Itisalsopossible tocapture S-ECGs corresponding toallthreesensevectors (Primary,\\nSecondary, andAlternate) byusingtheCapture AllSense Vectors button ontheUtilities\\nscreen(Figure33Utilities screen onpage50).\\nView previously-captured S-ECGs\\nWhentheProgrammer isonline:\\n1.Select theMainMenuicon.\\n2.Select theFollow Upbutton.\\n3.Select theEvents button. TheCaptured S-ECG screen appears.\\n4.Select oneCaptured S-ECG orInduction S-ECG fromthelist.TheS-ECG details screen\\nappears.\\n5.Select anddragthecalipers toviewdetails.\\n6.Select theContinue button toreturn totheCaptured S-ECG listscreen.\\nWhentheProgrammer isoffline:\\n1.Select theStored Patient Sessions button fromeithertheProgrammer start-upscreen\\northeMainMenu.\\n2.Select thedesired stored patient session.\\n3.Select oneCaptured S-ECG fromthelist.TheCaptured S-ECG Details screen appears.\\nNOTE:Notallstored patient sessions contain captured S-ECGs. Amessage tothat\\neffectispresente dwhensuchpatient sessions areopened. Inthiseventselectthe\\nMainMenuicon,thenselecttheEndSession button. Thisaction returnsyoutothe\\nProgrammer start-upscreen.\\n4.Select anddragthecalipers toviewdetails.\\n5.Select theContinue button toreturn totheCaptured S-ECG listscreen.\\nUtilities Screen\\nTheS-ICDapplication Utilities screen provides accesstoadditional devicefeatures. These\\nmayinclude AcquireReferenc eS-ECG, Capture AllSense Vectors, Beeper Control,Manual\\nSetup, SMART Settings, andAFMonitor .\\nToaccesstheUtilities screenduring anOnline session:\\n1.Select theMainMenuicontodisplay theMainMenuscreen.\\n2.Select theUtilities button. TheUtilities screen appears asillustrated inthefollowing\\nfigure.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 52}), Document(page_content='50\\nTheAFMonitor button ismodel-dependent. TheUtilities screen connected toaModel A219pulsegenerator shows\\ntheAFMonitor button; theUtilities screen connectedtoaModel A209pulsegenerator doesnot.\\nFigure 33. Utilities screen\\nAcquire Reference S-ECG\\nToacquireamanual Referenc eS-ECG:\\n1.FromtheUtilities screen (accessible fromtheMainMenuscreen), selecttheAcquire\\nReferenceS-ECG button toaccesstheAcquireReferenc eS-ECG screen.\\n2.Select Continue toacquireaReferenceS-ECG. TheS-ICDapplication willbegin\\nacquiringtheReferenc eS-ECG. Amessage willappear requesting thatthepatient\\nremainstill.ThereferenceS-ECG QRStemplate isrecordedandstoredinthepulse\\ngenerat or\\nNOTE:WhentheContinue button ispressed, ifaReferenceS-ECG iscurrently\\nstored inthepulsegenerat or,itwillbedeleted andcannot berecovered.\\n3.Select theContinue button tocomplete theprocessandreturntotheUtilities screen.\\nTheCancelbutton canbeusedatanytimetoendS-ECG acquisition andreturntothe\\nUtilities screen.\\nCapture AllSense Vectors\\nTheCapture AllSense Vectors button ontheUtilities screenconfigures temporary settings\\nthatallowyoutocapture S-ECGs generated fromeachofthethreesensevectors (Primar y,\\nSecondary, andAlternate). Thisprocesstakesapproximately oneminute. Theoriginal\\nsettings configuration isreturned afterallS-ECGs havebeencaptured.\\nTocapture thethreesensevectors:\\n1.FromtheUtilities screen (accessible fromtheMainMenuscreen), selecttheCapture\\nAllSense Vectors button.\\n2.TheCapturing 12SecondS-ECG screen willappear anddisplay thestatus ofthesense\\nvector capture process.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 53}), Document(page_content='51Oncecaptured, thethreeS-ECGs canbeviewed byfollowing thestepsoutlined in\"View\\npreviously-captured S-ECGs\" onpage49.\\nBeeper Contr ol\\nThepulsegenerator hasaninternal warning system (Beeper) thatmayemitanaudible\\ntonetoalertthepatient tocertaindevice conditions thatrequireprompt consultatio nwith\\nthephysician. These conditions mayinclude:\\n•Electrodeimpedance outofrange\\n•Prolonged chargetimes\\n•Failed DeviceIntegrity Check\\n•Irregularbattery depletion\\nThisinternal warning system isautomatically activated attimeofimplant. Oncetrigger ed,\\niftheBeeper isenabled, tonesbeepfor16seconds everyninehoursuntilthetrigger\\ncondition hasbeenresolved. Ifthetriggering condition reoccurs, thenthetoneswillonce\\nagainalertthepatient toconsult thephysician.\\nCAUTION: Patients should beadvised tocontact theirphysician immediately whenever\\ntheyheartonescoming fromtheirS-ICDdevice.\\nNOTE:AccesstotheResetBeeper display screen isenabled onlywhenanalertcondition\\noccurs.Ifanalertcondition isactivated, anotification screen willappear uponconnection.\\nWARNING:\\n!\\nTheS-ICDpulsegenerator Beeper maynolonger beusable following anMRIscan.\\nExposur etothestrong magnetic fieldofanMRIscanner maycauseapermanent lossof\\ntheBeeper volume. Thiscannot berecovered, evenafterleaving theMRscanenvironment\\nandexiting MRIProtection Mode. Before anMRIprocedureisperformed, aphysician and\\npatient should weigh thebenefit oftheMRprocedureagainst theriskoflosing the\\nBeeper .Itisstrongly recommended thatpatients arefollowed onLATITUDE™ NXT(a\\nremote patient management system) afteranMRIscaniftheyarenotalready .Otherwise,\\nanin-clinic follow-up schedule ofeverythreemonths isstrongly recommended tomonitor\\ndevice performance.\\nReset Beeper\\nToresettheBeeper ,selecttheBeeper Control button fromtheUtilities screen (accessible\\nfromtheMainMenu) toopentheSetBeeper Function screen.\\nSelect theResetBeeper button tosuspend audible beeping tonestriggered byanalert\\ncondition. Ifthealertcondition isnotcorrected, theaudible beeping toneswillbe\\nreactivated during thenextautomatic S-ICDSystem self-check.\\nDisable Beeper (SQ-Rx devices)\\nInSQ-Rx devices,Beeper Control allows forthedeactivation ofbeeping onalertconditions\\n(Disable Beeper). Perform thefollowing stepstodisable theBeeper:\\nNOTE:TheDisable Beeper function isonlyavailable oncedeviceERIorEOLisreached.\\n1.FromtheUtilities screen, selectBeeper Control toopentheSetBeeper Function\\nscreen.\\n2.Select Disable Beeper todisable theBeeper forthedevice.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 54}), Document(page_content='52NOTE:Thiswillpermanently disable allbeeping onalertconditions fortheSQ-Rx device.\\nHowever ,thiswillnotaffectBeeper functionality forwhenamagnet isplaced onthe\\ndeviceorwhentheS-ICDDevice Programmer Application connects tothedevice.\\nEnable/Disable Beeper (EMBLEM S-ICD device s)\\nInEMBLEM S-ICDdevices, theBeeper mustbetested before beingenabled ordisabled.\\nPerform thefollowing stepstotesttheBeeper:\\nNOTE:ForEMBLEM S-ICDdevices,theTestBeeper function isavailable onlywhen\\nbeeping foranalertcondition isnotactive.\\n1.FromtheUtilities screen, selectBeeper Control.\\n2.Select theTestBeeper button fromtheSetBeeper Function screen.\\n3.Evaluate iftheBeeper isaudible usingastethosc ope.\\n4.IftheBeeper isaudible, selecttheYes,Enable Beeper button. IftheBeeper isnot\\naudible oryouwishtopermanently disable beeping functionality ,selecttheNo,\\nDisable Beeper button.\\nCAUTION: IntheProgrammer stepstoprogramandtesttheBeeper ,selecting No,\\nDisable Beeper willdisable beeping functionality foralertconditions, whenamagnet is\\nplaced overthedevice,andwhentheS-ICDapplication connects tothedevice.\\nIftheBeeper isnotaudible tothepatient, itisstrongly recommended thatthepatient has\\nafollow-up schedule ofatleasteverythreemonths eitheronLATITUDE NXTorin-clinic to\\nmonitor device performance.\\nForadditional information regarding theBeeper ,refertotheS-ICDMRITechnical Guide or\\ncontact Boston Scientific usingtheinformation onthebackcover.\\nManual Setup\\nManual Setupenables theusertoperform thesystem impedance testandselectthe\\nelectro desensing configuration andgainsetting inthepulsegenerator .During Manual\\nSetup, thesystem willalsoautomatically enable SMART Passifappropr iate.\\n1.FromtheUtilities screen (accessible fromtheMainMenuscreen), selecttheManual\\nSetupbutton. TheMeasur eImpedance screen appears.\\n2.Select theTestbutton toperform thesystem impedance test.Thesystem impedanc e\\ntestresultsscreen isdisplayed.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 55}), Document(page_content='53\\nFigure 34. Manual Setup: System Impedance Test results screen\\n3.Select theContinue button.\\n4.Therearethreeavailable sensing vectors thatcanbemanually selected fromthe\\nManual Setupscreen (Figure35Manual Setupscreen withsensing vector andgain\\noptions onpage54).\\n• Primary :Sensing fromtheproximalelectrode ringonthesubcutaneous\\nelectrode tothesurface oftheactivepulsegenerator\\n• Secondary: Sensing fromthedistalsensing electrode ringonthesubcutaneous\\nelectrode tothesurface oftheactivepulsegenerator\\n• Alternate: Sensing fromthedistalsensing electrode ringtotheproximal\\nsensing electro deringonthesubcutaneous electro de\\nThegainsetting adjusts thesensed S-ECG signal sensitivity .Itmaybemanually selected\\nwiththeSelect Gainswitch ontheManual Setupscreen.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 56}), Document(page_content='54\\nFigure 35. Manual Setup screen with sensing vector andgain options\\n•1xGain(±4mV):1xGainshould beselected whenthesignal amplitude islarge\\nenough tocauseclipping whenthe2xgainisselected.\\n•2xGain(±2mV):2xGainshould beselected whenthesignal amplitude issmall\\nenough toallowuseofamoresensitive setting without causing clipping ofthe\\ncaptured signal. The2xgainselection amplifies thesignal twiceasmuchasthe1x\\ngainselection.\\nNOTE:Thegainsetting mayaffectcertification phase performanc e.Specifically ,using2x\\ngainmayimproveidentification ofnoise.\\nToprogramthemanually selected senseconfigur ation:\\n1.Select theProgrambutton tosavethesensevector andgainsettings.\\n2.Select theContinue button. Whenthecontinue button isselected, thedevicewill\\nautomatically evaluate ifSMART Passshould beenabled. RefertotheS-ICDUser’s\\nManual foradditional information aboutSMART Pass.Forassistance, contact Boston\\nScientific usingtheinformation onthebackcover.\\n3.TheAcquireReferenceS-ECG processisautomatically enabled during theManual\\nSetupProcess.Select theContinue button toacquireareferenceS-ECG. A\\nconfirmation screen willappear whenthecaptured referenceS-ECG isacquired.\\nSMART Settings\\nTheSMART Settings screen allows theusertoaccessinformation andfunctions forthe\\nSMART Charge andSMART Passfeatures.\\nSMART Charge\\nThroug htheSMART Charge feature, thepulsegenerator charge initiation sequence adapts\\ntotheoccurrenceofnon-sustained ventricular arrhythmia episodes bydelaying capacitor\\ncharging.Thisconservesbattery lifeandmayprevent unnecessary shocks fornon-\\nsustained arrhythmias. Forfurther information abouttheSMART Charge feature, referto\\ntheEMBLEM™ S-ICD, EMBLEM™ MRIS-ICDUser’s Manual available online atwww.\\nbostonscientific -elabeling.com.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 57}), Document(page_content='55TheSMART Charge delayisextended automatically whenanuntreatedventricular\\narrhythmia episode isrecorded. TheSMART Charge starting valuecanbeconfigur ed.To\\nconfigure theSMART Charge starting value:\\n1.FromtheDevice Settings screen, selecttheSMART tabtonavigate totheSMART\\nSettings tab.TheSMART Settings screenappears. SeeFigure 36SMART Settings\\nscreen onpage55.\\nFigure 36. SMART Settings screen\\n2.Select theConfigure button toselecttheSMART Charge starting value. SeeFigure 37\\nSMART Charge Configuration screen onpage55.\\nFigure 37. SMART ChargeConfiguration screen\\n3.Aconfirmation window willappear withthemessage: “SMART Charge successfully\\nset.”', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 58}), Document(page_content='564.PresstheContinue button toreturn totheSMART Settings screen.\\nDisabling SMART Pass\\nTheSMART Passfeature isdesigned toreduce oversensing whilestillmaintaining an\\nappropriate sensing margin. Thedevicecontinuously monitors theECGsignal amplitude\\nandautomatically disables SMART Passifunder-sensing issuspected.\\nNOTE:IfSMART Passisdisabled, another automatic ormanual setupmustbeperformed\\ntore-enable thefeature.\\nAFMonitor\\nTheAFMonitor feature isdesigned toassistinthediagnosis ofatrialfibrillation.\\nToenable ordisable theAFMonitor feature, usetheOn/Off toggle button ontheDevice\\nSettings screen’sAFMonitor tab.\\nNOTE:Printdesiredreportsand/or savesession data(viaEndSession) priorto\\nprogramming AFMonitor Off.WhenAFMonitor isprogrammed Off,currentlystoredAF\\nMonitor statistics arecleared andcannolonger beprinted orsaved.\\nSelect theProgrambutton toapplythechanges andprogramthepulsegenerator .\\nThefollowing statistics areavailable ontheAFMonitor screenbyselecting theAFMonitor\\nbutton:\\n•Dayswithmeasured AF:Provides thenumber ofdayswithin thelast90whereAF\\nwasdetected\\n•Estimate ofmeasure dAF:Providesthetotalpercentofdetected AFwithin thelast90\\ndays\\nForfurther information aboutAFMonitor, refertotheEMBLEM™ S-ICD, EMBLEM™ MRIS-\\nICDUser’s Manual available online atwww.bostonscientific -elabeling.com.\\nAdditional S-ICD Application Features\\nRescue Shock\\nTheRescue Shockiconisavailable inthenavigation barontheS-ICDapplication display\\nwhentheSetupProcessiscomplete, andapulsegeneratorisactively communicating with\\ntheS-ICDapplication. During activecommunication, amaximum (80J)rescue shockcanbe\\ndeliver eduponcommand.\\nTodeliver arescue shock:\\n1.Select eithertheredRescue ShockIconatthetopoftheprogrammer screenorthe\\nredSTATbutton\\n ontheProgrammer .TheRescue Shockscreen appears\\n(Figure38Rescue Shockscreenonpage57).', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 59}), Document(page_content='57\\nFigure 38. Rescue Shock screen\\n2.Select theShockbutton tobegincharging thepulsegeneratorforarescueshock. A\\nredbackground screen withtheword“Charging” willappear andasirentonewillbe\\nheardfromtheProgrammer .Selecting theAbortbutton willprevent delivery ofa\\nrescueshockandwillreturntotheDeviceSettings screen.\\n3.Aconfirmation screenwillappear withnotification thattheshockwasdelivered\\nsuccessfully alongwiththecorresponding shockimpedanc e.\\nWARNING:\\n!\\nAlways haveexternal defibrillation equipment andmedical personnel skilled inCPR\\navailable during implant andfollow uptesting. Ifnotterminated inatimely fashion, an\\ninduced ventricular tachyarrhythmia canresultinthepatient’s death.\\nWARNING:\\n!\\nHighshocking electrodeimpedance mayreduce VT/VF conversion success.\\nCAUTION: Areported shockimpedance valueofgreater than110ohmsfromadeliver ed\\nshockcouldindicate sub-optimal system placement .Careshould betakentoplaceboth\\nthepulsegenerat orandelectro dedirectlyonthefasciawithout underlying adipose tissue.\\nAdipose tissuecanaddsignificant impedanc etothehighvoltage shockcurrentpathway .\\nCAUTION: Areported shockimpedance valueoflessthan25ohmsfromadeliver ed\\nshockcouldindicate aproblem withthedevice. Thedelivered shockmayhavebeen\\ncompromised, and/or anyfuturetherapy fromthedevicemaybecompromised. Ifa\\nreported impedance valueoflessthan25ohmsisobserved, correctfunctioning ofthe\\ndeviceshould beverified.\\nIfforanyreason theshockcouldnotbedeliver ed,aredbackground screen willappear\\nwithamessage stating, “Theshockcouldnotbedeliver ed.”', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 60}), Document(page_content='58NOTE:Intheeventtelemetry islost,pulsegenerator commands— including Rescue\\nShocks— willnotbeavailable untiltelemetry isreestablished.\\nManual Shock\\nManual Shockallows theusertodeliver asynchroniz edshockduring asinusrhythm, an\\natrialrhythm, oraventricular rhythm. Theshockenergy levelisuser-configur edinthe10\\nto80joulerangeandthepolarity isalsouser-configur ed(Figure39Manual Shockonpage\\n58).Manual shockmayalsobeutilized atalowenergytoassess system impedanc e/\\nintegrity eitheratimplant oraswarrante dbypatient condition. Amanual shockmaybe\\nadminister edwiththeTherapyModesettoOnorOff.\\nToaccessManual Shock, selecttheShockTestbutton onthemainmenu. TheShockTest\\nSelection screenwillappear .Select theManual Shockbutton toviewtheManual Shock\\nTestscreen.\\nFigure 39. Manual Shock\\nWARNING:\\n!\\nAlways haveexternal defibrillation equipment andmedical personnel skilled inCPR\\navailable during implant andfollow uptesting. Ifnotterminated inatimely fashion, an\\ninduced ventricular tachyarrhythmia canresultinthepatient’s death.\\nS-ICD System Magnet Use\\nABoston Scientific magnet orCameron Health magnet greaterthan60gaussisanon-\\nsterile accessory thatmaybeusedtotemporarily inhibit thedelivery oftherapy fromthe\\npulsegenerat or.\\nFordetailed information aboutusingthemagnet, refertotheappropriate S-ICDUser’s\\nManual.\\nBehaviors ofmagnet application include:\\n•Suspend arrhythmia detection andinhibit shocktherapydelivery', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 61}), Document(page_content='59•Terminate post-shock pacing therapy\\n•Prohibitarrhythmia induction testing\\n•Activate thepulsegenerat or’sbeeper witheachdetected QRScomple xfor60\\nsecondsifbeeper isturned onandisaudible\\nWARNING:\\n!\\nUsecaution whenplacing amagnet overtheS-ICDpulsegenerator because itsuspends\\narrhythmia detection andtherapy response. Removing themagnet resumes arrhythmia\\ndetection andtherapyrespon se.\\nWARNING:\\n!\\nInpatients withanS-ICDpulsegenerator deepimplant placeme nt(greaterdistance\\nbetween themagnet andthepulsegenerator) magnet application mayfailtoelicitthe\\nmagnet response. Inthiscasethemagnet cannot beusedtoinhibit therapy .\\nCAUTION: Donotplaceamagnet ontheProgrammer .\\nNOTE:Aprogrammer commanded Rescue Shockcanoverride theuseofthemagnet as\\nlongasthemagnet wasinplacepriortotheinitiation oftheprogramming command. If\\nthemagnet isapplied aftertheinitialcommand, theRescue Shockwillbeterminated.\\nNOTE:Magnet application doesnotaffectwireless communication between thepulse\\ngeneratorandtheProgrammer .\\nMAINTENANCE, TROUBLESHOO TING, HANDLING, STANDARDS,\\nAND SPECIFICATIONS\\nRefertotheLATITUDE Programming System Operator’s Manual ,Model 3300for\\nmaintenanc e,troubleshooting, handling (including symbols ondevices andpackaging),\\nstandard s,andspecifications information fortheModel 3300Programmer device.\\nWARRANTY INFORMATION\\nAwarranty cardispackaged withtheLATITUDE Programmi ngSystem. Unless otherwise\\nagreed,theLATITUDE Programming System remains theproperty ofBoston Scientific and\\nBoston Scientific mustperform allnecessaryservicingandrepairwork.Foradditional\\nwarrantyinformation, contact Boston Scientific usingthewarranty information onthecard.', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 62}), Document(page_content='', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 63}), Document(page_content='', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 64}), Document(page_content='', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 65}), Document(page_content='', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 66}), Document(page_content='Boston Scientific Corporation\\n4100Hamline Avenue North\\nSt.Paul,MN55112-5798 USA\\nwww.bostonscientific.com\\n1.800.CARDIAC (227.3422)\\n+1.651.582.4000\\n©2021Boston Scientific Corporation oritsaffiliates.\\nAllrightsreserved.\\n92123951-002 ENUS2021-08\\nFCCID:ESCCRM330017 (Contains FCCID:PD97265NG)\\nELEC TRONI C\\n \\nEQUI PMENT\\n \\nSHOULD\\n \\nBE\\n \\nCOLLEC TED\\n \\nAND\\n \\nDISPOSED\\n \\nSEPARATEL\\nY\\n \\nIN\\n \\nACCORDANC\\nE\\n \\nWITH\\n \\nLOCAL REG ULA TIONS\\n*92123951-002*', metadata={'source': 'raw_data/92123951-002_EMBLEM_S-ICD_APPLICATION_OM_en_S.pdf', 'page': 67}), Document(page_content='PHYSICIAN’S TECHNICAL GUIDE\\nHeartLogicTM Heart Failure Diagnostic Service\\nThis feature requires one of the following external devices:\\n                3300, 6290, 6299\\nThis feature is immediately available for the following pulse generators:\\n                 D500, D501, D512, D513, D520, D521, D532, D533, G524, G525, G526, \\nG528, G537, G547, G548\\nThis feature is available by subscription for the following pulse generators: \\n                 D120, D121, D220, D221, D232, D233, D400, D401, D412, D413, D420, D421, \\nD432, D433, G124, G125, G126, G128, G138, G224, G225, G228,G237 G247, G248, G424, G425, G426, G428, G437, G447, G448\\nCAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician trained or experienced in device implant and follow-up procedures.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 0}), Document(page_content='', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 1}), Document(page_content='Table of Contents\\nFEATURE DESCRIPTION  .................................................................................................................................................... 1\\nSENSOR DATA COLLECTION FOR HeartLogic  .................................................................................................................... 4\\nHeart Sounds  .............................................................................................................................................................. 6\\nRespiratory Sensor  ..................................................................................................................................................... 6\\nThoracic Impedance  ................................................................................................................................................... 7\\nNight Heart Rate......................................................................................................................................................... 7\\nSleep Incline  ............................................................................................................................................................... 7\\nLongevity Information  ................................................................................................................................................ 8\\nHeartLogic INDEX AND ALERTS  ...................................................................................................................................... 9\\nCriteria for Alert State  ................................................................................................................................................. 9\\nCriteria for No Alert State  .......................................................................................................................................... 10\\nUSING HeartLogic  ........................................................................................................................................................... 11\\nReading the HeartLogic Index  ................................................................................................................................... 12\\nConfiguring the HeartLogic Threshold  ...................................................................................................................... 16\\nConfiguring HeartLogic Alerts  .................................................................................................................................. 20\\nFrequently Asked Questions (FAQs)  .......................................................................................................................... 21\\nSYMBOLS ON PACKAGING  ............................................................................................................................................. 24', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 2}), Document(page_content='', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 3}), Document(page_content='1FEATURE DESCRIPTION\\nThe HeartLogic™ Heart Failure Diagnostic Service (HeartLogic) is comprised of a composite trend called the HeartLogic \\nIndex, a configurable yellow Alert, and the device measured Heart Sounds trends. Different components of HeartLogic and Heart Sounds are delivered depending on the reading/configuration platform being used; refer to Table 1 on page \\n2 for details. The HeartLogic Index and Alert are a validated diagnostic tool to detect gradual worsening of heart failure (HF) over days or weeks using multiple physiologic measurements.\\nThe HeartLogic Index aggregates measurements from multiple device-based sensors (Heart Sounds, Thoracic \\nImpedance, Respiration, and Night Heart Rate) and reflects changes over time in the patient’s sensor trend data from their respective baseline values. Baseline values for each sensor trend are assessed based on data spanning up to three recent months and are updated daily (i.e., moving baseline). HeartLogic provides additive information for clinicians to use in context with standard-of-care patient treatment and should not replace standard-of-care treatment.\\nHeartLogic can be turned On or Off via the LATITUDE™ system. It is nominally On in the NG4 premium tier devices \\n(RESONATE HF and PERCIVA HF CRT-Ds and ICDs). In non-premium tier NG4 devices (RESONATE, PERCIVA, MOMENTUM, and VIGILANT), HeartLogic is nominally Off and can be enabled through LATITUDE customer service. Contact your Boston Scientific Sales Representative using the information on the back cover of this manual for more information on enabling HeartLogic.\\nNOTE: The Model 3120 LATITUDE™ programming system is outdated and should not be used with HeartLogic™. For \\nassistance, contact your Boston Scientific Sales Representative. \\nNOTE: The HeartLogic Index and Alert were validated using data from the MultiSENSE study. The Multisensor Chronic \\nEvaluations in Ambulatory Heart Failure Patients (MultiSENSE) study was a multi-center, non-randomized, feasibility study designed to collect chronic ambulatory data from multiple sensors available to implanted cardiac devices in order to develop an algorithm for the early detection of worsening Heart Failure (HF). The MultiSENSE data was divided into a \\nThe following are trademarks of Boston Scientific Corporation or its affiliates: HeartLogic, LATITUDE.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 4}), Document(page_content='2Development Set and a Test Set. The Development Set was used to develop the HeartLogic Index and Alert algorithm, \\nwhile the Test Set was used to independently validate the algorithm performance. For further details, refer to the MultiSENSE Study Summary.) \\nHeartLogic’s impact on clinical outcome has not been established. HeartLogic has not been shown to reduce HF events. \\nA post- approval study is planned to study clinical outcomes.\\nHeartLogic does not provide a real-time alert. Rather, it is designed to detect chronic worsening of HF and may not be \\nsensitive to fast or abrupt changes of HF status. It does not actively alert the clinician in real-time, and use of individual HeartLogic Index values for day-to-day patient management has not been established.\\nTable 1 on page 3 shows the HeartLogic data views available for each reading/configuration platform.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 5}), Document(page_content='3Table 1.  HeartLogic Data Availability Table\\nTrend View3300 \\n(HeartLogic disabled*)3300 \\n(HeartLogic enabled*)Latitude \\nwith HeartLogic\\nNight Heart Rate Trend X X X\\nRespiratory Rate Trend X X X\\nSleep Incline Trend X X X\\nThoracic Impedance Trend X X X\\nS1 Trend X X\\nS3 Trend X X\\nHeartLogic Index Trend X X\\nHeartLogic ThresholdX\\nContributing Trend Bars X\\nHeartLogic Alert X\\n*See your Boston Scientific representative about enabling the HeartLogic display', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 6}), Document(page_content='4SENSOR DATA COLLECTION FOR HeartLogic\\nThe heart failure sensor data collection is nominally set to On. Sensor data collection is required for the HeartLogic \\nindex calculation. Heart failure sensor data collection can be activated or deactivated through the Programmer by accessing the Setup Tab under Heart Failure Management and turning the Heart Failure Sensor Suite On or Off (see Figure 1  on page 5). The Heart Failure Sensor Suite activation includes Heart Sounds, Thoracic Impedance, \\nNight Heart Rate, and Sleep Incline. See below for a description of these trends.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 7}), Document(page_content='5\\nFigure 1.  Heart Failure Management Setup Tab\\nIf left at the nominal at the time of device implant, sensor data collection begins the next day. However, due to \\ninitialization, the HeartLogic Index is not available until 30 days after the data collection begins. In certain patients, this initialization period may extend up to 37 days. The HeartLogic Index also may not be available if there is insufficient data or if some of the input sensor data are not available.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 8}), Document(page_content='6If the sensors are reprogrammed from On to Off and then back to On, some sensors may become temporarily \\nunavailable (until automatically re-initialized), which may subsequently impact the availability of the HeartLogic Index.\\nHeart Sounds\\nHeart Sounds uses the pulse generator’s accelerometer to detect cardiac vibrations, which are used to measure the \\nintensity of the following 2 heart sounds:\\n• Device-measured S1\\n• Device-measured S3\\nThe daily value of each trend is aggregated from multiple samples each day. If a minimum number of valid samples are not collected, then a daily value will not be available for that day.\\nHeart Sounds data collection has an interaction with rate responsive pacing. Heart Sounds is only collected during \\nperiods of patient inactivity. Once data collection for a Heart Sounds sample has started, activity sensor for rate responsive pacing is not available for 30 seconds. A Heart Sounds sample is typically taken every 20 minutes.\\nA Heart Sounds sample cannot be measured if the patient’s heart rate is too high or too variable. For example, if \\nfrequent PVCs result in too high a heart rate, or if AF causes heart rate to be too variable, these conditions may affect the device’s ability to record Heart Sounds. In addition, other criteria are used to qualify a given sample.\\nRespiratory Sensor\\nThe Respiratory Sensor uses transthoracic impedance measurements to collect respiration-related data, specifically \\nrespiration rate and tidal volume. Respiration rate and tidal volume are combined to produce additional respiration metrics.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 9}), Document(page_content='7NOTE: The Respiratory Sensor is controlled independently and is nominally On. If the Respiratory Sensor is turned Off, \\nthe HeartLogic Index does not take respiration data into account. The performance is the best when all sensors are available. HeartLogic is still validated in the Respiratory Sensor Off configuration.  See the MultiSENSE Study Summary for supporting data.\\nThoracic Impedance\\nThe Thoracic Impedance sensor measures impedance between electrodes on the RV lead and the pulse generator (PG) \\ncan. Thoracic Impedance may be associated with the fluid level in the patient’s chest and may track fluid level changes. When a patient’s fluid level increases, thoracic impedance decreases. Any lead integrity issue may affect the device’s ability to record transthoracic impedance.\\nNight Heart Rate\\nThe Night Heart Rate sensor measures a patient’s heart rate between the hours of midnight and 6 AM. This period is \\nnon-programmable. The data from this trend can be affected if a patient travels to another time zone or if the pulse generator (PG) clock is incorrect. The PG clock can be programmed by synchronizing it to the programmer clock at the time of device interrogation. For accurate PG clock programming, it is important to ensure that the programmer clock is correct.\\nSleep Incline\\nThe Sleep Incline sensor measures the patient’s average nighttime elevation angles (sleep incline).NOTE: Sleep Incline is part of the Heart Failure Sensor Suite but does not contribute to the HeartLogic Index.Initialization and calibration must be completed before Sleep Incline trending occurs. Initialization is automatic; \\ncalibration requires clinician and patient action.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 10}), Document(page_content='8• Initialization. The initialization of the Sleep Incline sensor occurs automatically after implant and typically \\ntakes 5 to 7 days. Initialization may take longer if a patient lacks diversity in their body orientations during this period.\\nOnce the initialization is complete, calibration can take place.\\n• Calibration. Calibration is performed via the programmer during a patient follow-up visit, after implant \\nand initialization are complete. Calibration determines PG orientation within the patient’s body. To perform calibration, the patient must adopt an upright posture, either sitting or standing, before the physician presses the Calibrate button on the programmer. The Calibrate button is shown in Figure 1 on page 5 .\\nThe programmer notifies the clinician of the completion of calibration for the particular posture. If not enough stable data was collected, the programmer will indicate this and ask for the posture to be repeated.\\nWhile an upright posture is the only required posture for calibrating the Sleep Incline sensor, accuracy is increased by \\nperforming a second calibration using a supine posture. Repeat the above process to collect readings for the second posture. The accuracy of the sleep incline trend depends on a proper body calibration. If the patient is not fully vertical or horizontal when the programmer captures the upright and supine postures respectively, then the trend values will be distorted. Calibration can be repeated as often as the clinician desires.\\n• Trending. The Sleep Incline Trend aggregates periodic measurements over the patient’s sleep schedule. To program the patient’s sleep schedule, access the General tab of the Patient Information screen. The first sample is taken 1 hour after the programmed Sleep Start and the last sample is taken 1 hour prior to the end of the programmed Sleep Duration. For a measurement to be successful, the patient must be at low activity.\\nLongevity Information\\nWhen the Heart Failure Sensor Suite is programmed to Off for the life of the device, longevity is increased by \\napproximately 1 month.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 11}), Document(page_content='9A HeartLogic subscription with daily alert checks and weekly interrogations will decrease longevity by approximately 2 \\nmonths when used for the life of the device.\\nDaily interrogations to refresh HeartLogic following an alert for 30 days each year will decrease longevity by an \\nadditional 1 month.\\nRefer to the Physician’s Technical Manual for more information about device longevity.\\nHeartLogic INDEX AND ALERTSNOTE: HeartLogic Threshold, contribution bars, and alerts are only available when HeartLogic is used with LATITUDE \\nNXT.\\nThe HeartLogic Index values have a range between 0 and 100. In general, a large sensor change relative to its moving \\nbaseline in the direction of worsening HF leads to a higher HeartLogic Index value. Based on the HeartLogic Index value, an alert state is assigned each day, consisting of two distinct values:\\n• “Alert” (which is indicative of an increased likelihood of experiencing a worsening HF event), and\\n• “No Alert”\\nThese values are based on the comparison of the HeartLogic Index value to the HeartLogic Alert threshold and recovery threshold.\\n• The alert threshold is configurable between 10 and 40, with a nominal value of 16.\\n• The recovery threshold is set automatically based on the selected alert threshold, and it is always less than the corresponding alert threshold.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 12}), Document(page_content='10Criteria for Alert State\\nOn a given day, the state is considered to be Alert if:\\n• The value of the HeartLogic Index on that day is at or above the alert threshold, or\\n• The value of the HeartLogic Index on that day is at or above the recovery threshold, and the alert state on \\nthe preceding day was Alert, or\\n• The value of the HeartLogic Index on that day is not available, and the alert state on the preceding day was Alert.\\nCriteria for No Alert State\\nOn a given day, the state is considered to be No Alert if:\\n• The value of the HeartLogic Index on that day is below the recovery threshold, or\\n• The value of the HeartLogic Index on that day is below the alert threshold, and the alert state on the \\npreceding day was No Alert, or\\n• The value of the HeartLogic Index on that day is not available, and the alert state on the preceding day was No Alert.\\nThe alert is issued on the first day that the alert state transitions from No Alert to Alert. The alert is designed to detect gradual worsening HF events (HFEs). The feature was validated using data from the MultiSENSE study, in which HFEs were defined as worsening HF with signs/symptoms of congestive heart failure that occur at least 45 days following the start of sensor data collection and:\\n• Patient was hospitalized overnight (i.e., calendar date change).\\n• Patient was not hospitalized and received one or more IV medications including diuretics, inotropes, vasodilators, other parenteral therapy, or aquapheresis.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 13}), Document(page_content='11Because the sensor data is aggregated only at the end of each day, the alert is delivered via LATITUDE NXT System \\nthe next day. The alert is available for review and can be dismissed by the user through the LATITUDE NXT System; however, if the alert is dismissed and the patient continues to be in alert state, another alert will be issued 7 days later. The LATITUDE NXT System also displays a status indicator whenever the HeartLogic Index is in the alert state; this indicator cannot be dismissed. Reports from the LATITUDE Consult system show the status indicator when the HeartLogic Index is in the alert state.\\nThe alert is considered recovered when the alert state transitions from Alert to No Alert. Such a transition is indicative \\nof current sensor values no longer being different than the moving baseline. Changing from a state of Alert to No Alert does not necessarily indicate that a patient is no longer in worsening heart failure; instead, the patient may be improving, staying the same, or worsening at a slower rate. Additionally, abrupt unavailability of individual sensor data may result in a sudden decrease in the HeartLogic Index.\\nUSING HeartLogic\\nHeartLogic is intended to be used by qualified health care practitioners via remote monitoring or at the point of care \\nfor HF surveillance, such as hospitals or clinic facilities, in conjunction with clinical evaluation that is part of standard clinical practice.\\nThe HeartLogic Alert signifies an increased risk for an HFE for the patient; consider contacting the patient for additional \\nsurveillance. As observed in the Test Set Cohort of the MultiSENSE data, less than 1% of all alerts resulted in an HFE in less than 3 days; detected HFEs occurred with a median duration of 34 days from the start of the alerts associated with the detected HFEs.\\nHeartLogic is designed to detect chronic worsening of HF and may not be sensitive to fast or abrupt changes of HF \\nstatus, and it does not actively alert the clinician in real-time. Use of individual HeartLogic Index values for day-to-day patient management has not been established. Instead, consult the overall HeartLogic Index trend and/or Alert.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 14}), Document(page_content='12Since baseline values for each sensor trend are assessed based on data spanning up to three recent months, any \\nsustained atypical deviation over this period may impact the moving baseline and subsequently the HeartLogic Index. For example, if the patient worsens and the sensor trends remain in a worsened state that is not further deteriorating for a sustained duration, it may result in a decrease in the HeartLogic Index and alert recovery in a patient whose HF status has not improved. In the MultiSENSE study, 3 patients experienced HFEs within 30 days after an alert had recovered. These HFEs happened 4, 7, and 22 days after the alert recovery. Conversely, if there are unusually large and sustained excursions in the sensor data in the direction opposite to that of worsening HF (e.g., hypovolemic state) in the last three months, it may result in an unusually higher HeartLogic Index value and alert issuing in an otherwise stable patient.\\nReview all patient data (including those that contributed to the Index) on the Heart Failure Patient Management \\nReports in their entirety, and physiologic and/or clinical data from other sources. No changes to patient treatment \\nshould be made based on a HeartLogic Alert alone without standard-of-care patient evaluation. Likewise, no reduction in patient care should be made based solely on the absence of a HeartLogic Alert.\\nReading the HeartLogic Index\\nFigure 2 on page 13 shows the HeartLogic Index in No Alert State.\\n• The solid black line depicts the HeartLogic Index, which changes over time for this specific sample patient.\\n• The Y-axis shows the value of the HeartLogic Index, which can range from 0 to 100.\\n• The horizontal dashed line shows the alert threshold. For this patient, the HeartLogic Index has remained \\nbelow the alert threshold.\\n• The HeartLogic Index value for the most recent day is shown in the large box on the left side of the display.\\n• The Zoom settings, located in the upper left of the screen, can show up to one year of data (if data is available).', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 15}), Document(page_content='13\\nFigure 2.  HeartLogic Index example', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 16}), Document(page_content='14Figure 3 on page 15 shows the HeartLogic Index transitioning from an initial No Alert state to an Alert state.\\n• In this case, the alert threshold appears as the dashed horizontal line in the initial portions of the graph, \\nwhich corresponds to the patient being in the No Alert state (prior to November 2015).\\n• The HeartLogic Index crossed the alert threshold in November, transitioning into Alert state, at which point the alert threshold (dashed line) steps down to the recovery threshold. As described previously, the system automatically sets the recovery threshold based on the chosen alert threshold. Since the value of the HeartLogic Index for the most recent day is above the recovery threshold, and the alert state on the preceding day was Alert, the state continues to be Alert.\\nWhile the HeartLogic Index is in the Alert state, the changes in some of the individual contributing trends (S3, S3/S1 Ratio, Thoracic Impedance, Respiratory Rate, and Night Heart Rate) are also displayed. The shaded portion of each bar corresponding to a contributing trend indicates the degree of worsening HF measured in that trend as of the date shown.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 17}), Document(page_content='15\\nFigure 3.  HeartLogic Index in transition to Alert state', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 18}), Document(page_content='16Configuring the HeartLogic Threshold\\nThe performance in the Test Set Cohort of the MultiSENSE study was used as the basis for the HeartLogic nominal alert \\nthreshold value. The sensitivity (proportion of HFEs detected) is 70% when each HFE is counted independently; the sensitivity is 65% when only the initial HFE is counted, and not repeated HFEs associated with a single alert. The alert threshold is configurable, enabling physicians to tailor the feature to their clinical practice preferences and inter-patient variability.\\nUsing lower threshold settings increases HeartLogic Alert’s sensitivity to detect worsening HF. If the user wants the \\nHeartLogic Alert to be more sensitive to sensor changes reflected by the HeartLogic Index, the user should decrease the alert threshold. However, lower threshold settings may also lead to the generation of more alerts.\\nConversely, if the user wants the HeartLogic Alert to be less sensitive to sensor changes reflected by the HeartLogic \\nIndex, the user should increase the alert threshold. Increasing the alert threshold reduces HeartLogic Alert’s sensitivity to detect worsening HF, and it may result in the generation of fewer alerts.\\nAdjustments to the alert threshold should be based on user preference. See Figure 4 on page 18 and Table 2 on \\npage 19 to see the relationship between sensitivity (proportion of HFEs detected) and the unexplained alert rate (UAR, the number of alerts per patient year that are not associated with worsening heart failure) in the Test Set Cohort of the MultiSENSE study as the threshold is changed.\\nChanging the alert threshold from the nominal is not recommended, unless:\\n• The patient has an HFE without an associated alert while the HeartLogic Index is available.\\n• Unexplainable alerts have occurred.\\nWhen configuring the HeartLogic Alert threshold, consider the following:\\n• Reviewing the HeartLogic Index values for previous HFEs, as well as when the patient was deemed to be \\nclinically stable, aids in understanding the patient’s history and condition.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 19}), Document(page_content='17• To increase the likelihood of detecting an HFE, it is recommended to set the alert threshold below the \\ncalculated HeartLogic Index values of any previous HFEs.\\n• To reduce the likelihood of alerting when the patient is not experiencing HFE, it is recommended to set the alert threshold above the calculated HeartLogic Index values when the patient was deemed to be clinically stable.\\n• Decreasing the alert threshold, may result in the following (see Figure 4 on page 18 and Table 2 on page 19):\\n• The feature may be less likely to miss an HFE.\\n• The feature may be more likely to issue an alert.\\n• Minor changes in the physiologic measurements contributing to the HeartLogic Index are more likely to trigger an alert.\\n• Clinicians may receive an increased number of alerts.\\n• Increasing the alert threshold may result in the following (see Figure 4 on page 18 and Table 2 on page 19):\\n• The feature may be more likely to miss an HFE.\\n• The feature may be less likely to issue an alert.\\n• If the alert threshold is configured too high, clinicians may not receive alert for true HFEs.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 20}), Document(page_content='18\\nFigure 4.  HeartLogic Alert Performance in terms of Sensitivity (proportion of HF events detected) and Unexplained \\nAlert Rates (Alerts not associated with worsening HF) at various Configurable Alert Thresholds as observed during the independent validation in the Test Set Cohort of the MultiSENSE study (Nominal alert threshold = 16)', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 21}), Document(page_content='19Table 2.  Sensitivity and UAR of HeartLogic Alert algorithm at various configurable thresholds \\nas observed during the independent validation in the Test Set Cohort of the MultiSENSE study\\nAlert Threshold Sensitivity (%) UAR (per patient year)\\n10 80 2.69\\n12 74 2.09\\n14 74 1.70\\n16 (nominal) 70 1.48\\n18 70 1.22\\n20 62 1.07\\n22 60 0.93\\n24 54 0.82\\n26 54 0.70\\n28 54 0.58\\n30 48 0.49\\n32 44 0.40\\n34 42 0.34\\n36 34 0.28\\n38 30 0.25\\n40 22 0.20', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 22}), Document(page_content='20Configuring HeartLogic Alerts\\nTo change when a HeartLogic Alert is issued, configure the HeartLogic Alert threshold through the LATITUDE NXT \\nSystem. The alert configuration user interface for the LATITUDE NXT System is shown in Figure 5 on page 20 . As \\ndescribed previously, the HeartLogic Alert threshold is nominally set to 16 and may be configured within the range of 10 to 40 with a step of 2. Changes made to the alert configuration will not be effective until the Communicator calls the LATITUDE server to obtain the new configuration (within 7 days). Also, the user may set the system to interrogate the device and upload data to the LATITUDE NXT System on a daily basis following an alert. This functionality may allow the user to more closely monitor the HeartLogic Index when it is in the alert state.\\nFigure 5.  LATITUDE NXT Alert Configuration', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 23}), Document(page_content='21Frequently Asked Questions (FAQs)\\n1. Why did the HeartLogic Alert occur for my patient?\\nThe HeartLogic Index aggregates measurements from multiple device-based sensors (Heart Sounds, Thoracic \\nImpedance, Respiration, and Night Heart Rate) and reflects changes over time in the patient’s sensor data from their respective moving baseline values. The alert occurred because the sensor changes resulted in a significant enough change in the HeartLogic Index to cross the alert threshold. The alert signifies an increased risk for a heart failure event for the patient; consider contacting the patient for additional surveillance per your standard of care for the patient.\\n2. How do I know what triggered the alert?\\nThe HeartLogic Index aggregates measurements from multiple device-based sensors and reflects changes \\nover time in the patient’s sensor data from their respective moving baseline values. When the HeartLogic Index transitions into an alert state, the degree of changes of individual contributing trends are shown as shaded area in the bar plots (see Figure 3 on page 15) below the HeartLogic Index.\\n3. What does the OK in the box next to the HeartLogic Index mean?\\nThe display of OK means that the HeartLogic Index for the patient is not in alert state. No reduction in patient \\ncare should be made based solely on absence of a HeartLogic Alert.\\n4. I received another alert for a patient within 7 days. What do I do?\\nA subsequent alert within 7 days indicates that the patient continues to be in the alert state ; consider \\ncontacting the patient for additional surveillance per your standard of care for patients.\\n5. What should I do when alert occurs? How soon should I act upon an alert?Based upon MultiSENSE study data, less than 1% of the alerts resulted in an HFE in less than 3 days. Consider \\ncontacting the patient for additional surveillance per your standard of care for patients in an appropriate time frame.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 24}), Document(page_content='226. What should I do if the patient is not symptomatic when I call to follow up on an alert?\\nThe alert is an early indicator of potential HF event, and sensor changes driving the alert may precede \\nsymptom changes. Review all the data in the Heart Failure Management report, such as individual sensor trends, AT/AF burden, arrhythmic events, and percent pacing and/or clinical data coming from other sources, and follow your standard of care for patients.\\n7. What should I do if the patient is not symptomatic and the alert persists?\\nContinue to review all the data in the Heart Failure Management report such as individual sensor trends, AT/\\nAF burden, arrhythmic events, and percent pacing, and follow your standard of care for patients.\\n8. Why am I getting alerts for a patient without any subsequent clinical worsening of HF?\\nSome patients have other comorbidities or conditions that may result in sensor changes common with \\nworsening HF. Some patients may have more variations in their sensor data that are not always associated with subsequent worsening HF. Based on experience from MultiSENSE, atrial fibrillation is the most frequent cause of unexplained alerts despite the patient not having worsening HF. Ventricular arrhythmia and infection are the most common medical conditions that may cause alerts despite the patient not having worsening HF. To reduce the number of alerts, follow the instruction in the section “Configuring the HeartLogic \\nThreshold” on page 16 to increase the threshold. However, increasing the alert threshold will also reduce the likelihood of detecting a future HFE.\\n9. Why did I not receive any alert for one of my patients that had an HFE?\\nDue to the heterogeneity of heart failure, some patients may have fewer changes in their sensor data prior \\nto worsening HF. Absence of alert prior to an HFE indicates that the sensor changes leading up to HFE did not result in sufficient changes in the HeartLogic Index values to cross the alert threshold. Consider setting the alert threshold below the HeartLogic Index values just prior to the HFE event. However, lowering the alert threshold will also result in receiving an increased number of alerts in the future.', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 25}), Document(page_content='2310. Can I tailor the alert threshold uniquely for my clinic?\\nThe HeartLogic Alert threshold provides the opportunity to choose your own balance between unexplained \\nalert rate and sensitivity to HFEs. The nominal alert threshold was chosen based upon sensitivity of 70% and an unexplained alert rate of 1.48 per patient year as observed during the algorithm validation in an independent Test Set Cohort of the MultiSENSE study (see Table 2 on page 19). If your clinic wishes to operate at a different sensitivity level, consider changing the alert threshold. However, note that increasing the alert threshold will also reduce the sensitivity of detecting future HFEs.\\n11. Can I use the HeartLogic Index value for day-to-day patient management?\\nUse of the HeartLogic Index for day-to-day patient management has not been established. Review all patient \\ndata, including those that contributed to the Index and physiologic and/or clinical data coming from other sources, and follow your standard of care for patients.\\n12. Following the HeartLogic Alert, I treated my patient, but the Index does not decrease and the alert is not turning off. What do I do?\\nDue to the long-term averaging involved, the Index may not be sensitive to faster changes in sensor data over \\na shorter time frame. As such, sensor changes due to acute interventions may not be immediately reflected in the Index. Use of the HeartLogic Index for day-to-day patient management has not been established. ', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 26}), Document(page_content='24SYMBOLS ON PACKAGING\\nThe following symbols may be used on packaging and labeling:\\nTable 3.  Symbols on packaging\\nSymbols Description\\nReference Number\\nManufacturer', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 27}), Document(page_content='', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 28}), Document(page_content='For additional reference information, go to \\nwww.bostonscientific-elabeling.com.\\nBoston Scientific Corporation\\n4100 Hamline Avenue NorthSt. Paul, MN  55112-5798  USA\\n1.800.CARDIAC (227.3422)\\n+1.651.582.4000\\nwww.bostonscientific.com\\n© 2020 Boston Scientific Corporation or its affiliates.\\nAll rights reserved.\\n51114093-001 en USA 2020-10\\n*51114093-001*', metadata={'source': 'raw_data/51114093-001A_HeartLogic_PTG_en_S.pdf', 'page': 29}), Document(page_content='USER’SMANUAL\\nEMBLEM™S-ICD\\nSubcutaneous Electr ode\\nRREEFF3501\\nCAUTION: Federallaw(USA)restrictsthis\\ndevicetosalebyorontheorderofaphysician\\ntrainedorexperiencedindeviceimplantand\\nfollow-up procedures.', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 0}), Document(page_content='', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 1}), Document(page_content='TableofContents\\nINFORMATION FORUSE..........................................................................1\\nDescription .......................................................................................1\\nRelatedInformation .............................................................................1\\nMRConditional SystemInformation ............................................................1\\nIndications forUse...............................................................................2\\nContraindicatio ns.................................................................................2\\nWarnings .........................................................................................2\\nPrecautions.......................................................................................5\\nPotentialAdverseEvents........................................................................7\\nWarrantyInformation ............................................................................9\\nPRE-IMPLANT INFORMATION ....................................................................9\\nSurgicalPreparation.............................................................................9\\nItemsIncludedinPackage......................................................................9\\nAccessories.......................................................................................9\\nIMPLANTATION ...................................................................................10\\nOverview.........................................................................................10\\nPOST-IMPLANT ...................................................................................13\\nPostImplantFollow-Up Procedures...........................................................13\\nExplantation andDisposal......................................................................13\\nSPECIFICATIONS ..................................................................................14\\nEMBLEMS-ICDSubcutaneous ElectrodeSpecifications ......................................14\\nDefinitions ofPackageLabelSymbols........................................................16', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 2}), Document(page_content='Thisproductmaybeprotected byoneormorepatents.Patentinformation canbeobtainedathttp://\\nwww.bostonscientific.co m/patents. Thefollowing aretrademarksofBostonScientificCorporation or\\nitsaffiliates:EMBLEM, IMAGEREADY.\\n8 cm\\n45 cm4\\n1\\n2\\n7\\n6\\n8\\n9\\n5\\n3[1]Anchoring Hole,[2]DistalSensingElectrode, [3]Defibrillation Coil,[4]Proximal\\nSensingElectrode,[5]Integrated SutureSleeve,[6]Terminalelectrodeconnection for\\nproximalsensingelectrode, [7]SQ-1S-ICDconnector(non-standard), [8]Terminal\\nelectrodeconnection fordefibrillation coil,[9]TerminalPin(electrodeconnection for\\ndistalsensingelectrode)', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 3}), Document(page_content='1INFORMATION FORUSE\\nDescription\\nTheEMBLEMS-ICDsubcutaneous electrode (the“subcutaneous electrode”) isacomponent\\noftheBostonScientificS-ICDSystem,whichisprescribed forpatientswhencardiac\\narrhythmia management iswarranted.TheS-ICDSystemdetectscardiacactivityand\\nprovidesdefibrillation therapy.Thesubcutaneous electrode istypicallyimplanted withthe\\ndistalportionpositioned paralleltotheleftsternalborderandtheproximalendconnected\\ntoanEMBLEMS-ICDSystempulsegeneratorviaanSQ-1S-ICDconnector1.The\\nsubcutaneous electrode isalsocompatible withtheCameronHealthModel1010SQ-RX\\npulsegenerator.\\nThesubcutaneous electrodeincludesonehighvoltageshockelectrode coilforthepurpose\\nofproviding defibrillation energy.Theshockelectrodeisconstructed usingmultifilars of\\nmetallicwireformedintoadefibrillation coil8centimeters inlength.Defibrillation is\\ndeliveredbetweenthecoilonthesubcutaneous electrode andtheelectrically conductive\\npulsegeneratorcase.\\nThesubcutaneous electrodealsoincludesproximalanddistalsensingringelectrodes.\\nThesesenseelectrodesareconstructed usingmetallictubingmechanically affixedtothe\\nbodyofthesubcutaneous electrode. Sensingoccursbetweenthetwoelectrically\\nconductive ringsonthesubcutaneous electrodeorbetweeneitheroftheringsonthe\\nsubcutaneous electrode andtheelectrically conductive pulsegenerator case.\\nRelatedInformation\\nInstructions inthismanualshouldbeusedinconjunction withotherresourcematerial,\\nincluding theapplicable S-ICDpulsegenerator user’smanualandelectrode implanttools\\nuser’smanual.\\nRefertotheImageReady MRConditional S-ICDSystemMRITechnical Guide(hereafter\\nreferredtoastheMRITechnical Guide)forinformation aboutMRIscanning.\\nAsummary oftheS-ICDSystemClinicalInvestigation, including observed adverseevents,\\ncanbeobtainedbycontacting BostonScientificusingtheinformation onthebackcover.\\nIntendedAudience\\nThisliteratureisintendedforusebyprofessionalstrainedorexperiencedindeviceimplant\\nand/orfollow-up procedures.\\nMRConditional SystemInformation\\nABostonScientific/Camer onHealthsubcutaneous electrodecanbeusedaspartofthe\\nImageReady S-ICDSystemwhenconnected toaBostonScientificMRConditional S-ICD\\npulsegenerator.PatientswithanMRConditional S-ICDSystemmaybeeligibletoundergo\\nMRIscansifperformed whenallConditions ofUse,asdefinedintheMRITechnical Guide,\\naremet.Components requiredforMRConditional statusincludespecificmodelsofBoston\\nScientificS-ICDpulsegenerators,electrodes, andaccessories; theProgrammer; and\\nProgrammer SoftwareApplication. ForthemodelnumbersofMRConditional S-ICDpulse\\n1.SQ-1isanon-standard connectoruniquetotheS-ICDSystem', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 4}), Document(page_content='2generatorandcomponents,aswellasacomplete description oftheImageReady S-ICD\\nSystem,refertotheMRITechnical Guide.\\nRefertotheMRITechnical Guideforacomprehensive listofWarnings, Precautions,and\\nConditions ofUsethatareapplicable toMRIscanningofpatientsimplanted withan\\nImageReady S-ICDSystem.\\nImplant-relatedMRIConditions ofUse\\nThefollowing subsetoftheMRIConditions ofUsepertainstoimplantation andisincluded\\nasaguidetoensureimplantation ofacomplete ImageReady S-ICDSystem.Forafulllist\\nofConditions ofUse,andpotentialadverseeventsapplicable whentheConditions ofUse\\naremetornotmet,refertotheMRITechnical Guide.AllitemsonthefulllistofConditions\\nofUsemustbemetinorderforanMRIscantobeconsideredMRConditional.\\n•Patientisimplanted withanImageReady S-ICDSystem\\n•Nootheractiveorabandoned implanted devices,components, oraccessoriespresent\\nsuchasleadadaptors, extenders ,leads,orpulsegenerators\\n•Patientisjudgedtobeclinicallycapableoftolerating noTachycardia protectionfor\\ntheentiredurationinwhichthepulsegeneratorisinMRIProtectionMode\\n•Atleastsix(6)weekshaveelapsedsinceimplantation and/oranyelectroderevision\\norsurgicalmodification oftheImageReady S-ICDSystem\\n•Noevidenceofafracturedelectrode orcompromised pulsegenerator-electrode\\nsystemintegrity\\nNOTE:Otherimplanted devicesorpatientconditions maycauseapatienttobeineligible\\nforanMRIscan,independent ofthestatusofthepatient’sImageReady S-ICDSystem.\\nIndications forUse\\nTheS-ICDSystemisintendedtoprovidedefibrillation therapyforthetreatmentoflife-\\nthreatening ventricular tachyarrhythmias inpatientswhodonothavesymptomatic\\nbradycardia,incessantventricular tachycardia,orspontaneous, frequentlyrecurring\\nventricular tachycardia thatisreliablyterminated withantitachycar diapacing.\\nContraindications\\nUnipolarstimulation andimpedanc e-basedfeaturesarecontraindicated forusewiththeS-\\nICDSystem.\\nWARNINGS\\nNOTE:BeforeusingtheS-ICDSystem,readandfollowallwarnings andprecautions\\nprovidedintheapplicable S-ICDpulsegenerator user’smanual.\\nGeneral\\n•Labelingknowledge. ReadthismanualthoroughlybeforeusingtheS-ICDSystemto\\navoiddamagetothepulsegenerator and/orsubcutaneous electrode. Suchdamage\\ncanresultinpatientinjuryordeath.\\n•Forsinglepatient/singleprocedureuseonly.Donotreuse,reprocess,or\\nresterilize.Reuse,reprocessing,orresterilization maycompromise thestructural\\nintegrityofthedeviceand/orleadtodevicefailurewhich,inturn,mayresultin\\npatientinjury,illness,ordeath.Reuse,reprocessing,orresterilization mayalsocreate', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 5}), Document(page_content='3ariskofcontamination ofthedeviceand/orcausepatientinfectionorcross-infection,\\nincluding, butnotlimitedto,thetransmission ofinfectious disease(s) fromone\\npatienttoanother.Contamination ofthedevicemayleadtoinjury,illness,ordeath\\nofthepatient.\\n•Component compatibility.AllBostonScientificS-ICDimplantable components are\\ndesigned forusewiththeBostonScientificorCameronHealthS-ICDSystemonly.\\nConnection ofanyS-ICDSystemcomponents toanon-compatible componenthasnot\\nbeentestedandcouldresultinfailuretodeliverlife-saving defibrillation therapy.\\n•Backupdefibrillation protection. Alwayshaveexternaldefibrillation equipment and\\nmedicalpersonnel skilledinCPRavailableduringimplantandfollow-up testing.If\\nnotterminated inatimelyfashion,aninducedventricular tachyarrhythmia canresult\\ninthepatient’sdeath.\\nClinicalconsiderations\\n•Myopotentials. TheS-ICDSystemmaysensemyopotentials whichmayresultin\\nover/under sensing.\\nHandling\\n•Properhandling. Handlethecomponents oftheS-ICDSystemwithcareatalltimes\\nandmaintainpropersteriletechnique. Failuretodosomayleadtoinjury,illness,or\\ndeathofthepatient.\\n•Donotdamagecomponents. Donotmodify,cut,kink,crush,stretch,orotherwise\\ndamageanycomponentoftheS-ICDSystem.Impairment totheS-ICDSystemmay\\nresultinaninappropriateshockorfailuretodelivertherapytothepatient.\\n•Handlingthesubcutaneous electrode.Usecautionhandlingthesubcutaneous\\nelectrode.Donotdirectlycontacttheshockingcoil,sensingelectrodes,electrode\\nbody,orconnector withanysurgicalinstruments suchasforceps,hemostats, or\\nclamps.Thiscoulddamagetheelectrode,possiblyleadingtocompromised sensing,\\nlossoftherapy,orinappropriatetherapy.\\nImplantation\\n•Armpositioning. Attention isrequiredtoplacementofthearmipsilateral tothe\\ndeviceimplanttoavoidinjuryoftheulnarnerveandbrachialplexuswhilethepatient\\nisinthesupinepositionduringdeviceimplantation andbeforeVFinduction orshock\\ndelivery.Thepatientshouldbepositioned withthearmabducted toanangleofno\\nmorethan60°withthehandinasupinated (palmup)positionduringtheimplant\\nphaseoftheprocedure.Securingthearmtoanarmboardisstandardpracticeto\\nmaintainpositioning ofthearmduringdeviceimplantation. Donotstrapthearmtoo\\ntightlyduringdefibrillation testing.Elevation ofthetorsothroughuseofawedge\\nmayalsoaddstresstotheshoulderjointandshouldbeavoidedduringdefibrillation\\ntesting.\\n•Systemmigration. Useappropriate anchoring techniques asdescribed inthe\\nimplantproceduretopreventS-ICDSystemdislodgement and/ormigration.\\nDislodgement and/ormigration oftheS-ICDSystemmayresultinaninappropriate\\nshockorfailuretodelivertherapytothepatient.', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 6}), Document(page_content='4•DonotimplantinMRIsiteZoneIII.Implantofthesystemcannotbeperformed in\\nanMRIsiteZoneIII(andhigher)asdefinedbytheAmerican CollegeofRadiology\\nGuidance Document onMRSafePractices2.Someoftheaccessoriesusedwithpulse\\ngenerators andelectrodes, including thetorquewrenchandelectrode implanttools,\\narenotMRConditional andshouldnotbebroughtintotheMRIscannerroom,the\\ncontrolroom,ortheMRIsiteZoneIIIorIVareas.\\n•Highshockingelectrodeimpedance. Highshockingelectrode impedance may\\nreduceVT/VFconversionsuccess.\\n•Usingthetunnelingtool.Handlethetunneling toolwithcare.Alwaysbeawareof\\nthelocationofthetooltiprelativetopatientanatomy.Thetunneling toolisnot\\nintendedtobeusedforintrathoracicaccess.Enteringthethoraciccavityoradvancing\\nthetoolundertheribsorsternumcouldleadtounintended tissuedamageincluding\\norganorvesselperforation, orinadvertent leadplacement inthemediastinum or\\nthoraciccavitywithitsattendant risk.\\n•Excessivetension.Whenpositioning theelectrode andpulsegenerator,avoid\\nexcessivetensionontheelectrode, particularly iftheelectrode bodyextendsoverthe\\npulsegenerator.Thiscouldcausestructural damage,abrasion,and/orconductor\\ndiscontinuity .\\n•Excessiveflexing.Although pliable,theelectrode isnotdesigned totolerate\\nexcessiveflexing,tightradiusbending,kinking,ortwisting.Thiscouldcause\\nstructural damage,conductor discontinui ty,electrode migration,and/or\\ndislodgement. Seethefollowing figureforguidance oncorrectelectrodeplacement .\\n2\\n1\\n[1]Correctplacement [2]Incorrectplacement\\nFigure1.Correctelectrodeplacementtoavoidexcessiveflexing\\n•Electrode/connection malfunction. Electrodefracture,abrasion,under-insertion of\\ntheelectrode connectorintothepulsegeneratorconnector port,oraloosesetscrew\\nconnection mayresultincompromisedsensing,lossoftherapy,orinappropriate\\ntherapy.\\n2.KanalE,BarkovichAJ,BellC,etal.ACRguidance document onMRsafepractices:2013.J.Magn.Reson.\\nImaging2013;37:501-530.', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 7}), Document(page_content='5Post-Implant\\n•Diathermy.Donotexposeapatientwithanimplanted S-ICDSystemtodiathermy .\\nTheinteraction ofdiathermy therapywithanimplanted S-ICDpulsegenerator or\\nelectrodecandamagethepulsegenerator andcausepatientinjury.\\n•MagneticResonance Imaging(MRI)exposure. UnlessalloftheMRIConditions of\\nUse(asdescribed intheMRITechnical Guide)aremet,MRIscanningofthepatient\\ndoesnotmeetMRConditional requirements fortheimplanted system,and\\nsignificant harmtoordeathofthepatientand/ordamagetotheimplanted system\\nmayresult.\\nRefertotheMRITechnical Guideforpotentialadverseeventsapplicable when\\nConditions ofUsearemetornotmet,aswellasforacomplete listofMRI-related\\nWarnings andPrecautions.\\n•SaltwaterEnvironments. Immersion insaltwater andsimilarconductive fluid\\nenvironments(i.e.ocean,saltwater pools)maydivertsomedefibrillation shock\\nenergyawayfromthepatient’sheartintothesurroundingconductive fluid(as\\nevidencedbyalower-than-normal shockimpedance). ThismayreduceVT/VF\\nconversion success,especially inpatientswithlowBMI.\\nPRECAUTIONS\\nClinicalConsiderations\\n•Pediatricuse.TheS-ICDSystemhasnotbeenevaluated forpediatricuse.\\n•Availabletherapies. TheS-ICDSystemdoesnotprovidelong-term bradycardia\\npacing,cardiacresynchronization therapy(CRT),orantitachycar diapacing(ATP).\\nSterilization andStorage\\n•Ifpackageisdamaged. Theblistertraysandcontentsaresterilizedwithethylene\\noxidegasbeforefinalpackaging. Whenthepulsegenerator and/orsubcutaneous\\nelectrodeisreceived,itissterileprovidedthecontainer isintact.Ifthepackaging is\\nwet,punctured,opened,orotherwise damaged, returnthepulsegenerator and/or\\nsubcutaneous electrodetoBostonScientific.\\n•Usebydate.Implantthepulsegeneratorand/orsubcutaneous electrodebeforeor\\nontheUSEBYdateonthepackagelabelbecausethisdatereflectsavalidated shelf\\nlife.Forexample, ifthedateisJanuary1,donotimplantonorafterJanuary2.\\n•Storagetemperature. Therecommended storagetemperatur erangeis-18°Cto+55°\\nC(0°Fto+131°F).\\nImplantation\\n•Creatingthesubcutaneous tunnels.UseBostonScientifictoolsandaccessories\\ndesigned foruseinimplanting thesubcutaneous electrode tocreatethe\\nsubcutaneous tunnelswhenimplanting andpositioning thesubcutaneous electrode.\\nAvoidtunneling closetoanyothersubcutaneously implanted medicaldevicesor\\ncomponents, forexample,animplantable insulinpump,drugpump,sternalwiring\\nfromprevioussternotomy ,orventricular assistdevice.\\n•Superiortunnellength.Ensurethesuperiortunnelislongenoughtoaccommodate\\ntheportionoftheelectrodefromthedistaltiptothesuturesleevewithoutbuckling', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 8}), Document(page_content='6orcurvingofthedefibrillation coil.Bucklingorcurvatureofthedefibrillation coil\\nwithinthesuperiortunnelcouldleadtocompromised sensingand/ortherapy\\ndelivery.Afterinsertionoftheelectrode intothesuperiortunnel,X-rayorfluoroscopy\\nmaybeusedtoconfirmthatnobucklingorcurvatureisobserved.\\n•Suturelocation. Sutureonlythoseareasindicated intheimplantinstructions.\\n•Donotsuturedirectlyoversubcutaneous electrodebody.Donotsuturedirectly\\noverthesubcutaneous electrodebody,asthismaycausestructural damage.Usethe\\nsuturesleevetopreventsubcutaneous electrodemovement.\\n•Donotbendthesubcutaneous electrodeneartheelectrode-header interface.\\nInsertthesubcutaneous electrodeconnector straightintothepulsegeneratorheader\\nport.Donotbendthesubcutaneous electrode nearthesubcutaneous electrode-\\nheaderinterface. Improper insertioncancauseinsulation orconnector damage.\\n•Sternalwires.Whenimplanting theS-ICDsysteminapatientwithsternalwires,\\nensurethatthereisnocontactbetweenthesternalwiresandthedistalandproximal\\nsenseelectrodes(forexample, byusingfluoroscopy).Compromisedsensingcanoccur\\nifmetal-to-metal contactoccursbetweenasenseelectrodeandasternalwire.If\\nnecessary,re-tunnel theelectrodetoensuresufficient separation betweenthesense\\nelectrodes andthesternalwires.\\nHospitalandMedicalEnvironments\\n•Externaldefibrillation. Externaldefibrillation orcardioversioncandamagethepulse\\ngenerator orsubcutaneous electrode. Tohelppreventdamagetoimplanted system\\ncomponents, considerthefollowing:\\n•Avoidplacingapad(orpaddle)directlyoverthepulsegeneratoror\\nsubcutaneous electrode. Positionthepads(orpaddles)asfarfromthe\\nimplanted systemcomponents aspossible.\\n•Setenergyoutputofexternaldefibrillation equipment aslowasclinically\\nacceptable.\\n•Following externalcardioversionordefibrillation, verifypulsegeneratorfunction\\n(seetheappropriate S-ICDpulsegeneratormanualforsuggested post-therapy\\nfollow-up actions).\\n•Cardiopulmonary resuscitation. Cardiopulmonary resuscitation (CPR)may\\ntemporarily interferewithsensingwhichmaycausedelayoftherapy,inhibition ofor\\ninappropriate therapy.\\n•Electrocauteryandradiofrequency(RF)ablation. Electrocautery andRFablation\\nmayinduceventricular arrhythmias and/orfibrillation, maycauseinappropriate\\nshocksandinhibition ofpost-shockpacing,andmayproduceunexpectedbehaviorin\\ntheProgrammerdisplayoroperation.Additionally ,exercisecautionwhenperforming\\nanyothertypeofcardiacablationprocedureinpatientswithimplanted devices.If\\nelectrocautery orRFablationismedically necessary,observethefollowing to\\nminimize risktothepatientanddevice:\\n•Haveexternaldefibrillation equipment available.\\n•Programthepulsegenerator toTherapyOffmode.\\n•Avoiddirectcontactbetweentheelectrocautery equipment orablationcatheters\\nandthepulsegeneratorandsubcutaneous electrode.', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 9}), Document(page_content='7•Keepthepathoftheelectricalcurrentasfarawayaspossiblefromthepulse\\ngenerator andsubcutaneous electrode.\\n•IfRFablationand/orelectrocautery isperformed ontissuenearthepulse\\ngenerator orsubcutaneous electrode,verifypulsegeneratorfunction(seethe\\nappropriate S-ICDpulsegenerator manualforsuggested post-therapyfollow-up\\nactions).\\n•Forelectrocautery ,useabipolarelectrocauterysystemwherepossibleanduse\\nshort,intermittent, andirregularburstsatthelowestfeasibleenergylevels.\\n•Maintainadistanceofatleast30centimeters (12inches)betweenElectrocautery\\nandRFAblationequipment andtheProgrammerandtelemetry wand.Similarly,\\nmaintainthissamedistancebetweentheProgrammer andtelemetry wandand\\nthepatientduringtheseprocedures.\\nWhentheprocedureisfinished,returnthepulsegenerator toTherapyOnmode.\\nExplantandDisposal\\n•Handlingatexplant.Beforeexplanting,completethefollowing actionstoprevent\\nunwanted shocks,overwritingofimportant therapyhistorydata,andaudibletones:\\n•ProgramthepulsegeneratortoTherapyOffmode.\\n•Disablethebeeper,ifavailable.\\n•Handlingattimeofdisposal. Cleananddisinfectimplanted components using\\nstandardbiohazard handlingtechniques sinceallexplantedcomponents are\\nconsidered biohazardo us.\\nPotentialAdverseEvents\\nPotentialadverseeventsrelatedtoimplantation oftheS-ICDSystemmayinclude,butare\\nnotlimitedto,thefollowing:\\n•Acceleration/induction ofatrialorventricular arrhythmia\\n•Adversereactiontoinduction testing\\n•Allergic/adverse reactiontosystemormedication\\n•Bleeding\\n•Conductor fracture\\n•Cystformation\\n•Death\\n•Delayedtherapydelivery\\n•Discomfor torprolongedhealingofincision\\n•Electrodedeformation and/orbreakage\\n•Electrodeinsulation failure\\n•Erosion/extrusion\\n•Failuretodelivertherapy\\n•Fever\\n•Hematoma/ser oma', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 10}), Document(page_content='8•Hemothorax\\n•Improper electrodeconnection tothedevice\\n•Inabilitytocommunicate withthedevice\\n•Inabilitytodefibrillate orpace\\n•Inappropriate post-shockpacing\\n•Inappropriate shockdelivery\\n•Infection\\n•Injurytoorpaininupperextremity,including clavicle,shoulder,andarm\\n•Keloidformation\\n•Migration ordislodgement\\n•Muscle/nerv estimulation\\n•Nervedamage\\n•Organinjuryorperforation\\n•Pneumothorax\\n•Post-shock/post -pacediscomfort\\n•Prematurebatterydepletion\\n•Randomcomponent failures\\n•Stroke\\n•Subcutaneous emphysema\\n•Surgicalrevisionorreplacement ofthesystem\\n•Syncope\\n•Tissuedamage\\n•Tissueredness,irritation, numbness ornecrosis\\n•Vesselinjuryorperforation\\nTransientproceduraladverseeventsareexpectedinsomepatients.Theseinclude,butare\\nnotlimitedto,discomfort, painandothersystemicsymptoms thatmightberelatedto\\nmedications orotherinterventions performed duringimplant.\\nForalistofpotentialadverseeventsassociated withMRIscanning, refertotheMRI\\nTechnical Guide.\\nIfanyadverseeventsoccur,invasivecorrectiveactionand/orS-ICDSystemmodification or\\nremovalmayberequired.\\nPatientswhoreceiveanS-ICDSystemmaydeveloppsychological disorders thatinclude,\\nbutarenotlimitedto,thefollowing:\\n•Depression/anxiety\\n•Fearofdevicemalfunction\\n•Fearofshocks\\n•Phantom shocks', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 11}), Document(page_content='9WarrantyInformation\\nAlimitedwarrantycertificateforthesubcutaneous electrode isavailableatwww.\\nbostonscientific.c om.Foracopy,contactBostonScientificusingtheinformation onthe\\nbackcover.\\nPRE-IMPLANT INFORMATION\\nSurgicalPreparation\\nConsiderthefollowing priortotheimplantation procedure:\\nTheS-ICDSystemisdesigned tobepositioned usinganatomical landmarks. However,itis\\nrecommended toreviewapre-implant chestX-rayinordertoconfirmthatapatientdoes\\nnothavenotablyatypicalanatomy(e.g.,dextrocardia).Considermarkingtheintended\\npositionoftheimplanted systemcomponents and/orincisionspriortotheprocedure,\\nutilizinganatomical landmarks orfluoroscopyasaguide.Additionally ,ifdeviations from\\ntheimplantinstructions arerequiredtoaccommodate forphysicalbodysizeorhabitus,it\\nisrecommended thatapre-implant chestX-rayhasbeenreviewed.\\nWARNING: Attention isrequiredtoplacement ofthearmipsilateral tothedevice\\nimplanttoavoidinjuryoftheulnarnerveandbrachialplexuswhilethepatientisinthe\\nsupinepositionduringdeviceimplantation andbeforeVFinduction orshockdelivery.The\\npatientshouldbepositioned withthearmabducted toanangleofnomorethan60°with\\nthehandinasupinated (palmup)positionduringtheimplantphaseoftheprocedure.\\nSecuringthearmtoanarmboardisstandardpracticetomaintainpositioning ofthearm\\nduringdeviceimplantation. Donotstrapthearmtootightlyduringdefibrillation testing.\\nElevation ofthetorsothroughuseofawedgemayalsoaddstresstotheshoulderjoint\\nandshouldbeavoidedduringdefibrillation testing.\\nItemsIncludedinPackage\\nStoreinaclean,dryarea.Thefollowing pre-steriliz editemsareincludedwiththe\\nsubcutaneous electrode:\\n•Slitsuturesleeve\\nAdditionally ,productliteratureisincluded.\\nAccessories\\nSeparatelypackaged accessoriesareavailableinadditiontothosepackaged withthe\\nelectrode.Thefollowing accessoriesareusedforimplanting theelectrode, butarenot\\npackaged withtheelectrode:\\n•EMBLEMS-ICDElectrodeDeliverySystem(Model4712)\\n•EMBLEMS-ICDSubcutaneous ElectrodeInsertionTool(Model4711)\\n•SlitSutureSleeve;additional slitsuturesleevesthatarecompatible withthe\\nelectrodeareavailableasanaccessory(Model4760)\\nNOTE:LeadCap(Model7007)mayalsobeused.', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 12}), Document(page_content='10IMPLANTATION\\nOverview\\nNOTE:Implantation instructions forthesubcutaneous electrodeareincludedinthe\\nuser’smanualfortheelectrode implanttoolsthatwillbeused(see\"Accessories\"on\\npage9).Forexample,iftheelectrodewillbeimplanted usingtheEMBLEMS-ICD\\nElectrodeDeliverySystem(Model4712),refertotheEMBLEMS-ICDElectrodeDelivery\\nSystemUser’sManualforimplantinstructions.\\nThissectioncontainsanoverviewofinformation neededforimplanting theS-ICDsystem,\\nincluding thesubcutaneous electrode.\\nWARNING: AllBostonScientificS-ICDimplantable components aredesigned forusewith\\ntheBostonScientificorCameronHealthS-ICDSystemonly.Connection ofanyS-ICD\\nSystemcomponents toanon-compatiblecomponent hasnotbeentestedandcouldresult\\ninfailuretodeliverlife-saving defibrillation therapy.\\nWARNING: Implantofthesystemcannotbeperformed inanMRIsiteZoneIII(and\\nhigher)asdefinedbytheAmerican CollegeofRadiology Guidance Document onMRSafe\\nPractices3.Someoftheaccessoriesusedwithpulsegeneratorsandelectrodes, including\\nthetorquewrenchandelectrodeimplanttools,arenotMRConditional andshouldnotbe\\nbroughtintotheMRIscannerroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nNOTE:Iftheelectrodeterminalwillnotbeconnected toapulsegeneratoratthetimeof\\nelectrodeimplantation, youmustcaptheelectrodeterminalbeforeclosingthepocket\\nincision.Theleadcapisdesigned specifically forthispurpose.Placeasuturearoundthe\\nleadcaptokeepitinplace.\\nNOTE:UseofaBostonScientific/Cameron Healthelectrodeisrequiredforanimplanted\\nsystemtobeconsideredMRConditional. RefertotheMRITechnical Guideformodel\\nnumbersofsystemcomponents neededtosatisfytheConditions ofUse.\\nThepulsegeneratorandsubcutaneous electrodearetypicallyimplanted subcutaneously in\\ntheleftthoracicregion.Theelectrodeimplanttoolsareusedtocreatethesubcutaneous\\ntunnelsinwhichtheelectrode isinserted.Thedefibrillation coilmustbepositioned\\nparalleltothesternum,incloseproximity toorincontactwiththedeepfascia,below\\nadiposetissue,approximately 1-2centimeters fromthesternalmidline(Figure2Placement\\noftheS-ICDSystem(Model3501Electrode Shown)onpage11andFigure3Subcutaneous\\nTissueLayersonpage11).\\n3.KanalE,BarkovichAJ,BellC,etal.ACRguidance document onMRsafepractices:2013.J.Magn.Reson.\\nImaging2013;37:501-530.', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 13}), Document(page_content='11\\nFigure2.PlacementoftheS-ICDSystem(Model3501ElectrodeShown)\\n1\\n5\\n4\\n3\\n2\\n6\\n[1]Skin,[2]Hypodermal layer,[3]Adiposetissue,[4]Deepfascia,[5]Sub-fascial tissue\\n(muscleorbone),[6]Correctlocationforsubcutaneous tunnelsandtheS-ICD\\nSubcutaneous Electrode\\nFigure3.Subcutaneous TissueLayers\\nPlacementofthepulsegeneratorandelectrodecanbeachievedusingvarioustechniques.\\nToensureoptimalplacement ofthesubcutaneous electrodeatthefascialplane,physician', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 14}), Document(page_content='12preferenceandpatientassessment shouldbeconsideredwhenchoosingtheimplant\\nmethod.\\nCareshouldbetakentoplaceboththepulsegenerator andelectrode directlyonthefascia\\nwithoutunderlying adiposetissue.Adiposetissuecanaddsignificant impedance tothe\\nhighvoltageshockcurrentpathway.\\nToachievehighconversion successratesforVT/VF,thesystemplacement should\\nmaximize theheartmassbetweenthepulsegenerator andelectrode. Thiscreatesthebest\\nvectorforthedefibrillation currentwhilemaintaining acceptablesensingparameters. To\\naccomplishthis,theelectrode shouldbepositioned paralleltothesternum,betweenthe\\nmidtoparasternallineonthefascia,withminimaladiposetissueundertheelectrode\\nshockingcoilandsensingcontactareas.Thepulsegeneratorshouldalsobeonthefascia\\nwithminimalunderlying adiposetissue,andonthemid-axillary lineorposterioraxillary\\nline.Intermuscular placement ofthepulsegenerator helpsachieveposteriorpositionand\\ngoodelectricalcontactwithsurroundingtissue.Ensurethatneithertheelectrode northe\\npulsegenerator areplacedinferiorrelativetotheheartmass.\\nAftersystemplacement, iffailuretoconvertVT/VFwithanadequate safetymarginoccurs\\neitherduringdefibrillation testingorlaterspontaneous ambulatory episode(s), the\\nphysician shouldreviewthepositionofboththeelectrodeandpulsegenerator byuseof\\nanatomical landmarks orX-ray/fluoroscopy.Additionally ,theshockingelectrode\\nimpedance shouldbeevaluated.\\nWARNING: Highshockingelectrodeimpedanc emayreduceVT/VFconversionsuccess.\\nHighshockingelectrodeimpedance mayberelatedtolackofgoodtissuecontact,\\ninadequate pulsegenerator toelectrode mechanical connection ,orcertainpatient\\nconditions, andmaybeassociated with,butarenotlimitedto:\\n•Adiposetissueunderthepulsegenerator,ormoretypically,undertheshockingcoil\\noftheelectrode.\\n•Airentrapmentproximaltotheincision(s) (sternaltunnelorpulsegeneratorpocket).\\n•Marginalelectrode insertionorconnection withinthepulsegeneratorheader.\\n•Debriswithinthepulsegeneratorheaderbore.\\n•Largerbodyhabitus.\\n•Significant pulsegeneratororelectrode migration (anambulator yconsideration). For\\nexample, ifthepulsegenerator orelectrodemigratesawayfromthefascia.\\nLowshockingelectrode impedance maybeassociated with,butarenotlimitedto:\\n•Smallerbodyhabitus.\\n•Patientconditions suchaspleuraleffusion,whichdecreases theimpedanc eofthe\\nshockingcurrentpathway.\\n•Significant pulsegeneratororelectrode migration (anambulator yconsideration). For\\nexample, duringTwiddler’s Syndrome, theelectrode canbecomedislodged and\\ndrawnintothepulsegenerator pocketsothatbothshockingsurfacesareveryclose\\ntoeachother.\\nDepending onpatientbodyhabitusandanatomy,thephysician maychoosetoposition\\nthedevicebetweentheserratusanteriormuscleandthelatissimus dorsimuscle.Device\\nfixationtothemusculatur eisneededtosecureitsposition,ensureperformance, andto\\nminimize woundcomplications.', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 15}), Document(page_content='13Goodtissuecontactwiththeelectrode andpulsegeneratorisimportant tooptimize\\nsensingandtherapydelivery.Usestandardsurgicaltechniques toobtaingoodtissue\\ncontact.Forexample,keepthetissuemoistandflushedwithsterilesaline,expelany\\nresidualairoutthroughtheincisionspriortoclosingand,whenclosingtheskin,takecare\\nnottointroduceairintothesubcutaneous tissue.\\nRefertotheuser’smanualfortheelectrodeimplanttoolsthatwillbeusedtoimplantthe\\nsubcutaneous electrode forimplantation instructions, including creatingthesubcutaneous\\ntunnels,insertingtheelectrode, anchoring theelectrode,andcheckingtheelectrode\\npositionpriortoclosing.\\nPOST-IMPLANT\\nPostImplantFollow-UpProcedures\\nItisrecommended thatdevicefunctions beevaluated withperiodicfollow-up testingby\\ntrainedpersonnel toenablereviewofdeviceperformanc eandassociated patienthealth\\nstatusthroughoutthelifeofthedevice.Refertotheappropriatepulsegenerator literature\\nformoreinformation.\\nWARNING: Alwayshaveexternaldefibrillation equipment andmedicalpersonnel skilled\\ninCPRavailableduringimplantandfollow-up testing.Ifnotterminated inatimely\\nfashion,aninducedventricular tachyarrhythmia canresultinthepatient’sdeath.\\nExplantation andDisposal\\nContactBostonScientificwhenanyofthefollowing occur:\\n•Whenaproductisremovedfromservice.\\n•Intheeventofpatientdeath(regardlessofcause),alongwithanautopsyreport,if\\nperformed.\\n•Forotherobservation orcomplication reasons.\\nCAUTION: Beforeexplanting,complete thefollowing actionstopreventunwanted\\nshocks,overwritingofimportant therapyhistorydata,andaudibletones:\\n•ProgramthepulsegeneratortoTherapyOffmode.\\n•Disablethebeeper,ifavailable.\\nConsiderthefollowing itemswhenexplantingandreturningthepulsegenerator and/or\\nsubcutaneous electrode:\\n•Interrogatethepulsegenerator andprintallreports.\\n•Disconnect thesubcutaneous electrode fromthepulsegenerator.\\n•Ifsubcutaneous electrodeisnotexplantedandterminalwillnotbeconnected toa\\npulsegenerator,captheelectrodeterminalbeforeclosingthepocketincision.The\\nleadcapisdesigned specifically forthispurpose.Placeasuturearoundtheleadcap\\ntokeepitinplace.\\n•Ifsubcutaneous electrodeisexplanted, attempttoremoveitintact,andreturnit\\nregardlessofcondition. Donotremovethesubcutaneous electrodewithhemostats\\noranyotherclamping toolthatmaydamageit.Resorttotoolsonlyifmanual\\nmanipulation cannotfreethesubcutaneous electrode.', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 16}), Document(page_content=\"14•Wash,butdonotsubmerge,thepulsegeneratorandsubcutaneous electrodeto\\nremovebodyfluidsanddebrisusingadisinfectant solution.Donotallowfluidsto\\nenterthepulsegenerator'sconnector port.\\nCAUTION: Cleananddisinfectimplanted components usingstandardbiohazard\\nhandlingtechniques sinceallexplanted components areconsideredbiohazardous.\\nReturnallexplantedcomponents toBostonScientificregardless ofcondition. Fora\\nReturned ProductKit,contactBostonScientificusingtheinformation onthebackcover.\\nNOTE:Examination ofexplantedpulsegeneratorsandsubcutaneous electrodesby\\nBostonScientificcanprovideinformation forcontinued improvementinsystemreliability\\nandwarrantyconsiderations.\\nForallcomponentsthatarenotreturnedtoBostonScientific, tominimizeriskofinfection\\normicrobialhazardsafteruse,disposeofproductandpackaging asfollows:\\n•Afteruse,allexplantedcomponents areconsideredbiohazardous. Othercomponents\\nmayalsocontainbiohazardo ussubstances.\\n•Components thatcontainbiohazardous substancesshouldbedisposedina\\nbiohazard container thatislabeledwiththebiological hazardsymbolandtakentoa\\ndesignated facilityforbiohazardouswasteforpropertreatment inaccordancewith\\nhospital,administrat ive,and/orlocalgovernment policy.\\n•Biohazardous substancesshouldbetreatedwithanappropriate thermalorchemical\\nprocess.\\nNOTE:Untreatedbiohazardous substancesshouldnotbedisposedofinthe\\nmunicipal wastesystem.\\nNOTE:Disposalofexplanted pulsegeneratorsand/orsubcutaneous electrodesis\\nsubjecttoapplicable lawsandregulations.\\nWARNING: Donotreuse,reprocess,orresterilize.Reuse,reprocessing,orresterilization\\nmaycompromisethestructural integrityofthedeviceand/orleadtodevicefailurewhich,\\ninturn,mayresultinpatientinjury,illness,ordeath.Reuse,reprocessing,orresterilization\\nmayalsocreateariskofcontamination ofthedeviceand/orcausepatientinfectionor\\ncross-infection, including, butnotlimitedto,thetransmission ofinfectious disease(s) from\\nonepatienttoanother.Contamination ofthedevicemayleadtoinjury,illness,ordeathof\\nthepatient.\\nSPECIFICATIONS\\nEMBLEMS-ICDSubcutaneous ElectrodeSpecifications\\nTable1.ElectrodeSpecifications\\nSpecification Value\\nConnector SQ-1S-ICDconnector(non-standar d)\\nLength 45cm\\nDistalTipSize 3.84mm\", metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 17}), Document(page_content='15Table1.ElectrodeSpecifications (continued)\\nSpecification Value\\nCoilSize 9Fr\\nElectrode ShaftSize 7Fr\\nDistalSensingSurfaceArea 36mm2\\nProximalSensingSurfaceArea 46mm2\\nSensingLocation Distalelectrode attip\\nProximalelectrode 120mmfromtip\\nDefibrillation SurfaceArea 750mm2\\nDefibrillation Location 20mmfromtip\\nInsulation Material Polycarbonate polyurethane\\nElectrode Material,SensingConductors and\\nConnector PinsMP35N™a\\nSlitSutureSleeveMaterial Silicone\\nIntegrated SutureSleeveMaterial Radiopaque WhiteSilicone\\nStorageTemperatur eRange -18°Cto+55°C(0°Fto+131°F)\\nMaximum outerdiameteratSQ-1S-ICDconnector\\nseals4.0mm\\nDefibrillation coildiameter 3.0mm\\nLeadshockimpedance 25-200Ωb\\nMaximum LeadConductor Resistance\\nFromhighvoltageterminalringconnectionto\\ndefibrillation coil1Ω\\nFromlowvoltageterminalpintodistal\\nsensingelectrode ring50Ω\\nFromlowvoltagedistalterminalsensing\\nelectrodeconnectiontoproximalsensing\\nelectrodering50Ω\\na.MP35Nisatrademark ofSPSTechnologies, Inc.\\nb.post-shockpacingusesthesamevectorasshocking\\nTable2.Patient-contacting Materials\\nMaterial ApproximatePercentage(%)ofTotal\\nExposedSurfaceArea\\n(Totalnominalsurfaceareaofelectrodelead≈55cm2)', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 18}), Document(page_content='16Table2.Patient-contacting Materials (continued)\\nPolycarbonate polyurethane 40%\\nMetalalloy(MP35N™ ) 35%\\nSilicone 25%\\nTiO2(Titanium Dioxide),BaSO4(Bariumsulfate),\\npolyester polyurethaneAdditives and/orTraceamounts\\na.MP35Nisatrademark ofSPSTechnologies, Inc.\\nb.Traceamountsmakeuplessthan5%(combined)ofthetotalsurfacearea.\\nDefinitions ofPackageLabelSymbols\\nThefollowing symbolsmaybeusedonpackaging andlabeling.\\nTable3.PackagingSymbols\\nSymbol Description\\nSterilized usingethyleneoxide\\nDateofmanufacture\\nUseby\\nSerialnumber\\nReferencenumber\\nTemperatur elimitation\\nOpenhere\\nConsultinstructions foruseonthiswebsite:\\nwww.bostonscientific -elabeling.com\\nContents\\nSTERILIZE2\\nDonotresterilize\\nSingleuse.Donotre-use', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 19}), Document(page_content='17Table3.PackagingSymbols(continued)\\nSymbol Description\\nDonotuseifpackageisdamaged andconsult\\ninstructions foruse\\nManufacture r\\nMRConditional\\nSQ-1\\nNon-standar dconnector cavity\\nDoublesterilebarriersystem\\nUniqueDeviceIdentifier', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 20}), Document(page_content='', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 21}), Document(page_content='', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 22}), Document(page_content='Manufacturer\\nBostonScientificCorporation\\n4100HamlineAvenueNorth\\nSt.Paul,MN55112–5798 USA\\nwww.bostonscientific.com\\n1.800.CARDIAC (227.3422)\\n+1.651.582.4000\\n©2021BostonScientificCorporation oritsaffiliates.\\nAllrightsreserved.\\n92346951-002 ENUS2021-09\\n*92346951-002*', metadata={'source': 'raw_data/92346951-002_EMBLEM_S-ICD_UM_en_S.pdf', 'page': 23}), Document(page_content='MODEL 3877 EMBLEM™ S-ICD SYSTEM APPLICATION*\\nSUPPLEMENT FOR PULSE GENERATOR MANUALS\\nS-ICD PHYSICIAN’S TECHNICAL MANUALS\\n*FOR THE LATITUDE™ PROGRAMMING SYSTEM, MODEL 3300', metadata={'source': 'raw_data/92123954-001_EMBLEM_PTM_en_S.pdf', 'page': 0}), Document(page_content='', metadata={'source': 'raw_data/92123954-001_EMBLEM_PTM_en_S.pdf', 'page': 1}), Document(page_content='1This supplement provides a high-level overview of the key differences in the S-ICD software application \\nsoftware between the Model 3300 LATITUDE™ Programming System1 (Programmer) and the Model 3200 \\nEMBLEM™ S-ICD Programmer. \\nCurrent S-ICD pulse generator manuals describe features and functionalities when used with the Model 3200 \\nEMBLEM S-ICD Programmer. This literature supplements the content in those manuals with information specific \\nto the Model 3300 LATITUDE Programming System.\\nNOTE: The LATITUDE Programming System, Model 3300, has the same basic capabilities and intended use as \\nthe EMBLEM S-ICD Programmer, Model 3200.\\nPrimary Resources\\nSeparate operator manuals are provided for the Model 3300 LATITUDE Programming System and the Model \\n3877 EMBLEM S-ICD Application. Please read these manuals first:\\n • LATITUDE Programming System Operator’s Manual, Model 3300\\n • Network and Connectivity Operator’s Manual, Model 3924\\n • EMBLEM S-ICD Application Operator’s Manual, Model 3877\\nFor electronic copies, go to www.bostonscientific-elabeling.com. For hard copies, contact Boston Scientific \\nusing the information on the back of this supplement.\\nGENERAL DIFFERENCES\\nConnecting to an S-ICD Device\\n • The required Model 3203 S-ICD Wand connects to a port on the right side of the Programmer ( Figure \\n1 on page 3 ).\\n • The Model 3877 S-ICD Device Programmer application and Model 3889 Automated Screening Tool \\napplication are accessed from the main menu of the Model 3300 Programmer:\\n • To access the Model 3877 S-ICD application, select S-ICD Applications icon from the Programmer \\nMain Menu, then select S-ICD Device Programmer Application, as shown in Figure 2 on page \\n4. Press the Scan for Devices button to find and connect to an S-ICD device.\\n • The Model 3877 S-ICD Application loads about 30 seconds after the S-ICD Device Programmer \\nApplication button is pressed.\\n • The battery status for the Programmer is visible on the upper right of the S-ICD application main \\nscreen ( Figure 3 on page 5 ).\\n1 The Model 3300 Programmer may not yet be available in all geographies. For additional information,   \\ncontact Boston Scientific using the information on the back of this supplement.', metadata={'source': 'raw_data/92123954-001_EMBLEM_PTM_en_S.pdf', 'page': 2}), Document(page_content='2Rescue Shock\\n • To provide a rescue shock, interrogate the S-ICD pulse generator (PG), enable therapy on the S-ICD \\nPG (Programmer screen displays “Therapy:  On”), and press either the red STAT hard key at the upper \\nright of the Model 3300 Programmer or the Rescue Shock button \\n  from the S-ICD application. \\n • The STAT Operation is for defibrillation therapy only; there is no STAT pacing available.\\nUtilities \\n • Programmer Language: The programmer language is selected from the Model 3300 Utilities \\ntoolbar. Select the Setup tab and then the appropriate language.\\n • Time Zone: The time zone is selected from the Model 3300 Utilities toolbar. Select the Date and \\nTime tab and then the appropriate time zone.\\n • Noise Filter Configuration: The noise filter configuration for the Model 3300 Programmer is now \\na separate selection (50 or 60 Hz) in the S-ICD application and is set at the factory according to the \\ngeography.2 \\n •Bluetooth®  Communication: Bluetooth®  communication is enabled from the Model 3300 Utilities \\ntoolbar. Select the Network Setup tab and then the Bluetooth ® tab to activate the Bluetooth ® \\ncapability of the Model 3300 Programmer. This is necessary in order to have the S-ICD application \\nuse Bluetooth ® printers and communicate with other Bluetooth ® enabled computers.\\nPatient Data\\n • The microSD™ card port on the Model 3200 Programmer has been replaced by USB ports on the \\nModel 3300 Programmer.\\n • To save patient and  device information, insert a USB drive3 while you are at the S-ICD application \\nmain screen ( Figure 3 on page 5 ). After a short delay, the Copy Data screen displays, and data \\ncan be copied to the USB drive. \\n • To store patient and device data on the Model 3300 Programmer internal drive, the user must first \\ninterrogate the pulse generator. Then, pressing the End Session button from the S-ICD Main Menu \\n(see Figure 4 on page 5 ) stores the patient data on the internal drive. To access stored S-ICD \\ndata, launch the S-ICD application, then select Stored Patient Sessions (see Figure 3 on page 5 ).\\n • Patient data on the Model 3300 hard drive is encrypted. When exporting patient data to a USB drive, \\nthe Model 3300 Programmer provides an option to create a password on the USB drive.\\n • The S-ICD software maintains a maximum of 50 patient files; the oldest is deleted and overwritten \\nwhen the 51st patient file is created. \\n2 The filter setting can be changed if the Programmer is moved to a different geography.\\n3 A USB storage device must be formatted to FAT32 to be recognized by the Programmer.', metadata={'source': 'raw_data/92123954-001_EMBLEM_PTM_en_S.pdf', 'page': 3}), Document(page_content='3 • Stored patient and device data older than 90 days is automatically purged without notification to the \\nuser.\\n1\\nA/RV\\nLV\\n[1] Model 3203 S-ICD Wand Connection Port\\nFigure 1.  Right-hand (Patient) Side of the Model 3300 Programmer\\nDESCRIPTION\\nThe pulse generator and subcutaneous electrode constitute the implantable portion of the S-ICD System. The \\npulse generator can be used only with the Model 3203 Telemetry Wand and either a) the Model 3200 EMBLEM \\nS-ICD programmer or b) the Model 3300 LATITUDE Programming System.\\nSETTING UP THE PULSE GENERATOR USING THE MODEL 3300 PROGRAMMER\\nA brief setup process must be completed before the device can deliver therapy. Additional details can be found \\nin the EMBLEM™ S-ICD Application Operator’s Manual, Model 3877 . \\nTo initiate the process: (see Figure 2 on page 4 )\\n1. From the main screen of the 3300 Programmer, press the S-ICD Applications button.\\n2. The S-ICD Applications window displays.\\n3. Press the S-ICD Device Programmer Application button.\\n4. Wait until the application loads (about 30 seconds) and displays the S-ICD application main screen.\\n5. From the S-ICD application main screen, begin a programming session for the S-ICD PG by pressing the \\nScan For Devices button.', metadata={'source': 'raw_data/92123954-001_EMBLEM_PTM_en_S.pdf', 'page': 4}), Document(page_content='46. Select an S-ICD PG from the list.\\n7. If the S-ICD PG selected is still in shelf mode, press the Continue button to exit shelf mode.\\n8. Start the manual or automatic setup process.\\nProgrammer Settings\\nStored Patient Sessions\\nExport Programmer Data\\nPower OffScan For Devices\\n1\\n2\\n3\\n4\\n5\\n[1] Model 3300 Main Menu [2] S-ICD Applications button [3] S-ICD Applications [4] Start S-ICD Application dialog [5] S-ICD \\nApplication main screen\\nFigure 2.  Accessing the S-ICD Application  (representative images)', metadata={'source': 'raw_data/92123954-001_EMBLEM_PTM_en_S.pdf', 'page': 5}), Document(page_content='5Figure 3.  \\nS-ICD Application main screen\\nFigure 4.  \\nS-ICD Main Menu\\nTRADEMARK STATEMENT\\nThe following are trademarks of Boston Scientific Corporation or its affiliates: LATITUDE and EMBLEM.\\nThe Bluetooth ® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of \\nsuch marks is under license.\\nmicroSD (secure digital) is a trademark of the SD Association (SD-3C, LLC)', metadata={'source': 'raw_data/92123954-001_EMBLEM_PTM_en_S.pdf', 'page': 6}), Document(page_content='manufacturer\\nBoston Scientific Corporation\\n4100 Hamline Avenue North\\nSt. Paul, MN 55112-5798 USA\\nmanufactured  at\\nCardiac Pacemakers Incorporated \\n4100 Hamline Avenue North\\nSt. Paul, MN 55112-5798 USA\\n1.800.CARDIAC (227.3422)\\n+1.651.582.4000 \\nwww.bostonscientific.com\\nauthorized  representative  in the european  community\\nGuidant Europe NV/SA; Boston Scientific\\nGreen Square, Lambroekstraat 5D\\n1831 Diegem, Belgium\\naustralian  sponsor  address\\nBoston Scientific (Australia) Pty Ltd\\nPO Box 332\\nBOTANY NSW 1455 Australia\\nFree Phone 1 800 676 133\\nFree Fax 1 800 836 66692123954-001  en  2020-01   \\n© 2020 Boston Scientific Corporation or its affiliates.\\nAll Rights Reserved.*92123954-001*', metadata={'source': 'raw_data/92123954-001_EMBLEM_PTM_en_S.pdf', 'page': 7}), Document(page_content='PHYSICIAN’S TECHNICAL MANUAL\\nRESONATE™HFCRT-D,\\nRESONATE™CRT-D,\\nRESONATE™X4CRT-D,\\nVIGILANT™CRT-D,\\nVIGILANT™X4CRT-D,\\nMOMENTUM™CRT-D,\\nMOMENTUM™X4CRT-D\\nCARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR\\nREFG524,G525,G526,G528,G537,G547,G548,G424,G425,G426,G428,G437,G447,G448,\\nG224,G225,G228,G237,G247,G248,G124,G125,G126,G128,G138\\nCAUTION: Federallaw(USA)restricts\\nthisdevicetosalebyoronthe\\norderofaphysician trainedor\\nexperiencedindeviceimplantand\\nfollow-up procedures.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 0}), Document(page_content='', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 1}), Document(page_content='TableofContents\\nTrademarkStatement ..........................................................................................................................1\\nAdditional Information .........................................................................................................................1\\nDeviceDescription ...............................................................................................................................1\\nRelatedInformation .............................................................................................................................4\\nIndications andUsage..........................................................................................................................5\\nContraindications................................................................................................................................5\\nWarnings...........................................................................................................................................5\\nPrecautions ........................................................................................................................................8\\nSupplemental Precautionary Information ................................................................................................21\\nPost-TherapyPulseGeneratorFollowUp.......................................................................................21\\nMagnetic Resonance Imaging(MRI).............................................................................................22\\nTranscutaneous ElectricalNerveStimulation (TENS).........................................................................25\\nElectrocautery andRadioFrequency (RF)Ablation...........................................................................26\\nIonizingRadiation .....................................................................................................................27\\nElevatedPressures...................................................................................................................28\\nPotentialAdverseEvents....................................................................................................................30\\nMechanical Specifications. ...................................................................................................................33\\nItemsIncludedinPackage...................................................................................................................37\\nSymbolsonPackaging .......................................................................................................................38\\nCharacteristics asShipped...................................................................................................................42\\nX-RayIdentifier.................................................................................................................................44\\nFederalCommunications Commission (FCC)............................................................................................45\\nPulseGenerator Longevity ..................................................................................................................45\\nWarrantyInformation .........................................................................................................................50\\nProductReliability .............................................................................................................................50\\nPatientCounseling Information .............................................................................................................51', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 2}), Document(page_content='PatientHandbook ....................................................................................................................52\\nLeadConnections ..............................................................................................................................53\\nImplanting thePulseGenerator...........................................................................................................58\\nCheckEquipment .....................................................................................................................59\\nInterrogate andCheckthePulseGenerator....................................................................................59\\nImplanttheLeadSystem...........................................................................................................60\\nTakeBaselineMeasurements. .....................................................................................................62\\nFormtheImplantation Pocket.....................................................................................................65\\nConnecttheLeadstothePulseGenerator .....................................................................................66\\nEvaluateLeadSignals................................................................................................................71\\nProgramthePulseGenerator ......................................................................................................73\\nTestforAbilitytoConvertVentricular Fibrillation andInducible\\nArrhythmias ...................................................................................................................76\\nTachyarrhythmia ProgrammingConsiderations. ..............................................................................79\\nImplantthePulseGenerator. ......................................................................................................80\\nComplete andReturntheImplantation Form..................................................................................81\\nBidirectional TorqueWrench................................................................................................................82\\nFollowUpTesting.............................................................................................................................84\\nExplantation andDisposal...................................................................................................................85', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 3}), Document(page_content='1TRADEMARK STATEMENT\\nThefollowing aretrademarks ofBostonScientificCorporation oritsaffiliates:\\nAcuShock,AVT,CONTAK,CONTAKRENEWAL,EASYVIEW,ENDURALIFE,HeartLogic, IMAGEREADY ,\\nLATITUDE,MOMENTUM, Onset/Stability ,PaceSafe,QuickCapture,QuickConvert,QUICKNOTES,\\nRESONATE,RHYTHMID,RHYTHMMATCH,SafetyCore,SmartBlanking,SmartDelay,VectorGuide,\\nVIGILANT,ZIP,ZOOM,ZOOMVIEW.\\nADDITIONAL INFORMATION\\nForadditional referenceinformation, gotowww.bostonscientific -elabeling.com.\\nDEVICEDESCRIPTION\\nThismanualcontainsinformation abouttheRESONATE HF,RESONATE, VIGILANT, andMOMENTUM familiesofcardiac\\nresynchronization therapydefibrillators (CRT-Ds)(specificmodelsarelistedin\"Mechanical Specifications\" onpage33):\\nNOTE:Thismanualmaycontaininformation formodelnumbersthatarenotcurrentlyapproved forsaleinallgeographies.\\nForacompletelistofmodelnumbersapproved inyourgeography ,consultwithyourlocalsalesrepresentative. Somemodel\\nnumbersmaycontainfewerfeatures;forthosedevices,disregardinformation aboutunavailable features.Referencestonames\\nofnon-quadripolar devicesalsoapplytothecorresponding quadripolar devices.\\nNOTE:AlldevicesexceptforthosewithanLV:LV-1leadconnectionareconsideredMRConditional. Referto\"Magnetic\\nResonance Imaging(MRI)\"onpage22andtheImageReady MRConditional Defibrillation SystemMRITechnical Guideformore\\ninformation.\\nTherapies\\nThesepulsegenerators haveasmall,thin,physiologic shapethatminimizespocketsizeandmayminimize devicemigration.\\nTheyprovideavarietyoftherapies, including:\\n•Ventricular tachyarrhythmia therapy,whichisusedtotreatrhythmsassociated withsuddencardiacdeath(SCD)suchas\\nVTandVF', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 4}), Document(page_content='2•CardiacResynchronization Therapy(CRT),whichtreatsheartfailurebyresynchronizingventricular contractionsthrough\\nbiventricular electricalstimulation\\n•Bradycardiapacing,including adaptiveratepacing,todetectandtreatbradyarrhythmias andtoprovidecardiacrate\\nsupportafterdefibrillation therapy\\nCardioversion/defibrillation therapiesinclude:\\n•Arangeoflow-andhigh-energy shocksusingabiphasicwaveform\\n•Thechoiceofmultipleshockvectors:\\n–Distalshockelectrode toproximalshockelectrode andpulsegenerator case(TRIADelectrode system)\\n–Distalshockelectrode toproximalshockelectrode (RVCoiltoRACoil)\\n–Distalshockelectrode topulsegenerator case(RVCoiltoCan)\\nLeads\\nThepulsegenerator hasindependently programmable outputsandacceptsoneormoreofthefollowing leads,depending on\\nthemodel:\\n•OneIS-11atriallead\\n•OneLV-1unipolarorbipolarleftventricular lead\\n•OneIS-1unipolarorbipolarleftventricular lead\\n•OneIS42quadripolar leftventricular lead\\n•OneDF-1/IS-13cardioversion/defibrillation lead\\n1.IS-1referstotheinternational standardISO5841-3:2013.\\n2.IS4referstotheinternational standardISO27186:2010.\\n3.DF-1referstotheinternational standardISO11318:2002.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 5}), Document(page_content=\"3•OneDF4-LLHH orDF4-LLHO4multipolar connector cardioversion/defibrillation lead\\nLeadswitheitheraGDT-LLHH/LLHO orDF4-LLHH/LLHO labelareequivalent andarecompatible withadevicecontaining either\\naGDT-LLHH orDF4-LLHH port.\\nThepulsegenerator andtheleadsconstitute theimplantable portionofthepulsegenerator system.\\nNOTE:UseofBostonScientificMRConditional leadsisrequiredforanimplanted systemtobeconsideredMRConditional.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnical Guideformodelnumbersofpulsegenerators,\\nleads,accessories,andothersystemcomponents neededtosatisfytheConditions ofUse.\\nProgramming System\\nThesepulsegenerators canonlybeusedwiththeModel3300LATITUDE ProgrammingSystem.TheLATITUDE Programming\\nSystemistheexternalportionofthepulsegenerator system.\\nNOTE:The2868softwareapplication onthemodel3120LATITUDE programmingsystemisoutdated andshouldnotbeused\\nwiththepulsegenerators. Forassistance, call+1.651.582.4000 (worldwide) orcontactyourlocalBostonScientificrepresentative.\\nThe3300LATITUDE ProgrammingSystemincludes:\\n•Model3300Programmer\\n•Model3868SoftwareApplication\\n•Model6395AccessoryTelemetry Wand\\nYoucanusetheprogrammingsystemtodothefollowing:\\n•Interrogate thepulsegenerator\\n•Programthepulsegenerator toprovideavarietyoftherapyoptions\\n•Accessthepulsegenerator's diagnostic features\\n4.DF4referstotheinternational standardISO27186:2010.\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 6}), Document(page_content=\"4•Performnoninvasive diagnostic testing\\n•Accesstherapyhistorydata\\n•Storea12secondtraceoftheECG/EGM displayfromanyscreen\\n•Accessaninteractive Demonstration ModeorPatientDataModewithoutthepresenceofapulsegenerator\\n•Printpatientdataincluding pulsegenerator therapyoptionsandtherapyhistorydata\\n•Savepatientdata\\nYoucanprogramthepulsegenerator usingtwomethods: automatically usingIndications-Based Programming(IBP)or\\nmanually.\\nRELATEDINFORMATION\\nRefertothelead'sinstruction manualforimplantinformation, generalwarnings andprecautions, indications, contraindications,\\nandtechnicalspecifications. Readthismaterialcarefullyforimplantprocedureinstructions specifictothechosenlead\\nconfigurations.\\nRefertothePRMsystemOperator's ManualorZOOMWirelessTransmitterReferenceGuideforspecificinformation aboutthe\\nPRMorZOOMWirelessTransmitter suchassetup,maintenance, andhandling.\\nRefertothesepulsegenerators’ ReferenceGuideforadditional referenceinformation suchasusingthePRMsoftware,\\ntachyarrhythmia detection andtherapy,pacingtherapy,sensing,anddiagnostics.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnical Guideforinformation aboutMRIscanning.\\nRefertotheHeartLogic Technical Guideforinformation abouttheHeartLogic HeartFailureDiagnostic Service.\\nLATITUDE NXTisaremotemonitoring systemthatprovidespulsegenerator dataforclinicians. Allpulsegenerators described in\\nthismanualaredesigned tobeLATITUDE NXTenabled;availability variesbyregion.\\n•Physicians/Clinicians—LATITUDE NXTenablesyoutoperiodically monitorbothpatientanddevicestatusremotelyand\\nautomatically .TheLATITUDE NXTsystemprovidespatientdatathatcanbeusedaspartoftheclinicalevaluation ofthe\\npatient.\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 7}), Document(page_content='5•Patients—A keycomponent ofthesystemistheLATITUDE Communicator ,aneasy-to-use, in-homemonitoring device.\\nTheCommunicator automatically readsimplanted devicedatafromacompatible BostonScientificpulsegenerator at\\ntimesscheduled bythephysician. TheCommunicator sendsthisdatatotheLATITUDE NXTsecureserver.TheLATITUDE\\nNXTserverdisplaysthepatientdataontheLATITUDE NXTWebsite,whichisreadilyaccessibleovertheInternetto\\nauthorized physicians andclinicians.\\nRefertotheLATITUDE NXTClinicianManualformoreinformation.\\nINTENDED AUDIENCE\\nThisliteratureisintendedforusebyprofessionals trainedorexperience dindeviceimplantand/orfollow-up procedures.\\nINDICATIONS ANDUSAGE\\nTheseBostonScientificCardiacResynchronization TherapyDefibrillators (CRT-Ds)areindicated forpatientswithheartfailure\\nwhoreceivestableoptimalpharmacologic therapy(OPT)forheartfailureandwhomeetanyoneofthefollowing classifications:\\n•Moderate tosevereheartfailure(NYHAClassIII-IV)withEF≤35%andQRSduration≥120ms\\n•Leftbundlebranchblock(LBBB)withQRSduration≥130ms,EF≤30%,andmild(NYHAClassII)ischemicornonischemic\\nheartfailureorasymptomatic (NYHAClassI)ischemicheartfailure\\nCONTRAINDICATIONS\\nTherearenocontraindications forthisdevice.\\nWARNINGS\\nGeneral\\n•Labelingknowledge. Readthismanualthoroughly beforeimplantation toavoiddamagetothepulsegenerator and/or\\nlead.Suchdamagecanresultinpatientinjuryordeath.\\n•Forsinglepatient/singleprocedureuseonly.Donotreuse,reprocess,orresterilize.Reuse,reprocessing, or\\nresterilization maycompromisethestructural integrityofthedeviceand/orleadtodevicefailurewhich,inturn,mayresult', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 8}), Document(page_content=\"6inpatientinjury,illness,ordeath.Reuse,reprocessing,orresterilization mayalsocreateariskofcontamination ofthe\\ndeviceand/orcausepatientinfectionorcross-infection, including, butnotlimitedto,thetransmission ofinfectious\\ndisease(s) fromonepatienttoanother.Contamination ofthedevicemayleadtoinjury,illness,ordeathofthepatient.\\n•Backupdefibrillation protection. Alwayshaveexternaldefibrillation equipment availableduringimplantand\\nelectrophysiologic testing.Ifnotterminated inatimelyfashion,aninducedventricular tachyarrhythmia canresultinthe\\npatient'sdeath.\\n•Resuscitation availability .Ensurethatanexternaldefibrillator andmedicalpersonnel skilledinCPRarepresentduring\\npost-implantdevicetestingshouldthepatientrequireexternalrescue.\\n•Patchleads.Donotusedefibrillation patchleadswiththepulsegenerator system,orinjurytothepatientmayoccur.\\n•Separatepulsegenerator. Donotusethispulsegenerator withanotherpulsegenerator.Thiscombination couldcause\\npulsegenerator interaction, resultinginpatientinjuryoralackoftherapydelivery.\\nHandling\\n•Avoidshockduringhandling. Programthepulsegenerator TachyMode(s)toOffduringimplant,explant,orpostmortem\\nprocedurestoavoidinadvertent highvoltageshocks.\\n•Donotkinkleads.Donotkink,twist,orbraidtheleadwithotherleadsasdoingsocouldcauseleadinsulation abrasion\\ndamageorconductordamage.\\n•HandlingtheleadwithoutConnector Tool.ForleadsthatrequiretheuseofaConnector Tool,usecautionhandlingthe\\nleadterminalwhentheConnector Toolisnotpresentonthelead.Donotdirectlycontacttheleadterminalwithany\\nsurgicalinstruments orelectricalconnections suchasPSA(alligator) clips,ECGconnections, forceps,hemostats, and\\nclamps.Thiscoulddamagetheleadterminal,possiblycompromisingthesealingintegrityandresultinlossoftherapyor\\ninappropriate therapy,suchasashortwithintheheader.\\n•Handlingtheterminalwhiletunneling. DonotcontactanyotherportionoftheDF4–LLHH orDF4–LLHO leadterminal,\\notherthantheterminalpin,evenwhentheleadcapisinplace.\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 9}), Document(page_content='7DonotcontactanyotherportionoftheIS4–LLLLleadterminal,otherthantheterminalpin,evenwhentheleadcapisin\\nplace.\\n•Appropriateleadconnections. Whenimplanting asystemwhichusesbothaDF4-LLHH/LLHO andIS4-LLLLlead,ensure\\nthattheleadsareinsertedandsecuredintheappropriat eports.Insertingaleadintoanincorrectportwillresultin\\nunanticipated devicebehavior(potentially leavingthepatientwithouteffectivetherapy).\\nProgramming andDeviceOperations\\n•Atrialtrackingmodes.Donotuseatrialtrackingmodesinpatientswithchronicrefractoryatrialtachyarrhythmias.\\nTrackingofatrialarrhythmias couldresultinventricular tachyarrhythmias.\\n•Atrial-only modes.Donotuseatrial-only modesinpatientswithheartfailurebecausesuchmodesdonotprovideCRT.\\n•Ventricular sensing.Leftventricular leaddislodgement toapositionneartheatriacanresultinatrialoversensing and\\nleftventricular pacinginhibition.\\n•SlowVT.Physicians shouldusemedicaldiscretion whenimplanting thisdeviceinpatientswhopresentwithslowVT.\\nProgramming therapyforslowmonomorphic VTmayprecludeCRTdeliveryatfasterratesiftheseratesareinthe\\ntachyarrhythmia zones.\\nPost-Implant\\n•Protectedenvironments. Advisepatientstoseekmedicalguidance beforeenteringenvironments thatcouldadversely\\naffecttheoperation oftheactiveimplantable medicaldevice,including areasprotected byawarningnoticethatprevents\\nentrybypatientswhohaveapulsegenerator.\\n•MagneticResonance Imaging(MRI)exposure. AlldevicesexceptforthosewithanLV:LV-1leadconnectionare\\nconsideredMRConditional. Forthesedevices,unlessalloftheMRIConditions ofUsearemet,MRIscanningofthepatient\\ndoesnotmeetMRConditional requirements fortheimplanted system.Significant harmtoordeathofthepatientand/or\\ndamagetotheimplanted systemmayresult.Donotexposepatientswithnon-MRConditional devicestoMRIscanning.\\nStrongmagnetic fieldsmaydamagethepulsegenerator and/orleadsystem,possiblyresultingininjurytoordeathofthe\\npatient.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 10}), Document(page_content='8Forpotentialadverseeventsapplicable whentheConditions ofUsearemetornotmet,refertotheImageReady MR\\nConditional Defibrillation SystemMRITechnical Guide.Foradditional warnings, precautions, andConditions ofUse,refer\\nto\"Magnetic Resonance Imaging(MRI)\"onpage22.\\n•Diathermy .Donotsubjectapatientwithanimplanted pulsegenerator and/orleadtodiathermy sincediathermy may\\ncausefibrillation, burningofthemyocardium, andirreversibledamagetothepulsegenerator becauseofinduced\\ncurrents.\\n•EnsurePTMisenabled. Ifdesired,ensurethatPatientTriggered Monitorisenabledpriortosendingthepatienthomeby\\nconfirming theMagnetResponse isprogrammedtoStoreEGM.Ifthefeatureisinadvertently leftintheInhibitTherapy\\nsetting,thepatientcouldpotentially disabletachyarrhythmia detection andtherapy.\\n•MagnetResponse settoInhibitTherapy.OncethePatientTriggered Monitorfeaturehasbeentriggered bythemagnet\\nandanEGMhasbeenstored,orafter60dayshaveelapsedfromthedaythatStoreEGMwasenabled,theMagnet\\nResponse programmingautomatically willbesettoInhibitTherapy.Whenthishappens, thepatientshouldnotapplythe\\nmagnetbecausetachyarrhythmia therapycouldbeinhibited.\\nPRECAUTIONS\\nClinicalConsiderations\\n•Pacemaker-mediated tachycardia (PMT).Programmingminimum PVARPlessthanretrogradeV–Aconduction may\\nincreasethelikelihood ofaPMT.\\n•MVSensormodes.ThesafetyandefficacyoftheMVSensormodeshavenotbeenclinicallyestablished inpatientswith\\nabdominal implantsites.\\n•MVSensormodeperformance. MVSensorperformance maybeadversely affectedundertransientconditions suchas\\npneumothorax, pericardial effusion,orpleuraleffusion.ConsiderprogrammingtheMVSensorOffuntiltheseconditions\\nareresolved.\\n•Adaptive-rate modes.Adaptive-rate modesbasedcompletelyorinpartonMVmightbeinappropriateforpatientswho\\ncanachieverespiratorycyclesshorterthanonesecond(greaterthan60breathsperminute).Higherrespiration rates', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 11}), Document(page_content='9attenuate theimpedance signal,whichdiminishes theMVrateresponse(i.e.,thepacingratewilldroptowardthe\\nprogrammedLRL).\\nAdaptive-ra temodesbasedcompletely orinpartonMVshouldnotbeusedforpatientswith:\\n•Aseparatepacemaker\\n•Aleadotherthanabipolartransvenous lead—MV measurement hasonlybeentestedwithabipolartransvenous\\nlead\\n•Amechanical ventilator—use oftheventilator mightresultinaninappropriate MVSensor-drivenrate\\n•RateAdaptivePacinginHeartFailurePatients. TheclinicalbenefitofRateAdaptivePacinginheartfailurepatientshas\\nnotbeenstudied.RateAdaptivePacingshouldbeusedwithmedicaldiscretion ifthepatientdevelopsanindication such\\naschronotrop icincompetenc e.Patientswithheartfailuremayhavehemodynamic compromiseatrapidsensor-driven\\nrates,andthephysician maywishtoprogramlessaggressive rateadaptiveparameters inaccordancewithpatient\\ncondition.Heartfailure-relatedrespiratorychangesinpatient’sminuteventilation (MV)mayinappropriately increase\\npacedratetotheupperrate(MSR),forinstanceduringheartfailureatrest.Ifthisoccurs,physicians mayconsiderturning\\noffrateresponsive pacingormodifying theRateAdaptivePacingsettings.RateAdaptivePacingmaybehelpfulforheart\\nfailurepatientswithcoexistingbradyarrhythmic conditions.\\nSterilization andStorage\\n•Ifpackageisdamaged. Theblistertraysandcontentsaresterilizedwithethyleneoxidegasbeforefinalpackaging.\\nWhenthepulsegenerator and/orleadisreceived,itissterileprovidedthecontainer isintact.Ifthepackaging iswet,\\npunctured,opened,orotherwise damaged, returnthepulsegenerator and/orleadtoBostonScientific.\\n•Ifdeviceisdropped.Donotimplantadevicewhichhasbeendroppedwhileoutsideofitsintactshelfpackage.Donot\\nimplantadevicewhichhasbeendroppedfromaheightofmorethan24inches(61cm)whilewithinitsintactshelf\\npackage.Sterility,integrity,and/orfunctioncannotbeguaranteedundertheseconditions, andthedeviceshouldbe\\nreturnedtoBostonScientificforinspection.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 12}), Document(page_content=\"10•Storagetemperature andequilibration. Recommended storagetemperatur esare0°C–50°C (32°F–122°F). Allowthe\\ndevicetoreachapropertemperature beforeusingtelemetry communication capabilities, programming,orimplanting the\\ndevicebecausetemperatureextremesmayaffectinitialdevicefunction.\\n•Devicestorage.Storethepulsegenerator inacleanareaawayfrommagnets, kitscontaining magnets, andsourcesof\\nEMItoavoiddevicedamage.\\n•Usebydate.Implantthepulsegenerator and/orleadbeforeorontheUSEBYdateonthepackagelabelbecausethis\\ndatereflectsavalidated shelflife.Forexample, ifthedateisJanuary1,donotimplantonorafterJanuary2.\\nImplantation\\n•Expectedbenefits. Determine whethertheexpecteddevicebenefitsprovidedbyprogrammable optionsoutweigh the\\npossibility ofmorerapidbatterydepletion.\\n•Evaluatepatientforsurgery.Theremaybeadditional factorsregardingthepatient'soverallhealthandmedical\\ncondition that,whilenotrelatedtodevicefunctionorpurpose,couldrenderthepatientapoorcandidate forimplantation\\nofthissystem.Cardiachealthadvocacy groupsmayhavepublished guidelines thatmaybehelpfulinconducting this\\nevaluation.\\n•Leadcompatibility .Priortoimplantation, confirmthelead-to-pulse generator compatibility .Usingincompatible leads\\nandpulsegenerators candamagetheconnector and/orresultinpotentialadverseconsequenc es,suchasundersensing of\\ncardiacactivityorfailuretodelivernecessary therapy.\\n•Telemetry wand.Makesureasteriletelemetry wandisavailableshouldlossofZIPtelemetry occur.Verifythatthewand\\ncaneasilybeconnectedtotheprogrammerandiswithinreachofthepulsegenerator.\\n•Line-powered equipment. Exerciseextremecautioniftestingleadsusingline-powere dequipment becauseleakage\\ncurrentexceeding10µAcaninduceventricular fibrillation. Ensurethatanyline-powere dequipment iswithin\\nspecifications.\\n•Replacement device.Implanting areplacement deviceinasubcutaneous pocketthatpreviously housedalargerdevice\\nmayresultinpocketairentrapment, migration, erosion,orinsufficient grounding betweenthedeviceandtissue.Irrigating\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 13}), Document(page_content='11thepocketwithsterilesalinesolutiondecreases thepossibility ofpocketairentrapment andinsufficient grounding.\\nSuturingthedeviceinplacereducesthepossibility ofmigration anderosion.\\n•Donotbendtheleadnearthelead-header interface. Inserttheleadterminalstraightintotheleadport.Donotbend\\ntheleadnearthelead-header interface.Improper insertioncancauseinsulation orconnector damage.\\n•Absenceofalead.Theabsenceofaleadorpluginaleadportmayaffectdeviceperformance andpotentially leavethe\\npatientwithouteffectivetherapy.Ifaleadisnotused,verifythattheplugandlabeledheaderportmatch(i.e.,IS-1,DF-1,\\nLV-1,IS4,orDF4).Fullyinserttheplugintheunusedportandthentightenthesetscrewontotheplug.Verifyappropriate\\ndevicefunctionusingtheprogrammer.\\n•Afunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriate sensingandpacinginall\\nchambers, regardlessofprogrammedconfiguration.ThisincludesCRTdevicesprogrammedtoAAI(R)orLV-Only\\npacing.\\n•Lackofafunctional RVleadmayresultinundersensing, and/oroversensing andleavethepatientwithouteffective\\ntherapy.\\n•Electrodeconnections. Donotinsertaleadintothepulsegenerator connectorwithouttakingthefollowing precautions\\ntoensureproperleadinsertion:\\n•Insertthetorquewrenchintothepreslitdepression ofthesealplugbeforeinsertingtheleadintotheport,to\\nreleaseanytrappedfluidorair.\\n•Visuallyverifythatthesetscrewissufficiently retractedtoallowinsertion. Usethetorquewrenchtoloosenthe\\nsetscrewifnecessary.\\n•Fullyinserteachleadintoitsleadportandthentightenthesetscrewontotheterminalpin.\\n•Defibrillation leadimpedance. Iftotalshockingleadimpedance duringimplantislessthan20Ω,verifytheproximalcoil\\nisnotincontactwiththepulsegenerator surface.Ameasurement oflessthan20Ωisanindication ofashortsomewhere\\ninthesystem.Ifrepeatedmeasurements showthetotalshockingleadimpedance islessthan20Ω,theleadand/orpulse\\ngenerator mayneedtobereplaced.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 14}), Document(page_content=\"12•Shuntingenergy.Donotallowanyobjectthatiselectrically conductivetocomeintocontactwiththeleadordevice\\nduringinduction becauseitmayshuntenergy,resultinginlessenergygettingtothepatient,andmaydamagethe\\nimplanted system.\\n•Donotsuturedirectlyoverlead.Donotsuturedirectlyovertheleadbody,asthismaycausestructural damage.Usethe\\nsuturesleevetosecuretheleadproximaltothevenousentrysitetopreventleadmovement.\\n•MVSensor.DonotprogramtheMVSensortoOnuntilafterthepulsegenerator hasbeenimplanted andsystemintegrity\\nhasbeentestedandverified.\\n•Programming MVSensorforrespiratory disorders orabnormal breathing. Forpatientswithrespiratory disorders or\\nabnormal breathing patterns,thephysician shouldusemedicaljudgment whenprogrammingtheMVSensortoOn.To\\nmitigateinappropriatesensor-drivenrates,thephysician mayevaluatetherateresponseandconsideralowerResponse\\nFactor.\\n•Diaphragmatic stimulation. Patientsshouldbetestedfordiaphragmatic stimulation bypacingtheLVleadthroughthe\\npulsegenerator at7.5Vandadjusting theleadconfigurationsandleadpositionasnecessary.PSAtestingathigher\\noutputs(e.g.,10.0V)mayalsobeconsideredtobettercharacteriz estimulation margins.Theprobability ofdiaphragmatic\\nstimulation increases whenapacingsystemincludesanLVleadbecauseofthislead'sproximity tothephrenicnerve.\\nDeviceProgramming\\n•Devicecommunication. Useonlythedesignated programmerandsoftwareapplication tocommunicate withthispulse\\ngenerator.\\n•STATPACEsettings. Whenapulsegenerator isprogrammedtoSTATPACEsettings,itwillcontinuetopaceatthehigh-\\nenergySTATPACEvaluesifitisnotreprogrammed.TheuseofSTATPACEparameters willlikelydecreasedevicelongevity.\\n•Biventricular pacingtherapy.ProgrammingthedevicetoprovideRV-onlypacingisnotintendedforthetreatmentof\\nheartfailure.TheclinicaleffectsofRV-onlypacingforthetreatment ofheartfailurehavenotbeenestablished.\\n•Pacingandsensingmargins.ConsiderleadmaturationinyourchoiceofPacingAmplitude, pacingPulseWidth,and\\nSensitivity settings.\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 15}), Document(page_content='13•AnacutePacingThreshold greaterthan1.5VorachronicPacingThreshold greaterthan3Vcanresultinlossof\\ncapturebecausethresholds mayincreaseovertime.\\n•AnR-WaveAmplitude lessthan5mVoraP-WaveAmplitude lessthan2mVcanresultinundersensing because\\nthesensedamplitude maydecreaseafterimplantation.\\n•PacingLeadImpedance shouldbegreaterthantheprogrammedLowImpedance Limitandlessthanthe\\nprogrammedHighImpedance Limit.\\n•Properprogramming oftheleadconfiguration. IftheLeadConfigurat ionisprogrammedtoBipolarwhenaunipolar\\nleadisimplanted, pacingwillnotoccur.\\n•Properprogramming oftheshockvector.IftheShockVectorisprogrammedtoRVcoil>>RAc oilandtheleaddoesnot\\nhaveanRAcoil,shockingwillnotoccur.\\n•Programming forsupraventricular tachyarrhythmias (SVTs).Determine ifthedeviceandprogrammable optionsare\\nappropriat eforpatientswithSVTsbecauseSVTscaninitiateunwanted devicetherapy.\\n•AVDelay.Toensureahighpercentageofbiventricular pacing,theprogrammedAVDelaysettingmustbelessthanthe\\npatient’sintrinsicPRinterval.\\n•Adaptive-rate pacing.Rateadaptivepacingshouldbeusedwithcareinpatientswhoareunabletotolerateincreased\\npacingrates.\\n•Ventricular refractory periods(VRPs)inadaptive-rate pacing.Adaptive-ra tepacingisnotlimitedbyrefractoryperiods.\\nAlongrefractoryperiodprogrammedincombinationwithahighMSRcanresultinasynchronous pacingduringrefractory\\nperiodssincethecombinationcancauseaverysmallsensingwindowornoneatall.UseDynamicAVDelayorDynamic\\nPVARPtooptimizesensingwindows. IfyouareprogrammingafixedAVDelay,considerthesensingoutcomes.\\n•AtrialTachyResponse (ATR).ATRshouldbeprogramm edtoOnifthepatienthasahistoryofatrialtachyarrhythmias.\\nThedeliveryofCRTiscompromisedbecauseAVsynchrony isdisrupted iftheATRmodeswitchoccurs.\\n•Threshold test.DuringmanualLVThreshold andQuickCapturetests,RVBackupPacingisunavailable.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 16}), Document(page_content=\"14•RVS-LVSDelaytesting.Ensurethepatientisclinicallycapableoftolerating lowrateRVBackupPacingandlackofLV\\npacingduringanRVS-LVSDelaytest.\\n•Shockwaveform polarity.ForIS-1/DF-1leads,neverchangetheshockwaveform polaritybyphysically switching thelead\\nanodesandcathodesinthepulsegenerator header—usetheprogramm ablePolarityfeature.Devicedamageor\\nnonconversion ofthearrhythmia post-operatively mayresultifthepolarityisswitchedphysically.\\n•TachyModetoOff.Topreventinappropriate shocks,ensurethatthepulsegenerator's TachyModeisprogrammedtoOff\\nwhennotinuseandbeforehandlingthedevice.Fortachyarrhythmia detection andtherapy,verifythattheTachyModeis\\nprogrammedtoMonitor+Therapy.\\n•Atrialoversensing. Takecaretoensurethatartifactsfromtheventricles arenotpresentontheatrialchannel,oratrial\\noversensing mayresult.Ifventricular artifactsarepresentintheatrialchannel,theatrialleadmayneedtoberepositioned\\ntominimize itsinteraction.\\n•ATRentrycount.ExercisecarewhenprogrammingtheEntryCounttolowvaluesinconjunction withashortATR\\nDuration. Thiscombination allowsmodeswitching withveryfewfastatrialbeats.Forexample, iftheEntryCountwas\\nprogrammedto2andtheATRDurationto0,ATRmodeswitching couldoccuron2fastatrialintervals. Intheseinstances,\\nashortseriesofpremature atrialeventscouldcausethedevicetomodeswitch.\\n•ATRexitcount.ExercisecarewhenprogrammingtheExitCounttolowvalues.Forexample,iftheExitCountwas\\nprogrammedto2,afewcyclesofatrialundersensing couldcausetermination ofmodeswitching.\\n•Properprogramming withoutanatriallead.Ifanatrialleadisnotimplanted (portispluggedinstead),oranatriallead\\nisabandoned butremainsconnected totheheader,deviceprogrammingshouldbeconsistent withthenumberandtype\\nofleadsactuallyinuse.\\n•Atrialsensingprogrammed toOff.WhenatrialsensingisprogrammedtoOffinaDDI(R)orDDD(R)mode,anyatrial\\npacingthatoccurswillbeasynchronous. Additionally ,featuresthatrequireatrialsensingmaynotfunctionasexpected.\\n•Cross-chamber artifacts. Sensitivity adjustments associated withSmartBlankingmaynotbesufficient toinhibitdetection\\nofcross-chamber artifactsifthecross-chamber artifactsaretoolarge.Considerotherfactorsthatimpactthesize/\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 17}), Document(page_content='15amplitude ofcross-chamber artifactsincluding lead-placement, pacingoutput,programmedSensitivity settings,shock\\noutput,andtimesincelastdelivered shock.\\n•SignalArtifactMonitorProgramming Considerations. Formaximum sensitivity indetecting andpreventing potential\\nsignalartifact-generatedoversensing, itisrecommended thattheSignalArtifactMonitor(SAM)isprogrammedOnany\\ntimetheMV/Respir atorySensorisprogrammedtoOnorPassive.TurningtheSignalArtifactMonitorOffmayputthe\\npatientatincreased riskofoversensing, unlesstheMV/Respiratory SensorisalsoprogrammedOff.\\n•TurningtheSignalArtifactMonitorOff.TurningtheSignalArtifactMonitorOffmayputthepatientatincreased riskof\\noversensing, unlesstheMV/Respiratory SensorisalsoprogrammedtoOff.\\n•Leftventricular leadconfiguration. ProperprogrammingoftheLVcoronaryvenousLeadConfigurat ionisessentialfor\\nproperLVleadfunction.ProgramtheLeadConfiguration inaccordancewiththenumberofelectrodes ontheLVlead;\\notherwise, erraticLVsensing,lossofLVpacing,orineffective LVpacingmightoccur.\\n•LeftVentricular ProtectionPeriod(LVPP).UseofalongLVPPreducesthemaximum LVpacingrateandmayinhibitCRT\\nathigherpacingrates.\\n•MVRecalibration. ToobtainanaccurateMVbaselinefollowing anysurgicalprocedureinvolving thepulsegenerator or\\nleads,anew,manualcalibration shouldbeperformed. Leadmaturation, airentrapment inthepocket,pulsegenerator\\nmotionduetoinadequate suturing,externaldefibrillation orcardioversion, orotherpatientcomplications(e.g.,\\npneumothor ax)requireanewMVbaselineforappropriate MVbehavior.\\n•Sensingadjustment. Following anysensingrangeadjustment oranymodification ofthesensinglead,alwaysverify\\nappropriat esensing.ProgrammingSensitivity tothehighestvalue(lowestsensitivity) mayresultindelayeddetection or\\nundersensing ofcardiacactivity.Likewise,programmingtothelowestvalue(highestsensitivity) mayresultinoversensing\\nofnon-cardiac signals.\\n•Patientsheartonescomingfromtheirdevice.Patientsshouldbeadvisedtocontacttheirphysician immediately ifthey\\nheartonescomingfromtheirdevice.\\n•UseofPatientTriggered Monitor. UsecarewhenusingPatientTriggered Monitor,becausethefollowing conditions will\\nexistwhileitisenabled:', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 18}), Document(page_content='16•Allothermagnetfeatures,including inhibiting therapy,aredisabled. TheMagnet/Beeper featurewillnotindicate\\nmagnetposition.\\n•Devicelongevity isimpacted. Tohelpreducethelongevity impact,PTMonlyallowsstorageofoneepisode,and\\nPTMisautomatically disabledafter60daysifdatastoragewasnevertriggered.\\n•OncetheEGMisstored(or60dayselapses),PTMisdisabledandthedeviceMagnetResponse automatically willbe\\nsettoInhibitTherapy.However,thepulsegenerator willnotinhibittherapyuntilthemagnetisremovedfor3\\nsecondsandplacedonthedeviceagain.\\nEnvironmental andMedicalTherapyHazards\\n•Avoidelectromagnetic interference (EMI).AdvisepatientstoavoidsourcesofEMIbecauseEMImaycausethepulse\\ngenerator todeliverinappropriate therapyorinhibitappropriate therapy.\\nMovingawayfromthesourceoftheEMIorturningoffthesourceusuallyallowsthepulsegenerator toreturntonormal\\noperation.\\nExamples ofpotentialEMIsourcesare:\\n•Electricalpowersources,arcweldingorresistanceweldingequipment, androboticjacks\\n•Highvoltagepowerdistribution lines\\n•Electricalsmeltingfurnaces\\n•LargeRFtransmitters suchasradar\\n•Radiotransmitters, including thoseusedtocontroltoys\\n•Electronic surveillance (antitheft) devices\\n•Analternator onacarthatisrunning\\n•Medicaltreatments anddiagnostic testsinwhichanelectricalcurrentispassedthroughthebody,suchasTENS,\\nelectrocautery ,electrolysis/thermolysis, electrodiagnostic testing,electromyogra phy,ornerveconduction studies', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 19}), Document(page_content='17•Anyexternally applieddevicethatusesanautomatic leaddetection alarmsystem(e.g.,anEKGmachine)\\n•WirelessECG.WirelessECGissusceptibletoRFinterferenc e,andmayhaveanintermittent orlostsignal.Ifinterferenc eis\\npresent,especially duringdiagnostic testing,considerusingasurfaceECGinstead.\\nHospitalandMedicalEnvironments\\n•Mechanical ventilators. ProgramtheMV/Respir atorySensortoOffduringmechanical ventilation. Otherwise, the\\nfollowing mayoccur:\\n•Inappropriate MVSensor-drivenrate\\n•Misleading respiration-based trending\\n•Conducted electricalcurrent.Anymedicalequipment, treatment, therapy,ordiagnostic testthatintroduceselectrical\\ncurrentintothepatienthasthepotentialtointerferewithpulsegenerator function.\\n•Externalpatientmonitors(e.g.,respiratorymonitors, surfaceECGmonitors, hemodynamic monitors) maycause:\\n–Inappropriate MVSensor-driven rate(uptomaximum sensor-drivenrate)\\n–Misleading respiration-based trending\\n•Medicaltherapies, treatments, anddiagnostic teststhatuseconductedelectricalcurrent(e.g.,TENS,electrocautery ,\\nelectrolysis/thermolysis, electrodiagnostic testing,electromy ography,ornerveconduction studies)mayinterfere\\nwithordamagethepulsegenerator.ProgramthedevicetoElectrocauteryProtection Modepriortothetreatment,\\nandmonitordeviceperformance duringthetreatment. Afterthetreatment,verifypulsegenerator function(\"Post-\\nTherapyPulseGenerator FollowUp\"onpage21).\\nToresolvesuspected interactions withRespiratory Sensor-baseddiagnostics, deactivate thepulsegenerator\\'s Respiratory\\nSensorbyprogrammingittoOff.\\n•Internaldefibrillation. Donotuseinternaldefibrillation paddlesorcatheters unlessthepulsegenerator isdisconnected\\nfromtheleadsbecausetheleadsmayshuntenergy.Thiscouldresultininjurytothepatientanddamagetothe\\nimplanted system.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 20}), Document(page_content='18•Externaldefibrillation. Itcantakeupto15secondsforsensingtorecoverafteranexternalshockisdelivered. Innon-\\nemergency situations, forpacemakerdependent patients,considerprogrammingthepulsegenerator toanasynchronous\\npacingmodeandprogrammingtheMV/Respiratory SensortoOffpriortoperforming externalcardioversion or\\ndefibrillation.\\nAvoidplacingapad(orpaddle)directlyoveranysubcutaneous leads.\\nExternaldefibrillation orcardioversioncandamagethepulsegenerator.Tohelppreventdamagetothepulsegenerator,\\nconsiderthefollowing:\\n•Avoidplacingapad(orpaddle)directlyoverthepulsegenerator.Positionthepads(orpaddles)asfarfromthe\\npulsegenerator aspossible.\\n•Positionthepads(orpaddles)inaposterior-anteriororientation whenthedeviceisimplanted intherightpectoral\\nregionorananterior-apexorientation whenthedeviceisimplanted intheleftpectoralregion.\\n•Setenergyoutputofexternaldefibrillation equipment aslowasclinicallyacceptable.\\nFollowing externalcardioversion ordefibrillation, verifypulsegenerator function(\"Post-TherapyPulseGenerator Follow\\nUp\"onpage21).\\n•Lithotripsy .Extracorporealshockwavelithotripsy (ESWL)maycauseelectromagnetic interferenc ewithordamagetothe\\npulsegenerator.IfESWLismedically necessary,considerthefollowing tominimize thepotentialforencountering\\ninteraction:\\n•FocustheESWLbeamatleast15cm(6in)awayfromthepulsegenerator.\\n•Depending onthepacingneedsofthepatient,programtheBradyModetoOfforanon-rate-r esponsive VVImode.\\n•ProgramtheTachyModetoOfftopreventinappropriate shocks.\\n•Ultrasound energy.Therapeutic ultrasound (e.g.,lithotripsy) energymaydamagethepulsegenerator.Iftherapeutic\\nultrasound energymustbeused,avoidfocusingnearthepulsegenerator site.Diagnostic ultrasound (e.g.,\\nechocardiogra phy)isnotknowntobeharmfultothepulsegenerator.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 21}), Document(page_content='19•Electricalinterference. Electricalinterferenceor“noise”fromdevicessuchaselectrocautery andmonitoring equipment\\nmayinterferewithestablishing ormaintaining telemetry forinterrogating orprogrammingthedevice.Inthepresenceof\\nsuchinterferenc e,movetheprogrammerawayfromelectricaldevices,andensurethatthewandcordandcablesarenot\\ncrossingoneanother.Iftelemetry iscancelled asaresultofinterferenc e,thedeviceshouldbere-interrogatedpriorto\\nevaluating information frompulsegenerator memory.\\n•Radiofrequency (RF)interference. RFsignalsfromdevicesthatoperateatfrequencies nearthatofthepulsegenerator\\nmayinterruptZIPtelemetry whileinterrogating orprogrammingthepulsegenerator.ThisRFinterferenc ecanbereduced\\nbyincreasing thedistancebetweentheinterfering deviceandthePRMandpulsegenerator.\\n•Centrallineguidewire insertion. Usecautionwheninsertingguidewires forplacement ofothertypesofcentralvenous\\ncathetersystemssuchasPIClinesorHickmancatheters inlocationswherepulsegenerator leadsmaybeencounter ed.\\nInsertionofsuchguidewires intoveinscontaining leadscouldresultintheleadsbeingdamaged ordislodged.\\nHomeandOccupational Environments\\n•Homeappliances. Homeappliances thatareingoodworkingorderandproperlygrounded donotusuallyproduce\\nenoughEMItointerferewithpulsegenerator operation. Therehavebeenreportsofpulsegenerator disturbances caused\\nbyelectrichandtoolsorelectricrazorsuseddirectlyoverthepulsegenerator implantsite.\\n•Magneticfields.Advisepatientsthatextended exposuretostrong(greaterthan10gaussor1mTesla)magnetic fields\\nmaytriggerthemagnetfeature.Examples ofmagnetic sourcesinclude:\\n•Industrial transforme rsandmotors\\n•MRIscanners\\nNOTE:ThemagnetfeatureisdisabledwhenthedeviceisinMRIProtection Mode.Referto\"Magnetic Resonance\\nImaging(MRI)\"onpage22andtheImageReady MRConditional Defibrillation SystemMRITechnical Guideformore\\ninformation.\\n•Largestereospeakers\\n•Telephone receiversifheldwithin1.27cm(0.5inches)ofthepulsegenerator', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 22}), Document(page_content=\"20•Magnetic wandssuchasthoseusedforairportsecurityandintheBingogame\\n•ElectronicArticleSurveillance (EAS)andsecuritysystems. Advisepatientshowtoavoidimpacttocardiacdevice\\nfunctionduetoantitheftandsecuritygates,tagdeactivators, ortagreadersthatincluderadiofrequency identification\\n(RFID)equipment. Thesesystemsmaybefoundattheentrancesandexitsofstores,atcheckoutcounters, inpublic\\nlibraries,andinpoint-of-entryaccesscontrolsystems.Patientsshouldavoidlingeringnearorleaningagainstantitheft\\nandsecuritygatesandtagreaders.Inaddition,patientsshouldavoidleaningagainstcheckoutcounter-mounted and\\nhandheld tagdeactivation systems.Anti-theft gates,securitygates,andentrycontrolsystemsareunlikelytoaffectcardiac\\ndevicefunctionwhenpatientswalkthroughthematanormalpace.Ifthepatientisnearanelectronic antitheft, security,\\norentrycontrolsystemandexperiencessymptoms, theyshouldpromptlymoveawayfromnearbyequipment andinform\\ntheirdoctor.\\n•Cellularphones.Advisepatientstoholdcellularphonestotheearoppositethesideoftheimplanted device.Patients\\nshouldnotcarryacellularphonethatisturnedoninabreastpocketoronabeltwithin15cm(6inches)oftheimplanted\\ndevicesincesomecellularphonesmaycausethepulsegenerator todeliverinappropriate therapyorinhibitappropriate\\ntherapy.\\nFollow-up Testing\\n•Conversion testing.SuccessfulVForVTconversion duringarrhythmia conversion testingisnoassurancethatconversion\\nwilloccurpost-operatively .Beawarethatchangesinthepatient'scondition, drugregimen,andotherfactorsmaychange\\ntheDFT,whichmayresultinnonconversion ofthearrhythmia post-operatively .\\n•Pacingthreshold testing.Ifthepatient'sconditionordrugregimenhaschangedordeviceparameters havebeen\\nreprogrammed, considerperforming apacingthresholdtesttoconfirmadequate marginsforpacecapture.\\n•Follow-up considerations forpatientsleavingthecountry.Pulsegenerator follow-up considerationsshouldbemade\\ninadvanceforpatientswhoplantotravelorrelocatepost-implanttoacountryotherthanthecountryinwhichtheir\\ndevicewasimplanted. Regulatory approvalstatusfordevicesandassociated programmersoftwareconfigurationsvaries\\nbycountry;certaincountries maynothaveapprovalorcapability tofollowspecificproducts.\\nContactBostonScientific, usingtheinformation onthebackcover,forhelpindetermining feasibility ofdevicefollow-up in\\nthepatient'sdestination country.\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 23}), Document(page_content='21ExplantandDisposal\\n•Incineration. Besurethatthepulsegenerator isremovedbeforecremation. Cremation andincineration temperatur es\\nmightcausethepulsegenerator toexplode.\\n•Devicehandling. Beforeexplanting, cleaning,orshippingthedevice,complete thefollowing actionstoprevent\\nunwanted shocks,overwriting ofimportant therapyhistorydata,andaudibletones:\\n•Programthepulsegenerator TachyandBradyModestoOff.\\n•ProgramtheMagnetResponse featuretoOff.\\n•ProgramtheBeepwhenExplantisIndicated featuretoOff.\\n•ProgramtheBeepWhenOut-of-Range featuretoOff.\\n•Handlingattimeofdisposal. Cleananddisinfectthedeviceusingstandardbiohazard handlingtechniques sinceall\\nexplantedcomponents areconsideredbiohazardous.\\nSUPPLEMENTAL PRECAUTIONARY INFORMATION\\nPost-TherapyPulseGenerator FollowUp\\nFollowing anysurgeryormedicalprocedurewiththepotentialtoaffectpulsegenerator function,youshouldperforma\\nthorough follow-up, whichmayincludethefollowing:\\n•Interrogating thepulsegenerator withaprogrammer\\n•Reviewing clinicaleventsandfaultcodes\\n•Reviewing theArrhythmia Logbook, including storedelectrograms(EGMs)\\n•Reviewing real-timeEGMs\\n•Testingtheleads(threshold, amplitude, andimpedance)\\n•Performing amanualcapacitorre-formation', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 24}), Document(page_content='22•Reviewing MVSensor-baseddiagnostics, MVSensorperformance, andperforming amanualMVSensorcalibration if\\ndesired\\n•Reviewing RespiratorySensor-baseddiagnostics\\n•Verifyingbatterystatus\\n•Programminganypermanent bradyparametertoanewvalueandthenreprogrammingitbacktothedesiredvalue\\n•ProgrammingtheTachyModetoanewvalueandthenreprogramming itbacktothedesiredvalue\\n•Savingallpatientdata\\n•Verifyingtheappropriate finalprogrammingpriortoallowingthepatienttoleavetheclinic\\nMagneticResonance Imaging(MRI)\\nMRIProtection ModeisavailableinalldevicesexceptforthosewithanLV:LV-1leadconnection.\\nThefollowing Warnings andPrecautions, andConditions ofUseareapplicable toMRIscanningofpatientsimplanted withan\\nImageReady MRConditional Defibrillation System.RefertotheImageReady MRConditional Defibrillation SystemMRITechnical\\nGuideatwww.bostonscientific- elabeling.com foracomprehensivelistofWarnings andPrecautions, andConditions ofUsethat\\nareapplicable toMRIscanningofpatientsimplanted withanImageReady MRConditional Defibrillation System.\\nMRConditional Defibrillation SystemWarnings andPrecautions\\nWARNING: AlldevicesexceptforthosewithanLV:LV-1leadconnection areconsideredMRConditional. Forthesedevices,\\nunlessalloftheMRIConditions ofUsearemet,MRIscanningofthepatientdoesnotmeetMRConditional requirementsforthe\\nimplanted system.Significant harmtoordeathofthepatientand/ordamagetotheimplanted systemmayresult.Donot\\nexposepatientswithnon-MRConditional devicestoMRIscanning. Strongmagnetic fieldsmaydamagethepulsegenerator\\nand/orleadsystem,possiblyresultingininjurytoordeathofthepatient.\\nForpotentialadverseeventsapplicable whentheConditions ofUsearemetornotmet,refertotheImageReady MRConditional\\nDefibrillation SystemMRITechnical Guide.Foradditional warnings, precautions, andConditions ofUse,referto\"Magnetic\\nResonanceImaging(MRI)\"onpage22.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 25}), Document(page_content='23WARNING: MRIscanningafterExplantstatushasbeenreachedmayleadtopremature batterydepletion, ashortened device\\nreplacementwindow,orsuddenlossoftherapy.Afterperforming anMRIscanonadevicethathasreachedExplantstatus,\\nverifypulsegenerator function(\"Post-TherapyPulseGenerator FollowUp\"onpage21)andscheduledevicereplacement.\\nWARNING: Determine thebeepertypebeforeanMRIscan.TheArmature Beepermaynolongerbeusablefollowing anMRI\\nscan.Comingincontactwiththestrongmagnetic fieldofanMRIscannermaycauseapermanent lossoftheArmature Beeper\\nvolume.Thiscannotberecovered,evenafterleavingtheMRIscanenvironment andexitingMRIProtection Mode.Forthe\\nArmature Beeper,beforeanMRIscanisperformed, aphysician andpatientshouldweighthebenefitoftheMRIscanagainst\\ntheriskoflosingtheBeeper;aftertheMRIscan,performBeeperevaluation testtodetermine iftheBeeperisusable.Ifthe\\nBeeperisnotusable,itisstronglyrecommended thatpatientsarefollowedonLATITUDE NXTafteranMRIscaniftheyarenot\\nalready.Otherwise, anin-clinicfollow-up scheduleofeverythreemonthsisstronglyrecommended tomonitordevice\\nperformance.\\nWARNING: DuringMRIProtection Mode,thepatientwillnotreceiveTachycardia therapy(including ATPanddefibrillation),\\nand,ifBradyModeisprogrammedtoOff,willnotreceiveBradycardiapacing(including backuppacing)andCardiac\\nResynchronization Therapy.Thereforethepatientmustbecontinuously monitored fortheentiredurationinwhichthesystemis\\ninMRIProtection Mode,including duringthescan.\\nWARNING: IftheMRIProtection Time-out valueisprogrammedtoOff,thepatientwillnotreceiveTachycardia therapy,and\\nthepacingoptionsarelimitedtoOfforAsynchronous untilthepulsegenerator isprogrammedoutofMRIProtection Modeand\\nbacktonormaloperation.\\nWARNING: DuringMRIProtection Mode,Tachycardia therapyissuspended. Thesystemwillnotdetectventricular\\narrhythmias andthepatientwillnotreceiveATPorshockdefibrillation therapyuntilthepulsegenerator isprogrammedbackto\\nnormaloperation. Onlyscanthepatientifjudgedtobeclinicallycapableoftolerating noTachycardia protection fortheentire\\ndurationinwhichthepulsegenerator isinMRIProtection Mode.\\nWARNING: Theriskofarrhythmia maybeincreased withasynchronous pacing(AOO,VOO,DOO).Whenprogramming\\nasynchronous pacingduringMRIProtection Mode,selectapacingratethatavoidscompetitivepacingandminimize thetimein\\nMRIProtection Mode.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 26}), Document(page_content='24WARNING: Intherareeventthatnon-recoverableorrepeatfaultconditions occurwhilethedeviceisprogramm edinMRI\\nProtectionMode,thesubsequent devicebehaviorwillbedetermined bytheMRIProtection BradyModesetting.\\n•IfMRIBradyModeissettoOff,thedevicewillenterSafetyMode(permanent VVIunipolarpacingandtachycardia\\ntherapyenabled).\\n•IfMRIBradyModeissettoasynchronous pacing(AOO,VOO,DOO),bothbradycardiatherapyandtachycardiatherapy\\nwillbepermanently disabled.\\nWARNING: TheProgrammerisMRUnsafeandmustremainoutsidetheMRIsiteZoneIII(andhigher)asdefinedbythe\\nAmerican CollegeofRadiology Guidance Document onMRSafePractices5.Undernocircumstanc esshouldtheProgrammerbe\\nbroughtintotheMRIscannerroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nWARNING: Implantofthesystemcannotbeperformed inanMRIsiteZoneIII(andhigher)asdefinedbytheAmerican\\nCollegeofRadiology Guidance Document onMRSafePractices5.Someoftheaccessoriespackaged withpulsegenerators and\\nleads,including thetorquewrenchandstyletwires,arenotMRConditional andshouldnotbebroughtintotheMRIscanner\\nroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nCAUTION: Thephysician choosingMRIProtection Modeparameter valueswillneedtoexerciseprofessional judgment to\\ndetermine anindividual patient’sabilitytotoleratethedevicesettingsrequiredforMRConditional scanning, inconjunction with\\nthephysicalconditionsrequiredduringascan(forexample,prolonged timeinasupineposition).\\nCAUTION: Thepresenceoftheimplanted defibrillation systemmaycauseMRIimageartifacts.\\nNOTE:Otherimplanted devicesorpatientconditions maycauseapatienttobeineligible foranMRIscan,independent ofthe\\nstatusofthepatient’sImageReady MRConditional Defibrillation System.\\nMRConditions ofUse\\nThefollowing subsetoftheMRIConditions ofUsepertainstoimplantation andmustbemetinorderforapatientwithan\\nImageReady Defibrillation SystemtoundergoanMRIscan.AdherencetotheConditions ofUsemustbeverifiedpriortoeach\\n5.KanalE,Barkovich AJ,BellC,etal.ACRguidance document onMRsafepractices:2013.J.Magn.Reson.Imaging2013;37:501-530.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 27}), Document(page_content='25scantoensurethatthemostuptodateinformation hasbeenusedtoassessthepatient’seligibility andreadiness foranMR\\nConditional scan.RefertotheImageReady MRConditional Defibrillation SystemMRITechnical Guideatwww.bostonscientific -\\nelabeling.com foracomprehensive listofWarnings andPrecautions, andConditions ofUsethatareapplicable toMRIscanning\\nofpatientsimplanted withanImageReady MRConditional Defibrillation System.\\nCardiology\\n1.Patientisimplanted withanImageReady MRConditional Defibrillation System\\n2.Nootheractiveorabandoned implanted devices,components, oraccessoriespresentsuchasleadadaptors, extenders,\\nleads,orpulsegenerators\\n3.Patientisjudgedtobeclinicallycapableoftolerating noTachycardia protection fortheentiredurationinwhichthepulse\\ngenerator isinMRIProtection Mode\\n4.Pulsegenerator implantlocationrestricted toleftorrightpectoralregion\\n5.Atleastsix(6)weekshaveelapsedsinceimplantation and/oranyleadrevisionorsurgicalmodification oftheMR\\nConditional Defibrillation System\\n6.Noevidenceofafracturedleadorcompromisedpulsegenerator-leadsystemintegrity\\nTranscutaneous ElectricalNerveStimulation (TENS)\\nCAUTION: TENSinvolvespassingelectricalcurrentthroughthebody,andmayinterferewithpulsegenerator function.IfTENS\\nismedically necessary,evaluatetheTENStherapysettingsforcompatibility withthepulsegenerator.Thefollowing guidelines\\nmayreducethelikelihood ofinteraction:\\n•PlacetheTENSelectrodes asclosetogetherandasfarawayfromthepulsegenerator andleadsaspossible.\\n•Usethelowestclinically-appropriate TENSenergyoutput.\\n•Considercardiacmonitoring duringTENSuse,especially forpacemaker-dependent patients.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 28}), Document(page_content='26Additional stepscanbetakentohelpreduceinterferenc eduringin-clinicuseofTENS:\\n•Ifinterferenceissuspected duringin-clinicuse,turnofftheTENSunit.\\n•DonotchangeTENSsettingsuntilyouhaveverifiedthatthenewsettingsdonotinterferewithpulsegenerator function.\\nIfTENSismedically necessary outsidetheclinicalsetting(at-homeuse),providepatientswiththefollowing instructions:\\n•DonotchangetheTENSsettingsorelectrode positions unlessinstructed todoso.\\n•EndeachTENSsessionbyturningofftheunitbeforeremoving theelectrodes.\\n•IfthepatientreceivesashockduringTENSuse,oriftheyexperience symptoms oflightheadedness, dizziness, orlossof\\nconsciousness, theyshouldturnofftheTENSunitandcontacttheirphysician.\\nFollowthesestepstousethePRMtoevaluatepulsegenerator functionduringTENSuse:\\n1.Programthepulsegenerator TachyModetoMonitorOnly.\\n2.Observereal-timeEGMsatprescribed TENSoutputsettings,notingwhenappropriate sensingorinterferenc eoccurs.\\nNOTE:Patienttriggered monitoring maybeusedasanadditional methodtoconfirmdevicefunctionduringTENSuse.\\n3.Whenfinished,turnofftheTENSunitandreprogramtheTachyModetoMonitor+Therapy.\\nYoushouldalsoperformathorough follow-up evaluation ofthepulsegenerator following TENS,toensurethatdevicefunction\\nhasnotbeencompromised(\"Post-TherapyPulseGenerator FollowUp\"onpage21).\\nForadditional information, contactBostonScientificusingtheinformation onthebackcover.\\nElectrocauteryandRadioFrequency (RF)Ablation\\nCAUTION: ElectrocauteryandRFablationmayinduceventricular arrhythmias and/orfibrillation, andmaycauseasynchronous\\npacing,inhibition ofpacing,inappropriate shocks,and/orareduction inpulsegenerator pacingoutputpossiblyleadingtoloss\\nofcapture.RFablationmayalsocauseventricular pacinguptotheMTRand/orchangesinpacingthresholds. Additionally ,\\nexercisecautionwhenperforming anyothertypeofcardiacablationprocedureinpatientswithimplanted devices.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 29}), Document(page_content='27Ifelectrocautery orRFablationismedically necessary,observethefollowing tominimize risktothepatientanddevice:\\n•Depending onthepacingneedsofthepatient,programtheTachyModetoElectrocautery Protection ModeorOff.\\n•Havetemporary pacingandexternaldefibrillation equipment available.\\n•Avoiddirectcontactbetweentheelectrocautery equipment orablationcatheters andthepulsegenerator andleads.RF\\nablationclosetotheleadelectrode maydamagethelead-tissue interface.\\n•Keepthepathoftheelectricalcurrentasfarawayaspossiblefromthepulsegenerator andleads.\\n•IfRFablationand/orelectrocautery isperformed ontissuenearthedeviceorleads,monitorpre-andpost-\\nmeasurements forsensingandpacingthresholds andimpedances todetermine theintegrityandstabilityofthesystem.\\n•Forelectrocautery ,useabipolarelectrocautery systemwherepossibleanduseshort,intermittent, andirregularburstsat\\nthelowestfeasibleenergylevels.\\n•RFablationequipment maycausetelemetry interferenc ebetweenthepulsegenerator andPRM.Ifdeviceprogramming\\nchangesarenecessary duringanRFablationprocedure,turnofftheRFablationequipment beforeinterrogation.\\nWhentheprocedureisfinished,canceltheElectrocautery Protection ModeorprogramTachyModetoMonitor+Therapyin\\nordertoreactivate thepreviously programmedtherapymodes.\\nIonizingRadiation\\nCAUTION: Itisnotpossibletospecifyasaferadiationdosageorguarantee properpulsegenerator functionfollowing\\nexposuretoionizingradiation. Multiplefactorscollectively determine theimpactofradiationtherapyonanimplanted pulse\\ngenerator,including proximity ofthepulsegenerator totheradiationbeam,typeandenergyleveloftheradiationbeam,dose\\nrate,totaldosedelivered overthelifeofthepulsegenerator,andshielding ofthepulsegenerator.Theimpactofionizing\\nradiationwillalsovaryfromonepulsegenerator toanotherandmayrangefromnochangesinfunctiontoalossofpacingand\\ndefibrillation therapy.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 30}), Document(page_content='28Sourcesofionizingradiationvarysignificantly intheirpotentialimpactonanimplanted pulsegenerator.Severaltherapeutic\\nradiationsourcesarecapableofinterfering withordamaging animplanted pulsegenerator,including thoseusedforthe\\ntreatmentofcancer,suchasradioactive cobalt,linearaccelerators,radioactive seeds,andbetatrons.\\nPriortoacourseoftherapeutic radiationtreatment, thepatient\\'sradiationoncologist andcardiologist orelectrophysiologist\\nshouldconsiderallpatientmanagement options,including increased follow-up anddevicereplacement.Otherconsiderations\\ninclude:\\n•Maximizing shielding ofthepulsegenerator withinthetreatment field\\n•Determining theappropriate levelofpatientmonitoring duringtreatment\\nEvaluatepulsegenerator operation duringandfollowing thecourseofradiationtreatment toexerciseasmuchdevice\\nfunctionality aspossible(\"Post-TherapyPulseGenerator FollowUp\"onpage21).Theextent,timing,andfrequency ofthis\\nevaluation relativetotheradiationtherapyregimenaredependent uponcurrentpatienthealth,andtherefore shouldbe\\ndetermined bytheattending cardiologist orelectrophysiologist.\\nManypulsegenerator diagnostics areperformed automatically onceperhour,sopulsegenerator evaluation shouldnotbe\\nconcludeduntilpulsegenerator diagnostics havebeenupdatedandreviewed (atleastonehourafterradiationexposure).The\\neffectsofradiationexposureontheimplanted pulsegenerator mayremainundetected untilsometimefollowing exposure.For\\nthisreason,continuetomonitorpulsegenerator functioncloselyandusecautionwhenprogrammingafeatureintheweeksor\\nmonthsfollowing radiationtherapy.\\nElevatedPressures\\nTheInternational Standards Organization (ISO)hasnotapproved astandardiz edpressuretestforimplantable pulsegenerators\\nthatexperience hyperbaric oxygentherapy(HBOT)orSCUBAdiving.However,BostonScientificdeveloped atestprotocolto\\nevaluatedeviceperformance uponexposuretoelevatedatmospheric pressures.Thefollowing summary ofpressuretesting\\nshouldnotbeviewedasandisnotanendorsement ofHBOTorSCUBAdiving.\\nCAUTION: ElevatedpressuresduetoHBOTorSCUBAdivingmaydamagethepulsegenerator.Duringlaboratory testing,all\\npulsegenerators inthetestsamplefunctioned asdesigned whenexposedtomorethan1000cyclesatapressureupto5.0', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 31}), Document(page_content=\"29ATA.Laboratory testingdidnotcharacteriz etheimpactofelevatedpressureonpulsegenerator performance orphysiological\\nresponsewhileimplanted inahumanbody.\\nPressureforeachtestcyclebeganatambient/r oompressure,increased toahighpressurelevel,andthenreturnedtoambient\\npressure.Although dwelltime(theamountoftimeunderelevatedpressure)mayhaveanimpactonhumanphysiology ,testing\\nindicated itdidnotimpactpulsegenerator performance. Pressurevalueequivalencies areprovidedbelow(Table1Pressure\\nValueEquivalencies onpage29).\\nTable1.PressureValueEquivalencies\\nPressurevalueequivalencies\\nAtmospheres Absolute 5.0ATA\\nSeawaterdeptha40m(130ft)\\nPressure,absolute 72.8psia\\nPressure,gaugeb58.1psig\\nBar 5.0\\nkPaAbsolute 500\\na.Allpressureswerederivedassuming seawaterdensityof1030kg/m3.\\nb.Pressureasreadonagaugeordial(psia=psig+14.7psi).\\nPriortoSCUBAdivingorstartinganHBOTprogram,thepatient'sattending cardiologis torelectrophysiologist shouldbe\\nconsulted tofullyunderstand thepotentialconsequenc esrelativetothepatient'sspecifichealthcondition. ADiveMedicine\\nSpecialist mayalsobeconsulted priortoSCUBAdiving.\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 32}), Document(page_content='30Morefrequentdevicefollow-up maybewarranted inconjunctionwithHBOTorSCUBAdiving.Evaluatepulsegenerator\\noperationfollowing highpressureexposure(\"Post-TherapyPulseGeneratorFollowUp\"onpage21).Theextent,timing,and\\nfrequencyofthisevaluation relativetothehighpressureexposurearedependent uponcurrentpatienthealth,andshouldbe\\ndetermined bytheattending cardiologist orelectrophysiologist.\\nIfyouhaveadditional questions, orwouldlikemoredetailregardingthetestprotocolortestresultsspecifictoHBOTorSCUBA\\ndiving,contactBostonScientificusingtheinformation onthebackcover.\\nPOTENTIALADVERSEEVENTS\\nBasedontheliteratureandonpulsegenerator and/orleadimplantexperience, thefollowing alphabetical listincludesthe\\npossibleadverseeventsassociated withimplantation ofproductsdescribed inthisliterature:\\n•Airembolism\\n•Allergicreaction\\n•Bleeding\\n•Bradycardia\\n•Cardiactamponade\\n•Chronicnervedamage\\n•Component failure\\n•Conductor coilfracture\\n•Death\\n•Electrolyte imbalance/dehydr ation\\n•Elevatedthresholds\\n•Erosion\\n•Excessive fibrotictissuegrowth\\n•Extracardiacstimulation (muscle/nerve stimulation)', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 33}), Document(page_content='31•Failuretoconvertaninducedarrhythmia\\n•Fluidaccumulation\\n•Foreignbodyrejectionphenomena\\n•Formation ofhematomas orseromas\\n•Heartblock\\n•Inabilitytodefibrillate orpace\\n•Inappropriate therapy(e.g.,shocksandantitachycardia pacing[ATP]whereapplicable, pacing)\\n•Incisional pain\\n•Incomplete leadconnectionwithpulsegenerator\\n•Infectionincluding endocarditis\\n•Insulating myocardium duringdefibrillation withinternalorexternalpaddles\\n•Leaddislodgment\\n•Leadfracture\\n•Leadinsulation breakage orabrasion\\n•Leadperforation\\n•Leadtipdeformation and/orbreakage\\n•Localtissuereaction\\n•Lossofcapture\\n•Myocardial infarction (MI)\\n•Myocardial necrosis\\n•Myocardial trauma(e.g.,tissuedamage,valvedamage)\\n•Myopotential sensing\\n•Oversensing/undersensing', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 34}), Document(page_content='32•Pacemaker-mediated tachycardia (PMT)\\n•Pericardial rub,effusion\\n•Pneumothorax\\n•Pulsegenerator migration\\n•Shuntingcurrentduringdefibrillation withinternalorexternalpaddles\\n•Syncope\\n•Tachyarrhythmias, whichincludeaccelerationofarrhythmias andearly,recurrentatrialfibrillation\\n•Thrombosis/thr omboemboli\\n•Valvedamage\\n•Vasovagal response\\n•Venousocclusion\\n•Venoustrauma(e.g.,perforation, dissection, erosion)\\n•Worsening heartfailure\\nForalistofpotentialadverseeventsassociated withMRIscanning, refertotheImageReady MRConditional Defibrillation\\nSystemMRITechnical Guide.\\nPatientsmaydeveloppsychological intoleranc etoapulsegenerator systemandmayexperiencethefollowing:\\n•Dependency\\n•Depression\\n•Fearofprematurebatterydepletion\\n•Fearofshockingwhileconscious\\n•Fearthatshockingcapability maybelost\\n•Imagined shocking\\n•Fearofdevicemalfunction', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 35}), Document(page_content='33Additionally ,potentialadverseeventsassociated withtheimplantation ofacoronaryvenousleadsysteminclude:\\n•Allergicreactiontocontrastmedia\\n•Breakage/failure ofimplantinstruments\\n•Prolonged exposuretofluoroscopicradiation\\n•Renalfailurefromcontrastmediausedtovisualizecoronaryveins\\nMECHANICAL SPECIFICATIONS\\nAllmodelshaveacaseelectrode surfaceareaof6192mm².Usablebatterycapacityis1.9Ahandresidualusablebattery\\ncapacityatExplantis0.15Ah.Mechanical specifications specifictoeachmodelarelistedbelow.\\nTable2.Mechanical Specifications -RESONATE HFCRT-Ds\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nG524 5.37x8.18x0.99 73.6 32.5 RA:IS-1;RV:\\nDF4;LV:IS-1Yes\\nG525 5.37x8.08x0.99 72.8 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS-1Yes\\nG526 5.37x8.08x0.99 72.9 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:LV-1No\\nG528 5.37x8.08x0.99 73.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 36}), Document(page_content='34Table2.Mechanical Specifications -RESONATE HFCRT-Ds(continued)\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nG537 5.37x8.18x0.99 73.8 32.5 RA:IS-1;RV:\\nDF4;LV:IS4Yes\\nG547 5.37x8.18x0.99 73.8 32.5 RA:IS-1;RV:\\nDF4;LV:IS4Yes\\nG548 5.37x8.08x0.99 73.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes\\nTable3.Mechanical Specifications -RESONATE CRT-Ds\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nG424 5.37x8.18x0.99 73.6 32.5 RA:IS-1;RV:\\nDF4;LV:IS-1Yes\\nG425 5.37x8.08x0.99 72.8 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS-1Yes\\nG426 5.37x8.08x0.99 72.9 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:LV-1No', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 37}), Document(page_content='35Table3.Mechanical Specifications -RESONATE CRT-Ds(continued)\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nG428 5.37x8.08x0.99 73.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes\\nG437 5.37x8.18x0.99 73.8 32.5 RA:IS-1;RV:\\nDF4;LV:IS4Yes\\nG447 5.37x8.18x0.99 73.8 32.5 RA:IS-1;RV:\\nDF4;LV:IS4Yes\\nG448 5.37x8.08x0.99 73.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes\\nTable4.Mechanical Specifications -VIGILANTCRT-Ds\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nG224 5.37x8.18x0.99 73.6 32.5 RA:IS-1;RV:\\nDF4;LV:IS-1Yes\\nG225 5.37x8.08x0.99 72.8 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS-1Yes', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 38}), Document(page_content='36Table4.Mechanical Specifications -VIGILANTCRT-Ds(continued)\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume\\n(cm3)Connector TypeMRConditional\\nG228 5.37x8.08x0.99 73.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes\\nG237 5.37x8.18x0.99 73.8 32.5 RA:IS-1;RV:\\nDF4;LV:IS4Yes\\nG247 5.37x8.18x0.99 73.8 32.5 RA:IS-1;RV:\\nDF4;LV:IS4Yes\\nG248 5.37x8.08x0.99 73.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes\\nTable5.Mechanical Specifications -MOMENTUM CRT-Ds\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume(cm3)Connector TypeMRConditional\\nG124 5.37x8.18x0.99 73.6 32.5 RA:IS-1;RV:\\nDF4;LV:IS-1Yes\\nG125 5.37x8.08x\\n0.9972.8 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS-1Yes', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 39}), Document(page_content='37Table5.Mechanical Specifications -MOMENTUM CRT-Ds(continued)\\nModel Dimensions\\nWxHxD(cm)Mass(g) Volume(cm3)Connector TypeMRConditional\\nG126 5.37x8.08x\\n0.9972.9 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:LV-1No\\nG128 5.37x8.08x\\n0.9973.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes\\nG138 5.37x8.08x\\n0.9973.4 32.0 RA:IS-1;RV:IS-\\n1/DF–1;LV:IS4Yes\\nMaterialspecifications areshownbelow:\\n•Case:hermetically sealedtitanium\\n•Header:implantation-grade polymer\\n•PowerSupply:lithium-manganese dioxidecell;BostonScientificENDURALIFE; 401988\\nITEMSINCLUDED INPACKAGE\\nThefollowing itemsareincludedwiththepulsegenerator:\\n•Onetorquewrench\\n•Productliterature\\nNOTE:Accessories(e.g.,wrenches) areintendedforone-time useonly.Theyshouldnotberesterilizedorreused.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 40}), Document(page_content='38WARNING: Implantofthesystemcannotbeperformed inanMRIsiteZoneIII(andhigher)asdefinedbytheAmerican\\nCollegeofRadiology Guidance Document onMRSafePractices6.Someoftheaccessoriespackaged withpulsegenerators and\\nleads,including thetorquewrenchandstyletwires,arenotMRConditional andshouldnotbebroughtintotheMRIscanner\\nroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nSYMBOLSONPACKAGING\\nThefollowing symbolsmaybeusedonpackaging andlabeling:\\nTable6.Symbolsonpackaging\\nSymbol Description\\nReferenceNumber\\nContents\\nPulsegenerator\\nTorquewrench\\nLiteratureenclosed\\n6.KanalE,Barkovich AJ,BellC,etal.ACRguidance document onMRsafepractices:2013.J.Magn.Reson.Imaging2013;37:501-530.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 41}), Document(page_content='39Table6.Symbolsonpackaging (continued)\\nSymbol Description\\nSerialNumber\\nUseBy\\nLotNumber\\nDateofManufacture\\nNon-Ionizing Electromagnetic Radiation\\nSterilized usingethyleneoxide.\\nSTERILIZE2\\nDoNotResterilize\\nSingleuse.Donotre-use.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 42}), Document(page_content='40Table6.Symbolsonpackaging (continued)\\nSymbol Description\\nDonotuseifpackageisdamaged.\\nDangerous Voltage\\nConsultinstructions foruseonthiswebsite:www.\\nbostonscientific -elabeling.com\\nTemperatur elimitation.\\nPlacetelemetry wandhere', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 43}), Document(page_content='41Table6.Symbolsonpackaging (continued)\\nSymbol Description\\n,\\nOpenHere\\nManufacturer\\nMRConditional\\nCRT-DRA,RV,LV\\nICDRA,RV\\nICDRV\\nUncoated device', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 44}), Document(page_content='42Table6.Symbolsonpackaging (continued)\\nSymbol Description\\nRFTelemetry\\nDoublesterilebarriersystem\\nCHARACTERISTICS ASSHIPPED\\nRefertothetableforpulsegenerator settingsatshipment (Table7Characteristics asshippedonpage42).\\nTable7.Characteristics asshipped\\nParameter Setting\\nTachyMode Storage\\nTachyTherapyavailable ATP,Shock\\nPacingMode Storage\\nPacingTherapyavailable DDDR\\nSensor Accelerometer', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 45}), Document(page_content='43Table7.Characteristics asshipped(continued)\\nParameter Setting\\nSensor Blend(AccelandMV)(MOMENTUM andRESONATE HFmodels)\\nPace/Sense Configuration RA:BI/BI\\nPace/Sense Configuration RV:BI/BI\\nPace/Sense Configuration LV:Off\\nPace/Sense Configuration LV:BI/BI(Quadripolar Models)\\nThepulsegenerator isshippedinapower-savingStoragemodetoextenditsshelflife.InStoragemode,allfeaturesare\\ninactiveexcept:\\n•Telemetry support,whichallowsinterrogation andprogramming\\n•Real-time clock\\n•Commanded capacitorre-formation\\n•STATSHOCKandSTATPACEcommands\\nThedeviceleavesStoragemodewhenoneofthefollowing actionsoccurs;however,programmingotherparameters willnot\\naffecttheStoragemode:\\n•STATSHOCKorSTATPACEiscommanded\\n•TachyModeisprogramm edto:\\n•Off', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 46}), Document(page_content='44•MonitorOnly\\n•Monitor+Therapy\\nOnceyouhaveprogramm edthepulsegenerator outofStoragemode,thedevicecannotbereprogrammedtothatmode.\\nX-RAYIDENTIFIER\\nThepulsegenerator hasanidentifierthatisvisibleonanx-rayorfluoroscopicimage.Thisidentifierprovidesnoninvasive\\nconfirmationofthemanufacturer andconsistsofthefollowing:\\n•Theletters,BSC,toidentifyBostonScientificasthemanufacturer .\\n•Thenumber,140,toidentifythepulsegenerators.\\nThex-rayidentifierisembedded intheheaderofthedevice.Foraleftsidepectoralimplant,theidentifierwillbevisiblebyx-\\nrayorfluorographyattheapproximate locationshown(Figure1X-rayidentifieronpage44).\\n1\\n2\\n3\\n[1]X-RayIdentifier[2]Header[3]PulseGeneratorCase\\nFigure1.X-rayidentifier', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 47}), Document(page_content=\"45Forinformation onidentifying thedeviceviatheProgrammer,refertotheProgrammerOperator's Manual.\\nThepulsegenerator modelnumberandserialnumberareaccessiblefromtheProgrammerSummary screenoncethepulse\\ngenerator isinterrogated. Additional information suchasdateofmanufacture canbeobtainedbycontactingBostonScientific\\nandproviding themodelnumberandserialnumber.\\nFEDERALCOMMUNICATIONS COMMISSION (FCC)\\nThisdevicecomplieswithTitle47,Part15oftheFCCrules.Operationissubjecttothefollowing twoconditions:\\n•Thisdevicemaynotcauseharmfulinterferenc e,and\\n•Thisdevicemustacceptanyinterferenc ereceived,including interferenc ethatmaycauseundesired operation.\\nForpulsegenerators operating withatransmitfrequency of402to405MHz:thistransmitter isauthorizedbyruleunderthe\\nMedicalDeviceRadiocommunication Service(inpart95oftheFCCRules)andmustnotcauseharmfulinterferenc etostations\\noperating inthe400.150–406.000 MHzbandintheMeteorological Aids(i.e.,transmitters andreceiversusedtocommunicate\\nweatherdata),theMeteorological Satellite,ortheEarthExploration SatelliteServicesandmustacceptinterferenc ethatmaybe\\ncausedbysuchstations,including interferenc ethatmaycauseundesired operation. Thistransmitter shallbeusedonlyin\\naccordancewiththeFCCRulesgoverning theMedicalDeviceRadiocomm unication Service.Analoganddigitalvoice\\ncommunications areprohibited. Although thistransmitterhasbeenapproved bytheFederalCommunications Commission,\\nthereisnoguarantee thatitwillnotreceiveinterferenc eorthatanyparticular transmission fromthistransmitter willbefree\\nfrominterference.\\nCAUTION: Changesormodifications notexpresslyapproved byBostonScientificcouldvoidtheuser'sauthoritytooperatethe\\nequipment.\\nRESONATE HF,RESONATE, VIGILANT, andMOMENTUM devicesoperateinthe402–405MHzbandusingFSKmodulation with\\nradiatedpowerconforming totheapplicable 25μWlimit.TheFCCIDisESCCRMG17912. Wandedtelemetry operatesat57kHz\\nandusesQPSKmodulation.\\nPULSEGENERATOR LONGEVITY\\nBasedonsimulated studies,itisanticipated thatthesepulsegenerators haveaveragelongevity toexplantasshownbelow.\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 48}), Document(page_content='46RefertothePRMSummary andBatteryDetailSummary screensforanestimateofpulsegenerator longevity specifictothe\\nimplanted device.\\nThelongevity expectations, whichaccountfortheenergyusedduringmanufacture andstorage,applyattheconditions shown\\ninthetablesalongwiththefollowing:\\n•Assumes70ppmLRL;DDDRmode;100%biventricular pacing;15%atriumpacingand0.4mspacingPulseWidth(RA,\\nRV,LV);sensorsOn,HeartFailureSensorSuiteOn.\\nThefollowing longevity tablesandconditions ofuseapplytoRESONATE HF,RESONATE, VIGILANT, andMOMENTUM\\ndevices.\\nProjectedlongevity iscalculated assuming 2maximum energychargingcyclesperyear,including automatic capacitorre-forms\\nandtherapeutic shocks.Thesecalculations alsoassume3-channel EGMOnsetisonandthatthepulsegenerator spends3\\nmonthsinStoragemodeduringshippingandstorage.\\nPaceSafeOnforRAATandRVATprovidesanoutputof2Xthethreshold withaminimum outputof2.0V.\\nPaceSafeOnforLVATprovidesa1.0Vsafetymarginabovethethreshold withaminimum outputof1.0V.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 49}), Document(page_content='47Table8.Pulsegenerator lifeexpectancy estimation (implanttoexplant)withENDURALIFE battery\\nAllModelsa\\nPacing Longevity (years)\\nVentricular\\nChambersRA/RV LVLVbd500Ωwith\\nLATITUDEb700Ωwith\\nLATITUDEb700ΩNo\\nLATITUDE, MV/RS,\\norHFSSc\\nBiV 2.0V 2.0VOff 11.3 11.9 13.0\\nBiV 2.0V 3.0VOff 10.2 10.9 11.9\\nBiV 2.0V 3.5VOff 9.5 10.4 11.2\\nBiV 2.5V 3.0VOff 9.7 10.5 11.3\\nBiV 2.5V 3.5VOff 9.1 10.0 10.8\\nBiV 3.5V 3.5VOff 8.1 9.0 9.7\\nBiVMSP 2.0V 2.0V2.0V 10.3 10.9 11.9\\nBiVMSP 2.5V 3.0V3.0V 8.2 9.1 9.7\\nBiVMSP 2.5V 3.5V3.5V 7.4 8.3 8.9\\nLV-Only 2.0V/Off2.0VOff 12.9 13.2 14.7', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 50}), Document(page_content='48Table8.Pulsegenerator lifeexpectancy estimation (implanttoexplant)withENDURALIFE battery(continued)\\nAllModelsa\\nPacing Longevity (years)\\nVentricular\\nChambersRA/RV LVLVbd500Ωwith\\nLATITUDEb700Ωwith\\nLATITUDEb700ΩNo\\nLATITUDE, MV/RS,\\norHFSSc\\nLV-Only 2.5V/Off3.0VOff 11.3 12.0 13.2\\nLV-Only 2.5V/Off 3.5VOff 10.6 11.3 12.4\\nLV-OnlyMSP 2.0V/Off2.0V2.0V 11.5 12.1 13.3\\nLV-OnlyMSP 2.5V/Off3.0V3.0V 9.3 10.2 11.0\\nLV-OnlyMSP 2.5V/Off 3.5V3.5V 8.3 9.3 10.0\\na.AssumesZIPtelemetry usefor2hoursatimplantandfor40minutesannuallyforin-clinicfollow-up checks.\\nb.AssumesstandarduseoftheLATITUDE Communicator asfollows:DailyDeviceCheckon,quarterlyscheduled remotefollowups,andother\\ntypicalinterrogations.\\nc.AssumesLATITUDE Communicator isnotused,MinuteVentilation (MV)/Respiratory SensorisOff,andHeartFailureSensorSuiteisOff.\\nd.AppliestomodelswithMultiSitePacing(MSP).\\nNOTE:Theenergyconsumption inthelongevity tableisbasedupontheoretical electricalprinciples andverifiedviabench\\ntestingonly.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 51}), Document(page_content='49Thepulsegenerator longevity mayincreasewithadecreaseinanyofthefollowing:\\n•Pacingrate\\n•Pacingpulseamplitude(s)\\n•Pacingpulsewidth(s)\\n•Percentageofpacedtosensedevents\\n•Chargingfrequency\\nLongevity isalsoaffectedinthefollowing circumstanc es:7\\n•Adecreaseinpacingimpedance mayreducelongevity.\\n•WhentheMV/Respiratory SensorisprogrammedOffforthelifeofthedevice,longevity isincreased byapproximately 4\\nmonths.\\n•WhenPatientTriggered MonitorisprogrammedtoOnfor60days,longevity isreducedbyapproximately 3days.\\n•WhentheLATITUDE Communicator isnotusedforthelifeofthedevice,longevity isincreasedbyapproximately 4\\nmonths.\\n•Onehourofadditional ZIPwandless telemetry reduceslongevity byapproximately 7days.\\n•Fivepatient-initiated LATITUDE Communicator interrogations perweekforayearreduceslongevity byapproximately 31\\ndays.\\n•Anadditional maximum-energy shockreduceslongevity byapproximate ly16days.\\n•SixhoursinMRIProtection Modereduceslongevity byapproximately 3days.\\n•Anadditional 6monthsinStoragemodepriortoimplantwillreducelongevity by45days.\\n•WhentheHeartFailureSensorSuiteisprogrammedtoOffforthelifeofthedevice,longevity isincreased by\\napproximately 1month.\\n7.Assumesimplanted settingsof70ppmLRL;DDDRmode;15%atriumpacing;100%biventricular pacing;0.4mspacingPulseWidth;500Ω\\npacingImpedance; 2.5VpacingpulseAmplitude (RA,RV);3.0VpacingpulseAmplitude (LV).', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 52}), Document(page_content=\"50•AHeartLogic subscription withdailyalertchecksandweeklyinterrogations willdecreaselongevity byapproximately 2\\nmonthswhenusedforthelifeofthedevice.\\n•Dailyinterrogations torefreshHeartLogic following analertfor30dayseachyearwilldecreaselongevity byanadditional\\n1month.\\n•WhentheSignalArtifactMonitorisprogrammedOnforthelifeofthedevice,longevity isreducedbyapproximate ly2\\nmonths.\\nDevicelongevity mayalsobeaffectedby:\\n•Tolerancesofelectronic components\\n•Variations inprogramm edparameters\\n•Variations inusageasaresultofpatientcondition\\nWARRANTY INFORMATION\\nAlimitedwarrantycertificate forthepulsegenerator isavailableatwww.bostonscientific.com. Foracopy,contactBoston\\nScientificusingtheinformation onthebackcover.\\nPRODUCTRELIABILITY\\nItisBostonScientific's intenttoprovideimplantable devicesofhighqualityandreliability.However,thesedevicesmayexhibit\\nmalfunctions thatmayresultinlostorcompromisedabilitytodelivertherapy.Thesemalfunctions mayincludethefollowing:\\n•Prematurebatterydepletion\\n•Sensingorpacingissues\\n•Inabilitytoshock\\n•Errorcodes\\n•Lossoftelemetry\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 53}), Document(page_content=\"51RefertoBostonScientific's CRMProductPerformance Reportonwww.bostonscientific.com formoreinformation aboutdevice\\nperformance, including thetypesandratesofmalfunctions thatthesedeviceshaveexperienced historically .Whilehistorical\\ndatamaynotbepredictive offuturedeviceperformance, suchdatacanprovideimportant contextforunderstanding theoverall\\nreliability ofthesetypesofproducts.\\nSometimes devicemalfunctions resultintheissuanceofproductadvisories. BostonScientificdetermines theneedtoissue\\nproductadvisories basedontheestimated malfunction rateandtheclinicalimplication ofthemalfunction. WhenBoston\\nScientificcommunicates productadvisoryinformation, thedecisionwhethertoreplaceadeviceshouldtakeintoaccountthe\\nrisksofthemalfunction, therisksofthereplacementprocedure,andtheperformance todateofthereplacementdevice.\\nPATIENTCOUNSELING INFORMATION\\nThefollowing topicsshouldbediscussed withthepatientpriortodischarge:\\n•Externaldefibrillation—the patientshouldcontacttheirphysician tohavetheirpulsegenerator systemevaluated ifthey\\nreceiveexternaldefibrillation\\n•Beepingtones—the patientshouldcontacttheirphysician immediately iftheyheartonescomingfromtheirpulse\\ngenerator\\n•Signsandsymptoms ofinfection\\n•Symptoms thatshouldbereported(e.g.,sustained high-rate pacingrequiring reprogramming)\\n•Protected environments—the patientshouldseekmedicalguidance beforeenteringareasprotected byawarningnotice\\nthatpreventsentrybypatientswhohaveapulsegenerator\\n•MRIscanning—the physician following thepatient'sdevicemustbeconsultedtodetermine eligibility foranMRIscan.\\nBeforeanMRIprocedureisperformed, aphysician andpatientshouldweighthebenefitoftheMRprocedureagainstthe\\nriskoflosingtheBeeper.\\nWARNING: Determine thebeepertypebeforeanMRIscan.TheArmature Beepermaynolongerbeusablefollowing anMRI\\nscan.Comingincontactwiththestrongmagnetic fieldofanMRIscannermaycauseapermanent lossoftheArmature Beeper\\nvolume.Thiscannotberecovered,evenafterleavingtheMRIscanenvironment andexitingMRIProtection Mode.Forthe\\nArmature Beeper,beforeanMRIscanisperformed, aphysician andpatientshouldweighthebenefitoftheMRIscanagainst\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 54}), Document(page_content='52theriskoflosingtheBeeper;aftertheMRIscan,performBeeperevaluation testtodetermine iftheBeeperisusable.Ifthe\\nBeeperisnotusable,itisstronglyrecommended thatpatientsarefollowedonLATITUDE NXTafteranMRIscaniftheyarenot\\nalready.Otherwise, anin-clinicfollow-up scheduleofeverythreemonthsisstronglyrecommended tomonitordevice\\nperformance.\\n•AvoidingpotentialsourcesofEMIinhome,work,andmedicalenvironments\\n•Personsadministering CPR—thepresenceofvoltage(tingling) onthepatient\\'sbodysurfacemaybeexperienced when\\nthepulsegenerator deliversashock\\n•Reliability oftheirpulsegenerator (\"Product Reliability\" onpage50)\\n•Activityrestrictions (ifapplicable)\\n•Minimum heartrate(lowerratelimitofthepulsegenerator)\\n•Frequency offollowup\\n•Travelorrelocation—follow-up arrangementsshouldbemadeinadvanceifthepatientisleavingthecountryofimplant\\n•PatientIDcard—the patientshouldbeadvisedtocarrytheirpatientIDcardatalltimes(atemporary patientIDcardis\\nprovidedwiththedevice,andapermanent IDcardwillbesenttothepatient4to6weeksaftertheimplantformis\\nreceivedbyBostonScientific)\\nNOTE:PatientsshouldpresenttheirpatientIDcardbeforeenteringprotected environments suchasforMRI\\nscanning.\\nPatientHandbook\\nThePatientHandbook isprovidedforeachdevice.\\nItisrecommended thatyoudiscusstheinformation inthePatientHandbook withconcernedindividuals bothbeforeandafter\\nimplantation sotheyarefullyfamiliarwithpulsegenerator operation.\\nInaddition,forpatientswithanImageReady MRConditional Defibrillation System,anImageReady MRConditional Defibrillation\\nSystemMRIPatientGuideisavailable.\\nForadditional copies,contactBostonScientificusingtheinformation onthebackcover.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 55}), Document(page_content='53LEADCONNECTIONS\\nLeadconnections areillustrated below.\\nCAUTION: Priortoimplantation, confirmthelead-to-pulse generator compatibility .Usingincompatibleleadsandpulse\\ngenerators candamagetheconnector and/orresultinpotentialadverseconsequenc es,suchasundersensing ofcardiacactivity\\norfailuretodelivernecessary therapy.\\nWhendeactivating alead,ensuretheleadisfullyinsulated andelectricalnonactivebyusingleadcaps.Whendeactivating a\\nleadport,verifythattheplugandlabeledheaderportmatch.Verifywithaprogrammertheappropriate devicefunctionand\\nnewlyestablished configuration.Theabsenceofaleadorportplugmayaffectdeviceperformance andpotentially leavethe\\npatientwithouteffectivetherapy.\\nNOTE:UseofBostonScientificMRConditional leadsisrequiredforanimplanted systemtobeconsideredMRConditional.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnical Guideformodelnumbersofpulsegenerators,\\nleads,accessories,andothersystemcomponents neededtosatisfytheConditions ofUse.\\nCAUTION: IftheLeadConfiguration isprogrammedtoBipolarwhenaunipolarleadisimplanted, pacingwillnotoccur.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 56}), Document(page_content='54\\n6\\n4\\n5\\n7\\nIS-1 \\nBI\\nDF4-LLHH\\nRV\\nR\\nA\\nIS4-LLLL\\nLV\\n32\\n1[1]RA:White[2]LV:Green[3]RV:Red[4]RA(-)[5]LV(-)[6]SutureHoles[7]RV(-)\\nFigure2.Leadconnectionsandsetscrewlocations, RA:IS-1,RV:DF4-LLHH, LV:IS4-LLLL', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 57}), Document(page_content='55\\n11\\n6\\n7\\n10\\n8\\n9\\nIS-1 \\nBI\\nLV\\nRV\\n–\\n+\\nRA\\nDF-1\\nDF-1\\nIS-1 \\nBI\\n1\\n2\\n3\\n45\\nLV-1 \\nUNI/BI[1]Defib(-):Red[2]Defib(+):Blue[3]RA:White[4]LV:Green[5]RV:White[6]Defib(+)[7]Defib(-)[8]RA(-)[9]RV(-)[10]LV\\n(-)[11]SutureHole\\nFigure3.Leadconnections andsetscrewlocations, RA:IS-1,RV:IS-1/DF-1,LV:LV-1', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 58}), Document(page_content='56\\n6\\n4\\n5\\n7IS-1 \\nBI\\nDF4-LLHH\\nRV\\nRA\\nLV\\nIS-1 \\nUNI/BI\\n1\\n2\\n3[1]RA:White[2]LV:Green[3]RV:Red[4]RA(-)[5]LV(-)[6]SutureHoles[7]RV(-)\\nFigure4.Leadconnections andsetscrewlocations, RA:IS-1,RV:DF4-LLHH, LV:IS-1', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 59}), Document(page_content='57\\n11\\n6\\n7\\n10\\n8\\n9\\nIS-1 \\nB\\nI\\nIS4-LLLL\\nLV\\nR\\nV\\n–\\n+\\nRA\\nDF-1\\nDF-1\\nIS-1 \\nB\\nI\\n1\\n2\\n3\\n45[1]Defib(-):Red[2]Defib(+):Blue[3]RA:White[4]LV:Green[5]RV:White[6]Defib(+)[7]Defib(-)[8]RA(-)[9]RV(-)[10]LV\\n(-)[11]SutureHole\\nFigure5.Leadconnections andsetscrewlocations, RA:IS-1,RV:IS-1/DF-1,LV:IS4-LLLL', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 60}), Document(page_content='58\\n11\\n6\\n7\\n10\\n8\\n9\\nIS-1 \\nBI\\nLV\\nRV\\n–\\n+\\nRA\\nDF-1\\nDF-1\\nIS-1 \\nBI\\nIS-1 \\nUNI/BI1\\n2\\n3\\n45[1]Defib(-):Red[2]Defib(+):Blue[3]RA:White[4]LV:Green[5]RV:White[6]Defib(+)[7]Defib(-)[8]RA(-)[9]RV(-)[10]LV\\n(-)[11]SutureHole\\nFigure6.Leadconnections andsetscrewlocations, RA:IS-1,RV:IS-1/DF-1,LV:IS-1\\nNOTE:Thepulsegenerator caseisusedasadefibrillating electrode unlessthepulsegenerator hasbeenprogrammedtothe\\nDistalCoiltoProximalCoil(or“ColdCan”)ShockVector.\\nIMPLANTING THEPULSEGENERATOR\\nImplantthepulsegenerator byperforming thefollowing stepsinthesequence provided. Somepatientsmayrequirepacing\\ntherapiesimmediately uponconnecting theleadstothepulsegenerator.Insuchcases,considerprogrammingthepulse\\ngenerator beforeorinparallelwithimplanting theleadsystemandformingtheimplantation pocket.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 61}), Document(page_content='59WARNING: Implantofthesystemcannotbeperformed inanMRIsiteZoneIII(andhigher)asdefinedbytheAmerican\\nCollegeofRadiology Guidance Document onMRSafePractices8.Someoftheaccessoriespackaged withpulsegenerators and\\nleads,including thetorquewrenchandstyletwires,arenotMRConditional andshouldnotbebroughtintotheMRIscanner\\nroom,thecontrolroom,ortheMRIsiteZoneIIIorIVareas.\\nStepA:CheckEquipment\\nItisrecommended thatinstrumentation forcardiacmonitoring, defibrillation, andleadsignalmeasurement shouldbeavailable\\nduringtheimplantprocedure.ThisincludesthePRMsystemwithitsrelatedaccessoriesandthesoftwareapplication. Before\\nbeginning theimplantation procedure,becomecompletelyfamiliarwiththeoperation ofalltheequipment andtheinformation\\nintherespective operator\\'s anduser\\'smanuals. Verifytheoperational statusofallequipment thatmaybeusedduringthe\\nprocedure.Incaseofaccidental damageorcontamination, thefollowing shouldbeavailable:\\n•Sterileduplicates ofallimplantable items\\n•Sterilewand\\n•SterilePSAcables\\n•Torqueandnon-torque wrenches\\nDuringtheimplantation procedure,alwayshaveastandardexternaldefibrillator withexternalpadsorpaddlesavailableforuse\\nduringdefibrillation threshold testing.\\nStepB:InterrogateandCheckthePulseGenerator\\nThePRMcommunicates withthepulsegenerator usingatelemetry wand.Afterinitiatingcommunication withthewand,the\\nPRMcanusewandless ZIPtelemetry (two-way RFcommunication) tointerfacewithRFcapablepulsegenerators. Telemetry is\\nrequiredtodirectcommands fromthePRMsystem,modifydeviceparameter settingsandconductdiagnostics tests.\\nForadditional technicalspecifications regardingtelemetry function,referto\"FederalCommunications Commission (FCC)\"on\\npage45.\\n8.KanalE,Barkovich AJ,BellC,etal.ACRguidance document onMRsafepractices:2013.J.Magn.Reson.Imaging2013;37:501-530.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 62}), Document(page_content=\"60Tomaintainsterility,testthepulsegenerator asdescribed belowbeforeopeningthesterileblistertray.Thepulsegenerator\\nshouldbeatroomtemperatur etoensureaccuratelymeasured parameters.\\n1.Interrogate thepulsegenerator usingthePRM.Verifythatthepulsegenerator's TachyModeisprogrammedtoStorage.\\nIfotherwise, contactBostonScientificusingtheinformation onthebackcover.\\nTobeginaZIPtelemetry session,verifythattheZOOMWirelessTransmitter isconnected tothePRMviatheUSBcable\\nandthatthegreenlightontopofthetransmitter isilluminated. Toinitiatecommunication withalldevices,positionthe\\nwandoverthePGandusethePRMtoInterrogate thepulsegenerator.Keepthetelemetry wandinpositionuntileithera\\nmessageappears,indicating thatthetelemetry wandmayberemovedfromproximity ofthepulsegenerator,ortheZIP\\ntelemetry lightilluminates onthePRMsystem.SelecttheEndSessionbuttontoquitatelemetry sessionandreturnto\\nthestartupscreen.Radiofrequency interferenc emaytemporarily disruptZIPtelemetry communication. Increasing the\\ndistancefromthesourceofinterfering signalsorrepositioning theZOOMWirelessTransmitter mayimproveZIP\\ntelemetry performance. IfZIPtelemetry performance isnotsatisfactory ,theoptionofusingwandedtelemetry is\\navailable.\\n2.Performamanualcapacitorre-formation.\\n3.Reviewthepulsegenerator's currentbatterystatus.Countersshouldbeatzero.Ifthepulsegenerator batterystatusis\\nnotatfullcapacity,donotimplantthepulsegenerator.ContactBostonScientificusingtheinformation onthebackcover.\\nStepC:ImplanttheLeadSystem\\nThepulsegenerator requiresaleadsystemforsensing,pacing,anddelivering shocks.Thepulsegenerator canuseitscaseasa\\ndefibrillating electrode.\\nAfunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriate sensingandpacinginallchambers,\\nregardless ofprogrammedconfiguration,inconjunction withalltherapyrequiredleads.\\nSelectionofleadconfigurationandspecificsurgicalproceduresisamatterofprofessional judgment. Thefollowing leadsare\\navailableforusewiththepulsegenerator depending onthedevicemodel.\\n•Bipolarendocardial cardioversion/defibrillation andpacingleadsystem\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 63}), Document(page_content=\"61•Ventricular endocardial bipolarlead\\n•Atrialbipolarlead\\n•Unipolarorbipolarleftventricular lead\\n•Superiorvenacavaleadcoupledwithaventricular patchlead\\n•Quadripolar leftventricular lead\\nNOTE:Ifacoronaryvenousleadcannotbeusedandthephysician's medicaljudgment indicatesthatalimitedleft\\nthoracotomyisjustifiedtoplaceanepicardial lead,theuseofeitherasutureable,steroid-eluting pace/senseepicardial leador\\nsutureless epicardial pace/sense leadisrecommended.\\nNOTE:UseofBostonScientificMRConditional leadsisrequiredforanimplanted systemtobeconsideredMRConditional.\\nRefertotheImageReady MRConditional Defibrillation SystemMRITechnical Guideformodelnumbersofpulsegenerators,\\nleads,accessories,andothersystemcomponents neededtosatisfytheConditions ofUse,andforwarnings andprecautions\\nregardingMRIscanning.\\nCAUTION: Theabsenceofaleadorpluginaleadportmayaffectdeviceperformance andpotentially leavethepatient\\nwithouteffectivetherapy.Ifaleadisnotused,verifythattheplugandlabeledheaderportmatch(i.e.,IS-1,DF-1,LV-1,IS4,or\\nDF4).Fullyinserttheplugintheunusedportandthentightenthesetscrewontotheplug.Verifyappropriate devicefunction\\nusingtheprogrammer.\\n•Afunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriate sensingandpacinginall\\nchambers, regardlessofprogrammedconfiguration.ThisincludesCRTdevicesprogrammedtoAAI(R)orLV-Onlypacing.\\n•Lackofafunctional RVleadmayresultinundersensing, and/oroversensing andleavethepatientwithouteffective\\ntherapy.\\nCAUTION: Donotsuturedirectlyovertheleadbody,asthismaycausestructural damage.Usethesuturesleevetosecure\\ntheleadproximaltothevenousentrysitetopreventleadmovement.\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 64}), Document(page_content='62Whichever leadconfigurationisusedforbothpacing/sensing anddefibrillating, severalconsiderationsandcautionsshouldbe\\nheeded.Factorssuchascardiomegaly ordrugtherapymaynecessitate repositioning ofthedefibrillating leadsorsubstituting\\noneleadforanothertofacilitatearrhythmia conversion. Insomeinstances, noleadconfigurationmaybefoundthatprovides\\nreliablearrhythmia termination atenergylevelsavailablefromthepulsegenerator.Implantation ofthepulsegenerator isnot\\nrecommended inthesecases.\\nImplanttheleadsviathesurgicalapproach chosen.\\nNOTE:Shouldleadperformance changesoccurwhichcannotberesolvedwithprogramming,theleadmayneedtobe\\nreplacedifnoadapterisavailable.\\nNOTE:Useofadaptersisinconsistent withtheConditions ofUserequiredforMRConditional status.RefertotheImageReady\\nMRConditional Defibrillation SystemMRITechnical Guideforwarnings, precautions, andotherinformation aboutMRIscanning.\\nStepD:TakeBaselineMeasurements\\nOncetheleadsareimplanted, takebaselinemeasurements. Evaluatetheleadsignals.Ifperforming apulsegenerator\\nreplacement procedure,existingleadsshouldbereevaluated, (e.g.,signalamplitudes, pacingthresholds,andimpedance). The\\nuseofradiographymayhelpensureleadpositionandintegrity.Iftestingresultsareunsatisfactory ,leadsystemrepositioning or\\nreplacement mayberequired.\\n•Connectthepace/senselead(s)toapacingsystemanalyzer(PSA).\\nWARNING: ForleadsthatrequiretheuseofaConnector Tool,usecautionhandlingtheleadterminalwhentheConnector\\nToolisnotpresentonthelead.Donotdirectlycontacttheleadterminalwithanysurgicalinstruments orelectricalconnections\\nsuchasPSA(alligator) clips,ECGconnections,forceps,hemostats, andclamps.Thiscoulddamagetheleadterminal,possibly\\ncompromisingthesealingintegrityandresultinlossoftherapyorinappropriate therapy,suchasashortwithintheheader.\\n•Pace/sense leadmeasurements, measuredapproximate ly10minutesafterinitialplacement (acute)orduringa\\nreplacementprocedure(chronic), arelistedbelow.Valuesotherthanwhataresuggested inthetablemaybeclinically\\nacceptableifappropriate sensingcanbedocumented withthecurrentlyprogrammedvalues.Considerreprogramming', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 65}), Document(page_content='63thesensitivity parameter ifinappropriate sensingisobserved. Notethatthepulsegenerator measurements maynot\\nexactlycorrelatetothePSAmeasurements duetosignalfiltering.\\nTable9.Leadmeasurements\\nPace/senselead(acute) Pace/senselead(chronic)Shockinglead(acuteand\\nchronic)\\nR-WaveAmplitudeab>5mV >5mV >1.0mV\\nP-WaveAmplitudeab>1.5mV >1.5mV\\nR-WaveDurationbcd<100ms <100ms\\nPacingThreshold (right\\nventricle)<1.5Vendocardial\\n<2.0Vepicardial<3.0Vendocardial\\n<3.5Vepicardial\\nPacingThreshold (left\\nventricle)<2.5Vcoronaryvenous\\n<2.0Vepicardial<3.5Vcoronaryvenous\\n<3.5Vepicardial\\nPacingThreshold (atrium) <1.5Vendocardial <3.0Vendocardial\\nLeadimpedance (at5.0V\\nand0.5msatrium)e>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 66}), Document(page_content=\"64Table9.Leadmeasurements (continued)\\nPace/senselead(acute) Pace/senselead(chronic)Shockinglead(acuteand\\nchronic)\\nLeadimpedance (at5.0V\\nand0.5msrightventricle)e>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg>20Ω\\n<programmedHigh\\nImpedance Limit(125–200\\nΩ)\\nLeadimpedance (at5.0V\\nand0.5msleftventricle)>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg>programmedLow\\nImpedance Limitf\\n<programmedHigh\\nImpedance Limitg\\na.Amplitudes lessthan2mVcauseinaccurate ratecountinginthechronicstate,andresultininabilitytosenseatachyarrhythmia orthe\\nmisinterpretation ofanormalrhythmasabnormal.\\nb.LowerR-waveamplitudes andlongerdurationmaybeassociated withplacement inischemicorscarredtissues.Sincesignalqualitymay\\ndeteriorate chronically ,effortsshouldbemadetomeettheabovecriteriabyrepositioning theleadstoobtainsignalswiththelargestpossible\\namplitude andshortestduration.\\nc.Durations longerthan135ms(thepulsegenerator's refractoryperiod)mayresultininaccuratecardiacratedetermination, inabilitytosensea\\ntachyarrhythmia, orinthemisinterpretation ofanormalrhythmasabnormal.\\nd.Thismeasurement isnotinclusiveofcurrentofinjury.\\ne.Changesinthedefibrillation electrode surfacearea,suchaschanging fromatriadconfigurationtoasinglecoilconfiguration,canaffectthe\\nimpedance measurements. Baselinedefibrillation impedance measurements shouldfallwithintherecommended valuesindicated inthetable.\\nf.TheLowImpedance Limitisprogrammable between200–500Ω.\\ng.TheHighImpedance Limitisprogrammable between2000–3000 Ω.\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 67}), Document(page_content=\"65Iftheleadintegrityisinquestion, standardleadtroubleshooting testsshouldbeusedtoassesstheleadsystemintegrity.\\nTroubleshooting testsinclude,butarenotlimitedto,thefollowing:\\n•Electrogramanalysiswithpocketmanipulation\\n•X-rayorfluoroscopicimagereview\\n•Additional maximum-energy shocks\\n•ProgrammingtheShockLeadVector\\n•WirelessECG\\n•Invasivevisualinspection\\nStepE:FormtheImplantation Pocket\\nUsingstandardoperating procedurestoprepareanimplantation pocket,choosethepositionofthepocketbasedonthe\\nimplanted leadconfigurationandthepatient'sbodyhabitus.Givingconsiderationtopatientanatomyandpulsegenerator size\\nandmotion,gentlycoilanyexcessleadandplaceadjacenttothepulsegenerator.Itisimportant toplacetheleadintothe\\npocketinamannerthatminimizes leadtension,twisting,sharpangles,and/orpressure.Pulsegenerators aretypically\\nimplanted subcutaneously inordertominimize tissuetraumaandfacilitateexplant.However,deeperimplantation (e.g.,\\nsubpectoral) mayhelpavoiderosionorextrusion insomepatients.\\nIfanabdominal implantissuitable,itisrecommended thatimplantation occurontheleftabdominal side.\\nNOTE:Anabdominal implantsiteisinconsistent withtheConditions ofUseforMRConditional MRIscanning. Refertothe\\nImageReady MRConditional Defibrillation SystemMRITechnical Guideforwarnings, precautions andotherinformation about\\nMRIscanning.\\nIfitisnecessary totunnelthelead,considerthefollowing:\\nWARNING: ForleadsthatrequiretheuseofaConnector Tool,usecautionhandlingtheleadterminalwhentheConnector\\nToolisnotpresentonthelead.Donotdirectlycontacttheleadterminalwithanysurgicalinstruments orelectricalconnections\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 68}), Document(page_content='66suchasPSA(alligator) clips,ECGconnections,forceps,hemostats, andclamps.Thiscoulddamagetheleadterminal,possibly\\ncompromisingthesealingintegrityandresultinlossoftherapyorinappropriate therapy,suchasashortwithintheheader.\\nWARNING: DonotcontactanyotherportionoftheDF4–LLHH orDF4–LLHO leadterminal,otherthantheterminalpin,even\\nwhentheleadcapisinplace.\\nDonotcontactanyotherportionoftheIS4–LLLLleadterminal,otherthantheterminalpin,evenwhentheleadcapisinplace.\\n•Ifacompatibletunnelerisnotused,captheleadterminalpins.APenrosedrain,largechesttube,ortunneling toolmay\\nbeusedtotunneltheleads.\\n•ForDF4-LLHH orDF4-LLHO leads,ifacompatible tunneling tipand/ortunnelerkitisnotused,captheleadterminaland\\ngriponlytheterminalpinwithahemostat orequivalent.\\n•ForIS4-LLLLleads,ifacompatibletunneling tipand/ortunnelerkitisnotused,captheleadterminalandgriponlythe\\nterminalpinwithahemostat orequivalent.\\n•Gentlytunneltheleadssubcutaneously totheimplantation pocket,ifnecessary.\\n•Reevaluate allleadsignalstodetermine ifanyoftheleadshavebeendamaged duringthetunneling procedure.\\nIftheleadsarenotconnected toapulsegenerator atthetimeofleadimplantation, theymustbecappedbeforeclosingthe\\nincision.\\nStepF:ConnecttheLeadstothePulseGenerator\\nToconnectleadstothepulsegenerator,useonlythetoolsprovidedinthepulsegenerator steriletrayoraccessorykit.Failure\\ntousethesuppliedtorquewrenchmayresultindamagetothesetscrews, sealplugs,orconnector threads.Donotimplantthe\\npulsegenerator ifthesealplugsappeartobedamaged. Retainthetoolsuntilalltestingproceduresarecomplete andthepulse\\ngenerator isimplanted.\\nNOTE:Somepatientsmayrequirepacingtherapies immediately uponconnectingtheleadstothepulsegenerator.Insuch\\ncases,considerprogrammingthepulsegenerator beforecontinuing.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 69}), Document(page_content='67Leadsshouldbeconnected tothepulsegenerator inthefollowing sequence (forpulsegenerator headerandsetscrewlocation\\nillustrations, referto\"LeadConnections\" onpage53):\\n1.Rightventricle. ConnecttheRVleadfirstbecauseitisrequiredtoestablishRV-based timingcyclesthatyield\\nappropriate sensingandpacinginallchambers, regardless oftheprogrammedconfiguration.\\n•InmodelswithanIS-1RVleadport,insertandsecuretheterminalpinofanIS-1RVpace/sense lead.\\n•InmodelswithaDF4-LLHH RVleadport,insertandsecuretheterminalpinofaDF4-LLHH orDF4-LLHO lead.\\n2.Rightatrium.\\n•InmodelswithanIS-1RAleadport,insertandsecuretheterminalpinofanIS-1atrialpace/sense lead.\\n3.Leftventricle.\\n•InmodelswithanIS-1LVleadport,insertandsecuretheterminalpinofanIS-1coronaryvenouspace/sense lead.\\n•InmodelswithanLV-1LVleadport,insertandsecuretheterminalpinofanLV-1coronaryvenouspace/sense\\nlead.\\n•InmodelswithaIS4-LLLLLVleadport,insertandsecuretheterminalpinofaIS4-LLLLlead.\\nWARNING: Whenimplanting asystemwhichusesbothaDF4-LLHH/LLHO andIS4-LLLLlead,ensurethattheleadsare\\ninsertedandsecuredintheappropriat eports.Insertingaleadintoanincorrectportwillresultinunanticipated devicebehavior\\n(potentially leavingthepatientwithouteffectivetherapy).\\n4.Defibrillation lead.\\n•InmodelswithDF-1leadports,firstinsertandsecurethedefibrillation leadanode(+,proximal) intothe(+)DF-1\\nleadport.Theninsertandsecuretheleadcathode(–,distal)intothe(–)DF-1leadport.\\nCAUTION: ForIS-1/DF-1leads,neverchangetheshockwaveform polaritybyphysically switching theleadanodesand\\ncathodesinthepulsegenerator header—use theprogrammable Polarityfeature.Devicedamageornonconversion ofthe\\narrhythmia post-operatively mayresultifthepolarityisswitchedphysically.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 70}), Document(page_content='68Connecteachleadtothepulsegenerator byfollowing thesesteps(foradditional information aboutthetorquewrench,referto\\n\"BidirectionalTorqueWrench\"onpage82):\\n1.Checkforthepresenceofanybloodorotherbodyfluidsintheleadportsonthepulsegenerator header.Iffluid\\ninadvertently enterstheports,cleanthemthoroughly withsterilewater.\\n2.Ifapplicable, removeanddiscardthetipprotection beforeusingthetorquewrench.\\n3.Gentlyinsertthetorquewrenchbladeintothesetscrewbypassingitthroughthepreslit,centerdepression oftheseal\\nplugata90°angle(Figure7Insertingthetorquewrenchonpage69).Thiswillopenupthesealplug,relievingany\\npotentialpressurebuild-upfromtheleadportbyproviding apathwaytoreleasetrappedfluidorair.\\nNOTE:Failuretoproperlyinsertthetorquewrenchinthepreslitdepression ofthesealplugmayresultindamageto\\nthepluganditssealingproperties.\\nCAUTION: Donotinsertaleadintothepulsegenerator connector withouttakingthefollowing precautionstoensure\\nproperleadinsertion:\\n•Insertthetorquewrenchintothepreslitdepression ofthesealplugbeforeinsertingtheleadintotheport,to\\nreleaseanytrappedfluidorair.\\n•Visuallyverifythatthesetscrewissufficiently retractedtoallowinsertion. Usethetorquewrenchtoloosenthe\\nsetscrewifnecessary.\\n•Fullyinserteachleadintoitsleadportandthentightenthesetscrewontotheterminalpin.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 71}), Document(page_content='69\\nFigure7.Insertingthetorquewrench\\n4.Withthetorquewrenchinplace,fullyinserttheleadterminalintotheleadport.Theleadterminalpinshouldbeclearly\\nvisiblebeyondtheconnector blockwhenviewedthroughthesideofthepulsegenerator header.Placepressureonthe\\nleadtomaintainitspositionandensurethatitremainsfullyinsertedintheleadport.\\nCAUTION: Inserttheleadterminalstraightintotheleadport.Donotbendtheleadnearthelead-header interface.\\nImproper insertioncancauseinsulation orconnectordamage.\\nNOTE:Ifnecessary,lubricatetheentireleadterminal(areashowninFigure8DF4LeadTerminalonpage69)sparingly\\nwithsterilewaterorsterilemineraloiltomakeinsertioneasier.\\nFigure8.DF4LeadTerminal', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 72}), Document(page_content='70\\nFigure9.IS4LeadTerminal\\nNOTE:ForIS-1leads,becertainthattheterminalpinvisiblyextendsbeyondtheconnector blockatleast1mm.\\nNOTE:ForDF4-LLHH orDF4-LLHO leads,theterminalpinmustbeinsertedbeyondthesetscrewblocktoenablea\\nproperconnection. Visualization oftheterminalpininsertionindicatorbeyondthesetscrewblockmaybeusedtoconfirm\\nthattheterminalpinisfullyinsertedintotheleadport.\\nNOTE:ForIS4-LLLLleads,theterminalpinmustbeinsertedbeyondthesetscrewblocktoenableaproperconnection.\\nVisualization oftheterminalpininsertionindicatorbeyondthesetscrewblockmaybeusedtoconfirmthattheterminal\\npinisfullyinsertedintotheleadport.\\n5.Applygentledownward pressureonthetorquewrenchuntilthebladeisfullyengagedwithinthesetscrewcavity,taking\\ncaretoavoiddamagetothesealplug.Tightenthesetscrewbyslowlyturningthetorquewrenchclockwise, untilit\\nratchetsonce.Thetorquewrenchispresettoapplytheproperamountofforcetothecaptivesetscrew; additional\\nrotationandforceisunnecessary .\\n6.Removethetorquewrench.\\n7.Applygentletractiontotheleadtoensureasecureconnection.\\n8.Iftheleadterminalisnotsecure,attempttoreseatthesetscrew.Reinsertthetorquewrenchasdescribed above,and\\nloosenthesetscrewbyslowlyturningthewrenchcounterclockwise, untiltheleadisloose.Thenrepeatthesequence\\nabove.\\n9.Ifaleadportisnotused,insertaplugintotheunusedportandtightenthesetscrew.\\nCAUTION: Theabsenceofaleadorpluginaleadportmayaffectdeviceperformance andpotentially leavethe\\npatientwithouteffectivetherapy.Ifaleadisnotused,verifythattheplugandlabeledheaderportmatch(i.e.,IS-1,DF-1,\\nLV-1,IS4,orDF4).Fullyinserttheplugintheunusedportandthentightenthesetscrewontotheplug.Verifyappropriate\\ndevicefunctionusingtheprogrammer.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 73}), Document(page_content=\"71•Afunctional RVleadisrequiredtoestablishRV-based timingcyclesthatyieldappropriate sensingandpacingin\\nallchambers, regardless ofprogrammedconfiguration.ThisincludesCRTdevicesprogramm edtoAAI(R)orLV-\\nOnlypacing.\\n•Lackofafunctional RVleadmayresultinundersensing, and/oroversensing andleavethepatientwithout\\neffectivetherapy.\\nStepG:EvaluateLeadSignals\\n1.Takethepulsegenerator outofpower-savingStoragemodebyprogrammingtheTachyModetoOff.\\nCAUTION: Topreventinappropriate shocks,ensurethatthepulsegenerator's TachyModeisprogrammedtoOffwhennot\\ninuseandbeforehandlingthedevice.Fortachyarrhythmia detection andtherapy,verifythattheTachyModeisprogrammedto\\nMonitor+Therapy.\\n2.Insertthepulsegenerator intotheimplantation pocket.\\n3.Evaluatethepace/senseanddefibrillation leadsignalsbyviewingthereal-timeEGMsandmarkers.Thesignalfromthe\\nimplanted defibrillation leadsshouldbecontinuous andwithoutartifact,similartoabody-surface ECG.Adiscontinuous\\nsignalmayindicateapoorconnection, leadfractureorotherwise damaged lead,oraninsulation breakthatwould\\nnecessitate leadreplacement.Inadequate signalsmayresultinfailureofthepulsegenerator systemtodetectan\\narrhythmia, inabilitytodeliverprogrammedtherapy,orunnecessary deliveryoftherapy.Leadmeasurements should\\nreflectthoseabove(Table9Leadmeasurements onpage63).\\nCAUTION: Takecaretoensurethatartifactsfromtheventricles arenotpresentontheatrialchannel,oratrialoversensing\\nmayresult.Ifventricular artifactsarepresentintheatrialchannel,theatrialleadmayneedtoberepositioned tominimize its\\ninteraction.\\n4.Evaluateallleadimpedances.\\nCAUTION: Iftotalshockingleadimpedance duringimplantislessthan20Ω,verifytheproximalcoilisnotincontactwith\\nthepulsegenerator surface.Ameasurement oflessthan20Ωisanindication ofashortsomewhere inthesystem.Ifrepeated\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 74}), Document(page_content=\"72measurementsshowthetotalshockingleadimpedance islessthan20Ω,theleadand/orpulsegenerator mayneedtobe\\nreplaced.\\nCAUTION: Patientsshouldbetestedfordiaphragmatic stimulation bypacingtheLVleadthroughthepulsegenerator at\\n7.5Vandadjusting theleadconfigurationsandleadpositionasnecessary.PSAtestingathigheroutputs(e.g.,10.0V)mayalso\\nbeconsideredtobettercharacteriz estimulation margins.Theprobability ofdiaphragmatic stimulation increases whenapacing\\nsystemincludesanLVleadbecauseofthislead'sproximity tothephrenicnerve.\\nTheHighImpedance Limitisnominally setto2000Ω,andisprogrammable between2000and3000Ωin250Ωincrements.\\nTheLowImpedance Limitisnominally setto200Ω,andisprogrammable between200and500Ωin50Ωincrements.\\nConsiderthefollowing factorswhenchoosingavaluefortheimpedance limits:\\n•Forchronicleads,historicalimpedance measurements forthelead,aswellasotherelectricalperformance indicators such\\nasstabilityovertime\\n•Fornewlyimplanted leads,thestartingmeasured impedance value\\nNOTE:Depending onleadmaturation effects,duringfollow-up testingthephysician maychoosetoreprogramthe\\nimpedanc elimits.\\n•Pacingdependenc eofthepatient\\n•Recommended impedanc erangeforthelead(s)beingused,ifavailable\\nTheShockLowImpedance Limitisfixedat20Ω.TheShockHighImpedance Limitisnominally setto125Ω,andis\\nprogrammable between125and200Ωin25Ωincrements. Considerthefollowing factorswhenchoosingavaluefortheHigh\\nImpedanc eLimits:\\n•Forchronicleads,historicalimpedance measurements forthelead,aswellasotherelectricalperformance indicators such\\nasstabilityovertime\\n•Fornewlyimplanted leads,thestartingmeasured impedance value\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 75}), Document(page_content=\"73NOTE:Depending onleadmaturation effects,duringfollow-up testingthephysician maychoosetoreprogramtheHigh\\nImpedance Limits.\\n•Recommended impedance rangeforthelead(s)beingused,ifavailable\\n•Theimpedance valueofahighormaximum energyshockimpedance test\\nShockingleadimpedance readingsbetween20ΩandtheprogrammedHighImpedance Limitareconsideredin-range. Ifabrupt\\norlargeimpedance fluctuations orout-of-range conditions areobserved, considerthefollowing:\\n•Verifytheconfiguration—ensure theprogrammedShockVectormatchestheconfigurationoftheimplanted lead(e.g.,\\nuseRVCoiltoCanwithasingle-coil lead).\\n•Verifytheconnection—ensur etheshockinglead'sterminalpinsareplacedinthecorrectleadportsandverifyasecure\\nleadconnection.\\n•Verifythecontact—ensur ethedeviceisinsideawetimplantpocketsincethepulsegenerator caseservesasanactive\\nelectrode intheV-TRIADconfiguration.Avoidpocketmanipulation duringthetest.\\n•Turnoffsourcesofexternalnoise(e.g.,electrocautery equipment, monitors).\\n•Useothertroubleshooting tools,asneeded,tofurtherassessleadsystemintegrity,including electrogramanalysis,X-ray\\norfluoroscopicimagereview,orinternalvisualinspection.\\nNOTE:Becausethisdeviceusesasubthreshold testpulsetoconductshockleadimpedance measurements, itcanbedifficult\\ntomeasureresponses totestsignalswhenelectricalinterferenc eor“noise”(e.g.,electrocautery orexternalmonitoring\\nequipment attacheddirectlytothepatient)ispresentduringthetest.Thismayresultinimpedance measurement variations,\\nparticularly atimplant.Intheabsenceofsuchelectricalinterferenc e,shockleadimpedance readingswillbemorestable.\\nStepH:ProgramthePulseGenerator\\n1.ChecktheProgrammerClockandsetandsynchroniz ethepulsegenerator asnecessary sothatthepropertimeappears\\nonprintedreportsandPRMstripchartrecordings.\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 76}), Document(page_content='742.ItmaybeusefultoprogramtheBeepDuringCapacitor ChargefeaturetoOnduringconversion testingandimplantation\\ntohelprecognizewhenthepulsegenerator ischargingtodeliverashock.\\n3.Performamanualcapacitorre-formationifnotalreadyperformed.\\n4.Programthepulsegenerator appropriat elyifaleadport(s)isnotused.\\n5.Programthepulsegenerator todesiredparameters appropriate forthepatientforconversion testing.\\nConsiderthefollowing whenprogrammingthepulsegenerator:\\n•Theminimum 2Xvoltageor3Xpulsewidthsafetymarginisrecommended foreachchamberbasedonthecapture\\nthresholds, whichshouldprovideanadequate safetymarginandhelppreservebatterylongevity.\\n•WhenSmartBlankingisused,itispossiblethatpolarization artifactsfollowing atrialpacingmaybedetectedasR-waves\\nandinhibitventricular pacing(aftertachytherapyorhigh-output ventricular pacing).Ifthepatientispacemaker-\\ndependent, testforpropersensingaftershocktherapy.Ifoversensing isoccurring post-shock,bepreparedtousethe\\nSTATPACEcommand.\\n•Programmingalongerblankingperiodmayincreasethelikelihood ofundersensing R-waves.\\n•Programmingashorterblankingperiodmayincreasethelikelihood forventricular oversensing ofanatrialpacedevent.\\n•Toreducetheriskofventricular undersensing duetoV-BlankafterA-Pace(whenadual-chamber pacingmodewithRate\\nSmoothing orRateAdaptivePacingisnecessary):\\n–ReducetheLRL\\n–ShortentheAVDelayoruseDynamicAVDelayandreducetheminimum DynamicAVDelaysetting\\n–IncreasetheDownRateSmoothing percentagetothelargestpossiblevalue\\n–DecreasetheRecoveryTimeforRateAdaptivePacingmodes\\n–ReducetheMTRorMPRifDownRateSmoothing ison', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 77}), Document(page_content='75–ReducetheMSRifthepacingmodeisrateadaptive\\n•WhenreprogrammingtheRhythmMatch Thresholdvalue,considerthefollowing:\\n–Reviewthemeasured RhythmMatch valuesforpreviousepisodesofVTandSVT(inducedorspontaneous)\\n–Toincreasethelikelihood ofappropriate treatment ofVT,theRhythmMatch Threshold shouldbeprogrammed\\nabovethemeasured RhythmMatch valuesofanyVTs\\n–Toincreasethelikelihood ofappropriate inhibition oftherapyforSVT,theRhythmMatch Threshold shouldbe\\nprogrammedbelowthemeasured RhythmMatch valuesofanySVTs\\n–Ingeneral,thesensitivity ofVTdetection declineswithlowerprogrammedRhythmMatch Threshold values,\\nthereforeformaximum sensitivity toVT,thehighestappropriate RhythmMatch Threshold valueshouldbe\\nprogrammed.\\n–Measured RhythmMatch valuesmayalsobeusefulforprogrammingotherRhythmIDparameters including Atrial\\nTachyarrhythmia Discrimination, AFibRateThreshold,andStability\\n•WhenprogrammingMTR,considerthepatient’scondition, age,generalhealth,sinusnodefunction,andthatahighMTR\\nmaybeinappropriateforpatientswhoexperience anginaorothersymptoms ofmyocardial ischemiaathigherrates.\\n•WhenprogrammingMSR,considerthepatient’scondition, age,generalhealthandthatadaptive-rat epacingathigher\\nratesmaybeinappropriate forpatientswhoexperienceanginaorothersymptoms ofmyocardial ischemiaatthese\\nhigherrates.Anappropriate MSRshouldbeselectedbasedonanassessment ofthehighestpacingratethatthepatient\\ncantoleratewell.\\n•Forheartfailurepatientswithsecond-andthird-degr eeAVblock,programminglongAtrialRefractory periodsin\\ncombination withcertainAVDelayperiodscancause2:1blocktooccurabruptlyattheprogrammedMTR.\\n•Certainconditions maycausethetemporary lossofCRTorAVsynchrony duetoWenckebach-lik ebehavior,andheart\\nfailurepatientsmaybecomesymptomatic ifCRTiscompromised.Considerpatientcondition whenprogrammingfeatures\\nsuchasMTR,AFR,RateSmoothing, andfeaturesthatswitchtoVVIorVVI-likebehavior.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 78}), Document(page_content=\"76•PriortoprogrammingRVATon,considerperforming aCommanded Ventricular Automatic ThresholdMeasurement to\\nverifythatthefeaturefunctions asexpected.\\n•Inpacemaker-dependent patients,usecarewhenconsidering settingNoiseResponse toInhibitPacingaspacingwillnot\\noccurinthepresenceofnoise.\\n•Toresolvesuspected impedance-based interactions withtheMV/Respiratory Sensor,programthesensortoOff.\\nCAUTION: Topreventinappropriateshocks,ensurethatthepulsegenerator's TachyModeisprogrammedtoOffwhennot\\ninuseandbeforehandlingthedevice.Fortachyarrhythmia detection andtherapy,verifythattheTachyModeisprogrammedto\\nMonitor+Therapy.\\nStepI:TestforAbilitytoConvertVentricular Fibrillation andInducibleArrhythmias\\nAfterobtaining acceptablesignalsfromtheimplanted leads,thephysician maychoosetoperformVTandVFconversion testing\\ntodetermine (1)iftheconfigurationandpositionoftheimplanted leadsareappropriate forthepatientand(2)ifthepulse\\ngenerator’ sprogrammedshockenergyormaximum-shock energywillbesufficient toconvertarrhythmias reliablyand(3)if\\nAGCanddetection enhancementsareprogrammedappropriately todetectVF/VT.Aconversion testconsistsofinducingthe\\narrhythmia andthenattempting toconvertthearrhythmia withapreselected energylevel.\\nDemonstr atingconversion ofventricular fibrillation issuggested beforeimplanting apulsegenerator becauseashockdelivered\\nduringventricular tachycardia hasthepotentialtoacceleratethearrhythmia. Intraoperativetestingmaybeminimizedby\\nperforming onlyVFtestingattimeofimplantandperforming VTtestingpost-operatively intheelectrophysiology labpriorto\\nthepatient’sdischarge.\\nIftheconversion isunsuccessful,thepatientshouldberescuedusinganappropriate externaldefibrillator .Aspartoftheoverall\\nclinicalevaluation duringconversion testingandevaluation ofspontaneous episodesduringfollowup,ensurethereisnodelay\\norinterruption intachyarrhythmia detection andtherapydelivery.Performadditional evaluation ifanydiversion ofcharging\\ncyclesorshockdeliveryisobserved.\\nIfconversion testingisperformed, thepermanently programmedparameters maybethesameasthoseusedduringtesting,or\\ntheymaybemodifiedtodifferentvalues.Thedevicecanbeprogrammedwiththeintendedfinalparameter settingsforallVT/\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 79}), Document(page_content=\"77VF(multiplezones),orwithasinglezoneVFsettingwitharatethreshold belowthatofanyknownarrhythmia. Whenno\\nconversion testingisperformed inpatientswithprimaryprevention indications, aphysician shouldconsiderthathighdetection\\nratescanlimittheabilityofthedevicetoaccuratelydetectandtreatpolymorphic tachyarrhythmias. Itisimportant toevaluate\\nthedevice'sstoreddiagnostic dataandEGMs,including theintervalplot,afterconversion testing(referto“Tachyarrhythmia\\nProgrammingConsiderations” below).Programmingfinalratethresholds forVT/VFtohighervalues,orlesssensitiveAGC\\nsettings,thanthetestedparameters mayresultinunder-detection oflaterspontaneous tachyarrhythmias.\\nWARNING: Alwayshaveexternaldefibrillation equipment availableduringimplantandelectrophysiologic testing.Ifnot\\nterminated inatimelyfashion,aninducedventricular tachyarrhythmia canresultinthepatient'sdeath.\\nNOTE:Ifopenchestsurgeryisperformed andachestretractorisused,removeitbeforeconversion testingtobestsimulate\\ntheambulatory conditions inwhichthepulsegenerator willoperateandtoavoidpotentialshuntingofenergy.\\nInducethePatient’sArrhythmia\\nAnarrhythmia canbeinducedbyusingtheinduction featuresofthepulsegenerator.\\nAllowthepatient’sbloodpressureandelectrophysiologic statustoreturntobaselinebetweenarrhythmia inductions, whether\\nsuccessfulorunsuccessful.Theminimum timebetweenconversion testsshouldbebasedontheclinical(hemodynamic and\\nmetabolic) stabilityofthepatientandthephysician’s discretion.\\nDuringeacharrhythmia induction, notetheheartratetodetermine theappropriate ratethreshold values.Ventricular cycle\\nlengthsthatoccurclosetobutbelowthelowestprogrammedratethreshold valuemaybedetectedasnormalsinusrhythm.To\\nprovidesufficient opportunity fordetection, theratethreshold value(s)shouldbeprogramm edatleast10bpmbelowtherate\\nofthearrhythmia(s) intendedtobetreated.\\nPerformtheInduction\\n1.Verifythepulsegenerator isintheimplantation pocket.Temporarily closethepocketenoughtoensurethatthepulse\\ngenerator willremaininpositionduringconversion testing.Makesurethepulsegenerator hasgoodcontactwith\\nsurrounding tissue;flushthepocketwithsalinesolution,ifnecessary,toavoidadrypocket.\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 80}), Document(page_content='78CAUTION: Donotallowanyobjectthatiselectrically conductive tocomeintocontactwiththeleadordeviceduring\\ninduction becauseitmayshuntenergy,resultinginlessenergygettingtothepatient,andmaydamagetheimplanted system.\\n2.Verifymagnetfunctionandtelemetry toensurethepulsegenerator iswithinacceptablerange.\\n3.Programtheappropriat eparameters andchangethepulsegenerator TachyModetoMonitor+Therapy.\\n4.Performtheinduction usingtheprogrammer.\\nTestingEnergyRequirements andThresholds forSuccessfulDefibrillation\\nDefibrillation energyrequirements andthreshold testingforsuccessfuldefibrillation shouldbeperformed atimplant.\\nShocksintendedforVForpolymorphic VTtherapyshouldbeprogrammedwitha10Jsafetymarginabovetheshockenergy\\nlevelthatthephysician determines isrequiredforsuccessfulVFconversion. Insomesituations, analternative safetymargin\\n(abovetheshockenergylevelrequiredforsuccessfulVFconversion) maybedetermined bythephysician tobeadequate.\\nDifferenttestmethodsfordetermining defibrillation thresholds aredescribed inclinicalliteratureandinclude,butarenot\\nlimitedto:\\n•Steppingdowntofailuredefibrillation threshold testingtodetermine theDFTandverifyingthelastsuccessfulenergy\\neitheronce[1x(DFT+)]ortwice[2x(DFT++)].\\n•Selectingthedefibrillation energyrequirementtestingbysubtracting theacceptedsafetymarginfromthedevice\\nmaximum output.\\nDefininganimplantation safetymarginandtherelationship totheprobabilityforsuccessisdescribed inclinicalliterature.Any\\nresultfromasingletestmethodmaybeanexampleofstatistical variation, andaone-time conversion ofarhythmdisturbance\\nataparticular energyleveldoesnotguaranteeorensurethattheenergylevelisreliableforconversion.\\nAsasafetymarginwitha41Jsystem,itisrecommended thattheconversion testbeperformed attheDFTleveltwotimesif\\ntheDFTorselectedenergylevelis31J,oronetimeiftheDFTorselectedenergylevelis21Jwithnofailurestoconvert.\\nAlwayshaveastandardexternaldefibrillator withexternalpadsorpaddlesavailableforuseduringdefibrillation threshold\\ntesting.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 81}), Document(page_content='79Ifimplantation safetymarginandinitialconversion at31Jisunsuccessful,consideracombination ofdifferentmethodsto\\noptimizethedefibrillation fieldandefficacy.Possibilities include,butarenotlimitedto:\\n•Optimizetheleadposition—placetheleadasapicalandseptalaspossibletodirectmostoftheenergytotheleft\\nventricular massasdescribed inclinicalliterature.\\n•Reversepolarity—useelectronic deviceprogrammingoptionstochangepolarity.Donotphysically switchthelead\\nanodesandcathodesinthepulsegenerator header.\\n•ReprogramtheShockLeadVectorconfigurationinthedevice(e.g.,removetheproximalcoilfromaTRIADconfiguration\\ntoasingleshockvectorsuchastheRVCoiltoCanconfiguration).\\n•Addadditional defibrillation coilsorleadstoincreasethedefibrillation surfacearea.\\nNOTE:RefertoTable9Leadmeasurements onpage63foracceptableleadmeasurements afterleadrepositioning or\\nreprogramming.\\nStepJ:Tachyarrhythmia Programming Considerations\\nDetection Zones\\nSelecttheappropriat enumberoftherapyzones(VT-1,VT,VF)totreattheexpectedventricular tachyarrhythmias basedonthe\\ntachyarrhythmia hemodynamic stability,patientindications, andtheindividual patientclinicalcharacteristics. Toprovide\\nsufficient opportunity fordetection, theratethreshold value(s)shouldbeprogrammedatleast10bpmbelowtherateofknown\\narrhythmia(s) intendedtobetreated.\\nNOTE:Thedevicedetection andsubsequent therapymaybedifferentforthesameunderlying tachyarrhythmia depending on\\nthenumberofzonesandprogrammedparameters suchasratethreshold, detection time,anddetection enhancements (if\\napplied).\\nEpisodeStorageReview\\nDevicediagnostics arestoredinthepulsegenerator andareviewableviathePRMorLATITUDE NXT.Diagnostics enablea\\nreviewofdevicedetection andresponsetoinducedandspontaneous tachyarrhythmias. Storedelectrogramsincludeaninterval', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 82}), Document(page_content='80plot.Evaluating theintervalplothelpstoidentifydetectedbeatsincluding thosebelowtheratethreshold. Beatsbelowthe\\nprogrammedratethreshold maydelayorinhibitdevicedetection ofatachyarrhythmia, andconsiderationshouldbegivento\\nreprogramtheratestoimprovedetection. Inspection ofthestoredelectrograms,withuseoftheon-screen calipersforEGM\\namplitude andtimingmeasurement, permitsthephysician tointerpretwhetherthereareventricular beatswhicharenot\\ndetected. Ifthereareunmarked beats,thenanassessment shouldoccurtodetermine ifprogrammingslowerratezoneswould\\nimprovedetection.\\nDetection andAutomatic GainControl(AGC)\\nTherightventricular AGCissettoanominalvalueof0.6mVandcanbeadjustedusingthePRM.Adjustment oftheAGCmay\\nbeconsideredforcaseswithlowamplitude EGMs,delayintimetotherapy,orperthephysician’s discretion inindividual cases.\\nAnyadjustment oftheAGCmustbeevaluated incombinationwiththeprogrammeddetection ratethresholds/z onestoensure\\nappropriat eratedetection oftheexpectedtachyarrhythmia. TheAGCmaynotreachitsprogrammedfloorwhen\\ntachyarrhythmia detection ratesarerapidandthearrhythmia ispolymorphic. Alwaysevaluatetherateofthedetection zones\\nandtheAGCsettingincombination usingtheepisodestorageinformation. Ifaphysician examines theEGMsandbelievesthe\\ndeviceisnotdetecting ventricular beat(s)intheappropriate zone,thenreprogramming detection ratethresholds toslowerrates\\nmayfacilitatetheoveralldetection behavior.Adjusting theAGCwithconversion testingmaybeconsidered.Changesinthe\\npatient’smetabolic state,alongwithprescription drugs,mayaffectthesizeofthewaveform ontheEGM.AGCreprogramming\\nmaynotbenecessary whenmarkersindicatedevicesensingisappropriate, butthesensedintervalsarebelowtheratecriteria.\\nMarkers\\nMarkerssuchasVT-1,VT,andVF,including themeasured cyclelength,arerecordedandassociated withtheprogrammed\\ndetection zones.Thepresenceofmarkersindicatesthatthedevicehasdetectedacertainbeat.Fluctuating tachycardiarates\\nthatarecloseto,orjustbelow,thelowestratethreshold maybemarkedasVS(ventricular sense).Reviewoftheintervalplot\\nprovidesanoverviewoftheprogrammedratethresholds andintervaldistribution duringtheepisodes. Thisinformation enables\\nclinicaladjustment ofdetection parameters perthephysician’s discretion.\\nStepK:ImplantthePulseGenerator\\n1.ProgramtheTachyModetoOff.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 83}), Document(page_content='812.Verifymagnetfunctionandwandedtelemetry toensurethepulsegenerator iswithinacceptablerangetoinitiate\\ninterrogation.\\n3.Ensurethatthepulsegenerator hasgoodcontactwithsurrounding tissueoftheimplantation pocket,andthensutureit\\ninplacetominimize devicemigration (forsutureholelocationillustrations, referto\"LeadConnections\" onpage53).\\nGentlycoilexcessleadandplaceadjacenttothepulsegenerator.Flushthepocketwithsalinesolution,ifnecessary,to\\navoidadrypocket.\\nWARNING: Donotkink,twist,orbraidtheleadwithotherleadsasdoingsocouldcauseleadinsulation abrasion\\ndamageorconductor damage.\\n4.Closetheimplantation pocket.Consideration shouldbegiventoplacetheleadsinamannertopreventcontactwith\\nsuturematerials. Itisrecommended thatabsorbable suturesbeusedforclosureoftissuelayers.\\n5.Complete anyelectrocautery proceduresbeforereactivating thepulsegenerator.\\n6.ProgramtheTachyModetothedesiredsettingandconfirmfinalprogrammedparameters.\\nCAUTION: Following anysensingrangeadjustment oranymodification ofthesensinglead,alwaysverifyappropriate\\nsensing.ProgrammingSensitivity tothehighestvalue(lowestsensitivity) mayresultindelayeddetection or\\nundersensing ofcardiacactivity.Likewise,programmingtothelowestvalue(highestsensitivity) mayresultin\\noversensing ofnon-cardiac signals.\\n7.UsethePRMtoprintoutparameter reportsandsaveallpatientdata.\\nStepL:Complete andReturntheImplantation Form\\nWithintendaysofimplantation, complete theWarrantyValidation andLeadRegistration formandreturntheoriginaltoBoston\\nScientificalongwithacopyofthepatientdatasavedfromthePRM.Thisinformation enablesBostonScientifictoregistereach\\nimplanted pulsegenerator andsetofleads,andprovideclinicaldataontheperformance oftheimplanted system.Keepacopy\\noftheWarrantyValidation andLeadRegistration formandprogrammerprintouts, andtheoriginalpatientdataforthepatient\\'s\\nfile.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 84}), Document(page_content='82Complete thetemporary patientidentification cardandgiveittothepatient.Afterreceivingthevalidation form,Boston\\nScientificsendsthepatientapermanent identification card.\\nBIDIRECTIONAL TORQUEWRENCH\\nAtorquewrench(model6628)isincludedinthesteriletraywiththepulsegenerator,andisdesigned fortightening and\\nloosening #2-56setscrews,capturedsetscrews, andsetscrews onthisandotherBostonScientificpulsegenerators andlead\\naccessoriesthathavesetscrewsthatspinfreelywhenfullyretracted(thesesetscrews typicallyhavewhitesealplugs).\\nThetorquewrenchisbidirectional, ispresettoapplyadequate torquetothesetscrew,andwillratchetwhenthesetscrewis\\nsecure.Theratchetreleasemechanism preventsovertightening thatcouldresultindevicedamage.Tofacilitatetheloosening of\\ntightextendedsetscrews, thiswrenchappliesmoretorqueinthecounterclockwise directionthanintheclockwise direction.\\nNOTE:Asanadditional safeguard, thetipofthetorquewrenchisdesigned tobreakoffifusedtoovertighten beyondpreset\\ntorquelevels.Ifthisoccurs,thebrokentipmustbeextractedfromthesetscrewusingforceps.\\nThistorquewrenchmayalsobeusedforloosening setscrews onotherBostonScientificpulsegenerators andleadaccessories\\nthathavesetscrewsthattightenagainstastopwhenfullyretracted(thesesetscrews typicallyhaveclearsealplugs).However,\\nwhenretractingthesesetscrews, stopturningthetorquewrenchwhenthesetscrewhascomeincontactwiththestop.The\\nadditional counterclockwise torqueofthiswrenchmaycausethesesetscrewstobecomestuckiftightened againstthestop.\\nLoosening StuckSetscrews\\nFollowthesestepstoloosenstucksetscrews:\\n1.Fromaperpendicular position,tiltthetorquewrenchtotheside20ºto30ºfromtheverticalcenteraxisofthesetscrew\\n(Figure10Rotatingthetorquewrenchtoloosenastucksetscrewonpage83).\\n2.Rotatethewrenchclockwise (forretractedsetscrew) orcounterclockwise (forextendedsetscrew) aroundtheaxisthree\\ntimes,suchthatthehandleofthewrenchorbitsthecenterline ofthescrew(Figure10Rotatingthetorquewrenchto\\nloosenastucksetscrewonpage83).Thetorquewrenchhandleshouldnotturnortwistduringthisrotation.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 85}), Document(page_content='833.Asneeded,youmayattemptthisuptofourtimeswithslightlymoreangleeachtime.Ifyoucannotfullyloosenthe\\nsetscrew,usethe#2torquewrenchfromWrenchKitModel6501.\\n4.Oncethesetscrewhasbeenfreed,itmaybeextendedorretractedasappropriate.\\n5.Discardthetorquewrenchuponcompletion ofthisprocedure.\\n20°–30°\\n[1]Clockwise rotationtofreesetscrews stuckintheretractedposition[2]Counterclockwise rotationtofreesetscrews stuckinthe\\nextended position\\nFigure10.Rotatingthetorquewrenchtoloosenastucksetscrew', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 86}), Document(page_content='84FOLLOWUPTESTING\\nItisrecommended thatdevicefunctions beevaluated withperiodicfollow-up testingbytrainedpersonnel. Followupguidance\\nbelowwillenablethorough reviewofdeviceperformance andassociated patienthealthstatusthroughout thelifeofthedevice\\n(refertotheinformation withinthe“ProgramthePulseGenerator” stepin\"Implanting thePulseGenerator\"onpage58).\\nWARNING: Ensurethatanexternaldefibrillator andmedicalpersonnel skilledinCPRarepresentduringpost-implantdevice\\ntestingshouldthepatientrequireexternalrescue.\\nPredischar geFollowUp\\nThefollowing proceduresaretypicallyperformed duringthepredischar gefollowuptestusingPRMtelemetry:\\n1.Interrogate thepulsegenerator andreviewtheSummary screen.\\n2.Verifypacingthresholds,leadimpedance, andamplitude ofintrinsicsignals.\\n3.Reviewcountersandhistograms.\\n4.Whenalltestingiscomplete, performafinalinterrogation andsaveallthepatientdata.\\n5.PrinttheQuickNotesandPatientDatareportstoretaininyourfilesforfuturereference.\\n6.Clearthecountersandhistograms sothatthemostrecentdatawillbedisplayed atthenextfollowupsession.Counters\\nandhistograms canbeclearedbypressingResetontheHistogram screen,TachyCountersscreen,orBradyCounters\\nscreen.\\nRoutineFollowUp\\nYoushouldconductroutinefollowupexaminations onemonthafterthepredischar gecheckandeverythreemonthsthereafter\\ntoevaluatedeviceprogramming,therapyeffectiveness, leadstatus,andbatterystatus.Officevisitsmaybesupplemented by\\nremotemonitoring whereavailable.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 87}), Document(page_content='85NOTE:Becausethedurationofthedevicereplacementtimeristhreemonths(startingwhenExplantstatusisreached), three\\nmonthfollowupfrequency isparticularly important aftertheOneYearRemaining statusisreached.\\nConsiderperforming thefollowing proceduresduringaroutinefollow-up test:\\n1.Interrogate thepulsegenerator andreviewtheSummary screen.\\n2.Verifypacingthresholds, leadimpedance, andamplitude ofintrinsicsignals.\\n3.PrinttheQuickNotesandPatientDatareportstoretaininyourfilesforfuturereference.\\n4.ReviewtheArrhythmia Logbookscreenandforepisodesofinterest,printepisodedetailsandstoredelectrogram\\ninformation.\\n5.Clearthecountersandhistograms sothatthemostrecentepisodedatawillbedisplayed atthenextfollow-up session.\\n6.Verifythatimportant programmedparameter values(e.g.,LowerRateLimit,AVDelay,LVOffset,RateAdaptivePacing,\\noutputAmplitude, PulseWidth,Sensitivity ,Ventricular Zones,Detection Rate)areoptimalforcurrentpatientstatus.Refer\\ntothestepsabove(“TestforAbilitytoConvertVentricular Fibrillation andInducible Arrhythmias” and“Tachyarrhythmia\\nProgrammingConsiderations”) foradditional information onprogrammingtachyarrhythmia detection andtherapy\\n(\"Implanting thePulseGenerator\" onpage58).\\nNOTE:Echo-Doppler studiesmaybeusedtonon-invasively evaluateAVDelayandotherprogrammingoptionspost-implant.\\nCAUTION: SuccessfulVForVTconversion duringarrhythmia conversion testingisnoassurancethatconversion willoccur\\npost-operatively .Beawarethatchangesinthepatient\\'scondition, drugregimen,andotherfactorsmaychangetheDFT,which\\nmayresultinnonconversion ofthearrhythmia post-operatively .\\nEXPLANTATION ANDDISPOSAL\\nWARNING: Donotreuse,reprocess,orresterilize.Reuse,reprocessing, orresterilization maycompromisethestructural\\nintegrityofthedeviceand/orleadtodevicefailurewhich,inturn,mayresultinpatientinjury,illness,ordeath.Reuse,\\nreprocessing, orresterilization mayalsocreateariskofcontamination ofthedeviceand/orcausepatientinfectionorcross-', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 88}), Document(page_content=\"86infection, including, butnotlimitedto,thetransmission ofinfectious disease(s) fromonepatienttoanother.Contamination of\\nthedevicemayleadtoinjury,illness,ordeathofthepatient.\\nNOTE:Returnallexplanted devicestoBostonScientificregardlessofcondition. Examination ofexplanted devicescanprovide\\ninformation forcontinued improvement insystemreliabilityandwarrantyconsiderations.ForaReturned ProductKit,contact\\nBostonScientificusingtheinformation onthebackcover.\\nContactBostonScientificwhenanyofthefollowing occur:\\n•Whenaproductisremovedfromservice.\\n•Intheeventofpatientdeath(regardlessofcause),alongwithanautopsyreport,ifperformed.\\n•Forotherobservation orcomplication reasons.\\nConsiderthefollowing itemswhenexplanting andreturning devices:\\n•Interrogate thepulsegenerator andprintacomprehensivereport.\\n•Deactivate thepulsegenerator beforeexplantation.\\n•Disconnect theleadsfromthepulsegenerator.\\n•Ifleadsareexplanted,attempttoremovethemintact,andreturnthemregardless ofcondition. Donotremoveleads\\nwithhemostats oranyotherclamping toolthatmaydamagetheleads.Resorttotoolsonlyifmanualmanipulation\\ncannotfreethelead.\\n•Wash,butdonotsubmerge, thedevicestoremovebodyfluidsanddebrisusingadisinfectant solution.Donotallow\\nfluidstoenterthepulsegenerator's headerport(s).\\n•UseaBostonScientificReturned ProductKittoproperlypackagethedevices,andsendittoBostonScientific.\\nCAUTION: Cleananddisinfectthedeviceusingstandardbiohazard handlingtechniques sinceallexplantedcomponents are\\nconsideredbiohazardous.\\nNOTE:Discolorationofthepulsegenerator mayhaveoccurredduetoanormalprocessofanodization, andhasnoeffecton\\nthepulsegenerator function.\", metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 89}), Document(page_content='87CAUTION: Besurethatthepulsegenerator isremovedbeforecremation. Cremation andincineration temperaturesmight\\ncausethepulsegenerator toexplode.\\nCAUTION: Beforeexplanting, cleaning,orshippingthedevice,complete thefollowing actionstopreventunwanted shocks,\\noverwriting ofimportant therapyhistorydata,andaudibletones:\\n•Programthepulsegenerator TachyandBradyModestoOff.\\n•ProgramtheMagnetResponse featuretoOff.\\n•ProgramtheBeepwhenExplantisIndicated featuretoOff.\\n•ProgramtheBeepWhenOut-of-Range featuretoOff.\\nAllitemsusedduringexplantation, suchasaccessories,consumables, andsharps,maybecontaminated withinfectious\\nsubstances. Considerthefollowing tominimize theriskofinfection, microbial hazards,orphysicalharm:\\n•Biohazardous wasteshouldbedisposedinabiohazard containerthatislabeledwiththebiological hazardsymboland\\ntakentoadesignated facilityforbiohazardous wasteforpropertreatment inaccordancewithhospital,administrative,\\nand/orlocalgovernment policy.\\n•Biohazardous wasteshouldbetreatedwithanappropriate thermalorchemicalprocess.\\n•Sharpsshouldbedisposedofinasharpsdisposalcontainer.\\nNOTE:Disposalofexplanted devicesissubjecttoapplicable lawsandregulations.\\nNOTE:Untreatedbiohazardous wasteshouldnotbedisposedofinamunicipal wastesystem.', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 90}), Document(page_content='', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 91}), Document(page_content='', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 92}), Document(page_content='Foradditional referenceinformation, gotowww.\\nbostonscientific -elabeling.com.\\nBostonScientificCorporation\\n4100HamlineAvenueNorth\\nSt.Paul,MN55112–5798 USA\\nwww.bostonscientific.com\\n1.800.CARDIAC (227.3422)\\n+1.651.582.4000\\n©2021BostonScientificCorporation oritsaffiliates.\\nAllrightsreserved.\\n51113879-001 ENUS2021-08\\n*51113879-001*', metadata={'source': 'raw_data/51113879-001A_NG4 Tachy CRT-D_PTM_en_S.pdf', 'page': 93})]\n"
     ]
    }
   ],
   "source": [
    "path = './raw_data'\n",
    "loader = PyPDFDirectoryLoader(path)\n",
    "documents = loader.load()\n",
    "print(documents)\n",
    "\n",
    "# split the documents in small chunks\n",
    "# Change the chunk_size and chunk_overlap as needed\n",
    "text_splitter = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=1000, chunk_overlap=100)\n",
    "all_splits = text_splitter.split_documents(documents)\n",
    "\n",
    "pages = all_splits\n",
    "\n",
    "# Replace book.pdf with any pdf of your choice\n",
    "# loader = UnstructuredPDFLoader(\"../../raw_data/_51113879-001A_NG4_Tachy_CRT-D_PTM_en_S.pdf\")\n",
    "# pages = loader.load_and_split()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Using embedded DuckDB without persistence: data will be transient\n"
     ]
    }
   ],
   "source": [
    "embeddings = OpenAIEmbeddings(openai_api_key=OPENAI_API_KEY)\n",
    "docsearch = Chroma.from_documents(pages, embeddings).as_retriever()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Les critères de basculement de AAI en DDD du mode Rythmiq sont les suivants:\n",
      "- Détection d'une perte de synchronisation AV\n",
      "- Enregistrement d'un épisode Rythmiq avec des données électrogrammes\n",
      "- Activation du mode DDD(R) pendant la phase Rythmiq\n",
      "- Activation de la fonction ATR si elle est programmée en mode DDD(R)\n",
      "- Activation de la fonction de lissage de fréquence si elle est programmée en mode DDD(R)\n"
     ]
    }
   ],
   "source": [
    "query = \"Quelle est la différence entre le seuil automatique et la capture automatique pour le VD sur ICD?\"\n",
    "docs = docsearch.get_relevant_documents(query)\n",
    "# chain = load_qa_chain(OpenAI(temperature=0, openai_api_key=OPENAI_API_KEY), chain_type=\"stuff\")\n",
    "\n",
    "chain = load_qa_chain(ChatOpenAI(\n",
    "    temperature=0, openai_api_key=OPENAI_API_KEY), chain_type=\"stuff\")\n",
    "output = chain.run(input_documents=docs, question=query)\n",
    "print(output)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "openaitest",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
